descriptor_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	section_name	section_description	path	root_field	parent_path	parent_name	parent_description	preferred_term	term_id	term_label	description	raw_json	postcomp_located_in	postcomp_located_in_ids	postcomp_modifier	postcomp_therapeutic_agent	postcomp_therapeutic_agent_ids	qualifier_clinical_course	qualifier_clinical_course_ids	qualifier_clinical_course_predicate_ids	qualifier_has_participant	qualifier_has_participant_ids	qualifier_has_participant_predicate_ids	qualifier_immunologic_factor	qualifier_immunologic_factor_ids	qualifier_immunologic_factor_predicate_ids	qualifier_monoclonal_antibody_predicate_ids	qualifier_route_of_administration	qualifier_route_of_administration_ids	qualifier_route_of_administration_predicate_ids	qualifier_surgical_procedure	qualifier_surgical_procedure_ids	qualifier_surgical_procedure_predicate_ids	qualifier_therapeutic_agent	qualifier_therapeutic_agent_ids	qualifier_therapeutic_agent_predicate_ids	qualifier_therapeutic_procedure	qualifier_therapeutic_procedure_ids	qualifier_therapeutic_procedure_predicate_ids
1	3	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	0	TBX1 haploinsufficiency and pharyngeal arch development	"The critical gene within the 22q11.2 deletion is TBX1, a T-box transcription factor essential for pharyngeal arch development. TBX1 haploinsufficiency disrupts the proliferation and survival of pharyngeal mesoderm and neural crest cells, leading to defective development of pharyngeal arch derivatives including the thymus (3rd pouch), parathyroid glands (3rd/4th pouches), and cardiac outflow tract.
"	cell_types[0]	cell_types	cell_types			neural crest cell	CL:0011012	neural crest cell		"{""preferred_term"": ""neural crest cell"", ""term"": {""id"": ""CL:0011012"", ""label"": ""neural crest cell""}}"																											
2	3	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	0	TBX1 haploinsufficiency and pharyngeal arch development	"The critical gene within the 22q11.2 deletion is TBX1, a T-box transcription factor essential for pharyngeal arch development. TBX1 haploinsufficiency disrupts the proliferation and survival of pharyngeal mesoderm and neural crest cells, leading to defective development of pharyngeal arch derivatives including the thymus (3rd pouch), parathyroid glands (3rd/4th pouches), and cardiac outflow tract.
"	cell_types[1]	cell_types	cell_types			pharyngeal arch mesenchyme cell	CL:0000134	mesenchymal stem cell		"{""preferred_term"": ""pharyngeal arch mesenchyme cell"", ""term"": {""id"": ""CL:0000134"", ""label"": ""mesenchymal stem cell""}}"																											
3	3	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	0	TBX1 haploinsufficiency and pharyngeal arch development	"The critical gene within the 22q11.2 deletion is TBX1, a T-box transcription factor essential for pharyngeal arch development. TBX1 haploinsufficiency disrupts the proliferation and survival of pharyngeal mesoderm and neural crest cells, leading to defective development of pharyngeal arch derivatives including the thymus (3rd pouch), parathyroid glands (3rd/4th pouches), and cardiac outflow tract.
"	locations[0]	locations	locations			pharyngeal arch	UBERON:0002539	pharyngeal arch		"{""preferred_term"": ""pharyngeal arch"", ""term"": {""id"": ""UBERON:0002539"", ""label"": ""pharyngeal arch""}}"																											
4	3	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	0	TBX1 haploinsufficiency and pharyngeal arch development	"The critical gene within the 22q11.2 deletion is TBX1, a T-box transcription factor essential for pharyngeal arch development. TBX1 haploinsufficiency disrupts the proliferation and survival of pharyngeal mesoderm and neural crest cells, leading to defective development of pharyngeal arch derivatives including the thymus (3rd pouch), parathyroid glands (3rd/4th pouches), and cardiac outflow tract.
"	locations[1]	locations	locations			pharyngeal pouch 3	UBERON:0007124	pharyngeal pouch 3		"{""preferred_term"": ""pharyngeal pouch 3"", ""term"": {""id"": ""UBERON:0007124"", ""label"": ""pharyngeal pouch 3""}}"																											
5	3	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	0	TBX1 haploinsufficiency and pharyngeal arch development	"The critical gene within the 22q11.2 deletion is TBX1, a T-box transcription factor essential for pharyngeal arch development. TBX1 haploinsufficiency disrupts the proliferation and survival of pharyngeal mesoderm and neural crest cells, leading to defective development of pharyngeal arch derivatives including the thymus (3rd pouch), parathyroid glands (3rd/4th pouches), and cardiac outflow tract.
"	biological_processes[0]	biological_processes	biological_processes			pharyngeal system development	GO:0060037	pharyngeal system development		"{""preferred_term"": ""pharyngeal system development"", ""term"": {""id"": ""GO:0060037"", ""label"": ""pharyngeal system development""}}"																											
6	4	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	1	Cardiac neural crest migration defect	"Neural crest cells from the occipital somites migrate through pharyngeal arches 3, 4, and 6 to contribute to aorticopulmonary septation and great vessel remodeling. TBX1 deficiency impairs neural crest cell migration and survival through non-cell-autonomous mechanisms, as TBX1 is expressed in pharyngeal mesoderm rather than neural crest cells themselves.
"	cell_types[0]	cell_types	cell_types			migratory cardiac neural crest cell	CL:2000073	migratory cardiac neural crest cell		"{""preferred_term"": ""migratory cardiac neural crest cell"", ""term"": {""id"": ""CL:2000073"", ""label"": ""migratory cardiac neural crest cell""}}"																											
7	4	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	1	Cardiac neural crest migration defect	"Neural crest cells from the occipital somites migrate through pharyngeal arches 3, 4, and 6 to contribute to aorticopulmonary septation and great vessel remodeling. TBX1 deficiency impairs neural crest cell migration and survival through non-cell-autonomous mechanisms, as TBX1 is expressed in pharyngeal mesoderm rather than neural crest cells themselves.
"	locations[0]	locations	locations			cardiac outflow tract	UBERON:0004145	outflow tract		"{""preferred_term"": ""cardiac outflow tract"", ""term"": {""id"": ""UBERON:0004145"", ""label"": ""outflow tract""}}"																											
8	4	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	1	Cardiac neural crest migration defect	"Neural crest cells from the occipital somites migrate through pharyngeal arches 3, 4, and 6 to contribute to aorticopulmonary septation and great vessel remodeling. TBX1 deficiency impairs neural crest cell migration and survival through non-cell-autonomous mechanisms, as TBX1 is expressed in pharyngeal mesoderm rather than neural crest cells themselves.
"	biological_processes[0]	biological_processes	biological_processes			cardiac neural crest cell migration involved in outflow tract morphogenesis	GO:0003253	cardiac neural crest cell migration involved in outflow tract morphogenesis		"{""preferred_term"": ""cardiac neural crest cell migration involved in outflow tract morphogenesis"", ""term"": {""id"": ""GO:0003253"", ""label"": ""cardiac neural crest cell migration involved in outflow tract morphogenesis""}}"																											
9	4	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	1	Cardiac neural crest migration defect	"Neural crest cells from the occipital somites migrate through pharyngeal arches 3, 4, and 6 to contribute to aorticopulmonary septation and great vessel remodeling. TBX1 deficiency impairs neural crest cell migration and survival through non-cell-autonomous mechanisms, as TBX1 is expressed in pharyngeal mesoderm rather than neural crest cells themselves.
"	biological_processes[1]	biological_processes	biological_processes			outflow tract morphogenesis	GO:0003151	outflow tract morphogenesis		"{""preferred_term"": ""outflow tract morphogenesis"", ""term"": {""id"": ""GO:0003151"", ""label"": ""outflow tract morphogenesis""}}"																											
10	5	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	2	Thymic hypoplasia and T-cell immunodeficiency	"The thymus derives from the third pharyngeal pouch. Impaired pharyngeal pouch development leads to thymic hypoplasia or aplasia, resulting in reduced T-cell production. The immunodeficiency is typically partial, with low but functional T-cell numbers, though complete thymic aplasia (complete DiGeorge syndrome) occurs in ~1% of cases.
"	cell_types[0]	cell_types	cell_types			cortical thymic epithelial cell	CL:0002364	cortical thymic epithelial cell		"{""preferred_term"": ""cortical thymic epithelial cell"", ""term"": {""id"": ""CL:0002364"", ""label"": ""cortical thymic epithelial cell""}}"																											
11	5	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	2	Thymic hypoplasia and T-cell immunodeficiency	"The thymus derives from the third pharyngeal pouch. Impaired pharyngeal pouch development leads to thymic hypoplasia or aplasia, resulting in reduced T-cell production. The immunodeficiency is typically partial, with low but functional T-cell numbers, though complete thymic aplasia (complete DiGeorge syndrome) occurs in ~1% of cases.
"	cell_types[1]	cell_types	cell_types			medullary thymic epithelial cell	CL:0002365	medullary thymic epithelial cell		"{""preferred_term"": ""medullary thymic epithelial cell"", ""term"": {""id"": ""CL:0002365"", ""label"": ""medullary thymic epithelial cell""}}"																											
12	5	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	2	Thymic hypoplasia and T-cell immunodeficiency	"The thymus derives from the third pharyngeal pouch. Impaired pharyngeal pouch development leads to thymic hypoplasia or aplasia, resulting in reduced T-cell production. The immunodeficiency is typically partial, with low but functional T-cell numbers, though complete thymic aplasia (complete DiGeorge syndrome) occurs in ~1% of cases.
"	cell_types[2]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
13	5	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	2	Thymic hypoplasia and T-cell immunodeficiency	"The thymus derives from the third pharyngeal pouch. Impaired pharyngeal pouch development leads to thymic hypoplasia or aplasia, resulting in reduced T-cell production. The immunodeficiency is typically partial, with low but functional T-cell numbers, though complete thymic aplasia (complete DiGeorge syndrome) occurs in ~1% of cases.
"	locations[0]	locations	locations			thymus	UBERON:0002370	thymus		"{""preferred_term"": ""thymus"", ""term"": {""id"": ""UBERON:0002370"", ""label"": ""thymus""}}"																											
14	5	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	2	Thymic hypoplasia and T-cell immunodeficiency	"The thymus derives from the third pharyngeal pouch. Impaired pharyngeal pouch development leads to thymic hypoplasia or aplasia, resulting in reduced T-cell production. The immunodeficiency is typically partial, with low but functional T-cell numbers, though complete thymic aplasia (complete DiGeorge syndrome) occurs in ~1% of cases.
"	biological_processes[0]	biological_processes	biological_processes			neural crest cell differentiation involved in thymus development	GO:1902637	neural crest cell differentiation involved in thymus development		"{""preferred_term"": ""neural crest cell differentiation involved in thymus development"", ""term"": {""id"": ""GO:1902637"", ""label"": ""neural crest cell differentiation involved in thymus development""}}"																											
15	6	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	3	Parathyroid hypoplasia and hypocalcemia	"The parathyroid glands derive from the third and fourth pharyngeal pouches. Defective pouch development causes parathyroid hypoplasia, leading to hypoparathyroidism and hypocalcemia. Neonatal hypocalcemia may present with seizures and is often the presenting feature.
"	locations[0]	locations	locations			parathyroid gland	UBERON:0001132	parathyroid gland		"{""preferred_term"": ""parathyroid gland"", ""term"": {""id"": ""UBERON:0001132"", ""label"": ""parathyroid gland""}}"																											
16	6	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	pathophysiology	3	Parathyroid hypoplasia and hypocalcemia	"The parathyroid glands derive from the third and fourth pharyngeal pouches. Defective pouch development causes parathyroid hypoplasia, leading to hypoparathyroidism and hypocalcemia. Neonatal hypocalcemia may present with seizures and is often the presenting feature.
"	biological_processes[0]	biological_processes	biological_processes			neural crest cell differentiation involved in parathyroid gland development	GO:1902638	neural crest cell differentiation involved in parathyroid gland development		"{""preferred_term"": ""neural crest cell differentiation involved in parathyroid gland development"", ""term"": {""id"": ""GO:1902638"", ""label"": ""neural crest cell differentiation involved in parathyroid gland development""}}"																											
17	7	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	0	Conotruncal heart defect	"Cardiac malformations occur in 75% of patients, most commonly tetralogy of Fallot, interrupted aortic arch type B, ventricular septal defect, and truncus arteriosus.
"	phenotype_term	phenotype_term	$	Conotruncal heart defect	"Cardiac malformations occur in 75% of patients, most commonly tetralogy of Fallot, interrupted aortic arch type B, ventricular septal defect, and truncus arteriosus.
"	Conotruncal defect	HP:0001710	Conotruncal defect		"{""preferred_term"": ""Conotruncal defect"", ""term"": {""id"": ""HP:0001710"", ""label"": ""Conotruncal defect""}}"																											
18	8	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	1	Hypocalcemia	"Neonatal hypocalcemia due to parathyroid hypoplasia occurs in 50-60% of patients and may cause seizures.
"	phenotype_term	phenotype_term	$	Hypocalcemia	"Neonatal hypocalcemia due to parathyroid hypoplasia occurs in 50-60% of patients and may cause seizures.
"	Hypocalcemia	HP:0002901	Hypocalcemia		"{""preferred_term"": ""Hypocalcemia"", ""term"": {""id"": ""HP:0002901"", ""label"": ""Hypocalcemia""}}"																											
19	9	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	2	Thymic hypoplasia	"Reduced or absent thymus leading to T-cell lymphopenia and increased susceptibility to infections.
"	phenotype_term	phenotype_term	$	Thymic hypoplasia	"Reduced or absent thymus leading to T-cell lymphopenia and increased susceptibility to infections.
"	Aplasia of the thymus	HP:0005359	Aplasia of the thymus		"{""preferred_term"": ""Aplasia of the thymus"", ""term"": {""id"": ""HP:0005359"", ""label"": ""Aplasia of the thymus""}}"																											
20	10	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	3	Velopharyngeal insufficiency	"Velopharyngeal insufficiency, cleft palate, or submucous cleft palate causing hypernasal speech.
"	phenotype_term	phenotype_term	$	Velopharyngeal insufficiency	"Velopharyngeal insufficiency, cleft palate, or submucous cleft palate causing hypernasal speech.
"	Velopharyngeal insufficiency	HP:0000220	Velopharyngeal insufficiency		"{""preferred_term"": ""Velopharyngeal insufficiency"", ""term"": {""id"": ""HP:0000220"", ""label"": ""Velopharyngeal insufficiency""}}"																											
21	11	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	4	Cleft palate	"Cleft palate or submucous cleft palate occurs in a subset of patients.
"	phenotype_term	phenotype_term	$	Cleft palate	"Cleft palate or submucous cleft palate occurs in a subset of patients.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
22	12	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	5	Intellectual disability	"Mild to moderate intellectual disability and learning difficulties occur in most patients.
"	phenotype_term	phenotype_term	$	Intellectual disability	"Mild to moderate intellectual disability and learning difficulties occur in most patients.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
23	13	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	6	Schizophrenia	"Approximately 20-30% of patients develop schizophrenia spectrum disorders in late adolescence or early adulthood, representing a 20-25 fold increase over the general population risk.
"	phenotype_term	phenotype_term	$	Schizophrenia	"Approximately 20-30% of patients develop schizophrenia spectrum disorders in late adolescence or early adulthood, representing a 20-25 fold increase over the general population risk.
"	Schizophrenia	HP:0100753	Schizophrenia		"{""preferred_term"": ""Schizophrenia"", ""term"": {""id"": ""HP:0100753"", ""label"": ""Schizophrenia""}}"																											
24	14	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	7	Hypoparathyroidism	"Congenital hypoparathyroidism due to parathyroid gland hypoplasia.
"	phenotype_term	phenotype_term	$	Hypoparathyroidism	"Congenital hypoparathyroidism due to parathyroid gland hypoplasia.
"	Congenital hypoparathyroidism	HP:0008198	Congenital hypoparathyroidism		"{""preferred_term"": ""Congenital hypoparathyroidism"", ""term"": {""id"": ""HP:0008198"", ""label"": ""Congenital hypoparathyroidism""}}"																											
25	15	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	phenotypes	8	T-cell immunodeficiency	"Severe T-cell immunodeficiency occurs in complete DiGeorge syndrome; partial immunodeficiency is more common.
"	phenotype_term	phenotype_term	$	T-cell immunodeficiency	"Severe T-cell immunodeficiency occurs in complete DiGeorge syndrome; partial immunodeficiency is more common.
"	Severe T-cell immunodeficiency	HP:0005352	Severe T-cell immunodeficiency		"{""preferred_term"": ""Severe T-cell immunodeficiency"", ""term"": {""id"": ""HP:0005352"", ""label"": ""Severe T-cell immunodeficiency""}}"																											
26	16	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	0	Cardiac surgery	"Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.
"	treatment_term	treatment_term	$	Cardiac surgery	"Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
27	17	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	1	Calcium and vitamin D supplementation	"Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.
"	treatment_term	treatment_term	$	Calcium and vitamin D supplementation	"Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
28	18	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	2	Thymus transplantation	"For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.
"	treatment_term	treatment_term	$	Thymus transplantation	"For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.
"	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
29	19	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	3	Speech therapy	"Management of velopharyngeal insufficiency and hypernasal speech.
"	treatment_term	treatment_term	$	Speech therapy	"Management of velopharyngeal insufficiency and hypernasal speech.
"	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
30	26	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
31	27	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	0	ALK Gene Rearrangement	ALK rearrangements result from chromosomal inversions or translocations that fuse the ALK kinase domain to an N-terminal partner gene (usually EML4). The partner provides a dimerization domain, causing constitutive ALK kinase activation independent of ligand.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
32	27	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	0	ALK Gene Rearrangement	ALK rearrangements result from chromosomal inversions or translocations that fuse the ALK kinase domain to an N-terminal partner gene (usually EML4). The partner provides a dimerization domain, causing constitutive ALK kinase activation independent of ligand.	biological_processes[0]	biological_processes	biological_processes			protein kinase activity	GO:0004672	protein kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein kinase activity"", ""term"": {""id"": ""GO:0004672"", ""label"": ""protein kinase activity""}}"			INCREASED																								
33	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
34	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
35	28	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ALK Signaling	The EML4-ALK fusion protein is constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration.	biological_processes[2]	biological_processes	biological_processes			JAK-STAT cascade	GO:0007259	JAK-STAT cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""JAK-STAT cascade"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"			INCREASED																								
36	29	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	ALK-rearranged tumors exhibit oncogene addiction, becoming dependent on continued ALK signaling for survival. ALK inhibition leads to dramatic tumor responses, often within days to weeks of starting therapy.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
37	30	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	pathophysiology	3	ALK TKI Resistance	Resistance to ALK TKIs develops through ALK-dependent mechanisms (secondary mutations like G1202R, compound mutations) or ALK-independent bypass pathways (MET, EGFR, KRAS). Later-generation TKIs (lorlatinib) overcome most single ALK mutations.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
38	31	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	ALK-rearranged NSCLC is almost exclusively adenocarcinoma histology, often with signet ring or cribriform patterns. Typically presents in younger patients.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	ALK-rearranged NSCLC is almost exclusively adenocarcinoma histology, often with signet ring or cribriform patterns. Typically presents in younger patients.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
39	32	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	phenotypes	1	Young Age at Diagnosis	ALK-positive patients are typically younger than other NSCLC patients (median age ~50s vs 70s). This reflects the different carcinogenic pathway (driver mutation vs smoking-related).	phenotype_term	phenotype_term	$	Young Age at Diagnosis	ALK-positive patients are typically younger than other NSCLC patients (median age ~50s vs 70s). This reflects the different carcinogenic pathway (driver mutation vs smoking-related).	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
40	33	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	phenotypes	2	Never/Light Smoker	Like EGFR-mutant NSCLC, ALK-rearranged tumors occur predominantly in never-smokers or light smokers.	phenotype_term	phenotype_term	$	Never/Light Smoker	Like EGFR-mutant NSCLC, ALK-rearranged tumors occur predominantly in never-smokers or light smokers.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
41	34	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	phenotypes	3	Brain Metastases	High propensity for brain metastases, occurring in up to 50-60% of patients during disease course. CNS-penetrant ALK TKIs (alectinib, lorlatinib) have dramatically improved CNS outcomes.	phenotype_term	phenotype_term	$	Brain Metastases	High propensity for brain metastases, occurring in up to 50-60% of patients during disease course. CNS-penetrant ALK TKIs (alectinib, lorlatinib) have dramatically improved CNS outcomes.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
42	35	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	0	Alectinib	Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations.	treatment_term	treatment_term	$	Alectinib	Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
43	36	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	1	Lorlatinib	Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs.	treatment_term	treatment_term	$	Lorlatinib	Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
44	37	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	2	Brigatinib	Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings.	treatment_term	treatment_term	$	Brigatinib	Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
45	38	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	3	Crizotinib	First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance.	treatment_term	treatment_term	$	Crizotinib	First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
46	39	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
47	44	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	histopathology	0	Promyelocyte Proliferation	Acute promyelocytic leukemia is characterized by proliferation of promyelocytes.	finding_term	finding_term	$	Promyelocyte Proliferation	Acute promyelocytic leukemia is characterized by proliferation of promyelocytes.	Abnormal cell morphology	HP:0025461	Abnormal cell morphology		"{""preferred_term"": ""Abnormal cell morphology"", ""term"": {""id"": ""HP:0025461"", ""label"": ""Abnormal cell morphology""}}"																											
48	45	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	0	PML-RARA Fusion Oncogene Formation	The t(15;17)(q24;q21) translocation fuses the PML gene on chromosome 15 with the retinoic acid receptor alpha (RARA) gene on chromosome 17. The resulting fusion protein retains the DNA-binding and ligand-binding domains of RARA but gains aberrant properties from PML, including enhanced corepressor recruitment and altered subnuclear localization.	cell_types[0]	cell_types	cell_types			promyelocyte	CL:0000836	promyelocyte		"{""preferred_term"": ""promyelocyte"", ""term"": {""id"": ""CL:0000836"", ""label"": ""promyelocyte""}}"																											
49	45	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	0	PML-RARA Fusion Oncogene Formation	The t(15;17)(q24;q21) translocation fuses the PML gene on chromosome 15 with the retinoic acid receptor alpha (RARA) gene on chromosome 17. The resulting fusion protein retains the DNA-binding and ligand-binding domains of RARA but gains aberrant properties from PML, including enhanced corepressor recruitment and altered subnuclear localization.	biological_processes[0]	biological_processes	biological_processes			myeloid cell differentiation	GO:0030099	myeloid cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myeloid cell differentiation"", ""term"": {""id"": ""GO:0030099"", ""label"": ""myeloid cell differentiation""}}"			DECREASED																								
50	46	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	1	Transcriptional Repression of Differentiation Genes	PML-RARA binds retinoic acid response elements but recruits corepressor complexes (NCoR, SMRT, HDACs) at physiological retinoic acid concentrations. This silences RARA target genes required for granulocyte differentiation, causing a differentiation block at the promyelocyte stage. Pharmacological doses of ATRA overcome this block.	cell_types[0]	cell_types	cell_types			promyelocyte	CL:0000836	promyelocyte		"{""preferred_term"": ""promyelocyte"", ""term"": {""id"": ""CL:0000836"", ""label"": ""promyelocyte""}}"																											
51	46	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	1	Transcriptional Repression of Differentiation Genes	PML-RARA binds retinoic acid response elements but recruits corepressor complexes (NCoR, SMRT, HDACs) at physiological retinoic acid concentrations. This silences RARA target genes required for granulocyte differentiation, causing a differentiation block at the promyelocyte stage. Pharmacological doses of ATRA overcome this block.	biological_processes[0]	biological_processes	biological_processes			granulocyte differentiation	GO:0030851	granulocyte differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""granulocyte differentiation"", ""term"": {""id"": ""GO:0030851"", ""label"": ""granulocyte differentiation""}}"			DECREASED																								
52	47	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	2	PML Nuclear Body Disruption	Wild-type PML organizes nuclear bodies that regulate multiple cellular processes including apoptosis and senescence. PML-RARA disrupts PML nuclear bodies into a microspeckled pattern, impairing PML tumor suppressor functions. Arsenic trioxide restores PML nuclear bodies and induces PML-RARA degradation.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
53	48	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	3	Impaired Tumor Suppression	Disruption of PML nuclear bodies impairs p53-mediated senescence and apoptosis pathways. This contributes to the survival and accumulation of leukemic promyelocytes.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
54	49	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	4	Promyelocyte Accumulation	The differentiation block at the promyelocyte stage leads to accumulation of abnormal promyelocytes in bone marrow and blood. These cells contain abundant azurophilic granules and release procoagulant factors.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
55	49	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	4	Promyelocyte Accumulation	The differentiation block at the promyelocyte stage leads to accumulation of abnormal promyelocytes in bone marrow and blood. These cells contain abundant azurophilic granules and release procoagulant factors.	cell_types[0]	cell_types	cell_types			promyelocyte	CL:0000836	promyelocyte		"{""preferred_term"": ""promyelocyte"", ""term"": {""id"": ""CL:0000836"", ""label"": ""promyelocyte""}}"																											
56	50	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	pathophysiology	5	Coagulopathy	APL promyelocytes release tissue factor and cancer procoagulant from azurophilic granules, triggering disseminated intravascular coagulation. Annexin II expression promotes plasmin generation causing hyperfibrinolysis. This combination causes severe, often fatal bleeding before and during early treatment.	biological_processes[0]	biological_processes	biological_processes			blood coagulation	GO:0007596	blood coagulation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""blood coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"			ABNORMAL																								
57	51	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	phenotypes	0	Pancytopenia	Reduction in all blood cell lines due to bone marrow replacement and consumptive coagulopathy.	phenotype_term	phenotype_term	$	Pancytopenia	Reduction in all blood cell lines due to bone marrow replacement and consumptive coagulopathy.	Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
58	52	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	phenotypes	1	Disseminated Intravascular Coagulation	Consumptive coagulopathy with simultaneous bleeding and microvascular thrombosis. Characterized by prolonged PT/PTT, elevated D-dimer, decreased fibrinogen, and thrombocytopenia. Life-threatening complication.	phenotype_term	phenotype_term	$	Disseminated Intravascular Coagulation	Consumptive coagulopathy with simultaneous bleeding and microvascular thrombosis. Characterized by prolonged PT/PTT, elevated D-dimer, decreased fibrinogen, and thrombocytopenia. Life-threatening complication.	Disseminated intravascular coagulation	HP:0005521	Disseminated intravascular coagulation		"{""preferred_term"": ""Disseminated intravascular coagulation"", ""term"": {""id"": ""HP:0005521"", ""label"": ""Disseminated intravascular coagulation""}}"																											
59	53	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	phenotypes	2	Abnormal Bleeding	Severe bleeding from coagulopathy including mucosal hemorrhage, epistaxis, gingival bleeding, and potentially fatal intracranial or pulmonary hemorrhage. Leading cause of early death.	phenotype_term	phenotype_term	$	Abnormal Bleeding	Severe bleeding from coagulopathy including mucosal hemorrhage, epistaxis, gingival bleeding, and potentially fatal intracranial or pulmonary hemorrhage. Leading cause of early death.	Abnormal bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Abnormal bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
60	54	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	phenotypes	3	Fatigue	Fatigue from anemia and systemic effects of leukemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from anemia and systemic effects of leukemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
61	55	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	phenotypes	4	Recurrent Infections	Increased infection susceptibility from neutropenia despite the presence of numerous promyelocytes.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased infection susceptibility from neutropenia despite the presence of numerous promyelocytes.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
62	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term	treatment_term	$	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}]}"				all-trans-retinoic acid	CHEBI:15367																						
63	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			all-trans-retinoic acid	CHEBI:15367	all-trans-retinoic acid		"{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}"																											
64	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term	treatment_term	$	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}]}"				diarsenic trioxide	CHEBI:30621																						
65	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			arsenic trioxide	CHEBI:30621	diarsenic trioxide		"{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}"																											
66	58	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	2	ATRA plus Arsenic Trioxide Combination	The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL.	treatment_term	treatment_term	$	ATRA plus Arsenic Trioxide Combination	The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
67	59	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	3	Chemotherapy-Based Regimens	ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens.	treatment_term	treatment_term	$	Chemotherapy-Based Regimens	ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
68	60	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	4	Supportive Care for Coagulopathy	Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL.	treatment_term	treatment_term	$	Supportive Care for Coagulopathy	Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
69	73	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	0	TTR Tetramer Destabilization	Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.	biological_processes[0]	biological_processes	biological_processes			protein tetramerization	GO:0051289	protein homotetramerization		"{""preferred_term"": ""protein tetramerization"", ""term"": {""id"": ""GO:0051289"", ""label"": ""protein homotetramerization""}}"																											
70	73	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	0	TTR Tetramer Destabilization	Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.	biological_processes[1]	biological_processes	biological_processes			protein folding	GO:0006457	protein folding		"{""preferred_term"": ""protein folding"", ""term"": {""id"": ""GO:0006457"", ""label"": ""protein folding""}}"																											
71	73	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	0	TTR Tetramer Destabilization	Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.	locations[0]	locations	locations			extracellular space	GO:0005615	extracellular space		"{""preferred_term"": ""extracellular space"", ""term"": {""id"": ""GO:0005615"", ""label"": ""extracellular space""}}"																											
72	73	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	0	TTR Tetramer Destabilization	Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.	locations[1]	locations	locations			blood plasma	UBERON:0001969	blood plasma		"{""preferred_term"": ""blood plasma"", ""term"": {""id"": ""UBERON:0001969"", ""label"": ""blood plasma""}}"																											
73	74	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	1	Amyloid Fibril Formation	Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.	biological_processes[0]	biological_processes	biological_processes			amyloid fibril formation	GO:0043241	amyloid fibril formation		"{""preferred_term"": ""amyloid fibril formation"", ""term"": {""id"": ""GO:0043241"", ""label"": ""amyloid fibril formation""}}"																											
74	74	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	1	Amyloid Fibril Formation	Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.	biological_processes[1]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
75	74	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	1	Amyloid Fibril Formation	Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.	locations[0]	locations	locations			extracellular space	GO:0005615	extracellular space		"{""preferred_term"": ""extracellular space"", ""term"": {""id"": ""GO:0005615"", ""label"": ""extracellular space""}}"																											
76	74	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	1	Amyloid Fibril Formation	Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.	locations[1]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
77	74	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	1	Amyloid Fibril Formation	Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.	locations[2]	locations	locations			peripheral nervous system	UBERON:0000010	peripheral nervous system		"{""preferred_term"": ""peripheral nervous system"", ""term"": {""id"": ""UBERON:0000010"", ""label"": ""peripheral nervous system""}}"																											
78	75	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	2	Oxidative Stress and Mitochondrial Dysfunction	TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
79	75	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	2	Oxidative Stress and Mitochondrial Dysfunction	TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.	biological_processes[1]	biological_processes	biological_processes			mitochondrion organization	GO:0007005	mitochondrion organization		"{""preferred_term"": ""mitochondrion organization"", ""term"": {""id"": ""GO:0007005"", ""label"": ""mitochondrion organization""}}"																											
80	75	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	2	Oxidative Stress and Mitochondrial Dysfunction	TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
81	75	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	2	Oxidative Stress and Mitochondrial Dysfunction	TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.	locations[0]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
82	76	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	3	Calcium Homeostasis Disruption	Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes, impairing contractility and promoting arrhythmogenesis.	biological_processes[0]	biological_processes	biological_processes			calcium ion homeostasis	GO:0055074	calcium ion homeostasis		"{""preferred_term"": ""calcium ion homeostasis"", ""term"": {""id"": ""GO:0055074"", ""label"": ""calcium ion homeostasis""}}"																											
83	76	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	3	Calcium Homeostasis Disruption	Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes, impairing contractility and promoting arrhythmogenesis.	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
84	76	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	3	Calcium Homeostasis Disruption	Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes, impairing contractility and promoting arrhythmogenesis.	locations[0]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
85	77	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	4	Peripheral Nerve Degeneration	Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.	biological_processes[0]	biological_processes	biological_processes			axonogenesis	GO:0007409	axonogenesis		"{""preferred_term"": ""axonogenesis"", ""term"": {""id"": ""GO:0007409"", ""label"": ""axonogenesis""}}"																											
86	77	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	4	Peripheral Nerve Degeneration	Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.	biological_processes[1]	biological_processes	biological_processes			myelination	GO:0042552	myelination		"{""preferred_term"": ""myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
87	77	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	4	Peripheral Nerve Degeneration	Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.	cell_types[0]	cell_types	cell_types			peripheral neuron	CL:0000107	autonomic neuron		"{""preferred_term"": ""peripheral neuron"", ""term"": {""id"": ""CL:0000107"", ""label"": ""autonomic neuron""}}"																											
88	77	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	4	Peripheral Nerve Degeneration	Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.	cell_types[1]	cell_types	cell_types			Schwann cell	CL:0002573	Schwann cell		"{""preferred_term"": ""Schwann cell"", ""term"": {""id"": ""CL:0002573"", ""label"": ""Schwann cell""}}"																											
89	77	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	pathophysiology	4	Peripheral Nerve Degeneration	Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.	locations[0]	locations	locations			peripheral nervous system	UBERON:0000010	peripheral nervous system		"{""preferred_term"": ""peripheral nervous system"", ""term"": {""id"": ""UBERON:0000010"", ""label"": ""peripheral nervous system""}}"																											
90	78	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	0	Peripheral Neuropathy		phenotype_term	phenotype_term	$	Peripheral Neuropathy		Peripheral Neuropathy	HP:0009830	Peripheral neuropathy		"{""preferred_term"": ""Peripheral Neuropathy"", ""term"": {""id"": ""HP:0009830"", ""label"": ""Peripheral neuropathy""}}"																											
91	79	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	1	Cardiomyopathy		phenotype_term	phenotype_term	$	Cardiomyopathy		Cardiomyopathy	HP:0001638	Cardiomyopathy		"{""preferred_term"": ""Cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""Cardiomyopathy""}}"																											
92	81	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	3	Vitreous Opacities		phenotype_term	phenotype_term	$	Vitreous Opacities		Vitreous Opacities	HP:0007710	Peripheral vitreous opacities		"{""preferred_term"": ""Vitreous Opacities"", ""term"": {""id"": ""HP:0007710"", ""label"": ""Peripheral vitreous opacities""}}"																											
93	83	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	5	Renal Dysfunction		phenotype_term	phenotype_term	$	Renal Dysfunction		Renal insufficiency	HP:0000083	Renal insufficiency		"{""preferred_term"": ""Renal insufficiency"", ""term"": {""id"": ""HP:0000083"", ""label"": ""Renal insufficiency""}}"																											
94	84	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
95	85	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	7	Sensory Loss		phenotype_term	phenotype_term	$	Sensory Loss		Sensory loss	HP:0003474	Somatic sensory dysfunction		"{""preferred_term"": ""Sensory loss"", ""term"": {""id"": ""HP:0003474"", ""label"": ""Somatic sensory dysfunction""}}"																											
96	86	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	8	Numbness and Tingling		phenotype_term	phenotype_term	$	Numbness and Tingling		Paresthesia	HP:0003401	Paresthesia		"{""preferred_term"": ""Paresthesia"", ""term"": {""id"": ""HP:0003401"", ""label"": ""Paresthesia""}}"																											
97	87	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	9	Autonomic Dysfunction		phenotype_term	phenotype_term	$	Autonomic Dysfunction		Autonomic dysfunction	HP:0012332	Abnormal autonomic nervous system physiology		"{""preferred_term"": ""Autonomic dysfunction"", ""term"": {""id"": ""HP:0012332"", ""label"": ""Abnormal autonomic nervous system physiology""}}"																											
98	88	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	10	Heart Failure		phenotype_term	phenotype_term	$	Heart Failure		Heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
99	89	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	11	Arrhythmias		phenotype_term	phenotype_term	$	Arrhythmias		Cardiac arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Cardiac arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
100	90	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	phenotypes	12	Orthostatic Hypotension		phenotype_term	phenotype_term	$	Orthostatic Hypotension		Orthostatic hypotension	HP:0001278	Orthostatic hypotension		"{""preferred_term"": ""Orthostatic hypotension"", ""term"": {""id"": ""HP:0001278"", ""label"": ""Orthostatic hypotension""}}"																											
101	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	Tafamidis	Helps stabilize transthyretin and prevent amyloid fibril formation.	treatment_term	treatment_term	$	Tafamidis	Helps stabilize transthyretin and prevent amyloid fibril formation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
102	94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	Patisiran	Reduces production of transthyretin protein to decrease amyloid formation.	treatment_term	treatment_term	$	Patisiran	Reduces production of transthyretin protein to decrease amyloid formation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
103	95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	Inotersen	Reduces TTR protein production to limit amyloid accumulation.	treatment_term	treatment_term	$	Inotersen	Reduces TTR protein production to limit amyloid accumulation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
104	96	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	3	Liver Transplant	Considered for hereditary cases to reduce production of mutant TTR.	treatment_term	treatment_term	$	Liver Transplant	Considered for hereditary cases to reduce production of mutant TTR.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
105	97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	Heart Transplant	May be necessary for those with severe cardiomyopathy.	treatment_term	treatment_term	$	Heart Transplant	May be necessary for those with severe cardiomyopathy.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
106	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	Supportive Care	Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.	treatment_term	treatment_term	$	Supportive Care	Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
107	102	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	inheritance	0	Autosomal Dominant (de novo)	"Almost all cases arise from de novo heterozygous mutations in COL2A1, as affected individuals do not survive to reproduce. Germline mosaicism can lead to recurrence in siblings.
"	inheritance_term	inheritance_term	$	Autosomal Dominant (de novo)	"Almost all cases arise from de novo heterozygous mutations in COL2A1, as affected individuals do not survive to reproduce. Germline mosaicism can lead to recurrence in siblings.
"	Autosomal dominant inheritance	HP:0000006	Autosomal dominant inheritance		"{""preferred_term"": ""Autosomal dominant inheritance"", ""term"": {""id"": ""HP:0000006"", ""label"": ""Autosomal dominant inheritance""}}"																											
108	103	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	0	Type II Collagen Structural Defect	"Mutations in COL2A1 disrupt the triple helix structure of type II collagen, the major structural protein of cartilage. Glycine substitutions in the Gly-X-Y repeat domain prevent proper helix formation, leading to intracellular retention and degradation of abnormal procollagen chains.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
109	103	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	0	Type II Collagen Structural Defect	"Mutations in COL2A1 disrupt the triple helix structure of type II collagen, the major structural protein of cartilage. Glycine substitutions in the Gly-X-Y repeat domain prevent proper helix formation, leading to intracellular retention and degradation of abnormal procollagen chains.
"	cell_types[1]	cell_types	cell_types			Growth Plate Chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth Plate Chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
110	103	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	0	Type II Collagen Structural Defect	"Mutations in COL2A1 disrupt the triple helix structure of type II collagen, the major structural protein of cartilage. Glycine substitutions in the Gly-X-Y repeat domain prevent proper helix formation, leading to intracellular retention and degradation of abnormal procollagen chains.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
111	103	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	0	Type II Collagen Structural Defect	"Mutations in COL2A1 disrupt the triple helix structure of type II collagen, the major structural protein of cartilage. Glycine substitutions in the Gly-X-Y repeat domain prevent proper helix formation, leading to intracellular retention and degradation of abnormal procollagen chains.
"	biological_processes[1]	biological_processes	biological_processes			Cartilage Development	GO:0051216	cartilage development		"{""preferred_term"": ""Cartilage Development"", ""term"": {""id"": ""GO:0051216"", ""label"": ""cartilage development""}}"																											
112	103	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	0	Type II Collagen Structural Defect	"Mutations in COL2A1 disrupt the triple helix structure of type II collagen, the major structural protein of cartilage. Glycine substitutions in the Gly-X-Y repeat domain prevent proper helix formation, leading to intracellular retention and degradation of abnormal procollagen chains.
"	biological_processes[2]	biological_processes	biological_processes			Endochondral Bone Development	GO:0060351	cartilage development involved in endochondral bone morphogenesis		"{""preferred_term"": ""Endochondral Bone Development"", ""term"": {""id"": ""GO:0060351"", ""label"": ""cartilage development involved in endochondral bone morphogenesis""}}"																											
113	104	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	pathophysiology	1	Extracellular Matrix Deficiency	"Defective type II collagen secretion results in severely abnormal cartilage extracellular matrix. The cartilage lacks normal fibrillar architecture and fails to provide the template for endochondral ossification.
"	biological_processes[0]	biological_processes	biological_processes			ECM Organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""ECM Organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
114	106	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	0	Severe Micromelia	"Extremely shortened limbs affecting all segments, with limb length severely reduced relative to trunk.
"	phenotype_term	phenotype_term	$	Severe Micromelia	"Extremely shortened limbs affecting all segments, with limb length severely reduced relative to trunk.
"	Micromelia	HP:0002983	Micromelia		"{""preferred_term"": ""Micromelia"", ""term"": {""id"": ""HP:0002983"", ""label"": ""Micromelia""}}"																											
115	107	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	1	Deficient Vertebral Ossification	"Vertebral bodies show absent or severely deficient ossification, characteristic of the severe collagenopathy spectrum.
"	phenotype_term	phenotype_term	$	Deficient Vertebral Ossification	"Vertebral bodies show absent or severely deficient ossification, characteristic of the severe collagenopathy spectrum.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
116	108	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	2	Short Ribs	"Severely shortened ribs contributing to a small, narrow thorax and pulmonary hypoplasia.
"	phenotype_term	phenotype_term	$	Short Ribs	"Severely shortened ribs contributing to a small, narrow thorax and pulmonary hypoplasia.
"	Short ribs	HP:0000773	Short ribs		"{""preferred_term"": ""Short ribs"", ""term"": {""id"": ""HP:0000773"", ""label"": ""Short ribs""}}"																											
117	109	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	3	Hydrops Fetalis	"Fetal hydrops commonly observed, contributing to prenatal or early neonatal death.
"	phenotype_term	phenotype_term	$	Hydrops Fetalis	"Fetal hydrops commonly observed, contributing to prenatal or early neonatal death.
"	Hydrops fetalis	HP:0001789	Hydrops fetalis		"{""preferred_term"": ""Hydrops fetalis"", ""term"": {""id"": ""HP:0001789"", ""label"": ""Hydrops fetalis""}}"																											
118	110	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	4	Flat Face	"Characteristic flat facial profile with depressed nasal bridge.
"	phenotype_term	phenotype_term	$	Flat Face	"Characteristic flat facial profile with depressed nasal bridge.
"	Flat face	HP:0012368	Flat face		"{""preferred_term"": ""Flat face"", ""term"": {""id"": ""HP:0012368"", ""label"": ""Flat face""}}"																											
119	111	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	5	Micrognathia	"Small jaw contributing to the characteristic facial appearance.
"	phenotype_term	phenotype_term	$	Micrognathia	"Small jaw contributing to the characteristic facial appearance.
"	Micrognathia	HP:0000347	Micrognathia		"{""preferred_term"": ""Micrognathia"", ""term"": {""id"": ""HP:0000347"", ""label"": ""Micrognathia""}}"																											
120	112	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	6	Cleft Palate	"Cleft palate observed in some affected individuals.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Cleft palate observed in some affected individuals.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
121	113	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	phenotypes	7	Pulmonary Hypoplasia	"Underdeveloped lungs due to small thoracic cavity, the primary cause of lethality.
"	phenotype_term	phenotype_term	$	Pulmonary Hypoplasia	"Underdeveloped lungs due to small thoracic cavity, the primary cause of lethality.
"	Pulmonary hypoplasia	HP:0002089	Pulmonary hypoplasia		"{""preferred_term"": ""Pulmonary hypoplasia"", ""term"": {""id"": ""HP:0002089"", ""label"": ""Pulmonary hypoplasia""}}"																											
122	116	6	Achondroplasia	Achondroplasia.yaml	inheritance	0	Autosomal dominant	"Achondroplasia follows autosomal dominant inheritance with complete penetrance. Approximately 80% of cases arise from de novo mutations, typically in the paternal germline with advanced paternal age as a risk factor. Homozygous achondroplasia is lethal.
"	inheritance_term	inheritance_term	$	Autosomal dominant	"Achondroplasia follows autosomal dominant inheritance with complete penetrance. Approximately 80% of cases arise from de novo mutations, typically in the paternal germline with advanced paternal age as a risk factor. Homozygous achondroplasia is lethal.
"	Autosomal dominant inheritance	HP:0000006	Autosomal dominant inheritance		"{""preferred_term"": ""Autosomal dominant inheritance"", ""term"": {""id"": ""HP:0000006"", ""label"": ""Autosomal dominant inheritance""}}"																											
123	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	gene	gene	$	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	FGFR3	hgnc:3690	FGFR3	Fibroblast growth factor receptor 3, a transmembrane tyrosine kinase receptor that negatively regulates endochondral bone growth.	"{""description"": ""Fibroblast growth factor receptor 3, a transmembrane tyrosine kinase receptor that negatively regulates endochondral bone growth."", ""modifier"": ""INCREASED"", ""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"			INCREASED																								
124	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	cell_types[0]	cell_types	cell_types			Growth plate chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth plate chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
125	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	cell_types[1]	cell_types	cell_types			Hypertrophic chondrocyte	CL:0000743	hypertrophic chondrocyte		"{""preferred_term"": ""Hypertrophic chondrocyte"", ""term"": {""id"": ""CL:0000743"", ""label"": ""hypertrophic chondrocyte""}}"																											
126	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	biological_processes[0]	biological_processes	biological_processes			FGFR signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
127	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	biological_processes[1]	biological_processes	biological_processes			Endochondral ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
128	117	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling	"The FGFR3 G380R mutation causes constitutive activation of the receptor, leading to enhanced downstream signaling through STAT1, MAPK, and other pathways. This results in premature cell cycle arrest of growth plate chondrocytes, reduced chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation. The receptor normally serves as a negative regulator of bone growth; its overactivation leads to the shortened long bones characteristic of achondroplasia.
"	biological_processes[2]	biological_processes	biological_processes			Chondrocyte differentiation	GO:0002062	chondrocyte differentiation		"{""preferred_term"": ""Chondrocyte differentiation"", ""term"": {""id"": ""GO:0002062"", ""label"": ""chondrocyte differentiation""}}"																											
129	118	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	1	Impaired growth plate cartilage development	"In the growth plate, FGFR3 overactivation disrupts the normal columnar organization of chondrocytes and reduces the height of the proliferative and hypertrophic zones. This results in shortened and disorganized growth plates with reduced longitudinal bone growth, particularly affecting the long bones of the limbs (rhizomelic pattern) and the skull base (leading to foramen magnum stenosis).
"	cell_types[0]	cell_types	cell_types			Columnar chondrocyte	CL:0000744	columnar chondrocyte		"{""preferred_term"": ""Columnar chondrocyte"", ""term"": {""id"": ""CL:0000744"", ""label"": ""columnar chondrocyte""}}"																											
130	118	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	1	Impaired growth plate cartilage development	"In the growth plate, FGFR3 overactivation disrupts the normal columnar organization of chondrocytes and reduces the height of the proliferative and hypertrophic zones. This results in shortened and disorganized growth plates with reduced longitudinal bone growth, particularly affecting the long bones of the limbs (rhizomelic pattern) and the skull base (leading to foramen magnum stenosis).
"	biological_processes[0]	biological_processes	biological_processes			Growth plate chondrocyte differentiation	GO:0003418	growth plate cartilage chondrocyte differentiation		"{""preferred_term"": ""Growth plate chondrocyte differentiation"", ""term"": {""id"": ""GO:0003418"", ""label"": ""growth plate cartilage chondrocyte differentiation""}}"																											
131	118	6	Achondroplasia	Achondroplasia.yaml	pathophysiology	1	Impaired growth plate cartilage development	"In the growth plate, FGFR3 overactivation disrupts the normal columnar organization of chondrocytes and reduces the height of the proliferative and hypertrophic zones. This results in shortened and disorganized growth plates with reduced longitudinal bone growth, particularly affecting the long bones of the limbs (rhizomelic pattern) and the skull base (leading to foramen magnum stenosis).
"	biological_processes[1]	biological_processes	biological_processes			Bone development	GO:0060348	bone development		"{""preferred_term"": ""Bone development"", ""term"": {""id"": ""GO:0060348"", ""label"": ""bone development""}}"																											
132	119	6	Achondroplasia	Achondroplasia.yaml	phenotypes	0	Disproportionate short stature	"Adults with achondroplasia have an average height of approximately 131 cm (males) and 124 cm (females). The short stature is disproportionate with rhizomelic (proximal) limb shortening.
"	phenotype_term	phenotype_term	$	Disproportionate short stature	"Adults with achondroplasia have an average height of approximately 131 cm (males) and 124 cm (females). The short stature is disproportionate with rhizomelic (proximal) limb shortening.
"	Disproportionate short-limb short stature	HP:0008873	Disproportionate short-limb short stature		"{""preferred_term"": ""Disproportionate short-limb short stature"", ""term"": {""id"": ""HP:0008873"", ""label"": ""Disproportionate short-limb short stature""}}"																											
133	120	6	Achondroplasia	Achondroplasia.yaml	phenotypes	1	Rhizomelic limb shortening	"Proximal segments of the limbs (humerus and femur) are disproportionately shortened compared to middle and distal segments.
"	phenotype_term	phenotype_term	$	Rhizomelic limb shortening	"Proximal segments of the limbs (humerus and femur) are disproportionately shortened compared to middle and distal segments.
"	Rhizomelic arm shortening	HP:0004991	Rhizomelic arm shortening		"{""preferred_term"": ""Rhizomelic arm shortening"", ""term"": {""id"": ""HP:0004991"", ""label"": ""Rhizomelic arm shortening""}}"																											
134	121	6	Achondroplasia	Achondroplasia.yaml	phenotypes	2	Macrocephaly	"Enlarged head circumference with frontal bossing is characteristic. The skull base (chondrocranium) is affected by impaired endochondral ossification while the cranial vault (membranous bone) grows normally.
"	phenotype_term	phenotype_term	$	Macrocephaly	"Enlarged head circumference with frontal bossing is characteristic. The skull base (chondrocranium) is affected by impaired endochondral ossification while the cranial vault (membranous bone) grows normally.
"	Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
135	122	6	Achondroplasia	Achondroplasia.yaml	phenotypes	3	Frontal bossing	Prominent forehead due to relative overgrowth of the frontal bones.	phenotype_term	phenotype_term	$	Frontal bossing	Prominent forehead due to relative overgrowth of the frontal bones.	Frontal bossing	HP:0002007	Frontal bossing		"{""preferred_term"": ""Frontal bossing"", ""term"": {""id"": ""HP:0002007"", ""label"": ""Frontal bossing""}}"																											
136	123	6	Achondroplasia	Achondroplasia.yaml	phenotypes	4	Midface retrusion	"Hypoplasia of the midface structures due to impaired growth of the skull base, contributing to the characteristic facial appearance.
"	phenotype_term	phenotype_term	$	Midface retrusion	"Hypoplasia of the midface structures due to impaired growth of the skull base, contributing to the characteristic facial appearance.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
137	124	6	Achondroplasia	Achondroplasia.yaml	phenotypes	5	Trident hand	"Characteristic hand configuration with short fingers and increased space between the middle and ring fingers, creating a trident appearance.
"	phenotype_term	phenotype_term	$	Trident hand	"Characteristic hand configuration with short fingers and increased space between the middle and ring fingers, creating a trident appearance.
"	Trident hand	HP:0004060	Trident hand		"{""preferred_term"": ""Trident hand"", ""term"": {""id"": ""HP:0004060"", ""label"": ""Trident hand""}}"																											
138	125	6	Achondroplasia	Achondroplasia.yaml	phenotypes	6	Genu varum	"Bowing of the legs (bowlegs) is common and may worsen with weight-bearing, sometimes requiring surgical correction.
"	phenotype_term	phenotype_term	$	Genu varum	"Bowing of the legs (bowlegs) is common and may worsen with weight-bearing, sometimes requiring surgical correction.
"	Genu varum	HP:0002970	Genu varum		"{""preferred_term"": ""Genu varum"", ""term"": {""id"": ""HP:0002970"", ""label"": ""Genu varum""}}"																											
139	126	6	Achondroplasia	Achondroplasia.yaml	phenotypes	7	Lumbar hyperlordosis	"Exaggerated lumbar lordosis develops as children begin to walk, contributing to the characteristic posture.
"	phenotype_term	phenotype_term	$	Lumbar hyperlordosis	"Exaggerated lumbar lordosis develops as children begin to walk, contributing to the characteristic posture.
"	Lumbar hyperlordosis	HP:0002938	Lumbar hyperlordosis		"{""preferred_term"": ""Lumbar hyperlordosis"", ""term"": {""id"": ""HP:0002938"", ""label"": ""Lumbar hyperlordosis""}}"																											
140	127	6	Achondroplasia	Achondroplasia.yaml	treatments	0	Vosoritide (Voxzogo)	"C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.
"	treatment_term	treatment_term	$	Vosoritide (Voxzogo)	"C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.
"	Vosoritide therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Vosoritide therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
141	128	6	Achondroplasia	Achondroplasia.yaml	treatments	1	Surgical limb lengthening	"Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
"	treatment_term	treatment_term	$	Surgical limb lengthening	"Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
"	Limb lengthening surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Limb lengthening surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
142	129	6	Achondroplasia	Achondroplasia.yaml	treatments	2	Foramen magnum decompression	"Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.
"	treatment_term	treatment_term	$	Foramen magnum decompression	"Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.
"	Foramen magnum decompression	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Foramen magnum decompression"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
143	130	6	Achondroplasia	Achondroplasia.yaml	treatments	3	Management of spinal stenosis	"Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
"	treatment_term	treatment_term	$	Management of spinal stenosis	"Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
"	Spinal surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
144	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	cell_types[0]	cell_types	cell_types			Retinal Ganglion Cell	CL:0000740	retinal ganglion cell		"{""preferred_term"": ""Retinal Ganglion Cell"", ""term"": {""id"": ""CL:0000740"", ""label"": ""retinal ganglion cell""}}"																											
145	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	locations[0]	locations	locations			Visual Cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""Visual Cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
146	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	locations[1]	locations	locations			Trigeminal Ganglion	UBERON:0001675	trigeminal ganglion		"{""preferred_term"": ""Trigeminal Ganglion"", ""term"": {""id"": ""UBERON:0001675"", ""label"": ""trigeminal ganglion""}}"																											
147	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	locations[2]	locations	locations			Trigeminal Nerve	UBERON:0001645	trigeminal nerve		"{""preferred_term"": ""Trigeminal Nerve"", ""term"": {""id"": ""UBERON:0001645"", ""label"": ""trigeminal nerve""}}"																											
148	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	locations[3]	locations	locations			Retina	UBERON:0000966	retina		"{""preferred_term"": ""Retina"", ""term"": {""id"": ""UBERON:0000966"", ""label"": ""retina""}}"																											
149	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	biological_processes[0]	biological_processes	biological_processes			Visual Perception	GO:0007601	visual perception		"{""preferred_term"": ""Visual Perception"", ""term"": {""id"": ""GO:0007601"", ""label"": ""visual perception""}}"																											
150	139	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	0	Optic-Trigeminal Cross-Activation	Abrupt luminance changes activate visual pathways that cross-activate trigeminal and autonomic circuits, leading to nasal prickle and sneezing in susceptible individuals.	biological_processes[1]	biological_processes	biological_processes			Sensory Perception of Pain	GO:0019233	sensory perception of pain		"{""preferred_term"": ""Sensory Perception of Pain"", ""term"": {""id"": ""GO:0019233"", ""label"": ""sensory perception of pain""}}"																											
151	140	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	1	Parasympathetic Generalization	Light-evoked activation in parasympathetic pathways spreads to nasal secretomotor pathways, causing nasal prickle preceding the sneeze.	cell_types[0]	cell_types	cell_types			Autonomic Neuron	CL:0000107	autonomic neuron		"{""preferred_term"": ""Autonomic Neuron"", ""term"": {""id"": ""CL:0000107"", ""label"": ""autonomic neuron""}}"																											
152	140	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	1	Parasympathetic Generalization	Light-evoked activation in parasympathetic pathways spreads to nasal secretomotor pathways, causing nasal prickle preceding the sneeze.	locations[0]	locations	locations			Nasal Cavity	UBERON:0001707	nasal cavity		"{""preferred_term"": ""Nasal Cavity"", ""term"": {""id"": ""UBERON:0001707"", ""label"": ""nasal cavity""}}"																											
153	141	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	2	Central Cortical Processing	Visual cortex excitability (particularly cuneus) and co-activation of somatosensory cortices (insula and secondary somatosensory cortex) during photic sneezing suggests a centrally mediated reflex.	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
154	141	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	2	Central Cortical Processing	Visual cortex excitability (particularly cuneus) and co-activation of somatosensory cortices (insula and secondary somatosensory cortex) during photic sneezing suggests a centrally mediated reflex.	locations[0]	locations	locations			Cerebral Cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""Cerebral Cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
155	141	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	2	Central Cortical Processing	Visual cortex excitability (particularly cuneus) and co-activation of somatosensory cortices (insula and secondary somatosensory cortex) during photic sneezing suggests a centrally mediated reflex.	locations[1]	locations	locations			Insula	UBERON:0002022	insula of Rolando		"{""preferred_term"": ""Insula"", ""term"": {""id"": ""UBERON:0002022"", ""label"": ""insula of Rolando""}}"																											
156	141	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	2	Central Cortical Processing	Visual cortex excitability (particularly cuneus) and co-activation of somatosensory cortices (insula and secondary somatosensory cortex) during photic sneezing suggests a centrally mediated reflex.	biological_processes[0]	biological_processes	biological_processes			Sensory Processing	GO:0050890	cognition		"{""preferred_term"": ""Sensory Processing"", ""term"": {""id"": ""GO:0050890"", ""label"": ""cognition""}}"																											
157	142	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	3	Brainstem Sneeze Circuit	The sneeze reflex is mediated by neuromedin B (NMB) signaling from nasal sensory neurons to NMB receptor-expressing neurons in the sneeze-evoking region of the brainstem, which project to the caudal ventral respiratory group to execute the sneeze motor pattern.	cell_types[0]	cell_types	cell_types			Sensory Neuron	CL:0000101	sensory neuron		"{""preferred_term"": ""Sensory Neuron"", ""term"": {""id"": ""CL:0000101"", ""label"": ""sensory neuron""}}"																											
158	142	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	3	Brainstem Sneeze Circuit	The sneeze reflex is mediated by neuromedin B (NMB) signaling from nasal sensory neurons to NMB receptor-expressing neurons in the sneeze-evoking region of the brainstem, which project to the caudal ventral respiratory group to execute the sneeze motor pattern.	locations[0]	locations	locations			Medulla Oblongata	UBERON:0001896	medulla oblongata		"{""preferred_term"": ""Medulla Oblongata"", ""term"": {""id"": ""UBERON:0001896"", ""label"": ""medulla oblongata""}}"																											
159	142	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	3	Brainstem Sneeze Circuit	The sneeze reflex is mediated by neuromedin B (NMB) signaling from nasal sensory neurons to NMB receptor-expressing neurons in the sneeze-evoking region of the brainstem, which project to the caudal ventral respiratory group to execute the sneeze motor pattern.	locations[1]	locations	locations			Trigeminal Nucleus	UBERON:0002925	trigeminal nucleus		"{""preferred_term"": ""Trigeminal Nucleus"", ""term"": {""id"": ""UBERON:0002925"", ""label"": ""trigeminal nucleus""}}"																											
160	142	7	Achoo Syndrome	Achoo_Syndrome.yaml	pathophysiology	3	Brainstem Sneeze Circuit	The sneeze reflex is mediated by neuromedin B (NMB) signaling from nasal sensory neurons to NMB receptor-expressing neurons in the sneeze-evoking region of the brainstem, which project to the caudal ventral respiratory group to execute the sneeze motor pattern.	biological_processes[0]	biological_processes	biological_processes			Respiratory Reflex	GO:0002087	regulation of respiratory gaseous exchange by neurological system process		"{""preferred_term"": ""Respiratory Reflex"", ""term"": {""id"": ""GO:0002087"", ""label"": ""regulation of respiratory gaseous exchange by neurological system process""}}"																											
161	145	7	Achoo Syndrome	Achoo_Syndrome.yaml	phenotypes	2	Migraine	Increased odds of migraine in individuals with photic sneeze syndrome.	phenotype_term	phenotype_term	$	Migraine	Increased odds of migraine in individuals with photic sneeze syndrome.	Migraine	HP:0002076	Migraine		"{""preferred_term"": ""Migraine"", ""term"": {""id"": ""HP:0002076"", ""label"": ""Migraine""}}"																											
162	147	7	Achoo Syndrome	Achoo_Syndrome.yaml	phenotypes	4	Photophobia	Light sensitivity or intolerance to bright light, sharing trigeminal nerve involvement with the photic sneeze reflex.	phenotype_term	phenotype_term	$	Photophobia	Light sensitivity or intolerance to bright light, sharing trigeminal nerve involvement with the photic sneeze reflex.	Photophobia	HP:0000613	Photophobia		"{""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}"																											
163	150	7	Achoo Syndrome	Achoo_Syndrome.yaml	treatments	0	Sunglasses	Wearing sunglasses before exposure to bright light may prevent triggering of the reflex.	treatment_term	treatment_term	$	Sunglasses	Wearing sunglasses before exposure to bright light may prevent triggering of the reflex.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
164	154	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	0	NCT00421993	Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks.	target_phenotypes[0]	target_phenotypes	target_phenotypes			comedonal acne	HP:0040137	Comedonal acne		"{""preferred_term"": ""comedonal acne"", ""term"": {""id"": ""HP:0040137"", ""label"": ""Comedonal acne""}}"																											
165	154	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	0	NCT00421993	Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks.	target_phenotypes[1]	target_phenotypes	target_phenotypes			erythematous papule	HP:0030350	Erythematous papule		"{""preferred_term"": ""erythematous papule"", ""term"": {""id"": ""HP:0030350"", ""label"": ""Erythematous papule""}}"																											
166	154	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	0	NCT00421993	Multicenter, randomized, double-blind trial comparing adapalene/benzoyl peroxide gel with monotherapies and vehicle in acne vulgaris over 12 weeks.	target_phenotypes[2]	target_phenotypes	target_phenotypes			pustule	HP:0200039	Pustule		"{""preferred_term"": ""pustule"", ""term"": {""id"": ""HP:0200039"", ""label"": ""Pustule""}}"																											
167	155	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	1	NCT02249767	Double-blind, randomized, parallel-group study assessing tretinoin gel bioequivalence in patients with mild acne vulgaris.	target_phenotypes[0]	target_phenotypes	target_phenotypes			comedonal acne	HP:0040137	Comedonal acne		"{""preferred_term"": ""comedonal acne"", ""term"": {""id"": ""HP:0040137"", ""label"": ""Comedonal acne""}}"																											
168	155	8	Acne Vulgaris	Acne_Vulgaris.yaml	clinical_trials	1	NCT02249767	Double-blind, randomized, parallel-group study assessing tretinoin gel bioequivalence in patients with mild acne vulgaris.	target_phenotypes[1]	target_phenotypes	target_phenotypes			erythematous papule	HP:0030350	Erythematous papule		"{""preferred_term"": ""erythematous papule"", ""term"": {""id"": ""HP:0030350"", ""label"": ""Erythematous papule""}}"																											
169	157	8	Acne Vulgaris	Acne_Vulgaris.yaml	datasets	1		Spatial transcriptomics of healthy, non-lesional, comedonal, and pustular acne skin using a panel targeting sebaceous differentiation, lipid metabolism, and retinoid signaling.	organism	organism	$		Spatial transcriptomics of healthy, non-lesional, comedonal, and pustular acne skin using a panel targeting sebaceous differentiation, lipid metabolism, and retinoid signaling.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
170	158	8	Acne Vulgaris	Acne_Vulgaris.yaml	datasets	2		Spatial transcriptomics and MERFISH profiling of human facial sebaceous glands to map sebocyte differentiation stages.	organism	organism	$		Spatial transcriptomics and MERFISH profiling of human facial sebaceous glands to map sebocyte differentiation stages.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
171	159	8	Acne Vulgaris	Acne_Vulgaris.yaml	differential_diagnoses	0	PAPASH syndrome	"Autoinflammatory syndrome combining acne with pyoderma gangrenosum, hidradenitis suppurativa, and inflammatory arthritis.
"	disease_term	disease_term	$	PAPASH syndrome	"Autoinflammatory syndrome combining acne with pyoderma gangrenosum, hidradenitis suppurativa, and inflammatory arthritis.
"	PAPASH syndrome	MONDO:0958343	PAPASH syndrome		"{""preferred_term"": ""PAPASH syndrome"", ""term"": {""id"": ""MONDO:0958343"", ""label"": ""PAPASH syndrome""}}"																											
172	160	8	Acne Vulgaris	Acne_Vulgaris.yaml	differential_diagnoses	1	Rosacea	"Chronic inflammatory facial dermatosis with papules and pustules but no comedones. Central facial erythema, flushing, and telangiectasias can mimic inflammatory acne on the face.
"	disease_term	disease_term	$	Rosacea	"Chronic inflammatory facial dermatosis with papules and pustules but no comedones. Central facial erythema, flushing, and telangiectasias can mimic inflammatory acne on the face.
"	rosacea	MONDO:0006604	rosacea		"{""preferred_term"": ""rosacea"", ""term"": {""id"": ""MONDO:0006604"", ""label"": ""rosacea""}}"																											
173	161	8	Acne Vulgaris	Acne_Vulgaris.yaml	differential_diagnoses	2	Bacterial folliculitis	"Infection or inflammation of hair follicles producing papules and pustules on hair-bearing skin, often the trunk or extremities, that can resemble acne lesions but lacks comedones and is frequently pruritic.
"	disease_term	disease_term	$	Bacterial folliculitis	"Infection or inflammation of hair follicles producing papules and pustules on hair-bearing skin, often the trunk or extremities, that can resemble acne lesions but lacks comedones and is frequently pruritic.
"	folliculitis	MONDO:0006552	folliculitis		"{""preferred_term"": ""folliculitis"", ""term"": {""id"": ""MONDO:0006552"", ""label"": ""folliculitis""}}"																											
174	169	8	Acne Vulgaris	Acne_Vulgaris.yaml	infectious_agent	0	Cutibacterium acnes	Commensal skin bacterium that proliferates in occluded follicles and contributes to inflammatory acne lesions.	infectious_agent_term	infectious_agent_term	$	Cutibacterium acnes	Commensal skin bacterium that proliferates in occluded follicles and contributes to inflammatory acne lesions.	Cutibacterium acnes	NCBITaxon:1747	Cutibacterium acnes		"{""preferred_term"": ""Cutibacterium acnes"", ""term"": {""id"": ""NCBITaxon:1747"", ""label"": ""Cutibacterium acnes""}}"																											
175	170	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	0	Follicular keratinization	"Dysregulated keratinocyte differentiation and desquamation within the follicular epithelium promotes retention hyperkeratosis.
"	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
176	170	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	0	Follicular keratinization	"Dysregulated keratinocyte differentiation and desquamation within the follicular epithelium promotes retention hyperkeratosis.
"	locations[0]	locations	locations			pilosebaceous unit	UBERON:0011932	pilosebaceous unit		"{""preferred_term"": ""pilosebaceous unit"", ""term"": {""id"": ""UBERON:0011932"", ""label"": ""pilosebaceous unit""}}"																											
177	171	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	1	Microcomedone formation	"Follicular obstruction from retained keratin and sebum leads to early microcomedone development that seeds later visible comedones.
"	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
178	171	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	1	Microcomedone formation	"Follicular obstruction from retained keratin and sebum leads to early microcomedone development that seeds later visible comedones.
"	locations[0]	locations	locations			pilosebaceous unit	UBERON:0011932	pilosebaceous unit		"{""preferred_term"": ""pilosebaceous unit"", ""term"": {""id"": ""UBERON:0011932"", ""label"": ""pilosebaceous unit""}}"																											
179	172	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	2	Sebum overproduction	"Androgen and IGF-1 signaling increase sebocyte activity, elevating sebum output and creating a lipid-rich follicular environment.
"	cell_types[0]	cell_types	cell_types			sebocyte	CL:0000317	sebocyte		"{""preferred_term"": ""sebocyte"", ""term"": {""id"": ""CL:0000317"", ""label"": ""sebocyte""}}"																											
180	172	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	2	Sebum overproduction	"Androgen and IGF-1 signaling increase sebocyte activity, elevating sebum output and creating a lipid-rich follicular environment.
"	biological_processes[0]	biological_processes	biological_processes			lipid metabolism	GO:0006629	lipid metabolic process		"{""preferred_term"": ""lipid metabolism"", ""term"": {""id"": ""GO:0006629"", ""label"": ""lipid metabolic process""}}"																											
181	173	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	3	Sebum compositional change	"Altered fatty acid ratios and oxidation products within sebum contribute to comedogenesis and inflammatory signaling.
"	cell_types[0]	cell_types	cell_types			sebocyte	CL:0000317	sebocyte		"{""preferred_term"": ""sebocyte"", ""term"": {""id"": ""CL:0000317"", ""label"": ""sebocyte""}}"																											
182	173	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	3	Sebum compositional change	"Altered fatty acid ratios and oxidation products within sebum contribute to comedogenesis and inflammatory signaling.
"	biological_processes[0]	biological_processes	biological_processes			lipid metabolism	GO:0006629	lipid metabolic process		"{""preferred_term"": ""lipid metabolism"", ""term"": {""id"": ""GO:0006629"", ""label"": ""lipid metabolic process""}}"																											
183	174	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	4	C. acnes follicular colonization	"Cutibacterium acnes expands within occluded follicles and contributes to lesion progression from noninflammatory comedones to inflamed papules.
"	cell_types[0]	cell_types	cell_types			sebocyte	CL:0000317	sebocyte		"{""preferred_term"": ""sebocyte"", ""term"": {""id"": ""CL:0000317"", ""label"": ""sebocyte""}}"																											
184	174	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	4	C. acnes follicular colonization	"Cutibacterium acnes expands within occluded follicles and contributes to lesion progression from noninflammatory comedones to inflamed papules.
"	locations[0]	locations	locations			pilosebaceous unit	UBERON:0011932	pilosebaceous unit		"{""preferred_term"": ""pilosebaceous unit"", ""term"": {""id"": ""UBERON:0011932"", ""label"": ""pilosebaceous unit""}}"																											
185	175	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	5	Inflammasome activation	"Innate immune sensing activates inflammasome pathways that amplify inflammatory signaling in acne lesions.
"	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
186	175	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	5	Inflammasome activation	"Innate immune sensing activates inflammasome pathways that amplify inflammatory signaling in acne lesions.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
187	176	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	6	Cytokine-driven inflammation	"Inflammasome and innate immune activation drive cytokine release that recruits neutrophils and sustains inflammatory lesion formation.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
188	176	8	Acne Vulgaris	Acne_Vulgaris.yaml	pathophysiology	6	Cytokine-driven inflammation	"Inflammasome and innate immune activation drive cytokine release that recruits neutrophils and sustains inflammatory lesion formation.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
189	177	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	0	Comedones	"Non-inflammatory lesions including open comedones (blackheads) and closed comedones (whiteheads) resulting from follicular plugging.
"	phenotype_term	phenotype_term	$	Comedones	"Non-inflammatory lesions including open comedones (blackheads) and closed comedones (whiteheads) resulting from follicular plugging.
"	comedonal acne	HP:0040137	Comedonal acne		"{""preferred_term"": ""comedonal acne"", ""term"": {""id"": ""HP:0040137"", ""label"": ""Comedonal acne""}}"																											
190	178	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	1	Inflammatory papules	"Small, raised, erythematous lesions resulting from inflammation around occluded follicles.
"	phenotype_term	phenotype_term	$	Inflammatory papules	"Small, raised, erythematous lesions resulting from inflammation around occluded follicles.
"	erythematous papule	HP:0030350	Erythematous papule		"{""preferred_term"": ""erythematous papule"", ""term"": {""id"": ""HP:0030350"", ""label"": ""Erythematous papule""}}"																											
191	179	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	2	Pustules	"Inflamed lesions containing purulent material, representing more advanced inflammatory response.
"	phenotype_term	phenotype_term	$	Pustules	"Inflamed lesions containing purulent material, representing more advanced inflammatory response.
"	pustule	HP:0200039	Pustule		"{""preferred_term"": ""pustule"", ""term"": {""id"": ""HP:0200039"", ""label"": ""Pustule""}}"																											
192	180	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	3	Nodules and cysts	"Deep, painful lesions representing severe inflammatory acne with potential for scarring.
"	phenotype_term	phenotype_term	$	Nodules and cysts	"Deep, painful lesions representing severe inflammatory acne with potential for scarring.
"	cystic acne	HP:0033188	Cystic acne		"{""preferred_term"": ""cystic acne"", ""term"": {""id"": ""HP:0033188"", ""label"": ""Cystic acne""}}"																											
193	181	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	4	Post-inflammatory hyperpigmentation	"Darkening of skin at sites of resolved acne lesions, particularly common in individuals with darker skin tones. This sequela results from inflammatory damage to melanocytes and is a common concern in patients with skin of color.
"	phenotype_term	phenotype_term	$	Post-inflammatory hyperpigmentation	"Darkening of skin at sites of resolved acne lesions, particularly common in individuals with darker skin tones. This sequela results from inflammatory damage to melanocytes and is a common concern in patients with skin of color.
"	hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
194	182	8	Acne Vulgaris	Acne_Vulgaris.yaml	phenotypes	5	Scarring	"Permanent textural changes including atrophic (ice pick, boxcar, rolling) and hypertrophic scars resulting from severe or inadequately treated acne.
"	phenotype_term	phenotype_term	$	Scarring	"Permanent textural changes including atrophic (ice pick, boxcar, rolling) and hypertrophic scars resulting from severe or inadequately treated acne.
"	atrophic scars	HP:0001075	Atrophic scars		"{""preferred_term"": ""atrophic scars"", ""term"": {""id"": ""HP:0001075"", ""label"": ""Atrophic scars""}}"																											
195	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term	treatment_term	$	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Retinoid	NCIT:C68299	NCIT:C2259			
196	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
197	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			retinoid	NCIT:C68299	Retinoid		"{""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}"																											
198	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term	treatment_term	$	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Trifarotene	NCIT:C118577	NCIT:C2259			
199	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
200	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			trifarotene	NCIT:C118577	Trifarotene		"{""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}"																											
201	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term	treatment_term	$	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	antimicrobial agent therapy	MAXO:0001021	antimicrobial agent therapy		"{""preferred_term"": ""antimicrobial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0001021"", ""label"": ""antimicrobial agent therapy""}}"																						Benzoyl Peroxide	NCIT:C47411	NCIT:C2259			
202	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
203	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}"																											
204	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term	treatment_term	$	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																						Antibiotic	NCIT:C258	NCIT:C2259			
205	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
206	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			antibiotic	NCIT:C258	Antibiotic		"{""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}"																											
207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	treatment_term	$	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Clindamycin Phosphate; Adapalene; Benzoyl Peroxide	NCIT:C47978; NCIT:C28989; NCIT:C47411	NCIT:C2259			
208	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
209	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			clindamycin phosphate	NCIT:C47978	Clindamycin Phosphate		"{""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}"																											
210	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
211	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			adapalene	NCIT:C28989	Adapalene		"{""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}"																											
212	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
213	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}"																											
214	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term	treatment_term	$	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																						Tetracycline Antibiotic	NCIT:C1595	NCIT:C2259			
215	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
216	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tetracycline antibiotic	NCIT:C1595	Tetracycline Antibiotic		"{""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}"																											
217	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term	treatment_term	$	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Isotretinoin	NCIT:C603	NCIT:C2259			
218	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
219	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			isotretinoin	NCIT:C603	Isotretinoin		"{""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}"																											
220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	treatment_term	$	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																						Oral Contraceptive; Spironolactone	NCIT:C389; NCIT:C840	NCIT:C2259			
221	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
222	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral contraceptive	NCIT:C389	Oral Contraceptive		"{""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}"																											
223	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
224	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			spironolactone	NCIT:C840	Spironolactone		"{""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}"																											
225	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term	treatment_term	$	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																									Chemical Peel	NCIT:C93203	NCIT:C49236
226	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
227	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	treatment_term	$	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Azelaic Acid	NCIT:C47407	NCIT:C2259	Chemical Peel	NCIT:C93203	NCIT:C49236
229	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
230	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
231	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
232	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			azelaic acid	NCIT:C47407	Azelaic Acid		"{""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}"																											
233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	treatment_term	$	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Glycolic Acid; Topical Trichloroacetic Acid	NCIT:C83737; NCIT:C125002	NCIT:C2259	Chemical Peel	NCIT:C93203	NCIT:C49236
234	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
235	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
236	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
237	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			glycolic acid	NCIT:C83737	Glycolic Acid		"{""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}"																											
238	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
239	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			topical trichloroacetic acid	NCIT:C125002	Topical Trichloroacetic Acid		"{""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}"																											
240	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term	treatment_term	$	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																									Laser Therapy	NCIT:C15466	NCIT:C49236
241	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
242	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	treatment_term	$	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Vitamin C; Topical Vitamin E	NCIT:C68507; NCIT:C67081	NCIT:C2259			
244	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
245	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			vitamin C	NCIT:C68507	Vitamin C		"{""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}"																											
246	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
247	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			topical vitamin E	NCIT:C67081	Topical Vitamin E		"{""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}"																											
248	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term	treatment_term	$	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Phototherapy	NCIT:C15301	NCIT:C49236
249	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
250	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			phototherapy	NCIT:C15301	Phototherapy		"{""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}"																											
251	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term	treatment_term	$	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Phototherapy	NCIT:C15301	NCIT:C49236
252	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
253	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			phototherapy	NCIT:C15301	Phototherapy		"{""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}"																											
254	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term	treatment_term	$	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Photodynamic Therapy	NCIT:C15300	NCIT:C49236
255	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
256	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			photodynamic therapy	NCIT:C15300	Photodynamic Therapy		"{""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}"																											
257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	treatment_term	$	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Platelet-rich Plasma	NCIT:C106557	NCIT:C2259	Laser Therapy	NCIT:C15466	NCIT:C49236
258	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
259	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
260	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
261	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			platelet-rich plasma	NCIT:C106557	Platelet-rich Plasma		"{""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}"																											
262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	treatment_term	$	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																									Laser Therapy; Infrared Laser Therapy	NCIT:C15466; NCIT:C66918	NCIT:C49236
263	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
264	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
265	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
266	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			infrared laser therapy	NCIT:C66918	Infrared Laser Therapy		"{""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}"																											
267	206	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	diagnosis	0	HIV Antibody Test		diagnosis_term	diagnosis_term	$	HIV Antibody Test		serology testing	MAXO:0000609	serology testing		"{""preferred_term"": ""serology testing"", ""term"": {""id"": ""MAXO:0000609"", ""label"": ""serology testing""}}"																											
268	207	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	diagnosis	1	HIV Viral Load Test		diagnosis_term	diagnosis_term	$	HIV Viral Load Test		clinical quantitative reverse transcription PCR testing	MAXO:0000594	clinical quantitative reverse transcription PCR testing		"{""preferred_term"": ""clinical quantitative reverse transcription PCR testing"", ""term"": {""id"": ""MAXO:0000594"", ""label"": ""clinical quantitative reverse transcription PCR testing""}}"																											
269	217	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	infectious_agent	0	Human Immunodeficiency Virus (HIV)		infectious_agent_term	infectious_agent_term	$	Human Immunodeficiency Virus (HIV)		Human immunodeficiency virus 1	NCBITaxon:11676	Human immunodeficiency virus 1		"{""preferred_term"": ""Human immunodeficiency virus 1"", ""term"": {""id"": ""NCBITaxon:11676"", ""label"": ""Human immunodeficiency virus 1""}}"																											
270	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	cell_types[0]	cell_types	cell_types			CD4 T-lymphocyte	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4 T-lymphocyte"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
271	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	biological_processes[0]	biological_processes	biological_processes			reverse transcription	GO:0001171	reverse transcription		"{""preferred_term"": ""reverse transcription"", ""term"": {""id"": ""GO:0001171"", ""label"": ""reverse transcription""}}"																											
272	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	biological_processes[1]	biological_processes	biological_processes			DNA integration	GO:0015074	DNA integration		"{""preferred_term"": ""DNA integration"", ""term"": {""id"": ""GO:0015074"", ""label"": ""DNA integration""}}"																											
273	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	biological_processes[2]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
274	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	genes[0]	genes	genes			CD4	hgnc:1678	CD4		"{""preferred_term"": ""CD4"", ""term"": {""id"": ""hgnc:1678"", ""label"": ""CD4""}}"																											
275	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	genes[1]	genes	genes			CCR5	hgnc:1606	CCR5		"{""preferred_term"": ""CCR5"", ""term"": {""id"": ""hgnc:1606"", ""label"": ""CCR5""}}"																											
276	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	genes[2]	genes	genes			CXCR4	hgnc:2561	CXCR4		"{""preferred_term"": ""CXCR4"", ""term"": {""id"": ""hgnc:2561"", ""label"": ""CXCR4""}}"																											
277	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
278	218	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	0	CD4 T-cell Depletion	HIV infects and destroys CD4 T-cells, critical for immune system function.	locations[1]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
279	219	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	1	Immune System Collapse	Progressive loss of CD4 T-cells leads to severe immunodeficiency.	cell_types[0]	cell_types	cell_types			CD4 T-lymphocyte	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4 T-lymphocyte"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
280	220	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	2	Opportunistic Infections	Impaired immunity allows opportunistic pathogens to cause infections.	biological_processes[0]	biological_processes	biological_processes			pyroptotic inflammatory response	GO:0070269	pyroptotic inflammatory response		"{""preferred_term"": ""pyroptotic inflammatory response"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptotic inflammatory response""}}"																											
281	221	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	3	CNS Reservoir and Neuroinflammation	HIV invades the CNS early, establishing persistent reservoirs in microglia and macrophages that contribute to neuroinflammation and neurocognitive impairment.	cell_types[0]	cell_types	cell_types			microglia	CL:0000129	microglial cell		"{""preferred_term"": ""microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
282	221	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	3	CNS Reservoir and Neuroinflammation	HIV invades the CNS early, establishing persistent reservoirs in microglia and macrophages that contribute to neuroinflammation and neurocognitive impairment.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
283	221	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	3	CNS Reservoir and Neuroinflammation	HIV invades the CNS early, establishing persistent reservoirs in microglia and macrophages that contribute to neuroinflammation and neurocognitive impairment.	genes[0]	genes	genes			SAMHD1	hgnc:15925	SAMHD1		"{""preferred_term"": ""SAMHD1"", ""term"": {""id"": ""hgnc:15925"", ""label"": ""SAMHD1""}}"																											
284	221	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	3	CNS Reservoir and Neuroinflammation	HIV invades the CNS early, establishing persistent reservoirs in microglia and macrophages that contribute to neuroinflammation and neurocognitive impairment.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
285	222	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	4	Host Restriction Factor Defense	Multiple host restriction factors inhibit HIV replication through distinct molecular mechanisms, but are counteracted by viral accessory proteins (Vif, Vpu, Nef).	genes[0]	genes	genes			APOBEC3G	hgnc:17357	APOBEC3G		"{""preferred_term"": ""APOBEC3G"", ""term"": {""id"": ""hgnc:17357"", ""label"": ""APOBEC3G""}}"																											
286	222	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	4	Host Restriction Factor Defense	Multiple host restriction factors inhibit HIV replication through distinct molecular mechanisms, but are counteracted by viral accessory proteins (Vif, Vpu, Nef).	genes[1]	genes	genes			TRIM5	hgnc:16276	TRIM5		"{""preferred_term"": ""TRIM5"", ""term"": {""id"": ""hgnc:16276"", ""label"": ""TRIM5""}}"																											
287	222	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	4	Host Restriction Factor Defense	Multiple host restriction factors inhibit HIV replication through distinct molecular mechanisms, but are counteracted by viral accessory proteins (Vif, Vpu, Nef).	genes[2]	genes	genes			BST2	hgnc:1119	BST2		"{""preferred_term"": ""BST2"", ""term"": {""id"": ""hgnc:1119"", ""label"": ""BST2""}}"																											
288	222	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	4	Host Restriction Factor Defense	Multiple host restriction factors inhibit HIV replication through distinct molecular mechanisms, but are counteracted by viral accessory proteins (Vif, Vpu, Nef).	genes[3]	genes	genes			SERINC5	hgnc:18825	SERINC5		"{""preferred_term"": ""SERINC5"", ""term"": {""id"": ""hgnc:18825"", ""label"": ""SERINC5""}}"																											
289	222	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	4	Host Restriction Factor Defense	Multiple host restriction factors inhibit HIV replication through distinct molecular mechanisms, but are counteracted by viral accessory proteins (Vif, Vpu, Nef).	biological_processes[0]	biological_processes	biological_processes			defense response to virus	GO:0051607	defense response to virus		"{""preferred_term"": ""defense response to virus"", ""term"": {""id"": ""GO:0051607"", ""label"": ""defense response to virus""}}"																											
290	223	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	pathophysiology	5	AIDS-related Cancers	Weakened immune surveillance increases risk of certain cancers.	biological_processes[0]	biological_processes	biological_processes			immune response to tumor cell	GO:0002418	immune response to tumor cell		"{""modifier"": ""DECREASED"", ""preferred_term"": ""immune response to tumor cell"", ""term"": {""id"": ""GO:0002418"", ""label"": ""immune response to tumor cell""}}"			DECREASED																								
291	224	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	0	Pneumocystis Pneumonia		phenotype_term	phenotype_term	$	Pneumocystis Pneumonia		Pneumocystis jirovecii pneumonia	HP:0020102	Pneumocystis jirovecii pneumonia		"{""preferred_term"": ""Pneumocystis jirovecii pneumonia"", ""term"": {""id"": ""HP:0020102"", ""label"": ""Pneumocystis jirovecii pneumonia""}}"																											
292	225	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	1	Candidiasis		phenotype_term	phenotype_term	$	Candidiasis		Recurrent candida infections	HP:0005401	Recurrent candida infections		"{""preferred_term"": ""Recurrent candida infections"", ""term"": {""id"": ""HP:0005401"", ""label"": ""Recurrent candida infections""}}"																											
293	226	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	2	Kaposi Sarcoma		phenotype_term	phenotype_term	$	Kaposi Sarcoma		Kaposi's sarcoma	HP:0100726	Kaposi's sarcoma		"{""preferred_term"": ""Kaposi's sarcoma"", ""term"": {""id"": ""HP:0100726"", ""label"": ""Kaposi's sarcoma""}}"																											
294	227	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	3	HIV-associated Dementia		phenotype_term	phenotype_term	$	HIV-associated Dementia		Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
295	228	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	4	Lymphopenia		phenotype_term	phenotype_term	$	Lymphopenia		Decreased total lymphocyte count	HP:0001888	Decreased total lymphocyte count		"{""preferred_term"": ""Decreased total lymphocyte count"", ""term"": {""id"": ""HP:0001888"", ""label"": ""Decreased total lymphocyte count""}}"																											
296	229	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	phenotypes	5	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
297	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	Antiretroviral Therapy	Combination of drugs that suppress HIV replication and preserve immune function.	treatment_term	treatment_term	$	Antiretroviral Therapy	Combination of drugs that suppress HIV replication and preserve immune function.	antiretroviral therapy	MAXO:0000573	antiretroviral therapy		"{""preferred_term"": ""antiretroviral therapy"", ""term"": {""id"": ""MAXO:0000573"", ""label"": ""antiretroviral therapy""}}"																											
298	236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	Prophylaxis for Opportunistic Infections	Preventive treatments to reduce risk of common opportunistic infections.	treatment_term	treatment_term	$	Prophylaxis for Opportunistic Infections	Preventive treatments to reduce risk of common opportunistic infections.	preventative therapy	MAXO:0000017	preventative therapy		"{""preferred_term"": ""preventative therapy"", ""term"": {""id"": ""MAXO:0000017"", ""label"": ""preventative therapy""}}"																											
299	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	Treatment of Opportunistic Infections	Specific therapies targeting diagnosed opportunistic infections.	treatment_term	treatment_term	$	Treatment of Opportunistic Infections	Specific therapies targeting diagnosed opportunistic infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
300	243	10	Addison's Disease	Addisons_Disease.yaml	environmental	0	Infections		exposure_term	exposure_term	$	Infections		Infectious agent exposure	ECTO:3000000	exposure to organism		"{""preferred_term"": ""Infectious agent exposure"", ""term"": {""id"": ""ECTO:3000000"", ""label"": ""exposure to organism""}}"																											
301	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta cytotoxic T cell	CL:0000794	CD8-positive, alpha-beta cytotoxic T cell		"{""preferred_term"": ""CD8-positive, alpha-beta cytotoxic T cell"", ""term"": {""id"": ""CL:0000794"", ""label"": ""CD8-positive, alpha-beta cytotoxic T cell""}}"																											
302	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	cell_types[1]	cell_types	cell_types			T-helper 1 cell	CL:0000545	T-helper 1 cell		"{""preferred_term"": ""T-helper 1 cell"", ""term"": {""id"": ""CL:0000545"", ""label"": ""T-helper 1 cell""}}"																											
303	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	cell_types[2]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
304	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	biological_processes[0]	biological_processes	biological_processes			adaptive immune response	GO:0002250	adaptive immune response		"{""preferred_term"": ""adaptive immune response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
305	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	biological_processes[1]	biological_processes	biological_processes			T cell mediated cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T cell mediated cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
306	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	biological_processes[2]	biological_processes	biological_processes			type 1 immune response	GO:0042093	type 1 immune response		"{""preferred_term"": ""type 1 immune response"", ""term"": {""id"": ""GO:0042093"", ""label"": ""type 1 immune response""}}"																											
307	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	biological_processes[3]	biological_processes	biological_processes			antigen processing and presentation of peptide antigen via MHC class II	GO:0002495	antigen processing and presentation of peptide antigen via MHC class II		"{""preferred_term"": ""antigen processing and presentation of peptide antigen via MHC class II"", ""term"": {""id"": ""GO:0002495"", ""label"": ""antigen processing and presentation of peptide antigen via MHC class II""}}"																											
308	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	locations[0]	locations	locations			adrenal cortex	UBERON:0001235	adrenal cortex		"{""preferred_term"": ""adrenal cortex"", ""term"": {""id"": ""UBERON:0001235"", ""label"": ""adrenal cortex""}}"																											
309	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	locations[1]	locations	locations			zona glomerulosa of adrenal gland	UBERON:0002104	zona glomerulosa of adrenal gland		"{""preferred_term"": ""zona glomerulosa of adrenal gland"", ""term"": {""id"": ""UBERON:0002104"", ""label"": ""zona glomerulosa of adrenal gland""}}"																											
310	254	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	0	Autoimmune Adrenalitis	The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.	locations[2]	locations	locations			zona fasciculata of adrenal gland	UBERON:0002105	zona fasciculata of adrenal gland		"{""preferred_term"": ""zona fasciculata of adrenal gland"", ""term"": {""id"": ""UBERON:0002105"", ""label"": ""zona fasciculata of adrenal gland""}}"																											
311	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[0]	biological_processes	biological_processes			glucocorticoid biosynthetic process	GO:0006704	glucocorticoid biosynthetic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""glucocorticoid biosynthetic process"", ""term"": {""id"": ""GO:0006704"", ""label"": ""glucocorticoid biosynthetic process""}}"			DECREASED																								
312	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[1]	biological_processes	biological_processes			gluconeogenesis	GO:0006094	gluconeogenesis		"{""modifier"": ""DECREASED"", ""preferred_term"": ""gluconeogenesis"", ""term"": {""id"": ""GO:0006094"", ""label"": ""gluconeogenesis""}}"			DECREASED																								
313	255	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	1	Reduced Cortisol Production	Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.	biological_processes[2]	biological_processes	biological_processes			response to stress	GO:0006950	response to stress		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to stress"", ""term"": {""id"": ""GO:0006950"", ""label"": ""response to stress""}}"			ABNORMAL																								
314	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[0]	biological_processes	biological_processes			mineralocorticoid biosynthetic process	GO:0006705	mineralocorticoid biosynthetic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""mineralocorticoid biosynthetic process"", ""term"": {""id"": ""GO:0006705"", ""label"": ""mineralocorticoid biosynthetic process""}}"			DECREASED																								
315	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[1]	biological_processes	biological_processes			sodium ion transport	GO:0006814	sodium ion transport		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""sodium ion transport"", ""term"": {""id"": ""GO:0006814"", ""label"": ""sodium ion transport""}}"			ABNORMAL																								
316	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	biological_processes[2]	biological_processes	biological_processes			potassium ion transport	GO:0006813	potassium ion transport		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""potassium ion transport"", ""term"": {""id"": ""GO:0006813"", ""label"": ""potassium ion transport""}}"			ABNORMAL																								
317	256	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	2	Reduced Aldosterone Production	Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.	locations[0]	locations	locations			zona glomerulosa of adrenal gland	UBERON:0002104	zona glomerulosa of adrenal gland		"{""preferred_term"": ""zona glomerulosa of adrenal gland"", ""term"": {""id"": ""UBERON:0002104"", ""label"": ""zona glomerulosa of adrenal gland""}}"																											
318	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[0]	genes	genes			HLA-DRB1				"{""preferred_term"": ""HLA-DRB1""}"																											
319	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[1]	genes	genes			HLA-DQA1				"{""preferred_term"": ""HLA-DQA1""}"																											
320	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[2]	genes	genes			HLA-DQB1				"{""preferred_term"": ""HLA-DQB1""}"																											
321	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[3]	genes	genes			CTLA4	hgnc:2505	CTLA4		"{""preferred_term"": ""CTLA4"", ""term"": {""id"": ""hgnc:2505"", ""label"": ""CTLA4""}}"																											
322	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[4]	genes	genes			PTPN22	hgnc:9652	PTPN22		"{""preferred_term"": ""PTPN22"", ""term"": {""id"": ""hgnc:9652"", ""label"": ""PTPN22""}}"																											
323	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[5]	genes	genes			BACH2	hgnc:936	BACH2		"{""preferred_term"": ""BACH2"", ""term"": {""id"": ""hgnc:936"", ""label"": ""BACH2""}}"																											
324	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[6]	genes	genes			CLEC16A	hgnc:26922	CLEC16A		"{""preferred_term"": ""CLEC16A"", ""term"": {""id"": ""hgnc:26922"", ""label"": ""CLEC16A""}}"																											
325	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[7]	genes	genes			NLRP1	hgnc:22861	NLRP1		"{""preferred_term"": ""NLRP1"", ""term"": {""id"": ""hgnc:22861"", ""label"": ""NLRP1""}}"																											
326	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[8]	genes	genes			CIITA	hgnc:1752	CIITA		"{""preferred_term"": ""CIITA"", ""term"": {""id"": ""hgnc:1752"", ""label"": ""CIITA""}}"																											
327	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	genes[9]	genes	genes			STAT4	hgnc:11365	STAT4		"{""preferred_term"": ""STAT4"", ""term"": {""id"": ""hgnc:11365"", ""label"": ""STAT4""}}"																											
328	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[0]	biological_processes	biological_processes			negative regulation of T cell receptor signaling pathway	GO:0050860	negative regulation of T cell receptor signaling pathway		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""negative regulation of T cell receptor signaling pathway"", ""term"": {""id"": ""GO:0050860"", ""label"": ""negative regulation of T cell receptor signaling pathway""}}"			ABNORMAL																								
329	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[1]	biological_processes	biological_processes			antigen processing and presentation	GO:0019882	antigen processing and presentation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""antigen processing and presentation"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"			ABNORMAL																								
330	257	10	Addison's Disease	Addisons_Disease.yaml	pathophysiology	3	Polygenic Susceptibility	Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.	biological_processes[2]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"			INCREASED																								
331	258	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	0	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
332	259	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	1	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
333	260	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	2	Hyperpigmentation		phenotype_term	phenotype_term	$	Hyperpigmentation		Hyperpigmentation	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
334	261	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	3	Muscle Weakness		phenotype_term	phenotype_term	$	Muscle Weakness		Muscle weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
335	262	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	4	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
336	263	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	5	Hypotension		phenotype_term	phenotype_term	$	Hypotension		Hypotension	HP:0002615	Hypotension		"{""preferred_term"": ""Hypotension"", ""term"": {""id"": ""HP:0002615"", ""label"": ""Hypotension""}}"																											
337	264	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	6	Salt Craving		phenotype_term	phenotype_term	$	Salt Craving		Salt Craving	HP:0030083	Salt craving		"{""preferred_term"": ""Salt Craving"", ""term"": {""id"": ""HP:0030083"", ""label"": ""Salt craving""}}"																											
338	265	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	7	Hypoglycemia		phenotype_term	phenotype_term	$	Hypoglycemia		Hypoglycemia	HP:0001943	Hypoglycemia		"{""preferred_term"": ""Hypoglycemia"", ""term"": {""id"": ""HP:0001943"", ""label"": ""Hypoglycemia""}}"																											
339	266	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	8	Hyponatremia		phenotype_term	phenotype_term	$	Hyponatremia		Hyponatremia	HP:0002902	Hyponatremia		"{""preferred_term"": ""Hyponatremia"", ""term"": {""id"": ""HP:0002902"", ""label"": ""Hyponatremia""}}"																											
340	267	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	9	Hyperkalemia		phenotype_term	phenotype_term	$	Hyperkalemia		Hyperkalemia	HP:0002153	Hyperkalemia		"{""preferred_term"": ""Hyperkalemia"", ""term"": {""id"": ""HP:0002153"", ""label"": ""Hyperkalemia""}}"																											
341	269	10	Addison's Disease	Addisons_Disease.yaml	phenotypes	11	Nausea and Vomiting		phenotype_term	phenotype_term	$	Nausea and Vomiting		Nausea and vomiting	HP:0002017	Nausea and vomiting		"{""preferred_term"": ""Nausea and vomiting"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
342	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	Glucocorticoid Replacement	Hydrocortisone or prednisone to replace cortisol.	treatment_term	treatment_term	$	Glucocorticoid Replacement	Hydrocortisone or prednisone to replace cortisol.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
343	273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	Mineralocorticoid Replacement	Fludrocortisone to replace aldosterone and manage electrolyte balance.	treatment_term	treatment_term	$	Mineralocorticoid Replacement	Fludrocortisone to replace aldosterone and manage electrolyte balance.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
344	274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	Salt Supplementation	Increased salt intake to manage hyponatremia.	treatment_term	treatment_term	$	Salt Supplementation	Increased salt intake to manage hyponatremia.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
345	275	10	Addison's Disease	Addisons_Disease.yaml	treatments	3	Emergency Medical ID	Patients should carry an ID indicating their condition for emergency situations.	treatment_term	treatment_term	$	Emergency Medical ID	Patients should carry an ID indicating their condition for emergency situations.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
346	276	10	Addison's Disease	Addisons_Disease.yaml	treatments	4	Stress Dose Adjustments	Increased dose of corticosteroids during illness or stress.	treatment_term	treatment_term	$	Stress Dose Adjustments	Increased dose of corticosteroids during illness or stress.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
347	288	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	histopathology	0	T-Cell Lymphoproliferative Neoplasm	Adult T-cell lymphoma/leukemia is a rare T-cell lymphoproliferative neoplasm.	finding_term	finding_term	$	T-Cell Lymphoproliferative Neoplasm	Adult T-cell lymphoma/leukemia is a rare T-cell lymphoproliferative neoplasm.	Adult T-Cell Leukemia/Lymphoma	NCIT:C3184	Adult T-Cell Leukemia/Lymphoma		"{""preferred_term"": ""Adult T-Cell Leukemia/Lymphoma"", ""term"": {""id"": ""NCIT:C3184"", ""label"": ""Adult T-Cell Leukemia/Lymphoma""}}"																											
348	289	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	infectious_agent	0	Human T-Lymphotropic Virus Type 1 (HTLV-1)	HTLV-1 is a deltaretrovirus that infects CD4+ T cells. Transmission occurs through breastfeeding, sexual contact, blood transfusion, and injection drug use. After infection, HTLV-1 integrates into the host genome and establishes lifelong persistent infection. The viral Tax protein is the major transforming factor, activating NF-kappaB, inducing genomic instability, and promoting T-cell proliferation. HBZ (HTLV-1 basic leucine zipper factor) expressed from the antisense strand also contributes to leukemogenesis.	infectious_agent_term	infectious_agent_term	$	Human T-Lymphotropic Virus Type 1 (HTLV-1)	HTLV-1 is a deltaretrovirus that infects CD4+ T cells. Transmission occurs through breastfeeding, sexual contact, blood transfusion, and injection drug use. After infection, HTLV-1 integrates into the host genome and establishes lifelong persistent infection. The viral Tax protein is the major transforming factor, activating NF-kappaB, inducing genomic instability, and promoting T-cell proliferation. HBZ (HTLV-1 basic leucine zipper factor) expressed from the antisense strand also contributes to leukemogenesis.	Human T-cell leukemia virus type I	NCBITaxon:11908	Human T-cell leukemia virus type I		"{""preferred_term"": ""Human T-cell leukemia virus type I"", ""term"": {""id"": ""NCBITaxon:11908"", ""label"": ""Human T-cell leukemia virus type I""}}"																											
349	290	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	0	HTLV-1 Infection and Tax Oncoprotein Expression	HTLV-1 preferentially infects CD4+ T cells and integrates into the host genome. The viral Tax protein is the primary driver of transformation, functioning as a transcriptional activator that hijacks multiple cellular pathways. Tax activates NF-kappaB, CREB/ATF, and AP-1 transcription factors, driving T-cell proliferation and survival.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
350	290	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	0	HTLV-1 Infection and Tax Oncoprotein Expression	HTLV-1 preferentially infects CD4+ T cells and integrates into the host genome. The viral Tax protein is the primary driver of transformation, functioning as a transcriptional activator that hijacks multiple cellular pathways. Tax activates NF-kappaB, CREB/ATF, and AP-1 transcription factors, driving T-cell proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			viral transcription	GO:0019083	viral transcription		"{""preferred_term"": ""viral transcription"", ""term"": {""id"": ""GO:0019083"", ""label"": ""viral transcription""}}"																											
351	291	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	1	Tax-Mediated NF-kappaB Activation	Tax activates both canonical and non-canonical NF-kappaB pathways through direct interaction with IKK complex and NIK. Constitutive NF-kappaB activation drives expression of anti-apoptotic genes (BCL-XL, cIAP, survivin), cytokines (IL-2, IL-15), and cell cycle regulators, promoting T-cell survival and proliferation.	biological_processes[0]	biological_processes	biological_processes			positive regulation of NF-kappaB transcription factor activity	GO:0051092	positive regulation of NF-kappaB transcription factor activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of NF-kappaB transcription factor activity"", ""term"": {""id"": ""GO:0051092"", ""label"": ""positive regulation of NF-kappaB transcription factor activity""}}"			INCREASED																								
352	292	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	2	Genomic Instability and Accumulation of Mutations	Tax impairs multiple DNA repair pathways including nucleotide excision repair, base excision repair, and double-strand break repair. This leads to accumulation of somatic mutations over the decades-long latency period. Tax also causes aneuploidy through centrosome amplification and mitotic checkpoint dysfunction.	biological_processes[0]	biological_processes	biological_processes			DNA damage response	GO:0006974	DNA damage response		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""DNA damage response""}}"			DECREASED																								
353	293	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	3	Apoptosis Resistance	Multiple mechanisms contribute to apoptosis resistance: NF-kappaB-mediated upregulation of BCL-XL and cIAP, Tax-mediated p53 inhibition, and HBZ-mediated enhancement of regulatory T-cell survival. This allows accumulation of cells with genomic abnormalities.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
354	294	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	4	Uncontrolled T-Cell Proliferation	Combined effects of constitutive NF-kappaB activation, accumulated mutations, and apoptosis resistance result in clonal expansion of HTLV-1-infected T cells. ATLL cells acquire a CD4+CD25+FOXP3+ regulatory T-cell phenotype with immunosuppressive properties.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
355	294	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	pathophysiology	4	Uncontrolled T-Cell Proliferation	Combined effects of constitutive NF-kappaB activation, accumulated mutations, and apoptosis resistance result in clonal expansion of HTLV-1-infected T cells. ATLL cells acquire a CD4+CD25+FOXP3+ regulatory T-cell phenotype with immunosuppressive properties.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
356	295	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	0	Leukocytosis	"Elevated white blood cell count with characteristic ""flower cells"" showing multilobated nuclei. Peripheral blood involvement is prominent in acute and chronic forms."	phenotype_term	phenotype_term	$	Leukocytosis	"Elevated white blood cell count with characteristic ""flower cells"" showing multilobated nuclei. Peripheral blood involvement is prominent in acute and chronic forms."	Increased total leukocyte count	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Increased total leukocyte count"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
357	296	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	1	Lymphadenopathy	Generalized lymphadenopathy is common, particularly prominent in lymphoma-type ATLL.	phenotype_term	phenotype_term	$	Lymphadenopathy	Generalized lymphadenopathy is common, particularly prominent in lymphoma-type ATLL.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
358	297	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	2	Hypercalcemia	Hypercalcemia occurs in up to 70% of acute ATLL cases due to ATLL cell production of PTHrP (parathyroid hormone-related protein) and osteoclast- activating cytokines. Can be severe and life-threatening.	phenotype_term	phenotype_term	$	Hypercalcemia	Hypercalcemia occurs in up to 70% of acute ATLL cases due to ATLL cell production of PTHrP (parathyroid hormone-related protein) and osteoclast- activating cytokines. Can be severe and life-threatening.	Hypercalcemia	HP:0003072	Hypercalcemia		"{""preferred_term"": ""Hypercalcemia"", ""term"": {""id"": ""HP:0003072"", ""label"": ""Hypercalcemia""}}"																											
359	298	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	3	Skin Lesions	Skin involvement with erythematous papules, nodules, plaques, or erythroderma. Prominent in smoldering and chronic forms. May resemble mycosis fungoides.	phenotype_term	phenotype_term	$	Skin Lesions	Skin involvement with erythematous papules, nodules, plaques, or erythroderma. Prominent in smoldering and chronic forms. May resemble mycosis fungoides.	Abnormal skin morphology	HP:0011121	Abnormal skin morphology		"{""preferred_term"": ""Abnormal skin morphology"", ""term"": {""id"": ""HP:0011121"", ""label"": ""Abnormal skin morphology""}}"																											
360	299	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	4	Hepatomegaly	Liver enlargement from leukemic infiltration, common in acute ATLL.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from leukemic infiltration, common in acute ATLL.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
361	300	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	5	Splenomegaly	Splenic enlargement from leukemic infiltration.	phenotype_term	phenotype_term	$	Splenomegaly	Splenic enlargement from leukemic infiltration.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
362	301	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	phenotypes	6	Opportunistic Infections	ATLL cells have regulatory T-cell properties causing profound immunosuppression. Opportunistic infections including Pneumocystis, Strongyloides, and fungal infections are common and major causes of death.	phenotype_term	phenotype_term	$	Opportunistic Infections	ATLL cells have regulatory T-cell properties causing profound immunosuppression. Opportunistic infections including Pneumocystis, Strongyloides, and fungal infections are common and major causes of death.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
363	302	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	0	Chemotherapy	Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.	treatment_term	treatment_term	$	Chemotherapy	Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
364	303	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	1	Mogamulizumab	Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.	treatment_term	treatment_term	$	Mogamulizumab	Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
365	304	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
366	305	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	3	Interferon-alpha and Zidovudine	Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.	treatment_term	treatment_term	$	Interferon-alpha and Zidovudine	Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
367	309	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	environmental	0	Aflatoxin B1 Exposure	Aflatoxin B1 (AFB1) is produced by Aspergillus flavus and A. parasiticus fungi that contaminate corn, peanuts, and other crops during storage in warm, humid conditions. After ingestion, AFB1 is metabolized in the liver to a highly reactive epoxide that forms DNA adducts, preferentially at the third position of codon 249 in TP53, causing the characteristic G>T transversion (R249S mutation).	exposure_term	exposure_term	$	Aflatoxin B1 Exposure	Aflatoxin B1 (AFB1) is produced by Aspergillus flavus and A. parasiticus fungi that contaminate corn, peanuts, and other crops during storage in warm, humid conditions. After ingestion, AFB1 is metabolized in the liver to a highly reactive epoxide that forms DNA adducts, preferentially at the third position of codon 249 in TP53, causing the characteristic G>T transversion (R249S mutation).	exposure to aflatoxin	ECTO:0001108	exposure to aflatoxin		"{""preferred_term"": ""exposure to aflatoxin"", ""term"": {""id"": ""ECTO:0001108"", ""label"": ""exposure to aflatoxin""}}"																											
368	313	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	histopathology	0	Hepatocellular Carcinoma	Hepatocellular carcinoma is the most common primary liver malignancy.	finding_term	finding_term	$	Hepatocellular Carcinoma	Hepatocellular carcinoma is the most common primary liver malignancy.	Hepatocellular Carcinoma	NCIT:C3099	Hepatocellular Carcinoma		"{""preferred_term"": ""Hepatocellular Carcinoma"", ""term"": {""id"": ""NCIT:C3099"", ""label"": ""Hepatocellular Carcinoma""}}"																											
369	314	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	infectious_agent	0	Hepatitis B Virus (HBV)	Chronic HBV infection is a major cofactor in aflatoxin-related HCC, with synergistic interaction dramatically increasing cancer risk. HBV contributes through chronic inflammation, hepatocyte regeneration, HBx protein effects, and viral DNA integration. The combination of HBV and aflatoxin exposure increases HCC risk approximately 60-fold compared to unexposed individuals.	infectious_agent_term	infectious_agent_term	$	Hepatitis B Virus (HBV)	Chronic HBV infection is a major cofactor in aflatoxin-related HCC, with synergistic interaction dramatically increasing cancer risk. HBV contributes through chronic inflammation, hepatocyte regeneration, HBx protein effects, and viral DNA integration. The combination of HBV and aflatoxin exposure increases HCC risk approximately 60-fold compared to unexposed individuals.	Hepatitis B virus	NCBITaxon:10407	Hepatitis B virus		"{""preferred_term"": ""Hepatitis B virus"", ""term"": {""id"": ""NCBITaxon:10407"", ""label"": ""Hepatitis B virus""}}"																											
370	315	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	0	Aflatoxin B1 Metabolic Activation	AFB1 is absorbed from the gut and transported to the liver where it undergoes cytochrome P450-mediated oxidation (primarily CYP3A4 and CYP1A2) to form AFB1-8,9-epoxide, a highly reactive electrophile. This epoxide binds covalently to DNA, forming pro-mutagenic adducts primarily at guanine residues.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
371	315	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	0	Aflatoxin B1 Metabolic Activation	AFB1 is absorbed from the gut and transported to the liver where it undergoes cytochrome P450-mediated oxidation (primarily CYP3A4 and CYP1A2) to form AFB1-8,9-epoxide, a highly reactive electrophile. This epoxide binds covalently to DNA, forming pro-mutagenic adducts primarily at guanine residues.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
372	316	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	1	TP53 R249S Hotspot Mutation	The aflatoxin-DNA adduct forms preferentially at the third position of codon 249 in TP53, causing a G>T transversion that results in arginine-to-serine substitution (R249S). This mutation is found in approximately 50% of HCCs in high-aflatoxin regions but is rare in low-exposure areas. The R249S mutation impairs p53 DNA binding and transcriptional activity, eliminating its tumor suppressor function.	biological_processes[0]	biological_processes	biological_processes			DNA damage response	GO:0006974	DNA damage response		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""DNA damage response""}}"			DECREASED																								
373	317	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	2	HBV-Aflatoxin Synergistic Interaction	HBV and aflatoxin interact synergistically through multiple mechanisms: HBV-induced chronic inflammation increases hepatocyte proliferation, allowing fixation of aflatoxin-induced mutations; HBx protein inhibits DNA repair; and viral integration may disrupt tumor suppressor genes. The multiplicative interaction results in approximately 60-fold increased HCC risk compared to unexposed individuals.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
374	318	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	3	Loss of Cell Cycle Checkpoint Control	TP53 R249S mutation combined with HBx-mediated p53 inhibition and Rb pathway inactivation results in loss of cell cycle checkpoint control. Cells with DNA damage continue to proliferate, accumulating additional mutations.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
375	319	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	4	Apoptosis Resistance	Loss of functional p53 impairs the intrinsic apoptotic pathway in response to DNA damage. Combined with HBV-associated survival signals, this allows accumulation of cells with oncogenic mutations.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
376	320	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	5	Uncontrolled Hepatocyte Proliferation	The combination of impaired checkpoints, apoptosis resistance, chronic inflammation, and hepatocyte regeneration drives clonal expansion of transformed cells, eventually leading to HCC development.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
377	320	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	pathophysiology	5	Uncontrolled Hepatocyte Proliferation	The combination of impaired checkpoints, apoptosis resistance, chronic inflammation, and hepatocyte regeneration drives clonal expansion of transformed cells, eventually leading to HCC development.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
378	321	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	0	Abdominal Pain	Right upper quadrant pain from hepatic capsule stretching or tumor necrosis.	phenotype_term	phenotype_term	$	Abdominal Pain	Right upper quadrant pain from hepatic capsule stretching or tumor necrosis.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
379	322	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	1	Weight Loss	Unintentional weight loss from cancer cachexia and decreased appetite.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss from cancer cachexia and decreased appetite.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
380	323	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	2	Hepatomegaly	Liver enlargement, often palpable, from tumor mass. May be nodular on examination.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement, often palpable, from tumor mass. May be nodular on examination.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
381	324	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	3	Fatigue	Profound fatigue from advanced malignancy and often underlying liver dysfunction.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue from advanced malignancy and often underlying liver dysfunction.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
382	325	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	4	Jaundice	Jaundice may develop from biliary obstruction or hepatic failure in advanced disease.	phenotype_term	phenotype_term	$	Jaundice	Jaundice may develop from biliary obstruction or hepatic failure in advanced disease.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
383	326	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	phenotypes	5	Ascites	Ascites develops from portal hypertension and hypoalbuminemia in advanced disease.	phenotype_term	phenotype_term	$	Ascites	Ascites develops from portal hypertension and hypoalbuminemia in advanced disease.	Ascites	HP:0001541	Ascites		"{""preferred_term"": ""Ascites"", ""term"": {""id"": ""HP:0001541"", ""label"": ""Ascites""}}"																											
384	327	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	0	Surgical Resection	Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations.	treatment_term	treatment_term	$	Surgical Resection	Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
385	328	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	1	Liver Transplantation	Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability.	treatment_term	treatment_term	$	Liver Transplantation	Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
386	329	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	2	Locoregional Therapy	Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease.	treatment_term	treatment_term	$	Locoregional Therapy	Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
387	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term	treatment_term	$	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}]}"				sorafenib	CHEBI:50924																						
388	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sorafenib	CHEBI:50924	sorafenib		"{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}"																											
389	331	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	4	Aflatoxin Exposure Prevention	Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction.	treatment_term	treatment_term	$	Aflatoxin Exposure Prevention	Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
390	346	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	pathophysiology	0	Drusen Accumulation	"Lipid and protein deposits accumulate between retinal pigment epithelium and Bruch's membrane. Drusen indicate RPE dysfunction and are early hallmark of AMD.
"	cell_types[0]	cell_types	cell_types			Retinal Pigment Epithelial Cell	CL:0002586	retinal pigment epithelial cell		"{""preferred_term"": ""Retinal Pigment Epithelial Cell"", ""term"": {""id"": ""CL:0002586"", ""label"": ""retinal pigment epithelial cell""}}"																											
391	347	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	pathophysiology	1	RPE Dysfunction and Loss	"Oxidative stress, lipofuscin accumulation, and inflammation damage RPE cells. RPE loss leads to photoreceptor death and geographic atrophy in dry AMD.
"	biological_processes[0]	biological_processes	biological_processes			Oxidative Stress Response	GO:0006979	response to oxidative stress		"{""preferred_term"": ""Oxidative Stress Response"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
392	348	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	pathophysiology	2	Complement Dysregulation	"Excessive complement activation in the macula contributes to chronic inflammation and tissue damage. CFH variants are major genetic risk factor.
"	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
393	349	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	pathophysiology	3	Choroidal Neovascularization	"In wet AMD, VEGF-driven abnormal blood vessel growth from choroid invades through Bruch's membrane. These fragile vessels leak and bleed, causing rapid vision loss.
"	biological_processes[0]	biological_processes	biological_processes			Angiogenesis	GO:0001525	angiogenesis		"{""preferred_term"": ""Angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"																											
394	350	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	phenotypes	0	Central Vision Loss		phenotype_term	phenotype_term	$	Central Vision Loss		Central Vision Loss	HP:0000551	Color vision defect		"{""preferred_term"": ""Central Vision Loss"", ""term"": {""id"": ""HP:0000551"", ""label"": ""Color vision defect""}}"																											
395	351	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	phenotypes	1	Metamorphopsia		phenotype_term	phenotype_term	$	Metamorphopsia		Visual Distortion	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual Distortion"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
396	352	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	phenotypes	2	Difficulty Reading		phenotype_term	phenotype_term	$	Difficulty Reading		Reading Difficulty	HP:0000505	Visual impairment		"{""preferred_term"": ""Reading Difficulty"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
397	353	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	phenotypes	3	Scotoma		phenotype_term	phenotype_term	$	Scotoma		Central Scotoma	HP:0001123	Visual field defect		"{""preferred_term"": ""Central Scotoma"", ""term"": {""id"": ""HP:0001123"", ""label"": ""Visual field defect""}}"																											
398	354	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	phenotypes	4	Decreased Contrast Sensitivity		phenotype_term	phenotype_term	$	Decreased Contrast Sensitivity		Reduced Contrast Sensitivity	HP:0000505	Visual impairment		"{""preferred_term"": ""Reduced Contrast Sensitivity"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
399	361	14	Ainhum	Ainhum.yaml	diagnosis	0	Radiographic examination of the feet	Radiography aids early diagnosis and staging.	diagnosis_term	diagnosis_term	$	Radiographic examination of the feet	Radiography aids early diagnosis and staging.	radiograph imaging procedure	MAXO:0000595	radiograph imaging procedure		"{""preferred_term"": ""radiograph imaging procedure"", ""term"": {""id"": ""MAXO:0000595"", ""label"": ""radiograph imaging procedure""}}"																											
400	363	14	Ainhum	Ainhum.yaml	differential_diagnoses	1	Vohwinkel syndrome	Hereditary keratoderma with ainhumoid constriction bands that can mimic true ainhum.	disease_term	disease_term	$	Vohwinkel syndrome	Hereditary keratoderma with ainhumoid constriction bands that can mimic true ainhum.	Vohwinkel syndrome	MONDO:0007422	keratoderma hereditarium mutilans		"{""preferred_term"": ""Vohwinkel syndrome"", ""term"": {""id"": ""MONDO:0007422"", ""label"": ""keratoderma hereditarium mutilans""}}"																											
401	364	14	Ainhum	Ainhum.yaml	differential_diagnoses	2	Olmsted syndrome	Mutilating palmoplantar keratoderma with ainhum and digital autoamputation.	disease_term	disease_term	$	Olmsted syndrome	Mutilating palmoplantar keratoderma with ainhum and digital autoamputation.	Olmsted syndrome	MONDO:0031421	Olmsted syndrome		"{""preferred_term"": ""Olmsted syndrome"", ""term"": {""id"": ""MONDO:0031421"", ""label"": ""Olmsted syndrome""}}"																											
402	365	14	Ainhum	Ainhum.yaml	differential_diagnoses	3	Critical limb ischemia	Critical limb ischemia can cause spontaneous sub-amputation and may mimic advanced ainhum.	disease_term	disease_term	$	Critical limb ischemia	Critical limb ischemia can cause spontaneous sub-amputation and may mimic advanced ainhum.	limb ischemia	MONDO:0000491	limb ischemia		"{""preferred_term"": ""limb ischemia"", ""term"": {""id"": ""MONDO:0000491"", ""label"": ""limb ischemia""}}"																											
403	366	14	Ainhum	Ainhum.yaml	pathophysiology	0	Constricting groove forms around proximal toe	A groove or fissure of constricting tissue develops around a toe, most often the fifth toe.	locations[0]	locations	locations			pedal digit 5	UBERON:0003635	pedal digit 5		"{""preferred_term"": ""pedal digit 5"", ""term"": {""id"": ""UBERON:0003635"", ""label"": ""pedal digit 5""}}"																											
404	370	14	Ainhum	Ainhum.yaml	phenotypes	0	Digital constriction ring	Constricting ring encircles the affected digit.	phenotype_term	phenotype_term	$	Digital constriction ring	Constricting ring encircles the affected digit.	Digital constriction ring	HP:0010491	Digital constriction ring		"{""preferred_term"": ""Digital constriction ring"", ""term"": {""id"": ""HP:0010491"", ""label"": ""Digital constriction ring""}}"																											
405	371	14	Ainhum	Ainhum.yaml	phenotypes	1	Osteolysis	Resorption of phalanges is seen in affected digits.	phenotype_term	phenotype_term	$	Osteolysis	Resorption of phalanges is seen in affected digits.	Osteolysis	HP:0002797	Osteolysis		"{""preferred_term"": ""Osteolysis"", ""term"": {""id"": ""HP:0002797"", ""label"": ""Osteolysis""}}"																											
406	372	14	Ainhum	Ainhum.yaml	phenotypes	2	Autoamputation of digits	Progressive constriction leads to autoamputation of the affected digit.	phenotype_term	phenotype_term	$	Autoamputation of digits	Progressive constriction leads to autoamputation of the affected digit.	Autoamputation of digits	HP:0007460	Autoamputation of digits		"{""located_in"": {""preferred_term"": ""toe"", ""term"": {""id"": ""UBERON:0001466"", ""label"": ""pedal digit""}}, ""preferred_term"": ""Autoamputation of digits"", ""term"": {""id"": ""HP:0007460"", ""label"": ""Autoamputation of digits""}}"	pedal digit	UBERON:0001466																									
407	372	14	Ainhum	Ainhum.yaml	phenotypes	2	Autoamputation of digits	Progressive constriction leads to autoamputation of the affected digit.	phenotype_term.located_in	phenotype_term	phenotype_term			toe	UBERON:0001466	pedal digit		"{""preferred_term"": ""toe"", ""term"": {""id"": ""UBERON:0001466"", ""label"": ""pedal digit""}}"																											
408	373	14	Ainhum	Ainhum.yaml	phenotypes	3	Skin ulcer	Ainhum can present with foot ulceration.	phenotype_term	phenotype_term	$	Skin ulcer	Ainhum can present with foot ulceration.	Skin ulcer	HP:0200042	Skin ulcer		"{""preferred_term"": ""Skin ulcer"", ""term"": {""id"": ""HP:0200042"", ""label"": ""Skin ulcer""}}"																											
409	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term	treatment_term	$	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																			Excision	NCIT:C15232	NCIT:C15329						
410	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
411	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
412	377	15	Akinetopsia	Akinetopsia.yaml	differential_diagnoses	0	Parkinson's disease	Parkinson's disease can present with visual illusions including akinetopsia, and should be considered when evaluating motion blindness.	disease_term	disease_term	$	Parkinson's disease	Parkinson's disease can present with visual illusions including akinetopsia, and should be considered when evaluating motion blindness.	Parkinson disease	MONDO:0005180	Parkinson disease		"{""preferred_term"": ""Parkinson disease"", ""term"": {""id"": ""MONDO:0005180"", ""label"": ""Parkinson disease""}}"																											
413	378	15	Akinetopsia	Akinetopsia.yaml	differential_diagnoses	1	Posterior cortical atrophy	Posterior cortical atrophy (visual-variant Alzheimer's disease) can present with higher visual processing deficits including akinetopsia.	disease_term	disease_term	$	Posterior cortical atrophy	Posterior cortical atrophy (visual-variant Alzheimer's disease) can present with higher visual processing deficits including akinetopsia.	posterior cortical atrophy	MONDO:0018899	posterior cortical atrophy		"{""preferred_term"": ""posterior cortical atrophy"", ""term"": {""id"": ""MONDO:0018899"", ""label"": ""posterior cortical atrophy""}}"																											
414	379	15	Akinetopsia	Akinetopsia.yaml	differential_diagnoses	2	Occipital or occipito-parietal infarction (stroke)	Occipital or occipito-parietal infarction can present with visual disorders including akinetopsia and should be considered in the differential.	disease_term	disease_term	$	Occipital or occipito-parietal infarction (stroke)	Occipital or occipito-parietal infarction can present with visual disorders including akinetopsia and should be considered in the differential.	stroke disorder	MONDO:0005098	stroke disorder		"{""preferred_term"": ""stroke disorder"", ""term"": {""id"": ""MONDO:0005098"", ""label"": ""stroke disorder""}}"																											
415	386	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	0	V5/MT motion-processing cortex dysfunction	The disorder reflects disruption of cortical area V5/MT, a key node for visual motion perception, leading to failure of normal motion integration.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
416	386	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	0	V5/MT motion-processing cortex dysfunction	The disorder reflects disruption of cortical area V5/MT, a key node for visual motion perception, leading to failure of normal motion integration.	locations[0]	locations	locations			visual cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""visual cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
417	386	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	0	V5/MT motion-processing cortex dysfunction	The disorder reflects disruption of cortical area V5/MT, a key node for visual motion perception, leading to failure of normal motion integration.	locations[1]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
418	387	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	1	Left V5/MT susceptibility to acute interference	In right-handed individuals, left V5/MT appears particularly susceptible to acute interference during experimental disruption, implicating hemispheric vulnerability in motion perception.	locations[0]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
419	388	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	2	Right-hemispheric V5/MT predominance in clinical cases	Clinical cases more often involve right-hemispheric V5/MT afflictions, suggesting dominance of the right V5/MT in motion perception.	locations[0]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
420	389	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	3	Severity depends on surviving motion network components and stimulus speed	The severity of motion blindness depends on remaining components of the visual motion network and the speed of moving objects.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
421	389	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	3	Severity depends on surviving motion network components and stimulus speed	The severity of motion blindness depends on remaining components of the visual motion network and the speed of moving objects.	locations[0]	locations	locations			visual cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""visual cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
422	389	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	3	Severity depends on surviving motion network components and stimulus speed	The severity of motion blindness depends on remaining components of the visual motion network and the speed of moving objects.	locations[1]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
423	390	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	4	Structural neurological damage to motion network	Structural neurological conditions such as stroke or neurodegenerative disease most often underlie akinetopsia by damaging cortical motion processing regions.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
424	390	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	4	Structural neurological damage to motion network	Structural neurological conditions such as stroke or neurodegenerative disease most often underlie akinetopsia by damaging cortical motion processing regions.	locations[0]	locations	locations			visual cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""visual cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
425	390	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	4	Structural neurological damage to motion network	Structural neurological conditions such as stroke or neurodegenerative disease most often underlie akinetopsia by damaging cortical motion processing regions.	locations[1]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
426	391	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	5	Paroxysmal or intoxication-related cortical dysfunction	A subset of cases arise from transient cortical dysfunction due to intoxications or paroxysmal neurological disorders such as epilepsy.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
427	391	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	5	Paroxysmal or intoxication-related cortical dysfunction	A subset of cases arise from transient cortical dysfunction due to intoxications or paroxysmal neurological disorders such as epilepsy.	locations[0]	locations	locations			visual cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""visual cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
428	391	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	5	Paroxysmal or intoxication-related cortical dysfunction	A subset of cases arise from transient cortical dysfunction due to intoxications or paroxysmal neurological disorders such as epilepsy.	locations[1]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
429	392	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	6	Epileptic hyperexcitability of MT/V5 cortex	Paroxysmal hyperexcitability in right temporal and parietal cortices, including MT/V5, can trigger akinetopsia episodes.	locations[0]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
430	393	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	7	Induced disruption from TMS or medications	Akinetopsia can be induced by transcranial magnetic stimulation or certain medications, implying reversible disruption of motion-processing circuits.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
431	393	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	7	Induced disruption from TMS or medications	Akinetopsia can be induced by transcranial magnetic stimulation or certain medications, implying reversible disruption of motion-processing circuits.	locations[0]	locations	locations			visual cortex	UBERON:0000411	visual cortex		"{""preferred_term"": ""visual cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
432	393	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	7	Induced disruption from TMS or medications	Akinetopsia can be induced by transcranial magnetic stimulation or certain medications, implying reversible disruption of motion-processing circuits.	locations[1]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
433	394	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	8	Bilateral V5/MT lesions	Bilateral injury to V5/MT within the secondary visual cortex disrupts motion-processing circuitry.	locations[0]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
434	395	15	Akinetopsia	Akinetopsia.yaml	pathophysiology	9	Global akinetopsia with chronic course	Global motion blindness with chronicity most often occurs when V5/MT is affected bilaterally.	locations[0]	locations	locations			secondary visual cortex	UBERON:0022232	secondary visual cortex		"{""preferred_term"": ""secondary visual cortex"", ""term"": {""id"": ""UBERON:0022232"", ""label"": ""secondary visual cortex""}}"																											
435	396	15	Akinetopsia	Akinetopsia.yaml	phenotypes	0	Visual motion blindness with freeze-frame perception	Moving objects are perceived as disjointed jumps or freeze frames rather than smooth continuous motion.	phenotype_term	phenotype_term	$	Visual motion blindness with freeze-frame perception	Moving objects are perceived as disjointed jumps or freeze frames rather than smooth continuous motion.	Visual agnosia	HP:0030222	Visual agnosia		"{""preferred_term"": ""Visual agnosia"", ""term"": {""id"": ""HP:0030222"", ""label"": ""Visual agnosia""}}"																											
436	397	15	Akinetopsia	Akinetopsia.yaml	phenotypes	1	Hemiakinetopsia	Motion blindness restricted to one hemifield of vision in a subset of clinical cases.	phenotype_term	phenotype_term	$	Hemiakinetopsia	Motion blindness restricted to one hemifield of vision in a subset of clinical cases.	Visual field defect	HP:0001123	Visual field defect		"{""preferred_term"": ""Visual field defect"", ""term"": {""id"": ""HP:0001123"", ""label"": ""Visual field defect""}}"																											
437	399	15	Akinetopsia	Akinetopsia.yaml	treatments	0	Treat underlying condition	Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.	treatment_term	treatment_term	$	Treat underlying condition	Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.	medical action	MAXO:0000001	medical action		"{""preferred_term"": ""medical action"", ""term"": {""id"": ""MAXO:0000001"", ""label"": ""medical action""}}"																											
438	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term	treatment_term	$	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}]}"				carbamazepine	CHEBI:3387																						
439	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			carbamazepine	CHEBI:3387	carbamazepine		"{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}"																											
440	401	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	datasets	0		Single-cell RNA sequencing of liver tissue from patients with alcoholic liver disease.	organism	organism	$		Single-cell RNA sequencing of liver tissue from patients with alcoholic liver disease.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
441	401	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	datasets	0		Single-cell RNA sequencing of liver tissue from patients with alcoholic liver disease.	sample_types[0]	sample_types	sample_types			liver tissue				"{""preferred_term"": ""liver tissue"", ""tissue_term"": {""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}}"																											
442	401	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	datasets	0		Single-cell RNA sequencing of liver tissue from patients with alcoholic liver disease.	sample_types[0].tissue_term	sample_types	sample_types[0]			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
443	402	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	pathophysiology	0	Alcohol metabolism and cellular stress	Alcohol metabolism and cellular stress cause hepatocyte and immune cell injury with cytokine and chemokine production.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
444	402	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	pathophysiology	0	Alcohol metabolism and cellular stress	Alcohol metabolism and cellular stress cause hepatocyte and immune cell injury with cytokine and chemokine production.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
445	403	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	pathophysiology	1	Gut-liver axis and endotoxin translocation	Ethanol damages the intestinal barrier, releasing endotoxins that contribute to ALD pathogenesis.	biological_processes[0]	biological_processes	biological_processes			response to lipopolysaccharide	GO:0032496	response to lipopolysaccharide		"{""preferred_term"": ""response to lipopolysaccharide"", ""term"": {""id"": ""GO:0032496"", ""label"": ""response to lipopolysaccharide""}}"																											
446	404	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	phenotypes	0	Hepatic steatosis	Early fatty liver injury in alcohol-associated liver disease.	phenotype_term	phenotype_term	$	Hepatic steatosis	Early fatty liver injury in alcohol-associated liver disease.	Hepatic steatosis	HP:0001397	Hepatic steatosis		"{""preferred_term"": ""Hepatic steatosis"", ""term"": {""id"": ""HP:0001397"", ""label"": ""Hepatic steatosis""}}"																											
447	405	16	Alcoholic Liver Disease	Alcoholic_Liver_Disease.yaml	phenotypes	1	Hepatic fibrosis	Fibrosis developing from chronic inflammatory injury.	phenotype_term	phenotype_term	$	Hepatic fibrosis	Fibrosis developing from chronic inflammatory injury.	Hepatic fibrosis	HP:0001395	Hepatic fibrosis		"{""preferred_term"": ""Hepatic fibrosis"", ""term"": {""id"": ""HP:0001395"", ""label"": ""Hepatic fibrosis""}}"																											
448	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	cell_types[0]	cell_types	cell_types			Neurons	CL:0000540	neuron		"{""preferred_term"": ""Neurons"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
449	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	cell_types[1]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
450	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	cell_types[2]	cell_types	cell_types			Astrocytes	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocytes"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
451	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	biological_processes[0]	biological_processes	biological_processes			Protein misfolding	GO:0006457	protein folding		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Protein misfolding"", ""term"": {""id"": ""GO:0006457"", ""label"": ""protein folding""}}"			ABNORMAL																								
452	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	biological_processes[1]	biological_processes	biological_processes			Aggregation	GO:0034205	amyloid-beta formation		"{""preferred_term"": ""Aggregation"", ""term"": {""id"": ""GO:0034205"", ""label"": ""amyloid-beta formation""}}"																											
453	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	biological_processes[2]	biological_processes	biological_processes			Neuroinflammation	GO:0150076	neuroinflammatory response		"{""preferred_term"": ""Neuroinflammation"", ""term"": {""id"": ""GO:0150076"", ""label"": ""neuroinflammatory response""}}"																											
454	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	locations[0]	locations	locations			Cerebral Cortex				"{""preferred_term"": ""Cerebral Cortex""}"																											
455	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	locations[1]	locations	locations			Hippocampus				"{""preferred_term"": ""Hippocampus""}"																											
456	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	locations[2]	locations	locations			Subcortical Regions				"{""preferred_term"": ""Subcortical Regions""}"																											
457	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	chemical_entities[0]	chemical_entities	chemical_entities			Amyloid-beta peptides (A40, A42)				"{""preferred_term"": ""Amyloid-beta peptides (A40, A42)""}"																											
458	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	genes[0]	genes	genes			APP	hgnc:620	APP		"{""preferred_term"": ""APP"", ""term"": {""id"": ""hgnc:620"", ""label"": ""APP""}}"																											
459	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	genes[1]	genes	genes			PSEN1	hgnc:9508	PSEN1		"{""preferred_term"": ""PSEN1"", ""term"": {""id"": ""hgnc:9508"", ""label"": ""PSEN1""}}"																											
460	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	genes[2]	genes	genes			PSEN2	hgnc:9509	PSEN2		"{""preferred_term"": ""PSEN2"", ""term"": {""id"": ""hgnc:9509"", ""label"": ""PSEN2""}}"																											
461	420	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	0	Amyloid Plaque Formation	Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.	pathways[0]	pathways	pathways			Amyloid precursor protein processing	GO:0042982	amyloid precursor protein metabolic process		"{""preferred_term"": ""Amyloid precursor protein processing"", ""term"": {""id"": ""GO:0042982"", ""label"": ""amyloid precursor protein metabolic process""}}"																											
462	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	cell_types[0]	cell_types	cell_types			Neurons	CL:0000540	neuron		"{""preferred_term"": ""Neurons"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
463	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	biological_processes[0]	biological_processes	biological_processes			Protein hyperphosphorylation	GO:0006468	protein phosphorylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Protein hyperphosphorylation"", ""term"": {""id"": ""GO:0006468"", ""label"": ""protein phosphorylation""}}"			INCREASED																								
464	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	biological_processes[1]	biological_processes	biological_processes			Microtubule destabilization	GO:0007019	microtubule depolymerization		"{""preferred_term"": ""Microtubule destabilization"", ""term"": {""id"": ""GO:0007019"", ""label"": ""microtubule depolymerization""}}"																											
465	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	locations[0]	locations	locations			Entorhinal Cortex				"{""preferred_term"": ""Entorhinal Cortex""}"																											
466	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	locations[1]	locations	locations			Hippocampus				"{""preferred_term"": ""Hippocampus""}"																											
467	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	locations[2]	locations	locations			Neocortex				"{""preferred_term"": ""Neocortex""}"																											
468	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	chemical_entities[0]	chemical_entities	chemical_entities			Tau protein				"{""preferred_term"": ""Tau protein""}"																											
469	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	genes[0]	genes	genes			MAPT	hgnc:6893	MAPT		"{""preferred_term"": ""MAPT"", ""term"": {""id"": ""hgnc:6893"", ""label"": ""MAPT""}}"																											
470	421	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.	pathways[0]	pathways	pathways			Tau phosphorylation cascade	GO:0006468	protein phosphorylation		"{""preferred_term"": ""Tau phosphorylation cascade"", ""term"": {""id"": ""GO:0006468"", ""label"": ""protein phosphorylation""}}"																											
471	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	cell_types[0]	cell_types	cell_types			Neurons	CL:0000540	neuron		"{""preferred_term"": ""Neurons"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
472	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	biological_processes[0]	biological_processes	biological_processes			Neurotransmitter release	GO:0007269	neurotransmitter secretion		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Neurotransmitter release"", ""term"": {""id"": ""GO:0007269"", ""label"": ""neurotransmitter secretion""}}"			DECREASED																								
473	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	biological_processes[1]	biological_processes	biological_processes			Synaptic plasticity	GO:0048167	regulation of synaptic plasticity		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Synaptic plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"			DECREASED																								
474	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	locations[0]	locations	locations			Synapses				"{""preferred_term"": ""Synapses""}"																											
475	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	locations[1]	locations	locations			Neuronal dendrites				"{""preferred_term"": ""Neuronal dendrites""}"																											
476	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	chemical_entities[0]	chemical_entities	chemical_entities			Acetylcholine	CHEBI:15355	acetylcholine		"{""preferred_term"": ""Acetylcholine"", ""term"": {""id"": ""CHEBI:15355"", ""label"": ""acetylcholine""}}"																											
477	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	chemical_entities[1]	chemical_entities	chemical_entities			Glutamate	CHEBI:14321	glutamate(1-)		"{""preferred_term"": ""Glutamate"", ""term"": {""id"": ""CHEBI:14321"", ""label"": ""glutamate(1-)""}}"																											
478	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	chemical_entities[2]	chemical_entities	chemical_entities			GABA	CHEBI:16865	gamma-aminobutyric acid		"{""preferred_term"": ""GABA"", ""term"": {""id"": ""CHEBI:16865"", ""label"": ""gamma-aminobutyric acid""}}"																											
479	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	pathways[0]	pathways	pathways			Synaptic vesicle recycling	GO:0099504	synaptic vesicle cycle		"{""preferred_term"": ""Synaptic vesicle recycling"", ""term"": {""id"": ""GO:0099504"", ""label"": ""synaptic vesicle cycle""}}"																											
480	422	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.	pathways[1]	pathways	pathways			Neurotransmitter receptor signaling	GO:0050804	modulation of chemical synaptic transmission		"{""preferred_term"": ""Neurotransmitter receptor signaling"", ""term"": {""id"": ""GO:0050804"", ""label"": ""modulation of chemical synaptic transmission""}}"																											
481	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	cell_types[0]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
482	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	cell_types[1]	cell_types	cell_types			Astrocytes	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocytes"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
483	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	biological_processes[0]	biological_processes	biological_processes			Immune activation	GO:0002253	activation of immune response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Immune activation"", ""term"": {""id"": ""GO:0002253"", ""label"": ""activation of immune response""}}"			INCREASED																								
484	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	biological_processes[1]	biological_processes	biological_processes			Cytokine production	GO:0001816	cytokine production		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Cytokine production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"			INCREASED																								
485	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	biological_processes[2]	biological_processes	biological_processes			Phagocytosis	GO:0006909	phagocytosis		"{""preferred_term"": ""Phagocytosis"", ""term"": {""id"": ""GO:0006909"", ""label"": ""phagocytosis""}}"																											
486	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	chemical_entities[0]	chemical_entities	chemical_entities			Cytokines				"{""preferred_term"": ""Cytokines""}"																											
487	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	chemical_entities[1]	chemical_entities	chemical_entities			Chemokines				"{""preferred_term"": ""Chemokines""}"																											
488	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	chemical_entities[2]	chemical_entities	chemical_entities			Complement proteins				"{""preferred_term"": ""Complement proteins""}"																											
489	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	pathways[0]	pathways	pathways			NF-B signaling	GO:0007249	canonical NF-kappaB signal transduction		"{""preferred_term"": ""NF-B signaling"", ""term"": {""id"": ""GO:0007249"", ""label"": ""canonical NF-kappaB signal transduction""}}"																											
490	423	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	3	Neuroinflammation	Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.	pathways[1]	pathways	pathways			NLRP3 inflammasome activation	GO:0044546	NLRP3 inflammasome complex assembly		"{""preferred_term"": ""NLRP3 inflammasome activation"", ""term"": {""id"": ""GO:0044546"", ""label"": ""NLRP3 inflammasome complex assembly""}}"																											
491	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	biological_processes[0]	biological_processes	biological_processes			Free radical production	GO:1903409	reactive oxygen species biosynthetic process		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Free radical production"", ""term"": {""id"": ""GO:1903409"", ""label"": ""reactive oxygen species biosynthetic process""}}"			INCREASED																								
492	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	biological_processes[1]	biological_processes	biological_processes			Antioxidant defense	GO:0006979	response to oxidative stress		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Antioxidant defense"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"			DECREASED																								
493	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	cellular_components[0]	cellular_components	cellular_components			Mitochondria	GO:0005739	mitochondrion		"{""preferred_term"": ""Mitochondria"", ""term"": {""id"": ""GO:0005739"", ""label"": ""mitochondrion""}}"																											
494	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	cellular_components[1]	cellular_components	cellular_components			Cell membranes	GO:0005886	plasma membrane		"{""preferred_term"": ""Cell membranes"", ""term"": {""id"": ""GO:0005886"", ""label"": ""plasma membrane""}}"																											
495	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	chemical_entities[0]	chemical_entities	chemical_entities			Reactive oxygen species (ROS)	CHEBI:26523	reactive oxygen species		"{""preferred_term"": ""Reactive oxygen species (ROS)"", ""term"": {""id"": ""CHEBI:26523"", ""label"": ""reactive oxygen species""}}"																											
496	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	chemical_entities[1]	chemical_entities	chemical_entities			Reactive nitrogen species (RNS)	CHEBI:62764	reactive nitrogen species		"{""preferred_term"": ""Reactive nitrogen species (RNS)"", ""term"": {""id"": ""CHEBI:62764"", ""label"": ""reactive nitrogen species""}}"																											
497	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	pathways[0]	pathways	pathways			Mitochondrial electron transport chain	GO:0022904	respiratory electron transport chain		"{""preferred_term"": ""Mitochondrial electron transport chain"", ""term"": {""id"": ""GO:0022904"", ""label"": ""respiratory electron transport chain""}}"																											
498	424	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	4	Oxidative Stress	Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.	pathways[1]	pathways	pathways			NADPH oxidase activation				"{""preferred_term"": ""NADPH oxidase activation""}"																											
499	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	cell_types[0]	cell_types	cell_types			Endothelial cells	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial cells"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
500	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	cell_types[1]	cell_types	cell_types			Pericytes	CL:0000669	pericyte		"{""preferred_term"": ""Pericytes"", ""term"": {""id"": ""CL:0000669"", ""label"": ""pericyte""}}"																											
501	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	biological_processes[0]	biological_processes	biological_processes			Blood-brain barrier regulation	GO:1905603	regulation of blood-brain barrier permeability		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""Blood-brain barrier regulation"", ""term"": {""id"": ""GO:1905603"", ""label"": ""regulation of blood-brain barrier permeability""}}"			DYSREGULATED																								
502	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	biological_processes[1]	biological_processes	biological_processes			Cerebral blood flow	GO:0120275	cerebral blood circulation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Cerebral blood flow"", ""term"": {""id"": ""GO:0120275"", ""label"": ""cerebral blood circulation""}}"			DECREASED																								
503	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	locations[0]	locations	locations			Cerebral blood vessels				"{""preferred_term"": ""Cerebral blood vessels""}"																											
504	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	locations[1]	locations	locations			Blood-brain barrier				"{""preferred_term"": ""Blood-brain barrier""}"																											
505	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	pathways[0]	pathways	pathways			Neurovascular coupling				"{""preferred_term"": ""Neurovascular coupling""}"																											
506	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	pathways[1]	pathways	pathways			Perivascular drainage				"{""preferred_term"": ""Perivascular drainage""}"																											
507	425	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	5	Vascular Dysfunction	Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.	genes[0]	genes	genes			LRP1	hgnc:6692	LRP1		"{""preferred_term"": ""LRP1"", ""term"": {""id"": ""hgnc:6692"", ""label"": ""LRP1""}}"																											
508	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	cell_types[0]	cell_types	cell_types			Neurons	CL:0000540	neuron		"{""preferred_term"": ""Neurons"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
509	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[0]	biological_processes	biological_processes			Autophagy	GO:0006914	autophagy		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"			DECREASED																								
510	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[1]	biological_processes	biological_processes			Lysosomal degradation	GO:0007041	lysosomal transport		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Lysosomal degradation"", ""term"": {""id"": ""GO:0007041"", ""label"": ""lysosomal transport""}}"			DECREASED																								
511	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	biological_processes[2]	biological_processes	biological_processes			Protein catabolic process	GO:0030163	protein catabolic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Protein catabolic process"", ""term"": {""id"": ""GO:0030163"", ""label"": ""protein catabolic process""}}"			DECREASED																								
512	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	locations[0]	locations	locations			Hippocampus				"{""preferred_term"": ""Hippocampus""}"																											
513	426	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	pathophysiology	6	Autophagy-Lysosomal Dysfunction	Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.	locations[1]	locations	locations			Cerebral Cortex				"{""preferred_term"": ""Cerebral Cortex""}"																											
514	427	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	phenotypes	0	Memory Loss		phenotype_term	phenotype_term	$	Memory Loss		Memory impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
515	428	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	phenotypes	1	Executive Dysfunction		phenotype_term	phenotype_term	$	Executive Dysfunction		Impaired executive functioning	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Impaired executive functioning"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
516	429	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	phenotypes	2	Behavioral Changes		phenotype_term	phenotype_term	$	Behavioral Changes		Behavioral abnormality	HP:0000708	Atypical behavior		"{""preferred_term"": ""Behavioral abnormality"", ""term"": {""id"": ""HP:0000708"", ""label"": ""Atypical behavior""}}"																											
517	430	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	phenotypes	3	Aphasia		phenotype_term	phenotype_term	$	Aphasia		Aphasia	HP:0002381	Aphasia		"{""preferred_term"": ""Aphasia"", ""term"": {""id"": ""HP:0002381"", ""label"": ""Aphasia""}}"																											
518	431	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	phenotypes	4	Apraxia		phenotype_term	phenotype_term	$	Apraxia		Apraxia	HP:0002186	Apraxia		"{""preferred_term"": ""Apraxia"", ""term"": {""id"": ""HP:0002186"", ""label"": ""Apraxia""}}"																											
519	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
520	435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Medication that regulates glutamate activity to improve symptoms (e.g., memantine).	treatment_term	treatment_term	$	NMDA Receptor Antagonist	Medication that regulates glutamate activity to improve symptoms (e.g., memantine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
521	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	Cognitive Therapy	Non-pharmacological interventions to maintain cognitive function.	treatment_term	treatment_term	$	Cognitive Therapy	Non-pharmacological interventions to maintain cognitive function.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
522	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	Supportive Care	Includes occupational therapy, speech therapy, and caregiver support.	treatment_term	treatment_term	$	Supportive Care	Includes occupational therapy, speech therapy, and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
523	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	Lifestyle Modifications	Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.	treatment_term	treatment_term	$	Lifestyle Modifications	Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
524	446	18	Alopecia Areata	Alopecia_Areata.yaml	pathophysiology	0	Loss of Hair Follicle Immune Privilege	Hair follicles normally maintain immune privilege through low MHC class I expression and local immunosuppressive factors. Collapse of immune privilege exposes hair follicle antigens to immune surveillance.	biological_processes[0]	biological_processes	biological_processes			Immune Response	GO:0006955	immune response		"{""preferred_term"": ""Immune Response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
525	447	18	Alopecia Areata	Alopecia_Areata.yaml	pathophysiology	1	CD8+ T Cell-Mediated Attack	NKG2D-expressing CD8+ T cells infiltrate the hair bulb and attack hair follicle cells. IFN-gamma produced by these cells induces MHC class I upregulation and further T cell recruitment.	cell_types[0]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
526	447	18	Alopecia Areata	Alopecia_Areata.yaml	pathophysiology	1	CD8+ T Cell-Mediated Attack	NKG2D-expressing CD8+ T cells infiltrate the hair bulb and attack hair follicle cells. IFN-gamma produced by these cells induces MHC class I upregulation and further T cell recruitment.	biological_processes[0]	biological_processes	biological_processes			T Cell Cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T Cell Cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
527	448	18	Alopecia Areata	Alopecia_Areata.yaml	pathophysiology	2	JAK-STAT Signaling Activation	IFN-gamma signaling through JAK1/2-STAT1 pathway drives disease pathogenesis. This pathway is a key therapeutic target, with JAK inhibitors showing efficacy in alopecia areata.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT Signaling	GO:0007259	receptor signaling pathway via JAK-STAT		"{""preferred_term"": ""JAK-STAT Signaling"", ""term"": {""id"": ""GO:0007259"", ""label"": ""receptor signaling pathway via JAK-STAT""}}"																											
528	449	18	Alopecia Areata	Alopecia_Areata.yaml	pathophysiology	3	Chemokine-Mediated Immune Cell Recruitment	CXCL12 and other chemokines recruit and activate CD8+ T cells to the hair follicle. IFN-gamma induces CXCL12 production from dermal fibroblasts, amplifying immune cell infiltration and contributing to disease progression.	biological_processes[0]	biological_processes	biological_processes			Immune Response	GO:0006955	immune response		"{""preferred_term"": ""Immune Response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
529	450	18	Alopecia Areata	Alopecia_Areata.yaml	phenotypes	0	Patchy Hair Loss		phenotype_term	phenotype_term	$	Patchy Hair Loss		Alopecia	HP:0001596	Alopecia		"{""preferred_term"": ""Alopecia"", ""term"": {""id"": ""HP:0001596"", ""label"": ""Alopecia""}}"																											
530	451	18	Alopecia Areata	Alopecia_Areata.yaml	phenotypes	1	Nail Changes		phenotype_term	phenotype_term	$	Nail Changes		Abnormal Nail Morphology	HP:0001597	Abnormal nail morphology		"{""preferred_term"": ""Abnormal Nail Morphology"", ""term"": {""id"": ""HP:0001597"", ""label"": ""Abnormal nail morphology""}}"																											
531	456	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	differential_diagnoses	0	Smoking-Related COPD	"Smoking-related COPD and AAT deficiency both present with emphysema, airway obstruction, and progressive lung disease. The key overlap is that smokers with AAT deficiency develop much earlier and more severe disease. Distinguishing between primary smoking-related COPD and AAT deficiency is critical because AAT-deficient patients benefit from augmentation therapy.
"	disease_term	disease_term	$	Smoking-Related COPD	"Smoking-related COPD and AAT deficiency both present with emphysema, airway obstruction, and progressive lung disease. The key overlap is that smokers with AAT deficiency develop much earlier and more severe disease. Distinguishing between primary smoking-related COPD and AAT deficiency is critical because AAT-deficient patients benefit from augmentation therapy.
"	chronic obstructive pulmonary disease	MONDO:0005002	chronic obstructive pulmonary disease		"{""preferred_term"": ""chronic obstructive pulmonary disease"", ""term"": {""id"": ""MONDO:0005002"", ""label"": ""chronic obstructive pulmonary disease""}}"																											
532	457	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	differential_diagnoses	1	Idiopathic Pulmonary Fibrosis (IPF)	"IPF and AAT deficiency can both present with progressive lung disease and dyspnea. However, IPF is characterized by pulmonary fibrosis with reduced diffusing capacity, while AAT deficiency primarily causes emphysema with airway obstruction.
"	disease_term	disease_term	$	Idiopathic Pulmonary Fibrosis (IPF)	"IPF and AAT deficiency can both present with progressive lung disease and dyspnea. However, IPF is characterized by pulmonary fibrosis with reduced diffusing capacity, while AAT deficiency primarily causes emphysema with airway obstruction.
"	idiopathic pulmonary fibrosis	MONDO:0800504	idiopathic pulmonary fibrosis		"{""preferred_term"": ""idiopathic pulmonary fibrosis"", ""term"": {""id"": ""MONDO:0800504"", ""label"": ""idiopathic pulmonary fibrosis""}}"																											
533	458	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	differential_diagnoses	2	Primary Biliary Cholangitis (PBC)	"PBC and AAT deficiency can both present with progressive liver disease and cirrhosis. Both are rare genetic/autoimmune liver diseases that can require liver transplantation. However, underlying mechanisms, systemic manifestations, and diagnostic tests differ.
"	disease_term	disease_term	$	Primary Biliary Cholangitis (PBC)	"PBC and AAT deficiency can both present with progressive liver disease and cirrhosis. Both are rare genetic/autoimmune liver diseases that can require liver transplantation. However, underlying mechanisms, systemic manifestations, and diagnostic tests differ.
"	primary biliary cholangitis	MONDO:0005388	primary biliary cholangitis		"{""preferred_term"": ""primary biliary cholangitis"", ""term"": {""id"": ""MONDO:0005388"", ""label"": ""primary biliary cholangitis""}}"																											
534	459	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	differential_diagnoses	3	Hereditary Hemochromatosis	"Both hereditary hemochromatosis and AAT deficiency present with progressive liver cirrhosis and hepatocellular carcinoma risk. Both are genetic disorders affecting liver function. However, systemic manifestations, iron metabolism, and liver injury mechanisms differ.
"	disease_term	disease_term	$	Hereditary Hemochromatosis	"Both hereditary hemochromatosis and AAT deficiency present with progressive liver cirrhosis and hepatocellular carcinoma risk. Both are genetic disorders affecting liver function. However, systemic manifestations, iron metabolism, and liver injury mechanisms differ.
"	hereditary hemochromatosis	MONDO:0006507	hereditary hemochromatosis		"{""preferred_term"": ""hereditary hemochromatosis"", ""term"": {""id"": ""MONDO:0006507"", ""label"": ""hereditary hemochromatosis""}}"																											
535	460	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	0	Protease-Antiprotease Imbalance in Lung	"Alpha-1 antitrypsin (AAT) is the major inhibitor of neutrophil elastase in the lung. Deficiency of AAT leads to unopposed elastase activity, causing progressive destruction of alveolar walls and development of emphysema, particularly affecting the lower lobes.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
536	460	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	0	Protease-Antiprotease Imbalance in Lung	"Alpha-1 antitrypsin (AAT) is the major inhibitor of neutrophil elastase in the lung. Deficiency of AAT leads to unopposed elastase activity, causing progressive destruction of alveolar walls and development of emphysema, particularly affecting the lower lobes.
"	biological_processes[0]	biological_processes	biological_processes			neutrophil degranulation	GO:0043312	neutrophil degranulation		"{""preferred_term"": ""neutrophil degranulation"", ""term"": {""id"": ""GO:0043312"", ""label"": ""neutrophil degranulation""}}"																											
537	461	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	1	Hepatic Protein Aggregation	"The Z variant of AAT (E342K, PiZZ genotype) causes misfolding of AAT protein in hepatocytes. Misfolded AAT accumulates in the endoplasmic reticulum, forming polymers that cannot be secreted, leading to hepatocyte injury and liver disease.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
538	461	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	1	Hepatic Protein Aggregation	"The Z variant of AAT (E342K, PiZZ genotype) causes misfolding of AAT protein in hepatocytes. Misfolded AAT accumulates in the endoplasmic reticulum, forming polymers that cannot be secreted, leading to hepatocyte injury and liver disease.
"	biological_processes[0]	biological_processes	biological_processes			response to endoplasmic reticulum stress	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""response to endoplasmic reticulum stress"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
539	462	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	2	Neutrophil Recruitment to Lung Parenchyma	"Inflammatory signals recruit neutrophils to the lung tissue, particularly in response to cigarette smoke, respiratory infections, or other inflammatory stimuli.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
540	462	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	2	Neutrophil Recruitment to Lung Parenchyma	"Inflammatory signals recruit neutrophils to the lung tissue, particularly in response to cigarette smoke, respiratory infections, or other inflammatory stimuli.
"	biological_processes[0]	biological_processes	biological_processes			leukocyte migration	GO:0050900	leukocyte migration		"{""preferred_term"": ""leukocyte migration"", ""term"": {""id"": ""GO:0050900"", ""label"": ""leukocyte migration""}}"																											
541	463	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	3	Neutrophil Elastase Release	"Activated neutrophils release elastase and other proteases that, in the absence of sufficient alpha-1 antitrypsin inhibition, remain enzymatically active and degrade structural proteins.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
542	463	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	3	Neutrophil Elastase Release	"Activated neutrophils release elastase and other proteases that, in the absence of sufficient alpha-1 antitrypsin inhibition, remain enzymatically active and degrade structural proteins.
"	biological_processes[0]	biological_processes	biological_processes			proteolysis	GO:0006508	proteolysis		"{""preferred_term"": ""proteolysis"", ""term"": {""id"": ""GO:0006508"", ""label"": ""proteolysis""}}"																											
543	464	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	pathophysiology	4	Alveolar Tissue Destruction	"Progressive degradation of alveolar walls and elastin fibers leads to loss of structural integrity, air trapping, and emphysema development.
"	biological_processes[0]	biological_processes	biological_processes			extracellular matrix disassembly	GO:0022617	extracellular matrix disassembly		"{""preferred_term"": ""extracellular matrix disassembly"", ""term"": {""id"": ""GO:0022617"", ""label"": ""extracellular matrix disassembly""}}"																											
544	465	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	0	Emphysema	"Progressive destruction of alveolar tissue leading to air trapping, hyperinflation, and decreased gas exchange. Characteristically affects the lung bases, unlike smoking-related emphysema which affects the upper lobes.
"	phenotype_term	phenotype_term	$	Emphysema	"Progressive destruction of alveolar tissue leading to air trapping, hyperinflation, and decreased gas exchange. Characteristically affects the lung bases, unlike smoking-related emphysema which affects the upper lobes.
"	panacinar emphysema	HP:0032967	Panacinar emphysema		"{""preferred_term"": ""panacinar emphysema"", ""term"": {""id"": ""HP:0032967"", ""label"": ""Panacinar emphysema""}}"																											
545	466	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	1	Chronic Obstructive Pulmonary Disease	"Airflow limitation that is not fully reversible, with symptoms of chronic cough, sputum production, and dyspnea. Often presents at a younger age than typical COPD.
"	phenotype_term	phenotype_term	$	Chronic Obstructive Pulmonary Disease	"Airflow limitation that is not fully reversible, with symptoms of chronic cough, sputum production, and dyspnea. Often presents at a younger age than typical COPD.
"	emphysema	HP:0002097	Emphysema		"{""preferred_term"": ""emphysema"", ""term"": {""id"": ""HP:0002097"", ""label"": ""Emphysema""}}"																											
546	467	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	2	Liver Cirrhosis	"Progressive liver fibrosis and cirrhosis resulting from accumulation of abnormal AAT polymers in hepatocytes. More common in ZZ homozygotes.
"	phenotype_term	phenotype_term	$	Liver Cirrhosis	"Progressive liver fibrosis and cirrhosis resulting from accumulation of abnormal AAT polymers in hepatocytes. More common in ZZ homozygotes.
"	cirrhosis	HP:0001394	Cirrhosis		"{""preferred_term"": ""cirrhosis"", ""term"": {""id"": ""HP:0001394"", ""label"": ""Cirrhosis""}}"																											
547	468	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	3	Hepatomegaly	"Enlarged liver due to AAT polymer accumulation in hepatocytes, which may progress to cirrhosis.
"	phenotype_term	phenotype_term	$	Hepatomegaly	"Enlarged liver due to AAT polymer accumulation in hepatocytes, which may progress to cirrhosis.
"	hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
548	469	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	4	Dyspnea	"Shortness of breath on exertion, often the presenting symptom, which may progress to dyspnea at rest in advanced disease.
"	phenotype_term	phenotype_term	$	Dyspnea	"Shortness of breath on exertion, often the presenting symptom, which may progress to dyspnea at rest in advanced disease.
"	dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
549	470	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	5	Wheezing	"Bronchospasm and airway obstruction causing audible wheezing, which may be mistaken for asthma.
"	phenotype_term	phenotype_term	$	Wheezing	"Bronchospasm and airway obstruction causing audible wheezing, which may be mistaken for asthma.
"	wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
550	471	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	phenotypes	6	Panniculitis	"Rare but potentially serious cutaneous manifestation characterized by painful subcutaneous inflammation. AAT-associated panniculitis can present as nodular lesions and may be associated with systemic illness. Intravenous AAT augmentation therapy has been shown to be effective.
"	phenotype_term	phenotype_term	$	Panniculitis	"Rare but potentially serious cutaneous manifestation characterized by painful subcutaneous inflammation. AAT-associated panniculitis can present as nodular lesions and may be associated with systemic illness. Intravenous AAT augmentation therapy has been shown to be effective.
"	panniculitis	HP:0012490	Panniculitis		"{""preferred_term"": ""panniculitis"", ""term"": {""id"": ""HP:0012490"", ""label"": ""Panniculitis""}}"																											
551	472	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	0	Alpha-1 Antitrypsin Augmentation Therapy	"Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
"	treatment_term	treatment_term	$	Alpha-1 Antitrypsin Augmentation Therapy	"Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
552	474	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	2	Bronchodilators	"Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
"	treatment_term	treatment_term	$	Bronchodilators	"Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
553	475	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	3	Lung Transplantation	"For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
"	treatment_term	treatment_term	$	Lung Transplantation	"For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
"	transplantation procedure	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
554	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	Liver Transplantation	"For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
"	treatment_term	treatment_term	$	Liver Transplantation	"For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
"	transplantation procedure	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
555	485	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	histopathology	0	Rhabdomyosarcoma	Rhabdomyosarcoma is a malignant tumor of mesenchymal origin.	finding_term	finding_term	$	Rhabdomyosarcoma	Rhabdomyosarcoma is a malignant tumor of mesenchymal origin.	Rhabdomyosarcoma	NCIT:C3359	Rhabdomyosarcoma		"{""preferred_term"": ""Rhabdomyosarcoma"", ""term"": {""id"": ""NCIT:C3359"", ""label"": ""Rhabdomyosarcoma""}}"																											
556	486	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	0	PAX-FOXO1 Fusion Oncogene	The t(2;13) or t(1;13) translocations fuse the DNA-binding domain of PAX3 or PAX7 with the transactivation domain of FOXO1. The resulting fusion protein functions as a potent aberrant transcription factor that activates PAX target genes to supraphysiological levels, driving proliferation while blocking terminal myogenic differentiation.	cell_types[0]	cell_types	cell_types			skeletal muscle myoblast	CL:0000515	skeletal muscle myoblast		"{""preferred_term"": ""skeletal muscle myoblast"", ""term"": {""id"": ""CL:0000515"", ""label"": ""skeletal muscle myoblast""}}"																											
557	486	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	0	PAX-FOXO1 Fusion Oncogene	The t(2;13) or t(1;13) translocations fuse the DNA-binding domain of PAX3 or PAX7 with the transactivation domain of FOXO1. The resulting fusion protein functions as a potent aberrant transcription factor that activates PAX target genes to supraphysiological levels, driving proliferation while blocking terminal myogenic differentiation.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			ABNORMAL																								
558	486	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	0	PAX-FOXO1 Fusion Oncogene	The t(2;13) or t(1;13) translocations fuse the DNA-binding domain of PAX3 or PAX7 with the transactivation domain of FOXO1. The resulting fusion protein functions as a potent aberrant transcription factor that activates PAX target genes to supraphysiological levels, driving proliferation while blocking terminal myogenic differentiation.	locations[0]	locations	locations			zone of skin	UBERON:0000014	zone of skin		"{""preferred_term"": ""zone of skin"", ""term"": {""id"": ""UBERON:0000014"", ""label"": ""zone of skin""}}"																											
559	487	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	1	Blocked Myogenic Differentiation	PAX-FOXO1 fusion protein blocks the normal myogenic differentiation program by interfering with MYOD1 and myogenin function. Tumor cells express early myogenic markers (desmin, myogenin) but fail to complete differentiation into mature skeletal muscle, remaining in a proliferative progenitor state.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
560	488	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	pathophysiology	2	Aberrant Cell Proliferation	PAX-FOXO1 activates genes promoting cell cycle progression and survival, including MYCN, which is commonly amplified in ARMS. The fusion protein also suppresses apoptosis through multiple mechanisms, contributing to tumor aggressiveness.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
561	489	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	phenotypes	0	Soft Tissue Mass	A rapidly growing, often painless soft tissue mass is the most common presenting finding. ARMS frequently arises in the extremities, trunk, or head and neck region.	phenotype_term	phenotype_term	$	Soft Tissue Mass	A rapidly growing, often painless soft tissue mass is the most common presenting finding. ARMS frequently arises in the extremities, trunk, or head and neck region.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
562	490	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	phenotypes	1	Proptosis	Orbital involvement can cause proptosis and visual disturbance. The parameningeal region including orbit is a common primary site.	phenotype_term	phenotype_term	$	Proptosis	Orbital involvement can cause proptosis and visual disturbance. The parameningeal region including orbit is a common primary site.	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
563	491	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	phenotypes	2	Weight Loss	Systemic symptoms including weight loss may occur with advanced or metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Systemic symptoms including weight loss may occur with advanced or metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
564	492	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	phenotypes	3	Metastatic Disease	ARMS has a high propensity for metastasis. Approximately 50% of patients with PAX-FOXO1 fusion-positive disease present with or develop metastases to lung, bone marrow, and bone.	phenotype_term	phenotype_term	$	Metastatic Disease	ARMS has a high propensity for metastasis. Approximately 50% of patients with PAX-FOXO1 fusion-positive disease present with or develop metastases to lung, bone marrow, and bone.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				vincristine; actinomycin D; cyclophosphamide	CHEBI:28445; CHEBI:27666; CHEBI:4026																						
566	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
567	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
568	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
569	494	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
570	495	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive.	treatment_term	treatment_term	$	Radiation Therapy	Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
571	500	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	0	Amyloid-Beta Plaque Formation	"Extracellular accumulation of amyloid-beta (A) peptides into senile plaques. A is produced through sequential cleavage of amyloid precursor protein (APP) by -secretase and -secretase. Soluble oligomeric forms of A are toxic to synapses and interfere with synaptic plasticity and memory formation.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
572	500	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	0	Amyloid-Beta Plaque Formation	"Extracellular accumulation of amyloid-beta (A) peptides into senile plaques. A is produced through sequential cleavage of amyloid precursor protein (APP) by -secretase and -secretase. Soluble oligomeric forms of A are toxic to synapses and interfere with synaptic plasticity and memory formation.
"	cell_types[1]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
573	500	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	0	Amyloid-Beta Plaque Formation	"Extracellular accumulation of amyloid-beta (A) peptides into senile plaques. A is produced through sequential cleavage of amyloid precursor protein (APP) by -secretase and -secretase. Soluble oligomeric forms of A are toxic to synapses and interfere with synaptic plasticity and memory formation.
"	biological_processes[0]	biological_processes	biological_processes			amyloid precursor protein catabolic process	GO:0042987	amyloid precursor protein catabolic process		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""amyloid precursor protein catabolic process"", ""term"": {""id"": ""GO:0042987"", ""label"": ""amyloid precursor protein catabolic process""}}"			ABNORMAL																								
574	501	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	1	Neurofibrillary Tangle Formation	"Intracellular accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles (NFTs). Tau normally stabilizes microtubules, but abnormal hyperphosphorylation by various kinases reduces its affinity for microtubules, leading to accumulation of free tau that aggregates into paired helical filaments and NFTs. This causes mitochondrial dysfunction, impairs synaptic plasticity, and triggers neuroinflammation.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
575	502	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	2	Synaptic Dysfunction	"Oligomeric forms of A and tau are toxic to synapses, interfering with molecular pathways required for synaptic plasticity and memory. This synaptic dysfunction precedes neuronal death and correlates with cognitive impairment severity.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
576	503	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	3	Neuroinflammation	"Chronic activation of microglia and astrocytes in response to A plaques and tau tangles. While initially attempting to clear pathological proteins, sustained inflammation produces pro-inflammatory cytokines and reactive oxygen species that damage neurons and exacerbate neurodegeneration.
"	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
577	504	21	Alzheimer's Disease	Alzheimers_Disease.yaml	pathophysiology	4	Neuronal Death	"Progressive loss of neurons, particularly in the hippocampus and cortex, leading to brain atrophy. Neuronal death results from accumulated damage from A toxicity, tau pathology, mitochondrial dysfunction, oxidative stress, and neuroinflammation.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
578	505	21	Alzheimer's Disease	Alzheimers_Disease.yaml	phenotypes	0	Memory Impairment		phenotype_term	phenotype_term	$	Memory Impairment		Memory impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
579	506	21	Alzheimer's Disease	Alzheimers_Disease.yaml	phenotypes	1	Cognitive Impairment		phenotype_term	phenotype_term	$	Cognitive Impairment		Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
580	507	21	Alzheimer's Disease	Alzheimers_Disease.yaml	phenotypes	2	Dementia		phenotype_term	phenotype_term	$	Dementia		Dementia	HP:0000726	Dementia		"{""preferred_term"": ""Dementia"", ""term"": {""id"": ""HP:0000726"", ""label"": ""Dementia""}}"																											
581	508	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function.	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
582	509	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease.	treatment_term	treatment_term	$	NMDA Receptor Antagonist	Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
583	510	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	2	Cognitive Stimulation and Rehabilitation	Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life.	treatment_term	treatment_term	$	Cognitive Stimulation and Rehabilitation	Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
584	513	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	datasets	0		Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.	organism	organism	$		Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.	Homo sapiens	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""Homo sapiens"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
585	513	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	datasets	0		Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.	sample_types[0]	sample_types	sample_types			spinal cord	UBERON:0002240	spinal cord		"{""preferred_term"": ""spinal cord"", ""term"": {""id"": ""UBERON:0002240"", ""label"": ""spinal cord""}}"																											
586	514	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	datasets	1		Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.	organism	organism	$		Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.	Homo sapiens	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""Homo sapiens"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
587	514	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	datasets	1		Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.	sample_types[0]	sample_types	sample_types			skeletal muscle tissue	UBERON:0001134	skeletal muscle tissue		"{""preferred_term"": ""skeletal muscle tissue"", ""term"": {""id"": ""UBERON:0001134"", ""label"": ""skeletal muscle tissue""}}"																											
588	515	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	differential_diagnoses	0	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.	disease_term	disease_term	$	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	MONDO:0006702	chronic inflammatory demyelinating polyradiculoneuropathy		"{""preferred_term"": ""Chronic Inflammatory Demyelinating Polyradiculoneuropathy"", ""term"": {""id"": ""MONDO:0006702"", ""label"": ""chronic inflammatory demyelinating polyradiculoneuropathy""}}"																											
589	516	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	differential_diagnoses	1	Multiple Sclerosis	Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.	disease_term	disease_term	$	Multiple Sclerosis	Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.	multiple sclerosis	MONDO:0005301	multiple sclerosis		"{""preferred_term"": ""multiple sclerosis"", ""term"": {""id"": ""MONDO:0005301"", ""label"": ""multiple sclerosis""}}"																											
590	517	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	differential_diagnoses	2	Multifocal Motor Neuropathy	Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.	disease_term	disease_term	$	Multifocal Motor Neuropathy	Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.	multifocal motor neuropathy	MONDO:0018979	multifocal motor neuropathy		"{""preferred_term"": ""multifocal motor neuropathy"", ""term"": {""id"": ""MONDO:0018979"", ""label"": ""multifocal motor neuropathy""}}"																											
591	531	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	0	Motor Neuron Degeneration	"Progressive death of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss results in muscle weakness, atrophy, and fasciculations.
"	cell_types[0]	cell_types	cell_types			motor neuron	CL:0000100	motor neuron		"{""preferred_term"": ""motor neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
592	531	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	0	Motor Neuron Degeneration	"Progressive death of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss results in muscle weakness, atrophy, and fasciculations.
"	locations[0]	locations	locations			primary motor cortex	UBERON:0001384	primary motor cortex		"{""preferred_term"": ""primary motor cortex"", ""term"": {""id"": ""UBERON:0001384"", ""label"": ""primary motor cortex""}}"																											
593	532	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	1	TDP-43 Proteinopathy	"Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately 97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function and toxic gain of function. This impairs RNA splicing including STMN2.
"	genes[0]	genes	genes			TARDBP	hgnc:11571	TARDBP		"{""preferred_term"": ""TARDBP"", ""term"": {""id"": ""hgnc:11571"", ""label"": ""TARDBP""}}"																											
594	532	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	1	TDP-43 Proteinopathy	"Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately 97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function and toxic gain of function. This impairs RNA splicing including STMN2.
"	biological_processes[0]	biological_processes	biological_processes			RNA splicing	GO:0000375	RNA splicing, via transesterification reactions		"{""preferred_term"": ""RNA splicing"", ""term"": {""id"": ""GO:0000375"", ""label"": ""RNA splicing, via transesterification reactions""}}"																											
595	533	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	2	C9orf72 Repeat Expansion Toxicity	"Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
"	genes[0]	genes	genes			C9orf72	hgnc:28337	C9orf72		"{""preferred_term"": ""C9orf72"", ""term"": {""id"": ""hgnc:28337"", ""label"": ""C9orf72""}}"																											
596	534	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	3	Glutamate Excitotoxicity	"Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation in the synaptic cleft, causing prolonged activation of glutamate receptors on motor neurons. This results in calcium overload and subsequent neuronal death.
"	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
597	534	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	3	Glutamate Excitotoxicity	"Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation in the synaptic cleft, causing prolonged activation of glutamate receptors on motor neurons. This results in calcium overload and subsequent neuronal death.
"	biological_processes[0]	biological_processes	biological_processes			neurotransmitter transport	GO:0006836	neurotransmitter transport		"{""preferred_term"": ""neurotransmitter transport"", ""term"": {""id"": ""GO:0006836"", ""label"": ""neurotransmitter transport""}}"																											
598	535	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	4	Oxidative Stress	"Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded protein aggregation and increased oxidative stress contributing to neuronal death.
"	genes[0]	genes	genes			SOD1	hgnc:11179	SOD1		"{""preferred_term"": ""SOD1"", ""term"": {""id"": ""hgnc:11179"", ""label"": ""SOD1""}}"																											
599	535	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	4	Oxidative Stress	"Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded protein aggregation and increased oxidative stress contributing to neuronal death.
"	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
600	536	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	5	Neuroinflammation	"Activated microglia and astrocytes contribute to motor neuron death through the release of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors. This non-cell-autonomous mechanism amplifies neurodegeneration.
"	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
601	536	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	5	Neuroinflammation	"Activated microglia and astrocytes contribute to motor neuron death through the release of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors. This non-cell-autonomous mechanism amplifies neurodegeneration.
"	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
602	537	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	6	Microglial TREM2 Signaling	"TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered TREM2 signaling is implicated in ALS progression through dysregulated microglial responses to motor neuron injury.
"	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
603	537	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	6	Microglial TREM2 Signaling	"TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered TREM2 signaling is implicated in ALS progression through dysregulated microglial responses to motor neuron injury.
"	genes[0]	genes	genes			TREM2	hgnc:17761	TREM2		"{""preferred_term"": ""TREM2"", ""term"": {""id"": ""hgnc:17761"", ""label"": ""TREM2""}}"																											
604	537	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	6	Microglial TREM2 Signaling	"TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered TREM2 signaling is implicated in ALS progression through dysregulated microglial responses to motor neuron injury.
"	biological_processes[0]	biological_processes	biological_processes			microglial cell activation	GO:0001774	microglial cell activation		"{""preferred_term"": ""microglial cell activation"", ""term"": {""id"": ""GO:0001774"", ""label"": ""microglial cell activation""}}"																											
605	538	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	7	Axonal Transport Dysfunction	"Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
"	genes[0]	genes	genes			KIF5A	hgnc:8938	KIF5A		"{""preferred_term"": ""KIF5A"", ""term"": {""id"": ""hgnc:8938"", ""label"": ""KIF5A""}}"																											
606	538	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	7	Axonal Transport Dysfunction	"Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
"	genes[1]	genes	genes			DCTN1	hgnc:2701	DCTN1		"{""preferred_term"": ""DCTN1"", ""term"": {""id"": ""hgnc:2701"", ""label"": ""DCTN1""}}"																											
607	538	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	7	Axonal Transport Dysfunction	"Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
"	genes[2]	genes	genes			PFN1	hgnc:8880	PFN1		"{""preferred_term"": ""PFN1"", ""term"": {""id"": ""hgnc:8880"", ""label"": ""PFN1""}}"																											
608	538	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	7	Axonal Transport Dysfunction	"Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
"	biological_processes[0]	biological_processes	biological_processes			anterograde axonal transport	GO:0008089	anterograde axonal transport		"{""preferred_term"": ""anterograde axonal transport"", ""term"": {""id"": ""GO:0008089"", ""label"": ""anterograde axonal transport""}}"																											
609	539	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	8	Impaired Autophagy	"Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
"	genes[0]	genes	genes			TBK1	hgnc:11584	TBK1		"{""preferred_term"": ""TBK1"", ""term"": {""id"": ""hgnc:11584"", ""label"": ""TBK1""}}"																											
610	539	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	8	Impaired Autophagy	"Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
"	genes[1]	genes	genes			OPTN	hgnc:17101	OPTN		"{""preferred_term"": ""OPTN"", ""term"": {""id"": ""hgnc:17101"", ""label"": ""OPTN""}}"																											
611	539	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	8	Impaired Autophagy	"Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
"	genes[2]	genes	genes			VCP	hgnc:12666	VCP		"{""preferred_term"": ""VCP"", ""term"": {""id"": ""hgnc:12666"", ""label"": ""VCP""}}"																											
612	539	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	8	Impaired Autophagy	"Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
"	genes[3]	genes	genes			SQSTM1	hgnc:11240	SQSTM1		"{""preferred_term"": ""SQSTM1"", ""term"": {""id"": ""hgnc:11240"", ""label"": ""SQSTM1""}}"																											
613	539	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	8	Impaired Autophagy	"Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
"	biological_processes[0]	biological_processes	biological_processes			autophagy	GO:0006914	autophagy		"{""preferred_term"": ""autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
614	540	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	9	Genetic Drivers and Therapeutic Translation	"Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
"	genes[0]	genes	genes			C9orf72	hgnc:28337	C9orf72		"{""preferred_term"": ""C9orf72"", ""term"": {""id"": ""hgnc:28337"", ""label"": ""C9orf72""}}"																											
615	540	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	9	Genetic Drivers and Therapeutic Translation	"Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
"	genes[1]	genes	genes			SOD1	hgnc:11179	SOD1		"{""preferred_term"": ""SOD1"", ""term"": {""id"": ""hgnc:11179"", ""label"": ""SOD1""}}"																											
616	540	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	9	Genetic Drivers and Therapeutic Translation	"Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
"	genes[2]	genes	genes			TARDBP	hgnc:11571	TARDBP		"{""preferred_term"": ""TARDBP"", ""term"": {""id"": ""hgnc:11571"", ""label"": ""TARDBP""}}"																											
617	540	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	pathophysiology	9	Genetic Drivers and Therapeutic Translation	"Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
"	genes[3]	genes	genes			FUS	hgnc:4016	FUS		"{""preferred_term"": ""FUS"", ""term"": {""id"": ""hgnc:4016"", ""label"": ""FUS""}}"																											
618	541	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	0	Muscle Weakness	Progressive loss of voluntary muscle strength affecting limbs, trunk, and respiratory muscles.	phenotype_term	phenotype_term	$	Muscle Weakness	Progressive loss of voluntary muscle strength affecting limbs, trunk, and respiratory muscles.	Muscle weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
619	542	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	1	Fasciculations	Visible involuntary muscle twitching resulting from spontaneous motor unit discharges.	phenotype_term	phenotype_term	$	Fasciculations	Visible involuntary muscle twitching resulting from spontaneous motor unit discharges.	Fasciculations	HP:0002380	Fasciculations		"{""preferred_term"": ""Fasciculations"", ""term"": {""id"": ""HP:0002380"", ""label"": ""Fasciculations""}}"																											
620	543	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	2	Spasticity	Increased muscle tone and stiffness due to upper motor neuron involvement.	phenotype_term	phenotype_term	$	Spasticity	Increased muscle tone and stiffness due to upper motor neuron involvement.	Spasticity	HP:0001257	Spasticity		"{""preferred_term"": ""Spasticity"", ""term"": {""id"": ""HP:0001257"", ""label"": ""Spasticity""}}"																											
621	544	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	3	Hyperreflexia	Exaggerated deep tendon reflexes indicating upper motor neuron dysfunction.	phenotype_term	phenotype_term	$	Hyperreflexia	Exaggerated deep tendon reflexes indicating upper motor neuron dysfunction.	Hyperreflexia	HP:0001347	Hyperreflexia		"{""preferred_term"": ""Hyperreflexia"", ""term"": {""id"": ""HP:0001347"", ""label"": ""Hyperreflexia""}}"																											
622	545	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	4	Dysarthria	Difficulty with speech articulation due to weakness of bulbar muscles.	phenotype_term	phenotype_term	$	Dysarthria	Difficulty with speech articulation due to weakness of bulbar muscles.	Dysarthria	HP:0001260	Dysarthria		"{""preferred_term"": ""Dysarthria"", ""term"": {""id"": ""HP:0001260"", ""label"": ""Dysarthria""}}"																											
623	546	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	5	Dysphagia	Difficulty swallowing due to weakness of pharyngeal and esophageal muscles.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing due to weakness of pharyngeal and esophageal muscles.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
624	547	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	6	Respiratory Insufficiency	Progressive weakness of diaphragm and intercostal muscles leading to ventilatory failure. This is the most common cause of death in ALS.	phenotype_term	phenotype_term	$	Respiratory Insufficiency	Progressive weakness of diaphragm and intercostal muscles leading to ventilatory failure. This is the most common cause of death in ALS.	Respiratory insufficiency due to muscle weakness	HP:0002747	Respiratory insufficiency due to muscle weakness		"{""preferred_term"": ""Respiratory insufficiency due to muscle weakness"", ""term"": {""id"": ""HP:0002747"", ""label"": ""Respiratory insufficiency due to muscle weakness""}}"																											
625	548	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	phenotypes	7	Generalized Amyotrophy	Wasting of skeletal muscles due to denervation following motor neuron loss.	phenotype_term	phenotype_term	$	Generalized Amyotrophy	Wasting of skeletal muscles due to denervation following motor neuron loss.	Generalized amyotrophy	HP:0003700	Generalized amyotrophy		"{""preferred_term"": ""Generalized amyotrophy"", ""term"": {""id"": ""HP:0003700"", ""label"": ""Generalized amyotrophy""}}"																											
626	549	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	0	Riluzole	"Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
"	treatment_term	treatment_term	$	Riluzole	"Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
627	550	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	1	Edaravone	"Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
"	treatment_term	treatment_term	$	Edaravone	"Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
628	551	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	2	Tofersen	"Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
"	treatment_term	treatment_term	$	Tofersen	"Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
629	552	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	3	Non-invasive Ventilation	"Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
"	treatment_term	treatment_term	$	Non-invasive Ventilation	"Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
"	noninvasive ventilation	MAXO:0000506	noninvasive ventilation		"{""preferred_term"": ""noninvasive ventilation"", ""term"": {""id"": ""MAXO:0000506"", ""label"": ""noninvasive ventilation""}}"																											
630	553	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	4	Physical Therapy	"Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
"	treatment_term	treatment_term	$	Physical Therapy	"Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
631	554	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	5	Speech Therapy	"Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
"	treatment_term	treatment_term	$	Speech Therapy	"Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
"	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
632	555	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	6	Percutaneous Endoscopic Gastrostomy	"Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
"	treatment_term	treatment_term	$	Percutaneous Endoscopic Gastrostomy	"Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
633	556	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	7	Multidisciplinary Care	"Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
"	treatment_term	treatment_term	$	Multidisciplinary Care	"Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
634	562	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	pathophysiology	0	HLA-B27-Associated Immune Activation	HLA-B27 misfolding in the endoplasmic reticulum triggers the unfolded protein response and IL-23 production. Aberrant antigen presentation may also activate autoreactive T cells against joint antigens.	biological_processes[0]	biological_processes	biological_processes			Antigen Presentation	GO:0019882	antigen processing and presentation		"{""preferred_term"": ""Antigen Presentation"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"																											
635	563	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	pathophysiology	1	IL-23/IL-17 Axis Activation	IL-23-driven expansion of Th17 cells and innate lymphoid cells produces IL-17, driving inflammation at entheses and in the spine. This pathway is a key therapeutic target.	cell_types[0]	cell_types	cell_types			T Helper Cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""T Helper Cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
636	563	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	pathophysiology	1	IL-23/IL-17 Axis Activation	IL-23-driven expansion of Th17 cells and innate lymphoid cells produces IL-17, driving inflammation at entheses and in the spine. This pathway is a key therapeutic target.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
637	564	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	pathophysiology	2	Enthesitis and New Bone Formation	Inflammation at entheses (tendon/ligament insertions) leads to erosion followed by aberrant bone formation. Syndesmophytes and ankylosis result from dysregulated osteoblast activity driven by Wnt and BMP signaling.	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
638	564	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	pathophysiology	2	Enthesitis and New Bone Formation	Inflammation at entheses (tendon/ligament insertions) leads to erosion followed by aberrant bone formation. Syndesmophytes and ankylosis result from dysregulated osteoblast activity driven by Wnt and BMP signaling.	biological_processes[0]	biological_processes	biological_processes			Bone Formation	GO:0001503	ossification		"{""preferred_term"": ""Bone Formation"", ""term"": {""id"": ""GO:0001503"", ""label"": ""ossification""}}"																											
639	565	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	phenotypes	0	Inflammatory Back Pain		phenotype_term	phenotype_term	$	Inflammatory Back Pain		Back Pain	HP:0003418	Back pain		"{""preferred_term"": ""Back Pain"", ""term"": {""id"": ""HP:0003418"", ""label"": ""Back pain""}}"																											
640	566	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	phenotypes	1	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
641	567	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	phenotypes	2	Spinal Stiffness		phenotype_term	phenotype_term	$	Spinal Stiffness		Limited Spinal Mobility	HP:0003306	Spinal rigidity		"{""preferred_term"": ""Limited Spinal Mobility"", ""term"": {""id"": ""HP:0003306"", ""label"": ""Spinal rigidity""}}"																											
642	568	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	phenotypes	3	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
643	578	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	environmental	0	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
644	579	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	environmental	1	Infection		exposure_term	exposure_term	$	Infection		Infectious agent exposure	ECTO:3000000	exposure to organism		"{""preferred_term"": ""Infectious agent exposure"", ""term"": {""id"": ""ECTO:3000000"", ""label"": ""exposure to organism""}}"																											
645	585	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	pathophysiology	0	Antibody Production	The immune system produces antiphospholipid antibodies that target proteins associated with phospholipids in cell membranes.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
646	585	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	pathophysiology	0	Antibody Production	The immune system produces antiphospholipid antibodies that target proteins associated with phospholipids in cell membranes.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
647	588	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	pathophysiology	3	Organ Damage	Clots in vital organs can impair function and cause significant damage.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
648	588	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	pathophysiology	3	Organ Damage	Clots in vital organs can impair function and cause significant damage.	locations[1]	locations	locations			kidneys	UBERON:0002113	kidney		"{""preferred_term"": ""kidneys"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
649	588	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	pathophysiology	3	Organ Damage	Clots in vital organs can impair function and cause significant damage.	locations[2]	locations	locations			lungs	UBERON:0002048	lung		"{""preferred_term"": ""lungs"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
650	591	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	0	Deep Vein Thrombosis		phenotype_term	phenotype_term	$	Deep Vein Thrombosis		Deep Vein Thrombosis	HP:0004850	Recurrent deep vein thrombosis		"{""preferred_term"": ""Deep Vein Thrombosis"", ""term"": {""id"": ""HP:0004850"", ""label"": ""Recurrent deep vein thrombosis""}}"																											
651	592	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	1	Preterm Birth		phenotype_term	phenotype_term	$	Preterm Birth		Preterm Birth	HP:0001622	Premature birth		"{""preferred_term"": ""Preterm Birth"", ""term"": {""id"": ""HP:0001622"", ""label"": ""Premature birth""}}"																											
652	593	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	2	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
653	595	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	4	Preeclampsia		phenotype_term	phenotype_term	$	Preeclampsia		Preeclampsia	MONDO:0005081	preeclampsia		"{""preferred_term"": ""Preeclampsia"", ""term"": {""id"": ""MONDO:0005081"", ""label"": ""preeclampsia""}}"																											
654	596	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	5	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
655	598	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	7	Livedo Reticularis		phenotype_term	phenotype_term	$	Livedo Reticularis		Livedo Reticularis	HP:0033505	Livedo reticularis		"{""preferred_term"": ""Livedo Reticularis"", ""term"": {""id"": ""HP:0033505"", ""label"": ""Livedo reticularis""}}"																											
656	600	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	9	Pulmonary Embolism		phenotype_term	phenotype_term	$	Pulmonary Embolism		Pulmonary embolism	HP:0002204	Pulmonary embolism		"{""preferred_term"": ""Pulmonary embolism"", ""term"": {""id"": ""HP:0002204"", ""label"": ""Pulmonary embolism""}}"																											
657	601	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	phenotypes	10	Stroke		phenotype_term	phenotype_term	$	Stroke		Stroke	HP:0001297	Stroke		"{""preferred_term"": ""Stroke"", ""term"": {""id"": ""HP:0001297"", ""label"": ""Stroke""}}"																											
658	606	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"The S252W and P253R mutations in FGFR2 alter ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. This leads to enhanced and prolonged receptor signaling, causing premature fusion of cranial sutures and abnormal limb development. The mutations affect the linker region between immunoglobulin-like domains II and III, altering ligand-receptor interactions.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
659	606	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"The S252W and P253R mutations in FGFR2 alter ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. This leads to enhanced and prolonged receptor signaling, causing premature fusion of cranial sutures and abnormal limb development. The mutations affect the linker region between immunoglobulin-like domains II and III, altering ligand-receptor interactions.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
660	606	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"The S252W and P253R mutations in FGFR2 alter ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. This leads to enhanced and prolonged receptor signaling, causing premature fusion of cranial sutures and abnormal limb development. The mutations affect the linker region between immunoglobulin-like domains II and III, altering ligand-receptor interactions.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
661	607	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	1	Premature Suture Fusion	"Enhanced FGFR2 signaling in cranial suture mesenchyme promotes premature osteogenic differentiation and fusion of the coronal sutures, restricting skull growth perpendicular to the fused sutures and causing characteristic turricephaly (tower skull).
"	biological_processes[0]	biological_processes	biological_processes			Osteoblast Differentiation	GO:0001649	osteoblast differentiation		"{""preferred_term"": ""Osteoblast Differentiation"", ""term"": {""id"": ""GO:0001649"", ""label"": ""osteoblast differentiation""}}"																											
662	608	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	2	ERK1/2 and PKC Pathway Dysregulation	"The Apert S252W mutation activates distinct downstream signaling pathways compared to wild-type FGFR2. While wild-type FGFR2 signals primarily through ERK1/2, the mutant receptor additionally activates protein kinase C alpha (PKC), which mediates the enhanced osteogenic differentiation characteristic of Apert syndrome.
"	cell_types[0]	cell_types	cell_types			Mesenchymal stem cell	CL:0000134	mesenchymal stem cell		"{""preferred_term"": ""Mesenchymal stem cell"", ""term"": {""id"": ""CL:0000134"", ""label"": ""mesenchymal stem cell""}}"																											
663	608	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	2	ERK1/2 and PKC Pathway Dysregulation	"The Apert S252W mutation activates distinct downstream signaling pathways compared to wild-type FGFR2. While wild-type FGFR2 signals primarily through ERK1/2, the mutant receptor additionally activates protein kinase C alpha (PKC), which mediates the enhanced osteogenic differentiation characteristic of Apert syndrome.
"	biological_processes[0]	biological_processes	biological_processes			ERK1/2 Cascade	GO:0070371	ERK1 and ERK2 cascade		"{""preferred_term"": ""ERK1/2 Cascade"", ""term"": {""id"": ""GO:0070371"", ""label"": ""ERK1 and ERK2 cascade""}}"																											
664	608	25	Apert Syndrome	Apert_Syndrome.yaml	pathophysiology	2	ERK1/2 and PKC Pathway Dysregulation	"The Apert S252W mutation activates distinct downstream signaling pathways compared to wild-type FGFR2. While wild-type FGFR2 signals primarily through ERK1/2, the mutant receptor additionally activates protein kinase C alpha (PKC), which mediates the enhanced osteogenic differentiation characteristic of Apert syndrome.
"	biological_processes[1]	biological_processes	biological_processes			Protein Kinase C Signaling	GO:0070528	protein kinase C signaling		"{""preferred_term"": ""Protein Kinase C Signaling"", ""term"": {""id"": ""GO:0070528"", ""label"": ""protein kinase C signaling""}}"																											
665	609	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	0	Coronal Craniosynostosis	"Bilateral coronal suture fusion causing brachycephaly with turricephaly (tower-shaped skull) and flat occiput.
"	phenotype_term	phenotype_term	$	Coronal Craniosynostosis	"Bilateral coronal suture fusion causing brachycephaly with turricephaly (tower-shaped skull) and flat occiput.
"	Coronal craniosynostosis	HP:0004440	Coronal craniosynostosis		"{""preferred_term"": ""Coronal craniosynostosis"", ""term"": {""id"": ""HP:0004440"", ""label"": ""Coronal craniosynostosis""}}"																											
666	610	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	1	Midface Retrusion	"Severe midface hypoplasia with class III malocclusion, contributing to obstructive sleep apnea and feeding difficulties.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Severe midface hypoplasia with class III malocclusion, contributing to obstructive sleep apnea and feeding difficulties.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
667	611	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	2	Proptosis	"Shallow orbits cause ocular proptosis with risk of exposure keratopathy.
"	phenotype_term	phenotype_term	$	Proptosis	"Shallow orbits cause ocular proptosis with risk of exposure keratopathy.
"	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
668	612	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	3	Syndactyly of Hands	"Symmetric complex syndactyly of digits 2-4 (type I) or 2-5 (type II/III), creating the characteristic ""mitten hand"" appearance. Both osseous and cutaneous syndactyly are present.
"	phenotype_term	phenotype_term	$	Syndactyly of Hands	"Symmetric complex syndactyly of digits 2-4 (type I) or 2-5 (type II/III), creating the characteristic ""mitten hand"" appearance. Both osseous and cutaneous syndactyly are present.
"	Finger syndactyly	HP:0006101	Finger syndactyly		"{""preferred_term"": ""Finger syndactyly"", ""term"": {""id"": ""HP:0006101"", ""label"": ""Finger syndactyly""}}"																											
669	613	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	4	Syndactyly of Feet	"Syndactyly of toes, typically involving toes 2-4, creating ""sock feet.""
"	phenotype_term	phenotype_term	$	Syndactyly of Feet	"Syndactyly of toes, typically involving toes 2-4, creating ""sock feet.""
"	Toe syndactyly	HP:0001770	Toe syndactyly		"{""preferred_term"": ""Toe syndactyly"", ""term"": {""id"": ""HP:0001770"", ""label"": ""Toe syndactyly""}}"																											
670	614	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	5	Broad Thumb	"Broad, radially deviated thumbs are characteristic.
"	phenotype_term	phenotype_term	$	Broad Thumb	"Broad, radially deviated thumbs are characteristic.
"	Broad thumb	HP:0011304	Broad thumb		"{""preferred_term"": ""Broad thumb"", ""term"": {""id"": ""HP:0011304"", ""label"": ""Broad thumb""}}"																											
671	615	25	Apert Syndrome	Apert_Syndrome.yaml	phenotypes	6	Intellectual Disability	"Variable intellectual disability, ranging from normal intelligence to moderate impairment. Early surgical intervention may improve outcomes.
"	phenotype_term	phenotype_term	$	Intellectual Disability	"Variable intellectual disability, ranging from normal intelligence to moderate impairment. Early surgical intervention may improve outcomes.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
672	616	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.
"	treatment_term	treatment_term	$	Cranial Vault Remodeling	"Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
673	617	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.
"	treatment_term	treatment_term	$	Midface Advancement	"Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
674	618	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	2	Syndactyly Release	"Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.
"	treatment_term	treatment_term	$	Syndactyly Release	"Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.
"	Hand surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Hand surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
675	622	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	environmental	0	Hormone Replacement Therapy	Estrogen replacement helps manage symptoms.	exposure_term	exposure_term	$	Hormone Replacement Therapy	Estrogen replacement helps manage symptoms.	Hormone exposure	ECTO:0000516	exposure to hormone	Therapeutic exposure to exogenous hormones to correct endocrine deficiencies.	"{""description"": ""Therapeutic exposure to exogenous hormones to correct endocrine deficiencies."", ""preferred_term"": ""Hormone exposure"", ""term"": {""id"": ""ECTO:0000516"", ""label"": ""exposure to hormone""}}"																											
676	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	cell_types[0]	cell_types	cell_types			granulosa cell	CL:0000501	granulosa cell	Ovarian site of aromatase expression for estrogen synthesis	"{""description"": ""Ovarian site of aromatase expression for estrogen synthesis"", ""preferred_term"": ""granulosa cell"", ""term"": {""id"": ""CL:0000501"", ""label"": ""granulosa cell""}}"																											
677	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	cell_types[1]	cell_types	cell_types			trophoblast cell	CL:0000351	trophoblast cell	Placental aromatase site; loss causes maternal and fetal virilization	"{""description"": ""Placental aromatase site; loss causes maternal and fetal virilization"", ""preferred_term"": ""trophoblast cell"", ""term"": {""id"": ""CL:0000351"", ""label"": ""trophoblast cell""}}"																											
678	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	cell_types[2]	cell_types	cell_types			Leydig cell	CL:0000178	Leydig cell	Testicular androgen source; peripheral aromatization affects systemic hormone balance	"{""description"": ""Testicular androgen source; peripheral aromatization affects systemic hormone balance"", ""preferred_term"": ""Leydig cell"", ""term"": {""id"": ""CL:0000178"", ""label"": ""Leydig cell""}}"																											
679	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	cell_types[3]	cell_types	cell_types			adipocyte	CL:0000136	adipocyte	Peripheral aromatase expression site contributing to local estrogen production	"{""description"": ""Peripheral aromatase expression site contributing to local estrogen production"", ""preferred_term"": ""adipocyte"", ""term"": {""id"": ""CL:0000136"", ""label"": ""adipocyte""}}"																											
680	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	biological_processes[0]	biological_processes	biological_processes			estrogen biosynthetic process	GO:0006703	estrogen biosynthetic process	Aromatase-catalyzed estrogen synthesis is directly impaired	"{""description"": ""Aromatase-catalyzed estrogen synthesis is directly impaired"", ""preferred_term"": ""estrogen biosynthetic process"", ""term"": {""id"": ""GO:0006703"", ""label"": ""estrogen biosynthetic process""}}"																											
681	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	biological_processes[1]	biological_processes	biological_processes			steroid biosynthetic process	GO:0006694	steroid biosynthetic process	Overall steroidogenesis altered with accumulation of androgens	"{""description"": ""Overall steroidogenesis altered with accumulation of androgens"", ""preferred_term"": ""steroid biosynthetic process"", ""term"": {""id"": ""GO:0006694"", ""label"": ""steroid biosynthetic process""}}"																											
682	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	biological_processes[2]	biological_processes	biological_processes			androgen metabolic process	GO:0008209	androgen metabolic process	Androgen metabolism shifts toward accumulation of C19 steroids	"{""description"": ""Androgen metabolism shifts toward accumulation of C19 steroids"", ""preferred_term"": ""androgen metabolic process"", ""term"": {""id"": ""GO:0008209"", ""label"": ""androgen metabolic process""}}"																											
683	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	locations[0]	locations	locations			ovary	UBERON:0000992	ovary	Site of granulosa aromatase; ovarian development and fertility impacted	"{""description"": ""Site of granulosa aromatase; ovarian development and fertility impacted"", ""preferred_term"": ""ovary"", ""term"": {""id"": ""UBERON:0000992"", ""label"": ""ovary""}}"																											
684	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	locations[1]	locations	locations			placenta	UBERON:0001987	placenta	Crucial for fetal estrogen production; maternal virilization if deficient	"{""description"": ""Crucial for fetal estrogen production; maternal virilization if deficient"", ""preferred_term"": ""placenta"", ""term"": {""id"": ""UBERON:0001987"", ""label"": ""placenta""}}"																											
685	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	locations[2]	locations	locations			testis	UBERON:0000473	testis	Androgen source; 46,XY genital phenotype often milder than 46,XX	"{""description"": ""Androgen source; 46,XY genital phenotype often milder than 46,XX"", ""preferred_term"": ""testis"", ""term"": {""id"": ""UBERON:0000473"", ""label"": ""testis""}}"																											
686	627	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	0	CYP19A1 Gene Mutation	Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.	locations[3]	locations	locations			bone tissue	UBERON:0002481	bone tissue	Affected by estrogen deficiency causing delayed epiphyseal closure and osteopenia	"{""description"": ""Affected by estrogen deficiency causing delayed epiphyseal closure and osteopenia"", ""preferred_term"": ""bone tissue"", ""term"": {""id"": ""UBERON:0002481"", ""label"": ""bone tissue""}}"																											
687	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	cell_types[0]	cell_types	cell_types			osteoblast	CL:0000062	osteoblast	Bone-forming cell; estrogen deficiency increases bone resorption risk	"{""description"": ""Bone-forming cell; estrogen deficiency increases bone resorption risk"", ""preferred_term"": ""osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
688	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	cell_types[1]	cell_types	cell_types			osteoclast	CL:0000092	osteoclast	Bone-resorbing cell; activity increases when estrogen is low	"{""description"": ""Bone-resorbing cell; activity increases when estrogen is low"", ""preferred_term"": ""osteoclast"", ""term"": {""id"": ""CL:0000092"", ""label"": ""osteoclast""}}"																											
689	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	biological_processes[0]	biological_processes	biological_processes			estrogen receptor signaling pathway	GO:0030520	estrogen receptor signaling pathway	Downstream estrogen signaling reduced affecting multiple tissues	"{""description"": ""Downstream estrogen signaling reduced affecting multiple tissues"", ""preferred_term"": ""estrogen receptor signaling pathway"", ""term"": {""id"": ""GO:0030520"", ""label"": ""estrogen receptor signaling pathway""}}"																											
690	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	biological_processes[1]	biological_processes	biological_processes			regulation of gonadotropin secretion	GO:0032274	regulation of gonadotropin secretion	HPG feedback disrupted causing hypergonadotropic hypogonadism	"{""description"": ""HPG feedback disrupted causing hypergonadotropic hypogonadism"", ""preferred_term"": ""regulation of gonadotropin secretion"", ""term"": {""id"": ""GO:0032274"", ""label"": ""regulation of gonadotropin secretion""}}"																											
691	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	biological_processes[2]	biological_processes	biological_processes			bone remodeling	GO:0046849	bone remodeling	Imbalanced osteoblast/osteoclast activity leading to bone loss	"{""description"": ""Imbalanced osteoblast/osteoclast activity leading to bone loss"", ""preferred_term"": ""bone remodeling"", ""term"": {""id"": ""GO:0046849"", ""label"": ""bone remodeling""}}"																											
692	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	biological_processes[3]	biological_processes	biological_processes			endochondral ossification	GO:0001958	endochondral ossification	Delayed epiphyseal closure due to low estrogen levels	"{""description"": ""Delayed epiphyseal closure due to low estrogen levels"", ""preferred_term"": ""endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
693	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	locations[0]	locations	locations			uterus	UBERON:0000995	uterus	Estrogen-dependent organ; hypoplasia and poor endometrial development possible	"{""description"": ""Estrogen-dependent organ; hypoplasia and poor endometrial development possible"", ""preferred_term"": ""uterus"", ""term"": {""id"": ""UBERON:0000995"", ""label"": ""uterus""}}"																											
694	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	locations[1]	locations	locations			bone tissue	UBERON:0002481	bone tissue	Chronic hypoestrogenism results in low bone mass and fracture risk	"{""description"": ""Chronic hypoestrogenism results in low bone mass and fracture risk"", ""preferred_term"": ""bone tissue"", ""term"": {""id"": ""UBERON:0002481"", ""label"": ""bone tissue""}}"																											
695	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	locations[2]	locations	locations			adipose tissue	UBERON:0001013	adipose tissue	Peripheral aromatase loss alters metabolic regulation and lipid profiles	"{""description"": ""Peripheral aromatase loss alters metabolic regulation and lipid profiles"", ""preferred_term"": ""adipose tissue"", ""term"": {""id"": ""UBERON:0001013"", ""label"": ""adipose tissue""}}"																											
696	628	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	pathophysiology	1	Estrogen Deficiency	Lack of estrogen production due to deficient aromatase activity.	locations[3]	locations	locations			brain	UBERON:0000955	brain	Central estrogen actions on behavior and HPG axis signaling disrupted	"{""description"": ""Central estrogen actions on behavior and HPG axis signaling disrupted"", ""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
697	630	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	1	Delayed Puberty	Failure to develop secondary sexual characteristics at the expected age due to estrogen deficiency.	phenotype_term	phenotype_term	$	Delayed Puberty	Failure to develop secondary sexual characteristics at the expected age due to estrogen deficiency.	Delayed Puberty	HP:0000823	Delayed puberty	Lack of pubertal development by age 13 in girls or 14 in boys.	"{""description"": ""Lack of pubertal development by age 13 in girls or 14 in boys."", ""preferred_term"": ""Delayed Puberty"", ""term"": {""id"": ""HP:0000823"", ""label"": ""Delayed puberty""}}"																											
698	631	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	2	Osteoporosis	Reduced bone mineral density and increased fracture risk resulting from inadequate estrogen-mediated bone remodeling.	phenotype_term	phenotype_term	$	Osteoporosis	Reduced bone mineral density and increased fracture risk resulting from inadequate estrogen-mediated bone remodeling.	Osteoporosis	HP:0000939	Osteoporosis	Decreased bone mass and structural deterioration leading to increased fracture risk.	"{""description"": ""Decreased bone mass and structural deterioration leading to increased fracture risk."", ""preferred_term"": ""Osteoporosis"", ""term"": {""id"": ""HP:0000939"", ""label"": ""Osteoporosis""}}"																											
699	632	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	3	Hypergonadotropic Hypogonadism	Elevated gonadotropin levels (FSH, LH) with inadequate gonadal function due to lack of estrogen negative feedback.	phenotype_term	phenotype_term	$	Hypergonadotropic Hypogonadism	Elevated gonadotropin levels (FSH, LH) with inadequate gonadal function due to lack of estrogen negative feedback.	Hypergonadotropic Hypogonadism	HP:0000815	Hypergonadotropic hypogonadism	Gonadal failure with elevated pituitary gonadotropins due to loss of negative feedback.	"{""description"": ""Gonadal failure with elevated pituitary gonadotropins due to loss of negative feedback."", ""preferred_term"": ""Hypergonadotropic Hypogonadism"", ""term"": {""id"": ""HP:0000815"", ""label"": ""Hypergonadotropic hypogonadism""}}"																											
700	633	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	4	Primary Amenorrhea	Absence of menstruation by age 15 due to estrogen deficiency preventing endometrial development.	phenotype_term	phenotype_term	$	Primary Amenorrhea	Absence of menstruation by age 15 due to estrogen deficiency preventing endometrial development.	Primary Amenorrhea	HP:0000786	Primary amenorrhea	Absence of menarche by age 15 in females with otherwise normal development.	"{""description"": ""Absence of menarche by age 15 in females with otherwise normal development."", ""preferred_term"": ""Primary Amenorrhea"", ""term"": {""id"": ""HP:0000786"", ""label"": ""Primary amenorrhea""}}"																											
701	634	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	5	Polycystic Ovaries	Multiple ovarian cysts due to elevated gonadotropins and lack of estrogen-mediated follicular maturation.	phenotype_term	phenotype_term	$	Polycystic Ovaries	Multiple ovarian cysts due to elevated gonadotropins and lack of estrogen-mediated follicular maturation.	Polycystic Ovaries	HP:0000147	Polycystic ovaries	Ovaries containing multiple small follicular cysts with thickened stroma.	"{""description"": ""Ovaries containing multiple small follicular cysts with thickened stroma."", ""preferred_term"": ""Polycystic Ovaries"", ""term"": {""id"": ""HP:0000147"", ""label"": ""Polycystic ovaries""}}"																											
702	635	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	6	Tall Stature	Continued linear growth beyond normal age due to delayed epiphyseal closure from estrogen deficiency.	phenotype_term	phenotype_term	$	Tall Stature	Continued linear growth beyond normal age due to delayed epiphyseal closure from estrogen deficiency.	Tall Stature	HP:0000098	Tall stature	Height significantly above the population mean for age and sex.	"{""description"": ""Height significantly above the population mean for age and sex."", ""preferred_term"": ""Tall Stature"", ""term"": {""id"": ""HP:0000098"", ""label"": ""Tall stature""}}"																											
703	636	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	7	Clitoromegaly	Enlarged clitoris due to prenatal androgen exposure in 46,XX individuals.	phenotype_term	phenotype_term	$	Clitoromegaly	Enlarged clitoris due to prenatal androgen exposure in 46,XX individuals.	Clitoral hypertrophy	HP:0008665	Clitoral hypertrophy	Abnormal enlargement of the clitoris.	"{""description"": ""Abnormal enlargement of the clitoris."", ""preferred_term"": ""Clitoral hypertrophy"", ""term"": {""id"": ""HP:0008665"", ""label"": ""Clitoral hypertrophy""}}"																											
704	637	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	8	Insulin Resistance	Metabolic alterations including reduced insulin sensitivity associated with low aromatase activity.	phenotype_term	phenotype_term	$	Insulin Resistance	Metabolic alterations including reduced insulin sensitivity associated with low aromatase activity.	Insulin resistance	HP:0000855	Insulin resistance	Reduced responsiveness to normal insulin levels.	"{""description"": ""Reduced responsiveness to normal insulin levels."", ""preferred_term"": ""Insulin resistance"", ""term"": {""id"": ""HP:0000855"", ""label"": ""Insulin resistance""}}"																											
705	638	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	phenotypes	9	Dyslipidemia	Adverse lipid profile associated with low aromatase activity and estrogen deficiency.	phenotype_term	phenotype_term	$	Dyslipidemia	Adverse lipid profile associated with low aromatase activity and estrogen deficiency.	Abnormal circulating lipid concentration	HP:0003119	Abnormal circulating lipid concentration	Abnormal lipid levels in the blood.	"{""description"": ""Abnormal lipid levels in the blood."", ""preferred_term"": ""Abnormal circulating lipid concentration"", ""term"": {""id"": ""HP:0003119"", ""label"": ""Abnormal circulating lipid concentration""}}"																											
706	642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	Estrogen Replacement Therapy	Corrects estrogen deficiency and supports normal sexual development and bone health.	treatment_term	treatment_term	$	Estrogen Replacement Therapy	Corrects estrogen deficiency and supports normal sexual development and bone health.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	Therapeutic administration of estrogen to replace deficient endogenous hormone production.	"{""description"": ""Therapeutic administration of estrogen to replace deficient endogenous hormone production."", ""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
707	643	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	1	Antiandrogen Therapy	Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide.	treatment_term	treatment_term	$	Antiandrogen Therapy	Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Drug therapy using antiandrogens to block androgen effects and reduce virilization.	"{""description"": ""Drug therapy using antiandrogens to block androgen effects and reduce virilization."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
708	644	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	2	Surgical Management	May be considered for ambiguous genitalia or other anatomical abnormalities.	treatment_term	treatment_term	$	Surgical Management	May be considered for ambiguous genitalia or other anatomical abnormalities.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention for anatomical abnormalities such as ambiguous genitalia.	"{""description"": ""Operative intervention for anatomical abnormalities such as ambiguous genitalia."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
709	647	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	environmental	0	Arsenic Exposure	Chronic exposure to inorganic arsenic through contaminated drinking water is the primary route of exposure affecting large populations. Occupational exposure occurs in mining, smelting, pesticide manufacturing, and wood preservation. The latency period between exposure and cancer development is typically 20-40 years. Arsenic is methylated in the liver to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA); the intermediate MMA(III) is particularly toxic. Individual variation in arsenic metabolism affects cancer susceptibility.	exposure_term	exposure_term	$	Arsenic Exposure	Chronic exposure to inorganic arsenic through contaminated drinking water is the primary route of exposure affecting large populations. Occupational exposure occurs in mining, smelting, pesticide manufacturing, and wood preservation. The latency period between exposure and cancer development is typically 20-40 years. Arsenic is methylated in the liver to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA); the intermediate MMA(III) is particularly toxic. Individual variation in arsenic metabolism affects cancer susceptibility.	exposure to arsenic	ECTO:9000032	exposure to arsenic		"{""preferred_term"": ""exposure to arsenic"", ""term"": {""id"": ""ECTO:9000032"", ""label"": ""exposure to arsenic""}}"																											
710	651	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	histopathology	0	Skin Carcinomas	Common arsenic-induced skin cancers include Bowen's disease, basal cell carcinoma, and squamous cell carcinoma.	finding_term	finding_term	$	Skin Carcinomas	Common arsenic-induced skin cancers include Bowen's disease, basal cell carcinoma, and squamous cell carcinoma.	Skin Carcinoma	NCIT:C4914	Skin Carcinoma		"{""preferred_term"": ""Skin Carcinoma"", ""term"": {""id"": ""NCIT:C4914"", ""label"": ""Skin Carcinoma""}}"																											
711	652	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	0	Arsenic Uptake and Metabolism	Inorganic arsenic is absorbed from the gut or lungs and undergoes hepatic methylation by arsenic (+3 oxidation state) methyltransferase (AS3MT). The metabolic pathway produces monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). The trivalent intermediate MMA(III) is highly reactive and toxic. Genetic polymorphisms in AS3MT affect methylation efficiency and cancer risk.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
712	652	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	0	Arsenic Uptake and Metabolism	Inorganic arsenic is absorbed from the gut or lungs and undergoes hepatic methylation by arsenic (+3 oxidation state) methyltransferase (AS3MT). The metabolic pathway produces monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). The trivalent intermediate MMA(III) is highly reactive and toxic. Genetic polymorphisms in AS3MT affect methylation efficiency and cancer risk.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
713	653	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	1	Oxidative Stress and DNA Damage	Arsenic generates reactive oxygen species (ROS) through multiple mechanisms including mitochondrial dysfunction and NADPH oxidase activation. ROS cause oxidative DNA damage including 8-oxoguanine formation, DNA strand breaks, and chromosomal aberrations. Unlike classic genotoxins, arsenic does not form direct DNA adducts but induces damage through indirect mechanisms.	biological_processes[0]	biological_processes	biological_processes			DNA damage response	GO:0006974	DNA damage response		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""DNA damage response""}}"			ABNORMAL																								
714	654	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	2	Epigenetic Dysregulation	Arsenic causes global DNA hypomethylation while inducing promoter-specific hypermethylation of tumor suppressor genes. This occurs partly through competition for methyl groups (arsenic methylation depletes SAM) and altered DNMT activity. Histone modifications and miRNA expression are also affected, contributing to aberrant gene expression patterns.	biological_processes[0]	biological_processes	biological_processes			DNA methylation	GO:0006306	DNA methylation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""DNA methylation"", ""term"": {""id"": ""GO:0006306"", ""label"": ""DNA methylation""}}"			ABNORMAL																								
715	655	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	3	Impaired DNA Repair	Arsenic inhibits multiple DNA repair pathways including nucleotide excision repair, base excision repair, and mismatch repair. It inhibits zinc finger proteins involved in repair by displacing zinc. PARP-1, XPA, and other repair factors are direct targets. This repair deficiency synergizes with oxidative damage to promote mutagenesis.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
716	656	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	4	Tumor Suppressor Gene Silencing	Arsenic-induced promoter hypermethylation silences tumor suppressor genes including p16INK4A, RASSF1A, and p53. This epigenetic silencing contributes to cell cycle dysregulation and resistance to apoptosis without requiring genetic mutation.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
717	657	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	5	Genomic Instability	The combination of oxidative DNA damage, impaired repair, and aberrant mitotic spindle function leads to genomic instability, aneuploidy, and chromosomal aberrations. Arsenic disrupts spindle assembly by targeting tubulin and centrosome function.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			ABNORMAL																								
718	658	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Combined effects of epigenetic silencing, genomic instability, and constitutive growth signaling drive proliferation of transformed cells in target organs. The skin, lung, and bladder are particularly susceptible due to their exposure to arsenic and its metabolites.	cell_types[0]	cell_types	cell_types			epithelial cell	CL:0000066	epithelial cell		"{""preferred_term"": ""epithelial cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
719	658	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Combined effects of epigenetic silencing, genomic instability, and constitutive growth signaling drive proliferation of transformed cells in target organs. The skin, lung, and bladder are particularly susceptible due to their exposure to arsenic and its metabolites.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
720	659	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	0	Palmoplantar Hyperkeratosis	Characteristic arsenic keratoses appearing as punctate or nodular hyperkeratotic lesions on palms and soles. Pathognomonic for chronic arsenic poisoning. May progress to squamous cell carcinoma.	phenotype_term	phenotype_term	$	Palmoplantar Hyperkeratosis	Characteristic arsenic keratoses appearing as punctate or nodular hyperkeratotic lesions on palms and soles. Pathognomonic for chronic arsenic poisoning. May progress to squamous cell carcinoma.	Hyperkeratosis	HP:0000962	Hyperkeratosis		"{""preferred_term"": ""Hyperkeratosis"", ""term"": {""id"": ""HP:0000962"", ""label"": ""Hyperkeratosis""}}"																											
721	660	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	1	Skin Hyperpigmentation	"Characteristic ""raindrop"" pattern of hyperpigmentation with interspersed hypopigmented macules, typically on the trunk. One of the earliest signs of chronic arsenicosis."	phenotype_term	phenotype_term	$	Skin Hyperpigmentation	"Characteristic ""raindrop"" pattern of hyperpigmentation with interspersed hypopigmented macules, typically on the trunk. One of the earliest signs of chronic arsenicosis."	Hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
722	661	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	2	Skin Cancer	Multiple squamous cell carcinomas and basal cell carcinomas, often in sun-protected areas. May arise from keratotic lesions or Bowen disease (squamous carcinoma in situ). Bowen disease appears as well-demarcated erythematous plaques.	phenotype_term	phenotype_term	$	Skin Cancer	Multiple squamous cell carcinomas and basal cell carcinomas, often in sun-protected areas. May arise from keratotic lesions or Bowen disease (squamous carcinoma in situ). Bowen disease appears as well-demarcated erythematous plaques.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
723	662	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	3	Lung Cancer	Increased risk of lung cancer, particularly squamous cell carcinoma. Synergistic with tobacco smoking. May occur after 20-40 year latency.	phenotype_term	phenotype_term	$	Lung Cancer	Increased risk of lung cancer, particularly squamous cell carcinoma. Synergistic with tobacco smoking. May occur after 20-40 year latency.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
724	663	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	4	Bladder Cancer	Transitional cell carcinoma of the urinary bladder. One of the most strongly associated arsenic-related internal malignancies. Latency period of 20-40 years.	phenotype_term	phenotype_term	$	Bladder Cancer	Transitional cell carcinoma of the urinary bladder. One of the most strongly associated arsenic-related internal malignancies. Latency period of 20-40 years.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
725	664	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	phenotypes	5	Blackfoot Disease	Endemic peripheral vascular disease in Taiwan characterized by progressive atherosclerosis leading to gangrene and spontaneous amputation. Classic manifestation of chronic arsenic toxicity.	phenotype_term	phenotype_term	$	Blackfoot Disease	Endemic peripheral vascular disease in Taiwan characterized by progressive atherosclerosis leading to gangrene and spontaneous amputation. Classic manifestation of chronic arsenic toxicity.	Peripheral arterial stenosis	HP:0004950	Peripheral arterial stenosis		"{""preferred_term"": ""Peripheral arterial stenosis"", ""term"": {""id"": ""HP:0004950"", ""label"": ""Peripheral arterial stenosis""}}"																											
726	666	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	1	Surgical Excision	Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
727	667	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	2	Topical Therapy	Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions.	treatment_term	treatment_term	$	Topical Therapy	Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
728	668	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	3	Systemic Cancer Treatment	Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics.	treatment_term	treatment_term	$	Systemic Cancer Treatment	Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
729	673	28	Asthma	Asthma.yaml	clinical_trials	0	NCT05813288	A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
730	673	28	Asthma	Asthma.yaml	clinical_trials	0	NCT05813288	A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Breathlessness	HP:0002094	Dyspnea		"{""preferred_term"": ""Breathlessness"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
731	673	28	Asthma	Asthma.yaml	clinical_trials	0	NCT05813288	A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease.	target_phenotypes[2]	target_phenotypes	target_phenotypes			Chest Tightness	HP:0031352	Chest tightness		"{""preferred_term"": ""Chest Tightness"", ""term"": {""id"": ""HP:0031352"", ""label"": ""Chest tightness""}}"																											
732	673	28	Asthma	Asthma.yaml	clinical_trials	0	NCT05813288	A randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of dexpramipexole in participants with severe eosinophilic asthma. The trial evaluated a novel oral treatment approach over 52 weeks in patients with inadequately controlled disease.	target_phenotypes[3]	target_phenotypes	target_phenotypes			Coughing	HP:0012735	Cough		"{""preferred_term"": ""Coughing"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
733	674	28	Asthma	Asthma.yaml	datasets	0		Bronchial epithelial brushings from mild-to-moderate asthmatics (not on inhaled steroids) and healthy controls, stratified by Type 2 inflammation markers (POSTN, SERPINB2, CLCA1).	organism	organism	$		Bronchial epithelial brushings from mild-to-moderate asthmatics (not on inhaled steroids) and healthy controls, stratified by Type 2 inflammation markers (POSTN, SERPINB2, CLCA1).	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
734	674	28	Asthma	Asthma.yaml	datasets	0		Bronchial epithelial brushings from mild-to-moderate asthmatics (not on inhaled steroids) and healthy controls, stratified by Type 2 inflammation markers (POSTN, SERPINB2, CLCA1).	sample_types[0]	sample_types	sample_types			bronchial epithelial cells				"{""cell_type_term"": {""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}, ""preferred_term"": ""bronchial epithelial cells"", ""tissue_term"": {""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}}"																											
735	674	28	Asthma	Asthma.yaml	datasets	0		Bronchial epithelial brushings from mild-to-moderate asthmatics (not on inhaled steroids) and healthy controls, stratified by Type 2 inflammation markers (POSTN, SERPINB2, CLCA1).	sample_types[0].tissue_term	sample_types	sample_types[0]			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
736	674	28	Asthma	Asthma.yaml	datasets	0		Bronchial epithelial brushings from mild-to-moderate asthmatics (not on inhaled steroids) and healthy controls, stratified by Type 2 inflammation markers (POSTN, SERPINB2, CLCA1).	sample_types[0].cell_type_term	sample_types	sample_types[0]			bronchial epithelial cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
737	675	28	Asthma	Asthma.yaml	datasets	1		Bronchial epithelial cells from normal controls, mild-moderate, and severe asthmatic patients to identify severity-associated gene expression.	organism	organism	$		Bronchial epithelial cells from normal controls, mild-moderate, and severe asthmatic patients to identify severity-associated gene expression.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
738	675	28	Asthma	Asthma.yaml	datasets	1		Bronchial epithelial cells from normal controls, mild-moderate, and severe asthmatic patients to identify severity-associated gene expression.	sample_types[0]	sample_types	sample_types			bronchial epithelial cells				"{""cell_type_term"": {""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}, ""preferred_term"": ""bronchial epithelial cells""}"																											
739	675	28	Asthma	Asthma.yaml	datasets	1		Bronchial epithelial cells from normal controls, mild-moderate, and severe asthmatic patients to identify severity-associated gene expression.	sample_types[0].cell_type_term	sample_types	sample_types[0]			bronchial epithelial cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
740	676	28	Asthma	Asthma.yaml	datasets	2		Large cohort study of nasal epithelial cells comparing asthmatic and control subjects.	organism	organism	$		Large cohort study of nasal epithelial cells comparing asthmatic and control subjects.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
741	676	28	Asthma	Asthma.yaml	datasets	2		Large cohort study of nasal epithelial cells comparing asthmatic and control subjects.	sample_types[0]	sample_types	sample_types			nasal epithelial cells				"{""preferred_term"": ""nasal epithelial cells"", ""tissue_term"": {""preferred_term"": ""nasal cavity mucosa"", ""term"": {""id"": ""UBERON:0001826"", ""label"": ""nasal cavity mucosa""}}}"																											
742	676	28	Asthma	Asthma.yaml	datasets	2		Large cohort study of nasal epithelial cells comparing asthmatic and control subjects.	sample_types[0].tissue_term	sample_types	sample_types[0]			nasal cavity mucosa	UBERON:0001826	nasal cavity mucosa		"{""preferred_term"": ""nasal cavity mucosa"", ""term"": {""id"": ""UBERON:0001826"", ""label"": ""nasal cavity mucosa""}}"																											
743	677	28	Asthma	Asthma.yaml	datasets	3		Single-cell RNA sequencing of airway epithelial cells from asthmatic patients revealing cell-type specific transcriptional changes.	organism	organism	$		Single-cell RNA sequencing of airway epithelial cells from asthmatic patients revealing cell-type specific transcriptional changes.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
744	677	28	Asthma	Asthma.yaml	datasets	3		Single-cell RNA sequencing of airway epithelial cells from asthmatic patients revealing cell-type specific transcriptional changes.	sample_types[0]	sample_types	sample_types			airway epithelial cells				"{""cell_type_term"": {""preferred_term"": ""epithelial cell of tracheobronchial tree"", ""term"": {""id"": ""CL:0002202"", ""label"": ""epithelial cell of tracheobronchial tree""}}, ""preferred_term"": ""airway epithelial cells""}"																											
745	677	28	Asthma	Asthma.yaml	datasets	3		Single-cell RNA sequencing of airway epithelial cells from asthmatic patients revealing cell-type specific transcriptional changes.	sample_types[0].cell_type_term	sample_types	sample_types[0]			epithelial cell of tracheobronchial tree	CL:0002202	epithelial cell of tracheobronchial tree		"{""preferred_term"": ""epithelial cell of tracheobronchial tree"", ""term"": {""id"": ""CL:0002202"", ""label"": ""epithelial cell of tracheobronchial tree""}}"																											
746	678	28	Asthma	Asthma.yaml	datasets	4		Primary human bronchial epithelial cells grown at air-liquid interface, exposed to whole tobacco cigarette smoke and electronic cigarette aerosol.	organism	organism	$		Primary human bronchial epithelial cells grown at air-liquid interface, exposed to whole tobacco cigarette smoke and electronic cigarette aerosol.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
747	678	28	Asthma	Asthma.yaml	datasets	4		Primary human bronchial epithelial cells grown at air-liquid interface, exposed to whole tobacco cigarette smoke and electronic cigarette aerosol.	sample_types[0]	sample_types	sample_types			primary bronchial epithelial cells (ALI culture)				"{""cell_type_term"": {""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}, ""preferred_term"": ""primary bronchial epithelial cells (ALI culture)""}"																											
748	678	28	Asthma	Asthma.yaml	datasets	4		Primary human bronchial epithelial cells grown at air-liquid interface, exposed to whole tobacco cigarette smoke and electronic cigarette aerosol.	sample_types[0].cell_type_term	sample_types	sample_types[0]			bronchial epithelial cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""bronchial epithelial cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
749	678	28	Asthma	Asthma.yaml	datasets	4		Primary human bronchial epithelial cells grown at air-liquid interface, exposed to whole tobacco cigarette smoke and electronic cigarette aerosol.	exposures[0]	exposures	exposures			tobacco smoke exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""tobacco smoke exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
750	679	28	Asthma	Asthma.yaml	datasets	5		Gene expression from lung tissue of ovalbumin-sensitized and challenged BALB/c mice modeling allergic airway inflammation.	organism	organism	$		Gene expression from lung tissue of ovalbumin-sensitized and challenged BALB/c mice modeling allergic airway inflammation.	mouse	NCBITaxon:10090	Mus musculus		"{""preferred_term"": ""mouse"", ""term"": {""id"": ""NCBITaxon:10090"", ""label"": ""Mus musculus""}}"																											
751	679	28	Asthma	Asthma.yaml	datasets	5		Gene expression from lung tissue of ovalbumin-sensitized and challenged BALB/c mice modeling allergic airway inflammation.	sample_types[0]	sample_types	sample_types			whole lung tissue				"{""preferred_term"": ""whole lung tissue"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
752	679	28	Asthma	Asthma.yaml	datasets	5		Gene expression from lung tissue of ovalbumin-sensitized and challenged BALB/c mice modeling allergic airway inflammation.	sample_types[0].tissue_term	sample_types	sample_types[0]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
753	679	28	Asthma	Asthma.yaml	datasets	5		Gene expression from lung tissue of ovalbumin-sensitized and challenged BALB/c mice modeling allergic airway inflammation.	exposures[0]	exposures	exposures			ovalbumin allergen challenge	ECTO:0000726	exposure to allergen		"{""preferred_term"": ""ovalbumin allergen challenge"", ""term"": {""id"": ""ECTO:0000726"", ""label"": ""exposure to allergen""}}"																											
754	680	28	Asthma	Asthma.yaml	environmental	0	Allergens		exposure_term	exposure_term	$	Allergens		Allergen exposure	ECTO:0000726	exposure to allergen		"{""preferred_term"": ""Allergen exposure"", ""term"": {""id"": ""ECTO:0000726"", ""label"": ""exposure to allergen""}}"																											
755	681	28	Asthma	Asthma.yaml	environmental	1	Air Pollution		exposure_term	exposure_term	$	Air Pollution		Air pollution exposure	ECTO:8000036	exposure to air pollution		"{""preferred_term"": ""Air pollution exposure"", ""term"": {""id"": ""ECTO:8000036"", ""label"": ""exposure to air pollution""}}"																											
756	682	28	Asthma	Asthma.yaml	environmental	2	Tobacco Smoke		exposure_term	exposure_term	$	Tobacco Smoke		Tobacco smoke exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoke exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
757	683	28	Asthma	Asthma.yaml	environmental	3	Occupational Exposures		exposure_term	exposure_term	$	Occupational Exposures		Occupational chemical exposure	ECTO:0000231	exposure to chemical		"{""preferred_term"": ""Occupational chemical exposure"", ""term"": {""id"": ""ECTO:0000231"", ""label"": ""exposure to chemical""}}"																											
758	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[0]	cell_types	cell_types			Mast Cell	CL:0000097	mast cell		"{""preferred_term"": ""Mast Cell"", ""term"": {""id"": ""CL:0000097"", ""label"": ""mast cell""}}"																											
759	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[1]	cell_types	cell_types			Eosinophil	CL:0000771	eosinophil		"{""preferred_term"": ""Eosinophil"", ""term"": {""id"": ""CL:0000771"", ""label"": ""eosinophil""}}"																											
760	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[2]	cell_types	cell_types			T-Lymphocyte	CL:0000084	T cell		"{""preferred_term"": ""T-Lymphocyte"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
761	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[3]	cell_types	cell_types			Bronchial Epithelial Cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""Bronchial Epithelial Cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
762	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[4]	cell_types	cell_types			Basophil	CL:0000767	basophil		"{""preferred_term"": ""Basophil"", ""term"": {""id"": ""CL:0000767"", ""label"": ""basophil""}}"																											
763	695	28	Asthma	Asthma.yaml	pathophysiology	0	Airway Inflammation	Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.	cell_types[5]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
764	696	28	Asthma	Asthma.yaml	pathophysiology	1	Bronchoconstriction	During an asthma attack, smooth muscles around the airways tighten and narrow the airway.	cell_types[0]	cell_types	cell_types			Smooth Muscle Cells	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cells"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
765	697	28	Asthma	Asthma.yaml	pathophysiology	2	Mucus Overproduction	Inflammatory cells infiltrate the airways, increasing mucus production, which can block airways and further impair breathing.	cell_types[0]	cell_types	cell_types			Goblet Cell	CL:0000160	goblet cell		"{""preferred_term"": ""Goblet Cell"", ""term"": {""id"": ""CL:0000160"", ""label"": ""goblet cell""}}"																											
766	697	28	Asthma	Asthma.yaml	pathophysiology	2	Mucus Overproduction	Inflammatory cells infiltrate the airways, increasing mucus production, which can block airways and further impair breathing.	cell_types[1]	cell_types	cell_types			Bronchial Epithelial Cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""Bronchial Epithelial Cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
767	697	28	Asthma	Asthma.yaml	pathophysiology	2	Mucus Overproduction	Inflammatory cells infiltrate the airways, increasing mucus production, which can block airways and further impair breathing.	cell_types[2]	cell_types	cell_types			Mucosal Epithelial Cell	CL:0002202	epithelial cell of tracheobronchial tree		"{""preferred_term"": ""Mucosal Epithelial Cell"", ""term"": {""id"": ""CL:0002202"", ""label"": ""epithelial cell of tracheobronchial tree""}}"																											
768	698	28	Asthma	Asthma.yaml	pathophysiology	3	Airway Remodeling	Long-standing inflammation can lead to structural changes in the airway, permanently affecting lung function.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
769	698	28	Asthma	Asthma.yaml	pathophysiology	3	Airway Remodeling	Long-standing inflammation can lead to structural changes in the airway, permanently affecting lung function.	cell_types[1]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
770	698	28	Asthma	Asthma.yaml	pathophysiology	3	Airway Remodeling	Long-standing inflammation can lead to structural changes in the airway, permanently affecting lung function.	cell_types[2]	cell_types	cell_types			Bronchial Epithelial Cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""Bronchial Epithelial Cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
771	699	28	Asthma	Asthma.yaml	phenotypes	0	Wheezing		phenotype_term	phenotype_term	$	Wheezing		Wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
772	700	28	Asthma	Asthma.yaml	phenotypes	1	Coughing		phenotype_term	phenotype_term	$	Coughing		Coughing	HP:0012735	Cough		"{""preferred_term"": ""Coughing"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
773	702	28	Asthma	Asthma.yaml	phenotypes	3	Chest Tightness		phenotype_term	phenotype_term	$	Chest Tightness		Chest Tightness	HP:0031352	Chest tightness		"{""preferred_term"": ""Chest Tightness"", ""term"": {""id"": ""HP:0031352"", ""label"": ""Chest tightness""}}"																											
774	704	28	Asthma	Asthma.yaml	phenotypes	5	Cyanosis		phenotype_term	phenotype_term	$	Cyanosis		Cyanosis	HP:0000961	Cyanosis		"{""preferred_term"": ""Cyanosis"", ""term"": {""id"": ""HP:0000961"", ""label"": ""Cyanosis""}}"																											
775	705	28	Asthma	Asthma.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
776	706	28	Asthma	Asthma.yaml	phenotypes	7	Exercise Intolerance		phenotype_term	phenotype_term	$	Exercise Intolerance		Exercise Intolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Exercise Intolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
777	707	28	Asthma	Asthma.yaml	phenotypes	8	Sleep Disturbance		phenotype_term	phenotype_term	$	Sleep Disturbance		Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
778	708	28	Asthma	Asthma.yaml	phenotypes	9	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
779	709	28	Asthma	Asthma.yaml	phenotypes	10	Respiratory Distress		phenotype_term	phenotype_term	$	Respiratory Distress		Respiratory Distress	HP:0002098	Respiratory distress		"{""preferred_term"": ""Respiratory Distress"", ""term"": {""id"": ""HP:0002098"", ""label"": ""Respiratory distress""}}"																											
780	710	28	Asthma	Asthma.yaml	phenotypes	11	Reduced Exercise Tolerance		phenotype_term	phenotype_term	$	Reduced Exercise Tolerance		Reduced Exercise Tolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Reduced Exercise Tolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
781	711	28	Asthma	Asthma.yaml	treatments	0	Inhaled Corticosteroid	Reduce inflammation and prevent flare-ups.	treatment_term	treatment_term	$	Inhaled Corticosteroid	Reduce inflammation and prevent flare-ups.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
782	712	28	Asthma	Asthma.yaml	treatments	1	Long-acting Beta Agonist	Relax the muscles around the airways.	treatment_term	treatment_term	$	Long-acting Beta Agonist	Relax the muscles around the airways.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
783	713	28	Asthma	Asthma.yaml	treatments	2	Leukotriene Modifier	Reduce inflammation, decrease mucus secretion, and prevent airway constriction.	treatment_term	treatment_term	$	Leukotriene Modifier	Reduce inflammation, decrease mucus secretion, and prevent airway constriction.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
784	714	28	Asthma	Asthma.yaml	treatments	3	Anti-IgE Therapy	Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.	treatment_term	treatment_term	$	Anti-IgE Therapy	Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
785	715	28	Asthma	Asthma.yaml	treatments	4	Short-acting Beta Agonist	Provides rapid relief from acute asthma symptoms.	treatment_term	treatment_term	$	Short-acting Beta Agonist	Provides rapid relief from acute asthma symptoms.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
786	731	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	pathophysiology	0	Atrial Electrical Remodeling	"Rapid atrial rates cause shortening of atrial refractory period and loss of rate adaptation, promoting AF maintenance. AF begets AF.
"	cell_types[0]	cell_types	cell_types			Atrial Cardiomyocyte	CL:0002129	regular atrial cardiac myocyte		"{""preferred_term"": ""Atrial Cardiomyocyte"", ""term"": {""id"": ""CL:0002129"", ""label"": ""regular atrial cardiac myocyte""}}"																											
787	731	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	pathophysiology	0	Atrial Electrical Remodeling	"Rapid atrial rates cause shortening of atrial refractory period and loss of rate adaptation, promoting AF maintenance. AF begets AF.
"	biological_processes[0]	biological_processes	biological_processes			Cardiac Conduction	GO:0086001	cardiac muscle cell action potential		"{""preferred_term"": ""Cardiac Conduction"", ""term"": {""id"": ""GO:0086001"", ""label"": ""cardiac muscle cell action potential""}}"																											
788	732	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	pathophysiology	1	Atrial Structural Remodeling	"Atrial fibrosis and dilation create substrate for AF maintenance. Fibrosis disrupts normal conduction and creates reentrant circuits.
"	cell_types[0]	cell_types	cell_types			Cardiac Fibroblast	CL:0002548	fibroblast of cardiac tissue		"{""preferred_term"": ""Cardiac Fibroblast"", ""term"": {""id"": ""CL:0002548"", ""label"": ""fibroblast of cardiac tissue""}}"																											
789	735	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	0	Palpitations		phenotype_term	phenotype_term	$	Palpitations		Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
790	736	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	1	Irregular Pulse		phenotype_term	phenotype_term	$	Irregular Pulse		Arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
791	737	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
792	738	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	3	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
793	739	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	4	Dizziness		phenotype_term	phenotype_term	$	Dizziness		Dizziness	HP:0002321	Vertigo		"{""preferred_term"": ""Dizziness"", ""term"": {""id"": ""HP:0002321"", ""label"": ""Vertigo""}}"																											
794	740	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	phenotypes	5	Stroke		phenotype_term	phenotype_term	$	Stroke		Stroke	HP:0001297	Stroke		"{""preferred_term"": ""Stroke"", ""term"": {""id"": ""HP:0001297"", ""label"": ""Stroke""}}"																											
795	741	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	0	Anticoagulation	Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score.	treatment_term	treatment_term	$	Anticoagulation	Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
796	742	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	1	Rate Control	Beta blockers, calcium channel blockers, or digoxin.	treatment_term	treatment_term	$	Rate Control	Beta blockers, calcium channel blockers, or digoxin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
797	743	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	2	Rhythm Control	Antiarrhythmic drugs (amiodarone, flecainide, sotalol).	treatment_term	treatment_term	$	Rhythm Control	Antiarrhythmic drugs (amiodarone, flecainide, sotalol).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
798	744	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	3	Catheter Ablation	Pulmonary vein isolation for rhythm control.	treatment_term	treatment_term	$	Catheter Ablation	Pulmonary vein isolation for rhythm control.	radiofrequency ablation therapy	MAXO:0001395	radiofrequency ablation therapy		"{""preferred_term"": ""radiofrequency ablation therapy"", ""term"": {""id"": ""MAXO:0001395"", ""label"": ""radiofrequency ablation therapy""}}"																											
799	751	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	0	Fungal Gut Fermentation	"Overgrowth of fermenting fungi, particularly Candida and Saccharomyces species, in the gastrointestinal tract converts dietary carbohydrates into ethanol through alcoholic fermentation. Glucose is metabolized through glycolysis to pyruvate, which is then converted to acetaldehyde by pyruvate decarboxylase and subsequently reduced to ethanol by alcohol dehydrogenase.
"	cell_types[0]	cell_types	cell_types			Enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""Enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
800	751	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	0	Fungal Gut Fermentation	"Overgrowth of fermenting fungi, particularly Candida and Saccharomyces species, in the gastrointestinal tract converts dietary carbohydrates into ethanol through alcoholic fermentation. Glucose is metabolized through glycolysis to pyruvate, which is then converted to acetaldehyde by pyruvate decarboxylase and subsequently reduced to ethanol by alcohol dehydrogenase.
"	biological_processes[0]	biological_processes	biological_processes			Fermentation	GO:0006113	fermentation		"{""preferred_term"": ""Fermentation"", ""term"": {""id"": ""GO:0006113"", ""label"": ""fermentation""}}"																											
801	751	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	0	Fungal Gut Fermentation	"Overgrowth of fermenting fungi, particularly Candida and Saccharomyces species, in the gastrointestinal tract converts dietary carbohydrates into ethanol through alcoholic fermentation. Glucose is metabolized through glycolysis to pyruvate, which is then converted to acetaldehyde by pyruvate decarboxylase and subsequently reduced to ethanol by alcohol dehydrogenase.
"	biological_processes[1]	biological_processes	biological_processes			Ethanol Metabolic Process	GO:0006067	ethanol metabolic process		"{""preferred_term"": ""Ethanol Metabolic Process"", ""term"": {""id"": ""GO:0006067"", ""label"": ""ethanol metabolic process""}}"																											
802	752	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	1	Bacterial Fermentation by Klebsiella	"High-alcohol-producing Klebsiella pneumoniae and related species can generate endogenous ethanol through the 2,3-butanediol fermentation pathway. These bacteria possess multiple copies of alcohol dehydrogenase genes enabling excessive ethanol production even under aerobic conditions.
"	cell_types[0]	cell_types	cell_types			Enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""Enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
803	752	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	1	Bacterial Fermentation by Klebsiella	"High-alcohol-producing Klebsiella pneumoniae and related species can generate endogenous ethanol through the 2,3-butanediol fermentation pathway. These bacteria possess multiple copies of alcohol dehydrogenase genes enabling excessive ethanol production even under aerobic conditions.
"	biological_processes[0]	biological_processes	biological_processes			Fermentation	GO:0006113	fermentation		"{""preferred_term"": ""Fermentation"", ""term"": {""id"": ""GO:0006113"", ""label"": ""fermentation""}}"																											
804	753	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	2	Impaired Hepatic Ethanol Clearance	"The liver normally clears endogenous ethanol through first-pass metabolism via alcohol dehydrogenase. When ethanol production exceeds hepatic clearance capacity or hepatic function is compromised, ethanol enters systemic circulation causing intoxication symptoms.
"	cell_types[0]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
805	753	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	pathophysiology	2	Impaired Hepatic Ethanol Clearance	"The liver normally clears endogenous ethanol through first-pass metabolism via alcohol dehydrogenase. When ethanol production exceeds hepatic clearance capacity or hepatic function is compromised, ethanol enters systemic circulation causing intoxication symptoms.
"	biological_processes[0]	biological_processes	biological_processes			Ethanol Metabolic Process	GO:0006067	ethanol metabolic process		"{""preferred_term"": ""Ethanol Metabolic Process"", ""term"": {""id"": ""GO:0006067"", ""label"": ""ethanol metabolic process""}}"																											
806	754	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	0	Alcohol Intoxication Symptoms	"Patients exhibit signs and symptoms of alcohol intoxication including disorientation, slurred speech, and impaired coordination despite not consuming alcohol.
"	phenotype_term	phenotype_term	$	Alcohol Intoxication Symptoms	"Patients exhibit signs and symptoms of alcohol intoxication including disorientation, slurred speech, and impaired coordination despite not consuming alcohol.
"	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
807	755	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	1	Dysarthria	Slurred speech is a common presenting symptom.	phenotype_term	phenotype_term	$	Dysarthria	Slurred speech is a common presenting symptom.	Slurred Speech	HP:0001260	Dysarthria		"{""preferred_term"": ""Slurred Speech"", ""term"": {""id"": ""HP:0001260"", ""label"": ""Dysarthria""}}"																											
808	756	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	2	Gait Disturbance	Walking difficulties and unsteady gait due to alcohol intoxication.	phenotype_term	phenotype_term	$	Gait Disturbance	Walking difficulties and unsteady gait due to alcohol intoxication.	Gait Disturbance	HP:0001288	Gait disturbance		"{""preferred_term"": ""Gait Disturbance"", ""term"": {""id"": ""HP:0001288"", ""label"": ""Gait disturbance""}}"																											
809	757	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	3	Confusion	Episodes of confusion and disorientation associated with elevated blood alcohol.	phenotype_term	phenotype_term	$	Confusion	Episodes of confusion and disorientation associated with elevated blood alcohol.	Confusion	HP:0001289	Confusion		"{""preferred_term"": ""Confusion"", ""term"": {""id"": ""HP:0001289"", ""label"": ""Confusion""}}"																											
810	758	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	4	Memory Impairment	Memory problems and cognitive impairment during intoxication episodes.	phenotype_term	phenotype_term	$	Memory Impairment	Memory problems and cognitive impairment during intoxication episodes.	Memory Impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory Impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
811	759	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	5	Abdominal Distention	Bloating from gas production during fermentation.	phenotype_term	phenotype_term	$	Abdominal Distention	Bloating from gas production during fermentation.	Abdominal Distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal Distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
812	760	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	6	Vomiting	Nausea and vomiting associated with intoxication episodes.	phenotype_term	phenotype_term	$	Vomiting	Nausea and vomiting associated with intoxication episodes.	Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
813	761	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	phenotypes	7	Seizures	Seizures can occur in severe cases.	phenotype_term	phenotype_term	$	Seizures	Seizures can occur in severe cases.	Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
814	762	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	0	Antifungal Therapy	"Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.
"	treatment_term	treatment_term	$	Antifungal Therapy	"Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
815	763	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	1	Low Carbohydrate Diet	"Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.
"	treatment_term	treatment_term	$	Low Carbohydrate Diet	"Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.
"	Dietary Intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""Dietary Intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
816	765	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	3	Fecal Microbiota Transplantation	"FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.
"	treatment_term	treatment_term	$	Fecal Microbiota Transplantation	"FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.
"	Fecal Microbiota Transplantation	MAXO:0000748	fecal microbiota transplantation		"{""preferred_term"": ""Fecal Microbiota Transplantation"", ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}"																											
817	771	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	0	Warm Autoantibody-Mediated Hemolysis	IgG autoantibodies coat red blood cells and are recognized by Fc receptors on splenic macrophages, leading to extravascular hemolysis through phagocytosis. Partial phagocytosis creates spherocytes with reduced membrane.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
818	771	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	0	Warm Autoantibody-Mediated Hemolysis	IgG autoantibodies coat red blood cells and are recognized by Fc receptors on splenic macrophages, leading to extravascular hemolysis through phagocytosis. Partial phagocytosis creates spherocytes with reduced membrane.	cell_types[1]	cell_types	cell_types			Red Blood Cell	CL:0000232	erythrocyte		"{""preferred_term"": ""Red Blood Cell"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
819	771	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	0	Warm Autoantibody-Mediated Hemolysis	IgG autoantibodies coat red blood cells and are recognized by Fc receptors on splenic macrophages, leading to extravascular hemolysis through phagocytosis. Partial phagocytosis creates spherocytes with reduced membrane.	biological_processes[0]	biological_processes	biological_processes			Phagocytosis	GO:0006909	phagocytosis		"{""preferred_term"": ""Phagocytosis"", ""term"": {""id"": ""GO:0006909"", ""label"": ""phagocytosis""}}"																											
820	772	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	1	Cold Agglutinin-Mediated Hemolysis	IgM autoantibodies bind RBCs at low temperatures and activate complement. C3b-coated cells undergo extravascular hemolysis in the liver, or MAC formation causes intravascular hemolysis.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
821	773	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	2	B Cell Dysregulation	Loss of B cell tolerance allows production of anti-RBC autoantibodies. In secondary AIHA, underlying conditions (lymphoma, CLL, SLE) drive autoantibody production.	cell_types[0]	cell_types	cell_types			B Cell	CL:0000236	B cell		"{""preferred_term"": ""B Cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
822	773	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	pathophysiology	2	B Cell Dysregulation	Loss of B cell tolerance allows production of anti-RBC autoantibodies. In secondary AIHA, underlying conditions (lymphoma, CLL, SLE) drive autoantibody production.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
823	774	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	phenotypes	0	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
824	775	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	phenotypes	1	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
825	776	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	phenotypes	2	Splenomegaly		phenotype_term	phenotype_term	$	Splenomegaly		Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
826	777	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
827	790	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	0	T Cell-Mediated Hepatocyte Destruction	Autoreactive CD4+ T cells recognize liver autoantigens and orchestrate the immune attack. CD8+ cytotoxic T cells directly kill hepatocytes expressing aberrant MHC class II molecules.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
828	790	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	0	T Cell-Mediated Hepatocyte Destruction	Autoreactive CD4+ T cells recognize liver autoantigens and orchestrate the immune attack. CD8+ cytotoxic T cells directly kill hepatocytes expressing aberrant MHC class II molecules.	cell_types[1]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
829	790	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	0	T Cell-Mediated Hepatocyte Destruction	Autoreactive CD4+ T cells recognize liver autoantigens and orchestrate the immune attack. CD8+ cytotoxic T cells directly kill hepatocytes expressing aberrant MHC class II molecules.	cell_types[2]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
830	790	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	0	T Cell-Mediated Hepatocyte Destruction	Autoreactive CD4+ T cells recognize liver autoantigens and orchestrate the immune attack. CD8+ cytotoxic T cells directly kill hepatocytes expressing aberrant MHC class II molecules.	biological_processes[0]	biological_processes	biological_processes			T Cell Cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T Cell Cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
831	791	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	1	Autoantibody Production	Characteristic autoantibodies include ANA, SMA (anti-actin), anti-LKM1 (anti-CYP2D6), and anti-SLA. While useful for diagnosis, their direct pathogenic role is uncertain.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
832	792	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	2	Regulatory T Cell Deficiency	Impaired function and reduced numbers of regulatory T cells (Tregs) fail to suppress autoreactive T cells, allowing ongoing liver damage.	cell_types[0]	cell_types	cell_types			Regulatory T Cell	CL:0000815	regulatory T cell		"{""preferred_term"": ""Regulatory T Cell"", ""term"": {""id"": ""CL:0000815"", ""label"": ""regulatory T cell""}}"																											
833	792	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	pathophysiology	2	Regulatory T Cell Deficiency	Impaired function and reduced numbers of regulatory T cells (Tregs) fail to suppress autoreactive T cells, allowing ongoing liver damage.	biological_processes[0]	biological_processes	biological_processes			Immune Regulation	GO:0002682	regulation of immune system process		"{""preferred_term"": ""Immune Regulation"", ""term"": {""id"": ""GO:0002682"", ""label"": ""regulation of immune system process""}}"																											
834	793	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	phenotypes	0	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
835	794	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	phenotypes	1	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
836	795	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	phenotypes	2	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
837	796	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	phenotypes	3	Arthralgia		phenotype_term	phenotype_term	$	Arthralgia		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
838	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	cell_types[0]	cell_types	cell_types			migratory neural crest cell	CL:0000333	migratory neural crest cell		"{""preferred_term"": ""migratory neural crest cell"", ""term"": {""id"": ""CL:0000333"", ""label"": ""migratory neural crest cell""}}"																											
839	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	biological_processes[0]	biological_processes	biological_processes			neural crest cell migration	GO:0001755	neural crest cell migration		"{""preferred_term"": ""neural crest cell migration"", ""term"": {""id"": ""GO:0001755"", ""label"": ""neural crest cell migration""}}"																											
840	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	biological_processes[1]	biological_processes	biological_processes			eye morphogenesis	GO:0048592	eye morphogenesis		"{""preferred_term"": ""eye morphogenesis"", ""term"": {""id"": ""GO:0048592"", ""label"": ""eye morphogenesis""}}"																											
841	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	biological_processes[2]	biological_processes	biological_processes			canonical Wnt signaling pathway	GO:0060070	canonical Wnt signaling pathway		"{""preferred_term"": ""canonical Wnt signaling pathway"", ""term"": {""id"": ""GO:0060070"", ""label"": ""canonical Wnt signaling pathway""}}"																											
842	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	locations[0]	locations	locations			trabecular meshwork	UBERON:0001810	trabecular meshwork		"{""preferred_term"": ""trabecular meshwork"", ""term"": {""id"": ""UBERON:0001810"", ""label"": ""trabecular meshwork""}}"																											
843	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	locations[1]	locations	locations			corneal endothelium	UBERON:0001772	corneal endothelium		"{""preferred_term"": ""corneal endothelium"", ""term"": {""id"": ""UBERON:0001772"", ""label"": ""corneal endothelium""}}"																											
844	809	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	0	Disrupted Neural Crest-Derived Periocular Mesenchyme Development	PITX2 and FOXC1 haploinsufficiency in cranial neural crest-derived periocular mesenchyme disrupts signaling integration (retinoic acid-PITX2-DKK2 pathway, Hippo/YAP-TAZ-FOXC1 axis, TGF-beta/ECM interactions) leading to failure of normal regression of transient mesenchyme at the iridocorneal angle and maldevelopment of trabecular meshwork and Schlemm's canal.	locations[2]	locations	locations			iris stroma	UBERON:0011821	iris stroma		"{""preferred_term"": ""iris stroma"", ""term"": {""id"": ""UBERON:0011821"", ""label"": ""iris stroma""}}"																											
845	810	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	1	Dysregulated Transcription Factor Activity	Mutations in the PITX2 gene disrupt its function as a transcription factor, impairing its ability to bind DNA and regulate gene expression critical for eye development. Most mutations cause defects in DNA binding or transcriptional activation, while some increase transactivation activity, leading to unregulated gene expression during embryogenesis.	biological_processes[0]	biological_processes	biological_processes			regulation of transcription by RNA polymerase II	GO:0006357	regulation of transcription by RNA polymerase II		"{""preferred_term"": ""regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0006357"", ""label"": ""regulation of transcription by RNA polymerase II""}}"																											
846	810	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	pathophysiology	1	Dysregulated Transcription Factor Activity	Mutations in the PITX2 gene disrupt its function as a transcription factor, impairing its ability to bind DNA and regulate gene expression critical for eye development. Most mutations cause defects in DNA binding or transcriptional activation, while some increase transactivation activity, leading to unregulated gene expression during embryogenesis.	biological_processes[1]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
847	814	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	0	Glaucoma		phenotype_term	phenotype_term	$	Glaucoma		Glaucoma	HP:0000501	Glaucoma		"{""preferred_term"": ""Glaucoma"", ""term"": {""id"": ""HP:0000501"", ""label"": ""Glaucoma""}}"																											
848	815	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	1	Posterior Embryotoxon		phenotype_term	phenotype_term	$	Posterior Embryotoxon		Posterior Embryotoxon	HP:0000627	Posterior embryotoxon		"{""preferred_term"": ""Posterior Embryotoxon"", ""term"": {""id"": ""HP:0000627"", ""label"": ""Posterior embryotoxon""}}"																											
849	818	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	4	Dental Anomalies		phenotype_term	phenotype_term	$	Dental Anomalies		Abnormal dental morphology	HP:0006482	Abnormal dental morphology		"{""preferred_term"": ""Abnormal dental morphology"", ""term"": {""id"": ""HP:0006482"", ""label"": ""Abnormal dental morphology""}}"																											
850	819	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	5	Craniofacial Dysmorphism		phenotype_term	phenotype_term	$	Craniofacial Dysmorphism		Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
851	821	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	7	Hearing Loss		phenotype_term	phenotype_term	$	Hearing Loss		Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
852	822	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	phenotypes	8	Congenital Heart Defects		phenotype_term	phenotype_term	$	Congenital Heart Defects		Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
853	824	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	0	Glaucoma Pharmacotherapy	Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management.	treatment_term	treatment_term	$	Glaucoma Pharmacotherapy	Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
854	825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	Glaucoma Surgery	Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset.	treatment_term	treatment_term	$	Glaucoma Surgery	Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
855	826	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	2	Dental Management	Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction.	treatment_term	treatment_term	$	Dental Management	Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
856	828	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	variants	0	p.Val136Leu		gene	gene	$	p.Val136Leu		PITX2				"{""preferred_term"": ""PITX2""}"																											
857	834	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	histopathology	0	Papillary Thyroid Carcinoma	Papillary thyroid carcinomas are the most common thyroid cancers.	finding_term	finding_term	$	Papillary Thyroid Carcinoma	Papillary thyroid carcinomas are the most common thyroid cancers.	Thyroid Gland Papillary Carcinoma	NCIT:C4035	Thyroid Gland Papillary Carcinoma		"{""preferred_term"": ""Thyroid Gland Papillary Carcinoma"", ""term"": {""id"": ""NCIT:C4035"", ""label"": ""Thyroid Gland Papillary Carcinoma""}}"																											
858	835	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The BRAF V600E mutation causes constitutive activation of the RAF kinase by mimicking the phosphorylated active state. This results in ligand-independent activation of the MAPK pathway driving thyroid follicular cell proliferation and dedifferentiation.	cell_types[0]	cell_types	cell_types			thyroid follicular cell	CL:0002258	thyroid follicular cell		"{""preferred_term"": ""thyroid follicular cell"", ""term"": {""id"": ""CL:0002258"", ""label"": ""thyroid follicular cell""}}"																											
859	835	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The BRAF V600E mutation causes constitutive activation of the RAF kinase by mimicking the phosphorylated active state. This results in ligand-independent activation of the MAPK pathway driving thyroid follicular cell proliferation and dedifferentiation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
860	835	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The BRAF V600E mutation causes constitutive activation of the RAF kinase by mimicking the phosphorylated active state. This results in ligand-independent activation of the MAPK pathway driving thyroid follicular cell proliferation and dedifferentiation.	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
861	836	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	1	MEK-ERK Pathway Hyperactivation	Mutant BRAF constitutively phosphorylates and activates MEK1/2, leading to sustained ERK1/2 activation. This drives uncontrolled proliferation and is the rationale for combined BRAF/MEK inhibition therapy.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
862	837	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	pathophysiology	2	Thyroid Dedifferentiation	BRAF V600E-driven MAPK activation suppresses expression of thyroid differentiation genes including NIS (sodium-iodide symporter), leading to radioiodine refractoriness. This loss of differentiation is associated with more aggressive disease behavior.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
863	838	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	phenotypes	0	Thyroid Nodule	Most patients present with a thyroid nodule detected on physical examination or incidentally on imaging. BRAF-mutant tumors may have more aggressive ultrasound features.	phenotype_term	phenotype_term	$	Thyroid Nodule	Most patients present with a thyroid nodule detected on physical examination or incidentally on imaging. BRAF-mutant tumors may have more aggressive ultrasound features.	Thyroid carcinoma	HP:0002890	Thyroid carcinoma		"{""preferred_term"": ""Thyroid carcinoma"", ""term"": {""id"": ""HP:0002890"", ""label"": ""Thyroid carcinoma""}}"																											
864	839	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	phenotypes	1	Cervical Lymphadenopathy	Cervical lymph node metastases are common at presentation in BRAF-mutant PTC and may be the initial finding prompting diagnosis.	phenotype_term	phenotype_term	$	Cervical Lymphadenopathy	Cervical lymph node metastases are common at presentation in BRAF-mutant PTC and may be the initial finding prompting diagnosis.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
865	840	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	phenotypes	2	Fatigue	Fatigue may occur in advanced disease, particularly with thyroid hormone imbalance or systemic metastatic disease.	phenotype_term	phenotype_term	$	Fatigue	Fatigue may occur in advanced disease, particularly with thyroid hormone imbalance or systemic metastatic disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
866	841	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
867	842	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression.	treatment_term	treatment_term	$	Radioiodine Therapy	Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	treatment_term	$	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}, {""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}]}"				dabrafenib; trametinib	CHEBI:75045; CHEBI:75998																						
869	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dabrafenib	CHEBI:75045	dabrafenib		"{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}"																											
870	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			trametinib	CHEBI:75998	trametinib		"{""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}"																											
871	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term	treatment_term	$	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
872	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
873	852	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	histopathology	0	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	finding_term	finding_term	$	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	Adenocarcinoma	NCIT:C2852	Adenocarcinoma		"{""preferred_term"": ""Adenocarcinoma"", ""term"": {""id"": ""NCIT:C2852"", ""label"": ""Adenocarcinoma""}}"																											
874	853	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The V600E mutation substitutes glutamic acid for valine at position 600 in the activation segment of BRAF kinase. This mimics phosphorylation-induced activation, locking BRAF in an active conformation. The mutant kinase signals constitutively through MEK and ERK without upstream RAS activation.	cell_types[0]	cell_types	cell_types			colon epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colon epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
875	853	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	0	BRAF V600E Constitutive Activation	The V600E mutation substitutes glutamic acid for valine at position 600 in the activation segment of BRAF kinase. This mimics phosphorylation-induced activation, locking BRAF in an active conformation. The mutant kinase signals constitutively through MEK and ERK without upstream RAS activation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
876	854	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	1	Uncontrolled MAPK Pathway Signaling	Constitutive BRAF V600E activation leads to continuous phosphorylation of MEK1/2, which phosphorylates ERK1/2. Activated ERK translocates to the nucleus and drives expression of genes promoting cell proliferation, survival, and invasion. This signaling is independent of growth factor receptor activation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
877	854	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	1	Uncontrolled MAPK Pathway Signaling	Constitutive BRAF V600E activation leads to continuous phosphorylation of MEK1/2, which phosphorylates ERK1/2. Activated ERK translocates to the nucleus and drives expression of genes promoting cell proliferation, survival, and invasion. This signaling is independent of growth factor receptor activation.	biological_processes[1]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
878	855	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	2	Enhanced Cell Proliferation	Sustained ERK signaling promotes entry into the cell cycle by inducing cyclin D1 and other proliferative genes while suppressing cell cycle inhibitors. This drives continuous tumor cell division independent of external growth signals.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
879	856	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	pathophysiology	3	EGFR Feedback Reactivation	Unlike melanoma, colorectal cancer cells have high EGFR expression. When BRAF is inhibited, relief of ERK-mediated negative feedback leads to rapid EGFR reactivation, which signals through RAS and CRAF to restore MAPK pathway activity. This explains why BRAF inhibitor monotherapy fails in colorectal cancer but works in melanoma.	biological_processes[0]	biological_processes	biological_processes			ERBB signaling pathway	GO:0038127	ERBB signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""ERBB signaling pathway"", ""term"": {""id"": ""GO:0038127"", ""label"": ""ERBB signaling pathway""}}"			INCREASED																								
880	857	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	phenotypes	0	Colon Cancer	BRAF V600E colorectal cancer shows strong predilection for the right colon (proximal colon). Tumors are often diagnosed at advanced stage with peritoneal and distant lymph node metastases.	phenotype_term	phenotype_term	$	Colon Cancer	BRAF V600E colorectal cancer shows strong predilection for the right colon (proximal colon). Tumors are often diagnosed at advanced stage with peritoneal and distant lymph node metastases.	Colon cancer	HP:0003003	Colon cancer		"{""preferred_term"": ""Colon cancer"", ""term"": {""id"": ""HP:0003003"", ""label"": ""Colon cancer""}}"																											
881	858	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	phenotypes	1	Abdominal Pain	Abdominal discomfort from tumor mass effect, particularly with bulky right-sided tumors.	phenotype_term	phenotype_term	$	Abdominal Pain	Abdominal discomfort from tumor mass effect, particularly with bulky right-sided tumors.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
882	859	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	phenotypes	2	Anemia	Iron deficiency anemia from chronic occult blood loss is common, particularly as right-sided tumors may bleed without visible hematochezia.	phenotype_term	phenotype_term	$	Anemia	Iron deficiency anemia from chronic occult blood loss is common, particularly as right-sided tumors may bleed without visible hematochezia.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
883	860	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	phenotypes	3	Weight Loss	Unintentional weight loss is common, reflecting the aggressive nature of BRAF-mutant disease and frequent presentation at advanced stage.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is common, reflecting the aggressive nature of BRAF-mutant disease and frequent presentation at advanced stage.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
884	861	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	phenotypes	4	Fatigue	Fatigue from anemia, advanced disease burden, or tumor-related cachexia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from anemia, advanced disease burden, or tumor-related cachexia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
885	862	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	0	Encorafenib plus Cetuximab	FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy.	treatment_term	treatment_term	$	Encorafenib plus Cetuximab	FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
886	863	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	1	Encorafenib plus Cetuximab plus Binimetinib	Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.	treatment_term	treatment_term	$	Encorafenib plus Cetuximab plus Binimetinib	Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
887	864	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	2	FOLFOXIRI plus Bevacizumab	Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup.	treatment_term	treatment_term	$	FOLFOXIRI plus Bevacizumab	Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
888	865	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit.	treatment_term	treatment_term	$	Surgical Resection	Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
889	870	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
890	871	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	0	BRAF V600E Oncogenic Mutation	The BRAF V600E mutation substitutes glutamic acid for valine at codon 600 in the activation segment. This mimics phosphorylation, causing constitutive kinase activation. V600E signals as a monomer independent of upstream RAS, unlike wild-type BRAF which requires RAS-mediated dimerization.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
891	871	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	0	BRAF V600E Oncogenic Mutation	The BRAF V600E mutation substitutes glutamic acid for valine at codon 600 in the activation segment. This mimics phosphorylation, causing constitutive kinase activation. V600E signals as a monomer independent of upstream RAS, unlike wild-type BRAF which requires RAS-mediated dimerization.	biological_processes[0]	biological_processes	biological_processes			protein kinase activity	GO:0004672	protein kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein kinase activity"", ""term"": {""id"": ""GO:0004672"", ""label"": ""protein kinase activity""}}"			INCREASED																								
892	872	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	BRAF V600E constitutively phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. This leads to uncontrolled proliferation and survival signaling. The lack of dependence on upstream RAS makes the tumor exquisitely sensitive to BRAF inhibition.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
893	873	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Survival	Constitutive ERK signaling drives expression of cyclin D1 and other cell cycle genes, promoting uncontrolled proliferation. ERK also inhibits pro-apoptotic proteins through phosphorylation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
894	874	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	pathophysiology	3	BRAF/MEK Inhibitor Resistance	Resistance to BRAF/MEK inhibition can develop through MAPK pathway reactivation (BRAF amplification, MEK mutations, NRAS mutations), bypass pathway activation (PI3K-AKT), or histologic transformation. Combination BRAF+MEK inhibition delays resistance compared to BRAF inhibitor monotherapy.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
895	875	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	BRAF V600E NSCLC is predominantly adenocarcinoma histology. May have micropapillary or lepidic patterns.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	BRAF V600E NSCLC is predominantly adenocarcinoma histology. May have micropapillary or lepidic patterns.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
896	876	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	phenotypes	1	Variable Smoking History	BRAF V600E occurs in both smokers and never-smokers. The association with smoking is weaker than KRAS mutations but present.	phenotype_term	phenotype_term	$	Variable Smoking History	BRAF V600E occurs in both smokers and never-smokers. The association with smoking is weaker than KRAS mutations but present.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
897	877	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	phenotypes	2	Female Predominance	BRAF V600E NSCLC shows slight female predominance compared to overall NSCLC population.	phenotype_term	phenotype_term	$	Female Predominance	BRAF V600E NSCLC shows slight female predominance compared to overall NSCLC population.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
898	878	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	phenotypes	3	Brain Metastases	Brain metastases occur in BRAF V600E NSCLC. Dabrafenib plus trametinib has demonstrated intracranial activity.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in BRAF V600E NSCLC. Dabrafenib plus trametinib has demonstrated intracranial activity.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
899	879	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	0	Dabrafenib plus Trametinib	Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial.	treatment_term	treatment_term	$	Dabrafenib plus Trametinib	Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
900	880	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	1	Dabrafenib Monotherapy	BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation.	treatment_term	treatment_term	$	Dabrafenib Monotherapy	BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
901	881	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	2	Encorafenib plus Binimetinib	Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action.	treatment_term	treatment_term	$	Encorafenib plus Binimetinib	Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
902	882	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
903	883	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
904	886	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	histopathology	0	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	finding_term	finding_term	$	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	Melanocytic Neoplasm	NCIT:C7058	Melanocytic Neoplasm		"{""preferred_term"": ""Melanocytic Neoplasm"", ""term"": {""id"": ""NCIT:C7058"", ""label"": ""Melanocytic Neoplasm""}}"																											
905	887	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	0	BRAF V600 Oncogenic Mutation	BRAF V600 mutations, predominantly V600E and V600K, result in substitution of the valine residue in the activation loop of the BRAF kinase. This removes an autoinhibitory mechanism, causing constitutive kinase activity independent of upstream RAS signaling. The mutant BRAF signals as a monomer, unlike wild-type BRAF which requires dimerization for activation.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
906	887	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	0	BRAF V600 Oncogenic Mutation	BRAF V600 mutations, predominantly V600E and V600K, result in substitution of the valine residue in the activation loop of the BRAF kinase. This removes an autoinhibitory mechanism, causing constitutive kinase activity independent of upstream RAS signaling. The mutant BRAF signals as a monomer, unlike wild-type BRAF which requires dimerization for activation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
907	888	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	Mutant BRAF continuously phosphorylates and activates MEK1/2, which in turn activates ERK1/2. This constitutive MAPK signaling drives expression of genes promoting cell cycle progression, survival, and proliferation. The pathway operates independently of growth factor stimulation.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
908	888	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	1	Constitutive MAPK Pathway Activation	Mutant BRAF continuously phosphorylates and activates MEK1/2, which in turn activates ERK1/2. This constitutive MAPK signaling drives expression of genes promoting cell cycle progression, survival, and proliferation. The pathway operates independently of growth factor stimulation.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
909	889	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK signaling drives melanocyte proliferation through ERK-mediated phosphorylation and stabilization of transcription factors controlling cell cycle progression, including upregulation of cyclin D1 and suppression of cell cycle inhibitors such as p27.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
910	889	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK signaling drives melanocyte proliferation through ERK-mediated phosphorylation and stabilization of transcription factors controlling cell cycle progression, including upregulation of cyclin D1 and suppression of cell cycle inhibitors such as p27.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
911	889	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK signaling drives melanocyte proliferation through ERK-mediated phosphorylation and stabilization of transcription factors controlling cell cycle progression, including upregulation of cyclin D1 and suppression of cell cycle inhibitors such as p27.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
912	890	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	pathophysiology	3	Apoptosis Resistance	BRAF V600 signaling promotes melanoma cell survival through multiple anti-apoptotic mechanisms, including upregulation of BCL2 family members and suppression of pro-apoptotic BIM. This contributes to tumor persistence and therapy resistance.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
913	891	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	phenotypes	0	Cutaneous Melanoma	Melanoma arising from cutaneous melanocytes. BRAF V600-mutant melanomas are typically associated with intermittent UV exposure sites and often display superficial spreading or nodular histologic patterns.	phenotype_term	phenotype_term	$	Cutaneous Melanoma	Melanoma arising from cutaneous melanocytes. BRAF V600-mutant melanomas are typically associated with intermittent UV exposure sites and often display superficial spreading or nodular histologic patterns.	Cutaneous melanoma	HP:0012056	Cutaneous melanoma		"{""preferred_term"": ""Cutaneous melanoma"", ""term"": {""id"": ""HP:0012056"", ""label"": ""Cutaneous melanoma""}}"																											
914	892	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	phenotypes	1	Pigmented Skin Lesion	The primary tumor typically presents as an asymmetric, irregularly bordered pigmented lesion with color variegation, often arising from a pre-existing nevus or de novo on sun-exposed skin.	phenotype_term	phenotype_term	$	Pigmented Skin Lesion	The primary tumor typically presents as an asymmetric, irregularly bordered pigmented lesion with color variegation, often arising from a pre-existing nevus or de novo on sun-exposed skin.	Neoplasm of the skin	HP:0008069	Neoplasm of the skin		"{""preferred_term"": ""Neoplasm of the skin"", ""term"": {""id"": ""HP:0008069"", ""label"": ""Neoplasm of the skin""}}"																											
915	893	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	0	Dabrafenib plus Trametinib	First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas.	treatment_term	treatment_term	$	Dabrafenib plus Trametinib	First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
916	894	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	1	Vemurafenib plus Cobimetinib	Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects.	treatment_term	treatment_term	$	Vemurafenib plus Cobimetinib	Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
917	895	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	2	Encorafenib plus Binimetinib	Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency.	treatment_term	treatment_term	$	Encorafenib plus Binimetinib	Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
918	896	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
919	902	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	histopathology	0	Acinar Adenocarcinoma	The most common prostatic cancers are acinary adenocarcinomas.	finding_term	finding_term	$	Acinar Adenocarcinoma	The most common prostatic cancers are acinary adenocarcinomas.	Prostate Acinar Adenocarcinoma	NCIT:C5596	Prostate Acinar Adenocarcinoma		"{""preferred_term"": ""Prostate Acinar Adenocarcinoma"", ""term"": {""id"": ""NCIT:C5596"", ""label"": ""Prostate Acinar Adenocarcinoma""}}"																											
920	903	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	0	Homologous Recombination Repair Deficiency	Loss of functional BRCA1 or BRCA2 impairs homologous recombination repair (HRR), the high-fidelity pathway for repairing DNA double-strand breaks. This leads to accumulation of genomic instability and reliance on error-prone repair pathways.	cell_types[0]	cell_types	cell_types			prostate gland cell	CL:0002231	epithelial cell of prostate		"{""preferred_term"": ""prostate gland cell"", ""term"": {""id"": ""CL:0002231"", ""label"": ""epithelial cell of prostate""}}"																											
921	903	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	0	Homologous Recombination Repair Deficiency	Loss of functional BRCA1 or BRCA2 impairs homologous recombination repair (HRR), the high-fidelity pathway for repairing DNA double-strand breaks. This leads to accumulation of genomic instability and reliance on error-prone repair pathways.	biological_processes[0]	biological_processes	biological_processes			double-strand break repair via homologous recombination	GO:0000724	double-strand break repair via homologous recombination		"{""modifier"": ""DECREASED"", ""preferred_term"": ""double-strand break repair via homologous recombination"", ""term"": {""id"": ""GO:0000724"", ""label"": ""double-strand break repair via homologous recombination""}}"			DECREASED																								
922	903	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	0	Homologous Recombination Repair Deficiency	Loss of functional BRCA1 or BRCA2 impairs homologous recombination repair (HRR), the high-fidelity pathway for repairing DNA double-strand breaks. This leads to accumulation of genomic instability and reliance on error-prone repair pathways.	locations[0]	locations	locations			prostate gland	UBERON:0002367	prostate gland		"{""preferred_term"": ""prostate gland"", ""term"": {""id"": ""UBERON:0002367"", ""label"": ""prostate gland""}}"																											
923	904	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	1	Genomic Instability	HRR deficiency leads to genomic instability characterized by chromosomal rearrangements, copy number alterations, and mutational signatures typical of BRCA deficiency. This drives aggressive tumor behavior but also creates therapeutic vulnerabilities.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
924	905	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	pathophysiology	2	Synthetic Lethality with PARP Inhibition	PARP enzymes are essential for single-strand break repair. In HRR-deficient cells, PARP inhibition causes accumulation of double-strand breaks that cannot be repaired, leading to synthetic lethality and selective tumor cell death.	biological_processes[0]	biological_processes	biological_processes			single-strand break repair	GO:0000012	single-strand break repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""single-strand break repair"", ""term"": {""id"": ""GO:0000012"", ""label"": ""single-strand break repair""}}"			DECREASED																								
925	906	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	phenotypes	0	Lower Urinary Tract Symptoms	Urinary frequency, urgency, hesitancy, and weak stream due to prostate enlargement from tumor growth.	phenotype_term	phenotype_term	$	Lower Urinary Tract Symptoms	Urinary frequency, urgency, hesitancy, and weak stream due to prostate enlargement from tumor growth.	Abnormality of the urinary system	HP:0000079	Abnormality of the urinary system		"{""preferred_term"": ""Abnormality of the urinary system"", ""term"": {""id"": ""HP:0000079"", ""label"": ""Abnormality of the urinary system""}}"																											
926	907	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	phenotypes	1	Bone Pain	Bone metastases are common in advanced prostate cancer and may present earlier in BRCA-mutant disease. Osteoblastic lesions are typical.	phenotype_term	phenotype_term	$	Bone Pain	Bone metastases are common in advanced prostate cancer and may present earlier in BRCA-mutant disease. Osteoblastic lesions are typical.	Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
927	908	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	phenotypes	2	Fatigue	Constitutional symptoms are common in metastatic disease and may be exacerbated by androgen deprivation therapy.	phenotype_term	phenotype_term	$	Fatigue	Constitutional symptoms are common in metastatic disease and may be exacerbated by androgen deprivation therapy.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
928	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term	treatment_term	$	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}"				olaparib	CHEBI:83766																						
929	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"																											
930	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term	treatment_term	$	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}]}"				rucaparib	CHEBI:134689																						
931	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			rucaparib	CHEBI:134689	rucaparib		"{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}"																											
932	911	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	2	Platinum Chemotherapy	HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered.	treatment_term	treatment_term	$	Platinum Chemotherapy	HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
933	912	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	3	Androgen Deprivation Therapy	Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone.	treatment_term	treatment_term	$	Androgen Deprivation Therapy	Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
934	920	39	Bacterial meningitis	Bacterial_meningitis.yaml	differential_diagnoses	0	Viral Meningitis	Aseptic meningitis with lower inflammatory biomarkers and typically milder CSF abnormalities.	disease_term	disease_term	$	Viral Meningitis	Aseptic meningitis with lower inflammatory biomarkers and typically milder CSF abnormalities.	viral meningitis	MONDO:0007015	viral meningitis		"{""preferred_term"": ""viral meningitis"", ""term"": {""id"": ""MONDO:0007015"", ""label"": ""viral meningitis""}}"																											
935	921	39	Bacterial meningitis	Bacterial_meningitis.yaml	differential_diagnoses	1	Tuberculous Meningitis	Subacute meningeal infection from Mycobacterium tuberculosis with lower D-dimer and CRP than acute bacterial meningitis.	disease_term	disease_term	$	Tuberculous Meningitis	Subacute meningeal infection from Mycobacterium tuberculosis with lower D-dimer and CRP than acute bacterial meningitis.	meningeal tuberculosis	MONDO:0006042	meningeal tuberculosis		"{""preferred_term"": ""meningeal tuberculosis"", ""term"": {""id"": ""MONDO:0006042"", ""label"": ""meningeal tuberculosis""}}"																											
936	922	39	Bacterial meningitis	Bacterial_meningitis.yaml	differential_diagnoses	2	Encephalitis or Cerebritis/Abscess	Parenchymal infection or inflammation with focal lesions rather than isolated meningeal involvement.	disease_term	disease_term	$	Encephalitis or Cerebritis/Abscess	Parenchymal infection or inflammation with focal lesions rather than isolated meningeal involvement.	encephalitis	MONDO:0019956	encephalitis		"{""preferred_term"": ""encephalitis"", ""term"": {""id"": ""MONDO:0019956"", ""label"": ""encephalitis""}}"																											
937	927	39	Bacterial meningitis	Bacterial_meningitis.yaml	infectious_agent	0	Neisseria meningitidis	A common cause of bacterial meningitis, particularly in children and young adults.	infectious_agent_term	infectious_agent_term	$	Neisseria meningitidis	A common cause of bacterial meningitis, particularly in children and young adults.	Neisseria meningitidis	NCBITaxon:487	Neisseria meningitidis		"{""preferred_term"": ""Neisseria meningitidis"", ""term"": {""id"": ""NCBITaxon:487"", ""label"": ""Neisseria meningitidis""}}"																											
938	928	39	Bacterial meningitis	Bacterial_meningitis.yaml	infectious_agent	1	Streptococcus pneumoniae	The most common cause of bacterial meningitis in adults.	infectious_agent_term	infectious_agent_term	$	Streptococcus pneumoniae	The most common cause of bacterial meningitis in adults.	Streptococcus pneumoniae	NCBITaxon:1313	Streptococcus pneumoniae		"{""preferred_term"": ""Streptococcus pneumoniae"", ""term"": {""id"": ""NCBITaxon:1313"", ""label"": ""Streptococcus pneumoniae""}}"																											
939	929	39	Bacterial meningitis	Bacterial_meningitis.yaml	infectious_agent	2	Haemophilus influenzae	Was a common cause in children before the Hib vaccine.	infectious_agent_term	infectious_agent_term	$	Haemophilus influenzae	Was a common cause in children before the Hib vaccine.	Haemophilus influenzae	NCBITaxon:727			"{""preferred_term"": ""Haemophilus influenzae"", ""term"": {""id"": ""NCBITaxon:727""}}"																											
940	930	39	Bacterial meningitis	Bacterial_meningitis.yaml	infectious_agent	3	Listeria monocytogenes	Can cause meningitis in newborns, pregnant women, and immunocompromised individuals.	infectious_agent_term	infectious_agent_term	$	Listeria monocytogenes	Can cause meningitis in newborns, pregnant women, and immunocompromised individuals.	Listeria monocytogenes	NCBITaxon:1639	Listeria monocytogenes		"{""preferred_term"": ""Listeria monocytogenes"", ""term"": {""id"": ""NCBITaxon:1639"", ""label"": ""Listeria monocytogenes""}}"																											
941	931	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	0	Bacterial Invasion	Bacteria enter the bloodstream and cross the blood-brain barrier to infect the meninges.	locations[0]	locations	locations			blood-brain barrier	UBERON:0000120	blood-brain barrier		"{""preferred_term"": ""blood-brain barrier"", ""term"": {""id"": ""UBERON:0000120"", ""label"": ""blood-brain barrier""}}"																											
942	931	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	0	Bacterial Invasion	Bacteria enter the bloodstream and cross the blood-brain barrier to infect the meninges.	locations[1]	locations	locations			meninges	UBERON:0002360	meninges		"{""preferred_term"": ""meninges"", ""term"": {""id"": ""UBERON:0002360"", ""label"": ""meninges""}}"																											
943	931	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	0	Bacterial Invasion	Bacteria enter the bloodstream and cross the blood-brain barrier to infect the meninges.	locations[2]	locations	locations			cerebrospinal fluid	UBERON:0001359	cerebrospinal fluid		"{""preferred_term"": ""cerebrospinal fluid"", ""term"": {""id"": ""UBERON:0001359"", ""label"": ""cerebrospinal fluid""}}"																											
944	931	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	0	Bacterial Invasion	Bacteria enter the bloodstream and cross the blood-brain barrier to infect the meninges.	cell_types[0]	cell_types	cell_types			brain microvascular endothelial cell	CL:2000044	brain microvascular endothelial cell		"{""preferred_term"": ""brain microvascular endothelial cell"", ""term"": {""id"": ""CL:2000044"", ""label"": ""brain microvascular endothelial cell""}}"																											
945	931	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	0	Bacterial Invasion	Bacteria enter the bloodstream and cross the blood-brain barrier to infect the meninges.	cell_types[1]	cell_types	cell_types			choroid plexus epithelial cell	CL:0000706	choroid plexus epithelial cell		"{""preferred_term"": ""choroid plexus epithelial cell"", ""term"": {""id"": ""CL:0000706"", ""label"": ""choroid plexus epithelial cell""}}"																											
946	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	locations[0]	locations	locations			subarachnoid space	UBERON:0001496	subarachnoid space		"{""preferred_term"": ""subarachnoid space"", ""term"": {""id"": ""UBERON:0001496"", ""label"": ""subarachnoid space""}}"																											
947	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
948	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
949	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	cell_types[2]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
950	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	chemical_entities[0]	chemical_entities	chemical_entities			Cytokines	CHEBI:59527	cytokine		"{""preferred_term"": ""Cytokines"", ""term"": {""id"": ""CHEBI:59527"", ""label"": ""cytokine""}}"																											
951	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	chemical_entities[1]	chemical_entities	chemical_entities			Chemokines	CHEBI:80222	chemokine		"{""preferred_term"": ""Chemokines"", ""term"": {""id"": ""CHEBI:80222"", ""label"": ""chemokine""}}"																											
952	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
953	932	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	1	Inflammation	Bacterial components trigger a strong inflammatory response in the subarachnoid space.	biological_processes[1]	biological_processes	biological_processes			innate immune response	GO:0045087	innate immune response		"{""preferred_term"": ""innate immune response"", ""term"": {""id"": ""GO:0045087"", ""label"": ""innate immune response""}}"																											
954	933	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	2	Increased Intracranial Pressure	Inflammation and accumulation of purulent exudate lead to increased intracranial pressure.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
955	933	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	2	Increased Intracranial Pressure	Inflammation and accumulation of purulent exudate lead to increased intracranial pressure.	locations[1]	locations	locations			cerebrospinal fluid	UBERON:0001359	cerebrospinal fluid		"{""preferred_term"": ""cerebrospinal fluid"", ""term"": {""id"": ""UBERON:0001359"", ""label"": ""cerebrospinal fluid""}}"																											
956	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	genes[0]	genes	genes			TLR2	hgnc:11849	TLR2		"{""preferred_term"": ""TLR2"", ""term"": {""id"": ""hgnc:11849"", ""label"": ""TLR2""}}"																											
957	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	genes[1]	genes	genes			TLR4	hgnc:11850	TLR4		"{""preferred_term"": ""TLR4"", ""term"": {""id"": ""hgnc:11850"", ""label"": ""TLR4""}}"																											
958	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	locations[0]	locations	locations			blood-brain barrier	UBERON:0000120	blood-brain barrier		"{""preferred_term"": ""blood-brain barrier"", ""term"": {""id"": ""UBERON:0000120"", ""label"": ""blood-brain barrier""}}"																											
959	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	locations[1]	locations	locations			meninges	UBERON:0002360	meninges		"{""preferred_term"": ""meninges"", ""term"": {""id"": ""UBERON:0002360"", ""label"": ""meninges""}}"																											
960	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
961	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
962	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	cell_types[2]	cell_types	cell_types			brain microvascular endothelial cell	CL:2000044	brain microvascular endothelial cell		"{""preferred_term"": ""brain microvascular endothelial cell"", ""term"": {""id"": ""CL:2000044"", ""label"": ""brain microvascular endothelial cell""}}"																											
963	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	biological_processes[0]	biological_processes	biological_processes			toll-like receptor signaling pathway	GO:0002224	toll-like receptor signaling pathway		"{""preferred_term"": ""toll-like receptor signaling pathway"", ""term"": {""id"": ""GO:0002224"", ""label"": ""toll-like receptor signaling pathway""}}"																											
964	934	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	3	TLR-Mediated Innate Immune Activation	Pattern recognition receptors TLR2 and TLR4 recognize bacterial components and initiate NF-kB-dependent cytokine responses.	biological_processes[1]	biological_processes	biological_processes			I-kappaB kinase/NF-kappaB signaling	GO:0007249	I-kappaB kinase/NF-kappaB signaling		"{""preferred_term"": ""I-kappaB kinase/NF-kappaB signaling"", ""term"": {""id"": ""GO:0007249"", ""label"": ""I-kappaB kinase/NF-kappaB signaling""}}"																											
965	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	genes[0]	genes	genes			NLRP3	hgnc:16400	NLRP3		"{""preferred_term"": ""NLRP3"", ""term"": {""id"": ""hgnc:16400"", ""label"": ""NLRP3""}}"																											
966	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	genes[1]	genes	genes			CASP1	hgnc:1499	CASP1		"{""preferred_term"": ""CASP1"", ""term"": {""id"": ""hgnc:1499"", ""label"": ""CASP1""}}"																											
967	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
968	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	locations[1]	locations	locations			cerebrospinal fluid	UBERON:0001359	cerebrospinal fluid		"{""preferred_term"": ""cerebrospinal fluid"", ""term"": {""id"": ""UBERON:0001359"", ""label"": ""cerebrospinal fluid""}}"																											
969	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
970	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
971	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	biological_processes[0]	biological_processes	biological_processes			inflammasome complex assembly	GO:0061702	inflammasome complex assembly		"{""preferred_term"": ""inflammasome complex assembly"", ""term"": {""id"": ""GO:0061702"", ""label"": ""inflammasome complex assembly""}}"																											
972	935	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	4	Inflammasome Activation and Pyroptosis	NLRP3 inflammasome activation drives caspase-1-mediated IL-1beta and IL-18 maturation and pyroptotic cell death, amplifying inflammation and tissue injury.	biological_processes[1]	biological_processes	biological_processes			pyroptosis	GO:0070269	pyroptosis		"{""preferred_term"": ""pyroptosis"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptosis""}}"																											
973	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	genes[0]	genes	genes			IL22	hgnc:5982	IL22		"{""preferred_term"": ""IL22"", ""term"": {""id"": ""hgnc:5982"", ""label"": ""IL22""}}"																											
974	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	genes[1]	genes	genes			STAT3	hgnc:11364	STAT3		"{""preferred_term"": ""STAT3"", ""term"": {""id"": ""hgnc:11364"", ""label"": ""STAT3""}}"																											
975	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	genes[2]	genes	genes			VEGFA	hgnc:12680	VEGFA		"{""preferred_term"": ""VEGFA"", ""term"": {""id"": ""hgnc:12680"", ""label"": ""VEGFA""}}"																											
976	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	genes[3]	genes	genes			EGR1	hgnc:3238	EGR1		"{""preferred_term"": ""EGR1"", ""term"": {""id"": ""hgnc:3238"", ""label"": ""EGR1""}}"																											
977	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	genes[4]	genes	genes			MMP9	hgnc:7176	MMP9		"{""preferred_term"": ""MMP9"", ""term"": {""id"": ""hgnc:7176"", ""label"": ""MMP9""}}"																											
978	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	locations[0]	locations	locations			blood-brain barrier	UBERON:0000120	blood-brain barrier		"{""preferred_term"": ""blood-brain barrier"", ""term"": {""id"": ""UBERON:0000120"", ""label"": ""blood-brain barrier""}}"																											
979	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	cell_types[0]	cell_types	cell_types			brain microvascular endothelial cell	CL:2000044	brain microvascular endothelial cell		"{""preferred_term"": ""brain microvascular endothelial cell"", ""term"": {""id"": ""CL:2000044"", ""label"": ""brain microvascular endothelial cell""}}"																											
980	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT cascade	GO:0007259	JAK-STAT cascade		"{""preferred_term"": ""JAK-STAT cascade"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"																											
981	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	biological_processes[1]	biological_processes	biological_processes			VEGF-activated receptor activity	GO:0005021	vascular endothelial growth factor-activated receptor activity		"{""preferred_term"": ""VEGF-activated receptor activity"", ""term"": {""id"": ""GO:0005021"", ""label"": ""vascular endothelial growth factor-activated receptor activity""}}"																											
982	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	biological_processes[2]	biological_processes	biological_processes			tight junction organization	GO:0120193	tight junction organization		"{""preferred_term"": ""tight junction organization"", ""term"": {""id"": ""GO:0120193"", ""label"": ""tight junction organization""}}"																											
983	936	39	Bacterial meningitis	Bacterial_meningitis.yaml	pathophysiology	5	Blood-Brain Barrier Disruption	Host inflammatory signaling and bacterial virulence factors cause breakdown of tight junctions and increased vascular permeability.	biological_processes[3]	biological_processes	biological_processes			extracellular matrix disassembly	GO:0022617	extracellular matrix disassembly		"{""preferred_term"": ""extracellular matrix disassembly"", ""term"": {""id"": ""GO:0022617"", ""label"": ""extracellular matrix disassembly""}}"																											
984	937	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	0	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
985	940	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	3	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
986	941	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	4	Photophobia		phenotype_term	phenotype_term	$	Photophobia		Photophobia	HP:0000613	Photophobia		"{""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}"																											
987	942	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	5	Hearing Loss		phenotype_term	phenotype_term	$	Hearing Loss		Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
988	943	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	6	Hydrocephalus		phenotype_term	phenotype_term	$	Hydrocephalus		Hydrocephalus	HP:0000238	Hydrocephalus		"{""preferred_term"": ""Hydrocephalus"", ""term"": {""id"": ""HP:0000238"", ""label"": ""Hydrocephalus""}}"																											
989	945	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	8	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
990	946	39	Bacterial meningitis	Bacterial_meningitis.yaml	phenotypes	9	Focal Neurological Deficits		phenotype_term	phenotype_term	$	Focal Neurological Deficits		Focal Neurological Deficits	HP:0001268	Mental deterioration		"{""preferred_term"": ""Focal Neurological Deficits"", ""term"": {""id"": ""HP:0001268"", ""label"": ""Mental deterioration""}}"																											
991	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term	treatment_term	$	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Broad Spectrum Antibiotic	NCIT:C2883	NCIT:C2259			
992	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
993	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}"																											
994	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term	treatment_term	$	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Anti-Infective Agent	NCIT:C28254	NCIT:C2259			
995	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
996	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			anti-infective agent	NCIT:C28254	Anti-Infective Agent		"{""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}"																											
997	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term	treatment_term	$	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Dexamethasone	NCIT:C620	NCIT:C2259			
998	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
999	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			dexamethasone	NCIT:C620	Dexamethasone		"{""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}"																											
1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	treatment_term	$	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}}], ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																						Anticonvulsant Agent	NCIT:C614	NCIT:C2259	Fluid Replacement Therapy	NCIT:C15693	NCIT:C49236
1001	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
1002	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			fluid therapy	NCIT:C15693	Fluid Replacement Therapy		"{""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}"																											
1003	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1004	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			anticonvulsant agent	NCIT:C614	Anticonvulsant Agent		"{""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}"																											
1005	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term	treatment_term	$	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}, ""value"": {""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}}], ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"												Vaccine	NCIT:C15260	NCIT:C307													
1006	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			immunologic factor	NCIT:C307	Immunologic Factor		"{""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}"																											
1007	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			vaccine	NCIT:C15260	Vaccine		"{""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}"																											
1008	963	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	0			genes[0]	genes	genes			Bbs1				"{""preferred_term"": ""Bbs1""}"																											
1009	964	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	1			genes[0]	genes	genes			Bbs4				"{""preferred_term"": ""Bbs4""}"																											
1010	965	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	2			genes[0]	genes	genes			Bbs6				"{""preferred_term"": ""Bbs6""}"																											
1011	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[0]	genes	genes			Bbs1				"{""preferred_term"": ""Bbs1""}"																											
1012	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[1]	genes	genes			Bbs2				"{""preferred_term"": ""Bbs2""}"																											
1013	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[2]	genes	genes			Bbs4				"{""preferred_term"": ""Bbs4""}"																											
1014	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[3]	genes	genes			Bbs5				"{""preferred_term"": ""Bbs5""}"																											
1015	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[4]	genes	genes			Bbs7				"{""preferred_term"": ""Bbs7""}"																											
1016	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[5]	genes	genes			Bbs9				"{""preferred_term"": ""Bbs9""}"																											
1017	966	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	animal_models	3			genes[6]	genes	genes			Bbs18				"{""preferred_term"": ""Bbs18""}"																											
1018	975	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	inheritance	0	Autosomal recessive	"Bardet-Biedl syndrome is classically autosomal recessive with clinically variable presentation. Complex inheritance is not typical for BBS1.
"	inheritance_term	inheritance_term	$	Autosomal recessive	"Bardet-Biedl syndrome is classically autosomal recessive with clinically variable presentation. Complex inheritance is not typical for BBS1.
"	Autosomal recessive inheritance	HP:0000007	Autosomal recessive inheritance		"{""preferred_term"": ""Autosomal recessive inheritance"", ""term"": {""id"": ""HP:0000007"", ""label"": ""Autosomal recessive inheritance""}}"																											
1019	976	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the function of primary cilia due to mutations in BBS genes lead to a wide range of symptoms.	cellular_components[0]	cellular_components	cellular_components			Primary Cilium	GO:0005929	cilium		"{""preferred_term"": ""Primary Cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
1020	977	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	1	BBSome Assembly and Intraflagellar Transport Defects	The BBSome is an octameric protein complex (BBS1/2/4/5/7/8/9/BBIP1) whose assembly requires chaperonin-like proteins (BBS6, BBS10, BBS12). The BBSome cooperates with intraflagellar transport (IFT) machinery to regulate ciliary entry, retention, and retrieval of membrane proteins including GPCRs. Disruption of BBSome-mediated trafficking causes mislocalization of ciliary cargos and impaired ciliary signaling across multiple tissues.	cellular_components[0]	cellular_components	cellular_components			BBSome	GO:0034464	BBSome		"{""preferred_term"": ""BBSome"", ""term"": {""id"": ""GO:0034464"", ""label"": ""BBSome""}}"																											
1021	977	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	1	BBSome Assembly and Intraflagellar Transport Defects	The BBSome is an octameric protein complex (BBS1/2/4/5/7/8/9/BBIP1) whose assembly requires chaperonin-like proteins (BBS6, BBS10, BBS12). The BBSome cooperates with intraflagellar transport (IFT) machinery to regulate ciliary entry, retention, and retrieval of membrane proteins including GPCRs. Disruption of BBSome-mediated trafficking causes mislocalization of ciliary cargos and impaired ciliary signaling across multiple tissues.	cellular_components[1]	cellular_components	cellular_components			Ciliary Transition Zone	GO:0035869	ciliary transition zone		"{""preferred_term"": ""Ciliary Transition Zone"", ""term"": {""id"": ""GO:0035869"", ""label"": ""ciliary transition zone""}}"																											
1022	977	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	1	BBSome Assembly and Intraflagellar Transport Defects	The BBSome is an octameric protein complex (BBS1/2/4/5/7/8/9/BBIP1) whose assembly requires chaperonin-like proteins (BBS6, BBS10, BBS12). The BBSome cooperates with intraflagellar transport (IFT) machinery to regulate ciliary entry, retention, and retrieval of membrane proteins including GPCRs. Disruption of BBSome-mediated trafficking causes mislocalization of ciliary cargos and impaired ciliary signaling across multiple tissues.	biological_processes[0]	biological_processes	biological_processes			Intraflagellar Transport	GO:0042073	intraflagellar transport		"{""preferred_term"": ""Intraflagellar Transport"", ""term"": {""id"": ""GO:0042073"", ""label"": ""intraflagellar transport""}}"																											
1023	977	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	1	BBSome Assembly and Intraflagellar Transport Defects	The BBSome is an octameric protein complex (BBS1/2/4/5/7/8/9/BBIP1) whose assembly requires chaperonin-like proteins (BBS6, BBS10, BBS12). The BBSome cooperates with intraflagellar transport (IFT) machinery to regulate ciliary entry, retention, and retrieval of membrane proteins including GPCRs. Disruption of BBSome-mediated trafficking causes mislocalization of ciliary cargos and impaired ciliary signaling across multiple tissues.	biological_processes[1]	biological_processes	biological_processes			Protein Localization to Cilium	GO:0061512	protein localization to cilium		"{""preferred_term"": ""Protein Localization to Cilium"", ""term"": {""id"": ""GO:0061512"", ""label"": ""protein localization to cilium""}}"																											
1024	977	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	1	BBSome Assembly and Intraflagellar Transport Defects	The BBSome is an octameric protein complex (BBS1/2/4/5/7/8/9/BBIP1) whose assembly requires chaperonin-like proteins (BBS6, BBS10, BBS12). The BBSome cooperates with intraflagellar transport (IFT) machinery to regulate ciliary entry, retention, and retrieval of membrane proteins including GPCRs. Disruption of BBSome-mediated trafficking causes mislocalization of ciliary cargos and impaired ciliary signaling across multiple tissues.	locations[0]	locations	locations			Photoreceptor Connecting Cilium	GO:0042622	photoreceptor inner segment		"{""preferred_term"": ""Photoreceptor Connecting Cilium"", ""term"": {""id"": ""GO:0042622"", ""label"": ""photoreceptor inner segment""}}"																											
1025	978	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	2	Hypothalamic Leptin Resistance	Impaired ciliary localization and trafficking of leptin receptors and other GPCRs (e.g., serotonin 5-HT2C receptor, MC4R) in hypothalamic POMC neurons due to BBSome dysfunction. This disrupts melanocortin signaling pathways that regulate appetite and energy homeostasis, leading to hyperphagia and obesity.	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1026	978	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	2	Hypothalamic Leptin Resistance	Impaired ciliary localization and trafficking of leptin receptors and other GPCRs (e.g., serotonin 5-HT2C receptor, MC4R) in hypothalamic POMC neurons due to BBSome dysfunction. This disrupts melanocortin signaling pathways that regulate appetite and energy homeostasis, leading to hyperphagia and obesity.	locations[0]	locations	locations			Hypothalamus	UBERON:0001898	hypothalamus		"{""preferred_term"": ""Hypothalamus"", ""term"": {""id"": ""UBERON:0001898"", ""label"": ""hypothalamus""}}"																											
1027	978	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	2	Hypothalamic Leptin Resistance	Impaired ciliary localization and trafficking of leptin receptors and other GPCRs (e.g., serotonin 5-HT2C receptor, MC4R) in hypothalamic POMC neurons due to BBSome dysfunction. This disrupts melanocortin signaling pathways that regulate appetite and energy homeostasis, leading to hyperphagia and obesity.	biological_processes[0]	biological_processes	biological_processes			Regulation of Appetite	GO:0032098	regulation of appetite		"{""preferred_term"": ""Regulation of Appetite"", ""term"": {""id"": ""GO:0032098"", ""label"": ""regulation of appetite""}}"																											
1028	978	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	2	Hypothalamic Leptin Resistance	Impaired ciliary localization and trafficking of leptin receptors and other GPCRs (e.g., serotonin 5-HT2C receptor, MC4R) in hypothalamic POMC neurons due to BBSome dysfunction. This disrupts melanocortin signaling pathways that regulate appetite and energy homeostasis, leading to hyperphagia and obesity.	biological_processes[1]	biological_processes	biological_processes			Leptin Receptor Signaling	GO:0038110	interleukin-35-mediated signaling pathway		"{""preferred_term"": ""Leptin Receptor Signaling"", ""term"": {""id"": ""GO:0038110"", ""label"": ""interleukin-35-mediated signaling pathway""}}"																											
1029	979	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	3	Renal Ciliary Dysfunction	Renal tubular epithelial cells depend on primary cilia for proper solute handling and signaling. BBSome-mediated ciliary dysfunction disrupts these processes, leading to concentrating and diluting defects, progressive renal cysts, dysplasia, and chronic kidney disease.	cell_types[0]	cell_types	cell_types			Renal Tubular Epithelial Cell	CL:0002306	epithelial cell of proximal tubule		"{""preferred_term"": ""Renal Tubular Epithelial Cell"", ""term"": {""id"": ""CL:0002306"", ""label"": ""epithelial cell of proximal tubule""}}"																											
1030	979	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	pathophysiology	3	Renal Ciliary Dysfunction	Renal tubular epithelial cells depend on primary cilia for proper solute handling and signaling. BBSome-mediated ciliary dysfunction disrupts these processes, leading to concentrating and diluting defects, progressive renal cysts, dysplasia, and chronic kidney disease.	locations[0]	locations	locations			Kidney	UBERON:0002113	kidney		"{""preferred_term"": ""Kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
1031	980	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	0	Retinitis Pigmentosa	Progressive rod-cone dystrophy leading to night blindness in childhood and progressive vision loss, often resulting in legal blindness by early adulthood.	phenotype_term	phenotype_term	$	Retinitis Pigmentosa	Progressive rod-cone dystrophy leading to night blindness in childhood and progressive vision loss, often resulting in legal blindness by early adulthood.	Retinitis Pigmentosa	HP:0000510	Rod-cone dystrophy		"{""preferred_term"": ""Retinitis Pigmentosa"", ""term"": {""id"": ""HP:0000510"", ""label"": ""Rod-cone dystrophy""}}"																											
1032	981	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	1	Polydactyly	Postaxial polydactyly, typically presenting as extra digits on the ulnar side of the hands and/or fibular side of the feet.	phenotype_term	phenotype_term	$	Polydactyly	Postaxial polydactyly, typically presenting as extra digits on the ulnar side of the hands and/or fibular side of the feet.	Polydactyly	HP:0010442	Polydactyly		"{""preferred_term"": ""Polydactyly"", ""term"": {""id"": ""HP:0010442"", ""label"": ""Polydactyly""}}"																											
1033	982	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	2	Truncal Obesity	Early-onset obesity beginning in childhood with predominantly central distribution, often associated with hyperphagia.	phenotype_term	phenotype_term	$	Truncal Obesity	Early-onset obesity beginning in childhood with predominantly central distribution, often associated with hyperphagia.	Truncal Obesity	HP:0001956	Truncal obesity		"{""preferred_term"": ""Truncal Obesity"", ""term"": {""id"": ""HP:0001956"", ""label"": ""Truncal obesity""}}"																											
1034	983	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	3	Hyperphagia	Excessive eating and insatiable appetite due to disrupted leptin and melanocortin signaling in the hypothalamus resulting from impaired ciliary GPCR trafficking in POMC neurons.	phenotype_term	phenotype_term	$	Hyperphagia	Excessive eating and insatiable appetite due to disrupted leptin and melanocortin signaling in the hypothalamus resulting from impaired ciliary GPCR trafficking in POMC neurons.	Hyperphagia	HP:0002591	Polyphagia		"{""preferred_term"": ""Hyperphagia"", ""term"": {""id"": ""HP:0002591"", ""label"": ""Polyphagia""}}"																											
1035	984	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	4	Intellectual Disability	Variable cognitive impairment ranging from mild learning difficulties to moderate intellectual disability.	phenotype_term	phenotype_term	$	Intellectual Disability	Variable cognitive impairment ranging from mild learning difficulties to moderate intellectual disability.	Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1036	986	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	6	Developmental Delay		phenotype_term	phenotype_term	$	Developmental Delay		Developmental Delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Developmental Delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
1037	988	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	8	Hypogonadism		phenotype_term	phenotype_term	$	Hypogonadism		Hypogonadism	HP:0000135	Hypogonadism		"{""preferred_term"": ""Hypogonadism"", ""term"": {""id"": ""HP:0000135"", ""label"": ""Hypogonadism""}}"																											
1038	993	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	13	Night Blindness		phenotype_term	phenotype_term	$	Night Blindness		Night Blindness	HP:0000662	Nyctalopia		"{""preferred_term"": ""Night Blindness"", ""term"": {""id"": ""HP:0000662"", ""label"": ""Nyctalopia""}}"																											
1039	994	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	phenotypes	14	Progressive Vision Loss		phenotype_term	phenotype_term	$	Progressive Vision Loss		Progressive Vision Loss	HP:0000529	Progressive visual loss		"{""preferred_term"": ""Progressive Vision Loss"", ""term"": {""id"": ""HP:0000529"", ""label"": ""Progressive visual loss""}}"																											
1040	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	Supportive Therapy	Addressing specific symptoms like vision support, weight management, and physical therapy.	treatment_term	treatment_term	$	Supportive Therapy	Addressing specific symptoms like vision support, weight management, and physical therapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1041	997	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	1	Genetic Counseling	For affected individuals and families to understand inheritance patterns, risks, and implications.	treatment_term	treatment_term	$	Genetic Counseling	For affected individuals and families to understand inheritance patterns, risks, and implications.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1042	998	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	2	Surgical Interventions	For polydactyly or other structural anomalies as needed.	treatment_term	treatment_term	$	Surgical Interventions	For polydactyly or other structural anomalies as needed.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1043	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	Dietary and Lifestyle Modifications	To manage obesity and associated metabolic conditions.	treatment_term	treatment_term	$	Dietary and Lifestyle Modifications	To manage obesity and associated metabolic conditions.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1044	1000	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	4	Gene Therapy	Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration.	treatment_term	treatment_term	$	Gene Therapy	Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
1045	1001	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	5	Setmelanotide	An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking.	treatment_term	treatment_term	$	Setmelanotide	An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1046	1010	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	histopathology	0	Basal Cell Carcinoma	Basal cell carcinomas are common cutaneous carcinomas.	finding_term	finding_term	$	Basal Cell Carcinoma	Basal cell carcinomas are common cutaneous carcinomas.	Basal Cell Carcinoma	NCIT:C156767	Basal Cell Carcinoma		"{""preferred_term"": ""Basal Cell Carcinoma"", ""term"": {""id"": ""NCIT:C156767"", ""label"": ""Basal Cell Carcinoma""}}"																											
1047	1011	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	0	PTCH1 Loss of Function	PTCH1 (Patched 1) encodes a transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Loss-of-function mutations in PTCH1 release SMO from inhibition, resulting in constitutive Hedgehog pathway activation. PTCH1 mutations occur in approximately 70% of sporadic BCCs and are the germline cause of Gorlin syndrome.	cell_types[0]	cell_types	cell_types			basal cell of epidermis	CL:0002187	basal cell of epidermis		"{""preferred_term"": ""basal cell of epidermis"", ""term"": {""id"": ""CL:0002187"", ""label"": ""basal cell of epidermis""}}"																											
1048	1011	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	0	PTCH1 Loss of Function	PTCH1 (Patched 1) encodes a transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Loss-of-function mutations in PTCH1 release SMO from inhibition, resulting in constitutive Hedgehog pathway activation. PTCH1 mutations occur in approximately 70% of sporadic BCCs and are the germline cause of Gorlin syndrome.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
1049	1011	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	0	PTCH1 Loss of Function	PTCH1 (Patched 1) encodes a transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Loss-of-function mutations in PTCH1 release SMO from inhibition, resulting in constitutive Hedgehog pathway activation. PTCH1 mutations occur in approximately 70% of sporadic BCCs and are the germline cause of Gorlin syndrome.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
1050	1012	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	1	SMO Activating Mutations	Smoothened (SMO) is a G-protein coupled receptor-like protein that transduces Hedgehog signal. Activating mutations in SMO, though less common than PTCH1 loss, render SMO constitutively active regardless of PTCH1 status. Some SMO mutations confer resistance to vismodegib.	cell_types[0]	cell_types	cell_types			basal cell of epidermis	CL:0002187	basal cell of epidermis		"{""preferred_term"": ""basal cell of epidermis"", ""term"": {""id"": ""CL:0002187"", ""label"": ""basal cell of epidermis""}}"																											
1051	1012	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	1	SMO Activating Mutations	Smoothened (SMO) is a G-protein coupled receptor-like protein that transduces Hedgehog signal. Activating mutations in SMO, though less common than PTCH1 loss, render SMO constitutively active regardless of PTCH1 status. Some SMO mutations confer resistance to vismodegib.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
1052	1013	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	2	Constitutive Hedgehog Pathway Activation	Loss of PTCH1 or activating SMO mutations result in constitutive activation of the Hedgehog signaling cascade. Active SMO translocates to the primary cilium and promotes activation of GLI transcription factors (GLI1, GLI2), which drive expression of target genes promoting proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
1053	1014	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	3	GLI Transcription Factor Activation	Active Hedgehog signaling promotes GLI transcription factor processing and nuclear translocation. GLI1 and GLI2 activate transcription of target genes including PTCH1, GLI1 (positive feedback), cyclin D1, MYC, and BCL2, promoting proliferation and survival of basal cells.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1054	1015	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	4	Uncontrolled Basal Cell Proliferation	Constitutive Hedgehog signaling drives proliferation of basal cells through GLI-mediated transcription of cell cycle regulators, leading to tumor formation. The proliferating cells maintain a basal cell phenotype with peripheral palisading characteristic of BCC histology.	cell_types[0]	cell_types	cell_types			basal cell of epidermis	CL:0002187	basal cell of epidermis		"{""preferred_term"": ""basal cell of epidermis"", ""term"": {""id"": ""CL:0002187"", ""label"": ""basal cell of epidermis""}}"																											
1055	1015	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	4	Uncontrolled Basal Cell Proliferation	Constitutive Hedgehog signaling drives proliferation of basal cells through GLI-mediated transcription of cell cycle regulators, leading to tumor formation. The proliferating cells maintain a basal cell phenotype with peripheral palisading characteristic of BCC histology.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
1056	1015	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	pathophysiology	4	Uncontrolled Basal Cell Proliferation	Constitutive Hedgehog signaling drives proliferation of basal cells through GLI-mediated transcription of cell cycle regulators, leading to tumor formation. The proliferating cells maintain a basal cell phenotype with peripheral palisading characteristic of BCC histology.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1057	1016	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	phenotypes	0	Basal Cell Carcinoma	Most common skin malignancy, typically presenting as pearly papule or nodule with telangiectasias on sun-exposed skin. Multiple clinical subtypes exist with varying biological behavior.	phenotype_term	phenotype_term	$	Basal Cell Carcinoma	Most common skin malignancy, typically presenting as pearly papule or nodule with telangiectasias on sun-exposed skin. Multiple clinical subtypes exist with varying biological behavior.	Basal cell carcinoma	HP:0002671	Basal cell carcinoma		"{""preferred_term"": ""Basal cell carcinoma"", ""term"": {""id"": ""HP:0002671"", ""label"": ""Basal cell carcinoma""}}"																											
1058	1017	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	phenotypes	1	Skin Neoplasm	Cutaneous tumors arising predominantly on chronically sun-exposed areas including the head, neck, and upper extremities. The face is the most common location.	phenotype_term	phenotype_term	$	Skin Neoplasm	Cutaneous tumors arising predominantly on chronically sun-exposed areas including the head, neck, and upper extremities. The face is the most common location.	Neoplasm of the skin	HP:0008069	Neoplasm of the skin		"{""preferred_term"": ""Neoplasm of the skin"", ""term"": {""id"": ""HP:0008069"", ""label"": ""Neoplasm of the skin""}}"																											
1059	1018	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	0	Surgical Excision	Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue.	treatment_term	treatment_term	$	Surgical Excision	Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1060	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term	treatment_term	$	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}"				vismodegib	CHEBI:66903																						
1061	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"																											
1062	1020	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	2	Sonidegib	Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib.	treatment_term	treatment_term	$	Sonidegib	Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1063	1021	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins.	treatment_term	treatment_term	$	Radiation Therapy	Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1064	1022	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	4	Topical Therapy	Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes.	treatment_term	treatment_term	$	Topical Therapy	Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1065	1023	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	5	Immune Checkpoint Inhibitors	Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1066	1029	42	Behcet's Disease	Behcets_Disease.yaml	pathophysiology	0	HLA-B51-Associated Immune Dysregulation	Strong association with HLA-B51. Aberrant peptide presentation and cross-reactivity with microbial antigens may trigger autoinflammatory responses. ERAP1 variants affect peptide processing for HLA-B51.	biological_processes[0]	biological_processes	biological_processes			Antigen Presentation	GO:0019882	antigen processing and presentation		"{""preferred_term"": ""Antigen Presentation"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"																											
1067	1030	42	Behcet's Disease	Behcets_Disease.yaml	pathophysiology	1	Neutrophil Hyperactivation	Neutrophils show enhanced chemotaxis, phagocytosis, and oxidative burst. Pathergy response (exaggerated skin reaction to minor trauma) reflects neutrophil hyperreactivity. NETs may contribute to vascular damage.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
1068	1030	42	Behcet's Disease	Behcets_Disease.yaml	pathophysiology	1	Neutrophil Hyperactivation	Neutrophils show enhanced chemotaxis, phagocytosis, and oxidative burst. Pathergy response (exaggerated skin reaction to minor trauma) reflects neutrophil hyperreactivity. NETs may contribute to vascular damage.	biological_processes[0]	biological_processes	biological_processes			Neutrophil Activation	GO:0042119	neutrophil activation		"{""preferred_term"": ""Neutrophil Activation"", ""term"": {""id"": ""GO:0042119"", ""label"": ""neutrophil activation""}}"																											
1069	1031	42	Behcet's Disease	Behcets_Disease.yaml	pathophysiology	2	Th1/Th17 Cytokine Imbalance	Elevated IL-17, IFN-gamma, and TNF-alpha drive tissue inflammation. IL-23/IL-17 axis is particularly important and represents a therapeutic target.	cell_types[0]	cell_types	cell_types			T Helper Cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""T Helper Cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
1070	1031	42	Behcet's Disease	Behcets_Disease.yaml	pathophysiology	2	Th1/Th17 Cytokine Imbalance	Elevated IL-17, IFN-gamma, and TNF-alpha drive tissue inflammation. IL-23/IL-17 axis is particularly important and represents a therapeutic target.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1071	1032	42	Behcet's Disease	Behcets_Disease.yaml	phenotypes	0	Oral Ulcers		phenotype_term	phenotype_term	$	Oral Ulcers		Oral Ulcer	HP:0000155	Oral ulcer		"{""preferred_term"": ""Oral Ulcer"", ""term"": {""id"": ""HP:0000155"", ""label"": ""Oral ulcer""}}"																											
1072	1033	42	Behcet's Disease	Behcets_Disease.yaml	phenotypes	1	Genital Ulcers		phenotype_term	phenotype_term	$	Genital Ulcers		Abnormality of the Genitourinary System	HP:0000119	Abnormality of the genitourinary system		"{""preferred_term"": ""Abnormality of the Genitourinary System"", ""term"": {""id"": ""HP:0000119"", ""label"": ""Abnormality of the genitourinary system""}}"																											
1073	1034	42	Behcet's Disease	Behcets_Disease.yaml	phenotypes	2	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
1074	1035	42	Behcet's Disease	Behcets_Disease.yaml	phenotypes	3	Skin Lesions		phenotype_term	phenotype_term	$	Skin Lesions		Skin Rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin Rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
1075	1041	43	Bejel	Bejel.yaml	infectious_agent	0	Treponema pallidum subsp. endemicum	Treponemal agent of bejel.	infectious_agent_term	infectious_agent_term	$	Treponema pallidum subsp. endemicum	Treponemal agent of bejel.	Treponema pallidum subsp. endemicum	NCBITaxon:53436	Treponema pallidum subsp. endemicum		"{""preferred_term"": ""Treponema pallidum subsp. endemicum"", ""term"": {""id"": ""NCBITaxon:53436"", ""label"": ""Treponema pallidum subsp. endemicum""}}"																											
1076	1042	43	Bejel	Bejel.yaml	phenotypes	0	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
1077	1043	43	Bejel	Bejel.yaml	phenotypes	1	Optic atrophy		phenotype_term	phenotype_term	$	Optic atrophy		Optic atrophy	HP:0000648	Optic atrophy		"{""preferred_term"": ""Optic atrophy"", ""term"": {""id"": ""HP:0000648"", ""label"": ""Optic atrophy""}}"																											
1078	1044	43	Bejel	Bejel.yaml	treatments	0	Penicillin therapy	Penicillin therapy is effective for endemic treponematoses.	treatment_term	treatment_term	$	Penicillin therapy	Penicillin therapy is effective for endemic treponematoses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1079	1056	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	0	Prostatic Stromal and Epithelial Proliferation	"Age-related increase in prostatic stromal and glandular tissue, particularly in the transition zone. Dihydrotestosterone (DHT) drives proliferation through androgen receptors.
"	cell_types[0]	cell_types	cell_types			Prostatic Epithelial Cell	CL:0002231	epithelial cell of prostate		"{""preferred_term"": ""Prostatic Epithelial Cell"", ""term"": {""id"": ""CL:0002231"", ""label"": ""epithelial cell of prostate""}}"																											
1080	1056	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	0	Prostatic Stromal and Epithelial Proliferation	"Age-related increase in prostatic stromal and glandular tissue, particularly in the transition zone. Dihydrotestosterone (DHT) drives proliferation through androgen receptors.
"	biological_processes[0]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell population proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"																											
1081	1058	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	2	Detrusor Dysfunction	"Chronic obstruction leads to detrusor muscle hypertrophy and later decompensation. Results in overactive bladder symptoms and incomplete emptying.
"	cell_types[0]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
1082	1059	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	3	Androgen-Dependent Growth	"DHT converted from testosterone by 5-alpha reductase drives prostatic growth. 5-alpha reductase inhibitors shrink prostate.
"	biological_processes[0]	biological_processes	biological_processes			Androgen Response	GO:0030521	androgen receptor signaling pathway		"{""preferred_term"": ""Androgen Response"", ""term"": {""id"": ""GO:0030521"", ""label"": ""androgen receptor signaling pathway""}}"																											
1083	1060	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	4	Hypoxia-Induced Epithelial-Mesenchymal Transition	"Hypoxic basal epithelial cells (BE5) drive nodular formation through upregulation of FOS and activation of EMT signaling, particularly in glandular nodules of the transition zone.
"	biological_processes[0]	biological_processes	biological_processes			Epithelial to Mesenchymal Transition	GO:0001837	epithelial to mesenchymal transition		"{""preferred_term"": ""Epithelial to Mesenchymal Transition"", ""term"": {""id"": ""GO:0001837"", ""label"": ""epithelial to mesenchymal transition""}}"																											
1084	1061	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	5	TGF-beta/ROCK1 Mediated Stromal Hyperplasia	"Aberrant activation of TGF-beta/ROCK1 pathway recruits mesenchymal stem cells that differentiate into fibroblasts and myofibroblasts, driving stromal hyperplasia and fibrosis.
"	biological_processes[0]	biological_processes	biological_processes			TGF-beta Signaling	GO:0007179	transforming growth factor beta receptor signaling pathway		"{""preferred_term"": ""TGF-beta Signaling"", ""term"": {""id"": ""GO:0007179"", ""label"": ""transforming growth factor beta receptor signaling pathway""}}"																											
1085	1062	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	6	ROCK-Mediated Fibrosis and Beta-Catenin Signaling	"ROCK1/2 activation promotes fibrosis, EMT, and cell proliferation by stabilizing beta-catenin and activating downstream targets including C-MYC, Snail, and Survivin. ROCK inhibition reverses these processes.
"	biological_processes[0]	biological_processes	biological_processes			Wnt Signaling Pathway	GO:0016055	Wnt signaling pathway		"{""preferred_term"": ""Wnt Signaling Pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"																											
1086	1063	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	7	Oxidative Stress and Epithelial Plasticity	"Low-androgen signaling epithelial populations show increased vulnerability to oxidative stress due to reduced antioxidant defenses. Mitochondrial ROS drives cell proliferation and stemness in BPH.
"	biological_processes[0]	biological_processes	biological_processes			Response to Oxidative Stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""Response to Oxidative Stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
1087	1064	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	pathophysiology	8	Inflammation and IL-6 Signaling	"Periodontal pathogens and inflammatory stimuli upregulate IL-6, IL-6R, and gp130, activating the Akt pathway to promote epithelial and stromal proliferation while inhibiting apoptosis.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1088	1065	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	0	Urinary Frequency		phenotype_term	phenotype_term	$	Urinary Frequency		Urinary Frequency	HP:0000012	Urinary urgency		"{""preferred_term"": ""Urinary Frequency"", ""term"": {""id"": ""HP:0000012"", ""label"": ""Urinary urgency""}}"																											
1089	1066	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	1	Nocturia		phenotype_term	phenotype_term	$	Nocturia		Nocturia	HP:0000017	Nocturia		"{""preferred_term"": ""Nocturia"", ""term"": {""id"": ""HP:0000017"", ""label"": ""Nocturia""}}"																											
1090	1067	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	2	Weak Urinary Stream		phenotype_term	phenotype_term	$	Weak Urinary Stream		Weak Stream	HP:0000016	Urinary retention		"{""preferred_term"": ""Weak Stream"", ""term"": {""id"": ""HP:0000016"", ""label"": ""Urinary retention""}}"																											
1091	1068	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	3	Hesitancy		phenotype_term	phenotype_term	$	Hesitancy		Urinary Hesitancy	HP:0000016	Urinary retention		"{""preferred_term"": ""Urinary Hesitancy"", ""term"": {""id"": ""HP:0000016"", ""label"": ""Urinary retention""}}"																											
1092	1069	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	4	Incomplete Emptying		phenotype_term	phenotype_term	$	Incomplete Emptying		Incomplete Emptying	HP:0000016	Urinary retention		"{""preferred_term"": ""Incomplete Emptying"", ""term"": {""id"": ""HP:0000016"", ""label"": ""Urinary retention""}}"																											
1093	1070	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	phenotypes	5	Urinary Retention		phenotype_term	phenotype_term	$	Urinary Retention		Urinary Retention	HP:0000016	Urinary retention		"{""preferred_term"": ""Urinary Retention"", ""term"": {""id"": ""HP:0000016"", ""label"": ""Urinary retention""}}"																											
1094	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1095	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	cell_types[1]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
1096	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	cell_types[2]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1097	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	biological_processes[0]	biological_processes	biological_processes			Glycoprotein catabolism	GO:0006516	glycoprotein catabolic process		"{""preferred_term"": ""Glycoprotein catabolism"", ""term"": {""id"": ""GO:0006516"", ""label"": ""glycoprotein catabolic process""}}"																											
1098	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	locations[0]	locations	locations			Lysosome	GO:0005764	lysosome		"{""preferred_term"": ""Lysosome"", ""term"": {""id"": ""GO:0005764"", ""label"": ""lysosome""}}"																											
1099	1083	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	pathophysiology	0	Beta-mannosidase deficiency	"Loss or marked reduction of beta-mannosidase activity impairs lysosomal catabolism of glycoprotein-derived oligosaccharides, leading to intra-lysosomal storage and cellular vacuolation. Electron microscopy demonstrates prominent lysosomal enlargement in patient cells.
"	locations[1]	locations	locations			Brain	UBERON:0000955	brain		"{""preferred_term"": ""Brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
1100	1084	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	phenotypes	0	Intellectual disability	Variable cognitive impairment reported across patients, degree correlates imperfectly with genotype or residual activity.	phenotype_term	phenotype_term	$	Intellectual disability	Variable cognitive impairment reported across patients, degree correlates imperfectly with genotype or residual activity.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1101	1085	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	phenotypes	1	Sensorineural hearing impairment	Early, often prelingual sensorineural hearing loss is a common and characteristic clinical feature.	phenotype_term	phenotype_term	$	Sensorineural hearing impairment	Early, often prelingual sensorineural hearing loss is a common and characteristic clinical feature.	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
1102	1086	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	phenotypes	2	Seizures	Epileptic manifestations reported in some patients with CNS involvement.	phenotype_term	phenotype_term	$	Seizures	Epileptic manifestations reported in some patients with CNS involvement.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
1103	1087	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	phenotypes	3	Angiokeratoma	Cutaneous vascular lesions reported in some cases, with skin cell vacuolation.	phenotype_term	phenotype_term	$	Angiokeratoma	Cutaneous vascular lesions reported in some cases, with skin cell vacuolation.	Angiokeratoma	HP:0001014	Angiokeratoma		"{""preferred_term"": ""Angiokeratoma"", ""term"": {""id"": ""HP:0001014"", ""label"": ""Angiokeratoma""}}"																											
1104	1088	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	treatments	0	Supportive care	"Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.
"	treatment_term	treatment_term	$	Supportive care	"Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1105	1103	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	0	Monoamine Dysregulation	"Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
1106	1103	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	0	Monoamine Dysregulation	"Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.
"	cell_types[1]	cell_types	cell_types			Serotonergic Neuron	CL:0000850	serotonergic neuron		"{""preferred_term"": ""Serotonergic Neuron"", ""term"": {""id"": ""CL:0000850"", ""label"": ""serotonergic neuron""}}"																											
1107	1103	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	0	Monoamine Dysregulation	"Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.
"	cell_types[2]	cell_types	cell_types			Noradrenergic Neuron	CL:0008025	noradrenergic neuron		"{""preferred_term"": ""Noradrenergic Neuron"", ""term"": {""id"": ""CL:0008025"", ""label"": ""noradrenergic neuron""}}"																											
1108	1103	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	0	Monoamine Dysregulation	"Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.
"	biological_processes[0]	biological_processes	biological_processes			Neurotransmitter Signaling	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Neurotransmitter Signaling"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
1109	1104	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	1	Mitochondrial Dysfunction	"Impaired cellular energy metabolism and oxidative stress affect neuronal function. Mitochondrial abnormalities linked to mood dysregulation.
"	biological_processes[0]	biological_processes	biological_processes			Mitochondrial Function	GO:0007005	mitochondrion organization		"{""preferred_term"": ""Mitochondrial Function"", ""term"": {""id"": ""GO:0007005"", ""label"": ""mitochondrion organization""}}"																											
1110	1105	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	2	Circadian Rhythm Disruption	"Disrupted sleep-wake cycles and circadian gene expression contribute to mood instability. Sleep deprivation can trigger mania.
"	biological_processes[0]	biological_processes	biological_processes			Circadian Rhythm	GO:0007623	circadian rhythm		"{""preferred_term"": ""Circadian Rhythm"", ""term"": {""id"": ""GO:0007623"", ""label"": ""circadian rhythm""}}"																											
1111	1106	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	3	Neuroplasticity Alterations	"Reduced BDNF and altered synaptic plasticity in mood circuits. Lithium and other mood stabilizers enhance neuroplasticity.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1112	1106	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	3	Neuroplasticity Alterations	"Reduced BDNF and altered synaptic plasticity in mood circuits. Lithium and other mood stabilizers enhance neuroplasticity.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Plasticity	GO:0048167	regulation of synaptic plasticity		"{""preferred_term"": ""Synaptic Plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"																											
1113	1107	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	4	Neuroinflammation	"Elevated inflammatory markers during mood episodes. Microglial activation and cytokine abnormalities contribute to pathophysiology.
"	cell_types[0]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
1114	1107	46	Bipolar Disorder	Bipolar_Disorder.yaml	pathophysiology	4	Neuroinflammation	"Elevated inflammatory markers during mood episodes. Microglial activation and cytokine abnormalities contribute to pathophysiology.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1115	1108	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	0	Manic Episodes		phenotype_term	phenotype_term	$	Manic Episodes		Mania	HP:0100754	Mania		"{""preferred_term"": ""Mania"", ""term"": {""id"": ""HP:0100754"", ""label"": ""Mania""}}"																											
1116	1109	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	1	Depressive Episodes		phenotype_term	phenotype_term	$	Depressive Episodes		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
1117	1110	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	2	Sleep Disturbance		phenotype_term	phenotype_term	$	Sleep Disturbance		Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
1118	1111	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	3	Psychosis		phenotype_term	phenotype_term	$	Psychosis		Psychosis	HP:0000709	Psychosis		"{""preferred_term"": ""Psychosis"", ""term"": {""id"": ""HP:0000709"", ""label"": ""Psychosis""}}"																											
1119	1112	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	4	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
1120	1113	46	Bipolar Disorder	Bipolar_Disorder.yaml	phenotypes	5	Cognitive Impairment		phenotype_term	phenotype_term	$	Cognitive Impairment		Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
1121	1124	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	0	NCT02958917	Randomized, double-blind, placebo-controlled study evaluating pirfenidone in fibrotic hypersensitivity pneumonitis.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1122	1124	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	0	NCT02958917	Randomized, double-blind, placebo-controlled study evaluating pirfenidone in fibrotic hypersensitivity pneumonitis.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Pulmonary fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
1123	1125	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	1	NCT02496182	Study evaluating addition of pirfenidone to prednisone and azathioprine in chronic hypersensitivity pneumonitis with pulmonary fibrosis.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
1124	1125	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	1	NCT02496182	Study evaluating addition of pirfenidone to prednisone and azathioprine in chronic hypersensitivity pneumonitis with pulmonary fibrosis.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
1125	1126	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	2	NCT04844359	Observational study developing and validating a prognostic blood transcriptomic signature in chronic hypersensitivity pneumonitis.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
1126	1126	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	clinical_trials	2	NCT04844359	Observational study developing and validating a prognostic blood transcriptomic signature in chronic hypersensitivity pneumonitis.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1127	1127	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	0		Bulk RNA-seq of whole lung tissue from chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and control samples.	organism	organism	$		Bulk RNA-seq of whole lung tissue from chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and control samples.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
1128	1127	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	0		Bulk RNA-seq of whole lung tissue from chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and control samples.	sample_types[0]	sample_types	sample_types			lung tissue				"{""preferred_term"": ""lung tissue"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
1129	1127	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	0		Bulk RNA-seq of whole lung tissue from chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and control samples.	sample_types[0].tissue_term	sample_types	sample_types[0]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1130	1128	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	1		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	organism	organism	$		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
1131	1128	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	1		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	sample_types[0]	sample_types	sample_types			peripheral blood mononuclear cell				"{""cell_type_term"": {""preferred_term"": ""peripheral blood mononuclear cell"", ""term"": {""id"": ""CL:2000001"", ""label"": ""peripheral blood mononuclear cell""}}, ""preferred_term"": ""peripheral blood mononuclear cell""}"																											
1132	1128	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	1		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	sample_types[0].cell_type_term	sample_types	sample_types[0]			peripheral blood mononuclear cell	CL:2000001	peripheral blood mononuclear cell		"{""preferred_term"": ""peripheral blood mononuclear cell"", ""term"": {""id"": ""CL:2000001"", ""label"": ""peripheral blood mononuclear cell""}}"																											
1133	1128	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	1		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	sample_types[1]	sample_types	sample_types			bronchoalveolar lavage				"{""preferred_term"": ""bronchoalveolar lavage"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
1134	1128	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	datasets	1		Single-cell and single-nucleus RNA-seq of PBMCs and BAL cells from fibrotic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and controls.	sample_types[1].tissue_term	sample_types	sample_types[1]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1135	1134	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	differential_diagnoses	0	Idiopathic Pulmonary Fibrosis	Idiopathic pulmonary fibrosis can mimic chronic hypersensitivity pneumonitis with dyspnea and fibrosis, but has distinct HRCT distribution and feature patterns.	disease_term	disease_term	$	Idiopathic Pulmonary Fibrosis	Idiopathic pulmonary fibrosis can mimic chronic hypersensitivity pneumonitis with dyspnea and fibrosis, but has distinct HRCT distribution and feature patterns.	idiopathic pulmonary fibrosis	MONDO:0800504	idiopathic pulmonary fibrosis		"{""preferred_term"": ""idiopathic pulmonary fibrosis"", ""term"": {""id"": ""MONDO:0800504"", ""label"": ""idiopathic pulmonary fibrosis""}}"																											
1136	1135	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	differential_diagnoses	1	Pulmonary Sarcoidosis	Advanced-stage sarcoidosis can present with fibrotic lung changes but shows a characteristic upper and mid-lung predominance on HRCT.	disease_term	disease_term	$	Pulmonary Sarcoidosis	Advanced-stage sarcoidosis can present with fibrotic lung changes but shows a characteristic upper and mid-lung predominance on HRCT.	sarcoidosis	MONDO:0019338	sarcoidosis		"{""preferred_term"": ""sarcoidosis"", ""term"": {""id"": ""MONDO:0019338"", ""label"": ""sarcoidosis""}}"																											
1137	1136	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	differential_diagnoses	2	Hypersensitivity Pneumonitis from Home Mold Exposure	Non-avian hypersensitivity pneumonitis triggered by home mold exposure can present with similar ILD features.	disease_term	disease_term	$	Hypersensitivity Pneumonitis from Home Mold Exposure	Non-avian hypersensitivity pneumonitis triggered by home mold exposure can present with similar ILD features.	hypersensitivity pneumonitis	MONDO:0017853	hypersensitivity pneumonitis		"{""preferred_term"": ""hypersensitivity pneumonitis"", ""term"": {""id"": ""MONDO:0017853"", ""label"": ""hypersensitivity pneumonitis""}}"																											
1138	1137	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	environmental	0	Bird Antigen Exposure	Exposure to bird proteins from bird breeding, feather products, or fertilizer with fowl droppings.	exposure_term	exposure_term	$	Bird Antigen Exposure	Exposure to bird proteins from bird breeding, feather products, or fertilizer with fowl droppings.	exposure to animal waste material	ECTO:7000098	exposure to animal waste material		"{""preferred_term"": ""exposure to animal waste material"", ""term"": {""id"": ""ECTO:7000098"", ""label"": ""exposure to animal waste material""}}"																											
1139	1140	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	genetic	0	MUC5B		gene_term	gene_term	$	MUC5B		MUC5B	hgnc:7516	MUC5B		"{""preferred_term"": ""MUC5B"", ""term"": {""id"": ""hgnc:7516"", ""label"": ""MUC5B""}}"																											
1140	1141	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	genetic	1	TOLLIP		gene_term	gene_term	$	TOLLIP		TOLLIP	hgnc:16476	TOLLIP		"{""preferred_term"": ""TOLLIP"", ""term"": {""id"": ""hgnc:16476"", ""label"": ""TOLLIP""}}"																											
1141	1145	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	0	Exposure to Avian Proteins	Repeated inhalation of avian proteins from bird droppings, feathers, or serum triggers bird-related hypersensitivity pneumonitis.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1142	1146	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	1	Expansion of Resident Monocytes and Interstitial Macrophages	Bird antigen exposure is associated with increased resident monocytes, interstitial macrophages, and type 2 dendritic cells in the lung.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
1143	1146	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	1	Expansion of Resident Monocytes and Interstitial Macrophages	Bird antigen exposure is associated with increased resident monocytes, interstitial macrophages, and type 2 dendritic cells in the lung.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1144	1146	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	1	Expansion of Resident Monocytes and Interstitial Macrophages	Bird antigen exposure is associated with increased resident monocytes, interstitial macrophages, and type 2 dendritic cells in the lung.	cell_types[2]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
1145	1146	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	1	Expansion of Resident Monocytes and Interstitial Macrophages	Bird antigen exposure is associated with increased resident monocytes, interstitial macrophages, and type 2 dendritic cells in the lung.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1146	1147	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	2	Reduction of Inflammatory Monocytes and Alveolar Macrophages	Bird antigen exposure is associated with reduced inflammatory monocytes, alveolar macrophages, and tolerogenic dendritic cells in the lung.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
1147	1147	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	2	Reduction of Inflammatory Monocytes and Alveolar Macrophages	Bird antigen exposure is associated with reduced inflammatory monocytes, alveolar macrophages, and tolerogenic dendritic cells in the lung.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1148	1147	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	2	Reduction of Inflammatory Monocytes and Alveolar Macrophages	Bird antigen exposure is associated with reduced inflammatory monocytes, alveolar macrophages, and tolerogenic dendritic cells in the lung.	cell_types[2]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
1149	1147	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	2	Reduction of Inflammatory Monocytes and Alveolar Macrophages	Bird antigen exposure is associated with reduced inflammatory monocytes, alveolar macrophages, and tolerogenic dendritic cells in the lung.	cell_types[3]	cell_types	cell_types			alveolar macrophage	CL:0000583	alveolar macrophage		"{""preferred_term"": ""alveolar macrophage"", ""term"": {""id"": ""CL:0000583"", ""label"": ""alveolar macrophage""}}"																											
1150	1147	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	2	Reduction of Inflammatory Monocytes and Alveolar Macrophages	Bird antigen exposure is associated with reduced inflammatory monocytes, alveolar macrophages, and tolerogenic dendritic cells in the lung.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1151	1148	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	3	Th1/Th2 to Th2/Th17 Cytokine Shift	Early disease shows a mixed Th1/Th2 response, while progression shifts toward a Th2/Th17 mixed response.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
1152	1148	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	3	Th1/Th2 to Th2/Th17 Cytokine Shift	Early disease shows a mixed Th1/Th2 response, while progression shifts toward a Th2/Th17 mixed response.	biological_processes[0]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
1153	1148	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	3	Th1/Th2 to Th2/Th17 Cytokine Shift	Early disease shows a mixed Th1/Th2 response, while progression shifts toward a Th2/Th17 mixed response.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1154	1149	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	4	Bird Antigen-Driven Humoral Response	Bird antigen exposure triggers B cell activation and elevated serum IgG/IgA to avian proteins in bird-related hypersensitivity pneumonitis.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1155	1149	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	4	Bird Antigen-Driven Humoral Response	Bird antigen exposure triggers B cell activation and elevated serum IgG/IgA to avian proteins in bird-related hypersensitivity pneumonitis.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"																											
1156	1149	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	4	Bird Antigen-Driven Humoral Response	Bird antigen exposure triggers B cell activation and elevated serum IgG/IgA to avian proteins in bird-related hypersensitivity pneumonitis.	biological_processes[1]	biological_processes	biological_processes			antigen processing and presentation	GO:0019882	antigen processing and presentation		"{""preferred_term"": ""antigen processing and presentation"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"																											
1157	1149	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	4	Bird Antigen-Driven Humoral Response	Bird antigen exposure triggers B cell activation and elevated serum IgG/IgA to avian proteins in bird-related hypersensitivity pneumonitis.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1158	1150	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	5	Species-Specific Bird Antigen Panels	Diagnostic panels for bird-related hypersensitivity pneumonitis use antigens from pigeon, parrot, and budgerigar species.	triggers[0]	triggers	triggers			pigeon	NCBITaxon:8932	Columba livia		"{""preferred_term"": ""pigeon"", ""term"": {""id"": ""NCBITaxon:8932"", ""label"": ""Columba livia""}}"																											
1159	1150	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	5	Species-Specific Bird Antigen Panels	Diagnostic panels for bird-related hypersensitivity pneumonitis use antigens from pigeon, parrot, and budgerigar species.	triggers[1]	triggers	triggers			parrot	NCBITaxon:9223	Psittaciformes		"{""preferred_term"": ""parrot"", ""term"": {""id"": ""NCBITaxon:9223"", ""label"": ""Psittaciformes""}}"																											
1160	1150	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	5	Species-Specific Bird Antigen Panels	Diagnostic panels for bird-related hypersensitivity pneumonitis use antigens from pigeon, parrot, and budgerigar species.	triggers[2]	triggers	triggers			budgerigar	NCBITaxon:13146	Melopsittacus undulatus		"{""preferred_term"": ""budgerigar"", ""term"": {""id"": ""NCBITaxon:13146"", ""label"": ""Melopsittacus undulatus""}}"																											
1161	1151	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	6	Classical Monocyte Enrichment	Fibrotic hypersensitivity pneumonitis shows elevated classical monocytes enriched for CCL3hi/CCL4hi and S100Ahi states.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
1162	1151	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	6	Classical Monocyte Enrichment	Fibrotic hypersensitivity pneumonitis shows elevated classical monocytes enriched for CCL3hi/CCL4hi and S100Ahi states.	biological_processes[0]	biological_processes	biological_processes			chemokine-mediated signaling pathway	GO:0070098	chemokine-mediated signaling pathway		"{""preferred_term"": ""chemokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0070098"", ""label"": ""chemokine-mediated signaling pathway""}}"																											
1163	1151	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	6	Classical Monocyte Enrichment	Fibrotic hypersensitivity pneumonitis shows elevated classical monocytes enriched for CCL3hi/CCL4hi and S100Ahi states.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1164	1152	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	7	Monocyte-to-SPP1hi Macrophage Differentiation	Specific classical monocyte states differentiate into SPP1hi lung macrophages associated with fibrosis.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
1165	1152	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	7	Monocyte-to-SPP1hi Macrophage Differentiation	Specific classical monocyte states differentiate into SPP1hi lung macrophages associated with fibrosis.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1166	1152	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	7	Monocyte-to-SPP1hi Macrophage Differentiation	Specific classical monocyte states differentiate into SPP1hi lung macrophages associated with fibrosis.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1167	1153	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	8	Cytotoxic T Cell Program with Profibrotic Signaling	Fibrotic hypersensitivity pneumonitis features GZMhi cytotoxic T cells with transcriptional programs implicating TGF, TNF, and NFB pathways.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
1168	1153	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	8	Cytotoxic T Cell Program with Profibrotic Signaling	Fibrotic hypersensitivity pneumonitis features GZMhi cytotoxic T cells with transcriptional programs implicating TGF, TNF, and NFB pathways.	biological_processes[0]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
1169	1153	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	8	Cytotoxic T Cell Program with Profibrotic Signaling	Fibrotic hypersensitivity pneumonitis features GZMhi cytotoxic T cells with transcriptional programs implicating TGF, TNF, and NFB pathways.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1170	1154	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	9	MMP14-High Macrophage Profibrotic Activity	MMP14-high macrophages with an M2-like phenotype promote fibroblast-to-myofibroblast transition in hypersensitivity pneumonitis models, contributing to fibrotic remodeling.	cell_types[0]	cell_types	cell_types			alveolar macrophage	CL:0000583	alveolar macrophage		"{""preferred_term"": ""alveolar macrophage"", ""term"": {""id"": ""CL:0000583"", ""label"": ""alveolar macrophage""}}"																											
1171	1154	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	9	MMP14-High Macrophage Profibrotic Activity	MMP14-high macrophages with an M2-like phenotype promote fibroblast-to-myofibroblast transition in hypersensitivity pneumonitis models, contributing to fibrotic remodeling.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1172	1154	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	9	MMP14-High Macrophage Profibrotic Activity	MMP14-high macrophages with an M2-like phenotype promote fibroblast-to-myofibroblast transition in hypersensitivity pneumonitis models, contributing to fibrotic remodeling.	locations[0]	locations	locations			alveolus of lung	UBERON:0002299	alveolus of lung		"{""preferred_term"": ""alveolus of lung"", ""term"": {""id"": ""UBERON:0002299"", ""label"": ""alveolus of lung""}}"																											
1173	1155	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	pathophysiology	10	TLR2 and NF-B Regulation of MMP14 and Exosome Secretion	TLR2 and NF-B signaling regulate MMP14 expression and macrophage exosome secretion in antigen-stimulated hypersensitivity pneumonitis models.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1174	1156	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	0	Dyspnea	Exertional or progressive shortness of breath associated with inflammatory and fibrotic lung involvement.	phenotype_term	phenotype_term	$	Dyspnea	Exertional or progressive shortness of breath associated with inflammatory and fibrotic lung involvement.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1175	1157	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	1	Cough	Persistent or recurrent cough associated with hypersensitivity pneumonitis.	phenotype_term	phenotype_term	$	Cough	Persistent or recurrent cough associated with hypersensitivity pneumonitis.	Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
1176	1158	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	2	Pulmonary Fibrosis	Fibrotic remodeling in chronic or progressive disease.	phenotype_term	phenotype_term	$	Pulmonary Fibrosis	Fibrotic remodeling in chronic or progressive disease.	Pulmonary fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
1177	1159	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	3	Hypoxemia	Reduced blood oxygenation during active disease.	phenotype_term	phenotype_term	$	Hypoxemia	Reduced blood oxygenation during active disease.	Hypoxemia	HP:0012418	Hypoxemia		"{""preferred_term"": ""Hypoxemia"", ""term"": {""id"": ""HP:0012418"", ""label"": ""Hypoxemia""}}"																											
1178	1160	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	4	Fatigue	Systemic fatigue during symptomatic episodes.	phenotype_term	phenotype_term	$	Fatigue	Systemic fatigue during symptomatic episodes.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1179	1161	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	phenotypes	5	Fever	Flu-like systemic symptoms during acute exposure episodes.	phenotype_term	phenotype_term	$	Fever	Flu-like systemic symptoms during acute exposure episodes.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	treatment_term	$	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}"				prednisone; azathioprine	CHEBI:8382; CHEBI:2948																						
1181	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"																											
1182	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"																											
1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	treatment_term	$	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}"				mycophenolate mofetil; azathioprine	CHEBI:8764; CHEBI:2948																						
1184	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			mycophenolate mofetil	CHEBI:8764	mycophenolate mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}"																											
1185	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"																											
1186	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term	treatment_term	$	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}]}"				pirfenidone	CHEBI:32016																						
1187	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			pirfenidone	CHEBI:32016	pirfenidone		"{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}"																											
1188	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term	treatment_term	$	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}]}"				nintedanib	CHEBI:85164																						
1189	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			nintedanib	CHEBI:85164	nintedanib		"{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}"																											
1190	1173	48	Botulism	Botulism.yaml	phenotypes	0	Paralysis		phenotype_term	phenotype_term	$	Paralysis		Paralysis	HP:0003470	Paralysis		"{""preferred_term"": ""Paralysis"", ""term"": {""id"": ""HP:0003470"", ""label"": ""Paralysis""}}"																											
1191	1174	48	Botulism	Botulism.yaml	treatments	0	Botulinum Antitoxin	Administration of botulinum antitoxin to neutralize circulating toxin.	treatment_term	treatment_term	$	Botulinum Antitoxin	Administration of botulinum antitoxin to neutralize circulating toxin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1192	1177	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	phenotypes	0	Breast Mass		phenotype_term	phenotype_term	$	Breast Mass		Breast mass	HP:0032408	Breast mass		"{""preferred_term"": ""Breast mass"", ""term"": {""id"": ""HP:0032408"", ""label"": ""Breast mass""}}"																											
1193	1178	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	0	Surgical Excision	Surgical removal of symptomatic fibroadenomas.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of symptomatic fibroadenomas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1194	1179	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	1	Conservative Management	Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma.	treatment_term	treatment_term	$	Conservative Management	Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1195	1187	50	Bronchiectasis	Bronchiectasis.yaml	environmental	0	Pollution		exposure_term	exposure_term	$	Pollution		Air pollution exposure	ECTO:8000036	exposure to air pollution		"{""preferred_term"": ""Air pollution exposure"", ""term"": {""id"": ""ECTO:8000036"", ""label"": ""exposure to air pollution""}}"																											
1196	1188	50	Bronchiectasis	Bronchiectasis.yaml	environmental	1	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
1197	1193	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	2	Impaired Mucociliary Clearance	Damage and dilation of airways hinder effective clearance of mucus, allowing for accumulation and further infection.	cell_types[0]	cell_types	cell_types			airway epithelial cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""airway epithelial cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
1198	1193	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	2	Impaired Mucociliary Clearance	Damage and dilation of airways hinder effective clearance of mucus, allowing for accumulation and further infection.	cell_types[1]	cell_types	cell_types			ciliated epithelial cell	CL:0000067	ciliated epithelial cell		"{""preferred_term"": ""ciliated epithelial cell"", ""term"": {""id"": ""CL:0000067"", ""label"": ""ciliated epithelial cell""}}"																											
1199	1193	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	2	Impaired Mucociliary Clearance	Damage and dilation of airways hinder effective clearance of mucus, allowing for accumulation and further infection.	biological_processes[0]	biological_processes	biological_processes			mucociliary clearance	GO:0003351	epithelial cilium movement involved in extracellular fluid movement		"{""preferred_term"": ""mucociliary clearance"", ""term"": {""id"": ""GO:0003351"", ""label"": ""epithelial cilium movement involved in extracellular fluid movement""}}"																											
1200	1193	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	2	Impaired Mucociliary Clearance	Damage and dilation of airways hinder effective clearance of mucus, allowing for accumulation and further infection.	biological_processes[1]	biological_processes	biological_processes			cilium movement	GO:0003341	cilium movement		"{""preferred_term"": ""cilium movement"", ""term"": {""id"": ""GO:0003341"", ""label"": ""cilium movement""}}"																											
1201	1193	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	2	Impaired Mucociliary Clearance	Damage and dilation of airways hinder effective clearance of mucus, allowing for accumulation and further infection.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1202	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
1203	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	biological_processes[0]	biological_processes	biological_processes			neutrophil degranulation	GO:0043312	neutrophil degranulation		"{""preferred_term"": ""neutrophil degranulation"", ""term"": {""id"": ""GO:0043312"", ""label"": ""neutrophil degranulation""}}"																											
1204	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	biological_processes[1]	biological_processes	biological_processes			neutrophil extracellular trap formation	GO:0036148	NETosis		"{""preferred_term"": ""neutrophil extracellular trap formation"", ""term"": {""id"": ""GO:0036148"", ""label"": ""NETosis""}}"																											
1205	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	biological_processes[2]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1206	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1207	1194	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	3	Neutrophil-Driven Inflammation	Excessive neutrophil recruitment, degranulation, and NET formation release proteases (neutrophil elastase, proteinase 3, cathepsin G) that degrade extracellular matrix, impair ciliary function, and damage epithelial barriers.	locations[1]	locations	locations			extracellular space	GO:0005615	extracellular region		"{""preferred_term"": ""extracellular space"", ""term"": {""id"": ""GO:0005615"", ""label"": ""extracellular region""}}"																											
1208	1195	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	4	Protease-Antiprotease Imbalance	Excess neutrophil serine proteases (NE, PR3, CatG) overwhelm antiproteases (SLPI, A1AT), degrading structural proteins and perpetuating tissue damage.	biological_processes[0]	biological_processes	biological_processes			proteolysis	GO:0006508	proteolysis		"{""preferred_term"": ""proteolysis"", ""term"": {""id"": ""GO:0006508"", ""label"": ""proteolysis""}}"																											
1209	1195	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	4	Protease-Antiprotease Imbalance	Excess neutrophil serine proteases (NE, PR3, CatG) overwhelm antiproteases (SLPI, A1AT), degrading structural proteins and perpetuating tissue damage.	locations[0]	locations	locations			extracellular space	GO:0005615	extracellular region		"{""preferred_term"": ""extracellular space"", ""term"": {""id"": ""GO:0005615"", ""label"": ""extracellular region""}}"																											
1210	1196	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	5	Goblet Cell Hyperplasia and Mucus Hypersecretion	Increased goblet cell numbers and overproduction of gel-forming mucins (MUC5AC, MUC5B) lead to mucus hyperconcentration and impaired clearance.	cell_types[0]	cell_types	cell_types			goblet cell	CL:0000160	goblet cell		"{""preferred_term"": ""goblet cell"", ""term"": {""id"": ""CL:0000160"", ""label"": ""goblet cell""}}"																											
1211	1196	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	5	Goblet Cell Hyperplasia and Mucus Hypersecretion	Increased goblet cell numbers and overproduction of gel-forming mucins (MUC5AC, MUC5B) lead to mucus hyperconcentration and impaired clearance.	biological_processes[0]	biological_processes	biological_processes			mucus secretion	GO:0070254	mucus secretion		"{""preferred_term"": ""mucus secretion"", ""term"": {""id"": ""GO:0070254"", ""label"": ""mucus secretion""}}"																											
1212	1196	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	5	Goblet Cell Hyperplasia and Mucus Hypersecretion	Increased goblet cell numbers and overproduction of gel-forming mucins (MUC5AC, MUC5B) lead to mucus hyperconcentration and impaired clearance.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1213	1197	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	6	Inflammasome Activation and IL-1beta Signaling	NLRP3 inflammasome activation drives IL-1beta production, which directly impairs ciliary function, disrupts tight junctions, promotes mucus hyperconcentration, and is associated with severe disease and Proteobacteria enrichment.	biological_processes[0]	biological_processes	biological_processes			NLRP3 inflammasome complex assembly	GO:0072559	NLRP3 inflammasome complex assembly		"{""preferred_term"": ""NLRP3 inflammasome complex assembly"", ""term"": {""id"": ""GO:0072559"", ""label"": ""NLRP3 inflammasome complex assembly""}}"																											
1214	1197	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	6	Inflammasome Activation and IL-1beta Signaling	NLRP3 inflammasome activation drives IL-1beta production, which directly impairs ciliary function, disrupts tight junctions, promotes mucus hyperconcentration, and is associated with severe disease and Proteobacteria enrichment.	biological_processes[1]	biological_processes	biological_processes			interleukin-1 beta production	GO:0032611	interleukin-1 beta production		"{""preferred_term"": ""interleukin-1 beta production"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
1215	1197	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	6	Inflammasome Activation and IL-1beta Signaling	NLRP3 inflammasome activation drives IL-1beta production, which directly impairs ciliary function, disrupts tight junctions, promotes mucus hyperconcentration, and is associated with severe disease and Proteobacteria enrichment.	cell_types[0]	cell_types	cell_types			airway epithelial cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""airway epithelial cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
1216	1197	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	6	Inflammasome Activation and IL-1beta Signaling	NLRP3 inflammasome activation drives IL-1beta production, which directly impairs ciliary function, disrupts tight junctions, promotes mucus hyperconcentration, and is associated with severe disease and Proteobacteria enrichment.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1217	1198	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	7	Microbiome Dysbiosis	Reduced microbial diversity with Proteobacteria dominance, particularly Pseudomonas aeruginosa and Haemophilus influenzae, drives chronic infection, exacerbations, and disease progression.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1218	1198	50	Bronchiectasis	Bronchiectasis.yaml	pathophysiology	7	Microbiome Dysbiosis	Reduced microbial diversity with Proteobacteria dominance, particularly Pseudomonas aeruginosa and Haemophilus influenzae, drives chronic infection, exacerbations, and disease progression.	locations[1]	locations	locations			respiratory tract mucus	UBERON:0016403	respiratory tract mucus		"{""preferred_term"": ""respiratory tract mucus"", ""term"": {""id"": ""UBERON:0016403"", ""label"": ""respiratory tract mucus""}}"																											
1219	1199	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	0	Chronic Cough		phenotype_term	phenotype_term	$	Chronic Cough		Chronic Cough	HP:0034315	Chronic cough		"{""preferred_term"": ""Chronic Cough"", ""term"": {""id"": ""HP:0034315"", ""label"": ""Chronic cough""}}"																											
1220	1200	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	1	Sputum Production		phenotype_term	phenotype_term	$	Sputum Production		Sputum Production	HP:0033709	Increased sputum production		"{""preferred_term"": ""Sputum Production"", ""term"": {""id"": ""HP:0033709"", ""label"": ""Increased sputum production""}}"																											
1221	1201	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	2	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1222	1202	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	3	Hemoptysis		phenotype_term	phenotype_term	$	Hemoptysis		Hemoptysis	HP:0002105	Hemoptysis		"{""preferred_term"": ""Hemoptysis"", ""term"": {""id"": ""HP:0002105"", ""label"": ""Hemoptysis""}}"																											
1223	1203	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	4	Recurrent Respiratory Infections		phenotype_term	phenotype_term	$	Recurrent Respiratory Infections		Recurrent Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
1224	1204	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	5	Fixed Airflow Obstruction		phenotype_term	phenotype_term	$	Fixed Airflow Obstruction		Chronic pulmonary obstruction	HP:0006510	Chronic pulmonary obstruction		"{""preferred_term"": ""Chronic pulmonary obstruction"", ""term"": {""id"": ""HP:0006510"", ""label"": ""Chronic pulmonary obstruction""}}"																											
1225	1205	50	Bronchiectasis	Bronchiectasis.yaml	phenotypes	6	Wheezing		phenotype_term	phenotype_term	$	Wheezing		Wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
1226	1209	50	Bronchiectasis	Bronchiectasis.yaml	treatments	0	Airway Clearance Techniques	Physical therapies to enhance mucus clearance, such as chest physiotherapy.	treatment_term	treatment_term	$	Airway Clearance Techniques	Physical therapies to enhance mucus clearance, such as chest physiotherapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1227	1210	50	Bronchiectasis	Bronchiectasis.yaml	treatments	1	Antibiotic Therapy	Used to treat and prevent bacterial infections in the airways.	treatment_term	treatment_term	$	Antibiotic Therapy	Used to treat and prevent bacterial infections in the airways.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1228	1211	50	Bronchiectasis	Bronchiectasis.yaml	treatments	2	Bronchodilators	Medications to open airways and improve breathing.	treatment_term	treatment_term	$	Bronchodilators	Medications to open airways and improve breathing.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1229	1212	50	Bronchiectasis	Bronchiectasis.yaml	treatments	3	Inhaled Corticosteroids	Reduce inflammation in the airways.	treatment_term	treatment_term	$	Inhaled Corticosteroids	Reduce inflammation in the airways.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
1230	1213	50	Bronchiectasis	Bronchiectasis.yaml	treatments	4	Surgery	Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist.	treatment_term	treatment_term	$	Surgery	Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1231	1214	50	Bronchiectasis	Bronchiectasis.yaml	treatments	5	Vaccinations	Prevent respiratory infections and exacerbations.	treatment_term	treatment_term	$	Vaccinations	Prevent respiratory infections and exacerbations.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1232	1224	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	histopathology	0	Aggressive B-Cell Lymphoma	Burkitt lymphoma is an aggressive form of B cell lymphoma.	finding_term	finding_term	$	Aggressive B-Cell Lymphoma	Burkitt lymphoma is an aggressive form of B cell lymphoma.	Aggressive B-Cell Non-Hodgkin Lymphoma	NCIT:C178541	Aggressive B-Cell Non-Hodgkin Lymphoma		"{""preferred_term"": ""Aggressive B-Cell Non-Hodgkin Lymphoma"", ""term"": {""id"": ""NCIT:C178541"", ""label"": ""Aggressive B-Cell Non-Hodgkin Lymphoma""}}"																											
1233	1225	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	infectious_agent	0	Epstein-Barr Virus (EBV)	EBV infection is nearly universal in endemic Burkitt lymphoma (>95%) but variable in sporadic (15-30%) and immunodeficiency-associated (25-40%) forms. EBV provides survival signals through EBNA1 and contributes to genomic instability, but MYC translocation is the essential oncogenic driver. EBV latency type I is typically observed with expression of EBNA1 and EBERs only.	infectious_agent_term	infectious_agent_term	$	Epstein-Barr Virus (EBV)	EBV infection is nearly universal in endemic Burkitt lymphoma (>95%) but variable in sporadic (15-30%) and immunodeficiency-associated (25-40%) forms. EBV provides survival signals through EBNA1 and contributes to genomic instability, but MYC translocation is the essential oncogenic driver. EBV latency type I is typically observed with expression of EBNA1 and EBERs only.	Human gammaherpesvirus 4	NCBITaxon:10376	Human gammaherpesvirus 4		"{""preferred_term"": ""Human gammaherpesvirus 4"", ""term"": {""id"": ""NCBITaxon:10376"", ""label"": ""Human gammaherpesvirus 4""}}"																											
1234	1226	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	0	MYC Translocation and Oncogene Activation	The hallmark of Burkitt lymphoma is translocation of the MYC oncogene on chromosome 8 to an immunoglobulin locus, most commonly t(8;14)(q24;q32) involving the IGH locus, or less commonly t(2;8) or t(8;22) involving light chain loci. This places MYC under control of immunoglobulin enhancers, resulting in constitutive MYC overexpression.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1235	1226	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	0	MYC Translocation and Oncogene Activation	The hallmark of Burkitt lymphoma is translocation of the MYC oncogene on chromosome 8 to an immunoglobulin locus, most commonly t(8;14)(q24;q32) involving the IGH locus, or less commonly t(2;8) or t(8;22) involving light chain loci. This places MYC under control of immunoglobulin enhancers, resulting in constitutive MYC overexpression.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			INCREASED																								
1236	1227	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	1	Uncontrolled B-Cell Proliferation	MYC is a master transcriptional regulator of cell growth and proliferation. Constitutive MYC expression drives continuous cell cycle progression, resulting in one of the fastest doubling times of any human tumor (approximately 24 hours). The proliferation fraction approaches 100% (Ki-67 staining).	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1237	1227	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	1	Uncontrolled B-Cell Proliferation	MYC is a master transcriptional regulator of cell growth and proliferation. Constitutive MYC expression drives continuous cell cycle progression, resulting in one of the fastest doubling times of any human tumor (approximately 24 hours). The proliferation fraction approaches 100% (Ki-67 staining).	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1238	1228	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	2	Apoptosis Resistance	While MYC normally sensitizes cells to apoptosis, Burkitt lymphoma cells acquire mutations or alterations that counteract MYC-induced apoptosis. TP53 mutations occur in approximately 30% of cases. EBV-encoded EBNA1 and EBERs provide additional survival signals in EBV-positive cases.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
1239	1229	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	pathophysiology	3	High-Grade Malignancy with Rapid Tumor Growth	The combination of constitutive MYC-driven proliferation and apoptosis resistance results in rapidly growing tumors. The high proliferation rate paradoxically makes the tumor highly sensitive to chemotherapy, contributing to excellent cure rates with intensive treatment.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1240	1230	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	0	Abdominal Mass	Rapidly enlarging abdominal mass, typically ileocecal, is the most common presentation in sporadic Burkitt lymphoma. May cause bowel obstruction or intussusception.	phenotype_term	phenotype_term	$	Abdominal Mass	Rapidly enlarging abdominal mass, typically ileocecal, is the most common presentation in sporadic Burkitt lymphoma. May cause bowel obstruction or intussusception.	Abdominal distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
1241	1231	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	1	Jaw Mass	Characteristic presentation in endemic Burkitt lymphoma. Rapidly growing jaw or facial tumors, often involving the mandible or maxilla with dental abnormalities.	phenotype_term	phenotype_term	$	Jaw Mass	Characteristic presentation in endemic Burkitt lymphoma. Rapidly growing jaw or facial tumors, often involving the mandible or maxilla with dental abnormalities.	Abnormal mandible morphology	HP:0000277	Abnormal mandible morphology		"{""preferred_term"": ""Abnormal mandible morphology"", ""term"": {""id"": ""HP:0000277"", ""label"": ""Abnormal mandible morphology""}}"																											
1242	1232	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	2	Lymphadenopathy	Bulky lymphadenopathy with rapid growth. May involve multiple nodal sites.	phenotype_term	phenotype_term	$	Lymphadenopathy	Bulky lymphadenopathy with rapid growth. May involve multiple nodal sites.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
1243	1233	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	3	Weight Loss	Rapid weight loss due to high metabolic demands of rapidly proliferating tumor.	phenotype_term	phenotype_term	$	Weight Loss	Rapid weight loss due to high metabolic demands of rapidly proliferating tumor.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1244	1234	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	4	Fatigue	Profound fatigue related to tumor burden and metabolic effects.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue related to tumor burden and metabolic effects.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1245	1235	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	5	Hepatomegaly	Liver involvement may occur with advanced disease.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver involvement may occur with advanced disease.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
1246	1236	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	phenotypes	6	Splenomegaly	Splenic involvement may occur, particularly in advanced disease.	phenotype_term	phenotype_term	$	Splenomegaly	Splenic involvement may occur, particularly in advanced disease.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
1247	1237	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	0	Intensive Chemotherapy	Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement.	treatment_term	treatment_term	$	Intensive Chemotherapy	Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1248	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}]}"				rituximab	CHEBI:64357																						
1249	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			rituximab	CHEBI:64357	rituximab		"{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}"																											
1250	1239	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	2	Tumor Lysis Syndrome Prophylaxis	Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death.	treatment_term	treatment_term	$	Tumor Lysis Syndrome Prophylaxis	Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1251	1240	52	Buruli ulcer	Buruli_Ulcer.yaml	infectious_agent	0	Mycobacterium ulcerans	Slow-growing mycobacterium that produces mycolactone toxin.	infectious_agent_term	infectious_agent_term	$	Mycobacterium ulcerans	Slow-growing mycobacterium that produces mycolactone toxin.	Mycobacterium ulcerans	NCBITaxon:1809	Mycobacterium ulcerans		"{""preferred_term"": ""Mycobacterium ulcerans"", ""term"": {""id"": ""NCBITaxon:1809"", ""label"": ""Mycobacterium ulcerans""}}"																											
1252	1242	52	Buruli ulcer	Buruli_Ulcer.yaml	phenotypes	0	Skin ulcer		phenotype_term	phenotype_term	$	Skin ulcer		Skin ulcer	HP:0200042	Skin ulcer		"{""preferred_term"": ""Skin ulcer"", ""term"": {""id"": ""HP:0200042"", ""label"": ""Skin ulcer""}}"																											
1253	1243	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	0	Antimycobacterial therapy	Antimycobacterial therapy is effective for early lesions.	treatment_term	treatment_term	$	Antimycobacterial therapy	Antimycobacterial therapy is effective for early lesions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1254	1244	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	1	Surgical management	Surgery may be required for advanced ulcerated lesions.	treatment_term	treatment_term	$	Surgical management	Surgery may be required for advanced ulcerated lesions.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1255	1246	53	CHIME_syndrome	CHIME_syndrome.yaml	pathophysiology	0	PIGL Gene Mutations	Mutations in PIGL gene disrupt glycosylphosphatidylinositol (GPI) anchor biosynthesis. PIGL encodes a de-N-acetylase required for GPI anchor formation, essential for anchoring various cell surface proteins including receptors, enzymes, and adhesion molecules.	biological_processes[0]	biological_processes	biological_processes			glycosylphosphatidylinositol biosynthetic process	GO:0006506	GPI anchor biosynthetic process		"{""preferred_term"": ""glycosylphosphatidylinositol biosynthetic process"", ""term"": {""id"": ""GO:0006506"", ""label"": ""GPI anchor biosynthetic process""}}"																											
1256	1247	53	CHIME_syndrome	CHIME_syndrome.yaml	pathophysiology	1	GPI Anchor Deficiency	Reduced levels of GPI-anchored proteins on cell surface due to impaired biosynthesis, affecting normal cellular functions and signaling pathways. This leads to the multisystem phenotype characteristic of CHIME syndrome.	biological_processes[0]	biological_processes	biological_processes			cell adhesion	GO:0007155	cell adhesion		"{""preferred_term"": ""cell adhesion"", ""term"": {""id"": ""GO:0007155"", ""label"": ""cell adhesion""}}"																											
1257	1247	53	CHIME_syndrome	CHIME_syndrome.yaml	pathophysiology	1	GPI Anchor Deficiency	Reduced levels of GPI-anchored proteins on cell surface due to impaired biosynthesis, affecting normal cellular functions and signaling pathways. This leads to the multisystem phenotype characteristic of CHIME syndrome.	biological_processes[1]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"																											
1258	1247	53	CHIME_syndrome	CHIME_syndrome.yaml	pathophysiology	1	GPI Anchor Deficiency	Reduced levels of GPI-anchored proteins on cell surface due to impaired biosynthesis, affecting normal cellular functions and signaling pathways. This leads to the multisystem phenotype characteristic of CHIME syndrome.	biological_processes[2]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
1259	1248	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	0	Chorioretinal Coloboma		phenotype_term	phenotype_term	$	Chorioretinal Coloboma		Chorioretinal coloboma	HP:0000567	Chorioretinal coloboma		"{""preferred_term"": ""Chorioretinal coloboma"", ""term"": {""id"": ""HP:0000567"", ""label"": ""Chorioretinal coloboma""}}"																											
1260	1249	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	1	Congenital Heart Defects		phenotype_term	phenotype_term	$	Congenital Heart Defects		Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
1261	1250	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	2	Ichthyosiform Dermatosis		phenotype_term	phenotype_term	$	Ichthyosiform Dermatosis		Ichthyosis	HP:0008064	Ichthyosis		"{""preferred_term"": ""Ichthyosis"", ""term"": {""id"": ""HP:0008064"", ""label"": ""Ichthyosis""}}"																											
1262	1251	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	3	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1263	1252	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	4	Conductive Hearing Loss		phenotype_term	phenotype_term	$	Conductive Hearing Loss		Conductive hearing impairment	HP:0000405	Conductive hearing impairment		"{""preferred_term"": ""Conductive hearing impairment"", ""term"": {""id"": ""HP:0000405"", ""label"": ""Conductive hearing impairment""}}"																											
1264	1253	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	5	Seizure Disorder		phenotype_term	phenotype_term	$	Seizure Disorder		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
1265	1254	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	6	Dysmorphic Facial Features		phenotype_term	phenotype_term	$	Dysmorphic Facial Features		Dysmorphic facial features	HP:0001999	Abnormal facial shape		"{""preferred_term"": ""Dysmorphic facial features"", ""term"": {""id"": ""HP:0001999"", ""label"": ""Abnormal facial shape""}}"																											
1266	1255	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	7	Genitourinary Abnormalities		phenotype_term	phenotype_term	$	Genitourinary Abnormalities		Abnormality of the genitourinary system	HP:0000119	Abnormality of the genitourinary system		"{""preferred_term"": ""Abnormality of the genitourinary system"", ""term"": {""id"": ""HP:0000119"", ""label"": ""Abnormality of the genitourinary system""}}"																											
1267	1256	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	8	Large Birth Size		phenotype_term	phenotype_term	$	Large Birth Size		Large for gestational age	HP:0001520	Large for gestational age		"{""preferred_term"": ""Large for gestational age"", ""term"": {""id"": ""HP:0001520"", ""label"": ""Large for gestational age""}}"																											
1268	1257	53	CHIME_syndrome	CHIME_syndrome.yaml	phenotypes	9	Feeding Difficulties		phenotype_term	phenotype_term	$	Feeding Difficulties		Feeding difficulties	HP:0011968	Feeding difficulties		"{""preferred_term"": ""Feeding difficulties"", ""term"": {""id"": ""HP:0011968"", ""label"": ""Feeding difficulties""}}"																											
1269	1259	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	0	Supportive Care	Multidisciplinary care addressing individual symptoms and complications.	treatment_term	treatment_term	$	Supportive Care	Multidisciplinary care addressing individual symptoms and complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1270	1260	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	1	Cardiac Surgery	Surgical correction of congenital heart defects when indicated.	treatment_term	treatment_term	$	Cardiac Surgery	Surgical correction of congenital heart defects when indicated.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1271	1261	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	2	Seizure Management	Antiepileptic medications for seizure control.	treatment_term	treatment_term	$	Seizure Management	Antiepileptic medications for seizure control.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1272	1262	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	3	Dermatologic Care	Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases.	treatment_term	treatment_term	$	Dermatologic Care	Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1273	1263	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	4	Hearing Aids	Assistive devices for conductive hearing loss.	treatment_term	treatment_term	$	Hearing Aids	Assistive devices for conductive hearing loss.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1274	1264	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	5	Educational Support	Special educational services tailored to intellectual disability.	treatment_term	treatment_term	$	Educational Support	Special educational services tailored to intellectual disability.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
1275	1267	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	0	CTCF Haploinsufficiency	"Heterozygous loss-of-function mutations in CTCF lead to reduced functional CTCF protein levels, disrupting its role as a master regulator of chromatin architecture. CTCF is essential for establishing insulator elements that define topologically associating domain (TAD) boundaries. Both frameshift and missense variants (affecting zinc finger domains) result in functional haploinsufficiency through nonsense-mediated decay or impaired DNA binding.
"	cell_types[0]	cell_types	cell_types			neural progenitor cell	CL:0011020	neural progenitor cell		"{""preferred_term"": ""neural progenitor cell"", ""term"": {""id"": ""CL:0011020"", ""label"": ""neural progenitor cell""}}"																											
1276	1267	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	0	CTCF Haploinsufficiency	"Heterozygous loss-of-function mutations in CTCF lead to reduced functional CTCF protein levels, disrupting its role as a master regulator of chromatin architecture. CTCF is essential for establishing insulator elements that define topologically associating domain (TAD) boundaries. Both frameshift and missense variants (affecting zinc finger domains) result in functional haploinsufficiency through nonsense-mediated decay or impaired DNA binding.
"	cell_types[1]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1277	1267	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	0	CTCF Haploinsufficiency	"Heterozygous loss-of-function mutations in CTCF lead to reduced functional CTCF protein levels, disrupting its role as a master regulator of chromatin architecture. CTCF is essential for establishing insulator elements that define topologically associating domain (TAD) boundaries. Both frameshift and missense variants (affecting zinc finger domains) result in functional haploinsufficiency through nonsense-mediated decay or impaired DNA binding.
"	biological_processes[0]	biological_processes	biological_processes			chromatin organization	GO:0006325	chromatin organization		"{""preferred_term"": ""chromatin organization"", ""term"": {""id"": ""GO:0006325"", ""label"": ""chromatin organization""}}"																											
1278	1267	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	0	CTCF Haploinsufficiency	"Heterozygous loss-of-function mutations in CTCF lead to reduced functional CTCF protein levels, disrupting its role as a master regulator of chromatin architecture. CTCF is essential for establishing insulator elements that define topologically associating domain (TAD) boundaries. Both frameshift and missense variants (affecting zinc finger domains) result in functional haploinsufficiency through nonsense-mediated decay or impaired DNA binding.
"	biological_processes[1]	biological_processes	biological_processes			regulation of gene expression	GO:0010468	regulation of gene expression		"{""preferred_term"": ""regulation of gene expression"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"																											
1279	1267	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	0	CTCF Haploinsufficiency	"Heterozygous loss-of-function mutations in CTCF lead to reduced functional CTCF protein levels, disrupting its role as a master regulator of chromatin architecture. CTCF is essential for establishing insulator elements that define topologically associating domain (TAD) boundaries. Both frameshift and missense variants (affecting zinc finger domains) result in functional haploinsufficiency through nonsense-mediated decay or impaired DNA binding.
"	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
1280	1268	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	1	Chromatin Architecture Disruption	"Reduced CTCF function leads to aberrant chromatin looping and disrupted TAD boundaries, causing inappropriate enhancer-promoter interactions. CTCF normally mediates formation of chromatin loops that define TADs, and its depletion causes blurred domain boundaries and altered three-dimensional genome structure. The R567W mutation specifically affects CTCF binding to peripheral motifs, causing local chromatin structure alterations particularly at the clustered protocadherin locus.
"	biological_processes[0]	biological_processes	biological_processes			chromosome organization	GO:0051276	chromosome organization		"{""preferred_term"": ""chromosome organization"", ""term"": {""id"": ""GO:0051276"", ""label"": ""chromosome organization""}}"																											
1281	1268	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	1	Chromatin Architecture Disruption	"Reduced CTCF function leads to aberrant chromatin looping and disrupted TAD boundaries, causing inappropriate enhancer-promoter interactions. CTCF normally mediates formation of chromatin loops that define TADs, and its depletion causes blurred domain boundaries and altered three-dimensional genome structure. The R567W mutation specifically affects CTCF binding to peripheral motifs, causing local chromatin structure alterations particularly at the clustered protocadherin locus.
"	biological_processes[1]	biological_processes	biological_processes			regulation of chromatin organization	GO:1902275	regulation of chromatin organization		"{""preferred_term"": ""regulation of chromatin organization"", ""term"": {""id"": ""GO:1902275"", ""label"": ""regulation of chromatin organization""}}"																											
1282	1268	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	1	Chromatin Architecture Disruption	"Reduced CTCF function leads to aberrant chromatin looping and disrupted TAD boundaries, causing inappropriate enhancer-promoter interactions. CTCF normally mediates formation of chromatin loops that define TADs, and its depletion causes blurred domain boundaries and altered three-dimensional genome structure. The R567W mutation specifically affects CTCF binding to peripheral motifs, causing local chromatin structure alterations particularly at the clustered protocadherin locus.
"	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
1283	1269	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	2	Neurodevelopmental Gene Dysregulation	"CTCF haploinsufficiency leads to widespread gene dysregulation affecting neurodevelopmental pathways. RNA-sequencing in affected individuals revealed 3,828 deregulated genes enriched for known neurodevelopmental disorder genes and transcriptional regulation processes. Downregulated genes are enriched for transcription-related processes, while upregulated genes are enriched for translational and ribosomal processes.
"	cell_types[0]	cell_types	cell_types			neural progenitor cell	CL:0011020	neural progenitor cell		"{""preferred_term"": ""neural progenitor cell"", ""term"": {""id"": ""CL:0011020"", ""label"": ""neural progenitor cell""}}"																											
1284	1269	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	2	Neurodevelopmental Gene Dysregulation	"CTCF haploinsufficiency leads to widespread gene dysregulation affecting neurodevelopmental pathways. RNA-sequencing in affected individuals revealed 3,828 deregulated genes enriched for known neurodevelopmental disorder genes and transcriptional regulation processes. Downregulated genes are enriched for transcription-related processes, while upregulated genes are enriched for translational and ribosomal processes.
"	cell_types[1]	cell_types	cell_types			cerebral cortex neuron	CL:0010012	cerebral cortex neuron		"{""preferred_term"": ""cerebral cortex neuron"", ""term"": {""id"": ""CL:0010012"", ""label"": ""cerebral cortex neuron""}}"																											
1285	1269	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	2	Neurodevelopmental Gene Dysregulation	"CTCF haploinsufficiency leads to widespread gene dysregulation affecting neurodevelopmental pathways. RNA-sequencing in affected individuals revealed 3,828 deregulated genes enriched for known neurodevelopmental disorder genes and transcriptional regulation processes. Downregulated genes are enriched for transcription-related processes, while upregulated genes are enriched for translational and ribosomal processes.
"	biological_processes[0]	biological_processes	biological_processes			regulation of gene expression	GO:0010468	regulation of gene expression		"{""preferred_term"": ""regulation of gene expression"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"																											
1286	1270	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	3	Abnormal Neural Progenitor Cell Development	"CTCF mutations induce premature depletion of stem-like neural progenitor cells and accelerate maturation of GABAergic neurons within the developing cortex. The R567W mutation causes reduced proportions of neural progenitors and radial glial cells, with increased postmitotic neuroblasts and inhibitory GABAergic neurons, disrupting the balanced development of excitatory and inhibitory neural circuits.
"	cell_types[0]	cell_types	cell_types			neural progenitor cell	CL:0011020	neural progenitor cell		"{""preferred_term"": ""neural progenitor cell"", ""term"": {""id"": ""CL:0011020"", ""label"": ""neural progenitor cell""}}"																											
1287	1270	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	3	Abnormal Neural Progenitor Cell Development	"CTCF mutations induce premature depletion of stem-like neural progenitor cells and accelerate maturation of GABAergic neurons within the developing cortex. The R567W mutation causes reduced proportions of neural progenitors and radial glial cells, with increased postmitotic neuroblasts and inhibitory GABAergic neurons, disrupting the balanced development of excitatory and inhibitory neural circuits.
"	cell_types[1]	cell_types	cell_types			cerebral cortex GABAergic interneuron	CL:0010011	cerebral cortex GABAergic interneuron		"{""preferred_term"": ""cerebral cortex GABAergic interneuron"", ""term"": {""id"": ""CL:0010011"", ""label"": ""cerebral cortex GABAergic interneuron""}}"																											
1288	1270	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	pathophysiology	3	Abnormal Neural Progenitor Cell Development	"CTCF mutations induce premature depletion of stem-like neural progenitor cells and accelerate maturation of GABAergic neurons within the developing cortex. The R567W mutation causes reduced proportions of neural progenitors and radial glial cells, with increased postmitotic neuroblasts and inhibitory GABAergic neurons, disrupting the balanced development of excitatory and inhibitory neural circuits.
"	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
1289	1271	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	0	Intellectual Disability	"Intellectual disability of variable severity is a core feature, ranging from learning difficulties and normal IQ to severe intellectual disability. Some individuals attend mainstream school or graduate from college, while others require substantial lifelong support.
"	phenotype_term	phenotype_term	$	Intellectual Disability	"Intellectual disability of variable severity is a core feature, ranging from learning difficulties and normal IQ to severe intellectual disability. Some individuals attend mainstream school or graduate from college, while others require substantial lifelong support.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1290	1272	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	1	Global Developmental Delay	"Delayed achievement of developmental milestones including motor and language domains. Walking age ranges from 12 months to over 3 years, and age of first words ranges from 12 months to absent speech at 12 years.
"	phenotype_term	phenotype_term	$	Global Developmental Delay	"Delayed achievement of developmental milestones including motor and language domains. Walking age ranges from 12 months to over 3 years, and age of first words ranges from 12 months to absent speech at 12 years.
"	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
1291	1273	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	2	Feeding Difficulties	"Feeding problems in infancy, including poor feeding and failure to thrive, are among the most common features. Many affected individuals require temporary tube feeding.
"	phenotype_term	phenotype_term	$	Feeding Difficulties	"Feeding problems in infancy, including poor feeding and failure to thrive, are among the most common features. Many affected individuals require temporary tube feeding.
"	Feeding difficulties in infancy	HP:0008872	Feeding difficulties in infancy		"{""preferred_term"": ""Feeding difficulties in infancy"", ""term"": {""id"": ""HP:0008872"", ""label"": ""Feeding difficulties in infancy""}}"																											
1292	1274	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	3	Microcephaly	"Microcephaly or borderline microcephaly is present in approximately 30-50% of affected individuals, reflecting impaired neurogenesis and brain development.
"	phenotype_term	phenotype_term	$	Microcephaly	"Microcephaly or borderline microcephaly is present in approximately 30-50% of affected individuals, reflecting impaired neurogenesis and brain development.
"	Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
1293	1275	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	4	Short Stature	"Postnatal growth restriction and short stature are observed in a subset of affected individuals. Intrauterine growth restriction may also occur.
"	phenotype_term	phenotype_term	$	Short Stature	"Postnatal growth restriction and short stature are observed in a subset of affected individuals. Intrauterine growth restriction may also occur.
"	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
1294	1276	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	5	Behavioral Abnormalities	"Behavioral issues are common and include autistic features, attention deficit and hyperactivity disorder (ADHD)-like features, aggression, and other behavioral disturbances.
"	phenotype_term	phenotype_term	$	Behavioral Abnormalities	"Behavioral issues are common and include autistic features, attention deficit and hyperactivity disorder (ADHD)-like features, aggression, and other behavioral disturbances.
"	Autistic behavior	HP:0000729	Autistic behavior		"{""preferred_term"": ""Autistic behavior"", ""term"": {""id"": ""HP:0000729"", ""label"": ""Autistic behavior""}}"																											
1295	1277	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	6	Hypotonia	"Muscular hypotonia is commonly observed, contributing to motor developmental delays and feeding difficulties.
"	phenotype_term	phenotype_term	$	Hypotonia	"Muscular hypotonia is commonly observed, contributing to motor developmental delays and feeding difficulties.
"	Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
1296	1278	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	7	Congenital Heart Defects	"Cardiac defects occur in approximately 30% of affected individuals, including various structural heart abnormalities.
"	phenotype_term	phenotype_term	$	Congenital Heart Defects	"Cardiac defects occur in approximately 30% of affected individuals, including various structural heart abnormalities.
"	Abnormal heart morphology	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Abnormal heart morphology"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
1297	1279	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	8	Cleft Palate	"Palatal anomalies including cleft palate or high palate are present in approximately one-third of affected individuals.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Palatal anomalies including cleft palate or high palate are present in approximately one-third of affected individuals.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
1298	1280	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	9	Hearing Loss	"Conductive and/or sensorineural hearing loss occurs in approximately one-quarter of affected individuals.
"	phenotype_term	phenotype_term	$	Hearing Loss	"Conductive and/or sensorineural hearing loss occurs in approximately one-quarter of affected individuals.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
1299	1281	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	phenotypes	10	Seizures	"Febrile or nonfebrile seizures occur in a minority of affected individuals.
"	phenotype_term	phenotype_term	$	Seizures	"Febrile or nonfebrile seizures occur in a minority of affected individuals.
"	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
1300	1285	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	0	Supportive Developmental Therapies	"Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.
"	treatment_term	treatment_term	$	Supportive Developmental Therapies	"Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1301	1288	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	3	Behavioral Management	"Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.
"	treatment_term	treatment_term	$	Behavioral Management	"Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1302	1289	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	4	Genetic Counseling	"Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.
"	treatment_term	treatment_term	$	Genetic Counseling	"Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1303	1298	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	0	Fetal Akinesia	Reduced fetal movement during development leads to connective tissue accumulation and shortening around joints, resulting in fixed flexion deformities at birth. This is the fundamental pathomechanism across arthrogryposis types.	cell_types[0]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
1304	1299	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	1	Sarcomere Dysfunction	Pathogenic variants in sarcomeric proteins (TNNT3, TNNI2, TPM2, MYH3, ACTC1) impair muscle contraction/relaxation dynamics, reducing fetal limb motion and producing non-progressive congenital contractures.	cell_types[0]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
1305	1299	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	1	Sarcomere Dysfunction	Pathogenic variants in sarcomeric proteins (TNNT3, TNNI2, TPM2, MYH3, ACTC1) impair muscle contraction/relaxation dynamics, reducing fetal limb motion and producing non-progressive congenital contractures.	biological_processes[0]	biological_processes	biological_processes			sarcomere organization	GO:0045214	sarcomere organization		"{""preferred_term"": ""sarcomere organization"", ""term"": {""id"": ""GO:0045214"", ""label"": ""sarcomere organization""}}"																											
1306	1299	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	1	Sarcomere Dysfunction	Pathogenic variants in sarcomeric proteins (TNNT3, TNNI2, TPM2, MYH3, ACTC1) impair muscle contraction/relaxation dynamics, reducing fetal limb motion and producing non-progressive congenital contractures.	biological_processes[1]	biological_processes	biological_processes			muscle contraction	GO:0006936	muscle contraction		"{""preferred_term"": ""muscle contraction"", ""term"": {""id"": ""GO:0006936"", ""label"": ""muscle contraction""}}"																											
1307	1300	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	2	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	gene	gene	$	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	PRG4	hgnc:9364	PRG4	Encodes lubricin, a secreted mucinous glycoprotein that provides boundary lubrication and anti-adhesive properties at joint surfaces.	"{""description"": ""Encodes lubricin, a secreted mucinous glycoprotein that provides boundary lubrication and anti-adhesive properties at joint surfaces."", ""preferred_term"": ""PRG4"", ""term"": {""id"": ""hgnc:9364"", ""label"": ""PRG4""}}"																											
1308	1300	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	2	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	cell_types[0]	cell_types	cell_types			type B synovial cell	CL:0002301	type B synovial cell		"{""preferred_term"": ""type B synovial cell"", ""term"": {""id"": ""CL:0002301"", ""label"": ""type B synovial cell""}}"																											
1309	1300	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	2	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	cell_types[1]	cell_types	cell_types			chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
1310	1300	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	2	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	locations[0]	locations	locations			synovial membrane of joint	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane of joint"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
1311	1300	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	2	PRG4/Lubricin Deficiency	Loss of PRG4 function abolishes surface lubrication and anti-adhesive properties of synovial and cartilage interfaces, provoking non-inflammatory arthropathy, synovial hyperplasia, and progressive joint stiffness. Camptodactyly is often the earliest manifestation in CACP syndrome.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1312	1301	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	3	Flexor Tendon Abnormalities	Abnormalities or shortening in the flexor tendons can contribute to the inability to fully extend one or more fingers.	locations[0]	locations	locations			tendon	UBERON:0000043	tendon		"{""preferred_term"": ""tendon"", ""term"": {""id"": ""UBERON:0000043"", ""label"": ""tendon""}}"																											
1313	1302	55	Camptodactyly	Camptodactyly.yaml	pathophysiology	4	Joint Contracture	Permanent soft tissue shortening around joints, leading to fixed flexion deformity. Results from fibroconnective remodeling of volar plate and tendon sheaths.	locations[0]	locations	locations			interphalangeal joint of manual digit	UBERON:0007721	interphalangeal joint of manual digit		"{""preferred_term"": ""interphalangeal joint of manual digit"", ""term"": {""id"": ""UBERON:0007721"", ""label"": ""interphalangeal joint of manual digit""}}"																											
1314	1303	55	Camptodactyly	Camptodactyly.yaml	phenotypes	0	Camptodactyly		phenotype_term	phenotype_term	$	Camptodactyly		Camptodactyly	HP:0012385	Camptodactyly		"{""preferred_term"": ""Camptodactyly"", ""term"": {""id"": ""HP:0012385"", ""label"": ""Camptodactyly""}}"																											
1315	1304	55	Camptodactyly	Camptodactyly.yaml	phenotypes	1	Finger Flexion Contracture		phenotype_term	phenotype_term	$	Finger Flexion Contracture		Finger Flexion Contracture	HP:0012785	Flexion contracture of finger		"{""preferred_term"": ""Finger Flexion Contracture"", ""term"": {""id"": ""HP:0012785"", ""label"": ""Flexion contracture of finger""}}"																											
1316	1305	55	Camptodactyly	Camptodactyly.yaml	phenotypes	2	Joint Stiffness		phenotype_term	phenotype_term	$	Joint Stiffness		Joint stiffness	HP:0001387	Joint stiffness		"{""preferred_term"": ""Joint stiffness"", ""term"": {""id"": ""HP:0001387"", ""label"": ""Joint stiffness""}}"																											
1317	1307	55	Camptodactyly	Camptodactyly.yaml	phenotypes	4	Arachnodactyly		phenotype_term	phenotype_term	$	Arachnodactyly		Arachnodactyly	HP:0001166	Arachnodactyly		"{""preferred_term"": ""Arachnodactyly"", ""term"": {""id"": ""HP:0001166"", ""label"": ""Arachnodactyly""}}"																											
1318	1309	55	Camptodactyly	Camptodactyly.yaml	treatments	0	Physical Therapy	Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases.	treatment_term	treatment_term	$	Physical Therapy	Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1319	1310	55	Camptodactyly	Camptodactyly.yaml	treatments	1	Serial Splinting	Progressive splinting to gradually extend the affected joints over time.	treatment_term	treatment_term	$	Serial Splinting	Progressive splinting to gradually extend the affected joints over time.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
1320	1311	55	Camptodactyly	Camptodactyly.yaml	treatments	2	Surgical Release	Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release.	treatment_term	treatment_term	$	Surgical Release	Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1321	1312	55	Camptodactyly	Camptodactyly.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support and properly align affected fingers.	treatment_term	treatment_term	$	Orthotic Interventions	Use of orthotic devices to support and properly align affected fingers.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
1322	1313	55	Camptodactyly	Camptodactyly.yaml	treatments	4	Genetic Counseling	Recommended for syndromic forms to assess inheritance patterns and recurrence risks.	treatment_term	treatment_term	$	Genetic Counseling	Recommended for syndromic forms to assess inheritance patterns and recurrence risks.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1323	1318	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	pathophysiology	0	RAS-MAPK Pathway Hyperactivation	"Mutations in BRAF, MEK1, or MEK2 cause constitutive or enhanced activation of the RAS-MAPK signaling cascade, affecting cell proliferation and differentiation during development. BRAF mutations are most common (~75%), followed by MEK1/MEK2 mutations.
"	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1324	1318	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	pathophysiology	0	RAS-MAPK Pathway Hyperactivation	"Mutations in BRAF, MEK1, or MEK2 cause constitutive or enhanced activation of the RAS-MAPK signaling cascade, affecting cell proliferation and differentiation during development. BRAF mutations are most common (~75%), followed by MEK1/MEK2 mutations.
"	cell_types[1]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
1325	1318	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	pathophysiology	0	RAS-MAPK Pathway Hyperactivation	"Mutations in BRAF, MEK1, or MEK2 cause constitutive or enhanced activation of the RAS-MAPK signaling cascade, affecting cell proliferation and differentiation during development. BRAF mutations are most common (~75%), followed by MEK1/MEK2 mutations.
"	biological_processes[0]	biological_processes	biological_processes			MAPK Cascade	GO:0000165	MAPK cascade		"{""preferred_term"": ""MAPK Cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
1326	1318	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	pathophysiology	0	RAS-MAPK Pathway Hyperactivation	"Mutations in BRAF, MEK1, or MEK2 cause constitutive or enhanced activation of the RAS-MAPK signaling cascade, affecting cell proliferation and differentiation during development. BRAF mutations are most common (~75%), followed by MEK1/MEK2 mutations.
"	biological_processes[1]	biological_processes	biological_processes			ERK1/2 Cascade	GO:0070371	ERK1 and ERK2 cascade		"{""preferred_term"": ""ERK1/2 Cascade"", ""term"": {""id"": ""GO:0070371"", ""label"": ""ERK1 and ERK2 cascade""}}"																											
1327	1318	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	pathophysiology	0	RAS-MAPK Pathway Hyperactivation	"Mutations in BRAF, MEK1, or MEK2 cause constitutive or enhanced activation of the RAS-MAPK signaling cascade, affecting cell proliferation and differentiation during development. BRAF mutations are most common (~75%), followed by MEK1/MEK2 mutations.
"	biological_processes[2]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell population proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"																											
1328	1319	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	0	Distinctive Facies	"Characteristic craniofacial features including high forehead, bitemporal narrowing, hypoplastic supraorbital ridges, and downslanting palpebral fissures.
"	phenotype_term	phenotype_term	$	Distinctive Facies	"Characteristic craniofacial features including high forehead, bitemporal narrowing, hypoplastic supraorbital ridges, and downslanting palpebral fissures.
"	Abnormal facial shape	HP:0001999	Abnormal facial shape		"{""preferred_term"": ""Abnormal facial shape"", ""term"": {""id"": ""HP:0001999"", ""label"": ""Abnormal facial shape""}}"																											
1329	1320	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	1	Congenital Heart Defects	"Cardiac malformations including pulmonary valve stenosis, atrial septal defect, and hypertrophic cardiomyopathy.
"	phenotype_term	phenotype_term	$	Congenital Heart Defects	"Cardiac malformations including pulmonary valve stenosis, atrial septal defect, and hypertrophic cardiomyopathy.
"	Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
1330	1321	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	2	Pulmonary Valve Stenosis	"Pulmonary valve stenosis is the most common cardiac defect.
"	phenotype_term	phenotype_term	$	Pulmonary Valve Stenosis	"Pulmonary valve stenosis is the most common cardiac defect.
"	Pulmonary valve stenosis	HP:0001642	Pulmonic stenosis		"{""preferred_term"": ""Pulmonary valve stenosis"", ""term"": {""id"": ""HP:0001642"", ""label"": ""Pulmonic stenosis""}}"																											
1331	1322	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	3	Sparse Hair	"Sparse, curly, friable hair is characteristic.
"	phenotype_term	phenotype_term	$	Sparse Hair	"Sparse, curly, friable hair is characteristic.
"	Sparse hair	HP:0008070	Sparse hair		"{""preferred_term"": ""Sparse hair"", ""term"": {""id"": ""HP:0008070"", ""label"": ""Sparse hair""}}"																											
1332	1323	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	4	Keratosis Pilaris	"Keratosis pilaris affecting the face and limbs.
"	phenotype_term	phenotype_term	$	Keratosis Pilaris	"Keratosis pilaris affecting the face and limbs.
"	Keratosis pilaris	HP:0032152	Keratosis pilaris		"{""preferred_term"": ""Keratosis pilaris"", ""term"": {""id"": ""HP:0032152"", ""label"": ""Keratosis pilaris""}}"																											
1333	1324	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	5	Failure to Thrive	"Feeding difficulties and failure to thrive in infancy.
"	phenotype_term	phenotype_term	$	Failure to Thrive	"Feeding difficulties and failure to thrive in infancy.
"	Failure to thrive	HP:0001508	Failure to thrive		"{""preferred_term"": ""Failure to thrive"", ""term"": {""id"": ""HP:0001508"", ""label"": ""Failure to thrive""}}"																											
1334	1325	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	6	Intellectual Disability	"Moderate to severe intellectual disability is typical. Neurological involvement in CFC is more severe than in other RASopathies.
"	phenotype_term	phenotype_term	$	Intellectual Disability	"Moderate to severe intellectual disability is typical. Neurological involvement in CFC is more severe than in other RASopathies.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1335	1326	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	7	Short Stature	"Postnatal growth deficiency leading to short stature.
"	phenotype_term	phenotype_term	$	Short Stature	"Postnatal growth deficiency leading to short stature.
"	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
1336	1327	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	8	Kyphoscoliosis	"Spinal curvature abnormalities are common skeletal features.
"	phenotype_term	phenotype_term	$	Kyphoscoliosis	"Spinal curvature abnormalities are common skeletal features.
"	Kyphoscoliosis	HP:0002751	Kyphoscoliosis		"{""preferred_term"": ""Kyphoscoliosis"", ""term"": {""id"": ""HP:0002751"", ""label"": ""Kyphoscoliosis""}}"																											
1337	1328	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	9	Seizures	"Epilepsy is common in CFC syndrome with gene-specific frequencies. Seizures occur in approximately 57% of BRAF cases, 61% of MAP2K1 cases, and 30% of MAP2K2 cases.
"	phenotype_term	phenotype_term	$	Seizures	"Epilepsy is common in CFC syndrome with gene-specific frequencies. Seizures occur in approximately 57% of BRAF cases, 61% of MAP2K1 cases, and 30% of MAP2K2 cases.
"	Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
1338	1329	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	phenotypes	10	Polyhydramnios	"Prenatal manifestation of RAS/MAPK dysregulation, commonly observed on second and third trimester ultrasound.
"	phenotype_term	phenotype_term	$	Polyhydramnios	"Prenatal manifestation of RAS/MAPK dysregulation, commonly observed on second and third trimester ultrasound.
"	Polyhydramnios	HP:0001561	Polyhydramnios		"{""preferred_term"": ""Polyhydramnios"", ""term"": {""id"": ""HP:0001561"", ""label"": ""Polyhydramnios""}}"																											
1339	1330	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	0	Cardiac Management	"Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.
"	treatment_term	treatment_term	$	Cardiac Management	"Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.
"	Cardiac surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cardiac surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1340	1331	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	1	Nutritional Support	"Nutritional interventions for failure to thrive, including tube feeding when necessary.
"	treatment_term	treatment_term	$	Nutritional Support	"Nutritional interventions for failure to thrive, including tube feeding when necessary.
"	Nutritional support	MAXO:0000088	dietary intervention		"{""preferred_term"": ""Nutritional support"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1341	1332	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.
"	treatment_term	treatment_term	$	MEK Inhibitor Therapy	"MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1342	1345	57	Celiac Disease	Celiac_Disease.yaml	pathophysiology	0	Gluten-Triggered Immune Response	"Gluten peptides (gliadin) cross the intestinal epithelium and are deamidated by tissue transglutaminase (tTG). Deamidated peptides bind HLA-DQ2/DQ8 and activate CD4+ T cells.
"	cell_types[0]	cell_types	cell_types			T Helper Cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""T Helper Cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
1343	1345	57	Celiac Disease	Celiac_Disease.yaml	pathophysiology	0	Gluten-Triggered Immune Response	"Gluten peptides (gliadin) cross the intestinal epithelium and are deamidated by tissue transglutaminase (tTG). Deamidated peptides bind HLA-DQ2/DQ8 and activate CD4+ T cells.
"	biological_processes[0]	biological_processes	biological_processes			Antigen Processing	GO:0019882	antigen processing and presentation		"{""preferred_term"": ""Antigen Processing"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"																											
1344	1346	57	Celiac Disease	Celiac_Disease.yaml	pathophysiology	1	Intestinal Epithelial Damage	"Activated T cells release IFN-gamma and other cytokines causing villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes. Leads to malabsorption.
"	cell_types[0]	cell_types	cell_types			Intestinal Epithelial Cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""Intestinal Epithelial Cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1345	1346	57	Celiac Disease	Celiac_Disease.yaml	pathophysiology	1	Intestinal Epithelial Damage	"Activated T cells release IFN-gamma and other cytokines causing villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes. Leads to malabsorption.
"	biological_processes[0]	biological_processes	biological_processes			Apoptosis	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptosis"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
1346	1347	57	Celiac Disease	Celiac_Disease.yaml	pathophysiology	2	Autoantibody Production	"B cells produce antibodies against tTG (anti-tTG IgA) and deamidated gliadin peptides (anti-DGP). These serve as diagnostic markers and may contribute to pathology.
"	cell_types[0]	cell_types	cell_types			Plasma Cell	CL:0000786	plasma cell		"{""preferred_term"": ""Plasma Cell"", ""term"": {""id"": ""CL:0000786"", ""label"": ""plasma cell""}}"																											
1347	1349	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	0	Chronic Diarrhea		phenotype_term	phenotype_term	$	Chronic Diarrhea		Chronic Diarrhea	HP:0002028	Chronic diarrhea		"{""preferred_term"": ""Chronic Diarrhea"", ""term"": {""id"": ""HP:0002028"", ""label"": ""Chronic diarrhea""}}"																											
1348	1350	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	1	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1349	1351	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	2	Bloating		phenotype_term	phenotype_term	$	Bloating		Abdominal Distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal Distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
1350	1352	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	3	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight Loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight Loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1351	1353	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	4	Iron Deficiency Anemia		phenotype_term	phenotype_term	$	Iron Deficiency Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1352	1354	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1353	1355	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	6	Dermatitis Herpetiformis		phenotype_term	phenotype_term	$	Dermatitis Herpetiformis		Skin Rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin Rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
1354	1356	57	Celiac Disease	Celiac_Disease.yaml	phenotypes	7	Osteoporosis		phenotype_term	phenotype_term	$	Osteoporosis		Reduced Bone Density	HP:0004349	Reduced bone mineral density		"{""preferred_term"": ""Reduced Bone Density"", ""term"": {""id"": ""HP:0004349"", ""label"": ""Reduced bone mineral density""}}"																											
1355	1369	58	Cervical Cancer	Cervical_Cancer.yaml	histopathology	0	Squamous Cell Carcinoma	Squamous cell carcinoma is the most common malignant cervical tumor.	finding_term	finding_term	$	Squamous Cell Carcinoma	Squamous cell carcinoma is the most common malignant cervical tumor.	Squamous Cell Carcinoma	NCIT:C2929	Squamous Cell Carcinoma		"{""preferred_term"": ""Squamous Cell Carcinoma"", ""term"": {""id"": ""NCIT:C2929"", ""label"": ""Squamous Cell Carcinoma""}}"																											
1356	1370	58	Cervical Cancer	Cervical_Cancer.yaml	infectious_agent	0	Human Papillomavirus (HPV)	High-risk HPV types, particularly HPV-16 and HPV-18, cause greater than 95% of cervical cancers. HPV-16 is responsible for approximately 50% of cases and HPV-18 for approximately 20%. Persistent infection with high-risk types is necessary but not sufficient for cancer development.	infectious_agent_term	infectious_agent_term	$	Human Papillomavirus (HPV)	High-risk HPV types, particularly HPV-16 and HPV-18, cause greater than 95% of cervical cancers. HPV-16 is responsible for approximately 50% of cases and HPV-18 for approximately 20%. Persistent infection with high-risk types is necessary but not sufficient for cancer development.	Human papillomavirus 16	NCBITaxon:333760	Human papillomavirus 16		"{""preferred_term"": ""Human papillomavirus 16"", ""term"": {""id"": ""NCBITaxon:333760"", ""label"": ""Human papillomavirus 16""}}"																											
1357	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	cell_types[0]	cell_types	cell_types			epithelial cell of cervix	CL:0002535	epithelial cell of cervix		"{""preferred_term"": ""epithelial cell of cervix"", ""term"": {""id"": ""CL:0002535"", ""label"": ""epithelial cell of cervix""}}"																											
1358	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	biological_processes[0]	biological_processes	biological_processes			proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process		"{""modifier"": ""INCREASED"", ""preferred_term"": ""proteasome-mediated ubiquitin-dependent protein catabolic process"", ""term"": {""id"": ""GO:0043161"", ""label"": ""proteasome-mediated ubiquitin-dependent protein catabolic process""}}"			INCREASED																								
1359	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
1360	1371	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	0	E6 Oncoprotein-Mediated p53 Degradation	The HPV E6 oncoprotein binds to the cellular E3 ubiquitin ligase E6AP and targets p53 for proteasomal degradation. Loss of p53 function eliminates DNA damage checkpoints, allows cells with genomic instability to survive, and prevents apoptosis of infected cells.	locations[0]	locations	locations			uterine cervix	UBERON:0000002	uterine cervix		"{""preferred_term"": ""uterine cervix"", ""term"": {""id"": ""UBERON:0000002"", ""label"": ""uterine cervix""}}"																											
1361	1372	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	1	E7 Oncoprotein-Mediated pRB Inactivation	The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle progression. E7 also targets pRB family members p107 and p130, and destabilizes pRB through proteasomal degradation.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			ABNORMAL																								
1362	1372	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	1	E7 Oncoprotein-Mediated pRB Inactivation	The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRB), releasing E2F transcription factors to drive uncontrolled cell cycle progression. E7 also targets pRB family members p107 and p130, and destabilizes pRB through proteasomal degradation.	biological_processes[1]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
1363	1373	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	2	HPV Genome Integration	Integration of HPV DNA into the host genome disrupts the viral E2 gene, which normally represses E6/E7 expression. This results in constitutive overexpression of E6 and E7 oncoproteins, a critical step in malignant progression from CIN3 to invasive carcinoma.	biological_processes[0]	biological_processes	biological_processes			viral DNA integration into host DNA	GO:0044826	viral DNA integration into host DNA		"{""preferred_term"": ""viral DNA integration into host DNA"", ""term"": {""id"": ""GO:0044826"", ""label"": ""viral DNA integration into host DNA""}}"																											
1364	1374	58	Cervical Cancer	Cervical_Cancer.yaml	pathophysiology	3	Cervical Intraepithelial Neoplasia Progression	HPV infection induces a spectrum of preinvasive lesions graded as CIN1, CIN2, and CIN3 (carcinoma in situ). Low-grade lesions (CIN1) often regress, while high-grade lesions (CIN2/3) have significant risk of progression to invasive carcinoma over 10-20 years if untreated.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1365	1375	58	Cervical Cancer	Cervical_Cancer.yaml	phenotypes	0	Abnormal Vaginal Bleeding	The most common presenting symptom, including postcoital bleeding, intermenstrual bleeding, or postmenopausal bleeding. Often the first sign of invasive disease.	phenotype_term	phenotype_term	$	Abnormal Vaginal Bleeding	The most common presenting symptom, including postcoital bleeding, intermenstrual bleeding, or postmenopausal bleeding. Often the first sign of invasive disease.	Metrorrhagia	HP:0100608	Metrorrhagia		"{""preferred_term"": ""Metrorrhagia"", ""term"": {""id"": ""HP:0100608"", ""label"": ""Metrorrhagia""}}"																											
1366	1377	58	Cervical Cancer	Cervical_Cancer.yaml	phenotypes	2	Pelvic Pain	Pelvic pain typically indicates locally advanced disease with parametrial invasion, pelvic sidewall involvement, or nerve compression.	phenotype_term	phenotype_term	$	Pelvic Pain	Pelvic pain typically indicates locally advanced disease with parametrial invasion, pelvic sidewall involvement, or nerve compression.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1367	1378	58	Cervical Cancer	Cervical_Cancer.yaml	phenotypes	3	Urinary Symptoms	Hematuria, dysuria, or urinary frequency may occur with bladder invasion in advanced disease.	phenotype_term	phenotype_term	$	Urinary Symptoms	Hematuria, dysuria, or urinary frequency may occur with bladder invasion in advanced disease.	Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
1368	1379	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	0	HPV Vaccination	Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.	treatment_term	treatment_term	$	HPV Vaccination	Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1369	1380	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	1	Cone Biopsy/LEEP	Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.	treatment_term	treatment_term	$	Cone Biopsy/LEEP	Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1370	1381	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	2	Radical Hysterectomy	Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.	treatment_term	treatment_term	$	Radical Hysterectomy	Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1371	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term	treatment_term	$	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
1372	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
1373	1383	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	4	Pembrolizumab	PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.	treatment_term	treatment_term	$	Pembrolizumab	PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1374	1384	59	Chagas disease	Chagas_Disease.yaml	infectious_agent	0	Trypanosoma cruzi	Kinetoplastid protozoan parasite that causes Chagas disease.	infectious_agent_term	infectious_agent_term	$	Trypanosoma cruzi	Kinetoplastid protozoan parasite that causes Chagas disease.	Trypanosoma cruzi	NCBITaxon:5693	Trypanosoma cruzi		"{""preferred_term"": ""Trypanosoma cruzi"", ""term"": {""id"": ""NCBITaxon:5693"", ""label"": ""Trypanosoma cruzi""}}"																											
1375	1386	59	Chagas disease	Chagas_Disease.yaml	phenotypes	0	Cardiomyopathy		phenotype_term	phenotype_term	$	Cardiomyopathy		Cardiomyopathy	HP:0001638	Cardiomyopathy		"{""preferred_term"": ""Cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""Cardiomyopathy""}}"																											
1376	1387	59	Chagas disease	Chagas_Disease.yaml	phenotypes	1	Heart failure		phenotype_term	phenotype_term	$	Heart failure		Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
1377	1389	59	Chagas disease	Chagas_Disease.yaml	treatments	0	Benznidazole or nifurtimox therapy	Antitrypanosomal therapy for Chagas disease.	treatment_term	treatment_term	$	Benznidazole or nifurtimox therapy	Antitrypanosomal therapy for Chagas disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1378	1390	60	Chikungunya	Chikungunya.yaml	infectious_agent	0	Chikungunya virus	Alphavirus responsible for chikungunya disease.	infectious_agent_term	infectious_agent_term	$	Chikungunya virus	Alphavirus responsible for chikungunya disease.	Chikungunya virus	NCBITaxon:37124	Chikungunya virus		"{""preferred_term"": ""Chikungunya virus"", ""term"": {""id"": ""NCBITaxon:37124"", ""label"": ""Chikungunya virus""}}"																											
1379	1391	60	Chikungunya	Chikungunya.yaml	phenotypes	0	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1380	1392	60	Chikungunya	Chikungunya.yaml	phenotypes	1	Skin rash		phenotype_term	phenotype_term	$	Skin rash		Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
1381	1393	60	Chikungunya	Chikungunya.yaml	phenotypes	2	Arthralgia		phenotype_term	phenotype_term	$	Arthralgia		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
1382	1395	60	Chikungunya	Chikungunya.yaml	treatments	0	Symptomatic management	Supportive care for acute chikungunya.	treatment_term	treatment_term	$	Symptomatic management	Supportive care for acute chikungunya.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1383	1400	61	Cholera	Cholera.yaml	environmental	0	Contaminated Water		environment_context	environment_context	$	Contaminated Water		Contaminated water environment	ENVO:00002186	contaminated water		"{""preferred_term"": ""Contaminated water environment"", ""term"": {""id"": ""ENVO:00002186"", ""label"": ""contaminated water""}}"																											
1384	1414	61	Cholera	Cholera.yaml	infectious_agent	0	Vibrio cholerae	A bacterium that causes severe diarrhea by producing a toxin that triggers excess water and electrolyte loss in the intestines.	infectious_agent_term	infectious_agent_term	$	Vibrio cholerae	A bacterium that causes severe diarrhea by producing a toxin that triggers excess water and electrolyte loss in the intestines.	Vibrio cholerae	NCBITaxon:666	Vibrio cholerae		"{""preferred_term"": ""Vibrio cholerae"", ""term"": {""id"": ""NCBITaxon:666"", ""label"": ""Vibrio cholerae""}}"																											
1385	1423	61	Cholera	Cholera.yaml	pathophysiology	0	Cholera Toxin Binding and Uptake	Cholera toxin B subunit (CTB) binds to GM1 ganglioside and alternative fucosylated glycan receptors (e.g., Lewis X) on the apical surface of intestinal epithelial cells, initiating receptor-mediated endocytosis and retrograde trafficking to the endoplasmic reticulum.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1386	1423	61	Cholera	Cholera.yaml	pathophysiology	0	Cholera Toxin Binding and Uptake	Cholera toxin B subunit (CTB) binds to GM1 ganglioside and alternative fucosylated glycan receptors (e.g., Lewis X) on the apical surface of intestinal epithelial cells, initiating receptor-mediated endocytosis and retrograde trafficking to the endoplasmic reticulum.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1387	1423	61	Cholera	Cholera.yaml	pathophysiology	0	Cholera Toxin Binding and Uptake	Cholera toxin B subunit (CTB) binds to GM1 ganglioside and alternative fucosylated glycan receptors (e.g., Lewis X) on the apical surface of intestinal epithelial cells, initiating receptor-mediated endocytosis and retrograde trafficking to the endoplasmic reticulum.	biological_processes[0]	biological_processes	biological_processes			endocytosis	GO:0006897	endocytosis		"{""preferred_term"": ""endocytosis"", ""term"": {""id"": ""GO:0006897"", ""label"": ""endocytosis""}}"																											
1388	1423	61	Cholera	Cholera.yaml	pathophysiology	0	Cholera Toxin Binding and Uptake	Cholera toxin B subunit (CTB) binds to GM1 ganglioside and alternative fucosylated glycan receptors (e.g., Lewis X) on the apical surface of intestinal epithelial cells, initiating receptor-mediated endocytosis and retrograde trafficking to the endoplasmic reticulum.	biological_processes[1]	biological_processes	biological_processes			retrograde vesicle-mediated transport	GO:0006890	retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum		"{""preferred_term"": ""retrograde vesicle-mediated transport"", ""term"": {""id"": ""GO:0006890"", ""label"": ""retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum""}}"																											
1389	1424	61	Cholera	Cholera.yaml	pathophysiology	1	ERAD-mediated CTA1 Translocation	The A1 enzymatic subunit of cholera toxin is unfolded by protein disulfide isomerase in the ER and hijacks the ER-associated degradation (ERAD) machinery to retro-translocate into the cytosol, where it refolds to become enzymatically active.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1390	1424	61	Cholera	Cholera.yaml	pathophysiology	1	ERAD-mediated CTA1 Translocation	The A1 enzymatic subunit of cholera toxin is unfolded by protein disulfide isomerase in the ER and hijacks the ER-associated degradation (ERAD) machinery to retro-translocate into the cytosol, where it refolds to become enzymatically active.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1391	1424	61	Cholera	Cholera.yaml	pathophysiology	1	ERAD-mediated CTA1 Translocation	The A1 enzymatic subunit of cholera toxin is unfolded by protein disulfide isomerase in the ER and hijacks the ER-associated degradation (ERAD) machinery to retro-translocate into the cytosol, where it refolds to become enzymatically active.	biological_processes[0]	biological_processes	biological_processes			ERAD pathway	GO:0030433	ubiquitin-dependent ERAD pathway		"{""preferred_term"": ""ERAD pathway"", ""term"": {""id"": ""GO:0030433"", ""label"": ""ubiquitin-dependent ERAD pathway""}}"																											
1392	1425	61	Cholera	Cholera.yaml	pathophysiology	2	Gs ADP-Ribosylation	Cytosolic CTA1 catalyzes ADP-ribosylation of the Gs subunit (GNAS) using NAD+ as substrate, locking adenylyl cyclase in a constitutively active state.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1393	1425	61	Cholera	Cholera.yaml	pathophysiology	2	Gs ADP-Ribosylation	Cytosolic CTA1 catalyzes ADP-ribosylation of the Gs subunit (GNAS) using NAD+ as substrate, locking adenylyl cyclase in a constitutively active state.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1394	1425	61	Cholera	Cholera.yaml	pathophysiology	2	Gs ADP-Ribosylation	Cytosolic CTA1 catalyzes ADP-ribosylation of the Gs subunit (GNAS) using NAD+ as substrate, locking adenylyl cyclase in a constitutively active state.	biological_processes[0]	biological_processes	biological_processes			adenylate cyclase-activating G protein-coupled receptor signaling pathway	GO:0007189	adenylate cyclase-activating G protein-coupled receptor signaling pathway		"{""preferred_term"": ""adenylate cyclase-activating G protein-coupled receptor signaling pathway"", ""term"": {""id"": ""GO:0007189"", ""label"": ""adenylate cyclase-activating G protein-coupled receptor signaling pathway""}}"																											
1395	1426	61	Cholera	Cholera.yaml	pathophysiology	3	Cholera Toxin	Vibrio cholerae produces a toxin that activates adenylate cyclase in intestinal epithelial cells, leading to increased cyclic AMP (cAMP) levels.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1396	1426	61	Cholera	Cholera.yaml	pathophysiology	3	Cholera Toxin	Vibrio cholerae produces a toxin that activates adenylate cyclase in intestinal epithelial cells, leading to increased cyclic AMP (cAMP) levels.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1397	1427	61	Cholera	Cholera.yaml	pathophysiology	4	Increased cAMP	Elevated cAMP levels cause cells to secrete large amounts of chloride ions into the intestinal lumen, followed by water and other electrolytes.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1398	1427	61	Cholera	Cholera.yaml	pathophysiology	4	Increased cAMP	Elevated cAMP levels cause cells to secrete large amounts of chloride ions into the intestinal lumen, followed by water and other electrolytes.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1399	1427	61	Cholera	Cholera.yaml	pathophysiology	4	Increased cAMP	Elevated cAMP levels cause cells to secrete large amounts of chloride ions into the intestinal lumen, followed by water and other electrolytes.	biological_processes[0]	biological_processes	biological_processes			cAMP-mediated signaling	GO:0019933	cAMP-mediated signaling		"{""preferred_term"": ""cAMP-mediated signaling"", ""term"": {""id"": ""GO:0019933"", ""label"": ""cAMP-mediated signaling""}}"																											
1400	1427	61	Cholera	Cholera.yaml	pathophysiology	4	Increased cAMP	Elevated cAMP levels cause cells to secrete large amounts of chloride ions into the intestinal lumen, followed by water and other electrolytes.	biological_processes[1]	biological_processes	biological_processes			chloride transmembrane transport	GO:1902476	chloride transmembrane transport		"{""preferred_term"": ""chloride transmembrane transport"", ""term"": {""id"": ""GO:1902476"", ""label"": ""chloride transmembrane transport""}}"																											
1401	1428	61	Cholera	Cholera.yaml	pathophysiology	5	Profuse Watery Diarrhea	Rapid loss of fluids and electrolytes through diarrhea, which can lead to severe dehydration and hypovolemic shock.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1402	1429	61	Cholera	Cholera.yaml	pathophysiology	6	Colonization and Biofilm Formation	V. cholerae uses the toxin-coregulated pilus (TCP) to traverse the intestinal mucus barrier, adhere to epithelial cells, and form microcolonies. TCP expression is controlled by the ToxR/TcpP/ToxT regulatory cascade. Biofilm formation enhances bacterial survival and transmission.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1403	1429	61	Cholera	Cholera.yaml	pathophysiology	6	Colonization and Biofilm Formation	V. cholerae uses the toxin-coregulated pilus (TCP) to traverse the intestinal mucus barrier, adhere to epithelial cells, and form microcolonies. TCP expression is controlled by the ToxR/TcpP/ToxT regulatory cascade. Biofilm formation enhances bacterial survival and transmission.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1404	1429	61	Cholera	Cholera.yaml	pathophysiology	6	Colonization and Biofilm Formation	V. cholerae uses the toxin-coregulated pilus (TCP) to traverse the intestinal mucus barrier, adhere to epithelial cells, and form microcolonies. TCP expression is controlled by the ToxR/TcpP/ToxT regulatory cascade. Biofilm formation enhances bacterial survival and transmission.	biological_processes[0]	biological_processes	biological_processes			biofilm formation	GO:0042710	biofilm formation		"{""preferred_term"": ""biofilm formation"", ""term"": {""id"": ""GO:0042710"", ""label"": ""biofilm formation""}}"																											
1405	1429	61	Cholera	Cholera.yaml	pathophysiology	6	Colonization and Biofilm Formation	V. cholerae uses the toxin-coregulated pilus (TCP) to traverse the intestinal mucus barrier, adhere to epithelial cells, and form microcolonies. TCP expression is controlled by the ToxR/TcpP/ToxT regulatory cascade. Biofilm formation enhances bacterial survival and transmission.	biological_processes[1]	biological_processes	biological_processes			bacterial adhesion to host	GO:0044406	adhesion of symbiont to host		"{""preferred_term"": ""bacterial adhesion to host"", ""term"": {""id"": ""GO:0044406"", ""label"": ""adhesion of symbiont to host""}}"																											
1406	1430	61	Cholera	Cholera.yaml	pathophysiology	7	Accessory Toxins and Virulence Factors	V. cholerae produces multiple accessory toxins beyond cholera toxin, including MARTX (actin disruption and phagocyte inhibition), hemolysin HlyA (pore formation), zonula occludens toxin Zot (tight junction disruption), and accessory cholera enterotoxin Ace, which contribute to pathogenesis in a strain-dependent manner.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1407	1430	61	Cholera	Cholera.yaml	pathophysiology	7	Accessory Toxins and Virulence Factors	V. cholerae produces multiple accessory toxins beyond cholera toxin, including MARTX (actin disruption and phagocyte inhibition), hemolysin HlyA (pore formation), zonula occludens toxin Zot (tight junction disruption), and accessory cholera enterotoxin Ace, which contribute to pathogenesis in a strain-dependent manner.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1408	1430	61	Cholera	Cholera.yaml	pathophysiology	7	Accessory Toxins and Virulence Factors	V. cholerae produces multiple accessory toxins beyond cholera toxin, including MARTX (actin disruption and phagocyte inhibition), hemolysin HlyA (pore formation), zonula occludens toxin Zot (tight junction disruption), and accessory cholera enterotoxin Ace, which contribute to pathogenesis in a strain-dependent manner.	biological_processes[0]	biological_processes	biological_processes			disruption of cells of other organism	GO:0044364	disruption of cells of other organism		"{""preferred_term"": ""disruption of cells of other organism"", ""term"": {""id"": ""GO:0044364"", ""label"": ""disruption of cells of other organism""}}"																											
1409	1430	61	Cholera	Cholera.yaml	pathophysiology	7	Accessory Toxins and Virulence Factors	V. cholerae produces multiple accessory toxins beyond cholera toxin, including MARTX (actin disruption and phagocyte inhibition), hemolysin HlyA (pore formation), zonula occludens toxin Zot (tight junction disruption), and accessory cholera enterotoxin Ace, which contribute to pathogenesis in a strain-dependent manner.	biological_processes[1]	biological_processes	biological_processes			tight junction organization	GO:0120193	tight junction organization		"{""preferred_term"": ""tight junction organization"", ""term"": {""id"": ""GO:0120193"", ""label"": ""tight junction organization""}}"																											
1410	1431	61	Cholera	Cholera.yaml	pathophysiology	8	Host Metabolic Reprogramming	Cholera toxin-driven signaling reprograms host epithelial metabolism, leading to release of host-derived nutrients (long-chain fatty acids, lactate, glycerol) into the intestinal lumen that fuel V. cholerae growth and enhance transmission.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
1411	1431	61	Cholera	Cholera.yaml	pathophysiology	8	Host Metabolic Reprogramming	Cholera toxin-driven signaling reprograms host epithelial metabolism, leading to release of host-derived nutrients (long-chain fatty acids, lactate, glycerol) into the intestinal lumen that fuel V. cholerae growth and enhance transmission.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
1412	1431	61	Cholera	Cholera.yaml	pathophysiology	8	Host Metabolic Reprogramming	Cholera toxin-driven signaling reprograms host epithelial metabolism, leading to release of host-derived nutrients (long-chain fatty acids, lactate, glycerol) into the intestinal lumen that fuel V. cholerae growth and enhance transmission.	biological_processes[0]	biological_processes	biological_processes			regulation of lipid metabolic process	GO:0019216	regulation of lipid metabolic process		"{""preferred_term"": ""regulation of lipid metabolic process"", ""term"": {""id"": ""GO:0019216"", ""label"": ""regulation of lipid metabolic process""}}"																											
1413	1433	61	Cholera	Cholera.yaml	phenotypes	1	Dehydration		phenotype_term	phenotype_term	$	Dehydration		Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
1414	1434	61	Cholera	Cholera.yaml	phenotypes	2	Hypovolemic Shock		phenotype_term	phenotype_term	$	Hypovolemic Shock		Hypovolemic Shock	HP:0031274	Hypovolemic shock		"{""preferred_term"": ""Hypovolemic Shock"", ""term"": {""id"": ""HP:0031274"", ""label"": ""Hypovolemic shock""}}"																											
1415	1435	61	Cholera	Cholera.yaml	phenotypes	3	Dehydration		phenotype_term	phenotype_term	$	Dehydration		Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
1416	1436	61	Cholera	Cholera.yaml	phenotypes	4	Hypovolemic Shock		phenotype_term	phenotype_term	$	Hypovolemic Shock		Hypovolemic Shock	HP:0031274	Hypovolemic shock		"{""preferred_term"": ""Hypovolemic Shock"", ""term"": {""id"": ""HP:0031274"", ""label"": ""Hypovolemic shock""}}"																											
1417	1437	61	Cholera	Cholera.yaml	phenotypes	5	Hypokalemia		phenotype_term	phenotype_term	$	Hypokalemia		Hypokalemia	HP:0002900	Hypokalemia		"{""preferred_term"": ""Hypokalemia"", ""term"": {""id"": ""HP:0002900"", ""label"": ""Hypokalemia""}}"																											
1418	1438	61	Cholera	Cholera.yaml	phenotypes	6	Metabolic Acidosis		phenotype_term	phenotype_term	$	Metabolic Acidosis		Metabolic Acidosis	HP:0001942	Metabolic acidosis		"{""preferred_term"": ""Metabolic Acidosis"", ""term"": {""id"": ""HP:0001942"", ""label"": ""Metabolic acidosis""}}"																											
1419	1439	61	Cholera	Cholera.yaml	phenotypes	7	Muscle Cramps		phenotype_term	phenotype_term	$	Muscle Cramps		Muscle Cramps	HP:0003394	Muscle spasm		"{""preferred_term"": ""Muscle Cramps"", ""term"": {""id"": ""HP:0003394"", ""label"": ""Muscle spasm""}}"																											
1420	1440	61	Cholera	Cholera.yaml	phenotypes	8	Severe Dehydration		phenotype_term	phenotype_term	$	Severe Dehydration		Severe Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Severe Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
1421	1441	61	Cholera	Cholera.yaml	phenotypes	9	Shock		phenotype_term	phenotype_term	$	Shock		Shock	HP:0031273	Shock		"{""preferred_term"": ""Shock"", ""term"": {""id"": ""HP:0031273"", ""label"": ""Shock""}}"																											
1422	1442	61	Cholera	Cholera.yaml	phenotypes	10	Sunken Eyes		phenotype_term	phenotype_term	$	Sunken Eyes		Sunken Eyes	HP:0000490	Deeply set eye		"{""preferred_term"": ""Sunken Eyes"", ""term"": {""id"": ""HP:0000490"", ""label"": ""Deeply set eye""}}"																											
1423	1443	61	Cholera	Cholera.yaml	phenotypes	11	Low Blood Pressure		phenotype_term	phenotype_term	$	Low Blood Pressure		Low Blood Pressure	HP:0002615	Hypotension		"{""preferred_term"": ""Low Blood Pressure"", ""term"": {""id"": ""HP:0002615"", ""label"": ""Hypotension""}}"																											
1424	1444	61	Cholera	Cholera.yaml	phenotypes	12	Tachycardia		phenotype_term	phenotype_term	$	Tachycardia		Tachycardia	HP:0001649	Tachycardia		"{""preferred_term"": ""Tachycardia"", ""term"": {""id"": ""HP:0001649"", ""label"": ""Tachycardia""}}"																											
1425	1445	61	Cholera	Cholera.yaml	phenotypes	13	Acute Kidney Injury		phenotype_term	phenotype_term	$	Acute Kidney Injury		Acute Kidney Injury	HP:0001919	Acute kidney injury		"{""preferred_term"": ""Acute Kidney Injury"", ""term"": {""id"": ""HP:0001919"", ""label"": ""Acute kidney injury""}}"																											
1426	1460	61	Cholera	Cholera.yaml	treatments	0	Oral Rehydration Solution (ORS)	Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes.	treatment_term	treatment_term	$	Oral Rehydration Solution (ORS)	Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes.	hydrotherapy	MAXO:0000458	hydrotherapy		"{""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}"																											
1427	1461	61	Cholera	Cholera.yaml	treatments	1	Intravenous Rehydration	Used for severe dehydration when rapid fluid replacement is necessary.	treatment_term	treatment_term	$	Intravenous Rehydration	Used for severe dehydration when rapid fluid replacement is necessary.	hydrotherapy	MAXO:0000458	hydrotherapy		"{""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}"																											
1428	1462	61	Cholera	Cholera.yaml	treatments	2	Antibiotics	Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin.	treatment_term	treatment_term	$	Antibiotics	Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1429	1463	61	Cholera	Cholera.yaml	treatments	3	Zinc Supplementation	Recommended for children to reduce the duration and severity of diarrhea.	treatment_term	treatment_term	$	Zinc Supplementation	Recommended for children to reduce the duration and severity of diarrhea.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
1430	1464	61	Cholera	Cholera.yaml	treatments	4	Vaccination	Oral cholera vaccines can provide protection in endemic areas or during outbreaks.	treatment_term	treatment_term	$	Vaccination	Oral cholera vaccines can provide protection in endemic areas or during outbreaks.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1431	1465	62	Chromoblastomycosis	Chromoblastomycosis.yaml	infectious_agent	0	Fonsecaea pedrosoi	Dematiaceous fungus and common etiologic agent.	infectious_agent_term	infectious_agent_term	$	Fonsecaea pedrosoi	Dematiaceous fungus and common etiologic agent.	Fonsecaea pedrosoi	NCBITaxon:40355	Fonsecaea pedrosoi		"{""preferred_term"": ""Fonsecaea pedrosoi"", ""term"": {""id"": ""NCBITaxon:40355"", ""label"": ""Fonsecaea pedrosoi""}}"																											
1432	1466	62	Chromoblastomycosis	Chromoblastomycosis.yaml	infectious_agent	1	Cladophialophora carrionii	Dematiaceous fungus and common etiologic agent.	infectious_agent_term	infectious_agent_term	$	Cladophialophora carrionii	Dematiaceous fungus and common etiologic agent.	Cladophialophora carrionii	NCBITaxon:86049	Cladophialophora carrionii		"{""preferred_term"": ""Cladophialophora carrionii"", ""term"": {""id"": ""NCBITaxon:86049"", ""label"": ""Cladophialophora carrionii""}}"																											
1433	1467	62	Chromoblastomycosis	Chromoblastomycosis.yaml	phenotypes	0	Verrucous papule		phenotype_term	phenotype_term	$	Verrucous papule		Verrucous papule	HP:0012500	Verrucous papule		"{""preferred_term"": ""Verrucous papule"", ""term"": {""id"": ""HP:0012500"", ""label"": ""Verrucous papule""}}"																											
1434	1468	62	Chromoblastomycosis	Chromoblastomycosis.yaml	phenotypes	1	Skin plaque		phenotype_term	phenotype_term	$	Skin plaque		Skin plaque	HP:0200035	Skin plaque		"{""preferred_term"": ""Skin plaque"", ""term"": {""id"": ""HP:0200035"", ""label"": ""Skin plaque""}}"																											
1435	1473	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	0	T Cell-Mediated Demyelination	CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to demyelination. T cells recognize myelin antigens and produce inflammatory cytokines that damage Schwann cells.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
1436	1473	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	0	T Cell-Mediated Demyelination	CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to demyelination. T cells recognize myelin antigens and produce inflammatory cytokines that damage Schwann cells.	cell_types[1]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
1437	1473	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	0	T Cell-Mediated Demyelination	CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to demyelination. T cells recognize myelin antigens and produce inflammatory cytokines that damage Schwann cells.	biological_processes[0]	biological_processes	biological_processes			Adaptive Immune Response	GO:0002250	adaptive immune response		"{""preferred_term"": ""Adaptive Immune Response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
1438	1474	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	1	Antibody and Complement-Mediated Damage	Autoantibodies against myelin proteins and nodal/paranodal antigens (neurofascin, contactin-1) contribute to demyelination. Complement deposition amplifies nerve damage.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
1439	1474	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	1	Antibody and Complement-Mediated Damage	Autoantibodies against myelin proteins and nodal/paranodal antigens (neurofascin, contactin-1) contribute to demyelination. Complement deposition amplifies nerve damage.	biological_processes[1]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
1440	1475	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	2	Macrophage-Mediated Myelin Stripping	Activated macrophages invade nerve fibers and actively strip myelin from axons, causing segmental demyelination visible on nerve biopsy.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1441	1475	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	pathophysiology	2	Macrophage-Mediated Myelin Stripping	Activated macrophages invade nerve fibers and actively strip myelin from axons, causing segmental demyelination visible on nerve biopsy.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1442	1476	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	phenotypes	0	Progressive Weakness		phenotype_term	phenotype_term	$	Progressive Weakness		Limb Muscle Weakness	HP:0003690	Limb muscle weakness		"{""preferred_term"": ""Limb Muscle Weakness"", ""term"": {""id"": ""HP:0003690"", ""label"": ""Limb muscle weakness""}}"																											
1443	1477	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	phenotypes	1	Areflexia		phenotype_term	phenotype_term	$	Areflexia		Areflexia	HP:0001284	Areflexia		"{""preferred_term"": ""Areflexia"", ""term"": {""id"": ""HP:0001284"", ""label"": ""Areflexia""}}"																											
1444	1478	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	phenotypes	2	Sensory Loss		phenotype_term	phenotype_term	$	Sensory Loss		Peripheral Sensory Neuropathy	HP:0000763	Sensory neuropathy		"{""preferred_term"": ""Peripheral Sensory Neuropathy"", ""term"": {""id"": ""HP:0000763"", ""label"": ""Sensory neuropathy""}}"																											
1445	1479	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1446	1499	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	pathophysiology	0	Nephron Loss	"Progressive loss of functional nephrons from any cause leads to compensatory hyperfiltration in remaining nephrons, which paradoxically accelerates further damage and fibrosis.
"	cell_types[0]	cell_types	cell_types			Podocyte	CL:0000653	podocyte		"{""preferred_term"": ""Podocyte"", ""term"": {""id"": ""CL:0000653"", ""label"": ""podocyte""}}"																											
1447	1499	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	pathophysiology	0	Nephron Loss	"Progressive loss of functional nephrons from any cause leads to compensatory hyperfiltration in remaining nephrons, which paradoxically accelerates further damage and fibrosis.
"	cell_types[1]	cell_types	cell_types			Tubular Epithelial Cell	CL:0002306	epithelial cell of proximal tubule		"{""preferred_term"": ""Tubular Epithelial Cell"", ""term"": {""id"": ""CL:0002306"", ""label"": ""epithelial cell of proximal tubule""}}"																											
1448	1500	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	pathophysiology	1	Glomerulosclerosis	"Scarring and hardening of glomeruli impairs filtration function. Driven by hemodynamic stress, inflammation, and metabolic factors.
"	biological_processes[0]	biological_processes	biological_processes			Fibrosis	GO:0048251	elastic fiber assembly		"{""preferred_term"": ""Fibrosis"", ""term"": {""id"": ""GO:0048251"", ""label"": ""elastic fiber assembly""}}"																											
1449	1501	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	pathophysiology	2	Tubulointerstitial Fibrosis	"Fibrotic replacement of tubular structures by collagen-producing myofibroblasts. The final common pathway of CKD progression.
"	cell_types[0]	cell_types	cell_types			Myofibroblast	CL:0000186	myofibroblast cell		"{""preferred_term"": ""Myofibroblast"", ""term"": {""id"": ""CL:0000186"", ""label"": ""myofibroblast cell""}}"																											
1450	1502	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	pathophysiology	3	RAAS Activation	"Inappropriately activated renin-angiotensin-aldosterone system promotes glomerular hypertension, fibrosis, and sodium retention.
"	biological_processes[0]	biological_processes	biological_processes			RAAS Signaling	GO:0002018	renin-angiotensin regulation of aldosterone production		"{""preferred_term"": ""RAAS Signaling"", ""term"": {""id"": ""GO:0002018"", ""label"": ""renin-angiotensin regulation of aldosterone production""}}"																											
1451	1503	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	0	Decreased GFR		phenotype_term	phenotype_term	$	Decreased GFR		Decreased GFR	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Decreased GFR"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
1452	1504	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	1	Proteinuria		phenotype_term	phenotype_term	$	Proteinuria		Proteinuria	HP:0000093	Proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""Proteinuria""}}"																											
1453	1505	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	2	Hypertension		phenotype_term	phenotype_term	$	Hypertension		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
1454	1506	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	3	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1455	1507	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	4	Metabolic Acidosis		phenotype_term	phenotype_term	$	Metabolic Acidosis		Metabolic Acidosis	HP:0001942	Metabolic acidosis		"{""preferred_term"": ""Metabolic Acidosis"", ""term"": {""id"": ""HP:0001942"", ""label"": ""Metabolic acidosis""}}"																											
1456	1508	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1457	1509	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	phenotypes	6	Peripheral Edema		phenotype_term	phenotype_term	$	Peripheral Edema		Peripheral Edema	HP:0012398	Peripheral edema		"{""preferred_term"": ""Peripheral Edema"", ""term"": {""id"": ""HP:0012398"", ""label"": ""Peripheral edema""}}"																											
1458	1527	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	histopathology	0	Small B-Cell Clonal Expansion	Chronic lymphocytic leukemia is characterized by clonal expansion of CLL B cells.	finding_term	finding_term	$	Small B-Cell Clonal Expansion	Chronic lymphocytic leukemia is characterized by clonal expansion of CLL B cells.	Small Lymphocytic Lymphoma	NCIT:C7540	Small Lymphocytic Lymphoma		"{""preferred_term"": ""Small Lymphocytic Lymphoma"", ""term"": {""id"": ""NCIT:C7540"", ""label"": ""Small Lymphocytic Lymphoma""}}"																											
1459	1528	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	0	B-cell Receptor Signaling Dysregulation	CLL cells exhibit constitutive B-cell receptor (BCR) signaling, either through autonomous signaling or antigen-driven activation. This chronic BCR stimulation activates downstream kinases including BTK, PI3K, and SYK, driving proliferation and survival. BCR signaling intensity correlates with clinical aggressiveness.	cell_types[0]	cell_types	cell_types			mature B cell	CL:0000785	mature B cell		"{""preferred_term"": ""mature B cell"", ""term"": {""id"": ""CL:0000785"", ""label"": ""mature B cell""}}"																											
1460	1528	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	0	B-cell Receptor Signaling Dysregulation	CLL cells exhibit constitutive B-cell receptor (BCR) signaling, either through autonomous signaling or antigen-driven activation. This chronic BCR stimulation activates downstream kinases including BTK, PI3K, and SYK, driving proliferation and survival. BCR signaling intensity correlates with clinical aggressiveness.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"			INCREASED																								
1461	1529	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	1	BTK Pathway Activation	Bruton tyrosine kinase (BTK) is essential for BCR signaling and CLL cell survival. BTK activation promotes NF-kB signaling, cell adhesion, and tissue homing. BTK inhibitors disrupt these signals, mobilizing CLL cells from protective tissue microenvironments and inducing apoptosis.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
1462	1530	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	2	Microenvironmental Survival Signals	CLL cells depend on interactions with the tissue microenvironment including nurse-like cells, T cells, and stromal cells in lymph nodes and bone marrow. These interactions provide survival signals through chemokines, cytokines, and direct cell contact. Disrupting these interactions is therapeutically important.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
1463	1530	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	2	Microenvironmental Survival Signals	CLL cells depend on interactions with the tissue microenvironment including nurse-like cells, T cells, and stromal cells in lymph nodes and bone marrow. These interactions provide survival signals through chemokines, cytokines, and direct cell contact. Disrupting these interactions is therapeutically important.	locations[1]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
1464	1530	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	2	Microenvironmental Survival Signals	CLL cells depend on interactions with the tissue microenvironment including nurse-like cells, T cells, and stromal cells in lymph nodes and bone marrow. These interactions provide survival signals through chemokines, cytokines, and direct cell contact. Disrupting these interactions is therapeutically important.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1465	1531	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	3	NF-kB Activation and Survival	NF-kB transcription factors are constitutively activated in CLL and promote expression of anti-apoptotic genes including BCL2, MCL1, and XIAP. This contributes to the apoptosis resistance characteristic of CLL cells.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
1466	1532	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	pathophysiology	4	CLL Cell Accumulation	The combination of defective apoptosis, microenvironmental support, and low-level proliferation leads to progressive accumulation of clonal B cells. CLL is primarily a disease of accumulation rather than rapid proliferation.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1467	1533	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	0	Lymphoproliferative Disorder	Persistent elevation of blood lymphocyte count (at least 5000/uL clonal B lymphocytes) is required for CLL diagnosis. Many patients are diagnosed incidentally from routine blood tests.	phenotype_term	phenotype_term	$	Lymphoproliferative Disorder	Persistent elevation of blood lymphocyte count (at least 5000/uL clonal B lymphocytes) is required for CLL diagnosis. Many patients are diagnosed incidentally from routine blood tests.	Lymphoproliferative disorder	HP:0005523	Lymphoproliferative disorder		"{""preferred_term"": ""Lymphoproliferative disorder"", ""term"": {""id"": ""HP:0005523"", ""label"": ""Lymphoproliferative disorder""}}"																											
1468	1534	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	1	Lymphadenopathy	Enlarged lymph nodes are common, may be generalized, and can become massive. Lymph node involvement is incorporated in staging systems.	phenotype_term	phenotype_term	$	Lymphadenopathy	Enlarged lymph nodes are common, may be generalized, and can become massive. Lymph node involvement is incorporated in staging systems.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
1469	1535	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	2	Splenomegaly	Spleen enlargement from CLL infiltration. Massive splenomegaly may cause cytopenias from sequestration.	phenotype_term	phenotype_term	$	Splenomegaly	Spleen enlargement from CLL infiltration. Massive splenomegaly may cause cytopenias from sequestration.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
1470	1536	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	3	Anemia	Anemia may result from bone marrow infiltration, autoimmune hemolytic anemia (AIHA), or hypersplenism.	phenotype_term	phenotype_term	$	Anemia	Anemia may result from bone marrow infiltration, autoimmune hemolytic anemia (AIHA), or hypersplenism.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1471	1537	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	4	Thrombocytopenia	Low platelet count from marrow infiltration, immune thrombocytopenia (ITP), or hypersplenism.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count from marrow infiltration, immune thrombocytopenia (ITP), or hypersplenism.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
1472	1538	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	5	Recurrent Infections	Increased susceptibility to bacterial and viral infections due to hypogammaglobulinemia and immune dysfunction. Herpes zoster and respiratory infections are common.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased susceptibility to bacterial and viral infections due to hypogammaglobulinemia and immune dysfunction. Herpes zoster and respiratory infections are common.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
1473	1539	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	6	Night Sweats	B symptoms including night sweats indicate more active disease and may warrant treatment initiation.	phenotype_term	phenotype_term	$	Night Sweats	B symptoms including night sweats indicate more active disease and may warrant treatment initiation.	Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
1474	1540	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	phenotypes	7	Weight Loss	Unintentional weight loss is a B symptom indicating active disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is a B symptom indicating active disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1475	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term	treatment_term	$	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}"				ibrutinib	CHEBI:76612																						
1476	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"																											
1477	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term	treatment_term	$	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}"				acalabrutinib	CHEBI:167707																						
1478	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"																											
1479	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term	treatment_term	$	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
1480	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
1481	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term	treatment_term	$	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}]}"				cyclophosphamide	CHEBI:4027																						
1482	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"																											
1483	1545	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	4	Watch and Wait	Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients.	treatment_term	treatment_term	$	Watch and Wait	Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients.	surveillance for malignancies	MAXO:0001492	surveillance for malignancies		"{""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}"																											
1484	1547	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	biochemical	1	BCR-ABL1 Fusion Transcript		biomarker_term	biomarker_term	$	BCR-ABL1 Fusion Transcript		BCR-ABL1 fusion protein	NCIT:C36715	BCR-ABL1 Fusion Protein Expression		"{""preferred_term"": ""BCR-ABL1 fusion protein"", ""term"": {""id"": ""NCIT:C36715"", ""label"": ""BCR-ABL1 Fusion Protein Expression""}}"																											
1485	1549	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	histopathology	0	Philadelphia Chromosome Positive Neoplasm	CML is defined by the presence of the Philadelphia chromosome (BCR-ABL1 fusion).	finding_term	finding_term	$	Philadelphia Chromosome Positive Neoplasm	CML is defined by the presence of the Philadelphia chromosome (BCR-ABL1 fusion).	B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1	NCIT:C36312	B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1		"{""preferred_term"": ""B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1"", ""term"": {""id"": ""NCIT:C36312"", ""label"": ""B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1""}}"																											
1486	1550	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene Formation	The t(9;22)(q34;q11) translocation juxtaposes the ABL1 tyrosine kinase gene on chromosome 9 with the BCR gene on chromosome 22, creating the Philadelphia chromosome. The resulting BCR-ABL1 fusion protein has constitutive tyrosine kinase activity independent of normal regulatory mechanisms.	cell_types[0]	cell_types	cell_types			hematopoietic stem cell	CL:0000037	hematopoietic stem cell		"{""preferred_term"": ""hematopoietic stem cell"", ""term"": {""id"": ""CL:0000037"", ""label"": ""hematopoietic stem cell""}}"																											
1487	1550	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene Formation	The t(9;22)(q34;q11) translocation juxtaposes the ABL1 tyrosine kinase gene on chromosome 9 with the BCR gene on chromosome 22, creating the Philadelphia chromosome. The resulting BCR-ABL1 fusion protein has constitutive tyrosine kinase activity independent of normal regulatory mechanisms.	biological_processes[0]	biological_processes	biological_processes			protein phosphorylation	GO:0006468	protein phosphorylation		"{""preferred_term"": ""protein phosphorylation"", ""term"": {""id"": ""GO:0006468"", ""label"": ""protein phosphorylation""}}"																											
1488	1550	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene Formation	The t(9;22)(q34;q11) translocation juxtaposes the ABL1 tyrosine kinase gene on chromosome 9 with the BCR gene on chromosome 22, creating the Philadelphia chromosome. The resulting BCR-ABL1 fusion protein has constitutive tyrosine kinase activity independent of normal regulatory mechanisms.	gene_products[0]	gene_products	gene_products			BCR-ABL1 fusion protein	NCIT:C16325	BCR/ABL1 Fusion Protein		"{""preferred_term"": ""BCR-ABL1 fusion protein"", ""term"": {""id"": ""NCIT:C16325"", ""label"": ""BCR/ABL1 Fusion Protein""}}"																											
1489	1551	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	1	Constitutive Tyrosine Kinase Activation	The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, bypassing normal growth factor regulation. This activates multiple downstream signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, promoting cell proliferation and survival.	cell_types[0]	cell_types	cell_types			myeloid cell	CL:0000763	myeloid cell		"{""preferred_term"": ""myeloid cell"", ""term"": {""id"": ""CL:0000763"", ""label"": ""myeloid cell""}}"																											
1490	1551	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	1	Constitutive Tyrosine Kinase Activation	The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, bypassing normal growth factor regulation. This activates multiple downstream signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, promoting cell proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
1491	1551	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	1	Constitutive Tyrosine Kinase Activation	The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, bypassing normal growth factor regulation. This activates multiple downstream signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, promoting cell proliferation and survival.	biological_processes[1]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
1492	1552	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	2	Uncontrolled Myeloid Proliferation	BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells, leading to marked expansion of the granulocytic lineage. The bone marrow becomes hypercellular with a massively expanded myeloid compartment.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
1493	1552	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	2	Uncontrolled Myeloid Proliferation	BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells, leading to marked expansion of the granulocytic lineage. The bone marrow becomes hypercellular with a massively expanded myeloid compartment.	cell_types[0]	cell_types	cell_types			granulocyte	CL:0000094	granulocyte		"{""preferred_term"": ""granulocyte"", ""term"": {""id"": ""CL:0000094"", ""label"": ""granulocyte""}}"																											
1494	1552	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	2	Uncontrolled Myeloid Proliferation	BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells, leading to marked expansion of the granulocytic lineage. The bone marrow becomes hypercellular with a massively expanded myeloid compartment.	cell_types[1]	cell_types	cell_types			myeloid progenitor cell	CL:0000049	common myeloid progenitor		"{""preferred_term"": ""myeloid progenitor cell"", ""term"": {""id"": ""CL:0000049"", ""label"": ""common myeloid progenitor""}}"																											
1495	1552	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	2	Uncontrolled Myeloid Proliferation	BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells, leading to marked expansion of the granulocytic lineage. The bone marrow becomes hypercellular with a massively expanded myeloid compartment.	biological_processes[0]	biological_processes	biological_processes			myeloid cell homeostasis	GO:0002262	myeloid cell homeostasis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""myeloid cell homeostasis"", ""term"": {""id"": ""GO:0002262"", ""label"": ""myeloid cell homeostasis""}}"			ABNORMAL																								
1496	1553	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	3	Apoptosis Resistance	BCR-ABL1 activates anti-apoptotic pathways, particularly through PI3K-AKT signaling and upregulation of BCL2 family members. This confers resistance to programmed cell death, allowing accumulation of leukemic cells.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
1497	1554	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	pathophysiology	4	Genomic Instability and Disease Progression	BCR-ABL1 induces genomic instability through reactive oxygen species generation and impaired DNA repair. This promotes acquisition of additional mutations and chromosomal abnormalities, driving progression from chronic phase to blast crisis.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
1498	1555	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	0	Leukocytosis	Marked elevation of white blood cell count, often exceeding 100,000/L at diagnosis. The differential shows increased granulocytes at all stages of maturation with a left shift to myelocytes and metamyelocytes.	phenotype_term	phenotype_term	$	Leukocytosis	Marked elevation of white blood cell count, often exceeding 100,000/L at diagnosis. The differential shows increased granulocytes at all stages of maturation with a left shift to myelocytes and metamyelocytes.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
1499	1556	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	1	Basophilia	Elevated basophil count is characteristic of CML and may indicate disease acceleration when markedly increased.	phenotype_term	phenotype_term	$	Basophilia	Elevated basophil count is characteristic of CML and may indicate disease acceleration when markedly increased.	Basophilia	HP:0031807	Increased total basophil count		"{""preferred_term"": ""Basophilia"", ""term"": {""id"": ""HP:0031807"", ""label"": ""Increased total basophil count""}}"																											
1500	1557	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	2	Thrombocytosis	Elevated platelet count occurs in many patients and may precede diagnosis. Extreme thrombocytosis can occur in some cases.	phenotype_term	phenotype_term	$	Thrombocytosis	Elevated platelet count occurs in many patients and may precede diagnosis. Extreme thrombocytosis can occur in some cases.	Thrombocytosis	HP:0001894	Thrombocytosis		"{""preferred_term"": ""Thrombocytosis"", ""term"": {""id"": ""HP:0001894"", ""label"": ""Thrombocytosis""}}"																											
1501	1558	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	3	Anemia	Normochromic normocytic anemia develops due to bone marrow replacement by leukemic cells and ineffective erythropoiesis.	phenotype_term	phenotype_term	$	Anemia	Normochromic normocytic anemia develops due to bone marrow replacement by leukemic cells and ineffective erythropoiesis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1502	1559	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	4	Fatigue	Profound fatigue is common, related to anemia and hypermetabolic state from rapid cell turnover.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue is common, related to anemia and hypermetabolic state from rapid cell turnover.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1503	1560	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	5	Splenomegaly	Massive splenomegaly from extramedullary hematopoiesis is characteristic. The spleen may extend to the pelvis and cause abdominal discomfort, early satiety, and left upper quadrant pain.	phenotype_term	phenotype_term	$	Splenomegaly	Massive splenomegaly from extramedullary hematopoiesis is characteristic. The spleen may extend to the pelvis and cause abdominal discomfort, early satiety, and left upper quadrant pain.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
1504	1561	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	phenotypes	6	Hepatomegaly	Liver enlargement from extramedullary hematopoiesis and leukemic infiltration.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from extramedullary hematopoiesis and leukemic infiltration.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
1505	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term	treatment_term	$	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
1506	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
1507	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term	treatment_term	$	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}]}"				dasatinib	CHEBI:49375																						
1508	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"																											
1509	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term	treatment_term	$	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}]}"				nilotinib	CHEBI:52172																						
1510	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			nilotinib	CHEBI:52172	nilotinib		"{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}"																											
1511	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term	treatment_term	$	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}"				ponatinib	CHEBI:78543																						
1512	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"																											
1513	1569	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
1514	1572	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	environmental	0	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
1515	1573	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	environmental	1	Air Pollution		exposure_term	exposure_term	$	Air Pollution		Air pollution exposure	ECTO:8000036	exposure to air pollution		"{""preferred_term"": ""Air pollution exposure"", ""term"": {""id"": ""ECTO:8000036"", ""label"": ""exposure to air pollution""}}"																											
1516	1574	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	environmental	2	Occupational Dust and Chemicals		exposure_term	exposure_term	$	Occupational Dust and Chemicals		Occupational dust exposure	ECTO:7000001	exposure to dust		"{""preferred_term"": ""Occupational dust exposure"", ""term"": {""id"": ""ECTO:7000001"", ""label"": ""exposure to dust""}}"																											
1517	1584	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	0	Airflow Limitation	Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.	cell_types[0]	cell_types	cell_types			Epithelial Cell	CL:0000066	epithelial cell		"{""preferred_term"": ""Epithelial Cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
1518	1584	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	0	Airflow Limitation	Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1519	1584	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	0	Airflow Limitation	Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.	biological_processes[1]	biological_processes	biological_processes			airway remodeling			Structural changes in airway architecture	"{""description"": ""Structural changes in airway architecture"", ""preferred_term"": ""airway remodeling""}"																											
1520	1584	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	0	Airflow Limitation	Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1521	1584	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	0	Airflow Limitation	Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.	locations[1]	locations	locations			small airway			Terminal and respiratory bronchioles	"{""description"": ""Terminal and respiratory bronchioles"", ""preferred_term"": ""small airway""}"																											
1522	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
1523	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1524	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	cell_types[2]	cell_types	cell_types			T-lymphocyte	CL:0000084	T cell		"{""preferred_term"": ""T-lymphocyte"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
1525	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1526	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	biological_processes[1]	biological_processes	biological_processes			neutrophil degranulation	GO:0043312	neutrophil degranulation		"{""preferred_term"": ""neutrophil degranulation"", ""term"": {""id"": ""GO:0043312"", ""label"": ""neutrophil degranulation""}}"																											
1527	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1528	1585	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	1	Chronic Inflammation	Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.	locations[1]	locations	locations			alveolus of lung	UBERON:0002299	alveolus of lung		"{""preferred_term"": ""alveolus of lung"", ""term"": {""id"": ""UBERON:0002299"", ""label"": ""alveolus of lung""}}"																											
1529	1586	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	2	Airway Remodeling	Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.	cell_types[0]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
1530	1586	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	2	Airway Remodeling	Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1531	1586	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	2	Airway Remodeling	Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.	biological_processes[1]	biological_processes	biological_processes			fibrosis			Excessive deposition of connective tissue	"{""description"": ""Excessive deposition of connective tissue"", ""preferred_term"": ""fibrosis""}"																											
1532	1586	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	2	Airway Remodeling	Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1533	1586	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	2	Airway Remodeling	Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.	locations[1]	locations	locations			small airway			Terminal and respiratory bronchioles	"{""description"": ""Terminal and respiratory bronchioles"", ""preferred_term"": ""small airway""}"																											
1534	1587	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	3	Alveolar Destruction	Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.	cell_types[0]	cell_types	cell_types			Alveolar Macrophage	CL:0000583	alveolar macrophage		"{""preferred_term"": ""Alveolar Macrophage"", ""term"": {""id"": ""CL:0000583"", ""label"": ""alveolar macrophage""}}"																											
1535	1587	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	3	Alveolar Destruction	Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.	biological_processes[0]	biological_processes	biological_processes			proteolysis	GO:0006508	proteolysis		"{""preferred_term"": ""proteolysis"", ""term"": {""id"": ""GO:0006508"", ""label"": ""proteolysis""}}"																											
1536	1587	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	3	Alveolar Destruction	Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.	biological_processes[1]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1537	1587	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	3	Alveolar Destruction	Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.	locations[0]	locations	locations			alveolus of lung	UBERON:0002299	alveolus of lung		"{""preferred_term"": ""alveolus of lung"", ""term"": {""id"": ""UBERON:0002299"", ""label"": ""alveolus of lung""}}"																											
1538	1587	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	3	Alveolar Destruction	Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.	locations[1]	locations	locations			lung parenchyma	UBERON:0008946	lung parenchyma		"{""preferred_term"": ""lung parenchyma"", ""term"": {""id"": ""UBERON:0008946"", ""label"": ""lung parenchyma""}}"																											
1539	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	cell_types[0]	cell_types	cell_types			airway epithelial cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""airway epithelial cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
1540	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	cell_types[1]	cell_types	cell_types			Alveolar Macrophage	CL:0000583	alveolar macrophage		"{""preferred_term"": ""Alveolar Macrophage"", ""term"": {""id"": ""CL:0000583"", ""label"": ""alveolar macrophage""}}"																											
1541	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
1542	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	biological_processes[1]	biological_processes	biological_processes			mitochondrion organization	GO:0007005	mitochondrion organization		"{""preferred_term"": ""mitochondrion organization"", ""term"": {""id"": ""GO:0007005"", ""label"": ""mitochondrion organization""}}"																											
1543	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	biological_processes[2]	biological_processes	biological_processes			mitophagy	GO:0000422	mitophagy		"{""preferred_term"": ""mitophagy"", ""term"": {""id"": ""GO:0000422"", ""label"": ""mitophagy""}}"																											
1544	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1545	1588	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	4	Oxidative Stress and Mitochondrial Dysfunction	Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.	locations[1]	locations	locations			alveolus of lung	UBERON:0002299	alveolus of lung		"{""preferred_term"": ""alveolus of lung"", ""term"": {""id"": ""UBERON:0002299"", ""label"": ""alveolus of lung""}}"																											
1546	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	cell_types[0]	cell_types	cell_types			goblet cell	CL:0000160	goblet cell		"{""preferred_term"": ""goblet cell"", ""term"": {""id"": ""CL:0000160"", ""label"": ""goblet cell""}}"																											
1547	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	cell_types[1]	cell_types	cell_types			club cell	CL:0000158	club cell		"{""preferred_term"": ""club cell"", ""term"": {""id"": ""CL:0000158"", ""label"": ""club cell""}}"																											
1548	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	biological_processes[0]	biological_processes	biological_processes			mucus secretion	GO:0070254	mucus secretion		"{""preferred_term"": ""mucus secretion"", ""term"": {""id"": ""GO:0070254"", ""label"": ""mucus secretion""}}"																											
1549	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	biological_processes[1]	biological_processes	biological_processes			cilium movement	GO:0003341	cilium movement		"{""preferred_term"": ""cilium movement"", ""term"": {""id"": ""GO:0003341"", ""label"": ""cilium movement""}}"																											
1550	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1551	1589	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	5	Mucus Hypersecretion	Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.	locations[1]	locations	locations			small airway			Terminal and respiratory bronchioles	"{""description"": ""Terminal and respiratory bronchioles"", ""preferred_term"": ""small airway""}"																											
1552	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1553	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	cell_types[1]	cell_types	cell_types			airway epithelial cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""airway epithelial cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
1554	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	biological_processes[0]	biological_processes	biological_processes			NLRP3 inflammasome complex assembly	GO:0072559	NLRP3 inflammasome complex assembly		"{""preferred_term"": ""NLRP3 inflammasome complex assembly"", ""term"": {""id"": ""GO:0072559"", ""label"": ""NLRP3 inflammasome complex assembly""}}"																											
1555	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1556	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	locations[0]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
1557	1590	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	6	NLRP3 Inflammasome Activation	Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1/IL-18 release.	locations[1]	locations	locations			alveolus of lung	UBERON:0002299	alveolus of lung		"{""preferred_term"": ""alveolus of lung"", ""term"": {""id"": ""UBERON:0002299"", ""label"": ""alveolus of lung""}}"																											
1558	1591	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	7	Cellular Senescence	Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.	cell_types[0]	cell_types	cell_types			airway epithelial cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""airway epithelial cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
1559	1591	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	7	Cellular Senescence	Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.	cell_types[1]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1560	1591	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	7	Cellular Senescence	Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.	biological_processes[0]	biological_processes	biological_processes			cellular senescence	GO:0090398	cellular senescence		"{""preferred_term"": ""cellular senescence"", ""term"": {""id"": ""GO:0090398"", ""label"": ""cellular senescence""}}"																											
1561	1591	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	7	Cellular Senescence	Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1562	1591	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	pathophysiology	7	Cellular Senescence	Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.	locations[0]	locations	locations			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
1563	1592	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	0	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1564	1593	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	1	Chronic Cough		phenotype_term	phenotype_term	$	Chronic Cough		Chronic Cough	HP:0034315	Chronic cough		"{""preferred_term"": ""Chronic Cough"", ""term"": {""id"": ""HP:0034315"", ""label"": ""Chronic cough""}}"																											
1565	1594	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	2	Sputum Production		phenotype_term	phenotype_term	$	Sputum Production		Sputum Production	HP:0033709	Increased sputum production		"{""preferred_term"": ""Sputum Production"", ""term"": {""id"": ""HP:0033709"", ""label"": ""Increased sputum production""}}"																											
1566	1595	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	3	Wheezing		phenotype_term	phenotype_term	$	Wheezing		Wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
1567	1597	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	5	Respiratory Failure		phenotype_term	phenotype_term	$	Respiratory Failure		Respiratory Failure	HP:0002878	Respiratory failure		"{""preferred_term"": ""Respiratory Failure"", ""term"": {""id"": ""HP:0002878"", ""label"": ""Respiratory failure""}}"																											
1568	1598	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1569	1599	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	7	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1570	1600	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	8	Exercise Intolerance		phenotype_term	phenotype_term	$	Exercise Intolerance		Exercise Intolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Exercise Intolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
1571	1601	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	9	Hypoxemia		phenotype_term	phenotype_term	$	Hypoxemia		Hypoxemia	HP:0012418	Hypoxemia		"{""preferred_term"": ""Hypoxemia"", ""term"": {""id"": ""HP:0012418"", ""label"": ""Hypoxemia""}}"																											
1572	1602	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	phenotypes	10	Hypercapnia		phenotype_term	phenotype_term	$	Hypercapnia		Hypercapnia	HP:0012416	Hypercapnia		"{""preferred_term"": ""Hypercapnia"", ""term"": {""id"": ""HP:0012416"", ""label"": ""Hypercapnia""}}"																											
1573	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	Smoking Cessation	Stopping smoking to slow disease progression and improve outcomes.	treatment_term	treatment_term	$	Smoking Cessation	Stopping smoking to slow disease progression and improve outcomes.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
1574	1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	Bronchodilators	Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).	treatment_term	treatment_term	$	Bronchodilators	Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1575	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	Inhaled Corticosteroids	Reduce airway inflammation and frequency of exacerbations.	treatment_term	treatment_term	$	Inhaled Corticosteroids	Reduce airway inflammation and frequency of exacerbations.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
1576	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	Phosphodiesterase-4 Inhibitors	Reduce inflammation and relax airways.	treatment_term	treatment_term	$	Phosphodiesterase-4 Inhibitors	Reduce inflammation and relax airways.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1577	1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	Oxygen Therapy	Long-term oxygen use for patients with severe chronic hypoxemia.	treatment_term	treatment_term	$	Oxygen Therapy	Long-term oxygen use for patients with severe chronic hypoxemia.	artificial respiration	MAXO:0000503	artificial respiration		"{""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}"																											
1578	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	Pulmonary Rehabilitation	Exercise training, education, and support to improve quality of life and physical conditioning.	treatment_term	treatment_term	$	Pulmonary Rehabilitation	Exercise training, education, and support to improve quality of life and physical conditioning.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1579	1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	Lung Volume Reduction Surgery	Surgical removal of damaged lung tissue for severe emphysema.	treatment_term	treatment_term	$	Lung Volume Reduction Surgery	Surgical removal of damaged lung tissue for severe emphysema.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1580	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	Lung Transplantation	Considered in end-stage COPD with severe impairment.	treatment_term	treatment_term	$	Lung Transplantation	Considered in end-stage COPD with severe impairment.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
1581	1613	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	8	Mucolytic Therapy	N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.	treatment_term	treatment_term	$	Mucolytic Therapy	N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1582	1614	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	9	Macrolide Antibiotics	Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.	treatment_term	treatment_term	$	Macrolide Antibiotics	Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1583	1615	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	10	Biologic Therapies	Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.	treatment_term	treatment_term	$	Biologic Therapies	Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1584	1628	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	0	Recurrent Acinar Cell Injury	"Repeated episodes of pancreatic inflammation cause progressive acinar cell damage. Alcohol, smoking, and genetic factors are major causes. Premature trypsin activation injures cells.
"	cell_types[0]	cell_types	cell_types			Pancreatic Acinar Cell	CL:0002064	pancreatic acinar cell		"{""preferred_term"": ""Pancreatic Acinar Cell"", ""term"": {""id"": ""CL:0002064"", ""label"": ""pancreatic acinar cell""}}"																											
1585	1628	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	0	Recurrent Acinar Cell Injury	"Repeated episodes of pancreatic inflammation cause progressive acinar cell damage. Alcohol, smoking, and genetic factors are major causes. Premature trypsin activation injures cells.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1586	1629	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	1	Pancreatic Fibrosis	"Activated pancreatic stellate cells produce excessive collagen, leading to progressive fibrosis. Fibrosis replaces functional parenchyma and causes ductal strictures.
"	cell_types[0]	cell_types	cell_types			Pancreatic Stellate Cell	CL:0002410	pancreatic stellate cell		"{""preferred_term"": ""Pancreatic Stellate Cell"", ""term"": {""id"": ""CL:0002410"", ""label"": ""pancreatic stellate cell""}}"																											
1587	1629	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	1	Pancreatic Fibrosis	"Activated pancreatic stellate cells produce excessive collagen, leading to progressive fibrosis. Fibrosis replaces functional parenchyma and causes ductal strictures.
"	biological_processes[0]	biological_processes	biological_processes			Extracellular Matrix Organization				"{""preferred_term"": ""Extracellular Matrix Organization""}"																											
1588	1630	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	2	Exocrine Insufficiency	"Loss of acinar cell mass leads to insufficient digestive enzyme production. Steatorrhea and malabsorption occur when >90% of exocrine function is lost.
"	biological_processes[0]	biological_processes	biological_processes			Digestive System Process				"{""preferred_term"": ""Digestive System Process""}"																											
1589	1631	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	pathophysiology	3	Endocrine Insufficiency	"Progressive loss of islet cells leads to diabetes mellitus (type 3c). Often occurs later in disease course.
"	cell_types[0]	cell_types	cell_types			Pancreatic Beta Cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""Pancreatic Beta Cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
1590	1632	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	phenotypes	0	Chronic Abdominal Pain		phenotype_term	phenotype_term	$	Chronic Abdominal Pain		Chronic Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Chronic Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1591	1633	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	phenotypes	1	Steatorrhea		phenotype_term	phenotype_term	$	Steatorrhea		Steatorrhea	HP:0002570	Steatorrhea		"{""preferred_term"": ""Steatorrhea"", ""term"": {""id"": ""HP:0002570"", ""label"": ""Steatorrhea""}}"																											
1592	1634	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	phenotypes	2	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight Loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight Loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1593	1635	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	phenotypes	3	Diabetes Mellitus		phenotype_term	phenotype_term	$	Diabetes Mellitus		Diabetes	HP:0000819	Diabetes mellitus		"{""preferred_term"": ""Diabetes"", ""term"": {""id"": ""HP:0000819"", ""label"": ""Diabetes mellitus""}}"																											
1594	1636	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	phenotypes	4	Nausea and Vomiting		phenotype_term	phenotype_term	$	Nausea and Vomiting		Nausea and Vomiting	HP:0002017	Nausea and vomiting		"{""preferred_term"": ""Nausea and Vomiting"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
1595	1651	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	histopathology	0	Clear Cell Renal Cell Carcinoma	Clear cell RCC is the most common histologic subtype of renal cell carcinoma.	finding_term	finding_term	$	Clear Cell Renal Cell Carcinoma	Clear cell RCC is the most common histologic subtype of renal cell carcinoma.	Clear Cell Renal Cell Carcinoma	NCIT:C4033	Clear Cell Renal Cell Carcinoma		"{""preferred_term"": ""Clear Cell Renal Cell Carcinoma"", ""term"": {""id"": ""NCIT:C4033"", ""label"": ""Clear Cell Renal Cell Carcinoma""}}"																											
1596	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF- subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF- accumulates and constitutively activates hypoxia response genes.	cell_types[0]	cell_types	cell_types			kidney epithelial cell	CL:0002518	kidney epithelial cell		"{""preferred_term"": ""kidney epithelial cell"", ""term"": {""id"": ""CL:0002518"", ""label"": ""kidney epithelial cell""}}"																											
1597	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF- subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF- accumulates and constitutively activates hypoxia response genes.	biological_processes[0]	biological_processes	biological_processes			cellular response to hypoxia	GO:0071456	cellular response to hypoxia		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cellular response to hypoxia"", ""term"": {""id"": ""GO:0071456"", ""label"": ""cellular response to hypoxia""}}"			INCREASED																								
1598	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF- subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF- accumulates and constitutively activates hypoxia response genes.	biological_processes[1]	biological_processes	biological_processes			proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""proteasome-mediated ubiquitin-dependent protein catabolic process"", ""term"": {""id"": ""GO:0043161"", ""label"": ""proteasome-mediated ubiquitin-dependent protein catabolic process""}}"			DECREASED																								
1599	1652	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	0	VHL Tumor Suppressor Inactivation	Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF- subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF- accumulates and constitutively activates hypoxia response genes.	locations[0]	locations	locations			kidney	UBERON:0002113	kidney		"{""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
1600	1653	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	1	HIF-2 Stabilization	Without VHL-mediated degradation, HIF-2 protein accumulates in the cytoplasm and translocates to the nucleus where it dimerizes with HIF-1 (ARNT) to form an active transcription factor. HIF-2 is the critical HIF isoform in ccRCC.	biological_processes[0]	biological_processes	biological_processes			protein stabilization	GO:0050821	protein stabilization		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein stabilization"", ""term"": {""id"": ""GO:0050821"", ""label"": ""protein stabilization""}}"			INCREASED																								
1601	1654	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	2	VEGF-Driven Angiogenesis	HIF-2 transcriptionally activates VEGF (vascular endothelial growth factor), driving tumor neovascularization. The resulting hypervascular phenotype is characteristic of ccRCC and the basis for VEGFR-targeted therapy.	biological_processes[0]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
1602	1654	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	2	VEGF-Driven Angiogenesis	HIF-2 transcriptionally activates VEGF (vascular endothelial growth factor), driving tumor neovascularization. The resulting hypervascular phenotype is characteristic of ccRCC and the basis for VEGFR-targeted therapy.	biological_processes[1]	biological_processes	biological_processes			vascular endothelial growth factor receptor signaling pathway	GO:0048010	vascular endothelial growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""vascular endothelial growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0048010"", ""label"": ""vascular endothelial growth factor receptor signaling pathway""}}"			INCREASED																								
1603	1655	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	3	Growth Factor Pathway Activation	HIF-2 activates transcription of growth-promoting genes including TGF- (which activates EGFR signaling) and cyclin D1 (which promotes cell cycle progression). This drives tumor cell proliferation independent of angiogenesis.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1604	1656	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	pathophysiology	4	Epigenetic Dysregulation	Secondary mutations in chromatin remodeling genes (PBRM1 in 40%, BAP1 in 15%, SETD2 in 15%) contribute to ccRCC progression. BAP1 mutations are associated with higher grade tumors and worse prognosis compared to PBRM1 mutations. These mutations cooperate with VHL loss to drive tumor evolution.	biological_processes[0]	biological_processes	biological_processes			chromatin remodeling	GO:0006338	chromatin remodeling		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""chromatin remodeling"", ""term"": {""id"": ""GO:0006338"", ""label"": ""chromatin remodeling""}}"			ABNORMAL																								
1605	1657	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	phenotypes	0	Renal Mass	ccRCC typically presents as a solid renal mass, often discovered incidentally on imaging. Classic triad of flank pain, hematuria, and palpable mass occurs in minority of cases.	phenotype_term	phenotype_term	$	Renal Mass	ccRCC typically presents as a solid renal mass, often discovered incidentally on imaging. Classic triad of flank pain, hematuria, and palpable mass occurs in minority of cases.	Renal neoplasm	HP:0009726	Renal neoplasm		"{""preferred_term"": ""Renal neoplasm"", ""term"": {""id"": ""HP:0009726"", ""label"": ""Renal neoplasm""}}"																											
1606	1658	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	phenotypes	1	Hematuria	Gross or microscopic hematuria occurs when tumor invades the collecting system.	phenotype_term	phenotype_term	$	Hematuria	Gross or microscopic hematuria occurs when tumor invades the collecting system.	Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
1607	1659	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	phenotypes	2	Fatigue	Fatigue is common and may be related to paraneoplastic syndromes or advanced disease.	phenotype_term	phenotype_term	$	Fatigue	Fatigue is common and may be related to paraneoplastic syndromes or advanced disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1608	1660	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	phenotypes	3	Weight Loss	Unintentional weight loss may occur with metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss may occur with metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1609	1661	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	phenotypes	4	Metastatic Disease	ccRCC commonly metastasizes to lung, bone, liver, and brain. Metastases are often highly vascular and may be hypervascular on imaging.	phenotype_term	phenotype_term	$	Metastatic Disease	ccRCC commonly metastasizes to lung, bone, liver, and brain. Metastases are often highly vascular and may be hypervascular on imaging.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
1610	1662	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	0	Nephrectomy	Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.	treatment_term	treatment_term	$	Nephrectomy	Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	treatment_term	$	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}, {""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}, {""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}"				sunitinib; pazopanib; axitinib; cabozantinib	CHEBI:38940; CHEBI:71219; CHEBI:66910; CHEBI:72317																						
1612	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"																											
1613	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			pazopanib	CHEBI:71219	pazopanib		"{""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}"																											
1614	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			axitinib	CHEBI:66910	axitinib		"{""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}"																											
1615	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"																											
1616	1664	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.	treatment_term	treatment_term	$	Belzutifan	First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1617	1665	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.	immunotherapy procedure	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
1618	1671	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	histopathology	0	Malignant Melanoma of Soft Parts	Clear cell sarcoma is also known as malignant melanoma of soft parts.	finding_term	finding_term	$	Malignant Melanoma of Soft Parts	Clear cell sarcoma is also known as malignant melanoma of soft parts.	Clear Cell Sarcoma of Soft Tissue	NCIT:C3745	Clear Cell Sarcoma of Soft Tissue		"{""preferred_term"": ""Clear Cell Sarcoma of Soft Tissue"", ""term"": {""id"": ""NCIT:C3745"", ""label"": ""Clear Cell Sarcoma of Soft Tissue""}}"																											
1619	1672	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	0	EWSR1-ATF1 Fusion Oncogene	The t(12;22)(q13;q12) translocation fuses the EWSR1 gene on chromosome 22 with ATF1 on chromosome 12 in approximately 90% of cases. The fusion protein functions as an aberrant transcription factor that constitutively activates MITF (microphthalmia-associated transcription factor), driving melanocytic differentiation and survival programs.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			ABNORMAL																								
1620	1672	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	0	EWSR1-ATF1 Fusion Oncogene	The t(12;22)(q13;q12) translocation fuses the EWSR1 gene on chromosome 22 with ATF1 on chromosome 12 in approximately 90% of cases. The fusion protein functions as an aberrant transcription factor that constitutively activates MITF (microphthalmia-associated transcription factor), driving melanocytic differentiation and survival programs.	locations[0]	locations	locations			tendon	UBERON:0000043	tendon		"{""preferred_term"": ""tendon"", ""term"": {""id"": ""UBERON:0000043"", ""label"": ""tendon""}}"																											
1621	1673	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	1	MITF Activation	EWSR1-ATF1 directly activates transcription of MITF, the master transcription factor of melanocyte lineage. MITF in turn activates genes involved in melanogenesis, cell survival, and proliferation. This explains the melanocytic phenotype despite soft tissue origin.	biological_processes[0]	biological_processes	biological_processes			regulation of gene expression	GO:0010468	regulation of gene expression		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of gene expression"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"			ABNORMAL																								
1622	1674	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	pathophysiology	2	Melanocytic Differentiation	Downstream of MITF activation, CCS cells express melanocytic markers including S100, HMB45, Melan-A, and tyrosinase. Melanin pigment may be present. However, unlike melanoma, CCS lacks UV-induced mutations and BRAF/NRAS alterations typical of cutaneous melanoma.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			ABNORMAL																								
1623	1675	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	phenotypes	0	Soft Tissue Mass	A slowly growing deep soft tissue mass, most commonly in the foot, ankle, or knee region. The mass is often attached to tendons or aponeuroses. May be present for years before diagnosis.	phenotype_term	phenotype_term	$	Soft Tissue Mass	A slowly growing deep soft tissue mass, most commonly in the foot, ankle, or knee region. The mass is often attached to tendons or aponeuroses. May be present for years before diagnosis.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
1624	1676	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	phenotypes	1	Localized Pain	Pain and tenderness at the tumor site. The association with tendons may cause pain with movement.	phenotype_term	phenotype_term	$	Localized Pain	Pain and tenderness at the tumor site. The association with tendons may cause pain with movement.	Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
1625	1677	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	phenotypes	2	Lymph Node Involvement	Regional lymph node metastasis occurs more commonly than in other soft tissue sarcomas, reflecting the melanocytic biology. Sentinel lymph node biopsy is often performed.	phenotype_term	phenotype_term	$	Lymph Node Involvement	Regional lymph node metastasis occurs more commonly than in other soft tissue sarcomas, reflecting the melanocytic biology. Sentinel lymph node biopsy is often performed.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
1626	1678	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	phenotypes	3	Weight Loss	Weight loss is uncommon at presentation but may occur with advanced metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Weight loss is uncommon at presentation but may occur with advanced metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1627	1679	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	0	Wide Surgical Resection	Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors.	treatment_term	treatment_term	$	Wide Surgical Resection	Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1628	1680	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	1	Sentinel Lymph Node Biopsy	Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management.	treatment_term	treatment_term	$	Sentinel Lymph Node Biopsy	Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1629	1681	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1630	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term	treatment_term	$	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				doxorubicin	CHEBI:28748																						
1631	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1632	1683	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	differential_diagnoses	0	Ulcerative colitis	Chronic immune-mediated colitis that can flare with bloody diarrhea and may coexist with CDI.	disease_term	disease_term	$	Ulcerative colitis	Chronic immune-mediated colitis that can flare with bloody diarrhea and may coexist with CDI.	ulcerative colitis	MONDO:0005101	ulcerative colitis		"{""preferred_term"": ""ulcerative colitis"", ""term"": {""id"": ""MONDO:0005101"", ""label"": ""ulcerative colitis""}}"																											
1633	1684	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	differential_diagnoses	1	Lymphocytic colitis	Microscopic colitis subtype causing chronic watery diarrhea that can mimic or coexist with CDI.	disease_term	disease_term	$	Lymphocytic colitis	Microscopic colitis subtype causing chronic watery diarrhea that can mimic or coexist with CDI.	lymphocytic colitis	MONDO:0000704	lymphocytic colitis		"{""preferred_term"": ""lymphocytic colitis"", ""term"": {""id"": ""MONDO:0000704"", ""label"": ""lymphocytic colitis""}}"																											
1634	1685	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	differential_diagnoses	2	Ischemic colitis	Colonic ischemia presenting with acute abdominal pain and diarrhea that can be confused with infectious colitis.	disease_term	disease_term	$	Ischemic colitis	Colonic ischemia presenting with acute abdominal pain and diarrhea that can be confused with infectious colitis.	ischemic colitis	MONDO:0000701	ischemic colitis		"{""preferred_term"": ""ischemic colitis"", ""term"": {""id"": ""MONDO:0000701"", ""label"": ""ischemic colitis""}}"																											
1635	1686	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	differential_diagnoses	3	Strongyloidiasis hyperinfection	Parasitic hyperinfection that can present with diarrhea and mimic severe CDI in immunosuppressed hosts.	disease_term	disease_term	$	Strongyloidiasis hyperinfection	Parasitic hyperinfection that can present with diarrhea and mimic severe CDI in immunosuppressed hosts.	strongyloidiasis	MONDO:0005974	strongyloidiasis		"{""preferred_term"": ""strongyloidiasis"", ""term"": {""id"": ""MONDO:0005974"", ""label"": ""strongyloidiasis""}}"																											
1636	1687	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	differential_diagnoses	4	Acute appendicitis	Extraintestinal manifestation with right lower quadrant pain that can coexist with or be mistaken for CDI.	disease_term	disease_term	$	Acute appendicitis	Extraintestinal manifestation with right lower quadrant pain that can coexist with or be mistaken for CDI.	appendicitis	MONDO:0005649	appendicitis		"{""preferred_term"": ""appendicitis"", ""term"": {""id"": ""MONDO:0005649"", ""label"": ""appendicitis""}}"																											
1637	1689	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	infectious_agent	0	Clostridioides difficile		infectious_agent_term	infectious_agent_term	$	Clostridioides difficile		Clostridioides difficile	NCBITaxon:1496	Clostridioides difficile		"{""preferred_term"": ""Clostridioides difficile"", ""term"": {""id"": ""NCBITaxon:1496"", ""label"": ""Clostridioides difficile""}}"																											
1638	1690	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	0	Antibiotic-Induced Microbial Depletion	"Broad-spectrum antibiotics (especially fluoroquinolones, clindamycin, cephalosporins) cause indiscriminate killing of gut commensals, dramatically reducing microbial diversity and biomass. This creates ecological opportunity for C. difficile colonization.
"	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
1639	1694	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	4	Toxin Production (TcdA/TcdB)	"C. difficile secretes two large clostridial glucosylating toxins: TcdA (enterotoxin, 308 kDa) and TcdB (cytotoxin, 270 kDa). Both are glucosyltransferases that inactivate Rho family GTPases (Rho, Rac, Cdc42) by monoglucosylation of a critical threonine residue, disrupting the actin cytoskeleton.
"	biological_processes[0]	biological_processes	biological_processes			Pathogenesis	GO:0009405	pathogenesis		"{""preferred_term"": ""Pathogenesis"", ""term"": {""id"": ""GO:0009405"", ""label"": ""pathogenesis""}}"																											
1640	1695	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	5	Epithelial Cell Death and Barrier Disruption	"Toxin-mediated Rho GTPase inactivation causes actin cytoskeleton condensation, loss of cell-cell junctions, and epithelial cell rounding followed by death. This creates gaps in the epithelial barrier, exposing the lamina propria to luminal contents.
"	cell_types[0]	cell_types	cell_types			Colonic Epithelial Cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""Colonic Epithelial Cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
1641	1696	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	6	Neutrophil Recruitment and Inflammation	"TcdA triggers IL-8 and other chemokine release from epithelial cells, causing massive neutrophil influx into the colonic mucosa. Neutrophils form the characteristic ""volcano lesions"" and contribute to tissue damage through degranulation, reactive oxygen species, and NET formation.
"	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
1642	1696	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	6	Neutrophil Recruitment and Inflammation	"TcdA triggers IL-8 and other chemokine release from epithelial cells, causing massive neutrophil influx into the colonic mucosa. Neutrophils form the characteristic ""volcano lesions"" and contribute to tissue damage through degranulation, reactive oxygen species, and NET formation.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
1643	1697	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	pathophysiology	7	Pseudomembranous Colitis	"Characteristic raised yellow-white plaques on colonic mucosa composed of fibrin, mucus, neutrophils, and cellular debris overlying areas of epithelial necrosis. Represents severe C. difficile infection with high morbidity. Fluid secretion and diarrhea result from barrier loss and inflammation.
"	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
1644	1698	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	phenotypes	0	Diarrhea	Watery diarrhea, often foul-smelling, is the hallmark symptom.	phenotype_term	phenotype_term	$	Diarrhea	Watery diarrhea, often foul-smelling, is the hallmark symptom.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
1645	1699	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	phenotypes	1	Abdominal pain	Cramping abdominal pain accompanying diarrhea.	phenotype_term	phenotype_term	$	Abdominal pain	Cramping abdominal pain accompanying diarrhea.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1646	1700	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	phenotypes	2	Fever	Systemic inflammatory response to infection.	phenotype_term	phenotype_term	$	Fever	Systemic inflammatory response to infection.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	treatment_term	$	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																Oral Route of Administration	NCIT:C38288	NCIT:C38114				vancomycin	NCIT:C288	NCIT:C2259			
1648	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1649	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral route of administration	NCIT:C38288	Oral Route of Administration		"{""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}"																											
1650	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1651	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			vancomycin	NCIT:C288	vancomycin		"{""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}"																											
1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	treatment_term	$	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																Oral Route of Administration	NCIT:C38288	NCIT:C38114				fidaxomicin	NCIT:C95509	NCIT:C2259			
1653	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1654	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral route of administration	NCIT:C38288	Oral Route of Administration		"{""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}"																											
1655	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1656	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			fidaxomicin	NCIT:C95509	fidaxomicin		"{""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}"																											
1657	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term	treatment_term	$	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	fecal microbiota transplantation	MAXO:0000748	fecal microbiota transplantation		"{""preferred_term"": ""fecal microbiota transplantation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}, ""value"": {""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}}], ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}"						recurrent disease	MONDO:0700096	NCIT:C28008																			
1658	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			clinical course	NCIT:C28008	Clinical Course		"{""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}"																											
1659	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			recurrent disease	MONDO:0700096	recurrent disease		"{""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}"																											
1660	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term	treatment_term	$	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Bezlotoxumab	NCIT:C121379	NCIT:C2259			
1661	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1662	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			bezlotoxumab	NCIT:C121379	Bezlotoxumab		"{""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}"																											
1663	1705	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	4	Loop ileostomy with colonic lavage	Organ-preserving surgical approach for fulminant CDI when medical therapy fails.	treatment_term	treatment_term	$	Loop ileostomy with colonic lavage	Organ-preserving surgical approach for fulminant CDI when medical therapy fails.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1664	1710	72	Collagenous Sprue	Collagenous_Sprue.yaml	differential_diagnoses	0	Celiac disease	"Celiac disease presents with similar clinical manifestations including diarrhea, weight loss, and villous atrophy. However, it is distinguished by positive tissue transglutaminase (tTG) and endomysial antibodies, and typically responds well to a gluten-free diet. In contrast, collagenous sprue patients lack celiac serology and respond poorly to gluten-free diet alone.
"	disease_term	disease_term	$	Celiac disease	"Celiac disease presents with similar clinical manifestations including diarrhea, weight loss, and villous atrophy. However, it is distinguished by positive tissue transglutaminase (tTG) and endomysial antibodies, and typically responds well to a gluten-free diet. In contrast, collagenous sprue patients lack celiac serology and respond poorly to gluten-free diet alone.
"	celiac disease	MONDO:0005130	celiac disease		"{""preferred_term"": ""celiac disease"", ""term"": {""id"": ""MONDO:0005130"", ""label"": ""celiac disease""}}"																											
1665	1711	72	Collagenous Sprue	Collagenous_Sprue.yaml	differential_diagnoses	1	Pulmonary hemosiderosis	"Pulmonary hemosiderosis involves recurrent pulmonary bleeding with hemosiderin accumulation in lungs. While collagenous sprue can have pulmonary manifestations through shared immune mechanisms, isolated pulmonary hemosiderosis is characterized by lung involvement without the characteristic small bowel pathology and gastrointestinal symptoms of collagenous sprue.
"	disease_term	disease_term	$	Pulmonary hemosiderosis	"Pulmonary hemosiderosis involves recurrent pulmonary bleeding with hemosiderin accumulation in lungs. While collagenous sprue can have pulmonary manifestations through shared immune mechanisms, isolated pulmonary hemosiderosis is characterized by lung involvement without the characteristic small bowel pathology and gastrointestinal symptoms of collagenous sprue.
"	pulmonary hemosiderosis	MONDO:0008346	pulmonary hemosiderosis		"{""preferred_term"": ""pulmonary hemosiderosis"", ""term"": {""id"": ""MONDO:0008346"", ""label"": ""pulmonary hemosiderosis""}}"																											
1666	1712	72	Collagenous Sprue	Collagenous_Sprue.yaml	differential_diagnoses	2	Microscopic colitis	"Microscopic colitis includes both lymphocytic and collagenous colitis subtypes, presenting with chronic watery diarrhea and increased intraepithelial lymphocytes. Collagenous colitis can affect the small intestine and present as collagenous sprue, but the histologic patterns and clinical context help differentiate them. Collagenous sprue has more pronounced villous atrophy and is often associated with celiac-like presentations.
"	disease_term	disease_term	$	Microscopic colitis	"Microscopic colitis includes both lymphocytic and collagenous colitis subtypes, presenting with chronic watery diarrhea and increased intraepithelial lymphocytes. Collagenous colitis can affect the small intestine and present as collagenous sprue, but the histologic patterns and clinical context help differentiate them. Collagenous sprue has more pronounced villous atrophy and is often associated with celiac-like presentations.
"	microscopic colitis	MONDO:0000702	microscopic colitis		"{""preferred_term"": ""microscopic colitis"", ""term"": {""id"": ""MONDO:0000702"", ""label"": ""microscopic colitis""}}"																											
1667	1713	72	Collagenous Sprue	Collagenous_Sprue.yaml	differential_diagnoses	3	Refractory celiac disease	"Refractory celiac disease (RCD) occurs in patients with confirmed celiac disease who fail to respond clinically and/or histologically to a gluten-free diet. While both collagenous sprue and RCD can be resistant to gluten-free diet, RCD patients have positive celiac serology and documented prior response to gluten-free diet initially, distinguishing them from collagenous sprue which is seronegative.
"	disease_term	disease_term	$	Refractory celiac disease	"Refractory celiac disease (RCD) occurs in patients with confirmed celiac disease who fail to respond clinically and/or histologically to a gluten-free diet. While both collagenous sprue and RCD can be resistant to gluten-free diet, RCD patients have positive celiac serology and documented prior response to gluten-free diet initially, distinguishing them from collagenous sprue which is seronegative.
"	refractory celiac disease	MONDO:0018353	refractory celiac disease		"{""preferred_term"": ""refractory celiac disease"", ""term"": {""id"": ""MONDO:0018353"", ""label"": ""refractory celiac disease""}}"																											
1668	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	cell_types[0]	cell_types	cell_types			intraepithelial lymphocyte	CL:0002496	intraepithelial lymphocyte		"{""preferred_term"": ""intraepithelial lymphocyte"", ""term"": {""id"": ""CL:0002496"", ""label"": ""intraepithelial lymphocyte""}}"																											
1669	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	cell_types[1]	cell_types	cell_types			plasma cell	CL:0000786	plasma cell		"{""preferred_term"": ""plasma cell"", ""term"": {""id"": ""CL:0000786"", ""label"": ""plasma cell""}}"																											
1670	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	cell_types[2]	cell_types	cell_types			eosinophil	CL:0000041	mature eosinophil		"{""preferred_term"": ""eosinophil"", ""term"": {""id"": ""CL:0000041"", ""label"": ""mature eosinophil""}}"																											
1671	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	biological_processes[0]	biological_processes	biological_processes			T cell mediated immune response	GO:0002292	T cell differentiation involved in immune response		"{""preferred_term"": ""T cell mediated immune response"", ""term"": {""id"": ""GO:0002292"", ""label"": ""T cell differentiation involved in immune response""}}"																											
1672	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	biological_processes[1]	biological_processes	biological_processes			response to cytokine	GO:0034097	response to cytokine		"{""preferred_term"": ""response to cytokine"", ""term"": {""id"": ""GO:0034097"", ""label"": ""response to cytokine""}}"																											
1673	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	locations[0]	locations	locations			small intestinal mucosa	UBERON:0001273	small intestine		"{""preferred_term"": ""small intestinal mucosa"", ""term"": {""id"": ""UBERON:0001273"", ""label"": ""small intestine""}}"																											
1674	1722	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	0	Mucosal immune activation with intraepithelial lymphocytosis	"Collagenous sprue is initiated by mucosal immune activation characterized by increased intraepithelial lymphocytes (IELs), particularly CD8+ T cells, and lamina propria inflammation with plasma cells and eosinophils. IL-15 and TNF- signaling drive this T cell-mediated immune response, leading to epithelial cell apoptosis, crypt hyperplasia, and villous atrophy. This immune activation is not associated with celiac serology despite overlapping histologic features with celiac disease.
"	locations[1]	locations	locations			lamina propria	UBERON:0001982	lamina propria		"{""preferred_term"": ""lamina propria"", ""term"": {""id"": ""UBERON:0001982"", ""label"": ""lamina propria""}}"																											
1675	1723	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	1	Epithelial barrier dysfunction and tight junction disruption	"Immune-mediated epithelial damage impairs the intestinal epithelial barrier through disruption of tight junction proteins, particularly zonula occludens-1 (ZO-1/TJP1). Loss of barrier function allows increased paracellular transport and bacterial antigen exposure, perpetuating the inflammatory cycle. Crypt epithelial apoptosis and reduced junctional integrity compromise the epithelial seal, contributing to persistent diarrhea and protein-losing enteropathy.
"	biological_processes[0]	biological_processes	biological_processes			cell junction organization	GO:0034330	cell junction organization		"{""preferred_term"": ""cell junction organization"", ""term"": {""id"": ""GO:0034330"", ""label"": ""cell junction organization""}}"																											
1676	1723	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	1	Epithelial barrier dysfunction and tight junction disruption	"Immune-mediated epithelial damage impairs the intestinal epithelial barrier through disruption of tight junction proteins, particularly zonula occludens-1 (ZO-1/TJP1). Loss of barrier function allows increased paracellular transport and bacterial antigen exposure, perpetuating the inflammatory cycle. Crypt epithelial apoptosis and reduced junctional integrity compromise the epithelial seal, contributing to persistent diarrhea and protein-losing enteropathy.
"	biological_processes[1]	biological_processes	biological_processes			epithelial cell differentiation	GO:0030855	epithelial cell differentiation		"{""preferred_term"": ""epithelial cell differentiation"", ""term"": {""id"": ""GO:0030855"", ""label"": ""epithelial cell differentiation""}}"																											
1677	1724	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	2	Subepithelial collagen deposition and fibrotic remodeling	"Excessive collagen accumulation beneath the intestinal epithelium is the pathologic hallmark of collagenous sprue, defined by a thickened subepithelial collagen band >10 micrometers (normal 5-7 m). This results from TGF-driven myofibroblast activation and differentiation from fibroblasts, with increased expression of collagen type I (COL1A1) and upregulation of tissue inhibitors of metalloproteinases (TIMP1). Simultaneously, matrix metalloproteinase (MMP1, MMP9) activity is reduced, creating an imbalance favoring ECM accumulation. The collagen band may entrap capillaries and stromal cells, disrupting villous architecture and nutrient absorption.
"	cell_types[0]	cell_types	cell_types			myofibroblast	CL:0000186	myofibroblast cell		"{""preferred_term"": ""myofibroblast"", ""term"": {""id"": ""CL:0000186"", ""label"": ""myofibroblast cell""}}"																											
1678	1724	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	2	Subepithelial collagen deposition and fibrotic remodeling	"Excessive collagen accumulation beneath the intestinal epithelium is the pathologic hallmark of collagenous sprue, defined by a thickened subepithelial collagen band >10 micrometers (normal 5-7 m). This results from TGF-driven myofibroblast activation and differentiation from fibroblasts, with increased expression of collagen type I (COL1A1) and upregulation of tissue inhibitors of metalloproteinases (TIMP1). Simultaneously, matrix metalloproteinase (MMP1, MMP9) activity is reduced, creating an imbalance favoring ECM accumulation. The collagen band may entrap capillaries and stromal cells, disrupting villous architecture and nutrient absorption.
"	cell_types[1]	cell_types	cell_types			capillary endothelial cell	CL:0002144	capillary endothelial cell		"{""preferred_term"": ""capillary endothelial cell"", ""term"": {""id"": ""CL:0002144"", ""label"": ""capillary endothelial cell""}}"																											
1679	1724	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	2	Subepithelial collagen deposition and fibrotic remodeling	"Excessive collagen accumulation beneath the intestinal epithelium is the pathologic hallmark of collagenous sprue, defined by a thickened subepithelial collagen band >10 micrometers (normal 5-7 m). This results from TGF-driven myofibroblast activation and differentiation from fibroblasts, with increased expression of collagen type I (COL1A1) and upregulation of tissue inhibitors of metalloproteinases (TIMP1). Simultaneously, matrix metalloproteinase (MMP1, MMP9) activity is reduced, creating an imbalance favoring ECM accumulation. The collagen band may entrap capillaries and stromal cells, disrupting villous architecture and nutrient absorption.
"	biological_processes[0]	biological_processes	biological_processes			positive regulation of collagen biosynthetic process	GO:0032965	positive regulation of collagen biosynthetic process		"{""preferred_term"": ""positive regulation of collagen biosynthetic process"", ""term"": {""id"": ""GO:0032965"", ""label"": ""positive regulation of collagen biosynthetic process""}}"																											
1680	1724	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	2	Subepithelial collagen deposition and fibrotic remodeling	"Excessive collagen accumulation beneath the intestinal epithelium is the pathologic hallmark of collagenous sprue, defined by a thickened subepithelial collagen band >10 micrometers (normal 5-7 m). This results from TGF-driven myofibroblast activation and differentiation from fibroblasts, with increased expression of collagen type I (COL1A1) and upregulation of tissue inhibitors of metalloproteinases (TIMP1). Simultaneously, matrix metalloproteinase (MMP1, MMP9) activity is reduced, creating an imbalance favoring ECM accumulation. The collagen band may entrap capillaries and stromal cells, disrupting villous architecture and nutrient absorption.
"	biological_processes[1]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1681	1724	72	Collagenous Sprue	Collagenous_Sprue.yaml	pathophysiology	2	Subepithelial collagen deposition and fibrotic remodeling	"Excessive collagen accumulation beneath the intestinal epithelium is the pathologic hallmark of collagenous sprue, defined by a thickened subepithelial collagen band >10 micrometers (normal 5-7 m). This results from TGF-driven myofibroblast activation and differentiation from fibroblasts, with increased expression of collagen type I (COL1A1) and upregulation of tissue inhibitors of metalloproteinases (TIMP1). Simultaneously, matrix metalloproteinase (MMP1, MMP9) activity is reduced, creating an imbalance favoring ECM accumulation. The collagen band may entrap capillaries and stromal cells, disrupting villous architecture and nutrient absorption.
"	locations[0]	locations	locations			subepithelial lamina propria	UBERON:0001982	lamina propria		"{""preferred_term"": ""subepithelial lamina propria"", ""term"": {""id"": ""UBERON:0001982"", ""label"": ""lamina propria""}}"																											
1682	1725	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	0	Chronic watery diarrhea	"Persistent diarrhea is the primary clinical manifestation, resulting from impaired nutrient and fluid absorption due to altered intestinal architecture, epithelial barrier dysfunction, and villous atrophy.
"	phenotype_term	phenotype_term	$	Chronic watery diarrhea	"Persistent diarrhea is the primary clinical manifestation, resulting from impaired nutrient and fluid absorption due to altered intestinal architecture, epithelial barrier dysfunction, and villous atrophy.
"	Chronic diarrhea	HP:0002028	Chronic diarrhea		"{""preferred_term"": ""Chronic diarrhea"", ""term"": {""id"": ""HP:0002028"", ""label"": ""Chronic diarrhea""}}"																											
1683	1726	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	1	Weight loss	"Progressive weight loss secondary to malabsorption and chronic diarrhea, often marked and severe.
"	phenotype_term	phenotype_term	$	Weight loss	"Progressive weight loss secondary to malabsorption and chronic diarrhea, often marked and severe.
"	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1684	1727	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	2	Abdominal pain	"Cramping or sharp abdominal pain accompanying diarrhea and gastrointestinal inflammation.
"	phenotype_term	phenotype_term	$	Abdominal pain	"Cramping or sharp abdominal pain accompanying diarrhea and gastrointestinal inflammation.
"	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1685	1728	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	3	Malabsorption	"Defective nutrient absorption leading to nutritional deficiencies, steatorrhea, and secondary anemia.
"	phenotype_term	phenotype_term	$	Malabsorption	"Defective nutrient absorption leading to nutritional deficiencies, steatorrhea, and secondary anemia.
"	Malabsorption	HP:0002024	Malabsorption		"{""preferred_term"": ""Malabsorption"", ""term"": {""id"": ""HP:0002024"", ""label"": ""Malabsorption""}}"																											
1686	1729	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	4	Protein-losing enteropathy	"Loss of plasma proteins into the intestinal lumen due to epithelial barrier dysfunction and mucosal inflammation.
"	phenotype_term	phenotype_term	$	Protein-losing enteropathy	"Loss of plasma proteins into the intestinal lumen due to epithelial barrier dysfunction and mucosal inflammation.
"	Protein-losing enteropathy	HP:0002243	Protein-losing enteropathy		"{""preferred_term"": ""Protein-losing enteropathy"", ""term"": {""id"": ""HP:0002243"", ""label"": ""Protein-losing enteropathy""}}"																											
1687	1730	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	5	Anemia	"Iron-deficiency anemia resulting from malabsorption and chronic intestinal blood loss.
"	phenotype_term	phenotype_term	$	Anemia	"Iron-deficiency anemia resulting from malabsorption and chronic intestinal blood loss.
"	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1688	1731	72	Collagenous Sprue	Collagenous_Sprue.yaml	phenotypes	6	Hypoalbuminemia	"Low serum albumin due to protein-losing enteropathy and malabsorption.
"	phenotype_term	phenotype_term	$	Hypoalbuminemia	"Low serum albumin due to protein-losing enteropathy and malabsorption.
"	Hypoalbuminemia	HP:0003073	Hypoalbuminemia		"{""preferred_term"": ""Hypoalbuminemia"", ""term"": {""id"": ""HP:0003073"", ""label"": ""Hypoalbuminemia""}}"																											
1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	treatment_term	$	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy		"{""preferred_term"": ""topical corticosteroid therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}}, {""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}}], ""term"": {""id"": ""MAXO:0001553"", ""label"": ""topical corticosteroid therapy""}}"																Gastrointestinal Route of Administration	NCIT:C38295	NCIT:C38114				Budesonide	NCIT:C66948	NCIT:C2259			
1690	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1691	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			budesonide	NCIT:C66948	Budesonide		"{""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}"																											
1692	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1693	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			gastrointestinal route	NCIT:C38295	Gastrointestinal Route of Administration		"{""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}"																											
1694	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term	treatment_term	$	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Azathioprine	NCIT:C620	NCIT:C2259			
1695	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1696	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			azathioprine	NCIT:C620	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}"																											
1697	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term	treatment_term	$	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Infliximab	NCIT:C2894	NCIT:C2259			
1698	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1699	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			infliximab	NCIT:C2894	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}"																											
1700	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term	treatment_term	$	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Tacrolimus	NCIT:C2982	NCIT:C2259			
1701	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1702	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tacrolimus	NCIT:C2982	Tacrolimus		"{""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}"																											
1703	1736	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	4	Medication discontinuation (Olmesartan withdrawal)	"Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.
"	treatment_term	treatment_term	$	Medication discontinuation (Olmesartan withdrawal)	"Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.
"	medication management	MAXO:0000950	supportive care		"{""preferred_term"": ""medication management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1704	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term	treatment_term	$	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}}], ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																						Iron Supplement	NCIT:C2346	NCIT:C2259			
1705	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1706	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			iron supplement	NCIT:C2346	Iron Supplement		"{""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}"																											
1707	1738	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	datasets	0		Microarray dataset with colorectal cancer and non-tumoral mucosa samples used for molecular classification and outcome studies.	organism	organism	$		Microarray dataset with colorectal cancer and non-tumoral mucosa samples used for molecular classification and outcome studies.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
1708	1738	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	datasets	0		Microarray dataset with colorectal cancer and non-tumoral mucosa samples used for molecular classification and outcome studies.	sample_types[0]	sample_types	sample_types			colon tissue				"{""preferred_term"": ""colon tissue"", ""tissue_term"": {""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}}"																											
1709	1738	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	datasets	0		Microarray dataset with colorectal cancer and non-tumoral mucosa samples used for molecular classification and outcome studies.	sample_types[0].tissue_term	sample_types	sample_types[0]			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
1710	1741	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	phenotypes	0	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1711	1742	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	phenotypes	1	Hematochezia		phenotype_term	phenotype_term	$	Hematochezia		Hematochezia	HP:0002573	Hematochezia		"{""preferred_term"": ""Hematochezia"", ""term"": {""id"": ""HP:0002573"", ""label"": ""Hematochezia""}}"																											
1712	1743	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	phenotypes	2	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1713	1744	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	treatments	0	Surgical Resection	Surgical removal of the colon tumor when localized.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of the colon tumor when localized.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1714	1752	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	histopathology	0	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	finding_term	finding_term	$	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	Myeloblasts Present	NCIT:C155995	Myeloblasts Present		"{""preferred_term"": ""Myeloblasts Present"", ""term"": {""id"": ""NCIT:C155995"", ""label"": ""Myeloblasts Present""}}"																											
1715	1753	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	0	CBF Transcription Factor Complex Disruption	The core binding factor complex consists of RUNX1 (alpha subunit) and CBFB (beta subunit). RUNX1 binds DNA while CBFB stabilizes this binding. Both t(8;21) and inv(16) produce fusion proteins that dominantly inhibit normal CBF function, disrupting transcription of genes essential for myeloid differentiation.	cell_types[0]	cell_types	cell_types			myeloid progenitor cell	CL:0000049	common myeloid progenitor		"{""preferred_term"": ""myeloid progenitor cell"", ""term"": {""id"": ""CL:0000049"", ""label"": ""common myeloid progenitor""}}"																											
1716	1753	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	0	CBF Transcription Factor Complex Disruption	The core binding factor complex consists of RUNX1 (alpha subunit) and CBFB (beta subunit). RUNX1 binds DNA while CBFB stabilizes this binding. Both t(8;21) and inv(16) produce fusion proteins that dominantly inhibit normal CBF function, disrupting transcription of genes essential for myeloid differentiation.	biological_processes[0]	biological_processes	biological_processes			myeloid cell differentiation	GO:0030099	myeloid cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myeloid cell differentiation"", ""term"": {""id"": ""GO:0030099"", ""label"": ""myeloid cell differentiation""}}"			DECREASED																								
1717	1754	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	1	Differentiation Block at Myeloid Stage	CBF fusion proteins recruit corepressor complexes including HDACs and NCoR, converting CBF from a transcriptional activator to a repressor. This silences differentiation genes while partially preserving some myeloid identity, resulting in blasts with partial maturation features.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
1718	1754	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	1	Differentiation Block at Myeloid Stage	CBF fusion proteins recruit corepressor complexes including HDACs and NCoR, converting CBF from a transcriptional activator to a repressor. This silences differentiation genes while partially preserving some myeloid identity, resulting in blasts with partial maturation features.	biological_processes[0]	biological_processes	biological_processes			granulocyte differentiation	GO:0030851	granulocyte differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""granulocyte differentiation"", ""term"": {""id"": ""GO:0030851"", ""label"": ""granulocyte differentiation""}}"			DECREASED																								
1719	1755	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	2	Self-Renewal Maintenance	CBF fusion proteins maintain expression of self-renewal genes while blocking differentiation. Additional mutations, particularly in receptor tyrosine kinases (KIT, FLT3), provide proliferative signals that cooperate with CBF fusions to cause overt leukemia.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1720	1756	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	3	Leukemic Blast Accumulation	The combination of differentiation block, maintained self-renewal, and cooperating mutations leads to accumulation of immature myeloid blasts in the bone marrow, causing bone marrow failure and circulating leukemia.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
1721	1756	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	pathophysiology	3	Leukemic Blast Accumulation	The combination of differentiation block, maintained self-renewal, and cooperating mutations leads to accumulation of immature myeloid blasts in the bone marrow, causing bone marrow failure and circulating leukemia.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
1722	1757	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	0	Anemia	Normocytic anemia from bone marrow replacement and ineffective erythropoiesis.	phenotype_term	phenotype_term	$	Anemia	Normocytic anemia from bone marrow replacement and ineffective erythropoiesis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1723	1758	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	1	Thrombocytopenia	Low platelet count due to marrow failure, causing bleeding risk.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count due to marrow failure, causing bleeding risk.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
1724	1759	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	2	Leukocytosis	Elevated white blood cell count with circulating blasts. Some patients may present with normal or low counts.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count with circulating blasts. Some patients may present with normal or low counts.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
1725	1760	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	3	Fatigue	Fatigue related to anemia and systemic effects of leukemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue related to anemia and systemic effects of leukemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1726	1761	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	4	Recurrent Infections	Increased susceptibility to infections due to neutropenia and dysfunctional granulocytes.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased susceptibility to infections due to neutropenia and dysfunctional granulocytes.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
1727	1762	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	phenotypes	5	Hepatomegaly	Liver enlargement from leukemic infiltration, more common in inv(16) subtype.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from leukemic infiltration, more common in inv(16) subtype.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
1728	1763	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	0	Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation	Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation	Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1729	1764	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	1	Gemtuzumab Ozogamicin	CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation.	treatment_term	treatment_term	$	Gemtuzumab Ozogamicin	CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1730	1765	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	2	MRD-Guided Therapy	Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse.	treatment_term	treatment_term	$	MRD-Guided Therapy	Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse.	genetic testing	MAXO:0000127	genetic testing		"{""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}"																											
1731	1766	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
1732	1779	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	0	Atherosclerotic Plaque Formation	"Lipid accumulation in arterial walls triggers inflammatory response, leading to foam cell formation and fibrous cap development. Progressive plaque growth narrows the coronary arteries.
"	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1733	1779	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	0	Atherosclerotic Plaque Formation	"Lipid accumulation in arterial walls triggers inflammatory response, leading to foam cell formation and fibrous cap development. Progressive plaque growth narrows the coronary arteries.
"	cell_types[1]	cell_types	cell_types			Foam Cell	CL:0000891	foam cell		"{""preferred_term"": ""Foam Cell"", ""term"": {""id"": ""CL:0000891"", ""label"": ""foam cell""}}"																											
1734	1779	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	0	Atherosclerotic Plaque Formation	"Lipid accumulation in arterial walls triggers inflammatory response, leading to foam cell formation and fibrous cap development. Progressive plaque growth narrows the coronary arteries.
"	cell_types[2]	cell_types	cell_types			Vascular Smooth Muscle Cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""Vascular Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
1735	1779	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	0	Atherosclerotic Plaque Formation	"Lipid accumulation in arterial walls triggers inflammatory response, leading to foam cell formation and fibrous cap development. Progressive plaque growth narrows the coronary arteries.
"	biological_processes[0]	biological_processes	biological_processes			Lipid Accumulation	GO:0034383	low-density lipoprotein particle clearance		"{""preferred_term"": ""Lipid Accumulation"", ""term"": {""id"": ""GO:0034383"", ""label"": ""low-density lipoprotein particle clearance""}}"																											
1736	1780	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	1	Endothelial Dysfunction	"Damage to the endothelial lining promotes lipid deposition, platelet adhesion, and inflammatory cell recruitment. Reduced nitric oxide production impairs vasodilation.
"	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
1737	1780	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	1	Endothelial Dysfunction	"Damage to the endothelial lining promotes lipid deposition, platelet adhesion, and inflammatory cell recruitment. Reduced nitric oxide production impairs vasodilation.
"	biological_processes[0]	biological_processes	biological_processes			Nitric Oxide Production	GO:0006809	nitric oxide biosynthetic process		"{""preferred_term"": ""Nitric Oxide Production"", ""term"": {""id"": ""GO:0006809"", ""label"": ""nitric oxide biosynthetic process""}}"																											
1738	1781	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	2	Plaque Rupture and Thrombosis	"Unstable plaques with thin fibrous caps are prone to rupture, exposing thrombogenic material and triggering acute coronary events (myocardial infarction).
"	cell_types[0]	cell_types	cell_types			Platelet	CL:0000233	platelet		"{""preferred_term"": ""Platelet"", ""term"": {""id"": ""CL:0000233"", ""label"": ""platelet""}}"																											
1739	1781	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	pathophysiology	2	Plaque Rupture and Thrombosis	"Unstable plaques with thin fibrous caps are prone to rupture, exposing thrombogenic material and triggering acute coronary events (myocardial infarction).
"	biological_processes[0]	biological_processes	biological_processes			Thrombosis	GO:0007596	blood coagulation		"{""preferred_term"": ""Thrombosis"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
1740	1782	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	phenotypes	0	Angina Pectoris		phenotype_term	phenotype_term	$	Angina Pectoris		Angina Pectoris	HP:0001681	Angina pectoris		"{""preferred_term"": ""Angina Pectoris"", ""term"": {""id"": ""HP:0001681"", ""label"": ""Angina pectoris""}}"																											
1741	1783	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	phenotypes	1	Dyspnea on Exertion		phenotype_term	phenotype_term	$	Dyspnea on Exertion		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
1742	1784	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	phenotypes	2	Myocardial Infarction		phenotype_term	phenotype_term	$	Myocardial Infarction		Myocardial Infarction	HP:0001658	Myocardial infarction		"{""preferred_term"": ""Myocardial Infarction"", ""term"": {""id"": ""HP:0001658"", ""label"": ""Myocardial infarction""}}"																											
1743	1793	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	0	Constitutive RAS-MAPK Activation	"HRAS mutations (most commonly G12S, G12A, G13C) cause constitutive activation of the RAS protein, leading to enhanced and prolonged signaling through the MAPK/ERK pathway. This affects cell proliferation, differentiation, and survival in multiple tissues.
"	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1744	1793	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	0	Constitutive RAS-MAPK Activation	"HRAS mutations (most commonly G12S, G12A, G13C) cause constitutive activation of the RAS protein, leading to enhanced and prolonged signaling through the MAPK/ERK pathway. This affects cell proliferation, differentiation, and survival in multiple tissues.
"	cell_types[1]	cell_types	cell_types			Atrial Cardiomyocyte	CL:0002129	regular atrial cardiac myocyte		"{""preferred_term"": ""Atrial Cardiomyocyte"", ""term"": {""id"": ""CL:0002129"", ""label"": ""regular atrial cardiac myocyte""}}"																											
1745	1793	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	0	Constitutive RAS-MAPK Activation	"HRAS mutations (most commonly G12S, G12A, G13C) cause constitutive activation of the RAS protein, leading to enhanced and prolonged signaling through the MAPK/ERK pathway. This affects cell proliferation, differentiation, and survival in multiple tissues.
"	biological_processes[0]	biological_processes	biological_processes			RAS Signaling	GO:0007265	Ras protein signal transduction		"{""preferred_term"": ""RAS Signaling"", ""term"": {""id"": ""GO:0007265"", ""label"": ""Ras protein signal transduction""}}"																											
1746	1793	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	0	Constitutive RAS-MAPK Activation	"HRAS mutations (most commonly G12S, G12A, G13C) cause constitutive activation of the RAS protein, leading to enhanced and prolonged signaling through the MAPK/ERK pathway. This affects cell proliferation, differentiation, and survival in multiple tissues.
"	biological_processes[1]	biological_processes	biological_processes			MAPK Cascade	GO:0000165	MAPK cascade		"{""preferred_term"": ""MAPK Cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
1747	1793	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	0	Constitutive RAS-MAPK Activation	"HRAS mutations (most commonly G12S, G12A, G13C) cause constitutive activation of the RAS protein, leading to enhanced and prolonged signaling through the MAPK/ERK pathway. This affects cell proliferation, differentiation, and survival in multiple tissues.
"	biological_processes[2]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell population proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"																											
1748	1794	76	Costello Syndrome	Costello_Syndrome.yaml	pathophysiology	1	Tumor Predisposition	"The same activating HRAS mutations that cause Costello syndrome are found as somatic mutations in various cancers. Germline activation creates a predisposition to embryonal tumors, particularly rhabdomyosarcoma.
"	biological_processes[0]	biological_processes	biological_processes			Cell Cycle Regulation	GO:0051726	regulation of cell cycle		"{""preferred_term"": ""Cell Cycle Regulation"", ""term"": {""id"": ""GO:0051726"", ""label"": ""regulation of cell cycle""}}"																											
1749	1795	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	0	Failure to Thrive	"Severe feeding difficulties and failure to thrive in infancy, often requiring tube feeding.
"	phenotype_term	phenotype_term	$	Failure to Thrive	"Severe feeding difficulties and failure to thrive in infancy, often requiring tube feeding.
"	Failure to thrive	HP:0001508	Failure to thrive		"{""preferred_term"": ""Failure to thrive"", ""term"": {""id"": ""HP:0001508"", ""label"": ""Failure to thrive""}}"																											
1750	1796	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	1	Coarse Facial Features	"Distinctive craniofacial appearance with coarse features, full lips, large mouth, and depressed nasal bridge.
"	phenotype_term	phenotype_term	$	Coarse Facial Features	"Distinctive craniofacial appearance with coarse features, full lips, large mouth, and depressed nasal bridge.
"	Coarse facial features	HP:0000280	Coarse facial features		"{""preferred_term"": ""Coarse facial features"", ""term"": {""id"": ""HP:0000280"", ""label"": ""Coarse facial features""}}"																											
1751	1797	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	2	Hypertrophic Cardiomyopathy	"Cardiac involvement is common, including hypertrophic cardiomyopathy affecting approximately 60-65% of patients.
"	phenotype_term	phenotype_term	$	Hypertrophic Cardiomyopathy	"Cardiac involvement is common, including hypertrophic cardiomyopathy affecting approximately 60-65% of patients.
"	Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
1752	1798	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	3	Multifocal Atrial Tachycardia	"During early childhood, approximately 50% of patients develop multifocal atrial tachycardia (MAT), a treatment-resistant tachyarrhythmia caused by HRAS-driven pacemaker-nodal transcriptional reprogramming in atrial cardiomyocytes.
"	phenotype_term	phenotype_term	$	Multifocal Atrial Tachycardia	"During early childhood, approximately 50% of patients develop multifocal atrial tachycardia (MAT), a treatment-resistant tachyarrhythmia caused by HRAS-driven pacemaker-nodal transcriptional reprogramming in atrial cardiomyocytes.
"	Atrial tachycardia	HP:0005115	Supraventricular arrhythmia		"{""preferred_term"": ""Atrial tachycardia"", ""term"": {""id"": ""HP:0005115"", ""label"": ""Supraventricular arrhythmia""}}"																											
1753	1799	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	4	Short Stature	"Postnatal growth deficiency leading to short stature.
"	phenotype_term	phenotype_term	$	Short Stature	"Postnatal growth deficiency leading to short stature.
"	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
1754	1800	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	5	Intellectual Disability	"Variable intellectual disability, typically mild to moderate.
"	phenotype_term	phenotype_term	$	Intellectual Disability	"Variable intellectual disability, typically mild to moderate.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1755	1801	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	6	Joint Hypermobility	"Joint laxity affecting multiple joints.
"	phenotype_term	phenotype_term	$	Joint Hypermobility	"Joint laxity affecting multiple joints.
"	Joint hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
1756	1802	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	7	Ulnar Deviation of Hands	"Characteristic ulnar deviation of the hands.
"	phenotype_term	phenotype_term	$	Ulnar Deviation of Hands	"Characteristic ulnar deviation of the hands.
"	Ulnar deviation of the hand	HP:0001193	Ulnar deviation of the hand or of fingers of the hand		"{""preferred_term"": ""Ulnar deviation of the hand"", ""term"": {""id"": ""HP:0001193"", ""label"": ""Ulnar deviation of the hand or of fingers of the hand""}}"																											
1757	1803	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	8	Papillomata	"Development of papillomata, particularly around the nose and mouth.
"	phenotype_term	phenotype_term	$	Papillomata	"Development of papillomata, particularly around the nose and mouth.
"	Papilloma	HP:0012740	Papilloma		"{""preferred_term"": ""Papilloma"", ""term"": {""id"": ""HP:0012740"", ""label"": ""Papilloma""}}"																											
1758	1804	76	Costello Syndrome	Costello_Syndrome.yaml	phenotypes	9	Predisposition to Malignancy	"Increased risk of malignancies including rhabdomyosarcoma, neuroblastoma, and bladder carcinoma. Lifetime cancer risk estimated at 15-17%.
"	phenotype_term	phenotype_term	$	Predisposition to Malignancy	"Increased risk of malignancies including rhabdomyosarcoma, neuroblastoma, and bladder carcinoma. Lifetime cancer risk estimated at 15-17%.
"	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
1759	1805	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	0	Cardiac Monitoring	"Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.
"	treatment_term	treatment_term	$	Cardiac Monitoring	"Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.
"	Cardiac monitoring	MAXO:0000003	diagnostic procedure		"{""preferred_term"": ""Cardiac monitoring"", ""term"": {""id"": ""MAXO:0000003"", ""label"": ""diagnostic procedure""}}"																											
1760	1806	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	1	Tumor Surveillance	"Regular screening for embryonal tumors, particularly in childhood.
"	treatment_term	treatment_term	$	Tumor Surveillance	"Regular screening for embryonal tumors, particularly in childhood.
"	Cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""Cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
1761	1807	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.
"	treatment_term	treatment_term	$	MEK Inhibitor Therapy	"MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1762	1813	77	Crohn Disease	Crohn_Disease.yaml	environmental	0	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
1763	1814	77	Crohn Disease	Crohn_Disease.yaml	environmental	1	Diet		exposure_term	exposure_term	$	Diet		Dietary exposure				"{""preferred_term"": ""Dietary exposure""}"																											
1764	1815	77	Crohn Disease	Crohn_Disease.yaml	environmental	2	Stress		exposure_term	exposure_term	$	Stress		Psychological stress exposure				"{""preferred_term"": ""Psychological stress exposure""}"																											
1765	1827	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	2	Paneth Cell Autophagy Impairment	Defective autophagy in Paneth cells due to mutations in autophagy genes (ATG16L1, ATG5) causes abnormal granule formation and impaired antimicrobial peptide secretion.	cell_types[0]	cell_types	cell_types			Paneth cell	CL:0000510	paneth cell		"{""preferred_term"": ""Paneth cell"", ""term"": {""id"": ""CL:0000510"", ""label"": ""paneth cell""}}"																											
1766	1827	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	2	Paneth Cell Autophagy Impairment	Defective autophagy in Paneth cells due to mutations in autophagy genes (ATG16L1, ATG5) causes abnormal granule formation and impaired antimicrobial peptide secretion.	biological_processes[0]	biological_processes	biological_processes			Autophagy	GO:0006914	autophagy		"{""preferred_term"": ""Autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
1767	1827	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	2	Paneth Cell Autophagy Impairment	Defective autophagy in Paneth cells due to mutations in autophagy genes (ATG16L1, ATG5) causes abnormal granule formation and impaired antimicrobial peptide secretion.	locations[0]	locations	locations			Terminal ileum	UBERON:0001211	ileum		"{""preferred_term"": ""Terminal ileum"", ""term"": {""id"": ""UBERON:0001211"", ""label"": ""ileum""}}"																											
1768	1828	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	3	Antimicrobial Defense Deficiency	Reduced secretion of antimicrobial peptides (defensins, lysozyme) allows increased bacterial translocation across the intestinal epithelium.	biological_processes[0]	biological_processes	biological_processes			Antimicrobial humoral response	GO:0019730	antimicrobial humoral response		"{""preferred_term"": ""Antimicrobial humoral response"", ""term"": {""id"": ""GO:0019730"", ""label"": ""antimicrobial humoral response""}}"																											
1769	1828	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	3	Antimicrobial Defense Deficiency	Reduced secretion of antimicrobial peptides (defensins, lysozyme) allows increased bacterial translocation across the intestinal epithelium.	locations[0]	locations	locations			Terminal ileum	UBERON:0001211	ileum		"{""preferred_term"": ""Terminal ileum"", ""term"": {""id"": ""UBERON:0001211"", ""label"": ""ileum""}}"																											
1770	1829	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	4	Macrophage Autophagy Dysfunction	Impaired autophagy in lamina propria macrophages leads to defective clearance of intracellular bacteria and inflammatory cytokine release.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1771	1829	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	4	Macrophage Autophagy Dysfunction	Impaired autophagy in lamina propria macrophages leads to defective clearance of intracellular bacteria and inflammatory cytokine release.	biological_processes[0]	biological_processes	biological_processes			Autophagy	GO:0006914	autophagy		"{""preferred_term"": ""Autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
1772	1829	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	4	Macrophage Autophagy Dysfunction	Impaired autophagy in lamina propria macrophages leads to defective clearance of intracellular bacteria and inflammatory cytokine release.	locations[0]	locations	locations			Intestinal lamina propria	UBERON:0011878	lamina propria of small intestine		"{""preferred_term"": ""Intestinal lamina propria"", ""term"": {""id"": ""UBERON:0011878"", ""label"": ""lamina propria of small intestine""}}"																											
1773	1830	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	5	IL-23/Th17 Axis Dysregulation	Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.	cell_types[0]	cell_types	cell_types			Th17 cell	CL:0000899	T-helper 17 cell		"{""preferred_term"": ""Th17 cell"", ""term"": {""id"": ""CL:0000899"", ""label"": ""T-helper 17 cell""}}"																											
1774	1830	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	5	IL-23/Th17 Axis Dysregulation	Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.	cell_types[1]	cell_types	cell_types			Dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""Dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
1775	1830	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	5	IL-23/Th17 Axis Dysregulation	Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.	biological_processes[0]	biological_processes	biological_processes			Th17 cell differentiation	GO:0072538	T-helper 17 type immune response		"{""preferred_term"": ""Th17 cell differentiation"", ""term"": {""id"": ""GO:0072538"", ""label"": ""T-helper 17 type immune response""}}"																											
1776	1830	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	5	IL-23/Th17 Axis Dysregulation	Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.	biological_processes[1]	biological_processes	biological_processes			IL-23 signaling				"{""preferred_term"": ""IL-23 signaling""}"																											
1777	1830	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	5	IL-23/Th17 Axis Dysregulation	Overactive IL-23 signaling drives pathogenic Th17 cell differentiation and chronic intestinal inflammation.	locations[0]	locations	locations			Intestinal mucosa	UBERON:0001211	ileum		"{""preferred_term"": ""Intestinal mucosa"", ""term"": {""id"": ""UBERON:0001211"", ""label"": ""ileum""}}"																											
1778	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1779	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	cell_types[1]	cell_types	cell_types			Myofibroblast	CL:0000186	myofibroblast cell		"{""preferred_term"": ""Myofibroblast"", ""term"": {""id"": ""CL:0000186"", ""label"": ""myofibroblast cell""}}"																											
1780	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	biological_processes[0]	biological_processes	biological_processes			Extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""Extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
1781	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	biological_processes[1]	biological_processes	biological_processes			Tissue remodeling	GO:0048771	tissue remodeling		"{""preferred_term"": ""Tissue remodeling"", ""term"": {""id"": ""GO:0048771"", ""label"": ""tissue remodeling""}}"																											
1782	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	locations[0]	locations	locations			Intestinal wall	UBERON:0001262	wall of intestine		"{""preferred_term"": ""Intestinal wall"", ""term"": {""id"": ""UBERON:0001262"", ""label"": ""wall of intestine""}}"																											
1783	1831	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	6	Fibrosis and Stricture Formation	Chronic inflammation leads to fibroblast activation, extracellular matrix deposition, and intestinal strictures.	locations[1]	locations	locations			Mesenteric adipose tissue	UBERON:0003427	mesenteric fat pad		"{""preferred_term"": ""Mesenteric adipose tissue"", ""term"": {""id"": ""UBERON:0003427"", ""label"": ""mesenteric fat pad""}}"																											
1784	1832	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	7	TL1A-Mediated T Cell Activation	Tumor necrosis factor-like ligand 1A (TL1A) activates T cells through death receptor 3 (DR3), promoting inflammatory cytokine production and recruitment of myeloid cells to sites of tissue damage.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
1785	1832	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	7	TL1A-Mediated T Cell Activation	Tumor necrosis factor-like ligand 1A (TL1A) activates T cells through death receptor 3 (DR3), promoting inflammatory cytokine production and recruitment of myeloid cells to sites of tissue damage.	biological_processes[0]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
1786	1832	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	7	TL1A-Mediated T Cell Activation	Tumor necrosis factor-like ligand 1A (TL1A) activates T cells through death receptor 3 (DR3), promoting inflammatory cytokine production and recruitment of myeloid cells to sites of tissue damage.	locations[0]	locations	locations			Rectal mucosa	UBERON:0003346	rectal mucosa		"{""preferred_term"": ""Rectal mucosa"", ""term"": {""id"": ""UBERON:0003346"", ""label"": ""rectal mucosa""}}"																											
1787	1833	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	8	Myeloid Cell Recruitment to Perianal Tissue	Chemokine-driven infiltration of macrophages and other myeloid cells into perianal tissues, establishing chronic inflammation.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1788	1833	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	8	Myeloid Cell Recruitment to Perianal Tissue	Chemokine-driven infiltration of macrophages and other myeloid cells into perianal tissues, establishing chronic inflammation.	biological_processes[0]	biological_processes	biological_processes			Leukocyte migration	GO:0050900	leukocyte migration		"{""preferred_term"": ""Leukocyte migration"", ""term"": {""id"": ""GO:0050900"", ""label"": ""leukocyte migration""}}"																											
1789	1833	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	8	Myeloid Cell Recruitment to Perianal Tissue	Chemokine-driven infiltration of macrophages and other myeloid cells into perianal tissues, establishing chronic inflammation.	locations[0]	locations	locations			Perianal region	UBERON:0012336	perianal space		"{""preferred_term"": ""Perianal region"", ""term"": {""id"": ""UBERON:0012336"", ""label"": ""perianal space""}}"																											
1790	1834	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	9	Myeloid-Stromal Cell Crosstalk	Interferon-driven macrophage activation promotes fibroblast activation and matrix degradation, creating tissue disruption that leads to fistula tract formation.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
1791	1834	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	9	Myeloid-Stromal Cell Crosstalk	Interferon-driven macrophage activation promotes fibroblast activation and matrix degradation, creating tissue disruption that leads to fistula tract formation.	cell_types[1]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
1792	1834	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	9	Myeloid-Stromal Cell Crosstalk	Interferon-driven macrophage activation promotes fibroblast activation and matrix degradation, creating tissue disruption that leads to fistula tract formation.	biological_processes[0]	biological_processes	biological_processes			Type II interferon signaling	GO:0060337	type I interferon signaling pathway		"{""preferred_term"": ""Type II interferon signaling"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon signaling pathway""}}"																											
1793	1834	77	Crohn Disease	Crohn_Disease.yaml	pathophysiology	9	Myeloid-Stromal Cell Crosstalk	Interferon-driven macrophage activation promotes fibroblast activation and matrix degradation, creating tissue disruption that leads to fistula tract formation.	locations[0]	locations	locations			Perianal region	UBERON:0012336	perianal space		"{""preferred_term"": ""Perianal region"", ""term"": {""id"": ""UBERON:0012336"", ""label"": ""perianal space""}}"																											
1794	1835	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	0	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
1795	1836	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	1	Diarrhea		phenotype_term	phenotype_term	$	Diarrhea		Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
1796	1837	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1797	1839	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	4	Intestinal Obstruction		phenotype_term	phenotype_term	$	Intestinal Obstruction		Intestinal Obstruction	HP:0004796	Gastrointestinal obstruction		"{""preferred_term"": ""Intestinal Obstruction"", ""term"": {""id"": ""HP:0004796"", ""label"": ""Gastrointestinal obstruction""}}"																											
1798	1840	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	5	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
1799	1841	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	6	Erythema Nodosum		phenotype_term	phenotype_term	$	Erythema Nodosum		Erythema Nodosum	HP:0012219	Erythema nodosum		"{""preferred_term"": ""Erythema Nodosum"", ""term"": {""id"": ""HP:0012219"", ""label"": ""Erythema nodosum""}}"																											
1800	1842	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	7	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
1801	1843	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	8	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1802	1844	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	9	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1803	1845	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	10	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight Loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight Loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1804	1846	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	11	Malnutrition		phenotype_term	phenotype_term	$	Malnutrition		Malnutrition	HP:0004395	Malnutrition		"{""preferred_term"": ""Malnutrition"", ""term"": {""id"": ""HP:0004395"", ""label"": ""Malnutrition""}}"																											
1805	1847	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	12	Dehydration		phenotype_term	phenotype_term	$	Dehydration		Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
1806	1849	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	14	Perianal Fistula		phenotype_term	phenotype_term	$	Perianal Fistula		Perianal abscess	HP:0009789	Perianal abscess		"{""preferred_term"": ""Perianal abscess"", ""term"": {""id"": ""HP:0009789"", ""label"": ""Perianal abscess""}}"																											
1807	1850	77	Crohn Disease	Crohn_Disease.yaml	phenotypes	15	Transmural Inflammation		phenotype_term	phenotype_term	$	Transmural Inflammation		Intestinal inflammation				"{""preferred_term"": ""Intestinal inflammation""}"																											
1808	1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	Aminosalicylates	Anti-inflammatory drugs used for mild to moderate disease.	treatment_term	treatment_term	$	Aminosalicylates	Anti-inflammatory drugs used for mild to moderate disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1809	1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	Corticosteroids	Used for short-term control during flare-ups to reduce inflammation.	treatment_term	treatment_term	$	Corticosteroids	Used for short-term control during flare-ups to reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1810	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	Immunomodulators	Drugs like azathioprine and methotrexate to suppress the immune response.	treatment_term	treatment_term	$	Immunomodulators	Drugs like azathioprine and methotrexate to suppress the immune response.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1811	1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	Biologics	Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.	treatment_term	treatment_term	$	Biologics	Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1812	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	Nutritional Therapy	Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.	treatment_term	treatment_term	$	Nutritional Therapy	Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1813	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	Surgery	Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.	treatment_term	treatment_term	$	Surgery	Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1814	1859	77	Crohn Disease	Crohn_Disease.yaml	treatments	6	Anti-IL-23 Biologics	Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.	treatment_term	treatment_term	$	Anti-IL-23 Biologics	Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1815	1860	77	Crohn Disease	Crohn_Disease.yaml	treatments	7	TL1A Inhibitors	Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.	treatment_term	treatment_term	$	TL1A Inhibitors	Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1816	1861	77	Crohn Disease	Crohn_Disease.yaml	treatments	8	JAK Inhibitors	Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.	treatment_term	treatment_term	$	JAK Inhibitors	Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1817	1865	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	differential_diagnoses	0	Ulcerative Colitis	"Early-stage CCS can present with abdominal pain, diarrhea, bloody stool, and colonoscopy findings of colitis-like appearance, making it clinically indistinguishable from ulcerative colitis. Both conditions present with chronic diarrhea, gastrointestinal inflammation, and mucosal changes. However, CCS typically involves the entire GI tract including the small intestine and is accompanied by distinctive cutaneous manifestations (alopecia, nail dystrophy, hyperpigmentation) that develop later in the disease course.
"	disease_term	disease_term	$	Ulcerative Colitis	"Early-stage CCS can present with abdominal pain, diarrhea, bloody stool, and colonoscopy findings of colitis-like appearance, making it clinically indistinguishable from ulcerative colitis. Both conditions present with chronic diarrhea, gastrointestinal inflammation, and mucosal changes. However, CCS typically involves the entire GI tract including the small intestine and is accompanied by distinctive cutaneous manifestations (alopecia, nail dystrophy, hyperpigmentation) that develop later in the disease course.
"	ulcerative colitis	MONDO:0005101	ulcerative colitis		"{""preferred_term"": ""ulcerative colitis"", ""term"": {""id"": ""MONDO:0005101"", ""label"": ""ulcerative colitis""}}"																											
1818	1866	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	differential_diagnoses	1	Peutz-Jeghers Syndrome	"Both PJS and CCS present with gastrointestinal polyposis and can have cutaneous manifestations. PJS is characterized by hamartomatous polyps throughout the GI tract and characteristic mucocutaneous pigmentation. However, the clinical presentation, genetic basis, and associated systemic features differ significantly. PJS polyps are typically larger and less diffuse than in CCS, and PJS carries increased cancer risk through a different mechanism (STK11 mutations).
"	disease_term	disease_term	$	Peutz-Jeghers Syndrome	"Both PJS and CCS present with gastrointestinal polyposis and can have cutaneous manifestations. PJS is characterized by hamartomatous polyps throughout the GI tract and characteristic mucocutaneous pigmentation. However, the clinical presentation, genetic basis, and associated systemic features differ significantly. PJS polyps are typically larger and less diffuse than in CCS, and PJS carries increased cancer risk through a different mechanism (STK11 mutations).
"	Peutz-Jeghers syndrome	MONDO:0008280	Peutz-Jeghers syndrome		"{""preferred_term"": ""Peutz-Jeghers syndrome"", ""term"": {""id"": ""MONDO:0008280"", ""label"": ""Peutz-Jeghers syndrome""}}"																											
1819	1867	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	differential_diagnoses	2	Eosinophilic Gastroenteritis	"EGE presents with similar symptoms to CCS including chronic diarrhea, abdominal pain, and GI inflammation with mucosal edema. Early in the disease course, before polyp formation is evident, patients with CCS may present with diffuse gastroduodenal mucosal edema and eosinophilic infiltration that resembles EGE. Both conditions can present with protein-losing enteropathy and nutritional deficiencies. Careful endoscopy and follow-up imaging are required to differentiate the two conditions.
"	disease_term	disease_term	$	Eosinophilic Gastroenteritis	"EGE presents with similar symptoms to CCS including chronic diarrhea, abdominal pain, and GI inflammation with mucosal edema. Early in the disease course, before polyp formation is evident, patients with CCS may present with diffuse gastroduodenal mucosal edema and eosinophilic infiltration that resembles EGE. Both conditions can present with protein-losing enteropathy and nutritional deficiencies. Careful endoscopy and follow-up imaging are required to differentiate the two conditions.
"	eosinophilic gastroenteritis	MONDO:0016129	eosinophilic gastroenteritis		"{""preferred_term"": ""eosinophilic gastroenteritis"", ""term"": {""id"": ""MONDO:0016129"", ""label"": ""eosinophilic gastroenteritis""}}"																											
1820	1868	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	differential_diagnoses	3	Familial Adenomatous Polyposis	"FAP presents with hundreds to thousands of adenomatous polyps throughout the colon and rectum, similar to the polyposis seen in CCS. Both conditions carry significant cancer risk and require surveillance and intervention. However, FAP is autosomal dominant (APC mutations) whereas CCS is sporadic and nonhereditary. The polyp types, anatomical distribution, and systemic manifestations are distinctly different.
"	disease_term	disease_term	$	Familial Adenomatous Polyposis	"FAP presents with hundreds to thousands of adenomatous polyps throughout the colon and rectum, similar to the polyposis seen in CCS. Both conditions carry significant cancer risk and require surveillance and intervention. However, FAP is autosomal dominant (APC mutations) whereas CCS is sporadic and nonhereditary. The polyp types, anatomical distribution, and systemic manifestations are distinctly different.
"	classic familial adenomatous polyposis	MONDO:0021055	classic familial adenomatous polyposis		"{""preferred_term"": ""classic familial adenomatous polyposis"", ""term"": {""id"": ""MONDO:0021055"", ""label"": ""classic familial adenomatous polyposis""}}"																											
1821	1869	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	0	Hamartomatous polyp formation in the gastrointestinal tract	"Cronkhite-Canada syndrome is characterized by widespread hamartomatous polyps involving the entire gastrointestinal tract, most commonly the stomach, small intestine, and colon. The polyps are composed of abundant lamina propria inflammatory infiltrate with cystic glands. Pathological examination shows gland/crypt changes including cystic dilatation filled with protein fluid or mucus, gland withering and branching, and lamina propria edema.
"	biological_processes[0]	biological_processes	biological_processes			Epithelial cell proliferation	GO:0050673	epithelial cell proliferation		"{""preferred_term"": ""Epithelial cell proliferation"", ""term"": {""id"": ""GO:0050673"", ""label"": ""epithelial cell proliferation""}}"																											
1822	1869	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	0	Hamartomatous polyp formation in the gastrointestinal tract	"Cronkhite-Canada syndrome is characterized by widespread hamartomatous polyps involving the entire gastrointestinal tract, most commonly the stomach, small intestine, and colon. The polyps are composed of abundant lamina propria inflammatory infiltrate with cystic glands. Pathological examination shows gland/crypt changes including cystic dilatation filled with protein fluid or mucus, gland withering and branching, and lamina propria edema.
"	biological_processes[1]	biological_processes	biological_processes			Epithelial cell morphogenesis	GO:0003382	epithelial cell morphogenesis		"{""preferred_term"": ""Epithelial cell morphogenesis"", ""term"": {""id"": ""GO:0003382"", ""label"": ""epithelial cell morphogenesis""}}"																											
1823	1870	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	1	Autoimmune and IgG4-mediated inflammation	"Evidence supports an autoimmune/inflammatory pathophysiology with IgG4-positive plasma cell infiltration in polyps, frequent autoantibodies including antinuclear antibody positivity, and association with other autoimmune diseases. CCS often responds to immunosuppressive therapy, further supporting immune-mediated pathogenesis.
"	biological_processes[0]	biological_processes	biological_processes			Plasma cell differentiation	GO:0002317	plasma cell differentiation		"{""preferred_term"": ""Plasma cell differentiation"", ""term"": {""id"": ""GO:0002317"", ""label"": ""plasma cell differentiation""}}"																											
1824	1870	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	1	Autoimmune and IgG4-mediated inflammation	"Evidence supports an autoimmune/inflammatory pathophysiology with IgG4-positive plasma cell infiltration in polyps, frequent autoantibodies including antinuclear antibody positivity, and association with other autoimmune diseases. CCS often responds to immunosuppressive therapy, further supporting immune-mediated pathogenesis.
"	biological_processes[1]	biological_processes	biological_processes			Cytokine production	GO:0001816	cytokine production		"{""preferred_term"": ""Cytokine production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"																											
1825	1871	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	2	Epithelial barrier dysfunction and protein-losing enteropathy	"Mucosal inflammation and structural changes result in epithelial barrier dysfunction with protein loss into the gastrointestinal lumen. This leads to hypoalbuminemia, edema, malabsorption, and nutritional deficiencies that contribute to systemic manifestations including cutaneous findings.
"	biological_processes[0]	biological_processes	biological_processes			Tight junction	GO:0070160	tight junction		"{""preferred_term"": ""Tight junction"", ""term"": {""id"": ""GO:0070160"", ""label"": ""tight junction""}}"																											
1826	1872	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	pathophysiology	3	Helicobacter pylori infection and dysbiosis	"Helicobacter pylori infection has been reported in approximately 50% of CCS cases, and symptom improvement following H. pylori eradication has been documented in some patients. Broader dysbiosis may contribute to mucosal inflammation and disease pathogenesis.
"	biological_processes[0]	biological_processes	biological_processes			Defense response to bacterium	GO:0042742	defense response to bacterium		"{""preferred_term"": ""Defense response to bacterium"", ""term"": {""id"": ""GO:0042742"", ""label"": ""defense response to bacterium""}}"																											
1827	1873	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	0	Gastrointestinal polyposis	"Extensive hamartomatous polyps throughout the gastrointestinal tract, particularly in the stomach, duodenum, jejunum, ileum, and colon. Polyps may cause obstruction, bleeding, or protein loss.
"	phenotype_term	phenotype_term	$	Gastrointestinal polyposis	"Extensive hamartomatous polyps throughout the gastrointestinal tract, particularly in the stomach, duodenum, jejunum, ileum, and colon. Polyps may cause obstruction, bleeding, or protein loss.
"	Hamartomatous polyposis	HP:0004390	Hamartomatous polyposis		"{""preferred_term"": ""Hamartomatous polyposis"", ""term"": {""id"": ""HP:0004390"", ""label"": ""Hamartomatous polyposis""}}"																											
1828	1874	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	1	Alopecia	"Hair loss affecting the scalp and sometimes eyebrows and body hair. Typically reversible with disease remission. Pathophysiology may involve lymphocytic infiltration around hair bulbs and follicle atrophy, though malnutrition also contributes.
"	phenotype_term	phenotype_term	$	Alopecia	"Hair loss affecting the scalp and sometimes eyebrows and body hair. Typically reversible with disease remission. Pathophysiology may involve lymphocytic infiltration around hair bulbs and follicle atrophy, though malnutrition also contributes.
"	Alopecia	HP:0001596	Alopecia		"{""preferred_term"": ""Alopecia"", ""term"": {""id"": ""HP:0001596"", ""label"": ""Alopecia""}}"																											
1829	1875	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	2	Nail changes	"Onychodystrophy characterized by nail ridging, discoloration, thickening, and separation. Often reversible with disease remission. Typical nail changes include thin, soft, triangular nail plates.
"	phenotype_term	phenotype_term	$	Nail changes	"Onychodystrophy characterized by nail ridging, discoloration, thickening, and separation. Often reversible with disease remission. Typical nail changes include thin, soft, triangular nail plates.
"	Onychodystrophy	HP:0008394	Congenital onychodystrophy		"{""preferred_term"": ""Onychodystrophy"", ""term"": {""id"": ""HP:0008394"", ""label"": ""Congenital onychodystrophy""}}"																											
1830	1876	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	3	Hyperpigmentation	"Increased skin pigmentation, typically affecting the palms, soles, and dorsal surfaces of hands and feet. Pigmentation appears as brown macules or red nonpruritic nodular papules and can also involve the oral mucosa.
"	phenotype_term	phenotype_term	$	Hyperpigmentation	"Increased skin pigmentation, typically affecting the palms, soles, and dorsal surfaces of hands and feet. Pigmentation appears as brown macules or red nonpruritic nodular papules and can also involve the oral mucosa.
"	Hyperpigmentation	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
1831	1877	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	4	Chronic diarrhea	"Persistent diarrhea caused by malabsorption from the polyp-affected intestinal tract. Often described as watery diarrhea occurring multiple times daily, sometimes with occult or overt GI bleeding.
"	phenotype_term	phenotype_term	$	Chronic diarrhea	"Persistent diarrhea caused by malabsorption from the polyp-affected intestinal tract. Often described as watery diarrhea occurring multiple times daily, sometimes with occult or overt GI bleeding.
"	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
1832	1878	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	phenotypes	5	Protein-losing enteropathy	"Loss of plasma proteins into the gastrointestinal lumen, resulting in hypoalbuminemia, edema, and immune dysfunction. Mucosal inflammation with epithelial damage and villous atrophy leads to significant protein loss and nutritional compromise.
"	phenotype_term	phenotype_term	$	Protein-losing enteropathy	"Loss of plasma proteins into the gastrointestinal lumen, resulting in hypoalbuminemia, edema, and immune dysfunction. Mucosal inflammation with epithelial damage and villous atrophy leads to significant protein loss and nutritional compromise.
"	Protein-losing enteropathy	HP:0002243	Protein-losing enteropathy		"{""preferred_term"": ""Protein-losing enteropathy"", ""term"": {""id"": ""HP:0002243"", ""label"": ""Protein-losing enteropathy""}}"																											
1833	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	Corticosteroids	"Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
"	treatment_term	treatment_term	$	Corticosteroids	"Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
"	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
1834	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	Immunosuppressive agents	"Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
"	treatment_term	treatment_term	$	Immunosuppressive agents	"Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1835	1881	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	2	Supportive care	"Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
"	treatment_term	treatment_term	$	Supportive care	"Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1836	1884	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2, predominantly in the third immunoglobulin-like domain (Ig-III) and linker regions, cause constitutive receptor activation or altered ligand binding. This leads to premature osteogenic differentiation in cranial suture mesenchyme and suture fusion.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
1837	1884	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2, predominantly in the third immunoglobulin-like domain (Ig-III) and linker regions, cause constitutive receptor activation or altered ligand binding. This leads to premature osteogenic differentiation in cranial suture mesenchyme and suture fusion.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
1838	1884	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2, predominantly in the third immunoglobulin-like domain (Ig-III) and linker regions, cause constitutive receptor activation or altered ligand binding. This leads to premature osteogenic differentiation in cranial suture mesenchyme and suture fusion.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
1839	1885	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	0	Multiple Suture Craniosynostosis	"Premature fusion of multiple sutures including coronal, sagittal, and lambdoid, causing variable skull shape abnormalities.
"	phenotype_term	phenotype_term	$	Multiple Suture Craniosynostosis	"Premature fusion of multiple sutures including coronal, sagittal, and lambdoid, causing variable skull shape abnormalities.
"	Multiple suture craniosynostosis	HP:0011324	Multiple suture craniosynostosis		"{""preferred_term"": ""Multiple suture craniosynostosis"", ""term"": {""id"": ""HP:0011324"", ""label"": ""Multiple suture craniosynostosis""}}"																											
1840	1886	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	1	Midface Retrusion	"Midface hypoplasia is a hallmark feature, causing the characteristic facial appearance with relative mandibular prognathism.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Midface hypoplasia is a hallmark feature, causing the characteristic facial appearance with relative mandibular prognathism.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
1841	1887	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	2	Proptosis	"Shallow orbits cause significant ocular proptosis, which may lead to exposure keratopathy and vision problems.
"	phenotype_term	phenotype_term	$	Proptosis	"Shallow orbits cause significant ocular proptosis, which may lead to exposure keratopathy and vision problems.
"	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
1842	1888	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	3	Hypertelorism	"Widely spaced eyes due to craniofacial dysmorphism.
"	phenotype_term	phenotype_term	$	Hypertelorism	"Widely spaced eyes due to craniofacial dysmorphism.
"	Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
1843	1889	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	4	External Ear Abnormality	"Low-set ears and external auditory canal atresia may occur.
"	phenotype_term	phenotype_term	$	External Ear Abnormality	"Low-set ears and external auditory canal atresia may occur.
"	Abnormal external ear morphology	HP:0000377	Abnormal pinna morphology		"{""preferred_term"": ""Abnormal external ear morphology"", ""term"": {""id"": ""HP:0000377"", ""label"": ""Abnormal pinna morphology""}}"																											
1844	1890	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	phenotypes	5	Hearing Loss	"Conductive hearing loss due to middle ear anomalies or external auditory canal stenosis.
"	phenotype_term	phenotype_term	$	Hearing Loss	"Conductive hearing loss due to middle ear anomalies or external auditory canal stenosis.
"	Conductive hearing impairment	HP:0000405	Conductive hearing impairment		"{""preferred_term"": ""Conductive hearing impairment"", ""term"": {""id"": ""HP:0000405"", ""label"": ""Conductive hearing impairment""}}"																											
1845	1891	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.
"	treatment_term	treatment_term	$	Cranial Vault Remodeling	"Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1846	1892	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.
"	treatment_term	treatment_term	$	Midface Advancement	"Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1847	1895	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	pathophysiology	0	FGFR3 A391E Gain-of-Function	"The A391E mutation in the transmembrane domain of FGFR3 causes ligand-independent receptor dimerization and constitutive activation. This affects both skeletal (craniosynostosis) and cutaneous (acanthosis nigricans) tissues through enhanced downstream signaling including MAPK and STAT pathways.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
1848	1895	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	pathophysiology	0	FGFR3 A391E Gain-of-Function	"The A391E mutation in the transmembrane domain of FGFR3 causes ligand-independent receptor dimerization and constitutive activation. This affects both skeletal (craniosynostosis) and cutaneous (acanthosis nigricans) tissues through enhanced downstream signaling including MAPK and STAT pathways.
"	cell_types[1]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
1849	1895	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	pathophysiology	0	FGFR3 A391E Gain-of-Function	"The A391E mutation in the transmembrane domain of FGFR3 causes ligand-independent receptor dimerization and constitutive activation. This affects both skeletal (craniosynostosis) and cutaneous (acanthosis nigricans) tissues through enhanced downstream signaling including MAPK and STAT pathways.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
1850	1895	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	pathophysiology	0	FGFR3 A391E Gain-of-Function	"The A391E mutation in the transmembrane domain of FGFR3 causes ligand-independent receptor dimerization and constitutive activation. This affects both skeletal (craniosynostosis) and cutaneous (acanthosis nigricans) tissues through enhanced downstream signaling including MAPK and STAT pathways.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
1851	1895	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	pathophysiology	0	FGFR3 A391E Gain-of-Function	"The A391E mutation in the transmembrane domain of FGFR3 causes ligand-independent receptor dimerization and constitutive activation. This affects both skeletal (craniosynostosis) and cutaneous (acanthosis nigricans) tissues through enhanced downstream signaling including MAPK and STAT pathways.
"	biological_processes[2]	biological_processes	biological_processes			Epidermal Cell Differentiation	GO:0009913	epidermal cell differentiation		"{""preferred_term"": ""Epidermal Cell Differentiation"", ""term"": {""id"": ""GO:0009913"", ""label"": ""epidermal cell differentiation""}}"																											
1852	1896	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	phenotypes	0	Craniosynostosis	"Premature fusion of cranial sutures, typically multiple sutures including coronal sutures, similar to classic Crouzon syndrome.
"	phenotype_term	phenotype_term	$	Craniosynostosis	"Premature fusion of cranial sutures, typically multiple sutures including coronal sutures, similar to classic Crouzon syndrome.
"	Craniosynostosis	HP:0001363	Craniosynostosis		"{""preferred_term"": ""Craniosynostosis"", ""term"": {""id"": ""HP:0001363"", ""label"": ""Craniosynostosis""}}"																											
1853	1897	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	phenotypes	1	Midface Retrusion	"Midface hypoplasia with the characteristic Crouzon facial appearance.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Midface hypoplasia with the characteristic Crouzon facial appearance.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
1854	1898	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	phenotypes	2	Proptosis	"Ocular proptosis due to shallow orbits.
"	phenotype_term	phenotype_term	$	Proptosis	"Ocular proptosis due to shallow orbits.
"	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
1855	1899	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	phenotypes	3	Acanthosis Nigricans	"Hyperpigmented, velvety thickening of the skin, typically in flexural areas (neck, axillae, groin). This distinguishes CAN from classic Crouzon syndrome and reflects the broader tissue effects of the specific FGFR3 mutation.
"	phenotype_term	phenotype_term	$	Acanthosis Nigricans	"Hyperpigmented, velvety thickening of the skin, typically in flexural areas (neck, axillae, groin). This distinguishes CAN from classic Crouzon syndrome and reflects the broader tissue effects of the specific FGFR3 mutation.
"	Acanthosis nigricans	HP:0000956	Acanthosis nigricans		"{""preferred_term"": ""Acanthosis nigricans"", ""term"": {""id"": ""HP:0000956"", ""label"": ""Acanthosis nigricans""}}"																											
1856	1900	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	phenotypes	4	Hypertelorism	"Widely spaced eyes as in classic Crouzon syndrome.
"	phenotype_term	phenotype_term	$	Hypertelorism	"Widely spaced eyes as in classic Crouzon syndrome.
"	Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
1857	1901	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	0	Cranial Vault Surgery	"Surgical management of craniosynostosis similar to classic Crouzon syndrome.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical management of craniosynostosis similar to classic Crouzon syndrome.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1858	1902	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	1	Midface Advancement	"Surgical advancement of the hypoplastic midface.
"	treatment_term	treatment_term	$	Midface Advancement	"Surgical advancement of the hypoplastic midface.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1859	1904	81	Cushing's Syndrome	Cushings_Syndrome.yaml	pathophysiology	0	Chronic Cortisol Excess	"Cushing's syndrome results from prolonged exposure to excess glucocorticoids, either exogenous (iatrogenic from corticosteroid therapy) or endogenous (from pituitary adenomas secreting ACTH, adrenal tumors, or ectopic ACTH production). Elevated cortisol causes widespread metabolic, immunologic, and cardiovascular effects.
"	biological_processes[0]	biological_processes	biological_processes			glucocorticoid secretion	GO:0035933	glucocorticoid secretion		"{""preferred_term"": ""glucocorticoid secretion"", ""term"": {""id"": ""GO:0035933"", ""label"": ""glucocorticoid secretion""}}"																											
1860	1904	81	Cushing's Syndrome	Cushings_Syndrome.yaml	pathophysiology	0	Chronic Cortisol Excess	"Cushing's syndrome results from prolonged exposure to excess glucocorticoids, either exogenous (iatrogenic from corticosteroid therapy) or endogenous (from pituitary adenomas secreting ACTH, adrenal tumors, or ectopic ACTH production). Elevated cortisol causes widespread metabolic, immunologic, and cardiovascular effects.
"	cell_types[0]	cell_types	cell_types			glucocorticoid secreting cell	CL:0000460	glucocorticoid secreting cell		"{""preferred_term"": ""glucocorticoid secreting cell"", ""term"": {""id"": ""CL:0000460"", ""label"": ""glucocorticoid secreting cell""}}"																											
1861	1905	81	Cushing's Syndrome	Cushings_Syndrome.yaml	pathophysiology	1	Hypothalamic-Pituitary-Adrenal Axis Dysregulation	"In endogenous Cushing's, the normal negative feedback regulation of cortisol on the HPA axis is disrupted. ACTH-dependent forms involve autonomous ACTH secretion from pituitary or ectopic sources, while ACTH-independent forms involve autonomous adrenal cortisol production bypassing normal regulation.
"	cell_types[0]	cell_types	cell_types			corticotroph	CL:0002309	corticotroph		"{""preferred_term"": ""corticotroph"", ""term"": {""id"": ""CL:0002309"", ""label"": ""corticotroph""}}"																											
1862	1906	81	Cushing's Syndrome	Cushings_Syndrome.yaml	pathophysiology	2	Metabolic Consequences of Hypercortisolism	"Chronic cortisol excess induces insulin resistance, hepatic gluconeogenesis, protein catabolism in muscle and skin, redistribution of adipose tissue to central deposits, and altered lipid metabolism, leading to the characteristic phenotypic features of the syndrome.
"	biological_processes[0]	biological_processes	biological_processes			response to glucocorticoid	GO:0051384	response to glucocorticoid		"{""preferred_term"": ""response to glucocorticoid"", ""term"": {""id"": ""GO:0051384"", ""label"": ""response to glucocorticoid""}}"																											
1863	1907	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	0	Central Obesity	"Preferential fat deposition in the trunk, face (moon facies), and dorsocervical area (buffalo hump) with relative sparing of the extremities, characteristic of hypercortisolism.
"	phenotype_term	phenotype_term	$	Central Obesity	"Preferential fat deposition in the trunk, face (moon facies), and dorsocervical area (buffalo hump) with relative sparing of the extremities, characteristic of hypercortisolism.
"	truncal obesity	HP:0001956	Truncal obesity		"{""preferred_term"": ""truncal obesity"", ""term"": {""id"": ""HP:0001956"", ""label"": ""Truncal obesity""}}"																											
1864	1908	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	1	Purple Striae	"Wide (greater than 1 cm), violaceous stretch marks, typically on the abdomen, thighs, and upper arms, resulting from cortisol-induced collagen breakdown and skin thinning.
"	phenotype_term	phenotype_term	$	Purple Striae	"Wide (greater than 1 cm), violaceous stretch marks, typically on the abdomen, thighs, and upper arms, resulting from cortisol-induced collagen breakdown and skin thinning.
"	striae distensae	HP:0001065	Striae distensae		"{""preferred_term"": ""striae distensae"", ""term"": {""id"": ""HP:0001065"", ""label"": ""Striae distensae""}}"																											
1865	1909	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	2	Proximal Muscle Weakness	"Progressive weakness and wasting of proximal muscles, particularly of the lower extremities and pelvic girdle, due to cortisol-induced protein catabolism and myopathy.
"	phenotype_term	phenotype_term	$	Proximal Muscle Weakness	"Progressive weakness and wasting of proximal muscles, particularly of the lower extremities and pelvic girdle, due to cortisol-induced protein catabolism and myopathy.
"	proximal muscle weakness	HP:0003701	Proximal muscle weakness		"{""preferred_term"": ""proximal muscle weakness"", ""term"": {""id"": ""HP:0003701"", ""label"": ""Proximal muscle weakness""}}"																											
1866	1910	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	3	Hypertension	"Elevated blood pressure occurring in the majority of patients, resulting from cortisol's mineralocorticoid effects on sodium retention and vascular reactivity.
"	phenotype_term	phenotype_term	$	Hypertension	"Elevated blood pressure occurring in the majority of patients, resulting from cortisol's mineralocorticoid effects on sodium retention and vascular reactivity.
"	hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
1867	1911	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	4	Glucose Intolerance	"Impaired glucose tolerance or overt diabetes mellitus due to cortisol-induced insulin resistance and increased hepatic gluconeogenesis.
"	phenotype_term	phenotype_term	$	Glucose Intolerance	"Impaired glucose tolerance or overt diabetes mellitus due to cortisol-induced insulin resistance and increased hepatic gluconeogenesis.
"	glucose intolerance	HP:0001952	Glucose intolerance		"{""preferred_term"": ""glucose intolerance"", ""term"": {""id"": ""HP:0001952"", ""label"": ""Glucose intolerance""}}"																											
1868	1912	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	5	Osteoporosis	"Decreased bone mineral density and increased fracture risk due to cortisol's inhibitory effects on osteoblast function, calcium absorption, and increased bone resorption.
"	phenotype_term	phenotype_term	$	Osteoporosis	"Decreased bone mineral density and increased fracture risk due to cortisol's inhibitory effects on osteoblast function, calcium absorption, and increased bone resorption.
"	osteoporosis	HP:0000939	Osteoporosis		"{""preferred_term"": ""osteoporosis"", ""term"": {""id"": ""HP:0000939"", ""label"": ""Osteoporosis""}}"																											
1869	1913	81	Cushing's Syndrome	Cushings_Syndrome.yaml	phenotypes	6	Easy Bruising	"Increased skin fragility and easy bruising resulting from cortisol-induced loss of subcutaneous connective tissue and capillary fragility.
"	phenotype_term	phenotype_term	$	Easy Bruising	"Increased skin fragility and easy bruising resulting from cortisol-induced loss of subcutaneous connective tissue and capillary fragility.
"	bruising susceptibility	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""bruising susceptibility"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
1870	1914	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	0	Surgical Resection	"First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.
"	treatment_term	treatment_term	$	Surgical Resection	"First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1871	1915	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	1	Medical Therapy	"Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.
"	treatment_term	treatment_term	$	Medical Therapy	"Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1872	1916	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	2	Radiation Therapy	"Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.
"	treatment_term	treatment_term	$	Radiation Therapy	"Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1873	1917	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	3	Bilateral Adrenalectomy	"Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.
"	treatment_term	treatment_term	$	Bilateral Adrenalectomy	"Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.
"	adrenalectomy	MAXO:0001030	adrenalectomy		"{""preferred_term"": ""adrenalectomy"", ""term"": {""id"": ""MAXO:0001030"", ""label"": ""adrenalectomy""}}"																											
1874	1918	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	infectious_agent	0	Echinococcus granulosus	Tapeworm whose larval stage causes cystic echinococcosis.	infectious_agent_term	infectious_agent_term	$	Echinococcus granulosus	Tapeworm whose larval stage causes cystic echinococcosis.	Echinococcus granulosus	NCBITaxon:6210	Echinococcus granulosus		"{""preferred_term"": ""Echinococcus granulosus"", ""term"": {""id"": ""NCBITaxon:6210"", ""label"": ""Echinococcus granulosus""}}"																											
1875	1920	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	phenotypes	0	Hepatic cysts		phenotype_term	phenotype_term	$	Hepatic cysts		Hepatic cysts	HP:0001407	Hepatic cysts		"{""preferred_term"": ""Hepatic cysts"", ""term"": {""id"": ""HP:0001407"", ""label"": ""Hepatic cysts""}}"																											
1876	1922	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	0	Benzimidazole chemotherapy	Benzimidazole carbamates are used as chemotherapy.	treatment_term	treatment_term	$	Benzimidazole chemotherapy	Benzimidazole carbamates are used as chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1877	1923	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	1	Surgical and percutaneous approaches	Surgical approaches including percutaneous aspiration are used.	treatment_term	treatment_term	$	Surgical and percutaneous approaches	Surgical approaches including percutaneous aspiration are used.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1878	1934	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	pathophysiology	0	CFTR Dysfunction	"Mutations in CFTR gene cause defective chloride channel function. Impaired chloride and bicarbonate transport leads to thick, dehydrated secretions in airways, pancreas, and other organs.
"	biological_processes[0]	biological_processes	biological_processes			Chloride Transport	GO:0006821	chloride transport		"{""preferred_term"": ""Chloride Transport"", ""term"": {""id"": ""GO:0006821"", ""label"": ""chloride transport""}}"																											
1879	1935	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	pathophysiology	1	Airway Mucus Obstruction	"Defective CFTR leads to depleted airway surface liquid and thick mucus. Impaired mucociliary clearance causes chronic bacterial infection, inflammation, and progressive bronchiectasis.
"	cell_types[0]	cell_types	cell_types			Airway Epithelial Cell	CL:0002328	bronchial epithelial cell		"{""preferred_term"": ""Airway Epithelial Cell"", ""term"": {""id"": ""CL:0002328"", ""label"": ""bronchial epithelial cell""}}"																											
1880	1935	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	pathophysiology	1	Airway Mucus Obstruction	"Defective CFTR leads to depleted airway surface liquid and thick mucus. Impaired mucociliary clearance causes chronic bacterial infection, inflammation, and progressive bronchiectasis.
"	biological_processes[0]	biological_processes	biological_processes			Mucus Secretion	GO:0070254	mucus secretion		"{""preferred_term"": ""Mucus Secretion"", ""term"": {""id"": ""GO:0070254"", ""label"": ""mucus secretion""}}"																											
1881	1936	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	pathophysiology	2	Pancreatic Insufficiency	"Thick secretions obstruct pancreatic ducts, causing autodigestion, fibrosis, and exocrine pancreatic insufficiency. Malabsorption of fats and fat-soluble vitamins results.
"	cell_types[0]	cell_types	cell_types			Pancreatic Acinar Cell	CL:0002064	pancreatic acinar cell		"{""preferred_term"": ""Pancreatic Acinar Cell"", ""term"": {""id"": ""CL:0002064"", ""label"": ""pancreatic acinar cell""}}"																											
1882	1937	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	0	Recurrent Respiratory Infections		phenotype_term	phenotype_term	$	Recurrent Respiratory Infections		Recurrent Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
1883	1938	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	1	Bronchiectasis		phenotype_term	phenotype_term	$	Bronchiectasis		Bronchiectasis	HP:0002110	Bronchiectasis		"{""preferred_term"": ""Bronchiectasis"", ""term"": {""id"": ""HP:0002110"", ""label"": ""Bronchiectasis""}}"																											
1884	1939	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	2	Exocrine Pancreatic Insufficiency		phenotype_term	phenotype_term	$	Exocrine Pancreatic Insufficiency		Pancreatic Insufficiency	HP:0001738	Exocrine pancreatic insufficiency		"{""preferred_term"": ""Pancreatic Insufficiency"", ""term"": {""id"": ""HP:0001738"", ""label"": ""Exocrine pancreatic insufficiency""}}"																											
1885	1940	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	3	Steatorrhea		phenotype_term	phenotype_term	$	Steatorrhea		Steatorrhea	HP:0002570	Steatorrhea		"{""preferred_term"": ""Steatorrhea"", ""term"": {""id"": ""HP:0002570"", ""label"": ""Steatorrhea""}}"																											
1886	1941	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	4	Failure to Thrive		phenotype_term	phenotype_term	$	Failure to Thrive		Failure to Thrive	HP:0001508	Failure to thrive		"{""preferred_term"": ""Failure to Thrive"", ""term"": {""id"": ""HP:0001508"", ""label"": ""Failure to thrive""}}"																											
1887	1942	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	5	Meconium Ileus		phenotype_term	phenotype_term	$	Meconium Ileus		Meconium Ileus	HP:0004401	Meconium ileus		"{""preferred_term"": ""Meconium Ileus"", ""term"": {""id"": ""HP:0004401"", ""label"": ""Meconium ileus""}}"																											
1888	1943	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	phenotypes	6	Male Infertility		phenotype_term	phenotype_term	$	Male Infertility		Male Infertility	HP:0003251	Male infertility		"{""preferred_term"": ""Male Infertility"", ""term"": {""id"": ""HP:0003251"", ""label"": ""Male infertility""}}"																											
1889	1951	84	Danon disease	Danon_disease.yaml	genetic	0	LAMP2 mutations		gene_term	gene_term	$	LAMP2 mutations		LAMP2	hgnc:6501	LAMP2		"{""preferred_term"": ""LAMP2"", ""term"": {""id"": ""hgnc:6501"", ""label"": ""LAMP2""}}"																											
1890	1954	84	Danon disease	Danon_disease.yaml	pathophysiology	0	LAMP2 protein deficiency	"Mutations in the LAMP2 gene lead to deficiency of lysosome-associated membrane protein 2, particularly the LAMP-2B isoform which is essential for proper autophagosome-lysosome fusion in cardiac and skeletal muscle cells.
"	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
1891	1954	84	Danon disease	Danon_disease.yaml	pathophysiology	0	LAMP2 protein deficiency	"Mutations in the LAMP2 gene lead to deficiency of lysosome-associated membrane protein 2, particularly the LAMP-2B isoform which is essential for proper autophagosome-lysosome fusion in cardiac and skeletal muscle cells.
"	cell_types[1]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
1892	1954	84	Danon disease	Danon_disease.yaml	pathophysiology	0	LAMP2 protein deficiency	"Mutations in the LAMP2 gene lead to deficiency of lysosome-associated membrane protein 2, particularly the LAMP-2B isoform which is essential for proper autophagosome-lysosome fusion in cardiac and skeletal muscle cells.
"	biological_processes[0]	biological_processes	biological_processes			lysosome organization	GO:0007040	lysosome organization		"{""preferred_term"": ""lysosome organization"", ""term"": {""id"": ""GO:0007040"", ""label"": ""lysosome organization""}}"																											
1893	1955	84	Danon disease	Danon_disease.yaml	pathophysiology	1	Impaired autophagosome-lysosome fusion	"LAMP-2B deficiency causes a late-stage block in the autophagy pathway by preventing fusion of autophagosomes with lysosomes, leading to accumulation of unprocessed autophagosomes.
"	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
1894	1955	84	Danon disease	Danon_disease.yaml	pathophysiology	1	Impaired autophagosome-lysosome fusion	"LAMP-2B deficiency causes a late-stage block in the autophagy pathway by preventing fusion of autophagosomes with lysosomes, leading to accumulation of unprocessed autophagosomes.
"	cell_types[1]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
1895	1955	84	Danon disease	Danon_disease.yaml	pathophysiology	1	Impaired autophagosome-lysosome fusion	"LAMP-2B deficiency causes a late-stage block in the autophagy pathway by preventing fusion of autophagosomes with lysosomes, leading to accumulation of unprocessed autophagosomes.
"	biological_processes[0]	biological_processes	biological_processes			macroautophagy	GO:0016236	macroautophagy		"{""preferred_term"": ""macroautophagy"", ""term"": {""id"": ""GO:0016236"", ""label"": ""macroautophagy""}}"																											
1896	1955	84	Danon disease	Danon_disease.yaml	pathophysiology	1	Impaired autophagosome-lysosome fusion	"LAMP-2B deficiency causes a late-stage block in the autophagy pathway by preventing fusion of autophagosomes with lysosomes, leading to accumulation of unprocessed autophagosomes.
"	biological_processes[1]	biological_processes	biological_processes			autophagosome maturation	GO:0097352	autophagosome maturation		"{""preferred_term"": ""autophagosome maturation"", ""term"": {""id"": ""GO:0097352"", ""label"": ""autophagosome maturation""}}"																											
1897	1956	84	Danon disease	Danon_disease.yaml	pathophysiology	2	Autophagic vacuole accumulation	"Accumulation of autophagic vacuoles with sarcolemmal features (AVSFs) in cardiac and skeletal muscle. These vacuoles contain glycogen and undegraded cellular components, representing a histopathological hallmark distinct from other glycogen storage disorders.
"	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
1898	1956	84	Danon disease	Danon_disease.yaml	pathophysiology	2	Autophagic vacuole accumulation	"Accumulation of autophagic vacuoles with sarcolemmal features (AVSFs) in cardiac and skeletal muscle. These vacuoles contain glycogen and undegraded cellular components, representing a histopathological hallmark distinct from other glycogen storage disorders.
"	cell_types[1]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
1899	1956	84	Danon disease	Danon_disease.yaml	pathophysiology	2	Autophagic vacuole accumulation	"Accumulation of autophagic vacuoles with sarcolemmal features (AVSFs) in cardiac and skeletal muscle. These vacuoles contain glycogen and undegraded cellular components, representing a histopathological hallmark distinct from other glycogen storage disorders.
"	biological_processes[0]	biological_processes	biological_processes			macroautophagy	GO:0016236	macroautophagy		"{""preferred_term"": ""macroautophagy"", ""term"": {""id"": ""GO:0016236"", ""label"": ""macroautophagy""}}"																											
1900	1957	84	Danon disease	Danon_disease.yaml	pathophysiology	3	Impaired mitophagy	"Defective autophagosome-lysosome fusion specifically impairs the mitophagy pathway, preventing clearance of damaged and depolarized mitochondria from cardiomyocytes.
"	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
1901	1957	84	Danon disease	Danon_disease.yaml	pathophysiology	3	Impaired mitophagy	"Defective autophagosome-lysosome fusion specifically impairs the mitophagy pathway, preventing clearance of damaged and depolarized mitochondria from cardiomyocytes.
"	biological_processes[0]	biological_processes	biological_processes			mitophagy	GO:0000423	mitophagy		"{""preferred_term"": ""mitophagy"", ""term"": {""id"": ""GO:0000423"", ""label"": ""mitophagy""}}"																											
1902	1958	84	Danon disease	Danon_disease.yaml	pathophysiology	4	Mitochondrial dysfunction and oxidative stress	"Accumulation of damaged and depolarized mitochondria results in reduced mitochondrial respiration, increased reactive oxygen species production, and oxidative stress, contributing to cardiomyocyte injury and arrhythmogenesis.
"	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
1903	1958	84	Danon disease	Danon_disease.yaml	pathophysiology	4	Mitochondrial dysfunction and oxidative stress	"Accumulation of damaged and depolarized mitochondria results in reduced mitochondrial respiration, increased reactive oxygen species production, and oxidative stress, contributing to cardiomyocyte injury and arrhythmogenesis.
"	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
1904	1959	84	Danon disease	Danon_disease.yaml	phenotypes	0	Hypertrophic cardiomyopathy	"Progressive thickening of the heart muscle, particularly the left ventricle, is the most common and severe manifestation of Danon disease. This typically presents in childhood or adolescence in males and can lead to heart failure and arrhythmias. Cardiomyopathy is the leading cause of death and the main prognostic factor.
"	phenotype_term	phenotype_term	$	Hypertrophic cardiomyopathy	"Progressive thickening of the heart muscle, particularly the left ventricle, is the most common and severe manifestation of Danon disease. This typically presents in childhood or adolescence in males and can lead to heart failure and arrhythmias. Cardiomyopathy is the leading cause of death and the main prognostic factor.
"	Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
1905	1960	84	Danon disease	Danon_disease.yaml	phenotypes	1	Skeletal myopathy	"Weakness of skeletal muscles, particularly proximal muscles, is common in Danon disease. Muscle biopsy shows autophagic vacuoles with sarcolemmal features. This can cause difficulty with physical activities and may be progressive.
"	phenotype_term	phenotype_term	$	Skeletal myopathy	"Weakness of skeletal muscles, particularly proximal muscles, is common in Danon disease. Muscle biopsy shows autophagic vacuoles with sarcolemmal features. This can cause difficulty with physical activities and may be progressive.
"	Myopathy	HP:0003198	Myopathy		"{""preferred_term"": ""Myopathy"", ""term"": {""id"": ""HP:0003198"", ""label"": ""Myopathy""}}"																											
1906	1961	84	Danon disease	Danon_disease.yaml	phenotypes	2	Intellectual disability	"Cognitive impairment of variable severity is frequently observed in affected males, ranging from mild learning difficulties to more significant intellectual disability. This is part of the classic clinical triad in male patients.
"	phenotype_term	phenotype_term	$	Intellectual disability	"Cognitive impairment of variable severity is frequently observed in affected males, ranging from mild learning difficulties to more significant intellectual disability. This is part of the classic clinical triad in male patients.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
1907	1962	84	Danon disease	Danon_disease.yaml	phenotypes	3	Wolff-Parkinson-White syndrome	"Ventricular pre-excitation due to accessory atrioventricular electrical conduction pathways is frequently observed in Danon disease patients. This cardiac conduction abnormality may precede overt cardiomyopathy.
"	phenotype_term	phenotype_term	$	Wolff-Parkinson-White syndrome	"Ventricular pre-excitation due to accessory atrioventricular electrical conduction pathways is frequently observed in Danon disease patients. This cardiac conduction abnormality may precede overt cardiomyopathy.
"	Wolff-Parkinson-White syndrome	HP:0001716	Wolff-Parkinson-White syndrome		"{""preferred_term"": ""Wolff-Parkinson-White syndrome"", ""term"": {""id"": ""HP:0001716"", ""label"": ""Wolff-Parkinson-White syndrome""}}"																											
1908	1963	84	Danon disease	Danon_disease.yaml	phenotypes	4	Retinal dystrophy	"Photoreceptor and retinal pigment epithelium degeneration has been reported in some Danon disease patients, presenting as cone-rod dystrophy and progressive visual impairment.
"	phenotype_term	phenotype_term	$	Retinal dystrophy	"Photoreceptor and retinal pigment epithelium degeneration has been reported in some Danon disease patients, presenting as cone-rod dystrophy and progressive visual impairment.
"	Retinal dystrophy	HP:0000556	Retinal dystrophy		"{""preferred_term"": ""Retinal dystrophy"", ""term"": {""id"": ""HP:0000556"", ""label"": ""Retinal dystrophy""}}"																											
1909	1964	84	Danon disease	Danon_disease.yaml	treatments	0	Heart transplantation	"Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.
"	treatment_term	treatment_term	$	Heart transplantation	"Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.
"	heart transplantation	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""heart transplantation"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
1910	1965	84	Danon disease	Danon_disease.yaml	treatments	1	Gene therapy (AAV9.LAMP2B)	"Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.
"	treatment_term	treatment_term	$	Gene therapy (AAV9.LAMP2B)	"Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.
"	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
1911	1969	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	pathophysiology	0	Alpha-Synuclein Aggregation and Lewy Body Formation	"DLB is characterized morphologically by widespread cortical and subcortical alpha-synuclein aggregation forming Lewy bodies and Lewy neurites. The alpha-synuclein pathology leads to neuronal dysfunction and is central to the disease pathogenesis. The distribution and severity of Lewy body pathology correlates with cognitive impairment and clinical features.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1912	1970	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	pathophysiology	1	Autophagy-Lysosome Dysfunction	"Impaired autophagy and lysosomal functions are central to DLB pathogenesis. Neurons are particularly vulnerable to autophagy-lysosomal defects due to their postmitotic nature and polarized morphologies. Mutations in genes regulating autophagy and lysosomal functions, particularly GBA, contribute to impaired clearance of alpha-synuclein aggregates and damaged organelles. This dysfunction creates a vicious cycle where accumulating protein aggregates further impair the autophagic-lysosomal system.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1913	1971	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	pathophysiology	2	Neuronal Death	"Progressive loss of neurons due to alpha-synuclein pathology and associated proteinopathies, leading to brain atrophy particularly in cortical and limbic regions. The neurodegeneration underlies the progressive cognitive decline and other clinical features of DLB.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
1914	1972	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	phenotypes	0	Visual Hallucinations		phenotype_term	phenotype_term	$	Visual Hallucinations		Visual hallucination	HP:0002367	Visual hallucination		"{""preferred_term"": ""Visual hallucination"", ""term"": {""id"": ""HP:0002367"", ""label"": ""Visual hallucination""}}"																											
1915	1973	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	phenotypes	1	Parkinsonism		phenotype_term	phenotype_term	$	Parkinsonism		Parkinsonism	HP:0001300	Parkinsonism		"{""preferred_term"": ""Parkinsonism"", ""term"": {""id"": ""HP:0001300"", ""label"": ""Parkinsonism""}}"																											
1916	1974	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	phenotypes	2	Dementia		phenotype_term	phenotype_term	$	Dementia		Dementia	HP:0000726	Dementia		"{""preferred_term"": ""Dementia"", ""term"": {""id"": ""HP:0000726"", ""label"": ""Dementia""}}"																											
1917	1975	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	phenotypes	3	REM Sleep Behavior Disorder		phenotype_term	phenotype_term	$	REM Sleep Behavior Disorder		REM sleep behavior disorder	HP:5200291	REM sleep behavior disorder		"{""preferred_term"": ""REM sleep behavior disorder"", ""term"": {""id"": ""HP:5200291"", ""label"": ""REM sleep behavior disorder""}}"																											
1918	1976	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	0	Cholinesterase Inhibitors	Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1919	1977	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	1	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.	treatment_term	treatment_term	$	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1920	1978	86	Dengue	Dengue.yaml	infectious_agent	0	Dengue virus		infectious_agent_term	infectious_agent_term	$	Dengue virus		Dengue virus	NCBITaxon:12637	Dengue virus		"{""preferred_term"": ""Dengue virus"", ""term"": {""id"": ""NCBITaxon:12637"", ""label"": ""Dengue virus""}}"																											
1921	1980	86	Dengue	Dengue.yaml	phenotypes	0	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1922	1981	86	Dengue	Dengue.yaml	phenotypes	1	Skin rash		phenotype_term	phenotype_term	$	Skin rash		Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
1923	1989	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	histopathology	0	Dermal Soft Tissue Sarcoma	Dermatofibrosarcoma protuberans is a low- to intermediate-grade dermal soft tissue malignant tumor.	finding_term	finding_term	$	Dermal Soft Tissue Sarcoma	Dermatofibrosarcoma protuberans is a low- to intermediate-grade dermal soft tissue malignant tumor.	Dermatofibrosarcoma Protuberans	NCIT:C4683	Dermatofibrosarcoma Protuberans		"{""preferred_term"": ""Dermatofibrosarcoma Protuberans"", ""term"": {""id"": ""NCIT:C4683"", ""label"": ""Dermatofibrosarcoma Protuberans""}}"																											
1924	1990	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	0	COL1A1-PDGFB Fusion Oncogene	The t(17;22)(q22;q13) translocation or supernumerary ring chromosomes containing material from chromosomes 17 and 22 fuse the COL1A1 gene to PDGFB. This places PDGFB under control of the highly active COL1A1 promoter, resulting in constitutive expression of a functional PDGF-BB growth factor.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			ABNORMAL																								
1925	1990	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	0	COL1A1-PDGFB Fusion Oncogene	The t(17;22)(q22;q13) translocation or supernumerary ring chromosomes containing material from chromosomes 17 and 22 fuse the COL1A1 gene to PDGFB. This places PDGFB under control of the highly active COL1A1 promoter, resulting in constitutive expression of a functional PDGF-BB growth factor.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
1926	1991	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	1	Autocrine PDGFR Signaling	Tumor cells secrete mature PDGF-BB which binds to PDGFR-beta on the same or neighboring tumor cells, creating an autocrine/paracrine growth loop. PDGFR-beta activation drives proliferation through the MAPK and PI3K pathways. This signaling can be blocked by imatinib.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1927	1992	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	pathophysiology	2	Sustained Proliferation	Constitutive PDGFR-beta signaling drives sustained proliferation of dermal fibroblasts. The infiltrative growth pattern with finger-like projections into subcutaneous fat explains the high local recurrence rate after incomplete excision.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
1928	1993	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	phenotypes	0	Skin Nodule	A slow-growing dermal plaque or nodule that progressively enlarges over months to years. The tumor often has a protuberant or multinodular surface and may be skin-colored, red-brown, or violaceous.	phenotype_term	phenotype_term	$	Skin Nodule	A slow-growing dermal plaque or nodule that progressively enlarges over months to years. The tumor often has a protuberant or multinodular surface and may be skin-colored, red-brown, or violaceous.	Skin nodule	HP:0200036	Skin nodule		"{""preferred_term"": ""Skin nodule"", ""term"": {""id"": ""HP:0200036"", ""label"": ""Skin nodule""}}"																											
1929	1994	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	phenotypes	1	Soft Tissue Mass	As the tumor grows, it may form a larger soft tissue mass extending into subcutaneous tissues. The tumor has an infiltrative growth pattern.	phenotype_term	phenotype_term	$	Soft Tissue Mass	As the tumor grows, it may form a larger soft tissue mass extending into subcutaneous tissues. The tumor has an infiltrative growth pattern.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
1930	1995	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	phenotypes	2	Local Recurrence	High rates of local recurrence (20-50%) occur after inadequate excision due to the infiltrative growth pattern with subclinical extension beyond visible tumor margins.	phenotype_term	phenotype_term	$	Local Recurrence	High rates of local recurrence (20-50%) occur after inadequate excision due to the infiltrative growth pattern with subclinical extension beyond visible tumor margins.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
1931	1996	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	0	Wide Local Excision	Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates.	treatment_term	treatment_term	$	Wide Local Excision	Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1932	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term	treatment_term	$	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
1933	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
1934	1998	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1935	2004	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	0	Complement-Mediated Microangiopathy	Membrane attack complex (MAC) deposition on endomysial capillaries leads to capillary damage, ischemia, and perifascicular atrophy characteristic of dermatomyositis. This distinguishes it from polymyositis.	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
1936	2004	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	0	Complement-Mediated Microangiopathy	Membrane attack complex (MAC) deposition on endomysial capillaries leads to capillary damage, ischemia, and perifascicular atrophy characteristic of dermatomyositis. This distinguishes it from polymyositis.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
1937	2005	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	1	Type I Interferon Pathway Activation	Strong type I interferon signature in muscle and skin. Plasmacytoid dendritic cells accumulate in affected tissues and produce IFN-alpha, driving inflammation and MxA protein expression.	cell_types[0]	cell_types	cell_types			Plasmacytoid Dendritic Cell	CL:0000784	plasmacytoid dendritic cell		"{""preferred_term"": ""Plasmacytoid Dendritic Cell"", ""term"": {""id"": ""CL:0000784"", ""label"": ""plasmacytoid dendritic cell""}}"																											
1938	2005	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	1	Type I Interferon Pathway Activation	Strong type I interferon signature in muscle and skin. Plasmacytoid dendritic cells accumulate in affected tissues and produce IFN-alpha, driving inflammation and MxA protein expression.	biological_processes[0]	biological_processes	biological_processes			Type I Interferon Response	GO:0034340	response to type I interferon		"{""preferred_term"": ""Type I Interferon Response"", ""term"": {""id"": ""GO:0034340"", ""label"": ""response to type I interferon""}}"																											
1939	2006	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	2	Myositis-Specific Autoantibodies	Distinct autoantibodies define clinical phenotypes: anti-Mi-2 (classic dermatomyositis), anti-MDA5 (amyopathic with ILD), anti-TIF1-gamma (cancer-associated), and anti-NXP2 (calcinosis).	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
1940	2007	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	3	CD4+ T Cell and B Cell Infiltration	Perivascular and perimysial infiltration by CD4+ T cells and B cells contributes to muscle inflammation. B cells may form tertiary lymphoid structures in muscle tissue.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
1941	2007	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	3	CD4+ T Cell and B Cell Infiltration	Perivascular and perimysial infiltration by CD4+ T cells and B cells contributes to muscle inflammation. B cells may form tertiary lymphoid structures in muscle tissue.	cell_types[1]	cell_types	cell_types			B Cell	CL:0000236	B cell		"{""preferred_term"": ""B Cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1942	2007	88	Dermatomyositis	Dermatomyositis.yaml	pathophysiology	3	CD4+ T Cell and B Cell Infiltration	Perivascular and perimysial infiltration by CD4+ T cells and B cells contributes to muscle inflammation. B cells may form tertiary lymphoid structures in muscle tissue.	biological_processes[0]	biological_processes	biological_processes			Adaptive Immune Response	GO:0002250	adaptive immune response		"{""preferred_term"": ""Adaptive Immune Response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
1943	2008	88	Dermatomyositis	Dermatomyositis.yaml	phenotypes	0	Proximal Muscle Weakness		phenotype_term	phenotype_term	$	Proximal Muscle Weakness		Limb Muscle Weakness	HP:0003690	Limb muscle weakness		"{""preferred_term"": ""Limb Muscle Weakness"", ""term"": {""id"": ""HP:0003690"", ""label"": ""Limb muscle weakness""}}"																											
1944	2009	88	Dermatomyositis	Dermatomyositis.yaml	phenotypes	1	Skin Rash		phenotype_term	phenotype_term	$	Skin Rash		Skin Rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin Rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
1945	2010	88	Dermatomyositis	Dermatomyositis.yaml	phenotypes	2	Pulmonary Fibrosis		phenotype_term	phenotype_term	$	Pulmonary Fibrosis		Pulmonary Fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary Fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
1946	2011	88	Dermatomyositis	Dermatomyositis.yaml	phenotypes	3	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
1947	2022	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	histopathology	0	Desmoplastic Small Round Cell Tumor	Desmoplastic small round cell tumor is a rare and highly aggressive mesenchymal tumor.	finding_term	finding_term	$	Desmoplastic Small Round Cell Tumor	Desmoplastic small round cell tumor is a rare and highly aggressive mesenchymal tumor.	Desmoplastic Small Round Cell Tumor	NCIT:C8300	Desmoplastic Small Round Cell Tumor		"{""preferred_term"": ""Desmoplastic Small Round Cell Tumor"", ""term"": {""id"": ""NCIT:C8300"", ""label"": ""Desmoplastic Small Round Cell Tumor""}}"																											
1948	2023	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	0	EWSR1-WT1 Fusion Oncogene	The t(11;22)(p13;q12) translocation fuses EWSR1 on chromosome 22 with WT1 on chromosome 11. The resulting fusion protein contains the potent transcriptional activation domain of EWSR1 fused to the zinc finger DNA-binding domain of WT1. This chimeric transcription factor activates aberrant gene expression programs including PDGFA.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			ABNORMAL																								
1949	2023	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	0	EWSR1-WT1 Fusion Oncogene	The t(11;22)(p13;q12) translocation fuses EWSR1 on chromosome 22 with WT1 on chromosome 11. The resulting fusion protein contains the potent transcriptional activation domain of EWSR1 fused to the zinc finger DNA-binding domain of WT1. This chimeric transcription factor activates aberrant gene expression programs including PDGFA.	locations[0]	locations	locations			peritoneum	UBERON:0002358	peritoneum		"{""preferred_term"": ""peritoneum"", ""term"": {""id"": ""UBERON:0002358"", ""label"": ""peritoneum""}}"																											
1950	2024	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	1	PDGFA Activation	EWSR1-WT1 directly activates transcription of PDGFA, creating an autocrine growth loop that stimulates tumor cell proliferation and may contribute to the characteristic desmoplastic stromal reaction.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1951	2025	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	pathophysiology	2	Multiphenotypic Differentiation	DSRCT displays a unique multiphenotypic immunophenotype with co-expression of epithelial (cytokeratin, EMA), mesenchymal (vimentin, desmin), and neural (NSE) markers. This reflects the aberrant differentiation program driven by EWSR1-WT1.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			ABNORMAL																								
1952	2026	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	phenotypes	0	Abdominal Mass	Bulky abdominal masses are the hallmark presentation. Tumors are typically large and multiple at diagnosis, studding the peritoneal surfaces.	phenotype_term	phenotype_term	$	Abdominal Mass	Bulky abdominal masses are the hallmark presentation. Tumors are typically large and multiple at diagnosis, studding the peritoneal surfaces.	Abdominal mass	HP:0031500	Abdominal mass		"{""preferred_term"": ""Abdominal mass"", ""term"": {""id"": ""HP:0031500"", ""label"": ""Abdominal mass""}}"																											
1953	2027	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	phenotypes	1	Ascites	Malignant ascites is common due to extensive peritoneal involvement.	phenotype_term	phenotype_term	$	Ascites	Malignant ascites is common due to extensive peritoneal involvement.	Ascites	HP:0001541	Ascites		"{""preferred_term"": ""Ascites"", ""term"": {""id"": ""HP:0001541"", ""label"": ""Ascites""}}"																											
1954	2028	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	phenotypes	2	Weight Loss	Weight loss and cachexia are common with advanced disease burden.	phenotype_term	phenotype_term	$	Weight Loss	Weight loss and cachexia are common with advanced disease burden.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1955	2029	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	phenotypes	3	Fever	Fever may occur as a paraneoplastic symptom or with tumor necrosis.	phenotype_term	phenotype_term	$	Fever	Fever may occur as a paraneoplastic symptom or with tumor necrosis.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
1956	2030	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	phenotypes	4	Metastatic Disease	Metastases to liver, lung, and lymph nodes are common. Most patients have disseminated disease at diagnosis given the diffuse peritoneal involvement.	phenotype_term	phenotype_term	$	Metastatic Disease	Metastases to liver, lung, and lymph nodes are common. Most patients have disseminated disease at diagnosis given the diffuse peritoneal involvement.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}"				cyclophosphamide; doxorubicin; vincristine; ifosfamide; etoposide	CHEBI:4026; CHEBI:28748; CHEBI:28445; CHEBI:5864; CHEBI:4911																						
1958	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
1959	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1960	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
1961	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
1962	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[4]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
1963	2032	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	1	Cytoreductive Surgery	Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable.	treatment_term	treatment_term	$	Cytoreductive Surgery	Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1964	2033	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	2	Radiation Therapy	Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution.	treatment_term	treatment_term	$	Radiation Therapy	Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1965	2035	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	0	Peptic Ulcer Disease	Ulcerative mucosal defects of stomach or duodenum that commonly cause overt GI bleeding and can mimic Dieulafoy lesions endoscopically.	disease_term	disease_term	$	Peptic Ulcer Disease	Ulcerative mucosal defects of stomach or duodenum that commonly cause overt GI bleeding and can mimic Dieulafoy lesions endoscopically.	peptic ulcer disease	MONDO:0004247	peptic ulcer disease		"{""preferred_term"": ""peptic ulcer disease"", ""term"": {""id"": ""MONDO:0004247"", ""label"": ""peptic ulcer disease""}}"																											
1966	2036	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	1	Angiodysplasia of Colon	Dilated submucosal vessels typically in the colon that cause painless lower GI bleeding and can resemble vascular Dieulafoy bleeding sites.	disease_term	disease_term	$	Angiodysplasia of Colon	Dilated submucosal vessels typically in the colon that cause painless lower GI bleeding and can resemble vascular Dieulafoy bleeding sites.	angiodysplasia	MONDO:0002322	angiodysplasia		"{""preferred_term"": ""angiodysplasia"", ""term"": {""id"": ""MONDO:0002322"", ""label"": ""angiodysplasia""}}"																											
1967	2037	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	2	Gastric Antral Vascular Ectasia (GAVE)	Watermelon stomach with dilated antral vessels producing chronic or acute upper GI bleeding that must be distinguished from Dieulafoy lesions.	disease_term	disease_term	$	Gastric Antral Vascular Ectasia (GAVE)	Watermelon stomach with dilated antral vessels producing chronic or acute upper GI bleeding that must be distinguished from Dieulafoy lesions.	gastric antral vascular ectasia	MONDO:0006767	gastric antral vascular ectasia		"{""preferred_term"": ""gastric antral vascular ectasia"", ""term"": {""id"": ""MONDO:0006767"", ""label"": ""gastric antral vascular ectasia""}}"																											
1968	2038	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	3	Esophageal Varices	Dilated submucosal veins in the esophagus due to portal hypertension that can cause massive upper GI bleeding.	disease_term	disease_term	$	Esophageal Varices	Dilated submucosal veins in the esophagus due to portal hypertension that can cause massive upper GI bleeding.	esophageal varices	MONDO:0001221	esophageal varices		"{""preferred_term"": ""esophageal varices"", ""term"": {""id"": ""MONDO:0001221"", ""label"": ""esophageal varices""}}"																											
1969	2039	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	4	Gastric Carcinoma	Malignant epithelial tumor of the stomach that can ulcerate and bleed, mimicking Dieulafoy-related hemorrhage.	disease_term	disease_term	$	Gastric Carcinoma	Malignant epithelial tumor of the stomach that can ulcerate and bleed, mimicking Dieulafoy-related hemorrhage.	gastric carcinoma	MONDO:0004950	gastric carcinoma		"{""preferred_term"": ""gastric carcinoma"", ""term"": {""id"": ""MONDO:0004950"", ""label"": ""gastric carcinoma""}}"																											
1970	2040	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	differential_diagnoses	5	Meckel Diverticulum	Congenital ileal diverticulum that may harbor ectopic gastric mucosa causing brisk lower GI bleeding, particularly in younger patients.	disease_term	disease_term	$	Meckel Diverticulum	Congenital ileal diverticulum that may harbor ectopic gastric mucosa causing brisk lower GI bleeding, particularly in younger patients.	Meckel diverticulum	MONDO:0007955	Meckel diverticulum		"{""preferred_term"": ""Meckel diverticulum"", ""term"": {""id"": ""MONDO:0007955"", ""label"": ""Meckel diverticulum""}}"																											
1971	2046	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	phenotypes	0	Gastrointestinal Hemorrhage		phenotype_term	phenotype_term	$	Gastrointestinal Hemorrhage		Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
1972	2047	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	phenotypes	1	Hypotension from Acute Blood Loss		phenotype_term	phenotype_term	$	Hypotension from Acute Blood Loss		Hypotension	HP:0002615	Hypotension		"{""preferred_term"": ""Hypotension"", ""term"": {""id"": ""HP:0002615"", ""label"": ""Hypotension""}}"																											
1973	2048	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	0	Endoscopic Mechanical Hemostasis	"Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.
"	treatment_term	treatment_term	$	Endoscopic Mechanical Hemostasis	"Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1974	2049	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	1	Angiographic Embolization	"Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.
"	treatment_term	treatment_term	$	Angiographic Embolization	"Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1975	2050	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	2	Surgical Ligation or Wedge Resection	"Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.
"	treatment_term	treatment_term	$	Surgical Ligation or Wedge Resection	"Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1976	2061	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	histopathology	0	Diffuse Large B-Cell Lymphoma	Diffuse large B-cell lymphoma is the most common pathologic subtype.	finding_term	finding_term	$	Diffuse Large B-Cell Lymphoma	Diffuse large B-cell lymphoma is the most common pathologic subtype.	Diffuse Large B-Cell Lymphoma	NCIT:C8851	Diffuse Large B-Cell Lymphoma		"{""preferred_term"": ""Diffuse Large B-Cell Lymphoma"", ""term"": {""id"": ""NCIT:C8851"", ""label"": ""Diffuse Large B-Cell Lymphoma""}}"																											
1977	2062	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	0	Germinal Center B-cell Origin	DLBCL arises from germinal center or post-germinal center B cells undergoing somatic hypermutation and class switch recombination. These processes introduce DNA double-strand breaks that can lead to oncogenic translocations. The cell of origin determines molecular subtype and clinical behavior.	cell_types[0]	cell_types	cell_types			centrocyte	CL:0009111	centrocyte		"{""preferred_term"": ""centrocyte"", ""term"": {""id"": ""CL:0009111"", ""label"": ""centrocyte""}}"																											
1978	2062	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	0	Germinal Center B-cell Origin	DLBCL arises from germinal center or post-germinal center B cells undergoing somatic hypermutation and class switch recombination. These processes introduce DNA double-strand breaks that can lead to oncogenic translocations. The cell of origin determines molecular subtype and clinical behavior.	cell_types[1]	cell_types	cell_types			centroblast	CL:0009112	centroblast		"{""preferred_term"": ""centroblast"", ""term"": {""id"": ""CL:0009112"", ""label"": ""centroblast""}}"																											
1979	2062	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	0	Germinal Center B-cell Origin	DLBCL arises from germinal center or post-germinal center B cells undergoing somatic hypermutation and class switch recombination. These processes introduce DNA double-strand breaks that can lead to oncogenic translocations. The cell of origin determines molecular subtype and clinical behavior.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
1980	2063	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	1	BCL2 Overexpression and Apoptosis Resistance	BCL2 translocation t(14;18) occurs in approximately 30% of GCB-DLBCL, placing BCL2 under immunoglobulin enhancer control. Resulting BCL2 overexpression blocks the mitochondrial apoptosis pathway, allowing survival of cells that would normally die in the germinal center.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
1981	2064	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	2	MYC-Driven Proliferation	MYC rearrangements occur in 10-15% of DLBCL, most commonly with IGH but also with non-immunoglobulin partners. MYC overexpression drives cellular proliferation and metabolism. When combined with BCL2 rearrangement (double-hit lymphoma), creates highly aggressive disease.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
1982	2065	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	3	NF-kB Constitutive Activation	ABC-DLBCL shows constitutive NF-kB activation through various mechanisms including BCR signaling mutations (CD79A/B), CARD11 mutations, MYD88 L265P mutation, or A20 deletion. NF-kB promotes survival and contributes to the aggressive behavior of ABC subtype.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1983	2065	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	3	NF-kB Constitutive Activation	ABC-DLBCL shows constitutive NF-kB activation through various mechanisms including BCR signaling mutations (CD79A/B), CARD11 mutations, MYD88 L265P mutation, or A20 deletion. NF-kB promotes survival and contributes to the aggressive behavior of ABC subtype.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
1984	2066	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	4	Lymphoma Cell Accumulation	The combination of blocked apoptosis, enhanced proliferation, and constitutive survival signaling leads to aggressive expansion of large B-cell lymphoma involving lymph nodes and extranodal sites.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
1985	2066	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	pathophysiology	4	Lymphoma Cell Accumulation	The combination of blocked apoptosis, enhanced proliferation, and constitutive survival signaling leads to aggressive expansion of large B-cell lymphoma involving lymph nodes and extranodal sites.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
1986	2067	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	0	Lymphadenopathy	Rapidly enlarging lymphadenopathy is the most common presentation. Nodal disease may be localized or widespread.	phenotype_term	phenotype_term	$	Lymphadenopathy	Rapidly enlarging lymphadenopathy is the most common presentation. Nodal disease may be localized or widespread.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
1987	2068	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	1	Night Sweats	B symptoms including drenching night sweats indicate active disease and are incorporated into staging.	phenotype_term	phenotype_term	$	Night Sweats	B symptoms including drenching night sweats indicate active disease and are incorporated into staging.	Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
1988	2069	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	2	Weight Loss	Unintentional weight loss greater than 10% body weight in 6 months is a B symptom with prognostic significance.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss greater than 10% body weight in 6 months is a B symptom with prognostic significance.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
1989	2070	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	3	Fatigue	Fatigue from disease burden, cytokine release, and anemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from disease burden, cytokine release, and anemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
1990	2071	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	4	Splenomegaly	Spleen involvement occurs in some cases, particularly with advanced stage disease.	phenotype_term	phenotype_term	$	Splenomegaly	Spleen involvement occurs in some cases, particularly with advanced stage disease.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
1991	2072	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	phenotypes	5	Anemia	Anemia may result from bone marrow infiltration, hemolysis, or cytokine effects.	phenotype_term	phenotype_term	$	Anemia	Anemia may result from bone marrow infiltration, hemolysis, or cytokine effects.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	treatment_term	$	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}]}"				cyclophosphamide; doxorubicin; vincristine; prednisone	CHEBI:4027; CHEBI:28748; CHEBI:28445; CHEBI:8382																						
1993	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"																											
1994	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1995	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
1996	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"																											
1997	2074	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	1	Polatuzumab Vedotin plus R-CHP	CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.	treatment_term	treatment_term	$	Polatuzumab Vedotin plus R-CHP	CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1998	2075	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy for Double-Hit Lymphoma	High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.	treatment_term	treatment_term	$	Intensive Chemotherapy for Double-Hit Lymphoma	High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1999	2076	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	3	CAR-T Cell Therapy	CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
2000	2077	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	4	Autologous Stem Cell Transplantation	For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.	treatment_term	treatment_term	$	Autologous Stem Cell Transplantation	For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2001	2078	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	5	Radiation Therapy	Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.	treatment_term	treatment_term	$	Radiation Therapy	Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2002	2080	92	Dorsalgia	Dorsalgia.yaml	phenotypes	0	Back pain	Persistent pain localized to the back.	phenotype_term	phenotype_term	$	Back pain	Persistent pain localized to the back.	Back pain	HP:0003418	Back pain		"{""preferred_term"": ""Back pain"", ""term"": {""id"": ""HP:0003418"", ""label"": ""Back pain""}}"																											
2003	2093	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	1	Interferon Hyperactivation	Chronic hyperactivation of interferon signaling driven by triplication of interferon receptor genes on chromosome 21, leading to immune dysregulation and neuroinflammation. Microglia adopt disease-associated and interferon-responsive states contributing to neuroinflammation.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
2004	2093	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	1	Interferon Hyperactivation	Chronic hyperactivation of interferon signaling driven by triplication of interferon receptor genes on chromosome 21, leading to immune dysregulation and neuroinflammation. Microglia adopt disease-associated and interferon-responsive states contributing to neuroinflammation.	biological_processes[0]	biological_processes	biological_processes			type I interferon-mediated signaling pathway	GO:0060337	type I interferon-mediated signaling pathway		"{""preferred_term"": ""type I interferon-mediated signaling pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon-mediated signaling pathway""}}"																											
2005	2093	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	1	Interferon Hyperactivation	Chronic hyperactivation of interferon signaling driven by triplication of interferon receptor genes on chromosome 21, leading to immune dysregulation and neuroinflammation. Microglia adopt disease-associated and interferon-responsive states contributing to neuroinflammation.	biological_processes[1]	biological_processes	biological_processes			cell surface receptor signaling pathway via JAK-STAT	GO:0007259	cell surface receptor signaling pathway via JAK-STAT		"{""preferred_term"": ""cell surface receptor signaling pathway via JAK-STAT"", ""term"": {""id"": ""GO:0007259"", ""label"": ""cell surface receptor signaling pathway via JAK-STAT""}}"																											
2006	2093	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	1	Interferon Hyperactivation	Chronic hyperactivation of interferon signaling driven by triplication of interferon receptor genes on chromosome 21, leading to immune dysregulation and neuroinflammation. Microglia adopt disease-associated and interferon-responsive states contributing to neuroinflammation.	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
2007	2094	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	2	Neurodevelopmental Alterations	Impaired neurogenesis with progenitor cell-cycle defects and shift from neuron to astrocyte differentiation, leading to reduced neuronal output and circuit dysfunction. Astrocytes show increased numbers and reactive states due to lineage shift from neurogenesis to astrogliogenesis.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
2008	2094	93	Down_syndrome	Down_syndrome.yaml	pathophysiology	2	Neurodevelopmental Alterations	Impaired neurogenesis with progenitor cell-cycle defects and shift from neuron to astrocyte differentiation, leading to reduced neuronal output and circuit dysfunction. Astrocytes show increased numbers and reactive states due to lineage shift from neurogenesis to astrogliogenesis.	locations[0]	locations	locations			Ammon's horn	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""Ammon's horn"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
2009	2095	93	Down_syndrome	Down_syndrome.yaml	phenotypes	0	Dysmorphic Facial Features		phenotype_term	phenotype_term	$	Dysmorphic Facial Features		Upslanted palpebral fissure	HP:0000582	Upslanted palpebral fissure		"{""preferred_term"": ""Upslanted palpebral fissure"", ""term"": {""id"": ""HP:0000582"", ""label"": ""Upslanted palpebral fissure""}}"																											
2010	2096	93	Down_syndrome	Down_syndrome.yaml	phenotypes	1	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
2011	2097	93	Down_syndrome	Down_syndrome.yaml	phenotypes	2	Developmental Delay		phenotype_term	phenotype_term	$	Developmental Delay		Developmental Delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Developmental Delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
2012	2098	93	Down_syndrome	Down_syndrome.yaml	phenotypes	3	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
2013	2099	93	Down_syndrome	Down_syndrome.yaml	phenotypes	4	Congenital Heart Defects		phenotype_term	phenotype_term	$	Congenital Heart Defects		Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
2014	2100	93	Down_syndrome	Down_syndrome.yaml	phenotypes	5	Hypothyroidism		phenotype_term	phenotype_term	$	Hypothyroidism		Hypothyroidism	HP:0000821	Hypothyroidism		"{""preferred_term"": ""Hypothyroidism"", ""term"": {""id"": ""HP:0000821"", ""label"": ""Hypothyroidism""}}"																											
2015	2101	93	Down_syndrome	Down_syndrome.yaml	phenotypes	6	Leukemia Risk		phenotype_term	phenotype_term	$	Leukemia Risk		Leukemia	HP:0001909	Leukemia		"{""preferred_term"": ""Leukemia"", ""term"": {""id"": ""HP:0001909"", ""label"": ""Leukemia""}}"																											
2016	2102	93	Down_syndrome	Down_syndrome.yaml	phenotypes	7	Sleep Apnea		phenotype_term	phenotype_term	$	Sleep Apnea		Sleep Apnea	HP:0002870	Obstructive sleep apnea		"{""preferred_term"": ""Sleep Apnea"", ""term"": {""id"": ""HP:0002870"", ""label"": ""Obstructive sleep apnea""}}"																											
2017	2103	93	Down_syndrome	Down_syndrome.yaml	phenotypes	8	Autoimmunity		phenotype_term	phenotype_term	$	Autoimmunity		Autoimmunity	HP:0002960	Autoimmunity		"{""preferred_term"": ""Autoimmunity"", ""term"": {""id"": ""HP:0002960"", ""label"": ""Autoimmunity""}}"																											
2018	2104	93	Down_syndrome	Down_syndrome.yaml	phenotypes	9	Alzheimer Disease		phenotype_term	phenotype_term	$	Alzheimer Disease		Alzheimer disease	HP:0002511	Alzheimer disease		"{""preferred_term"": ""Alzheimer disease"", ""term"": {""id"": ""HP:0002511"", ""label"": ""Alzheimer disease""}}"																											
2019	2106	93	Down_syndrome	Down_syndrome.yaml	treatments	0	Early Intervention Programs	Support services including physical, occupational, and speech therapy.	treatment_term	treatment_term	$	Early Intervention Programs	Support services including physical, occupational, and speech therapy.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2020	2107	93	Down_syndrome	Down_syndrome.yaml	treatments	1	Cardiac Surgery	For congenital heart defect correction if needed.	treatment_term	treatment_term	$	Cardiac Surgery	For congenital heart defect correction if needed.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2021	2108	93	Down_syndrome	Down_syndrome.yaml	treatments	2	Hormone Replacement Therapy	For treating hypothyroidism.	treatment_term	treatment_term	$	Hormone Replacement Therapy	For treating hypothyroidism.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2022	2109	93	Down_syndrome	Down_syndrome.yaml	treatments	3	Educational Support	Tailored educational plans to support learning and development.	treatment_term	treatment_term	$	Educational Support	Tailored educational plans to support learning and development.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2023	2110	94	Dracunculiasis	Dracunculiasis.yaml	infectious_agent	0	Dracunculus medinensis	Guinea worm nematode causing dracunculiasis.	infectious_agent_term	infectious_agent_term	$	Dracunculus medinensis	Guinea worm nematode causing dracunculiasis.	Dracunculus medinensis	NCBITaxon:318479	Dracunculus medinensis		"{""preferred_term"": ""Dracunculus medinensis"", ""term"": {""id"": ""NCBITaxon:318479"", ""label"": ""Dracunculus medinensis""}}"																											
2024	2125	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	0	SCN1A Gene Mutation	Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1 sodium channel function, primarily affecting GABAergic inhibitory interneurons, particularly parvalbumin-positive fast-spiking interneurons.	cell_types[0]	cell_types	cell_types			inhibitory interneuron	CL:0000498	inhibitory interneuron		"{""preferred_term"": ""inhibitory interneuron"", ""term"": {""id"": ""CL:0000498"", ""label"": ""inhibitory interneuron""}}"																											
2025	2125	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	0	SCN1A Gene Mutation	Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1 sodium channel function, primarily affecting GABAergic inhibitory interneurons, particularly parvalbumin-positive fast-spiking interneurons.	biological_processes[0]	biological_processes	biological_processes			voltage-gated sodium channel activity	GO:0005248	voltage-gated sodium channel activity		"{""preferred_term"": ""voltage-gated sodium channel activity"", ""term"": {""id"": ""GO:0005248"", ""label"": ""voltage-gated sodium channel activity""}}"																											
2026	2125	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	0	SCN1A Gene Mutation	Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1 sodium channel function, primarily affecting GABAergic inhibitory interneurons, particularly parvalbumin-positive fast-spiking interneurons.	biological_processes[1]	biological_processes	biological_processes			neuronal action potential	GO:0019228	neuronal action potential		"{""preferred_term"": ""neuronal action potential"", ""term"": {""id"": ""GO:0019228"", ""label"": ""neuronal action potential""}}"																											
2027	2125	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	0	SCN1A Gene Mutation	Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1 sodium channel function, primarily affecting GABAergic inhibitory interneurons, particularly parvalbumin-positive fast-spiking interneurons.	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
2028	2125	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	0	SCN1A Gene Mutation	Heterozygous loss-of-function mutations in SCN1A cause reduced Nav1.1 sodium channel function, primarily affecting GABAergic inhibitory interneurons, particularly parvalbumin-positive fast-spiking interneurons.	locations[1]	locations	locations			Ammon's horn	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""Ammon's horn"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
2029	2126	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Reduced inhibitory interneuron function leads to excitatory-inhibitory imbalance and network hyperexcitability across cortico-hippocampal and thalamocortical circuits.	cell_types[0]	cell_types	cell_types			inhibitory interneuron	CL:0000498	inhibitory interneuron		"{""preferred_term"": ""inhibitory interneuron"", ""term"": {""id"": ""CL:0000498"", ""label"": ""inhibitory interneuron""}}"																											
2030	2126	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Reduced inhibitory interneuron function leads to excitatory-inhibitory imbalance and network hyperexcitability across cortico-hippocampal and thalamocortical circuits.	biological_processes[0]	biological_processes	biological_processes			synaptic transmission, GABAergic	GO:0051932	synaptic transmission, GABAergic		"{""preferred_term"": ""synaptic transmission, GABAergic"", ""term"": {""id"": ""GO:0051932"", ""label"": ""synaptic transmission, GABAergic""}}"																											
2031	2126	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Reduced inhibitory interneuron function leads to excitatory-inhibitory imbalance and network hyperexcitability across cortico-hippocampal and thalamocortical circuits.	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
2032	2126	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Reduced inhibitory interneuron function leads to excitatory-inhibitory imbalance and network hyperexcitability across cortico-hippocampal and thalamocortical circuits.	locations[1]	locations	locations			Ammon's horn	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""Ammon's horn"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
2033	2126	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Reduced inhibitory interneuron function leads to excitatory-inhibitory imbalance and network hyperexcitability across cortico-hippocampal and thalamocortical circuits.	locations[2]	locations	locations			dorsal plus ventral thalamus	UBERON:0001897	dorsal plus ventral thalamus		"{""preferred_term"": ""dorsal plus ventral thalamus"", ""term"": {""id"": ""UBERON:0001897"", ""label"": ""dorsal plus ventral thalamus""}}"																											
2034	2127	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	2	Astrocyte Dysregulation	Aberrant astrocyte calcium signaling and gliotransmission may exacerbate network hyperexcitability and seizure susceptibility.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
2035	2127	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	2	Astrocyte Dysregulation	Aberrant astrocyte calcium signaling and gliotransmission may exacerbate network hyperexcitability and seizure susceptibility.	locations[0]	locations	locations			cerebral cortex	UBERON:0000956	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000956"", ""label"": ""cerebral cortex""}}"																											
2036	2127	95	Dravet_syndrome	Dravet_syndrome.yaml	pathophysiology	2	Astrocyte Dysregulation	Aberrant astrocyte calcium signaling and gliotransmission may exacerbate network hyperexcitability and seizure susceptibility.	locations[1]	locations	locations			Ammon's horn	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""Ammon's horn"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
2037	2128	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	0	Seizures	Treatment-resistant seizures beginning in the first year of life, often triggered by fever, with progression to multiple seizure types.	phenotype_term	phenotype_term	$	Seizures	Treatment-resistant seizures beginning in the first year of life, often triggered by fever, with progression to multiple seizure types.	Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
2038	2129	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	1	Developmental Delay	Progressive developmental regression typically beginning after seizure onset, affecting motor, language, and social skills.	phenotype_term	phenotype_term	$	Developmental Delay	Progressive developmental regression typically beginning after seizure onset, affecting motor, language, and social skills.	Developmental Delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Developmental Delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
2039	2130	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	2	Intellectual Disability	Cognitive impairment ranging from mild to severe, often progressive in nature.	phenotype_term	phenotype_term	$	Intellectual Disability	Cognitive impairment ranging from mild to severe, often progressive in nature.	Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
2040	2131	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	3	Hyperactivity	Behavioral difficulties including hyperactivity and attention deficits.	phenotype_term	phenotype_term	$	Hyperactivity	Behavioral difficulties including hyperactivity and attention deficits.	Hyperactivity	HP:0000752	Hyperactivity		"{""preferred_term"": ""Hyperactivity"", ""term"": {""id"": ""HP:0000752"", ""label"": ""Hyperactivity""}}"																											
2041	2132	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	4	Febrile Seizures	Seizures triggered by fever, typically the presenting feature in infancy between 3 months and 6 years. Often prolonged hemiclonic seizures or status epilepticus.	phenotype_term	phenotype_term	$	Febrile Seizures	Seizures triggered by fever, typically the presenting feature in infancy between 3 months and 6 years. Often prolonged hemiclonic seizures or status epilepticus.	Febrile seizure (within the age range of 3 months to 6 years)	HP:0002373	Febrile seizure (within the age range of 3 months to 6 years)		"{""preferred_term"": ""Febrile seizure (within the age range of 3 months to 6 years)"", ""term"": {""id"": ""HP:0002373"", ""label"": ""Febrile seizure (within the age range of 3 months to 6 years)""}}"																											
2042	2133	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	5	Ataxia	Impaired coordination and balance, including gait abnormalities such as crouch gait. Motor impairment characteristic of Dravet syndrome.	phenotype_term	phenotype_term	$	Ataxia	Impaired coordination and balance, including gait abnormalities such as crouch gait. Motor impairment characteristic of Dravet syndrome.	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
2043	2134	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	6	Autism	Autism spectrum features including impaired social interaction, communication difficulties, and restricted repetitive behaviors.	phenotype_term	phenotype_term	$	Autism	Autism spectrum features including impaired social interaction, communication difficulties, and restricted repetitive behaviors.	Autism	HP:0000717	Autism		"{""preferred_term"": ""Autism"", ""term"": {""id"": ""HP:0000717"", ""label"": ""Autism""}}"																											
2044	2135	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	7	Respiratory Failure	Postictal respiratory compromise and sleep-associated breathing abnormalities contributing to SUDEP risk.	phenotype_term	phenotype_term	$	Respiratory Failure	Postictal respiratory compromise and sleep-associated breathing abnormalities contributing to SUDEP risk.	Respiratory failure	HP:0002878	Respiratory failure		"{""preferred_term"": ""Respiratory failure"", ""term"": {""id"": ""HP:0002878"", ""label"": ""Respiratory failure""}}"																											
2045	2136	95	Dravet_syndrome	Dravet_syndrome.yaml	phenotypes	8	Sudden Unexpected Death in Epilepsy	Markedly elevated risk of sudden unexpected death in epilepsy (SUDEP), accounting for up to 50% of deaths in Dravet syndrome. Linked to seizure burden, postictal cardiorespiratory dysfunction, and potential cardiac susceptibility.	phenotype_term	phenotype_term	$	Sudden Unexpected Death in Epilepsy	Markedly elevated risk of sudden unexpected death in epilepsy (SUDEP), accounting for up to 50% of deaths in Dravet syndrome. Linked to seizure burden, postictal cardiorespiratory dysfunction, and potential cardiac susceptibility.	Sudden unexpected death in epilepsy	HP:0033258	Sudden unexpected death in epilepsy		"{""preferred_term"": ""Sudden unexpected death in epilepsy"", ""term"": {""id"": ""HP:0033258"", ""label"": ""Sudden unexpected death in epilepsy""}}"																											
2046	2139	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	0	Antiepileptic Medications	Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures.	treatment_term	treatment_term	$	Antiepileptic Medications	Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2047	2140	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	1	Ketogenic Diet	High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients.	treatment_term	treatment_term	$	Ketogenic Diet	High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2048	2141	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	2	Supportive Therapies	Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment.	treatment_term	treatment_term	$	Supportive Therapies	Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2049	2142	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	3	Vagus Nerve Stimulation (VNS)	Implanted device that may help reduce seizure frequency in drug-resistant cases.	treatment_term	treatment_term	$	Vagus Nerve Stimulation (VNS)	Implanted device that may help reduce seizure frequency in drug-resistant cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2050	2143	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	4	Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)	Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals.	treatment_term	treatment_term	$	Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)	Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2051	2144	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	5	AAV Gene Therapy (ETX101)	Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival.	treatment_term	treatment_term	$	AAV Gene Therapy (ETX101)	Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2052	2145	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	6	Cannabidiol	Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome.	treatment_term	treatment_term	$	Cannabidiol	Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2053	2146	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	7	Fenfluramine	Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action.	treatment_term	treatment_term	$	Fenfluramine	Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2054	2147	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	8	Stiripentol	Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome.	treatment_term	treatment_term	$	Stiripentol	Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2055	2153	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	pathophysiology	0	Dystrophin Deficiency	"Mutations in the DMD gene cause absent or dysfunctional dystrophin protein. Dystrophin links the cytoskeleton to the extracellular matrix in muscle fibers, providing structural stability during contraction.
"	cell_types[0]	cell_types	cell_types			Skeletal Muscle Fiber	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Fiber"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
2056	2153	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	pathophysiology	0	Dystrophin Deficiency	"Mutations in the DMD gene cause absent or dysfunctional dystrophin protein. Dystrophin links the cytoskeleton to the extracellular matrix in muscle fibers, providing structural stability during contraction.
"	biological_processes[0]	biological_processes	biological_processes			Muscle Contraction	GO:0006936	muscle contraction		"{""preferred_term"": ""Muscle Contraction"", ""term"": {""id"": ""GO:0006936"", ""label"": ""muscle contraction""}}"																											
2057	2154	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	pathophysiology	1	Progressive Muscle Degeneration	"Without dystrophin, muscle fibers are susceptible to contraction-induced damage. Repeated cycles of degeneration and regeneration exhaust satellite cell pools, leading to fibrosis and fatty replacement of muscle tissue.
"	cell_types[0]	cell_types	cell_types			Skeletal Muscle Fiber	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Fiber"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
2058	2154	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	pathophysiology	1	Progressive Muscle Degeneration	"Without dystrophin, muscle fibers are susceptible to contraction-induced damage. Repeated cycles of degeneration and regeneration exhaust satellite cell pools, leading to fibrosis and fatty replacement of muscle tissue.
"	biological_processes[0]	biological_processes	biological_processes			Muscle Degeneration	GO:0061061	muscle structure development		"{""preferred_term"": ""Muscle Degeneration"", ""term"": {""id"": ""GO:0061061"", ""label"": ""muscle structure development""}}"																											
2059	2155	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	0	Progressive Muscle Weakness		phenotype_term	phenotype_term	$	Progressive Muscle Weakness		Progressive Muscle Weakness	HP:0003323	Progressive muscle weakness		"{""preferred_term"": ""Progressive Muscle Weakness"", ""term"": {""id"": ""HP:0003323"", ""label"": ""Progressive muscle weakness""}}"																											
2060	2156	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	1	Gowers Sign		phenotype_term	phenotype_term	$	Gowers Sign		Gowers Sign	HP:0003391	Gowers sign		"{""preferred_term"": ""Gowers Sign"", ""term"": {""id"": ""HP:0003391"", ""label"": ""Gowers sign""}}"																											
2061	2157	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	2	Pseudohypertrophy of Calves		phenotype_term	phenotype_term	$	Pseudohypertrophy of Calves		Calf Pseudohypertrophy	HP:0003707	Calf muscle pseudohypertrophy		"{""preferred_term"": ""Calf Pseudohypertrophy"", ""term"": {""id"": ""HP:0003707"", ""label"": ""Calf muscle pseudohypertrophy""}}"																											
2062	2158	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	3	Elevated Creatine Kinase		phenotype_term	phenotype_term	$	Elevated Creatine Kinase		Elevated Creatine Kinase	HP:0003236	Elevated circulating creatine kinase concentration		"{""preferred_term"": ""Elevated Creatine Kinase"", ""term"": {""id"": ""HP:0003236"", ""label"": ""Elevated circulating creatine kinase concentration""}}"																											
2063	2159	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	4	Cardiomyopathy		phenotype_term	phenotype_term	$	Cardiomyopathy		Dilated Cardiomyopathy	HP:0001644	Dilated cardiomyopathy		"{""preferred_term"": ""Dilated Cardiomyopathy"", ""term"": {""id"": ""HP:0001644"", ""label"": ""Dilated cardiomyopathy""}}"																											
2064	2160	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	phenotypes	5	Respiratory Insufficiency		phenotype_term	phenotype_term	$	Respiratory Insufficiency		Respiratory Insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory Insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
2065	2171	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	histopathology	0	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	finding_term	finding_term	$	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	Gastric Adenocarcinoma	NCIT:C4004	Gastric Adenocarcinoma		"{""preferred_term"": ""Gastric Adenocarcinoma"", ""term"": {""id"": ""NCIT:C4004"", ""label"": ""Gastric Adenocarcinoma""}}"																											
2066	2172	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	infectious_agent	0	Epstein-Barr Virus (EBV)	Clonal EBV infection of gastric epithelial cells is the initiating event. Unlike EBV lymphomas where infection occurs in B cells, EBV gastric cancer involves epithelial cell tropism. The virus establishes latent infection (type I/II latency) with expression of EBNA1, LMP2A, and EBERs, with variable LMP1 expression. EBV-encoded oncoproteins drive epigenetic reprogramming and activate survival signaling pathways.	infectious_agent_term	infectious_agent_term	$	Epstein-Barr Virus (EBV)	Clonal EBV infection of gastric epithelial cells is the initiating event. Unlike EBV lymphomas where infection occurs in B cells, EBV gastric cancer involves epithelial cell tropism. The virus establishes latent infection (type I/II latency) with expression of EBNA1, LMP2A, and EBERs, with variable LMP1 expression. EBV-encoded oncoproteins drive epigenetic reprogramming and activate survival signaling pathways.	Human gammaherpesvirus 4	NCBITaxon:10376	Human gammaherpesvirus 4		"{""preferred_term"": ""Human gammaherpesvirus 4"", ""term"": {""id"": ""NCBITaxon:10376"", ""label"": ""Human gammaherpesvirus 4""}}"																											
2067	2173	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	0	EBV Latent Infection of Gastric Epithelium	EBV establishes clonal latent infection in gastric epithelial cells, expressing a restricted set of latent genes including EBNA1 (required for viral genome maintenance), LMP2A (mimics B-cell receptor signaling), and non-coding EBERs. LMP1 expression is variable but when present activates NF-kappaB and MAPK pathways.	cell_types[0]	cell_types	cell_types			epithelial cell	CL:0000066	epithelial cell		"{""preferred_term"": ""epithelial cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
2068	2173	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	0	EBV Latent Infection of Gastric Epithelium	EBV establishes clonal latent infection in gastric epithelial cells, expressing a restricted set of latent genes including EBNA1 (required for viral genome maintenance), LMP2A (mimics B-cell receptor signaling), and non-coding EBERs. LMP1 expression is variable but when present activates NF-kappaB and MAPK pathways.	locations[0]	locations	locations			stomach	UBERON:0000945	stomach		"{""preferred_term"": ""stomach"", ""term"": {""id"": ""UBERON:0000945"", ""label"": ""stomach""}}"																											
2069	2173	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	0	EBV Latent Infection of Gastric Epithelium	EBV establishes clonal latent infection in gastric epithelial cells, expressing a restricted set of latent genes including EBNA1 (required for viral genome maintenance), LMP2A (mimics B-cell receptor signaling), and non-coding EBERs. LMP1 expression is variable but when present activates NF-kappaB and MAPK pathways.	biological_processes[0]	biological_processes	biological_processes			viral transcription	GO:0019083	viral transcription		"{""preferred_term"": ""viral transcription"", ""term"": {""id"": ""GO:0019083"", ""label"": ""viral transcription""}}"																											
2070	2174	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	1	Epigenetic Reprogramming and CIMP-High Phenotype	EBV-associated gastric cancer displays the most extreme CpG island methylator phenotype (CIMP) of any cancer type. EBV-encoded proteins, particularly LMP2A, induce aberrant DNA methylation leading to silencing of tumor suppressor genes including CDKN2A (p16), CDH1 (E-cadherin), and MLH1. This epigenetic reprogramming is a hallmark feature distinguishing EBV-positive from EBV-negative gastric cancers.	biological_processes[0]	biological_processes	biological_processes			DNA methylation	GO:0006306	DNA methylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""DNA methylation"", ""term"": {""id"": ""GO:0006306"", ""label"": ""DNA methylation""}}"			INCREASED																								
2071	2175	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	PIK3CA mutations occur in approximately 80% of EBV-positive gastric cancers, the highest frequency of any gastric cancer subtype. Combined with LMP2A signaling which activates PI3K through mimicry of B-cell receptor signaling, this leads to constitutive AKT activation promoting cell survival and proliferation.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
2072	2176	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	3	Tumor Suppressor Gene Silencing	Promoter hypermethylation silences multiple tumor suppressor genes. CDKN2A (p16INK4A) silencing removes G1/S checkpoint control. CDH1 (E-cadherin) silencing promotes epithelial-mesenchymal transition. Unlike other gastric cancer subtypes, TP53 mutations are rare in EBV-positive tumors.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
2073	2177	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	4	Uncontrolled Cell Proliferation	Combined effects of PI3K-AKT activation, tumor suppressor silencing, and viral oncogene expression drive uncontrolled proliferation of infected gastric epithelial cells, leading to tumor formation.	cell_types[0]	cell_types	cell_types			epithelial cell	CL:0000066	epithelial cell		"{""preferred_term"": ""epithelial cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
2074	2177	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	pathophysiology	4	Uncontrolled Cell Proliferation	Combined effects of PI3K-AKT activation, tumor suppressor silencing, and viral oncogene expression drive uncontrolled proliferation of infected gastric epithelial cells, leading to tumor formation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2075	2178	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	0	Abdominal Pain	Epigastric pain is a common presenting symptom, often initially attributed to dyspepsia or gastritis.	phenotype_term	phenotype_term	$	Abdominal Pain	Epigastric pain is a common presenting symptom, often initially attributed to dyspepsia or gastritis.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2076	2179	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	1	Weight Loss	Unintentional weight loss occurs due to decreased appetite and metabolic effects of malignancy.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss occurs due to decreased appetite and metabolic effects of malignancy.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2077	2180	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	2	Fatigue	Generalized fatigue related to chronic disease and often anemia from occult gastrointestinal blood loss.	phenotype_term	phenotype_term	$	Fatigue	Generalized fatigue related to chronic disease and often anemia from occult gastrointestinal blood loss.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2078	2181	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	3	Anemia	Iron deficiency anemia from chronic gastrointestinal blood loss is common.	phenotype_term	phenotype_term	$	Anemia	Iron deficiency anemia from chronic gastrointestinal blood loss is common.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2079	2182	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	4	Hepatomegaly	Liver enlargement may indicate metastatic disease.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement may indicate metastatic disease.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
2080	2183	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	phenotypes	5	Lymphadenopathy	Regional lymph node enlargement occurs with local spread.	phenotype_term	phenotype_term	$	Lymphadenopathy	Regional lymph node enlargement occurs with local spread.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
2081	2184	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	0	Surgical Resection	Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2082	2185	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	1	Chemotherapy	Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease.	treatment_term	treatment_term	$	Chemotherapy	Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2083	2186	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	2	Immune Checkpoint Inhibitors	EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2084	2193	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
2085	2194	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	0	EGFR Oncogenic Mutations	Activating EGFR mutations occur in the tyrosine kinase domain and cause constitutive receptor activation independent of ligand binding. Mutations alter the ATP-binding pocket, favoring the active kinase conformation and enhancing sensitivity to ATP-competitive TKIs.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
2086	2194	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	0	EGFR Oncogenic Mutations	Activating EGFR mutations occur in the tyrosine kinase domain and cause constitutive receptor activation independent of ligand binding. Mutations alter the ATP-binding pocket, favoring the active kinase conformation and enhancing sensitivity to ATP-competitive TKIs.	biological_processes[0]	biological_processes	biological_processes			epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""epidermal growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0007173"", ""label"": ""epidermal growth factor receptor signaling pathway""}}"			INCREASED																								
2087	2195	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive EGFR Signaling	Mutant EGFR is constitutively phosphorylated, activating downstream signaling cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The tumor becomes dependent on (addicted to) EGFR signaling for survival.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2088	2195	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive EGFR Signaling	Mutant EGFR is constitutively phosphorylated, activating downstream signaling cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The tumor becomes dependent on (addicted to) EGFR signaling for survival.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
2089	2196	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	EGFR-mutant tumors exhibit oncogene addiction, with survival critically dependent on continued EGFR signaling. EGFR inhibition leads to rapid tumor regression through induction of apoptosis and cell cycle arrest. This creates the therapeutic window for TKI therapy.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2090	2197	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	pathophysiology	3	TKI Resistance Mechanisms	Resistance to EGFR TKIs develops through multiple mechanisms: secondary EGFR mutations (T790M, C797S), bypass pathway activation (MET amplification, HER2 amplification), and histologic transformation (small cell or squamous). Understanding resistance guides sequential therapy selection.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
2091	2198	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	EGFR-mutant NSCLC is predominantly adenocarcinoma histology. Often presents as peripheral lung nodules with ground-glass or lepidic growth patterns.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	EGFR-mutant NSCLC is predominantly adenocarcinoma histology. Often presents as peripheral lung nodules with ground-glass or lepidic growth patterns.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
2092	2199	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	phenotypes	1	Never/Light Smoker Association	EGFR mutations are strongly associated with never-smoking or light smoking history. The tumor develops through different carcinogenic pathways than smoking-associated lung cancer.	phenotype_term	phenotype_term	$	Never/Light Smoker Association	EGFR mutations are strongly associated with never-smoking or light smoking history. The tumor develops through different carcinogenic pathways than smoking-associated lung cancer.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
2093	2200	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	phenotypes	2	Female and Asian Predominance	EGFR mutations are more common in females and individuals of East Asian ancestry. In Asian never-smoking females, EGFR mutation rate approaches 60%.	phenotype_term	phenotype_term	$	Female and Asian Predominance	EGFR mutations are more common in females and individuals of East Asian ancestry. In Asian never-smoking females, EGFR mutation rate approaches 60%.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
2094	2201	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	phenotypes	3	Brain Metastases	Brain metastases occur in approximately 25-40% of EGFR-mutant NSCLC patients, often at presentation or during disease course. CNS-penetrant TKIs (osimertinib) have improved CNS disease control.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in approximately 25-40% of EGFR-mutant NSCLC patients, often at presentation or during disease course. CNS-penetrant TKIs (osimertinib) have improved CNS disease control.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
2095	2202	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	0	Osimertinib	Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration.	treatment_term	treatment_term	$	Osimertinib	Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2096	2203	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	1	Erlotinib	First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.	treatment_term	treatment_term	$	Erlotinib	First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2097	2204	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	2	Gefitinib	First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib.	treatment_term	treatment_term	$	Gefitinib	First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2098	2205	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	3	Amivantamab	Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC.	treatment_term	treatment_term	$	Amivantamab	Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2099	2206	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2100	2214	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	histopathology	0	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	finding_term	finding_term	$	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	Invasive Breast Carcinoma of No Special Type	NCIT:C4194	Invasive Breast Carcinoma of No Special Type		"{""preferred_term"": ""Invasive Breast Carcinoma of No Special Type"", ""term"": {""id"": ""NCIT:C4194"", ""label"": ""Invasive Breast Carcinoma of No Special Type""}}"																											
2101	2215	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	0	Estrogen Receptor Activation	ER+ breast cancer is driven by estrogen-dependent activation of the estrogen receptor alpha (ER), a nuclear hormone receptor that functions as a ligand-activated transcription factor. Estrogen binding induces receptor dimerization, DNA binding, and transcriptional activation of target genes.	cell_types[0]	cell_types	cell_types			luminal epithelial cell of mammary gland	CL:0002326	luminal epithelial cell of mammary gland		"{""preferred_term"": ""luminal epithelial cell of mammary gland"", ""term"": {""id"": ""CL:0002326"", ""label"": ""luminal epithelial cell of mammary gland""}}"																											
2102	2215	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	0	Estrogen Receptor Activation	ER+ breast cancer is driven by estrogen-dependent activation of the estrogen receptor alpha (ER), a nuclear hormone receptor that functions as a ligand-activated transcription factor. Estrogen binding induces receptor dimerization, DNA binding, and transcriptional activation of target genes.	biological_processes[0]	biological_processes	biological_processes			intracellular estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""intracellular estrogen receptor signaling pathway"", ""term"": {""id"": ""GO:0030520"", ""label"": ""intracellular estrogen receptor signaling pathway""}}"			INCREASED																								
2103	2216	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	1	Estrogen-Driven Transcription	Activated ER binds estrogen response elements (EREs) in target gene promoters, recruiting coactivators and driving transcription of genes promoting cell cycle progression (CCND1), survival (BCL2), and growth factor signaling (IGF1R, EGFR). This creates estrogen-dependent tumor growth.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			INCREASED																								
2104	2217	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	2	Cell Cycle Progression	ER signaling drives expression of cyclin D1 (CCND1), which complexes with CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""INCREASED"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			INCREASED																								
2105	2217	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	pathophysiology	2	Cell Cycle Progression	ER signaling drives expression of cyclin D1 (CCND1), which complexes with CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2106	2218	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	phenotypes	0	Breast Carcinoma	ER+ breast cancers are typically invasive ductal or lobular carcinomas. Luminal A tumors are often lower grade with favorable histologic features.	phenotype_term	phenotype_term	$	Breast Carcinoma	ER+ breast cancers are typically invasive ductal or lobular carcinomas. Luminal A tumors are often lower grade with favorable histologic features.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
2107	2219	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	phenotypes	1	Estrogen Receptor Expression	Defining feature is ER expression 1% by immunohistochemistry. Higher ER expression (>10%) correlates with greater endocrine sensitivity. PR expression often accompanies ER positivity and indicates functional ER signaling.	phenotype_term	phenotype_term	$	Estrogen Receptor Expression	Defining feature is ER expression 1% by immunohistochemistry. Higher ER expression (>10%) correlates with greater endocrine sensitivity. PR expression often accompanies ER positivity and indicates functional ER signaling.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
2108	2220	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	phenotypes	2	Late Recurrence Pattern	Unlike TNBC, ER+ breast cancer can recur many years (10-20+) after initial diagnosis, necessitating long-term surveillance and extended adjuvant endocrine therapy.	phenotype_term	phenotype_term	$	Late Recurrence Pattern	Unlike TNBC, ER+ breast cancer can recur many years (10-20+) after initial diagnosis, necessitating long-term surveillance and extended adjuvant endocrine therapy.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
2109	2221	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	0	Aromatase Inhibitors	First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.	treatment_term	treatment_term	$	Aromatase Inhibitors	First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2110	2222	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	1	Tamoxifen	Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.	treatment_term	treatment_term	$	Tamoxifen	Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2111	2223	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	2	CDK4/6 Inhibitors	Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.	treatment_term	treatment_term	$	CDK4/6 Inhibitors	Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2112	2224	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	3	Fulvestrant	Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.	treatment_term	treatment_term	$	Fulvestrant	Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2113	2225	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	4	Alpelisib	PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.	treatment_term	treatment_term	$	Alpelisib	PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2114	2226	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	5	Elacestrant	Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.	treatment_term	treatment_term	$	Elacestrant	Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2115	2227	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	biochemical	0	Ebola Virus Antigen		assays[0]	assays	assays			Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)				"{""preferred_term"": ""Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)""}"																											
2116	2227	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	biochemical	0	Ebola Virus Antigen		assays[1]	assays	assays			Reverse Transcription Polymerase Chain Reaction (RT-PCR)				"{""preferred_term"": ""Reverse Transcription Polymerase Chain Reaction (RT-PCR)""}"																											
2117	2228	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	biochemical	1	Ebola Virus RNA		assays[0]	assays	assays			Reverse Transcription Polymerase Chain Reaction (RT-PCR)				"{""preferred_term"": ""Reverse Transcription Polymerase Chain Reaction (RT-PCR)""}"																											
2118	2229	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	environmental	0	Animal Reservoirs		exposure_term	exposure_term	$	Animal Reservoirs		Animal reservoir exposure	ECTO:3000001	exposure to virus		"{""preferred_term"": ""Animal reservoir exposure"", ""term"": {""id"": ""ECTO:3000001"", ""label"": ""exposure to virus""}}"																											
2119	2241	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	infectious_agent	0	Ebola Virus		infectious_agent_term	infectious_agent_term	$	Ebola Virus		Ebola virus	NCBITaxon:1570291	Ebola virus		"{""preferred_term"": ""Ebola virus"", ""term"": {""id"": ""NCBITaxon:1570291"", ""label"": ""Ebola virus""}}"																											
2120	2242	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	0	Viral Entry via Endocytosis	Ebola virus enters host cells through receptor-mediated macropinocytosis. The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes, triggering membrane fusion and release of viral genome into the cytoplasm.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
2121	2242	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	0	Viral Entry via Endocytosis	Ebola virus enters host cells through receptor-mediated macropinocytosis. The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes, triggering membrane fusion and release of viral genome into the cytoplasm.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2122	2242	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	0	Viral Entry via Endocytosis	Ebola virus enters host cells through receptor-mediated macropinocytosis. The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes, triggering membrane fusion and release of viral genome into the cytoplasm.	cell_types[2]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
2123	2242	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	0	Viral Entry via Endocytosis	Ebola virus enters host cells through receptor-mediated macropinocytosis. The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes, triggering membrane fusion and release of viral genome into the cytoplasm.	biological_processes[0]	biological_processes	biological_processes			symbiont entry into host cell	GO:0046718	symbiont entry into host cell		"{""preferred_term"": ""symbiont entry into host cell"", ""term"": {""id"": ""GO:0046718"", ""label"": ""symbiont entry into host cell""}}"																											
2124	2243	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	1	Immune Evasion and Viral Replication	Ebola viral proteins VP35 and VP24 antagonize the host interferon response. VP35 binds dsRNA and blocks RIG-I signaling, while VP24 prevents STAT1 nuclear import, thereby suppressing type I interferon signaling. This allows rapid viral replication and high viremia in infected monocytes, macrophages, and dendritic cells.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
2125	2243	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	1	Immune Evasion and Viral Replication	Ebola viral proteins VP35 and VP24 antagonize the host interferon response. VP35 binds dsRNA and blocks RIG-I signaling, while VP24 prevents STAT1 nuclear import, thereby suppressing type I interferon signaling. This allows rapid viral replication and high viremia in infected monocytes, macrophages, and dendritic cells.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2126	2243	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	1	Immune Evasion and Viral Replication	Ebola viral proteins VP35 and VP24 antagonize the host interferon response. VP35 binds dsRNA and blocks RIG-I signaling, while VP24 prevents STAT1 nuclear import, thereby suppressing type I interferon signaling. This allows rapid viral replication and high viremia in infected monocytes, macrophages, and dendritic cells.	cell_types[2]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
2127	2244	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	2	Endothelial Dysfunction and Vascular Leak	Ebola virus glycoprotein (GP) and secreted GP (sGP) contribute to endothelial cell activation and barrier disruption. This leads to increased vascular permeability, fluid extravasation, and hypovolemic shock. Endothelial dysfunction is a central feature of Ebola hemorrhagic fever.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
2128	2244	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	2	Endothelial Dysfunction and Vascular Leak	Ebola virus glycoprotein (GP) and secreted GP (sGP) contribute to endothelial cell activation and barrier disruption. This leads to increased vascular permeability, fluid extravasation, and hypovolemic shock. Endothelial dysfunction is a central feature of Ebola hemorrhagic fever.	locations[0]	locations	locations			blood vessel	UBERON:0001981	blood vessel		"{""preferred_term"": ""blood vessel"", ""term"": {""id"": ""UBERON:0001981"", ""label"": ""blood vessel""}}"																											
2129	2245	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	3	Coagulopathy and Disseminated Intravascular Coagulation	Ebola infection triggers systemic inflammatory response with cytokine release, endothelial activation, and tissue factor pathway activation. This leads to thromboinflammation, platelet activation, consumptive coagulopathy, and disseminated intravascular coagulation (DIC), resulting in hemorrhagic manifestations.	biological_processes[0]	biological_processes	biological_processes			blood coagulation	GO:0007596	blood coagulation		"{""preferred_term"": ""blood coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
2130	2245	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	3	Coagulopathy and Disseminated Intravascular Coagulation	Ebola infection triggers systemic inflammatory response with cytokine release, endothelial activation, and tissue factor pathway activation. This leads to thromboinflammation, platelet activation, consumptive coagulopathy, and disseminated intravascular coagulation (DIC), resulting in hemorrhagic manifestations.	locations[0]	locations	locations			blood vessel	UBERON:0001981	blood vessel		"{""preferred_term"": ""blood vessel"", ""term"": {""id"": ""UBERON:0001981"", ""label"": ""blood vessel""}}"																											
2131	2246	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	4	Multiorgan Involvement	Ebola virus infects multiple organs including liver, spleen, lymph nodes, and kidneys. Hepatic dysfunction with elevated liver enzymes (AST > ALT pattern) and splenic involvement contribute to multiorgan failure in severe cases.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
2132	2246	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	pathophysiology	4	Multiorgan Involvement	Ebola virus infects multiple organs including liver, spleen, lymph nodes, and kidneys. Hepatic dysfunction with elevated liver enzymes (AST > ALT pattern) and splenic involvement contribute to multiorgan failure in severe cases.	locations[1]	locations	locations			spleen	UBERON:0002106	spleen		"{""preferred_term"": ""spleen"", ""term"": {""id"": ""UBERON:0002106"", ""label"": ""spleen""}}"																											
2133	2247	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	0	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
2134	2248	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	1	Hemorrhage		phenotype_term	phenotype_term	$	Hemorrhage		Hemorrhage	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Hemorrhage"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
2135	2249	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	2	Vomiting		phenotype_term	phenotype_term	$	Vomiting		Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
2136	2250	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	3	Diarrhea		phenotype_term	phenotype_term	$	Diarrhea		Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
2137	2252	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2138	2253	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	6	Myalgia		phenotype_term	phenotype_term	$	Myalgia		Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
2139	2254	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	7	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2140	2255	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	8	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2141	2256	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	9	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
2142	2257	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	10	Hepatitis		phenotype_term	phenotype_term	$	Hepatitis		Hepatitis	HP:0012115	Hepatitis		"{""preferred_term"": ""Hepatitis"", ""term"": {""id"": ""HP:0012115"", ""label"": ""Hepatitis""}}"																											
2143	2258	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	11	Hypovolemic Shock		phenotype_term	phenotype_term	$	Hypovolemic Shock		Hypovolemic Shock	HP:0031273	Shock		"{""preferred_term"": ""Hypovolemic Shock"", ""term"": {""id"": ""HP:0031273"", ""label"": ""Shock""}}"																											
2144	2259	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	12	Dehydration		phenotype_term	phenotype_term	$	Dehydration		Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
2145	2260	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	13	Electrolyte Imbalances		phenotype_term	phenotype_term	$	Electrolyte Imbalances		Electrolyte Imbalances	HP:0003111	Abnormal blood ion concentration		"{""preferred_term"": ""Electrolyte Imbalances"", ""term"": {""id"": ""HP:0003111"", ""label"": ""Abnormal blood ion concentration""}}"																											
2146	2261	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	14	Multiorgan Failure		phenotype_term	phenotype_term	$	Multiorgan Failure		Multiorgan Failure				"{""preferred_term"": ""Multiorgan Failure""}"																											
2147	2262	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	15	Elevated Liver Enzymes		phenotype_term	phenotype_term	$	Elevated Liver Enzymes		Elevated Liver Enzymes	HP:0002910	Elevated circulating hepatic transaminase concentration		"{""preferred_term"": ""Elevated Liver Enzymes"", ""term"": {""id"": ""HP:0002910"", ""label"": ""Elevated circulating hepatic transaminase concentration""}}"																											
2148	2263	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	16	Impaired Liver Function		phenotype_term	phenotype_term	$	Impaired Liver Function		Impaired Liver Function	HP:0001410	Decreased liver function		"{""preferred_term"": ""Impaired Liver Function"", ""term"": {""id"": ""HP:0001410"", ""label"": ""Decreased liver function""}}"																											
2149	2264	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	phenotypes	17	Increased Risk of Bleeding		phenotype_term	phenotype_term	$	Increased Risk of Bleeding		Increased Risk of Bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Increased Risk of Bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
2150	2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	Supportive Care	Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.	treatment_term	treatment_term	$	Supportive Care	Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2151	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	Experimental Therapies	Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.	treatment_term	treatment_term	$	Experimental Therapies	Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
2152	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	Vaccination	The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.	treatment_term	treatment_term	$	Vaccination	The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
2153	2272	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	animal_models	0			genes[0]	genes	genes			COL5A1	hgnc:2209	COL5A1		"{""preferred_term"": ""COL5A1"", ""term"": {""id"": ""hgnc:2209"", ""label"": ""COL5A1""}}"																											
2154	2273	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	animal_models	1			genes[0]	genes	genes			COL3A1	hgnc:2201	COL3A1		"{""preferred_term"": ""COL3A1"", ""term"": {""id"": ""hgnc:2201"", ""label"": ""COL3A1""}}"																											
2155	2290	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	0	Collagen Abnormalities	Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.	biological_processes[0]	biological_processes	biological_processes			collagen fibril organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""collagen fibril organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
2156	2290	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	0	Collagen Abnormalities	Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.	biological_processes[1]	biological_processes	biological_processes			collagen biosynthetic process	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""collagen biosynthetic process"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
2157	2291	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen leads to weakened connective tissues throughout the body.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
2158	2291	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen leads to weakened connective tissues throughout the body.	cell_types[0]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
2159	2291	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen leads to weakened connective tissues throughout the body.	cell_types[1]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
2160	2291	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen leads to weakened connective tissues throughout the body.	locations[0]	locations	locations			dermis	UBERON:0002067	dermis		"{""preferred_term"": ""dermis"", ""term"": {""id"": ""UBERON:0002067"", ""label"": ""dermis""}}"																											
2161	2291	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen leads to weakened connective tissues throughout the body.	locations[1]	locations	locations			blood vessel	UBERON:0001981	blood vessel		"{""preferred_term"": ""blood vessel"", ""term"": {""id"": ""UBERON:0001981"", ""label"": ""blood vessel""}}"																											
2162	2293	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	3	Integrin-Mediated Mechanotransduction Dysregulation	Defective collagen matrix leads to altered integrin signaling, particularly upregulation of integrin v3, contributing to persistent inflammation and impaired wound healing in classical EDS.	biological_processes[0]	biological_processes	biological_processes			integrin-mediated signaling pathway	GO:0007229	integrin-mediated signaling pathway		"{""preferred_term"": ""integrin-mediated signaling pathway"", ""term"": {""id"": ""GO:0007229"", ""label"": ""integrin-mediated signaling pathway""}}"																											
2163	2293	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	3	Integrin-Mediated Mechanotransduction Dysregulation	Defective collagen matrix leads to altered integrin signaling, particularly upregulation of integrin v3, contributing to persistent inflammation and impaired wound healing in classical EDS.	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2164	2294	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	4	Autophagy and Proteostasis Dysfunction	Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.	biological_processes[0]	biological_processes	biological_processes			autophagy	GO:0006914	autophagy		"{""preferred_term"": ""autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
2165	2294	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	4	Autophagy and Proteostasis Dysfunction	Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.	biological_processes[1]	biological_processes	biological_processes			protein folding	GO:0006457	protein folding		"{""preferred_term"": ""protein folding"", ""term"": {""id"": ""GO:0006457"", ""label"": ""protein folding""}}"																											
2166	2294	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	4	Autophagy and Proteostasis Dysfunction	Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.	cellular_components[0]	cellular_components	cellular_components			lysosome	GO:0005764	lysosome		"{""preferred_term"": ""lysosome"", ""term"": {""id"": ""GO:0005764"", ""label"": ""lysosome""}}"																											
2167	2294	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	4	Autophagy and Proteostasis Dysfunction	Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.	cellular_components[1]	cellular_components	cellular_components			autophagosome	GO:0005776	autophagosome		"{""preferred_term"": ""autophagosome"", ""term"": {""id"": ""GO:0005776"", ""label"": ""autophagosome""}}"																											
2168	2295	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	5	Complement-Mediated ECM Degradation	Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.	biological_processes[0]	biological_processes	biological_processes			complement activation, classical pathway	GO:0006958	complement activation, classical pathway		"{""preferred_term"": ""complement activation, classical pathway"", ""term"": {""id"": ""GO:0006958"", ""label"": ""complement activation, classical pathway""}}"																											
2169	2295	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	5	Complement-Mediated ECM Degradation	Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.	biological_processes[1]	biological_processes	biological_processes			proteolysis	GO:0006508	proteolysis		"{""preferred_term"": ""proteolysis"", ""term"": {""id"": ""GO:0006508"", ""label"": ""proteolysis""}}"																											
2170	2295	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	pathophysiology	5	Complement-Mediated ECM Degradation	Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.	locations[0]	locations	locations			periodontium	UBERON:0002405	periodontium		"{""preferred_term"": ""periodontium"", ""term"": {""id"": ""UBERON:0002405"", ""label"": ""periodontium""}}"																											
2171	2296	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	0	Joint Hypermobility		phenotype_term	phenotype_term	$	Joint Hypermobility		Joint Hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint Hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
2172	2298	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	2	Poor Wound Healing		phenotype_term	phenotype_term	$	Poor Wound Healing		Poor Wound Healing	HP:0001058	Poor wound healing		"{""preferred_term"": ""Poor Wound Healing"", ""term"": {""id"": ""HP:0001058"", ""label"": ""Poor wound healing""}}"																											
2173	2300	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	4	Keratoconus		phenotype_term	phenotype_term	$	Keratoconus		Keratoconus	HP:0000563	Keratoconus		"{""preferred_term"": ""Keratoconus"", ""term"": {""id"": ""HP:0000563"", ""label"": ""Keratoconus""}}"																											
2174	2301	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	5	Mitral Valve Prolapse		phenotype_term	phenotype_term	$	Mitral Valve Prolapse		Mitral Valve Prolapse	HP:0001634	Mitral valve prolapse		"{""preferred_term"": ""Mitral Valve Prolapse"", ""term"": {""id"": ""HP:0001634"", ""label"": ""Mitral valve prolapse""}}"																											
2175	2303	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	7	Gastroesophageal Reflux		phenotype_term	phenotype_term	$	Gastroesophageal Reflux		Gastroesophageal Reflux	HP:0002020	Gastroesophageal reflux		"{""preferred_term"": ""Gastroesophageal Reflux"", ""term"": {""id"": ""HP:0002020"", ""label"": ""Gastroesophageal reflux""}}"																											
2176	2304	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	8	Keratoconus		phenotype_term	phenotype_term	$	Keratoconus		Keratoconus	HP:0000563	Keratoconus		"{""preferred_term"": ""Keratoconus"", ""term"": {""id"": ""HP:0000563"", ""label"": ""Keratoconus""}}"																											
2177	2305	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	9	Recurrent Joint Dislocations		phenotype_term	phenotype_term	$	Recurrent Joint Dislocations		Recurrent Joint Dislocations	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Recurrent Joint Dislocations"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
2178	2306	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	10	Chronic Joint Pain		phenotype_term	phenotype_term	$	Chronic Joint Pain		Chronic Joint Pain	HP:0002829	Arthralgia		"{""preferred_term"": ""Chronic Joint Pain"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
2179	2307	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	11	Decreased Bone Density		phenotype_term	phenotype_term	$	Decreased Bone Density		Decreased Bone Density	HP:0004349	Reduced bone mineral density		"{""preferred_term"": ""Decreased Bone Density"", ""term"": {""id"": ""HP:0004349"", ""label"": ""Reduced bone mineral density""}}"																											
2180	2308	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	phenotypes	12	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
2181	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	treatment_term	treatment_term	$	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2182	2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	Surgical Interventions	May be needed for severe joint instability or life-threatening complications like arterial dissections.	treatment_term	treatment_term	$	Surgical Interventions	May be needed for severe joint instability or life-threatening complications like arterial dissections.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2183	2314	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	2	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury.	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2184	2315	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support unstable joints.	treatment_term	treatment_term	$	Orthotic Interventions	Use of orthotic devices to support unstable joints.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2185	2319	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	0	Collagen Type V Abnormalities	Mutations in the COL5A1 gene lead to defective collagen type V synthesis and assembly.	biological_processes[0]	biological_processes	biological_processes			collagen fibril organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""collagen fibril organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
2186	2319	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	0	Collagen Type V Abnormalities	Mutations in the COL5A1 gene lead to defective collagen type V synthesis and assembly.	biological_processes[1]	biological_processes	biological_processes			collagen biosynthetic process	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""collagen biosynthetic process"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
2187	2320	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen type V leads to weakened connective tissues throughout the body.	cell_types[0]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
2188	2320	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen type V leads to weakened connective tissues throughout the body.	cell_types[1]	cell_types	cell_types			dermal fibroblast	CL:0002620	skin fibroblast		"{""preferred_term"": ""dermal fibroblast"", ""term"": {""id"": ""CL:0002620"", ""label"": ""skin fibroblast""}}"																											
2189	2320	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen type V leads to weakened connective tissues throughout the body.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
2190	2320	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	1	Connective Tissue Fragility	Abnormal collagen type V leads to weakened connective tissues throughout the body.	cellular_components[0]	cellular_components	cellular_components			extracellular matrix	GO:0031012	extracellular matrix		"{""preferred_term"": ""extracellular matrix"", ""term"": {""id"": ""GO:0031012"", ""label"": ""extracellular matrix""}}"																											
2191	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
2192	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
2193	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	locations[1]	locations	locations			tendon	UBERON:0000043	tendon		"{""preferred_term"": ""tendon"", ""term"": {""id"": ""UBERON:0000043"", ""label"": ""tendon""}}"																											
2194	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	locations[2]	locations	locations			corneal stroma	UBERON:0001772	corneal stroma		"{""preferred_term"": ""corneal stroma"", ""term"": {""id"": ""UBERON:0001772"", ""label"": ""corneal stroma""}}"																											
2195	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	biological_processes[0]	biological_processes	biological_processes			wound healing	GO:0042060	wound healing		"{""preferred_term"": ""wound healing"", ""term"": {""id"": ""GO:0042060"", ""label"": ""wound healing""}}"																											
2196	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	biological_processes[1]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"																											
2197	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	biological_processes[2]	biological_processes	biological_processes			integrin-mediated signaling pathway	GO:0007229	integrin-mediated signaling pathway		"{""preferred_term"": ""integrin-mediated signaling pathway"", ""term"": {""id"": ""GO:0007229"", ""label"": ""integrin-mediated signaling pathway""}}"																											
2198	2321	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	pathophysiology	2	Tissue Injury and Dysfunction	Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing. Impaired wound healing involves altered mechanosensitive integrin signaling and defective re-epithelialization.	cellular_components[0]	cellular_components	cellular_components			pericellular matrix	GO:0036046	pericellular matrix		"{""preferred_term"": ""pericellular matrix"", ""term"": {""id"": ""GO:0036046"", ""label"": ""pericellular matrix""}}"																											
2199	2322	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	0	Joint Hypermobility	Abnormally increased range of motion in multiple joints due to lax connective tissue.	phenotype_term	phenotype_term	$	Joint Hypermobility	Abnormally increased range of motion in multiple joints due to lax connective tissue.	Joint Hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint Hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
2200	2326	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	4	Mitral Valve Prolapse	Abnormal bulging of the mitral valve leaflets into the left atrium during systole due to connective tissue laxity.	phenotype_term	phenotype_term	$	Mitral Valve Prolapse	Abnormal bulging of the mitral valve leaflets into the left atrium during systole due to connective tissue laxity.	Mitral Valve Prolapse	HP:0001634	Mitral valve prolapse		"{""preferred_term"": ""Mitral Valve Prolapse"", ""term"": {""id"": ""HP:0001634"", ""label"": ""Mitral valve prolapse""}}"																											
2201	2327	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	5	Gastroesophageal Reflux	Backflow of stomach contents into the esophagus, possibly related to laxity of the lower esophageal sphincter.	phenotype_term	phenotype_term	$	Gastroesophageal Reflux	Backflow of stomach contents into the esophagus, possibly related to laxity of the lower esophageal sphincter.	Gastroesophageal Reflux	HP:0002020	Gastroesophageal reflux		"{""preferred_term"": ""Gastroesophageal Reflux"", ""term"": {""id"": ""HP:0002020"", ""label"": ""Gastroesophageal reflux""}}"																											
2202	2328	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	6	Molluscoid Pseudotumors	Fleshy, scar-associated lesions that develop over pressure points and areas of repeated trauma.	phenotype_term	phenotype_term	$	Molluscoid Pseudotumors	Fleshy, scar-associated lesions that develop over pressure points and areas of repeated trauma.	Molluscoid Pseudotumors	HP:0000993	Molluscoid pseudotumors		"{""preferred_term"": ""Molluscoid Pseudotumors"", ""term"": {""id"": ""HP:0000993"", ""label"": ""Molluscoid pseudotumors""}}"																											
2203	2329	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	7	Myopia	Nearsightedness, a refractive error where distant objects appear blurred.	phenotype_term	phenotype_term	$	Myopia	Nearsightedness, a refractive error where distant objects appear blurred.	Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
2204	2330	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	8	Recurrent Joint Dislocations	Repeated episodes of joints becoming displaced from their normal positions.	phenotype_term	phenotype_term	$	Recurrent Joint Dislocations	Repeated episodes of joints becoming displaced from their normal positions.	Recurrent Joint Dislocations	HP:0001373	Joint dislocation		"{""preferred_term"": ""Recurrent Joint Dislocations"", ""term"": {""id"": ""HP:0001373"", ""label"": ""Joint dislocation""}}"																											
2205	2331	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	9	Chronic Joint Pain	Persistent pain in multiple joints resulting from joint instability, subluxations, and degenerative changes.	phenotype_term	phenotype_term	$	Chronic Joint Pain	Persistent pain in multiple joints resulting from joint instability, subluxations, and degenerative changes.	Chronic Joint Pain	HP:0002829	Arthralgia		"{""preferred_term"": ""Chronic Joint Pain"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
2206	2332	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	phenotypes	10	Delayed Wound Healing	Prolonged time for wounds to heal with impaired re-epithelialization and abnormal granulation tissue formation.	phenotype_term	phenotype_term	$	Delayed Wound Healing	Prolonged time for wounds to heal with impaired re-epithelialization and abnormal granulation tissue formation.	Delayed Wound Healing	HP:0001030	Fragile skin		"{""preferred_term"": ""Delayed Wound Healing"", ""term"": {""id"": ""HP:0001030"", ""label"": ""Fragile skin""}}"																											
2207	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	treatment_term	treatment_term	$	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2208	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	Wound Care	Careful attention to wound healing and scar management.	treatment_term	treatment_term	$	Wound Care	Careful attention to wound healing and scar management.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2209	2338	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	3	Gastrointestinal Management	Treatment of gastroesophageal reflux and other GI symptoms as needed.	treatment_term	treatment_term	$	Gastrointestinal Management	Treatment of gastroesophageal reflux and other GI symptoms as needed.	gastrointestinal agent therapy	MAXO:0000267	gastrointestinal agent therapy		"{""preferred_term"": ""gastrointestinal agent therapy"", ""term"": {""id"": ""MAXO:0000267"", ""label"": ""gastrointestinal agent therapy""}}"																											
2210	2339	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	4	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2211	2347	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	histopathology	0	Rhabdomyosarcoma	Rhabdomyosarcoma is a malignant tumor of mesenchymal origin.	finding_term	finding_term	$	Rhabdomyosarcoma	Rhabdomyosarcoma is a malignant tumor of mesenchymal origin.	Rhabdomyosarcoma	NCIT:C3359	Rhabdomyosarcoma		"{""preferred_term"": ""Rhabdomyosarcoma"", ""term"": {""id"": ""NCIT:C3359"", ""label"": ""Rhabdomyosarcoma""}}"																											
2212	2348	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	0	Loss of Heterozygosity at 11p15	Loss of heterozygosity (LOH) at chromosome 11p15.5 is the hallmark genetic event in ERMS, occurring in approximately 80% of cases. This region contains the imprinted IGF2 gene, and LOH results in loss of the maternal allele with duplication of the paternal allele, leading to biallelic IGF2 expression and growth factor pathway activation.	cell_types[0]	cell_types	cell_types			skeletal muscle myoblast	CL:0000515	skeletal muscle myoblast		"{""preferred_term"": ""skeletal muscle myoblast"", ""term"": {""id"": ""CL:0000515"", ""label"": ""skeletal muscle myoblast""}}"																											
2213	2348	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	0	Loss of Heterozygosity at 11p15	Loss of heterozygosity (LOH) at chromosome 11p15.5 is the hallmark genetic event in ERMS, occurring in approximately 80% of cases. This region contains the imprinted IGF2 gene, and LOH results in loss of the maternal allele with duplication of the paternal allele, leading to biallelic IGF2 expression and growth factor pathway activation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2214	2349	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	1	IGF2 Overexpression	Loss of imprinting at 11p15 results in biallelic expression of IGF2, leading to autocrine and paracrine growth stimulation through IGF1R signaling. This promotes cell proliferation and survival in ERMS cells.	biological_processes[0]	biological_processes	biological_processes			regulation of cell population proliferation	GO:0042127	regulation of cell population proliferation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of cell population proliferation"", ""term"": {""id"": ""GO:0042127"", ""label"": ""regulation of cell population proliferation""}}"			ABNORMAL																								
2215	2350	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	pathophysiology	2	RAS Pathway Activation	Activating mutations in RAS pathway genes (NRAS, KRAS, HRAS) occur in approximately 35% of ERMS cases. FGFR4 mutations occur in 7-10% of cases. These mutations drive proliferation through MAPK and PI3K pathway activation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2216	2351	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	phenotypes	0	Soft Tissue Mass	A soft tissue mass is the most common presentation. Location varies by age and subtype, with head and neck common in younger children and genitourinary sites in adolescents.	phenotype_term	phenotype_term	$	Soft Tissue Mass	A soft tissue mass is the most common presentation. Location varies by age and subtype, with head and neck common in younger children and genitourinary sites in adolescents.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
2217	2352	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	phenotypes	1	Proptosis	Orbital ERMS commonly presents with proptosis and is associated with excellent prognosis. The orbit is a favorable primary site.	phenotype_term	phenotype_term	$	Proptosis	Orbital ERMS commonly presents with proptosis and is associated with excellent prognosis. The orbit is a favorable primary site.	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
2218	2353	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	phenotypes	2	Hematuria	Bladder or prostate ERMS may present with hematuria or urinary obstruction.	phenotype_term	phenotype_term	$	Hematuria	Bladder or prostate ERMS may present with hematuria or urinary obstruction.	Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
2219	2354	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	phenotypes	3	Weight Loss	Weight loss and failure to thrive may occur with advanced disease.	phenotype_term	phenotype_term	$	Weight Loss	Weight loss and failure to thrive may occur with advanced disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				vincristine; actinomycin D; cyclophosphamide	CHEBI:28445; CHEBI:27666; CHEBI:4026																						
2221	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
2222	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
2223	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
2224	2356	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2225	2357	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients.	treatment_term	treatment_term	$	Radiation Therapy	Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2226	2368	104	Endometriosis	Endometriosis.yaml	pathophysiology	0	Ectopic Endometrial Tissue	"Endometrial-like tissue grows outside the uterus, commonly on ovaries, fallopian tubes, and pelvic peritoneum. Responds to hormonal cycling with bleeding and inflammation.
"	cell_types[0]	cell_types	cell_types			Endometrial Stromal Cell	CL:0002255	stromal cell of endometrium		"{""preferred_term"": ""Endometrial Stromal Cell"", ""term"": {""id"": ""CL:0002255"", ""label"": ""stromal cell of endometrium""}}"																											
2227	2368	104	Endometriosis	Endometriosis.yaml	pathophysiology	0	Ectopic Endometrial Tissue	"Endometrial-like tissue grows outside the uterus, commonly on ovaries, fallopian tubes, and pelvic peritoneum. Responds to hormonal cycling with bleeding and inflammation.
"	biological_processes[0]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell population proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"																											
2228	2370	104	Endometriosis	Endometriosis.yaml	pathophysiology	2	Chronic Inflammation	"Ectopic lesions trigger chronic pelvic inflammation with elevated cytokines and prostaglandins. Inflammatory milieu contributes to pain and adhesion formation.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2229	2371	104	Endometriosis	Endometriosis.yaml	pathophysiology	3	Estrogen Dependence	"Endometriotic lesions produce their own estrogen via aromatase and are highly estrogen-responsive. Progesterone resistance impairs normal tissue regression.
"	biological_processes[0]	biological_processes	biological_processes			Estrogen Response	GO:0043627	response to estrogen		"{""preferred_term"": ""Estrogen Response"", ""term"": {""id"": ""GO:0043627"", ""label"": ""response to estrogen""}}"																											
2230	2372	104	Endometriosis	Endometriosis.yaml	pathophysiology	4	Immune Dysfunction	"Immune system alterations enable ectopic endometrial cells to evade clearance. Includes increased peritoneal macrophages, reduced NK cell cytotoxicity, T cell dysfunction, and elevated inflammatory cytokines. Crosstalk between endometrial stromal cells and macrophages impairs NK cell function via IL-10 and TGF-beta secretion.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2231	2373	104	Endometriosis	Endometriosis.yaml	pathophysiology	5	Hypoxia and Angiogenesis	"Ectopic lesions experience hypoxia which stabilizes HIF-1alpha, upregulating VEGF and promoting angiogenesis. Neovascularization supports lesion survival and growth. Ovarian endometriomas show particularly high expression of hypoxic and angiogenic factors.
"	biological_processes[0]	biological_processes	biological_processes			Response to Hypoxia	GO:0001666	response to hypoxia		"{""preferred_term"": ""Response to Hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"																											
2232	2373	104	Endometriosis	Endometriosis.yaml	pathophysiology	5	Hypoxia and Angiogenesis	"Ectopic lesions experience hypoxia which stabilizes HIF-1alpha, upregulating VEGF and promoting angiogenesis. Neovascularization supports lesion survival and growth. Ovarian endometriomas show particularly high expression of hypoxic and angiogenic factors.
"	biological_processes[1]	biological_processes	biological_processes			Angiogenesis	GO:0001525	angiogenesis		"{""preferred_term"": ""Angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"																											
2233	2375	104	Endometriosis	Endometriosis.yaml	phenotypes	0	Pelvic Pain		phenotype_term	phenotype_term	$	Pelvic Pain		Pelvic Pain	HP:0030016	Dyspareunia		"{""preferred_term"": ""Pelvic Pain"", ""term"": {""id"": ""HP:0030016"", ""label"": ""Dyspareunia""}}"																											
2234	2376	104	Endometriosis	Endometriosis.yaml	phenotypes	1	Dysmenorrhea		phenotype_term	phenotype_term	$	Dysmenorrhea		Dysmenorrhea	HP:0100607	Dysmenorrhea		"{""preferred_term"": ""Dysmenorrhea"", ""term"": {""id"": ""HP:0100607"", ""label"": ""Dysmenorrhea""}}"																											
2235	2377	104	Endometriosis	Endometriosis.yaml	phenotypes	2	Dyspareunia		phenotype_term	phenotype_term	$	Dyspareunia		Dyspareunia	HP:0030016	Dyspareunia		"{""preferred_term"": ""Dyspareunia"", ""term"": {""id"": ""HP:0030016"", ""label"": ""Dyspareunia""}}"																											
2236	2378	104	Endometriosis	Endometriosis.yaml	phenotypes	3	Infertility		phenotype_term	phenotype_term	$	Infertility		Infertility	HP:0000789	Infertility		"{""preferred_term"": ""Infertility"", ""term"": {""id"": ""HP:0000789"", ""label"": ""Infertility""}}"																											
2237	2379	104	Endometriosis	Endometriosis.yaml	phenotypes	4	Heavy Menstrual Bleeding		phenotype_term	phenotype_term	$	Heavy Menstrual Bleeding		Menorrhagia	HP:0000132	Menorrhagia		"{""preferred_term"": ""Menorrhagia"", ""term"": {""id"": ""HP:0000132"", ""label"": ""Menorrhagia""}}"																											
2238	2380	104	Endometriosis	Endometriosis.yaml	phenotypes	5	Painful Bowel Movements		phenotype_term	phenotype_term	$	Painful Bowel Movements		Dyschezia	HP:0002027	Abdominal pain		"{""preferred_term"": ""Dyschezia"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2239	2381	104	Endometriosis	Endometriosis.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2240	2405	105	Epilepsy	Epilepsy.yaml	pathophysiology	0	Neuronal Hyperexcitability	"Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission leads to synchronized, excessive neuronal firing. Ion channel dysfunction is a common mechanism.
"	cell_types[0]	cell_types	cell_types			Pyramidal Neuron	CL:0000598	pyramidal neuron		"{""preferred_term"": ""Pyramidal Neuron"", ""term"": {""id"": ""CL:0000598"", ""label"": ""pyramidal neuron""}}"																											
2241	2405	105	Epilepsy	Epilepsy.yaml	pathophysiology	0	Neuronal Hyperexcitability	"Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission leads to synchronized, excessive neuronal firing. Ion channel dysfunction is a common mechanism.
"	cell_types[1]	cell_types	cell_types			GABAergic Interneuron	CL:0000617	GABAergic neuron		"{""preferred_term"": ""GABAergic Interneuron"", ""term"": {""id"": ""CL:0000617"", ""label"": ""GABAergic neuron""}}"																											
2242	2405	105	Epilepsy	Epilepsy.yaml	pathophysiology	0	Neuronal Hyperexcitability	"Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission leads to synchronized, excessive neuronal firing. Ion channel dysfunction is a common mechanism.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Transmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Synaptic Transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
2243	2406	105	Epilepsy	Epilepsy.yaml	pathophysiology	1	Blood-Brain Barrier Disruption	"Loss of tight junction proteins (claudin-5) in brain endothelial cells leads to blood-brain barrier breakdown, allowing albumin extravasation and disruption of ionic homeostasis.
"	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
2244	2406	105	Epilepsy	Epilepsy.yaml	pathophysiology	1	Blood-Brain Barrier Disruption	"Loss of tight junction proteins (claudin-5) in brain endothelial cells leads to blood-brain barrier breakdown, allowing albumin extravasation and disruption of ionic homeostasis.
"	biological_processes[0]	biological_processes	biological_processes			Blood-Brain Barrier Maintenance	GO:0035633	maintenance of blood-brain barrier		"{""preferred_term"": ""Blood-Brain Barrier Maintenance"", ""term"": {""id"": ""GO:0035633"", ""label"": ""maintenance of blood-brain barrier""}}"																											
2245	2407	105	Epilepsy	Epilepsy.yaml	pathophysiology	2	Network Hyperexcitability	"Abnormal synchronization of neuronal networks that can recruit adjacent or distant brain regions, leading to seizure propagation.
"	biological_processes[0]	biological_processes	biological_processes			Neuronal Activity	GO:0019226	transmission of nerve impulse		"{""preferred_term"": ""Neuronal Activity"", ""term"": {""id"": ""GO:0019226"", ""label"": ""transmission of nerve impulse""}}"																											
2246	2408	105	Epilepsy	Epilepsy.yaml	pathophysiology	3	Neuroinflammation and Gliosis	"Activation of microglia and reactive astrocytes following brain injury or during seizures, releasing inflammatory mediators and undergoing morphological changes that alter the brain microenvironment.
"	cell_types[0]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
2247	2408	105	Epilepsy	Epilepsy.yaml	pathophysiology	3	Neuroinflammation and Gliosis	"Activation of microglia and reactive astrocytes following brain injury or during seizures, releasing inflammatory mediators and undergoing morphological changes that alter the brain microenvironment.
"	cell_types[1]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
2248	2408	105	Epilepsy	Epilepsy.yaml	pathophysiology	3	Neuroinflammation and Gliosis	"Activation of microglia and reactive astrocytes following brain injury or during seizures, releasing inflammatory mediators and undergoing morphological changes that alter the brain microenvironment.
"	biological_processes[0]	biological_processes	biological_processes			Neuroinflammatory Response	GO:0150076	neuroinflammatory response		"{""preferred_term"": ""Neuroinflammatory Response"", ""term"": {""id"": ""GO:0150076"", ""label"": ""neuroinflammatory response""}}"																											
2249	2409	105	Epilepsy	Epilepsy.yaml	pathophysiology	4	Synaptic Reorganization	"Aberrant sprouting, formation of new synaptic connections, and altered synaptic plasticity that promote recurrent excitatory circuits and seizure susceptibility.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Plasticity	GO:0048167	regulation of synaptic plasticity		"{""preferred_term"": ""Synaptic Plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"																											
2250	2410	105	Epilepsy	Epilepsy.yaml	pathophysiology	5	mTOR Pathway Hyperactivation	"Constitutive activation of the mechanistic target of rapamycin (mTOR) signaling pathway, driving abnormal neuronal growth and development of dysmorphic neurons in focal cortical malformations.
"	biological_processes[0]	biological_processes	biological_processes			mTOR Signaling	GO:0031929	TOR signaling		"{""preferred_term"": ""mTOR Signaling"", ""term"": {""id"": ""GO:0031929"", ""label"": ""TOR signaling""}}"																											
2251	2412	105	Epilepsy	Epilepsy.yaml	phenotypes	0	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
2252	2413	105	Epilepsy	Epilepsy.yaml	phenotypes	1	Postictal Confusion		phenotype_term	phenotype_term	$	Postictal Confusion		Confusion	HP:0001289	Confusion		"{""preferred_term"": ""Confusion"", ""term"": {""id"": ""HP:0001289"", ""label"": ""Confusion""}}"																											
2253	2414	105	Epilepsy	Epilepsy.yaml	phenotypes	2	Aura		phenotype_term	phenotype_term	$	Aura		Sensory Disturbance	HP:0003474	Somatic sensory dysfunction		"{""preferred_term"": ""Sensory Disturbance"", ""term"": {""id"": ""HP:0003474"", ""label"": ""Somatic sensory dysfunction""}}"																											
2254	2415	105	Epilepsy	Epilepsy.yaml	phenotypes	3	Memory Impairment		phenotype_term	phenotype_term	$	Memory Impairment		Memory Impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory Impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
2255	2416	105	Epilepsy	Epilepsy.yaml	phenotypes	4	Depression		phenotype_term	phenotype_term	$	Depression		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
2256	2417	105	Epilepsy	Epilepsy.yaml	phenotypes	5	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
2257	2431	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	0	Vascular Resistance	"Increased systemic vascular resistance due to structural and functional changes in resistance arterioles. Endothelial dysfunction, vascular remodeling, and increased smooth muscle tone contribute.
"	cell_types[0]	cell_types	cell_types			Vascular Smooth Muscle Cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""Vascular Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
2258	2431	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	0	Vascular Resistance	"Increased systemic vascular resistance due to structural and functional changes in resistance arterioles. Endothelial dysfunction, vascular remodeling, and increased smooth muscle tone contribute.
"	cell_types[1]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
2259	2431	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	0	Vascular Resistance	"Increased systemic vascular resistance due to structural and functional changes in resistance arterioles. Endothelial dysfunction, vascular remodeling, and increased smooth muscle tone contribute.
"	biological_processes[0]	biological_processes	biological_processes			Blood Pressure Regulation	GO:0008217	regulation of blood pressure		"{""preferred_term"": ""Blood Pressure Regulation"", ""term"": {""id"": ""GO:0008217"", ""label"": ""regulation of blood pressure""}}"																											
2260	2432	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	1	Renin-Angiotensin-Aldosterone System Dysregulation	"Overactivation of the RAAS leads to sodium retention, vasoconstriction, and vascular remodeling, all contributing to elevated blood pressure.
"	cell_types[0]	cell_types	cell_types			Kidney Granular Cell	CL:0000648	kidney granular cell		"{""preferred_term"": ""Kidney Granular Cell"", ""term"": {""id"": ""CL:0000648"", ""label"": ""kidney granular cell""}}"																											
2261	2432	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	1	Renin-Angiotensin-Aldosterone System Dysregulation	"Overactivation of the RAAS leads to sodium retention, vasoconstriction, and vascular remodeling, all contributing to elevated blood pressure.
"	biological_processes[0]	biological_processes	biological_processes			RAAS Pathway	GO:0002018	renin-angiotensin regulation of aldosterone production		"{""preferred_term"": ""RAAS Pathway"", ""term"": {""id"": ""GO:0002018"", ""label"": ""renin-angiotensin regulation of aldosterone production""}}"																											
2262	2433	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	2	Sympathetic Nervous System Overactivity	"Enhanced sympathetic tone increases heart rate, cardiac output, and peripheral vascular resistance through catecholamine release.
"	biological_processes[0]	biological_processes	biological_processes			Sympathetic Regulation	GO:0003082	positive regulation of systemic arterial blood pressure by norepinephrine-epinephrine		"{""preferred_term"": ""Sympathetic Regulation"", ""term"": {""id"": ""GO:0003082"", ""label"": ""positive regulation of systemic arterial blood pressure by norepinephrine-epinephrine""}}"																											
2263	2434	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	3	Immune and Inflammatory Activation	"Chronic immune activation involving both innate and adaptive immunity drives vascular inflammation and remodeling. T cells, monocytes, macrophages, and dendritic cells infiltrate target organs including arteries, kidneys, heart, and brain, releasing proinflammatory cytokines such as IL-17, IFN-gamma, and TNF-alpha that elevate blood pressure and cause end-organ damage.
"	cell_types[0]	cell_types	cell_types			T Cell	CL:0000084	T cell		"{""preferred_term"": ""T Cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
2264	2434	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	3	Immune and Inflammatory Activation	"Chronic immune activation involving both innate and adaptive immunity drives vascular inflammation and remodeling. T cells, monocytes, macrophages, and dendritic cells infiltrate target organs including arteries, kidneys, heart, and brain, releasing proinflammatory cytokines such as IL-17, IFN-gamma, and TNF-alpha that elevate blood pressure and cause end-organ damage.
"	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2265	2434	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	3	Immune and Inflammatory Activation	"Chronic immune activation involving both innate and adaptive immunity drives vascular inflammation and remodeling. T cells, monocytes, macrophages, and dendritic cells infiltrate target organs including arteries, kidneys, heart, and brain, releasing proinflammatory cytokines such as IL-17, IFN-gamma, and TNF-alpha that elevate blood pressure and cause end-organ damage.
"	cell_types[2]	cell_types	cell_types			Dendritic Cell	CL:0000451	dendritic cell		"{""preferred_term"": ""Dendritic Cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
2266	2434	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	3	Immune and Inflammatory Activation	"Chronic immune activation involving both innate and adaptive immunity drives vascular inflammation and remodeling. T cells, monocytes, macrophages, and dendritic cells infiltrate target organs including arteries, kidneys, heart, and brain, releasing proinflammatory cytokines such as IL-17, IFN-gamma, and TNF-alpha that elevate blood pressure and cause end-organ damage.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2267	2435	106	Essential Hypertension	Essential_Hypertension.yaml	pathophysiology	4	Oxidative Stress	"Increased production of reactive oxygen species (ROS) by NADPH oxidases and decreased antioxidant defenses lead to oxidative stress. ROS impair nitric oxide bioavailability, promote endothelial dysfunction, and activate inflammatory pathways, all contributing to elevated blood pressure and kidney injury.
"	biological_processes[0]	biological_processes	biological_processes			ROS Metabolic Process	GO:0072593	reactive oxygen species metabolic process		"{""preferred_term"": ""ROS Metabolic Process"", ""term"": {""id"": ""GO:0072593"", ""label"": ""reactive oxygen species metabolic process""}}"																											
2268	2436	106	Essential Hypertension	Essential_Hypertension.yaml	phenotypes	0	Elevated Blood Pressure		phenotype_term	phenotype_term	$	Elevated Blood Pressure		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
2269	2437	106	Essential Hypertension	Essential_Hypertension.yaml	phenotypes	1	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2270	2438	106	Essential Hypertension	Essential_Hypertension.yaml	phenotypes	2	Left Ventricular Hypertrophy		phenotype_term	phenotype_term	$	Left Ventricular Hypertrophy		Left Ventricular Hypertrophy	HP:0001712	Left ventricular hypertrophy		"{""preferred_term"": ""Left Ventricular Hypertrophy"", ""term"": {""id"": ""HP:0001712"", ""label"": ""Left ventricular hypertrophy""}}"																											
2271	2439	106	Essential Hypertension	Essential_Hypertension.yaml	phenotypes	3	Renal Damage		phenotype_term	phenotype_term	$	Renal Damage		Renal Insufficiency	HP:0000083	Renal insufficiency		"{""preferred_term"": ""Renal Insufficiency"", ""term"": {""id"": ""HP:0000083"", ""label"": ""Renal insufficiency""}}"																											
2272	2451	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	histopathology	0	Megakaryocytic Proliferation	Essential thrombocythemia is characterized by thrombocytosis.	finding_term	finding_term	$	Megakaryocytic Proliferation	Essential thrombocythemia is characterized by thrombocytosis.	Megakaryocyte Proliferation	NCIT:C19919	Megakaryocyte Proliferation		"{""preferred_term"": ""Megakaryocyte Proliferation"", ""term"": {""id"": ""NCIT:C19919"", ""label"": ""Megakaryocyte Proliferation""}}"																											
2273	2452	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL converge on constitutive JAK-STAT signaling activation. JAK2 V617F directly activates the kinase; CALR mutations cause aberrant activation of MPL receptor; MPL mutations cause constitutive thrombopoietin receptor activation.	cell_types[0]	cell_types	cell_types			megakaryocyte	CL:0000556	megakaryocyte		"{""preferred_term"": ""megakaryocyte"", ""term"": {""id"": ""CL:0000556"", ""label"": ""megakaryocyte""}}"																											
2274	2452	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL converge on constitutive JAK-STAT signaling activation. JAK2 V617F directly activates the kinase; CALR mutations cause aberrant activation of MPL receptor; MPL mutations cause constitutive thrombopoietin receptor activation.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""JAK-STAT signaling pathway"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"			INCREASED																								
2275	2452	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL converge on constitutive JAK-STAT signaling activation. JAK2 V617F directly activates the kinase; CALR mutations cause aberrant activation of MPL receptor; MPL mutations cause constitutive thrombopoietin receptor activation.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
2276	2453	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	1	Enhanced Megakaryopoiesis	Constitutive JAK-STAT signaling drives increased megakaryocyte proliferation and maturation. Unlike myelofibrosis, megakaryocytes in ET are large and mature without significant atypia or clustering.	biological_processes[0]	biological_processes	biological_processes			megakaryocyte differentiation	GO:0030219	megakaryocyte differentiation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""megakaryocyte differentiation"", ""term"": {""id"": ""GO:0030219"", ""label"": ""megakaryocyte differentiation""}}"			INCREASED																								
2277	2454	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	pathophysiology	2	Platelet Dysfunction and Thrombosis Risk	Despite elevated platelet counts, thrombosis risk is multifactorial and involves platelet activation, leukocyte-platelet interactions, and endothelial dysfunction. Paradoxically, extreme thrombocytosis (>1,000,000/uL) may cause acquired von Willebrand disease and bleeding.	biological_processes[0]	biological_processes	biological_processes			platelet activation	GO:0030168	platelet activation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""platelet activation"", ""term"": {""id"": ""GO:0030168"", ""label"": ""platelet activation""}}"			ABNORMAL																								
2278	2455	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	0	Thrombocytosis	Persistent platelet count of 450,000/uL or greater is a diagnostic criterion. Many patients have counts exceeding 1,000,000/uL at diagnosis.	phenotype_term	phenotype_term	$	Thrombocytosis	Persistent platelet count of 450,000/uL or greater is a diagnostic criterion. Many patients have counts exceeding 1,000,000/uL at diagnosis.	Thrombocytosis	HP:0001894	Thrombocytosis		"{""preferred_term"": ""Thrombocytosis"", ""term"": {""id"": ""HP:0001894"", ""label"": ""Thrombocytosis""}}"																											
2279	2456	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	1	Thrombosis	Arterial and venous thrombotic events are the major disease complications. Includes stroke, myocardial infarction, peripheral arterial occlusion, and deep vein thrombosis.	phenotype_term	phenotype_term	$	Thrombosis	Arterial and venous thrombotic events are the major disease complications. Includes stroke, myocardial infarction, peripheral arterial occlusion, and deep vein thrombosis.	Thrombosis	HP:0001977	Abnormal thrombosis		"{""preferred_term"": ""Thrombosis"", ""term"": {""id"": ""HP:0001977"", ""label"": ""Abnormal thrombosis""}}"																											
2280	2457	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	2	Headache	Headaches are common and may reflect microvascular disturbance. Erythromelalgia-associated headache responds well to aspirin.	phenotype_term	phenotype_term	$	Headache	Headaches are common and may reflect microvascular disturbance. Erythromelalgia-associated headache responds well to aspirin.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2281	2458	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	3	Erythromelalgia	Burning pain, redness, and warmth in extremities due to platelet-mediated arteriolar inflammation. Highly responsive to aspirin therapy.	phenotype_term	phenotype_term	$	Erythromelalgia	Burning pain, redness, and warmth in extremities due to platelet-mediated arteriolar inflammation. Highly responsive to aspirin therapy.	Abnormality of the hand	HP:0001155	Abnormality of the hand		"{""preferred_term"": ""Abnormality of the hand"", ""term"": {""id"": ""HP:0001155"", ""label"": ""Abnormality of the hand""}}"																											
2282	2459	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	4	Splenomegaly	Mild splenomegaly may be present but is less prominent than in polycythemia vera or primary myelofibrosis. Marked splenomegaly suggests transformation.	phenotype_term	phenotype_term	$	Splenomegaly	Mild splenomegaly may be present but is less prominent than in polycythemia vera or primary myelofibrosis. Marked splenomegaly suggests transformation.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
2283	2460	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	phenotypes	5	Fatigue	Fatigue and reduced quality of life are common despite the generally indolent disease course.	phenotype_term	phenotype_term	$	Fatigue	Fatigue and reduced quality of life are common despite the generally indolent disease course.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2284	2461	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	0	Low-Dose Aspirin	Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk.	treatment_term	treatment_term	$	Low-Dose Aspirin	Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2285	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term	treatment_term	$	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
2286	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
2287	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term	treatment_term	$	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}"				anagrelide	CHEBI:142290																						
2288	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"																											
2289	2464	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	3	Interferon-alpha	Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden.	treatment_term	treatment_term	$	Interferon-alpha	Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2290	2469	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	histopathology	0	Small Round Cell Tumor	Ewing sarcoma is a small round cell tumor of bone or soft tissue.	finding_term	finding_term	$	Small Round Cell Tumor	Ewing sarcoma is a small round cell tumor of bone or soft tissue.	Ewing Sarcoma	NCIT:C4817	Ewing Sarcoma		"{""preferred_term"": ""Ewing Sarcoma"", ""term"": {""id"": ""NCIT:C4817"", ""label"": ""Ewing Sarcoma""}}"																											
2291	2470	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	0	EWS-FLI1 Fusion Oncogene	The t(11;22)(q24;q12) translocation fuses the EWS gene (EWSR1) on chromosome 22 with the FLI1 gene on chromosome 11. The resulting EWS-FLI1 protein functions as an aberrant transcription factor that activates proliferative genes and represses differentiation programs. This single genetic event is the primary driver of Ewing sarcoma.	cell_types[0]	cell_types	cell_types			mesenchymal stem cell	CL:0000134	mesenchymal stem cell		"{""preferred_term"": ""mesenchymal stem cell"", ""term"": {""id"": ""CL:0000134"", ""label"": ""mesenchymal stem cell""}}"																											
2292	2470	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	0	EWS-FLI1 Fusion Oncogene	The t(11;22)(q24;q12) translocation fuses the EWS gene (EWSR1) on chromosome 22 with the FLI1 gene on chromosome 11. The resulting EWS-FLI1 protein functions as an aberrant transcription factor that activates proliferative genes and represses differentiation programs. This single genetic event is the primary driver of Ewing sarcoma.	biological_processes[0]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			ABNORMAL																								
2293	2470	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	0	EWS-FLI1 Fusion Oncogene	The t(11;22)(q24;q12) translocation fuses the EWS gene (EWSR1) on chromosome 22 with the FLI1 gene on chromosome 11. The resulting EWS-FLI1 protein functions as an aberrant transcription factor that activates proliferative genes and represses differentiation programs. This single genetic event is the primary driver of Ewing sarcoma.	locations[0]	locations	locations			bone tissue	UBERON:0002481	bone tissue		"{""preferred_term"": ""bone tissue"", ""term"": {""id"": ""UBERON:0002481"", ""label"": ""bone tissue""}}"																											
2294	2471	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	1	Aberrant Transcriptional Regulation	EWS-FLI1 binds to GGAA microsatellite repeats throughout the genome, creating de novo enhancers that activate oncogenic target genes including NKX2-2, NR0B1, and IGF1. This abnormal enhancer activity reprograms cell identity and drives the Ewing sarcoma phenotype.	biological_processes[0]	biological_processes	biological_processes			regulation of gene expression	GO:0010468	regulation of gene expression		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of gene expression"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"			ABNORMAL																								
2295	2472	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	pathophysiology	2	Blocked Differentiation	EWS-FLI1 represses genes required for mesenchymal differentiation, maintaining cells in a proliferative, undifferentiated state. The cell of origin remains debated but may be a neural crest-derived mesenchymal progenitor.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
2296	2473	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	phenotypes	0	Bone Pain	Localized bone pain is the most common presenting symptom, often present for weeks to months before diagnosis. Pain may be intermittent initially and worsen progressively.	phenotype_term	phenotype_term	$	Bone Pain	Localized bone pain is the most common presenting symptom, often present for weeks to months before diagnosis. Pain may be intermittent initially and worsen progressively.	Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
2297	2474	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	phenotypes	1	Soft Tissue Mass	A palpable mass may develop as tumor extends through the bone cortex into surrounding soft tissues. The mass is often firm and may be tender.	phenotype_term	phenotype_term	$	Soft Tissue Mass	A palpable mass may develop as tumor extends through the bone cortex into surrounding soft tissues. The mass is often firm and may be tender.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
2298	2475	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	phenotypes	2	Fever	Systemic symptoms including fever may occur, sometimes leading to initial misdiagnosis as osteomyelitis.	phenotype_term	phenotype_term	$	Fever	Systemic symptoms including fever may occur, sometimes leading to initial misdiagnosis as osteomyelitis.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
2299	2476	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	phenotypes	3	Weight Loss	Unintentional weight loss may occur with advanced or metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss may occur with advanced or metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2300	2477	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	phenotypes	4	Metastatic Disease	Approximately 25% of patients have metastases at diagnosis, most commonly to lungs, bone, and bone marrow. Metastatic disease significantly worsens prognosis.	phenotype_term	phenotype_term	$	Metastatic Disease	Approximately 25% of patients have metastases at diagnosis, most commonly to lungs, bone, and bone marrow. Metastatic disease significantly worsens prognosis.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	treatment_term	$	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}"				vincristine; doxorubicin; cyclophosphamide; ifosfamide; etoposide	CHEBI:27375; CHEBI:28748; CHEBI:4026; CHEBI:5864; CHEBI:4911																						
2302	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"																											
2303	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
2304	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
2305	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
2306	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[4]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
2307	2479	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	1	Surgical Resection	Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage.	treatment_term	treatment_term	$	Surgical Resection	Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2308	2480	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	2	Radiation Therapy	Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins.	treatment_term	treatment_term	$	Radiation Therapy	Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2309	2481	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	3	Adjuvant Chemotherapy	Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months.	treatment_term	treatment_term	$	Adjuvant Chemotherapy	Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2310	2488	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	histopathology	0	Well Differentiated Cholangiocarcinoma	Most cholangiocarcinomas are well differentiated.	finding_term	finding_term	$	Well Differentiated Cholangiocarcinoma	Most cholangiocarcinomas are well differentiated.	Cholangiocarcinoma	NCIT:C4436	Cholangiocarcinoma		"{""preferred_term"": ""Cholangiocarcinoma"", ""term"": {""id"": ""NCIT:C4436"", ""label"": ""Cholangiocarcinoma""}}"																											
2311	2489	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	0	FGFR2 Fusion and Constitutive Activation	FGFR2 fusions join the FGFR2 kinase domain to various partner genes (BICC1, PPHLN1, AHCYL1, and others). Partner genes typically provide oligomerization domains that cause ligand-independent FGFR2 dimerization and constitutive kinase activation. This drives oncogenic signaling through multiple downstream pathways.	cell_types[0]	cell_types	cell_types			intrahepatic cholangiocyte	CL:0002538	intrahepatic cholangiocyte		"{""preferred_term"": ""intrahepatic cholangiocyte"", ""term"": {""id"": ""CL:0002538"", ""label"": ""intrahepatic cholangiocyte""}}"																											
2312	2489	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	0	FGFR2 Fusion and Constitutive Activation	FGFR2 fusions join the FGFR2 kinase domain to various partner genes (BICC1, PPHLN1, AHCYL1, and others). Partner genes typically provide oligomerization domains that cause ligand-independent FGFR2 dimerization and constitutive kinase activation. This drives oncogenic signaling through multiple downstream pathways.	biological_processes[0]	biological_processes	biological_processes			fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""fibroblast growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"			INCREASED																								
2313	2489	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	0	FGFR2 Fusion and Constitutive Activation	FGFR2 fusions join the FGFR2 kinase domain to various partner genes (BICC1, PPHLN1, AHCYL1, and others). Partner genes typically provide oligomerization domains that cause ligand-independent FGFR2 dimerization and constitutive kinase activation. This drives oncogenic signaling through multiple downstream pathways.	locations[0]	locations	locations			intrahepatic bile duct	UBERON:0003704	intrahepatic bile duct		"{""preferred_term"": ""intrahepatic bile duct"", ""term"": {""id"": ""UBERON:0003704"", ""label"": ""intrahepatic bile duct""}}"																											
2314	2490	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	1	MAPK Pathway Activation	FGFR2 activation leads to recruitment of adaptor proteins (FRS2, GRB2) that activate RAS and the downstream MAPK cascade. This drives transcription of genes promoting cell proliferation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2315	2491	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	FGFR2 signaling activates PI3K through adaptor proteins, leading to AKT phosphorylation. This promotes cell survival and resistance to apoptosis. PI3K pathway activation may contribute to resistance to FGFR inhibitors.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
2316	2493	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	pathophysiology	4	Enhanced Cell Proliferation	Combined activation of MAPK, PI3K-AKT, and PLCgamma pathways drives enhanced cell proliferation. FGFR2 fusion-positive tumors are dependent on FGFR2 signaling, making them vulnerable to FGFR inhibition.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2317	2494	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	0	Hepatomegaly	Liver enlargement from tumor mass. Intrahepatic cholangiocarcinoma typically presents as a hepatic mass lesion.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from tumor mass. Intrahepatic cholangiocarcinoma typically presents as a hepatic mass lesion.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
2318	2495	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	1	Jaundice	Jaundice from biliary obstruction or extensive hepatic involvement. Less common in intrahepatic than in perihilar cholangiocarcinoma.	phenotype_term	phenotype_term	$	Jaundice	Jaundice from biliary obstruction or extensive hepatic involvement. Less common in intrahepatic than in perihilar cholangiocarcinoma.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
2319	2496	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	2	Abdominal Pain	Right upper quadrant pain or discomfort from tumor mass or liver capsule involvement.	phenotype_term	phenotype_term	$	Abdominal Pain	Right upper quadrant pain or discomfort from tumor mass or liver capsule involvement.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2320	2497	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	3	Weight Loss	Unintentional weight loss from cancer cachexia and decreased oral intake.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss from cancer cachexia and decreased oral intake.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2321	2498	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	4	Fatigue	Fatigue from hepatic dysfunction and advanced disease burden.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from hepatic dysfunction and advanced disease burden.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2322	2499	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	phenotypes	5	Nausea	Nausea from hepatic dysfunction or as a treatment-related side effect.	phenotype_term	phenotype_term	$	Nausea	Nausea from hepatic dysfunction or as a treatment-related side effect.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
2323	2500	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	0	Pemigatinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302).	treatment_term	treatment_term	$	Pemigatinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2324	2501	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	1	Futibatinib	Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism.	treatment_term	treatment_term	$	Futibatinib	Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2325	2502	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	2	Infigratinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study.	treatment_term	treatment_term	$	Infigratinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2326	2503	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	3	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2327	2504	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	4	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2328	2505	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	5	Surgical Resection	Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease.	treatment_term	treatment_term	$	Surgical Resection	Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2329	2510	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	histopathology	0	Urothelial Carcinoma	Bladder carcinomas are classified as urothelial carcinoma.	finding_term	finding_term	$	Urothelial Carcinoma	Bladder carcinomas are classified as urothelial carcinoma.	Urothelial Carcinoma	NCIT:C4030	Urothelial Carcinoma		"{""preferred_term"": ""Urothelial Carcinoma"", ""term"": {""id"": ""NCIT:C4030"", ""label"": ""Urothelial Carcinoma""}}"																											
2330	2511	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	0	FGFR3 Constitutive Activation	Activating mutations in FGFR3 cause ligand-independent receptor dimerization and autophosphorylation. The most common mutations affect cysteine residues in the extracellular domain, creating aberrant disulfide bonds that constitutively activate the receptor.	cell_types[0]	cell_types	cell_types			epithelial cell of urethra	CL:1000296	epithelial cell of urethra		"{""preferred_term"": ""epithelial cell of urethra"", ""term"": {""id"": ""CL:1000296"", ""label"": ""epithelial cell of urethra""}}"																											
2331	2511	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	0	FGFR3 Constitutive Activation	Activating mutations in FGFR3 cause ligand-independent receptor dimerization and autophosphorylation. The most common mutations affect cysteine residues in the extracellular domain, creating aberrant disulfide bonds that constitutively activate the receptor.	biological_processes[0]	biological_processes	biological_processes			fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""fibroblast growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"			INCREASED																								
2332	2511	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	0	FGFR3 Constitutive Activation	Activating mutations in FGFR3 cause ligand-independent receptor dimerization and autophosphorylation. The most common mutations affect cysteine residues in the extracellular domain, creating aberrant disulfide bonds that constitutively activate the receptor.	locations[0]	locations	locations			urinary bladder	UBERON:0001255	urinary bladder		"{""preferred_term"": ""urinary bladder"", ""term"": {""id"": ""UBERON:0001255"", ""label"": ""urinary bladder""}}"																											
2333	2512	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	FGFR3 activation stimulates the RAS-RAF-MEK-ERK signaling cascade through adaptor proteins FRS2 and GRB2. This drives uncontrolled urothelial cell proliferation and is a major effector of FGFR-mediated transformation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2334	2513	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	FGFR3 activation recruits PI3K and activates the PI3K-AKT-mTOR signaling pathway, promoting urothelial cell survival and resistance to apoptosis.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
2335	2514	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	phenotypes	0	Hematuria	Gross or microscopic hematuria is the most common presenting symptom of urothelial carcinoma. May be intermittent and painless initially.	phenotype_term	phenotype_term	$	Hematuria	Gross or microscopic hematuria is the most common presenting symptom of urothelial carcinoma. May be intermittent and painless initially.	Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
2336	2515	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	phenotypes	1	Dysuria	Painful urination may occur due to bladder irritation or tumor involvement. Often associated with urinary frequency and urgency.	phenotype_term	phenotype_term	$	Dysuria	Painful urination may occur due to bladder irritation or tumor involvement. Often associated with urinary frequency and urgency.	Dysuria	HP:0100518	Dysuria		"{""preferred_term"": ""Dysuria"", ""term"": {""id"": ""HP:0100518"", ""label"": ""Dysuria""}}"																											
2337	2516	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	phenotypes	2	Fatigue	Constitutional symptoms including fatigue are common in advanced disease and may be related to anemia from chronic blood loss.	phenotype_term	phenotype_term	$	Fatigue	Constitutional symptoms including fatigue are common in advanced disease and may be related to anemia from chronic blood loss.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2338	2517	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	0	Erdafitinib	Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients.	treatment_term	treatment_term	$	Erdafitinib	Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2339	2518	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	1	Platinum-Based Chemotherapy	Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen.	treatment_term	treatment_term	$	Platinum-Based Chemotherapy	Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2340	2519	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	2	Immune Checkpoint Inhibitors	PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2341	2524	111	FICUS syndrome	FICUS_syndrome.yaml	differential_diagnoses	0	Post-traumatic stress disorder	"Psychiatric disorder characterized by intrusive memories, avoidance, negative mood/cognition changes, and hyperarousal after trauma exposure.
"	disease_term	disease_term	$	Post-traumatic stress disorder	"Psychiatric disorder characterized by intrusive memories, avoidance, negative mood/cognition changes, and hyperarousal after trauma exposure.
"	post-traumatic stress disorder	MONDO:0005146	post-traumatic stress disorder		"{""preferred_term"": ""post-traumatic stress disorder"", ""term"": {""id"": ""MONDO:0005146"", ""label"": ""post-traumatic stress disorder""}}"																											
2342	2525	111	FICUS syndrome	FICUS_syndrome.yaml	differential_diagnoses	1	Major depressive disorder	"Depressive disorder characterized by persistent low mood, anhedonia, and functional impairment not necessarily linked to ICU caregiving.
"	disease_term	disease_term	$	Major depressive disorder	"Depressive disorder characterized by persistent low mood, anhedonia, and functional impairment not necessarily linked to ICU caregiving.
"	major depressive disorder	MONDO:0002009	major depressive disorder		"{""preferred_term"": ""major depressive disorder"", ""term"": {""id"": ""MONDO:0002009"", ""label"": ""major depressive disorder""}}"																											
2343	2526	111	FICUS syndrome	FICUS_syndrome.yaml	differential_diagnoses	2	Generalized anxiety disorder	"Anxiety disorder with excessive, persistent worry across domains, distinct from context-specific ICU caregiver stress.
"	disease_term	disease_term	$	Generalized anxiety disorder	"Anxiety disorder with excessive, persistent worry across domains, distinct from context-specific ICU caregiver stress.
"	generalized anxiety disorder	MONDO:0001942	generalized anxiety disorder		"{""preferred_term"": ""generalized anxiety disorder"", ""term"": {""id"": ""MONDO:0001942"", ""label"": ""generalized anxiety disorder""}}"																											
2344	2530	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	0	Anxiety symptoms		phenotype_term	phenotype_term	$	Anxiety symptoms		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
2345	2531	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	1	Depressive symptoms		phenotype_term	phenotype_term	$	Depressive symptoms		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
2346	2532	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	2	Posttraumatic stress symptoms		phenotype_term	phenotype_term	$	Posttraumatic stress symptoms		Posttraumatic stress symptom	HP:0033676	Posttraumatic stress symptom		"{""preferred_term"": ""Posttraumatic stress symptom"", ""term"": {""id"": ""HP:0033676"", ""label"": ""Posttraumatic stress symptom""}}"																											
2347	2533	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	3	Anger		phenotype_term	phenotype_term	$	Anger		Anger	HP:0031473	Anger		"{""preferred_term"": ""Anger"", ""term"": {""id"": ""HP:0031473"", ""label"": ""Anger""}}"																											
2348	2534	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	4	Agitation		phenotype_term	phenotype_term	$	Agitation		Agitation	HP:0000713	Agitation		"{""preferred_term"": ""Agitation"", ""term"": {""id"": ""HP:0000713"", ""label"": ""Agitation""}}"																											
2349	2535	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	5	Avoidance of stimuli associated with traumatic event		phenotype_term	phenotype_term	$	Avoidance of stimuli associated with traumatic event		Avoidance of stimuli associated with traumatic event	HP:0032942	Avoidance of stimuli associated with traumatic event		"{""preferred_term"": ""Avoidance of stimuli associated with traumatic event"", ""term"": {""id"": ""HP:0032942"", ""label"": ""Avoidance of stimuli associated with traumatic event""}}"																											
2350	2536	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	6	Abnormal fear-induced behavior		phenotype_term	phenotype_term	$	Abnormal fear-induced behavior		Abnormal fear-induced behavior	HP:0100852	Abnormal fear-induced behavior		"{""preferred_term"": ""Abnormal fear-induced behavior"", ""term"": {""id"": ""HP:0100852"", ""label"": ""Abnormal fear-induced behavior""}}"																											
2351	2537	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	7	Sleep disturbance		phenotype_term	phenotype_term	$	Sleep disturbance		Sleep disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
2352	2538	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	8	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2353	2539	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	9	Memory impairment		phenotype_term	phenotype_term	$	Memory impairment		Memory impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
2354	2540	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	10	Recurrent, involuntary, and intrusive distressing memories		phenotype_term	phenotype_term	$	Recurrent, involuntary, and intrusive distressing memories		Recurrent, involuntary, and intrusive distressing memories	HP:0032937	Recurrent, involuntary, and intrusive distressing memories		"{""preferred_term"": ""Recurrent, involuntary, and intrusive distressing memories"", ""term"": {""id"": ""HP:0032937"", ""label"": ""Recurrent, involuntary, and intrusive distressing memories""}}"																											
2355	2541	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	11	Hopelessness		phenotype_term	phenotype_term	$	Hopelessness		Hopelessness	HP:5200271	Hopelessness		"{""preferred_term"": ""Hopelessness"", ""term"": {""id"": ""HP:5200271"", ""label"": ""Hopelessness""}}"																											
2356	2542	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	12	Diminished health-related quality of life		phenotype_term	phenotype_term	$	Diminished health-related quality of life		Diminished health-related quality of life	HP:0033665	Diminished health-related quality of life		"{""preferred_term"": ""Diminished health-related quality of life"", ""term"": {""id"": ""HP:0033665"", ""label"": ""Diminished health-related quality of life""}}"																											
2357	2543	111	FICUS syndrome	FICUS_syndrome.yaml	phenotypes	13	Pain		phenotype_term	phenotype_term	$	Pain		Pain	HP:0012531	Pain		"{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
2358	2546	111	FICUS syndrome	FICUS_syndrome.yaml	treatments	0	Family support intervention	"Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.
"	treatment_term	treatment_term	$	Family support intervention	"Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.
"	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2359	2553	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	histopathology	0	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	finding_term	finding_term	$	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	Myeloblasts Present	NCIT:C155995	Myeloblasts Present		"{""preferred_term"": ""Myeloblasts Present"", ""term"": {""id"": ""NCIT:C155995"", ""label"": ""Myeloblasts Present""}}"																											
2360	2554	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	0	FLT3 Receptor Constitutive Activation	FLT3 is a class III receptor tyrosine kinase normally involved in hematopoietic progenitor cell survival and proliferation. FLT3-ITD mutations cause ligand-independent receptor dimerization and constitutive autophosphorylation. FLT3-TKD mutations stabilize the active kinase conformation. Both result in aberrant downstream signaling.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
2361	2554	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	0	FLT3 Receptor Constitutive Activation	FLT3 is a class III receptor tyrosine kinase normally involved in hematopoietic progenitor cell survival and proliferation. FLT3-ITD mutations cause ligand-independent receptor dimerization and constitutive autophosphorylation. FLT3-TKD mutations stabilize the active kinase conformation. Both result in aberrant downstream signaling.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
2362	2555	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	1	STAT5 Hyperactivation	FLT3-ITD mutations preferentially activate STAT5 signaling compared to wild-type FLT3 or TKD mutations. Phosphorylated STAT5 translocates to the nucleus and activates transcription of anti-apoptotic genes (BCL-XL, PIM1) and cell cycle regulators, promoting leukemic cell survival and proliferation.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
2363	2555	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	1	STAT5 Hyperactivation	FLT3-ITD mutations preferentially activate STAT5 signaling compared to wild-type FLT3 or TKD mutations. Phosphorylated STAT5 translocates to the nucleus and activates transcription of anti-apoptotic genes (BCL-XL, PIM1) and cell cycle regulators, promoting leukemic cell survival and proliferation.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
2364	2556	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	2	RAS-MAPK Pathway Activation	FLT3 signaling activates the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival. This pathway is critical for the proliferative advantage of FLT3-mutated leukemic cells.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2365	2557	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	3	Apoptosis Resistance	FLT3-ITD-mediated STAT5 activation upregulates anti-apoptotic proteins including BCL-XL, MCL-1, and PIM kinases. This confers resistance to apoptosis and contributes to the aggressive clinical behavior of FLT3-ITD AML.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
2366	2558	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	4	Uncontrolled Myeloblast Proliferation	The combined effects of enhanced survival signaling and cell cycle promotion lead to accumulation of immature myeloid blasts in the bone marrow and blood, replacing normal hematopoiesis.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
2367	2558	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	4	Uncontrolled Myeloblast Proliferation	The combined effects of enhanced survival signaling and cell cycle promotion lead to accumulation of immature myeloid blasts in the bone marrow and blood, replacing normal hematopoiesis.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
2368	2558	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	pathophysiology	4	Uncontrolled Myeloblast Proliferation	The combined effects of enhanced survival signaling and cell cycle promotion lead to accumulation of immature myeloid blasts in the bone marrow and blood, replacing normal hematopoiesis.	biological_processes[0]	biological_processes	biological_processes			myeloid cell differentiation	GO:0030099	myeloid cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myeloid cell differentiation"", ""term"": {""id"": ""GO:0030099"", ""label"": ""myeloid cell differentiation""}}"			DECREASED																								
2369	2559	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	0	Leukocytosis	Elevated white blood cell count is particularly common in FLT3-ITD AML, often exceeding 100,000/uL, reflecting the proliferative nature of the disease.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count is particularly common in FLT3-ITD AML, often exceeding 100,000/uL, reflecting the proliferative nature of the disease.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
2370	2560	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	1	Anemia	Normocytic normochromic anemia results from bone marrow replacement by leukemic blasts and ineffective erythropoiesis.	phenotype_term	phenotype_term	$	Anemia	Normocytic normochromic anemia results from bone marrow replacement by leukemic blasts and ineffective erythropoiesis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2371	2561	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	2	Thrombocytopenia	Low platelet count due to bone marrow failure, contributing to bleeding risk.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count due to bone marrow failure, contributing to bleeding risk.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
2372	2562	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	3	Fatigue	Profound fatigue related to anemia and hypermetabolic state from rapid leukemic cell turnover.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue related to anemia and hypermetabolic state from rapid leukemic cell turnover.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2373	2563	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	4	Recurrent Infections	Increased susceptibility to bacterial and fungal infections due to neutropenia from bone marrow failure.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased susceptibility to bacterial and fungal infections due to neutropenia from bone marrow failure.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
2374	2564	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	phenotypes	5	Abnormal Bleeding	Easy bruising, petechiae, mucosal bleeding, and prolonged bleeding from minor wounds due to thrombocytopenia.	phenotype_term	phenotype_term	$	Abnormal Bleeding	Easy bruising, petechiae, mucosal bleeding, and prolonged bleeding from minor wounds due to thrombocytopenia.	Abnormal bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Abnormal bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
2375	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term	treatment_term	$	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}]}"				midostaurin	CHEBI:63452																						
2376	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			midostaurin	CHEBI:63452	midostaurin		"{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}"																											
2377	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term	treatment_term	$	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}]}"				gilteritinib	CHEBI:145372																						
2378	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			gilteritinib	CHEBI:145372	gilteritinib		"{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}"																											
2379	2567	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	2	Intensive Chemotherapy (7+3)	Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2380	2568	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2381	2570	113	Fabry disease	Fabry_Disease.yaml	differential_diagnoses	0	Hypertrophic Cardiomyopathy (HCM)	"HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy, cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.
"	disease_term	disease_term	$	Hypertrophic Cardiomyopathy (HCM)	"HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy, cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.
"	Hypertrophic Cardiomyopathy	MONDO:0005045	hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic Cardiomyopathy"", ""term"": {""id"": ""MONDO:0005045"", ""label"": ""hypertrophic cardiomyopathy""}}"																											
2382	2571	113	Fabry disease	Fabry_Disease.yaml	differential_diagnoses	1	Cardiac Amyloidosis	"Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both. The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging without additional diagnostic markers.
"	disease_term	disease_term	$	Cardiac Amyloidosis	"Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both. The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging without additional diagnostic markers.
"	Amyloidosis	MONDO:0019065	amyloidosis		"{""preferred_term"": ""Amyloidosis"", ""term"": {""id"": ""MONDO:0019065"", ""label"": ""amyloidosis""}}"																											
2383	2572	113	Fabry disease	Fabry_Disease.yaml	differential_diagnoses	2	Myocarditis	"Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder. Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging. Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.
"	disease_term	disease_term	$	Myocarditis	"Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder. Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging. Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.
"	Myocarditis	MONDO:0004496	myocarditis		"{""preferred_term"": ""Myocarditis"", ""term"": {""id"": ""MONDO:0004496"", ""label"": ""myocarditis""}}"																											
2384	2573	113	Fabry disease	Fabry_Disease.yaml	differential_diagnoses	3	Chagas Disease	"Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic manifestations differ significantly.
"	disease_term	disease_term	$	Chagas Disease	"Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic manifestations differ significantly.
"	Chagas disease	MONDO:0001444	Chagas disease		"{""preferred_term"": ""Chagas disease"", ""term"": {""id"": ""MONDO:0001444"", ""label"": ""Chagas disease""}}"																											
2385	2574	113	Fabry disease	Fabry_Disease.yaml	differential_diagnoses	4	Sarcoidosis	"Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin, creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities, renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy. Neurological involvement (stroke, neuropathy) occurs in both conditions.
"	disease_term	disease_term	$	Sarcoidosis	"Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin, creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities, renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy. Neurological involvement (stroke, neuropathy) occurs in both conditions.
"	Sarcoidosis	MONDO:0019338	sarcoidosis		"{""preferred_term"": ""Sarcoidosis"", ""term"": {""id"": ""MONDO:0019338"", ""label"": ""sarcoidosis""}}"																											
2386	2576	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	0	Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation	"GLA mutations reduce or abolish -galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3) and its deacylated form lyso-Gb3 in lysosomes. Lyso-Gb3 is closely associated with disease severity and exerts direct cytotoxic effects on podocytes, neurons, and other cell types. Substrate accumulation initiates lysosomal dysfunction with impaired autophagy and reduced ATP production.
"	biological_processes[0]	biological_processes	biological_processes			glycosphingolipid metabolic process	GO:0006681	glycosphingolipid metabolic process		"{""preferred_term"": ""glycosphingolipid metabolic process"", ""term"": {""id"": ""GO:0006681"", ""label"": ""glycosphingolipid metabolic process""}}"																											
2387	2576	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	0	Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation	"GLA mutations reduce or abolish -galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3) and its deacylated form lyso-Gb3 in lysosomes. Lyso-Gb3 is closely associated with disease severity and exerts direct cytotoxic effects on podocytes, neurons, and other cell types. Substrate accumulation initiates lysosomal dysfunction with impaired autophagy and reduced ATP production.
"	biological_processes[1]	biological_processes	biological_processes			lysosomal catabolic process	GO:0090487	lysosomal catabolic process		"{""preferred_term"": ""lysosomal catabolic process"", ""term"": {""id"": ""GO:0090487"", ""label"": ""lysosomal catabolic process""}}"																											
2388	2576	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	0	Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation	"GLA mutations reduce or abolish -galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3) and its deacylated form lyso-Gb3 in lysosomes. Lyso-Gb3 is closely associated with disease severity and exerts direct cytotoxic effects on podocytes, neurons, and other cell types. Substrate accumulation initiates lysosomal dysfunction with impaired autophagy and reduced ATP production.
"	genes[0]	genes	genes			GLA	hgnc:4296	GLA		"{""preferred_term"": ""GLA"", ""term"": {""id"": ""hgnc:4296"", ""label"": ""GLA""}}"																											
2389	2577	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	1	Endoplasmic reticulum stress and unfolded protein response	"Misfolded -Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR). Persistent UPR activation causes apoptosis and inflammatory signaling through NF-B and MAPK pathways, contributing to cell death and tissue injury.
"	biological_processes[0]	biological_processes	biological_processes			response to unfolded protein	GO:0006986	response to unfolded protein		"{""preferred_term"": ""response to unfolded protein"", ""term"": {""id"": ""GO:0006986"", ""label"": ""response to unfolded protein""}}"																											
2390	2577	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	1	Endoplasmic reticulum stress and unfolded protein response	"Misfolded -Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR). Persistent UPR activation causes apoptosis and inflammatory signaling through NF-B and MAPK pathways, contributing to cell death and tissue injury.
"	biological_processes[1]	biological_processes	biological_processes			NF-kappaB signaling pathway	GO:0007249	NF-kappaB signaling pathway		"{""preferred_term"": ""NF-kappaB signaling pathway"", ""term"": {""id"": ""GO:0007249"", ""label"": ""NF-kappaB signaling pathway""}}"																											
2391	2578	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	2	Mitochondrial dysfunction and oxidative stress	"Gb3 and lyso-Gb3 accumulation impairs mitochondrial function with reduced ATP production, complex I/III impairment, and elevated reactive oxygen species (ROS) production. Oxidative damage correlates with cardiac hypertrophy and contributes to cell death and inflammation.
"	biological_processes[0]	biological_processes	biological_processes			reactive oxygen species metabolic process	GO:0072593	reactive oxygen species metabolic process		"{""preferred_term"": ""reactive oxygen species metabolic process"", ""term"": {""id"": ""GO:0072593"", ""label"": ""reactive oxygen species metabolic process""}}"																											
2392	2578	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	2	Mitochondrial dysfunction and oxidative stress	"Gb3 and lyso-Gb3 accumulation impairs mitochondrial function with reduced ATP production, complex I/III impairment, and elevated reactive oxygen species (ROS) production. Oxidative damage correlates with cardiac hypertrophy and contributes to cell death and inflammation.
"	biological_processes[1]	biological_processes	biological_processes			regulation of mitochondrial membrane potential	GO:0051881	regulation of mitochondrial membrane potential		"{""preferred_term"": ""regulation of mitochondrial membrane potential"", ""term"": {""id"": ""GO:0051881"", ""label"": ""regulation of mitochondrial membrane potential""}}"																											
2393	2579	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	3	Autophagy impairment	"Lysosomal Gb3 accumulation impairs autophagic flux, leading to accumulation of damaged proteins and organelles. Persistent podocyte injury despite enzyme replacement therapy is mediated in part by -synuclein accumulation, implicating lysosomal toxicity as a disease driver beyond Gb3 storage.
"	biological_processes[0]	biological_processes	biological_processes			autophagy	GO:0006914	autophagy		"{""preferred_term"": ""autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
2394	2579	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	3	Autophagy impairment	"Lysosomal Gb3 accumulation impairs autophagic flux, leading to accumulation of damaged proteins and organelles. Persistent podocyte injury despite enzyme replacement therapy is mediated in part by -synuclein accumulation, implicating lysosomal toxicity as a disease driver beyond Gb3 storage.
"	genes[0]	genes	genes			SNCA	hgnc:11138	SNCA		"{""preferred_term"": ""SNCA"", ""term"": {""id"": ""hgnc:11138"", ""label"": ""SNCA""}}"																											
2395	2580	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	4	Innate immune activation and inflammation	"Substrate accumulation activates NLRP3 inflammasome and NF-B-mediated inflammatory responses, leading to elevation of IL-1, IL-6, IL-18, and TNF-. Complement cascade is activated with elevated C3a and C5a, particularly in patients with anti-drug antibodies. These inflammatory mediators propagate endothelial dysfunction and tissue injury.
"	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
2396	2580	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	4	Innate immune activation and inflammation	"Substrate accumulation activates NLRP3 inflammasome and NF-B-mediated inflammatory responses, leading to elevation of IL-1, IL-6, IL-18, and TNF-. Complement cascade is activated with elevated C3a and C5a, particularly in patients with anti-drug antibodies. These inflammatory mediators propagate endothelial dysfunction and tissue injury.
"	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2397	2581	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	5	Endothelial dysfunction and vascular remodeling	"Gb3/lyso-Gb3 accumulation in endothelial cells leads to upregulation of adhesion molecules (VCAM1, ICAM1), eNOS uncoupling, and reduced nitric oxide availability. Vascular smooth muscle proliferation and remodeling occur, contributing to microvascular dysfunction and increased thrombotic risk.
"	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
2398	2581	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	5	Endothelial dysfunction and vascular remodeling	"Gb3/lyso-Gb3 accumulation in endothelial cells leads to upregulation of adhesion molecules (VCAM1, ICAM1), eNOS uncoupling, and reduced nitric oxide availability. Vascular smooth muscle proliferation and remodeling occur, contributing to microvascular dysfunction and increased thrombotic risk.
"	biological_processes[0]	biological_processes	biological_processes			leukocyte adhesion to endothelial cells	GO:0007107	leukocyte adhesion to endothelial cells		"{""preferred_term"": ""leukocyte adhesion to endothelial cells"", ""term"": {""id"": ""GO:0007107"", ""label"": ""leukocyte adhesion to endothelial cells""}}"																											
2399	2582	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	6	Fibrosis and extracellular matrix remodeling	"TGF--driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal transition and myofibroblast activation.
"	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
2400	2582	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	6	Fibrosis and extracellular matrix remodeling	"TGF--driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal transition and myofibroblast activation.
"	biological_processes[1]	biological_processes	biological_processes			transforming growth factor beta signaling pathway	GO:0007179	transforming growth factor beta signaling pathway		"{""preferred_term"": ""transforming growth factor beta signaling pathway"", ""term"": {""id"": ""GO:0007179"", ""label"": ""transforming growth factor beta signaling pathway""}}"																											
2401	2582	113	Fabry disease	Fabry_Disease.yaml	pathophysiology	6	Fibrosis and extracellular matrix remodeling	"TGF--driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal transition and myofibroblast activation.
"	genes[0]	genes	genes			TGFB1	hgnc:11766	TGFB1		"{""preferred_term"": ""TGFB1"", ""term"": {""id"": ""hgnc:11766"", ""label"": ""TGFB1""}}"																											
2402	2583	113	Fabry disease	Fabry_Disease.yaml	phenotypes	0	Acrodystrophic neuropathic pain	"Severe, burning pain affecting the extremities, particularly hands and feet, often the earliest clinical manifestation. Pain crises can be disabling. Pathophysiology involves neuronal sensitization from lyso-Gb3 effects and lysosomal dysfunction.
"	phenotype_term	phenotype_term	$	Acrodystrophic neuropathic pain	"Severe, burning pain affecting the extremities, particularly hands and feet, often the earliest clinical manifestation. Pain crises can be disabling. Pathophysiology involves neuronal sensitization from lyso-Gb3 effects and lysosomal dysfunction.
"	Pain	HP:0012531	Pain		"{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
2403	2584	113	Fabry disease	Fabry_Disease.yaml	phenotypes	1	Angiokeratomas	"Small, dark red skin lesions that cluster in the lower trunk and genital region. These are pathognomonic cutaneous manifestations of Fabry disease resulting from vascular dilatation with epidermal hyperkeratosis.
"	phenotype_term	phenotype_term	$	Angiokeratomas	"Small, dark red skin lesions that cluster in the lower trunk and genital region. These are pathognomonic cutaneous manifestations of Fabry disease resulting from vascular dilatation with epidermal hyperkeratosis.
"	Angiokeratoma	HP:0001014	Angiokeratoma		"{""preferred_term"": ""Angiokeratoma"", ""term"": {""id"": ""HP:0001014"", ""label"": ""Angiokeratoma""}}"																											
2404	2585	113	Fabry disease	Fabry_Disease.yaml	phenotypes	2	Proteinuria	"Urinary protein excretion, often the earliest sign of Fabry nephropathy. Progresses from microalbuminuria to overt proteinuria. Results from podocyte injury due to Gb3/lyso-Gb3 accumulation, autophagy impairment, and inflammatory signaling.
"	phenotype_term	phenotype_term	$	Proteinuria	"Urinary protein excretion, often the earliest sign of Fabry nephropathy. Progresses from microalbuminuria to overt proteinuria. Results from podocyte injury due to Gb3/lyso-Gb3 accumulation, autophagy impairment, and inflammatory signaling.
"	Proteinuria	HP:0000093	proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""proteinuria""}}"																											
2405	2586	113	Fabry disease	Fabry_Disease.yaml	phenotypes	3	Chronic kidney disease	"Progressive renal dysfunction leading to end-stage renal disease. Driven by podocyte loss, glomerulosclerosis, tubulointerstitial fibrosis, and persistent inflammation.
"	phenotype_term	phenotype_term	$	Chronic kidney disease	"Progressive renal dysfunction leading to end-stage renal disease. Driven by podocyte loss, glomerulosclerosis, tubulointerstitial fibrosis, and persistent inflammation.
"	Chronic kidney disease	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Chronic kidney disease"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
2406	2587	113	Fabry disease	Fabry_Disease.yaml	phenotypes	4	Left ventricular hypertrophy	"Concentric hypertrophy of the left ventricle resulting from cardiomyocyte lipid accumulation, oxidative stress, inflammation, and fibrosis. Increases arrhythmia risk and may progress to heart failure.
"	phenotype_term	phenotype_term	$	Left ventricular hypertrophy	"Concentric hypertrophy of the left ventricle resulting from cardiomyocyte lipid accumulation, oxidative stress, inflammation, and fibrosis. Increases arrhythmia risk and may progress to heart failure.
"	Cardiomyopathy	HP:0001638	cardiomyopathy		"{""preferred_term"": ""Cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""cardiomyopathy""}}"																											
2407	2588	113	Fabry disease	Fabry_Disease.yaml	phenotypes	5	Cardiac arrhythmia	"Atrial fibrillation and ventricular arrhythmias result from cardiomyocyte hypertrophy, fibrosis, and inflammatory remodeling that create arrhythmogenic substrate.
"	phenotype_term	phenotype_term	$	Cardiac arrhythmia	"Atrial fibrillation and ventricular arrhythmias result from cardiomyocyte hypertrophy, fibrosis, and inflammatory remodeling that create arrhythmogenic substrate.
"	Arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
2408	2589	113	Fabry disease	Fabry_Disease.yaml	phenotypes	6	Stroke	"Increased risk of ischemic stroke and transient ischemic attacks due to cerebrovascular dysfunction from endothelial dysfunction, microvascular remodeling, and pro-thrombotic state.
"	phenotype_term	phenotype_term	$	Stroke	"Increased risk of ischemic stroke and transient ischemic attacks due to cerebrovascular dysfunction from endothelial dysfunction, microvascular remodeling, and pro-thrombotic state.
"	Stroke	HP:0001297	stroke		"{""preferred_term"": ""Stroke"", ""term"": {""id"": ""HP:0001297"", ""label"": ""stroke""}}"																											
2409	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	treatment_term	treatment_term	$	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	enzyme replacement therapy	MAXO:0000933	enzyme replacement or supplementation therapy		"{""preferred_term"": ""enzyme replacement therapy"", ""term"": {""id"": ""MAXO:0000933"", ""label"": ""enzyme replacement or supplementation therapy""}}"																											
2410	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Proteinuria	HP:0000093	proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""proteinuria""}}"																											
2411	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Chronic kidney disease	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Chronic kidney disease"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
2412	2591	113	Fabry disease	Fabry_Disease.yaml	treatments	1	Pharmacological chaperone therapy	"Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
"	treatment_term	treatment_term	$	Pharmacological chaperone therapy	"Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2413	2592	113	Fabry disease	Fabry_Disease.yaml	treatments	2	Gene therapy	"AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
"	treatment_term	treatment_term	$	Gene therapy	"AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
"	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2414	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	treatment_term	treatment_term	$	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2415	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pain	HP:0012531	Pain		"{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
2416	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
2417	2599	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	0	APC Tumor Suppressor Loss	Germline heterozygous APC mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates APC function, initiating adenoma formation. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
2418	2599	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	0	APC Tumor Suppressor Loss	Germline heterozygous APC mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates APC function, initiating adenoma formation. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
2419	2600	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	1	Wnt/-Catenin Pathway Activation	APC normally functions in the destruction complex (with Axin, GSK3, CK1) to phosphorylate -catenin, targeting it for ubiquitination and proteasomal degradation. Loss of APC allows -catenin to accumulate, translocate to the nucleus, and activate Wnt target genes driving proliferation.	biological_processes[0]	biological_processes	biological_processes			Wnt signaling pathway	GO:0016055	Wnt signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Wnt signaling pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"			INCREASED																								
2420	2601	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	2	Uncontrolled Intestinal Epithelial Proliferation	Nuclear -catenin activates TCF/LEF transcription factors, driving expression of Wnt target genes including MYC, CCND1 (cyclin D1), and others that promote cell cycle progression. This results in uncontrolled proliferation of intestinal crypt cells, forming adenomatous polyps.	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
2421	2601	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	2	Uncontrolled Intestinal Epithelial Proliferation	Nuclear -catenin activates TCF/LEF transcription factors, driving expression of Wnt target genes including MYC, CCND1 (cyclin D1), and others that promote cell cycle progression. This results in uncontrolled proliferation of intestinal crypt cells, forming adenomatous polyps.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2422	2602	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	3	Adenoma Formation	Sustained Wnt pathway activation drives adenoma development. Adenomas are benign neoplasms but represent the first step in the adenoma-carcinoma sequence. In FAP, hundreds to thousands of adenomas develop, dramatically increasing the probability that one will progress to carcinoma.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
2423	2602	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	3	Adenoma Formation	Sustained Wnt pathway activation drives adenoma development. Adenomas are benign neoplasms but represent the first step in the adenoma-carcinoma sequence. In FAP, hundreds to thousands of adenomas develop, dramatically increasing the probability that one will progress to carcinoma.	locations[1]	locations	locations			rectum	UBERON:0001052	rectum		"{""preferred_term"": ""rectum"", ""term"": {""id"": ""UBERON:0001052"", ""label"": ""rectum""}}"																											
2424	2603	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	pathophysiology	4	Colorectal Cancer Progression	Adenomas acquire additional mutations in KRAS, TP53, SMAD4, and other genes through the adenoma-carcinoma sequence. In FAP, the large number of adenomas makes it virtually certain that at least one will progress to invasive adenocarcinoma without intervention.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2425	2604	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	0	Colorectal Polyposis	Hundreds to thousands of adenomatous polyps carpet the colon and rectum. Polyps typically appear in adolescence in classic FAP. The number and density of polyps correlates with mutation location in APC.	phenotype_term	phenotype_term	$	Colorectal Polyposis	Hundreds to thousands of adenomatous polyps carpet the colon and rectum. Polyps typically appear in adolescence in classic FAP. The number and density of polyps correlates with mutation location in APC.	Large intestinal polyposis	HP:0030255	Large intestinal polyposis		"{""preferred_term"": ""Large intestinal polyposis"", ""term"": {""id"": ""HP:0030255"", ""label"": ""Large intestinal polyposis""}}"																											
2426	2605	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	1	Colorectal Cancer	Without prophylactic surgery, colorectal cancer develops in nearly 100% of patients with classic FAP, typically by age 40. The average age of cancer diagnosis is 39 years without surveillance/intervention.	phenotype_term	phenotype_term	$	Colorectal Cancer	Without prophylactic surgery, colorectal cancer develops in nearly 100% of patients with classic FAP, typically by age 40. The average age of cancer diagnosis is 39 years without surveillance/intervention.	Colon cancer	HP:0003003	Colon cancer		"{""preferred_term"": ""Colon cancer"", ""term"": {""id"": ""HP:0003003"", ""label"": ""Colon cancer""}}"																											
2427	2606	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	2	Duodenal Adenomas	Duodenal adenomas, especially periampullary, occur in 80-90% of FAP patients. They carry risk of progression to duodenal/ampullary adenocarcinoma, which is a leading cause of death in post-colectomy FAP patients.	phenotype_term	phenotype_term	$	Duodenal Adenomas	Duodenal adenomas, especially periampullary, occur in 80-90% of FAP patients. They carry risk of progression to duodenal/ampullary adenocarcinoma, which is a leading cause of death in post-colectomy FAP patients.	Small intestinal polyposis	HP:0030256	Small intestinal polyposis		"{""preferred_term"": ""Small intestinal polyposis"", ""term"": {""id"": ""HP:0030256"", ""label"": ""Small intestinal polyposis""}}"																											
2428	2607	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	3	Desmoid Tumors	Desmoid tumors (aggressive fibromatoses) occur in 10-15% of FAP patients, often in the mesentery or abdominal wall. They can cause significant morbidity through local invasion and compression. More common with 3' APC mutations and after abdominal surgery.	phenotype_term	phenotype_term	$	Desmoid Tumors	Desmoid tumors (aggressive fibromatoses) occur in 10-15% of FAP patients, often in the mesentery or abdominal wall. They can cause significant morbidity through local invasion and compression. More common with 3' APC mutations and after abdominal surgery.	Desmoid tumor	HP:6001034	Desmoid tumor		"{""preferred_term"": ""Desmoid tumor"", ""term"": {""id"": ""HP:6001034"", ""label"": ""Desmoid tumor""}}"																											
2429	2608	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	4	Osteomas	Benign bony growths, particularly of the mandible and skull. Characteristic of Gardner syndrome phenotype. May be detected radiographically before polyposis becomes apparent.	phenotype_term	phenotype_term	$	Osteomas	Benign bony growths, particularly of the mandible and skull. Characteristic of Gardner syndrome phenotype. May be detected radiographically before polyposis becomes apparent.	Osteoma	HP:0100246	Osteoma		"{""preferred_term"": ""Osteoma"", ""term"": {""id"": ""HP:0100246"", ""label"": ""Osteoma""}}"																											
2430	2609	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	phenotypes	5	Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE)	Pigmented lesions of the retinal pigment epithelium present from birth. Multiple bilateral CHRPE lesions are highly specific for FAP and can be detected before polyp development, aiding early diagnosis.	phenotype_term	phenotype_term	$	Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE)	Pigmented lesions of the retinal pigment epithelium present from birth. Multiple bilateral CHRPE lesions are highly specific for FAP and can be detected before polyp development, aiding early diagnosis.	Abnormality of retinal pigmentation	HP:0007703	Abnormality of retinal pigmentation		"{""preferred_term"": ""Abnormality of retinal pigmentation"", ""term"": {""id"": ""HP:0007703"", ""label"": ""Abnormality of retinal pigmentation""}}"																											
2431	2610	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	0	Prophylactic Colectomy	Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically.	treatment_term	treatment_term	$	Prophylactic Colectomy	Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2432	2611	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	1	Endoscopic Surveillance	Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy.	treatment_term	treatment_term	$	Endoscopic Surveillance	Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy.	colonoscopy	MAXO:0001184	colonoscopy		"{""preferred_term"": ""colonoscopy"", ""term"": {""id"": ""MAXO:0001184"", ""label"": ""colonoscopy""}}"																											
2433	2612	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	2	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2434	2613	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	3	Chemoprevention	Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery.	treatment_term	treatment_term	$	Chemoprevention	Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2435	2617	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	environmental	1	Emotional Stress		exposure_term	exposure_term	$	Emotional Stress		Emotional stress exposure				"{""preferred_term"": ""Emotional stress exposure""}"																											
2436	2624	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	0	MEFV Gene Mutation	Mutations in the MEFV gene lead to dysfunctional pyrin, causing excessive inflammation.	gene	gene	$	MEFV Gene Mutation	Mutations in the MEFV gene lead to dysfunctional pyrin, causing excessive inflammation.	MEFV				"{""preferred_term"": ""MEFV""}"																											
2437	2625	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	1	RhoA-PKN Regulatory Pathway Dysregulation	Disruption of the RhoA-PKN1/2-14-3-3 checkpoint that normally restrains pyrin inflammasome activation, leading to lowered activation threshold.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
2438	2625	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	1	RhoA-PKN Regulatory Pathway Dysregulation	Disruption of the RhoA-PKN1/2-14-3-3 checkpoint that normally restrains pyrin inflammasome activation, leading to lowered activation threshold.	cell_types[1]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2439	2625	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	1	RhoA-PKN Regulatory Pathway Dysregulation	Disruption of the RhoA-PKN1/2-14-3-3 checkpoint that normally restrains pyrin inflammasome activation, leading to lowered activation threshold.	biological_processes[0]	biological_processes	biological_processes			interleukin-1 beta production	GO:0032611	interleukin-1 beta production		"{""preferred_term"": ""interleukin-1 beta production"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
2440	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
2441	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2442	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	cell_types[2]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2443	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	biological_processes[0]	biological_processes	biological_processes			pyroptotic inflammatory response	GO:0070269	pyroptotic inflammatory response		"{""preferred_term"": ""pyroptotic inflammatory response"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptotic inflammatory response""}}"																											
2444	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	biological_processes[1]	biological_processes	biological_processes			interleukin-1 beta production	GO:0032611	interleukin-1 beta production		"{""preferred_term"": ""interleukin-1 beta production"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
2445	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	locations[0]	locations	locations			peritoneum	UBERON:0002358	peritoneum		"{""preferred_term"": ""peritoneum"", ""term"": {""id"": ""UBERON:0002358"", ""label"": ""peritoneum""}}"																											
2446	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	locations[1]	locations	locations			pleura	UBERON:0000977	pleura		"{""preferred_term"": ""pleura"", ""term"": {""id"": ""UBERON:0000977"", ""label"": ""pleura""}}"																											
2447	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	locations[2]	locations	locations			synovial membrane of synovial joint	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane of synovial joint"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
2448	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	pathways[0]	pathways	pathways			IL-1	GO:0032611	interleukin-1 beta production		"{""preferred_term"": ""IL-1"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
2449	2626	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	2	Autoinflammatory Pathway Activation	Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.	pathways[1]	pathways	pathways			inflammasome				"{""preferred_term"": ""inflammasome""}"																											
2450	2627	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	3	Gasdermin D-Mediated Pyroptosis	Caspase-1 cleaves gasdermin D to form membrane pores, enabling cytokine release and pyroptotic cell death, amplifying inflammation.	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2451	2627	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	3	Gasdermin D-Mediated Pyroptosis	Caspase-1 cleaves gasdermin D to form membrane pores, enabling cytokine release and pyroptotic cell death, amplifying inflammation.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2452	2627	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	pathophysiology	3	Gasdermin D-Mediated Pyroptosis	Caspase-1 cleaves gasdermin D to form membrane pores, enabling cytokine release and pyroptotic cell death, amplifying inflammation.	biological_processes[0]	biological_processes	biological_processes			pyroptotic inflammatory response	GO:0070269	pyroptotic inflammatory response		"{""preferred_term"": ""pyroptotic inflammatory response"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptotic inflammatory response""}}"																											
2453	2628	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	0	Recurrent Fever		phenotype_term	phenotype_term	$	Recurrent Fever		Recurrent Fever	HP:0001954	Recurrent fever		"{""preferred_term"": ""Recurrent Fever"", ""term"": {""id"": ""HP:0001954"", ""label"": ""Recurrent fever""}}"																											
2454	2629	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	1	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
2455	2630	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	2	Peritonitis		phenotype_term	phenotype_term	$	Peritonitis		Peritonitis	HP:0002586	Peritonitis		"{""preferred_term"": ""Peritonitis"", ""term"": {""id"": ""HP:0002586"", ""label"": ""Peritonitis""}}"																											
2456	2631	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	3	Pleuritis		phenotype_term	phenotype_term	$	Pleuritis		Pleuritis	HP:0002102	Pleuritis		"{""preferred_term"": ""Pleuritis"", ""term"": {""id"": ""HP:0002102"", ""label"": ""Pleuritis""}}"																											
2457	2632	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	4	Pericarditis		phenotype_term	phenotype_term	$	Pericarditis		Pericarditis	HP:0001701	Pericarditis		"{""preferred_term"": ""Pericarditis"", ""term"": {""id"": ""HP:0001701"", ""label"": ""Pericarditis""}}"																											
2458	2633	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	5	Amyloidosis		phenotype_term	phenotype_term	$	Amyloidosis		Amyloidosis	HP:0011034	Amyloidosis		"{""preferred_term"": ""Amyloidosis"", ""term"": {""id"": ""HP:0011034"", ""label"": ""Amyloidosis""}}"																											
2459	2635	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	phenotypes	7	Myalgia		phenotype_term	phenotype_term	$	Myalgia		Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
2460	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	Colchicine	First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.	treatment_term	treatment_term	$	Colchicine	First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2461	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	Anti-IL-1 Therapy	Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).	treatment_term	treatment_term	$	Anti-IL-1 Therapy	Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2462	2640	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	2	NSAIDs	Used for symptom relief during acute attacks	treatment_term	treatment_term	$	NSAIDs	Used for symptom relief during acute attacks	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2463	2641	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	3	Lifestyle Modifications	Avoiding known triggers such as stress and infections where possible	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding known triggers such as stress and infections where possible	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2464	2644	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	0	NCT04069533	Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
2465	2644	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	0	NCT04069533	Phase II clinical trial evaluating lentiviral-mediated gene therapy for pediatric patients with Fanconi Anemia subtype A (FA-A). Autologous CD34+ hematopoietic stem cells are transduced ex vivo with a lentiviral vector carrying the FANCA gene, then reinfused with the goal of preventing bone marrow failure.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2466	2645	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	1	NCT00243399	Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
2467	2645	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	1	NCT00243399	Pilot trial evaluating oxandrolone (an androgen steroid) for treatment of bone marrow aplasia in Fanconi Anemia patients. The study assessed safety and efficacy of androgen therapy to stimulate production of red blood cells and platelets in FA patients with bone marrow failure.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2468	2646	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	2	NCT00630253	Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
2469	2646	116	Fanconi_Anemia	Fanconi_Anemia.yaml	clinical_trials	2	NCT00630253	Phase I/II study evaluating cyclophosphamide, fludarabine, and antithymocyte globulin conditioning followed by matched sibling donor hematopoietic cell transplantation (HSCT) in patients with Fanconi Anemia. Investigates reduced-intensity conditioning regimens tailored to FA patients' increased chemotherapy sensitivity.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2470	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[0]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
2471	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[1]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
2472	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[2]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Anterior pituitary hypoplasia	HP:0010627	Anterior pituitary hypoplasia		"{""preferred_term"": ""Anterior pituitary hypoplasia"", ""term"": {""id"": ""HP:0010627"", ""label"": ""Anterior pituitary hypoplasia""}}"																											
2473	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[3]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Interrupted pituitary stalk	HP:0034978	Interrupted pituitary stalk		"{""preferred_term"": ""Interrupted pituitary stalk"", ""term"": {""id"": ""HP:0034978"", ""label"": ""Interrupted pituitary stalk""}}"																											
2474	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[4]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
2475	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[5]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Microphthalmia	HP:0000568	Microphthalmia		"{""preferred_term"": ""Microphthalmia"", ""term"": {""id"": ""HP:0000568"", ""label"": ""Microphthalmia""}}"																											
2476	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[6]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Epicanthus	HP:0000286	Epicanthus		"{""preferred_term"": ""Epicanthus"", ""term"": {""id"": ""HP:0000286"", ""label"": ""Epicanthus""}}"																											
2477	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[7]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Ptosis	HP:0000508	Ptosis		"{""preferred_term"": ""Ptosis"", ""term"": {""id"": ""HP:0000508"", ""label"": ""Ptosis""}}"																											
2478	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[8]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Strabismus	HP:0000486	Strabismus		"{""preferred_term"": ""Strabismus"", ""term"": {""id"": ""HP:0000486"", ""label"": ""Strabismus""}}"																											
2479	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[9]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Cataract	HP:0000518	Cataract		"{""preferred_term"": ""Cataract"", ""term"": {""id"": ""HP:0000518"", ""label"": ""Cataract""}}"																											
2480	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[10]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Triangular face	HP:0000325	Triangular face		"{""preferred_term"": ""Triangular face"", ""term"": {""id"": ""HP:0000325"", ""label"": ""Triangular face""}}"																											
2481	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[11]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Micrognathia	HP:0000347	Micrognathia		"{""preferred_term"": ""Micrognathia"", ""term"": {""id"": ""HP:0000347"", ""label"": ""Micrognathia""}}"																											
2482	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[12]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
2483	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[13]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Abnormal heart morphology	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Abnormal heart morphology"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
2484	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[14]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Tracheoesophageal fistula	HP:0002575	Tracheoesophageal fistula		"{""preferred_term"": ""Tracheoesophageal fistula"", ""term"": {""id"": ""HP:0002575"", ""label"": ""Tracheoesophageal fistula""}}"																											
2485	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[15]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Esophageal atresia	HP:0002032	Esophageal atresia		"{""preferred_term"": ""Esophageal atresia"", ""term"": {""id"": ""HP:0002032"", ""label"": ""Esophageal atresia""}}"																											
2486	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[16]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Duodenal atresia	HP:0002247	Duodenal atresia		"{""preferred_term"": ""Duodenal atresia"", ""term"": {""id"": ""HP:0002247"", ""label"": ""Duodenal atresia""}}"																											
2487	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[17]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Jejunal atresia	HP:0005235	Jejunal atresia		"{""preferred_term"": ""Jejunal atresia"", ""term"": {""id"": ""HP:0005235"", ""label"": ""Jejunal atresia""}}"																											
2488	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[18]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Anal atresia	HP:0002023	Anal atresia		"{""preferred_term"": ""Anal atresia"", ""term"": {""id"": ""HP:0002023"", ""label"": ""Anal atresia""}}"																											
2489	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[19]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Annular pancreas	HP:0001734	Annular pancreas		"{""preferred_term"": ""Annular pancreas"", ""term"": {""id"": ""HP:0001734"", ""label"": ""Annular pancreas""}}"																											
2490	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[20]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Intestinal malrotation	HP:0002566	Intestinal malrotation		"{""preferred_term"": ""Intestinal malrotation"", ""term"": {""id"": ""HP:0002566"", ""label"": ""Intestinal malrotation""}}"																											
2491	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[21]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Abnormality of the genitourinary system	HP:0000119	Abnormality of the genitourinary system		"{""preferred_term"": ""Abnormality of the genitourinary system"", ""term"": {""id"": ""HP:0000119"", ""label"": ""Abnormality of the genitourinary system""}}"																											
2492	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[22]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Absent thumb	HP:0009777	Absent thumb		"{""preferred_term"": ""Absent thumb"", ""term"": {""id"": ""HP:0009777"", ""label"": ""Absent thumb""}}"																											
2493	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[23]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Hypoplasia of the radius	HP:0002984	Hypoplasia of the radius		"{""preferred_term"": ""Hypoplasia of the radius"", ""term"": {""id"": ""HP:0002984"", ""label"": ""Hypoplasia of the radius""}}"																											
2494	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[24]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Clinodactyly	HP:0030084	Clinodactyly		"{""preferred_term"": ""Clinodactyly"", ""term"": {""id"": ""HP:0030084"", ""label"": ""Clinodactyly""}}"																											
2495	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[25]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Aplasia/Hypoplasia of the ulna	HP:0006495	Aplasia/Hypoplasia of the ulna		"{""preferred_term"": ""Aplasia/Hypoplasia of the ulna"", ""term"": {""id"": ""HP:0006495"", ""label"": ""Aplasia/Hypoplasia of the ulna""}}"																											
2496	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[26]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Toe syndactyly	HP:0001770	Toe syndactyly		"{""preferred_term"": ""Toe syndactyly"", ""term"": {""id"": ""HP:0001770"", ""label"": ""Toe syndactyly""}}"																											
2497	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[27]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Talipes equinovarus	HP:0001762	Talipes equinovarus		"{""preferred_term"": ""Talipes equinovarus"", ""term"": {""id"": ""HP:0001762"", ""label"": ""Talipes equinovarus""}}"																											
2498	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[28]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Hemivertebrae	HP:0002937	Hemivertebrae		"{""preferred_term"": ""Hemivertebrae"", ""term"": {""id"": ""HP:0002937"", ""label"": ""Hemivertebrae""}}"																											
2499	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[29]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Fused cervical vertebrae	HP:0002949	Fused cervical vertebrae		"{""preferred_term"": ""Fused cervical vertebrae"", ""term"": {""id"": ""HP:0002949"", ""label"": ""Fused cervical vertebrae""}}"																											
2500	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[30]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
2501	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[31]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Kyphosis	HP:0002808	Kyphosis		"{""preferred_term"": ""Kyphosis"", ""term"": {""id"": ""HP:0002808"", ""label"": ""Kyphosis""}}"																											
2502	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[32]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Absent/hypoplastic coccyx	HP:0008436	Absent/hypoplastic coccyx		"{""preferred_term"": ""Absent/hypoplastic coccyx"", ""term"": {""id"": ""HP:0008436"", ""label"": ""Absent/hypoplastic coccyx""}}"																											
2503	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[33]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Cafe-au-lait spot	HP:0000957	Cafe-au-lait spot		"{""preferred_term"": ""Cafe-au-lait spot"", ""term"": {""id"": ""HP:0000957"", ""label"": ""Cafe-au-lait spot""}}"																											
2504	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[34]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
2505	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[35]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
2506	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[36]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Myelodysplasia	HP:0002863	Myelodysplasia		"{""preferred_term"": ""Myelodysplasia"", ""term"": {""id"": ""HP:0002863"", ""label"": ""Myelodysplasia""}}"																											
2507	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[37]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Leukemia	HP:0001909	Leukemia		"{""preferred_term"": ""Leukemia"", ""term"": {""id"": ""HP:0001909"", ""label"": ""Leukemia""}}"																											
2508	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[38]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Cryptorchidism	HP:0000028	Cryptorchidism		"{""preferred_term"": ""Cryptorchidism"", ""term"": {""id"": ""HP:0000028"", ""label"": ""Cryptorchidism""}}"																											
2509	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[39]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Hypospadias	HP:0000047	Hypospadias		"{""preferred_term"": ""Hypospadias"", ""term"": {""id"": ""HP:0000047"", ""label"": ""Hypospadias""}}"																											
2510	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[40]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Micropenis	HP:0000054	Micropenis		"{""preferred_term"": ""Micropenis"", ""term"": {""id"": ""HP:0000054"", ""label"": ""Micropenis""}}"																											
2511	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[41]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Aplasia/hypoplasia of the uterus	HP:0008684	Aplasia/hypoplasia of the uterus		"{""preferred_term"": ""Aplasia/hypoplasia of the uterus"", ""term"": {""id"": ""HP:0008684"", ""label"": ""Aplasia/hypoplasia of the uterus""}}"																											
2512	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[42]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Gonadal dysgenesis	HP:0000133	Gonadal dysgenesis		"{""preferred_term"": ""Gonadal dysgenesis"", ""term"": {""id"": ""HP:0000133"", ""label"": ""Gonadal dysgenesis""}}"																											
2513	2647	116	Fanconi_Anemia	Fanconi_Anemia.yaml	definitions	0	2024 FA Clinical Care Guidelines Screening Indicator Set (Table 1)	Manifestations listed in Table 1 of the 5th edition Fanconi Anemia Clinical Care Guidelines that should raise suspicion for FA and trigger diagnostic screening workup.	criteria_sets[0].core_clinical_characteristics[43]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Vaginal atresia	HP:0000148	Vaginal atresia		"{""preferred_term"": ""Vaginal atresia"", ""term"": {""id"": ""HP:0000148"", ""label"": ""Vaginal atresia""}}"																											
2514	2680	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	3	FA-A	Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes.	subtype_term	subtype_term	$	FA-A	Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes.	Fanconi anemia complementation group A	MONDO:0009215	Fanconi anemia complementation group A		"{""preferred_term"": ""Fanconi anemia complementation group A"", ""term"": {""id"": ""MONDO:0009215"", ""label"": ""Fanconi anemia complementation group A""}}"																											
2515	2680	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	3	FA-A	Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes.	genes[0]	genes	genes			FANCA	hgnc:3582	FANCA		"{""preferred_term"": ""FANCA"", ""term"": {""id"": ""hgnc:3582"", ""label"": ""FANCA""}}"																											
2516	2681	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	4	FA-B	X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association.	subtype_term	subtype_term	$	FA-B	X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association.	Fanconi anemia complementation group B	MONDO:0010351	Fanconi anemia complementation group B		"{""preferred_term"": ""Fanconi anemia complementation group B"", ""term"": {""id"": ""MONDO:0010351"", ""label"": ""Fanconi anemia complementation group B""}}"																											
2517	2681	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	4	FA-B	X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association.	genes[0]	genes	genes			FANCB	hgnc:3583	FANCB		"{""preferred_term"": ""FANCB"", ""term"": {""id"": ""hgnc:3583"", ""label"": ""FANCB""}}"																											
2518	2682	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	5	FA-C	Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).	subtype_term	subtype_term	$	FA-C	Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).	Fanconi anemia complementation group C	MONDO:0009213	Fanconi anemia complementation group C		"{""preferred_term"": ""Fanconi anemia complementation group C"", ""term"": {""id"": ""MONDO:0009213"", ""label"": ""Fanconi anemia complementation group C""}}"																											
2519	2682	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	5	FA-C	Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).	genes[0]	genes	genes			FANCC	hgnc:3584	FANCC		"{""preferred_term"": ""FANCC"", ""term"": {""id"": ""hgnc:3584"", ""label"": ""FANCC""}}"																											
2520	2683	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	6	FA-D1	Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer.	subtype_term	subtype_term	$	FA-D1	Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer.	Fanconi anemia complementation group D1	MONDO:0011584	Fanconi anemia complementation group D1		"{""preferred_term"": ""Fanconi anemia complementation group D1"", ""term"": {""id"": ""MONDO:0011584"", ""label"": ""Fanconi anemia complementation group D1""}}"																											
2521	2683	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	6	FA-D1	Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer.	genes[0]	genes	genes			BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2522	2684	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	7	FA-D2	FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype.	subtype_term	subtype_term	$	FA-D2	FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype.	Fanconi anemia complementation group D2	MONDO:0009214	Fanconi anemia complementation group D2		"{""preferred_term"": ""Fanconi anemia complementation group D2"", ""term"": {""id"": ""MONDO:0009214"", ""label"": ""Fanconi anemia complementation group D2""}}"																											
2523	2684	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	7	FA-D2	FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype.	genes[0]	genes	genes			FANCD2	hgnc:3585	FANCD2		"{""preferred_term"": ""FANCD2"", ""term"": {""id"": ""hgnc:3585"", ""label"": ""FANCD2""}}"																											
2524	2685	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	8	FA-E	FANCE is a component of the FA core complex that directly interacts with FANCD2.	subtype_term	subtype_term	$	FA-E	FANCE is a component of the FA core complex that directly interacts with FANCD2.	Fanconi anemia complementation group E	MONDO:0010953	Fanconi anemia complementation group E		"{""preferred_term"": ""Fanconi anemia complementation group E"", ""term"": {""id"": ""MONDO:0010953"", ""label"": ""Fanconi anemia complementation group E""}}"																											
2525	2685	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	8	FA-E	FANCE is a component of the FA core complex that directly interacts with FANCD2.	genes[0]	genes	genes			FANCE	hgnc:3586	FANCE		"{""preferred_term"": ""FANCE"", ""term"": {""id"": ""hgnc:3586"", ""label"": ""FANCE""}}"																											
2526	2686	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	9	FA-F	FANCF is a core complex adaptor protein required for complex assembly and stability.	subtype_term	subtype_term	$	FA-F	FANCF is a core complex adaptor protein required for complex assembly and stability.	Fanconi anemia complementation group F	MONDO:0011325	Fanconi anemia complementation group F		"{""preferred_term"": ""Fanconi anemia complementation group F"", ""term"": {""id"": ""MONDO:0011325"", ""label"": ""Fanconi anemia complementation group F""}}"																											
2527	2686	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	9	FA-F	FANCF is a core complex adaptor protein required for complex assembly and stability.	genes[0]	genes	genes			FANCF	hgnc:3587	FANCF		"{""preferred_term"": ""FANCF"", ""term"": {""id"": ""hgnc:3587"", ""label"": ""FANCF""}}"																											
2528	2687	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	10	FA-G	Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex.	subtype_term	subtype_term	$	FA-G	Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex.	Fanconi anemia complementation group G	MONDO:0013565	Fanconi anemia complementation group G		"{""preferred_term"": ""Fanconi anemia complementation group G"", ""term"": {""id"": ""MONDO:0013565"", ""label"": ""Fanconi anemia complementation group G""}}"																											
2529	2687	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	10	FA-G	Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex.	genes[0]	genes	genes			FANCG	hgnc:3588	FANCG		"{""preferred_term"": ""FANCG"", ""term"": {""id"": ""hgnc:3588"", ""label"": ""FANCG""}}"																											
2530	2688	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	11	FA-I	FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks.	subtype_term	subtype_term	$	FA-I	FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks.	Fanconi anemia complementation group I	MONDO:0012186	Fanconi anemia complementation group I		"{""preferred_term"": ""Fanconi anemia complementation group I"", ""term"": {""id"": ""MONDO:0012186"", ""label"": ""Fanconi anemia complementation group I""}}"																											
2531	2688	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	11	FA-I	FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks.	genes[0]	genes	genes			FANCI	hgnc:25568	FANCI		"{""preferred_term"": ""FANCI"", ""term"": {""id"": ""hgnc:25568"", ""label"": ""FANCI""}}"																											
2532	2689	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	12	FA-J	Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk.	subtype_term	subtype_term	$	FA-J	Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk.	Fanconi anemia complementation group J	MONDO:0012187	Fanconi anemia complementation group J		"{""preferred_term"": ""Fanconi anemia complementation group J"", ""term"": {""id"": ""MONDO:0012187"", ""label"": ""Fanconi anemia complementation group J""}}"																											
2533	2689	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	12	FA-J	Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk.	genes[0]	genes	genes			BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2534	2690	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	13	FA-L	FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI.	subtype_term	subtype_term	$	FA-L	FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI.	Fanconi anemia complementation group L	MONDO:0013566	Fanconi anemia complementation group L		"{""preferred_term"": ""Fanconi anemia complementation group L"", ""term"": {""id"": ""MONDO:0013566"", ""label"": ""Fanconi anemia complementation group L""}}"																											
2535	2690	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	13	FA-L	FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI.	genes[0]	genes	genes			FANCL	hgnc:20748	FANCL		"{""preferred_term"": ""FANCL"", ""term"": {""id"": ""hgnc:20748"", ""label"": ""FANCL""}}"																											
2536	2691	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	14	FA-N	Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele.	subtype_term	subtype_term	$	FA-N	Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele.	Fanconi anemia complementation group N	MONDO:0012565	Fanconi anemia complementation group N		"{""preferred_term"": ""Fanconi anemia complementation group N"", ""term"": {""id"": ""MONDO:0012565"", ""label"": ""Fanconi anemia complementation group N""}}"																											
2537	2691	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	14	FA-N	Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele.	genes[0]	genes	genes			PALB2	hgnc:26144	PALB2		"{""preferred_term"": ""PALB2"", ""term"": {""id"": ""hgnc:26144"", ""label"": ""PALB2""}}"																											
2538	2692	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	15	FA-O	Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.	subtype_term	subtype_term	$	FA-O	Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.	Fanconi anemia complementation group O	MONDO:0013248	Fanconi anemia complementation group O		"{""preferred_term"": ""Fanconi anemia complementation group O"", ""term"": {""id"": ""MONDO:0013248"", ""label"": ""Fanconi anemia complementation group O""}}"																											
2539	2692	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	15	FA-O	Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.	genes[0]	genes	genes			RAD51C	hgnc:9820	RAD51C		"{""preferred_term"": ""RAD51C"", ""term"": {""id"": ""hgnc:9820"", ""label"": ""RAD51C""}}"																											
2540	2693	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	16	FA-P	Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair.	subtype_term	subtype_term	$	FA-P	Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair.	Fanconi anemia complementation group P	MONDO:0013499	Fanconi anemia complementation group P		"{""preferred_term"": ""Fanconi anemia complementation group P"", ""term"": {""id"": ""MONDO:0013499"", ""label"": ""Fanconi anemia complementation group P""}}"																											
2541	2693	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	16	FA-P	Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair.	genes[0]	genes	genes			SLX4	hgnc:23845	SLX4		"{""preferred_term"": ""SLX4"", ""term"": {""id"": ""hgnc:23845"", ""label"": ""SLX4""}}"																											
2542	2694	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	17	FA-Q	Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome.	subtype_term	subtype_term	$	FA-Q	Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome.	Fanconi anemia complementation group Q	MONDO:0014108	Fanconi anemia complementation group Q		"{""preferred_term"": ""Fanconi anemia complementation group Q"", ""term"": {""id"": ""MONDO:0014108"", ""label"": ""Fanconi anemia complementation group Q""}}"																											
2543	2694	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	17	FA-Q	Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome.	genes[0]	genes	genes			ERCC4	hgnc:3436	ERCC4		"{""preferred_term"": ""ERCC4"", ""term"": {""id"": ""hgnc:3436"", ""label"": ""ERCC4""}}"																											
2544	2695	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	18	FA-R	Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo.	subtype_term	subtype_term	$	FA-R	Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo.	Fanconi anemia complementation group R	MONDO:0014986	Fanconi anemia complementation group R		"{""preferred_term"": ""Fanconi anemia complementation group R"", ""term"": {""id"": ""MONDO:0014986"", ""label"": ""Fanconi anemia complementation group R""}}"																											
2545	2695	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	18	FA-R	Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo.	genes[0]	genes	genes			RAD51	hgnc:9817	RAD51		"{""preferred_term"": ""RAD51"", ""term"": {""id"": ""hgnc:9817"", ""label"": ""RAD51""}}"																											
2546	2696	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	19	FA-S	Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk.	subtype_term	subtype_term	$	FA-S	Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk.	Fanconi anemia, complementation group S	MONDO:0054748	Fanconi anemia, complementation group S		"{""preferred_term"": ""Fanconi anemia, complementation group S"", ""term"": {""id"": ""MONDO:0054748"", ""label"": ""Fanconi anemia, complementation group S""}}"																											
2547	2696	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	19	FA-S	Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk.	genes[0]	genes	genes			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2548	2697	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	20	FA-T	Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex.	subtype_term	subtype_term	$	FA-T	Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex.	Fanconi anemia complementation group T	MONDO:0014638	Fanconi anemia complementation group T		"{""preferred_term"": ""Fanconi anemia complementation group T"", ""term"": {""id"": ""MONDO:0014638"", ""label"": ""Fanconi anemia complementation group T""}}"																											
2549	2697	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	20	FA-T	Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex.	genes[0]	genes	genes			UBE2T	hgnc:25009	UBE2T		"{""preferred_term"": ""UBE2T"", ""term"": {""id"": ""hgnc:25009"", ""label"": ""UBE2T""}}"																											
2550	2698	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	21	FA-U	Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair.	subtype_term	subtype_term	$	FA-U	Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair.	Fanconi anemia complementation group U	MONDO:0014987	Fanconi anemia complementation group U		"{""preferred_term"": ""Fanconi anemia complementation group U"", ""term"": {""id"": ""MONDO:0014987"", ""label"": ""Fanconi anemia complementation group U""}}"																											
2551	2698	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	21	FA-U	Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair.	genes[0]	genes	genes			XRCC2	hgnc:12829	XRCC2		"{""preferred_term"": ""XRCC2"", ""term"": {""id"": ""hgnc:12829"", ""label"": ""XRCC2""}}"																											
2552	2699	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	22	FA-V	Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling.	subtype_term	subtype_term	$	FA-V	Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling.	Fanconi anemia complementation group V	MONDO:0014985	Fanconi anemia complementation group V		"{""preferred_term"": ""Fanconi anemia complementation group V"", ""term"": {""id"": ""MONDO:0014985"", ""label"": ""Fanconi anemia complementation group V""}}"																											
2553	2699	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	22	FA-V	Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling.	genes[0]	genes	genes			MAD2L2	hgnc:6764	MAD2L2		"{""preferred_term"": ""MAD2L2"", ""term"": {""id"": ""hgnc:6764"", ""label"": ""MAD2L2""}}"																											
2554	2700	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	23	FA-W	Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination.	subtype_term	subtype_term	$	FA-W	Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination.	Fanconi anemia, complementation group W	MONDO:0044325	Fanconi anemia, complementation group W		"{""preferred_term"": ""Fanconi anemia, complementation group W"", ""term"": {""id"": ""MONDO:0044325"", ""label"": ""Fanconi anemia, complementation group W""}}"																											
2555	2700	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	23	FA-W	Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination.	genes[0]	genes	genes			RFWD3	hgnc:25539	RFWD3		"{""preferred_term"": ""RFWD3"", ""term"": {""id"": ""hgnc:25539"", ""label"": ""RFWD3""}}"																											
2556	2706	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	3	Hematopoietic Stem Cell Attrition	Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.	cell_types[0]	cell_types	cell_types			hematopoietic stem cell	CL:0000037	hematopoietic stem cell		"{""preferred_term"": ""hematopoietic stem cell"", ""term"": {""id"": ""CL:0000037"", ""label"": ""hematopoietic stem cell""}}"																											
2557	2706	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	3	Hematopoietic Stem Cell Attrition	Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.	biological_processes[0]	biological_processes	biological_processes			response to aldehyde	GO:0043437	response to aldehyde		"{""preferred_term"": ""response to aldehyde"", ""term"": {""id"": ""GO:0043437"", ""label"": ""response to aldehyde""}}"																											
2558	2706	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	3	Hematopoietic Stem Cell Attrition	Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.	biological_processes[1]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress		"{""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
2559	2706	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	3	Hematopoietic Stem Cell Attrition	Progressive depletion of long-term hematopoietic stem cells in bone marrow due to replication stress, aldehyde-induced DNA damage, and chronic inflammatory signaling.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
2560	2707	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	4	Translesion Synthesis Defect	Impaired ability to bypass DNA lesions during replication through translesion synthesis polymerases, requiring functional FANCD2-FANCI complex and PCNA monoubiquitination.	biological_processes[0]	biological_processes	biological_processes			translesion synthesis	GO:0019985	translesion synthesis		"{""preferred_term"": ""translesion synthesis"", ""term"": {""id"": ""GO:0019985"", ""label"": ""translesion synthesis""}}"																											
2561	2708	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	5	Homologous Recombination Impairment	Defective repair of DNA double-strand breaks following interstrand crosslink unhooking, due to mutations in FA genes involved in HR pathway including BRCA2, PALB2, and BRCA1.	biological_processes[0]	biological_processes	biological_processes			homologous recombination	GO:0035825	homologous recombination		"{""preferred_term"": ""homologous recombination"", ""term"": {""id"": ""GO:0035825"", ""label"": ""homologous recombination""}}"																											
2562	2709	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	6	Aldehyde-Induced Genotoxicity	Endogenous aldehydes (acetaldehyde and formaldehyde) from normal metabolism generate DNA interstrand crosslinks and DNA-protein crosslinks; impaired detoxification by ALDH2 and ADH5 exacerbates DNA damage burden.	biological_processes[0]	biological_processes	biological_processes			response to aldehyde	GO:0043437	response to aldehyde		"{""preferred_term"": ""response to aldehyde"", ""term"": {""id"": ""GO:0043437"", ""label"": ""response to aldehyde""}}"																											
2563	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	protein_complexes[0]	protein_complexes	protein_complexes			FA nuclear complex	GO:0043240	Fanconi anaemia nuclear complex		"{""preferred_term"": ""FA nuclear complex"", ""term"": {""id"": ""GO:0043240"", ""label"": ""Fanconi anaemia nuclear complex""}}"																											
2564	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	biological_processes[0]	biological_processes	biological_processes			protein ubiquitination	GO:0016567	protein ubiquitination		"{""preferred_term"": ""protein ubiquitination"", ""term"": {""id"": ""GO:0016567"", ""label"": ""protein ubiquitination""}}"																											
2565	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	genes[0]	genes	genes			FANCA	hgnc:3582	FANCA		"{""preferred_term"": ""FANCA"", ""term"": {""id"": ""hgnc:3582"", ""label"": ""FANCA""}}"																											
2566	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	genes[1]	genes	genes			FANCB	hgnc:3583	FANCB		"{""preferred_term"": ""FANCB"", ""term"": {""id"": ""hgnc:3583"", ""label"": ""FANCB""}}"																											
2567	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	genes[2]	genes	genes			FANCC	hgnc:3584	FANCC		"{""preferred_term"": ""FANCC"", ""term"": {""id"": ""hgnc:3584"", ""label"": ""FANCC""}}"																											
2568	2710	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	7	Core Complex Dysfunction	Mutations in FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T/FANCT) disrupt the E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI complex, abolishing the central signaling step of the FA pathway. FANCA mutations account for 60-70% of all FA cases.	genes[3]	genes	genes			FANCG	hgnc:3588	FANCG		"{""preferred_term"": ""FANCG"", ""term"": {""id"": ""hgnc:3588"", ""label"": ""FANCG""}}"																											
2569	2711	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	8	ID Complex Dysfunction	Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose monoubiquitination is the critical signaling event in FA pathway activation. In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled replication forks and recruit downstream nucleases and HR effectors. Loss of either subunit abolishes this signaling hub.	genes[0]	genes	genes			FANCD2	hgnc:3585	FANCD2		"{""preferred_term"": ""FANCD2"", ""term"": {""id"": ""hgnc:3585"", ""label"": ""FANCD2""}}"																											
2570	2711	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	8	ID Complex Dysfunction	Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose monoubiquitination is the critical signaling event in FA pathway activation. In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled replication forks and recruit downstream nucleases and HR effectors. Loss of either subunit abolishes this signaling hub.	genes[1]	genes	genes			FANCI	hgnc:25568	FANCI		"{""preferred_term"": ""FANCI"", ""term"": {""id"": ""hgnc:25568"", ""label"": ""FANCI""}}"																											
2571	2711	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	8	ID Complex Dysfunction	Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose monoubiquitination is the critical signaling event in FA pathway activation. In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled replication forks and recruit downstream nucleases and HR effectors. Loss of either subunit abolishes this signaling hub.	biological_processes[0]	biological_processes	biological_processes			protein monoubiquitination	GO:0006513	protein monoubiquitination		"{""preferred_term"": ""protein monoubiquitination"", ""term"": {""id"": ""GO:0006513"", ""label"": ""protein monoubiquitination""}}"																											
2572	2711	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	8	ID Complex Dysfunction	Mutations in FANCD2 or FANCI disrupt the central ID2 complex whose monoubiquitination is the critical signaling event in FA pathway activation. In wild type, the core complex E3 ligase monoubiquitinates both FANCD2 and FANCI, causing the ID2 heterodimer to clamp onto chromatin at stalled replication forks and recruit downstream nucleases and HR effectors. Loss of either subunit abolishes this signaling hub.	biological_processes[1]	biological_processes	biological_processes			interstrand cross-link repair	GO:0036297	interstrand cross-link repair		"{""preferred_term"": ""interstrand cross-link repair"", ""term"": {""id"": ""GO:0036297"", ""label"": ""interstrand cross-link repair""}}"																											
2573	2712	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	9	Downstream Effector Dysfunction	Mutations in downstream effector genes (BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51C/FANCO, XRCC2/FANCU) impair homologous recombination and translesion synthesis. These overlap with familial breast/ovarian cancer genes; biallelic mutations produce the most severe FA phenotypes with early-onset solid tumors and more congenital anomalies.	genes[0]	genes	genes			BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2574	2712	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	9	Downstream Effector Dysfunction	Mutations in downstream effector genes (BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51C/FANCO, XRCC2/FANCU) impair homologous recombination and translesion synthesis. These overlap with familial breast/ovarian cancer genes; biallelic mutations produce the most severe FA phenotypes with early-onset solid tumors and more congenital anomalies.	genes[1]	genes	genes			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2575	2713	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	10	Inflammatory Bone Marrow Microenvironment	Excess sterile inflammatory signaling (TNF-alpha, interferon-gamma, Type I interferons) in the bone marrow creates a hostile microenvironment for HSCs. Both hematopoietic and stromal cells contribute to chronic inflammation, driving proteostasis deregulation and accelerating stem cell attrition.	cell_types[0]	cell_types	cell_types			hematopoietic stem cell	CL:0000037	hematopoietic stem cell		"{""preferred_term"": ""hematopoietic stem cell"", ""term"": {""id"": ""CL:0000037"", ""label"": ""hematopoietic stem cell""}}"																											
2576	2713	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	10	Inflammatory Bone Marrow Microenvironment	Excess sterile inflammatory signaling (TNF-alpha, interferon-gamma, Type I interferons) in the bone marrow creates a hostile microenvironment for HSCs. Both hematopoietic and stromal cells contribute to chronic inflammation, driving proteostasis deregulation and accelerating stem cell attrition.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2577	2713	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	10	Inflammatory Bone Marrow Microenvironment	Excess sterile inflammatory signaling (TNF-alpha, interferon-gamma, Type I interferons) in the bone marrow creates a hostile microenvironment for HSCs. Both hematopoietic and stromal cells contribute to chronic inflammation, driving proteostasis deregulation and accelerating stem cell attrition.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
2578	2714	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	11	Developmental Progenitor Apoptosis	Unrepaired DNA damage in rapidly dividing embryonic progenitor cells activates p53-dependent apoptosis during critical developmental windows. This mechanism underlies the congenital malformations of FA, explaining the midline predominance of anomalies and correlation between pathway position and congenital abnormality burden.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
2579	2714	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	11	Developmental Progenitor Apoptosis	Unrepaired DNA damage in rapidly dividing embryonic progenitor cells activates p53-dependent apoptosis during critical developmental windows. This mechanism underlies the congenital malformations of FA, explaining the midline predominance of anomalies and correlation between pathway position and congenital abnormality burden.	biological_processes[1]	biological_processes	biological_processes			embryo development	GO:0009790	embryo development		"{""preferred_term"": ""embryo development"", ""term"": {""id"": ""GO:0009790"", ""label"": ""embryo development""}}"																											
2580	2715	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	12	Clonal Evolution	Progressive accumulation of somatic mutations and chromosomal aberrations in genomically unstable hematopoietic cells drives clonal selection and malignant transformation. Characteristic cytogenetic changes include gain of 1q and 3q and loss of 7q. Clones with selective growth advantage expand, leading to MDS and AML.	cell_types[0]	cell_types	cell_types			hematopoietic stem cell	CL:0000037	hematopoietic stem cell		"{""preferred_term"": ""hematopoietic stem cell"", ""term"": {""id"": ""CL:0000037"", ""label"": ""hematopoietic stem cell""}}"																											
2581	2715	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	12	Clonal Evolution	Progressive accumulation of somatic mutations and chromosomal aberrations in genomically unstable hematopoietic cells drives clonal selection and malignant transformation. Characteristic cytogenetic changes include gain of 1q and 3q and loss of 7q. Clones with selective growth advantage expand, leading to MDS and AML.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
2582	2716	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	13	Epithelial Cancer Susceptibility	Impaired genome maintenance in epithelial tissues renders them vulnerable to accumulation of oncogenic mutations. Squamous epithelia of the head/neck, oral cavity, esophagus, and anogenital regions are particularly susceptible due to high proliferative turnover and exposure to environmental mutagens including HPV.	cell_types[0]	cell_types	cell_types			epithelial cell	CL:0000066	epithelial cell		"{""preferred_term"": ""epithelial cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
2583	2718	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	15	Endocrine Gland Dysfunction	Widespread endocrine abnormalities affect approximately 73-80% of FA patients. Developmental pituitary/hypothalamic defects (68% have small pituitary on MRI), direct effects of genomic instability on endocrine cell function, and chronic illness contribute. Manifests as GH deficiency, hypothyroidism, glucose dysregulation, hypogonadism, dyslipidemia, and metabolic syndrome.	locations[0]	locations	locations			pituitary gland	UBERON:0000007	pituitary gland		"{""preferred_term"": ""pituitary gland"", ""term"": {""id"": ""UBERON:0000007"", ""label"": ""pituitary gland""}}"																											
2584	2720	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	17	CNS Developmental Anomalies	Midline brain structural defects from neural progenitor loss during early CNS development. Includes small pituitary (68%), posterior fossa abnormalities (30% including Chiari I malformation and Dandy-Walker variant), and corpus callosum structural variation (30%).	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
2585	2720	116	Fanconi_Anemia	Fanconi_Anemia.yaml	pathophysiology	17	CNS Developmental Anomalies	Midline brain structural defects from neural progenitor loss during early CNS development. Includes small pituitary (68%), posterior fossa abnormalities (30% including Chiari I malformation and Dandy-Walker variant), and corpus callosum structural variation (30%).	locations[1]	locations	locations			pituitary gland	UBERON:0000007	pituitary gland		"{""preferred_term"": ""pituitary gland"", ""term"": {""id"": ""UBERON:0000007"", ""label"": ""pituitary gland""}}"																											
2586	2722	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	0	Pancytopenia	Progressive decline in all blood cell lineages due to bone marrow failure.	phenotype_term	phenotype_term	$	Pancytopenia	Progressive decline in all blood cell lineages due to bone marrow failure.	Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
2587	2722	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	0	Pancytopenia	Progressive decline in all blood cell lineages due to bone marrow failure.	phenotype_contexts[1].genetic_context.gene	phenotype_contexts	phenotype_contexts[1].genetic_context			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2588	2722	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	0	Pancytopenia	Progressive decline in all blood cell lineages due to bone marrow failure.	phenotype_contexts[2].genetic_context.gene	phenotype_contexts	phenotype_contexts[2].genetic_context			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2589	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_term	phenotype_term	$	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	Leukemia	HP:0001909	Leukemia		"{""preferred_term"": ""Leukemia"", ""term"": {""id"": ""HP:0001909"", ""label"": ""Leukemia""}}"																											
2590	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[0].genetic_context.gene	phenotype_contexts	phenotype_contexts[0].genetic_context			FANCA	hgnc:3582	FANCA		"{""preferred_term"": ""FANCA"", ""term"": {""id"": ""hgnc:3582"", ""label"": ""FANCA""}}"																											
2591	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[1].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCC	hgnc:3584	FANCC		"{""preferred_term"": ""FANCC"", ""term"": {""id"": ""hgnc:3584"", ""label"": ""FANCC""}}"																											
2592	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[1].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2593	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[1].genetic_context.genes[2]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCG	hgnc:3588	FANCG		"{""preferred_term"": ""FANCG"", ""term"": {""id"": ""hgnc:3588"", ""label"": ""FANCG""}}"																											
2594	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[1].genetic_context.genes[3]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2595	2723	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	1	Increased Risk of Leukemia	Significantly elevated risk of developing leukemia, predominantly acute myeloid leukemia (AML) with an incidence of 13% by age 50. Acute lymphoblastic leukemia (ALL) also reported, especially in FANCD1/BRCA2 patients.	phenotype_contexts[4].genetic_context.gene	phenotype_contexts	phenotype_contexts[4].genetic_context			FANCG	hgnc:3588	FANCG		"{""preferred_term"": ""FANCG"", ""term"": {""id"": ""hgnc:3588"", ""label"": ""FANCG""}}"																											
2596	2724	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	2	Aplastic Anemia	Bone marrow failure resulting in severely reduced production of all blood cell types.	phenotype_term	phenotype_term	$	Aplastic Anemia	Bone marrow failure resulting in severely reduced production of all blood cell types.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2597	2725	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	3	Thrombocytopenia	Low platelet count due to progressive bone marrow failure in Fanconi anemia.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count due to progressive bone marrow failure in Fanconi anemia.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
2598	2726	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	4	Leukopenia	Decreased white blood cell count as part of hematopoietic failure in Fanconi anemia.	phenotype_term	phenotype_term	$	Leukopenia	Decreased white blood cell count as part of hematopoietic failure in Fanconi anemia.	Decreased total leukocyte count	HP:0001882	Decreased total leukocyte count		"{""preferred_term"": ""Decreased total leukocyte count"", ""term"": {""id"": ""HP:0001882"", ""label"": ""Decreased total leukocyte count""}}"																											
2599	2727	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	5	Short Stature	Growth deficiency present from birth, affecting approximately 60% of patients.	phenotype_term	phenotype_term	$	Short Stature	Growth deficiency present from birth, affecting approximately 60% of patients.	Short Stature	HP:0004322	Short stature		"{""preferred_term"": ""Short Stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
2600	2727	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	5	Short Stature	Growth deficiency present from birth, affecting approximately 60% of patients.	phenotype_contexts[1].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2601	2727	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	5	Short Stature	Growth deficiency present from birth, affecting approximately 60% of patients.	phenotype_contexts[1].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2602	2728	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	6	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	phenotype_term	phenotype_term	$	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	Skeletal Anomalies	HP:0005775	Multiple skeletal anomalies		"{""preferred_term"": ""Skeletal Anomalies"", ""term"": {""id"": ""HP:0005775"", ""label"": ""Multiple skeletal anomalies""}}"																											
2603	2728	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	6	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	phenotype_contexts[0].genetic_context.gene	phenotype_contexts	phenotype_contexts[0].genetic_context			FANCC	hgnc:3584	FANCC		"{""preferred_term"": ""FANCC"", ""term"": {""id"": ""hgnc:3584"", ""label"": ""FANCC""}}"																											
2604	2728	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	6	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	phenotype_contexts[1].genetic_context.gene	phenotype_contexts	phenotype_contexts[1].genetic_context			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2605	2728	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	6	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	phenotype_contexts[2].genetic_context.gene	phenotype_contexts	phenotype_contexts[2].genetic_context			FANCB	hgnc:3583	FANCB		"{""preferred_term"": ""FANCB"", ""term"": {""id"": ""hgnc:3583"", ""label"": ""FANCB""}}"																											
2606	2728	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	6	Skeletal Anomalies	Upper limb malformations including absent or hypoplastic thumbs, radial ray defects, and hip abnormalities.	phenotype_contexts[3].genetic_context.gene	phenotype_contexts	phenotype_contexts[3].genetic_context			FANCI	hgnc:25568	FANCI		"{""preferred_term"": ""FANCI"", ""term"": {""id"": ""hgnc:25568"", ""label"": ""FANCI""}}"																											
2607	2729	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	7	Caf-au-Lait Spots	Hyperpigmented skin macules commonly seen in FA patients.	phenotype_term	phenotype_term	$	Caf-au-Lait Spots	Hyperpigmented skin macules commonly seen in FA patients.	Caf-au-lait Spot	HP:0000957	Cafe-au-lait spot		"{""preferred_term"": ""Caf-au-lait Spot"", ""term"": {""id"": ""HP:0000957"", ""label"": ""Cafe-au-lait spot""}}"																											
2608	2730	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	8	Squamous Cell Carcinoma	Markedly increased risk of early-onset squamous cell carcinomas, particularly of the head and neck, oral cavity, esophagus, and anogenital regions.	phenotype_term	phenotype_term	$	Squamous Cell Carcinoma	Markedly increased risk of early-onset squamous cell carcinomas, particularly of the head and neck, oral cavity, esophagus, and anogenital regions.	Squamous cell carcinoma	HP:0002860	Squamous cell carcinoma		"{""preferred_term"": ""Squamous cell carcinoma"", ""term"": {""id"": ""HP:0002860"", ""label"": ""Squamous cell carcinoma""}}"																											
2609	2730	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	8	Squamous Cell Carcinoma	Markedly increased risk of early-onset squamous cell carcinomas, particularly of the head and neck, oral cavity, esophagus, and anogenital regions.	phenotype_contexts[2].genetic_context.gene	phenotype_contexts	phenotype_contexts[2].genetic_context			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2610	2732	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	10	Esophageal Atresia	Congenital interruption of the esophagus reported among Fanconi anemia gastrointestinal manifestations.	phenotype_term	phenotype_term	$	Esophageal Atresia	Congenital interruption of the esophagus reported among Fanconi anemia gastrointestinal manifestations.	Esophageal atresia	HP:0002032	Esophageal atresia		"{""preferred_term"": ""Esophageal atresia"", ""term"": {""id"": ""HP:0002032"", ""label"": ""Esophageal atresia""}}"																											
2611	2733	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	11	Duodenal Atresia	Congenital obstruction of the duodenum reported among Fanconi anemia gastrointestinal manifestations.	phenotype_term	phenotype_term	$	Duodenal Atresia	Congenital obstruction of the duodenum reported among Fanconi anemia gastrointestinal manifestations.	Duodenal atresia	HP:0002247	Duodenal atresia		"{""preferred_term"": ""Duodenal atresia"", ""term"": {""id"": ""HP:0002247"", ""label"": ""Duodenal atresia""}}"																											
2612	2734	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	12	Jejunal Atresia	Congenital jejunal occlusion reported among Fanconi anemia gastrointestinal manifestations.	phenotype_term	phenotype_term	$	Jejunal Atresia	Congenital jejunal occlusion reported among Fanconi anemia gastrointestinal manifestations.	Jejunal atresia	HP:0005235	Jejunal atresia		"{""preferred_term"": ""Jejunal atresia"", ""term"": {""id"": ""HP:0005235"", ""label"": ""Jejunal atresia""}}"																											
2613	2735	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	13	Anal Atresia	Congenital anorectal malformation reported in Fanconi anemia screening manifestations.	phenotype_term	phenotype_term	$	Anal Atresia	Congenital anorectal malformation reported in Fanconi anemia screening manifestations.	Anal atresia	HP:0002023	Anal atresia		"{""preferred_term"": ""Anal atresia"", ""term"": {""id"": ""HP:0002023"", ""label"": ""Anal atresia""}}"																											
2614	2736	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	14	Intestinal Malrotation	Congenital abnormal rotation/fixation of the intestine occurring in a subset of FA patients.	phenotype_term	phenotype_term	$	Intestinal Malrotation	Congenital abnormal rotation/fixation of the intestine occurring in a subset of FA patients.	Intestinal malrotation	HP:0002566	Intestinal malrotation		"{""preferred_term"": ""Intestinal malrotation"", ""term"": {""id"": ""HP:0002566"", ""label"": ""Intestinal malrotation""}}"																											
2615	2737	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	15	Annular Pancreas	Congenital ring of pancreatic tissue encircling the duodenum, reported among FA screening manifestations.	phenotype_term	phenotype_term	$	Annular Pancreas	Congenital ring of pancreatic tissue encircling the duodenum, reported among FA screening manifestations.	Annular pancreas	HP:0001734	Annular pancreas		"{""preferred_term"": ""Annular pancreas"", ""term"": {""id"": ""HP:0001734"", ""label"": ""Annular pancreas""}}"																											
2616	2738	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	16	Tracheoesophageal Fistula	Congenital fistulous connection between trachea and esophagus in a subset of FA patients.	phenotype_term	phenotype_term	$	Tracheoesophageal Fistula	Congenital fistulous connection between trachea and esophagus in a subset of FA patients.	Tracheoesophageal fistula	HP:0002575	Tracheoesophageal fistula		"{""preferred_term"": ""Tracheoesophageal fistula"", ""term"": {""id"": ""HP:0002575"", ""label"": ""Tracheoesophageal fistula""}}"																											
2617	2739	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	17	Genitourinary Malformations	Congenital abnormalities of the kidneys and reproductive organs.	phenotype_term	phenotype_term	$	Genitourinary Malformations	Congenital abnormalities of the kidneys and reproductive organs.	Genitourinary Abnormality	HP:0000119	Abnormality of the genitourinary system		"{""preferred_term"": ""Genitourinary Abnormality"", ""term"": {""id"": ""HP:0000119"", ""label"": ""Abnormality of the genitourinary system""}}"																											
2618	2739	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	17	Genitourinary Malformations	Congenital abnormalities of the kidneys and reproductive organs.	phenotype_contexts[0].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2619	2739	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	17	Genitourinary Malformations	Congenital abnormalities of the kidneys and reproductive organs.	phenotype_contexts[0].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2620	2740	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	18	Microcephaly	Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.	phenotype_term	phenotype_term	$	Microcephaly	Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.	Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
2621	2740	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	18	Microcephaly	Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.	phenotype_contexts[0].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2622	2740	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	18	Microcephaly	Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.	phenotype_contexts[0].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2623	2740	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	18	Microcephaly	Abnormally small head circumference, present in a subset of FA patients as part of congenital anomalies.	phenotype_contexts[1].genetic_context.gene	phenotype_contexts	phenotype_contexts[1].genetic_context			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2624	2741	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	19	Anterior Pituitary Hypoplasia	Small anterior pituitary as part of the central nervous system anomaly spectrum in Fanconi anemia.	phenotype_term	phenotype_term	$	Anterior Pituitary Hypoplasia	Small anterior pituitary as part of the central nervous system anomaly spectrum in Fanconi anemia.	Anterior pituitary hypoplasia	HP:0010627	Anterior pituitary hypoplasia		"{""preferred_term"": ""Anterior pituitary hypoplasia"", ""term"": {""id"": ""HP:0010627"", ""label"": ""Anterior pituitary hypoplasia""}}"																											
2625	2742	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	20	Interrupted Pituitary Stalk	Interruption of the pituitary stalk reported among central nervous system manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Interrupted Pituitary Stalk	Interruption of the pituitary stalk reported among central nervous system manifestations in Fanconi anemia.	Interrupted pituitary stalk	HP:0034978	Interrupted pituitary stalk		"{""preferred_term"": ""Interrupted pituitary stalk"", ""term"": {""id"": ""HP:0034978"", ""label"": ""Interrupted pituitary stalk""}}"																											
2626	2743	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	21	Micrognathia	Congenital mandibular hypoplasia reported within the facial anomaly spectrum of Fanconi anemia.	phenotype_term	phenotype_term	$	Micrognathia	Congenital mandibular hypoplasia reported within the facial anomaly spectrum of Fanconi anemia.	Micrognathia	HP:0000347	Micrognathia		"{""preferred_term"": ""Micrognathia"", ""term"": {""id"": ""HP:0000347"", ""label"": ""Micrognathia""}}"																											
2627	2744	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	22	Cleft Palate	Orofacial clefting reported as part of the congenital facial phenotype in Fanconi anemia.	phenotype_term	phenotype_term	$	Cleft Palate	Orofacial clefting reported as part of the congenital facial phenotype in Fanconi anemia.	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
2628	2745	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	23	Triangular Face	Triangular facial shape reported among congenital facial manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Triangular Face	Triangular facial shape reported among congenital facial manifestations in Fanconi anemia.	Triangular face	HP:0000325	Triangular face		"{""preferred_term"": ""Triangular face"", ""term"": {""id"": ""HP:0000325"", ""label"": ""Triangular face""}}"																											
2629	2746	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	24	Midface Retrusion	Retruded or hypoplastic midface reported among congenital facial manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Midface Retrusion	Retruded or hypoplastic midface reported among congenital facial manifestations in Fanconi anemia.	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
2630	2747	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	25	Pointed Chin	Pointed chin morphology reported among congenital facial manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Pointed Chin	Pointed chin morphology reported among congenital facial manifestations in Fanconi anemia.	Pointed chin	HP:0000307	Pointed chin		"{""preferred_term"": ""Pointed chin"", ""term"": {""id"": ""HP:0000307"", ""label"": ""Pointed chin""}}"																											
2631	2748	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	26	Facial Palsy	Congenital facial nerve weakness or palsy reported among facial manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Facial Palsy	Congenital facial nerve weakness or palsy reported among facial manifestations in Fanconi anemia.	Facial palsy	HP:0010628	Facial palsy		"{""preferred_term"": ""Facial palsy"", ""term"": {""id"": ""HP:0010628"", ""label"": ""Facial palsy""}}"																											
2632	2749	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	27	Hypertelorism	Increased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Hypertelorism	Increased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.	Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
2633	2750	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	28	Hypotelorism	Decreased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Hypotelorism	Decreased interpupillary and/or interorbital distance reported among facial anomalies in Fanconi anemia.	Hypotelorism	HP:0000601	Hypotelorism		"{""preferred_term"": ""Hypotelorism"", ""term"": {""id"": ""HP:0000601"", ""label"": ""Hypotelorism""}}"																											
2634	2751	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	29	Agenesis of Corpus Callosum	Absence of corpus callosum as part of the CNS developmental anomaly spectrum in Fanconi anemia.	phenotype_term	phenotype_term	$	Agenesis of Corpus Callosum	Absence of corpus callosum as part of the CNS developmental anomaly spectrum in Fanconi anemia.	Agenesis of corpus callosum	HP:0001274	Agenesis of corpus callosum		"{""preferred_term"": ""Agenesis of corpus callosum"", ""term"": {""id"": ""HP:0001274"", ""label"": ""Agenesis of corpus callosum""}}"																											
2635	2752	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	30	Cerebellar Hypoplasia	Underdevelopment of the cerebellum reported among FA central nervous system anomalies.	phenotype_term	phenotype_term	$	Cerebellar Hypoplasia	Underdevelopment of the cerebellum reported among FA central nervous system anomalies.	Cerebellar hypoplasia	HP:0001321	Cerebellar hypoplasia		"{""preferred_term"": ""Cerebellar hypoplasia"", ""term"": {""id"": ""HP:0001321"", ""label"": ""Cerebellar hypoplasia""}}"																											
2636	2753	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	31	Radial Ray Defects	Upper limb malformations affecting the radius and thumb, including hypoplasia or aplasia of the radius and thumb abnormalities.	phenotype_term	phenotype_term	$	Radial Ray Defects	Upper limb malformations affecting the radius and thumb, including hypoplasia or aplasia of the radius and thumb abnormalities.	Hypoplasia of the radius	HP:0002984	Hypoplasia of the radius		"{""preferred_term"": ""Hypoplasia of the radius"", ""term"": {""id"": ""HP:0002984"", ""label"": ""Hypoplasia of the radius""}}"																											
2637	2754	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	32	Absent or Hypoplastic Thumbs	Absent thumbs, hypoplastic thumbs, or supernumerary thumbs are common upper limb anomalies in FA, frequently accompanied by radial ray defects.	phenotype_term	phenotype_term	$	Absent or Hypoplastic Thumbs	Absent thumbs, hypoplastic thumbs, or supernumerary thumbs are common upper limb anomalies in FA, frequently accompanied by radial ray defects.	Absent thumb	HP:0009777	Absent thumb		"{""preferred_term"": ""Absent thumb"", ""term"": {""id"": ""HP:0009777"", ""label"": ""Absent thumb""}}"																											
2638	2755	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	33	Small Thenar Eminence	Hypoplastic or absent thenar eminence as part of the upper-limb anomaly spectrum in Fanconi anemia.	phenotype_term	phenotype_term	$	Small Thenar Eminence	Hypoplastic or absent thenar eminence as part of the upper-limb anomaly spectrum in Fanconi anemia.	Small thenar eminence	HP:0001245	Small thenar eminence		"{""preferred_term"": ""Small thenar eminence"", ""term"": {""id"": ""HP:0001245"", ""label"": ""Small thenar eminence""}}"																											
2639	2756	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	34	First Metacarpal Aplasia or Hypoplasia	Absent or hypoplastic first metacarpal reported among upper-limb manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	First Metacarpal Aplasia or Hypoplasia	Absent or hypoplastic first metacarpal reported among upper-limb manifestations in Fanconi anemia.	Aplasia/Hypoplasia of the 1st metacarpal	HP:0010026	Aplasia/Hypoplasia of the 1st metacarpal		"{""preferred_term"": ""Aplasia/Hypoplasia of the 1st metacarpal"", ""term"": {""id"": ""HP:0010026"", ""label"": ""Aplasia/Hypoplasia of the 1st metacarpal""}}"																											
2640	2757	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	35	Clinodactyly	Curvature deformity of digits reported among upper-limb anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Clinodactyly	Curvature deformity of digits reported among upper-limb anomalies in Fanconi anemia.	Clinodactyly	HP:0030084	Clinodactyly		"{""preferred_term"": ""Clinodactyly"", ""term"": {""id"": ""HP:0030084"", ""label"": ""Clinodactyly""}}"																											
2641	2758	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	36	Ulnar Aplasia or Hypoplasia	Short or dysplastic ulna as part of the upper-limb congenital anomaly spectrum in Fanconi anemia.	phenotype_term	phenotype_term	$	Ulnar Aplasia or Hypoplasia	Short or dysplastic ulna as part of the upper-limb congenital anomaly spectrum in Fanconi anemia.	Aplasia/Hypoplasia of the ulna	HP:0006495	Aplasia/Hypoplasia of the ulna		"{""preferred_term"": ""Aplasia/Hypoplasia of the ulna"", ""term"": {""id"": ""HP:0006495"", ""label"": ""Aplasia/Hypoplasia of the ulna""}}"																											
2642	2759	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	37	Hip Dysplasia	Congenital hip dislocation or dysplasia reported among lower-limb anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Hip Dysplasia	Congenital hip dislocation or dysplasia reported among lower-limb anomalies in Fanconi anemia.	Hip dysplasia	HP:0001385	Hip dysplasia		"{""preferred_term"": ""Hip dysplasia"", ""term"": {""id"": ""HP:0001385"", ""label"": ""Hip dysplasia""}}"																											
2643	2760	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	38	Hemivertebrae	Vertebral segmentation defect present in a subset of FA patients.	phenotype_term	phenotype_term	$	Hemivertebrae	Vertebral segmentation defect present in a subset of FA patients.	Hemivertebrae	HP:0002937	Hemivertebrae		"{""preferred_term"": ""Hemivertebrae"", ""term"": {""id"": ""HP:0002937"", ""label"": ""Hemivertebrae""}}"																											
2644	2761	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	39	Scoliosis	Abnormal lateral curvature of the spine reported among vertebral manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Scoliosis	Abnormal lateral curvature of the spine reported among vertebral manifestations in Fanconi anemia.	Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
2645	2762	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	40	Kyphosis	Excessive posterior spinal curvature reported among vertebral anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Kyphosis	Excessive posterior spinal curvature reported among vertebral anomalies in Fanconi anemia.	Kyphosis	HP:0002808	Kyphosis		"{""preferred_term"": ""Kyphosis"", ""term"": {""id"": ""HP:0002808"", ""label"": ""Kyphosis""}}"																											
2646	2763	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	41	Fused Cervical Vertebrae	Cervical vertebral fusion consistent with Klippel-Feil pattern reported among vertebral anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Fused Cervical Vertebrae	Cervical vertebral fusion consistent with Klippel-Feil pattern reported among vertebral anomalies in Fanconi anemia.	Fused cervical vertebrae	HP:0002949	Fused cervical vertebrae		"{""preferred_term"": ""Fused cervical vertebrae"", ""term"": {""id"": ""HP:0002949"", ""label"": ""Fused cervical vertebrae""}}"																											
2647	2764	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	42	Absent or Hypoplastic Coccyx	Coccygeal aplasia or hypoplasia reported among vertebral anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Absent or Hypoplastic Coccyx	Coccygeal aplasia or hypoplasia reported among vertebral anomalies in Fanconi anemia.	Absent/hypoplastic coccyx	HP:0008436	Absent/hypoplastic coccyx		"{""preferred_term"": ""Absent/hypoplastic coccyx"", ""term"": {""id"": ""HP:0008436"", ""label"": ""Absent/hypoplastic coccyx""}}"																											
2648	2765	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	43	Toe Syndactyly	Congenital fusion of toes reported as part of lower-limb anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Toe Syndactyly	Congenital fusion of toes reported as part of lower-limb anomalies in Fanconi anemia.	Toe syndactyly	HP:0001770	Toe syndactyly		"{""preferred_term"": ""Toe syndactyly"", ""term"": {""id"": ""HP:0001770"", ""label"": ""Toe syndactyly""}}"																											
2649	2766	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	44	Clubfoot	Congenital foot deformity listed among lower-limb manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Clubfoot	Congenital foot deformity listed among lower-limb manifestations in Fanconi anemia.	Talipes equinovarus	HP:0001762	Talipes equinovarus		"{""preferred_term"": ""Talipes equinovarus"", ""term"": {""id"": ""HP:0001762"", ""label"": ""Talipes equinovarus""}}"																											
2650	2767	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	45	Abnormal Toe Morphology	Structural toe abnormalities reported among lower-limb manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Abnormal Toe Morphology	Structural toe abnormalities reported among lower-limb manifestations in Fanconi anemia.	Abnormal toe morphology	HP:0001780	Abnormal toe morphology		"{""preferred_term"": ""Abnormal toe morphology"", ""term"": {""id"": ""HP:0001780"", ""label"": ""Abnormal toe morphology""}}"																											
2651	2768	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	46	Microphthalmia	Abnormally small eyes, part of the spectrum of ophthalmic anomalies seen in FA patients.	phenotype_term	phenotype_term	$	Microphthalmia	Abnormally small eyes, part of the spectrum of ophthalmic anomalies seen in FA patients.	Microphthalmia	HP:0000568	Microphthalmia		"{""preferred_term"": ""Microphthalmia"", ""term"": {""id"": ""HP:0000568"", ""label"": ""Microphthalmia""}}"																											
2652	2769	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	47	Strabismus	Misalignment of the eyes, a relatively common ophthalmic finding in FA patients.	phenotype_term	phenotype_term	$	Strabismus	Misalignment of the eyes, a relatively common ophthalmic finding in FA patients.	Strabismus	HP:0000486	Strabismus		"{""preferred_term"": ""Strabismus"", ""term"": {""id"": ""HP:0000486"", ""label"": ""Strabismus""}}"																											
2653	2770	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	48	Epicanthus	Medial canthal skin fold reported among ocular manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Epicanthus	Medial canthal skin fold reported among ocular manifestations in Fanconi anemia.	Epicanthus	HP:0000286	Epicanthus		"{""preferred_term"": ""Epicanthus"", ""term"": {""id"": ""HP:0000286"", ""label"": ""Epicanthus""}}"																											
2654	2771	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	49	Almond-Shaped Palpebral Fissures	Almond-shaped eye fissures reported among ocular manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Almond-Shaped Palpebral Fissures	Almond-shaped eye fissures reported among ocular manifestations in Fanconi anemia.	Almond-shaped palpebral fissure	HP:0007874	Almond-shaped palpebral fissure		"{""preferred_term"": ""Almond-shaped palpebral fissure"", ""term"": {""id"": ""HP:0007874"", ""label"": ""Almond-shaped palpebral fissure""}}"																											
2655	2772	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	50	Cataract	Lens opacity reported among ophthalmic anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Cataract	Lens opacity reported among ophthalmic anomalies in Fanconi anemia.	Cataract	HP:0000518	Cataract		"{""preferred_term"": ""Cataract"", ""term"": {""id"": ""HP:0000518"", ""label"": ""Cataract""}}"																											
2656	2773	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	51	Ptosis	Drooping upper eyelid reported among ophthalmic manifestations of Fanconi anemia.	phenotype_term	phenotype_term	$	Ptosis	Drooping upper eyelid reported among ophthalmic manifestations of Fanconi anemia.	Ptosis	HP:0000508	Ptosis		"{""preferred_term"": ""Ptosis"", ""term"": {""id"": ""HP:0000508"", ""label"": ""Ptosis""}}"																											
2657	2774	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	52	Congenital Heart Defects	Structural heart anomalies including ventricular septal defects, atrial septal defects, patent ductus arteriosus, and other cardiac malformations.	phenotype_term	phenotype_term	$	Congenital Heart Defects	Structural heart anomalies including ventricular septal defects, atrial septal defects, patent ductus arteriosus, and other cardiac malformations.	Abnormal heart morphology	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Abnormal heart morphology"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
2658	2775	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	53	Patent Ductus Arteriosus	Persistent patency of the ductus arteriosus reported among congenital cardiac anomalies in Fanconi anemia.	phenotype_term	phenotype_term	$	Patent Ductus Arteriosus	Persistent patency of the ductus arteriosus reported among congenital cardiac anomalies in Fanconi anemia.	Patent ductus arteriosus	HP:0001643	Patent ductus arteriosus		"{""preferred_term"": ""Patent ductus arteriosus"", ""term"": {""id"": ""HP:0001643"", ""label"": ""Patent ductus arteriosus""}}"																											
2659	2776	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	54	Atrial Septal Defect	Congenital interatrial septal defect included in the Fanconi anemia cardiac phenotype spectrum.	phenotype_term	phenotype_term	$	Atrial Septal Defect	Congenital interatrial septal defect included in the Fanconi anemia cardiac phenotype spectrum.	Atrial septal defect	HP:0001631	Atrial septal defect		"{""preferred_term"": ""Atrial septal defect"", ""term"": {""id"": ""HP:0001631"", ""label"": ""Atrial septal defect""}}"																											
2660	2777	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	55	Ventricular Septal Defect	Congenital interventricular septal defect included in the Fanconi anemia cardiac anomaly spectrum.	phenotype_term	phenotype_term	$	Ventricular Septal Defect	Congenital interventricular septal defect included in the Fanconi anemia cardiac anomaly spectrum.	Ventricular septal defect	HP:0001629	Ventricular septal defect		"{""preferred_term"": ""Ventricular septal defect"", ""term"": {""id"": ""HP:0001629"", ""label"": ""Ventricular septal defect""}}"																											
2661	2778	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	56	Coarctation of Aorta	Congenital narrowing of the aorta reported in Fanconi anemia cardiac manifestations.	phenotype_term	phenotype_term	$	Coarctation of Aorta	Congenital narrowing of the aorta reported in Fanconi anemia cardiac manifestations.	Coarctation of aorta	HP:0001680	Coarctation of aorta		"{""preferred_term"": ""Coarctation of aorta"", ""term"": {""id"": ""HP:0001680"", ""label"": ""Coarctation of aorta""}}"																											
2662	2779	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	57	Truncus Arteriosus	Persistent common arterial trunk reported among congenital cardiac manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Truncus Arteriosus	Persistent common arterial trunk reported among congenital cardiac manifestations in Fanconi anemia.	Truncus arteriosus	HP:0001660	Truncus arteriosus		"{""preferred_term"": ""Truncus arteriosus"", ""term"": {""id"": ""HP:0001660"", ""label"": ""Truncus arteriosus""}}"																											
2663	2780	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	58	Situs Inversus	Reversal of thoracoabdominal organ laterality reported among FA-associated congenital cardiovascular anomalies.	phenotype_term	phenotype_term	$	Situs Inversus	Reversal of thoracoabdominal organ laterality reported among FA-associated congenital cardiovascular anomalies.	Situs inversus totalis	HP:0001696	Situs inversus totalis		"{""preferred_term"": ""Situs inversus totalis"", ""term"": {""id"": ""HP:0001696"", ""label"": ""Situs inversus totalis""}}"																											
2664	2781	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	59	Hearing Loss	Conductive and/or sensorineural hearing loss, often associated with external ear anomalies or middle ear malformations.	phenotype_term	phenotype_term	$	Hearing Loss	Conductive and/or sensorineural hearing loss, often associated with external ear anomalies or middle ear malformations.	Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
2665	2782	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	60	Abnormal Pinna Morphology	Congenital pinna malformations reported in Fanconi anemia with structural ear abnormalities.	phenotype_term	phenotype_term	$	Abnormal Pinna Morphology	Congenital pinna malformations reported in Fanconi anemia with structural ear abnormalities.	Abnormal pinna morphology	HP:0000377	Abnormal pinna morphology		"{""preferred_term"": ""Abnormal pinna morphology"", ""term"": {""id"": ""HP:0000377"", ""label"": ""Abnormal pinna morphology""}}"																											
2666	2783	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	61	External Auditory Canal Atresia	Congenital absence or atresia of the external auditory canal in a subset of Fanconi anemia patients.	phenotype_term	phenotype_term	$	External Auditory Canal Atresia	Congenital absence or atresia of the external auditory canal in a subset of Fanconi anemia patients.	Atresia of the external auditory canal	HP:0000413	Atresia of the external auditory canal		"{""preferred_term"": ""Atresia of the external auditory canal"", ""term"": {""id"": ""HP:0000413"", ""label"": ""Atresia of the external auditory canal""}}"																											
2667	2784	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	62	External Auditory Canal Stenosis	Narrow external auditory canal reported among structural ear manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	External Auditory Canal Stenosis	Narrow external auditory canal reported among structural ear manifestations in Fanconi anemia.	Stenosis of the external auditory canal	HP:0000402	Stenosis of the external auditory canal		"{""preferred_term"": ""Stenosis of the external auditory canal"", ""term"": {""id"": ""HP:0000402"", ""label"": ""Stenosis of the external auditory canal""}}"																											
2668	2785	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	63	Middle Ear Ossicle Abnormalities	Structural anomalies of middle ear ossicles reported among Fanconi anemia otologic findings.	phenotype_term	phenotype_term	$	Middle Ear Ossicle Abnormalities	Structural anomalies of middle ear ossicles reported among Fanconi anemia otologic findings.	Abnormality of the middle ear ossicles	HP:0004452	Abnormality of the middle ear ossicles		"{""preferred_term"": ""Abnormality of the middle ear ossicles"", ""term"": {""id"": ""HP:0004452"", ""label"": ""Abnormality of the middle ear ossicles""}}"																											
2669	2786	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	64	Hypothyroidism	Thyroid hormone deficiency requiring monitoring and potentially replacement therapy.	phenotype_term	phenotype_term	$	Hypothyroidism	Thyroid hormone deficiency requiring monitoring and potentially replacement therapy.	Hypothyroidism	HP:0000821	Hypothyroidism		"{""preferred_term"": ""Hypothyroidism"", ""term"": {""id"": ""HP:0000821"", ""label"": ""Hypothyroidism""}}"																											
2670	2787	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	65	Growth Hormone Deficiency	Insufficient growth hormone production contributing to short stature beyond what is expected from the underlying condition alone.	phenotype_term	phenotype_term	$	Growth Hormone Deficiency	Insufficient growth hormone production contributing to short stature beyond what is expected from the underlying condition alone.	Secondary growth hormone deficiency	HP:0008240	Secondary growth hormone deficiency		"{""preferred_term"": ""Secondary growth hormone deficiency"", ""term"": {""id"": ""HP:0008240"", ""label"": ""Secondary growth hormone deficiency""}}"																											
2671	2788	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	66	Abnormal Glucose Homeostasis	Abnormal glucose and insulin metabolism including insulin resistance, impaired glucose tolerance, and diabetes mellitus.	phenotype_term	phenotype_term	$	Abnormal Glucose Homeostasis	Abnormal glucose and insulin metabolism including insulin resistance, impaired glucose tolerance, and diabetes mellitus.	Abnormal glucose homeostasis	HP:0011014	Abnormal glucose homeostasis		"{""preferred_term"": ""Abnormal glucose homeostasis"", ""term"": {""id"": ""HP:0011014"", ""label"": ""Abnormal glucose homeostasis""}}"																											
2672	2789	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	67	Delayed Puberty and Hypogonadism	Delayed onset of puberty and hypogonadism affecting both sexes, with males commonly showing cryptorchidism and females showing ovarian insufficiency.	phenotype_term	phenotype_term	$	Delayed Puberty and Hypogonadism	Delayed onset of puberty and hypogonadism affecting both sexes, with males commonly showing cryptorchidism and females showing ovarian insufficiency.	Delayed puberty	HP:0000823	Delayed puberty		"{""preferred_term"": ""Delayed puberty"", ""term"": {""id"": ""HP:0000823"", ""label"": ""Delayed puberty""}}"																											
2673	2790	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	68	Impaired Fertility	Reduced fertility in both sexes, with males often showing azoospermia or oligospermia due to gonadal failure, and females showing diminished ovarian reserve and premature menopause.	phenotype_term	phenotype_term	$	Impaired Fertility	Reduced fertility in both sexes, with males often showing azoospermia or oligospermia due to gonadal failure, and females showing diminished ovarian reserve and premature menopause.	Infertility	HP:0000789	Infertility		"{""preferred_term"": ""Infertility"", ""term"": {""id"": ""HP:0000789"", ""label"": ""Infertility""}}"																											
2674	2791	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	69	Cryptorchidism	Undescended testes, a common genitourinary malformation in male FA patients.	phenotype_term	phenotype_term	$	Cryptorchidism	Undescended testes, a common genitourinary malformation in male FA patients.	Cryptorchidism	HP:0000028	Cryptorchidism		"{""preferred_term"": ""Cryptorchidism"", ""term"": {""id"": ""HP:0000028"", ""label"": ""Cryptorchidism""}}"																											
2675	2791	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	69	Cryptorchidism	Undescended testes, a common genitourinary malformation in male FA patients.	phenotype_contexts[0].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2676	2791	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	69	Cryptorchidism	Undescended testes, a common genitourinary malformation in male FA patients.	phenotype_contexts[0].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[0].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2677	2792	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	70	Testicular Aplasia or Hypoplasia	Small or absent testes reported among male genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Testicular Aplasia or Hypoplasia	Small or absent testes reported among male genital manifestations in Fanconi anemia.	Aplasia/Hypoplasia of the testes	HP:0010468	Aplasia/Hypoplasia of the testes		"{""preferred_term"": ""Aplasia/Hypoplasia of the testes"", ""term"": {""id"": ""HP:0010468"", ""label"": ""Aplasia/Hypoplasia of the testes""}}"																											
2678	2793	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	71	Hypospadias	Ventral displacement of the urethral meatus as part of male genital anomalies in FA.	phenotype_term	phenotype_term	$	Hypospadias	Ventral displacement of the urethral meatus as part of male genital anomalies in FA.	Hypospadias	HP:0000047	Hypospadias		"{""preferred_term"": ""Hypospadias"", ""term"": {""id"": ""HP:0000047"", ""label"": ""Hypospadias""}}"																											
2679	2794	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	72	Micropenis	Congenital small phallus reported among male genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Micropenis	Congenital small phallus reported among male genital manifestations in Fanconi anemia.	Micropenis	HP:0000054	Micropenis		"{""preferred_term"": ""Micropenis"", ""term"": {""id"": ""HP:0000054"", ""label"": ""Micropenis""}}"																											
2680	2795	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	73	Bicornuate Uterus	Congenital uterine malformation reported among female genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Bicornuate Uterus	Congenital uterine malformation reported among female genital manifestations in Fanconi anemia.	Bicornuate uterus	HP:0000813	Bicornuate uterus		"{""preferred_term"": ""Bicornuate uterus"", ""term"": {""id"": ""HP:0000813"", ""label"": ""Bicornuate uterus""}}"																											
2681	2796	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	74	Uterine Aplasia or Hypoplasia	Hypoplastic or absent uterus reported among female genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Uterine Aplasia or Hypoplasia	Hypoplastic or absent uterus reported among female genital manifestations in Fanconi anemia.	Aplasia/hypoplasia of the uterus	HP:0008684	Aplasia/hypoplasia of the uterus		"{""preferred_term"": ""Aplasia/hypoplasia of the uterus"", ""term"": {""id"": ""HP:0008684"", ""label"": ""Aplasia/hypoplasia of the uterus""}}"																											
2682	2797	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	75	Gonadal Dysgenesis	Gonadal developmental abnormality reported among female genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Gonadal Dysgenesis	Gonadal developmental abnormality reported among female genital manifestations in Fanconi anemia.	Gonadal dysgenesis	HP:0000133	Gonadal dysgenesis		"{""preferred_term"": ""Gonadal dysgenesis"", ""term"": {""id"": ""HP:0000133"", ""label"": ""Gonadal dysgenesis""}}"																											
2683	2798	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	76	Ovarian Hypoplasia	Small or underdeveloped ovaries reported in female Fanconi anemia manifestations.	phenotype_term	phenotype_term	$	Ovarian Hypoplasia	Small or underdeveloped ovaries reported in female Fanconi anemia manifestations.	Aplasia/Hypoplasia of the ovary	HP:0010462	Aplasia/Hypoplasia of the ovary		"{""preferred_term"": ""Aplasia/Hypoplasia of the ovary"", ""term"": {""id"": ""HP:0010462"", ""label"": ""Aplasia/Hypoplasia of the ovary""}}"																											
2684	2799	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	77	Rectovaginal Fistula	Congenital fistulous communication between rectum and vagina reported in Fanconi anemia.	phenotype_term	phenotype_term	$	Rectovaginal Fistula	Congenital fistulous communication between rectum and vagina reported in Fanconi anemia.	Rectovaginal fistula	HP:0000143	Rectovaginal fistula		"{""preferred_term"": ""Rectovaginal fistula"", ""term"": {""id"": ""HP:0000143"", ""label"": ""Rectovaginal fistula""}}"																											
2685	2800	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	78	Vaginal Atresia	Congenital vaginal canal atresia reported among female genital manifestations in Fanconi anemia.	phenotype_term	phenotype_term	$	Vaginal Atresia	Congenital vaginal canal atresia reported among female genital manifestations in Fanconi anemia.	Vaginal atresia	HP:0000148	Vaginal atresia		"{""preferred_term"": ""Vaginal atresia"", ""term"": {""id"": ""HP:0000148"", ""label"": ""Vaginal atresia""}}"																											
2686	2801	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	79	Delayed Menarche	Later-than-expected onset of menarche reported in female Fanconi anemia manifestations.	phenotype_term	phenotype_term	$	Delayed Menarche	Later-than-expected onset of menarche reported in female Fanconi anemia manifestations.	Delayed menarche	HP:0012569	Delayed menarche		"{""preferred_term"": ""Delayed menarche"", ""term"": {""id"": ""HP:0012569"", ""label"": ""Delayed menarche""}}"																											
2687	2802	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	80	Premature Ovarian Insufficiency	Early loss of ovarian function corresponding to early menopause in female Fanconi anemia.	phenotype_term	phenotype_term	$	Premature Ovarian Insufficiency	Early loss of ovarian function corresponding to early menopause in female Fanconi anemia.	Premature ovarian insufficiency	HP:0008209	Premature ovarian insufficiency		"{""preferred_term"": ""Premature ovarian insufficiency"", ""term"": {""id"": ""HP:0008209"", ""label"": ""Premature ovarian insufficiency""}}"																											
2688	2803	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	81	Renal Anomalies	Congenital kidney malformations including ectopic kidneys, horseshoe kidneys, renal agenesis, or hypoplastic kidneys.	phenotype_term	phenotype_term	$	Renal Anomalies	Congenital kidney malformations including ectopic kidneys, horseshoe kidneys, renal agenesis, or hypoplastic kidneys.	Abnormality of the genitourinary system	HP:0000119	Abnormality of the genitourinary system		"{""preferred_term"": ""Abnormality of the genitourinary system"", ""term"": {""id"": ""HP:0000119"", ""label"": ""Abnormality of the genitourinary system""}}"																											
2689	2804	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	82	Intrauterine Growth Retardation	Low birth weight for gestational age, reflecting prenatal growth restriction.	phenotype_term	phenotype_term	$	Intrauterine Growth Retardation	Low birth weight for gestational age, reflecting prenatal growth restriction.	Intrauterine growth retardation	HP:0001511	Intrauterine growth retardation		"{""preferred_term"": ""Intrauterine growth retardation"", ""term"": {""id"": ""HP:0001511"", ""label"": ""Intrauterine growth retardation""}}"																											
2690	2805	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	83	Developmental Delay	Cognitive and/or motor developmental delays present in a subset of FA patients.	phenotype_term	phenotype_term	$	Developmental Delay	Cognitive and/or motor developmental delays present in a subset of FA patients.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
2691	2805	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	83	Developmental Delay	Cognitive and/or motor developmental delays present in a subset of FA patients.	phenotype_contexts[1].genetic_context.genes[0]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCD1/BRCA2	hgnc:1101	BRCA2		"{""preferred_term"": ""FANCD1/BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}"																											
2692	2805	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	83	Developmental Delay	Cognitive and/or motor developmental delays present in a subset of FA patients.	phenotype_contexts[1].genetic_context.genes[1]	phenotype_contexts	phenotype_contexts[1].genetic_context.genes			FANCJ/BRIP1	hgnc:20473	BRIP1		"{""preferred_term"": ""FANCJ/BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}"																											
2693	2805	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	83	Developmental Delay	Cognitive and/or motor developmental delays present in a subset of FA patients.	phenotype_contexts[2].genetic_context.gene	phenotype_contexts	phenotype_contexts[2].genetic_context			BRCA1	hgnc:1100	BRCA1		"{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}"																											
2694	2806	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	84	Hydrocephalus	Ventricular enlargement and cerebrospinal fluid accumulation reported among FA CNS anomalies.	phenotype_term	phenotype_term	$	Hydrocephalus	Ventricular enlargement and cerebrospinal fluid accumulation reported among FA CNS anomalies.	Hydrocephalus	HP:0000238	Hydrocephalus		"{""preferred_term"": ""Hydrocephalus"", ""term"": {""id"": ""HP:0000238"", ""label"": ""Hydrocephalus""}}"																											
2695	2807	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	85	Ventriculomegaly	Dilatation of the cerebral ventricles reported in the FA central nervous system anomaly spectrum.	phenotype_term	phenotype_term	$	Ventriculomegaly	Dilatation of the cerebral ventricles reported in the FA central nervous system anomaly spectrum.	Ventriculomegaly	HP:0002119	Ventriculomegaly		"{""preferred_term"": ""Ventriculomegaly"", ""term"": {""id"": ""HP:0002119"", ""label"": ""Ventriculomegaly""}}"																											
2696	2808	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	86	Hypopigmentation	Areas of decreased skin pigmentation, often in combination with hyperpigmented lesions such as caf-au-lait spots.	phenotype_term	phenotype_term	$	Hypopigmentation	Areas of decreased skin pigmentation, often in combination with hyperpigmented lesions such as caf-au-lait spots.	Abnormality of the skin	HP:0000951	Abnormality of the skin		"{""preferred_term"": ""Abnormality of the skin"", ""term"": {""id"": ""HP:0000951"", ""label"": ""Abnormality of the skin""}}"																											
2697	2809	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	87	Hyperpigmentation	Generalized or patchy increased skin pigmentation in the Fanconi anemia congenital anomaly spectrum.	phenotype_term	phenotype_term	$	Hyperpigmentation	Generalized or patchy increased skin pigmentation in the Fanconi anemia congenital anomaly spectrum.	Hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
2698	2810	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	88	Osteopenia and Osteoporosis	Reduced bone mineral density affecting the majority of adult FA patients, likely related to endocrine dysfunction, chronic illness, and potentially direct effects of FA pathway deficiency on osteoblast function.	phenotype_term	phenotype_term	$	Osteopenia and Osteoporosis	Reduced bone mineral density affecting the majority of adult FA patients, likely related to endocrine dysfunction, chronic illness, and potentially direct effects of FA pathway deficiency on osteoblast function.	Osteopenia	HP:0000938	Osteopenia		"{""preferred_term"": ""Osteopenia"", ""term"": {""id"": ""HP:0000938"", ""label"": ""Osteopenia""}}"																											
2699	2811	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	89	Dental and Craniofacial Anomalies	Dental anomalies including tooth agenesis, root abnormalities, tooth rotation, enamel defects, and craniofacial dysmorphisms.	phenotype_term	phenotype_term	$	Dental and Craniofacial Anomalies	Dental anomalies including tooth agenesis, root abnormalities, tooth rotation, enamel defects, and craniofacial dysmorphisms.	Abnormality of the dentition	HP:0000164	Abnormality of the dentition		"{""preferred_term"": ""Abnormality of the dentition"", ""term"": {""id"": ""HP:0000164"", ""label"": ""Abnormality of the dentition""}}"																											
2700	2812	116	Fanconi_Anemia	Fanconi_Anemia.yaml	phenotypes	90	Myelodysplastic Syndrome	Clonal hematopoietic disorder with dysplastic bone marrow and cytopenias, frequently preceding progression to acute myeloid leukemia.	phenotype_term	phenotype_term	$	Myelodysplastic Syndrome	Clonal hematopoietic disorder with dysplastic bone marrow and cytopenias, frequently preceding progression to acute myeloid leukemia.	Myelodysplasia	HP:0002863	Myelodysplasia		"{""preferred_term"": ""Myelodysplasia"", ""term"": {""id"": ""HP:0002863"", ""label"": ""Myelodysplasia""}}"																											
2701	2815	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	0	Hematopoietic Stem Cell Transplantation (HSCT)	The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.	treatment_term	treatment_term	$	Hematopoietic Stem Cell Transplantation (HSCT)	The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2702	2816	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	1	Androgen Therapy	Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.	treatment_term	treatment_term	$	Androgen Therapy	Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2703	2817	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	2	Growth Hormone Therapy	May be used to improve growth in affected children with short stature.	treatment_term	treatment_term	$	Growth Hormone Therapy	May be used to improve growth in affected children with short stature.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2704	2818	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	3	Supportive Care	Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.	treatment_term	treatment_term	$	Supportive Care	Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2705	2819	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	4	Cancer Surveillance	Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.	treatment_term	treatment_term	$	Cancer Surveillance	Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
2706	2820	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	5	Genetic Counseling	Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.	treatment_term	treatment_term	$	Genetic Counseling	Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2707	2824	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	0	Constitutive BMP Signaling Activation	The ACVR1 R206H mutation creates a pH-sensitive switch in the receptor's activation domain, leading to ligand-independent activation of BMP signaling and inappropriate osteogenic differentiation of connective tissue progenitors.	biological_processes[0]	biological_processes	biological_processes			BMP signaling pathway	GO:0030509	BMP signaling pathway		"{""preferred_term"": ""BMP signaling pathway"", ""term"": {""id"": ""GO:0030509"", ""label"": ""BMP signaling pathway""}}"																											
2708	2824	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	0	Constitutive BMP Signaling Activation	The ACVR1 R206H mutation creates a pH-sensitive switch in the receptor's activation domain, leading to ligand-independent activation of BMP signaling and inappropriate osteogenic differentiation of connective tissue progenitors.	biological_processes[1]	biological_processes	biological_processes			ossification	GO:0001503	ossification		"{""preferred_term"": ""ossification"", ""term"": {""id"": ""GO:0001503"", ""label"": ""ossification""}}"																											
2709	2825	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	1	Impaired FKBP1A Regulatory Binding	The R206H mutation reduces binding affinity for FKBP1A/FKBP12, a safeguard protein that normally prevents inappropriate BMP signaling, resulting in leaky activation of the pathway.	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
2710	2826	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	2	Activin A Neomorphic Signaling	The R206H mutation renders ACVR1 responsive to Activin A ligands, which normally antagonize BMP signaling. This neomorphic gain-of-function allows Activin A to aberrantly activate osteogenic signaling, driving heterotopic ossification. Anti-Activin A antibodies can block HO. Activin A is an obligate factor for the initiation of HO in FOP.	biological_processes[0]	biological_processes	biological_processes			BMP signaling pathway	GO:0030509	BMP signaling pathway		"{""preferred_term"": ""BMP signaling pathway"", ""term"": {""id"": ""GO:0030509"", ""label"": ""BMP signaling pathway""}}"																											
2711	2827	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	3	Heterotopic Ossification	Progressive formation of qualitatively normal bone in extraskeletal tissues including muscles, tendons, ligaments, and fascia, typically following episodic inflammatory flare-ups. The process occurs through endochondral ossification with distinct histological stages: inflammatory/catabolic phase, fibroproliferative phase, chondrogenic phase, and osteogenic phase.	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
2712	2827	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	3	Heterotopic Ossification	Progressive formation of qualitatively normal bone in extraskeletal tissues including muscles, tendons, ligaments, and fascia, typically following episodic inflammatory flare-ups. The process occurs through endochondral ossification with distinct histological stages: inflammatory/catabolic phase, fibroproliferative phase, chondrogenic phase, and osteogenic phase.	cell_types[1]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
2713	2827	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	3	Heterotopic Ossification	Progressive formation of qualitatively normal bone in extraskeletal tissues including muscles, tendons, ligaments, and fascia, typically following episodic inflammatory flare-ups. The process occurs through endochondral ossification with distinct histological stages: inflammatory/catabolic phase, fibroproliferative phase, chondrogenic phase, and osteogenic phase.	biological_processes[0]	biological_processes	biological_processes			Endochondral ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
2714	2827	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	3	Heterotopic Ossification	Progressive formation of qualitatively normal bone in extraskeletal tissues including muscles, tendons, ligaments, and fascia, typically following episodic inflammatory flare-ups. The process occurs through endochondral ossification with distinct histological stages: inflammatory/catabolic phase, fibroproliferative phase, chondrogenic phase, and osteogenic phase.	biological_processes[1]	biological_processes	biological_processes			Cartilage development	GO:0051216	cartilage development		"{""preferred_term"": ""Cartilage development"", ""term"": {""id"": ""GO:0051216"", ""label"": ""cartilage development""}}"																											
2715	2828	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	4	Inflammatory Triggering of Flare-ups	Macrophages, mast cells, and lymphocytes infiltrate affected tissues during the catabolic phase, releasing inflammatory cytokines that create a permissive microenvironment for heterotopic ossification. Mast cell depletion reduces HO by approximately 50%, and combined mast cell/macrophage depletion reduces HO by approximately 75%.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2716	2828	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	4	Inflammatory Triggering of Flare-ups	Macrophages, mast cells, and lymphocytes infiltrate affected tissues during the catabolic phase, releasing inflammatory cytokines that create a permissive microenvironment for heterotopic ossification. Mast cell depletion reduces HO by approximately 50%, and combined mast cell/macrophage depletion reduces HO by approximately 75%.	cell_types[1]	cell_types	cell_types			Mast cell	CL:0000097	mast cell		"{""preferred_term"": ""Mast cell"", ""term"": {""id"": ""CL:0000097"", ""label"": ""mast cell""}}"																											
2717	2828	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	pathophysiology	4	Inflammatory Triggering of Flare-ups	Macrophages, mast cells, and lymphocytes infiltrate affected tissues during the catabolic phase, releasing inflammatory cytokines that create a permissive microenvironment for heterotopic ossification. Mast cell depletion reduces HO by approximately 50%, and combined mast cell/macrophage depletion reduces HO by approximately 75%.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2718	2829	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	0	Congenital Great Toe Malformation		phenotype_term	phenotype_term	$	Congenital Great Toe Malformation		Abnormal hallux morphology	HP:0001844	Abnormal hallux morphology		"{""preferred_term"": ""Abnormal hallux morphology"", ""term"": {""id"": ""HP:0001844"", ""label"": ""Abnormal hallux morphology""}}"																											
2719	2830	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	1	Heterotopic Ossification		phenotype_term	phenotype_term	$	Heterotopic Ossification		Ectopic ossification in muscle tissue	HP:0011987	Ectopic ossification in muscle tissue		"{""preferred_term"": ""Ectopic ossification in muscle tissue"", ""term"": {""id"": ""HP:0011987"", ""label"": ""Ectopic ossification in muscle tissue""}}"																											
2720	2831	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	2	Progressive Joint Immobility		phenotype_term	phenotype_term	$	Progressive Joint Immobility		Limitation of joint mobility	HP:0001376	Limitation of joint mobility		"{""preferred_term"": ""Limitation of joint mobility"", ""term"": {""id"": ""HP:0001376"", ""label"": ""Limitation of joint mobility""}}"																											
2721	2832	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	3	Joint Stiffness		phenotype_term	phenotype_term	$	Joint Stiffness		Joint stiffness	HP:0001387	Joint stiffness		"{""preferred_term"": ""Joint stiffness"", ""term"": {""id"": ""HP:0001387"", ""label"": ""Joint stiffness""}}"																											
2722	2833	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	4	Scoliosis		phenotype_term	phenotype_term	$	Scoliosis		Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
2723	2834	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	phenotypes	5	Restrictive Ventilatory Defect		phenotype_term	phenotype_term	$	Restrictive Ventilatory Defect		Restrictive ventilatory defect	HP:0002091	Restrictive ventilatory defect		"{""preferred_term"": ""Restrictive ventilatory defect"", ""term"": {""id"": ""HP:0002091"", ""label"": ""Restrictive ventilatory defect""}}"																											
2724	2835	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	0	Palovarotene	Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).	treatment_term	treatment_term	$	Palovarotene	Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2725	2836	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	1	Corticosteroids	Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.	treatment_term	treatment_term	$	Corticosteroids	Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2726	2838	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	3	Genetic Counseling	Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.	treatment_term	treatment_term	$	Genetic Counseling	Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2727	2839	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	4	Garetosmab	Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.	treatment_term	treatment_term	$	Garetosmab	Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2728	2856	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	0	Central Sensitization	"Augmented pain processing in the central nervous system leads to amplified pain perception. Increased excitatory neurotransmitters (glutamate, substance P) and decreased inhibitory modulation.
"	biological_processes[0]	biological_processes	biological_processes			Pain Processing	GO:0048265	response to pain		"{""preferred_term"": ""Pain Processing"", ""term"": {""id"": ""GO:0048265"", ""label"": ""response to pain""}}"																											
2729	2857	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	1	Descending Pain Modulation Dysfunction	"Impaired descending inhibitory pathways that normally dampen pain signals. Reduced serotonin and norepinephrine in descending pathways contributes to pain amplification.
"	biological_processes[0]	biological_processes	biological_processes			Neurotransmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Neurotransmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
2730	2858	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	2	Neuroinflammation	"Glial cell activation and elevated inflammatory mediators in the CNS may contribute to central sensitization and symptom persistence.
"	cell_types[0]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
2731	2859	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	3	HPA Axis Dysregulation	"Blunted cortisol response to stress and altered diurnal cortisol rhythm may contribute to fatigue and pain sensitivity.
"	biological_processes[0]	biological_processes	biological_processes			Stress Response	GO:0006950	response to stress		"{""preferred_term"": ""Stress Response"", ""term"": {""id"": ""GO:0006950"", ""label"": ""response to stress""}}"																											
2732	2860	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	4	Small Fiber Pathology	"Structural and functional abnormalities of thinly myelinated A and unmyelinated C-fibers affecting approximately 50% of patients. Reduced intraepidermal nerve fiber density (IENFD) with proximal predominant pattern contributes ongoing peripheral nociceptive input.
"	cell_types[0]	cell_types	cell_types			Peripheral Sensory Neurons	CL:0000101	sensory neuron		"{""preferred_term"": ""Peripheral Sensory Neurons"", ""term"": {""id"": ""CL:0000101"", ""label"": ""sensory neuron""}}"																											
2733	2861	118	Fibromyalgia	Fibromyalgia.yaml	pathophysiology	5	Genetic Susceptibility	"Multiple genetic variants affect neurotransmitter systems, pain processing, and sensory signaling. CNS-enriched heritability with neural gene prioritization establishes genetic predisposition to altered pain perception and modulation.
"	biological_processes[0]	biological_processes	biological_processes			Pain Perception	GO:0019233	sensory perception of pain		"{""preferred_term"": ""Pain Perception"", ""term"": {""id"": ""GO:0019233"", ""label"": ""sensory perception of pain""}}"																											
2734	2862	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	0	Chronic Widespread Pain		phenotype_term	phenotype_term	$	Chronic Widespread Pain		Chronic Pain	HP:0012532	Chronic pain		"{""preferred_term"": ""Chronic Pain"", ""term"": {""id"": ""HP:0012532"", ""label"": ""Chronic pain""}}"																											
2735	2863	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	1	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2736	2864	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	2	Sleep Disturbance		phenotype_term	phenotype_term	$	Sleep Disturbance		Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
2737	2865	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	3	Cognitive Dysfunction		phenotype_term	phenotype_term	$	Cognitive Dysfunction		Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
2738	2866	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	4	Headaches		phenotype_term	phenotype_term	$	Headaches		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2739	2867	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	5	Depression		phenotype_term	phenotype_term	$	Depression		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
2740	2868	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	6	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
2741	2869	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	7	Hypersensitivity to Touch		phenotype_term	phenotype_term	$	Hypersensitivity to Touch		Hyperesthesia	HP:0007328	Impaired pain sensation		"{""preferred_term"": ""Hyperesthesia"", ""term"": {""id"": ""HP:0007328"", ""label"": ""Impaired pain sensation""}}"																											
2742	2870	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	8	Joint Stiffness		phenotype_term	phenotype_term	$	Joint Stiffness		Joint Stiffness	HP:0001387	Joint stiffness		"{""preferred_term"": ""Joint Stiffness"", ""term"": {""id"": ""HP:0001387"", ""label"": ""Joint stiffness""}}"																											
2743	2871	118	Fibromyalgia	Fibromyalgia.yaml	phenotypes	9	Autonomic Dysfunction		phenotype_term	phenotype_term	$	Autonomic Dysfunction		Autonomic Dysfunction	HP:0012332	Abnormal autonomic nervous system physiology		"{""preferred_term"": ""Autonomic Dysfunction"", ""term"": {""id"": ""HP:0012332"", ""label"": ""Abnormal autonomic nervous system physiology""}}"																											
2744	2872	118	Fibromyalgia	Fibromyalgia.yaml	treatments	0	Duloxetine	SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief.	treatment_term	treatment_term	$	Duloxetine	SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2745	2873	118	Fibromyalgia	Fibromyalgia.yaml	treatments	1	Milnacipran	SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation.	treatment_term	treatment_term	$	Milnacipran	SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2746	2874	118	Fibromyalgia	Fibromyalgia.yaml	treatments	2	Pregabalin	Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability.	treatment_term	treatment_term	$	Pregabalin	Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2747	2875	118	Fibromyalgia	Fibromyalgia.yaml	treatments	3	Gabapentin	Alpha-2-delta ligand, used off-label for neuropathic pain component.	treatment_term	treatment_term	$	Gabapentin	Alpha-2-delta ligand, used off-label for neuropathic pain component.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2748	2876	118	Fibromyalgia	Fibromyalgia.yaml	treatments	4	Amitriptyline	Low-dose tricyclic antidepressant for pain modulation and sleep improvement.	treatment_term	treatment_term	$	Amitriptyline	Low-dose tricyclic antidepressant for pain modulation and sleep improvement.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2749	2877	118	Fibromyalgia	Fibromyalgia.yaml	treatments	5	Aerobic Exercise	Structured physical activity with strong evidence for pain reduction and functional improvement.	treatment_term	treatment_term	$	Aerobic Exercise	Structured physical activity with strong evidence for pain reduction and functional improvement.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2750	2878	118	Fibromyalgia	Fibromyalgia.yaml	treatments	6	Cognitive Behavioral Therapy	Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification.	treatment_term	treatment_term	$	Cognitive Behavioral Therapy	Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification.	psychotherapy	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""psychotherapy"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2751	2879	118	Fibromyalgia	Fibromyalgia.yaml	treatments	7	Sleep Hygiene Education	Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns.	treatment_term	treatment_term	$	Sleep Hygiene Education	Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns.	patient education	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""patient education"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2752	2880	118	Fibromyalgia	Fibromyalgia.yaml	treatments	8	Mindfulness-Based Stress Reduction	Meditation and mindfulness practices for pain management and stress reduction.	treatment_term	treatment_term	$	Mindfulness-Based Stress Reduction	Meditation and mindfulness practices for pain management and stress reduction.	behavioral intervention	MAXO:0000010	cognitive and behavioral intervention		"{""preferred_term"": ""behavioral intervention"", ""term"": {""id"": ""MAXO:0000010"", ""label"": ""cognitive and behavioral intervention""}}"																											
2753	2881	118	Fibromyalgia	Fibromyalgia.yaml	treatments	9	Aquatic Therapy	Water-based exercise therapy for low-impact conditioning and pain relief.	treatment_term	treatment_term	$	Aquatic Therapy	Water-based exercise therapy for low-impact conditioning and pain relief.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2754	2882	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	0	Clonorchis sinensis	Liver fluke implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Clonorchis sinensis	Liver fluke implicated in foodborne trematodiases.	Clonorchis sinensis	NCBITaxon:79923	Clonorchis sinensis		"{""preferred_term"": ""Clonorchis sinensis"", ""term"": {""id"": ""NCBITaxon:79923"", ""label"": ""Clonorchis sinensis""}}"																											
2755	2883	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	1	Fasciola gigantica	Liver fluke implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Fasciola gigantica	Liver fluke implicated in foodborne trematodiases.	Fasciola gigantica	NCBITaxon:46835	Fasciola gigantica		"{""preferred_term"": ""Fasciola gigantica"", ""term"": {""id"": ""NCBITaxon:46835"", ""label"": ""Fasciola gigantica""}}"																											
2756	2884	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	2	Fasciola hepatica	Liver fluke implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Fasciola hepatica	Liver fluke implicated in foodborne trematodiases.	Fasciola hepatica	NCBITaxon:6192	Fasciola hepatica		"{""preferred_term"": ""Fasciola hepatica"", ""term"": {""id"": ""NCBITaxon:6192"", ""label"": ""Fasciola hepatica""}}"																											
2757	2885	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	3	Opisthorchis felineus	Liver fluke implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Opisthorchis felineus	Liver fluke implicated in foodborne trematodiases.	Opisthorchis felineus	NCBITaxon:147828	Opisthorchis felineus		"{""preferred_term"": ""Opisthorchis felineus"", ""term"": {""id"": ""NCBITaxon:147828"", ""label"": ""Opisthorchis felineus""}}"																											
2758	2886	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	4	Opisthorchis viverrini	Liver fluke implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Opisthorchis viverrini	Liver fluke implicated in foodborne trematodiases.	Opisthorchis viverrini	NCBITaxon:6198	Opisthorchis viverrini		"{""preferred_term"": ""Opisthorchis viverrini"", ""term"": {""id"": ""NCBITaxon:6198"", ""label"": ""Opisthorchis viverrini""}}"																											
2759	2887	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	5	Paragonimus spp.	Lung flukes implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Paragonimus spp.	Lung flukes implicated in foodborne trematodiases.	Paragonimus spp.	NCBITaxon:34503	Paragonimus		"{""preferred_term"": ""Paragonimus spp."", ""term"": {""id"": ""NCBITaxon:34503"", ""label"": ""Paragonimus""}}"																											
2760	2888	119	Foodborne trematodiases	Foodborne_Trematodiases.yaml	infectious_agent	6	Echinostoma spp.	Intestinal flukes implicated in foodborne trematodiases.	infectious_agent_term	infectious_agent_term	$	Echinostoma spp.	Intestinal flukes implicated in foodborne trematodiases.	Echinostoma spp.	NCBITaxon:27847	Echinostoma		"{""preferred_term"": ""Echinostoma spp."", ""term"": {""id"": ""NCBITaxon:27847"", ""label"": ""Echinostoma""}}"																											
2761	2894	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	pathophysiology	0	FMRP Deficiency	"Expansion of CGG trinucleotide repeat in FMR1 gene 5' UTR beyond 200 repeats causes hypermethylation and transcriptional silencing. This results in absence of fragile X mental retardation protein (FMRP), an RNA-binding protein essential for synaptic plasticity.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2762	2894	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	pathophysiology	0	FMRP Deficiency	"Expansion of CGG trinucleotide repeat in FMR1 gene 5' UTR beyond 200 repeats causes hypermethylation and transcriptional silencing. This results in absence of fragile X mental retardation protein (FMRP), an RNA-binding protein essential for synaptic plasticity.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Plasticity	GO:0048167	regulation of synaptic plasticity		"{""preferred_term"": ""Synaptic Plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"																											
2763	2895	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	pathophysiology	1	Abnormal Synaptic Development	"FMRP normally suppresses translation of many synaptic proteins. Its absence leads to excessive protein synthesis at synapses, abnormal dendritic spine morphology (long, thin spines), and impaired synaptic maturation and pruning.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2764	2895	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	pathophysiology	1	Abnormal Synaptic Development	"FMRP normally suppresses translation of many synaptic proteins. Its absence leads to excessive protein synthesis at synapses, abnormal dendritic spine morphology (long, thin spines), and impaired synaptic maturation and pruning.
"	biological_processes[0]	biological_processes	biological_processes			Synapse Organization	GO:0050808	synapse organization		"{""preferred_term"": ""Synapse Organization"", ""term"": {""id"": ""GO:0050808"", ""label"": ""synapse organization""}}"																											
2765	2896	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	0	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
2766	2897	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	1	Autism Spectrum Features		phenotype_term	phenotype_term	$	Autism Spectrum Features		Autistic Behavior	HP:0000729	Autistic behavior		"{""preferred_term"": ""Autistic Behavior"", ""term"": {""id"": ""HP:0000729"", ""label"": ""Autistic behavior""}}"																											
2767	2898	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	2	Macroorchidism		phenotype_term	phenotype_term	$	Macroorchidism		Macroorchidism	HP:0000053	Macroorchidism		"{""preferred_term"": ""Macroorchidism"", ""term"": {""id"": ""HP:0000053"", ""label"": ""Macroorchidism""}}"																											
2768	2899	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	3	Elongated Face		phenotype_term	phenotype_term	$	Elongated Face		Long Face	HP:0000276	Long face		"{""preferred_term"": ""Long Face"", ""term"": {""id"": ""HP:0000276"", ""label"": ""Long face""}}"																											
2769	2900	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	4	Large Ears		phenotype_term	phenotype_term	$	Large Ears		Large Ears	HP:0000400	Macrotia		"{""preferred_term"": ""Large Ears"", ""term"": {""id"": ""HP:0000400"", ""label"": ""Macrotia""}}"																											
2770	2901	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	5	Hyperactivity		phenotype_term	phenotype_term	$	Hyperactivity		Hyperactivity	HP:0000752	Hyperactivity		"{""preferred_term"": ""Hyperactivity"", ""term"": {""id"": ""HP:0000752"", ""label"": ""Hyperactivity""}}"																											
2771	2902	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	phenotypes	6	Joint Hypermobility		phenotype_term	phenotype_term	$	Joint Hypermobility		Joint Hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint Hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
2772	2908	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	datasets	0		Microarray expression profiling of frontal cortex, hippocampus, and cerebellum from FTLD-U and control brains.	organism	organism	$		Microarray expression profiling of frontal cortex, hippocampus, and cerebellum from FTLD-U and control brains.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
2773	2908	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	datasets	0		Microarray expression profiling of frontal cortex, hippocampus, and cerebellum from FTLD-U and control brains.	sample_types[0]	sample_types	sample_types			brain tissue				"{""preferred_term"": ""brain tissue"", ""tissue_term"": {""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}}"																											
2774	2908	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	datasets	0		Microarray expression profiling of frontal cortex, hippocampus, and cerebellum from FTLD-U and control brains.	sample_types[0].tissue_term	sample_types	sample_types[0]			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
2775	2912	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	pathophysiology	0	TDP-43 Proteinopathy	"TAR DNA-binding protein of 43 kDa (TDP-43) is the main ubiquitinated protein in tau-negative frontotemporal lobar degeneration (FTLD-TDP), accounting for over 50% of FTD cases. TDP-43 is typically a nuclear protein, and its aggregation and cytoplasmic translocation are thought to represent major pathogenic steps. The abnormal accumulation leads to neuronal dysfunction and death.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2776	2913	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	pathophysiology	1	Tau Proteinopathy	"FTLD-tau is characterized by accumulation of hyperphosphorylated tau protein, accounting for approximately 45% of FTD cases. This includes Pick's disease with characteristic Pick bodies. The tau pathology disrupts microtubule function and causes neuronal degeneration primarily in frontal and temporal regions.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2777	2914	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	pathophysiology	2	Frontal and Temporal Lobe Atrophy	"Progressive neuronal loss and atrophy predominantly affecting the frontal and temporal lobes, with patterns varying by genetic subtype. MAPT mutations show temporal predominance, while GRN and C9orf72 mutations may show more variable patterns. This structural degeneration underlies the behavioral and language deficits.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2778	2915	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	pathophysiology	3	Neuronal Death	"Progressive loss of neurons in frontal and temporal cortices due to protein aggregation toxicity, leading to brain atrophy and functional decline. The neurodegeneration progresses over years to decades, with biomarker changes detectable up to 30 years before symptom onset in genetic cases.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
2779	2917	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	phenotypes	1	Aphasia		phenotype_term	phenotype_term	$	Aphasia		Aphasia	HP:0002381	Aphasia		"{""preferred_term"": ""Aphasia"", ""term"": {""id"": ""HP:0002381"", ""label"": ""Aphasia""}}"																											
2780	2918	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	phenotypes	2	Personality Changes		phenotype_term	phenotype_term	$	Personality Changes		Personality changes	HP:0000751	Personality changes		"{""preferred_term"": ""Personality changes"", ""term"": {""id"": ""HP:0000751"", ""label"": ""Personality changes""}}"																											
2781	2919	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	phenotypes	3	Dementia		phenotype_term	phenotype_term	$	Dementia		Dementia	HP:0000726	Dementia		"{""preferred_term"": ""Dementia"", ""term"": {""id"": ""HP:0000726"", ""label"": ""Dementia""}}"																											
2782	2920	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	0	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.	treatment_term	treatment_term	$	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2783	2921	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	1	Speech and Language Therapy	Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.	treatment_term	treatment_term	$	Speech and Language Therapy	Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2784	2925	122	Galactosemia	Galactosemia.yaml	has_subtypes	0	Classic Galactosemia (GALT deficiency)	"Most common and severe form caused by GALT deficiency. Presents in neonates with life-threatening illness if untreated.
"	subtype_term	subtype_term	$	Classic Galactosemia (GALT deficiency)	"Most common and severe form caused by GALT deficiency. Presents in neonates with life-threatening illness if untreated.
"	classic galactosemia	MONDO:0009258	classic galactosemia		"{""preferred_term"": ""classic galactosemia"", ""term"": {""id"": ""MONDO:0009258"", ""label"": ""classic galactosemia""}}"																											
2785	2952	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	histopathology	0	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	finding_term	finding_term	$	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	Gastric Adenocarcinoma	NCIT:C4004	Gastric Adenocarcinoma		"{""preferred_term"": ""Gastric Adenocarcinoma"", ""term"": {""id"": ""NCIT:C4004"", ""label"": ""Gastric Adenocarcinoma""}}"																											
2786	2953	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	infectious_agent	0	Helicobacter pylori	H. pylori is a gram-negative spiral bacterium that colonizes the gastric epithelium. Infection is acquired in childhood and persists lifelong if untreated. Approximately 1-3% of infected individuals eventually develop gastric cancer, with risk modified by bacterial virulence factors, host genetics, and environmental factors including diet.	infectious_agent_term	infectious_agent_term	$	Helicobacter pylori	H. pylori is a gram-negative spiral bacterium that colonizes the gastric epithelium. Infection is acquired in childhood and persists lifelong if untreated. Approximately 1-3% of infected individuals eventually develop gastric cancer, with risk modified by bacterial virulence factors, host genetics, and environmental factors including diet.	Helicobacter pylori	NCBITaxon:210	Helicobacter pylori		"{""preferred_term"": ""Helicobacter pylori"", ""term"": {""id"": ""NCBITaxon:210"", ""label"": ""Helicobacter pylori""}}"																											
2787	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	cell_types[0]	cell_types	cell_types			epithelial cell of stomach	CL:0002178	epithelial cell of stomach		"{""preferred_term"": ""epithelial cell of stomach"", ""term"": {""id"": ""CL:0002178"", ""label"": ""epithelial cell of stomach""}}"																											
2788	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2789	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
2790	2954	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	0	CagA-Mediated Oncogenic Signaling	The cagA gene encodes the CagA oncoprotein, a major H. pylori virulence factor injected into host cells via a type IV secretion system. CagA is phosphorylated by host kinases and activates SHP-2, disrupting cell polarity, promoting proliferation, and inhibiting apoptosis. CagA-positive strains confer higher cancer risk.	locations[0]	locations	locations			stomach	UBERON:0000945	stomach		"{""preferred_term"": ""stomach"", ""term"": {""id"": ""UBERON:0000945"", ""label"": ""stomach""}}"																											
2791	2955	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	1	VacA-Induced Cellular Damage	VacA (vacuolating cytotoxin A) is a pore-forming toxin that induces vacuolation, mitochondrial dysfunction, and apoptosis in epithelial cells. It also suppresses T cell function, allowing bacterial persistence. Different VacA alleles (s1/s2, m1/m2) confer different cancer risk.	biological_processes[0]	biological_processes	biological_processes			cellular response to cytotoxic stimulus	GO:0034620	cellular response to oxidative stress		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cellular response to cytotoxic stimulus"", ""term"": {""id"": ""GO:0034620"", ""label"": ""cellular response to oxidative stress""}}"			INCREASED																								
2792	2956	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	2	Chronic Inflammation (Correa Cascade)	H. pylori induces chronic gastritis with infiltration of neutrophils, lymphocytes, and macrophages. Persistent inflammation generates reactive oxygen and nitrogen species that cause DNA damage. Over decades, this leads to atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately adenocarcinoma.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"			INCREASED																								
2793	2956	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	2	Chronic Inflammation (Correa Cascade)	H. pylori induces chronic gastritis with infiltration of neutrophils, lymphocytes, and macrophages. Persistent inflammation generates reactive oxygen and nitrogen species that cause DNA damage. Over decades, this leads to atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately adenocarcinoma.	biological_processes[1]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""modifier"": ""INCREASED"", ""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"			INCREASED																								
2794	2957	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	3	CDH1/E-cadherin Inactivation	Loss of E-cadherin function through somatic mutation, promoter methylation, or loss of heterozygosity occurs in diffuse-type gastric cancer and some intestinal-type tumors. E-cadherin loss disrupts cell-cell adhesion and activates Wnt/beta-catenin signaling, promoting invasion.	genes[0]	genes	genes			CDH1				"{""preferred_term"": ""CDH1""}"																											
2795	2957	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	pathophysiology	3	CDH1/E-cadherin Inactivation	Loss of E-cadherin function through somatic mutation, promoter methylation, or loss of heterozygosity occurs in diffuse-type gastric cancer and some intestinal-type tumors. E-cadherin loss disrupts cell-cell adhesion and activates Wnt/beta-catenin signaling, promoting invasion.	biological_processes[0]	biological_processes	biological_processes			cell-cell adhesion	GO:0098609	cell-cell adhesion		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell-cell adhesion"", ""term"": {""id"": ""GO:0098609"", ""label"": ""cell-cell adhesion""}}"			DECREASED																								
2796	2958	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	0	Abdominal Pain	Epigastric pain or discomfort is the most common presenting symptom, often initially attributed to dyspepsia or peptic ulcer disease.	phenotype_term	phenotype_term	$	Abdominal Pain	Epigastric pain or discomfort is the most common presenting symptom, often initially attributed to dyspepsia or peptic ulcer disease.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2797	2959	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	1	Early Satiety	Feeling full after eating small amounts occurs due to reduced gastric capacity from tumor growth or impaired gastric motility.	phenotype_term	phenotype_term	$	Early Satiety	Feeling full after eating small amounts occurs due to reduced gastric capacity from tumor growth or impaired gastric motility.	Early satiety	HP:0033842	Early satiety		"{""preferred_term"": ""Early satiety"", ""term"": {""id"": ""HP:0033842"", ""label"": ""Early satiety""}}"																											
2798	2960	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	2	Weight Loss	Unintentional weight loss is common and may be significant at presentation, reflecting reduced oral intake and catabolic state.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is common and may be significant at presentation, reflecting reduced oral intake and catabolic state.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2799	2961	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	3	Nausea	Nausea and vomiting may occur, particularly with tumors causing gastric outlet obstruction.	phenotype_term	phenotype_term	$	Nausea	Nausea and vomiting may occur, particularly with tumors causing gastric outlet obstruction.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
2800	2962	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	4	Dysphagia	Difficulty swallowing occurs with tumors involving the gastroesophageal junction (cardia) or causing esophageal compression.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing occurs with tumors involving the gastroesophageal junction (cardia) or causing esophageal compression.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
2801	2963	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	5	Gastrointestinal Bleeding	Melena, hematemesis, or occult blood loss leading to iron deficiency anemia may occur from tumor ulceration.	phenotype_term	phenotype_term	$	Gastrointestinal Bleeding	Melena, hematemesis, or occult blood loss leading to iron deficiency anemia may occur from tumor ulceration.	Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
2802	2964	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	phenotypes	6	Anorexia	Loss of appetite is a common early symptom, contributing to weight loss.	phenotype_term	phenotype_term	$	Anorexia	Loss of appetite is a common early symptom, contributing to weight loss.	Anorexia	HP:0002039	Anorexia		"{""preferred_term"": ""Anorexia"", ""term"": {""id"": ""HP:0002039"", ""label"": ""Anorexia""}}"																											
2803	2965	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	0	H. pylori Eradication	Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors.	treatment_term	treatment_term	$	H. pylori Eradication	Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2804	2966	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	1	Surgical Resection	Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2805	2967	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	2	Perioperative Chemotherapy	Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone.	treatment_term	treatment_term	$	Perioperative Chemotherapy	Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2806	2968	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	3	Trastuzumab	Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer.	treatment_term	treatment_term	$	Trastuzumab	Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2807	2969	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	4	Immune Checkpoint Inhibition	PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors.	treatment_term	treatment_term	$	Immune Checkpoint Inhibition	PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2808	2971	124	Gastric Ulcer	Gastric_Ulcer.yaml	phenotypes	0	Gastric ulcer	Ulceration of the gastric mucosa.	phenotype_term	phenotype_term	$	Gastric ulcer	Ulceration of the gastric mucosa.	Gastric ulcer	HP:0002592	Gastric ulcer		"{""preferred_term"": ""Gastric ulcer"", ""term"": {""id"": ""HP:0002592"", ""label"": ""Gastric ulcer""}}"																											
2809	2981	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	pathophysiology	0	Lower Esophageal Sphincter Dysfunction	"Transient relaxations or chronic hypotension of the LES allow retrograde flow of gastric contents into the esophagus. Hiatal hernia exacerbates sphincter incompetence.
"	biological_processes[0]	biological_processes	biological_processes			Smooth Muscle Contraction	GO:0006939	smooth muscle contraction		"{""preferred_term"": ""Smooth Muscle Contraction"", ""term"": {""id"": ""GO:0006939"", ""label"": ""smooth muscle contraction""}}"																											
2810	2982	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	pathophysiology	1	Esophageal Mucosal Injury	"Gastric acid and pepsin damage esophageal epithelium, causing inflammation and erosions. Bile reflux in some patients adds to mucosal damage.
"	cell_types[0]	cell_types	cell_types			Esophageal Epithelial Cell	CL:0002252	epithelial cell of esophagus		"{""preferred_term"": ""Esophageal Epithelial Cell"", ""term"": {""id"": ""CL:0002252"", ""label"": ""epithelial cell of esophagus""}}"																											
2811	2983	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	pathophysiology	2	Impaired Esophageal Clearance	"Reduced salivary neutralization, impaired peristalsis, and delayed acid clearance prolong mucosal exposure to refluxate.
"	biological_processes[0]	biological_processes	biological_processes			Digestion	GO:0007586	digestion		"{""preferred_term"": ""Digestion"", ""term"": {""id"": ""GO:0007586"", ""label"": ""digestion""}}"																											
2812	2987	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	phenotypes	0	Heartburn		phenotype_term	phenotype_term	$	Heartburn		Heartburn	HP:0410281	Dyspepsia		"{""preferred_term"": ""Heartburn"", ""term"": {""id"": ""HP:0410281"", ""label"": ""Dyspepsia""}}"																											
2813	2988	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	phenotypes	1	Regurgitation		phenotype_term	phenotype_term	$	Regurgitation		Regurgitation	HP:0002020	Gastroesophageal reflux		"{""preferred_term"": ""Regurgitation"", ""term"": {""id"": ""HP:0002020"", ""label"": ""Gastroesophageal reflux""}}"																											
2814	2989	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	phenotypes	2	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
2815	2990	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	phenotypes	3	Chronic Cough		phenotype_term	phenotype_term	$	Chronic Cough		Chronic Cough	HP:0012735	Cough		"{""preferred_term"": ""Chronic Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
2816	2991	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	phenotypes	4	Hoarse Voice		phenotype_term	phenotype_term	$	Hoarse Voice		Hoarse Voice	HP:0001609	Hoarse voice		"{""preferred_term"": ""Hoarse Voice"", ""term"": {""id"": ""HP:0001609"", ""label"": ""Hoarse voice""}}"																											
2817	2998	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	biochemical	0	KIT (CD117) Immunohistochemistry		biomarker_term	biomarker_term	$	KIT (CD117) Immunohistochemistry		KIT protein	NCIT:C17328	Mast/Stem Cell Growth Factor Receptor Kit		"{""preferred_term"": ""KIT protein"", ""term"": {""id"": ""NCIT:C17328"", ""label"": ""Mast/Stem Cell Growth Factor Receptor Kit""}}"																											
2818	3005	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	histopathology	0	Mesenchymal Tumor	Gastrointestinal stromal tumor is the most common mesenchymal tumor of the GI tract.	finding_term	finding_term	$	Mesenchymal Tumor	Gastrointestinal stromal tumor is the most common mesenchymal tumor of the GI tract.	Gastrointestinal Stromal Tumor	NCIT:C3868	Gastrointestinal Stromal Tumor		"{""preferred_term"": ""Gastrointestinal Stromal Tumor"", ""term"": {""id"": ""NCIT:C3868"", ""label"": ""Gastrointestinal Stromal Tumor""}}"																											
2819	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	cell_types[0]	cell_types	cell_types			interstitial cell of Cajal	CL:0002088	interstitial cell of Cajal		"{""preferred_term"": ""interstitial cell of Cajal"", ""term"": {""id"": ""CL:0002088"", ""label"": ""interstitial cell of Cajal""}}"																											
2820	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""receptor signaling protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004716"", ""label"": ""receptor signaling protein tyrosine kinase activity""}}"			INCREASED																								
2821	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	biological_processes[1]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
2822	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	gene_products[0]	gene_products	gene_products			KIT receptor	NCIT:C17328	Mast/Stem Cell Growth Factor Receptor Kit		"{""preferred_term"": ""KIT receptor"", ""term"": {""id"": ""NCIT:C17328"", ""label"": ""Mast/Stem Cell Growth Factor Receptor Kit""}}"																											
2823	3006	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.	locations[0]	locations	locations			gastrointestinal tract	UBERON:0005409	alimentary part of gastrointestinal system		"{""preferred_term"": ""gastrointestinal tract"", ""term"": {""id"": ""UBERON:0005409"", ""label"": ""alimentary part of gastrointestinal system""}}"																											
2824	3007	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	1	PDGFRA Receptor Activation	PDGFRA mutations, particularly D842V in the activation loop, result in constitutive kinase activity. These mutations activate similar downstream pathways as KIT but show different drug sensitivity profiles.	biological_processes[0]	biological_processes	biological_processes			platelet-derived growth factor receptor signaling pathway	GO:0048008	platelet-derived growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""platelet-derived growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0048008"", ""label"": ""platelet-derived growth factor receptor signaling pathway""}}"			INCREASED																								
2825	3008	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	2	RAS-MAPK Pathway Activation	Constitutive KIT or PDGFRA activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting cell proliferation. This pathway represents a potential therapeutic target when primary resistance to KIT/PDGFRA inhibitors occurs.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2826	3009	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	pathophysiology	3	PI3K-AKT Pathway Activation	Constitutive KIT or PDGFRA activation recruits PI3K and activates the PI3K-AKT-mTOR signaling cascade, promoting cell survival and resistance to apoptosis. This pathway cooperates with MAPK signaling to drive tumorigenesis.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
2827	3010	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	phenotypes	0	Abdominal Mass	A palpable abdominal mass is often the presenting sign, particularly with larger tumors. GISTs can range from small incidental findings to massive tumors.	phenotype_term	phenotype_term	$	Abdominal Mass	A palpable abdominal mass is often the presenting sign, particularly with larger tumors. GISTs can range from small incidental findings to massive tumors.	Abdominal mass	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal mass"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
2828	3011	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	phenotypes	1	Gastrointestinal Bleeding	GI bleeding may present as hematemesis, melena, or chronic occult blood loss leading to iron deficiency anemia. Bleeding occurs when tumors ulcerate into the GI lumen.	phenotype_term	phenotype_term	$	Gastrointestinal Bleeding	GI bleeding may present as hematemesis, melena, or chronic occult blood loss leading to iron deficiency anemia. Bleeding occurs when tumors ulcerate into the GI lumen.	Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
2829	3012	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	phenotypes	2	Bowel Obstruction	Large tumors may cause partial or complete intestinal obstruction, particularly in the small bowel.	phenotype_term	phenotype_term	$	Bowel Obstruction	Large tumors may cause partial or complete intestinal obstruction, particularly in the small bowel.	Intestinal obstruction	HP:0005214	Intestinal obstruction		"{""preferred_term"": ""Intestinal obstruction"", ""term"": {""id"": ""HP:0005214"", ""label"": ""Intestinal obstruction""}}"																											
2830	3013	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	phenotypes	3	Fatigue	Fatigue may result from chronic blood loss and anemia or from advanced disease.	phenotype_term	phenotype_term	$	Fatigue	Fatigue may result from chronic blood loss and anemia or from advanced disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2831	3014	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	phenotypes	4	Weight Loss	Unintentional weight loss may occur with advanced or metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss may occur with advanced or metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
2832	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term	treatment_term	$	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
2833	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
2834	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term	treatment_term	$	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}]}"				sunitinib	CHEBI:38940																						
2835	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"																											
2836	3017	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	2	Avapritinib	Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.	treatment_term	treatment_term	$	Avapritinib	Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2837	3018	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	3	Surgical Resection	Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.	treatment_term	treatment_term	$	Surgical Resection	Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2838	3026	127	Gaucher Disease	Gaucher_Disease.yaml	pathophysiology	0	Glucocerebrosidase Deficiency	"Mutations in the GBA gene cause deficient beta-glucocerebrosidase (glucosylceramidase) enzyme. This enzyme normally degrades glucocerebroside (glucosylceramide) in lysosomes. Without it, glucocerebroside accumulates primarily in macrophages.
"	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2839	3026	127	Gaucher Disease	Gaucher_Disease.yaml	pathophysiology	0	Glucocerebrosidase Deficiency	"Mutations in the GBA gene cause deficient beta-glucocerebrosidase (glucosylceramidase) enzyme. This enzyme normally degrades glucocerebroside (glucosylceramide) in lysosomes. Without it, glucocerebroside accumulates primarily in macrophages.
"	biological_processes[0]	biological_processes	biological_processes			Sphingolipid Catabolism	GO:0030148	sphingolipid biosynthetic process		"{""preferred_term"": ""Sphingolipid Catabolism"", ""term"": {""id"": ""GO:0030148"", ""label"": ""sphingolipid biosynthetic process""}}"																											
2840	3027	127	Gaucher Disease	Gaucher_Disease.yaml	pathophysiology	1	Gaucher Cell Formation	"Lipid-laden macrophages (Gaucher cells) accumulate in spleen, liver, bone marrow, and other organs. These cells have characteristic crinkled tissue paper appearance and cause organ dysfunction through infiltration and inflammatory cytokine release.
"	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2841	3027	127	Gaucher Disease	Gaucher_Disease.yaml	pathophysiology	1	Gaucher Cell Formation	"Lipid-laden macrophages (Gaucher cells) accumulate in spleen, liver, bone marrow, and other organs. These cells have characteristic crinkled tissue paper appearance and cause organ dysfunction through infiltration and inflammatory cytokine release.
"	biological_processes[0]	biological_processes	biological_processes			Macrophage Activation	GO:0042116	macrophage activation		"{""preferred_term"": ""Macrophage Activation"", ""term"": {""id"": ""GO:0042116"", ""label"": ""macrophage activation""}}"																											
2842	3028	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	0	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
2843	3029	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	1	Splenomegaly		phenotype_term	phenotype_term	$	Splenomegaly		Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
2844	3030	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	2	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
2845	3031	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	3	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
2846	3032	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	4	Bone Pain		phenotype_term	phenotype_term	$	Bone Pain		Bone Pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone Pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
2847	3033	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	5	Pathologic Fractures		phenotype_term	phenotype_term	$	Pathologic Fractures		Pathologic Fractures	HP:0002756	Pathologic fracture		"{""preferred_term"": ""Pathologic Fractures"", ""term"": {""id"": ""HP:0002756"", ""label"": ""Pathologic fracture""}}"																											
2848	3034	127	Gaucher Disease	Gaucher_Disease.yaml	phenotypes	6	Erlenmeyer Flask Deformity		phenotype_term	phenotype_term	$	Erlenmeyer Flask Deformity		Erlenmeyer Flask Deformity	HP:0004975	Erlenmeyer flask deformity of the femurs		"{""preferred_term"": ""Erlenmeyer Flask Deformity"", ""term"": {""id"": ""HP:0004975"", ""label"": ""Erlenmeyer flask deformity of the femurs""}}"																											
2849	3049	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	0	Amygdala Hyperactivity	"Exaggerated amygdala response to perceived threats leads to excessive fear and anxiety. Reduced prefrontal cortex regulation of amygdala activity.
"	cell_types[0]	cell_types	cell_types			Amygdala Pyramidal Neuron	CL:4023110	amygdala pyramidal neuron		"{""preferred_term"": ""Amygdala Pyramidal Neuron"", ""term"": {""id"": ""CL:4023110"", ""label"": ""amygdala pyramidal neuron""}}"																											
2850	3049	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	0	Amygdala Hyperactivity	"Exaggerated amygdala response to perceived threats leads to excessive fear and anxiety. Reduced prefrontal cortex regulation of amygdala activity.
"	biological_processes[0]	biological_processes	biological_processes			Fear Response	GO:0042596	fear response		"{""preferred_term"": ""Fear Response"", ""term"": {""id"": ""GO:0042596"", ""label"": ""fear response""}}"																											
2851	3050	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	1	GABA System Dysfunction	"Reduced GABAergic inhibition contributes to neuronal hyperexcitability and anxiety. Benzodiazepines enhance GABA function.
"	cell_types[0]	cell_types	cell_types			GABAergic Interneuron	CL:0011005	GABAergic interneuron		"{""preferred_term"": ""GABAergic Interneuron"", ""term"": {""id"": ""CL:0011005"", ""label"": ""GABAergic interneuron""}}"																											
2852	3050	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	1	GABA System Dysfunction	"Reduced GABAergic inhibition contributes to neuronal hyperexcitability and anxiety. Benzodiazepines enhance GABA function.
"	biological_processes[0]	biological_processes	biological_processes			GABAergic Transmission	GO:0051932	synaptic transmission, GABAergic		"{""preferred_term"": ""GABAergic Transmission"", ""term"": {""id"": ""GO:0051932"", ""label"": ""synaptic transmission, GABAergic""}}"																											
2853	3051	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	2	Serotonin Dysregulation	"Altered serotonin signaling, particularly in raphe-prefrontal circuits, contributes to anxiety. SSRIs are first-line treatment.
"	cell_types[0]	cell_types	cell_types			Serotonergic Neuron	CL:0000850	serotonergic neuron		"{""preferred_term"": ""Serotonergic Neuron"", ""term"": {""id"": ""CL:0000850"", ""label"": ""serotonergic neuron""}}"																											
2854	3051	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	2	Serotonin Dysregulation	"Altered serotonin signaling, particularly in raphe-prefrontal circuits, contributes to anxiety. SSRIs are first-line treatment.
"	biological_processes[0]	biological_processes	biological_processes			Serotonin Signaling	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Serotonin Signaling"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
2855	3052	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	3	HPA Axis Dysregulation	"Chronic activation of the stress response system with elevated cortisol contributes to sustained anxiety and physical symptoms.
"	biological_processes[0]	biological_processes	biological_processes			Stress Response	GO:0006950	response to stress		"{""preferred_term"": ""Stress Response"", ""term"": {""id"": ""GO:0006950"", ""label"": ""response to stress""}}"																											
2856	3053	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	4	Noradrenergic Hyperactivity	"Elevated norepinephrine activity in locus coeruleus contributes to hyperarousal and somatic symptoms of anxiety.
"	cell_types[0]	cell_types	cell_types			Noradrenergic Neuron	CL:0008025	noradrenergic neuron		"{""preferred_term"": ""Noradrenergic Neuron"", ""term"": {""id"": ""CL:0008025"", ""label"": ""noradrenergic neuron""}}"																											
2857	3055	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	6	Epigenetic Alterations	"DNA methylation changes in anxiety-related genes, particularly in monocytes and granulocytes. Methylation sites identified in genes involved in neurogenesis and fear memory.
"	cell_types[0]	cell_types	cell_types			Monocyte	CL:0000576	monocyte		"{""preferred_term"": ""Monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
2858	3055	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	pathophysiology	6	Epigenetic Alterations	"DNA methylation changes in anxiety-related genes, particularly in monocytes and granulocytes. Methylation sites identified in genes involved in neurogenesis and fear memory.
"	cell_types[1]	cell_types	cell_types			Granulocyte	CL:0000094	granulocyte		"{""preferred_term"": ""Granulocyte"", ""term"": {""id"": ""CL:0000094"", ""label"": ""granulocyte""}}"																											
2859	3056	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	0	Excessive Worry		phenotype_term	phenotype_term	$	Excessive Worry		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
2860	3057	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	1	Restlessness		phenotype_term	phenotype_term	$	Restlessness		Restlessness	HP:0000711	Restlessness		"{""preferred_term"": ""Restlessness"", ""term"": {""id"": ""HP:0000711"", ""label"": ""Restlessness""}}"																											
2861	3058	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2862	3059	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	3	Difficulty Concentrating		phenotype_term	phenotype_term	$	Difficulty Concentrating		Poor Concentration	HP:0007018	Attention deficit hyperactivity disorder		"{""preferred_term"": ""Poor Concentration"", ""term"": {""id"": ""HP:0007018"", ""label"": ""Attention deficit hyperactivity disorder""}}"																											
2863	3060	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	4	Muscle Tension		phenotype_term	phenotype_term	$	Muscle Tension		Muscle Tension	HP:0003552	Muscle stiffness		"{""preferred_term"": ""Muscle Tension"", ""term"": {""id"": ""HP:0003552"", ""label"": ""Muscle stiffness""}}"																											
2864	3061	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	5	Sleep Disturbance		phenotype_term	phenotype_term	$	Sleep Disturbance		Insomnia	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Insomnia"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
2865	3062	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	phenotypes	6	Irritability		phenotype_term	phenotype_term	$	Irritability		Irritability	HP:0000737	Irritability		"{""preferred_term"": ""Irritability"", ""term"": {""id"": ""HP:0000737"", ""label"": ""Irritability""}}"																											
2866	3075	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	0	Dendritic Cell Activation in Vessel Wall	Adventitial dendritic cells become activated and produce chemokines that recruit T cells and macrophages. Vascular dendritic cells may sense pathogen-associated or damage-associated molecular patterns.	cell_types[0]	cell_types	cell_types			Dendritic Cell	CL:0000451	dendritic cell		"{""preferred_term"": ""Dendritic Cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
2867	3075	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	0	Dendritic Cell Activation in Vessel Wall	Adventitial dendritic cells become activated and produce chemokines that recruit T cells and macrophages. Vascular dendritic cells may sense pathogen-associated or damage-associated molecular patterns.	biological_processes[0]	biological_processes	biological_processes			Immune Response	GO:0006955	immune response		"{""preferred_term"": ""Immune Response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
2868	3076	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	1	Th1 and Th17 T Cell Infiltration	CD4+ T cells infiltrate the arterial wall and produce IFN-gamma (Th1) and IL-17 (Th17). IFN-gamma activates macrophages and promotes giant cell formation, while IL-17 drives vascular inflammation.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
2869	3076	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	1	Th1 and Th17 T Cell Infiltration	CD4+ T cells infiltrate the arterial wall and produce IFN-gamma (Th1) and IL-17 (Th17). IFN-gamma activates macrophages and promotes giant cell formation, while IL-17 drives vascular inflammation.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2870	3076	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	1	Th1 and Th17 T Cell Infiltration	CD4+ T cells infiltrate the arterial wall and produce IFN-gamma (Th1) and IL-17 (Th17). IFN-gamma activates macrophages and promotes giant cell formation, while IL-17 drives vascular inflammation.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2871	3077	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	2	Giant Cell Formation and Intimal Hyperplasia	Multinucleated giant cells form at the media-intima junction. Smooth muscle cells proliferate causing intimal hyperplasia, leading to vessel stenosis and ischemic complications.	cell_types[0]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
2872	3077	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	pathophysiology	2	Giant Cell Formation and Intimal Hyperplasia	Multinucleated giant cells form at the media-intima junction. Smooth muscle cells proliferate causing intimal hyperplasia, leading to vessel stenosis and ischemic complications.	biological_processes[0]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell proliferation""}}"																											
2873	3078	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	phenotypes	0	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2874	3079	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	phenotypes	1	Visual Loss		phenotype_term	phenotype_term	$	Visual Loss		Visual Impairment	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual Impairment"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
2875	3080	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	phenotypes	2	Jaw Claudication		phenotype_term	phenotype_term	$	Jaw Claudication		Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
2876	3081	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2877	3101	130	Glaucoma	Glaucoma.yaml	pathophysiology	0	Elevated Intraocular Pressure	"Impaired aqueous humor drainage through trabecular meshwork leads to increased IOP in most cases. Elevated pressure damages retinal ganglion cells and optic nerve.
"	biological_processes[0]	biological_processes	biological_processes			Fluid Homeostasis	GO:0030104	water homeostasis		"{""preferred_term"": ""Fluid Homeostasis"", ""term"": {""id"": ""GO:0030104"", ""label"": ""water homeostasis""}}"																											
2878	3102	130	Glaucoma	Glaucoma.yaml	pathophysiology	1	Retinal Ganglion Cell Death	"Progressive apoptosis of retinal ganglion cells leads to irreversible vision loss. Mechanical stress, ischemia, and excitotoxicity contribute to cell death.
"	cell_types[0]	cell_types	cell_types			Retinal Ganglion Cell	CL:0000740	retinal ganglion cell		"{""preferred_term"": ""Retinal Ganglion Cell"", ""term"": {""id"": ""CL:0000740"", ""label"": ""retinal ganglion cell""}}"																											
2879	3102	130	Glaucoma	Glaucoma.yaml	pathophysiology	1	Retinal Ganglion Cell Death	"Progressive apoptosis of retinal ganglion cells leads to irreversible vision loss. Mechanical stress, ischemia, and excitotoxicity contribute to cell death.
"	biological_processes[0]	biological_processes	biological_processes			Apoptosis	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptosis"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
2880	3104	130	Glaucoma	Glaucoma.yaml	pathophysiology	3	Trabecular Meshwork Dysfunction	"Age-related changes, oxidative stress, and altered extracellular matrix reduce outflow facility. Increased resistance to aqueous outflow.
"	cell_types[0]	cell_types	cell_types			Trabecular Meshwork Cell	CL:0002367	trabecular meshwork cell		"{""preferred_term"": ""Trabecular Meshwork Cell"", ""term"": {""id"": ""CL:0002367"", ""label"": ""trabecular meshwork cell""}}"																											
2881	3105	130	Glaucoma	Glaucoma.yaml	phenotypes	0	Visual Field Loss		phenotype_term	phenotype_term	$	Visual Field Loss		Visual Field Defect	HP:0001123	Visual field defect		"{""preferred_term"": ""Visual Field Defect"", ""term"": {""id"": ""HP:0001123"", ""label"": ""Visual field defect""}}"																											
2882	3106	130	Glaucoma	Glaucoma.yaml	phenotypes	1	Optic Disc Cupping		phenotype_term	phenotype_term	$	Optic Disc Cupping		Optic Atrophy	HP:0000648	Optic atrophy		"{""preferred_term"": ""Optic Atrophy"", ""term"": {""id"": ""HP:0000648"", ""label"": ""Optic atrophy""}}"																											
2883	3107	130	Glaucoma	Glaucoma.yaml	phenotypes	2	Elevated Intraocular Pressure		phenotype_term	phenotype_term	$	Elevated Intraocular Pressure		Elevated IOP	HP:0012632	Abnormal intraocular pressure		"{""preferred_term"": ""Elevated IOP"", ""term"": {""id"": ""HP:0012632"", ""label"": ""Abnormal intraocular pressure""}}"																											
2884	3108	130	Glaucoma	Glaucoma.yaml	phenotypes	3	Halos Around Lights		phenotype_term	phenotype_term	$	Halos Around Lights		Visual Impairment	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual Impairment"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
2885	3109	130	Glaucoma	Glaucoma.yaml	phenotypes	4	Eye Pain		phenotype_term	phenotype_term	$	Eye Pain		Eye Pain	HP:0200026	Ocular pain		"{""preferred_term"": ""Eye Pain"", ""term"": {""id"": ""HP:0200026"", ""label"": ""Ocular pain""}}"																											
2886	3129	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	histopathology	0	Astrocytic Glioma	Glioblastoma is a malignant astrocytic glioma.	finding_term	finding_term	$	Astrocytic Glioma	Glioblastoma is a malignant astrocytic glioma.	Astrocytoma	NCIT:C60781	Astrocytoma		"{""preferred_term"": ""Astrocytoma"", ""term"": {""id"": ""NCIT:C60781"", ""label"": ""Astrocytoma""}}"																											
2887	3130	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	0	TERT Promoter Activation	TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. These mutations create de novo ETS transcription factor binding sites, leading to TERT upregulation and telomerase reactivation. This enables unlimited replicative potential and is a defining molecular feature.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
2888	3130	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	0	TERT Promoter Activation	TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. These mutations create de novo ETS transcription factor binding sites, leading to TERT upregulation and telomerase reactivation. This enables unlimited replicative potential and is a defining molecular feature.	biological_processes[0]	biological_processes	biological_processes			telomere maintenance via telomerase	GO:0007004	telomere maintenance via telomerase		"{""modifier"": ""INCREASED"", ""preferred_term"": ""telomere maintenance via telomerase"", ""term"": {""id"": ""GO:0007004"", ""label"": ""telomere maintenance via telomerase""}}"			INCREASED																								
2889	3130	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	0	TERT Promoter Activation	TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. These mutations create de novo ETS transcription factor binding sites, leading to TERT upregulation and telomerase reactivation. This enables unlimited replicative potential and is a defining molecular feature.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
2890	3131	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	1	Chromosome 7 Gain and Chromosome 10 Loss	Combined gain of chromosome 7 (+7) and loss of chromosome 10 (-10) is a defining molecular feature of IDH-wildtype glioblastoma, present in over 90% of cases. Chromosome 7 gain amplifies EGFR and MET. Chromosome 10 loss deletes PTEN and other tumor suppressors.	biological_processes[0]	biological_processes	biological_processes			chromosome organization	GO:0051276	chromosome organization		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""chromosome organization"", ""term"": {""id"": ""GO:0051276"", ""label"": ""chromosome organization""}}"			ABNORMAL																								
2891	3132	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	2	EGFR/MET Pathway Activation	EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification is often accompanied by EGFRvIII, a constitutively active deletion variant lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK and PI3K/AKT pathways.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
2892	3132	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	2	EGFR/MET Pathway Activation	EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification is often accompanied by EGFRvIII, a constitutively active deletion variant lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK and PI3K/AKT pathways.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
2893	3133	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	3	PTEN Tumor Suppressor Loss	PTEN loss through chromosome 10 deletion, mutation, or epigenetic silencing occurs in 40-50% of glioblastomas. Loss of PTEN phosphatase activity leads to constitutive PI3K/AKT/mTOR pathway activation, promoting survival and growth.	biological_processes[0]	biological_processes	biological_processes			negative regulation of phosphatidylinositol 3-kinase signaling	GO:0014067	negative regulation of phosphatidylinositol 3-kinase signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014067"", ""label"": ""negative regulation of phosphatidylinositol 3-kinase signaling""}}"			DECREASED																								
2894	3134	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	4	PI3K/AKT/mTOR Pathway Hyperactivation	Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation, or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis. This pathway is active in nearly all glioblastomas.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2895	3134	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	4	PI3K/AKT/mTOR Pathway Hyperactivation	Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation, or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis. This pathway is active in nearly all glioblastomas.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
2896	3135	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	5	Unlimited Replicative Potential	Telomerase reactivation through TERT promoter mutations enables glioblastoma cells to bypass replicative senescence and achieve unlimited proliferative capacity, a hallmark of cancer.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2897	3136	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Multiple converging pathways (RTK signaling, PI3K/AKT/mTOR, cell cycle dysregulation) drive rapid proliferation characteristic of glioblastoma. High mitotic index and proliferation markers (Ki-67 often >20%) are typical.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
2898	3136	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	pathophysiology	6	Uncontrolled Cell Proliferation	Multiple converging pathways (RTK signaling, PI3K/AKT/mTOR, cell cycle dysregulation) drive rapid proliferation characteristic of glioblastoma. High mitotic index and proliferation markers (Ki-67 often >20%) are typical.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
2899	3137	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	phenotypes	0	Headache	Headache from mass effect and increased intracranial pressure is common, often progressive and worse in the morning.	phenotype_term	phenotype_term	$	Headache	Headache from mass effect and increased intracranial pressure is common, often progressive and worse in the morning.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
2900	3138	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	phenotypes	1	Seizure	Seizures occur in 25-40% of patients, more commonly with cortical involvement. May be focal or generalized.	phenotype_term	phenotype_term	$	Seizure	Seizures occur in 25-40% of patients, more commonly with cortical involvement. May be focal or generalized.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
2901	3139	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	phenotypes	2	Cognitive Impairment	Progressive cognitive decline including memory, attention, and executive function deficits.	phenotype_term	phenotype_term	$	Cognitive Impairment	Progressive cognitive decline including memory, attention, and executive function deficits.	Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
2902	3140	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	phenotypes	3	Focal Neurological Deficit	Motor weakness, sensory changes, aphasia, or visual field deficits depending on tumor location. Often progresses rapidly.	phenotype_term	phenotype_term	$	Focal Neurological Deficit	Motor weakness, sensory changes, aphasia, or visual field deficits depending on tumor location. Often progresses rapidly.	Hemiparesis	HP:0001269	Hemiparesis		"{""preferred_term"": ""Hemiparesis"", ""term"": {""id"": ""HP:0001269"", ""label"": ""Hemiparesis""}}"																											
2903	3141	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	phenotypes	4	Personality Changes	Personality and behavioral changes, particularly with frontal lobe involvement. May include apathy, disinhibition, or emotional lability.	phenotype_term	phenotype_term	$	Personality Changes	Personality and behavioral changes, particularly with frontal lobe involvement. May include apathy, disinhibition, or emotional lability.	Personality changes	HP:0000751	Personality changes		"{""preferred_term"": ""Personality changes"", ""term"": {""id"": ""HP:0000751"", ""label"": ""Personality changes""}}"																											
2904	3142	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	0	Maximal Safe Resection	Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.	treatment_term	treatment_term	$	Maximal Safe Resection	Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2905	3143	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	1	Radiation Therapy	External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2906	3144	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	2	Temozolomide Chemotherapy	Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2907	3145	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	3	Tumor Treating Fields (TTFields)	Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.	treatment_term	treatment_term	$	Tumor Treating Fields (TTFields)	Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.	cranial electrical stimulation	MAXO:0000944	cranial electrical stimulation		"{""preferred_term"": ""cranial electrical stimulation"", ""term"": {""id"": ""MAXO:0000944"", ""label"": ""cranial electrical stimulation""}}"																											
2908	3146	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	4	Bevacizumab	Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.	treatment_term	treatment_term	$	Bevacizumab	Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2909	3150	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	3	Heinz Bodies		cell_types[0]	cell_types	cell_types			Red Blood Cells	CL:0000232	erythrocyte		"{""preferred_term"": ""Red Blood Cells"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2910	3151	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	4	Glutathione/GSSG Ratio		cell_types[0]	cell_types	cell_types			Red Blood Cells	CL:0000232	erythrocyte		"{""preferred_term"": ""Red Blood Cells"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2911	3152	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	environmental	0	Oxidative Stressors		exposure_term	exposure_term	$	Oxidative Stressors		Oxidative stress exposure	ECTO:0000231	exposure to chemical		"{""preferred_term"": ""Oxidative stress exposure"", ""term"": {""id"": ""ECTO:0000231"", ""label"": ""exposure to chemical""}}"																											
2912	3155	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	0	Decreased G6PD Enzyme Activity	Mutations in the G6PD gene lead to reduced or absent enzyme activity.	locations[0]	locations	locations			erythrocyte	UBERON:0000178	blood		"{""preferred_term"": ""erythrocyte"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
2913	3155	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	0	Decreased G6PD Enzyme Activity	Mutations in the G6PD gene lead to reduced or absent enzyme activity.	biological_processes[0]	biological_processes	biological_processes			pentose-phosphate shunt	GO:0006098	pentose-phosphate shunt		"{""preferred_term"": ""pentose-phosphate shunt"", ""term"": {""id"": ""GO:0006098"", ""label"": ""pentose-phosphate shunt""}}"																											
2914	3155	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	0	Decreased G6PD Enzyme Activity	Mutations in the G6PD gene lead to reduced or absent enzyme activity.	cell_types[0]	cell_types	cell_types			erythrocyte	CL:0000232	erythrocyte		"{""preferred_term"": ""erythrocyte"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2915	3156	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	1	Impaired Redox Homeostasis	Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.	biological_processes[0]	biological_processes	biological_processes			NADPH regeneration	GO:0006739	NADPH regeneration		"{""preferred_term"": ""NADPH regeneration"", ""term"": {""id"": ""GO:0006739"", ""label"": ""NADPH regeneration""}}"																											
2916	3156	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	1	Impaired Redox Homeostasis	Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.	biological_processes[1]	biological_processes	biological_processes			glutathione metabolic process	GO:0006749	glutathione metabolic process		"{""preferred_term"": ""glutathione metabolic process"", ""term"": {""id"": ""GO:0006749"", ""label"": ""glutathione metabolic process""}}"																											
2917	3156	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	1	Impaired Redox Homeostasis	Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.	cell_types[0]	cell_types	cell_types			erythrocyte	CL:0000232	erythrocyte		"{""preferred_term"": ""erythrocyte"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2918	3156	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	1	Impaired Redox Homeostasis	Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.	chemical_entities[0]	chemical_entities	chemical_entities			NADPH	CHEBI:16474	NADPH		"{""preferred_term"": ""NADPH"", ""term"": {""id"": ""CHEBI:16474"", ""label"": ""NADPH""}}"																											
2919	3156	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	1	Impaired Redox Homeostasis	Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.	chemical_entities[1]	chemical_entities	chemical_entities			glutathione	CHEBI:16856	glutathione		"{""preferred_term"": ""glutathione"", ""term"": {""id"": ""CHEBI:16856"", ""label"": ""glutathione""}}"																											
2920	3157	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	2	Oxidative Stress	Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
2921	3157	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	2	Oxidative Stress	Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.	cell_types[0]	cell_types	cell_types			erythrocyte	CL:0000232	erythrocyte		"{""preferred_term"": ""erythrocyte"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2922	3157	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	2	Oxidative Stress	Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.	locations[0]	locations	locations			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
2923	3157	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	2	Oxidative Stress	Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.	locations[1]	locations	locations			spleen	UBERON:0002106	spleen		"{""preferred_term"": ""spleen"", ""term"": {""id"": ""UBERON:0002106"", ""label"": ""spleen""}}"																											
2924	3157	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	2	Oxidative Stress	Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.	chemical_entities[0]	chemical_entities	chemical_entities			hydrogen peroxide	CHEBI:16240	hydrogen peroxide		"{""preferred_term"": ""hydrogen peroxide"", ""term"": {""id"": ""CHEBI:16240"", ""label"": ""hydrogen peroxide""}}"																											
2925	3158	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	3	Acute Hemolytic Anemia	Exposure to oxidative stressors, such as certain medications, foods, or infections, can trigger acute episodes of hemolysis.	biological_processes[0]	biological_processes	biological_processes			hemolysis in other organism	GO:0002937	hemolysis in other organism		"{""preferred_term"": ""hemolysis in other organism"", ""term"": {""id"": ""GO:0002937"", ""label"": ""hemolysis in other organism""}}"																											
2926	3158	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	3	Acute Hemolytic Anemia	Exposure to oxidative stressors, such as certain medications, foods, or infections, can trigger acute episodes of hemolysis.	cell_types[0]	cell_types	cell_types			erythrocyte	CL:0000232	erythrocyte		"{""preferred_term"": ""erythrocyte"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
2927	3158	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	3	Acute Hemolytic Anemia	Exposure to oxidative stressors, such as certain medications, foods, or infections, can trigger acute episodes of hemolysis.	locations[0]	locations	locations			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
2928	3158	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	pathophysiology	3	Acute Hemolytic Anemia	Exposure to oxidative stressors, such as certain medications, foods, or infections, can trigger acute episodes of hemolysis.	locations[1]	locations	locations			spleen	UBERON:0002106	spleen		"{""preferred_term"": ""spleen"", ""term"": {""id"": ""UBERON:0002106"", ""label"": ""spleen""}}"																											
2929	3159	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	0	Hemolytic Anemia		phenotype_term	phenotype_term	$	Hemolytic Anemia		Hemolytic Anemia	HP:0001878	Hemolytic anemia		"{""preferred_term"": ""Hemolytic Anemia"", ""term"": {""id"": ""HP:0001878"", ""label"": ""Hemolytic anemia""}}"																											
2930	3160	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	1	Dark Urine		phenotype_term	phenotype_term	$	Dark Urine		Dark Urine	HP:0040319	Dark urine		"{""preferred_term"": ""Dark Urine"", ""term"": {""id"": ""HP:0040319"", ""label"": ""Dark urine""}}"																											
2931	3161	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	2	Neonatal Jaundice		phenotype_term	phenotype_term	$	Neonatal Jaundice		Neonatal Jaundice	HP:0003265	Neonatal hyperbilirubinemia		"{""preferred_term"": ""Neonatal Jaundice"", ""term"": {""id"": ""HP:0003265"", ""label"": ""Neonatal hyperbilirubinemia""}}"																											
2932	3164	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	5	Pallor		phenotype_term	phenotype_term	$	Pallor		Pallor	HP:0000980	Pallor		"{""preferred_term"": ""Pallor"", ""term"": {""id"": ""HP:0000980"", ""label"": ""Pallor""}}"																											
2933	3165	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
2934	3166	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	7	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
2935	3167	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	phenotypes	8	Shortness of Breath		phenotype_term	phenotype_term	$	Shortness of Breath		Shortness of Breath	HP:0002094	Dyspnea		"{""preferred_term"": ""Shortness of Breath"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
2936	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	Avoidance of Oxidative Stressors	Identifying and avoiding triggers for acute hemolytic episodes	treatment_term	treatment_term	$	Avoidance of Oxidative Stressors	Identifying and avoiding triggers for acute hemolytic episodes	medical action avoidance	MAXO:0001014	medical action avoidance		"{""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
2937	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	Supportive Care During Acute Hemolysis	Hydration, blood transfusions if needed, and monitoring for complications	treatment_term	treatment_term	$	Supportive Care During Acute Hemolysis	Hydration, blood transfusions if needed, and monitoring for complications	blood transfusion	MAXO:0000756	blood transfusion		"{""preferred_term"": ""blood transfusion"", ""term"": {""id"": ""MAXO:0000756"", ""label"": ""blood transfusion""}}"																											
2938	3181	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	0	PTCH1 Germline Mutations	PTCH1 encodes Patched 1, a 12-pass transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Germline heterozygous loss-of-function mutations in PTCH1 predispose to tumors following Knudson's two-hit model. Loss of the remaining wild-type allele in somatic cells leads to constitutive Hedgehog pathway activation and tumor development.	cell_types[0]	cell_types	cell_types			basal cell of epidermis	CL:0002187	basal cell of epidermis		"{""preferred_term"": ""basal cell of epidermis"", ""term"": {""id"": ""CL:0002187"", ""label"": ""basal cell of epidermis""}}"																											
2939	3181	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	0	PTCH1 Germline Mutations	PTCH1 encodes Patched 1, a 12-pass transmembrane receptor that normally suppresses Smoothened (SMO) in the absence of Hedgehog ligand. Germline heterozygous loss-of-function mutations in PTCH1 predispose to tumors following Knudson's two-hit model. Loss of the remaining wild-type allele in somatic cells leads to constitutive Hedgehog pathway activation and tumor development.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
2940	3182	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	1	SUFU Germline Mutations	A minority of Gorlin syndrome cases (approximately 5%) are caused by germline mutations in SUFU (Suppressor of Fused), which encodes a negative regulator of GLI transcription factors. SUFU mutations are associated with markedly higher risk of medulloblastoma (up to 20-fold higher) compared to PTCH1 mutations, with tumors typically occurring before age 3 years.	biological_processes[0]	biological_processes	biological_processes			negative regulation of smoothened signaling pathway	GO:0045879	negative regulation of smoothened signaling pathway		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of smoothened signaling pathway"", ""term"": {""id"": ""GO:0045879"", ""label"": ""negative regulation of smoothened signaling pathway""}}"			DECREASED																								
2941	3183	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	pathophysiology	2	Constitutive Hedgehog Pathway Activation	Loss of PTCH1 function or SUFU mutations result in constitutive activation of the Hedgehog signaling cascade. Without functional PTCH1, Smoothened is no longer suppressed and activates GLI transcription factors, driving expression of target genes involved in proliferation, survival, and developmental patterning.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
2942	3184	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	0	Multiple Basal Cell Carcinomas	Patients typically develop multiple basal cell carcinomas, often beginning in childhood or adolescence. The number of tumors increases with age and UV exposure. BCCs may number in the hundreds over a lifetime.	phenotype_term	phenotype_term	$	Multiple Basal Cell Carcinomas	Patients typically develop multiple basal cell carcinomas, often beginning in childhood or adolescence. The number of tumors increases with age and UV exposure. BCCs may number in the hundreds over a lifetime.	Basal cell carcinoma	HP:0002671	Basal cell carcinoma		"{""preferred_term"": ""Basal cell carcinoma"", ""term"": {""id"": ""HP:0002671"", ""label"": ""Basal cell carcinoma""}}"																											
2943	3185	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	1	Palmar Pits	Small (1-3 mm) depressed lesions on the palms representing localized defects in the stratum corneum. Present in 65-87% of patients and are highly specific for the diagnosis.	phenotype_term	phenotype_term	$	Palmar Pits	Small (1-3 mm) depressed lesions on the palms representing localized defects in the stratum corneum. Present in 65-87% of patients and are highly specific for the diagnosis.	Palmar pits	HP:0010610	Palmar pits		"{""preferred_term"": ""Palmar pits"", ""term"": {""id"": ""HP:0010610"", ""label"": ""Palmar pits""}}"																											
2944	3186	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	2	Plantar Pits	Pits on the soles similar to palmar pits, also representing keratinization defects due to Hedgehog pathway abnormalities.	phenotype_term	phenotype_term	$	Plantar Pits	Pits on the soles similar to palmar pits, also representing keratinization defects due to Hedgehog pathway abnormalities.	Plantar pits	HP:0010612	Plantar pits		"{""preferred_term"": ""Plantar pits"", ""term"": {""id"": ""HP:0010612"", ""label"": ""Plantar pits""}}"																											
2945	3187	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	3	Odontogenic Keratocysts	Keratinizing cystic lesions arising in the jaw, typically appearing in the first decade of life. Multiple jaw cysts are highly suggestive of the diagnosis. Cysts have a high recurrence rate after surgical removal.	phenotype_term	phenotype_term	$	Odontogenic Keratocysts	Keratinizing cystic lesions arising in the jaw, typically appearing in the first decade of life. Multiple jaw cysts are highly suggestive of the diagnosis. Cysts have a high recurrence rate after surgical removal.	Odontogenic keratocysts of the jaw	HP:0010603	Odontogenic keratocysts of the jaw		"{""preferred_term"": ""Odontogenic keratocysts of the jaw"", ""term"": {""id"": ""HP:0010603"", ""label"": ""Odontogenic keratocysts of the jaw""}}"																											
2946	3188	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	4	Macrocephaly	Increased head circumference is common and may be associated with frontal bossing and a characteristic facial appearance.	phenotype_term	phenotype_term	$	Macrocephaly	Increased head circumference is common and may be associated with frontal bossing and a characteristic facial appearance.	Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
2947	3189	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	5	Rib Anomalies	Bifid, splayed, or fused ribs are common skeletal findings and may be detected incidentally on imaging.	phenotype_term	phenotype_term	$	Rib Anomalies	Bifid, splayed, or fused ribs are common skeletal findings and may be detected incidentally on imaging.	Abnormal rib morphology	HP:0000772	Abnormal rib morphology		"{""preferred_term"": ""Abnormal rib morphology"", ""term"": {""id"": ""HP:0000772"", ""label"": ""Abnormal rib morphology""}}"																											
2948	3190	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	6	Vertebral Anomalies	Vertebral fusion, hemivertebrae, and other spinal anomalies may occur.	phenotype_term	phenotype_term	$	Vertebral Anomalies	Vertebral fusion, hemivertebrae, and other spinal anomalies may occur.	Abnormal vertebral morphology	HP:0003468	Abnormal vertebral morphology		"{""preferred_term"": ""Abnormal vertebral morphology"", ""term"": {""id"": ""HP:0003468"", ""label"": ""Abnormal vertebral morphology""}}"																											
2949	3191	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	7	Calcification of Falx Cerebri	Ectopic calcification of the falx cerebri is a common radiologic finding, often present before age 20 and increasing with age.	phenotype_term	phenotype_term	$	Calcification of Falx Cerebri	Ectopic calcification of the falx cerebri is a common radiologic finding, often present before age 20 and increasing with age.	Calcification of falx cerebri	HP:0005462	Calcification of falx cerebri		"{""preferred_term"": ""Calcification of falx cerebri"", ""term"": {""id"": ""HP:0005462"", ""label"": ""Calcification of falx cerebri""}}"																											
2950	3192	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	8	Medulloblastoma	Increased risk of medulloblastoma, particularly the desmoplastic/nodular subtype. Risk is estimated at 1-5% for PTCH1 carriers but up to 20-fold higher in SUFU mutation carriers. Tumors typically occur in the first few years of life.	phenotype_term	phenotype_term	$	Medulloblastoma	Increased risk of medulloblastoma, particularly the desmoplastic/nodular subtype. Risk is estimated at 1-5% for PTCH1 carriers but up to 20-fold higher in SUFU mutation carriers. Tumors typically occur in the first few years of life.	Medulloblastoma	HP:0002885	Medulloblastoma		"{""preferred_term"": ""Medulloblastoma"", ""term"": {""id"": ""HP:0002885"", ""label"": ""Medulloblastoma""}}"																											
2951	3193	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	9	Cardiac Fibroma	Cardiac fibromas are benign tumors that may occur in Gorlin syndrome, sometimes detected incidentally or presenting with arrhythmias.	phenotype_term	phenotype_term	$	Cardiac Fibroma	Cardiac fibromas are benign tumors that may occur in Gorlin syndrome, sometimes detected incidentally or presenting with arrhythmias.	Cardiac fibroma	HP:0010617	Cardiac fibroma		"{""preferred_term"": ""Cardiac fibroma"", ""term"": {""id"": ""HP:0010617"", ""label"": ""Cardiac fibroma""}}"																											
2952	3194	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	phenotypes	10	Ovarian Fibroma	Ovarian fibromas may occur in affected females and can be bilateral.	phenotype_term	phenotype_term	$	Ovarian Fibroma	Ovarian fibromas may occur in affected females and can be bilateral.	Ovarian fibroma	HP:0010618	Ovarian fibroma		"{""preferred_term"": ""Ovarian fibroma"", ""term"": {""id"": ""HP:0010618"", ""label"": ""Ovarian fibroma""}}"																											
2953	3196	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	0	Surgical Excision	Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2954	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term	treatment_term	$	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}"				vismodegib	CHEBI:66903																						
2955	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"																											
2956	3198	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	2	Sonidegib	Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib.	treatment_term	treatment_term	$	Sonidegib	Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2957	3199	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	3	Laser Ablation Therapy	Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes.	treatment_term	treatment_term	$	Laser Ablation Therapy	Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes.	laser ablation therapy	MAXO:0000453	laser ablation therapy		"{""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}"																											
2958	3200	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	4	Topical Therapy	Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden.	treatment_term	treatment_term	$	Topical Therapy	Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2959	3201	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	5	Sun Avoidance	Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs.	treatment_term	treatment_term	$	Sun Avoidance	Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs.	sunlight avoidance	MAXO:0000055	sunlight avoidance		"{""preferred_term"": ""sunlight avoidance"", ""term"": {""id"": ""MAXO:0000055"", ""label"": ""sunlight avoidance""}}"																											
2960	3202	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	6	Genetic Counseling	Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members.	treatment_term	treatment_term	$	Genetic Counseling	Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2961	3214	134	Gout	Gout.yaml	pathophysiology	0	Hyperuricemia	"Elevated serum uric acid from increased purine metabolism or decreased renal excretion leads to supersaturation and crystal formation. Urate is the end product of purine catabolism in humans.
"	biological_processes[0]	biological_processes	biological_processes			Purine Metabolism	GO:0006144	purine nucleobase metabolic process		"{""preferred_term"": ""Purine Metabolism"", ""term"": {""id"": ""GO:0006144"", ""label"": ""purine nucleobase metabolic process""}}"																											
2962	3216	134	Gout	Gout.yaml	pathophysiology	2	Inflammasome Activation	"MSU crystals are phagocytosed by macrophages, activating NLRP3 inflammasome and triggering IL-1beta release, driving acute inflammatory flare.
"	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2963	3216	134	Gout	Gout.yaml	pathophysiology	2	Inflammasome Activation	"MSU crystals are phagocytosed by macrophages, activating NLRP3 inflammasome and triggering IL-1beta release, driving acute inflammatory flare.
"	biological_processes[0]	biological_processes	biological_processes			Inflammasome Activation	GO:0072559	NLRP3 inflammasome complex assembly		"{""preferred_term"": ""Inflammasome Activation"", ""term"": {""id"": ""GO:0072559"", ""label"": ""NLRP3 inflammasome complex assembly""}}"																											
2964	3217	134	Gout	Gout.yaml	pathophysiology	3	Neutrophil Recruitment	"IL-1beta and other cytokines recruit neutrophils to the joint, amplifying inflammation and causing the intense pain and swelling of acute gout attacks.
"	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2965	3219	134	Gout	Gout.yaml	pathophysiology	5	Neutrophil Extracellular Trap Formation	"Neutrophils form extracellular traps (NETs) in response to MSU crystals. NETs initially amplify inflammation but aggregated NETs (aggNETs) promote resolution by encapsulating crystals, degrading cytokines, and blocking further neutrophil recruitment. NETs also contribute to tophi formation.
"	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2966	3220	134	Gout	Gout.yaml	phenotypes	0	Acute Arthritis		phenotype_term	phenotype_term	$	Acute Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
2967	3221	134	Gout	Gout.yaml	phenotypes	1	Joint Swelling		phenotype_term	phenotype_term	$	Joint Swelling		Joint Swelling	HP:0001386	Joint swelling		"{""preferred_term"": ""Joint Swelling"", ""term"": {""id"": ""HP:0001386"", ""label"": ""Joint swelling""}}"																											
2968	3222	134	Gout	Gout.yaml	phenotypes	2	Joint Pain		phenotype_term	phenotype_term	$	Joint Pain		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
2969	3223	134	Gout	Gout.yaml	phenotypes	3	Nephrolithiasis		phenotype_term	phenotype_term	$	Nephrolithiasis		Kidney Stones	HP:0000787	Nephrolithiasis		"{""preferred_term"": ""Kidney Stones"", ""term"": {""id"": ""HP:0000787"", ""label"": ""Nephrolithiasis""}}"																											
2970	3232	135	Grange syndrome	Grange_syndrome.yaml	pathophysiology	0	YY1AP1 Loss-of-Function and INO80 Chromatin Remodeling Complex Disruption	Biallelic loss-of-function mutations in YY1AP1 disrupt the INO80 ATP-dependent chromatin-remodeling complex, impairing transcriptional programs essential for vascular smooth muscle cell (VSMC) differentiation and homeostasis.	biological_processes[0]	biological_processes	biological_processes			chromatin remodeling	GO:0006338	chromatin remodeling		"{""preferred_term"": ""chromatin remodeling"", ""term"": {""id"": ""GO:0006338"", ""label"": ""chromatin remodeling""}}"																											
2971	3232	135	Grange syndrome	Grange_syndrome.yaml	pathophysiology	0	YY1AP1 Loss-of-Function and INO80 Chromatin Remodeling Complex Disruption	Biallelic loss-of-function mutations in YY1AP1 disrupt the INO80 ATP-dependent chromatin-remodeling complex, impairing transcriptional programs essential for vascular smooth muscle cell (VSMC) differentiation and homeostasis.	biological_processes[1]	biological_processes	biological_processes			transcriptional regulation	GO:0006355	regulation of transcription, DNA-templated		"{""preferred_term"": ""transcriptional regulation"", ""term"": {""id"": ""GO:0006355"", ""label"": ""regulation of transcription, DNA-templated""}}"																											
2972	3233	135	Grange syndrome	Grange_syndrome.yaml	pathophysiology	1	Vascular Smooth Muscle Cell Dysfunction and Arterial Stenosis	Loss of YY1AP1 in vascular smooth muscle cells leads to increased p21/CDKN1A levels, G1/G2 cell-cycle arrest, reduced VSMC proliferation, and impaired TGF--driven upregulation of contractile markers (SM -actin, SM22, calponin), resulting in focal stenoses and occlusions in multiple arterial beds. Progressive vascular disease can lead to ischemic and hemorrhagic stroke, myocardial infarction, and other thrombovascular complications.	biological_processes[0]	biological_processes	biological_processes			smooth muscle cell differentiation	GO:0051145	smooth muscle cell differentiation		"{""preferred_term"": ""smooth muscle cell differentiation"", ""term"": {""id"": ""GO:0051145"", ""label"": ""smooth muscle cell differentiation""}}"																											
2973	3233	135	Grange syndrome	Grange_syndrome.yaml	pathophysiology	1	Vascular Smooth Muscle Cell Dysfunction and Arterial Stenosis	Loss of YY1AP1 in vascular smooth muscle cells leads to increased p21/CDKN1A levels, G1/G2 cell-cycle arrest, reduced VSMC proliferation, and impaired TGF--driven upregulation of contractile markers (SM -actin, SM22, calponin), resulting in focal stenoses and occlusions in multiple arterial beds. Progressive vascular disease can lead to ischemic and hemorrhagic stroke, myocardial infarction, and other thrombovascular complications.	biological_processes[1]	biological_processes	biological_processes			cell cycle arrest	GO:0007050	cell cycle arrest		"{""preferred_term"": ""cell cycle arrest"", ""term"": {""id"": ""GO:0007050"", ""label"": ""cell cycle arrest""}}"																											
2974	3234	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	0	Intellectual disability	Moderate to severe intellectual disability with delayed developmental milestones. Variable severity ranging from learning disabilities to developmental delay, with some cases showing normal or above-average cognitive function.	phenotype_term	phenotype_term	$	Intellectual disability	Moderate to severe intellectual disability with delayed developmental milestones. Variable severity ranging from learning disabilities to developmental delay, with some cases showing normal or above-average cognitive function.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
2975	3235	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	1	Micrognathia	Underdevelopment of the mandible, a characteristic craniofacial feature.	phenotype_term	phenotype_term	$	Micrognathia	Underdevelopment of the mandible, a characteristic craniofacial feature.	Micrognathia	HP:0000347	Micrognathia		"{""preferred_term"": ""Micrognathia"", ""term"": {""id"": ""HP:0000347"", ""label"": ""Micrognathia""}}"																											
2976	3236	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	2	Hypertelorism	Increased distance between the inner canthi of the eyes, documented in some Grange syndrome cases but not uniformly present.	phenotype_term	phenotype_term	$	Hypertelorism	Increased distance between the inner canthi of the eyes, documented in some Grange syndrome cases but not uniformly present.	Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
2977	3237	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	3	Brachydactyly	Shortened fingers and toes due to reduced length of metacarpals and metatarsals.	phenotype_term	phenotype_term	$	Brachydactyly	Shortened fingers and toes due to reduced length of metacarpals and metatarsals.	Brachydactyly	HP:0001156	Brachydactyly		"{""preferred_term"": ""Brachydactyly"", ""term"": {""id"": ""HP:0001156"", ""label"": ""Brachydactyly""}}"																											
2978	3238	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	4	Syndactyly	Webbing or fusion between digits, often requiring surgical correction in childhood.	phenotype_term	phenotype_term	$	Syndactyly	Webbing or fusion between digits, often requiring surgical correction in childhood.	Syndactyly	HP:0001159	Syndactyly		"{""preferred_term"": ""Syndactyly"", ""term"": {""id"": ""HP:0001159"", ""label"": ""Syndactyly""}}"																											
2979	3239	135	Grange syndrome	Grange_syndrome.yaml	phenotypes	5	Hypertension	Elevated blood pressure resulting from vascular stenosis and renal artery involvement, often presenting in childhood and contributing to serious vascular complications including hemorrhagic stroke.	phenotype_term	phenotype_term	$	Hypertension	Elevated blood pressure resulting from vascular stenosis and renal artery involvement, often presenting in childhood and contributing to serious vascular complications including hemorrhagic stroke.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
2980	3241	135	Grange syndrome	Grange_syndrome.yaml	treatments	0	Antithrombotic Therapy	Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.	treatment_term	treatment_term	$	Antithrombotic Therapy	Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.	drug therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2981	3242	135	Grange syndrome	Grange_syndrome.yaml	treatments	1	Cardiovascular Management	Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.	treatment_term	treatment_term	$	Cardiovascular Management	Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.	drug therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2982	3243	135	Grange syndrome	Grange_syndrome.yaml	treatments	2	Neurosurgical Intervention	Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.	treatment_term	treatment_term	$	Neurosurgical Intervention	Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2983	3245	135	Grange syndrome	Grange_syndrome.yaml	treatments	4	Surgical Correction of Acral Features	Surgical repair of hand syndactyly to improve function and appearance.	treatment_term	treatment_term	$	Surgical Correction of Acral Features	Surgical repair of hand syndactyly to improve function and appearance.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2984	3252	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	pathophysiology	0	ANCA-Mediated Neutrophil Activation	Anti-proteinase 3 (PR3) antibodies bind to primed neutrophils, causing activation, degranulation, and release of reactive oxygen species and lytic enzymes. This causes direct endothelial damage and vessel wall necrosis.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
2985	3252	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	pathophysiology	0	ANCA-Mediated Neutrophil Activation	Anti-proteinase 3 (PR3) antibodies bind to primed neutrophils, causing activation, degranulation, and release of reactive oxygen species and lytic enzymes. This causes direct endothelial damage and vessel wall necrosis.	biological_processes[0]	biological_processes	biological_processes			Neutrophil Activation	GO:0042119	neutrophil activation		"{""preferred_term"": ""Neutrophil Activation"", ""term"": {""id"": ""GO:0042119"", ""label"": ""neutrophil activation""}}"																											
2986	3253	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	pathophysiology	1	Granuloma Formation	Granulomatous inflammation with multinucleated giant cells, epithelioid macrophages, and necrosis affects the respiratory tract. T cells and macrophages organize into granulomas that destroy tissue.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
2987	3253	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	pathophysiology	1	Granuloma Formation	Granulomatous inflammation with multinucleated giant cells, epithelioid macrophages, and necrosis affects the respiratory tract. T cells and macrophages organize into granulomas that destroy tissue.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
2988	3254	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	pathophysiology	2	Complement Alternative Pathway Activation	The alternative complement pathway amplifies inflammation in GPA. C5a recruits and activates neutrophils, creating a positive feedback loop of vascular damage.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
2989	3255	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	phenotypes	0	Sinusitis		phenotype_term	phenotype_term	$	Sinusitis		Sinusitis	HP:0000246	Sinusitis		"{""preferred_term"": ""Sinusitis"", ""term"": {""id"": ""HP:0000246"", ""label"": ""Sinusitis""}}"																											
2990	3256	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	phenotypes	1	Pulmonary Nodules		phenotype_term	phenotype_term	$	Pulmonary Nodules		Pulmonary Infiltrates	HP:0002113	Pulmonary infiltrates		"{""preferred_term"": ""Pulmonary Infiltrates"", ""term"": {""id"": ""HP:0002113"", ""label"": ""Pulmonary infiltrates""}}"																											
2991	3257	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	phenotypes	2	Glomerulonephritis		phenotype_term	phenotype_term	$	Glomerulonephritis		Nephritis	HP:0000123	Nephritis		"{""preferred_term"": ""Nephritis"", ""term"": {""id"": ""HP:0000123"", ""label"": ""Nephritis""}}"																											
2992	3258	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	phenotypes	3	Saddle Nose Deformity		phenotype_term	phenotype_term	$	Saddle Nose Deformity		Saddle Nose	HP:0000455	Broad nasal tip		"{""preferred_term"": ""Saddle Nose"", ""term"": {""id"": ""HP:0000455"", ""label"": ""Broad nasal tip""}}"																											
2993	3269	137	Graves' Disease	Graves_Disease.yaml	environmental	0	Stress		exposure_term	exposure_term	$	Stress		Psychological stress exposure				"{""preferred_term"": ""Psychological stress exposure""}"																											
2994	3270	137	Graves' Disease	Graves_Disease.yaml	environmental	1	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
2995	3277	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	0	Autoantibody Production	The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
2996	3277	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	0	Autoantibody Production	The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
2997	3277	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	0	Autoantibody Production	The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.	biological_processes[0]	biological_processes	biological_processes			cAMP-mediated signaling	GO:0019933	cAMP-mediated signaling		"{""preferred_term"": ""cAMP-mediated signaling"", ""term"": {""id"": ""GO:0019933"", ""label"": ""cAMP-mediated signaling""}}"																											
2998	3277	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	0	Autoantibody Production	The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
2999	3278	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	1	Thyroid Overactivity	Excessive stimulation of the thyroid gland results in increased production of thyroid hormones (thyroxine, T4, and triiodothyronine, T3).	biological_processes[0]	biological_processes	biological_processes			thyroid hormone biosynthetic process	GO:0006590	thyroid hormone generation		"{""preferred_term"": ""thyroid hormone biosynthetic process"", ""term"": {""id"": ""GO:0006590"", ""label"": ""thyroid hormone generation""}}"																											
3000	3278	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	1	Thyroid Overactivity	Excessive stimulation of the thyroid gland results in increased production of thyroid hormones (thyroxine, T4, and triiodothyronine, T3).	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
3001	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
3002	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
3003	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	cell_types[2]	cell_types	cell_types			T follicular helper cell	CL:0002038	T follicular helper cell		"{""preferred_term"": ""T follicular helper cell"", ""term"": {""id"": ""CL:0002038"", ""label"": ""T follicular helper cell""}}"																											
3004	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	cell_types[3]	cell_types	cell_types			CD4-positive, alpha-beta T cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
3005	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	cell_types[4]	cell_types	cell_types			regulatory T cell	CL:0000815	regulatory T cell		"{""preferred_term"": ""regulatory T cell"", ""term"": {""id"": ""CL:0000815"", ""label"": ""regulatory T cell""}}"																											
3006	3279	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	2	Immune System Dysregulation	Dysregulated immune response leads to autoimmune attacks on the thyroid gland.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"																											
3007	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	cell_types[0]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
3008	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[0]	biological_processes	biological_processes			cAMP-mediated signaling	GO:0019933	cAMP-mediated signaling		"{""preferred_term"": ""cAMP-mediated signaling"", ""term"": {""id"": ""GO:0019933"", ""label"": ""cAMP-mediated signaling""}}"																											
3009	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[1]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
3010	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[2]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"																											
3011	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[3]	biological_processes	biological_processes			adipocyte differentiation	GO:0045444	adipocyte differentiation		"{""preferred_term"": ""adipocyte differentiation"", ""term"": {""id"": ""GO:0045444"", ""label"": ""adipocyte differentiation""}}"																											
3012	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[4]	biological_processes	biological_processes			hyaluronan biosynthetic process	GO:0030213	hyaluronan biosynthetic process		"{""preferred_term"": ""hyaluronan biosynthetic process"", ""term"": {""id"": ""GO:0030213"", ""label"": ""hyaluronan biosynthetic process""}}"																											
3013	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	biological_processes[5]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
3014	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	locations[0]	locations	locations			orbit	UBERON:0001697	orbit		"{""preferred_term"": ""orbit"", ""term"": {""id"": ""UBERON:0001697"", ""label"": ""orbit""}}"																											
3015	3280	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	3	TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts	In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.	locations[1]	locations	locations			extraocular muscle	UBERON:0001576	extraocular muscle		"{""preferred_term"": ""extraocular muscle"", ""term"": {""id"": ""UBERON:0001576"", ""label"": ""extraocular muscle""}}"																											
3016	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
3017	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	cell_types[1]	cell_types	cell_types			T follicular helper cell	CL:0002038	T follicular helper cell		"{""preferred_term"": ""T follicular helper cell"", ""term"": {""id"": ""CL:0002038"", ""label"": ""T follicular helper cell""}}"																											
3018	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"																											
3019	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	biological_processes[1]	biological_processes	biological_processes			adaptive immune response	GO:0002250	adaptive immune response		"{""preferred_term"": ""adaptive immune response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
3020	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	biological_processes[2]	biological_processes	biological_processes			germinal center formation	GO:0002467	germinal center formation		"{""preferred_term"": ""germinal center formation"", ""term"": {""id"": ""GO:0002467"", ""label"": ""germinal center formation""}}"																											
3021	3281	137	Graves' Disease	Graves_Disease.yaml	pathophysiology	4	Germinal Center Autoantibody Production	CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
3022	3282	137	Graves' Disease	Graves_Disease.yaml	phenotypes	0	Hyperthyroidism		phenotype_term	phenotype_term	$	Hyperthyroidism		Hyperthyroidism	HP:0000836	Hyperthyroidism		"{""preferred_term"": ""Hyperthyroidism"", ""term"": {""id"": ""HP:0000836"", ""label"": ""Hyperthyroidism""}}"																											
3023	3284	137	Graves' Disease	Graves_Disease.yaml	phenotypes	2	Goiter		phenotype_term	phenotype_term	$	Goiter		Goiter	HP:0000853	Goiter		"{""preferred_term"": ""Goiter"", ""term"": {""id"": ""HP:0000853"", ""label"": ""Goiter""}}"																											
3024	3285	137	Graves' Disease	Graves_Disease.yaml	phenotypes	3	Tachycardia		phenotype_term	phenotype_term	$	Tachycardia		Tachycardia	HP:0001649	Tachycardia		"{""preferred_term"": ""Tachycardia"", ""term"": {""id"": ""HP:0001649"", ""label"": ""Tachycardia""}}"																											
3025	3286	137	Graves' Disease	Graves_Disease.yaml	phenotypes	4	Tremor		phenotype_term	phenotype_term	$	Tremor		Tremor	HP:0001337	Tremor		"{""preferred_term"": ""Tremor"", ""term"": {""id"": ""HP:0001337"", ""label"": ""Tremor""}}"																											
3026	3287	137	Graves' Disease	Graves_Disease.yaml	phenotypes	5	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
3027	3288	137	Graves' Disease	Graves_Disease.yaml	phenotypes	6	Irritability		phenotype_term	phenotype_term	$	Irritability		Irritability	HP:0000737	Irritability		"{""preferred_term"": ""Irritability"", ""term"": {""id"": ""HP:0000737"", ""label"": ""Irritability""}}"																											
3028	3289	137	Graves' Disease	Graves_Disease.yaml	phenotypes	7	Pretibial Myxedema		phenotype_term	phenotype_term	$	Pretibial Myxedema		Pretibial Myxedema	HP:0200028	Pretibial myxedema		"{""preferred_term"": ""Pretibial Myxedema"", ""term"": {""id"": ""HP:0200028"", ""label"": ""Pretibial myxedema""}}"																											
3029	3290	137	Graves' Disease	Graves_Disease.yaml	phenotypes	8	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight Loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight Loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3030	3291	137	Graves' Disease	Graves_Disease.yaml	phenotypes	9	Increased Appetite		phenotype_term	phenotype_term	$	Increased Appetite		Increased Appetite	HP:0002591	Polyphagia		"{""preferred_term"": ""Increased Appetite"", ""term"": {""id"": ""HP:0002591"", ""label"": ""Polyphagia""}}"																											
3031	3292	137	Graves' Disease	Graves_Disease.yaml	phenotypes	10	Heat Intolerance		phenotype_term	phenotype_term	$	Heat Intolerance		Heat Intolerance	HP:0002046	Heat intolerance		"{""preferred_term"": ""Heat Intolerance"", ""term"": {""id"": ""HP:0002046"", ""label"": ""Heat intolerance""}}"																											
3032	3293	137	Graves' Disease	Graves_Disease.yaml	phenotypes	11	Sweating		phenotype_term	phenotype_term	$	Sweating		Sweating	HP:0000975	Hyperhidrosis		"{""preferred_term"": ""Sweating"", ""term"": {""id"": ""HP:0000975"", ""label"": ""Hyperhidrosis""}}"																											
3033	3294	137	Graves' Disease	Graves_Disease.yaml	phenotypes	12	Diplopia		phenotype_term	phenotype_term	$	Diplopia		Diplopia	HP:0000651	Diplopia		"{""preferred_term"": ""Diplopia"", ""term"": {""id"": ""HP:0000651"", ""label"": ""Diplopia""}}"																											
3034	3297	137	Graves' Disease	Graves_Disease.yaml	phenotypes	15	Atrial fibrillation		phenotype_term	phenotype_term	$	Atrial fibrillation		Atrial fibrillation	HP:0005110	Atrial fibrillation		"{""preferred_term"": ""Atrial fibrillation"", ""term"": {""id"": ""HP:0005110"", ""label"": ""Atrial fibrillation""}}"																											
3035	3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	Antithyroid Medications	Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.	treatment_term	treatment_term	$	Antithyroid Medications	Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3036	3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	Radioactive Iodine Therapy	Radioactive iodine is taken orally to destroy overactive thyroid cells.	treatment_term	treatment_term	$	Radioactive Iodine Therapy	Radioactive iodine is taken orally to destroy overactive thyroid cells.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
3037	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	Thyroidectomy	Surgical removal of part or all of the thyroid gland.	treatment_term	treatment_term	$	Thyroidectomy	Surgical removal of part or all of the thyroid gland.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3038	3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	Beta Blockers	Used to manage cardiovascular symptoms like tachycardia and palpitations.	treatment_term	treatment_term	$	Beta Blockers	Used to manage cardiovascular symptoms like tachycardia and palpitations.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3039	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	Corticosteroids	Used to reduce inflammation in severe ophthalmopathy.	treatment_term	treatment_term	$	Corticosteroids	Used to reduce inflammation in severe ophthalmopathy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3040	3309	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	pathophysiology	0	Molecular Mimicry and Antiganglioside Antibodies	Antibodies against bacterial lipooligosaccharides (especially from Campylobacter jejuni) cross-react with gangliosides on peripheral nerves. Anti-GM1, anti-GD1a, and anti-GQ1b antibodies are associated with specific clinical subtypes.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
3041	3310	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	pathophysiology	1	Complement-Mediated Nerve Damage	Antibody binding activates complement cascade, leading to membrane attack complex deposition on Schwann cells and nodes of Ranvier. This causes demyelination in AIDP or axonal damage in AMAN/AMSAN variants.	cell_types[0]	cell_types	cell_types			Schwann Cell	CL:0002573	Schwann cell		"{""preferred_term"": ""Schwann Cell"", ""term"": {""id"": ""CL:0002573"", ""label"": ""Schwann cell""}}"																											
3042	3310	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	pathophysiology	1	Complement-Mediated Nerve Damage	Antibody binding activates complement cascade, leading to membrane attack complex deposition on Schwann cells and nodes of Ranvier. This causes demyelination in AIDP or axonal damage in AMAN/AMSAN variants.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
3043	3311	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	pathophysiology	2	Macrophage-Mediated Demyelination	In AIDP, macrophages infiltrate peripheral nerves and strip myelin from axons. T cells may also contribute to the inflammatory milieu and tissue damage.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
3044	3311	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	pathophysiology	2	Macrophage-Mediated Demyelination	In AIDP, macrophages infiltrate peripheral nerves and strip myelin from axons. T cells may also contribute to the inflammatory milieu and tissue damage.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3045	3312	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	phenotypes	0	Areflexia		phenotype_term	phenotype_term	$	Areflexia		Areflexia	HP:0001284	Areflexia		"{""preferred_term"": ""Areflexia"", ""term"": {""id"": ""HP:0001284"", ""label"": ""Areflexia""}}"																											
3046	3313	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	phenotypes	1	Limb Weakness		phenotype_term	phenotype_term	$	Limb Weakness		Limb Muscle Weakness	HP:0003690	Limb muscle weakness		"{""preferred_term"": ""Limb Muscle Weakness"", ""term"": {""id"": ""HP:0003690"", ""label"": ""Limb muscle weakness""}}"																											
3047	3314	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	phenotypes	2	Respiratory Failure		phenotype_term	phenotype_term	$	Respiratory Failure		Respiratory Insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory Insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
3048	3315	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	phenotypes	3	Paresthesia		phenotype_term	phenotype_term	$	Paresthesia		Paresthesia	HP:0003401	Paresthesia		"{""preferred_term"": ""Paresthesia"", ""term"": {""id"": ""HP:0003401"", ""label"": ""Paresthesia""}}"																											
3049	3330	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	histopathology	0	Infiltrative Midline Glioma	Diffuse midline glioma, H3 K27M-mutant is an infiltrative midline glioma.	finding_term	finding_term	$	Infiltrative Midline Glioma	Diffuse midline glioma, H3 K27M-mutant is an infiltrative midline glioma.	Diffuse Midline Glioma, H3 K27-Altered	NCIT:C185368	Diffuse Midline Glioma, H3 K27-Altered		"{""preferred_term"": ""Diffuse Midline Glioma, H3 K27-Altered"", ""term"": {""id"": ""NCIT:C185368"", ""label"": ""Diffuse Midline Glioma, H3 K27-Altered""}}"																											
3050	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3051	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	biological_processes[0]	biological_processes	biological_processes			histone H3-K27 methylation	GO:0098532	histone H3-K27 methylation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""histone H3-K27 methylation"", ""term"": {""id"": ""GO:0098532"", ""label"": ""histone H3-K27 methylation""}}"			DECREASED																								
3052	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	locations[0]	locations	locations			pons	UBERON:0000988	pons		"{""preferred_term"": ""pons"", ""term"": {""id"": ""UBERON:0000988"", ""label"": ""pons""}}"																											
3053	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	locations[1]	locations	locations			dorsal plus ventral thalamus	UBERON:0001897	dorsal plus ventral thalamus		"{""preferred_term"": ""dorsal plus ventral thalamus"", ""term"": {""id"": ""UBERON:0001897"", ""label"": ""dorsal plus ventral thalamus""}}"																											
3054	3331	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	0	H3 K27M Oncohistone Mutation	Lysine-to-methionine substitution at position 27 of histone H3 (K27M) occurs in H3F3A (encoding H3.3) or HIST1H3B/HIST1H3C (encoding H3.1). Despite being present in only 5-15% of total H3 molecules, the mutant histone acts as a dominant negative, sequestering and inhibiting the PRC2 complex.	locations[2]	locations	locations			spinal cord	UBERON:0002240	spinal cord		"{""preferred_term"": ""spinal cord"", ""term"": {""id"": ""UBERON:0002240"", ""label"": ""spinal cord""}}"																											
3055	3332	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	1	PRC2 Complex Inhibition and H3K27me3 Loss	The H3 K27M mutant histone binds to and inhibits EZH2, the catalytic subunit of PRC2, which normally trimethylates H3K27. This results in global loss of H3K27me3, a repressive epigenetic mark, leading to aberrant gene activation and loss of cell identity.	biological_processes[0]	biological_processes	biological_processes			negative regulation of gene expression, epigenetic	GO:0045814	negative regulation of gene expression, epigenetic		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of gene expression, epigenetic"", ""term"": {""id"": ""GO:0045814"", ""label"": ""negative regulation of gene expression, epigenetic""}}"			DECREASED																								
3056	3333	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	2	Epigenetic Derepression and Aberrant Gene Activation	Global loss of H3K27me3 causes derepression of genes normally silenced during development, including proliferative and stemness genes. Paradoxically, some loci show retained or increased H3K27me3, suggesting complex redistribution rather than simple loss.	biological_processes[0]	biological_processes	biological_processes			gene expression	GO:0010467	gene expression		"{""modifier"": ""INCREASED"", ""preferred_term"": ""gene expression"", ""term"": {""id"": ""GO:0010467"", ""label"": ""gene expression""}}"			INCREASED																								
3057	3333	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	2	Epigenetic Derepression and Aberrant Gene Activation	Global loss of H3K27me3 causes derepression of genes normally silenced during development, including proliferative and stemness genes. Paradoxically, some loci show retained or increased H3K27me3, suggesting complex redistribution rather than simple loss.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3058	3334	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	3	Loss of Glial Differentiation	Epigenetic dysregulation prevents normal glial differentiation, maintaining cells in a proliferative, undifferentiated state. This contributes to the aggressive behavior and treatment resistance of these tumors.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3059	3334	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	pathophysiology	3	Loss of Glial Differentiation	Epigenetic dysregulation prevents normal glial differentiation, maintaining cells in a proliferative, undifferentiated state. This contributes to the aggressive behavior and treatment resistance of these tumors.	biological_processes[0]	biological_processes	biological_processes			glial cell differentiation	GO:0010001	glial cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""glial cell differentiation"", ""term"": {""id"": ""GO:0010001"", ""label"": ""glial cell differentiation""}}"			DECREASED																								
3060	3335	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	phenotypes	0	Cranial Nerve Palsy	Cranial nerve deficits are common in DIPG, particularly affecting CN VI (lateral gaze palsy) and CN VII (facial weakness). Part of the classic DIPG triad.	phenotype_term	phenotype_term	$	Cranial Nerve Palsy	Cranial nerve deficits are common in DIPG, particularly affecting CN VI (lateral gaze palsy) and CN VII (facial weakness). Part of the classic DIPG triad.	Cranial nerve paralysis	HP:0006824	Cranial nerve paralysis		"{""preferred_term"": ""Cranial nerve paralysis"", ""term"": {""id"": ""HP:0006824"", ""label"": ""Cranial nerve paralysis""}}"																											
3061	3336	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	phenotypes	1	Ataxia	Cerebellar ataxia from involvement of cerebellar pathways traversing the pons. Part of the classic DIPG triad.	phenotype_term	phenotype_term	$	Ataxia	Cerebellar ataxia from involvement of cerebellar pathways traversing the pons. Part of the classic DIPG triad.	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
3062	3337	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	phenotypes	2	Long Tract Signs	Pyramidal signs including spasticity, hyperreflexia, and weakness from corticospinal tract involvement. Part of the classic DIPG triad.	phenotype_term	phenotype_term	$	Long Tract Signs	Pyramidal signs including spasticity, hyperreflexia, and weakness from corticospinal tract involvement. Part of the classic DIPG triad.	Hemiparesis	HP:0001269	Hemiparesis		"{""preferred_term"": ""Hemiparesis"", ""term"": {""id"": ""HP:0001269"", ""label"": ""Hemiparesis""}}"																											
3063	3338	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	phenotypes	3	Headache	Headache from increased intracranial pressure or direct tumor effects. May be accompanied by vomiting.	phenotype_term	phenotype_term	$	Headache	Headache from increased intracranial pressure or direct tumor effects. May be accompanied by vomiting.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
3064	3339	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	phenotypes	4	Diplopia	Double vision from cranial nerve involvement, particularly CN VI causing lateral rectus weakness and inability to abduct the eye.	phenotype_term	phenotype_term	$	Diplopia	Double vision from cranial nerve involvement, particularly CN VI causing lateral rectus weakness and inability to abduct the eye.	Diplopia	HP:0000651	Diplopia		"{""preferred_term"": ""Diplopia"", ""term"": {""id"": ""HP:0000651"", ""label"": ""Diplopia""}}"																											
3065	3340	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	0	Radiation Therapy	Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone.	treatment_term	treatment_term	$	Radiation Therapy	Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3066	3341	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	1	Corticosteroids	Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression.	treatment_term	treatment_term	$	Corticosteroids	Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3067	3342	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	2	ONC201 (DRD2 Antagonist)	Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation.	treatment_term	treatment_term	$	ONC201 (DRD2 Antagonist)	Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3068	3346	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	histopathology	0	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	finding_term	finding_term	$	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	Invasive Breast Carcinoma of No Special Type	NCIT:C4194	Invasive Breast Carcinoma of No Special Type		"{""preferred_term"": ""Invasive Breast Carcinoma of No Special Type"", ""term"": {""id"": ""NCIT:C4194"", ""label"": ""Invasive Breast Carcinoma of No Special Type""}}"																											
3069	3347	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	0	ERBB2 Gene Amplification	HER2-positive breast cancer is driven by amplification of the ERBB2 gene on chromosome 17q12, resulting in overexpression of the HER2 receptor tyrosine kinase. Gene amplification typically results in 25-50 copies per cell, leading to massive receptor overexpression on the cell surface.	cell_types[0]	cell_types	cell_types			luminal epithelial cell of mammary gland	CL:0002326	luminal epithelial cell of mammary gland		"{""preferred_term"": ""luminal epithelial cell of mammary gland"", ""term"": {""id"": ""CL:0002326"", ""label"": ""luminal epithelial cell of mammary gland""}}"																											
3070	3347	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	0	ERBB2 Gene Amplification	HER2-positive breast cancer is driven by amplification of the ERBB2 gene on chromosome 17q12, resulting in overexpression of the HER2 receptor tyrosine kinase. Gene amplification typically results in 25-50 copies per cell, leading to massive receptor overexpression on the cell surface.	biological_processes[0]	biological_processes	biological_processes			ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""ERBB2 signaling pathway"", ""term"": {""id"": ""GO:0038128"", ""label"": ""ERBB2 signaling pathway""}}"			INCREASED																								
3071	3348	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	1	Constitutive Receptor Activation	Massive HER2 overexpression promotes spontaneous receptor homodimerization and heterodimerization with other ERBB family members (EGFR, HER3, HER4) without ligand binding. This constitutive activation drives downstream signaling cascades promoting proliferation, survival, and invasion.	biological_processes[0]	biological_processes	biological_processes			transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""transmembrane receptor protein tyrosine kinase signaling pathway"", ""term"": {""id"": ""GO:0007169"", ""label"": ""transmembrane receptor protein tyrosine kinase signaling pathway""}}"			INCREASED																								
3072	3349	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	2	Downstream Oncogenic Signaling	Activated HER2 signals through PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, promoting cell proliferation, survival, and resistance to apoptosis. HER2-HER3 heterodimers are particularly potent activators of the PI3K pathway.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
3073	3349	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	2	Downstream Oncogenic Signaling	Activated HER2 signals through PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, promoting cell proliferation, survival, and resistance to apoptosis. HER2-HER3 heterodimers are particularly potent activators of the PI3K pathway.	biological_processes[1]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
3074	3350	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	pathophysiology	3	Uncontrolled Proliferation	Constitutive HER2 signaling drives continuous cell cycle progression and resistance to apoptotic signals. HER2+ tumors are typically high grade with high proliferation indices (high Ki-67).	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3075	3351	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	phenotypes	0	Breast Carcinoma	HER2-positive breast cancers are typically invasive ductal carcinomas of high histologic grade. They often present as palpable masses or are detected on screening mammography.	phenotype_term	phenotype_term	$	Breast Carcinoma	HER2-positive breast cancers are typically invasive ductal carcinomas of high histologic grade. They often present as palpable masses or are detected on screening mammography.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
3076	3352	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	phenotypes	1	High Grade Tumor	HER2+ breast cancers are predominantly high grade (grade 2-3) with high mitotic rates and nuclear pleomorphism.	phenotype_term	phenotype_term	$	High Grade Tumor	HER2+ breast cancers are predominantly high grade (grade 2-3) with high mitotic rates and nuclear pleomorphism.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
3077	3353	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	phenotypes	2	HER2 Overexpression	Defining feature is HER2 protein overexpression (IHC 3+) or gene amplification (FISH HER2/CEP17 ratio 2.0 or HER2 copy number 6). IHC 2+ requires reflex FISH testing for confirmation.	phenotype_term	phenotype_term	$	HER2 Overexpression	Defining feature is HER2 protein overexpression (IHC 3+) or gene amplification (FISH HER2/CEP17 ratio 2.0 or HER2 copy number 6). IHC 2+ requires reflex FISH testing for confirmation.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
3078	3354	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	0	Trastuzumab	Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes.	treatment_term	treatment_term	$	Trastuzumab	Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3079	3355	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	1	Pertuzumab	Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings.	treatment_term	treatment_term	$	Pertuzumab	Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3080	3356	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3081	3357	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	3	Tucatinib	Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer.	treatment_term	treatment_term	$	Tucatinib	Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3082	3358	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	4	Neratinib	Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine.	treatment_term	treatment_term	$	Neratinib	Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3083	3365	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	histopathology	0	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	finding_term	finding_term	$	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	Adenocarcinoma	NCIT:C2852	Adenocarcinoma		"{""preferred_term"": ""Adenocarcinoma"", ""term"": {""id"": ""NCIT:C2852"", ""label"": ""Adenocarcinoma""}}"																											
3084	3366	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase on the cell surface. Amplified HER2 forms homodimers and heterodimers with other ERBB family members (particularly HER3), leading to ligand-independent receptor activation and downstream signaling.	cell_types[0]	cell_types	cell_types			colon epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colon epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
3085	3366	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase on the cell surface. Amplified HER2 forms homodimers and heterodimers with other ERBB family members (particularly HER3), leading to ligand-independent receptor activation and downstream signaling.	biological_processes[0]	biological_processes	biological_processes			ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""ERBB2 signaling pathway"", ""term"": {""id"": ""GO:0038128"", ""label"": ""ERBB2 signaling pathway""}}"			INCREASED																								
3086	3367	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	1	MAPK Pathway Activation	HER2 receptor activation leads to recruitment of adaptor proteins (GRB2/SOS) that activate RAS, initiating the MAPK signaling cascade. This drives cell proliferation and survival. The MAPK pathway is a major effector of HER2 oncogenic signaling in colorectal cancer.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
3087	3368	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	HER2 heterodimerization with HER3 is particularly potent at activating PI3K signaling because HER3 contains multiple PI3K binding sites. This leads to AKT activation, promoting cell survival and resistance to apoptosis. PI3K pathway activation may contribute to resistance to HER2-targeted therapy.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
3088	3369	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	3	Enhanced Cell Proliferation	Combined MAPK and PI3K pathway activation drives enhanced cell proliferation through cyclin D1 induction and cell cycle progression. This leads to uncontrolled tumor growth dependent on HER2 signaling.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
3089	3369	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	pathophysiology	3	Enhanced Cell Proliferation	Combined MAPK and PI3K pathway activation drives enhanced cell proliferation through cyclin D1 induction and cell cycle progression. This leads to uncontrolled tumor growth dependent on HER2 signaling.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3090	3370	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	phenotypes	0	Colon Cancer	HER2-positive colorectal cancer presents as a primary colonic or rectal malignancy. Left-sided (distal) tumors may be enriched in HER2-amplified cases.	phenotype_term	phenotype_term	$	Colon Cancer	HER2-positive colorectal cancer presents as a primary colonic or rectal malignancy. Left-sided (distal) tumors may be enriched in HER2-amplified cases.	Colon cancer	HP:0003003	Colon cancer		"{""preferred_term"": ""Colon cancer"", ""term"": {""id"": ""HP:0003003"", ""label"": ""Colon cancer""}}"																											
3091	3371	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	phenotypes	1	Abdominal Pain	Abdominal discomfort from tumor mass effect or bowel obstruction.	phenotype_term	phenotype_term	$	Abdominal Pain	Abdominal discomfort from tumor mass effect or bowel obstruction.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3092	3372	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	phenotypes	2	Hematochezia	Rectal bleeding from tumor ulceration, particularly with left-sided tumors.	phenotype_term	phenotype_term	$	Hematochezia	Rectal bleeding from tumor ulceration, particularly with left-sided tumors.	Hematochezia	HP:0002573	Hematochezia		"{""preferred_term"": ""Hematochezia"", ""term"": {""id"": ""HP:0002573"", ""label"": ""Hematochezia""}}"																											
3093	3373	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	phenotypes	3	Anemia	Iron deficiency anemia from chronic blood loss.	phenotype_term	phenotype_term	$	Anemia	Iron deficiency anemia from chronic blood loss.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
3094	3374	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	phenotypes	4	Weight Loss	Unintentional weight loss with advanced disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss with advanced disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3095	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term	treatment_term	$	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3096	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3097	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term	treatment_term	$	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3098	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3099	3377	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3100	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term	treatment_term	$	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3101	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3102	3379	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	4	Surgical Resection	Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions.	treatment_term	treatment_term	$	Surgical Resection	Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3103	3385	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	histopathology	0	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	finding_term	finding_term	$	Gastric Adenocarcinoma	Adenocarcinoma is the most common histologic type of gastric cancer.	Gastric Adenocarcinoma	NCIT:C4004	Gastric Adenocarcinoma		"{""preferred_term"": ""Gastric Adenocarcinoma"", ""term"": {""id"": ""NCIT:C4004"", ""label"": ""Gastric Adenocarcinoma""}}"																											
3104	3386	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase. High-level HER2 expression promotes constitutive receptor dimerization (particularly HER2 homodimers and HER2/HER3 heterodimers), leading to ligand-independent signaling. HER2 amplification is a driver event in gastric carcinogenesis.	cell_types[0]	cell_types	cell_types			epithelial cell of stomach	CL:0002178	epithelial cell of stomach		"{""preferred_term"": ""epithelial cell of stomach"", ""term"": {""id"": ""CL:0002178"", ""label"": ""epithelial cell of stomach""}}"																											
3105	3386	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase. High-level HER2 expression promotes constitutive receptor dimerization (particularly HER2 homodimers and HER2/HER3 heterodimers), leading to ligand-independent signaling. HER2 amplification is a driver event in gastric carcinogenesis.	biological_processes[0]	biological_processes	biological_processes			ERBB2 signaling pathway	GO:0038128	ERBB2 signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""ERBB2 signaling pathway"", ""term"": {""id"": ""GO:0038128"", ""label"": ""ERBB2 signaling pathway""}}"			INCREASED																								
3106	3386	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	0	ERBB2 (HER2) Amplification and Overexpression	ERBB2 gene amplification leads to overexpression of the HER2 receptor tyrosine kinase. High-level HER2 expression promotes constitutive receptor dimerization (particularly HER2 homodimers and HER2/HER3 heterodimers), leading to ligand-independent signaling. HER2 amplification is a driver event in gastric carcinogenesis.	locations[0]	locations	locations			stomach	UBERON:0000945	stomach		"{""preferred_term"": ""stomach"", ""term"": {""id"": ""UBERON:0000945"", ""label"": ""stomach""}}"																											
3107	3387	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	1	MAPK Pathway Activation	HER2 receptor activation recruits GRB2/SOS adaptor proteins, activating RAS and the downstream MAPK cascade. This drives transcription of genes promoting cell proliferation, including cyclin D1 and MYC.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
3108	3388	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	HER2/HER3 heterodimerization is particularly effective at activating PI3K because HER3 contains six PI3K binding motifs. PI3K activation leads to AKT phosphorylation, promoting cell survival, protein synthesis through mTOR, and resistance to apoptosis. PI3K pathway alterations may confer resistance to HER2-targeted therapy.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
3109	3389	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	pathophysiology	3	Enhanced Proliferation and Tumor Growth	Combined MAPK and PI3K/AKT pathway activation drives uncontrolled cell proliferation and tumor growth. HER2-positive tumors are dependent on HER2 signaling, making them vulnerable to HER2-targeted therapies.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3110	3390	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	0	Abdominal Pain	Epigastric pain or discomfort is a common presenting symptom, often initially attributed to dyspepsia or peptic ulcer disease.	phenotype_term	phenotype_term	$	Abdominal Pain	Epigastric pain or discomfort is a common presenting symptom, often initially attributed to dyspepsia or peptic ulcer disease.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3111	3391	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	1	Dysphagia	Difficulty swallowing occurs particularly with gastroesophageal junction tumors or proximal gastric cancers. Progressive dysphagia to solids is a concerning symptom.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing occurs particularly with gastroesophageal junction tumors or proximal gastric cancers. Progressive dysphagia to solids is a concerning symptom.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
3112	3392	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	2	Nausea	Nausea and early satiety may result from tumor mass effect or gastric outlet obstruction.	phenotype_term	phenotype_term	$	Nausea	Nausea and early satiety may result from tumor mass effect or gastric outlet obstruction.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
3113	3393	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	3	Gastrointestinal Hemorrhage	Bleeding from tumor ulceration may present as hematemesis, melena, or chronic occult blood loss leading to iron deficiency anemia.	phenotype_term	phenotype_term	$	Gastrointestinal Hemorrhage	Bleeding from tumor ulceration may present as hematemesis, melena, or chronic occult blood loss leading to iron deficiency anemia.	Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
3114	3394	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	4	Weight Loss	Unintentional weight loss is common due to decreased oral intake, dysphagia, nausea, and cancer-related cachexia.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is common due to decreased oral intake, dysphagia, nausea, and cancer-related cachexia.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3115	3395	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	5	Anemia	Iron deficiency anemia from chronic gastrointestinal blood loss is common at presentation.	phenotype_term	phenotype_term	$	Anemia	Iron deficiency anemia from chronic gastrointestinal blood loss is common at presentation.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
3116	3396	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	phenotypes	6	Fatigue	Fatigue related to anemia, nutritional deficiency, and advanced disease burden.	phenotype_term	phenotype_term	$	Fatigue	Fatigue related to anemia, nutritional deficiency, and advanced disease burden.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3117	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term	treatment_term	$	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3118	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3119	3398	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	1	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3120	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term	treatment_term	$	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3121	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3122	3400	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	3	Ramucirumab plus Paclitaxel	Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease.	treatment_term	treatment_term	$	Ramucirumab plus Paclitaxel	Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3123	3401	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	4	Surgical Resection	Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3124	3403	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	0	P4HTM Gene Loss-of-Function	Biallelic loss-of-function variants in P4HTM result in loss of ER-resident transmembrane prolyl 4-hydroxylase activity. The enzyme contains an EF-hand domain that allows calcium-dependent regulation of its catalytic activity, linking the genetic defect to both HIF signaling and calcium homeostasis pathways.	genes[0]	genes	genes			P4HTM				"{""preferred_term"": ""P4HTM""}"																											
3125	3404	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	1	Dysregulated Astrocyte Calcium Signaling	P4H-TM is a regulator of calcium dynamics and gliotransmission in astrocytes via a HIF-1-dependent mechanism. Loss of P4H-TM impairs receptor-operated and store-operated calcium entry (ROCE/SOCE), reduces mitochondrial calcium uptake and ATP production, and attenuates gliotransmission.	cell_types[0]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3126	3404	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	1	Dysregulated Astrocyte Calcium Signaling	P4H-TM is a regulator of calcium dynamics and gliotransmission in astrocytes via a HIF-1-dependent mechanism. Loss of P4H-TM impairs receptor-operated and store-operated calcium entry (ROCE/SOCE), reduces mitochondrial calcium uptake and ATP production, and attenuates gliotransmission.	biological_processes[0]	biological_processes	biological_processes			Calcium ion transmembrane transport	GO:0070588	calcium ion transmembrane transport		"{""preferred_term"": ""Calcium ion transmembrane transport"", ""term"": {""id"": ""GO:0070588"", ""label"": ""calcium ion transmembrane transport""}}"																											
3127	3404	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	1	Dysregulated Astrocyte Calcium Signaling	P4H-TM is a regulator of calcium dynamics and gliotransmission in astrocytes via a HIF-1-dependent mechanism. Loss of P4H-TM impairs receptor-operated and store-operated calcium entry (ROCE/SOCE), reduces mitochondrial calcium uptake and ATP production, and attenuates gliotransmission.	biological_processes[1]	biological_processes	biological_processes			Gliotransmitter secretion	GO:0099177	gliotransmitter secretion		"{""preferred_term"": ""Gliotransmitter secretion"", ""term"": {""id"": ""GO:0099177"", ""label"": ""gliotransmitter secretion""}}"																											
3128	3405	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	2	Central Respiratory Control Dysfunction	Loss of P4H-TM leads to impaired central respiratory control, with hypoventilation and blunted responses to hypoxia. Patients may require BiPAP support and are at risk for respiratory distress during infections.	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
3129	3405	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	2	Central Respiratory Control Dysfunction	Loss of P4H-TM leads to impaired central respiratory control, with hypoventilation and blunted responses to hypoxia. Patients may require BiPAP support and are at risk for respiratory distress during infections.	biological_processes[0]	biological_processes	biological_processes			Regulation of respiratory system process	GO:0044065	regulation of respiratory system process		"{""preferred_term"": ""Regulation of respiratory system process"", ""term"": {""id"": ""GO:0044065"", ""label"": ""regulation of respiratory system process""}}"																											
3130	3405	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	2	Central Respiratory Control Dysfunction	Loss of P4H-TM leads to impaired central respiratory control, with hypoventilation and blunted responses to hypoxia. Patients may require BiPAP support and are at risk for respiratory distress during infections.	biological_processes[1]	biological_processes	biological_processes			Response to hypoxia	GO:0001666	response to hypoxia		"{""preferred_term"": ""Response to hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"																											
3131	3406	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	pathophysiology	3	Mitochondrial Dysfunction	A subset of HIDEA patients show mitochondrial respiratory chain complex deficiency in muscle biopsies, suggesting that P4H-TM loss can affect mitochondrial function.	biological_processes[0]	biological_processes	biological_processes			Oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""Oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
3132	3407	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	0	Generalized Hypotonia	Decreased muscle tone present from infancy, contributing to motor delays.	phenotype_term	phenotype_term	$	Generalized Hypotonia	Decreased muscle tone present from infancy, contributing to motor delays.	Generalized hypotonia	HP:0001290	Generalized hypotonia		"{""preferred_term"": ""Generalized hypotonia"", ""term"": {""id"": ""HP:0001290"", ""label"": ""Generalized hypotonia""}}"																											
3133	3408	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	1	Central Hypoventilation	Reduced ventilation due to impaired central respiratory control, with blunted responses to hypoxia and hypercapnia. May require BiPAP support.	phenotype_term	phenotype_term	$	Central Hypoventilation	Reduced ventilation due to impaired central respiratory control, with blunted responses to hypoxia and hypercapnia. May require BiPAP support.	Central hypoventilation	HP:0007110	Central hypoventilation		"{""preferred_term"": ""Central hypoventilation"", ""term"": {""id"": ""HP:0007110"", ""label"": ""Central hypoventilation""}}"																											
3134	3409	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	2	Global Developmental Delay	Significant delays in motor, speech, and cognitive development beginning in infancy.	phenotype_term	phenotype_term	$	Global Developmental Delay	Significant delays in motor, speech, and cognitive development beginning in infancy.	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
3135	3410	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	3	Intellectual Disability	Cognitive impairment ranging from severe to profound, often with absent or severely limited speech.	phenotype_term	phenotype_term	$	Intellectual Disability	Cognitive impairment ranging from severe to profound, often with absent or severely limited speech.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
3136	3411	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	4	Epilepsy	Seizures in most patients, often beginning in infancy, with EEG showing multifocal spikes. Multiple seizure types may occur but are often relatively well-controlled with anticonvulsants.	phenotype_term	phenotype_term	$	Epilepsy	Seizures in most patients, often beginning in infancy, with EEG showing multifocal spikes. Multiple seizure types may occur but are often relatively well-controlled with anticonvulsants.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
3137	3412	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	5	Dysautonomia	Autonomic dysfunction including temperature dysregulation and constipation. Some patients show ROHHAD-like features including rapid weight gain.	phenotype_term	phenotype_term	$	Dysautonomia	Autonomic dysfunction including temperature dysregulation and constipation. Some patients show ROHHAD-like features including rapid weight gain.	Abnormality of the autonomic nervous system	HP:0002270	Abnormality of the autonomic nervous system		"{""preferred_term"": ""Abnormality of the autonomic nervous system"", ""term"": {""id"": ""HP:0002270"", ""label"": ""Abnormality of the autonomic nervous system""}}"																											
3138	3413	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	6	Abnormal Eye Movements	Eye movement abnormalities including rotary nystagmus, exotropia, and strabismus.	phenotype_term	phenotype_term	$	Abnormal Eye Movements	Eye movement abnormalities including rotary nystagmus, exotropia, and strabismus.	Strabismus	HP:0000486	Strabismus		"{""preferred_term"": ""Strabismus"", ""term"": {""id"": ""HP:0000486"", ""label"": ""Strabismus""}}"																											
3139	3414	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	7	Visual Impairment	Visual problems including myopia, hyperopia, astigmatism, optic atrophy, cortical blindness, or achromic fundi.	phenotype_term	phenotype_term	$	Visual Impairment	Visual problems including myopia, hyperopia, astigmatism, optic atrophy, cortical blindness, or achromic fundi.	Visual impairment	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual impairment"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
3140	3415	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	8	Gait Disturbance	Delayed walking or inability to walk, with unsteady wide-based gait in those who achieve ambulation.	phenotype_term	phenotype_term	$	Gait Disturbance	Delayed walking or inability to walk, with unsteady wide-based gait in those who achieve ambulation.	Gait disturbance	HP:0001288	Gait disturbance		"{""preferred_term"": ""Gait disturbance"", ""term"": {""id"": ""HP:0001288"", ""label"": ""Gait disturbance""}}"																											
3141	3416	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	9	Recurrent Respiratory Infections	Recurrent pneumonia and respiratory distress, likely related to hypoventilation and aspiration risk.	phenotype_term	phenotype_term	$	Recurrent Respiratory Infections	Recurrent pneumonia and respiratory distress, likely related to hypoventilation and aspiration risk.	Recurrent respiratory infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent respiratory infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
3142	3417	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	10	Scoliosis	Spinal curvature abnormality developing in some patients.	phenotype_term	phenotype_term	$	Scoliosis	Spinal curvature abnormality developing in some patients.	Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
3143	3418	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	11	Obesity	Tendency toward obesity, sometimes with rapid weight gain similar to ROHHAD syndrome.	phenotype_term	phenotype_term	$	Obesity	Tendency toward obesity, sometimes with rapid weight gain similar to ROHHAD syndrome.	Obesity	HP:0001513	Obesity		"{""preferred_term"": ""Obesity"", ""term"": {""id"": ""HP:0001513"", ""label"": ""Obesity""}}"																											
3144	3419	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	phenotypes	12	Coarse Facial Features	Some patients develop coarse facial features.	phenotype_term	phenotype_term	$	Coarse Facial Features	Some patients develop coarse facial features.	Coarse facial features	HP:0000280	Coarse facial features		"{""preferred_term"": ""Coarse facial features"", ""term"": {""id"": ""HP:0000280"", ""label"": ""Coarse facial features""}}"																											
3145	3422	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	0	Respiratory Support	Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections.	treatment_term	treatment_term	$	Respiratory Support	Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections.	Respiratory support	MAXO:0000950	supportive care		"{""preferred_term"": ""Respiratory support"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3146	3423	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	1	Anticonvulsant Therapy	Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties.	treatment_term	treatment_term	$	Anticonvulsant Therapy	Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties.	Anticonvulsant therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Anticonvulsant therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3147	3424	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	2	Physical Therapy	Rehabilitation to address hypotonia, motor delays, and gait abnormalities.	treatment_term	treatment_term	$	Physical Therapy	Rehabilitation to address hypotonia, motor delays, and gait abnormalities.	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3148	3425	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	3	Ophthalmologic Management	Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus.	treatment_term	treatment_term	$	Ophthalmologic Management	Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus.	Ophthalmologic management	MAXO:0000950	supportive care		"{""preferred_term"": ""Ophthalmologic management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3149	3428	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	environmental	0	Tobacco Smoking	Cigarette smoking is the dominant risk factor for HPV-negative HNSCC, with a dose-response relationship. Tobacco smoke contains numerous carcinogens including polycyclic aromatic hydrocarbons and nitrosamines that cause DNA adducts and mutations, particularly in TP53.	exposure_term	exposure_term	$	Tobacco Smoking	Cigarette smoking is the dominant risk factor for HPV-negative HNSCC, with a dose-response relationship. Tobacco smoke contains numerous carcinogens including polycyclic aromatic hydrocarbons and nitrosamines that cause DNA adducts and mutations, particularly in TP53.	exposure to tobacco smoking	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""exposure to tobacco smoking"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
3150	3429	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	environmental	1	Alcohol Consumption	Chronic alcohol consumption synergizes with tobacco to increase HNSCC risk multiplicatively. Alcohol acts as a solvent enhancing carcinogen penetration and is metabolized to acetaldehyde, a DNA-damaging agent. Ethanol is classified as a Group 1 carcinogen by IARC.	exposure_term	exposure_term	$	Alcohol Consumption	Chronic alcohol consumption synergizes with tobacco to increase HNSCC risk multiplicatively. Alcohol acts as a solvent enhancing carcinogen penetration and is metabolized to acetaldehyde, a DNA-damaging agent. Ethanol is classified as a Group 1 carcinogen by IARC.	exposure to ethanol	ECTO:9000027	exposure to ethanol		"{""preferred_term"": ""exposure to ethanol"", ""term"": {""id"": ""ECTO:9000027"", ""label"": ""exposure to ethanol""}}"																											
3151	3438	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	histopathology	0	Squamous Cell Carcinoma	Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.	finding_term	finding_term	$	Squamous Cell Carcinoma	Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.	Squamous Cell Carcinoma	NCIT:C2929	Squamous Cell Carcinoma		"{""preferred_term"": ""Squamous Cell Carcinoma"", ""term"": {""id"": ""NCIT:C2929"", ""label"": ""Squamous Cell Carcinoma""}}"																											
3152	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	cell_types[0]	cell_types	cell_types			squamous epithelial cell	CL:0000076	squamous epithelial cell		"{""preferred_term"": ""squamous epithelial cell"", ""term"": {""id"": ""CL:0000076"", ""label"": ""squamous epithelial cell""}}"																											
3153	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
3154	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3155	3439	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	0	TP53 Mutation and Inactivation	TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing the most common genetic alteration. Mutations are typically missense mutations in the DNA-binding domain caused by tobacco carcinogen-induced DNA adducts. Loss of p53 function eliminates cell cycle checkpoints and DNA damage repair.	genes[0]	genes	genes			TP53				"{""preferred_term"": ""TP53""}"																											
3156	3440	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	1	CDKN2A/p16 Inactivation	CDKN2A is inactivated by deletion, mutation, or promoter hypermethylation in approximately 60-70% of HPV-negative HNSCC. Loss of p16INK4a removes inhibition of CDK4/6, promoting cell cycle progression through the restriction point.	genes[0]	genes	genes			CDKN2A				"{""preferred_term"": ""CDKN2A""}"																											
3157	3440	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	1	CDKN2A/p16 Inactivation	CDKN2A is inactivated by deletion, mutation, or promoter hypermethylation in approximately 60-70% of HPV-negative HNSCC. Loss of p16INK4a removes inhibition of CDK4/6, promoting cell cycle progression through the restriction point.	biological_processes[0]	biological_processes	biological_processes			negative regulation of G1/S transition	GO:0045786	negative regulation of G1/S transition of mitotic cell cycle		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of G1/S transition"", ""term"": {""id"": ""GO:0045786"", ""label"": ""negative regulation of G1/S transition of mitotic cell cycle""}}"			DECREASED																								
3158	3441	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	2	EGFR Overexpression and Signaling	EGFR is overexpressed in 80-90% of HNSCC and amplified in a subset. EGFR signaling activates RAS-MAPK and PI3K-AKT pathways, promoting proliferation, survival, and invasion. EGFR is a validated therapeutic target in HNSCC.	biological_processes[0]	biological_processes	biological_processes			epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""epidermal growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0007173"", ""label"": ""epidermal growth factor receptor signaling pathway""}}"			INCREASED																								
3159	3442	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	3	NOTCH1 Inactivation	NOTCH1 loss-of-function mutations occur in approximately 15-20% of HPV-negative HNSCC. NOTCH signaling normally promotes squamous differentiation and growth arrest, functioning as a tumor suppressor in squamous epithelia.	genes[0]	genes	genes			NOTCH1				"{""preferred_term"": ""NOTCH1""}"																											
3160	3442	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	pathophysiology	3	NOTCH1 Inactivation	NOTCH1 loss-of-function mutations occur in approximately 15-20% of HPV-negative HNSCC. NOTCH signaling normally promotes squamous differentiation and growth arrest, functioning as a tumor suppressor in squamous epithelia.	biological_processes[0]	biological_processes	biological_processes			Notch signaling pathway	GO:0007219	Notch signaling pathway		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Notch signaling pathway"", ""term"": {""id"": ""GO:0007219"", ""label"": ""Notch signaling pathway""}}"			DECREASED																								
3161	3443	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	0	Oral Lesion	Non-healing ulcers, white or red patches (leukoplakia, erythroplakia), or masses in the oral cavity may represent primary tumors or precursor lesions.	phenotype_term	phenotype_term	$	Oral Lesion	Non-healing ulcers, white or red patches (leukoplakia, erythroplakia), or masses in the oral cavity may represent primary tumors or precursor lesions.	Oral ulcer	HP:0000155	Oral ulcer		"{""preferred_term"": ""Oral ulcer"", ""term"": {""id"": ""HP:0000155"", ""label"": ""Oral ulcer""}}"																											
3162	3444	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	1	Neck Mass	Cervical lymphadenopathy from nodal metastases is common at presentation. May be the presenting symptom, particularly for hypopharyngeal tumors.	phenotype_term	phenotype_term	$	Neck Mass	Cervical lymphadenopathy from nodal metastases is common at presentation. May be the presenting symptom, particularly for hypopharyngeal tumors.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
3163	3445	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	2	Dysphagia	Difficulty swallowing occurs with tumors of the tongue, oropharynx, hypopharynx, or any location causing obstruction.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing occurs with tumors of the tongue, oropharynx, hypopharynx, or any location causing obstruction.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
3164	3446	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	3	Hoarseness	Voice changes are characteristic of laryngeal carcinoma and an early symptom when the tumor involves the true vocal cords.	phenotype_term	phenotype_term	$	Hoarseness	Voice changes are characteristic of laryngeal carcinoma and an early symptom when the tumor involves the true vocal cords.	Hoarse voice	HP:0001609	Hoarse voice		"{""preferred_term"": ""Hoarse voice"", ""term"": {""id"": ""HP:0001609"", ""label"": ""Hoarse voice""}}"																											
3165	3447	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	4	Odynophagia	Painful swallowing occurs with ulcerative lesions or deep invasion of the pharyngeal mucosa.	phenotype_term	phenotype_term	$	Odynophagia	Painful swallowing occurs with ulcerative lesions or deep invasion of the pharyngeal mucosa.	Odynophagia	HP:0032043	Odynophagia		"{""preferred_term"": ""Odynophagia"", ""term"": {""id"": ""HP:0032043"", ""label"": ""Odynophagia""}}"																											
3166	3448	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	5	Weight Loss	Unintentional weight loss is common due to dysphagia, pain, and catabolic effects of cancer. May indicate advanced disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is common due to dysphagia, pain, and catabolic effects of cancer. May indicate advanced disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3167	3449	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	phenotypes	6	Otalgia	Referred ear pain (via cranial nerves IX and X) may occur with pharyngeal and laryngeal tumors despite a normal ear examination.	phenotype_term	phenotype_term	$	Otalgia	Referred ear pain (via cranial nerves IX and X) may occur with pharyngeal and laryngeal tumors despite a normal ear examination.	Otalgia	HP:0030766	Ear pain		"{""preferred_term"": ""Otalgia"", ""term"": {""id"": ""HP:0030766"", ""label"": ""Ear pain""}}"																											
3168	3450	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	0	Surgical Resection	Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins.	treatment_term	treatment_term	$	Surgical Resection	Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3169	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term	treatment_term	$	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
3170	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
3171	3452	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	2	Cetuximab	EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum.	treatment_term	treatment_term	$	Cetuximab	EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3172	3453	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	3	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy).	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3173	3461	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	histopathology	0	Squamous Cell Carcinoma	Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.	finding_term	finding_term	$	Squamous Cell Carcinoma	Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.	Squamous Cell Carcinoma	NCIT:C2929	Squamous Cell Carcinoma		"{""preferred_term"": ""Squamous Cell Carcinoma"", ""term"": {""id"": ""NCIT:C2929"", ""label"": ""Squamous Cell Carcinoma""}}"																											
3174	3462	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	infectious_agent	0	Human Papillomavirus Type 16	HPV-16 causes approximately 90% of HPV-positive oropharyngeal cancers. Unlike cervical cancer, HPV-18 plays a minor role in oropharyngeal carcinogenesis. Infection is believed to occur through orogenital contact.	infectious_agent_term	infectious_agent_term	$	Human Papillomavirus Type 16	HPV-16 causes approximately 90% of HPV-positive oropharyngeal cancers. Unlike cervical cancer, HPV-18 plays a minor role in oropharyngeal carcinogenesis. Infection is believed to occur through orogenital contact.	Human papillomavirus 16	NCBITaxon:333760	Human papillomavirus 16		"{""preferred_term"": ""Human papillomavirus 16"", ""term"": {""id"": ""NCBITaxon:333760"", ""label"": ""Human papillomavirus 16""}}"																											
3175	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	cell_types[0]	cell_types	cell_types			squamous epithelial cell	CL:0000076	squamous epithelial cell		"{""preferred_term"": ""squamous epithelial cell"", ""term"": {""id"": ""CL:0000076"", ""label"": ""squamous epithelial cell""}}"																											
3176	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	biological_processes[0]	biological_processes	biological_processes			proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process		"{""modifier"": ""INCREASED"", ""preferred_term"": ""proteasome-mediated ubiquitin-dependent protein catabolic process"", ""term"": {""id"": ""GO:0043161"", ""label"": ""proteasome-mediated ubiquitin-dependent protein catabolic process""}}"			INCREASED																								
3177	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3178	3463	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	0	E6-Mediated p53 Degradation	HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.	locations[0]	locations	locations			oropharynx	UBERON:0001729	oropharynx		"{""preferred_term"": ""oropharynx"", ""term"": {""id"": ""UBERON:0001729"", ""label"": ""oropharynx""}}"																											
3179	3464	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	1	E7-Mediated pRB Inactivation	HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB), releasing E2F transcription factors to drive S-phase entry. This causes compensatory overexpression of p16INK4a, which serves as a clinical biomarker for HPV-associated tumors.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			ABNORMAL																								
3180	3464	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	1	E7-Mediated pRB Inactivation	HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB), releasing E2F transcription factors to drive S-phase entry. This causes compensatory overexpression of p16INK4a, which serves as a clinical biomarker for HPV-associated tumors.	biological_processes[1]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
3181	3465	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	2	Viral Oncogene Integration	HPV genome integration into the host chromosome disrupts the E2 viral repressor, leading to constitutive E6/E7 expression. However, episomal HPV may also drive carcinogenesis in some HPV-positive oropharyngeal cancers.	biological_processes[0]	biological_processes	biological_processes			viral DNA integration into host DNA	GO:0044826	viral DNA integration into host DNA		"{""preferred_term"": ""viral DNA integration into host DNA"", ""term"": {""id"": ""GO:0044826"", ""label"": ""viral DNA integration into host DNA""}}"																											
3182	3466	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	pathophysiology	3	Immune Evasion	HPV-positive HNSCC evades immune surveillance through downregulation of antigen presentation and PD-L1 expression. However, these tumors are generally more immunogenic than HPV-negative HNSCC, contributing to better prognosis and response to immunotherapy.	biological_processes[0]	biological_processes	biological_processes			negative regulation of T cell mediated immunity	GO:0002710	negative regulation of T cell mediated immunity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""negative regulation of T cell mediated immunity"", ""term"": {""id"": ""GO:0002710"", ""label"": ""negative regulation of T cell mediated immunity""}}"			INCREASED																								
3183	3467	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	0	Neck Mass	Painless cervical lymphadenopathy is often the presenting symptom, frequently as a unilateral neck mass. The primary tumor may be small or occult while metastatic nodes are prominent.	phenotype_term	phenotype_term	$	Neck Mass	Painless cervical lymphadenopathy is often the presenting symptom, frequently as a unilateral neck mass. The primary tumor may be small or occult while metastatic nodes are prominent.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
3184	3468	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	1	Dysphagia	Difficulty swallowing develops as tumors grow in the tonsil or base of tongue, affecting the swallowing mechanism.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing develops as tumors grow in the tonsil or base of tongue, affecting the swallowing mechanism.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
3185	3469	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	2	Odynophagia	Painful swallowing may occur, particularly with larger primary tumors or ulcerative lesions.	phenotype_term	phenotype_term	$	Odynophagia	Painful swallowing may occur, particularly with larger primary tumors or ulcerative lesions.	Odynophagia	HP:0032043	Odynophagia		"{""preferred_term"": ""Odynophagia"", ""term"": {""id"": ""HP:0032043"", ""label"": ""Odynophagia""}}"																											
3186	3470	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	3	Sore Throat	Persistent unilateral sore throat or foreign body sensation may be an early symptom of tonsillar carcinoma.	phenotype_term	phenotype_term	$	Sore Throat	Persistent unilateral sore throat or foreign body sensation may be an early symptom of tonsillar carcinoma.	Sore throat	HP:0025439	Pharyngitis		"{""preferred_term"": ""Sore throat"", ""term"": {""id"": ""HP:0025439"", ""label"": ""Pharyngitis""}}"																											
3187	3471	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	4	Hoarseness	Voice changes may occur with large tumors or those involving the larynx or recurrent laryngeal nerve.	phenotype_term	phenotype_term	$	Hoarseness	Voice changes may occur with large tumors or those involving the larynx or recurrent laryngeal nerve.	Hoarse voice	HP:0001609	Hoarse voice		"{""preferred_term"": ""Hoarse voice"", ""term"": {""id"": ""HP:0001609"", ""label"": ""Hoarse voice""}}"																											
3188	3472	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	phenotypes	5	Weight Loss	Unintentional weight loss may occur due to dysphagia or advanced disease, though patients often present with earlier-stage disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss may occur due to dysphagia or advanced disease, though patients often present with earlier-stage disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3189	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term	treatment_term	$	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
3190	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
3191	3474	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	1	Transoral Robotic Surgery	Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.	treatment_term	treatment_term	$	Transoral Robotic Surgery	Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3192	3475	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	2	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3193	3476	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	3	HPV Vaccination	Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.	treatment_term	treatment_term	$	HPV Vaccination	Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3194	3488	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	pathophysiology	0	Autoimmune Thyroid Destruction	"T cell-mediated and antibody-mediated destruction of thyroid follicular cells leads to progressive loss of thyroid function. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
"	cell_types[0]	cell_types	cell_types			Thyroid Epithelial Cell	CL:0002257	epithelial cell of thyroid gland		"{""preferred_term"": ""Thyroid Epithelial Cell"", ""term"": {""id"": ""CL:0002257"", ""label"": ""epithelial cell of thyroid gland""}}"																											
3195	3488	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	pathophysiology	0	Autoimmune Thyroid Destruction	"T cell-mediated and antibody-mediated destruction of thyroid follicular cells leads to progressive loss of thyroid function. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
"	cell_types[1]	cell_types	cell_types			T Helper Cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""T Helper Cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
3196	3488	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	pathophysiology	0	Autoimmune Thyroid Destruction	"T cell-mediated and antibody-mediated destruction of thyroid follicular cells leads to progressive loss of thyroid function. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
"	biological_processes[0]	biological_processes	biological_processes			Autoimmune Response	GO:0002460	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains		"{""preferred_term"": ""Autoimmune Response"", ""term"": {""id"": ""GO:0002460"", ""label"": ""adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains""}}"																											
3197	3489	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	pathophysiology	1	Lymphocytic Infiltration	"Dense lymphocytic infiltration of the thyroid gland with germinal center formation. CD4+ T cells, CD8+ T cells, and B cells accumulate in the thyroid parenchyma.
"	cell_types[0]	cell_types	cell_types			B Cell	CL:0000236	B cell		"{""preferred_term"": ""B Cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
3198	3490	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	pathophysiology	2	Thyroid Hormone Deficiency	"Progressive destruction of thyroid tissue leads to decreased production of T3 and T4, resulting in hypothyroidism with elevated TSH through negative feedback.
"	biological_processes[0]	biological_processes	biological_processes			Thyroid Hormone Synthesis	GO:0006590	thyroid hormone generation		"{""preferred_term"": ""Thyroid Hormone Synthesis"", ""term"": {""id"": ""GO:0006590"", ""label"": ""thyroid hormone generation""}}"																											
3199	3491	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	0	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3200	3492	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	1	Weight Gain		phenotype_term	phenotype_term	$	Weight Gain		Weight Gain	HP:0004324	Increased body weight		"{""preferred_term"": ""Weight Gain"", ""term"": {""id"": ""HP:0004324"", ""label"": ""Increased body weight""}}"																											
3201	3493	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	2	Constipation		phenotype_term	phenotype_term	$	Constipation		Constipation	HP:0002019	Constipation		"{""preferred_term"": ""Constipation"", ""term"": {""id"": ""HP:0002019"", ""label"": ""Constipation""}}"																											
3202	3494	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	3	Dry Skin		phenotype_term	phenotype_term	$	Dry Skin		Dry Skin	HP:0000958	Dry skin		"{""preferred_term"": ""Dry Skin"", ""term"": {""id"": ""HP:0000958"", ""label"": ""Dry skin""}}"																											
3203	3495	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	4	Goiter		phenotype_term	phenotype_term	$	Goiter		Goiter	HP:0000853	Goiter		"{""preferred_term"": ""Goiter"", ""term"": {""id"": ""HP:0000853"", ""label"": ""Goiter""}}"																											
3204	3496	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	phenotypes	5	Depression		phenotype_term	phenotype_term	$	Depression		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
3205	3512	147	Heart Failure	Heart_Failure.yaml	pathophysiology	0	Myocardial Contractile Dysfunction	"Reduced cardiac output due to impaired ventricular contraction (systolic dysfunction) or relaxation (diastolic dysfunction). The heart cannot meet metabolic demands.
"	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3206	3512	147	Heart Failure	Heart_Failure.yaml	pathophysiology	0	Myocardial Contractile Dysfunction	"Reduced cardiac output due to impaired ventricular contraction (systolic dysfunction) or relaxation (diastolic dysfunction). The heart cannot meet metabolic demands.
"	biological_processes[0]	biological_processes	biological_processes			Cardiac Contraction	GO:0060047	heart contraction		"{""preferred_term"": ""Cardiac Contraction"", ""term"": {""id"": ""GO:0060047"", ""label"": ""heart contraction""}}"																											
3207	3513	147	Heart Failure	Heart_Failure.yaml	pathophysiology	1	Neurohormonal Activation	"Compensatory activation of RAAS and sympathetic nervous system initially maintains cardiac output but leads to maladaptive remodeling, sodium retention, and progressive dysfunction.
"	biological_processes[0]	biological_processes	biological_processes			RAAS Activation	GO:0002018	renin-angiotensin regulation of aldosterone production		"{""preferred_term"": ""RAAS Activation"", ""term"": {""id"": ""GO:0002018"", ""label"": ""renin-angiotensin regulation of aldosterone production""}}"																											
3208	3514	147	Heart Failure	Heart_Failure.yaml	pathophysiology	2	Ventricular Remodeling	"Structural changes including ventricular dilation, hypertrophy, and fibrosis that initially compensate but eventually worsen heart function.
"	cell_types[0]	cell_types	cell_types			Cardiac Fibroblast	CL:0002548	fibroblast of cardiac tissue		"{""preferred_term"": ""Cardiac Fibroblast"", ""term"": {""id"": ""CL:0002548"", ""label"": ""fibroblast of cardiac tissue""}}"																											
3209	3514	147	Heart Failure	Heart_Failure.yaml	pathophysiology	2	Ventricular Remodeling	"Structural changes including ventricular dilation, hypertrophy, and fibrosis that initially compensate but eventually worsen heart function.
"	biological_processes[0]	biological_processes	biological_processes			Cardiac Remodeling	GO:0060420	regulation of heart growth		"{""preferred_term"": ""Cardiac Remodeling"", ""term"": {""id"": ""GO:0060420"", ""label"": ""regulation of heart growth""}}"																											
3210	3516	147	Heart Failure	Heart_Failure.yaml	phenotypes	0	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3211	3517	147	Heart Failure	Heart_Failure.yaml	phenotypes	1	Peripheral Edema		phenotype_term	phenotype_term	$	Peripheral Edema		Peripheral Edema	HP:0012398	Peripheral edema		"{""preferred_term"": ""Peripheral Edema"", ""term"": {""id"": ""HP:0012398"", ""label"": ""Peripheral edema""}}"																											
3212	3518	147	Heart Failure	Heart_Failure.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3213	3519	147	Heart Failure	Heart_Failure.yaml	phenotypes	3	Orthopnea		phenotype_term	phenotype_term	$	Orthopnea		Orthopnea	HP:0012764	Orthopnea		"{""preferred_term"": ""Orthopnea"", ""term"": {""id"": ""HP:0012764"", ""label"": ""Orthopnea""}}"																											
3214	3520	147	Heart Failure	Heart_Failure.yaml	phenotypes	4	Exercise Intolerance		phenotype_term	phenotype_term	$	Exercise Intolerance		Exercise Intolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Exercise Intolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
3215	3521	147	Heart Failure	Heart_Failure.yaml	phenotypes	5	Cardiomegaly		phenotype_term	phenotype_term	$	Cardiomegaly		Cardiomegaly	HP:0001640	Cardiomegaly		"{""preferred_term"": ""Cardiomegaly"", ""term"": {""id"": ""HP:0001640"", ""label"": ""Cardiomegaly""}}"																											
3216	3533	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	0	HFE Loss Lowers Hepcidin	"Pathogenic HFE variants (most commonly C282Y homozygosity) blunt hepcidin induction, leaving circulating hepcidin inappropriately low relative to body iron stores.
"	biological_processes[0]	biological_processes	biological_processes			iron ion homeostasis	GO:0055072	iron ion homeostasis		"{""preferred_term"": ""iron ion homeostasis"", ""term"": {""id"": ""GO:0055072"", ""label"": ""iron ion homeostasis""}}"																											
3217	3534	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	1	Low Hepcidin Leads to Ferroportin Hyperabsorption	"Suppressed hepcidin fails to internalize and degrade ferroportin on enterocytes, so dietary iron efflux into plasma is unchecked, driving systemic iron overload.
"	biological_processes[0]	biological_processes	biological_processes			iron ion transport	GO:0006826	iron ion transport		"{""preferred_term"": ""iron ion transport"", ""term"": {""id"": ""GO:0006826"", ""label"": ""iron ion transport""}}"																											
3218	3535	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	2	Hepatic Iron Toxicity	"Excess iron deposits in hepatocytes leading to oxidative stress, lipid peroxidation, and hepatocellular damage. Progressive iron accumulation causes fibrosis and can lead to cirrhosis and hepatocellular carcinoma.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3219	3535	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	2	Hepatic Iron Toxicity	"Excess iron deposits in hepatocytes leading to oxidative stress, lipid peroxidation, and hepatocellular damage. Progressive iron accumulation causes fibrosis and can lead to cirrhosis and hepatocellular carcinoma.
"	biological_processes[0]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress		"{""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
3220	3536	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	3	Cardiac Iron Deposition	"Iron accumulation in cardiomyocytes causes oxidative damage and impaired contractility, leading to cardiomyopathy and cardiac failure, particularly dilated cardiomyopathy.
"	cell_types[0]	cell_types	cell_types			cardiac muscle cell	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiac muscle cell"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3221	3536	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	3	Cardiac Iron Deposition	"Iron accumulation in cardiomyocytes causes oxidative damage and impaired contractility, leading to cardiomyopathy and cardiac failure, particularly dilated cardiomyopathy.
"	biological_processes[0]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress		"{""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
3222	3537	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	4	Pancreatic Iron Toxicity	"Iron deposition in pancreatic beta cells causes oxidative damage and impaired insulin secretion, leading to diabetes mellitus (""bronze diabetes"").
"	cell_types[0]	cell_types	cell_types			type B pancreatic cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""type B pancreatic cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
3223	3537	148	Hemochromatosis	Hemochromatosis.yaml	pathophysiology	4	Pancreatic Iron Toxicity	"Iron deposition in pancreatic beta cells causes oxidative damage and impaired insulin secretion, leading to diabetes mellitus (""bronze diabetes"").
"	biological_processes[0]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress		"{""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
3224	3538	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	0	Hepatomegaly	"Enlarged liver due to iron accumulation in hepatocytes, often the earliest detectable physical finding.
"	phenotype_term	phenotype_term	$	Hepatomegaly	"Enlarged liver due to iron accumulation in hepatocytes, often the earliest detectable physical finding.
"	hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3225	3539	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	1	Skin Hyperpigmentation	"Bronze or grayish skin discoloration due to increased melanin and iron deposition in the dermis, a classic feature of hemochromatosis.
"	phenotype_term	phenotype_term	$	Skin Hyperpigmentation	"Bronze or grayish skin discoloration due to increased melanin and iron deposition in the dermis, a classic feature of hemochromatosis.
"	generalized bronze hyperpigmentation	HP:0007574	Generalized bronze hyperpigmentation		"{""preferred_term"": ""generalized bronze hyperpigmentation"", ""term"": {""id"": ""HP:0007574"", ""label"": ""Generalized bronze hyperpigmentation""}}"																											
3226	3540	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	2	Diabetes Mellitus	"Development of diabetes due to pancreatic beta cell destruction from iron toxicity, historically called ""bronze diabetes.""
"	phenotype_term	phenotype_term	$	Diabetes Mellitus	"Development of diabetes due to pancreatic beta cell destruction from iron toxicity, historically called ""bronze diabetes.""
"	diabetes mellitus	HP:0000819	Diabetes mellitus		"{""preferred_term"": ""diabetes mellitus"", ""term"": {""id"": ""HP:0000819"", ""label"": ""Diabetes mellitus""}}"																											
3227	3541	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	3	Arthropathy	"Joint pain and swelling, particularly affecting the second and third metacarpophalangeal joints, due to iron and calcium pyrophosphate deposition.
"	phenotype_term	phenotype_term	$	Arthropathy	"Joint pain and swelling, particularly affecting the second and third metacarpophalangeal joints, due to iron and calcium pyrophosphate deposition.
"	arthropathy	HP:0003040	Arthropathy		"{""preferred_term"": ""arthropathy"", ""term"": {""id"": ""HP:0003040"", ""label"": ""Arthropathy""}}"																											
3228	3542	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	4	Cardiomyopathy	"Heart muscle disease due to iron deposition in cardiomyocytes, which can lead to heart failure and arrhythmias.
"	phenotype_term	phenotype_term	$	Cardiomyopathy	"Heart muscle disease due to iron deposition in cardiomyocytes, which can lead to heart failure and arrhythmias.
"	cardiomyopathy	HP:0001638	Cardiomyopathy		"{""preferred_term"": ""cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""Cardiomyopathy""}}"																											
3229	3543	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	5	Hypogonadism	"Decreased gonadal function due to iron deposition in the pituitary gland, leading to reduced libido, erectile dysfunction, and testicular atrophy.
"	phenotype_term	phenotype_term	$	Hypogonadism	"Decreased gonadal function due to iron deposition in the pituitary gland, leading to reduced libido, erectile dysfunction, and testicular atrophy.
"	hypogonadotropic hypogonadism	HP:0000044	Hypogonadotropic hypogonadism		"{""preferred_term"": ""hypogonadotropic hypogonadism"", ""term"": {""id"": ""HP:0000044"", ""label"": ""Hypogonadotropic hypogonadism""}}"																											
3230	3544	148	Hemochromatosis	Hemochromatosis.yaml	phenotypes	6	Fatigue	"Chronic tiredness and weakness, one of the most common and earliest symptoms of hemochromatosis.
"	phenotype_term	phenotype_term	$	Fatigue	"Chronic tiredness and weakness, one of the most common and earliest symptoms of hemochromatosis.
"	fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3231	3546	148	Hemochromatosis	Hemochromatosis.yaml	treatments	1	Iron Chelation Therapy	"Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.
"	treatment_term	treatment_term	$	Iron Chelation Therapy	"Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3232	3547	148	Hemochromatosis	Hemochromatosis.yaml	treatments	2	Dietary Modification	"Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.
"	treatment_term	treatment_term	$	Dietary Modification	"Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3233	3548	148	Hemochromatosis	Hemochromatosis.yaml	treatments	3	Screening of Family Members	"Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.
"	treatment_term	treatment_term	$	Screening of Family Members	"Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3234	3556	149	Hemophilia A	Hemophilia_A.yaml	pathophysiology	0	Factor VIII Deficiency	"Mutations in the F8 gene cause deficient or dysfunctional factor VIII protein. Factor VIII is a cofactor for factor IXa in the intrinsic coagulation pathway, essential for thrombin generation and fibrin clot formation.
"	biological_processes[0]	biological_processes	biological_processes			Blood Coagulation	GO:0007596	blood coagulation		"{""preferred_term"": ""Blood Coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
3235	3557	149	Hemophilia A	Hemophilia_A.yaml	pathophysiology	1	Impaired Thrombin Generation	"Without functional factor VIII, the intrinsic tenase complex cannot form efficiently. This results in inadequate thrombin generation and unstable fibrin clot formation, leading to prolonged bleeding.
"	biological_processes[0]	biological_processes	biological_processes			Fibrin Clot Formation	GO:0072378	blood coagulation, fibrin clot formation		"{""preferred_term"": ""Fibrin Clot Formation"", ""term"": {""id"": ""GO:0072378"", ""label"": ""blood coagulation, fibrin clot formation""}}"																											
3236	3558	149	Hemophilia A	Hemophilia_A.yaml	phenotypes	0	Hemarthrosis		phenotype_term	phenotype_term	$	Hemarthrosis		Hemarthrosis	HP:0005261	Joint hemorrhage		"{""preferred_term"": ""Hemarthrosis"", ""term"": {""id"": ""HP:0005261"", ""label"": ""Joint hemorrhage""}}"																											
3237	3559	149	Hemophilia A	Hemophilia_A.yaml	phenotypes	1	Prolonged Bleeding		phenotype_term	phenotype_term	$	Prolonged Bleeding		Prolonged Bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Prolonged Bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
3238	3560	149	Hemophilia A	Hemophilia_A.yaml	phenotypes	2	Easy Bruising		phenotype_term	phenotype_term	$	Easy Bruising		Easy Bruising	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""Easy Bruising"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
3239	3561	149	Hemophilia A	Hemophilia_A.yaml	phenotypes	3	Muscle Hematomas		phenotype_term	phenotype_term	$	Muscle Hematomas		Muscle Hematoma	HP:0012233	Intramuscular hematoma		"{""preferred_term"": ""Muscle Hematoma"", ""term"": {""id"": ""HP:0012233"", ""label"": ""Intramuscular hematoma""}}"																											
3240	3562	149	Hemophilia A	Hemophilia_A.yaml	phenotypes	4	Prolonged aPTT		phenotype_term	phenotype_term	$	Prolonged aPTT		Prolonged aPTT	HP:0003645	Prolonged partial thromboplastin time		"{""preferred_term"": ""Prolonged aPTT"", ""term"": {""id"": ""HP:0003645"", ""label"": ""Prolonged partial thromboplastin time""}}"																											
3241	3569	150	Hemophilia B	Hemophilia_B.yaml	phenotypes	0	Abnormal Bleeding		phenotype_term	phenotype_term	$	Abnormal Bleeding		Abnormal bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Abnormal bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
3242	3570	150	Hemophilia B	Hemophilia_B.yaml	treatments	0	Factor IX Replacement	Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy.	treatment_term	treatment_term	$	Factor IX Replacement	Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3243	3571	150	Hemophilia B	Hemophilia_B.yaml	treatments	1	Prophylactic Factor IX Replacement	Regular prophylactic dosing to prevent bleeding and arthropathy.	treatment_term	treatment_term	$	Prophylactic Factor IX Replacement	Regular prophylactic dosing to prevent bleeding and arthropathy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3244	3587	151	Hepatitis B	Hepatitis_B.yaml	infectious_agent	0	Hepatitis B Virus (HBV)	A partially double-stranded DNA virus that infects hepatocytes via the NTCP receptor and establishes persistent cccDNA in the nucleus. HBx protein serves as a multifunctional regulator of viral transcription and host epigenetics.	infectious_agent_term	infectious_agent_term	$	Hepatitis B Virus (HBV)	A partially double-stranded DNA virus that infects hepatocytes via the NTCP receptor and establishes persistent cccDNA in the nucleus. HBx protein serves as a multifunctional regulator of viral transcription and host epigenetics.	Hepatitis B virus	NCBITaxon:10407	Hepatitis B virus		"{""preferred_term"": ""Hepatitis B virus"", ""term"": {""id"": ""NCBITaxon:10407"", ""label"": ""Hepatitis B virus""}}"																											
3245	3588	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	0	Hepatocyte Infection and cccDNA Formation	HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.	cell_types[0]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3246	3588	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	0	Hepatocyte Infection and cccDNA Formation	HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
3247	3588	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	0	Hepatocyte Infection and cccDNA Formation	HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.	biological_processes[0]	biological_processes	biological_processes			viral entry into host cell	GO:0046718	viral entry into host cell		"{""preferred_term"": ""viral entry into host cell"", ""term"": {""id"": ""GO:0046718"", ""label"": ""viral entry into host cell""}}"																											
3248	3588	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	0	Hepatocyte Infection and cccDNA Formation	HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.	biological_processes[1]	biological_processes	biological_processes			epigenetic regulation of gene expression	GO:0040029	epigenetic regulation of gene expression		"{""preferred_term"": ""epigenetic regulation of gene expression"", ""term"": {""id"": ""GO:0040029"", ""label"": ""epigenetic regulation of gene expression""}}"																											
3249	3589	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	1	HBV DNA Integration	Integration of viral dslDNA into host genome occurs at sites of DNA damage, driving insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes.	biological_processes[0]	biological_processes	biological_processes			DNA integration	GO:0015074	DNA integration		"{""preferred_term"": ""DNA integration"", ""term"": {""id"": ""GO:0015074"", ""label"": ""DNA integration""}}"																											
3250	3590	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	2	Chronic Inflammation	Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3251	3590	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	2	Chronic Inflammation	Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.	cell_types[1]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell		"{""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
3252	3590	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	2	Chronic Inflammation	Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.	cell_types[2]	cell_types	cell_types			inflammatory macrophage	CL:0000863	inflammatory macrophage	Liver-resident macrophages (Kupffer cells)	"{""description"": ""Liver-resident macrophages (Kupffer cells)"", ""preferred_term"": ""inflammatory macrophage"", ""term"": {""id"": ""CL:0000863"", ""label"": ""inflammatory macrophage""}}"																											
3253	3591	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	3	Immune Evasion and T Cell Exhaustion	HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3254	3591	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	3	Immune Evasion and T Cell Exhaustion	HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.	cell_types[1]	cell_types	cell_types			regulatory T cell	CL:0000815	regulatory T cell		"{""preferred_term"": ""regulatory T cell"", ""term"": {""id"": ""CL:0000815"", ""label"": ""regulatory T cell""}}"																											
3255	3591	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	3	Immune Evasion and T Cell Exhaustion	HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.	biological_processes[0]	biological_processes	biological_processes			negative regulation of T cell activation	GO:0050868	negative regulation of T cell activation		"{""preferred_term"": ""negative regulation of T cell activation"", ""term"": {""id"": ""GO:0050868"", ""label"": ""negative regulation of T cell activation""}}"																											
3256	3591	151	Hepatitis B	Hepatitis_B.yaml	pathophysiology	3	Immune Evasion and T Cell Exhaustion	HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.	biological_processes[1]	biological_processes	biological_processes			cGAS-STING signaling pathway	GO:0061761	cGAS-STING signaling pathway		"{""preferred_term"": ""cGAS-STING signaling pathway"", ""term"": {""id"": ""GO:0061761"", ""label"": ""cGAS-STING signaling pathway""}}"																											
3257	3594	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	0	Jaundice	Yellowing of the skin and eyes due to elevated bilirubin levels from impaired liver function.	phenotype_term	phenotype_term	$	Jaundice	Yellowing of the skin and eyes due to elevated bilirubin levels from impaired liver function.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
3258	3595	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	1	Fatigue	Persistent tiredness and weakness commonly experienced by patients with chronic hepatitis B infection.	phenotype_term	phenotype_term	$	Fatigue	Persistent tiredness and weakness commonly experienced by patients with chronic hepatitis B infection.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3259	3596	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	2	Abdominal Pain	Right upper quadrant pain or discomfort related to hepatic inflammation and liver capsule distension.	phenotype_term	phenotype_term	$	Abdominal Pain	Right upper quadrant pain or discomfort related to hepatic inflammation and liver capsule distension.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3260	3598	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	4	Nausea	Feeling of sickness with inclination to vomit, common during acute hepatitis B infection.	phenotype_term	phenotype_term	$	Nausea	Feeling of sickness with inclination to vomit, common during acute hepatitis B infection.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
3261	3599	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	5	Vomiting	Forceful expulsion of stomach contents, often accompanying nausea in acute hepatitis B.	phenotype_term	phenotype_term	$	Vomiting	Forceful expulsion of stomach contents, often accompanying nausea in acute hepatitis B.	Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
3262	3600	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	6	Fever	Elevated body temperature that may occur during acute HBV infection or flares of chronic disease.	phenotype_term	phenotype_term	$	Fever	Elevated body temperature that may occur during acute HBV infection or flares of chronic disease.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
3263	3601	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	7	Hepatomegaly	Enlargement of the liver detectable on physical examination or imaging, indicating hepatic inflammation.	phenotype_term	phenotype_term	$	Hepatomegaly	Enlargement of the liver detectable on physical examination or imaging, indicating hepatic inflammation.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3264	3602	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	8	Arthralgias	Joint pain without joint swelling, an extrahepatic manifestation of HBV infection.	phenotype_term	phenotype_term	$	Arthralgias	Joint pain without joint swelling, an extrahepatic manifestation of HBV infection.	Arthralgias	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgias"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
3265	3603	151	Hepatitis B	Hepatitis_B.yaml	phenotypes	9	Rash	Skin eruptions that may occur as an extrahepatic manifestation of HBV infection.	phenotype_term	phenotype_term	$	Rash	Skin eruptions that may occur as an extrahepatic manifestation of HBV infection.	Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
3266	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	Antiviral Medications	Includes drugs like tenofovir and entecavir to suppress HBV replication.	treatment_term	treatment_term	$	Antiviral Medications	Includes drugs like tenofovir and entecavir to suppress HBV replication.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3267	3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	Interferon Therapy	Boosts the immune system to fight the virus.	treatment_term	treatment_term	$	Interferon Therapy	Boosts the immune system to fight the virus.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3268	3614	151	Hepatitis B	Hepatitis_B.yaml	treatments	2	Liver Transplant	For end-stage liver disease.	treatment_term	treatment_term	$	Liver Transplant	For end-stage liver disease.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
3269	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	Vaccination	Hepatitis B vaccine provides prevention for uninfected individuals.	treatment_term	treatment_term	$	Vaccination	Hepatitis B vaccine provides prevention for uninfected individuals.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3270	3628	152	Hepatitis C	Hepatitis_C.yaml	infectious_agent	0	Hepatitis C virus		infectious_agent_term	infectious_agent_term	$	Hepatitis C virus		Hepacivirus hominis	NCBITaxon:3052230	Hepacivirus hominis		"{""preferred_term"": ""Hepacivirus hominis"", ""term"": {""id"": ""NCBITaxon:3052230"", ""label"": ""Hepacivirus hominis""}}"																											
3271	3629	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	0	Viral Replication and Hepatocyte Injury	"HCV is a positive-sense single-stranded RNA virus that replicates primarily in hepatocytes. Viral replication causes direct cytopathic effects and triggers immune-mediated hepatocyte destruction. The virus evades immune clearance through high mutation rates and quasispecies diversity.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3272	3629	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	0	Viral Replication and Hepatocyte Injury	"HCV is a positive-sense single-stranded RNA virus that replicates primarily in hepatocytes. Viral replication causes direct cytopathic effects and triggers immune-mediated hepatocyte destruction. The virus evades immune clearance through high mutation rates and quasispecies diversity.
"	biological_processes[0]	biological_processes	biological_processes			viral life cycle	GO:0019058	viral life cycle		"{""preferred_term"": ""viral life cycle"", ""term"": {""id"": ""GO:0019058"", ""label"": ""viral life cycle""}}"																											
3273	3630	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	1	Chronic Inflammation and Fibrosis	"Persistent HCV infection induces chronic hepatic inflammation with infiltration of lymphocytes and activation of hepatic stellate cells. This leads to progressive fibrosis through excessive collagen deposition, ultimately resulting in cirrhosis.
"	cell_types[0]	cell_types	cell_types			hepatic stellate cell	CL:0000632	hepatic stellate cell		"{""preferred_term"": ""hepatic stellate cell"", ""term"": {""id"": ""CL:0000632"", ""label"": ""hepatic stellate cell""}}"																											
3274	3630	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	1	Chronic Inflammation and Fibrosis	"Persistent HCV infection induces chronic hepatic inflammation with infiltration of lymphocytes and activation of hepatic stellate cells. This leads to progressive fibrosis through excessive collagen deposition, ultimately resulting in cirrhosis.
"	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
3275	3630	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	1	Chronic Inflammation and Fibrosis	"Persistent HCV infection induces chronic hepatic inflammation with infiltration of lymphocytes and activation of hepatic stellate cells. This leads to progressive fibrosis through excessive collagen deposition, ultimately resulting in cirrhosis.
"	biological_processes[0]	biological_processes	biological_processes			chronic inflammatory response	GO:0002544	chronic inflammatory response		"{""preferred_term"": ""chronic inflammatory response"", ""term"": {""id"": ""GO:0002544"", ""label"": ""chronic inflammatory response""}}"																											
3276	3630	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	1	Chronic Inflammation and Fibrosis	"Persistent HCV infection induces chronic hepatic inflammation with infiltration of lymphocytes and activation of hepatic stellate cells. This leads to progressive fibrosis through excessive collagen deposition, ultimately resulting in cirrhosis.
"	biological_processes[1]	biological_processes	biological_processes			hepatic stellate cell activation	GO:0035733	hepatic stellate cell activation		"{""preferred_term"": ""hepatic stellate cell activation"", ""term"": {""id"": ""GO:0035733"", ""label"": ""hepatic stellate cell activation""}}"																											
3277	3630	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	1	Chronic Inflammation and Fibrosis	"Persistent HCV infection induces chronic hepatic inflammation with infiltration of lymphocytes and activation of hepatic stellate cells. This leads to progressive fibrosis through excessive collagen deposition, ultimately resulting in cirrhosis.
"	biological_processes[2]	biological_processes	biological_processes			collagen biosynthetic process	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""collagen biosynthetic process"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
3278	3631	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	2	Immune Evasion	"HCV employs multiple strategies to evade host immune responses, including interference with interferon signaling, rapid viral mutation generating escape variants, and exhaustion of HCV-specific T cells.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3279	3631	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	2	Immune Evasion	"HCV employs multiple strategies to evade host immune responses, including interference with interferon signaling, rapid viral mutation generating escape variants, and exhaustion of HCV-specific T cells.
"	biological_processes[0]	biological_processes	biological_processes			symbiont-mediated suppression of host type I interferon-mediated signaling pathway	GO:0039502	symbiont-mediated suppression of host type I interferon-mediated signaling pathway		"{""preferred_term"": ""symbiont-mediated suppression of host type I interferon-mediated signaling pathway"", ""term"": {""id"": ""GO:0039502"", ""label"": ""symbiont-mediated suppression of host type I interferon-mediated signaling pathway""}}"																											
3280	3632	152	Hepatitis C	Hepatitis_C.yaml	pathophysiology	3	Hepatocellular Carcinoma Development	"Chronic inflammation, oxidative stress, and direct viral effects on cell signaling pathways contribute to hepatocarcinogenesis. Cirrhosis is the major risk factor, but HCC can occur in non-cirrhotic livers.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3281	3633	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	0	Fatigue	Chronic fatigue is the most common symptom, often persisting even after viral clearance.	phenotype_term	phenotype_term	$	Fatigue	Chronic fatigue is the most common symptom, often persisting even after viral clearance.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3282	3634	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	1	Jaundice	Yellow discoloration of skin and sclera due to elevated bilirubin, more common in acute infection.	phenotype_term	phenotype_term	$	Jaundice	Yellow discoloration of skin and sclera due to elevated bilirubin, more common in acute infection.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
3283	3635	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	2	Hepatomegaly	Enlarged liver due to inflammation and/or fatty infiltration.	phenotype_term	phenotype_term	$	Hepatomegaly	Enlarged liver due to inflammation and/or fatty infiltration.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3284	3636	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	3	Elevated Transaminases	Elevated ALT and AST indicating hepatocyte injury, though levels may fluctuate in chronic infection.	phenotype_term	phenotype_term	$	Elevated Transaminases	Elevated ALT and AST indicating hepatocyte injury, though levels may fluctuate in chronic infection.	Elevated circulating hepatic transaminase concentration	HP:0002910	Elevated circulating hepatic transaminase concentration		"{""preferred_term"": ""Elevated circulating hepatic transaminase concentration"", ""term"": {""id"": ""HP:0002910"", ""label"": ""Elevated circulating hepatic transaminase concentration""}}"																											
3285	3637	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	4	Cirrhosis	End-stage liver fibrosis developing in 15-30% of chronically infected patients over 20-30 years.	phenotype_term	phenotype_term	$	Cirrhosis	End-stage liver fibrosis developing in 15-30% of chronically infected patients over 20-30 years.	Cirrhosis	HP:0001394	Cirrhosis		"{""preferred_term"": ""Cirrhosis"", ""term"": {""id"": ""HP:0001394"", ""label"": ""Cirrhosis""}}"																											
3286	3638	152	Hepatitis C	Hepatitis_C.yaml	phenotypes	5	Hepatocellular Carcinoma	Primary liver cancer developing in 1-5% of cirrhotic patients annually.	phenotype_term	phenotype_term	$	Hepatocellular Carcinoma	Primary liver cancer developing in 1-5% of cirrhotic patients annually.	Hepatocellular carcinoma	HP:0001402	Hepatocellular carcinoma		"{""preferred_term"": ""Hepatocellular carcinoma"", ""term"": {""id"": ""HP:0001402"", ""label"": ""Hepatocellular carcinoma""}}"																											
3287	3639	152	Hepatitis C	Hepatitis_C.yaml	treatments	0	Direct-Acting Antivirals (DAAs)	"Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.
"	treatment_term	treatment_term	$	Direct-Acting Antivirals (DAAs)	"Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3288	3640	152	Hepatitis C	Hepatitis_C.yaml	treatments	1	Liver Transplantation	"Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.
"	treatment_term	treatment_term	$	Liver Transplantation	"Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.
"	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
3289	3641	152	Hepatitis C	Hepatitis_C.yaml	treatments	2	Hepatocellular Carcinoma Surveillance	"Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.
"	treatment_term	treatment_term	$	Hepatocellular Carcinoma Surveillance	"Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.
"	surveillance for malignancies	MAXO:0001492	surveillance for malignancies		"{""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}"																											
3290	3654	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	histopathology	0	Hepatocellular Carcinoma	Hepatocellular carcinoma is the most common primary liver malignancy.	finding_term	finding_term	$	Hepatocellular Carcinoma	Hepatocellular carcinoma is the most common primary liver malignancy.	Hepatocellular Carcinoma	NCIT:C3099	Hepatocellular Carcinoma		"{""preferred_term"": ""Hepatocellular Carcinoma"", ""term"": {""id"": ""NCIT:C3099"", ""label"": ""Hepatocellular Carcinoma""}}"																											
3291	3655	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	0	Chronic Liver Injury and Cirrhosis	Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent hepatocyte death and regeneration in an inflammatory environment promotes accumulation of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing oxidative stress and genomic instability.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3292	3655	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	0	Chronic Liver Injury and Cirrhosis	Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent hepatocyte death and regeneration in an inflammatory environment promotes accumulation of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing oxidative stress and genomic instability.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
3293	3656	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	1	Telomere Dysfunction and Genomic Instability	Chronic hepatocyte proliferation leads to telomere shortening, causing genomic instability. TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase to enable unlimited replication. This creates a checkpoint bypass allowing survival of genetically unstable cells.	biological_processes[0]	biological_processes	biological_processes			telomere maintenance	GO:0000723	telomere maintenance		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""telomere maintenance"", ""term"": {""id"": ""GO:0000723"", ""label"": ""telomere maintenance""}}"			ABNORMAL																								
3294	3657	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	2	Accumulation of Driver Mutations	Multiple driver genes are recurrently mutated in HCC, including TERT promoter (60%), TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
3295	3658	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	3	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1 lead to constitutive WNT pathway activation. This drives cell proliferation and is associated with a distinct molecular subclass of HCC with specific clinical features including cholestasis and immune exclusion.	biological_processes[0]	biological_processes	biological_processes			Wnt signaling pathway	GO:0016055	Wnt signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Wnt signaling pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"			INCREASED																								
3296	3659	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	4	TP53 Pathway Inactivation	TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated tumors. Loss of p53 function removes a critical checkpoint, allowing survival of cells with DNA damage and promoting genomic instability.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3297	3660	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	5	Enhanced Hepatocyte Proliferation	Combined effects of telomerase reactivation, cell cycle checkpoint loss, and mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3298	3661	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	pathophysiology	6	Angiogenesis and VEGF Signaling	HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes new blood vessel formation supplying the tumor. VEGF also has immunosuppressive effects, contributing to the immune-excluded microenvironment. This provides the rationale for anti-VEGF therapy in combination with immunotherapy.	biological_processes[0]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
3299	3662	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	0	Hepatomegaly	Liver enlargement from tumor mass. May be palpable as a hard, irregular mass in the right upper quadrant.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from tumor mass. May be palpable as a hard, irregular mass in the right upper quadrant.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3300	3663	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	1	Ascites	Abdominal fluid accumulation from portal hypertension (cirrhosis) and/or tumor-related factors. Presence indicates advanced disease and decompensated liver function.	phenotype_term	phenotype_term	$	Ascites	Abdominal fluid accumulation from portal hypertension (cirrhosis) and/or tumor-related factors. Presence indicates advanced disease and decompensated liver function.	Ascites	HP:0001541	Ascites		"{""preferred_term"": ""Ascites"", ""term"": {""id"": ""HP:0001541"", ""label"": ""Ascites""}}"																											
3301	3664	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	2	Jaundice	Yellowing of skin and sclera from elevated bilirubin. May result from biliary obstruction by tumor, hepatic failure, or diffuse tumor infiltration.	phenotype_term	phenotype_term	$	Jaundice	Yellowing of skin and sclera from elevated bilirubin. May result from biliary obstruction by tumor, hepatic failure, or diffuse tumor infiltration.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
3302	3665	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	3	Abdominal Pain	Right upper quadrant pain or discomfort from liver capsule distension or tumor growth. Sudden severe pain may indicate tumor rupture.	phenotype_term	phenotype_term	$	Abdominal Pain	Right upper quadrant pain or discomfort from liver capsule distension or tumor growth. Sudden severe pain may indicate tumor rupture.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3303	3666	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	4	Weight Loss	Unintentional weight loss is common in HCC due to cancer cachexia, reduced oral intake, and altered metabolism.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is common in HCC due to cancer cachexia, reduced oral intake, and altered metabolism.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3304	3667	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	5	Fatigue	Fatigue from liver dysfunction, anemia, and cancer-related factors.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from liver dysfunction, anemia, and cancer-related factors.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3305	3668	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	phenotypes	6	Nausea	Nausea and anorexia from liver dysfunction and advanced disease.	phenotype_term	phenotype_term	$	Nausea	Nausea and anorexia from liver dysfunction and advanced disease.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
3306	3669	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	0	Atezolizumab plus Bevacizumab	First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.	treatment_term	treatment_term	$	Atezolizumab plus Bevacizumab	First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3307	3670	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	1	Durvalumab plus Tremelimumab	Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.	treatment_term	treatment_term	$	Durvalumab plus Tremelimumab	Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3308	3671	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	2	Sorafenib	Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.	treatment_term	treatment_term	$	Sorafenib	Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3309	3672	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	3	Lenvatinib	Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.	treatment_term	treatment_term	$	Lenvatinib	Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3310	3673	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	4	Surgical Resection	Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.	treatment_term	treatment_term	$	Surgical Resection	Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3311	3674	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	5	Liver Transplantation	Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.	treatment_term	treatment_term	$	Liver Transplantation	Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
3312	3675	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	6	Transarterial Chemoembolization (TACE)	Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.	treatment_term	treatment_term	$	Transarterial Chemoembolization (TACE)	Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3313	3676	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	7	Radiofrequency/Microwave Ablation	Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.	treatment_term	treatment_term	$	Radiofrequency/Microwave Ablation	Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.	ablation therapy	MAXO:0000452	ablation therapy		"{""preferred_term"": ""ablation therapy"", ""term"": {""id"": ""MAXO:0000452"", ""label"": ""ablation therapy""}}"																											
3314	3683	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	0	BRCA1/2 Tumor Suppressor Loss	Germline heterozygous BRCA1 or BRCA2 mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates BRCA function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
3315	3684	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	1	Homologous Recombination Deficiency	BRCA1 and BRCA2 are essential components of the homologous recombination (HR) pathway for error-free repair of DNA double-strand breaks. Loss of BRCA function forces cells to rely on error-prone repair pathways such as non-homologous end joining, leading to genomic instability.	biological_processes[0]	biological_processes	biological_processes			homologous recombination	GO:0035825	homologous recombination		"{""modifier"": ""DECREASED"", ""preferred_term"": ""homologous recombination"", ""term"": {""id"": ""GO:0035825"", ""label"": ""homologous recombination""}}"			DECREASED																								
3316	3685	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	2	Genomic Instability	Loss of HR-mediated repair leads to accumulation of chromosomal aberrations, large-scale genomic rearrangements, and copy number alterations. This pattern of genomic instability, termed 'BRCAness' or homologous recombination deficiency (HRD), is characteristic of BRCA-deficient tumors and creates therapeutic vulnerability to PARP inhibitors.	biological_processes[0]	biological_processes	biological_processes			regulation of DNA damage checkpoint	GO:0010618	regulation of DNA damage checkpoint		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of DNA damage checkpoint"", ""term"": {""id"": ""GO:0010618"", ""label"": ""regulation of DNA damage checkpoint""}}"			ABNORMAL																								
3317	3686	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	pathophysiology	3	Tumor Development	Progressive accumulation of genomic alterations in BRCA-deficient cells leads to transformation and tumor development. The tissue specificity (breast, ovary) may relate to estrogen exposure and proliferative demands on these tissues, though the precise mechanisms remain incompletely understood.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3318	3687	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	phenotypes	0	Breast Cancer	Breast cancer risk is 70-80% for BRCA1 and 60-70% for BRCA2 mutation carriers. BRCA1-associated breast cancers are often triple-negative (ER-/PR-/HER2-) and high grade. BRCA2-associated breast cancers more often express hormone receptors. Risk of contralateral breast cancer is significantly elevated.	phenotype_term	phenotype_term	$	Breast Cancer	Breast cancer risk is 70-80% for BRCA1 and 60-70% for BRCA2 mutation carriers. BRCA1-associated breast cancers are often triple-negative (ER-/PR-/HER2-) and high grade. BRCA2-associated breast cancers more often express hormone receptors. Risk of contralateral breast cancer is significantly elevated.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
3319	3688	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	phenotypes	1	Ovarian Cancer	Ovarian cancer risk is 40-50% for BRCA1 and 15-30% for BRCA2 mutation carriers. Most are high-grade serous carcinomas. Typically presents at earlier ages than sporadic ovarian cancer. Risk-reducing salpingo-oophorectomy is often recommended.	phenotype_term	phenotype_term	$	Ovarian Cancer	Ovarian cancer risk is 40-50% for BRCA1 and 15-30% for BRCA2 mutation carriers. Most are high-grade serous carcinomas. Typically presents at earlier ages than sporadic ovarian cancer. Risk-reducing salpingo-oophorectomy is often recommended.	Ovarian carcinoma	HP:0025318	Ovarian carcinoma		"{""preferred_term"": ""Ovarian carcinoma"", ""term"": {""id"": ""HP:0025318"", ""label"": ""Ovarian carcinoma""}}"																											
3320	3689	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	phenotypes	2	Pancreatic Cancer	Lifetime risk of pancreatic cancer is increased to approximately 2-7%, particularly with BRCA2 mutations. BRCA2 is a recognized pancreatic cancer susceptibility gene. Surveillance may be considered in families with pancreatic cancer history.	phenotype_term	phenotype_term	$	Pancreatic Cancer	Lifetime risk of pancreatic cancer is increased to approximately 2-7%, particularly with BRCA2 mutations. BRCA2 is a recognized pancreatic cancer susceptibility gene. Surveillance may be considered in families with pancreatic cancer history.	Pancreatic adenocarcinoma	HP:0006725	Pancreatic adenocarcinoma		"{""preferred_term"": ""Pancreatic adenocarcinoma"", ""term"": {""id"": ""HP:0006725"", ""label"": ""Pancreatic adenocarcinoma""}}"																											
3321	3690	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	phenotypes	3	Prostate Cancer	BRCA2 mutations confer a 5-8 fold increased risk of prostate cancer, with earlier onset and more aggressive disease. BRCA1 mutations also increase risk but to a lesser degree. PARP inhibitors are effective in BRCA-mutated prostate cancer.	phenotype_term	phenotype_term	$	Prostate Cancer	BRCA2 mutations confer a 5-8 fold increased risk of prostate cancer, with earlier onset and more aggressive disease. BRCA1 mutations also increase risk but to a lesser degree. PARP inhibitors are effective in BRCA-mutated prostate cancer.	Prostate cancer	HP:0012125	Prostate cancer		"{""preferred_term"": ""Prostate cancer"", ""term"": {""id"": ""HP:0012125"", ""label"": ""Prostate cancer""}}"																											
3322	3691	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	phenotypes	4	Male Breast Cancer	Male breast cancer risk is elevated, particularly with BRCA2 mutations (6-8% lifetime risk). BRCA2 is the most common hereditary cause of male breast cancer.	phenotype_term	phenotype_term	$	Male Breast Cancer	Male breast cancer risk is elevated, particularly with BRCA2 mutations (6-8% lifetime risk). BRCA2 is the most common hereditary cause of male breast cancer.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
3323	3692	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	0	Risk-Reducing Mastectomy	Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact.	treatment_term	treatment_term	$	Risk-Reducing Mastectomy	Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3324	3693	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	1	Risk-Reducing Salpingo-Oophorectomy	Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally.	treatment_term	treatment_term	$	Risk-Reducing Salpingo-Oophorectomy	Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3325	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term	treatment_term	$	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}"				olaparib	CHEBI:83766																						
3326	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"																											
3327	3695	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	3	Enhanced Surveillance	For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited.	treatment_term	treatment_term	$	Enhanced Surveillance	For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
3328	3696	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	4	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3329	3702	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	phenotypes	0	Epistaxis		phenotype_term	phenotype_term	$	Epistaxis		Epistaxis	HP:0000421	Epistaxis		"{""preferred_term"": ""Epistaxis"", ""term"": {""id"": ""HP:0000421"", ""label"": ""Epistaxis""}}"																											
3330	3703	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	phenotypes	1	Easy Bruising		phenotype_term	phenotype_term	$	Easy Bruising		Bruising susceptibility	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""Bruising susceptibility"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
3331	3704	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	phenotypes	2	Menorrhagia		phenotype_term	phenotype_term	$	Menorrhagia		Menorrhagia	HP:0000132	Menorrhagia		"{""preferred_term"": ""Menorrhagia"", ""term"": {""id"": ""HP:0000132"", ""label"": ""Menorrhagia""}}"																											
3332	3705	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	0	Desmopressin	Vasopressin analog used to control mild bleeding episodes.	treatment_term	treatment_term	$	Desmopressin	Vasopressin analog used to control mild bleeding episodes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3333	3706	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	1	von Willebrand Factor/Factor VIII Concentrates	Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes.	treatment_term	treatment_term	$	von Willebrand Factor/Factor VIII Concentrates	Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3334	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	cell_types[0]	cell_types	cell_types			enteric neuron	CL:0007011	enteric neuron		"{""modifier"": ""ABSENT"", ""preferred_term"": ""enteric neuron"", ""term"": {""id"": ""CL:0007011"", ""label"": ""enteric neuron""}}"			ABSENT																								
3335	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	biological_processes[0]	biological_processes	biological_processes			neural crest cell migration	GO:0001755	neural crest cell migration		"{""modifier"": ""DECREASED"", ""preferred_term"": ""neural crest cell migration"", ""term"": {""id"": ""GO:0001755"", ""label"": ""neural crest cell migration""}}"			DECREASED																								
3336	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			DECREASED																								
3337	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	locations[0]	locations	locations			myenteric nerve plexus	UBERON:0002439	myenteric nerve plexus		"{""preferred_term"": ""myenteric nerve plexus"", ""term"": {""id"": ""UBERON:0002439"", ""label"": ""myenteric nerve plexus""}}"																											
3338	3723	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	0	Failure of Enteric Ganglion Cell Migration	Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.	locations[1]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
3339	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	cell_types[0]	cell_types	cell_types			enteric neuron	CL:0007011	enteric neuron		"{""modifier"": ""ABSENT"", ""preferred_term"": ""enteric neuron"", ""term"": {""id"": ""CL:0007011"", ""label"": ""enteric neuron""}}"			ABSENT																								
3340	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	biological_processes[0]	biological_processes	biological_processes			neuron differentiation	GO:0030182	neuron differentiation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""neuron differentiation"", ""term"": {""id"": ""GO:0030182"", ""label"": ""neuron differentiation""}}"			ABNORMAL																								
3341	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	biological_processes[1]	biological_processes	biological_processes			peristalsis	GO:0030432	peristalsis		"{""modifier"": ""DECREASED"", ""preferred_term"": ""peristalsis"", ""term"": {""id"": ""GO:0030432"", ""label"": ""peristalsis""}}"			DECREASED																								
3342	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	locations[0]	locations	locations			enteric nervous system	UBERON:0002005	enteric nervous system		"{""preferred_term"": ""enteric nervous system"", ""term"": {""id"": ""UBERON:0002005"", ""label"": ""enteric nervous system""}}"																											
3343	3724	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	pathophysiology	1	Disrupted Enteric Nervous System Development	The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.	locations[1]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
3344	3725	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	0	Chronic Constipation	Persistent difficulty passing stool due to inability of the aganglionic bowel segment to relax and propagate peristalsis.	phenotype_term	phenotype_term	$	Chronic Constipation	Persistent difficulty passing stool due to inability of the aganglionic bowel segment to relax and propagate peristalsis.	Chronic Constipation	HP:0012450	Chronic constipation	Persistently infrequent or difficult defecation lasting more than two weeks.	"{""description"": ""Persistently infrequent or difficult defecation lasting more than two weeks."", ""preferred_term"": ""Chronic Constipation"", ""term"": {""id"": ""HP:0012450"", ""label"": ""Chronic constipation""}}"																											
3345	3726	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	1	Abdominal Distension	Enlargement of the abdomen due to accumulation of gas and stool proximal to the functional obstruction.	phenotype_term	phenotype_term	$	Abdominal Distension	Enlargement of the abdomen due to accumulation of gas and stool proximal to the functional obstruction.	Abdominal distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
3346	3727	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	2	Megacolon	Abnormal dilation of the colon proximal to the aganglionic segment due to functional obstruction and stool accumulation.	phenotype_term	phenotype_term	$	Megacolon	Abnormal dilation of the colon proximal to the aganglionic segment due to functional obstruction and stool accumulation.	Megacolon	HP:6000852	Megacolon		"{""preferred_term"": ""Megacolon"", ""term"": {""id"": ""HP:6000852"", ""label"": ""Megacolon""}}"																											
3347	3728	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	3	Intestinal Obstruction	Functional blockage of the intestine due to absence of peristaltic movement in the aganglionic segment.	phenotype_term	phenotype_term	$	Intestinal Obstruction	Functional blockage of the intestine due to absence of peristaltic movement in the aganglionic segment.	Intestinal obstruction	HP:0005214	Intestinal obstruction		"{""preferred_term"": ""Intestinal obstruction"", ""term"": {""id"": ""HP:0005214"", ""label"": ""Intestinal obstruction""}}"																											
3348	3730	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	5	Failure to Thrive	Poor weight gain and growth due to feeding difficulties, malabsorption, and increased metabolic demands from chronic bowel dysfunction.	phenotype_term	phenotype_term	$	Failure to Thrive	Poor weight gain and growth due to feeding difficulties, malabsorption, and increased metabolic demands from chronic bowel dysfunction.	Failure to Thrive	HP:0001508	Failure to thrive	Inadequate physical growth or weight gain in infants and children.	"{""description"": ""Inadequate physical growth or weight gain in infants and children."", ""preferred_term"": ""Failure to Thrive"", ""term"": {""id"": ""HP:0001508"", ""label"": ""Failure to thrive""}}"																											
3349	3731	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	6	Enterocolitis	Severe inflammation of the intestine that can lead to sepsis, representing the most serious complication of Hirschsprung disease.	phenotype_term	phenotype_term	$	Enterocolitis	Severe inflammation of the intestine that can lead to sepsis, representing the most serious complication of Hirschsprung disease.	Enterocolitis	HP:0004387	Enterocolitis	Inflammation involving both the small intestine and colon.	"{""description"": ""Inflammation involving both the small intestine and colon."", ""preferred_term"": ""Enterocolitis"", ""term"": {""id"": ""HP:0004387"", ""label"": ""Enterocolitis""}}"																											
3350	3732	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	7	Failure to Thrive	Inadequate growth resulting from chronic feeding intolerance and nutritional deficits.	phenotype_term	phenotype_term	$	Failure to Thrive	Inadequate growth resulting from chronic feeding intolerance and nutritional deficits.	Failure to Thrive	HP:0001508	Failure to thrive	Poor weight gain and growth below expected standards for age.	"{""description"": ""Poor weight gain and growth below expected standards for age."", ""preferred_term"": ""Failure to Thrive"", ""term"": {""id"": ""HP:0001508"", ""label"": ""Failure to thrive""}}"																											
3351	3733	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	phenotypes	8	Developmental Delay	Delayed achievement of motor, cognitive, or social milestones, typically secondary to chronic illness and malnutrition.	phenotype_term	phenotype_term	$	Developmental Delay	Delayed achievement of motor, cognitive, or social milestones, typically secondary to chronic illness and malnutrition.	Developmental Delay	HP:0001263	Global developmental delay	Significant lag in achieving age-appropriate developmental milestones.	"{""description"": ""Significant lag in achieving age-appropriate developmental milestones."", ""preferred_term"": ""Developmental Delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
3352	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	Surgical Resection	Removal of the aganglionic segment of the bowel.	treatment_term	treatment_term	$	Surgical Resection	Removal of the aganglionic segment of the bowel.	surgical procedure	MAXO:0000004	surgical procedure	Operative excision of the non-functional aganglionic bowel segment.	"{""description"": ""Operative excision of the non-functional aganglionic bowel segment."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3353	3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	Pull-Through Procedure	Connecting the normal ganglionated bowel to the anus to restore bowel function.	treatment_term	treatment_term	$	Pull-Through Procedure	Connecting the normal ganglionated bowel to the anus to restore bowel function.	surgical procedure	MAXO:0000004	surgical procedure	Reconstructive operation anastomosing normal ganglionated bowel to the anus.	"{""description"": ""Reconstructive operation anastomosing normal ganglionated bowel to the anus."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3354	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	Ostomy	Temporary or permanent stoma creation to divert fecal flow.	treatment_term	treatment_term	$	Ostomy	Temporary or permanent stoma creation to divert fecal flow.	surgical procedure	MAXO:0000004	surgical procedure	Creation of a stoma to divert fecal flow, used temporarily or permanently.	"{""description"": ""Creation of a stoma to divert fecal flow, used temporarily or permanently."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3355	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	gene	gene	$	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	TBX5	hgnc:11610	TBX5		"{""preferred_term"": ""TBX5"", ""term"": {""id"": ""hgnc:11610"", ""label"": ""TBX5""}}"																											
3356	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	cell_types[0]	cell_types	cell_types			Cardiac muscle cell	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiac muscle cell"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3357	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	locations[0]	locations	locations			Heart atrium	UBERON:0002373	heart atrium		"{""preferred_term"": ""Heart atrium"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""heart atrium""}}"																											
3358	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	locations[1]	locations	locations			Forelimb bud	UBERON:0004385	forelimb bud		"{""preferred_term"": ""Forelimb bud"", ""term"": {""id"": ""UBERON:0004385"", ""label"": ""forelimb bud""}}"																											
3359	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	locations[2]	locations	locations			Atrial conduction system	UBERON:0004535	atrial conduction system		"{""preferred_term"": ""Atrial conduction system"", ""term"": {""id"": ""UBERON:0004535"", ""label"": ""atrial conduction system""}}"																											
3360	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	biological_processes[0]	biological_processes	biological_processes			Heart development	GO:0007507	heart development		"{""preferred_term"": ""Heart development"", ""term"": {""id"": ""GO:0007507"", ""label"": ""heart development""}}"																											
3361	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	biological_processes[1]	biological_processes	biological_processes			Atrial septum morphogenesis	GO:0003181	atrial septum morphogenesis		"{""preferred_term"": ""Atrial septum morphogenesis"", ""term"": {""id"": ""GO:0003181"", ""label"": ""atrial septum morphogenesis""}}"																											
3362	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	biological_processes[2]	biological_processes	biological_processes			Cardiac conduction	GO:0061337	cardiac conduction		"{""preferred_term"": ""Cardiac conduction"", ""term"": {""id"": ""GO:0061337"", ""label"": ""cardiac conduction""}}"																											
3363	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	biological_processes[3]	biological_processes	biological_processes			Limb bud formation	GO:0030326	limb bud formation		"{""preferred_term"": ""Limb bud formation"", ""term"": {""id"": ""GO:0030326"", ""label"": ""limb bud formation""}}"																											
3364	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	biological_processes[4]	biological_processes	biological_processes			Regulation of gene expression, epigenetic	GO:0040029	regulation of gene expression, epigenetic		"{""preferred_term"": ""Regulation of gene expression, epigenetic"", ""term"": {""id"": ""GO:0040029"", ""label"": ""regulation of gene expression, epigenetic""}}"																											
3365	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	cellular_components[0]	cellular_components	cellular_components			Chromatin	GO:0000785	chromatin		"{""preferred_term"": ""Chromatin"", ""term"": {""id"": ""GO:0000785"", ""label"": ""chromatin""}}"																											
3366	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	cellular_components[1]	cellular_components	cellular_components			Enhancer	GO:0035326	enhancer		"{""preferred_term"": ""Enhancer"", ""term"": {""id"": ""GO:0035326"", ""label"": ""enhancer""}}"																											
3367	3741	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	0	TBX5 Haploinsufficiency and Enhancer Dysfunction	"Holt-Oram syndrome is caused by heterozygous loss-of-function mutations in TBX5, a T-box transcription factor that acts as a dosage-sensitive regulator of cardiac and forelimb development. TBX5 haploinsufficiency disrupts enhancer accessibility and 3D chromatin architecture at regulatory regions controlling genes essential for atrial identity, chamber septation, and conduction system development. In the limb, TBX5 is critical for forelimb bud initiation and radial patterning in the lateral plate mesoderm. TBX5 cooperates with cardiac transcription factors GATA4 and NKX2-5 at conserved enhancers and requires chromatin remodeling partners (BAF/SWI-SNF and NuRD/CHD4) to maintain cell-type-specific gene expression programs.
"	cellular_components[2]	cellular_components	cellular_components			Nucleosome	GO:0000786	nucleosome		"{""preferred_term"": ""Nucleosome"", ""term"": {""id"": ""GO:0000786"", ""label"": ""nucleosome""}}"																											
3368	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	genes[0]	genes	genes			GATA4	hgnc:4172	GATA4		"{""preferred_term"": ""GATA4"", ""term"": {""id"": ""hgnc:4172"", ""label"": ""GATA4""}}"																											
3369	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	genes[1]	genes	genes			ZFPM2	hgnc:12855	ZFPM2		"{""preferred_term"": ""ZFPM2"", ""term"": {""id"": ""hgnc:12855"", ""label"": ""ZFPM2""}}"																											
3370	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	genes[2]	genes	genes			CHD4	hgnc:1914	CHD4		"{""preferred_term"": ""CHD4"", ""term"": {""id"": ""hgnc:1914"", ""label"": ""CHD4""}}"																											
3371	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	genes[3]	genes	genes			SMARCA4	hgnc:11100	SMARCA4		"{""preferred_term"": ""SMARCA4"", ""term"": {""id"": ""hgnc:11100"", ""label"": ""SMARCA4""}}"																											
3372	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	genes[4]	genes	genes			NKX2-5	hgnc:7781	NKX2-5		"{""preferred_term"": ""NKX2-5"", ""term"": {""id"": ""hgnc:7781"", ""label"": ""NKX2-5""}}"																											
3373	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	cell_types[0]	cell_types	cell_types			Cardiac muscle cell	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiac muscle cell"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3374	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	biological_processes[0]	biological_processes	biological_processes			Regulation of gene expression, epigenetic	GO:0040029	regulation of gene expression, epigenetic		"{""preferred_term"": ""Regulation of gene expression, epigenetic"", ""term"": {""id"": ""GO:0040029"", ""label"": ""regulation of gene expression, epigenetic""}}"																											
3375	3742	157	Holt-Oram syndrome	Holt_Oram.yaml	pathophysiology	1	Cofactor and Chromatin Remodeling Dysfunction	"TBX5 function depends critically on physical interactions with cardiac transcription factor GATA4 and the chromatin modulating protein ZFPM2/FOG2, which together co-occupy atrial-specific enhancers controlling genes required for atrial conduction and calcium handling. Additionally, TBX5 directly interacts with chromatin remodeling complexes including CHD4 (NuRD) and SMARCA4/BRG1 (BAF/SWI-SNF) to maintain accessible chromatin at cardiac enhancers. Reduced TBX5 dosage impairs the formation and maintenance of these enhancer-promoter loops and topologically associating domains (TADs), leading to widespread transcriptional dysregulation of conduction and chamber specification genes.
"	biological_processes[1]	biological_processes	biological_processes			Cardiac conduction	GO:0061337	cardiac conduction		"{""preferred_term"": ""Cardiac conduction"", ""term"": {""id"": ""GO:0061337"", ""label"": ""cardiac conduction""}}"																											
3376	3743	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	0	Upper limb abnormality	"Characteristic skeletal abnormalities of the upper limbs, ranging from thumb anomalies (thumb hypoplasia or aplasia) to severe bilateral upper limb malformations including radial ray defects, carpal abnormalities, and forearm hypoplasia.
"	phenotype_term	phenotype_term	$	Upper limb abnormality	"Characteristic skeletal abnormalities of the upper limbs, ranging from thumb anomalies (thumb hypoplasia or aplasia) to severe bilateral upper limb malformations including radial ray defects, carpal abnormalities, and forearm hypoplasia.
"	Upper limb abnormality	HP:0002817	abnormality of the upper limb		"{""preferred_term"": ""Upper limb abnormality"", ""term"": {""id"": ""HP:0002817"", ""label"": ""abnormality of the upper limb""}}"																											
3377	3744	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	1	Radial ray defect	"Abnormalities of the radial rays (digits 1-5 and their skeletal components on the radial side of the upper limb). Common manifestations include thumb hypoplasia, aplasia, radial bowing, and radial ray defects.
"	phenotype_term	phenotype_term	$	Radial ray defect	"Abnormalities of the radial rays (digits 1-5 and their skeletal components on the radial side of the upper limb). Common manifestations include thumb hypoplasia, aplasia, radial bowing, and radial ray defects.
"	Radial bowing	HP:0002986	radial bowing		"{""preferred_term"": ""Radial bowing"", ""term"": {""id"": ""HP:0002986"", ""label"": ""radial bowing""}}"																											
3378	3745	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	2	Triphalangeal thumb	"A thumb with three phalanges rather than the normal two, presenting as an elongated thumb with an additional bone segment.
"	phenotype_term	phenotype_term	$	Triphalangeal thumb	"A thumb with three phalanges rather than the normal two, presenting as an elongated thumb with an additional bone segment.
"	Triphalangeal thumb	HP:0001199	triphalangeal thumb		"{""preferred_term"": ""Triphalangeal thumb"", ""term"": {""id"": ""HP:0001199"", ""label"": ""triphalangeal thumb""}}"																											
3379	3746	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	3	Atrial septal defect	"Defects in the interatrial septum are the most common cardiac manifestation, typically ostium secundum type but can include other types of ASDs.
"	phenotype_term	phenotype_term	$	Atrial septal defect	"Defects in the interatrial septum are the most common cardiac manifestation, typically ostium secundum type but can include other types of ASDs.
"	Atrial septal defect	HP:0001631	atrial septal defect		"{""preferred_term"": ""Atrial septal defect"", ""term"": {""id"": ""HP:0001631"", ""label"": ""atrial septal defect""}}"																											
3380	3747	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	4	Atrioventricular block	"Electrical conduction defects in the heart, including first-degree atrioventricular block, progressive conduction abnormalities, and other forms of heart block.
"	phenotype_term	phenotype_term	$	Atrioventricular block	"Electrical conduction defects in the heart, including first-degree atrioventricular block, progressive conduction abnormalities, and other forms of heart block.
"	Atrioventricular block	HP:0001678	atrioventricular block		"{""preferred_term"": ""Atrioventricular block"", ""term"": {""id"": ""HP:0001678"", ""label"": ""atrioventricular block""}}"																											
3381	3748	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	5	Atrial fibrillation	"Irregular atrial electrical activity and ineffective atrial contractions, contributing to arrhythmia risk in HOS patients, particularly later in life.
"	phenotype_term	phenotype_term	$	Atrial fibrillation	"Irregular atrial electrical activity and ineffective atrial contractions, contributing to arrhythmia risk in HOS patients, particularly later in life.
"	Atrial fibrillation	HP:0005110	atrial fibrillation		"{""preferred_term"": ""Atrial fibrillation"", ""term"": {""id"": ""HP:0005110"", ""label"": ""atrial fibrillation""}}"																											
3382	3749	157	Holt-Oram syndrome	Holt_Oram.yaml	phenotypes	6	Ventricular septal defect	"Defects in the interventricular septum occurring with lesser frequency than ASDs but still common in HOS patients.
"	phenotype_term	phenotype_term	$	Ventricular septal defect	"Defects in the interventricular septum occurring with lesser frequency than ASDs but still common in HOS patients.
"	Ventricular septal defect	HP:0001629	ventricular septal defect		"{""preferred_term"": ""Ventricular septal defect"", ""term"": {""id"": ""HP:0001629"", ""label"": ""ventricular septal defect""}}"																											
3383	3750	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	0	Cardiac monitoring and evaluation	"Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.
"	treatment_term	treatment_term	$	Cardiac monitoring and evaluation	"Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.
"	cardiac electrophysiologist evaluation	MAXO:0000683	clinical cardiac electrophysiologist evaluation		"{""preferred_term"": ""cardiac electrophysiologist evaluation"", ""term"": {""id"": ""MAXO:0000683"", ""label"": ""clinical cardiac electrophysiologist evaluation""}}"																											
3384	3751	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	1	Surgical repair of cardiac defects	"Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.
"	treatment_term	treatment_term	$	Surgical repair of cardiac defects	"Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3385	3752	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	2	Orthopedic management	"Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.
"	treatment_term	treatment_term	$	Orthopedic management	"Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3386	3753	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	infectious_agent	0	Trypanosoma brucei gambiense	Subspecies causing gambiense human African trypanosomiasis.	infectious_agent_term	infectious_agent_term	$	Trypanosoma brucei gambiense	Subspecies causing gambiense human African trypanosomiasis.	Trypanosoma brucei gambiense	NCBITaxon:31285	Trypanosoma brucei gambiense		"{""preferred_term"": ""Trypanosoma brucei gambiense"", ""term"": {""id"": ""NCBITaxon:31285"", ""label"": ""Trypanosoma brucei gambiense""}}"																											
3387	3754	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	infectious_agent	1	Trypanosoma brucei rhodesiense	Subspecies causing rhodesiense human African trypanosomiasis.	infectious_agent_term	infectious_agent_term	$	Trypanosoma brucei rhodesiense	Subspecies causing rhodesiense human African trypanosomiasis.	Trypanosoma brucei rhodesiense	NCBITaxon:31286	Trypanosoma brucei rhodesiense		"{""preferred_term"": ""Trypanosoma brucei rhodesiense"", ""term"": {""id"": ""NCBITaxon:31286"", ""label"": ""Trypanosoma brucei rhodesiense""}}"																											
3388	3756	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	phenotypes	0	Sleep-wake cycle disturbance		phenotype_term	phenotype_term	$	Sleep-wake cycle disturbance		Sleep-wake cycle disturbance	HP:0006979	Sleep-wake cycle disturbance		"{""preferred_term"": ""Sleep-wake cycle disturbance"", ""term"": {""id"": ""HP:0006979"", ""label"": ""Sleep-wake cycle disturbance""}}"																											
3389	3760	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	treatments	0	Fexinidazole therapy	Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease.	treatment_term	treatment_term	$	Fexinidazole therapy	Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3390	3782	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	0	CAG Repeat Expansion in the HTT Gene	Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3391	3782	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	0	CAG Repeat Expansion in the HTT Gene	Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.	locations[1]	locations	locations			cerebral cortex	UBERON:0000955	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""cerebral cortex""}}"																											
3392	3782	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	0	CAG Repeat Expansion in the HTT Gene	Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.	biological_processes[0]	biological_processes	biological_processes			DNA mismatch repair	GO:0006298	mismatch repair		"{""preferred_term"": ""DNA mismatch repair"", ""term"": {""id"": ""GO:0006298"", ""label"": ""mismatch repair""}}"																											
3393	3783	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	1	Mutant Huntingtin Protein Aggregation	Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3394	3783	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	1	Mutant Huntingtin Protein Aggregation	Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.	locations[1]	locations	locations			cerebral cortex	UBERON:0000955	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""cerebral cortex""}}"																											
3395	3783	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	1	Mutant Huntingtin Protein Aggregation	Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.	cell_types[0]	cell_types	cell_types			medium spiny neuron	CL:1001474	medium spiny neuron		"{""preferred_term"": ""medium spiny neuron"", ""term"": {""id"": ""CL:1001474"", ""label"": ""medium spiny neuron""}}"																											
3396	3783	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	1	Mutant Huntingtin Protein Aggregation	Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.	biological_processes[0]	biological_processes	biological_processes			protein aggregation	GO:0070841	inclusion body assembly		"{""preferred_term"": ""protein aggregation"", ""term"": {""id"": ""GO:0070841"", ""label"": ""inclusion body assembly""}}"																											
3397	3783	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	1	Mutant Huntingtin Protein Aggregation	Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.	biological_processes[1]	biological_processes	biological_processes			autophagy	GO:0006914	autophagy		"{""preferred_term"": ""autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
3398	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3399	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	cell_types[0]	cell_types	cell_types			medium spiny neuron	CL:1001474	medium spiny neuron		"{""preferred_term"": ""medium spiny neuron"", ""term"": {""id"": ""CL:1001474"", ""label"": ""medium spiny neuron""}}"																											
3400	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3401	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	biological_processes[0]	biological_processes	biological_processes			chemical synaptic transmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""chemical synaptic transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
3402	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	biological_processes[1]	biological_processes	biological_processes			excitatory postsynaptic potential	GO:0060079	excitatory postsynaptic potential		"{""preferred_term"": ""excitatory postsynaptic potential"", ""term"": {""id"": ""GO:0060079"", ""label"": ""excitatory postsynaptic potential""}}"																											
3403	3784	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	2	Excitotoxicity	Overactivation of glutamate receptors leading to neuronal damage.	biological_processes[2]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
3404	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3405	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	locations[1]	locations	locations			cerebral cortex	UBERON:0000955	cerebral cortex		"{""preferred_term"": ""cerebral cortex"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""cerebral cortex""}}"																											
3406	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	cell_types[0]	cell_types	cell_types			medium spiny neuron	CL:1001474	medium spiny neuron		"{""preferred_term"": ""medium spiny neuron"", ""term"": {""id"": ""CL:1001474"", ""label"": ""medium spiny neuron""}}"																											
3407	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3408	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	biological_processes[0]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
3409	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	biological_processes[1]	biological_processes	biological_processes			mitochondrion organization	GO:0007005	mitochondrion organization		"{""preferred_term"": ""mitochondrion organization"", ""term"": {""id"": ""GO:0007005"", ""label"": ""mitochondrion organization""}}"																											
3410	3785	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	3	Mitochondrial Dysfunction	Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.	biological_processes[2]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
3411	3786	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	4	Neuroinflammation	Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3412	3786	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	4	Neuroinflammation	Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
3413	3786	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	4	Neuroinflammation	Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3414	3786	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	4	Neuroinflammation	Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3415	3786	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	4	Neuroinflammation	Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.	biological_processes[1]	biological_processes	biological_processes			microglial cell activation	GO:0001774	microglial cell activation		"{""preferred_term"": ""microglial cell activation"", ""term"": {""id"": ""GO:0001774"", ""label"": ""microglial cell activation""}}"																											
3416	3787	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	5	D2 Receptor Medium Spiny Neuron Selective Vulnerability	D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.	locations[0]	locations	locations			striatum	UBERON:0001880	striatum		"{""preferred_term"": ""striatum"", ""term"": {""id"": ""UBERON:0001880"", ""label"": ""striatum""}}"																											
3417	3787	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	5	D2 Receptor Medium Spiny Neuron Selective Vulnerability	D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.	cell_types[0]	cell_types	cell_types			medium spiny neuron	CL:1001474	medium spiny neuron		"{""preferred_term"": ""medium spiny neuron"", ""term"": {""id"": ""CL:1001474"", ""label"": ""medium spiny neuron""}}"																											
3418	3787	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	5	D2 Receptor Medium Spiny Neuron Selective Vulnerability	D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.	biological_processes[0]	biological_processes	biological_processes			protein aggregation	GO:0070841	inclusion body assembly		"{""preferred_term"": ""protein aggregation"", ""term"": {""id"": ""GO:0070841"", ""label"": ""inclusion body assembly""}}"																											
3419	3787	159	Huntington's Disease	Huntingtons_Disease.yaml	pathophysiology	5	D2 Receptor Medium Spiny Neuron Selective Vulnerability	D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.	biological_processes[1]	biological_processes	biological_processes			synaptic transmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""synaptic transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
3420	3788	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	0	Chorea		phenotype_term	phenotype_term	$	Chorea		Chorea	HP:0002072	Chorea		"{""preferred_term"": ""Chorea"", ""term"": {""id"": ""HP:0002072"", ""label"": ""Chorea""}}"																											
3421	3789	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	1	Dystonia	Involuntary muscle contractions causing twisting and repetitive movements or abnormal postures.	phenotype_term	phenotype_term	$	Dystonia	Involuntary muscle contractions causing twisting and repetitive movements or abnormal postures.	Dystonia	HP:0001332	Dystonia		"{""preferred_term"": ""Dystonia"", ""term"": {""id"": ""HP:0001332"", ""label"": ""Dystonia""}}"																											
3422	3790	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	2	Bradykinesia	Slowness of movement, a common motor symptom in Huntington's Disease.	phenotype_term	phenotype_term	$	Bradykinesia	Slowness of movement, a common motor symptom in Huntington's Disease.	Bradykinesia	HP:0002067	Bradykinesia		"{""preferred_term"": ""Bradykinesia"", ""term"": {""id"": ""HP:0002067"", ""label"": ""Bradykinesia""}}"																											
3423	3791	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	3	Cognitive Impairment	Progressive decline in cognitive function affecting memory, executive function, and other cognitive domains.	phenotype_term	phenotype_term	$	Cognitive Impairment	Progressive decline in cognitive function affecting memory, executive function, and other cognitive domains.	Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
3424	3792	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	4	Depression	Mood disorder characterized by persistent sadness and loss of interest, common psychiatric manifestation in HD.	phenotype_term	phenotype_term	$	Depression	Mood disorder characterized by persistent sadness and loss of interest, common psychiatric manifestation in HD.	Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
3425	3793	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	5	Weight Loss	Progressive unintentional weight loss due to metabolic changes and systemic effects.	phenotype_term	phenotype_term	$	Weight Loss	Progressive unintentional weight loss due to metabolic changes and systemic effects.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3426	3794	159	Huntington's Disease	Huntingtons_Disease.yaml	phenotypes	6	Dysphagia	Difficulty swallowing that occurs in later stages of the disease.	phenotype_term	phenotype_term	$	Dysphagia	Difficulty swallowing that occurs in later stages of the disease.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
3427	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	Tetrabenazine	Used to manage chorea by depleting dopamine.	treatment_term	treatment_term	$	Tetrabenazine	Used to manage chorea by depleting dopamine.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3428	3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	Antipsychotic Medications	Used for psychiatric symptoms like irritability and agitation.	treatment_term	treatment_term	$	Antipsychotic Medications	Used for psychiatric symptoms like irritability and agitation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3429	3798	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	2	Selective Serotonin Reuptake Inhibitors (SSRIs)	Used to manage depression.	treatment_term	treatment_term	$	Selective Serotonin Reuptake Inhibitors (SSRIs)	Used to manage depression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3430	3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	Physical Therapy	Helps maintain mobility and function.	treatment_term	treatment_term	$	Physical Therapy	Helps maintain mobility and function.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3431	3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	Speech Therapy	Helps manage dysarthria and dysphagia.	treatment_term	treatment_term	$	Speech Therapy	Helps manage dysarthria and dysphagia.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
3432	3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	Occupational Therapy	Assists with daily living activities.	treatment_term	treatment_term	$	Occupational Therapy	Assists with daily living activities.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3433	3802	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	6	Genetic Counseling	Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.	treatment_term	treatment_term	$	Genetic Counseling	Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3434	3812	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	1	Left Ventricular Hypertrophy	The heart muscle thickens to cope with increased workload, but this can lead to stiffness and impaired filling.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3435	3814	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	3	Cardiac Fibrosis	Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.	cell_types[0]	cell_types	cell_types			Cardiac Fibroblast	CL:0002548	fibroblast of cardiac tissue		"{""preferred_term"": ""Cardiac Fibroblast"", ""term"": {""id"": ""CL:0002548"", ""label"": ""fibroblast of cardiac tissue""}}"																											
3436	3814	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	3	Cardiac Fibrosis	Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
3437	3814	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	3	Cardiac Fibrosis	Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.	biological_processes[1]	biological_processes	biological_processes			collagen fibril organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""collagen fibril organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
3438	3814	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	3	Cardiac Fibrosis	Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.	locations[0]	locations	locations			myocardial interstitium				"{""preferred_term"": ""myocardial interstitium""}"																											
3439	3814	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	3	Cardiac Fibrosis	Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.	locations[1]	locations	locations			perivascular space				"{""preferred_term"": ""perivascular space""}"																											
3440	3815	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	4	Coronary Microvascular Dysfunction	Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
3441	3815	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	4	Coronary Microvascular Dysfunction	Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.	cell_types[1]	cell_types	cell_types			pericyte	CL:0000669	pericyte		"{""preferred_term"": ""pericyte"", ""term"": {""id"": ""CL:0000669"", ""label"": ""pericyte""}}"																											
3442	3815	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	4	Coronary Microvascular Dysfunction	Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.	biological_processes[0]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"																											
3443	3815	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	4	Coronary Microvascular Dysfunction	Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.	biological_processes[1]	biological_processes	biological_processes			regulation of nitric oxide biosynthetic process	GO:0045428	regulation of nitric oxide biosynthetic process		"{""preferred_term"": ""regulation of nitric oxide biosynthetic process"", ""term"": {""id"": ""GO:0045428"", ""label"": ""regulation of nitric oxide biosynthetic process""}}"																											
3444	3815	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	4	Coronary Microvascular Dysfunction	Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.	locations[0]	locations	locations			coronary microvasculature				"{""preferred_term"": ""coronary microvasculature""}"																											
3445	3816	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	5	Oxidative Stress and Mitochondrial Dysfunction	NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in response to mechanical stress and Ang II signaling. This oxidative stress damages mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways including NF-B.	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
3446	3816	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	5	Oxidative Stress and Mitochondrial Dysfunction	NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in response to mechanical stress and Ang II signaling. This oxidative stress damages mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways including NF-B.	biological_processes[1]	biological_processes	biological_processes			superoxide metabolic process	GO:0006801	superoxide metabolic process		"{""preferred_term"": ""superoxide metabolic process"", ""term"": {""id"": ""GO:0006801"", ""label"": ""superoxide metabolic process""}}"																											
3447	3816	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	5	Oxidative Stress and Mitochondrial Dysfunction	NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in response to mechanical stress and Ang II signaling. This oxidative stress damages mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways including NF-B.	biological_processes[2]	biological_processes	biological_processes			mitochondrial electron transport	GO:0006123	mitochondrial electron transport, NADH to ubiquinone		"{""preferred_term"": ""mitochondrial electron transport"", ""term"": {""id"": ""GO:0006123"", ""label"": ""mitochondrial electron transport, NADH to ubiquinone""}}"																											
3448	3816	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	5	Oxidative Stress and Mitochondrial Dysfunction	NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in response to mechanical stress and Ang II signaling. This oxidative stress damages mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways including NF-B.	cellular_components[0]	cellular_components	cellular_components			mitochondrion	GO:0005739	mitochondrion		"{""preferred_term"": ""mitochondrion"", ""term"": {""id"": ""GO:0005739"", ""label"": ""mitochondrion""}}"																											
3449	3817	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	6	Inflammasome Activation	Pressure overload and oxidative stress activate the NLRP3 inflammasome, leading to caspase-1 activation and release of IL-1 and IL-18. This inflammatory signaling amplifies cardiac fibrosis, hypertrophy, and adverse remodeling.	biological_processes[0]	biological_processes	biological_processes			inflammasome complex assembly	GO:0061702	inflammasome complex assembly		"{""preferred_term"": ""inflammasome complex assembly"", ""term"": {""id"": ""GO:0061702"", ""label"": ""inflammasome complex assembly""}}"																											
3450	3817	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	pathophysiology	6	Inflammasome Activation	Pressure overload and oxidative stress activate the NLRP3 inflammasome, leading to caspase-1 activation and release of IL-1 and IL-18. This inflammatory signaling amplifies cardiac fibrosis, hypertrophy, and adverse remodeling.	biological_processes[1]	biological_processes	biological_processes			interleukin-1 beta production	GO:0032611	interleukin-1 beta production		"{""preferred_term"": ""interleukin-1 beta production"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
3451	3818	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	0	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3452	3819	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	1	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
3453	3820	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	2	Arrhythmias		phenotype_term	phenotype_term	$	Arrhythmias		Arrhythmias	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmias"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
3454	3821	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3455	3822	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	4	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
3456	3823	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	5	Arrhythmias		phenotype_term	phenotype_term	$	Arrhythmias		Arrhythmias	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmias"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
3457	3824	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	6	Aortic Dissection		phenotype_term	phenotype_term	$	Aortic Dissection		Aortic Dissection	HP:0002647	Aortic dissection		"{""preferred_term"": ""Aortic Dissection"", ""term"": {""id"": ""HP:0002647"", ""label"": ""Aortic dissection""}}"																											
3458	3825	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	7	Stroke		phenotype_term	phenotype_term	$	Stroke		Stroke	HP:0001297	Stroke		"{""preferred_term"": ""Stroke"", ""term"": {""id"": ""HP:0001297"", ""label"": ""Stroke""}}"																											
3459	3826	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	8	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3460	3827	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	9	Proteinuria		phenotype_term	phenotype_term	$	Proteinuria		Proteinuria	HP:0000093	Proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""Proteinuria""}}"																											
3461	3828	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	10	Reduced Exercise Tolerance		phenotype_term	phenotype_term	$	Reduced Exercise Tolerance		Reduced Exercise Tolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Reduced Exercise Tolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
3462	3829	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	11	Microvascular Angina		phenotype_term	phenotype_term	$	Microvascular Angina		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
3463	3830	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	12	Palpitations		phenotype_term	phenotype_term	$	Palpitations		Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
3464	3831	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	13	Syncope		phenotype_term	phenotype_term	$	Syncope		Syncope	HP:0001279	Syncope		"{""preferred_term"": ""Syncope"", ""term"": {""id"": ""HP:0001279"", ""label"": ""Syncope""}}"																											
3465	3832	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	14	Heart Failure Exacerbations		phenotype_term	phenotype_term	$	Heart Failure Exacerbations		Heart Failure Exacerbations	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Heart Failure Exacerbations"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
3466	3833	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	15	Left Ventricular Diastolic Dysfunction		phenotype_term	phenotype_term	$	Left Ventricular Diastolic Dysfunction		Left ventricular diastolic dysfunction	HP:0025168	Left ventricular diastolic dysfunction		"{""preferred_term"": ""Left ventricular diastolic dysfunction"", ""term"": {""id"": ""HP:0025168"", ""label"": ""Left ventricular diastolic dysfunction""}}"																											
3467	3834	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	phenotypes	16	Concentric Left Ventricular Hypertrophy		phenotype_term	phenotype_term	$	Concentric Left Ventricular Hypertrophy		Left ventricular hypertrophy	HP:0001712	Left ventricular hypertrophy		"{""preferred_term"": ""Left ventricular hypertrophy"", ""term"": {""id"": ""HP:0001712"", ""label"": ""Left ventricular hypertrophy""}}"																											
3468	3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	Antihypertensive Therapy	Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.	treatment_term	treatment_term	$	Antihypertensive Therapy	Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
3469	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	ACE Inhibitors or ARBs	First-line agents that reduce workload on the heart.	treatment_term	treatment_term	$	ACE Inhibitors or ARBs	First-line agents that reduce workload on the heart.	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy		"{""preferred_term"": ""ACE inhibitor therapy"", ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}"																											
3470	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	Beta Blockers	Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.	treatment_term	treatment_term	$	Beta Blockers	Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3471	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	Diuretics	Reduce fluid overload and congestion in heart failure.	treatment_term	treatment_term	$	Diuretics	Reduce fluid overload and congestion in heart failure.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3472	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	Mineralocorticoid Receptor Antagonists	Further regulate fluid balance and have direct anti-fibrotic effects on the heart.	treatment_term	treatment_term	$	Mineralocorticoid Receptor Antagonists	Further regulate fluid balance and have direct anti-fibrotic effects on the heart.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3473	3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	Lifestyle Modifications	Sodium restriction, physical activity, stress reduction, and other supportive measures.	treatment_term	treatment_term	$	Lifestyle Modifications	Sodium restriction, physical activity, stress reduction, and other supportive measures.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3474	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3475	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	locations[0]	locations	locations			left ventricle	UBERON:0002084	heart left ventricle		"{""preferred_term"": ""left ventricle"", ""term"": {""id"": ""UBERON:0002084"", ""label"": ""heart left ventricle""}}"																											
3476	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	locations[1]	locations	locations			interventricular septum	UBERON:0002094	interventricular septum		"{""preferred_term"": ""interventricular septum"", ""term"": {""id"": ""UBERON:0002094"", ""label"": ""interventricular septum""}}"																											
3477	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	cellular_components[0]	cellular_components	cellular_components			sarcomere	GO:0030017	sarcomere		"{""preferred_term"": ""sarcomere"", ""term"": {""id"": ""GO:0030017"", ""label"": ""sarcomere""}}"																											
3478	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	cellular_components[1]	cellular_components	cellular_components			thick filament	GO:0005863	myosin filament		"{""preferred_term"": ""thick filament"", ""term"": {""id"": ""GO:0005863"", ""label"": ""myosin filament""}}"																											
3479	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	cellular_components[2]	cellular_components	cellular_components			thin filament	GO:0005865	striated muscle thin filament		"{""preferred_term"": ""thin filament"", ""term"": {""id"": ""GO:0005865"", ""label"": ""striated muscle thin filament""}}"																											
3480	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	biological_processes[0]	biological_processes	biological_processes			muscle contraction	GO:0006936	muscle contraction		"{""preferred_term"": ""muscle contraction"", ""term"": {""id"": ""GO:0006936"", ""label"": ""muscle contraction""}}"																											
3481	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	biological_processes[1]	biological_processes	biological_processes			regulation of heart contraction	GO:0008016	regulation of heart contraction		"{""preferred_term"": ""regulation of heart contraction"", ""term"": {""id"": ""GO:0008016"", ""label"": ""regulation of heart contraction""}}"																											
3482	3858	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	0	Sarcomere Protein Mutations	Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle. The central biophysical abnormality is sarcomere hypercontractility with increased myosin duty ratio and power, resulting in impaired relaxation and elevated energetic cost of contraction.	biological_processes[2]	biological_processes	biological_processes			ATP hydrolysis activity	GO:0016887	ATP hydrolysis activity		"{""preferred_term"": ""ATP hydrolysis activity"", ""term"": {""id"": ""GO:0016887"", ""label"": ""ATP hydrolysis activity""}}"																											
3483	3859	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	1	Myocyte Disarray	Disorganization of heart muscle cells contributes to the stiffness and dysfunction of the myocardium. Loss of physiological fiber alignment and orientation creates structural abnormalities that impair contractile efficiency and promote arrhythmogenic substrate.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3484	3859	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	1	Myocyte Disarray	Disorganization of heart muscle cells contributes to the stiffness and dysfunction of the myocardium. Loss of physiological fiber alignment and orientation creates structural abnormalities that impair contractile efficiency and promote arrhythmogenic substrate.	locations[0]	locations	locations			ventricular myocardium	UBERON:0002084	heart left ventricle		"{""preferred_term"": ""ventricular myocardium"", ""term"": {""id"": ""UBERON:0002084"", ""label"": ""heart left ventricle""}}"																											
3485	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	cell_types[0]	cell_types	cell_types			Interstitial Cells	CL:4030031	interstitial cell		"{""preferred_term"": ""Interstitial Cells"", ""term"": {""id"": ""CL:4030031"", ""label"": ""interstitial cell""}}"																											
3486	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	cell_types[1]	cell_types	cell_types			cardiac fibroblast	CL:0002548	fibroblast of cardiac tissue		"{""preferred_term"": ""cardiac fibroblast"", ""term"": {""id"": ""CL:0002548"", ""label"": ""fibroblast of cardiac tissue""}}"																											
3487	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	locations[0]	locations	locations			myocardial interstitium	UBERON:0002084	heart left ventricle		"{""preferred_term"": ""myocardial interstitium"", ""term"": {""id"": ""UBERON:0002084"", ""label"": ""heart left ventricle""}}"																											
3488	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
3489	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	biological_processes[1]	biological_processes	biological_processes			response to TGF-beta	GO:0071559	response to transforming growth factor beta		"{""preferred_term"": ""response to TGF-beta"", ""term"": {""id"": ""GO:0071559"", ""label"": ""response to transforming growth factor beta""}}"																											
3490	3860	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	2	Myocardial Fibrosis	Increased collagen deposition by interstitial cells contributes to myocardial stiffness. Activation of TGF-beta and MAPK signaling pathways promotes extracellular matrix remodeling and fibrosis, which is a progressive phenomenon associated with greater disease severity.	cellular_components[0]	cellular_components	cellular_components			extracellular matrix	GO:0031012	extracellular matrix		"{""preferred_term"": ""extracellular matrix"", ""term"": {""id"": ""GO:0031012"", ""label"": ""extracellular matrix""}}"																											
3491	3861	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	3	Altered Calcium Handling	Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3492	3861	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	3	Altered Calcium Handling	Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.	biological_processes[0]	biological_processes	biological_processes			calcium ion transport	GO:0006816	calcium ion transport		"{""preferred_term"": ""calcium ion transport"", ""term"": {""id"": ""GO:0006816"", ""label"": ""calcium ion transport""}}"																											
3493	3861	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	3	Altered Calcium Handling	Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.	biological_processes[1]	biological_processes	biological_processes			regulation of cardiac muscle contraction	GO:0055117	regulation of cardiac muscle contraction		"{""preferred_term"": ""regulation of cardiac muscle contraction"", ""term"": {""id"": ""GO:0055117"", ""label"": ""regulation of cardiac muscle contraction""}}"																											
3494	3861	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	3	Altered Calcium Handling	Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.	cellular_components[0]	cellular_components	cellular_components			sarcoplasmic reticulum	GO:0016529	sarcoplasmic reticulum		"{""preferred_term"": ""sarcoplasmic reticulum"", ""term"": {""id"": ""GO:0016529"", ""label"": ""sarcoplasmic reticulum""}}"																											
3495	3861	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	3	Altered Calcium Handling	Increased myofilament calcium sensitivity and impaired diastolic calcium removal lead to diastolic dysfunction and promote pro-hypertrophic signaling. Altered calcium homeostasis contributes to both contractile abnormalities and arrhythmogenic substrate.	locations[0]	locations	locations			left ventricle	UBERON:0002084	heart left ventricle		"{""preferred_term"": ""left ventricle"", ""term"": {""id"": ""UBERON:0002084"", ""label"": ""heart left ventricle""}}"																											
3496	3862	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	4	Mitochondrial Dysfunction	Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3497	3862	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	4	Mitochondrial Dysfunction	Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.	biological_processes[0]	biological_processes	biological_processes			ATP metabolic process	GO:0046034	ATP metabolic process		"{""preferred_term"": ""ATP metabolic process"", ""term"": {""id"": ""GO:0046034"", ""label"": ""ATP metabolic process""}}"																											
3498	3862	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	4	Mitochondrial Dysfunction	Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.	biological_processes[1]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
3499	3862	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	4	Mitochondrial Dysfunction	Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.	cellular_components[0]	cellular_components	cellular_components			mitochondrion	GO:0005739	mitochondrion		"{""preferred_term"": ""mitochondrion"", ""term"": {""id"": ""GO:0005739"", ""label"": ""mitochondrion""}}"																											
3500	3862	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	4	Mitochondrial Dysfunction	Elevated energetic cost of sarcomere hypercontractility leads to mitochondrial stress and downregulation of energy metabolism pathways. Impaired ATP production contributes to contractile dysfunction and cellular remodeling.	locations[0]	locations	locations			myocardium	UBERON:0002084	heart left ventricle		"{""preferred_term"": ""myocardium"", ""term"": {""id"": ""UBERON:0002084"", ""label"": ""heart left ventricle""}}"																											
3501	3863	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	5	Left Ventricular Outflow Tract Obstruction	Asymmetric septal hypertrophy combined with systolic anterior motion of the mitral valve creates dynamic obstruction to blood flow. Venturi forces draw the mitral valve toward the septum, elevating wall stress and contributing to ischemia and further hypertrophic remodeling.	cell_types[0]	cell_types	cell_types			Cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""Cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
3502	3863	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	5	Left Ventricular Outflow Tract Obstruction	Asymmetric septal hypertrophy combined with systolic anterior motion of the mitral valve creates dynamic obstruction to blood flow. Venturi forces draw the mitral valve toward the septum, elevating wall stress and contributing to ischemia and further hypertrophic remodeling.	locations[0]	locations	locations			interventricular septum	UBERON:0002094	interventricular septum		"{""preferred_term"": ""interventricular septum"", ""term"": {""id"": ""UBERON:0002094"", ""label"": ""interventricular septum""}}"																											
3503	3863	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	5	Left Ventricular Outflow Tract Obstruction	Asymmetric septal hypertrophy combined with systolic anterior motion of the mitral valve creates dynamic obstruction to blood flow. Venturi forces draw the mitral valve toward the septum, elevating wall stress and contributing to ischemia and further hypertrophic remodeling.	locations[1]	locations	locations			mitral valve	UBERON:0002135	mitral valve		"{""preferred_term"": ""mitral valve"", ""term"": {""id"": ""UBERON:0002135"", ""label"": ""mitral valve""}}"																											
3504	3863	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	pathophysiology	5	Left Ventricular Outflow Tract Obstruction	Asymmetric septal hypertrophy combined with systolic anterior motion of the mitral valve creates dynamic obstruction to blood flow. Venturi forces draw the mitral valve toward the septum, elevating wall stress and contributing to ischemia and further hypertrophic remodeling.	locations[2]	locations	locations			left ventricular outflow tract	UBERON:0016480	cardiac outflow tract		"{""preferred_term"": ""left ventricular outflow tract"", ""term"": {""id"": ""UBERON:0016480"", ""label"": ""cardiac outflow tract""}}"																											
3505	3864	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	0	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
3506	3865	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	1	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3507	3866	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	2	Syncope		phenotype_term	phenotype_term	$	Syncope		Syncope	HP:0001279	Syncope		"{""preferred_term"": ""Syncope"", ""term"": {""id"": ""HP:0001279"", ""label"": ""Syncope""}}"																											
3508	3867	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	3	Arrhythmias		phenotype_term	phenotype_term	$	Arrhythmias		Arrhythmias	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmias"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
3509	3868	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	4	Arrhythmias		phenotype_term	phenotype_term	$	Arrhythmias		Arrhythmias	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmias"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
3510	3870	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3511	3871	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	7	Palpitations		phenotype_term	phenotype_term	$	Palpitations		Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
3512	3872	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	8	Sudden Cardiac Death		phenotype_term	phenotype_term	$	Sudden Cardiac Death		Sudden Cardiac Death	HP:0001645	Sudden cardiac death		"{""preferred_term"": ""Sudden Cardiac Death"", ""term"": {""id"": ""HP:0001645"", ""label"": ""Sudden cardiac death""}}"																											
3513	3873	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	9	Left Ventricular Hypertrophy		phenotype_term	phenotype_term	$	Left Ventricular Hypertrophy		Left ventricular hypertrophy	HP:0001712	Left ventricular hypertrophy		"{""preferred_term"": ""Left ventricular hypertrophy"", ""term"": {""id"": ""HP:0001712"", ""label"": ""Left ventricular hypertrophy""}}"																											
3514	3874	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	phenotypes	10	Atrial Fibrillation		phenotype_term	phenotype_term	$	Atrial Fibrillation		Atrial fibrillation	HP:0005110	Atrial fibrillation		"{""preferred_term"": ""Atrial fibrillation"", ""term"": {""id"": ""HP:0005110"", ""label"": ""Atrial fibrillation""}}"																											
3515	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	Beta Blockers	Used to reduce heart rate and improve symptoms	treatment_term	treatment_term	$	Beta Blockers	Used to reduce heart rate and improve symptoms	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3516	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	Calcium Channel Blockers	Help to relax heart muscle and improve blood flow	treatment_term	treatment_term	$	Calcium Channel Blockers	Help to relax heart muscle and improve blood flow	calcium channel blocking agent therapy	MAXO:0000434	calcium channel blocking agent therapy		"{""preferred_term"": ""calcium channel blocking agent therapy"", ""term"": {""id"": ""MAXO:0000434"", ""label"": ""calcium channel blocking agent therapy""}}"																											
3517	3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	Septal Myectomy	Surgical removal of part of the thickened heart muscle	treatment_term	treatment_term	$	Septal Myectomy	Surgical removal of part of the thickened heart muscle	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3518	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	Alcohol Septal Ablation	Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle	treatment_term	treatment_term	$	Alcohol Septal Ablation	Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3519	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	Implantable Cardioverter Defibrillator (ICD)	Prevents sudden cardiac death in high-risk patients	treatment_term	treatment_term	$	Implantable Cardioverter Defibrillator (ICD)	Prevents sudden cardiac death in high-risk patients	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3520	3885	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	0	Type II Collagen Structural Defect	"COL2A1 mutations disrupt type II collagen triple helix assembly. In hypochondrogenesis, mutations typically allow some functional collagen production, resulting in a slightly less severe phenotype than ACG2. The abnormal collagen compromises cartilage extracellular matrix integrity.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
3521	3885	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	0	Type II Collagen Structural Defect	"COL2A1 mutations disrupt type II collagen triple helix assembly. In hypochondrogenesis, mutations typically allow some functional collagen production, resulting in a slightly less severe phenotype than ACG2. The abnormal collagen compromises cartilage extracellular matrix integrity.
"	cell_types[1]	cell_types	cell_types			Growth Plate Chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth Plate Chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
3522	3885	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	0	Type II Collagen Structural Defect	"COL2A1 mutations disrupt type II collagen triple helix assembly. In hypochondrogenesis, mutations typically allow some functional collagen production, resulting in a slightly less severe phenotype than ACG2. The abnormal collagen compromises cartilage extracellular matrix integrity.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
3523	3885	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	0	Type II Collagen Structural Defect	"COL2A1 mutations disrupt type II collagen triple helix assembly. In hypochondrogenesis, mutations typically allow some functional collagen production, resulting in a slightly less severe phenotype than ACG2. The abnormal collagen compromises cartilage extracellular matrix integrity.
"	biological_processes[1]	biological_processes	biological_processes			Cartilage Development	GO:0051216	cartilage development		"{""preferred_term"": ""Cartilage Development"", ""term"": {""id"": ""GO:0051216"", ""label"": ""cartilage development""}}"																											
3524	3886	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	1	Endoplasmic Reticulum Stress and Chondrocyte Apoptosis	"Misfolded type II collagen accumulates in the endoplasmic reticulum of chondrocytes, causing ER stress and activation of the unfolded protein response. Chronic ER stress leads to chondrocyte apoptosis, particularly in the growth plate, disrupting normal endochondral ossification.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
3525	3886	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	1	Endoplasmic Reticulum Stress and Chondrocyte Apoptosis	"Misfolded type II collagen accumulates in the endoplasmic reticulum of chondrocytes, causing ER stress and activation of the unfolded protein response. Chronic ER stress leads to chondrocyte apoptosis, particularly in the growth plate, disrupting normal endochondral ossification.
"	biological_processes[0]	biological_processes	biological_processes			ER Stress Response	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""ER Stress Response"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
3526	3886	162	Hypochondrogenesis	Hypochondrogenesis.yaml	pathophysiology	1	Endoplasmic Reticulum Stress and Chondrocyte Apoptosis	"Misfolded type II collagen accumulates in the endoplasmic reticulum of chondrocytes, causing ER stress and activation of the unfolded protein response. Chronic ER stress leads to chondrocyte apoptosis, particularly in the growth plate, disrupting normal endochondral ossification.
"	biological_processes[1]	biological_processes	biological_processes			Apoptosis	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptosis"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
3527	3887	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	0	Severe Micromelia	"Severely shortened limbs, though typically less extreme than in ACG2.
"	phenotype_term	phenotype_term	$	Severe Micromelia	"Severely shortened limbs, though typically less extreme than in ACG2.
"	Micromelia	HP:0002983	Micromelia		"{""preferred_term"": ""Micromelia"", ""term"": {""id"": ""HP:0002983"", ""label"": ""Micromelia""}}"																											
3528	3888	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	1	Platyspondyly	"Flattened vertebral bodies with variable ossification defects.
"	phenotype_term	phenotype_term	$	Platyspondyly	"Flattened vertebral bodies with variable ossification defects.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
3529	3889	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	2	Short Ribs	"Shortened ribs contributing to thoracic hypoplasia.
"	phenotype_term	phenotype_term	$	Short Ribs	"Shortened ribs contributing to thoracic hypoplasia.
"	Short ribs	HP:0000773	Short ribs		"{""preferred_term"": ""Short ribs"", ""term"": {""id"": ""HP:0000773"", ""label"": ""Short ribs""}}"																											
3530	3890	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	3	Hydrops Fetalis	"Fetal hydrops observed in many cases.
"	phenotype_term	phenotype_term	$	Hydrops Fetalis	"Fetal hydrops observed in many cases.
"	Hydrops fetalis	HP:0001789	Hydrops fetalis		"{""preferred_term"": ""Hydrops fetalis"", ""term"": {""id"": ""HP:0001789"", ""label"": ""Hydrops fetalis""}}"																											
3531	3891	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	4	Flat Face	"Characteristic flat facial profile with depressed nasal bridge.
"	phenotype_term	phenotype_term	$	Flat Face	"Characteristic flat facial profile with depressed nasal bridge.
"	Flat face	HP:0012368	Flat face		"{""preferred_term"": ""Flat face"", ""term"": {""id"": ""HP:0012368"", ""label"": ""Flat face""}}"																											
3532	3892	162	Hypochondrogenesis	Hypochondrogenesis.yaml	phenotypes	5	Pulmonary Hypoplasia	"Underdeveloped lungs due to small thorax, a major cause of mortality.
"	phenotype_term	phenotype_term	$	Pulmonary Hypoplasia	"Underdeveloped lungs due to small thorax, a major cause of mortality.
"	Pulmonary hypoplasia	HP:0002089	Pulmonary hypoplasia		"{""preferred_term"": ""Pulmonary hypoplasia"", ""term"": {""id"": ""HP:0002089"", ""label"": ""Pulmonary hypoplasia""}}"																											
3533	3896	163	Hypochondroplasia	Hypochondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	gene	gene	$	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	FGFR3	hgnc:3690	FGFR3	Fibroblast growth factor receptor 3 with activating mutation causing mild gain-of-function.	"{""description"": ""Fibroblast growth factor receptor 3 with activating mutation causing mild gain-of-function."", ""modifier"": ""INCREASED"", ""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"			INCREASED																								
3534	3896	163	Hypochondroplasia	Hypochondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	cell_types[0]	cell_types	cell_types			Growth plate chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth plate chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
3535	3896	163	Hypochondroplasia	Hypochondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	biological_processes[0]	biological_processes	biological_processes			FGFR signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
3536	3896	163	Hypochondroplasia	Hypochondroplasia.yaml	pathophysiology	0	FGFR3 gain-of-function signaling (mild)	"The FGFR3 N540K mutation causes constitutive activation of the receptor, but with less severe effects than the G380R mutation in achondroplasia. This results in moderately impaired endochondral ossification with reduced chondrocyte proliferation in the growth plate, leading to mild short stature.
"	biological_processes[1]	biological_processes	biological_processes			Endochondral ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
3537	3897	163	Hypochondroplasia	Hypochondroplasia.yaml	phenotypes	0	Mild short stature	"Adults typically have heights in the low-normal to mildly short range, with average adult height of 145-165 cm. Short stature may be proportionate or mildly disproportionate.
"	phenotype_term	phenotype_term	$	Mild short stature	"Adults typically have heights in the low-normal to mildly short range, with average adult height of 145-165 cm. Short stature may be proportionate or mildly disproportionate.
"	Mild short stature	HP:0003502	Mild short stature		"{""preferred_term"": ""Mild short stature"", ""term"": {""id"": ""HP:0003502"", ""label"": ""Mild short stature""}}"																											
3538	3898	163	Hypochondroplasia	Hypochondroplasia.yaml	phenotypes	1	Rhizomelic limb shortening (mild)	"Mild proximal limb shortening may be present but is less pronounced than in achondroplasia. Some individuals have proportionate shortening.
"	phenotype_term	phenotype_term	$	Rhizomelic limb shortening (mild)	"Mild proximal limb shortening may be present but is less pronounced than in achondroplasia. Some individuals have proportionate shortening.
"	Rhizomelic arm shortening	HP:0004991	Rhizomelic arm shortening		"{""preferred_term"": ""Rhizomelic arm shortening"", ""term"": {""id"": ""HP:0004991"", ""label"": ""Rhizomelic arm shortening""}}"																											
3539	3899	163	Hypochondroplasia	Hypochondroplasia.yaml	phenotypes	2	Relative macrocephaly	"Head circumference may be relatively large compared to body size, but frank macrocephaly is less common than in achondroplasia.
"	phenotype_term	phenotype_term	$	Relative macrocephaly	"Head circumference may be relatively large compared to body size, but frank macrocephaly is less common than in achondroplasia.
"	Relative macrocephaly	HP:0004482	Relative macrocephaly		"{""preferred_term"": ""Relative macrocephaly"", ""term"": {""id"": ""HP:0004482"", ""label"": ""Relative macrocephaly""}}"																											
3540	3900	163	Hypochondroplasia	Hypochondroplasia.yaml	phenotypes	3	Lumbar hyperlordosis	Exaggerated lumbar curvature, though generally milder than in achondroplasia.	phenotype_term	phenotype_term	$	Lumbar hyperlordosis	Exaggerated lumbar curvature, though generally milder than in achondroplasia.	Lumbar hyperlordosis	HP:0002938	Lumbar hyperlordosis		"{""preferred_term"": ""Lumbar hyperlordosis"", ""term"": {""id"": ""HP:0002938"", ""label"": ""Lumbar hyperlordosis""}}"																											
3541	3901	163	Hypochondroplasia	Hypochondroplasia.yaml	phenotypes	4	Genu varum	Mild bowing of the legs may occur.	phenotype_term	phenotype_term	$	Genu varum	Mild bowing of the legs may occur.	Genu varum	HP:0002970	Genu varum		"{""preferred_term"": ""Genu varum"", ""term"": {""id"": ""HP:0002970"", ""label"": ""Genu varum""}}"																											
3542	3902	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	0	Growth hormone therapy	"Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.
"	treatment_term	treatment_term	$	Growth hormone therapy	"Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.
"	Growth hormone therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Growth hormone therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3543	3903	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	1	Orthopedic management	"Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.
"	treatment_term	treatment_term	$	Orthopedic management	"Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3544	3910	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	histopathology	0	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	finding_term	finding_term	$	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	Myeloblasts Present	NCIT:C155995	Myeloblasts Present		"{""preferred_term"": ""Myeloblasts Present"", ""term"": {""id"": ""NCIT:C155995"", ""label"": ""Myeloblasts Present""}}"																											
3545	3911	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	0	IDH Neomorphic Enzyme Activity	Wild-type IDH1 and IDH2 convert isocitrate to alpha-ketoglutarate in the cytoplasm and mitochondria respectively. Mutant IDH enzymes gain neomorphic activity, reducing alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG), which accumulates to millimolar concentrations in leukemic cells.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
3546	3912	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	1	2-HG Accumulation and Dioxygenase Inhibition	2-HG is structurally similar to alpha-ketoglutarate and competitively inhibits alpha-ketoglutarate-dependent dioxygenases. Key targets include TET2 DNA demethylases, Jumonji-domain histone demethylases, and prolyl hydroxylases. This disrupts normal epigenetic regulation and hypoxia responses.	biological_processes[0]	biological_processes	biological_processes			DNA demethylation	GO:0080111	DNA demethylation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA demethylation"", ""term"": {""id"": ""GO:0080111"", ""label"": ""DNA demethylation""}}"			DECREASED																								
3547	3913	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	2	DNA Hypermethylation	Inhibition of TET2 by 2-HG impairs the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, disrupting active DNA demethylation. This causes hypermethylation at gene promoters, silencing differentiation genes and contributing to the leukemic phenotype.	biological_processes[0]	biological_processes	biological_processes			myeloid cell differentiation	GO:0030099	myeloid cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myeloid cell differentiation"", ""term"": {""id"": ""GO:0030099"", ""label"": ""myeloid cell differentiation""}}"			DECREASED																								
3548	3914	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	3	Histone Methylation Dysregulation	2-HG inhibits Jumonji-domain histone demethylases that remove methyl groups from lysine residues on histones. This causes accumulation of repressive histone marks and altered gene expression patterns contributing to leukemogenesis.	biological_processes[0]	biological_processes	biological_processes			histone demethylation	GO:0016577	histone demethylation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""histone demethylation"", ""term"": {""id"": ""GO:0016577"", ""label"": ""histone demethylation""}}"			DECREASED																								
3549	3915	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	4	Differentiation Block	The combined epigenetic effects of 2-HG on DNA methylation and histone modifications block normal myeloid differentiation, maintaining leukemic cells in an immature blast state. IDH inhibitors can overcome this block, inducing differentiation of leukemic blasts.	cell_types[0]	cell_types	cell_types			myeloid cell	CL:0000763	myeloid cell		"{""preferred_term"": ""myeloid cell"", ""term"": {""id"": ""CL:0000763"", ""label"": ""myeloid cell""}}"																											
3550	3915	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	pathophysiology	4	Differentiation Block	The combined epigenetic effects of 2-HG on DNA methylation and histone modifications block normal myeloid differentiation, maintaining leukemic cells in an immature blast state. IDH inhibitors can overcome this block, inducing differentiation of leukemic blasts.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
3551	3916	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	phenotypes	0	Anemia	Normocytic anemia from bone marrow replacement by leukemic blasts and ineffective erythropoiesis.	phenotype_term	phenotype_term	$	Anemia	Normocytic anemia from bone marrow replacement by leukemic blasts and ineffective erythropoiesis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
3552	3917	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	phenotypes	1	Thrombocytopenia	Low platelet count due to bone marrow infiltration.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count due to bone marrow infiltration.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
3553	3918	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	phenotypes	2	Leukocytosis	Elevated white blood cell count with circulating blasts, though IDH-mutated AML may present with lower blast counts than other subtypes.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count with circulating blasts, though IDH-mutated AML may present with lower blast counts than other subtypes.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
3554	3919	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	phenotypes	3	Fatigue	Fatigue from anemia and hypermetabolic state.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from anemia and hypermetabolic state.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3555	3920	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	phenotypes	4	Recurrent Infections	Susceptibility to infections from neutropenia and immune dysfunction.	phenotype_term	phenotype_term	$	Recurrent Infections	Susceptibility to infections from neutropenia and immune dysfunction.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
3556	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term	treatment_term	$	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}]}"				ivosidenib	CHEBI:145430																						
3557	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ivosidenib	CHEBI:145430	ivosidenib		"{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}"																											
3558	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term	treatment_term	$	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}]}"				enasidenib	CHEBI:145374																						
3559	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			enasidenib	CHEBI:145374	enasidenib		"{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}"																											
3560	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term	treatment_term	$	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
3561	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
3562	3924	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	3	Intensive Chemotherapy (7+3)	Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3563	3925	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
3564	3935	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	histopathology	0	Diffuse Glioma	Diffuse gliomas include IDH-mutant astrocytoma and oligodendroglioma subtypes.	finding_term	finding_term	$	Diffuse Glioma	Diffuse gliomas include IDH-mutant astrocytoma and oligodendroglioma subtypes.	Diffuse Glioma	NCIT:C129325	Diffuse Glioma		"{""preferred_term"": ""Diffuse Glioma"", ""term"": {""id"": ""NCIT:C129325"", ""label"": ""Diffuse Glioma""}}"																											
3565	3936	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous mutations in IDH1 (R132H most common, >90%) or IDH2 (R172) confer neomorphic enzyme activity, converting alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG). This occurs as an early clonal event in gliomagenesis.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3566	3936	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous mutations in IDH1 (R132H most common, >90%) or IDH2 (R172) confer neomorphic enzyme activity, converting alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG). This occurs as an early clonal event in gliomagenesis.	biological_processes[0]	biological_processes	biological_processes			tricarboxylic acid cycle	GO:0006099	tricarboxylic acid cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""tricarboxylic acid cycle"", ""term"": {""id"": ""GO:0006099"", ""label"": ""tricarboxylic acid cycle""}}"			ABNORMAL																								
3567	3936	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous mutations in IDH1 (R132H most common, >90%) or IDH2 (R172) confer neomorphic enzyme activity, converting alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG). This occurs as an early clonal event in gliomagenesis.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
3568	3937	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	1	2-HG Accumulation and Epigenetic Dysregulation	D-2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases including TET2 (DNA demethylation) and Jumonji-domain histone demethylases. This results in global DNA hypermethylation (G-CIMP phenotype) and histone hypermethylation, blocking cellular differentiation.	biological_processes[0]	biological_processes	biological_processes			DNA methylation	GO:0006306	DNA methylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""DNA methylation"", ""term"": {""id"": ""GO:0006306"", ""label"": ""DNA methylation""}}"			INCREASED																								
3569	3937	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	1	2-HG Accumulation and Epigenetic Dysregulation	D-2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases including TET2 (DNA demethylation) and Jumonji-domain histone demethylases. This results in global DNA hypermethylation (G-CIMP phenotype) and histone hypermethylation, blocking cellular differentiation.	biological_processes[1]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
3570	3938	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	2	Blocked Glial Differentiation	Epigenetic dysregulation caused by 2-HG prevents normal glial differentiation programs, maintaining cells in a proliferative progenitor-like state. This contributes to tumor formation but also underlies the better prognosis compared to IDH-wildtype tumors due to retained differentiation potential.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
3571	3938	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	pathophysiology	2	Blocked Glial Differentiation	Epigenetic dysregulation caused by 2-HG prevents normal glial differentiation programs, maintaining cells in a proliferative progenitor-like state. This contributes to tumor formation but also underlies the better prognosis compared to IDH-wildtype tumors due to retained differentiation potential.	biological_processes[0]	biological_processes	biological_processes			glial cell differentiation	GO:0010001	glial cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""glial cell differentiation"", ""term"": {""id"": ""GO:0010001"", ""label"": ""glial cell differentiation""}}"			DECREASED																								
3572	3939	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	phenotypes	0	Seizures	Seizures are the most common presenting symptom, occurring in 60-80% of patients. Lower-grade tumors have higher seizure frequency. Seizures may be focal or generalized.	phenotype_term	phenotype_term	$	Seizures	Seizures are the most common presenting symptom, occurring in 60-80% of patients. Lower-grade tumors have higher seizure frequency. Seizures may be focal or generalized.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
3573	3940	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	phenotypes	1	Headache	Headache occurs due to mass effect and increased intracranial pressure.	phenotype_term	phenotype_term	$	Headache	Headache occurs due to mass effect and increased intracranial pressure.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
3574	3941	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	phenotypes	2	Cognitive Impairment	Cognitive dysfunction including memory problems and executive function deficits may occur depending on tumor location.	phenotype_term	phenotype_term	$	Cognitive Impairment	Cognitive dysfunction including memory problems and executive function deficits may occur depending on tumor location.	Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
3575	3942	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	phenotypes	3	Focal Neurological Deficit	Motor weakness, sensory changes, or language deficits depending on tumor location.	phenotype_term	phenotype_term	$	Focal Neurological Deficit	Motor weakness, sensory changes, or language deficits depending on tumor location.	Focal neurological deficit	HP:0007367	Atrophy/Degeneration affecting the central nervous system		"{""preferred_term"": ""Focal neurological deficit"", ""term"": {""id"": ""HP:0007367"", ""label"": ""Atrophy/Degeneration affecting the central nervous system""}}"																											
3576	3943	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	0	Maximal Safe Resection	Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes.	treatment_term	treatment_term	$	Maximal Safe Resection	Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3577	3944	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	1	Radiation Therapy	External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3578	3945	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	2	Temozolomide Chemotherapy	Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3579	3946	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	3	Vorasidenib (IDH1/2 Inhibitor)	Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type.	treatment_term	treatment_term	$	Vorasidenib (IDH1/2 Inhibitor)	Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3580	3954	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	histopathology	0	Well Differentiated Cholangiocarcinoma	Most cholangiocarcinomas are well differentiated.	finding_term	finding_term	$	Well Differentiated Cholangiocarcinoma	Most cholangiocarcinomas are well differentiated.	Cholangiocarcinoma	NCIT:C4436	Cholangiocarcinoma		"{""preferred_term"": ""Cholangiocarcinoma"", ""term"": {""id"": ""NCIT:C4436"", ""label"": ""Cholangiocarcinoma""}}"																											
3581	3955	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	IDH1 R132 or IDH2 R140/R172 mutations are neomorphic, conferring a new enzymatic function. Instead of converting isocitrate to alpha-ketoglutarate (aKG), mutant IDH converts aKG to the oncometabolite D-2-hydroxyglutarate (2-HG). 2-HG accumulates to millimolar concentrations in tumor cells.	cell_types[0]	cell_types	cell_types			cholangiocyte	CL:1000488	cholangiocyte		"{""preferred_term"": ""cholangiocyte"", ""term"": {""id"": ""CL:1000488"", ""label"": ""cholangiocyte""}}"																											
3582	3955	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	IDH1 R132 or IDH2 R140/R172 mutations are neomorphic, conferring a new enzymatic function. Instead of converting isocitrate to alpha-ketoglutarate (aKG), mutant IDH converts aKG to the oncometabolite D-2-hydroxyglutarate (2-HG). 2-HG accumulates to millimolar concentrations in tumor cells.	biological_processes[0]	biological_processes	biological_processes			isocitrate dehydrogenase (NADP+) activity	GO:0004450	isocitrate dehydrogenase (NADP+) activity		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""isocitrate dehydrogenase (NADP+) activity"", ""term"": {""id"": ""GO:0004450"", ""label"": ""isocitrate dehydrogenase (NADP+) activity""}}"			ABNORMAL																								
3583	3955	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	IDH1 R132 or IDH2 R140/R172 mutations are neomorphic, conferring a new enzymatic function. Instead of converting isocitrate to alpha-ketoglutarate (aKG), mutant IDH converts aKG to the oncometabolite D-2-hydroxyglutarate (2-HG). 2-HG accumulates to millimolar concentrations in tumor cells.	locations[0]	locations	locations			intrahepatic bile duct	UBERON:0003704	intrahepatic bile duct		"{""preferred_term"": ""intrahepatic bile duct"", ""term"": {""id"": ""UBERON:0003704"", ""label"": ""intrahepatic bile duct""}}"																											
3584	3957	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	2	Epigenetic Dysregulation and DNA Hypermethylation	2-HG inhibition of TET2 blocks conversion of 5-methylcytosine to 5-hydroxymethylcytosine, causing DNA hypermethylation. This CpG island methylator phenotype (CIMP) silences tumor suppressor genes and differentiation programs, contributing to the block in cellular differentiation characteristic of IDH-mutant tumors.	biological_processes[0]	biological_processes	biological_processes			DNA methylation	GO:0006306	DNA methylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""DNA methylation"", ""term"": {""id"": ""GO:0006306"", ""label"": ""DNA methylation""}}"			INCREASED																								
3585	3959	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	pathophysiology	4	Differentiation Block and Tumor Growth	Combined epigenetic alterations block normal cholangiocyte differentiation, maintaining cells in a progenitor-like state with proliferative capacity. This promotes tumor growth while the cells retain sensitivity to IDH inhibition, which can restore differentiation programs.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3586	3960	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	0	Hepatomegaly	Liver enlargement from tumor mass. Intrahepatic cholangiocarcinoma typically presents as a liver mass.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from tumor mass. Intrahepatic cholangiocarcinoma typically presents as a liver mass.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3587	3961	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	1	Jaundice	Jaundice may result from biliary obstruction by tumor or diffuse hepatic involvement. Less common in intrahepatic compared to hilar or distal cholangiocarcinoma.	phenotype_term	phenotype_term	$	Jaundice	Jaundice may result from biliary obstruction by tumor or diffuse hepatic involvement. Less common in intrahepatic compared to hilar or distal cholangiocarcinoma.	Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
3588	3962	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	2	Abdominal Pain	Right upper quadrant pain or discomfort from tumor mass effect or liver capsule involvement.	phenotype_term	phenotype_term	$	Abdominal Pain	Right upper quadrant pain or discomfort from tumor mass effect or liver capsule involvement.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3589	3963	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	3	Weight Loss	Unintentional weight loss from cancer cachexia and reduced oral intake.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss from cancer cachexia and reduced oral intake.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
3590	3964	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	4	Fatigue	Fatigue from hepatic dysfunction and advanced disease.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from hepatic dysfunction and advanced disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3591	3965	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	phenotypes	5	Nausea	Nausea from hepatic dysfunction or disease-related effects.	phenotype_term	phenotype_term	$	Nausea	Nausea from hepatic dysfunction or disease-related effects.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
3592	3966	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	0	Ivosidenib	Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life.	treatment_term	treatment_term	$	Ivosidenib	Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3593	3967	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	1	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3594	3968	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	2	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3595	3969	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	3	Surgical Resection	Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients.	treatment_term	treatment_term	$	Surgical Resection	Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3596	3979	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	histopathology	0	Diffuse Glioma	Diffuse gliomas include IDH-mutant astrocytoma and oligodendroglioma subtypes.	finding_term	finding_term	$	Diffuse Glioma	Diffuse gliomas include IDH-mutant astrocytoma and oligodendroglioma subtypes.	Diffuse Glioma	NCIT:C129325	Diffuse Glioma		"{""preferred_term"": ""Diffuse Glioma"", ""term"": {""id"": ""NCIT:C129325"", ""label"": ""Diffuse Glioma""}}"																											
3597	3980	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous IDH1 R132 or IDH2 R172 mutations produce D-2-hydroxyglutarate (2-HG), an oncometabolite causing epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases. This is an early clonal event shared with IDH-mutant astrocytomas.	cell_types[0]	cell_types	cell_types			oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
3598	3980	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous IDH1 R132 or IDH2 R172 mutations produce D-2-hydroxyglutarate (2-HG), an oncometabolite causing epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases. This is an early clonal event shared with IDH-mutant astrocytomas.	biological_processes[0]	biological_processes	biological_processes			tricarboxylic acid cycle	GO:0006099	tricarboxylic acid cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""tricarboxylic acid cycle"", ""term"": {""id"": ""GO:0006099"", ""label"": ""tricarboxylic acid cycle""}}"			ABNORMAL																								
3599	3980	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	0	IDH1/2 Neomorphic Mutation	Heterozygous IDH1 R132 or IDH2 R172 mutations produce D-2-hydroxyglutarate (2-HG), an oncometabolite causing epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases. This is an early clonal event shared with IDH-mutant astrocytomas.	locations[0]	locations	locations			brain	UBERON:0000955	brain		"{""preferred_term"": ""brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
3600	3981	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	1	1p/19q Codeletion	The 1p/19q codeletion results from an unbalanced translocation t(1;19)(q10;p10) occurring early in tumorigenesis. This leads to loss of tumor suppressor genes including CIC on 19q and FUBP1 on 1p. The codeletion is associated with oligodendroglial differentiation and exceptional chemosensitivity.	biological_processes[0]	biological_processes	biological_processes			chromosome organization	GO:0051276	chromosome organization		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""chromosome organization"", ""term"": {""id"": ""GO:0051276"", ""label"": ""chromosome organization""}}"			ABNORMAL																								
3601	3982	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	2	G-CIMP Hypermethylation Phenotype	Glioma CpG island methylator phenotype (G-CIMP) results from 2-HG-mediated inhibition of TET enzymes and histone demethylases. This leads to widespread promoter hypermethylation, altered gene expression, and blocked differentiation. G-CIMP is associated with favorable prognosis.	biological_processes[0]	biological_processes	biological_processes			DNA methylation	GO:0006306	DNA methylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""DNA methylation"", ""term"": {""id"": ""GO:0006306"", ""label"": ""DNA methylation""}}"			INCREASED																								
3602	3983	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	3	CIC/FUBP1 Tumor Suppressor Loss	CIC (Capicua) on 19q13 is mutated in approximately 70% of oligodendrogliomas. FUBP1 on 1p31 is mutated in approximately 30%. These mutations cooperate with IDH mutation and 1p/19q codeletion to drive oligodendroglioma formation.	biological_processes[0]	biological_processes	biological_processes			negative regulation of cell population proliferation	GO:0008285	negative regulation of cell population proliferation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of cell population proliferation"", ""term"": {""id"": ""GO:0008285"", ""label"": ""negative regulation of cell population proliferation""}}"			DECREASED																								
3603	3984	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	4	Oligodendroglial Tumorigenesis	The combination of IDH mutation, 1p/19q codeletion, and CIC/FUBP1 mutations drives oligodendroglioma formation. These tumors retain oligodendroglial differentiation markers and maintain sensitivity to DNA-damaging agents, likely due to intact DNA damage response pathways.	cell_types[0]	cell_types	cell_types			oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
3604	3984	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	pathophysiology	4	Oligodendroglial Tumorigenesis	The combination of IDH mutation, 1p/19q codeletion, and CIC/FUBP1 mutations drives oligodendroglioma formation. These tumors retain oligodendroglial differentiation markers and maintain sensitivity to DNA-damaging agents, likely due to intact DNA damage response pathways.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3605	3985	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	phenotypes	0	Seizures	Seizures are the most common presenting symptom, occurring in 70-90% of patients. The high seizure frequency is attributed to cortical involvement and slow growth pattern. Seizure control often improves with tumor treatment.	phenotype_term	phenotype_term	$	Seizures	Seizures are the most common presenting symptom, occurring in 70-90% of patients. The high seizure frequency is attributed to cortical involvement and slow growth pattern. Seizure control often improves with tumor treatment.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
3606	3986	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	phenotypes	1	Headache	Headache from mass effect occurs less commonly than in higher-grade tumors due to slow growth.	phenotype_term	phenotype_term	$	Headache	Headache from mass effect occurs less commonly than in higher-grade tumors due to slow growth.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
3607	3987	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	phenotypes	2	Cognitive Impairment	Cognitive dysfunction may be subtle and develop slowly. Frontal lobe tumors may cause personality changes and executive dysfunction.	phenotype_term	phenotype_term	$	Cognitive Impairment	Cognitive dysfunction may be subtle and develop slowly. Frontal lobe tumors may cause personality changes and executive dysfunction.	Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
3608	3988	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	0	Maximal Safe Resection	Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control.	treatment_term	treatment_term	$	Maximal Safe Resection	Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3609	3989	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	1	Radiation Therapy	External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3610	3990	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	2	PCV Chemotherapy	Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma.	treatment_term	treatment_term	$	PCV Chemotherapy	Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3611	3991	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	3	Temozolomide Chemotherapy	Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3612	3999	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	0	Galactose-Deficient IgA1 Production	Aberrantly glycosylated IgA1 with reduced galactose in the hinge region is produced by mucosal B cells. This galactose-deficient IgA1 (Gd-IgA1) is the key autoantigen in IgA nephropathy.	cell_types[0]	cell_types	cell_types			B Cell	CL:0000236	B cell		"{""preferred_term"": ""B Cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
3613	3999	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	0	Galactose-Deficient IgA1 Production	Aberrantly glycosylated IgA1 with reduced galactose in the hinge region is produced by mucosal B cells. This galactose-deficient IgA1 (Gd-IgA1) is the key autoantigen in IgA nephropathy.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
3614	4000	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	1	Anti-Gd-IgA1 Autoantibody Formation	IgG and IgA autoantibodies recognize exposed GalNAc residues on Gd-IgA1. These autoantibodies form circulating immune complexes with Gd-IgA1 that deposit in the glomerular mesangium.	biological_processes[0]	biological_processes	biological_processes			Immune Complex Formation	GO:0006955	immune response		"{""preferred_term"": ""Immune Complex Formation"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
3615	4001	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	2	Mesangial Cell Activation and Proliferation	IgA immune complex deposition activates mesangial cells, causing proliferation, matrix expansion, and release of inflammatory mediators including cytokines and complement components.	cell_types[0]	cell_types	cell_types			Mesangial Cell	CL:0000650	mesangial cell		"{""preferred_term"": ""Mesangial Cell"", ""term"": {""id"": ""CL:0000650"", ""label"": ""mesangial cell""}}"																											
3616	4001	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	2	Mesangial Cell Activation and Proliferation	IgA immune complex deposition activates mesangial cells, causing proliferation, matrix expansion, and release of inflammatory mediators including cytokines and complement components.	biological_processes[0]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell proliferation""}}"																											
3617	4001	168	IgA Nephropathy	IgA_Nephropathy.yaml	pathophysiology	2	Mesangial Cell Activation and Proliferation	IgA immune complex deposition activates mesangial cells, causing proliferation, matrix expansion, and release of inflammatory mediators including cytokines and complement components.	biological_processes[1]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
3618	4002	168	IgA Nephropathy	IgA_Nephropathy.yaml	phenotypes	0	Hematuria		phenotype_term	phenotype_term	$	Hematuria		Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
3619	4003	168	IgA Nephropathy	IgA_Nephropathy.yaml	phenotypes	1	Proteinuria		phenotype_term	phenotype_term	$	Proteinuria		Proteinuria	HP:0000093	Proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""Proteinuria""}}"																											
3620	4004	168	IgA Nephropathy	IgA_Nephropathy.yaml	phenotypes	2	Hypertension		phenotype_term	phenotype_term	$	Hypertension		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
3621	4005	168	IgA Nephropathy	IgA_Nephropathy.yaml	phenotypes	3	Renal Insufficiency		phenotype_term	phenotype_term	$	Renal Insufficiency		Renal Insufficiency	HP:0000083	Renal insufficiency		"{""preferred_term"": ""Renal Insufficiency"", ""term"": {""id"": ""HP:0000083"", ""label"": ""Renal insufficiency""}}"																											
3622	4014	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	0	Antiplatelet Antibody Production	Autoantibodies (primarily IgG) target platelet surface glycoproteins, especially GPIIb/IIIa and GPIb/IX. Antibody-coated platelets are cleared by splenic macrophages through Fc receptor-mediated phagocytosis.	cell_types[0]	cell_types	cell_types			Platelet	CL:0000233	platelet		"{""preferred_term"": ""Platelet"", ""term"": {""id"": ""CL:0000233"", ""label"": ""platelet""}}"																											
3623	4014	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	0	Antiplatelet Antibody Production	Autoantibodies (primarily IgG) target platelet surface glycoproteins, especially GPIIb/IIIa and GPIb/IX. Antibody-coated platelets are cleared by splenic macrophages through Fc receptor-mediated phagocytosis.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
3624	4014	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	0	Antiplatelet Antibody Production	Autoantibodies (primarily IgG) target platelet surface glycoproteins, especially GPIIb/IIIa and GPIb/IX. Antibody-coated platelets are cleared by splenic macrophages through Fc receptor-mediated phagocytosis.	biological_processes[0]	biological_processes	biological_processes			Phagocytosis	GO:0006909	phagocytosis		"{""preferred_term"": ""Phagocytosis"", ""term"": {""id"": ""GO:0006909"", ""label"": ""phagocytosis""}}"																											
3625	4015	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	1	Impaired Megakaryopoiesis	Autoantibodies also target megakaryocytes, impairing platelet production. T cell-mediated megakaryocyte damage and cytokine effects further suppress thrombopoiesis.	cell_types[0]	cell_types	cell_types			Megakaryocyte	CL:0000556	megakaryocyte		"{""preferred_term"": ""Megakaryocyte"", ""term"": {""id"": ""CL:0000556"", ""label"": ""megakaryocyte""}}"																											
3626	4015	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	1	Impaired Megakaryopoiesis	Autoantibodies also target megakaryocytes, impairing platelet production. T cell-mediated megakaryocyte damage and cytokine effects further suppress thrombopoiesis.	biological_processes[0]	biological_processes	biological_processes			Platelet Formation	GO:0030220	platelet formation		"{""preferred_term"": ""Platelet Formation"", ""term"": {""id"": ""GO:0030220"", ""label"": ""platelet formation""}}"																											
3627	4016	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	2	T Cell Dysregulation	Th1/Th17 imbalance and reduced regulatory T cell function contribute to loss of tolerance. Cytotoxic T cells may directly kill platelets and megakaryocytes.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
3628	4016	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	2	T Cell Dysregulation	Th1/Th17 imbalance and reduced regulatory T cell function contribute to loss of tolerance. Cytotoxic T cells may directly kill platelets and megakaryocytes.	biological_processes[0]	biological_processes	biological_processes			Immune Regulation	GO:0002682	regulation of immune system process		"{""preferred_term"": ""Immune Regulation"", ""term"": {""id"": ""GO:0002682"", ""label"": ""regulation of immune system process""}}"																											
3629	4017	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	pathophysiology	3	Complement Activation	Classical complement pathway activation occurs in many ITP patients, with C3, C4, and C9 deposition on platelets. Complement activation enhances platelet opsonization and clearance. Elevated complement activation markers correlate with disease severity and platelet count.	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
3630	4018	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	phenotypes	0	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
3631	4019	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	phenotypes	1	Petechiae		phenotype_term	phenotype_term	$	Petechiae		Petechiae	HP:0000967	Petechiae		"{""preferred_term"": ""Petechiae"", ""term"": {""id"": ""HP:0000967"", ""label"": ""Petechiae""}}"																											
3632	4020	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	phenotypes	2	Epistaxis		phenotype_term	phenotype_term	$	Epistaxis		Epistaxis	HP:0000421	Epistaxis		"{""preferred_term"": ""Epistaxis"", ""term"": {""id"": ""HP:0000421"", ""label"": ""Epistaxis""}}"																											
3633	4021	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	phenotypes	3	Easy Bruising		phenotype_term	phenotype_term	$	Easy Bruising		Easy Bruisability	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""Easy Bruisability"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
3634	4028	170	Infectious Disease	Infectious_Disease.yaml	pathophysiology	1	Host Genetic Susceptibility and Immune Response	Host genetic factors and immune response pathways influence progression from exposure to mild or severe infection and determine disease outcomes.	biological_processes[0]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"			ABNORMAL																								
3635	4030	170	Infectious Disease	Infectious_Disease.yaml	treatments	0	Vaccination	Vaccines are key preventive strategies against infectious pathogens.	treatment_term	treatment_term	$	Vaccination	Vaccines are key preventive strategies against infectious pathogens.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3636	4031	170	Infectious Disease	Infectious_Disease.yaml	treatments	1	Antimicrobial Therapy	Antimicrobial drugs are used to treat infections caused by pathogens.	treatment_term	treatment_term	$	Antimicrobial Therapy	Antimicrobial drugs are used to treat infections caused by pathogens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3637	4032	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	0		Microarray analysis of jejunal mucosal biopsies from 53 IBS-D (diarrhea-predominant) patients and 40 healthy volunteers to identify differentially expressed genes related to intestinal barrier function and visceral hypersensitivity.	organism	organism	$		Microarray analysis of jejunal mucosal biopsies from 53 IBS-D (diarrhea-predominant) patients and 40 healthy volunteers to identify differentially expressed genes related to intestinal barrier function and visceral hypersensitivity.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
3638	4032	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	0		Microarray analysis of jejunal mucosal biopsies from 53 IBS-D (diarrhea-predominant) patients and 40 healthy volunteers to identify differentially expressed genes related to intestinal barrier function and visceral hypersensitivity.	sample_types[0]	sample_types	sample_types			jejunal mucosa biopsy				"{""preferred_term"": ""jejunal mucosa biopsy"", ""tissue_term"": {""preferred_term"": ""jejunum"", ""term"": {""id"": ""UBERON:0002115"", ""label"": ""jejunum""}}}"																											
3639	4032	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	0		Microarray analysis of jejunal mucosal biopsies from 53 IBS-D (diarrhea-predominant) patients and 40 healthy volunteers to identify differentially expressed genes related to intestinal barrier function and visceral hypersensitivity.	sample_types[0].tissue_term	sample_types	sample_types[0]			jejunum	UBERON:0002115	jejunum		"{""preferred_term"": ""jejunum"", ""term"": {""id"": ""UBERON:0002115"", ""label"": ""jejunum""}}"																											
3640	4033	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	1		Microarray profiling of jejunal mucosal biopsies from 5 IBS-D patients and 4 healthy volunteers as a pilot study to characterize gene expression patterns in diarrhea-predominant IBS.	organism	organism	$		Microarray profiling of jejunal mucosal biopsies from 5 IBS-D patients and 4 healthy volunteers as a pilot study to characterize gene expression patterns in diarrhea-predominant IBS.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
3641	4033	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	1		Microarray profiling of jejunal mucosal biopsies from 5 IBS-D patients and 4 healthy volunteers as a pilot study to characterize gene expression patterns in diarrhea-predominant IBS.	sample_types[0]	sample_types	sample_types			jejunal mucosa biopsy				"{""preferred_term"": ""jejunal mucosa biopsy"", ""tissue_term"": {""preferred_term"": ""jejunum"", ""term"": {""id"": ""UBERON:0002115"", ""label"": ""jejunum""}}}"																											
3642	4033	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	1		Microarray profiling of jejunal mucosal biopsies from 5 IBS-D patients and 4 healthy volunteers as a pilot study to characterize gene expression patterns in diarrhea-predominant IBS.	sample_types[0].tissue_term	sample_types	sample_types[0]			jejunum	UBERON:0002115	jejunum		"{""preferred_term"": ""jejunum"", ""term"": {""id"": ""UBERON:0002115"", ""label"": ""jejunum""}}"																											
3643	4034	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	2		16S rRNA gene sequencing of fecal samples from IBS patients and healthy controls at Beijing Friendship Hospital to investigate gut microbiota composition and identify potential biomarkers.	organism	organism	$		16S rRNA gene sequencing of fecal samples from IBS patients and healthy controls at Beijing Friendship Hospital to investigate gut microbiota composition and identify potential biomarkers.	human gut metagenome	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
3644	4034	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	2		16S rRNA gene sequencing of fecal samples from IBS patients and healthy controls at Beijing Friendship Hospital to investigate gut microbiota composition and identify potential biomarkers.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
3645	4034	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	2		16S rRNA gene sequencing of fecal samples from IBS patients and healthy controls at Beijing Friendship Hospital to investigate gut microbiota composition and identify potential biomarkers.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
3646	4035	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	3		16S rRNA V4 region sequencing from the American Gut Project citizen science initiative. Contains 942 IBS subjects (IBS-D, IBS-C, IBS-U subtypes) matched with 942 non-IBS controls by age, gender, BMI, geography, and dietary patterns.	organism	organism	$		16S rRNA V4 region sequencing from the American Gut Project citizen science initiative. Contains 942 IBS subjects (IBS-D, IBS-C, IBS-U subtypes) matched with 942 non-IBS controls by age, gender, BMI, geography, and dietary patterns.	human gut metagenome	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
3647	4035	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	3		16S rRNA V4 region sequencing from the American Gut Project citizen science initiative. Contains 942 IBS subjects (IBS-D, IBS-C, IBS-U subtypes) matched with 942 non-IBS controls by age, gender, BMI, geography, and dietary patterns.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
3648	4035	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	datasets	3		16S rRNA V4 region sequencing from the American Gut Project citizen science initiative. Contains 942 IBS subjects (IBS-D, IBS-C, IBS-U subtypes) matched with 942 non-IBS controls by age, gender, BMI, geography, and dietary patterns.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
3649	4043	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	pathophysiology	0	Visceral Hypersensitivity	"Enhanced perception of normal gut sensations leads to pain and discomfort. Lowered pain thresholds in response to balloon distension. Central sensitization contributes.
"	biological_processes[0]	biological_processes	biological_processes			Pain Perception	GO:0048265	response to pain		"{""preferred_term"": ""Pain Perception"", ""term"": {""id"": ""GO:0048265"", ""label"": ""response to pain""}}"																											
3650	4044	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	pathophysiology	1	Gut Dysmotility	"Altered intestinal motility patterns with either accelerated (diarrhea-predominant) or delayed (constipation-predominant) transit. Abnormal colonic contractions.
"	biological_processes[0]	biological_processes	biological_processes			Gut Motility	GO:0030432	peristalsis		"{""preferred_term"": ""Gut Motility"", ""term"": {""id"": ""GO:0030432"", ""label"": ""peristalsis""}}"																											
3651	4045	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	pathophysiology	2	Gut-Brain Axis Dysfunction	"Bidirectional communication between gut and brain is disrupted. Stress and psychological factors modulate gut function through autonomic and neuroendocrine pathways.
"	biological_processes[0]	biological_processes	biological_processes			Nervous System Process	GO:0050877	nervous system process		"{""preferred_term"": ""Nervous System Process"", ""term"": {""id"": ""GO:0050877"", ""label"": ""nervous system process""}}"																											
3652	4047	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	pathophysiology	4	Immune Activation and Mast Cell Degranulation	"Low-grade mucosal immune activation with increased mast cell density and degranulation near enteric nerves. Mast cell mediators including histamine and tryptase excite visceral sensory neurons, contributing to pain and hypersensitivity.
"	biological_processes[0]	biological_processes	biological_processes			Mast Cell Activation	GO:0045576	mast cell activation		"{""preferred_term"": ""Mast Cell Activation"", ""term"": {""id"": ""GO:0045576"", ""label"": ""mast cell activation""}}"																											
3653	4048	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	pathophysiology	5	Microbiome Dysbiosis	"Altered composition and function of gut microbiota may contribute to symptoms. Post-infectious IBS follows gastroenteritis in some patients.
"	biological_processes[0]	biological_processes	biological_processes			Host-Microbiome Interaction	GO:0044003	modification by symbiont of host morphology or physiology		"{""preferred_term"": ""Host-Microbiome Interaction"", ""term"": {""id"": ""GO:0044003"", ""label"": ""modification by symbiont of host morphology or physiology""}}"																											
3654	4049	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	0	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
3655	4050	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	1	Altered Bowel Habits		phenotype_term	phenotype_term	$	Altered Bowel Habits		Abnormal Stool Pattern	HP:0025085	Bloody diarrhea		"{""preferred_term"": ""Abnormal Stool Pattern"", ""term"": {""id"": ""HP:0025085"", ""label"": ""Bloody diarrhea""}}"																											
3656	4051	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	2	Bloating		phenotype_term	phenotype_term	$	Bloating		Abdominal Distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal Distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
3657	4052	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	3	Constipation		phenotype_term	phenotype_term	$	Constipation		Constipation	HP:0002019	Constipation		"{""preferred_term"": ""Constipation"", ""term"": {""id"": ""HP:0002019"", ""label"": ""Constipation""}}"																											
3658	4053	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	4	Diarrhea		phenotype_term	phenotype_term	$	Diarrhea		Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
3659	4054	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3660	4066	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal skeletal development in the feet. The specific mutations overlap with those causing Crouzon and Pfeiffer syndromes, with phenotype depending on genetic background and other modifying factors.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
3661	4066	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal skeletal development in the feet. The specific mutations overlap with those causing Crouzon and Pfeiffer syndromes, with phenotype depending on genetic background and other modifying factors.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
3662	4066	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	pathophysiology	0	FGFR2 Gain-of-Function Signaling	"Mutations in FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal skeletal development in the feet. The specific mutations overlap with those causing Crouzon and Pfeiffer syndromes, with phenotype depending on genetic background and other modifying factors.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
3663	4067	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	0	Craniosynostosis	"Variable craniosynostosis affecting one or more sutures.
"	phenotype_term	phenotype_term	$	Craniosynostosis	"Variable craniosynostosis affecting one or more sutures.
"	Craniosynostosis	HP:0001363	Craniosynostosis		"{""preferred_term"": ""Craniosynostosis"", ""term"": {""id"": ""HP:0001363"", ""label"": ""Craniosynostosis""}}"																											
3664	4068	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	1	Midface Retrusion	"Midface hypoplasia is common but variable in severity.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Midface hypoplasia is common but variable in severity.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
3665	4069	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	2	Broad Great Toes	"Broad, medially deviated great toes are a characteristic feature.
"	phenotype_term	phenotype_term	$	Broad Great Toes	"Broad, medially deviated great toes are a characteristic feature.
"	Broad hallux	HP:0010055	Broad hallux		"{""preferred_term"": ""Broad hallux"", ""term"": {""id"": ""HP:0010055"", ""label"": ""Broad hallux""}}"																											
3666	4070	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	3	Tarsal-Metatarsal Fusion	"Bony fusion of tarsal and metatarsal bones distinguishes Jackson-Weiss from other craniosynostosis syndromes.
"	phenotype_term	phenotype_term	$	Tarsal-Metatarsal Fusion	"Bony fusion of tarsal and metatarsal bones distinguishes Jackson-Weiss from other craniosynostosis syndromes.
"	Tarsal synostosis	HP:0008368	Tarsal synostosis		"{""preferred_term"": ""Tarsal synostosis"", ""term"": {""id"": ""HP:0008368"", ""label"": ""Tarsal synostosis""}}"																											
3667	4071	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	4	Short First Metatarsal	"Shortened first metatarsal may contribute to foot abnormalities.
"	phenotype_term	phenotype_term	$	Short First Metatarsal	"Shortened first metatarsal may contribute to foot abnormalities.
"	Short first metatarsal	HP:0010105	Short first metatarsal		"{""preferred_term"": ""Short first metatarsal"", ""term"": {""id"": ""HP:0010105"", ""label"": ""Short first metatarsal""}}"																											
3668	4072	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	phenotypes	5	Absence of Hand Abnormalities	"Unlike Apert and Pfeiffer syndromes, Jackson-Weiss syndrome typically does not involve hand abnormalities, which helps distinguish it from related FGFR2-associated craniosynostosis syndromes.
"	phenotype_term	phenotype_term	$	Absence of Hand Abnormalities	"Unlike Apert and Pfeiffer syndromes, Jackson-Weiss syndrome typically does not involve hand abnormalities, which helps distinguish it from related FGFR2-associated craniosynostosis syndromes.
"	Normal hand morphology	HP:0001155	Abnormality of the hand		"{""preferred_term"": ""Normal hand morphology"", ""term"": {""id"": ""HP:0001155"", ""label"": ""Abnormality of the hand""}}"																											
3669	4073	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when clinically indicated.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical correction of craniosynostosis when clinically indicated.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3670	4074	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	1	Foot Surgery	"Surgical management of foot deformities if causing functional problems.
"	treatment_term	treatment_term	$	Foot Surgery	"Surgical management of foot deformities if causing functional problems.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3671	4076	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	environmental	0	Photic Stimulation	Exposure to flickering or flashing lights that can trigger seizures in photosensitive individuals.	exposure_term	exposure_term	$	Photic Stimulation	Exposure to flickering or flashing lights that can trigger seizures in photosensitive individuals.	Light exposure	XCO:0000284	controlled visible light exposure	Exposure to visible light, particularly flickering or patterned stimuli that can provoke seizures.	"{""description"": ""Exposure to visible light, particularly flickering or patterned stimuli that can provoke seizures."", ""preferred_term"": ""Light exposure"", ""term"": {""id"": ""XCO:0000284"", ""label"": ""controlled visible light exposure""}}"																											
3672	4077	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	environmental	1	Sleep Deprivation	Insufficient sleep duration or quality that lowers seizure threshold and increases photosensitivity.	exposure_term	exposure_term	$	Sleep Deprivation	Insufficient sleep duration or quality that lowers seizure threshold and increases photosensitivity.	Sleep deprivation	XCO:0001069	sleep restriction	Restriction or deprivation of sleep that increases seizure susceptibility.	"{""description"": ""Restriction or deprivation of sleep that increases seizure susceptibility."", ""preferred_term"": ""Sleep deprivation"", ""term"": {""id"": ""XCO:0001069"", ""label"": ""sleep restriction""}}"																											
3673	4090	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Neurons in the brain exhibit increased excitability, particularly in response to visual stimuli.	cell_types[0]	cell_types	cell_types			Excitatory Glutamatergic Neuron	CL:0000679	glutamatergic neuron	Neurons that use glutamate as their primary neurotransmitter and mediate excitatory synaptic transmission.	"{""description"": ""Neurons that use glutamate as their primary neurotransmitter and mediate excitatory synaptic transmission."", ""preferred_term"": ""Excitatory Glutamatergic Neuron"", ""term"": {""id"": ""CL:0000679"", ""label"": ""glutamatergic neuron""}}"																											
3674	4090	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	pathophysiology	1	Neuronal Hyperexcitability	Neurons in the brain exhibit increased excitability, particularly in response to visual stimuli.	biological_processes[0]	biological_processes	biological_processes			chemical synaptic transmission	GO:0007268	chemical synaptic transmission	Process of synaptic signaling involving neurotransmitter release and receptor activation.	"{""description"": ""Process of synaptic signaling involving neurotransmitter release and receptor activation."", ""preferred_term"": ""chemical synaptic transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
3675	4091	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	pathophysiology	2	Disrupted Cortical Function	Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.	locations[0]	locations	locations			Visual Cortex	UBERON:0000411	visual cortex	Brain region in the occipital lobe responsible for processing visual information.	"{""description"": ""Brain region in the occipital lobe responsible for processing visual information."", ""preferred_term"": ""Visual Cortex"", ""term"": {""id"": ""UBERON:0000411"", ""label"": ""visual cortex""}}"																											
3676	4091	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	pathophysiology	2	Disrupted Cortical Function	Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.	locations[1]	locations	locations			Thalamus	UBERON:0001897	dorsal plus ventral thalamus	Central brain structure that relays sensory and motor signals to the cerebral cortex.	"{""description"": ""Central brain structure that relays sensory and motor signals to the cerebral cortex."", ""preferred_term"": ""Thalamus"", ""term"": {""id"": ""UBERON:0001897"", ""label"": ""dorsal plus ventral thalamus""}}"																											
3677	4091	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	pathophysiology	2	Disrupted Cortical Function	Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.	biological_processes[0]	biological_processes	biological_processes			visual perception	GO:0007601	visual perception	Process by which visual stimuli are received and interpreted by the nervous system.	"{""description"": ""Process by which visual stimuli are received and interpreted by the nervous system."", ""preferred_term"": ""visual perception"", ""term"": {""id"": ""GO:0007601"", ""label"": ""visual perception""}}"																											
3678	4092	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	phenotypes	0	Eyelid Myoclonia	Rapid, rhythmic jerking of the eyelids often accompanied by upward eye deviation and brief impairment of consciousness.	phenotype_term	phenotype_term	$	Eyelid Myoclonia	Rapid, rhythmic jerking of the eyelids often accompanied by upward eye deviation and brief impairment of consciousness.	Eyelid Myoclonia	HP:0011149	Absence seizure with eyelid myoclonia	Rapid, rhythmic jerking of the eyelids often associated with brief impairment of consciousness.	"{""description"": ""Rapid, rhythmic jerking of the eyelids often associated with brief impairment of consciousness."", ""preferred_term"": ""Eyelid Myoclonia"", ""term"": {""id"": ""HP:0011149"", ""label"": ""Absence seizure with eyelid myoclonia""}}"																											
3679	4093	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	phenotypes	1	Absences	Brief episodes of impaired awareness typically lasting seconds, often accompanying eyelid myoclonia.	phenotype_term	phenotype_term	$	Absences	Brief episodes of impaired awareness typically lasting seconds, often accompanying eyelid myoclonia.	Absence seizure with eyelid myoclonia	HP:0011149	Absence seizure with eyelid myoclonia	Brief impaired awareness seizures accompanied by eyelid jerking movements.	"{""description"": ""Brief impaired awareness seizures accompanied by eyelid jerking movements."", ""preferred_term"": ""Absence seizure with eyelid myoclonia"", ""term"": {""id"": ""HP:0011149"", ""label"": ""Absence seizure with eyelid myoclonia""}}"																											
3680	4094	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	phenotypes	2	Generalized Tonic-Clonic Seizures	Convulsive seizures involving bilateral stiffening and rhythmic jerking, occurring in a subset of patients.	phenotype_term	phenotype_term	$	Generalized Tonic-Clonic Seizures	Convulsive seizures involving bilateral stiffening and rhythmic jerking, occurring in a subset of patients.	Bilateral tonic-clonic seizure with generalized onset	HP:0025190	Bilateral tonic-clonic seizure with generalized onset	Convulsive seizures with bilateral motor manifestations and generalized onset.	"{""description"": ""Convulsive seizures with bilateral motor manifestations and generalized onset."", ""preferred_term"": ""Bilateral tonic-clonic seizure with generalized onset"", ""term"": {""id"": ""HP:0025190"", ""label"": ""Bilateral tonic-clonic seizure with generalized onset""}}"																											
3681	4098	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	phenotypes	6	Impaired Visual Functioning During Episodes	Temporary visual disturbance during seizure activity affecting visual processing and perception.	phenotype_term	phenotype_term	$	Impaired Visual Functioning During Episodes	Temporary visual disturbance during seizure activity affecting visual processing and perception.	Impaired Visual Functioning During Episodes	HP:0000572	Visual loss	Transient visual disturbance caused by involuntary eyelid movements during seizure episodes.	"{""description"": ""Transient visual disturbance caused by involuntary eyelid movements during seizure episodes."", ""preferred_term"": ""Impaired Visual Functioning During Episodes"", ""term"": {""id"": ""HP:0000572"", ""label"": ""Visual loss""}}"																											
3682	4101	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	0	Valproic Acid	First-line treatment, effective in controlling seizures in many patients.	treatment_term	treatment_term	$	Valproic Acid	First-line treatment, effective in controlling seizures in many patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy	First-line anticonvulsant treatment using valproic acid for seizure control.	"{""description"": ""First-line anticonvulsant treatment using valproic acid for seizure control."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3683	4102	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	1	Ethosuximide	May be used as an alternative or adjunctive therapy.	treatment_term	treatment_term	$	Ethosuximide	May be used as an alternative or adjunctive therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Anticonvulsant treatment primarily targeting absence seizures.	"{""description"": ""Anticonvulsant treatment primarily targeting absence seizures."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3684	4103	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	2	Levetiracetam	May be used as an alternative or adjunctive therapy.	treatment_term	treatment_term	$	Levetiracetam	May be used as an alternative or adjunctive therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy.	"{""description"": ""Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3685	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	Avoidance of Provocative Stimuli	Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.	treatment_term	treatment_term	$	Avoidance of Provocative Stimuli	Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.	medical action avoidance	MAXO:0001014	medical action avoidance	Behavioral intervention to avoid exposure to known seizure triggers.	"{""description"": ""Behavioral intervention to avoid exposure to known seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
3686	4105	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	4	Avoidance of Triggering Stimuli	Minimizing exposure to known triggers such as flashing lights or sleep deprivation.	treatment_term	treatment_term	$	Avoidance of Triggering Stimuli	Minimizing exposure to known triggers such as flashing lights or sleep deprivation.	medical action avoidance	MAXO:0001014	medical action avoidance	Lifestyle modification to minimize exposure to photic and other seizure triggers.	"{""description"": ""Lifestyle modification to minimize exposure to photic and other seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
3687	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	Sunglasses or Blue Light Filtering Glasses	Wear to reduce light sensitivity and potentially prevent seizures.	treatment_term	treatment_term	$	Sunglasses or Blue Light Filtering Glasses	Wear to reduce light sensitivity and potentially prevent seizures.	supportive care	MAXO:0000950	supportive care	Use of protective eyewear to reduce light-induced seizure triggers.	"{""description"": ""Use of protective eyewear to reduce light-induced seizure triggers."", ""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3688	4113	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	histopathology	0	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	finding_term	finding_term	$	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	Melanocytic Neoplasm	NCIT:C7058	Melanocytic Neoplasm		"{""preferred_term"": ""Melanocytic Neoplasm"", ""term"": {""id"": ""NCIT:C7058"", ""label"": ""Melanocytic Neoplasm""}}"																											
3689	4114	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	KIT mutations, most commonly in exons 11, 13, and 17, result in constitutive receptor activation independent of stem cell factor (SCF) ligand binding. Mutations may cause ligand-independent dimerization, altered kinase domain conformation, or loss of autoinhibitory mechanisms, leading to persistent downstream signaling.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
3690	4114	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	0	KIT Receptor Tyrosine Kinase Activation	KIT mutations, most commonly in exons 11, 13, and 17, result in constitutive receptor activation independent of stem cell factor (SCF) ligand binding. Mutations may cause ligand-independent dimerization, altered kinase domain conformation, or loss of autoinhibitory mechanisms, leading to persistent downstream signaling.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
3691	4115	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	1	MAPK Pathway Activation	Activated KIT recruits adapter proteins that engage RAS-MAPK signaling, driving melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle progression.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
3692	4116	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	KIT activates PI3K through recruitment and phosphorylation of adapter proteins. Subsequent AKT activation promotes cell survival through inhibition of pro-apoptotic proteins and activation of mTOR signaling.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
3693	4117	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	3	Uncontrolled Melanocyte Proliferation	Constitutive KIT signaling through MAPK and PI3K pathways drives abnormal melanocyte proliferation in acral and mucosal sites, leading to tumor formation.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
3694	4117	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	3	Uncontrolled Melanocyte Proliferation	Constitutive KIT signaling through MAPK and PI3K pathways drives abnormal melanocyte proliferation in acral and mucosal sites, leading to tumor formation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3695	4118	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	pathophysiology	4	Cell Survival and Anti-Apoptosis	PI3K-AKT activation downstream of KIT promotes melanoma cell survival through phosphorylation-mediated inactivation of pro-apoptotic proteins and activation of survival pathways.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3696	4119	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	phenotypes	0	Acral Lentiginous Melanoma	Melanoma arising on acral surfaces including palms, soles, and nail beds. Presents as pigmented macule with irregular borders, often diagnosed at advanced stage due to location.	phenotype_term	phenotype_term	$	Acral Lentiginous Melanoma	Melanoma arising on acral surfaces including palms, soles, and nail beds. Presents as pigmented macule with irregular borders, often diagnosed at advanced stage due to location.	Acral lentiginous melanoma	HP:0012060	Acral lentiginous melanoma		"{""preferred_term"": ""Acral lentiginous melanoma"", ""term"": {""id"": ""HP:0012060"", ""label"": ""Acral lentiginous melanoma""}}"																											
3697	4120	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	phenotypes	1	Cutaneous Melanoma	Melanoma arising on chronically sun-damaged skin may also harbor KIT mutations, though less commonly than acral or mucosal sites.	phenotype_term	phenotype_term	$	Cutaneous Melanoma	Melanoma arising on chronically sun-damaged skin may also harbor KIT mutations, though less commonly than acral or mucosal sites.	Cutaneous melanoma	HP:0012056	Cutaneous melanoma		"{""preferred_term"": ""Cutaneous melanoma"", ""term"": {""id"": ""HP:0012056"", ""label"": ""Cutaneous melanoma""}}"																											
3698	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term	treatment_term	$	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
3699	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
3700	4122	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	1	Nilotinib	Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance.	treatment_term	treatment_term	$	Nilotinib	Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3701	4123	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	2	Dasatinib	Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials.	treatment_term	treatment_term	$	Dasatinib	Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3702	4124	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3703	4132	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
3704	4133	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	0	KRAS G12C Oncogenic Mutation	The KRAS G12C mutation substitutes cysteine for glycine at codon 12, impairing GTPase activity and trapping KRAS in the active GTP-bound state. However, unlike other KRAS mutations, G12C retains some GTPase activity, cycling between active (GTP-bound) and inactive (GDP-bound) states. This cycling creates a therapeutic window for covalent inhibitors that bind the mutant cysteine in the GDP-bound state.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
3705	4133	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	0	KRAS G12C Oncogenic Mutation	The KRAS G12C mutation substitutes cysteine for glycine at codon 12, impairing GTPase activity and trapping KRAS in the active GTP-bound state. However, unlike other KRAS mutations, G12C retains some GTPase activity, cycling between active (GTP-bound) and inactive (GDP-bound) states. This cycling creates a therapeutic window for covalent inhibitors that bind the mutant cysteine in the GDP-bound state.	biological_processes[0]	biological_processes	biological_processes			small GTPase mediated signal transduction	GO:0007264	small GTPase mediated signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""small GTPase mediated signal transduction"", ""term"": {""id"": ""GO:0007264"", ""label"": ""small GTPase mediated signal transduction""}}"			INCREASED																								
3706	4134	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive RAS Signaling	Mutant KRAS drives constitutive activation of downstream effector pathways including RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The MAPK pathway is the predominant driver of oncogenic phenotypes in KRAS-mutant NSCLC.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
3707	4134	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	1	Constitutive RAS Signaling	Mutant KRAS drives constitutive activation of downstream effector pathways including RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The MAPK pathway is the predominant driver of oncogenic phenotypes in KRAS-mutant NSCLC.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
3708	4135	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Survival	Constitutive KRAS signaling promotes uncontrolled cell proliferation through ERK-mediated transcription of cell cycle genes and survival through AKT-mediated inhibition of apoptosis.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3709	4136	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	pathophysiology	3	KRAS G12C Inhibitor Resistance	Resistance to KRAS G12C inhibitors develops through multiple mechanisms: secondary KRAS mutations (Y96C, R68S, H95D/Q/R), KRAS amplification, bypass pathway activation (MET, EGFR, FGFR, PI3K), and histologic transformation. Adaptive feedback through RTK reactivation (EGFR, FGFR, SHP2) is common.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
3710	4137	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	KRAS G12C NSCLC is predominantly adenocarcinoma histology, though can occur in squamous cell carcinoma. Often presents as peripheral lung mass.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	KRAS G12C NSCLC is predominantly adenocarcinoma histology, though can occur in squamous cell carcinoma. Often presents as peripheral lung mass.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
3711	4138	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	phenotypes	1	Smoking Association	Unlike EGFR/ALK/ROS1 alterations, KRAS G12C mutations are strongly associated with smoking history. The G>T transversion pattern is characteristic of tobacco-induced mutagenesis.	phenotype_term	phenotype_term	$	Smoking Association	Unlike EGFR/ALK/ROS1 alterations, KRAS G12C mutations are strongly associated with smoking history. The G>T transversion pattern is characteristic of tobacco-induced mutagenesis.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
3712	4139	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	phenotypes	2	Brain Metastases	Brain metastases occur in KRAS G12C NSCLC, though CNS penetration of current KRAS inhibitors (sotorasib, adagrasib) varies. Adagrasib has demonstrated intracranial activity.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in KRAS G12C NSCLC, though CNS penetration of current KRAS inhibitors (sotorasib, adagrasib) varies. Adagrasib has demonstrated intracranial activity.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
3713	4140	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	0	Sotorasib	First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial.	treatment_term	treatment_term	$	Sotorasib	First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3714	4141	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	1	Adagrasib	Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial.	treatment_term	treatment_term	$	Adagrasib	Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3715	4142	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	2	KRAS G12C Inhibitor Combinations	Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling.	treatment_term	treatment_term	$	KRAS G12C Inhibitor Combinations	Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3716	4143	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3717	4144	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3718	4152	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	histopathology	0	Spindle Cell Vascular Tumor	Spindle cells represent the main cell type in Kaposi sarcoma lesions.	finding_term	finding_term	$	Spindle Cell Vascular Tumor	Spindle cells represent the main cell type in Kaposi sarcoma lesions.	Spindle Cell Pattern	NCIT:C53643	Spindle Cell Pattern		"{""preferred_term"": ""Spindle Cell Pattern"", ""term"": {""id"": ""NCIT:C53643"", ""label"": ""Spindle Cell Pattern""}}"																											
3719	4153	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	infectious_agent	0	Human Herpesvirus 8 (HHV-8/KSHV)	HHV-8 (KSHV) is the causative agent of all forms of Kaposi sarcoma. The virus encodes multiple oncoproteins that drive transformation: vGPCR (viral G protein- coupled receptor) activates angiogenic signaling; vFLIP activates NF-kappaB for cell survival; vCyclin drives cell cycle progression; LANA maintains viral latency and inhibits p53 and Rb tumor suppressors. The virus establishes latent infection in endothelial cells, with lytic reactivation contributing to paracrine signaling and tumor progression.	infectious_agent_term	infectious_agent_term	$	Human Herpesvirus 8 (HHV-8/KSHV)	HHV-8 (KSHV) is the causative agent of all forms of Kaposi sarcoma. The virus encodes multiple oncoproteins that drive transformation: vGPCR (viral G protein- coupled receptor) activates angiogenic signaling; vFLIP activates NF-kappaB for cell survival; vCyclin drives cell cycle progression; LANA maintains viral latency and inhibits p53 and Rb tumor suppressors. The virus establishes latent infection in endothelial cells, with lytic reactivation contributing to paracrine signaling and tumor progression.	Human gammaherpesvirus 8	NCBITaxon:37296	Human gammaherpesvirus 8		"{""preferred_term"": ""Human gammaherpesvirus 8"", ""term"": {""id"": ""NCBITaxon:37296"", ""label"": ""Human gammaherpesvirus 8""}}"																											
3720	4154	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	0	HHV-8 Latent Infection of Endothelial Cells	HHV-8 infects endothelial cells and establishes latent infection with expression of latency-associated nuclear antigen (LANA), vFLIP, and vCyclin. LANA maintains the viral episome and inhibits p53 and Rb tumor suppressor function. Latently infected cells undergo spindle cell transformation characteristic of KS.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
3721	4154	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	0	HHV-8 Latent Infection of Endothelial Cells	HHV-8 infects endothelial cells and establishes latent infection with expression of latency-associated nuclear antigen (LANA), vFLIP, and vCyclin. LANA maintains the viral episome and inhibits p53 and Rb tumor suppressor function. Latently infected cells undergo spindle cell transformation characteristic of KS.	biological_processes[0]	biological_processes	biological_processes			viral transcription	GO:0019083	viral transcription		"{""preferred_term"": ""viral transcription"", ""term"": {""id"": ""GO:0019083"", ""label"": ""viral transcription""}}"																											
3722	4155	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	1	vFLIP-Mediated NF-kappaB Activation	Viral FLICE inhibitory protein (vFLIP) constitutively activates NF-kappaB signaling by interacting with IKK complex. This promotes cell survival, inflammation, and cytokine production. vFLIP also inhibits caspase-8-mediated apoptosis, providing resistance to death receptor-induced cell death.	biological_processes[0]	biological_processes	biological_processes			positive regulation of NF-kappaB transcription factor activity	GO:0051092	positive regulation of NF-kappaB transcription factor activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of NF-kappaB transcription factor activity"", ""term"": {""id"": ""GO:0051092"", ""label"": ""positive regulation of NF-kappaB transcription factor activity""}}"			INCREASED																								
3723	4156	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	2	vCyclin-Mediated Cell Cycle Dysregulation	Viral cyclin (vCyclin) forms active complexes with CDK6 that are resistant to inhibition by p16INK4A, p21, and p27. This drives cells through G1/S checkpoint regardless of normal growth regulatory signals, contributing to uncontrolled proliferation.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			ABNORMAL																								
3724	4157	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	3	vGPCR-Mediated Angiogenic Signaling	The viral G protein-coupled receptor (vGPCR) is expressed during lytic reactivation and activates multiple signaling pathways in a ligand-independent manner, including VEGF production and MAPK activation. vGPCR is highly oncogenic and promotes the angiogenic, inflammatory microenvironment characteristic of KS lesions.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
3725	4158	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	4	Apoptosis Resistance and Cell Survival	Multiple viral genes cooperate to prevent apoptosis: vFLIP inhibits caspase-8 and activates NF-kappaB; LANA inhibits p53; vBCL-2 mimics cellular BCL-2. This multi-layered apoptosis resistance enables survival and accumulation of infected cells.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3726	4159	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	5	Uncontrolled Cell Proliferation	Combined effects of vCyclin, LANA-mediated Rb inhibition, and growth factor signaling drive spindle cell proliferation, forming the characteristic KS lesions.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3727	4160	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	6	Angiogenic Proliferation	KS lesions are highly vascular due to vGPCR-induced VEGF and inflammatory cytokine production. The aberrant angiogenesis creates the characteristic red-purple appearance and contributes to edema and hemorrhage.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
3728	4160	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	pathophysiology	6	Angiogenic Proliferation	KS lesions are highly vascular due to vGPCR-induced VEGF and inflammatory cytokine production. The aberrant angiogenesis creates the characteristic red-purple appearance and contributes to edema and hemorrhage.	biological_processes[0]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
3729	4161	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	phenotypes	0	Cutaneous Lesions	Characteristic red-purple to brown-black macules, papules, plaques, or nodules on the skin. Lesions are typically multifocal and may occur anywhere but favor the lower extremities, face (especially nose), and oral mucosa in AIDS-associated KS.	phenotype_term	phenotype_term	$	Cutaneous Lesions	Characteristic red-purple to brown-black macules, papules, plaques, or nodules on the skin. Lesions are typically multifocal and may occur anywhere but favor the lower extremities, face (especially nose), and oral mucosa in AIDS-associated KS.	Hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
3730	4162	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	phenotypes	1	Lymphedema	Localized or diffuse lymphedema, particularly of the lower extremities, face, or genitalia. Results from lymphatic obstruction by tumor and inflammatory processes.	phenotype_term	phenotype_term	$	Lymphedema	Localized or diffuse lymphedema, particularly of the lower extremities, face, or genitalia. Results from lymphatic obstruction by tumor and inflammatory processes.	Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
3731	4163	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	phenotypes	2	Lymphadenopathy	Lymph node involvement may occur, especially in endemic African variant (lymphadenopathic KS) and advanced AIDS-associated disease.	phenotype_term	phenotype_term	$	Lymphadenopathy	Lymph node involvement may occur, especially in endemic African variant (lymphadenopathic KS) and advanced AIDS-associated disease.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
3732	4164	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	phenotypes	3	GI Involvement	Visceral involvement of the gastrointestinal tract may cause bleeding, obstruction, or protein-losing enteropathy. Often asymptomatic and discovered on endoscopy.	phenotype_term	phenotype_term	$	GI Involvement	Visceral involvement of the gastrointestinal tract may cause bleeding, obstruction, or protein-losing enteropathy. Often asymptomatic and discovered on endoscopy.	Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
3733	4165	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	phenotypes	4	Pulmonary Involvement	Lung involvement presents with dyspnea, cough, and hemoptysis. Chest imaging shows diffuse infiltrates or nodules. Associated with poor prognosis.	phenotype_term	phenotype_term	$	Pulmonary Involvement	Lung involvement presents with dyspnea, cough, and hemoptysis. Chest imaging shows diffuse infiltrates or nodules. Associated with poor prognosis.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3734	4166	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	0	Antiretroviral Therapy	For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.	treatment_term	treatment_term	$	Antiretroviral Therapy	For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	treatment_term	$	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}]}"				doxorubicin; paclitaxel	CHEBI:28748; CHEBI:45863																						
3736	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
3737	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			paclitaxel	CHEBI:45863	paclitaxel		"{""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}"																											
3738	4168	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	2	Local Therapy	Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.	treatment_term	treatment_term	$	Local Therapy	Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3739	4169	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	3	Reduction of Immunosuppression	For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.	treatment_term	treatment_term	$	Reduction of Immunosuppression	For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3740	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	cell_types[0]	cell_types	cell_types			vascular endothelial cell	CL:0000071	blood vessel endothelial cell	Primary target cells undergoing activation and dysfunction	"{""description"": ""Primary target cells undergoing activation and dysfunction"", ""preferred_term"": ""vascular endothelial cell"", ""term"": {""id"": ""CL:0000071"", ""label"": ""blood vessel endothelial cell""}}"																											
3741	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	cell_types[1]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil	Recruited to vessel walls during necrotizing arteritis phase	"{""description"": ""Recruited to vessel walls during necrotizing arteritis phase"", ""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
3742	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	cell_types[2]	cell_types	cell_types			monocyte	CL:0000576	monocyte	Activated by immune complexes and FcR signaling	"{""description"": ""Activated by immune complexes and FcR signaling"", ""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
3743	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	cell_types[3]	cell_types	cell_types			macrophage	CL:0000235	macrophage	Present in coronary lesions producing cytokines	"{""description"": ""Present in coronary lesions producing cytokines"", ""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
3744	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	biological_processes[0]	biological_processes	biological_processes			endothelial cell activation	GO:0042118	endothelial cell activation	Cytokine-driven upregulation of adhesion molecules and inflammatory mediators	"{""description"": ""Cytokine-driven upregulation of adhesion molecules and inflammatory mediators"", ""preferred_term"": ""endothelial cell activation"", ""term"": {""id"": ""GO:0042118"", ""label"": ""endothelial cell activation""}}"																											
3745	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	biological_processes[1]	biological_processes	biological_processes			leukocyte adhesion to vascular endothelial cell	GO:1904996	positive regulation of leukocyte adhesion to vascular endothelial cell	ICAM-1/VCAM-1 mediated leukocyte recruitment	"{""description"": ""ICAM-1/VCAM-1 mediated leukocyte recruitment"", ""preferred_term"": ""leukocyte adhesion to vascular endothelial cell"", ""term"": {""id"": ""GO:1904996"", ""label"": ""positive regulation of leukocyte adhesion to vascular endothelial cell""}}"																											
3746	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	biological_processes[2]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response	Systemic hyperinflammatory syndrome with cytokine cascades	"{""description"": ""Systemic hyperinflammatory syndrome with cytokine cascades"", ""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3747	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	locations[0]	locations	locations			coronary artery	UBERON:0001621	coronary artery	Primary site of arteritis and aneurysm formation	"{""description"": ""Primary site of arteritis and aneurysm formation"", ""preferred_term"": ""coronary artery"", ""term"": {""id"": ""UBERON:0001621"", ""label"": ""coronary artery""}}"																											
3748	4196	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	0	Vascular Inflammation	Widespread inflammation of medium-sized arteries, including coronary arteries.	locations[1]	locations	locations			artery wall	UBERON:0035965	artery wall	All three layers (intima, media, adventitia) undergo inflammation	"{""description"": ""All three layers (intima, media, adventitia) undergo inflammation"", ""preferred_term"": ""artery wall"", ""term"": {""id"": ""UBERON:0035965"", ""label"": ""artery wall""}}"																											
3749	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta T cell	CL:0000625	CD8-positive, alpha-beta T cell	CD8+ T cells present in coronary lesions	"{""description"": ""CD8+ T cells present in coronary lesions"", ""preferred_term"": ""CD8-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3750	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[1]	cell_types	cell_types			T-helper 17 cell	CL:0000899	T-helper 17 cell	Th17 expansion associated with coronary damage and IVIG resistance	"{""description"": ""Th17 expansion associated with coronary damage and IVIG resistance"", ""preferred_term"": ""T-helper 17 cell"", ""term"": {""id"": ""CL:0000899"", ""label"": ""T-helper 17 cell""}}"																											
3751	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[2]	cell_types	cell_types			regulatory T cell	CL:0000815	regulatory T cell	Treg imbalance contributes to immune dysregulation	"{""description"": ""Treg imbalance contributes to immune dysregulation"", ""preferred_term"": ""regulatory T cell"", ""term"": {""id"": ""CL:0000815"", ""label"": ""regulatory T cell""}}"																											
3752	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[3]	cell_types	cell_types			plasmablast	CL:0000980	plasmablast	Convergent antigen-driven plasmablast responses in some patients	"{""description"": ""Convergent antigen-driven plasmablast responses in some patients"", ""preferred_term"": ""plasmablast"", ""term"": {""id"": ""CL:0000980"", ""label"": ""plasmablast""}}"																											
3753	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[4]	cell_types	cell_types			plasma cell	CL:0000786	plasma cell	IgA plasma cells found in coronary lesions	"{""description"": ""IgA plasma cells found in coronary lesions"", ""preferred_term"": ""plasma cell"", ""term"": {""id"": ""CL:0000786"", ""label"": ""plasma cell""}}"																											
3754	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	cell_types[5]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell	Involved in antigen presentation and T-cell activation	"{""description"": ""Involved in antigen presentation and T-cell activation"", ""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
3755	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[0]	biological_processes	biological_processes			NLRP3 inflammasome complex assembly	GO:0072559	NLRP3 inflammasome complex assembly	NLRP3 inflammasome activation leading to IL-1 release	"{""description"": ""NLRP3 inflammasome activation leading to IL-1 release"", ""preferred_term"": ""NLRP3 inflammasome complex assembly"", ""term"": {""id"": ""GO:0072559"", ""label"": ""NLRP3 inflammasome complex assembly""}}"																											
3756	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[1]	biological_processes	biological_processes			interleukin-1 beta production	GO:0032611	interleukin-1 beta production	IL-1 promotes endothelial injury and inflammation	"{""description"": ""IL-1 promotes endothelial injury and inflammation"", ""preferred_term"": ""interleukin-1 beta production"", ""term"": {""id"": ""GO:0032611"", ""label"": ""interleukin-1 beta production""}}"																											
3757	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[2]	biological_processes	biological_processes			tumor necrosis factor production	GO:0032640	tumor necrosis factor production	TNF- induces endothelial activation and NF-B signaling	"{""description"": ""TNF- induces endothelial activation and NF-B signaling"", ""preferred_term"": ""tumor necrosis factor production"", ""term"": {""id"": ""GO:0032640"", ""label"": ""tumor necrosis factor production""}}"																											
3758	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[3]	biological_processes	biological_processes			interleukin-17 production	GO:0032620	interleukin-17 production	IL-17 from Th17 cells promotes neutrophil recruitment	"{""description"": ""IL-17 from Th17 cells promotes neutrophil recruitment"", ""preferred_term"": ""interleukin-17 production"", ""term"": {""id"": ""GO:0032620"", ""label"": ""interleukin-17 production""}}"																											
3759	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[4]	biological_processes	biological_processes			calcium ion transmembrane transport	GO:0070588	calcium ion transmembrane transport	Dysregulated Ca2+/calcineurin-NFAT signaling pathway	"{""description"": ""Dysregulated Ca2+/calcineurin-NFAT signaling pathway"", ""preferred_term"": ""calcium ion transmembrane transport"", ""term"": {""id"": ""GO:0070588"", ""label"": ""calcium ion transmembrane transport""}}"																											
3760	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[5]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation	Enhanced T-cell activation via CD40-CD40L co-stimulation	"{""description"": ""Enhanced T-cell activation via CD40-CD40L co-stimulation"", ""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
3761	4197	177	Kawasaki Disease	Kawasaki_Disease.yaml	pathophysiology	1	Immune Response Dysregulation	An abnormal immune response leading to vessel wall damage and inflammation.	biological_processes[6]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation	Complement fixation contributes to vascular injury	"{""description"": ""Complement fixation contributes to vascular injury"", ""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
3762	4198	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	0	Fever	High fever lasting at least 5 days, a mandatory criterion for diagnosis of Kawasaki disease.	phenotype_term	phenotype_term	$	Fever	High fever lasting at least 5 days, a mandatory criterion for diagnosis of Kawasaki disease.	Fever	HP:0001945	Fever	Elevated body temperature above the normal range, typically above 38C (100.4F).	"{""description"": ""Elevated body temperature above the normal range, typically above 38C (100.4F)."", ""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
3763	4199	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	1	Rash	Polymorphous exanthem typically affecting the trunk and extremities, without vesicles or crusting.	phenotype_term	phenotype_term	$	Rash	Polymorphous exanthem typically affecting the trunk and extremities, without vesicles or crusting.	Skin rash	HP:0000988	Skin rash	Visible change in skin color or texture, typically involving erythema or papules.	"{""description"": ""Visible change in skin color or texture, typically involving erythema or papules."", ""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
3764	4200	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	2	Conjunctivitis	Bilateral bulbar conjunctival injection without exudate, typically limbal sparing.	phenotype_term	phenotype_term	$	Conjunctivitis	Bilateral bulbar conjunctival injection without exudate, typically limbal sparing.	Conjunctivitis	HP:0000509	Conjunctivitis	Inflammation of the conjunctiva resulting in redness and irritation of the eye.	"{""description"": ""Inflammation of the conjunctiva resulting in redness and irritation of the eye."", ""preferred_term"": ""Conjunctivitis"", ""term"": {""id"": ""HP:0000509"", ""label"": ""Conjunctivitis""}}"																											
3765	4205	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	7	Thrombocytosis	Elevated platelet count commonly found in the subacute phase of Kawasaki disease.	phenotype_term	phenotype_term	$	Thrombocytosis	Elevated platelet count commonly found in the subacute phase of Kawasaki disease.	Thrombocytosis	HP:0001894	Thrombocytosis	Abnormally increased platelet count in the blood.	"{""description"": ""Abnormally increased platelet count in the blood."", ""preferred_term"": ""Thrombocytosis"", ""term"": {""id"": ""HP:0001894"", ""label"": ""Thrombocytosis""}}"																											
3766	4206	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	8	Cervical Lymphadenopathy	Enlarged cervical lymph nodes, often unilateral, one of the classic diagnostic criteria for Kawasaki disease.	phenotype_term	phenotype_term	$	Cervical Lymphadenopathy	Enlarged cervical lymph nodes, often unilateral, one of the classic diagnostic criteria for Kawasaki disease.	Cervical lymphadenopathy	HP:0025289	Cervical lymphadenopathy	Enlargement of lymph nodes in the neck region.	"{""description"": ""Enlargement of lymph nodes in the neck region."", ""preferred_term"": ""Cervical lymphadenopathy"", ""term"": {""id"": ""HP:0025289"", ""label"": ""Cervical lymphadenopathy""}}"																											
3767	4207	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	9	Myocarditis	Inflammation of the myocardium that can occur during the acute phase of Kawasaki disease.	phenotype_term	phenotype_term	$	Myocarditis	Inflammation of the myocardium that can occur during the acute phase of Kawasaki disease.	Myocarditis	HP:0012819	Myocarditis	Inflammation of the cardiac muscle.	"{""description"": ""Inflammation of the cardiac muscle."", ""preferred_term"": ""Myocarditis"", ""term"": {""id"": ""HP:0012819"", ""label"": ""Myocarditis""}}"																											
3768	4208	177	Kawasaki Disease	Kawasaki_Disease.yaml	phenotypes	10	Aneurysm Formation	Vascular dilation resulting from inflammatory weakening of vessel walls, affecting coronary and other medium-sized arteries.	phenotype_term	phenotype_term	$	Aneurysm Formation	Vascular dilation resulting from inflammatory weakening of vessel walls, affecting coronary and other medium-sized arteries.	Aneurysm Formation	HP:0002617	Vascular dilatation	Abnormal focal dilation of a blood vessel due to weakening of the vessel wall.	"{""description"": ""Abnormal focal dilation of a blood vessel due to weakening of the vessel wall."", ""preferred_term"": ""Aneurysm Formation"", ""term"": {""id"": ""HP:0002617"", ""label"": ""Vascular dilatation""}}"																											
3769	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	First-line treatment to reduce inflammation and risk of coronary artery complications.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	First-line treatment to reduce inflammation and risk of coronary artery complications.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment of disease through the administration of medications.	"{""description"": ""Treatment of disease through the administration of medications."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3770	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	Aspirin	Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.	treatment_term	treatment_term	$	Aspirin	Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy	Treatment using medications that affect the cardiovascular system, including antiplatelet agents.	"{""description"": ""Treatment using medications that affect the cardiovascular system, including antiplatelet agents."", ""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
3771	4216	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	2	Anakinra	IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.	treatment_term	treatment_term	$	Anakinra	IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using IL-1 pathway inhibition for refractory inflammation.	"{""description"": ""Treatment using IL-1 pathway inhibition for refractory inflammation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3772	4217	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	3	Cyclosporine	Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.	treatment_term	treatment_term	$	Cyclosporine	Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using calcineurin inhibition to reduce T-cell activation.	"{""description"": ""Treatment using calcineurin inhibition to reduce T-cell activation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3773	4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	Corticosteroids	Used in cases resistant to IVIG or with severe inflammation.	treatment_term	treatment_term	$	Corticosteroids	Used in cases resistant to IVIG or with severe inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using corticosteroids to reduce inflammation in refractory cases.	"{""description"": ""Treatment using corticosteroids to reduce inflammation in refractory cases."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3774	4219	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	genetic	0	GJB2		gene_term	gene_term	$	GJB2		GJB2	hgnc:4284	GJB2		"{""preferred_term"": ""GJB2"", ""term"": {""id"": ""hgnc:4284"", ""label"": ""GJB2""}}"																											
3775	4220	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	genetic	1	LOR		gene_term	gene_term	$	LOR		LOR	hgnc:6663	LOR		"{""preferred_term"": ""LOR"", ""term"": {""id"": ""hgnc:6663"", ""label"": ""LOR""}}"																											
3776	4223	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	0	Gap Junction Dysfunction	"Mutations in GJB2 disrupt connexin 26 function, impairing gap junction-mediated intercellular communication in the epidermis and cochlea. The D66H mutation occurs at a highly conserved residue in the first extracellular domain and may interfere with connexon assembly, docking, or gating properties. This leads to defective ion homeostasis and impaired cellular coordination during differentiation.
"	cell_types[0]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
3777	4223	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	0	Gap Junction Dysfunction	"Mutations in GJB2 disrupt connexin 26 function, impairing gap junction-mediated intercellular communication in the epidermis and cochlea. The D66H mutation occurs at a highly conserved residue in the first extracellular domain and may interfere with connexon assembly, docking, or gating properties. This leads to defective ion homeostasis and impaired cellular coordination during differentiation.
"	biological_processes[0]	biological_processes	biological_processes			Gap junction assembly	GO:0016264	gap junction assembly		"{""preferred_term"": ""Gap junction assembly"", ""term"": {""id"": ""GO:0016264"", ""label"": ""gap junction assembly""}}"																											
3778	4223	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	0	Gap Junction Dysfunction	"Mutations in GJB2 disrupt connexin 26 function, impairing gap junction-mediated intercellular communication in the epidermis and cochlea. The D66H mutation occurs at a highly conserved residue in the first extracellular domain and may interfere with connexon assembly, docking, or gating properties. This leads to defective ion homeostasis and impaired cellular coordination during differentiation.
"	biological_processes[1]	biological_processes	biological_processes			Cell-cell signaling	GO:0007267	cell-cell signaling		"{""preferred_term"": ""Cell-cell signaling"", ""term"": {""id"": ""GO:0007267"", ""label"": ""cell-cell signaling""}}"																											
3779	4223	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	0	Gap Junction Dysfunction	"Mutations in GJB2 disrupt connexin 26 function, impairing gap junction-mediated intercellular communication in the epidermis and cochlea. The D66H mutation occurs at a highly conserved residue in the first extracellular domain and may interfere with connexon assembly, docking, or gating properties. This leads to defective ion homeostasis and impaired cellular coordination during differentiation.
"	locations[0]	locations	locations			Skin of palm and sole	UBERON:0013776	skin of palmar/plantar part of autopod		"{""preferred_term"": ""Skin of palm and sole"", ""term"": {""id"": ""UBERON:0013776"", ""label"": ""skin of palmar/plantar part of autopod""}}"																											
3780	4224	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	1	Abnormal Epidermal Differentiation	"Defective gap junction signaling leads to hyperproliferation and abnormal keratinization of palmoplantar epidermis, resulting in the characteristic thickened honeycomb-patterned skin. The mutation impairs epidermal differentiation as well as inner ear function.
"	cell_types[0]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
3781	4224	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	1	Abnormal Epidermal Differentiation	"Defective gap junction signaling leads to hyperproliferation and abnormal keratinization of palmoplantar epidermis, resulting in the characteristic thickened honeycomb-patterned skin. The mutation impairs epidermal differentiation as well as inner ear function.
"	biological_processes[0]	biological_processes	biological_processes			Keratinocyte differentiation	GO:0030216	keratinocyte differentiation		"{""preferred_term"": ""Keratinocyte differentiation"", ""term"": {""id"": ""GO:0030216"", ""label"": ""keratinocyte differentiation""}}"																											
3782	4225	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	2	Mutant Loricrin Nuclear Accumulation	"In the ichthyotic variant, mutant loricrin is mislocalized to the nuclei of granular layer keratinocytes and fails to incorporate into the cornified cell envelope. The frameshift mutation creates an abnormal C-terminal peptide containing nuclear localization signals, causing aberrant nuclear translocation and interference with late stages of epidermal differentiation.
"	cell_types[0]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
3783	4225	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	2	Mutant Loricrin Nuclear Accumulation	"In the ichthyotic variant, mutant loricrin is mislocalized to the nuclei of granular layer keratinocytes and fails to incorporate into the cornified cell envelope. The frameshift mutation creates an abnormal C-terminal peptide containing nuclear localization signals, causing aberrant nuclear translocation and interference with late stages of epidermal differentiation.
"	biological_processes[0]	biological_processes	biological_processes			Cornified envelope assembly	GO:1903575	cornified envelope assembly		"{""preferred_term"": ""Cornified envelope assembly"", ""term"": {""id"": ""GO:1903575"", ""label"": ""cornified envelope assembly""}}"																											
3784	4225	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	2	Mutant Loricrin Nuclear Accumulation	"In the ichthyotic variant, mutant loricrin is mislocalized to the nuclei of granular layer keratinocytes and fails to incorporate into the cornified cell envelope. The frameshift mutation creates an abnormal C-terminal peptide containing nuclear localization signals, causing aberrant nuclear translocation and interference with late stages of epidermal differentiation.
"	biological_processes[1]	biological_processes	biological_processes			Keratinocyte differentiation	GO:0030216	keratinocyte differentiation		"{""preferred_term"": ""Keratinocyte differentiation"", ""term"": {""id"": ""GO:0030216"", ""label"": ""keratinocyte differentiation""}}"																											
3785	4227	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	pathophysiology	4	Cochlear Dysfunction	"Connexin 26 is essential for potassium recycling in the cochlea. Its dysfunction disrupts the endocochlear potential required for auditory transduction, causing sensorineural hearing loss. This phenotype is specific to GJB2 mutations and is absent in the loricrin-associated variant.
"	locations[0]	locations	locations			Cochlea	UBERON:0001844	cochlea		"{""preferred_term"": ""Cochlea"", ""term"": {""id"": ""UBERON:0001844"", ""label"": ""cochlea""}}"																											
3786	4228	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	0	Palmoplantar Keratoderma	"Diffuse thickening of the skin on palms and soles with a characteristic honeycomb or starfish pattern, typically appearing in infancy or early childhood.
"	phenotype_term	phenotype_term	$	Palmoplantar Keratoderma	"Diffuse thickening of the skin on palms and soles with a characteristic honeycomb or starfish pattern, typically appearing in infancy or early childhood.
"	Palmoplantar keratoderma	HP:0000982	Palmoplantar keratoderma		"{""preferred_term"": ""Palmoplantar keratoderma"", ""term"": {""id"": ""HP:0000982"", ""label"": ""Palmoplantar keratoderma""}}"																											
3787	4229	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	1	Honeycomb Palmoplantar Hyperkeratosis	"The characteristic honeycomb pattern of hyperkeratosis on palms and soles, a hallmark feature of both GJB2 and LOR forms.
"	phenotype_term	phenotype_term	$	Honeycomb Palmoplantar Hyperkeratosis	"The characteristic honeycomb pattern of hyperkeratosis on palms and soles, a hallmark feature of both GJB2 and LOR forms.
"	Honeycomb palmoplantar hyperkeratosis	HP:0007465	Honeycomb palmoplantar hyperkeratosis		"{""preferred_term"": ""Honeycomb palmoplantar hyperkeratosis"", ""term"": {""id"": ""HP:0007465"", ""label"": ""Honeycomb palmoplantar hyperkeratosis""}}"																											
3788	4230	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	2	Pseudoainhum	"Constricting fibrous bands around digits, particularly affecting the fifth toe and other fingers, which may progress to autoamputation.
"	phenotype_term	phenotype_term	$	Pseudoainhum	"Constricting fibrous bands around digits, particularly affecting the fifth toe and other fingers, which may progress to autoamputation.
"	Autoamputation of digits	HP:0007460	Autoamputation of digits		"{""preferred_term"": ""Autoamputation of digits"", ""term"": {""id"": ""HP:0007460"", ""label"": ""Autoamputation of digits""}}"																											
3789	4231	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	3	Sensorineural Hearing Loss	"Bilateral, progressive hearing impairment ranging from mild to profound, typically presenting in early childhood. Present in classic GJB2-associated form but absent in loricrin-associated variant.
"	phenotype_term	phenotype_term	$	Sensorineural Hearing Loss	"Bilateral, progressive hearing impairment ranging from mild to profound, typically presenting in early childhood. Present in classic GJB2-associated form but absent in loricrin-associated variant.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
3790	4232	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	4	Starfish-Shaped Hyperkeratoses	"Distinctive star-shaped keratotic lesions on the dorsal surfaces of hands, feet, elbows, and knees.
"	phenotype_term	phenotype_term	$	Starfish-Shaped Hyperkeratoses	"Distinctive star-shaped keratotic lesions on the dorsal surfaces of hands, feet, elbows, and knees.
"	Hyperkeratosis	HP:0000962	Hyperkeratosis		"{""preferred_term"": ""Hyperkeratosis"", ""term"": {""id"": ""HP:0000962"", ""label"": ""Hyperkeratosis""}}"																											
3791	4233	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	5	Knuckle Pads	"Thickened skin over the knuckles (interphalangeal joints), presenting as keratotic structures on the dorsal surfaces of the hands, often with a starfish-like appearance.
"	phenotype_term	phenotype_term	$	Knuckle Pads	"Thickened skin over the knuckles (interphalangeal joints), presenting as keratotic structures on the dorsal surfaces of the hands, often with a starfish-like appearance.
"	Knuckle pad	HP:0032541	Knuckle pad		"{""preferred_term"": ""Knuckle pad"", ""term"": {""id"": ""HP:0032541"", ""label"": ""Knuckle pad""}}"																											
3792	4234	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	6	Ichthyosis	"Generalized scaling of the skin, characteristic of the loricrin-associated (Camisa) variant but absent in classic GJB2-associated form.
"	phenotype_term	phenotype_term	$	Ichthyosis	"Generalized scaling of the skin, characteristic of the loricrin-associated (Camisa) variant but absent in classic GJB2-associated form.
"	Ichthyosis	HP:0008064	Ichthyosis		"{""preferred_term"": ""Ichthyosis"", ""term"": {""id"": ""HP:0008064"", ""label"": ""Ichthyosis""}}"																											
3793	4235	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	phenotypes	7	Alopecia	"Sparse hair or patchy hair loss, particularly affecting eyebrows and eyelashes in some patients.
"	phenotype_term	phenotype_term	$	Alopecia	"Sparse hair or patchy hair loss, particularly affecting eyebrows and eyelashes in some patients.
"	Alopecia	HP:0001596	Alopecia		"{""preferred_term"": ""Alopecia"", ""term"": {""id"": ""HP:0001596"", ""label"": ""Alopecia""}}"																											
3794	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	cell_types[0]	cell_types	cell_types			Sertoli Cell	CL:0000216	Sertoli cell		"{""preferred_term"": ""Sertoli Cell"", ""term"": {""id"": ""CL:0000216"", ""label"": ""Sertoli cell""}}"																											
3795	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	cell_types[1]	cell_types	cell_types			Leydig Cell	CL:0000178	Leydig cell		"{""preferred_term"": ""Leydig Cell"", ""term"": {""id"": ""CL:0000178"", ""label"": ""Leydig cell""}}"																											
3796	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	cell_types[2]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
3797	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	cell_types[3]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
3798	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	biological_processes[0]	biological_processes	biological_processes			Spermatogenesis	GO:0007283	spermatogenesis		"{""preferred_term"": ""Spermatogenesis"", ""term"": {""id"": ""GO:0007283"", ""label"": ""spermatogenesis""}}"																											
3799	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	biological_processes[1]	biological_processes	biological_processes			Angiogenesis	GO:0001525	angiogenesis		"{""preferred_term"": ""Angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"																											
3800	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	biological_processes[2]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3801	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	biological_processes[3]	biological_processes	biological_processes			Extracellular Matrix Organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""Extracellular Matrix Organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
3802	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	locations[0]	locations	locations			Testis	UBERON:0000473	testis		"{""preferred_term"": ""Testis"", ""term"": {""id"": ""UBERON:0000473"", ""label"": ""testis""}}"																											
3803	4253	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	1	Testicular Microenvironment Dysfunction	Immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix remodeling and microvascular dysfunction impair spermatogenesis and testosterone export.	locations[1]	locations	locations			Seminiferous Tubule	UBERON:0001343	seminiferous tubule of testis		"{""preferred_term"": ""Seminiferous Tubule"", ""term"": {""id"": ""UBERON:0001343"", ""label"": ""seminiferous tubule of testis""}}"																											
3804	4254	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	2	Progressive Germ Cell Loss	Accelerated germ cell apoptosis beginning around puberty leads to spermatogenic failure and azoospermia in adulthood.	cell_types[0]	cell_types	cell_types			Spermatocyte	CL:0000017	spermatocyte		"{""preferred_term"": ""Spermatocyte"", ""term"": {""id"": ""CL:0000017"", ""label"": ""spermatocyte""}}"																											
3805	4254	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	2	Progressive Germ Cell Loss	Accelerated germ cell apoptosis beginning around puberty leads to spermatogenic failure and azoospermia in adulthood.	biological_processes[0]	biological_processes	biological_processes			Apoptotic Process	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptotic Process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
3806	4254	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	2	Progressive Germ Cell Loss	Accelerated germ cell apoptosis beginning around puberty leads to spermatogenic failure and azoospermia in adulthood.	biological_processes[1]	biological_processes	biological_processes			Spermatogenesis	GO:0007283	spermatogenesis		"{""preferred_term"": ""Spermatogenesis"", ""term"": {""id"": ""GO:0007283"", ""label"": ""spermatogenesis""}}"																											
3807	4254	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	2	Progressive Germ Cell Loss	Accelerated germ cell apoptosis beginning around puberty leads to spermatogenic failure and azoospermia in adulthood.	locations[0]	locations	locations			Seminiferous Tubule	UBERON:0001343	seminiferous tubule of testis		"{""preferred_term"": ""Seminiferous Tubule"", ""term"": {""id"": ""UBERON:0001343"", ""label"": ""seminiferous tubule of testis""}}"																											
3808	4255	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	3	Hypergonadotropic Hypogonadism	Leydig cell insufficiency and impaired testosterone export result in elevated LH/FSH and low systemic testosterone despite potentially elevated intratesticular testosterone.	cell_types[0]	cell_types	cell_types			Leydig Cell	CL:0000178	Leydig cell		"{""preferred_term"": ""Leydig Cell"", ""term"": {""id"": ""CL:0000178"", ""label"": ""Leydig cell""}}"																											
3809	4255	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	3	Hypergonadotropic Hypogonadism	Leydig cell insufficiency and impaired testosterone export result in elevated LH/FSH and low systemic testosterone despite potentially elevated intratesticular testosterone.	biological_processes[0]	biological_processes	biological_processes			Testosterone Biosynthetic Process	GO:0061370	testosterone biosynthetic process		"{""preferred_term"": ""Testosterone Biosynthetic Process"", ""term"": {""id"": ""GO:0061370"", ""label"": ""testosterone biosynthetic process""}}"																											
3810	4255	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	3	Hypergonadotropic Hypogonadism	Leydig cell insufficiency and impaired testosterone export result in elevated LH/FSH and low systemic testosterone despite potentially elevated intratesticular testosterone.	biological_processes[1]	biological_processes	biological_processes			Hormone Secretion	GO:0046879	hormone secretion		"{""preferred_term"": ""Hormone Secretion"", ""term"": {""id"": ""GO:0046879"", ""label"": ""hormone secretion""}}"																											
3811	4255	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	pathophysiology	3	Hypergonadotropic Hypogonadism	Leydig cell insufficiency and impaired testosterone export result in elevated LH/FSH and low systemic testosterone despite potentially elevated intratesticular testosterone.	locations[0]	locations	locations			Testis	UBERON:0000473	testis		"{""preferred_term"": ""Testis"", ""term"": {""id"": ""UBERON:0000473"", ""label"": ""testis""}}"																											
3812	4256	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	0	Hypogonadism		phenotype_term	phenotype_term	$	Hypogonadism		Hypogonadism	HP:0000135	Hypogonadism		"{""preferred_term"": ""Hypogonadism"", ""term"": {""id"": ""HP:0000135"", ""label"": ""Hypogonadism""}}"																											
3813	4257	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	1	Delayed Speech and Language Development		phenotype_term	phenotype_term	$	Delayed Speech and Language Development		Delayed Speech and Language Development	HP:0000750	Delayed speech and language development		"{""preferred_term"": ""Delayed Speech and Language Development"", ""term"": {""id"": ""HP:0000750"", ""label"": ""Delayed speech and language development""}}"																											
3814	4259	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	3	Tall Stature		phenotype_term	phenotype_term	$	Tall Stature		Tall Stature	HP:0000098	Tall stature		"{""preferred_term"": ""Tall Stature"", ""term"": {""id"": ""HP:0000098"", ""label"": ""Tall stature""}}"																											
3815	4261	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	5	Micropenis		phenotype_term	phenotype_term	$	Micropenis		Micropenis	HP:0000054	Micropenis		"{""preferred_term"": ""Micropenis"", ""term"": {""id"": ""HP:0000054"", ""label"": ""Micropenis""}}"																											
3816	4263	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	7	Attention Deficit		phenotype_term	phenotype_term	$	Attention Deficit		Attention Deficit Hyperactivity Disorder	HP:0007018	Attention deficit hyperactivity disorder		"{""preferred_term"": ""Attention Deficit Hyperactivity Disorder"", ""term"": {""id"": ""HP:0007018"", ""label"": ""Attention deficit hyperactivity disorder""}}"																											
3817	4264	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	8	Azoospermia		phenotype_term	phenotype_term	$	Azoospermia		Azoospermia	HP:0000027	Azoospermia		"{""preferred_term"": ""Azoospermia"", ""term"": {""id"": ""HP:0000027"", ""label"": ""Azoospermia""}}"																											
3818	4265	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	9	Small Testes		phenotype_term	phenotype_term	$	Small Testes		Small Testes	HP:0008734	Decreased testicular size		"{""preferred_term"": ""Small Testes"", ""term"": {""id"": ""HP:0008734"", ""label"": ""Decreased testicular size""}}"																											
3819	4266	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	10	Gynecomastia		phenotype_term	phenotype_term	$	Gynecomastia		Gynecomastia	HP:0000771	Gynecomastia		"{""preferred_term"": ""Gynecomastia"", ""term"": {""id"": ""HP:0000771"", ""label"": ""Gynecomastia""}}"																											
3820	4267	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	11	Insulin Resistance		phenotype_term	phenotype_term	$	Insulin Resistance		Insulin Resistance	HP:0000855	Insulin resistance		"{""preferred_term"": ""Insulin Resistance"", ""term"": {""id"": ""HP:0000855"", ""label"": ""Insulin resistance""}}"																											
3821	4268	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	12	Osteopenia		phenotype_term	phenotype_term	$	Osteopenia		Osteopenia	HP:0000938	Osteopenia		"{""preferred_term"": ""Osteopenia"", ""term"": {""id"": ""HP:0000938"", ""label"": ""Osteopenia""}}"																											
3822	4269	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	phenotypes	13	Increased Cardiovascular Risk		phenotype_term	phenotype_term	$	Increased Cardiovascular Risk		Abnormality of the Cardiovascular System	HP:0001626	Abnormality of the cardiovascular system		"{""preferred_term"": ""Abnormality of the Cardiovascular System"", ""term"": {""id"": ""HP:0001626"", ""label"": ""Abnormality of the cardiovascular system""}}"																											
3823	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	Testosterone Replacement Therapy	Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.	treatment_term	treatment_term	$	Testosterone Replacement Therapy	Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
3824	4272	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	1	Educational Support	Special education services and speech therapy to improve language and academic skills.	treatment_term	treatment_term	$	Educational Support	Special education services and speech therapy to improve language and academic skills.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
3825	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	Fertility Treatment	Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children.	treatment_term	treatment_term	$	Fertility Treatment	Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3826	4274	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	3	Psychological Support	Counseling and psychological support to address social, emotional, and behavioral challenges.	treatment_term	treatment_term	$	Psychological Support	Counseling and psychological support to address social, emotional, and behavioral challenges.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
3827	4275	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	4	Multidisciplinary Care	Comprehensive monitoring for metabolic, cardiovascular, and bone health complications.	treatment_term	treatment_term	$	Multidisciplinary Care	Comprehensive monitoring for metabolic, cardiovascular, and bone health complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3828	4278	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	pathophysiology	0	Type II Collagen Structural Abnormality	"Kniest dysplasia is typically caused by exon-skipping mutations or small in-frame deletions in COL2A1 that result in shortened collagen chains. These abnormal chains are incorporated into the extracellular matrix but form defective fibrils. The characteristic cartilage histology shows large empty areas (Swiss cheese appearance) due to abnormal collagen organization.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
3829	4278	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	pathophysiology	0	Type II Collagen Structural Abnormality	"Kniest dysplasia is typically caused by exon-skipping mutations or small in-frame deletions in COL2A1 that result in shortened collagen chains. These abnormal chains are incorporated into the extracellular matrix but form defective fibrils. The characteristic cartilage histology shows large empty areas (Swiss cheese appearance) due to abnormal collagen organization.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
3830	4278	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	pathophysiology	0	Type II Collagen Structural Abnormality	"Kniest dysplasia is typically caused by exon-skipping mutations or small in-frame deletions in COL2A1 that result in shortened collagen chains. These abnormal chains are incorporated into the extracellular matrix but form defective fibrils. The characteristic cartilage histology shows large empty areas (Swiss cheese appearance) due to abnormal collagen organization.
"	biological_processes[1]	biological_processes	biological_processes			Cartilage Development	GO:0051216	cartilage development		"{""preferred_term"": ""Cartilage Development"", ""term"": {""id"": ""GO:0051216"", ""label"": ""cartilage development""}}"																											
3831	4278	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	pathophysiology	0	Type II Collagen Structural Abnormality	"Kniest dysplasia is typically caused by exon-skipping mutations or small in-frame deletions in COL2A1 that result in shortened collagen chains. These abnormal chains are incorporated into the extracellular matrix but form defective fibrils. The characteristic cartilage histology shows large empty areas (Swiss cheese appearance) due to abnormal collagen organization.
"	biological_processes[2]	biological_processes	biological_processes			ECM Organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""ECM Organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
3832	4279	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	0	Disproportionate Short-Trunk Short Stature	"Severe short stature with disproportionately short trunk, typically apparent at birth.
"	phenotype_term	phenotype_term	$	Disproportionate Short-Trunk Short Stature	"Severe short stature with disproportionately short trunk, typically apparent at birth.
"	Disproportionate short-trunk short stature	HP:0003521	Disproportionate short-trunk short stature		"{""preferred_term"": ""Disproportionate short-trunk short stature"", ""term"": {""id"": ""HP:0003521"", ""label"": ""Disproportionate short-trunk short stature""}}"																											
3833	4280	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	1	Enlarged Joints	"Prominent, enlarged-appearing joints especially at knees and wrists, with restricted mobility.
"	phenotype_term	phenotype_term	$	Enlarged Joints	"Prominent, enlarged-appearing joints especially at knees and wrists, with restricted mobility.
"	Enlarged joints	HP:0003037	Enlarged joints		"{""preferred_term"": ""Enlarged joints"", ""term"": {""id"": ""HP:0003037"", ""label"": ""Enlarged joints""}}"																											
3834	4281	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	2	Joint Stiffness	"Progressive joint stiffness and contractures develop, limiting mobility.
"	phenotype_term	phenotype_term	$	Joint Stiffness	"Progressive joint stiffness and contractures develop, limiting mobility.
"	Joint stiffness	HP:0001387	Joint stiffness		"{""preferred_term"": ""Joint stiffness"", ""term"": {""id"": ""HP:0001387"", ""label"": ""Joint stiffness""}}"																											
3835	4282	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	3	Flat Face	"Midface hypoplasia with flat facial profile is characteristic.
"	phenotype_term	phenotype_term	$	Flat Face	"Midface hypoplasia with flat facial profile is characteristic.
"	Flat face	HP:0012368	Flat face		"{""preferred_term"": ""Flat face"", ""term"": {""id"": ""HP:0012368"", ""label"": ""Flat face""}}"																											
3836	4283	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	4	Cleft Palate	"Cleft palate occurs in many affected individuals.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Cleft palate occurs in many affected individuals.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
3837	4284	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	5	Myopia	"High myopia develops due to abnormal eye development.
"	phenotype_term	phenotype_term	$	Myopia	"High myopia develops due to abnormal eye development.
"	Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
3838	4285	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	6	Retinal Detachment	"Increased risk of retinal detachment due to vitreous abnormalities.
"	phenotype_term	phenotype_term	$	Retinal Detachment	"Increased risk of retinal detachment due to vitreous abnormalities.
"	Retinal detachment	HP:0000541	Retinal detachment		"{""preferred_term"": ""Retinal detachment"", ""term"": {""id"": ""HP:0000541"", ""label"": ""Retinal detachment""}}"																											
3839	4286	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	7	Hearing Loss	"Sensorineural or mixed hearing loss is common.
"	phenotype_term	phenotype_term	$	Hearing Loss	"Sensorineural or mixed hearing loss is common.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
3840	4287	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	8	Platyspondyly	"Flattened vertebral bodies contributing to short trunk.
"	phenotype_term	phenotype_term	$	Platyspondyly	"Flattened vertebral bodies contributing to short trunk.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
3841	4288	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	phenotypes	9	Dumbbell-Shaped Long Bones	"Characteristic radiographic appearance with flared metaphyses and relatively narrow diaphyses creating a dumbbell shape.
"	phenotype_term	phenotype_term	$	Dumbbell-Shaped Long Bones	"Characteristic radiographic appearance with flared metaphyses and relatively narrow diaphyses creating a dumbbell shape.
"	Dumbbell-shaped long bone	HP:0000947	Dumbbell-shaped long bone		"{""preferred_term"": ""Dumbbell-shaped long bone"", ""term"": {""id"": ""HP:0000947"", ""label"": ""Dumbbell-shaped long bone""}}"																											
3842	4289	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	0	Orthopedic Management	"Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3843	4292	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	3	Cleft Palate Repair	"Surgical repair of cleft palate in affected individuals.
"	treatment_term	treatment_term	$	Cleft Palate Repair	"Surgical repair of cleft palate in affected individuals.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3844	4299	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	differential_diagnoses	0	Idiopathic pulmonary hemosiderosis (IPH) without celiac disease	"Idiopathic pulmonary hemosiderosis (IPH) is a rare bleeding disorder of the lungs presenting with similar pulmonary manifestations to Lane Hamilton Syndrome: diffuse alveolar hemorrhage, hemoptysis, iron-deficiency anemia, and hemosiderin-laden macrophages on BAL. However, IPH occurs in the absence of underlying celiac disease or gluten sensitivity. IPH patients lack serologic evidence of celiac disease (negative anti-tTG and endomysial antibodies) and do not respond to gluten-free diet.
"	disease_term	disease_term	$	Idiopathic pulmonary hemosiderosis (IPH) without celiac disease	"Idiopathic pulmonary hemosiderosis (IPH) is a rare bleeding disorder of the lungs presenting with similar pulmonary manifestations to Lane Hamilton Syndrome: diffuse alveolar hemorrhage, hemoptysis, iron-deficiency anemia, and hemosiderin-laden macrophages on BAL. However, IPH occurs in the absence of underlying celiac disease or gluten sensitivity. IPH patients lack serologic evidence of celiac disease (negative anti-tTG and endomysial antibodies) and do not respond to gluten-free diet.
"	pulmonary hemosiderosis	MONDO:0008346	pulmonary hemosiderosis		"{""preferred_term"": ""pulmonary hemosiderosis"", ""term"": {""id"": ""MONDO:0008346"", ""label"": ""pulmonary hemosiderosis""}}"																											
3845	4300	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	differential_diagnoses	1	Vasculitis-associated pulmonary hemorrhage (ANCA-associated vasculitis)	"ANCA-associated vasculitides (granulomatosis with polyangiitis, microscopic polyangiitis) can present with pulmonary hemorrhage, hemoptysis, and hemoptysis-related anemia. Unlike Lane Hamilton Syndrome, vasculitis is characterized by capillaritis and immune complex deposition on lung biopsy, frank vasculitis of small vessels, and positive ANCA serology (c-ANCA or p-ANCA antibodies).
"	disease_term	disease_term	$	Vasculitis-associated pulmonary hemorrhage (ANCA-associated vasculitis)	"ANCA-associated vasculitides (granulomatosis with polyangiitis, microscopic polyangiitis) can present with pulmonary hemorrhage, hemoptysis, and hemoptysis-related anemia. Unlike Lane Hamilton Syndrome, vasculitis is characterized by capillaritis and immune complex deposition on lung biopsy, frank vasculitis of small vessels, and positive ANCA serology (c-ANCA or p-ANCA antibodies).
"	granulomatosis with polyangiitis	MONDO:0012105	granulomatosis with polyangiitis		"{""preferred_term"": ""granulomatosis with polyangiitis"", ""term"": {""id"": ""MONDO:0012105"", ""label"": ""granulomatosis with polyangiitis""}}"																											
3846	4302	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	differential_diagnoses	3	Goodpasture syndrome (anti-glomerular basement membrane disease)	"Goodpasture syndrome is an autoimmune condition causing pulmonary-renal vasculitis with diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. While it presents with hemoptysis and alveolar hemorrhage similar to Lane Hamilton Syndrome, Goodpasture syndrome features anti-GBM antibody positivity, linear IgG deposition on basement membranes, and acute progression without association with celiac disease.
"	disease_term	disease_term	$	Goodpasture syndrome (anti-glomerular basement membrane disease)	"Goodpasture syndrome is an autoimmune condition causing pulmonary-renal vasculitis with diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. While it presents with hemoptysis and alveolar hemorrhage similar to Lane Hamilton Syndrome, Goodpasture syndrome features anti-GBM antibody positivity, linear IgG deposition on basement membranes, and acute progression without association with celiac disease.
"	anti-glomerular basement membrane disease	MONDO:0009303	anti-glomerular basement membrane disease		"{""preferred_term"": ""anti-glomerular basement membrane disease"", ""term"": {""id"": ""MONDO:0009303"", ""label"": ""anti-glomerular basement membrane disease""}}"																											
3847	4303	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	differential_diagnoses	4	Acute leukemia with leukostasis and pulmonary hemorrhage	"Acute myeloid or lymphoid leukemia can present with diffuse alveolar hemorrhage secondary to leukostasis, thrombocytopenia, and coagulopathy. However, leukemia is distinguished by markedly elevated white blood cell counts, blasts on peripheral blood smear, and absence of underlying celiac disease or link to gluten exposure.
"	disease_term	disease_term	$	Acute leukemia with leukostasis and pulmonary hemorrhage	"Acute myeloid or lymphoid leukemia can present with diffuse alveolar hemorrhage secondary to leukostasis, thrombocytopenia, and coagulopathy. However, leukemia is distinguished by markedly elevated white blood cell counts, blasts on peripheral blood smear, and absence of underlying celiac disease or link to gluten exposure.
"	acute leukemia	MONDO:0010643	acute leukemia		"{""preferred_term"": ""acute leukemia"", ""term"": {""id"": ""MONDO:0010643"", ""label"": ""acute leukemia""}}"																											
3848	4304	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	0	Gluten-triggered intestinal autoimmunity in celiac disease	"Lane Hamilton Syndrome begins with celiac disease, an autoimmune condition triggered by gluten ingestion in genetically predisposed individuals. Gluten exposure activates intestinal immune responses with increased intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia in the small intestine, particularly the duodenum. This localized intestinal autoimmunity generates systemic immune activation and circulating autoantibodies, including anti-tissue transglutaminase (anti-tTG) and anti-endomysial antibodies.
"	cell_types[0]	cell_types	cell_types			T lymphocyte	CL:0000084	T cell		"{""preferred_term"": ""T lymphocyte"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
3849	4304	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	0	Gluten-triggered intestinal autoimmunity in celiac disease	"Lane Hamilton Syndrome begins with celiac disease, an autoimmune condition triggered by gluten ingestion in genetically predisposed individuals. Gluten exposure activates intestinal immune responses with increased intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia in the small intestine, particularly the duodenum. This localized intestinal autoimmunity generates systemic immune activation and circulating autoantibodies, including anti-tissue transglutaminase (anti-tTG) and anti-endomysial antibodies.
"	biological_processes[0]	biological_processes	biological_processes			antigen processing and presentation	GO:0019882	antigen processing and presentation		"{""preferred_term"": ""antigen processing and presentation"", ""term"": {""id"": ""GO:0019882"", ""label"": ""antigen processing and presentation""}}"																											
3850	4304	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	0	Gluten-triggered intestinal autoimmunity in celiac disease	"Lane Hamilton Syndrome begins with celiac disease, an autoimmune condition triggered by gluten ingestion in genetically predisposed individuals. Gluten exposure activates intestinal immune responses with increased intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia in the small intestine, particularly the duodenum. This localized intestinal autoimmunity generates systemic immune activation and circulating autoantibodies, including anti-tissue transglutaminase (anti-tTG) and anti-endomysial antibodies.
"	biological_processes[1]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
3851	4305	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	1	Immune-mediated increase in pulmonary capillary permeability	"Systemic immune mediators generated by intestinal celiac disease act on the pulmonary microvasculature, increasing capillary endothelial permeability without causing vasculitis or immune complex deposition. Mediators such as histamine (released by eosinophils and basophils), eosinophil cationic protein (ECP), and vascular endothelial growth factor (VEGF) increase endothelial gap formation between capillary endothelial cells. This allows erythrocyte extravasation into the alveolar space in the absence of structural vascular damage or capillaritis.
"	cell_types[0]	cell_types	cell_types			capillary endothelial cell	CL:0002144	capillary endothelial cell		"{""preferred_term"": ""capillary endothelial cell"", ""term"": {""id"": ""CL:0002144"", ""label"": ""capillary endothelial cell""}}"																											
3852	4305	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	1	Immune-mediated increase in pulmonary capillary permeability	"Systemic immune mediators generated by intestinal celiac disease act on the pulmonary microvasculature, increasing capillary endothelial permeability without causing vasculitis or immune complex deposition. Mediators such as histamine (released by eosinophils and basophils), eosinophil cationic protein (ECP), and vascular endothelial growth factor (VEGF) increase endothelial gap formation between capillary endothelial cells. This allows erythrocyte extravasation into the alveolar space in the absence of structural vascular damage or capillaritis.
"	cell_types[1]	cell_types	cell_types			eosinophil	CL:0000041	mature eosinophil		"{""preferred_term"": ""eosinophil"", ""term"": {""id"": ""CL:0000041"", ""label"": ""mature eosinophil""}}"																											
3853	4305	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	1	Immune-mediated increase in pulmonary capillary permeability	"Systemic immune mediators generated by intestinal celiac disease act on the pulmonary microvasculature, increasing capillary endothelial permeability without causing vasculitis or immune complex deposition. Mediators such as histamine (released by eosinophils and basophils), eosinophil cationic protein (ECP), and vascular endothelial growth factor (VEGF) increase endothelial gap formation between capillary endothelial cells. This allows erythrocyte extravasation into the alveolar space in the absence of structural vascular damage or capillaritis.
"	cell_types[2]	cell_types	cell_types			basophil	CL:0000767	basophil		"{""preferred_term"": ""basophil"", ""term"": {""id"": ""CL:0000767"", ""label"": ""basophil""}}"																											
3854	4305	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	1	Immune-mediated increase in pulmonary capillary permeability	"Systemic immune mediators generated by intestinal celiac disease act on the pulmonary microvasculature, increasing capillary endothelial permeability without causing vasculitis or immune complex deposition. Mediators such as histamine (released by eosinophils and basophils), eosinophil cationic protein (ECP), and vascular endothelial growth factor (VEGF) increase endothelial gap formation between capillary endothelial cells. This allows erythrocyte extravasation into the alveolar space in the absence of structural vascular damage or capillaritis.
"	biological_processes[0]	biological_processes	biological_processes			regulation of vascular permeability	GO:0043114	regulation of vascular permeability		"{""preferred_term"": ""regulation of vascular permeability"", ""term"": {""id"": ""GO:0043114"", ""label"": ""regulation of vascular permeability""}}"																											
3855	4305	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	1	Immune-mediated increase in pulmonary capillary permeability	"Systemic immune mediators generated by intestinal celiac disease act on the pulmonary microvasculature, increasing capillary endothelial permeability without causing vasculitis or immune complex deposition. Mediators such as histamine (released by eosinophils and basophils), eosinophil cationic protein (ECP), and vascular endothelial growth factor (VEGF) increase endothelial gap formation between capillary endothelial cells. This allows erythrocyte extravasation into the alveolar space in the absence of structural vascular damage or capillaritis.
"	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3856	4306	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	2	Alveolar hemorrhage and hemosiderin accumulation	"Increased capillary permeability allows red blood cells and hemoglobin to escape into the alveolar space, causing diffuse alveolar hemorrhage (DAH). Alveolar macrophages rapidly phagocytose the extravasated erythrocytes and break down hemoglobin, converting iron and heme into hemosiderin. These hemosiderin-laden macrophages (HLM) accumulate in alveolar spaces and can be detected via bronchoalveolar lavage (BAL) or lung biopsy, serving as a hallmark histologic finding of prior alveolar bleeding.
"	cell_types[0]	cell_types	cell_types			alveolar macrophage	CL:0000583	alveolar macrophage		"{""preferred_term"": ""alveolar macrophage"", ""term"": {""id"": ""CL:0000583"", ""label"": ""alveolar macrophage""}}"																											
3857	4306	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	2	Alveolar hemorrhage and hemosiderin accumulation	"Increased capillary permeability allows red blood cells and hemoglobin to escape into the alveolar space, causing diffuse alveolar hemorrhage (DAH). Alveolar macrophages rapidly phagocytose the extravasated erythrocytes and break down hemoglobin, converting iron and heme into hemosiderin. These hemosiderin-laden macrophages (HLM) accumulate in alveolar spaces and can be detected via bronchoalveolar lavage (BAL) or lung biopsy, serving as a hallmark histologic finding of prior alveolar bleeding.
"	cell_types[1]	cell_types	cell_types			pulmonary alveolar type 2 cell	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""pulmonary alveolar type 2 cell"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
3858	4306	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	2	Alveolar hemorrhage and hemosiderin accumulation	"Increased capillary permeability allows red blood cells and hemoglobin to escape into the alveolar space, causing diffuse alveolar hemorrhage (DAH). Alveolar macrophages rapidly phagocytose the extravasated erythrocytes and break down hemoglobin, converting iron and heme into hemosiderin. These hemosiderin-laden macrophages (HLM) accumulate in alveolar spaces and can be detected via bronchoalveolar lavage (BAL) or lung biopsy, serving as a hallmark histologic finding of prior alveolar bleeding.
"	biological_processes[0]	biological_processes	biological_processes			heme catabolic process	GO:0006785	heme catabolic process		"{""preferred_term"": ""heme catabolic process"", ""term"": {""id"": ""GO:0006785"", ""label"": ""heme catabolic process""}}"																											
3859	4306	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	2	Alveolar hemorrhage and hemosiderin accumulation	"Increased capillary permeability allows red blood cells and hemoglobin to escape into the alveolar space, causing diffuse alveolar hemorrhage (DAH). Alveolar macrophages rapidly phagocytose the extravasated erythrocytes and break down hemoglobin, converting iron and heme into hemosiderin. These hemosiderin-laden macrophages (HLM) accumulate in alveolar spaces and can be detected via bronchoalveolar lavage (BAL) or lung biopsy, serving as a hallmark histologic finding of prior alveolar bleeding.
"	biological_processes[1]	biological_processes	biological_processes			iron ion homeostasis	GO:0055072	iron ion homeostasis		"{""preferred_term"": ""iron ion homeostasis"", ""term"": {""id"": ""GO:0055072"", ""label"": ""iron ion homeostasis""}}"																											
3860	4307	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	3	Iron and heme-driven oxidative injury and chronic remodeling	"Chronic recurrent alveolar hemorrhage leads to progressive iron and heme overload in the alveolar space, driving oxidative stress through iron-catalyzed free radical generation (Fenton reaction) and heme-driven lipid peroxidation. Oxidative injury damages alveolar epithelial cells, triggering type II pneumocyte hyperplasia as a reparative response. Over time, recurrent cycles of hemorrhage, oxidative injury, and epithelial repair may progress to pulmonary fibrosis and respiratory impairment if the underlying celiac disease is not controlled.
"	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
3861	4307	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	3	Iron and heme-driven oxidative injury and chronic remodeling	"Chronic recurrent alveolar hemorrhage leads to progressive iron and heme overload in the alveolar space, driving oxidative stress through iron-catalyzed free radical generation (Fenton reaction) and heme-driven lipid peroxidation. Oxidative injury damages alveolar epithelial cells, triggering type II pneumocyte hyperplasia as a reparative response. Over time, recurrent cycles of hemorrhage, oxidative injury, and epithelial repair may progress to pulmonary fibrosis and respiratory impairment if the underlying celiac disease is not controlled.
"	biological_processes[1]	biological_processes	biological_processes			epithelium regeneration	GO:0060574	epithelium regeneration		"{""preferred_term"": ""epithelium regeneration"", ""term"": {""id"": ""GO:0060574"", ""label"": ""epithelium regeneration""}}"																											
3862	4307	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	pathophysiology	3	Iron and heme-driven oxidative injury and chronic remodeling	"Chronic recurrent alveolar hemorrhage leads to progressive iron and heme overload in the alveolar space, driving oxidative stress through iron-catalyzed free radical generation (Fenton reaction) and heme-driven lipid peroxidation. Oxidative injury damages alveolar epithelial cells, triggering type II pneumocyte hyperplasia as a reparative response. Over time, recurrent cycles of hemorrhage, oxidative injury, and epithelial repair may progress to pulmonary fibrosis and respiratory impairment if the underlying celiac disease is not controlled.
"	biological_processes[2]	biological_processes	biological_processes			reactive oxygen species metabolic process	GO:0072593	reactive oxygen species metabolic process		"{""preferred_term"": ""reactive oxygen species metabolic process"", ""term"": {""id"": ""GO:0072593"", ""label"": ""reactive oxygen species metabolic process""}}"																											
3863	4308	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	phenotypes	0	Diffuse alveolar hemorrhage	"Core pulmonary manifestation of Lane Hamilton Syndrome, characterized by bleeding into the alveolar spaces of the lungs with radiologic ground-glass opacities and hemosiderin-laden macrophages on histology.
"	phenotype_term	phenotype_term	$	Diffuse alveolar hemorrhage	"Core pulmonary manifestation of Lane Hamilton Syndrome, characterized by bleeding into the alveolar spaces of the lungs with radiologic ground-glass opacities and hemosiderin-laden macrophages on histology.
"	diffuse alveolar hemorrhage	HP:0025420	Diffuse alveolar hemorrhage		"{""preferred_term"": ""diffuse alveolar hemorrhage"", ""term"": {""id"": ""HP:0025420"", ""label"": ""Diffuse alveolar hemorrhage""}}"																											
3864	4309	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	phenotypes	1	Hemoptysis	"Coughing up blood or blood-tinged sputum, a common pulmonary symptom in Lane Hamilton Syndrome, though hemoptysis may be absent in some pediatric cases.
"	phenotype_term	phenotype_term	$	Hemoptysis	"Coughing up blood or blood-tinged sputum, a common pulmonary symptom in Lane Hamilton Syndrome, though hemoptysis may be absent in some pediatric cases.
"	hemoptysis	HP:0002105	Hemoptysis		"{""preferred_term"": ""hemoptysis"", ""term"": {""id"": ""HP:0002105"", ""label"": ""Hemoptysis""}}"																											
3865	4310	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	phenotypes	2	Iron-deficiency anemia	"Near-universal finding in Lane Hamilton Syndrome adults, resulting from chronic blood loss into the alveoli with hemoglobin and iron depletion.
"	phenotype_term	phenotype_term	$	Iron-deficiency anemia	"Near-universal finding in Lane Hamilton Syndrome adults, resulting from chronic blood loss into the alveoli with hemoglobin and iron depletion.
"	iron-deficiency anemia	HP:0001891	Iron deficiency anemia		"{""preferred_term"": ""iron-deficiency anemia"", ""term"": {""id"": ""HP:0001891"", ""label"": ""Iron deficiency anemia""}}"																											
3866	4311	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	phenotypes	3	Dyspnea	"Shortness of breath, a common pulmonary symptom resulting from alveolar hemorrhage and impaired gas exchange.
"	phenotype_term	phenotype_term	$	Dyspnea	"Shortness of breath, a common pulmonary symptom resulting from alveolar hemorrhage and impaired gas exchange.
"	dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3867	4314	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	0	Gluten-free diet	"Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.
"	treatment_term	treatment_term	$	Gluten-free diet	"Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3868	4315	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	1	Corticosteroids	"Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.
"	treatment_term	treatment_term	$	Corticosteroids	"Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3869	4316	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	2	Immunosuppressive therapy	"Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.
"	treatment_term	treatment_term	$	Immunosuppressive therapy	"Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3870	4317	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	0	Direct laryngoscopy	Direct laryngoscopy visualizes the interarytenoid region and cleft extent.	diagnosis_term	diagnosis_term	$	Direct laryngoscopy	Direct laryngoscopy visualizes the interarytenoid region and cleft extent.	laryngoscopy	MAXO:0001189	laryngoscopy		"{""preferred_term"": ""laryngoscopy"", ""term"": {""id"": ""MAXO:0001189"", ""label"": ""laryngoscopy""}}"																											
3871	4318	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	1	Bronchoscopy	Bronchoscopy evaluates the airway and defines the extent of the cleft.	diagnosis_term	diagnosis_term	$	Bronchoscopy	Bronchoscopy evaluates the airway and defines the extent of the cleft.	bronchoscopy	MAXO:0001183	bronchoscopy		"{""preferred_term"": ""bronchoscopy"", ""term"": {""id"": ""MAXO:0001183"", ""label"": ""bronchoscopy""}}"																											
3872	4319	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	2	Chest radiograph imaging	Chest radiographs show pulmonary complications that support diagnosis and guide repair.	diagnosis_term	diagnosis_term	$	Chest radiograph imaging	Chest radiographs show pulmonary complications that support diagnosis and guide repair.	chest radiograph procedure	MAXO:0010356	chest radiograph procedure		"{""preferred_term"": ""chest radiograph procedure"", ""term"": {""id"": ""MAXO:0010356"", ""label"": ""chest radiograph procedure""}}"																											
3873	4320	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	3	Flexible endoscopy with sustained pharyngeal inflation	Flexible endoscopy with sustained pharyngeal inflation can improve visualization of laryngeal clefts in infants.	diagnosis_term	diagnosis_term	$	Flexible endoscopy with sustained pharyngeal inflation	Flexible endoscopy with sustained pharyngeal inflation can improve visualization of laryngeal clefts in infants.	laryngoscopy	MAXO:0001189	laryngoscopy		"{""preferred_term"": ""laryngoscopy"", ""term"": {""id"": ""MAXO:0001189"", ""label"": ""laryngoscopy""}}"																											
3874	4321	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	4	Video fluoroscopic swallow study	Video fluoroscopic swallow study evaluates dysphagia severity and guides management of interarytenoid defects.	diagnosis_term	diagnosis_term	$	Video fluoroscopic swallow study	Video fluoroscopic swallow study evaluates dysphagia severity and guides management of interarytenoid defects.	barium swallow radiograph procedure	MAXO:0035082	barium swallow radiograph procedure		"{""preferred_term"": ""barium swallow radiograph procedure"", ""term"": {""id"": ""MAXO:0035082"", ""label"": ""barium swallow radiograph procedure""}}"																											
3875	4322	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	diagnosis	5	Computed tomography imaging	Chest CT may be obtained during evaluation but can miss laryngeal clefts without targeted endoscopic assessment.	diagnosis_term	diagnosis_term	$	Computed tomography imaging	Chest CT may be obtained during evaluation but can miss laryngeal clefts without targeted endoscopic assessment.	computed tomography procedure	MAXO:0000571	computed tomography procedure		"{""preferred_term"": ""computed tomography procedure"", ""term"": {""id"": ""MAXO:0000571"", ""label"": ""computed tomography procedure""}}"																											
3876	4323	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	differential_diagnoses	0	Esophageal atresia	Prenatal imaging features of LTEC can mimic esophageal atresia.	disease_term	disease_term	$	Esophageal atresia	Prenatal imaging features of LTEC can mimic esophageal atresia.	esophageal atresia	MONDO:0001044	esophageal atresia		"{""preferred_term"": ""esophageal atresia"", ""term"": {""id"": ""MONDO:0001044"", ""label"": ""esophageal atresia""}}"																											
3877	4324	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	differential_diagnoses	1	Tracheo-esophageal fistula	Fistulous communication can resemble LTEC and must be distinguished.	disease_term	disease_term	$	Tracheo-esophageal fistula	Fistulous communication can resemble LTEC and must be distinguished.	isolated tracheo-esophageal fistula	MONDO:0018694	isolated tracheo-esophageal fistula		"{""preferred_term"": ""isolated tracheo-esophageal fistula"", ""term"": {""id"": ""MONDO:0018694"", ""label"": ""isolated tracheo-esophageal fistula""}}"																											
3878	4325	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	differential_diagnoses	2	Gastroesophageal reflux disease	GERD can present with aspiration and feeding symptoms that overlap with LTEC.	disease_term	disease_term	$	Gastroesophageal reflux disease	GERD can present with aspiration and feeding symptoms that overlap with LTEC.	gastroesophageal reflux disease	MONDO:0007186	gastroesophageal reflux disease		"{""preferred_term"": ""gastroesophageal reflux disease"", ""term"": {""id"": ""MONDO:0007186"", ""label"": ""gastroesophageal reflux disease""}}"																											
3879	4326	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	differential_diagnoses	3	Congenital laryngomalacia	Laryngomalacia can cause stridor and aspiration symptoms resembling LTEC.	disease_term	disease_term	$	Congenital laryngomalacia	Laryngomalacia can cause stridor and aspiration symptoms resembling LTEC.	congenital laryngomalacia	MONDO:0007878	congenital laryngomalacia		"{""preferred_term"": ""congenital laryngomalacia"", ""term"": {""id"": ""MONDO:0007878"", ""label"": ""congenital laryngomalacia""}}"																											
3880	4327	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	0	SOX2		gene_term	gene_term	$	SOX2		SOX2	hgnc:11195	SOX2		"{""preferred_term"": ""SOX2"", ""term"": {""id"": ""hgnc:11195"", ""label"": ""SOX2""}}"																											
3881	4328	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	1	FOXF1		gene_term	gene_term	$	FOXF1		FOXF1	hgnc:3809	FOXF1		"{""preferred_term"": ""FOXF1"", ""term"": {""id"": ""hgnc:3809"", ""label"": ""FOXF1""}}"																											
3882	4329	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	2	FOXC1		gene_term	gene_term	$	FOXC1		FOXC1	hgnc:3800	FOXC1		"{""preferred_term"": ""FOXC1"", ""term"": {""id"": ""hgnc:3800"", ""label"": ""FOXC1""}}"																											
3883	4330	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	3	RERE		gene_term	gene_term	$	RERE		RERE	hgnc:9965	RERE		"{""preferred_term"": ""RERE"", ""term"": {""id"": ""hgnc:9965"", ""label"": ""RERE""}}"																											
3884	4331	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	0	Type 0 (interarytenoid cleft)	Interarytenoid notch above the vocal folds without extension into the cricoid cartilage.	subtype_term	subtype_term	$	Type 0 (interarytenoid cleft)	Interarytenoid notch above the vocal folds without extension into the cricoid cartilage.	laryngotracheoesophageal cleft type 0	MONDO:0017220	laryngotracheoesophageal cleft type 0		"{""preferred_term"": ""laryngotracheoesophageal cleft type 0"", ""term"": {""id"": ""MONDO:0017220"", ""label"": ""laryngotracheoesophageal cleft type 0""}}"																											
3885	4332	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	1	Type I	Supraglottic cleft extending to, but not through, the cricoid cartilage.	subtype_term	subtype_term	$	Type I	Supraglottic cleft extending to, but not through, the cricoid cartilage.	laryngotracheoesophageal cleft type 1	MONDO:0019761	laryngotracheoesophageal cleft type 1		"{""preferred_term"": ""laryngotracheoesophageal cleft type 1"", ""term"": {""id"": ""MONDO:0019761"", ""label"": ""laryngotracheoesophageal cleft type 1""}}"																											
3886	4333	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	2	Type II	Cleft extends through the cricoid cartilage into the cervical trachea.	subtype_term	subtype_term	$	Type II	Cleft extends through the cricoid cartilage into the cervical trachea.	laryngotracheoesophageal cleft type 2	MONDO:0019762	laryngotracheoesophageal cleft type 2		"{""preferred_term"": ""laryngotracheoesophageal cleft type 2"", ""term"": {""id"": ""MONDO:0019762"", ""label"": ""laryngotracheoesophageal cleft type 2""}}"																											
3887	4334	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	3	Type III	Cleft extends into the thoracic trachea.	subtype_term	subtype_term	$	Type III	Cleft extends into the thoracic trachea.	laryngotracheoesophageal cleft type 3	MONDO:0019763	laryngotracheoesophageal cleft type 3		"{""preferred_term"": ""laryngotracheoesophageal cleft type 3"", ""term"": {""id"": ""MONDO:0019763"", ""label"": ""laryngotracheoesophageal cleft type 3""}}"																											
3888	4335	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	4	Type IV	Cleft extends to the carina and may involve a mainstem bronchus.	subtype_term	subtype_term	$	Type IV	Cleft extends to the carina and may involve a mainstem bronchus.	laryngotracheoesophageal cleft type 4	MONDO:0019764	laryngotracheoesophageal cleft type 4		"{""preferred_term"": ""laryngotracheoesophageal cleft type 4"", ""term"": {""id"": ""MONDO:0019764"", ""label"": ""laryngotracheoesophageal cleft type 4""}}"																											
3889	4336	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	0	Failed foregut partitioning	Abnormal separation of the anterior foregut permits persistent communication between airway and esophagus.	locations[0]	locations	locations			foregut	UBERON:0001041	foregut		"{""preferred_term"": ""foregut"", ""term"": {""id"": ""UBERON:0001041"", ""label"": ""foregut""}}"																											
3890	4336	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	0	Failed foregut partitioning	Abnormal separation of the anterior foregut permits persistent communication between airway and esophagus.	biological_processes[0]	biological_processes	biological_processes			digestive tract development	GO:0048565	digestive tract development		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""digestive tract development"", ""term"": {""id"": ""GO:0048565"", ""label"": ""digestive tract development""}}"			DYSREGULATED																								
3891	4336	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	0	Failed foregut partitioning	Abnormal separation of the anterior foregut permits persistent communication between airway and esophagus.	biological_processes[1]	biological_processes	biological_processes			respiratory system development	GO:0060541	respiratory system development		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""respiratory system development"", ""term"": {""id"": ""GO:0060541"", ""label"": ""respiratory system development""}}"			DYSREGULATED																								
3892	4337	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	1	Disrupted BMP4 signaling during larynx development	Disruption of BMP4 signaling perturbs laryngeal development and is associated with laryngeal cleft in a mouse model.	biological_processes[0]	biological_processes	biological_processes			BMP signaling pathway	GO:0030509	BMP signaling pathway		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""BMP signaling pathway"", ""term"": {""id"": ""GO:0030509"", ""label"": ""BMP signaling pathway""}}"			DYSREGULATED																								
3893	4337	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	1	Disrupted BMP4 signaling during larynx development	Disruption of BMP4 signaling perturbs laryngeal development and is associated with laryngeal cleft in a mouse model.	biological_processes[1]	biological_processes	biological_processes			larynx development	GO:0120224	larynx development		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""larynx development"", ""term"": {""id"": ""GO:0120224"", ""label"": ""larynx development""}}"			DYSREGULATED																								
3894	4338	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	2	Posterior communication between larynx/trachea and esophagus	Abnormal posterior cleft connects the larynx/trachea with the esophagus.	locations[0]	locations	locations			larynx	UBERON:0001737	larynx		"{""preferred_term"": ""larynx"", ""term"": {""id"": ""UBERON:0001737"", ""label"": ""larynx""}}"																											
3895	4338	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	2	Posterior communication between larynx/trachea and esophagus	Abnormal posterior cleft connects the larynx/trachea with the esophagus.	locations[1]	locations	locations			trachea	UBERON:0003126	trachea		"{""preferred_term"": ""trachea"", ""term"": {""id"": ""UBERON:0003126"", ""label"": ""trachea""}}"																											
3896	4338	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	2	Posterior communication between larynx/trachea and esophagus	Abnormal posterior cleft connects the larynx/trachea with the esophagus.	locations[2]	locations	locations			esophagus	UBERON:0001043	esophagus		"{""preferred_term"": ""esophagus"", ""term"": {""id"": ""UBERON:0001043"", ""label"": ""esophagus""}}"																											
3897	4339	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	3	Foregut maldevelopment during respiratory and digestive tract development	Disrupted foregut development underlies formation of the cleft.	locations[0]	locations	locations			foregut	UBERON:0001041	foregut		"{""preferred_term"": ""foregut"", ""term"": {""id"": ""UBERON:0001041"", ""label"": ""foregut""}}"																											
3898	4339	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	3	Foregut maldevelopment during respiratory and digestive tract development	Disrupted foregut development underlies formation of the cleft.	biological_processes[0]	biological_processes	biological_processes			digestive tract development	GO:0048565	digestive tract development		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""digestive tract development"", ""term"": {""id"": ""GO:0048565"", ""label"": ""digestive tract development""}}"			DYSREGULATED																								
3899	4339	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	3	Foregut maldevelopment during respiratory and digestive tract development	Disrupted foregut development underlies formation of the cleft.	biological_processes[1]	biological_processes	biological_processes			respiratory system development	GO:0060541	respiratory system development		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""respiratory system development"", ""term"": {""id"": ""GO:0060541"", ""label"": ""respiratory system development""}}"			DYSREGULATED																								
3900	4340	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	pathophysiology	4	Enriched esophageal malformation gene expression in lateral plate mesoderm	Esophageal malformation genes show highest expression in lateral plate mesoderm during early development, implicating this tissue in maldevelopment.	locations[0]	locations	locations			lateral plate mesoderm	UBERON:0003081	lateral plate mesoderm		"{""preferred_term"": ""lateral plate mesoderm"", ""term"": {""id"": ""UBERON:0003081"", ""label"": ""lateral plate mesoderm""}}"																											
3901	4341	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	0	Vomiting		phenotype_term	phenotype_term	$	Vomiting		Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
3902	4342	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	1	Pneumonia		phenotype_term	phenotype_term	$	Pneumonia		Pneumonia	HP:0002090	Pneumonia		"{""preferred_term"": ""Pneumonia"", ""term"": {""id"": ""HP:0002090"", ""label"": ""Pneumonia""}}"																											
3903	4343	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	2	Aspiration pneumonia	Aspiration pneumonia due to airway-esophageal communication.	phenotype_term	phenotype_term	$	Aspiration pneumonia	Aspiration pneumonia due to airway-esophageal communication.	Aspiration pneumonia	HP:0011951	Aspiration pneumonia		"{""preferred_term"": ""Aspiration pneumonia"", ""term"": {""id"": ""HP:0011951"", ""label"": ""Aspiration pneumonia""}}"																											
3904	4344	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	3	Cough	Chronic or severe cough related to airway communication and aspiration.	phenotype_term	phenotype_term	$	Cough	Chronic or severe cough related to airway communication and aspiration.	Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
3905	4345	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	4	Choking episodes	Choking during feeding due to abnormal airway-esophageal communication.	phenotype_term	phenotype_term	$	Choking episodes	Choking during feeding due to abnormal airway-esophageal communication.	Choking episodes	HP:0030842	Choking episodes		"{""preferred_term"": ""Choking episodes"", ""term"": {""id"": ""HP:0030842"", ""label"": ""Choking episodes""}}"																											
3906	4346	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	5	Upper airway obstruction	Obstructive upper airway symptoms can occur even without aspiration.	phenotype_term	phenotype_term	$	Upper airway obstruction	Obstructive upper airway symptoms can occur even without aspiration.	Upper airway obstruction	HP:0002781	Upper airway obstruction		"{""preferred_term"": ""Upper airway obstruction"", ""term"": {""id"": ""HP:0002781"", ""label"": ""Upper airway obstruction""}}"																											
3907	4347	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	6	Dysphagia	Swallowing dysfunction requiring thickened feeds in some patients.	phenotype_term	phenotype_term	$	Dysphagia	Swallowing dysfunction requiring thickened feeds in some patients.	Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
3908	4348	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	7	Stridor	Noisy breathing due to upper airway involvement.	phenotype_term	phenotype_term	$	Stridor	Noisy breathing due to upper airway involvement.	Stridor	HP:0010307	Stridor		"{""preferred_term"": ""Stridor"", ""term"": {""id"": ""HP:0010307"", ""label"": ""Stridor""}}"																											
3909	4349	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	8	Hoarse voice	Voice changes due to abnormal laryngeal communication.	phenotype_term	phenotype_term	$	Hoarse voice	Voice changes due to abnormal laryngeal communication.	Hoarse voice	HP:0001609	Hoarse voice		"{""preferred_term"": ""Hoarse voice"", ""term"": {""id"": ""HP:0001609"", ""label"": ""Hoarse voice""}}"																											
3910	4350	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	9	Dyspnea	Shortness of breath during feeding or respiratory distress.	phenotype_term	phenotype_term	$	Dyspnea	Shortness of breath during feeding or respiratory distress.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
3911	4351	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	10	Wheezing	Audible wheeze due to airway compromise.	phenotype_term	phenotype_term	$	Wheezing	Audible wheeze due to airway compromise.	Wheezing	HP:0030828	Wheezing		"{""preferred_term"": ""Wheezing"", ""term"": {""id"": ""HP:0030828"", ""label"": ""Wheezing""}}"																											
3912	4352	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	11	Aspiration	Microaspiration due to abnormal communication between airway and esophagus.	phenotype_term	phenotype_term	$	Aspiration	Microaspiration due to abnormal communication between airway and esophagus.	Aspiration	HP:0002835	Aspiration		"{""preferred_term"": ""Aspiration"", ""term"": {""id"": ""HP:0002835"", ""label"": ""Aspiration""}}"																											
3913	4353	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	12	Atelectasis	Collapse of lung segments noted on chest imaging.	phenotype_term	phenotype_term	$	Atelectasis	Collapse of lung segments noted on chest imaging.	Atelectasis	HP:0100750	Atelectasis		"{""preferred_term"": ""Atelectasis"", ""term"": {""id"": ""HP:0100750"", ""label"": ""Atelectasis""}}"																											
3914	4354	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	phenotypes	13	Bronchial wall thickening	Bronchial wall thickening observed on chest imaging.	phenotype_term	phenotype_term	$	Bronchial wall thickening	Bronchial wall thickening observed on chest imaging.	Bronchial wall thickening	HP:0033542	Bronchial wall thickening		"{""preferred_term"": ""Bronchial wall thickening"", ""term"": {""id"": ""HP:0033542"", ""label"": ""Bronchial wall thickening""}}"																											
3915	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term	treatment_term	$	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																			Laser Surgery	NCIT:C15268	NCIT:C15329						
3916	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3917	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser surgery	NCIT:C15268	Laser Surgery		"{""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}"																											
3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	treatment_term	$	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																			Laser Surgery	NCIT:C15268	NCIT:C15329	Carbon Dioxide	NCIT:C65288	NCIT:C2259			
3919	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3920	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser surgery	NCIT:C15268	Laser Surgery		"{""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}"																											
3921	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
3922	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			carbon dioxide	NCIT:C65288	Carbon Dioxide		"{""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}"																											
3923	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term	treatment_term	$	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																						hyaluronic acid	CHEBI:16336	NCIT:C2259			
3924	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
3925	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			hyaluronic acid	CHEBI:16336	hyaluronic acid		"{""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}"																											
3926	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term	treatment_term	$	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																			Endoscopic Procedure	NCIT:C16546	NCIT:C15329						
3927	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3928	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			endoscopic procedure	NCIT:C16546	Endoscopic Procedure		"{""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}"																											
3929	4360	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	4	Anterior laryngofissure repair with posterior cartilage grafting	Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC.	treatment_term	treatment_term	$	Anterior laryngofissure repair with posterior cartilage grafting	Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3930	4361	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	5	Combined open and endoscopic repair for long clefts	Combined open and endoscopic approaches may be required for long clefts with tracheal extension.	treatment_term	treatment_term	$	Combined open and endoscopic repair for long clefts	Combined open and endoscopic approaches may be required for long clefts with tracheal extension.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3931	4362	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	0	Visceral leishmaniasis		subtype_term	subtype_term	$	Visceral leishmaniasis		visceral leishmaniasis	MONDO:0005445	visceral leishmaniasis		"{""preferred_term"": ""visceral leishmaniasis"", ""term"": {""id"": ""MONDO:0005445"", ""label"": ""visceral leishmaniasis""}}"																											
3932	4363	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	1	Cutaneous leishmaniasis		subtype_term	subtype_term	$	Cutaneous leishmaniasis		cutaneous leishmaniasis	MONDO:0005446	cutaneous leishmaniasis		"{""preferred_term"": ""cutaneous leishmaniasis"", ""term"": {""id"": ""MONDO:0005446"", ""label"": ""cutaneous leishmaniasis""}}"																											
3933	4364	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	2	Mucocutaneous leishmaniasis		subtype_term	subtype_term	$	Mucocutaneous leishmaniasis		mucocutaneous leishmaniasis	MONDO:0005859	mucocutaneous leishmaniasis		"{""preferred_term"": ""mucocutaneous leishmaniasis"", ""term"": {""id"": ""MONDO:0005859"", ""label"": ""mucocutaneous leishmaniasis""}}"																											
3934	4365	183	Leishmaniasis	Leishmaniasis.yaml	infectious_agent	0	Leishmania spp.	Protozoan parasites causing leishmaniasis.	infectious_agent_term	infectious_agent_term	$	Leishmania spp.	Protozoan parasites causing leishmaniasis.	Leishmania <genus>	NCBITaxon:5658	Leishmania <genus>		"{""preferred_term"": ""Leishmania <genus>"", ""term"": {""id"": ""NCBITaxon:5658"", ""label"": ""Leishmania <genus>""}}"																											
3935	4366	183	Leishmaniasis	Leishmaniasis.yaml	pathophysiology	0	Intracellular amastigote replication in macrophages	Promastigotes differentiate into amastigotes that multiply inside host macrophages.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
3936	4367	183	Leishmaniasis	Leishmaniasis.yaml	phenotypes	0	Cutaneous ulcers		phenotype_term	phenotype_term	$	Cutaneous ulcers		Skin ulcer	HP:0200042	Skin ulcer		"{""preferred_term"": ""Skin ulcer"", ""term"": {""id"": ""HP:0200042"", ""label"": ""Skin ulcer""}}"																											
3937	4369	183	Leishmaniasis	Leishmaniasis.yaml	treatments	0	Liposomal amphotericin B therapy	Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions.	treatment_term	treatment_term	$	Liposomal amphotericin B therapy	Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3938	4370	184	Leprosy	Leprosy.yaml	infectious_agent	0	Mycobacterium leprae	Acid-fast bacterium that causes leprosy.	infectious_agent_term	infectious_agent_term	$	Mycobacterium leprae	Acid-fast bacterium that causes leprosy.	Mycobacterium leprae	NCBITaxon:1769	Mycobacterium leprae		"{""preferred_term"": ""Mycobacterium leprae"", ""term"": {""id"": ""NCBITaxon:1769"", ""label"": ""Mycobacterium leprae""}}"																											
3939	4373	184	Leprosy	Leprosy.yaml	phenotypes	0	Peripheral neuropathy		phenotype_term	phenotype_term	$	Peripheral neuropathy		Peripheral neuropathy	HP:0009830	Peripheral neuropathy		"{""preferred_term"": ""Peripheral neuropathy"", ""term"": {""id"": ""HP:0009830"", ""label"": ""Peripheral neuropathy""}}"																											
3940	4374	184	Leprosy	Leprosy.yaml	phenotypes	1	Localized skin lesion		phenotype_term	phenotype_term	$	Localized skin lesion		Localized skin lesion	HP:0011355	Localized skin lesion		"{""preferred_term"": ""Localized skin lesion"", ""term"": {""id"": ""HP:0011355"", ""label"": ""Localized skin lesion""}}"																											
3941	4376	184	Leprosy	Leprosy.yaml	treatments	0	Multidrug therapy with rifampicin, dapsone, and clofazimine	Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease.	treatment_term	treatment_term	$	Multidrug therapy with rifampicin, dapsone, and clofazimine	Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3942	4381	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	0	TP53 Tumor Suppressor Loss	Germline heterozygous TP53 mutations result in haploinsufficiency for p53 function. Somatic loss or inactivation of the remaining wild-type allele (second hit) eliminates p53 tumor suppressor activity, removing a critical checkpoint against malignant transformation.	biological_processes[0]	biological_processes	biological_processes			signal transduction by p53 class mediator	GO:0072331	signal transduction by p53 class mediator		"{""modifier"": ""DECREASED"", ""preferred_term"": ""signal transduction by p53 class mediator"", ""term"": {""id"": ""GO:0072331"", ""label"": ""signal transduction by p53 class mediator""}}"			DECREASED																								
3943	4382	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	1	Loss of DNA Damage Response	p53 is a master regulator of the DNA damage response. Upon detecting DNA damage, p53 activates transcription of genes involved in cell cycle arrest, DNA repair, and apoptosis. Loss of p53 function eliminates this critical surveillance mechanism.	biological_processes[0]	biological_processes	biological_processes			DNA damage response, signal transduction by p53 class mediator	GO:0030330	DNA damage response, signal transduction by p53 class mediator		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA damage response, signal transduction by p53 class mediator"", ""term"": {""id"": ""GO:0030330"", ""label"": ""DNA damage response, signal transduction by p53 class mediator""}}"			DECREASED																								
3944	4383	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	2	Loss of Cell Cycle Checkpoint Control	p53 induces G1 arrest in response to DNA damage by activating p21 (CDKN1A) transcription, which inhibits cyclin-dependent kinases. Without p53, cells with damaged DNA continue through the cell cycle, replicating mutations.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			ABNORMAL																								
3945	4384	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	3	Impaired Apoptosis	p53 promotes apoptosis through transcriptional activation of pro-apoptotic genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53 allows damaged and potentially transformed cells to survive and proliferate.	biological_processes[0]	biological_processes	biological_processes			intrinsic apoptotic signaling pathway by p53 class mediator	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator		"{""modifier"": ""DECREASED"", ""preferred_term"": ""intrinsic apoptotic signaling pathway by p53 class mediator"", ""term"": {""id"": ""GO:0072332"", ""label"": ""intrinsic apoptotic signaling pathway by p53 class mediator""}}"			DECREASED																								
3946	4384	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	3	Impaired Apoptosis	p53 promotes apoptosis through transcriptional activation of pro-apoptotic genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53 allows damaged and potentially transformed cells to survive and proliferate.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
3947	4385	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	4	Genomic Instability	Loss of p53-mediated checkpoints and DNA repair coordination leads to progressive accumulation of genomic alterations including point mutations, chromosomal rearrangements, and aneuploidy. This genomic instability accelerates tumor development and drives cancer heterogeneity.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
3948	4386	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	pathophysiology	5	Tumor Development	The combination of impaired DNA damage response, loss of cell cycle checkpoints, defective apoptosis, and genomic instability creates a permissive environment for tumor development. Different tissues vary in susceptibility, explaining the characteristic cancer spectrum of LFS.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
3949	4387	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	0	Soft Tissue Sarcoma	Soft tissue sarcomas, particularly rhabdomyosarcoma in children and undifferentiated pleomorphic sarcoma in adults, are core tumors of LFS. Often present at young ages.	phenotype_term	phenotype_term	$	Soft Tissue Sarcoma	Soft tissue sarcomas, particularly rhabdomyosarcoma in children and undifferentiated pleomorphic sarcoma in adults, are core tumors of LFS. Often present at young ages.	Soft tissue sarcoma	HP:0030448	Soft tissue sarcoma		"{""preferred_term"": ""Soft tissue sarcoma"", ""term"": {""id"": ""HP:0030448"", ""label"": ""Soft tissue sarcoma""}}"																											
3950	4388	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	1	Osteosarcoma	Osteosarcoma is a core tumor of LFS, typically occurring in adolescence or young adulthood. Often affects the long bones.	phenotype_term	phenotype_term	$	Osteosarcoma	Osteosarcoma is a core tumor of LFS, typically occurring in adolescence or young adulthood. Often affects the long bones.	Osteosarcoma	HP:0002669	Osteosarcoma		"{""preferred_term"": ""Osteosarcoma"", ""term"": {""id"": ""HP:0002669"", ""label"": ""Osteosarcoma""}}"																											
3951	4389	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	2	Breast Cancer	Premenopausal breast cancer is a hallmark of female LFS patients. Lifetime risk approaches 85-90% in women. Often HER2-positive. Occurs at much younger ages than sporadic breast cancer.	phenotype_term	phenotype_term	$	Breast Cancer	Premenopausal breast cancer is a hallmark of female LFS patients. Lifetime risk approaches 85-90% in women. Often HER2-positive. Occurs at much younger ages than sporadic breast cancer.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
3952	4390	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	3	Adrenocortical Carcinoma	Pediatric adrenocortical carcinoma is highly associated with LFS. Most children with ACC should be tested for germline TP53 mutations. The R337H Brazilian founder mutation is particularly associated with ACC.	phenotype_term	phenotype_term	$	Adrenocortical Carcinoma	Pediatric adrenocortical carcinoma is highly associated with LFS. Most children with ACC should be tested for germline TP53 mutations. The R337H Brazilian founder mutation is particularly associated with ACC.	Adrenocortical carcinoma	HP:0006744	Adrenocortical carcinoma		"{""preferred_term"": ""Adrenocortical carcinoma"", ""term"": {""id"": ""HP:0006744"", ""label"": ""Adrenocortical carcinoma""}}"																											
3953	4391	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	4	Central Nervous System Tumors	Brain tumors including gliomas, choroid plexus carcinoma, and medulloblastoma occur with increased frequency. Choroid plexus carcinoma in childhood is highly suggestive of LFS.	phenotype_term	phenotype_term	$	Central Nervous System Tumors	Brain tumors including gliomas, choroid plexus carcinoma, and medulloblastoma occur with increased frequency. Choroid plexus carcinoma in childhood is highly suggestive of LFS.	Malignant neoplasm of the central nervous system	HP:0100836	Malignant neoplasm of the central nervous system		"{""preferred_term"": ""Malignant neoplasm of the central nervous system"", ""term"": {""id"": ""HP:0100836"", ""label"": ""Malignant neoplasm of the central nervous system""}}"																											
3954	4392	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	5	Leukemia	Acute leukemias, both lymphoblastic and myeloid, occur at increased frequency in LFS patients, often at young ages.	phenotype_term	phenotype_term	$	Leukemia	Acute leukemias, both lymphoblastic and myeloid, occur at increased frequency in LFS patients, often at young ages.	Acute leukemia	HP:0002488	Acute leukemia		"{""preferred_term"": ""Acute leukemia"", ""term"": {""id"": ""HP:0002488"", ""label"": ""Acute leukemia""}}"																											
3955	4393	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	phenotypes	6	Multiple Primary Cancers	Many LFS patients develop multiple independent primary cancers during their lifetime. This is a characteristic feature distinguishing LFS from sporadic cancer cases.	phenotype_term	phenotype_term	$	Multiple Primary Cancers	Many LFS patients develop multiple independent primary cancers during their lifetime. This is a characteristic feature distinguishing LFS from sporadic cancer cases.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
3956	4394	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	0	Cancer Surveillance Protocol	Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.	treatment_term	treatment_term	$	Cancer Surveillance Protocol	Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
3957	4395	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	1	Risk-Reducing Mastectomy	Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.	treatment_term	treatment_term	$	Risk-Reducing Mastectomy	Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3958	4396	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	2	Genetic Counseling	Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3959	4399	186	Lichen Simplex Chronicus	Lichen_Simplex_Chronicus.yaml	phenotypes	0	Lichenification	Lichenified plaques resulting from persistent scratching.	phenotype_term	phenotype_term	$	Lichenification	Lichenified plaques resulting from persistent scratching.	Lichenification	HP:0100725	Lichenification		"{""preferred_term"": ""Lichenification"", ""term"": {""id"": ""HP:0100725"", ""label"": ""Lichenification""}}"																											
3960	4417	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	pathophysiology	0	Hepatocyte Injury and Death	"Chronic liver injury from any cause leads to ongoing hepatocyte death, triggering inflammation and regenerative responses that promote fibrosis.
"	cell_types[0]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
3961	4418	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	pathophysiology	1	Hepatic Stellate Cell Activation	"Quiescent stellate cells transform into myofibroblasts, producing excessive collagen and extracellular matrix. This is the central event in liver fibrosis.
"	cell_types[0]	cell_types	cell_types			Hepatic Stellate Cell	CL:0000632	hepatic stellate cell		"{""preferred_term"": ""Hepatic Stellate Cell"", ""term"": {""id"": ""CL:0000632"", ""label"": ""hepatic stellate cell""}}"																											
3962	4418	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	pathophysiology	1	Hepatic Stellate Cell Activation	"Quiescent stellate cells transform into myofibroblasts, producing excessive collagen and extracellular matrix. This is the central event in liver fibrosis.
"	biological_processes[0]	biological_processes	biological_processes			Fibrosis	GO:0097186	amelogenesis		"{""preferred_term"": ""Fibrosis"", ""term"": {""id"": ""GO:0097186"", ""label"": ""amelogenesis""}}"																											
3963	4419	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	pathophysiology	2	Portal Hypertension	"Increased resistance to portal blood flow due to architectural distortion and nodule formation. Leads to varices, ascites, and splenomegaly.
"	cell_types[0]	cell_types	cell_types			Endothelial Cell of Hepatic Sinusoid	CL:1000398	endothelial cell of hepatic sinusoid		"{""preferred_term"": ""Endothelial Cell of Hepatic Sinusoid"", ""term"": {""id"": ""CL:1000398"", ""label"": ""endothelial cell of hepatic sinusoid""}}"																											
3964	4420	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	pathophysiology	3	Synthetic Dysfunction	"Reduced hepatocyte mass impairs production of clotting factors, albumin, and other proteins, leading to coagulopathy and hypoalbuminemia.
"	biological_processes[0]	biological_processes	biological_processes			Protein Synthesis	GO:0006412	translation		"{""preferred_term"": ""Protein Synthesis"", ""term"": {""id"": ""GO:0006412"", ""label"": ""translation""}}"																											
3965	4421	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	0	Ascites		phenotype_term	phenotype_term	$	Ascites		Ascites	HP:0001541	Ascites		"{""preferred_term"": ""Ascites"", ""term"": {""id"": ""HP:0001541"", ""label"": ""Ascites""}}"																											
3966	4422	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	1	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
3967	4423	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	2	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
3968	4424	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	3	Splenomegaly		phenotype_term	phenotype_term	$	Splenomegaly		Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
3969	4425	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	4	Coagulopathy		phenotype_term	phenotype_term	$	Coagulopathy		Coagulopathy	HP:0003256	Abnormality of the coagulation cascade		"{""preferred_term"": ""Coagulopathy"", ""term"": {""id"": ""HP:0003256"", ""label"": ""Abnormality of the coagulation cascade""}}"																											
3970	4426	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	5	Hepatic Encephalopathy		phenotype_term	phenotype_term	$	Hepatic Encephalopathy		Hepatic Encephalopathy	HP:0002480	Hepatic encephalopathy		"{""preferred_term"": ""Hepatic Encephalopathy"", ""term"": {""id"": ""HP:0002480"", ""label"": ""Hepatic encephalopathy""}}"																											
3971	4427	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3972	4438	188	Long COVID	Long_COVID.yaml	clinical_trials	0	NCT06452082	Retrospective observational study evaluating the effect of vitamin D3 supplementation in reducing the risk of developing Long COVID syndrome after acute COVID-19 illness and in reducing the risk of SARS-CoV-2 infection after vaccination.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
3973	4439	188	Long COVID	Long_COVID.yaml	datasets	0		"GEO bulk transcriptomic dataset paired with immune and hormonal profiling in long COVID patients meeting ME/CFS criteria, highlighting sex-specific dysregulation.
"	organism	organism	$		"GEO bulk transcriptomic dataset paired with immune and hormonal profiling in long COVID patients meeting ME/CFS criteria, highlighting sex-specific dysregulation.
"	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
3974	4440	188	Long COVID	Long_COVID.yaml	differential_diagnoses	0	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	"ME/CFS shares core symptoms with Long COVID, including fatigue, pain, sleep disturbance, and cognitive dysfunction; emerging blood biomarkers can help distinguish these conditions from post-COVID condition.
"	disease_term	disease_term	$	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	"ME/CFS shares core symptoms with Long COVID, including fatigue, pain, sleep disturbance, and cognitive dysfunction; emerging blood biomarkers can help distinguish these conditions from post-COVID condition.
"	Myalgic encephalomyelitis/chronic fatigue syndrome	MONDO:0005404	myalgic encephalomeyelitis/chronic fatigue syndrome		"{""preferred_term"": ""Myalgic encephalomyelitis/chronic fatigue syndrome"", ""term"": {""id"": ""MONDO:0005404"", ""label"": ""myalgic encephalomeyelitis/chronic fatigue syndrome""}}"																											
3975	4441	188	Long COVID	Long_COVID.yaml	differential_diagnoses	1	Fibromyalgia	"Fibromyalgia overlaps with Long COVID on fatigue, pain, sleep disturbance, and cognitive symptoms; biomarker panels can aid differentiation from post-COVID condition.
"	disease_term	disease_term	$	Fibromyalgia	"Fibromyalgia overlaps with Long COVID on fatigue, pain, sleep disturbance, and cognitive symptoms; biomarker panels can aid differentiation from post-COVID condition.
"	Fibromyalgia	MONDO:0005546	fibromyalgia		"{""preferred_term"": ""Fibromyalgia"", ""term"": {""id"": ""MONDO:0005546"", ""label"": ""fibromyalgia""}}"																											
3976	4442	188	Long COVID	Long_COVID.yaml	differential_diagnoses	2	Narcolepsy Type II	"Excessive daytime sleepiness after COVID-19 may reflect narcolepsy type II rather than Long COVID; identifying narcolepsy avoids misattribution of hypersomnolence to post-viral fatigue alone.
"	disease_term	disease_term	$	Narcolepsy Type II	"Excessive daytime sleepiness after COVID-19 may reflect narcolepsy type II rather than Long COVID; identifying narcolepsy avoids misattribution of hypersomnolence to post-viral fatigue alone.
"	narcolepsy without cataplexy	MONDO:0019371	narcolepsy without cataplexy		"{""preferred_term"": ""narcolepsy without cataplexy"", ""term"": {""id"": ""MONDO:0019371"", ""label"": ""narcolepsy without cataplexy""}}"																											
3977	4444	188	Long COVID	Long_COVID.yaml	differential_diagnoses	4	Persistent SARS-CoV-2 Infection in Immunocompromised Hosts	"In immunocompromised patients, prolonged fever or symptoms may reflect persistent SARS-CoV-2 infection rather than post-acute sequelae, and should be ruled out before labeling Long COVID.
"	disease_term	disease_term	$	Persistent SARS-CoV-2 Infection in Immunocompromised Hosts	"In immunocompromised patients, prolonged fever or symptoms may reflect persistent SARS-CoV-2 infection rather than post-acute sequelae, and should be ruled out before labeling Long COVID.
"	COVID-19	MONDO:0100096	COVID-19		"{""preferred_term"": ""COVID-19"", ""term"": {""id"": ""MONDO:0100096"", ""label"": ""COVID-19""}}"																											
3978	4445	188	Long COVID	Long_COVID.yaml	pathophysiology	0	Viral Persistence	"SARS-CoV-2 viral reservoirs may persist in tissues including gut, brain, and other organs for months after acute infection. The gastrointestinal tract has emerged as a particularly significant reservoir site, with viral RNA detected in approximately 30% of intestinal specimens from Long COVID patients.
"	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
3979	4445	188	Long COVID	Long_COVID.yaml	pathophysiology	0	Viral Persistence	"SARS-CoV-2 viral reservoirs may persist in tissues including gut, brain, and other organs for months after acute infection. The gastrointestinal tract has emerged as a particularly significant reservoir site, with viral RNA detected in approximately 30% of intestinal specimens from Long COVID patients.
"	cell_types[1]	cell_types	cell_types			CD8-positive T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3980	4446	188	Long COVID	Long_COVID.yaml	pathophysiology	1	Systemic Immune Activation	"Long COVID patients show ongoing systemic inflammation with altered T cell subset distributions and cytokine perturbations, indicating chronic immune activation and dysregulated signaling.
"	cell_types[0]	cell_types	cell_types			CD4-positive T cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4-positive T cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
3981	4446	188	Long COVID	Long_COVID.yaml	pathophysiology	1	Systemic Immune Activation	"Long COVID patients show ongoing systemic inflammation with altered T cell subset distributions and cytokine perturbations, indicating chronic immune activation and dysregulated signaling.
"	cell_types[1]	cell_types	cell_types			CD8-positive T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3982	4446	188	Long COVID	Long_COVID.yaml	pathophysiology	1	Systemic Immune Activation	"Long COVID patients show ongoing systemic inflammation with altered T cell subset distributions and cytokine perturbations, indicating chronic immune activation and dysregulated signaling.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
3983	4446	188	Long COVID	Long_COVID.yaml	pathophysiology	1	Systemic Immune Activation	"Long COVID patients show ongoing systemic inflammation with altered T cell subset distributions and cytokine perturbations, indicating chronic immune activation and dysregulated signaling.
"	biological_processes[1]	biological_processes	biological_processes			JAK-STAT signaling	GO:0007259	cell surface receptor signaling pathway via JAK-STAT		"{""preferred_term"": ""JAK-STAT signaling"", ""term"": {""id"": ""GO:0007259"", ""label"": ""cell surface receptor signaling pathway via JAK-STAT""}}"																											
3984	4447	188	Long COVID	Long_COVID.yaml	pathophysiology	2	T Cell Exhaustion and Tissue Trafficking	"SARS-CoV-2-specific CD8+ T cells exhibit exhaustion phenotypes while CD4+ T cells are poised to migrate to inflamed tissues, reflecting sustained antigen exposure and chronic activation in Long COVID.
"	cell_types[0]	cell_types	cell_types			CD4-positive T cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4-positive T cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
3985	4447	188	Long COVID	Long_COVID.yaml	pathophysiology	2	T Cell Exhaustion and Tissue Trafficking	"SARS-CoV-2-specific CD8+ T cells exhibit exhaustion phenotypes while CD4+ T cells are poised to migrate to inflamed tissues, reflecting sustained antigen exposure and chronic activation in Long COVID.
"	cell_types[1]	cell_types	cell_types			CD8-positive T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
3986	4447	188	Long COVID	Long_COVID.yaml	pathophysiology	2	T Cell Exhaustion and Tissue Trafficking	"SARS-CoV-2-specific CD8+ T cells exhibit exhaustion phenotypes while CD4+ T cells are poised to migrate to inflamed tissues, reflecting sustained antigen exposure and chronic activation in Long COVID.
"	biological_processes[0]	biological_processes	biological_processes			T cell migration	GO:0072678	T cell migration		"{""preferred_term"": ""T cell migration"", ""term"": {""id"": ""GO:0072678"", ""label"": ""T cell migration""}}"																											
3987	4447	188	Long COVID	Long_COVID.yaml	pathophysiology	2	T Cell Exhaustion and Tissue Trafficking	"SARS-CoV-2-specific CD8+ T cells exhibit exhaustion phenotypes while CD4+ T cells are poised to migrate to inflamed tissues, reflecting sustained antigen exposure and chronic activation in Long COVID.
"	biological_processes[1]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
3988	4448	188	Long COVID	Long_COVID.yaml	pathophysiology	3	Endothelial Dysfunction and Microclots	"Persistent endothelial damage and formation of amyloid-like fibrin microclots impair microcirculation. These anomalous fibrin deposits resist normal fibrinolysis and can block capillaries, limiting oxygen delivery to tissues and potentially explaining the diverse symptomatology of Long COVID.
"	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
3989	4448	188	Long COVID	Long_COVID.yaml	pathophysiology	3	Endothelial Dysfunction and Microclots	"Persistent endothelial damage and formation of amyloid-like fibrin microclots impair microcirculation. These anomalous fibrin deposits resist normal fibrinolysis and can block capillaries, limiting oxygen delivery to tissues and potentially explaining the diverse symptomatology of Long COVID.
"	cell_types[1]	cell_types	cell_types			platelet	CL:0000233	platelet		"{""preferred_term"": ""platelet"", ""term"": {""id"": ""CL:0000233"", ""label"": ""platelet""}}"																											
3990	4448	188	Long COVID	Long_COVID.yaml	pathophysiology	3	Endothelial Dysfunction and Microclots	"Persistent endothelial damage and formation of amyloid-like fibrin microclots impair microcirculation. These anomalous fibrin deposits resist normal fibrinolysis and can block capillaries, limiting oxygen delivery to tissues and potentially explaining the diverse symptomatology of Long COVID.
"	biological_processes[0]	biological_processes	biological_processes			fibrinolysis	GO:0042730	fibrinolysis		"{""preferred_term"": ""fibrinolysis"", ""term"": {""id"": ""GO:0042730"", ""label"": ""fibrinolysis""}}"																											
3991	4449	188	Long COVID	Long_COVID.yaml	pathophysiology	4	Serotonin Depletion Mechanisms	"Long COVID features reduced peripheral serotonin driven by diminished intestinal tryptophan absorption, platelet hyperactivation that depletes stored serotonin, and enhanced monoamine oxidase-mediated serotonin turnover.
"	biological_processes[0]	biological_processes	biological_processes			tryptophan transport	GO:0015827	tryptophan transport		"{""preferred_term"": ""tryptophan transport"", ""term"": {""id"": ""GO:0015827"", ""label"": ""tryptophan transport""}}"																											
3992	4449	188	Long COVID	Long_COVID.yaml	pathophysiology	4	Serotonin Depletion Mechanisms	"Long COVID features reduced peripheral serotonin driven by diminished intestinal tryptophan absorption, platelet hyperactivation that depletes stored serotonin, and enhanced monoamine oxidase-mediated serotonin turnover.
"	biological_processes[1]	biological_processes	biological_processes			platelet activation	GO:0030168	platelet activation		"{""preferred_term"": ""platelet activation"", ""term"": {""id"": ""GO:0030168"", ""label"": ""platelet activation""}}"																											
3993	4449	188	Long COVID	Long_COVID.yaml	pathophysiology	4	Serotonin Depletion Mechanisms	"Long COVID features reduced peripheral serotonin driven by diminished intestinal tryptophan absorption, platelet hyperactivation that depletes stored serotonin, and enhanced monoamine oxidase-mediated serotonin turnover.
"	biological_processes[2]	biological_processes	biological_processes			serotonin metabolic process	GO:0042427	serotonin metabolic process		"{""preferred_term"": ""serotonin metabolic process"", ""term"": {""id"": ""GO:0042427"", ""label"": ""serotonin metabolic process""}}"																											
3994	4450	188	Long COVID	Long_COVID.yaml	pathophysiology	5	Vagus-Hippocampal Signaling Impairment	"Peripheral serotonin depletion weakens vagus nerve activity, leading to impaired hippocampal responses and memory formation that contribute to cognitive symptoms in Long COVID.
"	biological_processes[0]	biological_processes	biological_processes			regulation of synaptic plasticity	GO:0048167	regulation of synaptic plasticity		"{""preferred_term"": ""regulation of synaptic plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"																											
3995	4450	188	Long COVID	Long_COVID.yaml	pathophysiology	5	Vagus-Hippocampal Signaling Impairment	"Peripheral serotonin depletion weakens vagus nerve activity, leading to impaired hippocampal responses and memory formation that contribute to cognitive symptoms in Long COVID.
"	biological_processes[1]	biological_processes	biological_processes			memory	GO:0007613	memory		"{""preferred_term"": ""memory"", ""term"": {""id"": ""GO:0007613"", ""label"": ""memory""}}"																											
3996	4451	188	Long COVID	Long_COVID.yaml	pathophysiology	6	Autonomic Nervous System Dysfunction	"Dysautonomia, particularly postural orthostatic tachycardia syndrome (POTS), develops in many Long COVID patients. This may be related to virus- or immune-mediated disruption of the autonomic nervous system resulting in orthostatic intolerance syndromes.
"	biological_processes[0]	biological_processes	biological_processes			mast cell activation	GO:0045576	mast cell activation		"{""preferred_term"": ""mast cell activation"", ""term"": {""id"": ""GO:0045576"", ""label"": ""mast cell activation""}}"																											
3997	4452	188	Long COVID	Long_COVID.yaml	pathophysiology	7	Impaired Mitochondrial Energy Production	"Long COVID is associated with reduced mitochondrial ATP production and impaired oxidative phosphorylation, contributing to fatigue, cognitive disturbances, and exercise intolerance.
"	biological_processes[0]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
3998	4452	188	Long COVID	Long_COVID.yaml	pathophysiology	7	Impaired Mitochondrial Energy Production	"Long COVID is associated with reduced mitochondrial ATP production and impaired oxidative phosphorylation, contributing to fatigue, cognitive disturbances, and exercise intolerance.
"	biological_processes[1]	biological_processes	biological_processes			ATP biosynthetic process	GO:0006754	ATP biosynthetic process		"{""preferred_term"": ""ATP biosynthetic process"", ""term"": {""id"": ""GO:0006754"", ""label"": ""ATP biosynthetic process""}}"																											
3999	4453	188	Long COVID	Long_COVID.yaml	pathophysiology	8	Metabolic Shift and Oxidative Stress	"Mitochondrial impairment drives a shift toward glycolysis with associated oxidative stress and metabolic disturbances, further exacerbating systemic symptoms in Long COVID.
"	biological_processes[0]	biological_processes	biological_processes			glycolytic process	GO:0006096	glycolytic process		"{""preferred_term"": ""glycolytic process"", ""term"": {""id"": ""GO:0006096"", ""label"": ""glycolytic process""}}"																											
4000	4453	188	Long COVID	Long_COVID.yaml	pathophysiology	8	Metabolic Shift and Oxidative Stress	"Mitochondrial impairment drives a shift toward glycolysis with associated oxidative stress and metabolic disturbances, further exacerbating systemic symptoms in Long COVID.
"	biological_processes[1]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
4001	4454	188	Long COVID	Long_COVID.yaml	pathophysiology	9	Mast Cell Activation	"Mast cell activation syndrome (MCAS) has been implicated in Long COVID pathophysiology. Mast cell degranulation releases pro-inflammatory mediators including histamine, contributing to fatigue, brain fog, cardiovascular symptoms, and gastrointestinal disturbances.
"	cell_types[0]	cell_types	cell_types			mast cell	CL:0000097	mast cell		"{""preferred_term"": ""mast cell"", ""term"": {""id"": ""CL:0000097"", ""label"": ""mast cell""}}"																											
4002	4455	188	Long COVID	Long_COVID.yaml	pathophysiology	10	Neuroinflammation	"Neuroinflammation in Long COVID involves microglial activation, blood-brain barrier disruption, and inflammatory cytokine penetration into the brain parenchyma. This contributes to cognitive dysfunction, memory impairment, and other neurological symptoms.
"	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
4003	4455	188	Long COVID	Long_COVID.yaml	pathophysiology	10	Neuroinflammation	"Neuroinflammation in Long COVID involves microglial activation, blood-brain barrier disruption, and inflammatory cytokine penetration into the brain parenchyma. This contributes to cognitive dysfunction, memory impairment, and other neurological symptoms.
"	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
4004	4455	188	Long COVID	Long_COVID.yaml	pathophysiology	10	Neuroinflammation	"Neuroinflammation in Long COVID involves microglial activation, blood-brain barrier disruption, and inflammatory cytokine penetration into the brain parenchyma. This contributes to cognitive dysfunction, memory impairment, and other neurological symptoms.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4005	4456	188	Long COVID	Long_COVID.yaml	phenotypes	0	Fatigue	Persistent, debilitating fatigue that is not relieved by rest.	phenotype_term	phenotype_term	$	Fatigue	Persistent, debilitating fatigue that is not relieved by rest.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4006	4457	188	Long COVID	Long_COVID.yaml	phenotypes	1	Cognitive Impairment	"Brain fog, difficulty concentrating, memory problems, and reduced executive function. Often referred to as cognitive dysfunction.
"	phenotype_term	phenotype_term	$	Cognitive Impairment	"Brain fog, difficulty concentrating, memory problems, and reduced executive function. Often referred to as cognitive dysfunction.
"	Memory impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
4007	4458	188	Long COVID	Long_COVID.yaml	phenotypes	2	Dyspnea	Shortness of breath and breathing difficulties persisting after acute infection.	phenotype_term	phenotype_term	$	Dyspnea	Shortness of breath and breathing difficulties persisting after acute infection.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
4008	4459	188	Long COVID	Long_COVID.yaml	phenotypes	3	Post-exertional Malaise	"Worsening of symptoms following physical or mental exertion, similar to myalgic encephalomyelitis/chronic fatigue syndrome.
"	phenotype_term	phenotype_term	$	Post-exertional Malaise	"Worsening of symptoms following physical or mental exertion, similar to myalgic encephalomyelitis/chronic fatigue syndrome.
"	Post-exertional malaise	HP:0030973	Postexertional symptom exacerbation		"{""preferred_term"": ""Post-exertional malaise"", ""term"": {""id"": ""HP:0030973"", ""label"": ""Postexertional symptom exacerbation""}}"																											
4009	4460	188	Long COVID	Long_COVID.yaml	phenotypes	4	Palpitations	Awareness of heartbeat, often associated with POTS or general autonomic dysfunction.	phenotype_term	phenotype_term	$	Palpitations	Awareness of heartbeat, often associated with POTS or general autonomic dysfunction.	Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
4010	4461	188	Long COVID	Long_COVID.yaml	phenotypes	5	Tachycardia	Elevated heart rate, often associated with POTS or general autonomic dysfunction.	phenotype_term	phenotype_term	$	Tachycardia	Elevated heart rate, often associated with POTS or general autonomic dysfunction.	Tachycardia	HP:0001649	Tachycardia		"{""preferred_term"": ""Tachycardia"", ""term"": {""id"": ""HP:0001649"", ""label"": ""Tachycardia""}}"																											
4011	4462	188	Long COVID	Long_COVID.yaml	phenotypes	6	Chest Pain	Persistent chest discomfort or pain.	phenotype_term	phenotype_term	$	Chest Pain	Persistent chest discomfort or pain.	Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
4012	4463	188	Long COVID	Long_COVID.yaml	phenotypes	7	Headache	Chronic or recurring headaches.	phenotype_term	phenotype_term	$	Headache	Chronic or recurring headaches.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4013	4464	188	Long COVID	Long_COVID.yaml	phenotypes	8	Sleep Disturbance	Insomnia, unrefreshing sleep, or altered sleep patterns.	phenotype_term	phenotype_term	$	Sleep Disturbance	Insomnia, unrefreshing sleep, or altered sleep patterns.	Sleep disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
4014	4465	188	Long COVID	Long_COVID.yaml	phenotypes	9	Anxiety	Increased anxiety levels and panic symptoms.	phenotype_term	phenotype_term	$	Anxiety	Increased anxiety levels and panic symptoms.	Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
4015	4466	188	Long COVID	Long_COVID.yaml	phenotypes	10	Depression	Depressed mood and emotional dysregulation.	phenotype_term	phenotype_term	$	Depression	Depressed mood and emotional dysregulation.	Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
4016	4467	188	Long COVID	Long_COVID.yaml	phenotypes	11	Anosmia	Loss or alteration of sense of smell persisting beyond acute infection.	phenotype_term	phenotype_term	$	Anosmia	Loss or alteration of sense of smell persisting beyond acute infection.	Anosmia	HP:0000458	Anosmia		"{""preferred_term"": ""Anosmia"", ""term"": {""id"": ""HP:0000458"", ""label"": ""Anosmia""}}"																											
4017	4468	188	Long COVID	Long_COVID.yaml	phenotypes	12	Ageusia	Loss or alteration of sense of taste.	phenotype_term	phenotype_term	$	Ageusia	Loss or alteration of sense of taste.	Ageusia	HP:0041051	Ageusia		"{""preferred_term"": ""Ageusia"", ""term"": {""id"": ""HP:0041051"", ""label"": ""Ageusia""}}"																											
4018	4469	188	Long COVID	Long_COVID.yaml	phenotypes	13	Myalgia	Muscle pain and body aches.	phenotype_term	phenotype_term	$	Myalgia	Muscle pain and body aches.	Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
4019	4470	188	Long COVID	Long_COVID.yaml	phenotypes	14	Arthralgia	Joint pain without inflammation.	phenotype_term	phenotype_term	$	Arthralgia	Joint pain without inflammation.	Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
4020	4471	188	Long COVID	Long_COVID.yaml	phenotypes	15	Orthostatic Tachycardia	Excessive heart rate increase upon standing, characteristic of POTS.	phenotype_term	phenotype_term	$	Orthostatic Tachycardia	Excessive heart rate increase upon standing, characteristic of POTS.	Orthostatic tachycardia	HP:0012173	Orthostatic tachycardia		"{""preferred_term"": ""Orthostatic tachycardia"", ""term"": {""id"": ""HP:0012173"", ""label"": ""Orthostatic tachycardia""}}"																											
4021	4472	188	Long COVID	Long_COVID.yaml	phenotypes	16	Cough	Persistent cough continuing beyond acute infection.	phenotype_term	phenotype_term	$	Cough	Persistent cough continuing beyond acute infection.	Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
4022	4473	188	Long COVID	Long_COVID.yaml	phenotypes	17	Pulmonary Opacity	Ground glass opacification or other pulmonary imaging abnormalities persisting after acute infection.	phenotype_term	phenotype_term	$	Pulmonary Opacity	Ground glass opacification or other pulmonary imaging abnormalities persisting after acute infection.	Pulmonary opacity	HP:0031457	Pulmonary opacity		"{""preferred_term"": ""Pulmonary opacity"", ""term"": {""id"": ""HP:0031457"", ""label"": ""Pulmonary opacity""}}"																											
4023	4474	188	Long COVID	Long_COVID.yaml	phenotypes	18	Insomnia	Difficulty falling asleep or staying asleep.	phenotype_term	phenotype_term	$	Insomnia	Difficulty falling asleep or staying asleep.	Insomnia	HP:0100785	Insomnia		"{""preferred_term"": ""Insomnia"", ""term"": {""id"": ""HP:0100785"", ""label"": ""Insomnia""}}"																											
4024	4475	188	Long COVID	Long_COVID.yaml	phenotypes	19	Diarrhea	Loose or watery bowel movements persisting after acute infection.	phenotype_term	phenotype_term	$	Diarrhea	Loose or watery bowel movements persisting after acute infection.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
4025	4476	188	Long COVID	Long_COVID.yaml	phenotypes	20	Nausea	Sensation of unease in the stomach with urge to vomit.	phenotype_term	phenotype_term	$	Nausea	Sensation of unease in the stomach with urge to vomit.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
4026	4478	188	Long COVID	Long_COVID.yaml	treatments	1	Symptom-directed Pharmacotherapy	"Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.
"	treatment_term	treatment_term	$	Symptom-directed Pharmacotherapy	"Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4027	4479	188	Long COVID	Long_COVID.yaml	treatments	2	Rehabilitation Therapy	"Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.
"	treatment_term	treatment_term	$	Rehabilitation Therapy	"Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4028	4480	188	Long COVID	Long_COVID.yaml	treatments	3	Antihistamine Therapy	"H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.
"	treatment_term	treatment_term	$	Antihistamine Therapy	"H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4029	4484	189	Ludwig's Angina	Ludwigs_Angina.yaml	differential_diagnoses	0	Submandibular Sialolithiasis	Obstructive salivary stone may mimic submandibular swelling without infection or airway involvement.	disease_term	disease_term	$	Submandibular Sialolithiasis	Obstructive salivary stone may mimic submandibular swelling without infection or airway involvement.	sialolithiasis	MONDO:0006970	sialolithiasis		"{""preferred_term"": ""sialolithiasis"", ""term"": {""id"": ""MONDO:0006970"", ""label"": ""sialolithiasis""}}"																											
4030	4494	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	0	Odontogenic Source Infection (Mandibular Molar)	Dental infection of a mandibular tooth provides the odontogenic nidus that seeds deeper spaces.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4031	4494	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	0	Odontogenic Source Infection (Mandibular Molar)	Dental infection of a mandibular tooth provides the odontogenic nidus that seeds deeper spaces.	biological_processes[0]	biological_processes	biological_processes			Response to bacterium	GO:0009617	response to bacterium		"{""preferred_term"": ""Response to bacterium"", ""term"": {""id"": ""GO:0009617"", ""label"": ""response to bacterium""}}"																											
4032	4494	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	0	Odontogenic Source Infection (Mandibular Molar)	Dental infection of a mandibular tooth provides the odontogenic nidus that seeds deeper spaces.	locations[0]	locations	locations			Root of tooth	UBERON:0011605	root of tooth		"{""preferred_term"": ""Root of tooth"", ""term"": {""id"": ""UBERON:0011605"", ""label"": ""root of tooth""}}"																											
4033	4494	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	0	Odontogenic Source Infection (Mandibular Molar)	Dental infection of a mandibular tooth provides the odontogenic nidus that seeds deeper spaces.	locations[1]	locations	locations			Mandibular molar tooth	UBERON:0001094	mandibular molar tooth		"{""preferred_term"": ""Mandibular molar tooth"", ""term"": {""id"": ""UBERON:0001094"", ""label"": ""mandibular molar tooth""}}"																											
4034	4495	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	1	Polymicrobial Cellulitis of Mouth Floor	Mixed oral flora invade submandibular and sublingual spaces, producing rapidly spreading cellulitis.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4035	4495	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	1	Polymicrobial Cellulitis of Mouth Floor	Mixed oral flora invade submandibular and sublingual spaces, producing rapidly spreading cellulitis.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4036	4495	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	1	Polymicrobial Cellulitis of Mouth Floor	Mixed oral flora invade submandibular and sublingual spaces, producing rapidly spreading cellulitis.	locations[0]	locations	locations			Floor of mouth	UBERON:0003688	floor of mouth		"{""preferred_term"": ""Floor of mouth"", ""term"": {""id"": ""UBERON:0003688"", ""label"": ""floor of mouth""}}"																											
4037	4495	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	1	Polymicrobial Cellulitis of Mouth Floor	Mixed oral flora invade submandibular and sublingual spaces, producing rapidly spreading cellulitis.	locations[1]	locations	locations			Submandibular space	UBERON:0012443	submandibular space		"{""preferred_term"": ""Submandibular space"", ""term"": {""id"": ""UBERON:0012443"", ""label"": ""submandibular space""}}"																											
4038	4496	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	2	Cervical Fascial Spread Across Submandibular-Sublingual Spaces	Infection tracks along cervical fascial planes through submandibular, sublingual, and submental spaces.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4039	4496	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	2	Cervical Fascial Spread Across Submandibular-Sublingual Spaces	Infection tracks along cervical fascial planes through submandibular, sublingual, and submental spaces.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4040	4496	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	2	Cervical Fascial Spread Across Submandibular-Sublingual Spaces	Infection tracks along cervical fascial planes through submandibular, sublingual, and submental spaces.	locations[0]	locations	locations			Submandibular gland	UBERON:0002048	submandibular gland		"{""preferred_term"": ""Submandibular gland"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""submandibular gland""}}"																											
4041	4496	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	2	Cervical Fascial Spread Across Submandibular-Sublingual Spaces	Infection tracks along cervical fascial planes through submandibular, sublingual, and submental spaces.	locations[1]	locations	locations			Sublingual gland	UBERON:0001839	sublingual gland		"{""preferred_term"": ""Sublingual gland"", ""term"": {""id"": ""UBERON:0001839"", ""label"": ""sublingual gland""}}"																											
4042	4497	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	3	Descending Necrotizing Mediastinitis Extension	Continued inferior spread can involve the mediastinum, producing necrotizing mediastinitis.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4043	4497	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	3	Descending Necrotizing Mediastinitis Extension	Continued inferior spread can involve the mediastinum, producing necrotizing mediastinitis.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4044	4497	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	3	Descending Necrotizing Mediastinitis Extension	Continued inferior spread can involve the mediastinum, producing necrotizing mediastinitis.	locations[0]	locations	locations			Mediastinum	UBERON:0002416	mediastinum		"{""preferred_term"": ""Mediastinum"", ""term"": {""id"": ""UBERON:0002416"", ""label"": ""mediastinum""}}"																											
4045	4498	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	4	Tongue Elevation and Airway Narrowing from Floor Edema	Submandibular and sublingual edema elevate the tongue and floor of mouth, narrowing the oropharyngeal airway and precipitating stridor or dyspnea.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4046	4498	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	4	Tongue Elevation and Airway Narrowing from Floor Edema	Submandibular and sublingual edema elevate the tongue and floor of mouth, narrowing the oropharyngeal airway and precipitating stridor or dyspnea.	biological_processes[0]	biological_processes	biological_processes			Regulation of vascular permeability	GO:0043112	regulation of vascular permeability		"{""preferred_term"": ""Regulation of vascular permeability"", ""term"": {""id"": ""GO:0043112"", ""label"": ""regulation of vascular permeability""}}"																											
4047	4498	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	4	Tongue Elevation and Airway Narrowing from Floor Edema	Submandibular and sublingual edema elevate the tongue and floor of mouth, narrowing the oropharyngeal airway and precipitating stridor or dyspnea.	locations[0]	locations	locations			Oropharynx	UBERON:0001729	oropharynx		"{""preferred_term"": ""Oropharynx"", ""term"": {""id"": ""UBERON:0001729"", ""label"": ""oropharynx""}}"																											
4048	4498	189	Ludwig's Angina	Ludwigs_Angina.yaml	pathophysiology	4	Tongue Elevation and Airway Narrowing from Floor Edema	Submandibular and sublingual edema elevate the tongue and floor of mouth, narrowing the oropharyngeal airway and precipitating stridor or dyspnea.	locations[1]	locations	locations			Floor of mouth	UBERON:0003688	floor of mouth		"{""preferred_term"": ""Floor of mouth"", ""term"": {""id"": ""UBERON:0003688"", ""label"": ""floor of mouth""}}"																											
4049	4499	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	0	Stridor		phenotype_term	phenotype_term	$	Stridor		Stridor	HP:0010307	Stridor		"{""preferred_term"": ""Stridor"", ""term"": {""id"": ""HP:0010307"", ""label"": ""Stridor""}}"																											
4050	4500	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	1	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
4051	4501	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	2	Trismus		phenotype_term	phenotype_term	$	Trismus		Trismus	HP:0000211	Trismus		"{""preferred_term"": ""Trismus"", ""term"": {""id"": ""HP:0000211"", ""label"": ""Trismus""}}"																											
4052	4502	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	3	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
4053	4503	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	4	Anterior Neck Swelling		phenotype_term	phenotype_term	$	Anterior Neck Swelling		Anterior neck swelling	HP:6000176	Anterior neck swelling		"{""preferred_term"": ""Anterior neck swelling"", ""term"": {""id"": ""HP:6000176"", ""label"": ""Anterior neck swelling""}}"																											
4054	4504	189	Ludwig's Angina	Ludwigs_Angina.yaml	phenotypes	5	Facial Nerve Palsy		phenotype_term	phenotype_term	$	Facial Nerve Palsy		Facial palsy	HP:0010628	Facial palsy		"{""preferred_term"": ""Facial palsy"", ""term"": {""id"": ""HP:0010628"", ""label"": ""Facial palsy""}}"																											
4055	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term	treatment_term	$	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																									Tracheostomy	NCIT:C50458	NCIT:C49236
4056	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4057	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tracheostomy	NCIT:C50458	Tracheostomy		"{""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}"																											
4058	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term	treatment_term	$	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Broad Spectrum Antibiotic	NCIT:C2883	NCIT:C2259			
4059	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4060	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}"																											
4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	treatment_term	$	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																									Drainage Procedure; Tooth Extraction	NCIT:C15286; NCIT:C5189	NCIT:C49236
4062	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4063	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			drainage procedure	NCIT:C15286	Drainage Procedure		"{""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}"																											
4064	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4065	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			tooth extraction	NCIT:C5189	Tooth Extraction		"{""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}"																											
4066	4508	190	Lung Carcinoma	Lung_Carcinoma.yaml	datasets	0		Microarray profiling of 226 primary lung adenocarcinomas for expression signatures associated with clinical features.	organism	organism	$		Microarray profiling of 226 primary lung adenocarcinomas for expression signatures associated with clinical features.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4067	4508	190	Lung Carcinoma	Lung_Carcinoma.yaml	datasets	0		Microarray profiling of 226 primary lung adenocarcinomas for expression signatures associated with clinical features.	sample_types[0]	sample_types	sample_types			lung tumor tissue				"{""preferred_term"": ""lung tumor tissue"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
4068	4508	190	Lung Carcinoma	Lung_Carcinoma.yaml	datasets	0		Microarray profiling of 226 primary lung adenocarcinomas for expression signatures associated with clinical features.	sample_types[0].tissue_term	sample_types	sample_types[0]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
4069	4509	190	Lung Carcinoma	Lung_Carcinoma.yaml	environmental	0	Tobacco Smoking	Cigarette smoking is the dominant risk factor for lung carcinoma and drives carcinogenesis through chronic exposure to tobacco carcinogens.	exposure_term	exposure_term	$	Tobacco Smoking	Cigarette smoking is the dominant risk factor for lung carcinoma and drives carcinogenesis through chronic exposure to tobacco carcinogens.	exposure to tobacco smoking	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""exposure to tobacco smoking"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
4070	4513	190	Lung Carcinoma	Lung_Carcinoma.yaml	pathophysiology	1	VEGFA-Mediated Angiogenesis	VEGFA-driven angiogenesis contributes to lung cancer progression and promotes a proangiogenic signaling network.	biological_processes[0]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
4071	4514	190	Lung Carcinoma	Lung_Carcinoma.yaml	phenotypes	0	Cough		phenotype_term	phenotype_term	$	Cough		Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
4072	4515	190	Lung Carcinoma	Lung_Carcinoma.yaml	phenotypes	1	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
4073	4516	190	Lung Carcinoma	Lung_Carcinoma.yaml	phenotypes	2	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4074	4517	190	Lung Carcinoma	Lung_Carcinoma.yaml	phenotypes	3	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
4075	4518	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy, particularly for small cell lung cancer.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy, particularly for small cell lung cancer.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4076	4519	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	1	Surgical Resection	Surgical removal of localized non-small cell lung carcinoma.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of localized non-small cell lung carcinoma.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4077	4523	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	0	NCT03769194	Randomized, controlled, observer-blind Phase 2 study evaluating immunogenicity and safety of VLA15, a multivalent recombinant OspA-based Lyme borreliosis vaccine candidate in healthy adults aged 18-65 years. Participants received 3 immunizations at monthly intervals.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Erythema migrans	HP:0031180	Erythema migrans		"{""preferred_term"": ""Erythema migrans"", ""term"": {""id"": ""HP:0031180"", ""label"": ""Erythema migrans""}}"																											
4078	4524	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	1	NCT06785402	Randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating pulse-dosed intravenous ceftriaxone for Post-Treatment Lyme Disease Syndrome (PTLDS). Investigates whether periodic high-dose antibiotic therapy can eliminate persistent Borrelia burgdorferi in patients with persistent symptoms.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4079	4524	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	1	NCT06785402	Randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating pulse-dosed intravenous ceftriaxone for Post-Treatment Lyme Disease Syndrome (PTLDS). Investigates whether periodic high-dose antibiotic therapy can eliminate persistent Borrelia burgdorferi in patients with persistent symptoms.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
4080	4525	191	Lyme Disease	Lyme_Disease.yaml	clinical_trials	2	NCT03584919	European prospective clinical trial comparing doxycycline and cefuroxime axetil for treatment of erythema migrans in adult patients. Participants were evaluated at baseline, 14 days, and 2, 6, and 12 months post-enrollment to assess treatment efficacy and long-term outcomes.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Erythema migrans	HP:0031180	Erythema migrans		"{""preferred_term"": ""Erythema migrans"", ""term"": {""id"": ""HP:0031180"", ""label"": ""Erythema migrans""}}"																											
4081	4526	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	0	Southern Tick-Associated Rash Illness (STARI)	Lone star tick-associated erythema migranslike rash without Borrelia burgdorferi infection.	disease_term	disease_term	$	Southern Tick-Associated Rash Illness (STARI)	Lone star tick-associated erythema migranslike rash without Borrelia burgdorferi infection.	Southern Tick-Associated Rash Illness	MONDO:0025294	tick-borne infectious disease		"{""preferred_term"": ""Southern Tick-Associated Rash Illness"", ""term"": {""id"": ""MONDO:0025294"", ""label"": ""tick-borne infectious disease""}}"																											
4082	4527	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	1	Cellulitis	Bacterial skin infection that can mimic early erythema migrans.	disease_term	disease_term	$	Cellulitis	Bacterial skin infection that can mimic early erythema migrans.	cellulitis	MONDO:0005230	cellulitis		"{""preferred_term"": ""cellulitis"", ""term"": {""id"": ""MONDO:0005230"", ""label"": ""cellulitis""}}"																											
4083	4528	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	2	Septic Arthritis	Acute bacterial arthritis of large joints.	disease_term	disease_term	$	Septic Arthritis	Acute bacterial arthritis of large joints.	infective arthritis	MONDO:0042485	infective arthritis		"{""preferred_term"": ""infective arthritis"", ""term"": {""id"": ""MONDO:0042485"", ""label"": ""infective arthritis""}}"																											
4084	4529	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	3	Rheumatoid Arthritis	Chronic symmetric inflammatory polyarthritis.	disease_term	disease_term	$	Rheumatoid Arthritis	Chronic symmetric inflammatory polyarthritis.	rheumatoid arthritis	MONDO:0008383	rheumatoid arthritis		"{""preferred_term"": ""rheumatoid arthritis"", ""term"": {""id"": ""MONDO:0008383"", ""label"": ""rheumatoid arthritis""}}"																											
4085	4530	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	4	Viral Encephalitis	CNS infection causing encephalopathy that can overlap with neuroborreliosis symptoms.	disease_term	disease_term	$	Viral Encephalitis	CNS infection causing encephalopathy that can overlap with neuroborreliosis symptoms.	viral encephalitis	MONDO:0006009	viral encephalitis		"{""preferred_term"": ""viral encephalitis"", ""term"": {""id"": ""MONDO:0006009"", ""label"": ""viral encephalitis""}}"																											
4086	4531	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	5	Multiple Sclerosis and Other Demyelinating Myelopathies	Demyelinating CNS disease that can mimic neuroborreliosis with cord lesions.	disease_term	disease_term	$	Multiple Sclerosis and Other Demyelinating Myelopathies	Demyelinating CNS disease that can mimic neuroborreliosis with cord lesions.	multiple sclerosis	MONDO:0005301	multiple sclerosis		"{""preferred_term"": ""multiple sclerosis"", ""term"": {""id"": ""MONDO:0005301"", ""label"": ""multiple sclerosis""}}"																											
4087	4532	191	Lyme Disease	Lyme_Disease.yaml	differential_diagnoses	6	Viral Myocarditis/Other Causes of AV Block	Cardiac conduction disease from viral myocarditis or idiopathic fibrosis.	disease_term	disease_term	$	Viral Myocarditis/Other Causes of AV Block	Cardiac conduction disease from viral myocarditis or idiopathic fibrosis.	myocarditis	MONDO:0004496	myocarditis		"{""preferred_term"": ""myocarditis"", ""term"": {""id"": ""MONDO:0004496"", ""label"": ""myocarditis""}}"																											
4088	4543	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	0	Spirochete Invasion and Dissemination	"Borrelia burgdorferi is transmitted through Ixodes tick bites. The spirochete disseminates from the skin through the bloodstream to multiple organ systems including joints, heart, and nervous system. Surface adhesins like BBK32 and decorin-binding proteins (DbpA/DbpB) facilitate tissue colonization.
"	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4089	4543	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	0	Spirochete Invasion and Dissemination	"Borrelia burgdorferi is transmitted through Ixodes tick bites. The spirochete disseminates from the skin through the bloodstream to multiple organ systems including joints, heart, and nervous system. Surface adhesins like BBK32 and decorin-binding proteins (DbpA/DbpB) facilitate tissue colonization.
"	biological_processes[0]	biological_processes	biological_processes			cell adhesion	GO:0007155	cell adhesion		"{""preferred_term"": ""cell adhesion"", ""term"": {""id"": ""GO:0007155"", ""label"": ""cell adhesion""}}"																											
4090	4544	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	1	Autoimmune Activation after Persistent Infection	"Prolonged exposure of the host immune system to Borrelia antigens can drive post-infectious autoimmunity, with reported triggers of systemic autoimmune disease after Lyme borreliosis.
"	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4091	4544	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	1	Autoimmune Activation after Persistent Infection	"Prolonged exposure of the host immune system to Borrelia antigens can drive post-infectious autoimmunity, with reported triggers of systemic autoimmune disease after Lyme borreliosis.
"	biological_processes[0]	biological_processes	biological_processes			immune system process	GO:0002376	immune system process		"{""preferred_term"": ""immune system process"", ""term"": {""id"": ""GO:0002376"", ""label"": ""immune system process""}}"																											
4092	4545	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	2	Inflammatory Response and Tissue Damage	"The host immune response to Borrelia antigens contributes to tissue damage. Spirochetal lipoproteins and peptidoglycan trigger robust innate immune activation with production of IL-6, IL-8, TNF, and chemokines (CCL3/CCL4). Persistent inflammation in joints may continue even after spirochete clearance.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4093	4545	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	2	Inflammatory Response and Tissue Damage	"The host immune response to Borrelia antigens contributes to tissue damage. Spirochetal lipoproteins and peptidoglycan trigger robust innate immune activation with production of IL-6, IL-8, TNF, and chemokines (CCL3/CCL4). Persistent inflammation in joints may continue even after spirochete clearance.
"	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
4094	4545	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	2	Inflammatory Response and Tissue Damage	"The host immune response to Borrelia antigens contributes to tissue damage. Spirochetal lipoproteins and peptidoglycan trigger robust innate immune activation with production of IL-6, IL-8, TNF, and chemokines (CCL3/CCL4). Persistent inflammation in joints may continue even after spirochete clearance.
"	cell_types[2]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4095	4545	191	Lyme Disease	Lyme_Disease.yaml	pathophysiology	2	Inflammatory Response and Tissue Damage	"The host immune response to Borrelia antigens contributes to tissue damage. Spirochetal lipoproteins and peptidoglycan trigger robust innate immune activation with production of IL-6, IL-8, TNF, and chemokines (CCL3/CCL4). Persistent inflammation in joints may continue even after spirochete clearance.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4096	4546	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	0	Erythema Migrans	Characteristic expanding circular rash at the site of tick bite, often with central clearing (bull's-eye appearance). Present in 70-80% of cases.	phenotype_term	phenotype_term	$	Erythema Migrans	Characteristic expanding circular rash at the site of tick bite, often with central clearing (bull's-eye appearance). Present in 70-80% of cases.	Erythema migrans	HP:0031180	Erythema migrans		"{""preferred_term"": ""Erythema migrans"", ""term"": {""id"": ""HP:0031180"", ""label"": ""Erythema migrans""}}"																											
4097	4547	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	1	Fatigue	Profound fatigue is common in all stages of Lyme disease and may persist in post-treatment Lyme disease syndrome.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue is common in all stages of Lyme disease and may persist in post-treatment Lyme disease syndrome.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4098	4548	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	2	Arthralgia	Joint pain, particularly affecting large joints such as the knee, commonly precedes frank arthritis.	phenotype_term	phenotype_term	$	Arthralgia	Joint pain, particularly affecting large joints such as the knee, commonly precedes frank arthritis.	Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
4099	4549	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	3	Facial Palsy	Unilateral or bilateral facial nerve palsy (Bell's palsy) in early disseminated disease, occurring in approximately 5% of untreated patients.	phenotype_term	phenotype_term	$	Facial Palsy	Unilateral or bilateral facial nerve palsy (Bell's palsy) in early disseminated disease, occurring in approximately 5% of untreated patients.	Facial palsy	HP:0010628	Facial palsy		"{""preferred_term"": ""Facial palsy"", ""term"": {""id"": ""HP:0010628"", ""label"": ""Facial palsy""}}"																											
4100	4550	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	4	Arthritis	Inflammatory arthritis, typically monoarticular or oligoarticular, affecting large joints especially the knee. Occurs in approximately 60% of untreated patients.	phenotype_term	phenotype_term	$	Arthritis	Inflammatory arthritis, typically monoarticular or oligoarticular, affecting large joints especially the knee. Occurs in approximately 60% of untreated patients.	Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
4101	4551	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	5	Atrioventricular Block	Cardiac involvement including AV block (first, second, or third degree) and myocarditis. Lyme carditis occurs in 1-5% of untreated patients.	phenotype_term	phenotype_term	$	Atrioventricular Block	Cardiac involvement including AV block (first, second, or third degree) and myocarditis. Lyme carditis occurs in 1-5% of untreated patients.	Atrioventricular block	HP:0001678	Atrioventricular block		"{""preferred_term"": ""Atrioventricular block"", ""term"": {""id"": ""HP:0001678"", ""label"": ""Atrioventricular block""}}"																											
4102	4552	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	6	Dementia (Reversible Neuroborreliosis)	Subcortical or reversible dementia presentations of neuroborreliosis that improve with antibiotic therapy.	phenotype_term	phenotype_term	$	Dementia (Reversible Neuroborreliosis)	Subcortical or reversible dementia presentations of neuroborreliosis that improve with antibiotic therapy.	Dementia	HP:0000726	Dementia		"{""preferred_term"": ""Dementia"", ""term"": {""id"": ""HP:0000726"", ""label"": ""Dementia""}}"																											
4103	4553	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	7	Myelitis	Inflammatory spinal cord involvement as a rare manifestation of acute neuroborreliosis, sometimes with mild clinical symptoms despite marked MRI edema.	phenotype_term	phenotype_term	$	Myelitis	Inflammatory spinal cord involvement as a rare manifestation of acute neuroborreliosis, sometimes with mild clinical symptoms despite marked MRI edema.	Myelitis	HP:0012486	Myelitis		"{""preferred_term"": ""Myelitis"", ""term"": {""id"": ""HP:0012486"", ""label"": ""Myelitis""}}"																											
4104	4554	191	Lyme Disease	Lyme_Disease.yaml	phenotypes	8	Bullous Skin Lesions	Autoimmune blistering lesions (epidermolysis bullosa acquisita-like) following Lyme infection; reported after atypical erythema migrans.	phenotype_term	phenotype_term	$	Bullous Skin Lesions	Autoimmune blistering lesions (epidermolysis bullosa acquisita-like) following Lyme infection; reported after atypical erythema migrans.	Subepidermal blistering	HP:0033804	Subepidermal blistering		"{""preferred_term"": ""Subepidermal blistering"", ""term"": {""id"": ""HP:0033804"", ""label"": ""Subepidermal blistering""}}"																											
4105	4555	191	Lyme Disease	Lyme_Disease.yaml	treatments	0	Oral Doxycycline	"First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.
"	treatment_term	treatment_term	$	Oral Doxycycline	"First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4106	4556	191	Lyme Disease	Lyme_Disease.yaml	treatments	1	Oral Amoxicillin	"Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.
"	treatment_term	treatment_term	$	Oral Amoxicillin	"Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4107	4557	191	Lyme Disease	Lyme_Disease.yaml	treatments	2	Intravenous Ceftriaxone	"Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.
"	treatment_term	treatment_term	$	Intravenous Ceftriaxone	"Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4108	4558	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	infectious_agent	0	Wuchereria bancrofti	Primary causative filarial nematode of lymphatic filariasis.	infectious_agent_term	infectious_agent_term	$	Wuchereria bancrofti	Primary causative filarial nematode of lymphatic filariasis.	Wuchereria bancrofti	NCBITaxon:6293	Wuchereria bancrofti		"{""preferred_term"": ""Wuchereria bancrofti"", ""term"": {""id"": ""NCBITaxon:6293"", ""label"": ""Wuchereria bancrofti""}}"																											
4109	4559	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	infectious_agent	1	Brugia malayi	Secondary causative agent of lymphatic filariasis.	infectious_agent_term	infectious_agent_term	$	Brugia malayi	Secondary causative agent of lymphatic filariasis.	Brugia malayi	NCBITaxon:6279	Brugia malayi		"{""preferred_term"": ""Brugia malayi"", ""term"": {""id"": ""NCBITaxon:6279"", ""label"": ""Brugia malayi""}}"																											
4110	4560	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	infectious_agent	2	Brugia timori	Regional causative agent of lymphatic filariasis.	infectious_agent_term	infectious_agent_term	$	Brugia timori	Regional causative agent of lymphatic filariasis.	Brugia timori	NCBITaxon:42155	Brugia timori		"{""preferred_term"": ""Brugia timori"", ""term"": {""id"": ""NCBITaxon:42155"", ""label"": ""Brugia timori""}}"																											
4111	4561	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	pathophysiology	0	Lymphatic vessel blockage and dysfunction	Adult lymphatic filariae in lymph vessels provoke blockage and host responses that impair lymphatic function and drive fibrosis.	locations[0]	locations	locations			lymphatic vessel	UBERON:0001473	lymphatic vessel		"{""preferred_term"": ""lymphatic vessel"", ""term"": {""id"": ""UBERON:0001473"", ""label"": ""lymphatic vessel""}}"																											
4112	4562	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	pathophysiology	1	Lymphatic vessel remodeling and dilation	Adult parasites damage lymphatic valves and remodel lymphatic vessels, causing lymphatic dilation.	locations[0]	locations	locations			lymphatic vessel	UBERON:0001473	lymphatic vessel		"{""preferred_term"": ""lymphatic vessel"", ""term"": {""id"": ""UBERON:0001473"", ""label"": ""lymphatic vessel""}}"																											
4113	4563	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	phenotypes	0	Lymphedema		phenotype_term	phenotype_term	$	Lymphedema		Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
4114	4564	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	phenotypes	1	Hydrocele		phenotype_term	phenotype_term	$	Hydrocele		Hydrocele testis	HP:0000034	Hydrocele testis		"{""preferred_term"": ""Hydrocele testis"", ""term"": {""id"": ""HP:0000034"", ""label"": ""Hydrocele testis""}}"																											
4115	4565	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	phenotypes	2	Elephantiasis	Severe, chronic lymphedema with tissue overgrowth.	phenotype_term	phenotype_term	$	Elephantiasis	Severe, chronic lymphedema with tissue overgrowth.	Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
4116	4567	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	treatments	0	Mass drug administration with albendazole plus ivermectin or DEC	WHO-recommended antifilarial drug combinations used to interrupt transmission.	treatment_term	treatment_term	$	Mass drug administration with albendazole plus ivermectin or DEC	WHO-recommended antifilarial drug combinations used to interrupt transmission.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4117	4568	193	Lymphoma	Lymphoma.yaml	datasets	0		Gene expression microarray dataset of 414 diffuse large B-cell lymphoma cases used for molecular subtype and outcome analyses.	organism	organism	$		Gene expression microarray dataset of 414 diffuse large B-cell lymphoma cases used for molecular subtype and outcome analyses.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4118	4568	193	Lymphoma	Lymphoma.yaml	datasets	0		Gene expression microarray dataset of 414 diffuse large B-cell lymphoma cases used for molecular subtype and outcome analyses.	sample_types[0]	sample_types	sample_types			lymph node tissue				"{""preferred_term"": ""lymph node tissue"", ""tissue_term"": {""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}}"																											
4119	4568	193	Lymphoma	Lymphoma.yaml	datasets	0		Gene expression microarray dataset of 414 diffuse large B-cell lymphoma cases used for molecular subtype and outcome analyses.	sample_types[0].tissue_term	sample_types	sample_types[0]			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
4120	4572	193	Lymphoma	Lymphoma.yaml	pathophysiology	1	Hodgkin/Reed-Sternberg Cell Origin	Hodgkin lymphoma is characterized by clonal Hodgkin/Reed-Sternberg cells that derive from B cells.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4121	4573	193	Lymphoma	Lymphoma.yaml	phenotypes	0	Lymphadenopathy		phenotype_term	phenotype_term	$	Lymphadenopathy		Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
4122	4574	193	Lymphoma	Lymphoma.yaml	phenotypes	1	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
4123	4575	193	Lymphoma	Lymphoma.yaml	phenotypes	2	Night Sweats		phenotype_term	phenotype_term	$	Night Sweats		Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
4124	4576	193	Lymphoma	Lymphoma.yaml	phenotypes	3	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4125	4577	193	Lymphoma	Lymphoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy regimens tailored to lymphoma subtype.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy regimens tailored to lymphoma subtype.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4126	4578	193	Lymphoma	Lymphoma.yaml	treatments	1	Radiation Therapy	Radiotherapy combined with chemotherapy for selected lymphoma subtypes.	treatment_term	treatment_term	$	Radiation Therapy	Radiotherapy combined with chemotherapy for selected lymphoma subtypes.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4127	4581	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	0		Large French multicenter cohort (Cartes d'Identite des Tumeurs program) with 566 colon tumor samples and 19 non-tumoral colorectal mucosa samples (585 total) including MSI status annotation. Contains 71 MSI-high and 439 MSS samples, useful for studying Lynch syndrome-associated molecular signatures.	organism	organism	$		Large French multicenter cohort (Cartes d'Identite des Tumeurs program) with 566 colon tumor samples and 19 non-tumoral colorectal mucosa samples (585 total) including MSI status annotation. Contains 71 MSI-high and 439 MSS samples, useful for studying Lynch syndrome-associated molecular signatures.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4128	4581	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	0		Large French multicenter cohort (Cartes d'Identite des Tumeurs program) with 566 colon tumor samples and 19 non-tumoral colorectal mucosa samples (585 total) including MSI status annotation. Contains 71 MSI-high and 439 MSS samples, useful for studying Lynch syndrome-associated molecular signatures.	sample_types[0]	sample_types	sample_types			colon tumor tissue	UBERON:0001155	colon		"{""preferred_term"": ""colon tumor tissue"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}, ""tissue_term"": {""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}}"																											
4129	4581	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	0		Large French multicenter cohort (Cartes d'Identite des Tumeurs program) with 566 colon tumor samples and 19 non-tumoral colorectal mucosa samples (585 total) including MSI status annotation. Contains 71 MSI-high and 439 MSS samples, useful for studying Lynch syndrome-associated molecular signatures.	sample_types[0].tissue_term	sample_types	sample_types[0]			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4130	4582	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	1		Independent validation cohort of 177 colon cancer samples from Moffitt Cancer Center with clinical outcome data including metastasis risk and survival information.	organism	organism	$		Independent validation cohort of 177 colon cancer samples from Moffitt Cancer Center with clinical outcome data including metastasis risk and survival information.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4131	4582	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	1		Independent validation cohort of 177 colon cancer samples from Moffitt Cancer Center with clinical outcome data including metastasis risk and survival information.	sample_types[0]	sample_types	sample_types			colon tumor tissue	UBERON:0001155	colon		"{""preferred_term"": ""colon tumor tissue"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}, ""tissue_term"": {""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}}"																											
4132	4582	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	1		Independent validation cohort of 177 colon cancer samples from Moffitt Cancer Center with clinical outcome data including metastasis risk and survival information.	sample_types[0].tissue_term	sample_types	sample_types[0]			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4133	4583	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	2		RNA-seq cohort of colorectal adenomas from Lynch syndrome patients, with comparator familial adenomatous polyposis adenomas, used for transcriptomic immune profiling of premalignant lesions.	organism	organism	$		RNA-seq cohort of colorectal adenomas from Lynch syndrome patients, with comparator familial adenomatous polyposis adenomas, used for transcriptomic immune profiling of premalignant lesions.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4134	4583	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	2		RNA-seq cohort of colorectal adenomas from Lynch syndrome patients, with comparator familial adenomatous polyposis adenomas, used for transcriptomic immune profiling of premalignant lesions.	sample_types[0]	sample_types	sample_types			colorectal adenoma tissue	UBERON:0001155	colon		"{""preferred_term"": ""colorectal adenoma tissue"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}, ""tissue_term"": {""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}}"																											
4135	4583	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	2		RNA-seq cohort of colorectal adenomas from Lynch syndrome patients, with comparator familial adenomatous polyposis adenomas, used for transcriptomic immune profiling of premalignant lesions.	sample_types[0].tissue_term	sample_types	sample_types[0]			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4136	4584	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	3		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	organism	organism	$		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4137	4584	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	3		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	sample_types[0]	sample_types	sample_types			urinary bladder tumor tissue	UBERON:0001255	urinary bladder		"{""preferred_term"": ""urinary bladder tumor tissue"", ""term"": {""id"": ""UBERON:0001255"", ""label"": ""urinary bladder""}, ""tissue_term"": {""preferred_term"": ""urinary bladder"", ""term"": {""id"": ""UBERON:0001255"", ""label"": ""urinary bladder""}}}"																											
4138	4584	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	3		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	sample_types[0].tissue_term	sample_types	sample_types[0]			urinary bladder	UBERON:0001255	urinary bladder		"{""preferred_term"": ""urinary bladder"", ""term"": {""id"": ""UBERON:0001255"", ""label"": ""urinary bladder""}}"																											
4139	4584	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	3		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	sample_types[1]	sample_types	sample_types			upper urinary tract tumor tissue	UBERON:0011143	upper urinary tract		"{""preferred_term"": ""upper urinary tract tumor tissue"", ""term"": {""id"": ""UBERON:0011143"", ""label"": ""upper urinary tract""}, ""tissue_term"": {""preferred_term"": ""upper urinary tract"", ""term"": {""id"": ""UBERON:0011143"", ""label"": ""upper urinary tract""}}}"																											
4140	4584	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	3		Microarray cohort of Lynch syndrome-associated urothelial cancers from bladder and upper urinary tract, profiled for molecular subtype mapping, MSI status, and clinicopathologic associations.	sample_types[1].tissue_term	sample_types	sample_types[1]			upper urinary tract	UBERON:0011143	upper urinary tract		"{""preferred_term"": ""upper urinary tract"", ""term"": {""id"": ""UBERON:0011143"", ""label"": ""upper urinary tract""}}"																											
4141	4585	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	4		FFPE colorectal cancer expression cohort spanning Lynch syndrome, familial colorectal cancer type X (FCCTX), and sporadic CRC, designed to identify hereditary pathway-level differences.	organism	organism	$		FFPE colorectal cancer expression cohort spanning Lynch syndrome, familial colorectal cancer type X (FCCTX), and sporadic CRC, designed to identify hereditary pathway-level differences.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4142	4585	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	4		FFPE colorectal cancer expression cohort spanning Lynch syndrome, familial colorectal cancer type X (FCCTX), and sporadic CRC, designed to identify hereditary pathway-level differences.	sample_types[0]	sample_types	sample_types			colorectal carcinoma tissue	UBERON:0001155	colon		"{""preferred_term"": ""colorectal carcinoma tissue"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}, ""tissue_term"": {""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}}"																											
4143	4585	194	Lynch Syndrome	Lynch_Syndrome.yaml	datasets	4		FFPE colorectal cancer expression cohort spanning Lynch syndrome, familial colorectal cancer type X (FCCTX), and sporadic CRC, designed to identify hereditary pathway-level differences.	sample_types[0].tissue_term	sample_types	sample_types[0]			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4144	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	locations[0]	locations	locations			nucleus	UBERON:0000062	nucleus		"{""preferred_term"": ""nucleus"", ""term"": {""id"": ""UBERON:0000062"", ""label"": ""nucleus""}}"																											
4145	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	cell_types[0]	cell_types	cell_types			colonic epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colonic epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
4146	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	cell_types[1]	cell_types	cell_types			endometrial epithelial cell	CL:0002656	glandular endometrial unciliated epithelial cell		"{""preferred_term"": ""endometrial epithelial cell"", ""term"": {""id"": ""CL:0002656"", ""label"": ""glandular endometrial unciliated epithelial cell""}}"																											
4147	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	cellular_components[0]	cellular_components	cellular_components			nucleoplasm	GO:0005654	nucleoplasm		"{""preferred_term"": ""nucleoplasm"", ""term"": {""id"": ""GO:0005654"", ""label"": ""nucleoplasm""}}"																											
4148	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	protein_complexes[0]	protein_complexes	protein_complexes			mismatch repair complex	GO:0032300	mismatch repair complex		"{""preferred_term"": ""mismatch repair complex"", ""term"": {""id"": ""GO:0032300"", ""label"": ""mismatch repair complex""}}"																											
4149	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[0]	biological_processes	biological_processes			mismatch repair	GO:0006298	mismatch repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""mismatch repair"", ""term"": {""id"": ""GO:0006298"", ""label"": ""mismatch repair""}}"			DECREASED																								
4150	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[1]	biological_processes	biological_processes			DNA-templated DNA replication maintenance of fidelity	GO:0045005	DNA-templated DNA replication maintenance of fidelity		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA-templated DNA replication maintenance of fidelity"", ""term"": {""id"": ""GO:0045005"", ""label"": ""DNA-templated DNA replication maintenance of fidelity""}}"			DECREASED																								
4151	4597	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.	biological_processes[2]	biological_processes	biological_processes			DNA damage response	GO:0006974	DNA damage response		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""DNA damage response""}}"			ABNORMAL																								
4152	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4153	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	locations[1]	locations	locations			endometrium	UBERON:0001295	endometrium		"{""preferred_term"": ""endometrium"", ""term"": {""id"": ""UBERON:0001295"", ""label"": ""endometrium""}}"																											
4154	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	cell_types[0]	cell_types	cell_types			colonic epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colonic epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
4155	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	cell_types[1]	cell_types	cell_types			endometrial epithelial cell	CL:0002656	glandular endometrial unciliated epithelial cell		"{""preferred_term"": ""endometrial epithelial cell"", ""term"": {""id"": ""CL:0002656"", ""label"": ""glandular endometrial unciliated epithelial cell""}}"																											
4156	4598	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	1	Microsatellite Instability	Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.	biological_processes[0]	biological_processes	biological_processes			DNA-templated DNA replication maintenance of fidelity	GO:0045005	DNA-templated DNA replication maintenance of fidelity		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA-templated DNA replication maintenance of fidelity"", ""term"": {""id"": ""GO:0045005"", ""label"": ""DNA-templated DNA replication maintenance of fidelity""}}"			DECREASED																								
4157	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4158	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	locations[1]	locations	locations			endometrium	UBERON:0001295	endometrium		"{""preferred_term"": ""endometrium"", ""term"": {""id"": ""UBERON:0001295"", ""label"": ""endometrium""}}"																											
4159	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	cell_types[0]	cell_types	cell_types			colonic epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colonic epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
4160	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	cell_types[1]	cell_types	cell_types			endometrial epithelial cell	CL:0002656	glandular endometrial unciliated epithelial cell		"{""preferred_term"": ""endometrial epithelial cell"", ""term"": {""id"": ""CL:0002656"", ""label"": ""glandular endometrial unciliated epithelial cell""}}"																											
4161	4599	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	2	Accelerated Tumor Development	The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4162	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4163	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	locations[1]	locations	locations			endometrium	UBERON:0001295	endometrium		"{""preferred_term"": ""endometrium"", ""term"": {""id"": ""UBERON:0001295"", ""label"": ""endometrium""}}"																											
4164	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
4165	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[0]	biological_processes	biological_processes			antigen processing and presentation of peptide antigen via MHC class I	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I		"{""modifier"": ""INCREASED"", ""preferred_term"": ""antigen processing and presentation of peptide antigen via MHC class I"", ""term"": {""id"": ""GO:0002474"", ""label"": ""antigen processing and presentation of peptide antigen via MHC class I""}}"			INCREASED																								
4166	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[1]	biological_processes	biological_processes			type I interferon-mediated signaling pathway	GO:0060337	type I interferon-mediated signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""type I interferon-mediated signaling pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon-mediated signaling pathway""}}"			INCREASED																								
4167	4600	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	3	Neoantigen Generation and Immune Activation	Frameshift mutations in coding repeats generate tumor neoantigens that activate tumor-infiltrating lymphocytes and create an immunogenic tumor microenvironment.	biological_processes[2]	biological_processes	biological_processes			T cell mediated cytotoxicity directed against tumor cell target	GO:0002419	T cell mediated cytotoxicity directed against tumor cell target		"{""modifier"": ""INCREASED"", ""preferred_term"": ""T cell mediated cytotoxicity directed against tumor cell target"", ""term"": {""id"": ""GO:0002419"", ""label"": ""T cell mediated cytotoxicity directed against tumor cell target""}}"			INCREASED																								
4168	4601	194	Lynch Syndrome	Lynch_Syndrome.yaml	pathophysiology	4	Immune Checkpoint Blockade Sensitivity	Lynch-associated dMMR/MSI tumors with high neoantigen burden are enriched for anti-tumor T-cell activity and show strong responses to PD-1 blockade.	biological_processes[0]	biological_processes	biological_processes			T cell mediated cytotoxicity directed against tumor cell target	GO:0002419	T cell mediated cytotoxicity directed against tumor cell target		"{""modifier"": ""INCREASED"", ""preferred_term"": ""T cell mediated cytotoxicity directed against tumor cell target"", ""term"": {""id"": ""GO:0002419"", ""label"": ""T cell mediated cytotoxicity directed against tumor cell target""}}"			INCREASED																								
4169	4602	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	0	Colorectal Cancer	Early-onset colorectal adenocarcinoma, often right-sided with mucinous histology and microsatellite instability.	phenotype_term	phenotype_term	$	Colorectal Cancer	Early-onset colorectal adenocarcinoma, often right-sided with mucinous histology and microsatellite instability.	colorectal cancer	MONDO:0005575	colorectal cancer		"{""preferred_term"": ""colorectal cancer"", ""term"": {""id"": ""MONDO:0005575"", ""label"": ""colorectal cancer""}}"																											
4170	4603	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	1	Endometrial Cancer	Uterine cancer developing at younger ages than sporadic cases, often the sentinel cancer in female Lynch syndrome carriers.	phenotype_term	phenotype_term	$	Endometrial Cancer	Uterine cancer developing at younger ages than sporadic cases, often the sentinel cancer in female Lynch syndrome carriers.	endometrial cancer	MONDO:0011962	endometrial cancer		"{""preferred_term"": ""endometrial cancer"", ""term"": {""id"": ""MONDO:0011962"", ""label"": ""endometrial cancer""}}"																											
4171	4604	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	2	Stomach Cancer	Gastric adenocarcinoma occurring at elevated rates in Lynch syndrome, particularly with certain MMR gene mutations.	phenotype_term	phenotype_term	$	Stomach Cancer	Gastric adenocarcinoma occurring at elevated rates in Lynch syndrome, particularly with certain MMR gene mutations.	Stomach Cancer	HP:0012126	Stomach cancer		"{""preferred_term"": ""Stomach Cancer"", ""term"": {""id"": ""HP:0012126"", ""label"": ""Stomach cancer""}}"																											
4172	4605	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	3	Urinary Tract Cancer	Upper urinary tract urothelial carcinoma affecting the ureter or renal pelvis.	phenotype_term	phenotype_term	$	Urinary Tract Cancer	Upper urinary tract urothelial carcinoma affecting the ureter or renal pelvis.	renal pelvis/ureter urothelial carcinoma	MONDO:0020654	renal pelvis/ureter urothelial carcinoma		"{""preferred_term"": ""renal pelvis/ureter urothelial carcinoma"", ""term"": {""id"": ""MONDO:0020654"", ""label"": ""renal pelvis/ureter urothelial carcinoma""}}"																											
4173	4606	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	4	Ovarian Cancer	Epithelial ovarian cancer with increased lifetime risk in Lynch syndrome carriers, typically non-serous histology.	phenotype_term	phenotype_term	$	Ovarian Cancer	Epithelial ovarian cancer with increased lifetime risk in Lynch syndrome carriers, typically non-serous histology.	ovarian carcinoma	MONDO:0005140	ovarian carcinoma		"{""preferred_term"": ""ovarian carcinoma"", ""term"": {""id"": ""MONDO:0005140"", ""label"": ""ovarian carcinoma""}}"																											
4174	4607	194	Lynch Syndrome	Lynch_Syndrome.yaml	phenotypes	5	Sebaceous Adenomas	Sebaceous gland tumors associated with Muir-Torre syndrome, a phenotypic variant of Lynch syndrome.	phenotype_term	phenotype_term	$	Sebaceous Adenomas	Sebaceous gland tumors associated with Muir-Torre syndrome, a phenotypic variant of Lynch syndrome.	sebaceous adenoma	MONDO:0002375	sebaceous adenoma		"{""preferred_term"": ""sebaceous adenoma"", ""term"": {""id"": ""MONDO:0002375"", ""label"": ""sebaceous adenoma""}}"																											
4175	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	Prophylactic Surgery	Preventive removal of the colon, uterus, or ovaries may be considered in some cases.	treatment_term	treatment_term	$	Prophylactic Surgery	Preventive removal of the colon, uterus, or ovaries may be considered in some cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4176	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term	treatment_term	$	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}]}"				acetylsalicylic acid	CHEBI:15365																						
4177	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acetylsalicylic acid	CHEBI:15365	acetylsalicylic acid		"{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}"																											
4178	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	Targeted Therapies	Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.	treatment_term	treatment_term	$	Targeted Therapies	Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4179	4614	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	pathophysiology	0	Impaired medium-chain fatty acid beta-oxidation	"MCAD catalyzes the first step of mitochondrial beta-oxidation for medium-chain fatty acyl-CoAs (C6-C12). Deficiency leads to accumulation of medium-chain acylcarnitines and failure to generate acetyl-CoA and ketone bodies during fasting.
"	locations[0]	locations	locations			mitochondrial matrix	GO:0005759	mitochondrial matrix		"{""preferred_term"": ""mitochondrial matrix"", ""term"": {""id"": ""GO:0005759"", ""label"": ""mitochondrial matrix""}}"																											
4180	4614	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	pathophysiology	0	Impaired medium-chain fatty acid beta-oxidation	"MCAD catalyzes the first step of mitochondrial beta-oxidation for medium-chain fatty acyl-CoAs (C6-C12). Deficiency leads to accumulation of medium-chain acylcarnitines and failure to generate acetyl-CoA and ketone bodies during fasting.
"	biological_processes[0]	biological_processes	biological_processes			fatty acid beta-oxidation	GO:0006635	fatty acid beta-oxidation		"{""preferred_term"": ""fatty acid beta-oxidation"", ""term"": {""id"": ""GO:0006635"", ""label"": ""fatty acid beta-oxidation""}}"																											
4181	4614	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	pathophysiology	0	Impaired medium-chain fatty acid beta-oxidation	"MCAD catalyzes the first step of mitochondrial beta-oxidation for medium-chain fatty acyl-CoAs (C6-C12). Deficiency leads to accumulation of medium-chain acylcarnitines and failure to generate acetyl-CoA and ketone bodies during fasting.
"	biological_processes[1]	biological_processes	biological_processes			medium-chain fatty acyl-CoA dehydrogenase activity	GO:0070991	medium-chain fatty acyl-CoA dehydrogenase activity		"{""preferred_term"": ""medium-chain fatty acyl-CoA dehydrogenase activity"", ""term"": {""id"": ""GO:0070991"", ""label"": ""medium-chain fatty acyl-CoA dehydrogenase activity""}}"																											
4182	4616	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	pathophysiology	2	Toxic metabolite accumulation	"Accumulation of medium-chain fatty acids and their conjugates (octanoate, octanoylcarnitine) may have direct toxic effects on brain and liver tissue. Accumulated acyl-CoA intermediates deplete free coenzyme A and may cause mitochondrial dysfunction.
"	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
4183	4616	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	pathophysiology	2	Toxic metabolite accumulation	"Accumulation of medium-chain fatty acids and their conjugates (octanoate, octanoylcarnitine) may have direct toxic effects on brain and liver tissue. Accumulated acyl-CoA intermediates deplete free coenzyme A and may cause mitochondrial dysfunction.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
4184	4617	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	phenotypes	0	Hypoketotic hypoglycemia	"Low blood glucose with inappropriately low or absent ketones during fasting or illness. Classic presenting feature.
"	phenotype_term	phenotype_term	$	Hypoketotic hypoglycemia	"Low blood glucose with inappropriately low or absent ketones during fasting or illness. Classic presenting feature.
"	Hypoketotic hypoglycemia	HP:0001985	Hypoketotic hypoglycemia		"{""preferred_term"": ""Hypoketotic hypoglycemia"", ""term"": {""id"": ""HP:0001985"", ""label"": ""Hypoketotic hypoglycemia""}}"																											
4185	4618	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	phenotypes	1	Hepatomegaly	"Fatty infiltration of the liver with hepatomegaly during metabolic crises.
"	phenotype_term	phenotype_term	$	Hepatomegaly	"Fatty infiltration of the liver with hepatomegaly during metabolic crises.
"	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
4186	4619	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	phenotypes	2	Lethargy	"Progressive lethargy during metabolic decompensation, may progress to coma.
"	phenotype_term	phenotype_term	$	Lethargy	"Progressive lethargy during metabolic decompensation, may progress to coma.
"	Lethargy	HP:0001254	Lethargy		"{""preferred_term"": ""Lethargy"", ""term"": {""id"": ""HP:0001254"", ""label"": ""Lethargy""}}"																											
4187	4620	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	phenotypes	3	Hypoglycemic seizures	"Seizures may occur secondary to severe hypoglycemia.
"	phenotype_term	phenotype_term	$	Hypoglycemic seizures	"Seizures may occur secondary to severe hypoglycemia.
"	Hypoglycemic seizures	HP:0002173	Hypoglycemic seizures		"{""preferred_term"": ""Hypoglycemic seizures"", ""term"": {""id"": ""HP:0002173"", ""label"": ""Hypoglycemic seizures""}}"																											
4188	4623	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	0	Avoidance of fasting	"Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.
"	treatment_term	treatment_term	$	Avoidance of fasting	"Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4189	4624	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	1	Emergency glucose administration	"During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.
"	treatment_term	treatment_term	$	Emergency glucose administration	"During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4190	4625	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	2	L-carnitine supplementation	"Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.
"	treatment_term	treatment_term	$	L-carnitine supplementation	"Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4191	4626	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	3	Dietary modification	"Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.
"	treatment_term	treatment_term	$	Dietary modification	"Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4192	4632	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
4193	4633	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	0	MET Exon 14 Splice Mutations	MET exon 14 skipping results from splice site mutations that cause exclusion of exon 14 during pre-mRNA splicing. Exon 14 encodes a juxtamembrane regulatory domain containing a CBL E3 ubiquitin ligase binding site (Y1003). Loss of this domain prevents receptor ubiquitination and degradation, leading to prolonged MET signaling after ligand stimulation.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
4194	4633	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	0	MET Exon 14 Splice Mutations	MET exon 14 skipping results from splice site mutations that cause exclusion of exon 14 during pre-mRNA splicing. Exon 14 encodes a juxtamembrane regulatory domain containing a CBL E3 ubiquitin ligase binding site (Y1003). Loss of this domain prevents receptor ubiquitination and degradation, leading to prolonged MET signaling after ligand stimulation.	biological_processes[0]	biological_processes	biological_processes			transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""transmembrane receptor protein tyrosine kinase signaling pathway"", ""term"": {""id"": ""GO:0007169"", ""label"": ""transmembrane receptor protein tyrosine kinase signaling pathway""}}"			INCREASED																								
4195	4634	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	1	Prolonged MET Signaling	METex14 skipping results in prolonged receptor activation and downstream signaling through RAS-MAPK, PI3K-AKT, and STAT3 pathways. HGF (hepatocyte growth factor) ligand binding triggers signaling, but receptor downregulation is impaired.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4196	4634	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	1	Prolonged MET Signaling	METex14 skipping results in prolonged receptor activation and downstream signaling through RAS-MAPK, PI3K-AKT, and STAT3 pathways. HGF (hepatocyte growth factor) ligand binding triggers signaling, but receptor downregulation is impaired.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
4197	4635	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	2	Cell Proliferation and Migration	MET signaling promotes cell proliferation, survival, motility, and invasion. The HGF-MET axis is particularly important for epithelial-mesenchymal transition and metastasis.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4198	4636	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	pathophysiology	3	MET Inhibitor Resistance	Resistance to MET inhibitors can develop through secondary MET kinase mutations (D1228N/V, Y1230C/H), MET amplification increase, or bypass pathway activation (KRAS, EGFR, HER3). On-target resistance mutations affect drug binding.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
4199	4637	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	METex14 NSCLC is predominantly adenocarcinoma histology, though can occur in sarcomatoid carcinoma with higher frequency than other molecular subtypes.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	METex14 NSCLC is predominantly adenocarcinoma histology, though can occur in sarcomatoid carcinoma with higher frequency than other molecular subtypes.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
4200	4638	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	phenotypes	1	Older Age at Diagnosis	Unlike ALK/ROS1-positive patients, METex14 patients are typically older (median age ~70s), reflecting a distinct demographic profile.	phenotype_term	phenotype_term	$	Older Age at Diagnosis	Unlike ALK/ROS1-positive patients, METex14 patients are typically older (median age ~70s), reflecting a distinct demographic profile.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
4201	4639	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	phenotypes	2	Variable Smoking History	METex14 alterations occur in both smokers and never-smokers, with approximately 50% having smoking history.	phenotype_term	phenotype_term	$	Variable Smoking History	METex14 alterations occur in both smokers and never-smokers, with approximately 50% having smoking history.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
4202	4640	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	phenotypes	3	Brain Metastases	Brain metastases occur in METex14 NSCLC. CNS penetration of MET inhibitors varies; capmatinib and tepotinib have shown intracranial activity.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in METex14 NSCLC. CNS penetration of MET inhibitors varies; capmatinib and tepotinib have shown intracranial activity.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
4203	4641	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	0	Capmatinib	Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity.	treatment_term	treatment_term	$	Capmatinib	Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4204	4642	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	1	Tepotinib	Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases.	treatment_term	treatment_term	$	Tepotinib	Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4205	4643	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	2	Crizotinib	Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable.	treatment_term	treatment_term	$	Crizotinib	Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4206	4644	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4207	4645	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4208	4656	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	histopathology	0	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	finding_term	finding_term	$	Adenocarcinoma	Adenocarcinoma is the most common pathologic subtype of colon cancer.	Adenocarcinoma	NCIT:C2852	Adenocarcinoma		"{""preferred_term"": ""Adenocarcinoma"", ""term"": {""id"": ""NCIT:C2852"", ""label"": ""Adenocarcinoma""}}"																											
4209	4657	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Loss of MMR protein function (MLH1, MSH2, MSH6, or PMS2) impairs the recognition and repair of DNA replication errors. The MMR system normally corrects base-base mismatches and insertion/deletion loops at microsatellite sequences. Deficiency leads to accumulation of thousands of somatic mutations.	cell_types[0]	cell_types	cell_types			colon epithelial cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""colon epithelial cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
4210	4657	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	0	DNA Mismatch Repair Deficiency	Loss of MMR protein function (MLH1, MSH2, MSH6, or PMS2) impairs the recognition and repair of DNA replication errors. The MMR system normally corrects base-base mismatches and insertion/deletion loops at microsatellite sequences. Deficiency leads to accumulation of thousands of somatic mutations.	biological_processes[0]	biological_processes	biological_processes			mismatch repair	GO:0006298	mismatch repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""mismatch repair"", ""term"": {""id"": ""GO:0006298"", ""label"": ""mismatch repair""}}"			DECREASED																								
4211	4658	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	1	Microsatellite Instability	Microsatellites are repetitive DNA sequences highly susceptible to replication errors. Without functional MMR, these sequences accumulate insertions and deletions, detectable as length variations (instability) compared to normal tissue. MSI-H is defined as instability at two or more of five standard markers.	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
4212	4660	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	3	Frameshift Mutations in Tumor Suppressors	Coding microsatellites in tumor suppressor genes (TGFbetaRII, BAX, ACVR2, IGF2R) accumulate frameshift mutations, inactivating their tumor suppressive functions. TGFbetaRII frameshift is particularly common, disrupting TGF-beta growth inhibition.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4213	4661	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	4	Neoantigen-Driven Immune Response	The high neoantigen burden in MSI-H tumors stimulates robust anti-tumor immunity. Tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells, recognize and attack tumor cells presenting neoantigens. However, tumors upregulate PD-L1 as an adaptive resistance mechanism.	cell_types[0]	cell_types	cell_types			CD8-positive, alpha-beta T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
4214	4661	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	pathophysiology	4	Neoantigen-Driven Immune Response	The high neoantigen burden in MSI-H tumors stimulates robust anti-tumor immunity. Tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells, recognize and attack tumor cells presenting neoantigens. However, tumors upregulate PD-L1 as an adaptive resistance mechanism.	biological_processes[0]	biological_processes	biological_processes			T cell mediated cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""T cell mediated cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"			INCREASED																								
4215	4663	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	phenotypes	0	Colon Cancer	MSI-H colorectal cancer presents as a primary colonic malignancy, with strong right-sided (proximal colon) predominance. Tumors often present at earlier stage compared to microsatellite stable cancers.	phenotype_term	phenotype_term	$	Colon Cancer	MSI-H colorectal cancer presents as a primary colonic malignancy, with strong right-sided (proximal colon) predominance. Tumors often present at earlier stage compared to microsatellite stable cancers.	Colon cancer	HP:0003003	Colon cancer		"{""preferred_term"": ""Colon cancer"", ""term"": {""id"": ""HP:0003003"", ""label"": ""Colon cancer""}}"																											
4216	4664	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	phenotypes	1	Abdominal Pain	Abdominal discomfort or pain may result from tumor mass effect or partial obstruction, particularly with right-sided tumors.	phenotype_term	phenotype_term	$	Abdominal Pain	Abdominal discomfort or pain may result from tumor mass effect or partial obstruction, particularly with right-sided tumors.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
4217	4665	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	phenotypes	2	Hematochezia	Rectal bleeding may occur, though less prominent than in left-sided colorectal cancers due to the proximal location of most MSI-H tumors.	phenotype_term	phenotype_term	$	Hematochezia	Rectal bleeding may occur, though less prominent than in left-sided colorectal cancers due to the proximal location of most MSI-H tumors.	Hematochezia	HP:0002573	Hematochezia		"{""preferred_term"": ""Hematochezia"", ""term"": {""id"": ""HP:0002573"", ""label"": ""Hematochezia""}}"																											
4218	4666	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	phenotypes	3	Anemia	Iron deficiency anemia from chronic occult blood loss is common, particularly with right-sided tumors where bleeding may not produce visible hematochezia.	phenotype_term	phenotype_term	$	Anemia	Iron deficiency anemia from chronic occult blood loss is common, particularly with right-sided tumors where bleeding may not produce visible hematochezia.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
4219	4667	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	phenotypes	4	Weight Loss	Unintentional weight loss may occur with advanced disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss may occur with advanced disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4220	4668	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	0	Pembrolizumab	Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients.	treatment_term	treatment_term	$	Pembrolizumab	Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4221	4669	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	1	Nivolumab plus Ipilimumab	Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition.	treatment_term	treatment_term	$	Nivolumab plus Ipilimumab	Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4222	4670	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	2	Dostarlimab	Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation.	treatment_term	treatment_term	$	Dostarlimab	Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4223	4671	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors.	treatment_term	treatment_term	$	Surgical Resection	Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4224	4680	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	histopathology	0	Endometrioid Adenocarcinoma	Endometrioid adenocarcinoma is the most frequent histological subtype.	finding_term	finding_term	$	Endometrioid Adenocarcinoma	Endometrioid adenocarcinoma is the most frequent histological subtype.	Endometrioid Adenocarcinoma	NCIT:C3769	Endometrioid Adenocarcinoma		"{""preferred_term"": ""Endometrioid Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3769"", ""label"": ""Endometrioid Adenocarcinoma""}}"																											
4225	4681	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	0	Mismatch Repair Deficiency	Loss of functional mismatch repair (MMR) proteins impairs the ability to correct base-base mismatches and insertion-deletion loops during DNA replication. This leads to accumulation of mutations, particularly at microsatellite regions.	cell_types[0]	cell_types	cell_types			endometrial epithelial cell	CL:0002149	epithelial cell of uterus		"{""preferred_term"": ""endometrial epithelial cell"", ""term"": {""id"": ""CL:0002149"", ""label"": ""epithelial cell of uterus""}}"																											
4226	4681	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	0	Mismatch Repair Deficiency	Loss of functional mismatch repair (MMR) proteins impairs the ability to correct base-base mismatches and insertion-deletion loops during DNA replication. This leads to accumulation of mutations, particularly at microsatellite regions.	biological_processes[0]	biological_processes	biological_processes			mismatch repair	GO:0006298	mismatch repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""mismatch repair"", ""term"": {""id"": ""GO:0006298"", ""label"": ""mismatch repair""}}"			DECREASED																								
4227	4681	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	0	Mismatch Repair Deficiency	Loss of functional mismatch repair (MMR) proteins impairs the ability to correct base-base mismatches and insertion-deletion loops during DNA replication. This leads to accumulation of mutations, particularly at microsatellite regions.	locations[0]	locations	locations			endometrium	UBERON:0001295	endometrium		"{""preferred_term"": ""endometrium"", ""term"": {""id"": ""UBERON:0001295"", ""label"": ""endometrium""}}"																											
4228	4682	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	1	Microsatellite Instability	Deficient mismatch repair leads to instability at microsatellite loci, short tandem repeat sequences throughout the genome. MSI-H status is defined by instability at multiple markers and serves as a biomarker for dMMR.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			DECREASED																								
4229	4683	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	pathophysiology	2	Hypermutation and Neoantigen Generation	MMR deficiency causes a hypermutated tumor phenotype with high tumor mutational burden (TMB). Frameshift mutations at coding microsatellites generate neoantigens recognized by the immune system, explaining the high response rates to immune checkpoint inhibition.	biological_processes[0]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"			INCREASED																								
4230	4684	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	phenotypes	0	Abnormal Uterine Bleeding	Postmenopausal bleeding or abnormal premenopausal bleeding is the most common presenting symptom of endometrial cancer regardless of MSI status.	phenotype_term	phenotype_term	$	Abnormal Uterine Bleeding	Postmenopausal bleeding or abnormal premenopausal bleeding is the most common presenting symptom of endometrial cancer regardless of MSI status.	Abnormal uterine bleeding	HP:0000132	Menorrhagia		"{""preferred_term"": ""Abnormal uterine bleeding"", ""term"": {""id"": ""HP:0000132"", ""label"": ""Menorrhagia""}}"																											
4231	4685	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	phenotypes	1	Fatigue	Constitutional symptoms may occur in advanced disease or secondary to anemia from chronic blood loss.	phenotype_term	phenotype_term	$	Fatigue	Constitutional symptoms may occur in advanced disease or secondary to anemia from chronic blood loss.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4232	4686	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	phenotypes	2	Pelvic Pain	Pelvic pain or pressure may indicate locally advanced disease with extension beyond the uterus.	phenotype_term	phenotype_term	$	Pelvic Pain	Pelvic pain or pressure may indicate locally advanced disease with extension beyond the uterus.	Pelvic pain	HP:0034267	Pelvic pain		"{""preferred_term"": ""Pelvic pain"", ""term"": {""id"": ""HP:0034267"", ""label"": ""Pelvic pain""}}"																											
4233	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term	treatment_term	$	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
4234	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
4235	4688	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	1	Pembrolizumab Monotherapy	PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions.	treatment_term	treatment_term	$	Pembrolizumab Monotherapy	PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4236	4689	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	2	Dostarlimab	PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors.	treatment_term	treatment_term	$	Dostarlimab	PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4237	4690	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	3	Hysterectomy	Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status.	treatment_term	treatment_term	$	Hysterectomy	Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4238	4707	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	0	Monoamine Deficiency	"Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.
"	cell_types[0]	cell_types	cell_types			Serotonergic Neuron	CL:0000850	serotonergic neuron		"{""preferred_term"": ""Serotonergic Neuron"", ""term"": {""id"": ""CL:0000850"", ""label"": ""serotonergic neuron""}}"																											
4239	4707	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	0	Monoamine Deficiency	"Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.
"	cell_types[1]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
4240	4707	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	0	Monoamine Deficiency	"Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.
"	cell_types[2]	cell_types	cell_types			Noradrenergic Neuron	CL:0008025	noradrenergic neuron		"{""preferred_term"": ""Noradrenergic Neuron"", ""term"": {""id"": ""CL:0008025"", ""label"": ""noradrenergic neuron""}}"																											
4241	4707	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	0	Monoamine Deficiency	"Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.
"	biological_processes[0]	biological_processes	biological_processes			Serotonin Signaling	GO:0007210	serotonin receptor signaling pathway		"{""preferred_term"": ""Serotonin Signaling"", ""term"": {""id"": ""GO:0007210"", ""label"": ""serotonin receptor signaling pathway""}}"																											
4242	4707	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	0	Monoamine Deficiency	"Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.
"	biological_processes[1]	biological_processes	biological_processes			Dopamine Signaling	GO:0007212	dopamine receptor signaling pathway		"{""preferred_term"": ""Dopamine Signaling"", ""term"": {""id"": ""GO:0007212"", ""label"": ""dopamine receptor signaling pathway""}}"																											
4243	4708	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	1	HPA Axis Dysregulation	"Hyperactivity of the hypothalamic-pituitary-adrenal axis leads to elevated cortisol, which may contribute to hippocampal atrophy and cognitive symptoms.
"	cell_types[0]	cell_types	cell_types			Corticotroph	CL:0002309	corticotroph		"{""preferred_term"": ""Corticotroph"", ""term"": {""id"": ""CL:0002309"", ""label"": ""corticotroph""}}"																											
4244	4708	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	1	HPA Axis Dysregulation	"Hyperactivity of the hypothalamic-pituitary-adrenal axis leads to elevated cortisol, which may contribute to hippocampal atrophy and cognitive symptoms.
"	biological_processes[0]	biological_processes	biological_processes			Cortisol Response	GO:0071385	cellular response to glucocorticoid stimulus		"{""preferred_term"": ""Cortisol Response"", ""term"": {""id"": ""GO:0071385"", ""label"": ""cellular response to glucocorticoid stimulus""}}"																											
4245	4709	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	2	Neuroplasticity Deficits	"Reduced BDNF and impaired synaptic plasticity in prefrontal cortex and hippocampus. Successful treatments restore neuroplasticity.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
4246	4709	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	2	Neuroplasticity Deficits	"Reduced BDNF and impaired synaptic plasticity in prefrontal cortex and hippocampus. Successful treatments restore neuroplasticity.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Plasticity	GO:0048167	regulation of synaptic plasticity		"{""preferred_term"": ""Synaptic Plasticity"", ""term"": {""id"": ""GO:0048167"", ""label"": ""regulation of synaptic plasticity""}}"																											
4247	4710	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	pathophysiology	3	Neuroinflammation	"Elevated inflammatory cytokines (IL-6, TNF-alpha, CRP) observed in depression. Inflammation may contribute to monoamine depletion and neuroplasticity deficits.
"	cell_types[0]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
4248	4712	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	0	Depressed Mood		phenotype_term	phenotype_term	$	Depressed Mood		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
4249	4713	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	1	Anhedonia		phenotype_term	phenotype_term	$	Anhedonia		Anhedonia	HP:0012154	Anhedonia		"{""preferred_term"": ""Anhedonia"", ""term"": {""id"": ""HP:0012154"", ""label"": ""Anhedonia""}}"																											
4250	4714	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	2	Sleep Disturbance		phenotype_term	phenotype_term	$	Sleep Disturbance		Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
4251	4715	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4252	4716	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	4	Poor Appetite		phenotype_term	phenotype_term	$	Poor Appetite		Poor Appetite	HP:0004396	Poor appetite		"{""preferred_term"": ""Poor Appetite"", ""term"": {""id"": ""HP:0004396"", ""label"": ""Poor appetite""}}"																											
4253	4717	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	5	Concentration Difficulties		phenotype_term	phenotype_term	$	Concentration Difficulties		Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
4254	4718	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	phenotypes	6	Psychomotor Changes		phenotype_term	phenotype_term	$	Psychomotor Changes		Psychomotor Abnormality	HP:0001266	Choreoathetosis		"{""preferred_term"": ""Psychomotor Abnormality"", ""term"": {""id"": ""HP:0001266"", ""label"": ""Choreoathetosis""}}"																											
4255	4726	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	biochemical	0	Mesothelin		biomarker_term	biomarker_term	$	Mesothelin		Mesothelin	NCIT:C20887	Mesothelin		"{""preferred_term"": ""Mesothelin"", ""term"": {""id"": ""NCIT:C20887"", ""label"": ""Mesothelin""}}"																											
4256	4728	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	environmental	0	Asbestos Exposure	Asbestos fibers, when inhaled or ingested, become lodged in mesothelial tissues where they cause chronic inflammation, oxidative stress, and DNA damage. The fibers persist indefinitely in tissue and are directly genotoxic, causing chromosomal abnormalities and mesothelial cell transformation. Occupational exposure accounts for approximately 80% of cases.	exposure_term	exposure_term	$	Asbestos Exposure	Asbestos fibers, when inhaled or ingested, become lodged in mesothelial tissues where they cause chronic inflammation, oxidative stress, and DNA damage. The fibers persist indefinitely in tissue and are directly genotoxic, causing chromosomal abnormalities and mesothelial cell transformation. Occupational exposure accounts for approximately 80% of cases.	exposure to asbestos	ECTO:9000033	exposure to asbestos		"{""preferred_term"": ""exposure to asbestos"", ""term"": {""id"": ""ECTO:9000033"", ""label"": ""exposure to asbestos""}}"																											
4257	4735	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	histopathology	0	Mesothelial Neoplasm	Malignant mesothelioma is a neoplasm arising from mesothelial cells lining serosal cavities.	finding_term	finding_term	$	Mesothelial Neoplasm	Malignant mesothelioma is a neoplasm arising from mesothelial cells lining serosal cavities.	Mesothelial Neoplasm	NCIT:C3786	Mesothelial Neoplasm		"{""preferred_term"": ""Mesothelial Neoplasm"", ""term"": {""id"": ""NCIT:C3786"", ""label"": ""Mesothelial Neoplasm""}}"																											
4258	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	cell_types[0]	cell_types	cell_types			mesothelial cell	CL:0000077	mesothelial cell		"{""preferred_term"": ""mesothelial cell"", ""term"": {""id"": ""CL:0000077"", ""label"": ""mesothelial cell""}}"																											
4259	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"			INCREASED																								
4260	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	biological_processes[1]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""modifier"": ""INCREASED"", ""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"			INCREASED																								
4261	4736	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	0	Asbestos-Induced Mesothelial Injury	Asbestos fibers penetrate the mesothelium and induce a cycle of cell death and regeneration. The fibers generate reactive oxygen species (ROS) and reactive nitrogen species that damage DNA, proteins, and lipids. Chronic inflammation driven by frustrated phagocytosis of long fibers promotes ongoing tissue damage and malignant transformation.	locations[0]	locations	locations			pleura	UBERON:0000977	pleura		"{""preferred_term"": ""pleura"", ""term"": {""id"": ""UBERON:0000977"", ""label"": ""pleura""}}"																											
4262	4737	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	1	BAP1 Tumor Suppressor Inactivation	BAP1 (BRCA1-associated protein 1) is a nuclear deubiquitinase that regulates chromatin remodeling, DNA damage response, and cell cycle progression. BAP1 loss, through germline mutation or somatic inactivation, occurs in 60-70% of mesotheliomas and predisposes to malignant transformation. BAP1 loss impairs homologous recombination repair and chromatin regulation.	genes[0]	genes	genes			BAP1				"{""preferred_term"": ""BAP1""}"																											
4263	4737	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	1	BAP1 Tumor Suppressor Inactivation	BAP1 (BRCA1-associated protein 1) is a nuclear deubiquitinase that regulates chromatin remodeling, DNA damage response, and cell cycle progression. BAP1 loss, through germline mutation or somatic inactivation, occurs in 60-70% of mesotheliomas and predisposes to malignant transformation. BAP1 loss impairs homologous recombination repair and chromatin regulation.	biological_processes[0]	biological_processes	biological_processes			histone deubiquitination	GO:0016578	histone deubiquitination		"{""modifier"": ""DECREASED"", ""preferred_term"": ""histone deubiquitination"", ""term"": {""id"": ""GO:0016578"", ""label"": ""histone deubiquitination""}}"			DECREASED																								
4264	4737	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	1	BAP1 Tumor Suppressor Inactivation	BAP1 (BRCA1-associated protein 1) is a nuclear deubiquitinase that regulates chromatin remodeling, DNA damage response, and cell cycle progression. BAP1 loss, through germline mutation or somatic inactivation, occurs in 60-70% of mesotheliomas and predisposes to malignant transformation. BAP1 loss impairs homologous recombination repair and chromatin regulation.	biological_processes[1]	biological_processes	biological_processes			DNA damage response	GO:0006974	DNA damage response		"{""modifier"": ""DECREASED"", ""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""DNA damage response""}}"			DECREASED																								
4265	4738	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	2	NF2/Merlin Inactivation	The NF2 gene encoding merlin is frequently inactivated in mesothelioma (approximately 50% of cases). Merlin loss activates YAP/TAZ signaling through the Hippo pathway, promoting cell proliferation and inhibiting contact-dependent growth arrest.	genes[0]	genes	genes			NF2				"{""preferred_term"": ""NF2""}"																											
4266	4738	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	2	NF2/Merlin Inactivation	The NF2 gene encoding merlin is frequently inactivated in mesothelioma (approximately 50% of cases). Merlin loss activates YAP/TAZ signaling through the Hippo pathway, promoting cell proliferation and inhibiting contact-dependent growth arrest.	biological_processes[0]	biological_processes	biological_processes			Hippo signaling	GO:0035329	hippo signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Hippo signaling"", ""term"": {""id"": ""GO:0035329"", ""label"": ""hippo signaling""}}"			DECREASED																								
4267	4739	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	3	CDKN2A/p16 Loss	Homozygous deletion of CDKN2A, encoding p16INK4a and p14ARF, occurs in approximately 70% of mesotheliomas. Loss of p16 removes CDK4/6 inhibition, promoting cell cycle progression, while p14ARF loss compromises p53 stabilization.	genes[0]	genes	genes			CDKN2A				"{""preferred_term"": ""CDKN2A""}"																											
4268	4739	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	pathophysiology	3	CDKN2A/p16 Loss	Homozygous deletion of CDKN2A, encoding p16INK4a and p14ARF, occurs in approximately 70% of mesotheliomas. Loss of p16 removes CDK4/6 inhibition, promoting cell cycle progression, while p14ARF loss compromises p53 stabilization.	biological_processes[0]	biological_processes	biological_processes			negative regulation of G1/S transition	GO:0045786	negative regulation of G1/S transition of mitotic cell cycle		"{""modifier"": ""DECREASED"", ""preferred_term"": ""negative regulation of G1/S transition"", ""term"": {""id"": ""GO:0045786"", ""label"": ""negative regulation of G1/S transition of mitotic cell cycle""}}"			DECREASED																								
4269	4740	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	phenotypes	0	Dyspnea	Progressive shortness of breath is the most common presenting symptom, typically caused by pleural effusion and tumor encasement of the lung.	phenotype_term	phenotype_term	$	Dyspnea	Progressive shortness of breath is the most common presenting symptom, typically caused by pleural effusion and tumor encasement of the lung.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
4270	4741	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	phenotypes	1	Pleural Effusion	Accumulation of fluid in the pleural space occurs in 80-95% of patients at presentation. The effusion is typically exudative and may be bloody.	phenotype_term	phenotype_term	$	Pleural Effusion	Accumulation of fluid in the pleural space occurs in 80-95% of patients at presentation. The effusion is typically exudative and may be bloody.	Pleural effusion	HP:0002202	Pleural effusion		"{""preferred_term"": ""Pleural effusion"", ""term"": {""id"": ""HP:0002202"", ""label"": ""Pleural effusion""}}"																											
4271	4742	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	phenotypes	2	Chest Pain	Dull, aching chest wall pain results from tumor invasion of the parietal pleura and chest wall. Pain may be localized or diffuse.	phenotype_term	phenotype_term	$	Chest Pain	Dull, aching chest wall pain results from tumor invasion of the parietal pleura and chest wall. Pain may be localized or diffuse.	Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
4272	4743	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	phenotypes	3	Weight Loss	Unintentional weight loss occurs as disease progresses and is associated with poor prognosis.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss occurs as disease progresses and is associated with poor prognosis.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4273	4744	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	phenotypes	4	Fatigue	Cancer-related fatigue is common and may be exacerbated by anemia, dyspnea, and cachexia.	phenotype_term	phenotype_term	$	Fatigue	Cancer-related fatigue is common and may be exacerbated by anemia, dyspnea, and cachexia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	treatment_term	$	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}]}"				cisplatin; pemetrexed	CHEBI:27899; CHEBI:63616																						
4275	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4276	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			pemetrexed	CHEBI:63616	pemetrexed		"{""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}"																											
4277	4746	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	1	Immune Checkpoint Inhibition	Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes.	treatment_term	treatment_term	$	Immune Checkpoint Inhibition	Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4278	4747	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	2	Surgical Resection	Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern.	treatment_term	treatment_term	$	Surgical Resection	Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4279	4748	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	3	Radiation Therapy	Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches.	treatment_term	treatment_term	$	Radiation Therapy	Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4280	4749	201	Malnutrition-Related Diabetes Mellitus	Malnutrition-related_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin deficiency from beta-cell impairment in undernutrition	Undernutrition-associated diabetes involves insulin deficiency from pancreatic beta-cell impairment.	cell_types[0]	cell_types	cell_types			pancreatic beta cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""pancreatic beta cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
4281	4749	201	Malnutrition-Related Diabetes Mellitus	Malnutrition-related_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin deficiency from beta-cell impairment in undernutrition	Undernutrition-associated diabetes involves insulin deficiency from pancreatic beta-cell impairment.	biological_processes[0]	biological_processes	biological_processes			insulin secretion	GO:0030073	insulin secretion		"{""preferred_term"": ""insulin secretion"", ""term"": {""id"": ""GO:0030073"", ""label"": ""insulin secretion""}}"																											
4282	4750	201	Malnutrition-Related Diabetes Mellitus	Malnutrition-related_Diabetes_Mellitus.yaml	phenotypes	0	Hyperglycemia with ketosis resistance	Severe hyperglycemia in undernourished individuals with resistance to ketosis.	phenotype_term	phenotype_term	$	Hyperglycemia with ketosis resistance	Severe hyperglycemia in undernourished individuals with resistance to ketosis.	Hyperglycemia	HP:0003074	Hyperglycemia		"{""preferred_term"": ""Hyperglycemia"", ""term"": {""id"": ""HP:0003074"", ""label"": ""Hyperglycemia""}}"																											
4283	4759	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	histopathology	0	Mature B-Cell Lymphoma	Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma.	finding_term	finding_term	$	Mature B-Cell Lymphoma	Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma.	Mature B-Cell Non-Hodgkin Lymphoma	NCIT:C7056	Mature B-Cell Non-Hodgkin Lymphoma		"{""preferred_term"": ""Mature B-Cell Non-Hodgkin Lymphoma"", ""term"": {""id"": ""NCIT:C7056"", ""label"": ""Mature B-Cell Non-Hodgkin Lymphoma""}}"																											
4284	4760	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	0	CCND1 Translocation and Cyclin D1 Overexpression	The t(11;14)(q13;q32) translocation places the CCND1 gene under control of the immunoglobulin heavy chain enhancer, causing constitutive overexpression of cyclin D1. This is the hallmark genetic event in MCL, occurring in virtually all cases, and drives cell cycle progression.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4285	4760	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	0	CCND1 Translocation and Cyclin D1 Overexpression	The t(11;14)(q13;q32) translocation places the CCND1 gene under control of the immunoglobulin heavy chain enhancer, causing constitutive overexpression of cyclin D1. This is the hallmark genetic event in MCL, occurring in virtually all cases, and drives cell cycle progression.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""INCREASED"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			INCREASED																								
4286	4761	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	1	Cell Cycle Dysregulation	Cyclin D1 overexpression accelerates G1 to S phase transition by activating CDK4/6, which phosphorylates retinoblastoma protein (RB1) and releases E2F transcription factors. This overcomes normal cell cycle checkpoints and drives proliferation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4287	4762	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	2	BTK and BCR Signaling Dependence	MCL cells are dependent on B-cell receptor signaling through BTK for survival. This pathway provides proliferative and anti-apoptotic signals essential for MCL cell maintenance. BTK inhibitors exploit this dependence, particularly effective in relapsed MCL.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"			INCREASED																								
4288	4763	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	3	NF-kB Activation	Constitutive NF-kB signaling is common in MCL, driven by BCR signaling and genetic alterations affecting the NF-kB pathway. NF-kB promotes expression of anti-apoptotic genes contributing to MCL cell survival.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
4289	4764	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	4	Uncontrolled B-cell Proliferation	The combination of cyclin D1-driven cell cycle progression, BCR signaling, NF-kB activation, and additional genetic alterations leads to uncontrolled B-cell proliferation with widespread tissue infiltration.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
4290	4764	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	4	Uncontrolled B-cell Proliferation	The combination of cyclin D1-driven cell cycle progression, BCR signaling, NF-kB activation, and additional genetic alterations leads to uncontrolled B-cell proliferation with widespread tissue infiltration.	locations[1]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
4291	4764	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	pathophysiology	4	Uncontrolled B-cell Proliferation	The combination of cyclin D1-driven cell cycle progression, BCR signaling, NF-kB activation, and additional genetic alterations leads to uncontrolled B-cell proliferation with widespread tissue infiltration.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4292	4765	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	0	Generalized Lymphadenopathy	Widespread lymph node enlargement is the most common presentation. Multiple nodal sites are typically involved at diagnosis.	phenotype_term	phenotype_term	$	Generalized Lymphadenopathy	Widespread lymph node enlargement is the most common presentation. Multiple nodal sites are typically involved at diagnosis.	Generalized lymphadenopathy	HP:0008940	Generalized lymphadenopathy		"{""preferred_term"": ""Generalized lymphadenopathy"", ""term"": {""id"": ""HP:0008940"", ""label"": ""Generalized lymphadenopathy""}}"																											
4293	4766	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	1	Splenomegaly	Spleen enlargement is common, particularly prominent in the leukemic non-nodal variant.	phenotype_term	phenotype_term	$	Splenomegaly	Spleen enlargement is common, particularly prominent in the leukemic non-nodal variant.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
4294	4767	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	2	Gastrointestinal Involvement	MCL has a propensity for gastrointestinal tract involvement with lymphomatous polyposis. Colonoscopy may reveal multiple polyps.	phenotype_term	phenotype_term	$	Gastrointestinal Involvement	MCL has a propensity for gastrointestinal tract involvement with lymphomatous polyposis. Colonoscopy may reveal multiple polyps.	Neoplasm of the gastrointestinal tract	HP:0007378	Neoplasm of the gastrointestinal tract		"{""preferred_term"": ""Neoplasm of the gastrointestinal tract"", ""term"": {""id"": ""HP:0007378"", ""label"": ""Neoplasm of the gastrointestinal tract""}}"																											
4295	4768	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	3	Night Sweats	B symptoms including night sweats are common and indicate systemic disease activity.	phenotype_term	phenotype_term	$	Night Sweats	B symptoms including night sweats are common and indicate systemic disease activity.	Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
4296	4769	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	4	Weight Loss	Unintentional weight loss is a B symptom indicating active disease.	phenotype_term	phenotype_term	$	Weight Loss	Unintentional weight loss is a B symptom indicating active disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4297	4770	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	5	Fatigue	Fatigue from disease burden and anemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from disease burden and anemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4298	4771	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	phenotypes	6	Anemia	Anemia from bone marrow infiltration is common given the high frequency of marrow involvement at diagnosis.	phenotype_term	phenotype_term	$	Anemia	Anemia from bone marrow infiltration is common given the high frequency of marrow involvement at diagnosis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
4299	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term	treatment_term	$	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}"				ibrutinib	CHEBI:76612																						
4300	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"																											
4301	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term	treatment_term	$	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}"				acalabrutinib	CHEBI:167707																						
4302	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"																											
4303	4774	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy with ASCT	For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients.	treatment_term	treatment_term	$	Intensive Chemotherapy with ASCT	For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4304	4775	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	3	Bendamustine-Rituximab	Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity.	treatment_term	treatment_term	$	Bendamustine-Rituximab	Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4305	4776	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
4306	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term	treatment_term	$	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
4307	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
4308	4796	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	0	Branched-Chain Alpha-Ketoacid Dehydrogenase Deficiency	"Mutations in genes encoding subunits of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH) cause deficient catabolism of branched-chain amino acids (leucine, isoleucine, valine). This leads to accumulation of these amino acids and their toxic ketoacid derivatives in blood and tissues. The BCKDH complex catalyzes the first irreversible step in BCAA catabolism.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
4309	4796	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	0	Branched-Chain Alpha-Ketoacid Dehydrogenase Deficiency	"Mutations in genes encoding subunits of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH) cause deficient catabolism of branched-chain amino acids (leucine, isoleucine, valine). This leads to accumulation of these amino acids and their toxic ketoacid derivatives in blood and tissues. The BCKDH complex catalyzes the first irreversible step in BCAA catabolism.
"	biological_processes[0]	biological_processes	biological_processes			branched-chain amino acid catabolic process	GO:0009083	branched-chain amino acid catabolic process		"{""preferred_term"": ""branched-chain amino acid catabolic process"", ""term"": {""id"": ""GO:0009083"", ""label"": ""branched-chain amino acid catabolic process""}}"																											
4310	4797	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	1	Leucine and Ketoacid Neurotoxicity	"Elevated leucine and its metabolite alpha-ketoisocaproic acid (KIC) are particularly neurotoxic. KIC inhibits key mitochondrial enzymes including alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase, disrupting brain energy metabolism. Leucine also competes for transport across the blood-brain barrier via LAT1, depleting other essential amino acids in the brain.
"	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
4311	4797	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	1	Leucine and Ketoacid Neurotoxicity	"Elevated leucine and its metabolite alpha-ketoisocaproic acid (KIC) are particularly neurotoxic. KIC inhibits key mitochondrial enzymes including alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase, disrupting brain energy metabolism. Leucine also competes for transport across the blood-brain barrier via LAT1, depleting other essential amino acids in the brain.
"	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
4312	4797	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	1	Leucine and Ketoacid Neurotoxicity	"Elevated leucine and its metabolite alpha-ketoisocaproic acid (KIC) are particularly neurotoxic. KIC inhibits key mitochondrial enzymes including alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase, disrupting brain energy metabolism. Leucine also competes for transport across the blood-brain barrier via LAT1, depleting other essential amino acids in the brain.
"	biological_processes[0]	biological_processes	biological_processes			generation of precursor metabolites and energy	GO:0006091	generation of precursor metabolites and energy		"{""preferred_term"": ""generation of precursor metabolites and energy"", ""term"": {""id"": ""GO:0006091"", ""label"": ""generation of precursor metabolites and energy""}}"																											
4313	4798	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	pathophysiology	2	Skeletal Muscle Dysfunction	"Skeletal muscle is a major site of BCAA metabolism and accumulates toxic ketoacids. MSUD causes muscle fiber abnormalities and atrophy, with KIC disrupting mitochondrial metabolism in myocytes and causing reduced TCA cycle flux and ATP depletion.
"	cell_types[0]	cell_types	cell_types			skeletal muscle fiber	CL:0008002	skeletal muscle fiber		"{""preferred_term"": ""skeletal muscle fiber"", ""term"": {""id"": ""CL:0008002"", ""label"": ""skeletal muscle fiber""}}"																											
4314	4799	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	0	Abnormal Urinary Odor		phenotype_term	phenotype_term	$	Abnormal Urinary Odor		Abnormal urinary odor	HP:0012088	Abnormal urinary odor		"{""preferred_term"": ""Abnormal urinary odor"", ""term"": {""id"": ""HP:0012088"", ""label"": ""Abnormal urinary odor""}}"																											
4315	4800	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	1	Poor Feeding		phenotype_term	phenotype_term	$	Poor Feeding		Feeding difficulties in infancy	HP:0008872	Feeding difficulties in infancy		"{""preferred_term"": ""Feeding difficulties in infancy"", ""term"": {""id"": ""HP:0008872"", ""label"": ""Feeding difficulties in infancy""}}"																											
4316	4801	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	2	Lethargy		phenotype_term	phenotype_term	$	Lethargy		Lethargy	HP:0001254	Lethargy		"{""preferred_term"": ""Lethargy"", ""term"": {""id"": ""HP:0001254"", ""label"": ""Lethargy""}}"																											
4317	4802	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	3	Encephalopathy		phenotype_term	phenotype_term	$	Encephalopathy		Acute encephalopathy	HP:0006846	Acute encephalopathy		"{""preferred_term"": ""Acute encephalopathy"", ""term"": {""id"": ""HP:0006846"", ""label"": ""Acute encephalopathy""}}"																											
4318	4803	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	4	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
4319	4804	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	5	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
4320	4805	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	6	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
4321	4806	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	7	Vomiting		phenotype_term	phenotype_term	$	Vomiting		Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
4322	4807	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	8	Coma		phenotype_term	phenotype_term	$	Coma		Coma	HP:0001259	Coma		"{""preferred_term"": ""Coma"", ""term"": {""id"": ""HP:0001259"", ""label"": ""Coma""}}"																											
4323	4808	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	9	Global Developmental Delay		phenotype_term	phenotype_term	$	Global Developmental Delay		Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
4324	4809	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	phenotypes	10	Elevated Branched Chain Amino Acids		phenotype_term	phenotype_term	$	Elevated Branched Chain Amino Acids		Elevated circulating branched chain amino acid concentration	HP:0008344	Elevated circulating branched chain amino acid concentration		"{""preferred_term"": ""Elevated circulating branched chain amino acid concentration"", ""term"": {""id"": ""HP:0008344"", ""label"": ""Elevated circulating branched chain amino acid concentration""}}"																											
4325	4810	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	0	BCAA-Restricted Diet	Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.	treatment_term	treatment_term	$	BCAA-Restricted Diet	Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4326	4811	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	1	Medical Formula	BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.	treatment_term	treatment_term	$	Medical Formula	BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4327	4812	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	2	Thiamine Supplementation	High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.	treatment_term	treatment_term	$	Thiamine Supplementation	High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4328	4813	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	3	Liver Transplantation	Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.	treatment_term	treatment_term	$	Liver Transplantation	Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
4329	4814	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	4	Intravenous BCAA-Free Solution	IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.	treatment_term	treatment_term	$	Intravenous BCAA-Free Solution	IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4330	4815	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	5	Acute Crisis Management	IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.	treatment_term	treatment_term	$	Acute Crisis Management	IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4331	4816	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	6	Phenylbutyrate	BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.	treatment_term	treatment_term	$	Phenylbutyrate	BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4332	4817	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	7	Metformin	Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.	treatment_term	treatment_term	$	Metformin	Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4333	4819	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	0		Advanced Study of Aortic Pathology (ASAP) dataset comparing aortic tissue gene expression from patients with thoracic aortic aneurysms and bicuspid (BAV) vs tricuspid (TAV) aortic valves. Includes mammary artery controls and transplant donor samples.	organism	organism	$		Advanced Study of Aortic Pathology (ASAP) dataset comparing aortic tissue gene expression from patients with thoracic aortic aneurysms and bicuspid (BAV) vs tricuspid (TAV) aortic valves. Includes mammary artery controls and transplant donor samples.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4334	4819	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	0		Advanced Study of Aortic Pathology (ASAP) dataset comparing aortic tissue gene expression from patients with thoracic aortic aneurysms and bicuspid (BAV) vs tricuspid (TAV) aortic valves. Includes mammary artery controls and transplant donor samples.	sample_types[0]	sample_types	sample_types			thoracic aorta tissue				"{""preferred_term"": ""thoracic aorta tissue"", ""tissue_term"": {""preferred_term"": ""thoracic aorta"", ""term"": {""id"": ""UBERON:0001515"", ""label"": ""thoracic aorta""}}}"																											
4335	4819	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	0		Advanced Study of Aortic Pathology (ASAP) dataset comparing aortic tissue gene expression from patients with thoracic aortic aneurysms and bicuspid (BAV) vs tricuspid (TAV) aortic valves. Includes mammary artery controls and transplant donor samples.	sample_types[0].tissue_term	sample_types	sample_types[0]			thoracic aorta	UBERON:0001515	thoracic aorta		"{""preferred_term"": ""thoracic aorta"", ""term"": {""id"": ""UBERON:0001515"", ""label"": ""thoracic aorta""}}"																											
4336	4820	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	1		Gene expression profiling comparing dissected ascending aorta tissue from acute Stanford type A aortic dissection patients to normal aorta controls, identifying pathogenesis pathways.	organism	organism	$		Gene expression profiling comparing dissected ascending aorta tissue from acute Stanford type A aortic dissection patients to normal aorta controls, identifying pathogenesis pathways.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4337	4820	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	1		Gene expression profiling comparing dissected ascending aorta tissue from acute Stanford type A aortic dissection patients to normal aorta controls, identifying pathogenesis pathways.	sample_types[0]	sample_types	sample_types			ascending aorta tissue				"{""preferred_term"": ""ascending aorta tissue"", ""tissue_term"": {""preferred_term"": ""ascending aorta"", ""term"": {""id"": ""UBERON:0001496"", ""label"": ""ascending aorta""}}}"																											
4338	4820	204	Marfan Syndrome	Marfan_Syndrome.yaml	datasets	1		Gene expression profiling comparing dissected ascending aorta tissue from acute Stanford type A aortic dissection patients to normal aorta controls, identifying pathogenesis pathways.	sample_types[0].tissue_term	sample_types	sample_types[0]			ascending aorta	UBERON:0001496	ascending aorta		"{""preferred_term"": ""ascending aorta"", ""term"": {""id"": ""UBERON:0001496"", ""label"": ""ascending aorta""}}"																											
4339	4824	204	Marfan Syndrome	Marfan_Syndrome.yaml	environmental	0	Physical Activity Restrictions	Avoidance of strenuous isometric exercise and contact sports to reduce hemodynamic stress on the aorta.	exposure_term	exposure_term	$	Physical Activity Restrictions	Avoidance of strenuous isometric exercise and contact sports to reduce hemodynamic stress on the aorta.	Physical activity exposure	XCO:0000059	physical activity	Exposure to physical exertion that may impact cardiovascular stress.	"{""description"": ""Exposure to physical exertion that may impact cardiovascular stress."", ""preferred_term"": ""Physical activity exposure"", ""term"": {""id"": ""XCO:0000059"", ""label"": ""physical activity""}}"																											
4340	4835	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	0	FBN1 Gene Mutation	Mutations in the FBN1 gene result in defective fibrillin-1 protein, which affects the elasticity and strength of connective tissues.	gene	gene	$	FBN1 Gene Mutation	Mutations in the FBN1 gene result in defective fibrillin-1 protein, which affects the elasticity and strength of connective tissues.	FBN1	hgnc:3603	FBN1	Gene encoding fibrillin-1, a structural glycoprotein essential for elastic fiber formation in connective tissue.	"{""description"": ""Gene encoding fibrillin-1, a structural glycoprotein essential for elastic fiber formation in connective tissue."", ""preferred_term"": ""FBN1"", ""term"": {""id"": ""hgnc:3603"", ""label"": ""FBN1""}}"																											
4341	4836	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	1	Dysregulated TGF-beta Signaling	Defective fibrillin-1 microfibrils fail to sequester latent TGF-beta complexes, leading to increased bioavailable TGF-beta and excessive SMAD2/3 signaling that drives vascular smooth muscle cell phenotypic switching and ECM remodeling.	biological_processes[0]	biological_processes	biological_processes			transforming growth factor beta receptor signaling pathway	GO:0007179	transforming growth factor beta receptor signaling pathway		"{""preferred_term"": ""transforming growth factor beta receptor signaling pathway"", ""term"": {""id"": ""GO:0007179"", ""label"": ""transforming growth factor beta receptor signaling pathway""}}"																											
4342	4836	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	1	Dysregulated TGF-beta Signaling	Defective fibrillin-1 microfibrils fail to sequester latent TGF-beta complexes, leading to increased bioavailable TGF-beta and excessive SMAD2/3 signaling that drives vascular smooth muscle cell phenotypic switching and ECM remodeling.	biological_processes[1]	biological_processes	biological_processes			SMAD protein signal transduction	GO:0060395	SMAD protein signal transduction		"{""preferred_term"": ""SMAD protein signal transduction"", ""term"": {""id"": ""GO:0060395"", ""label"": ""SMAD protein signal transduction""}}"																											
4343	4836	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	1	Dysregulated TGF-beta Signaling	Defective fibrillin-1 microfibrils fail to sequester latent TGF-beta complexes, leading to increased bioavailable TGF-beta and excessive SMAD2/3 signaling that drives vascular smooth muscle cell phenotypic switching and ECM remodeling.	cell_types[0]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
4344	4836	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	1	Dysregulated TGF-beta Signaling	Defective fibrillin-1 microfibrils fail to sequester latent TGF-beta complexes, leading to increased bioavailable TGF-beta and excessive SMAD2/3 signaling that drives vascular smooth muscle cell phenotypic switching and ECM remodeling.	locations[0]	locations	locations			aorta	UBERON:0000947	aorta		"{""preferred_term"": ""aorta"", ""term"": {""id"": ""UBERON:0000947"", ""label"": ""aorta""}}"																											
4345	4837	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	2	Extracellular Matrix Remodeling	Increased matrix metalloproteinase activity, elastic fiber fragmentation, altered collagen composition, and proteoglycan accumulation (especially versican) weaken the aortic wall medial layer.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
4346	4837	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	2	Extracellular Matrix Remodeling	Increased matrix metalloproteinase activity, elastic fiber fragmentation, altered collagen composition, and proteoglycan accumulation (especially versican) weaken the aortic wall medial layer.	biological_processes[1]	biological_processes	biological_processes			proteolysis	GO:0006508	proteolysis		"{""preferred_term"": ""proteolysis"", ""term"": {""id"": ""GO:0006508"", ""label"": ""proteolysis""}}"																											
4347	4837	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	2	Extracellular Matrix Remodeling	Increased matrix metalloproteinase activity, elastic fiber fragmentation, altered collagen composition, and proteoglycan accumulation (especially versican) weaken the aortic wall medial layer.	cell_types[0]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
4348	4837	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	2	Extracellular Matrix Remodeling	Increased matrix metalloproteinase activity, elastic fiber fragmentation, altered collagen composition, and proteoglycan accumulation (especially versican) weaken the aortic wall medial layer.	cell_types[1]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
4349	4837	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	2	Extracellular Matrix Remodeling	Increased matrix metalloproteinase activity, elastic fiber fragmentation, altered collagen composition, and proteoglycan accumulation (especially versican) weaken the aortic wall medial layer.	locations[0]	locations	locations			aorta tunica media	UBERON:0005797	aorta tunica media		"{""preferred_term"": ""aorta tunica media"", ""term"": {""id"": ""UBERON:0005797"", ""label"": ""aorta tunica media""}}"																											
4350	4838	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	3	Impaired Mechanotransduction	Perturbed integrin-fibrillin interactions alter focal adhesion signaling and mechanosensing, contributing to maladaptive vascular smooth muscle cell responses to hemodynamic stress.	biological_processes[0]	biological_processes	biological_processes			cellular response to mechanical stimulus	GO:0071260	cellular response to mechanical stimulus		"{""preferred_term"": ""cellular response to mechanical stimulus"", ""term"": {""id"": ""GO:0071260"", ""label"": ""cellular response to mechanical stimulus""}}"																											
4351	4838	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	3	Impaired Mechanotransduction	Perturbed integrin-fibrillin interactions alter focal adhesion signaling and mechanosensing, contributing to maladaptive vascular smooth muscle cell responses to hemodynamic stress.	biological_processes[1]	biological_processes	biological_processes			integrin-mediated signaling pathway	GO:0007229	integrin-mediated signaling pathway		"{""preferred_term"": ""integrin-mediated signaling pathway"", ""term"": {""id"": ""GO:0007229"", ""label"": ""integrin-mediated signaling pathway""}}"																											
4352	4838	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	3	Impaired Mechanotransduction	Perturbed integrin-fibrillin interactions alter focal adhesion signaling and mechanosensing, contributing to maladaptive vascular smooth muscle cell responses to hemodynamic stress.	cell_types[0]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
4353	4838	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	3	Impaired Mechanotransduction	Perturbed integrin-fibrillin interactions alter focal adhesion signaling and mechanosensing, contributing to maladaptive vascular smooth muscle cell responses to hemodynamic stress.	cell_types[1]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4354	4838	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	3	Impaired Mechanotransduction	Perturbed integrin-fibrillin interactions alter focal adhesion signaling and mechanosensing, contributing to maladaptive vascular smooth muscle cell responses to hemodynamic stress.	locations[0]	locations	locations			aorta	UBERON:0000947	aorta		"{""preferred_term"": ""aorta"", ""term"": {""id"": ""UBERON:0000947"", ""label"": ""aorta""}}"																											
4355	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4356	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	biological_processes[1]	biological_processes	biological_processes			leukocyte migration	GO:0050900	leukocyte migration		"{""preferred_term"": ""leukocyte migration"", ""term"": {""id"": ""GO:0050900"", ""label"": ""leukocyte migration""}}"																											
4357	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
4358	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	cell_types[1]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
4359	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	locations[0]	locations	locations			aorta tunica intima	UBERON:0006878	aorta tunica intima		"{""preferred_term"": ""aorta tunica intima"", ""term"": {""id"": ""UBERON:0006878"", ""label"": ""aorta tunica intima""}}"																											
4360	4839	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	4	Vascular Inflammation	Angiotensin II type 1 receptor signaling and chemokine pathways recruit macrophages and promote inflammatory mediators that exacerbate vascular smooth muscle cell dysfunction and ECM degradation.	locations[1]	locations	locations			aorta tunica media	UBERON:0005797	aorta tunica media		"{""preferred_term"": ""aorta tunica media"", ""term"": {""id"": ""UBERON:0005797"", ""label"": ""aorta tunica media""}}"																											
4361	4840	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	5	Mitochondrial Dysfunction	Emerging evidence implicates mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells and endothelial cells as contributors to thoracic aortic aneurysm progression in Marfan syndrome.	biological_processes[0]	biological_processes	biological_processes			mitochondrial ATP synthesis coupled electron transport	GO:0042775	mitochondrial ATP synthesis coupled electron transport		"{""preferred_term"": ""mitochondrial ATP synthesis coupled electron transport"", ""term"": {""id"": ""GO:0042775"", ""label"": ""mitochondrial ATP synthesis coupled electron transport""}}"																											
4362	4840	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	5	Mitochondrial Dysfunction	Emerging evidence implicates mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells and endothelial cells as contributors to thoracic aortic aneurysm progression in Marfan syndrome.	biological_processes[1]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
4363	4840	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	5	Mitochondrial Dysfunction	Emerging evidence implicates mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells and endothelial cells as contributors to thoracic aortic aneurysm progression in Marfan syndrome.	cell_types[0]	cell_types	cell_types			vascular associated smooth muscle cell	CL:0000359	vascular associated smooth muscle cell		"{""preferred_term"": ""vascular associated smooth muscle cell"", ""term"": {""id"": ""CL:0000359"", ""label"": ""vascular associated smooth muscle cell""}}"																											
4364	4840	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	5	Mitochondrial Dysfunction	Emerging evidence implicates mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells and endothelial cells as contributors to thoracic aortic aneurysm progression in Marfan syndrome.	cell_types[1]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4365	4840	204	Marfan Syndrome	Marfan_Syndrome.yaml	pathophysiology	5	Mitochondrial Dysfunction	Emerging evidence implicates mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells and endothelial cells as contributors to thoracic aortic aneurysm progression in Marfan syndrome.	locations[0]	locations	locations			aorta	UBERON:0000947	aorta		"{""preferred_term"": ""aorta"", ""term"": {""id"": ""UBERON:0000947"", ""label"": ""aorta""}}"																											
4366	4841	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	0	Aortic Aneurysm	Progressive dilation of the aortic root beginning in childhood, with risk of life-threatening aortic dissection.	phenotype_term	phenotype_term	$	Aortic Aneurysm	Progressive dilation of the aortic root beginning in childhood, with risk of life-threatening aortic dissection.	Aortic Aneurysm	HP:0004942	Aortic aneurysm	Abnormal dilation of the aorta due to weakening of the vessel wall.	"{""description"": ""Abnormal dilation of the aorta due to weakening of the vessel wall."", ""preferred_term"": ""Aortic Aneurysm"", ""term"": {""id"": ""HP:0004942"", ""label"": ""Aortic aneurysm""}}"																											
4367	4842	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	1	Tall Stature	Disproportionately tall stature with long limbs and increased arm span-to-height ratio.	phenotype_term	phenotype_term	$	Tall Stature	Disproportionately tall stature with long limbs and increased arm span-to-height ratio.	Tall Stature	HP:0000098	Tall stature	Height significantly above the population mean for age and sex.	"{""description"": ""Height significantly above the population mean for age and sex."", ""preferred_term"": ""Tall Stature"", ""term"": {""id"": ""HP:0000098"", ""label"": ""Tall stature""}}"																											
4368	4843	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	2	Arachnodactyly	Abnormally long, slender fingers and toes (spider-like digits), often demonstrated by positive wrist and thumb signs.	phenotype_term	phenotype_term	$	Arachnodactyly	Abnormally long, slender fingers and toes (spider-like digits), often demonstrated by positive wrist and thumb signs.	Arachnodactyly	HP:0001166	Arachnodactyly	Abnormally long and slender fingers and toes resembling spider legs.	"{""description"": ""Abnormally long and slender fingers and toes resembling spider legs."", ""preferred_term"": ""Arachnodactyly"", ""term"": {""id"": ""HP:0001166"", ""label"": ""Arachnodactyly""}}"																											
4369	4844	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	3	Ectopia Lentis	Superior and temporal displacement of the lens due to weakened zonular fibers, affecting visual acuity.	phenotype_term	phenotype_term	$	Ectopia Lentis	Superior and temporal displacement of the lens due to weakened zonular fibers, affecting visual acuity.	Ectopia Lentis	HP:0001083	Ectopia lentis	Displacement or malposition of the crystalline lens from its normal location.	"{""description"": ""Displacement or malposition of the crystalline lens from its normal location."", ""preferred_term"": ""Ectopia Lentis"", ""term"": {""id"": ""HP:0001083"", ""label"": ""Ectopia lentis""}}"																											
4370	4845	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	4	Scoliosis	Lateral curvature of the spine occurring in approximately 63% of Marfan syndrome patients, often progressive.	phenotype_term	phenotype_term	$	Scoliosis	Lateral curvature of the spine occurring in approximately 63% of Marfan syndrome patients, often progressive.	Scoliosis	HP:0002650	Scoliosis	Lateral curvature of the vertebral column.	"{""description"": ""Lateral curvature of the vertebral column."", ""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
4371	4846	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	5	Pneumothorax	Spontaneous lung collapse occurring in 5-11% of patients due to apical blebs from connective tissue abnormalities.	phenotype_term	phenotype_term	$	Pneumothorax	Spontaneous lung collapse occurring in 5-11% of patients due to apical blebs from connective tissue abnormalities.	Pneumothorax	HP:0002107	Pneumothorax	Presence of air or gas in the pleural cavity causing lung collapse.	"{""description"": ""Presence of air or gas in the pleural cavity causing lung collapse."", ""preferred_term"": ""Pneumothorax"", ""term"": {""id"": ""HP:0002107"", ""label"": ""Pneumothorax""}}"																											
4372	4847	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	6	Aortic Dissection	Life-threatening tear in the aortic wall allowing blood to enter between tissue layers, the leading cause of death in untreated Marfan syndrome.	phenotype_term	phenotype_term	$	Aortic Dissection	Life-threatening tear in the aortic wall allowing blood to enter between tissue layers, the leading cause of death in untreated Marfan syndrome.	Aortic Dissection	HP:0002647	Aortic dissection	Tear in the inner layer of the aortic wall allowing blood to flow between layers.	"{""description"": ""Tear in the inner layer of the aortic wall allowing blood to flow between layers."", ""preferred_term"": ""Aortic Dissection"", ""term"": {""id"": ""HP:0002647"", ""label"": ""Aortic dissection""}}"																											
4373	4848	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	7	Mitral Valve Prolapse	Myxomatous degeneration of mitral valve leaflets causing prolapse into the left atrium during systole, often accompanied by mitral regurgitation.	phenotype_term	phenotype_term	$	Mitral Valve Prolapse	Myxomatous degeneration of mitral valve leaflets causing prolapse into the left atrium during systole, often accompanied by mitral regurgitation.	Mitral valve prolapse	HP:0001634	Mitral valve prolapse	Abnormal systolic displacement of mitral valve leaflets into the left atrium.	"{""description"": ""Abnormal systolic displacement of mitral valve leaflets into the left atrium."", ""preferred_term"": ""Mitral valve prolapse"", ""term"": {""id"": ""HP:0001634"", ""label"": ""Mitral valve prolapse""}}"																											
4374	4849	204	Marfan Syndrome	Marfan_Syndrome.yaml	phenotypes	8	Aortic Root Aneurysm	Progressive enlargement of the aortic root diameter, typically measured by echocardiography and tracked using Z-scores adjusted for age and body surface area.	phenotype_term	phenotype_term	$	Aortic Root Aneurysm	Progressive enlargement of the aortic root diameter, typically measured by echocardiography and tracked using Z-scores adjusted for age and body surface area.	Aortic root aneurysm	HP:0002616	Aortic root aneurysm	Abnormal widening of the aortic root.	"{""description"": ""Abnormal widening of the aortic root."", ""preferred_term"": ""Aortic root aneurysm"", ""term"": {""id"": ""HP:0002616"", ""label"": ""Aortic root aneurysm""}}"																											
4375	4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	Beta Blockers	Used to reduce stress on the aorta and prevent its enlargement.	treatment_term	treatment_term	$	Beta Blockers	Used to reduce stress on the aorta and prevent its enlargement.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy	Treatment using medications that block beta-adrenergic receptors to reduce heart rate and blood pressure.	"{""description"": ""Treatment using medications that block beta-adrenergic receptors to reduce heart rate and blood pressure."", ""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
4376	4853	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	1	Angiotensin Receptor Blockers	ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers.	treatment_term	treatment_term	$	Angiotensin Receptor Blockers	ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using medications such as losartan to modulate pathological signaling pathways.	"{""description"": ""Treatment using medications such as losartan to modulate pathological signaling pathways."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4377	4854	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	2	Aortic Surgery	Recommended for severe aortic dilation to prevent dissection.	treatment_term	treatment_term	$	Aortic Surgery	Recommended for severe aortic dilation to prevent dissection.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to repair or replace damaged anatomical structures.	"{""description"": ""Operative intervention to repair or replace damaged anatomical structures."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4378	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	Orthopedic Interventions	Treatments for scoliosis and other skeletal abnormalities.	treatment_term	treatment_term	$	Orthopedic Interventions	Treatments for scoliosis and other skeletal abnormalities.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to correct skeletal abnormalities such as scoliosis.	"{""description"": ""Operative intervention to correct skeletal abnormalities such as scoliosis."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4379	4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	Vision Correction	Management of ocular issues such as ectopia lentis with glasses or surgery.	treatment_term	treatment_term	$	Vision Correction	Management of ocular issues such as ectopia lentis with glasses or surgery.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to correct lens dislocation or other ocular abnormalities.	"{""description"": ""Operative intervention to correct lens dislocation or other ocular abnormalities."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4380	4858	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	phenotypes	0	Gastrointestinal Bleeding		phenotype_term	phenotype_term	$	Gastrointestinal Bleeding		Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
4381	4859	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	phenotypes	1	Intestinal Obstruction		phenotype_term	phenotype_term	$	Intestinal Obstruction		Intestinal obstruction	HP:0005214	Intestinal obstruction		"{""preferred_term"": ""Intestinal obstruction"", ""term"": {""id"": ""HP:0005214"", ""label"": ""Intestinal obstruction""}}"																											
4382	4860	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	phenotypes	2	Diverticulitis		phenotype_term	phenotype_term	$	Diverticulitis		diverticulitis	MONDO:0004235	diverticulitis		"{""preferred_term"": ""diverticulitis"", ""term"": {""id"": ""MONDO:0004235"", ""label"": ""diverticulitis""}}"																											
4383	4861	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	phenotypes	3	Intestinal Perforation		phenotype_term	phenotype_term	$	Intestinal Perforation		intestinal perforation	MONDO:0006807	intestinal perforation		"{""preferred_term"": ""intestinal perforation"", ""term"": {""id"": ""MONDO:0006807"", ""label"": ""intestinal perforation""}}"																											
4384	4862	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	phenotypes	4	Intussusception		phenotype_term	phenotype_term	$	Intussusception		intussusception	MONDO:0007835	intussusception		"{""preferred_term"": ""intussusception"", ""term"": {""id"": ""MONDO:0007835"", ""label"": ""intussusception""}}"																											
4385	4866	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	0	Surgical Resection for Symptomatic Cases	All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum.	treatment_term	treatment_term	$	Surgical Resection for Symptomatic Cases	All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4386	4867	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	1	Incidental Diverticulectomy with Stapling Devices	For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device.	treatment_term	treatment_term	$	Incidental Diverticulectomy with Stapling Devices	For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4387	4869	206	Meckel Syndrome	Meckel_Syndrome.yaml	differential_diagnoses	0	Trisomy 13 (Patau syndrome)	Chromosomal aneuploidy with overlapping malformations that can mimic MKS.	disease_term	disease_term	$	Trisomy 13 (Patau syndrome)	Chromosomal aneuploidy with overlapping malformations that can mimic MKS.	trisomy 13	MONDO:0018068	trisomy 13		"{""preferred_term"": ""trisomy 13"", ""term"": {""id"": ""MONDO:0018068"", ""label"": ""trisomy 13""}}"																											
4388	4870	206	Meckel Syndrome	Meckel_Syndrome.yaml	differential_diagnoses	1	Trisomy 18 (Edwards syndrome)	Chromosomal aneuploidy with overlapping congenital anomalies that must be distinguished from MKS.	disease_term	disease_term	$	Trisomy 18 (Edwards syndrome)	Chromosomal aneuploidy with overlapping congenital anomalies that must be distinguished from MKS.	trisomy 18	MONDO:0018071	trisomy 18		"{""preferred_term"": ""trisomy 18"", ""term"": {""id"": ""MONDO:0018071"", ""label"": ""trisomy 18""}}"																											
4389	4871	206	Meckel Syndrome	Meckel_Syndrome.yaml	differential_diagnoses	2	Joubert syndrome	Related ciliopathy with overlapping developmental anomalies and shared genetic spectrum.	disease_term	disease_term	$	Joubert syndrome	Related ciliopathy with overlapping developmental anomalies and shared genetic spectrum.	Joubert syndrome	MONDO:0018772	Joubert syndrome		"{""preferred_term"": ""Joubert syndrome"", ""term"": {""id"": ""MONDO:0018772"", ""label"": ""Joubert syndrome""}}"																											
4390	4872	206	Meckel Syndrome	Meckel_Syndrome.yaml	differential_diagnoses	3	Bardet-Biedl syndrome	Ciliopathy with overlapping polydactyly and renal findings that requires differentiation from MKS.	disease_term	disease_term	$	Bardet-Biedl syndrome	Ciliopathy with overlapping polydactyly and renal findings that requires differentiation from MKS.	Bardet-Biedl syndrome	MONDO:0015229	Bardet-Biedl syndrome		"{""preferred_term"": ""Bardet-Biedl syndrome"", ""term"": {""id"": ""MONDO:0015229"", ""label"": ""Bardet-Biedl syndrome""}}"																											
4391	4873	206	Meckel Syndrome	Meckel_Syndrome.yaml	differential_diagnoses	4	Smith-Lemli-Opitz syndrome	Cholesterol biosynthesis disorder with overlapping malformations that can resemble MKS.	disease_term	disease_term	$	Smith-Lemli-Opitz syndrome	Cholesterol biosynthesis disorder with overlapping malformations that can resemble MKS.	Smith-Lemli-Opitz syndrome	MONDO:0010035	Smith-Lemli-Opitz syndrome		"{""preferred_term"": ""Smith-Lemli-Opitz syndrome"", ""term"": {""id"": ""MONDO:0010035"", ""label"": ""Smith-Lemli-Opitz syndrome""}}"																											
4392	4874	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	0	MKS1		gene_term	gene_term	$	MKS1		MKS1	hgnc:7121	MKS1		"{""preferred_term"": ""MKS1"", ""term"": {""id"": ""hgnc:7121"", ""label"": ""MKS1""}}"																											
4393	4875	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	1	TMEM67		gene_term	gene_term	$	TMEM67		TMEM67	hgnc:28396	TMEM67		"{""preferred_term"": ""TMEM67"", ""term"": {""id"": ""hgnc:28396"", ""label"": ""TMEM67""}}"																											
4394	4876	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	2	CC2D2A		gene_term	gene_term	$	CC2D2A		CC2D2A	hgnc:29253	CC2D2A		"{""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}"																											
4395	4877	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	3	TMEM216		gene_term	gene_term	$	TMEM216		TMEM216	hgnc:25018	TMEM216		"{""preferred_term"": ""TMEM216"", ""term"": {""id"": ""hgnc:25018"", ""label"": ""TMEM216""}}"																											
4396	4878	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	4	TMEM231		gene_term	gene_term	$	TMEM231		TMEM231	hgnc:37234	TMEM231		"{""preferred_term"": ""TMEM231"", ""term"": {""id"": ""hgnc:37234"", ""label"": ""TMEM231""}}"																											
4397	4879	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	5	B9D2		gene_term	gene_term	$	B9D2		B9D2	hgnc:28636	B9D2		"{""preferred_term"": ""B9D2"", ""term"": {""id"": ""hgnc:28636"", ""label"": ""B9D2""}}"																											
4398	4880	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	6	B9D1		gene_term	gene_term	$	B9D1		B9D1	hgnc:24123	B9D1		"{""preferred_term"": ""B9D1"", ""term"": {""id"": ""hgnc:24123"", ""label"": ""B9D1""}}"																											
4399	4881	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	7	CEP290		gene_term	gene_term	$	CEP290		CEP290	hgnc:29021	CEP290		"{""preferred_term"": ""CEP290"", ""term"": {""id"": ""hgnc:29021"", ""label"": ""CEP290""}}"																											
4400	4882	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	8	RPGRIP1L		gene_term	gene_term	$	RPGRIP1L		RPGRIP1L	hgnc:29168	RPGRIP1L		"{""preferred_term"": ""RPGRIP1L"", ""term"": {""id"": ""hgnc:29168"", ""label"": ""RPGRIP1L""}}"																											
4401	4883	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	9	NPHP3		gene_term	gene_term	$	NPHP3		NPHP3	hgnc:7907	NPHP3		"{""preferred_term"": ""NPHP3"", ""term"": {""id"": ""hgnc:7907"", ""label"": ""NPHP3""}}"																											
4402	4884	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	10	TCTN2		gene_term	gene_term	$	TCTN2		TCTN2	hgnc:25774	TCTN2		"{""preferred_term"": ""TCTN2"", ""term"": {""id"": ""hgnc:25774"", ""label"": ""TCTN2""}}"																											
4403	4885	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	11	TMEM237		gene_term	gene_term	$	TMEM237		TMEM237	hgnc:14432	TMEM237		"{""preferred_term"": ""TMEM237"", ""term"": {""id"": ""hgnc:14432"", ""label"": ""TMEM237""}}"																											
4404	4886	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	12	TMEM107		gene_term	gene_term	$	TMEM107		TMEM107	hgnc:28128	TMEM107		"{""preferred_term"": ""TMEM107"", ""term"": {""id"": ""hgnc:28128"", ""label"": ""TMEM107""}}"																											
4405	4887	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	13	TXNDC15		gene_term	gene_term	$	TXNDC15		TXNDC15	hgnc:20652	TXNDC15		"{""preferred_term"": ""TXNDC15"", ""term"": {""id"": ""hgnc:20652"", ""label"": ""TXNDC15""}}"																											
4406	4888	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	14	TMEM17		gene_term	gene_term	$	TMEM17		TMEM17	hgnc:26623	TMEM17		"{""preferred_term"": ""TMEM17"", ""term"": {""id"": ""hgnc:26623"", ""label"": ""TMEM17""}}"																											
4407	4889	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	15	KIF7		gene_term	gene_term	$	KIF7		KIF7	hgnc:30497	KIF7		"{""preferred_term"": ""KIF7"", ""term"": {""id"": ""hgnc:30497"", ""label"": ""KIF7""}}"																											
4408	4890	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	0	Meckel syndrome, type 1		subtype_term	subtype_term	$	Meckel syndrome, type 1		Meckel syndrome, type 1	MONDO:0009571	Meckel syndrome, type 1		"{""preferred_term"": ""Meckel syndrome, type 1"", ""term"": {""id"": ""MONDO:0009571"", ""label"": ""Meckel syndrome, type 1""}}"																											
4409	4891	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	1	Meckel syndrome, type 2		subtype_term	subtype_term	$	Meckel syndrome, type 2		Meckel syndrome, type 2	MONDO:0011296	Meckel syndrome, type 2		"{""preferred_term"": ""Meckel syndrome, type 2"", ""term"": {""id"": ""MONDO:0011296"", ""label"": ""Meckel syndrome, type 2""}}"																											
4410	4892	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	2	Meckel syndrome, type 3		subtype_term	subtype_term	$	Meckel syndrome, type 3		Meckel syndrome, type 3	MONDO:0011821	Meckel syndrome, type 3		"{""preferred_term"": ""Meckel syndrome, type 3"", ""term"": {""id"": ""MONDO:0011821"", ""label"": ""Meckel syndrome, type 3""}}"																											
4411	4893	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	3	Meckel syndrome, type 4		subtype_term	subtype_term	$	Meckel syndrome, type 4		Meckel syndrome, type 4	MONDO:0012626	Meckel syndrome, type 4		"{""preferred_term"": ""Meckel syndrome, type 4"", ""term"": {""id"": ""MONDO:0012626"", ""label"": ""Meckel syndrome, type 4""}}"																											
4412	4894	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	4	Meckel syndrome, type 5		subtype_term	subtype_term	$	Meckel syndrome, type 5		Meckel syndrome, type 5	MONDO:0012695	Meckel syndrome, type 5		"{""preferred_term"": ""Meckel syndrome, type 5"", ""term"": {""id"": ""MONDO:0012695"", ""label"": ""Meckel syndrome, type 5""}}"																											
4413	4895	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	5	Meckel syndrome, type 6		subtype_term	subtype_term	$	Meckel syndrome, type 6		Meckel syndrome, type 6	MONDO:0012848	Meckel syndrome, type 6		"{""preferred_term"": ""Meckel syndrome, type 6"", ""term"": {""id"": ""MONDO:0012848"", ""label"": ""Meckel syndrome, type 6""}}"																											
4414	4896	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	6	Meckel syndrome, type 8		subtype_term	subtype_term	$	Meckel syndrome, type 8		Meckel syndrome, type 8	MONDO:0013482	Meckel syndrome, type 8		"{""preferred_term"": ""Meckel syndrome, type 8"", ""term"": {""id"": ""MONDO:0013482"", ""label"": ""Meckel syndrome, type 8""}}"																											
4415	4897	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	7	Meckel syndrome, type 9		subtype_term	subtype_term	$	Meckel syndrome, type 9		Meckel syndrome, type 9	MONDO:0013630	Meckel syndrome, type 9		"{""preferred_term"": ""Meckel syndrome, type 9"", ""term"": {""id"": ""MONDO:0013630"", ""label"": ""Meckel syndrome, type 9""}}"																											
4416	4898	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	8	Meckel syndrome, type 10		subtype_term	subtype_term	$	Meckel syndrome, type 10		Meckel syndrome, type 10	MONDO:0013609	Meckel syndrome, type 10		"{""preferred_term"": ""Meckel syndrome, type 10"", ""term"": {""id"": ""MONDO:0013609"", ""label"": ""Meckel syndrome, type 10""}}"																											
4417	4899	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	9	Meckel syndrome, type 11		subtype_term	subtype_term	$	Meckel syndrome, type 11		Meckel syndrome, type 11	MONDO:0014164	Meckel syndrome, type 11		"{""preferred_term"": ""Meckel syndrome, type 11"", ""term"": {""id"": ""MONDO:0014164"", ""label"": ""Meckel syndrome, type 11""}}"																											
4418	4900	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	10	Meckel syndrome 13		subtype_term	subtype_term	$	Meckel syndrome 13		Meckel syndrome 13	MONDO:0033044	Meckel syndrome 13		"{""preferred_term"": ""Meckel syndrome 13"", ""term"": {""id"": ""MONDO:0033044"", ""label"": ""Meckel syndrome 13""}}"																											
4419	4901	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	11	Meckel syndrome 14		subtype_term	subtype_term	$	Meckel syndrome 14		meckel syndrome 14	MONDO:0030819	meckel syndrome 14		"{""preferred_term"": ""meckel syndrome 14"", ""term"": {""id"": ""MONDO:0030819"", ""label"": ""meckel syndrome 14""}}"																											
4420	4903	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	0	Primary cilium membrane protein dysfunction (TMEM67/meckelin)	Pathogenic variants in TMEM67 disrupt primary cilium membrane components.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4421	4904	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	1	Ciliary base protein dysfunction (MKS1)	Loss of MKS1 perturbs proteins associated with the ciliary base/basal body.	cellular_components[0]	cellular_components	cellular_components			ciliary basal body	GO:0036064	ciliary basal body		"{""preferred_term"": ""ciliary basal body"", ""term"": {""id"": ""GO:0036064"", ""label"": ""ciliary basal body""}}"																											
4422	4904	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	1	Ciliary base protein dysfunction (MKS1)	Loss of MKS1 perturbs proteins associated with the ciliary base/basal body.	cellular_components[1]	cellular_components	cellular_components			ciliary base	GO:0097546	ciliary base		"{""preferred_term"": ""ciliary base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4423	4905	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	2	Basal body localization without proper ciliogenesis	Basal bodies localize apically, yet cilia fail to form in many tissues.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4424	4905	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	2	Basal body localization without proper ciliogenesis	Basal bodies localize apically, yet cilia fail to form in many tissues.	cellular_components[1]	cellular_components	cellular_components			ciliary basal body	GO:0036064	ciliary basal body		"{""preferred_term"": ""ciliary basal body"", ""term"": {""id"": ""GO:0036064"", ""label"": ""ciliary basal body""}}"																											
4425	4905	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	2	Basal body localization without proper ciliogenesis	Basal bodies localize apically, yet cilia fail to form in many tissues.	cellular_components[2]	cellular_components	cellular_components			ciliary base	GO:0097546	ciliary base		"{""preferred_term"": ""ciliary base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4426	4905	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	2	Basal body localization without proper ciliogenesis	Basal bodies localize apically, yet cilia fail to form in many tissues.	biological_processes[0]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"			DYSREGULATED																								
4427	4906	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	3	Defective cilia formation across multiple tissues	Primary cilia fail to form in many tissues in vivo.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4428	4906	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	3	Defective cilia formation across multiple tissues	Primary cilia fail to form in many tissues in vivo.	cellular_components[1]	cellular_components	cellular_components			ciliary basal body	GO:0036064	ciliary basal body		"{""preferred_term"": ""ciliary basal body"", ""term"": {""id"": ""GO:0036064"", ""label"": ""ciliary basal body""}}"																											
4429	4906	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	3	Defective cilia formation across multiple tissues	Primary cilia fail to form in many tissues in vivo.	cellular_components[2]	cellular_components	cellular_components			ciliary base	GO:0097546	ciliary base		"{""preferred_term"": ""ciliary base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4430	4906	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	3	Defective cilia formation across multiple tissues	Primary cilia fail to form in many tissues in vivo.	biological_processes[0]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"			DYSREGULATED																								
4431	4907	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	4	Loss of primary cilia (failed ciliogenesis)	Primary cilia are absent, reflecting failed ciliogenesis.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4432	4907	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	4	Loss of primary cilia (failed ciliogenesis)	Primary cilia are absent, reflecting failed ciliogenesis.	cellular_components[1]	cellular_components	cellular_components			ciliary basal body	GO:0036064	ciliary basal body		"{""preferred_term"": ""ciliary basal body"", ""term"": {""id"": ""GO:0036064"", ""label"": ""ciliary basal body""}}"																											
4433	4907	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	4	Loss of primary cilia (failed ciliogenesis)	Primary cilia are absent, reflecting failed ciliogenesis.	cellular_components[2]	cellular_components	cellular_components			ciliary base	GO:0097546	ciliary base		"{""preferred_term"": ""ciliary base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4434	4907	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	4	Loss of primary cilia (failed ciliogenesis)	Primary cilia are absent, reflecting failed ciliogenesis.	biological_processes[0]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"			DYSREGULATED																								
4435	4908	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	5	Reduced axonemal microtubule posttranslational modifications	Disruption of the B9-TMEM67 complex at the transition zone reduces axonemal microtubule modifications.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4436	4908	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	5	Reduced axonemal microtubule posttranslational modifications	Disruption of the B9-TMEM67 complex at the transition zone reduces axonemal microtubule modifications.	cellular_components[1]	cellular_components	cellular_components			axoneme	GO:0005930	axoneme		"{""preferred_term"": ""axoneme"", ""term"": {""id"": ""GO:0005930"", ""label"": ""axoneme""}}"																											
4437	4908	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	5	Reduced axonemal microtubule posttranslational modifications	Disruption of the B9-TMEM67 complex at the transition zone reduces axonemal microtubule modifications.	cellular_components[2]	cellular_components	cellular_components			ciliary basal body	GO:0036064	ciliary basal body		"{""preferred_term"": ""ciliary basal body"", ""term"": {""id"": ""GO:0036064"", ""label"": ""ciliary basal body""}}"																											
4438	4908	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	5	Reduced axonemal microtubule posttranslational modifications	Disruption of the B9-TMEM67 complex at the transition zone reduces axonemal microtubule modifications.	cellular_components[3]	cellular_components	cellular_components			ciliary base	GO:0097546	ciliary base		"{""preferred_term"": ""ciliary base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4439	4909	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	6	Impaired initiation of ciliogenesis	B9 proteins facilitate early ciliogenesis; disruption impairs initiation.	biological_processes[0]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"			DYSREGULATED																								
4440	4910	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	7	TMEM67 cleavage uncouples ciliogenesis and Wnt signaling	Proteolytic cleavage of TMEM67 separates ciliary assembly from Wnt pathway activity.	biological_processes[0]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"			DYSREGULATED																								
4441	4910	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	7	TMEM67 cleavage uncouples ciliogenesis and Wnt signaling	Proteolytic cleavage of TMEM67 separates ciliary assembly from Wnt pathway activity.	biological_processes[1]	biological_processes	biological_processes			Wnt signaling pathway	GO:0016055	Wnt signaling pathway		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""Wnt signaling pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"			DYSREGULATED																								
4442	4911	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	8	TMEM17 loss disrupts Sonic Hedgehog signaling	TMEM17 dysfunction at the ciliary transition zone abrogates Sonic Hedgehog signaling.	biological_processes[0]	biological_processes	biological_processes			hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""hedgehog signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""hedgehog signaling pathway""}}"			DYSREGULATED																								
4443	4912	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	9	Altered Hedgehog signaling in neural tube patterning	Hedgehog signaling is altered during neural tube development.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4444	4912	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	9	Altered Hedgehog signaling in neural tube patterning	Hedgehog signaling is altered during neural tube development.	locations[0]	locations	locations			neural tube	UBERON:0001049	neural tube		"{""preferred_term"": ""neural tube"", ""term"": {""id"": ""UBERON:0001049"", ""label"": ""neural tube""}}"																											
4445	4912	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	9	Altered Hedgehog signaling in neural tube patterning	Hedgehog signaling is altered during neural tube development.	biological_processes[0]	biological_processes	biological_processes			hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""hedgehog signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""hedgehog signaling pathway""}}"			DYSREGULATED																								
4446	4913	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	10	Altered Hedgehog signaling in limb patterning	Hedgehog signaling is altered during limb development.	cellular_components[0]	cellular_components	cellular_components			primary cilium	GO:0005929	cilium		"{""preferred_term"": ""primary cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4447	4913	206	Meckel Syndrome	Meckel_Syndrome.yaml	pathophysiology	10	Altered Hedgehog signaling in limb patterning	Hedgehog signaling is altered during limb development.	biological_processes[0]	biological_processes	biological_processes			hedgehog signaling pathway	GO:0007224	hedgehog signaling pathway		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""hedgehog signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""hedgehog signaling pathway""}}"			DYSREGULATED																								
4448	4914	206	Meckel Syndrome	Meckel_Syndrome.yaml	phenotypes	0	Occipital encephalocele		phenotype_term	phenotype_term	$	Occipital encephalocele		Occipital encephalocele	HP:0002085	Occipital encephalocele		"{""preferred_term"": ""Occipital encephalocele"", ""term"": {""id"": ""HP:0002085"", ""label"": ""Occipital encephalocele""}}"																											
4449	4915	206	Meckel Syndrome	Meckel_Syndrome.yaml	phenotypes	1	Cystic renal dysplasia		phenotype_term	phenotype_term	$	Cystic renal dysplasia		Cystic renal dysplasia	HP:0000800	Cystic renal dysplasia		"{""preferred_term"": ""Cystic renal dysplasia"", ""term"": {""id"": ""HP:0000800"", ""label"": ""Cystic renal dysplasia""}}"																											
4450	4916	206	Meckel Syndrome	Meckel_Syndrome.yaml	phenotypes	2	Postaxial polydactyly		phenotype_term	phenotype_term	$	Postaxial polydactyly		Postaxial hand polydactyly	HP:0001162	Postaxial hand polydactyly		"{""preferred_term"": ""Postaxial hand polydactyly"", ""term"": {""id"": ""HP:0001162"", ""label"": ""Postaxial hand polydactyly""}}"																											
4451	4917	206	Meckel Syndrome	Meckel_Syndrome.yaml	phenotypes	3	Hepatic fibrosis		phenotype_term	phenotype_term	$	Hepatic fibrosis		Hepatic fibrosis	HP:0001395	Hepatic fibrosis		"{""preferred_term"": ""Hepatic fibrosis"", ""term"": {""id"": ""HP:0001395"", ""label"": ""Hepatic fibrosis""}}"																											
4452	4918	206	Meckel Syndrome	Meckel_Syndrome.yaml	phenotypes	4	Pulmonary hypoplasia		phenotype_term	phenotype_term	$	Pulmonary hypoplasia		Pulmonary hypoplasia	HP:0002089	Pulmonary hypoplasia		"{""preferred_term"": ""Pulmonary hypoplasia"", ""term"": {""id"": ""HP:0002089"", ""label"": ""Pulmonary hypoplasia""}}"																											
4453	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term	treatment_term	$	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Excision	NCIT:C15232	NCIT:C15329						
4454	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4455	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
4456	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term	treatment_term	$	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Shunt Device	NCIT:C50174	NCIT:C15329						
4457	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4458	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			shunt device	NCIT:C50174	Shunt Device		"{""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}"																											
4459	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term	treatment_term	$	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Excision	NCIT:C15232	NCIT:C15329						
4460	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4461	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
4462	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term	treatment_term	$	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}, ""value"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}}], ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"									CC2D2A	hgnc:29253	RO:0000057																
4463	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			has participant	RO:0000057	has participant		"{""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}"																											
4464	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			CC2D2A	hgnc:29253	CC2D2A		"{""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}"																											
4465	4924	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	biochemical	0	Serum Calcitonin		biomarker_term	biomarker_term	$	Serum Calcitonin		calcitonin	NCIT:C2281	Calcitonin		"{""preferred_term"": ""calcitonin"", ""term"": {""id"": ""NCIT:C2281"", ""label"": ""Calcitonin""}}"																											
4466	4925	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	biochemical	1	Serum CEA		biomarker_term	biomarker_term	$	Serum CEA		carcinoembryonic antigen	NCIT:C16384	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5		"{""preferred_term"": ""carcinoembryonic antigen"", ""term"": {""id"": ""NCIT:C16384"", ""label"": ""Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5""}}"																											
4467	4930	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	histopathology	0	Medullary Thyroid Carcinoma	Medullary thyroid carcinoma originates from parafollicular C cells.	finding_term	finding_term	$	Medullary Thyroid Carcinoma	Medullary thyroid carcinoma originates from parafollicular C cells.	Thyroid Gland Medullary Carcinoma	NCIT:C3879	Thyroid Gland Medullary Carcinoma		"{""preferred_term"": ""Thyroid Gland Medullary Carcinoma"", ""term"": {""id"": ""NCIT:C3879"", ""label"": ""Thyroid Gland Medullary Carcinoma""}}"																											
4468	4931	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	0	RET Proto-Oncogene Activation	Activating mutations in the RET receptor tyrosine kinase lead to constitutive kinase activity without ligand binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting C-cell proliferation and survival.	cell_types[0]	cell_types	cell_types			parafollicular cell	CL:0000570	parafollicular cell		"{""preferred_term"": ""parafollicular cell"", ""term"": {""id"": ""CL:0000570"", ""label"": ""parafollicular cell""}}"																											
4469	4931	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	0	RET Proto-Oncogene Activation	Activating mutations in the RET receptor tyrosine kinase lead to constitutive kinase activity without ligand binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting C-cell proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""receptor signaling protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004716"", ""label"": ""receptor signaling protein tyrosine kinase activity""}}"			INCREASED																								
4470	4931	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	0	RET Proto-Oncogene Activation	Activating mutations in the RET receptor tyrosine kinase lead to constitutive kinase activity without ligand binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting C-cell proliferation and survival.	gene_products[0]	gene_products	gene_products			RET receptor tyrosine kinase	NCIT:C18539	Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret		"{""preferred_term"": ""RET receptor tyrosine kinase"", ""term"": {""id"": ""NCIT:C18539"", ""label"": ""Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret""}}"																											
4471	4931	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	0	RET Proto-Oncogene Activation	Activating mutations in the RET receptor tyrosine kinase lead to constitutive kinase activity without ligand binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting C-cell proliferation and survival.	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
4472	4932	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	RET activation stimulates the RAS-RAF-MEK-ERK signaling cascade, driving uncontrolled C-cell proliferation. This pathway is a major effector of RET-mediated transformation in MTC.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4473	4933	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	RET activation recruits PI3K and activates the PI3K-AKT-mTOR signaling cascade, promoting C-cell survival and resistance to apoptosis. This cooperates with MAPK signaling to drive MTC tumorigenesis.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
4474	4934	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	phenotypes	0	Thyroid Nodule	MTC typically presents as a firm, painless thyroid nodule. In hereditary cases, bilateral or multifocal disease may be present at diagnosis.	phenotype_term	phenotype_term	$	Thyroid Nodule	MTC typically presents as a firm, painless thyroid nodule. In hereditary cases, bilateral or multifocal disease may be present at diagnosis.	Thyroid carcinoma	HP:0002890	Thyroid carcinoma		"{""preferred_term"": ""Thyroid carcinoma"", ""term"": {""id"": ""HP:0002890"", ""label"": ""Thyroid carcinoma""}}"																											
4475	4935	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	phenotypes	1	Diarrhea	Secretory diarrhea occurs in advanced MTC due to tumor secretion of vasoactive substances including calcitonin and prostaglandins.	phenotype_term	phenotype_term	$	Diarrhea	Secretory diarrhea occurs in advanced MTC due to tumor secretion of vasoactive substances including calcitonin and prostaglandins.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
4476	4936	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	phenotypes	2	Lymph Node Metastasis	Cervical lymph node involvement is common at diagnosis. The extent of nodal disease affects prognosis and surgical planning.	phenotype_term	phenotype_term	$	Lymph Node Metastasis	Cervical lymph node involvement is common at diagnosis. The extent of nodal disease affects prognosis and surgical planning.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
4477	4937	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4478	4938	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	1	Selpercatinib	Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated.	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4479	4939	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	2	Pralsetinib	Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile.	treatment_term	treatment_term	$	Pralsetinib	Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	treatment_term	$	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}"				vandetanib; cabozantinib	CHEBI:49960; CHEBI:72317																						
4481	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vandetanib	CHEBI:49960	vandetanib		"{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}"																											
4482	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"																											
4483	4950	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	histopathology	0	Malignant Pediatric Brain Tumor	Medulloblastoma is the most common malignant brain tumor of childhood.	finding_term	finding_term	$	Malignant Pediatric Brain Tumor	Medulloblastoma is the most common malignant brain tumor of childhood.	Medulloblastoma	NCIT:C3222	Medulloblastoma		"{""preferred_term"": ""Medulloblastoma"", ""term"": {""id"": ""NCIT:C3222"", ""label"": ""Medulloblastoma""}}"																											
4484	4951	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	0	SHH Pathway Activation	The SHH pathway is activated through loss of function mutations in PTCH1 (receptor that normally inhibits SMO), activating mutations in SMO, loss of SUFU (negative regulator), or amplification of downstream effectors (GLI2, MYCN). This leads to constitutive activation of GLI transcription factors.	cell_types[0]	cell_types	cell_types			cerebellar granule cell	CL:0001031	cerebellar granule cell		"{""preferred_term"": ""cerebellar granule cell"", ""term"": {""id"": ""CL:0001031"", ""label"": ""cerebellar granule cell""}}"																											
4485	4951	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	0	SHH Pathway Activation	The SHH pathway is activated through loss of function mutations in PTCH1 (receptor that normally inhibits SMO), activating mutations in SMO, loss of SUFU (negative regulator), or amplification of downstream effectors (GLI2, MYCN). This leads to constitutive activation of GLI transcription factors.	biological_processes[0]	biological_processes	biological_processes			smoothened signaling pathway	GO:0007224	smoothened signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""smoothened signaling pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"			INCREASED																								
4486	4951	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	0	SHH Pathway Activation	The SHH pathway is activated through loss of function mutations in PTCH1 (receptor that normally inhibits SMO), activating mutations in SMO, loss of SUFU (negative regulator), or amplification of downstream effectors (GLI2, MYCN). This leads to constitutive activation of GLI transcription factors.	locations[0]	locations	locations			cerebellum	UBERON:0002037	cerebellum		"{""preferred_term"": ""cerebellum"", ""term"": {""id"": ""UBERON:0002037"", ""label"": ""cerebellum""}}"																											
4487	4952	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	1	GLI Transcription Factor Activation	Activated SMO leads to nuclear translocation of GLI transcription factors (GLI1, GLI2) which activate target genes including PTCH1 (feedback), GLI1, MYCN, CCND1, and BCL2. GLI2 amplification can drive pathway activation independently of upstream components.	biological_processes[0]	biological_processes	biological_processes			positive regulation of gene expression	GO:0010628	positive regulation of gene expression		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of gene expression"", ""term"": {""id"": ""GO:0010628"", ""label"": ""positive regulation of gene expression""}}"			INCREASED																								
4488	4953	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	2	Cerebellar Granule Cell Proliferation	SHH signaling normally controls proliferation of granule neuron precursors in the external granule layer during cerebellar development. Constitutive pathway activation leads to unchecked proliferation of these precursors, resulting in tumor formation.	cell_types[0]	cell_types	cell_types			cerebellar granule cell	CL:0001031	cerebellar granule cell		"{""preferred_term"": ""cerebellar granule cell"", ""term"": {""id"": ""CL:0001031"", ""label"": ""cerebellar granule cell""}}"																											
4489	4953	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	2	Cerebellar Granule Cell Proliferation	SHH signaling normally controls proliferation of granule neuron precursors in the external granule layer during cerebellar development. Constitutive pathway activation leads to unchecked proliferation of these precursors, resulting in tumor formation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4490	4953	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	pathophysiology	2	Cerebellar Granule Cell Proliferation	SHH signaling normally controls proliferation of granule neuron precursors in the external granule layer during cerebellar development. Constitutive pathway activation leads to unchecked proliferation of these precursors, resulting in tumor formation.	biological_processes[1]	biological_processes	biological_processes			cerebellum development	GO:0021549	cerebellum development		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""cerebellum development"", ""term"": {""id"": ""GO:0021549"", ""label"": ""cerebellum development""}}"			ABNORMAL																								
4491	4954	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	phenotypes	0	Headache	Headache from increased intracranial pressure due to obstructive hydrocephalus. Often worse in morning.	phenotype_term	phenotype_term	$	Headache	Headache from increased intracranial pressure due to obstructive hydrocephalus. Often worse in morning.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4492	4955	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	phenotypes	1	Ataxia	Cerebellar ataxia with appendicular (limb) involvement when tumor is lateral, or truncal instability with midline tumors.	phenotype_term	phenotype_term	$	Ataxia	Cerebellar ataxia with appendicular (limb) involvement when tumor is lateral, or truncal instability with midline tumors.	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
4493	4956	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	phenotypes	2	Nausea and Vomiting	Vomiting from increased intracranial pressure, often in the morning.	phenotype_term	phenotype_term	$	Nausea and Vomiting	Vomiting from increased intracranial pressure, often in the morning.	Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
4494	4957	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	phenotypes	3	Macrocephaly	Increased head circumference in infants due to hydrocephalus from CSF obstruction. May be the presenting sign in young infants.	phenotype_term	phenotype_term	$	Macrocephaly	Increased head circumference in infants due to hydrocephalus from CSF obstruction. May be the presenting sign in young infants.	Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
4495	4958	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic.	treatment_term	treatment_term	$	Surgical Resection	Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4496	4959	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects.	treatment_term	treatment_term	$	Craniospinal Irradiation	Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4497	4960	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine.	treatment_term	treatment_term	$	Chemotherapy	Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4498	4961	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	3	SHH Pathway Inhibitors (Vismodegib/Sonidegib)	SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children.	treatment_term	treatment_term	$	SHH Pathway Inhibitors (Vismodegib/Sonidegib)	SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4499	4970	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	histopathology	0	Malignant Pediatric Brain Tumor	Medulloblastoma is the most common malignant brain tumor of childhood.	finding_term	finding_term	$	Malignant Pediatric Brain Tumor	Medulloblastoma is the most common malignant brain tumor of childhood.	Medulloblastoma	NCIT:C3222	Medulloblastoma		"{""preferred_term"": ""Medulloblastoma"", ""term"": {""id"": ""NCIT:C3222"", ""label"": ""Medulloblastoma""}}"																											
4500	4971	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	0	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) prevent phosphorylation at serine/threonine residues in exon 3, blocking proteasomal degradation. This leads to nuclear accumulation of beta-catenin, which complexes with TCF/LEF transcription factors to activate WNT target genes.	cell_types[0]	cell_types	cell_types			cerebellar granule cell	CL:0001031	cerebellar granule cell		"{""preferred_term"": ""cerebellar granule cell"", ""term"": {""id"": ""CL:0001031"", ""label"": ""cerebellar granule cell""}}"																											
4501	4971	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	0	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) prevent phosphorylation at serine/threonine residues in exon 3, blocking proteasomal degradation. This leads to nuclear accumulation of beta-catenin, which complexes with TCF/LEF transcription factors to activate WNT target genes.	biological_processes[0]	biological_processes	biological_processes			Wnt signaling pathway	GO:0016055	Wnt signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Wnt signaling pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"			INCREASED																								
4502	4971	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	0	WNT/Beta-Catenin Pathway Activation	Activating mutations in CTNNB1 (beta-catenin) prevent phosphorylation at serine/threonine residues in exon 3, blocking proteasomal degradation. This leads to nuclear accumulation of beta-catenin, which complexes with TCF/LEF transcription factors to activate WNT target genes.	locations[0]	locations	locations			cerebellum	UBERON:0002037	cerebellum		"{""preferred_term"": ""cerebellum"", ""term"": {""id"": ""UBERON:0002037"", ""label"": ""cerebellum""}}"																											
4503	4972	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	1	Nuclear Beta-Catenin Accumulation	Stabilized beta-catenin accumulates in the nucleus where it acts as a transcriptional coactivator with TCF/LEF family transcription factors. Nuclear beta-catenin immunostaining is a diagnostic hallmark of WNT-activated medulloblastoma.	biological_processes[0]	biological_processes	biological_processes			canonical Wnt signaling pathway	GO:0060070	canonical Wnt signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""canonical Wnt signaling pathway"", ""term"": {""id"": ""GO:0060070"", ""label"": ""canonical Wnt signaling pathway""}}"			INCREASED																								
4504	4973	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	2	WNT Target Gene Activation	Nuclear beta-catenin/TCF complexes drive expression of WNT target genes including MYC, CCND1 (cyclin D1), AXIN2, and DKK1. These genes promote proliferation and can serve as biomarkers of WNT pathway activation.	biological_processes[0]	biological_processes	biological_processes			positive regulation of gene expression	GO:0010628	positive regulation of gene expression		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of gene expression"", ""term"": {""id"": ""GO:0010628"", ""label"": ""positive regulation of gene expression""}}"			INCREASED																								
4505	4974	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	3	Cell Proliferation and Tumor Formation	WNT pathway activation drives proliferation of cerebellar progenitor cells, likely from the lower rhombic lip region. Despite constitutive pathway activation, these tumors have favorable biology, possibly due to their differentiation state or immunological features.	cell_types[0]	cell_types	cell_types			cerebellar granule cell	CL:0001031	cerebellar granule cell		"{""preferred_term"": ""cerebellar granule cell"", ""term"": {""id"": ""CL:0001031"", ""label"": ""cerebellar granule cell""}}"																											
4506	4974	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	pathophysiology	3	Cell Proliferation and Tumor Formation	WNT pathway activation drives proliferation of cerebellar progenitor cells, likely from the lower rhombic lip region. Despite constitutive pathway activation, these tumors have favorable biology, possibly due to their differentiation state or immunological features.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4507	4975	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	phenotypes	0	Headache	Headache from increased intracranial pressure due to obstructive hydrocephalus. Often worse in morning and may be accompanied by vomiting.	phenotype_term	phenotype_term	$	Headache	Headache from increased intracranial pressure due to obstructive hydrocephalus. Often worse in morning and may be accompanied by vomiting.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4508	4976	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	phenotypes	1	Ataxia	Cerebellar ataxia with truncal instability and gait disturbance from tumor involvement of cerebellar structures.	phenotype_term	phenotype_term	$	Ataxia	Cerebellar ataxia with truncal instability and gait disturbance from tumor involvement of cerebellar structures.	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
4509	4977	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	phenotypes	2	Nausea and Vomiting	Vomiting, often in the morning, from increased intracranial pressure and brainstem involvement.	phenotype_term	phenotype_term	$	Nausea and Vomiting	Vomiting, often in the morning, from increased intracranial pressure and brainstem involvement.	Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
4510	4978	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	phenotypes	3	Papilledema	Optic disc swelling from increased intracranial pressure. May lead to visual symptoms if prolonged.	phenotype_term	phenotype_term	$	Papilledema	Optic disc swelling from increased intracranial pressure. May lead to visual symptoms if prolonged.	Papilledema	HP:0001085	Papilledema		"{""preferred_term"": ""Papilledema"", ""term"": {""id"": ""HP:0001085"", ""label"": ""Papilledema""}}"																											
4511	4979	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes.	treatment_term	treatment_term	$	Surgical Resection	Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4512	4980	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis.	treatment_term	treatment_term	$	Craniospinal Irradiation	Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4513	4981	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival.	treatment_term	treatment_term	$	Chemotherapy	Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4514	4985	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	environmental	0	UV Radiation	Sunlight and tanning beds	exposure_term	exposure_term	$	UV Radiation	Sunlight and tanning beds	Ultraviolet radiation exposure	ECTO:0000006	exposure to ultraviolet radiation		"{""preferred_term"": ""Ultraviolet radiation exposure"", ""term"": {""id"": ""ECTO:0000006"", ""label"": ""exposure to ultraviolet radiation""}}"																											
4515	4994	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	histopathology	0	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	finding_term	finding_term	$	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	Melanocytic Neoplasm	NCIT:C7058	Melanocytic Neoplasm		"{""preferred_term"": ""Melanocytic Neoplasm"", ""term"": {""id"": ""NCIT:C7058"", ""label"": ""Melanocytic Neoplasm""}}"																											
4516	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	genes[0]	genes	genes			BRAF	hgnc:1097	BRAF		"{""preferred_term"": ""BRAF"", ""term"": {""id"": ""hgnc:1097"", ""label"": ""BRAF""}}"																											
4517	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	genes[1]	genes	genes			NRAS	hgnc:7989	NRAS		"{""preferred_term"": ""NRAS"", ""term"": {""id"": ""hgnc:7989"", ""label"": ""NRAS""}}"																											
4518	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
4519	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	cell_types[1]	cell_types	cell_types			neural crest cell	CL:0011012	neural crest cell		"{""preferred_term"": ""neural crest cell"", ""term"": {""id"": ""CL:0011012"", ""label"": ""neural crest cell""}}"																											
4520	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
4521	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	biological_processes[1]	biological_processes	biological_processes			cellular senescence	GO:0090398	cellular senescence		"{""preferred_term"": ""cellular senescence"", ""term"": {""id"": ""GO:0090398"", ""label"": ""cellular senescence""}}"																											
4522	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	biological_processes[2]	biological_processes	biological_processes			telomere maintenance	GO:0000723	telomere maintenance		"{""preferred_term"": ""telomere maintenance"", ""term"": {""id"": ""GO:0000723"", ""label"": ""telomere maintenance""}}"																											
4523	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	locations[0]	locations	locations			skin	UBERON:0002097	skin		"{""preferred_term"": ""skin"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin""}}"																											
4524	4995	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	0	Genetic Mutations	Post-zygotic mosaic mutations in NRAS (codon 61) and BRAF (V600E) occur during embryogenesis in neural crest-derived melanocyte precursors, driving constitutive MAPK signaling. NRAS mutations are dominant in large/giant CMN (68-94%), while BRAF mutations are less common. Progression to melanoma requires additional alterations including TERT activation, CDKN2A loss, TP53 mutations, and PTEN inactivation.	locations[1]	locations	locations			leptomeninx	UBERON:0000391	leptomeninx		"{""preferred_term"": ""leptomeninx"", ""term"": {""id"": ""UBERON:0000391"", ""label"": ""leptomeninx""}}"																											
4525	4997	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	2	PI3K-AKT-mTOR Pathway Activation	Compensatory activation of the PI3K-AKT-mTOR pathway occurs alongside MAPK signaling, often driven by PTEN loss. This pathway cross-talk promotes cell survival, invasion, and resistance to MEK inhibition. Combined targeting of both MAPK and PI3K pathways represents a rational therapeutic strategy.	genes[0]	genes	genes			PTEN	hgnc:9588	PTEN		"{""preferred_term"": ""PTEN"", ""term"": {""id"": ""hgnc:9588"", ""label"": ""PTEN""}}"																											
4526	4997	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	2	PI3K-AKT-mTOR Pathway Activation	Compensatory activation of the PI3K-AKT-mTOR pathway occurs alongside MAPK signaling, often driven by PTEN loss. This pathway cross-talk promotes cell survival, invasion, and resistance to MEK inhibition. Combined targeting of both MAPK and PI3K pathways represents a rational therapeutic strategy.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol-mediated signaling	GO:0048015	phosphatidylinositol-mediated signaling		"{""preferred_term"": ""phosphatidylinositol-mediated signaling"", ""term"": {""id"": ""GO:0048015"", ""label"": ""phosphatidylinositol-mediated signaling""}}"																											
4527	4997	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	pathophysiology	2	PI3K-AKT-mTOR Pathway Activation	Compensatory activation of the PI3K-AKT-mTOR pathway occurs alongside MAPK signaling, often driven by PTEN loss. This pathway cross-talk promotes cell survival, invasion, and resistance to MEK inhibition. Combined targeting of both MAPK and PI3K pathways represents a rational therapeutic strategy.	biological_processes[1]	biological_processes	biological_processes			TOR signaling	GO:0031929	TOR signaling		"{""preferred_term"": ""TOR signaling"", ""term"": {""id"": ""GO:0031929"", ""label"": ""TOR signaling""}}"																											
4528	5002	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	phenotypes	2	Lymphadenopathy		phenotype_term	phenotype_term	$	Lymphadenopathy		Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
4529	5003	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	phenotypes	3	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
4530	5006	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	phenotypes	6	Hydrocephalus		phenotype_term	phenotype_term	$	Hydrocephalus		Hydrocephalus	HP:0000238	Hydrocephalus		"{""preferred_term"": ""Hydrocephalus"", ""term"": {""id"": ""HP:0000238"", ""label"": ""Hydrocephalus""}}"																											
4531	5007	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	phenotypes	7	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
4532	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	Surgical Excision	Removal of the melanoma and surrounding tissue	treatment_term	treatment_term	$	Surgical Excision	Removal of the melanoma and surrounding tissue	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4533	5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	Immunotherapy	Use of drugs to stimulate the immune system to target melanoma cells	treatment_term	treatment_term	$	Immunotherapy	Use of drugs to stimulate the immune system to target melanoma cells	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4534	5012	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	2	Targeted Therapy	Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors	treatment_term	treatment_term	$	Targeted Therapy	Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4535	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	Radiation Therapy	Use of high-energy radiation to kill cancer cells or shrink tumors	treatment_term	treatment_term	$	Radiation Therapy	Use of high-energy radiation to kill cancer cells or shrink tumors	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4536	5014	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	4	Chemotherapy	Use of drugs to kill rapidly dividing cells, including cancer cells	treatment_term	treatment_term	$	Chemotherapy	Use of drugs to kill rapidly dividing cells, including cancer cells	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4537	5018	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	differential_diagnoses	0	Crohn's disease with orofacial manifestations	"Oral Crohn disease (OCD) and orofacial granulomatosis (OFG) present with non-caseating granulomatous inflammation histologically indistinguishable from MRS. However, Crohn's disease has significant gastrointestinal involvement (terminal ileum, colon) whereas MRS is primarily limited to orofacial structures.
"	disease_term	disease_term	$	Crohn's disease with orofacial manifestations	"Oral Crohn disease (OCD) and orofacial granulomatosis (OFG) present with non-caseating granulomatous inflammation histologically indistinguishable from MRS. However, Crohn's disease has significant gastrointestinal involvement (terminal ileum, colon) whereas MRS is primarily limited to orofacial structures.
"	Crohn disease	MONDO:0005011	Crohn disease		"{""preferred_term"": ""Crohn disease"", ""term"": {""id"": ""MONDO:0005011"", ""label"": ""Crohn disease""}}"																											
4538	5019	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	differential_diagnoses	1	Sarcoidosis	"Sarcoidosis can cause facial swelling and non-caseating granulomatous inflammation but presents as a systemic multiorgan disease with pulmonary and lymph node involvement, distinct from the primarily orofacial involvement in MRS. Sarcoidosis typically lacks recurrent facial nerve paralysis as a primary manifestation.
"	disease_term	disease_term	$	Sarcoidosis	"Sarcoidosis can cause facial swelling and non-caseating granulomatous inflammation but presents as a systemic multiorgan disease with pulmonary and lymph node involvement, distinct from the primarily orofacial involvement in MRS. Sarcoidosis typically lacks recurrent facial nerve paralysis as a primary manifestation.
"	sarcoidosis	MONDO:0019338	sarcoidosis		"{""preferred_term"": ""sarcoidosis"", ""term"": {""id"": ""MONDO:0019338"", ""label"": ""sarcoidosis""}}"																											
4539	5020	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	differential_diagnoses	2	Bell's palsy	"Bell's palsy presents with acute facial paralysis but lacks the chronic recurrent orofacial edema and granulomatous histopathology characteristic of MRS. Bell's palsy typically resolves within weeks whereas MRS has chronic relapsing course with persistent granulomatous changes between episodes.
"	disease_term	disease_term	$	Bell's palsy	"Bell's palsy presents with acute facial paralysis but lacks the chronic recurrent orofacial edema and granulomatous histopathology characteristic of MRS. Bell's palsy typically resolves within weeks whereas MRS has chronic relapsing course with persistent granulomatous changes between episodes.
"	Bell's palsy	MONDO:0005665	Bell's palsy		"{""preferred_term"": ""Bell's palsy"", ""term"": {""id"": ""MONDO:0005665"", ""label"": ""Bell's palsy""}}"																											
4540	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	cell_types[0]	cell_types	cell_types			epithelioid macrophage	CL:0002150	epithelioid macrophage		"{""preferred_term"": ""epithelioid macrophage"", ""term"": {""id"": ""CL:0002150"", ""label"": ""epithelioid macrophage""}}"																											
4541	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	cell_types[1]	cell_types	cell_types			T lymphocyte	CL:0000084	T cell		"{""preferred_term"": ""T lymphocyte"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4542	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	biological_processes[0]	biological_processes	biological_processes			granuloma formation	GO:0034612	response to tumor necrosis factor		"{""preferred_term"": ""granuloma formation"", ""term"": {""id"": ""GO:0034612"", ""label"": ""response to tumor necrosis factor""}}"																											
4543	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	biological_processes[1]	biological_processes	biological_processes			leukocyte migration	GO:0050900	leukocyte migration		"{""preferred_term"": ""leukocyte migration"", ""term"": {""id"": ""GO:0050900"", ""label"": ""leukocyte migration""}}"																											
4544	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	locations[0]	locations	locations			lip	UBERON:0000953	lip		"{""preferred_term"": ""lip"", ""term"": {""id"": ""UBERON:0000953"", ""label"": ""lip""}}"																											
4545	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	locations[1]	locations	locations			oral mucosa	UBERON:0001830	oral mucosa		"{""preferred_term"": ""oral mucosa"", ""term"": {""id"": ""UBERON:0001830"", ""label"": ""oral mucosa""}}"																											
4546	5029	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	0	Non-caseating granulomatous inflammation with epithelioid histiocytes	"Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
"	locations[2]	locations	locations			tongue	UBERON:0001723	tongue		"{""preferred_term"": ""tongue"", ""term"": {""id"": ""UBERON:0001723"", ""label"": ""tongue""}}"																											
4547	5030	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	1	Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF- involvement	"The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-, IFN-, and IL-12/23 signaling. These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
"	cell_types[0]	cell_types	cell_types			epithelioid macrophage	CL:0002150	epithelioid macrophage		"{""preferred_term"": ""epithelioid macrophage"", ""term"": {""id"": ""CL:0002150"", ""label"": ""epithelioid macrophage""}}"																											
4548	5030	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	1	Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF- involvement	"The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-, IFN-, and IL-12/23 signaling. These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
"	biological_processes[0]	biological_processes	biological_processes			response to tumor necrosis factor	GO:0034612	response to tumor necrosis factor		"{""preferred_term"": ""response to tumor necrosis factor"", ""term"": {""id"": ""GO:0034612"", ""label"": ""response to tumor necrosis factor""}}"																											
4549	5030	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	1	Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF- involvement	"The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-, IFN-, and IL-12/23 signaling. These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
"	biological_processes[1]	biological_processes	biological_processes			interferon-gamma-mediated signaling pathway	GO:0060333	interferon-gamma-mediated signaling pathway		"{""preferred_term"": ""interferon-gamma-mediated signaling pathway"", ""term"": {""id"": ""GO:0060333"", ""label"": ""interferon-gamma-mediated signaling pathway""}}"																											
4550	5030	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	1	Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF- involvement	"The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-, IFN-, and IL-12/23 signaling. These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
"	locations[0]	locations	locations			oral mucosa	UBERON:0001830	oral mucosa		"{""preferred_term"": ""oral mucosa"", ""term"": {""id"": ""UBERON:0001830"", ""label"": ""oral mucosa""}}"																											
4551	5031	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	2	Lymphatic dysfunction with intralymphatic histiocytosis and persistent edema	"Lymphatic dysfunction with intralymphatic histiocytosis characterized by dilated lymphatic channels with D2-40/podoplanin-positive endothelium and intraluminal CD68-positive histiocytes contributes to sustained edema. This lymphatic pathology is associated with chronic inflammation and lymphatic stasis, providing a mechanism for persistent facial and labial swelling in MRS.
"	cell_types[0]	cell_types	cell_types			endothelial cell of lymphatic vessel	CL:0002138	endothelial cell of lymphatic vessel		"{""preferred_term"": ""endothelial cell of lymphatic vessel"", ""term"": {""id"": ""CL:0002138"", ""label"": ""endothelial cell of lymphatic vessel""}}"																											
4552	5031	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	2	Lymphatic dysfunction with intralymphatic histiocytosis and persistent edema	"Lymphatic dysfunction with intralymphatic histiocytosis characterized by dilated lymphatic channels with D2-40/podoplanin-positive endothelium and intraluminal CD68-positive histiocytes contributes to sustained edema. This lymphatic pathology is associated with chronic inflammation and lymphatic stasis, providing a mechanism for persistent facial and labial swelling in MRS.
"	biological_processes[0]	biological_processes	biological_processes			lymphatic vessel development	GO:0001945	lymphatic vessel development		"{""preferred_term"": ""lymphatic vessel development"", ""term"": {""id"": ""GO:0001945"", ""label"": ""lymphatic vessel development""}}"																											
4553	5031	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	pathophysiology	2	Lymphatic dysfunction with intralymphatic histiocytosis and persistent edema	"Lymphatic dysfunction with intralymphatic histiocytosis characterized by dilated lymphatic channels with D2-40/podoplanin-positive endothelium and intraluminal CD68-positive histiocytes contributes to sustained edema. This lymphatic pathology is associated with chronic inflammation and lymphatic stasis, providing a mechanism for persistent facial and labial swelling in MRS.
"	locations[0]	locations	locations			lymphatic vessel	UBERON:0001473	lymphatic vessel		"{""preferred_term"": ""lymphatic vessel"", ""term"": {""id"": ""UBERON:0001473"", ""label"": ""lymphatic vessel""}}"																											
4554	5032	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	phenotypes	0	Recurrent facial edema	"Episodic or chronic swelling primarily affecting the lips and face. The edema is typically painless and may persist for hours to days before resolving spontaneously.
"	phenotype_term	phenotype_term	$	Recurrent facial edema	"Episodic or chronic swelling primarily affecting the lips and face. The edema is typically painless and may persist for hours to days before resolving spontaneously.
"	Facial edema	HP:0000282	Facial edema		"{""preferred_term"": ""Facial edema"", ""term"": {""id"": ""HP:0000282"", ""label"": ""Facial edema""}}"																											
4555	5033	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	phenotypes	1	Facial paralysis	"Facial nerve (cranial nerve VII) paralysis, often recurrent and bilateral alternately. Episodes may be intermittent with resolution, distinguishing MRS from other causes of isolated facial paralysis.
"	phenotype_term	phenotype_term	$	Facial paralysis	"Facial nerve (cranial nerve VII) paralysis, often recurrent and bilateral alternately. Episodes may be intermittent with resolution, distinguishing MRS from other causes of isolated facial paralysis.
"	Facial paralysis	HP:0007209	Facial paralysis		"{""preferred_term"": ""Facial paralysis"", ""term"": {""id"": ""HP:0007209"", ""label"": ""Facial paralysis""}}"																											
4556	5034	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	phenotypes	2	Lingual swelling and macroglossia	"Swelling and enlargement of the tongue (macroglossia) with granulomatous changes of oral mucosa. Diffuse mucosal edema with a granular appearance is characteristic.
"	phenotype_term	phenotype_term	$	Lingual swelling and macroglossia	"Swelling and enlargement of the tongue (macroglossia) with granulomatous changes of oral mucosa. Diffuse mucosal edema with a granular appearance is characteristic.
"	Macroglossia	HP:0000158	Macroglossia		"{""preferred_term"": ""Macroglossia"", ""term"": {""id"": ""HP:0000158"", ""label"": ""Macroglossia""}}"																											
4557	5035	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	phenotypes	3	Migraine	"Recurrent migraines with or without aura have been described in rare cases of Melkersson-Rosenthal syndrome, particularly in patients with concurrent SCN1A variants. This represents a rare neurological phenotype suggesting potential overlap between MRS and channelopathy-related disorders.
"	phenotype_term	phenotype_term	$	Migraine	"Recurrent migraines with or without aura have been described in rare cases of Melkersson-Rosenthal syndrome, particularly in patients with concurrent SCN1A variants. This represents a rare neurological phenotype suggesting potential overlap between MRS and channelopathy-related disorders.
"	Migraine	HP:0002076	Migraine		"{""preferred_term"": ""Migraine"", ""term"": {""id"": ""HP:0002076"", ""label"": ""Migraine""}}"																											
4558	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term	treatment_term	$	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	corticosteroid injection	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid injection"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}], ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																						Triamcinolone	NCIT:C901	NCIT:C2259			
4559	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4560	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			triamcinolone	NCIT:C901	Triamcinolone		"{""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}"																											
4561	5037	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	1	Systemic corticosteroids	"Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
"	treatment_term	treatment_term	$	Systemic corticosteroids	"Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
"	corticosteroid therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
4562	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term	treatment_term	$	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Infliximab	NCIT:C1789	NCIT:C2259			
4563	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4564	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			infliximab	NCIT:C1789	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}"																											
4565	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term	treatment_term	$	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"															NCIT:C20401												
4566	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent class	NCIT:C20401	Monoclonal Antibody		"{""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}"																											
4567	5040	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	4	Supportive care	"Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
"	treatment_term	treatment_term	$	Supportive care	"Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4568	5042	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	1	Ion Transport Dysfunction	"Abnormal regulation of fluid and ion homeostasis in the inner ear, particularly involving potassium transport in the stria vascularis and endolymphatic sac, contributes to endolymph accumulation and hydrops formation. Dysregulation of Na+/K+-ATPase, NKCC1, and K+ channels disrupts the electrochemical gradients required for normal endolymphatic fluid balance.
"	biological_processes[0]	biological_processes	biological_processes			potassium ion transport	GO:0006813	potassium ion transport		"{""preferred_term"": ""potassium ion transport"", ""term"": {""id"": ""GO:0006813"", ""label"": ""potassium ion transport""}}"																											
4569	5042	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	1	Ion Transport Dysfunction	"Abnormal regulation of fluid and ion homeostasis in the inner ear, particularly involving potassium transport in the stria vascularis and endolymphatic sac, contributes to endolymph accumulation and hydrops formation. Dysregulation of Na+/K+-ATPase, NKCC1, and K+ channels disrupts the electrochemical gradients required for normal endolymphatic fluid balance.
"	biological_processes[1]	biological_processes	biological_processes			sodium ion transport	GO:0006814	sodium ion transport		"{""preferred_term"": ""sodium ion transport"", ""term"": {""id"": ""GO:0006814"", ""label"": ""sodium ion transport""}}"																											
4570	5042	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	1	Ion Transport Dysfunction	"Abnormal regulation of fluid and ion homeostasis in the inner ear, particularly involving potassium transport in the stria vascularis and endolymphatic sac, contributes to endolymph accumulation and hydrops formation. Dysregulation of Na+/K+-ATPase, NKCC1, and K+ channels disrupts the electrochemical gradients required for normal endolymphatic fluid balance.
"	biological_processes[2]	biological_processes	biological_processes			water homeostasis	GO:0030104	water homeostasis		"{""preferred_term"": ""water homeostasis"", ""term"": {""id"": ""GO:0030104"", ""label"": ""water homeostasis""}}"																											
4571	5043	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	2	Autoimmune and Inflammatory Mechanisms	"Elevated inflammatory markers and autoantibodies have been found in some patients, suggesting that immune-mediated inner ear damage may contribute to disease pathogenesis in a subset of cases. Local (inner ear/endolymphatic sac) and systemic immune activation includes cytokine signaling and NF-B pathway engagement. TWEAK-FN14 receptor signaling and dysregulated Fc receptor polymorphisms contribute to immune complex-mediated injury.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4572	5043	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	2	Autoimmune and Inflammatory Mechanisms	"Elevated inflammatory markers and autoantibodies have been found in some patients, suggesting that immune-mediated inner ear damage may contribute to disease pathogenesis in a subset of cases. Local (inner ear/endolymphatic sac) and systemic immune activation includes cytokine signaling and NF-B pathway engagement. TWEAK-FN14 receptor signaling and dysregulated Fc receptor polymorphisms contribute to immune complex-mediated injury.
"	biological_processes[1]	biological_processes	biological_processes			NF-kB signaling	GO:0038123	nuclear factor-kappa B signaling		"{""preferred_term"": ""NF-kB signaling"", ""term"": {""id"": ""GO:0038123"", ""label"": ""nuclear factor-kappa B signaling""}}"																											
4573	5043	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	2	Autoimmune and Inflammatory Mechanisms	"Elevated inflammatory markers and autoantibodies have been found in some patients, suggesting that immune-mediated inner ear damage may contribute to disease pathogenesis in a subset of cases. Local (inner ear/endolymphatic sac) and systemic immune activation includes cytokine signaling and NF-B pathway engagement. TWEAK-FN14 receptor signaling and dysregulated Fc receptor polymorphisms contribute to immune complex-mediated injury.
"	biological_processes[2]	biological_processes	biological_processes			response to cytokine	GO:0071345	cellular response to cytokine stimulus		"{""preferred_term"": ""response to cytokine"", ""term"": {""id"": ""GO:0071345"", ""label"": ""cellular response to cytokine stimulus""}}"																											
4574	5044	212	Meniere's Disease	Menieres_Disease.yaml	pathophysiology	3	Blood-Labyrinth Barrier Dysfunction and Oxidative Stress	"The blood-labyrinth barrier (BLB) maintains inner-ear homeostasis through tight junctions between endothelial cells and pericytes. In MD, increased vascular permeability and oxidative/nitrosative stress damage the BLB, leading to edema and epithelial dysfunction. Elevated iNOS and nitrotyrosine levels indicate oxidative stress-mediated cascading cellular injury.
"	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
4575	5045	212	Meniere's Disease	Menieres_Disease.yaml	phenotypes	0	Episodic Vertigo	"Recurrent attacks of spinning vertigo lasting 20 minutes to several hours, often accompanied by nausea and vomiting. Episodes are unpredictable and can be severely debilitating.
"	phenotype_term	phenotype_term	$	Episodic Vertigo	"Recurrent attacks of spinning vertigo lasting 20 minutes to several hours, often accompanied by nausea and vomiting. Episodes are unpredictable and can be severely debilitating.
"	paroxysmal vertigo	HP:0010532	Paroxysmal vertigo		"{""preferred_term"": ""paroxysmal vertigo"", ""term"": {""id"": ""HP:0010532"", ""label"": ""Paroxysmal vertigo""}}"																											
4576	5046	212	Meniere's Disease	Menieres_Disease.yaml	phenotypes	1	Sensorineural Hearing Loss	"Fluctuating, progressive hearing loss initially affecting low frequencies, eventually becoming permanent and affecting all frequencies as the disease progresses.
"	phenotype_term	phenotype_term	$	Sensorineural Hearing Loss	"Fluctuating, progressive hearing loss initially affecting low frequencies, eventually becoming permanent and affecting all frequencies as the disease progresses.
"	low-frequency sensorineural hearing impairment	HP:0008573	Low-frequency sensorineural hearing impairment		"{""preferred_term"": ""low-frequency sensorineural hearing impairment"", ""term"": {""id"": ""HP:0008573"", ""label"": ""Low-frequency sensorineural hearing impairment""}}"																											
4577	5047	212	Meniere's Disease	Menieres_Disease.yaml	phenotypes	2	Tinnitus	"Ringing, buzzing, or roaring sounds in the affected ear, often low-pitched and fluctuating. May become constant with disease progression.
"	phenotype_term	phenotype_term	$	Tinnitus	"Ringing, buzzing, or roaring sounds in the affected ear, often low-pitched and fluctuating. May become constant with disease progression.
"	tinnitus	HP:0000360	Tinnitus		"{""preferred_term"": ""tinnitus"", ""term"": {""id"": ""HP:0000360"", ""label"": ""Tinnitus""}}"																											
4578	5048	212	Meniere's Disease	Menieres_Disease.yaml	phenotypes	3	Aural Fullness	"Sensation of pressure or fullness in the affected ear, often preceding or accompanying vertiginous episodes.
"	phenotype_term	phenotype_term	$	Aural Fullness	"Sensation of pressure or fullness in the affected ear, often preceding or accompanying vertiginous episodes.
"	aural fullness	HP:0031704	Abnormal ear physiology		"{""preferred_term"": ""aural fullness"", ""term"": {""id"": ""HP:0031704"", ""label"": ""Abnormal ear physiology""}}"																											
4579	5049	212	Meniere's Disease	Menieres_Disease.yaml	phenotypes	4	Nausea and Vomiting	"Autonomic symptoms accompanying acute vertigo episodes due to vestibular system dysfunction.
"	phenotype_term	phenotype_term	$	Nausea and Vomiting	"Autonomic symptoms accompanying acute vertigo episodes due to vestibular system dysfunction.
"	nausea and vomiting	HP:0002017	Nausea and vomiting		"{""preferred_term"": ""nausea and vomiting"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
4580	5050	212	Meniere's Disease	Menieres_Disease.yaml	treatments	0	Low-Sodium Diet	"Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.
"	treatment_term	treatment_term	$	Low-Sodium Diet	"Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4581	5051	212	Meniere's Disease	Menieres_Disease.yaml	treatments	1	Diuretic Therapy	"Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.
"	treatment_term	treatment_term	$	Diuretic Therapy	"Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4582	5052	212	Meniere's Disease	Menieres_Disease.yaml	treatments	2	Betahistine	"Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.
"	treatment_term	treatment_term	$	Betahistine	"Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4583	5053	212	Meniere's Disease	Menieres_Disease.yaml	treatments	3	Intratympanic Injections	"Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.
"	treatment_term	treatment_term	$	Intratympanic Injections	"Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4584	5054	212	Meniere's Disease	Menieres_Disease.yaml	treatments	4	Vestibular Rehabilitation	"Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.
"	treatment_term	treatment_term	$	Vestibular Rehabilitation	"Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4585	5055	212	Meniere's Disease	Menieres_Disease.yaml	treatments	5	Endolymphatic Sac Surgery	"Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.
"	treatment_term	treatment_term	$	Endolymphatic Sac Surgery	"Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4586	5063	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	histopathology	0	Cutaneous Neuroendocrine Carcinoma	Merkel carcinoma is a highly aggressive cutaneous neuroendocrine carcinoma.	finding_term	finding_term	$	Cutaneous Neuroendocrine Carcinoma	Merkel carcinoma is a highly aggressive cutaneous neuroendocrine carcinoma.	Merkel Cell Carcinoma	NCIT:C9231	Merkel Cell Carcinoma		"{""preferred_term"": ""Merkel Cell Carcinoma"", ""term"": {""id"": ""NCIT:C9231"", ""label"": ""Merkel Cell Carcinoma""}}"																											
4587	5064	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	infectious_agent	0	Merkel Cell Polyomavirus	MCPyV is a small DNA virus that clonally integrates into the host genome in approximately 80% of MCC cases. The virus expresses small T antigen (which promotes cell proliferation) and a truncated large T antigen (which retains RB1 binding but loses replication capacity). Viral T antigens drive tumorigenesis and are essential for tumor maintenance.	infectious_agent_term	infectious_agent_term	$	Merkel Cell Polyomavirus	MCPyV is a small DNA virus that clonally integrates into the host genome in approximately 80% of MCC cases. The virus expresses small T antigen (which promotes cell proliferation) and a truncated large T antigen (which retains RB1 binding but loses replication capacity). Viral T antigens drive tumorigenesis and are essential for tumor maintenance.	Merkel cell polyomavirus	NCBITaxon:493803	Merkel cell polyomavirus		"{""preferred_term"": ""Merkel cell polyomavirus"", ""term"": {""id"": ""NCBITaxon:493803"", ""label"": ""Merkel cell polyomavirus""}}"																											
4588	5065	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	0	Viral T Antigen Oncogenesis	In MCPyV-positive MCC, clonally integrated virus expresses truncated large T antigen (LT) that binds and inactivates RB tumor suppressor protein, releasing E2F transcription factors and driving cell cycle progression. Small T antigen (sT) promotes proliferation through multiple mechanisms including 4E-BP1 hyperphosphorylation and cap-dependent translation.	cell_types[0]	cell_types	cell_types			Merkel cell	CL:0000242	Merkel cell		"{""preferred_term"": ""Merkel cell"", ""term"": {""id"": ""CL:0000242"", ""label"": ""Merkel cell""}}"																											
4589	5065	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	0	Viral T Antigen Oncogenesis	In MCPyV-positive MCC, clonally integrated virus expresses truncated large T antigen (LT) that binds and inactivates RB tumor suppressor protein, releasing E2F transcription factors and driving cell cycle progression. Small T antigen (sT) promotes proliferation through multiple mechanisms including 4E-BP1 hyperphosphorylation and cap-dependent translation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4590	5065	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	0	Viral T Antigen Oncogenesis	In MCPyV-positive MCC, clonally integrated virus expresses truncated large T antigen (LT) that binds and inactivates RB tumor suppressor protein, releasing E2F transcription factors and driving cell cycle progression. Small T antigen (sT) promotes proliferation through multiple mechanisms including 4E-BP1 hyperphosphorylation and cap-dependent translation.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
4591	5066	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	1	RB1 Pathway Inactivation	In virus-positive MCC, viral large T antigen binds and inactivates RB1 protein. In virus-negative MCC, RB1 is frequently inactivated by somatic mutations. In both cases, loss of RB1 function releases E2F transcription factors to drive cell cycle progression and proliferation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4592	5067	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	2	UV-Induced Mutagenesis	In virus-negative MCC (approximately 20%), high levels of UV-induced mutations (C>T transitions at dipyrimidine sites) drive oncogenesis. These tumors have among the highest tumor mutational burdens of any cancer and frequently harbor mutations in TP53, RB1, and other tumor suppressors.	cell_types[0]	cell_types	cell_types			Merkel cell	CL:0000242	Merkel cell		"{""preferred_term"": ""Merkel cell"", ""term"": {""id"": ""CL:0000242"", ""label"": ""Merkel cell""}}"																											
4593	5067	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	2	UV-Induced Mutagenesis	In virus-negative MCC (approximately 20%), high levels of UV-induced mutations (C>T transitions at dipyrimidine sites) drive oncogenesis. These tumors have among the highest tumor mutational burdens of any cancer and frequently harbor mutations in TP53, RB1, and other tumor suppressors.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4594	5067	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	2	UV-Induced Mutagenesis	In virus-negative MCC (approximately 20%), high levels of UV-induced mutations (C>T transitions at dipyrimidine sites) drive oncogenesis. These tumors have among the highest tumor mutational burdens of any cancer and frequently harbor mutations in TP53, RB1, and other tumor suppressors.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
4595	5068	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	3	Uncontrolled Merkel Cell Proliferation	Whether driven by viral T antigens or UV-induced mutations, MCC cells exhibit uncontrolled proliferation. The neuroendocrine differentiation is retained, with expression of characteristic markers including CK20, chromogranin, and synaptophysin.	cell_types[0]	cell_types	cell_types			Merkel cell	CL:0000242	Merkel cell		"{""preferred_term"": ""Merkel cell"", ""term"": {""id"": ""CL:0000242"", ""label"": ""Merkel cell""}}"																											
4596	5068	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	pathophysiology	3	Uncontrolled Merkel Cell Proliferation	Whether driven by viral T antigens or UV-induced mutations, MCC cells exhibit uncontrolled proliferation. The neuroendocrine differentiation is retained, with expression of characteristic markers including CK20, chromogranin, and synaptophysin.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4597	5069	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	phenotypes	0	Neuroendocrine Neoplasm	Merkel cell carcinoma is a high-grade neuroendocrine carcinoma with characteristic small round blue cell histology and neuroendocrine marker expression (synaptophysin, chromogranin, CD56).	phenotype_term	phenotype_term	$	Neuroendocrine Neoplasm	Merkel cell carcinoma is a high-grade neuroendocrine carcinoma with characteristic small round blue cell histology and neuroendocrine marker expression (synaptophysin, chromogranin, CD56).	Neuroendocrine neoplasm	HP:0100634	Neuroendocrine neoplasm		"{""preferred_term"": ""Neuroendocrine neoplasm"", ""term"": {""id"": ""HP:0100634"", ""label"": ""Neuroendocrine neoplasm""}}"																											
4598	5070	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	phenotypes	1	Cutaneous Nodule	Rapidly growing, firm, painless, dome-shaped nodule typically red or violaceous in color. Often described by AEIOU criteria: Asymptomatic, Expanding rapidly, Immunosuppression, Older age, UV-exposed site.	phenotype_term	phenotype_term	$	Cutaneous Nodule	Rapidly growing, firm, painless, dome-shaped nodule typically red or violaceous in color. Often described by AEIOU criteria: Asymptomatic, Expanding rapidly, Immunosuppression, Older age, UV-exposed site.	Neoplasm of the skin	HP:0008069	Neoplasm of the skin		"{""preferred_term"": ""Neoplasm of the skin"", ""term"": {""id"": ""HP:0008069"", ""label"": ""Neoplasm of the skin""}}"																											
4599	5071	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	0	Avelumab	Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting.	treatment_term	treatment_term	$	Avelumab	Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4600	5072	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	1	Pembrolizumab	Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition.	treatment_term	treatment_term	$	Pembrolizumab	Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4601	5073	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	2	Surgical Excision	Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases.	treatment_term	treatment_term	$	Surgical Excision	Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4602	5074	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors.	treatment_term	treatment_term	$	Radiation Therapy	MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4603	5075	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	4	Chemotherapy	MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4604	5078	214	Migraine	Migraine.yaml	clinical_trials	0	NCT07040813	A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4605	5078	214	Migraine	Migraine.yaml	clinical_trials	0	NCT07040813	A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
4606	5079	214	Migraine	Migraine.yaml	clinical_trials	1	NCT06241313	Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4607	5079	214	Migraine	Migraine.yaml	clinical_trials	1	NCT06241313	Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Photophobia	HP:0000613	Photophobia		"{""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}"																											
4608	5079	214	Migraine	Migraine.yaml	clinical_trials	1	NCT06241313	Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase.	target_phenotypes[2]	target_phenotypes	target_phenotypes			Phonophobia	HP:0002183	Phonophobia		"{""preferred_term"": ""Phonophobia"", ""term"": {""id"": ""HP:0002183"", ""label"": ""Phonophobia""}}"																											
4609	5080	214	Migraine	Migraine.yaml	clinical_trials	2	NCT07061847	Study evaluating bilateral middle meningeal artery (MMA) lidocaine infusion as a novel interventional approach for chronic debilitating migraines. Investigates localized anesthesia targeting the pain-sensitive meningeal tissues implicated in migraine pathophysiology.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4610	5096	214	Migraine	Migraine.yaml	pathophysiology	0	Cortical Spreading Depression	"Wave of neuronal depolarization spreading across cortex underlies aura. Triggers activation of trigeminal pathways and may initiate headache phase.
"	biological_processes[0]	biological_processes	biological_processes			Neural Signaling	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Neural Signaling"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
4611	5097	214	Migraine	Migraine.yaml	pathophysiology	1	Trigeminovascular Activation	"Activation of trigeminal nerve fibers innervating meningeal blood vessels releases CGRP and other neuropeptides, causing neurogenic inflammation and pain.
"	biological_processes[0]	biological_processes	biological_processes			Pain Signaling	GO:0048265	response to pain		"{""preferred_term"": ""Pain Signaling"", ""term"": {""id"": ""GO:0048265"", ""label"": ""response to pain""}}"																											
4612	5100	214	Migraine	Migraine.yaml	phenotypes	0	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4613	5101	214	Migraine	Migraine.yaml	phenotypes	1	Photophobia		phenotype_term	phenotype_term	$	Photophobia		Photophobia	HP:0000613	Photophobia		"{""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}"																											
4614	5102	214	Migraine	Migraine.yaml	phenotypes	2	Phonophobia		phenotype_term	phenotype_term	$	Phonophobia		Phonophobia	HP:0002183	Phonophobia		"{""preferred_term"": ""Phonophobia"", ""term"": {""id"": ""HP:0002183"", ""label"": ""Phonophobia""}}"																											
4615	5103	214	Migraine	Migraine.yaml	phenotypes	3	Nausea		phenotype_term	phenotype_term	$	Nausea		Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
4616	5104	214	Migraine	Migraine.yaml	phenotypes	4	Visual Aura		phenotype_term	phenotype_term	$	Visual Aura		Visual Disturbance	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual Disturbance"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
4617	5105	214	Migraine	Migraine.yaml	phenotypes	5	Vertigo		phenotype_term	phenotype_term	$	Vertigo		Vertigo	HP:0002321	Vertigo		"{""preferred_term"": ""Vertigo"", ""term"": {""id"": ""HP:0002321"", ""label"": ""Vertigo""}}"																											
4618	5118	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	0	Anti-U1 RNP Autoimmunity	High-titer antibodies against U1 small nuclear ribonucleoprotein (U1 RNP) are the serological hallmark. These antibodies may directly contribute to disease through immune complex formation and cellular dysfunction.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
4619	5119	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	1	T Cell-Mediated Inflammation	CD4+ T cells recognizing U1 RNP antigens drive the autoimmune response. Th1 and Th17 cytokines contribute to tissue inflammation and damage across multiple organ systems.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
4620	5119	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	1	T Cell-Mediated Inflammation	CD4+ T cells recognizing U1 RNP antigens drive the autoimmune response. Th1 and Th17 cytokines contribute to tissue inflammation and damage across multiple organ systems.	biological_processes[0]	biological_processes	biological_processes			Adaptive Immune Response	GO:0002250	adaptive immune response		"{""preferred_term"": ""Adaptive Immune Response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
4621	5120	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	2	Vascular Dysfunction	Endothelial injury and proliferative vasculopathy similar to systemic sclerosis contribute to Raynaud's phenomenon and may lead to pulmonary arterial hypertension in some patients.	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4622	5120	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	2	Vascular Dysfunction	Endothelial injury and proliferative vasculopathy similar to systemic sclerosis contribute to Raynaud's phenomenon and may lead to pulmonary arterial hypertension in some patients.	biological_processes[0]	biological_processes	biological_processes			Blood Vessel Development	GO:0001568	blood vessel development		"{""preferred_term"": ""Blood Vessel Development"", ""term"": {""id"": ""GO:0001568"", ""label"": ""blood vessel development""}}"																											
4623	5121	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	3	Muscle Inflammation	Inflammatory myopathy with lymphocytic infiltration of skeletal muscle leads to proximal muscle weakness, similar to polymyositis.	cell_types[0]	cell_types	cell_types			Skeletal Muscle Cell	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Cell"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
4624	5121	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	3	Muscle Inflammation	Inflammatory myopathy with lymphocytic infiltration of skeletal muscle leads to proximal muscle weakness, similar to polymyositis.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4625	5122	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	pathophysiology	4	Type I Interferon Signature	Pervasive DNA hypomethylation at interferon-inducible genes drives constitutive type I interferon pathway activation. This epigenetic signature is shared with SLE and Sjogren syndrome but is particularly pronounced in MCTD, contributing to immune dysregulation and disease heterogeneity.	biological_processes[0]	biological_processes	biological_processes			Type I Interferon Signaling Pathway	GO:0060337	type I interferon signaling pathway		"{""preferred_term"": ""Type I Interferon Signaling Pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon signaling pathway""}}"																											
4626	5123	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	phenotypes	0	Raynaud Phenomenon		phenotype_term	phenotype_term	$	Raynaud Phenomenon		Raynaud Phenomenon	HP:0030880	Raynaud phenomenon		"{""preferred_term"": ""Raynaud Phenomenon"", ""term"": {""id"": ""HP:0030880"", ""label"": ""Raynaud phenomenon""}}"																											
4627	5124	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	phenotypes	1	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
4628	5125	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	phenotypes	2	Myopathy		phenotype_term	phenotype_term	$	Myopathy		Myopathy	HP:0003198	Myopathy		"{""preferred_term"": ""Myopathy"", ""term"": {""id"": ""HP:0003198"", ""label"": ""Myopathy""}}"																											
4629	5126	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	phenotypes	3	Edema		phenotype_term	phenotype_term	$	Edema		Edema	HP:0000969	Edema		"{""preferred_term"": ""Edema"", ""term"": {""id"": ""HP:0000969"", ""label"": ""Edema""}}"																											
4630	5133	216	Monkeypox	Monkeypox.yaml	datasets	0		RNA-seq comparing 2022 outbreak strain to endemic MPXV clades (I, IIa, IIb) in human keratinocytes and iPSC-derived colon organoids. Found MPXV replication more productive in keratinocytes and unique hypoxia-related gene expression triggered by 2022 outbreak strain.	organism	organism	$		RNA-seq comparing 2022 outbreak strain to endemic MPXV clades (I, IIa, IIb) in human keratinocytes and iPSC-derived colon organoids. Found MPXV replication more productive in keratinocytes and unique hypoxia-related gene expression triggered by 2022 outbreak strain.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4631	5133	216	Monkeypox	Monkeypox.yaml	datasets	0		RNA-seq comparing 2022 outbreak strain to endemic MPXV clades (I, IIa, IIb) in human keratinocytes and iPSC-derived colon organoids. Found MPXV replication more productive in keratinocytes and unique hypoxia-related gene expression triggered by 2022 outbreak strain.	sample_types[0]	sample_types	sample_types			keratinocyte				"{""cell_type_term"": {""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}, ""preferred_term"": ""keratinocyte""}"																											
4632	5133	216	Monkeypox	Monkeypox.yaml	datasets	0		RNA-seq comparing 2022 outbreak strain to endemic MPXV clades (I, IIa, IIb) in human keratinocytes and iPSC-derived colon organoids. Found MPXV replication more productive in keratinocytes and unique hypoxia-related gene expression triggered by 2022 outbreak strain.	sample_types[0].cell_type_term	sample_types	sample_types[0]			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
4633	5134	216	Monkeypox	Monkeypox.yaml	datasets	1		Microarray analysis of MK2 (monkey kidney) cells infected with monkeypox virus at 3 and 7 hours post-infection to identify host genes essential for viral replication. Examines how orthopoxvirus alters host gene expression targeting immune responses.	organism	organism	$		Microarray analysis of MK2 (monkey kidney) cells infected with monkeypox virus at 3 and 7 hours post-infection to identify host genes essential for viral replication. Examines how orthopoxvirus alters host gene expression targeting immune responses.	rhesus macaque	NCBITaxon:9544	Macaca mulatta		"{""preferred_term"": ""rhesus macaque"", ""term"": {""id"": ""NCBITaxon:9544"", ""label"": ""Macaca mulatta""}}"																											
4634	5134	216	Monkeypox	Monkeypox.yaml	datasets	1		Microarray analysis of MK2 (monkey kidney) cells infected with monkeypox virus at 3 and 7 hours post-infection to identify host genes essential for viral replication. Examines how orthopoxvirus alters host gene expression targeting immune responses.	sample_types[0]	sample_types	sample_types			kidney cell line				"{""preferred_term"": ""kidney cell line"", ""tissue_term"": {""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}}"																											
4635	5134	216	Monkeypox	Monkeypox.yaml	datasets	1		Microarray analysis of MK2 (monkey kidney) cells infected with monkeypox virus at 3 and 7 hours post-infection to identify host genes essential for viral replication. Examines how orthopoxvirus alters host gene expression targeting immune responses.	sample_types[0].tissue_term	sample_types	sample_types[0]			kidney	UBERON:0002113	kidney		"{""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
4636	5146	216	Monkeypox	Monkeypox.yaml	infectious_agent	0	Monkeypox Virus		infectious_agent_term	infectious_agent_term	$	Monkeypox Virus		Monkeypox virus	NCBITaxon:10244	Monkeypox virus		"{""preferred_term"": ""Monkeypox virus"", ""term"": {""id"": ""NCBITaxon:10244"", ""label"": ""Monkeypox virus""}}"																											
4637	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
4638	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	cell_types[1]	cell_types	cell_types			Langerhans cell	CL:0000453	Langerhans cell		"{""preferred_term"": ""Langerhans cell"", ""term"": {""id"": ""CL:0000453"", ""label"": ""Langerhans cell""}}"																											
4639	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	cell_types[2]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
4640	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	locations[0]	locations	locations			skin epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""skin epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
4641	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	locations[1]	locations	locations			mucosa	UBERON:0000344	mucosa		"{""preferred_term"": ""mucosa"", ""term"": {""id"": ""UBERON:0000344"", ""label"": ""mucosa""}}"																											
4642	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	biological_processes[0]	biological_processes	biological_processes			viral entry into host cell	GO:0046718	viral entry into host cell		"{""preferred_term"": ""viral entry into host cell"", ""term"": {""id"": ""GO:0046718"", ""label"": ""viral entry into host cell""}}"																											
4643	5147	216	Monkeypox	Monkeypox.yaml	pathophysiology	0	Viral Entry and Initial Replication	MPXV enters through skin or mucosa via fusion or endocytic pathways, initially infecting keratinocytes and skin-resident antigen-presenting cells. The virus replicates in cytoplasmic factories (Guarnieri bodies) associated with ER.	biological_processes[1]	biological_processes	biological_processes			viral genome replication	GO:0019079	viral genome replication		"{""preferred_term"": ""viral genome replication"", ""term"": {""id"": ""GO:0019079"", ""label"": ""viral genome replication""}}"																											
4644	5148	216	Monkeypox	Monkeypox.yaml	pathophysiology	1	Lymphatic Dissemination	Infected antigen-presenting cells (Langerhans cells, dendritic cells) migrate to draining lymph nodes where early viral amplification occurs, producing characteristic lymphadenopathy.	cell_types[0]	cell_types	cell_types			Langerhans cell	CL:0000453	Langerhans cell		"{""preferred_term"": ""Langerhans cell"", ""term"": {""id"": ""CL:0000453"", ""label"": ""Langerhans cell""}}"																											
4645	5148	216	Monkeypox	Monkeypox.yaml	pathophysiology	1	Lymphatic Dissemination	Infected antigen-presenting cells (Langerhans cells, dendritic cells) migrate to draining lymph nodes where early viral amplification occurs, producing characteristic lymphadenopathy.	cell_types[1]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
4646	5148	216	Monkeypox	Monkeypox.yaml	pathophysiology	1	Lymphatic Dissemination	Infected antigen-presenting cells (Langerhans cells, dendritic cells) migrate to draining lymph nodes where early viral amplification occurs, producing characteristic lymphadenopathy.	locations[0]	locations	locations			lymph node	UBERON:0000029	lymph node		"{""preferred_term"": ""lymph node"", ""term"": {""id"": ""UBERON:0000029"", ""label"": ""lymph node""}}"																											
4647	5148	216	Monkeypox	Monkeypox.yaml	pathophysiology	1	Lymphatic Dissemination	Infected antigen-presenting cells (Langerhans cells, dendritic cells) migrate to draining lymph nodes where early viral amplification occurs, producing characteristic lymphadenopathy.	biological_processes[0]	biological_processes	biological_processes			leukocyte migration	GO:0050900	leukocyte migration		"{""preferred_term"": ""leukocyte migration"", ""term"": {""id"": ""GO:0050900"", ""label"": ""leukocyte migration""}}"																											
4648	5149	216	Monkeypox	Monkeypox.yaml	pathophysiology	2	Hematogenous Spread and Viremia	From lymph nodes, virus disseminates via bloodstream to lymphoid organs, liver, and other tissues. Monocytes can be productively infected, potentially mediating systemic spread.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
4649	5149	216	Monkeypox	Monkeypox.yaml	pathophysiology	2	Hematogenous Spread and Viremia	From lymph nodes, virus disseminates via bloodstream to lymphoid organs, liver, and other tissues. Monocytes can be productively infected, potentially mediating systemic spread.	locations[0]	locations	locations			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
4650	5149	216	Monkeypox	Monkeypox.yaml	pathophysiology	2	Hematogenous Spread and Viremia	From lymph nodes, virus disseminates via bloodstream to lymphoid organs, liver, and other tissues. Monocytes can be productively infected, potentially mediating systemic spread.	locations[1]	locations	locations			spleen	UBERON:0002106	spleen		"{""preferred_term"": ""spleen"", ""term"": {""id"": ""UBERON:0002106"", ""label"": ""spleen""}}"																											
4651	5149	216	Monkeypox	Monkeypox.yaml	pathophysiology	2	Hematogenous Spread and Viremia	From lymph nodes, virus disseminates via bloodstream to lymphoid organs, liver, and other tissues. Monocytes can be productively infected, potentially mediating systemic spread.	locations[2]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
4652	5149	216	Monkeypox	Monkeypox.yaml	pathophysiology	2	Hematogenous Spread and Viremia	From lymph nodes, virus disseminates via bloodstream to lymphoid organs, liver, and other tissues. Monocytes can be productively infected, potentially mediating systemic spread.	biological_processes[0]	biological_processes	biological_processes			virion attachment to host cell	GO:0019062	virion attachment to host cell		"{""preferred_term"": ""virion attachment to host cell"", ""term"": {""id"": ""GO:0019062"", ""label"": ""virion attachment to host cell""}}"																											
4653	5150	216	Monkeypox	Monkeypox.yaml	pathophysiology	3	Viral Factory Formation	MPXV replicates entirely in the host cytoplasm, forming ER-associated viral factories (Guarnieri bodies) where genome replication and virion assembly occur.	biological_processes[0]	biological_processes	biological_processes			viral genome replication	GO:0019079	viral genome replication		"{""preferred_term"": ""viral genome replication"", ""term"": {""id"": ""GO:0019079"", ""label"": ""viral genome replication""}}"																											
4654	5150	216	Monkeypox	Monkeypox.yaml	pathophysiology	3	Viral Factory Formation	MPXV replicates entirely in the host cytoplasm, forming ER-associated viral factories (Guarnieri bodies) where genome replication and virion assembly occur.	biological_processes[1]	biological_processes	biological_processes			virion assembly	GO:0019068	virion assembly		"{""preferred_term"": ""virion assembly"", ""term"": {""id"": ""GO:0019068"", ""label"": ""virion assembly""}}"																											
4655	5151	216	Monkeypox	Monkeypox.yaml	pathophysiology	4	Extracellular Enveloped Virion Formation	The virus produces two infectious forms - intracellular mature virions (IMV) released by cell lysis, and extracellular enveloped virions (EEV) that acquire additional membrane for efficient cell-to-cell spread. Viral proteins F13L, B5R, A34R, and A36R orchestrate EEV formation and actin-based motility.	biological_processes[0]	biological_processes	biological_processes			viral budding via host ESCRT complex	GO:0039702	viral budding via host ESCRT complex		"{""preferred_term"": ""viral budding via host ESCRT complex"", ""term"": {""id"": ""GO:0039702"", ""label"": ""viral budding via host ESCRT complex""}}"																											
4656	5151	216	Monkeypox	Monkeypox.yaml	pathophysiology	4	Extracellular Enveloped Virion Formation	The virus produces two infectious forms - intracellular mature virions (IMV) released by cell lysis, and extracellular enveloped virions (EEV) that acquire additional membrane for efficient cell-to-cell spread. Viral proteins F13L, B5R, A34R, and A36R orchestrate EEV formation and actin-based motility.	biological_processes[1]	biological_processes	biological_processes			viral release from host cell	GO:0019076	viral release from host cell		"{""preferred_term"": ""viral release from host cell"", ""term"": {""id"": ""GO:0019076"", ""label"": ""viral release from host cell""}}"																											
4657	5152	216	Monkeypox	Monkeypox.yaml	pathophysiology	5	Immune Evasion	MPXV encodes multiple immunomodulatory proteins that antagonize innate sensing (TLR, cGAS-STING), block interferon signaling (downregulation of STAT1, JAK2, IRF3), inhibit NF-B activation, and impair dendritic cell maturation. NK cells expand but become functionally impaired.	cell_types[0]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell		"{""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4658	5152	216	Monkeypox	Monkeypox.yaml	pathophysiology	5	Immune Evasion	MPXV encodes multiple immunomodulatory proteins that antagonize innate sensing (TLR, cGAS-STING), block interferon signaling (downregulation of STAT1, JAK2, IRF3), inhibit NF-B activation, and impair dendritic cell maturation. NK cells expand but become functionally impaired.	cell_types[1]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
4659	5152	216	Monkeypox	Monkeypox.yaml	pathophysiology	5	Immune Evasion	MPXV encodes multiple immunomodulatory proteins that antagonize innate sensing (TLR, cGAS-STING), block interferon signaling (downregulation of STAT1, JAK2, IRF3), inhibit NF-B activation, and impair dendritic cell maturation. NK cells expand but become functionally impaired.	biological_processes[0]	biological_processes	biological_processes			type I interferon signaling pathway	GO:0060337	type I interferon signaling pathway		"{""preferred_term"": ""type I interferon signaling pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon signaling pathway""}}"																											
4660	5152	216	Monkeypox	Monkeypox.yaml	pathophysiology	5	Immune Evasion	MPXV encodes multiple immunomodulatory proteins that antagonize innate sensing (TLR, cGAS-STING), block interferon signaling (downregulation of STAT1, JAK2, IRF3), inhibit NF-B activation, and impair dendritic cell maturation. NK cells expand but become functionally impaired.	biological_processes[1]	biological_processes	biological_processes			innate immune response	GO:0045087	innate immune response		"{""preferred_term"": ""innate immune response"", ""term"": {""id"": ""GO:0045087"", ""label"": ""innate immune response""}}"																											
4661	5152	216	Monkeypox	Monkeypox.yaml	pathophysiology	5	Immune Evasion	MPXV encodes multiple immunomodulatory proteins that antagonize innate sensing (TLR, cGAS-STING), block interferon signaling (downregulation of STAT1, JAK2, IRF3), inhibit NF-B activation, and impair dendritic cell maturation. NK cells expand but become functionally impaired.	biological_processes[2]	biological_processes	biological_processes			I-kappaB kinase/NF-kappaB signaling	GO:0007249	I-kappaB kinase/NF-kappaB signaling		"{""preferred_term"": ""I-kappaB kinase/NF-kappaB signaling"", ""term"": {""id"": ""GO:0007249"", ""label"": ""I-kappaB kinase/NF-kappaB signaling""}}"																											
4662	5153	216	Monkeypox	Monkeypox.yaml	pathophysiology	6	Skin Lesion Pathogenesis	Epidermal keratinocytes undergo ballooning degeneration with cytoplasmic viral inclusions. Lesions evolve through characteristic stages - macule, papule, vesicle, pustule, and crust formation over approximately 3 weeks.	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
4663	5153	216	Monkeypox	Monkeypox.yaml	pathophysiology	6	Skin Lesion Pathogenesis	Epidermal keratinocytes undergo ballooning degeneration with cytoplasmic viral inclusions. Lesions evolve through characteristic stages - macule, papule, vesicle, pustule, and crust formation over approximately 3 weeks.	locations[0]	locations	locations			skin epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""skin epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
4664	5154	216	Monkeypox	Monkeypox.yaml	phenotypes	0	Rash		phenotype_term	phenotype_term	$	Rash		Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
4665	5155	216	Monkeypox	Monkeypox.yaml	phenotypes	1	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
4666	5156	216	Monkeypox	Monkeypox.yaml	phenotypes	2	Myalgia		phenotype_term	phenotype_term	$	Myalgia		Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
4667	5157	216	Monkeypox	Monkeypox.yaml	phenotypes	3	Lymphadenopathy		phenotype_term	phenotype_term	$	Lymphadenopathy		Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
4668	5158	216	Monkeypox	Monkeypox.yaml	phenotypes	4	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4669	5159	216	Monkeypox	Monkeypox.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4670	5160	216	Monkeypox	Monkeypox.yaml	phenotypes	6	Nausea		phenotype_term	phenotype_term	$	Nausea		Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
4671	5161	216	Monkeypox	Monkeypox.yaml	phenotypes	7	Vomiting		phenotype_term	phenotype_term	$	Vomiting		Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
4672	5163	216	Monkeypox	Monkeypox.yaml	phenotypes	9	Conjunctivitis		phenotype_term	phenotype_term	$	Conjunctivitis		Conjunctivitis	HP:0000509	Conjunctivitis		"{""preferred_term"": ""Conjunctivitis"", ""term"": {""id"": ""HP:0000509"", ""label"": ""Conjunctivitis""}}"																											
4673	5164	216	Monkeypox	Monkeypox.yaml	phenotypes	10	Pustule		phenotype_term	phenotype_term	$	Pustule		Pustular rash	HP:0033605	Pustular rash		"{""preferred_term"": ""Pustular rash"", ""term"": {""id"": ""HP:0033605"", ""label"": ""Pustular rash""}}"																											
4674	5165	216	Monkeypox	Monkeypox.yaml	phenotypes	11	Vesicles		phenotype_term	phenotype_term	$	Vesicles		Skin vesicle	HP:0200037	Skin vesicle		"{""preferred_term"": ""Skin vesicle"", ""term"": {""id"": ""HP:0200037"", ""label"": ""Skin vesicle""}}"																											
4675	5167	216	Monkeypox	Monkeypox.yaml	phenotypes	13	Scarring		phenotype_term	phenotype_term	$	Scarring		Scarring	HP:0100699	Scarring		"{""preferred_term"": ""Scarring"", ""term"": {""id"": ""HP:0100699"", ""label"": ""Scarring""}}"																											
4676	5168	216	Monkeypox	Monkeypox.yaml	phenotypes	14	Secondary Infections		phenotype_term	phenotype_term	$	Secondary Infections		Secondary Infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Secondary Infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
4677	5175	216	Monkeypox	Monkeypox.yaml	treatments	0	Supportive Care	Management of symptoms including fever, pain, and dehydration.	treatment_term	treatment_term	$	Supportive Care	Management of symptoms including fever, pain, and dehydration.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4678	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	Antiviral Therapy	Investigational treatments such as tecovirimat (TPOXX).	treatment_term	treatment_term	$	Antiviral Therapy	Investigational treatments such as tecovirimat (TPOXX).	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4679	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	Vaccination	Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.	treatment_term	treatment_term	$	Vaccination	Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
4680	5178	216	Monkeypox	Monkeypox.yaml	treatments	3	Cidofovir	DNA polymerase inhibitor considered for severe cases.	treatment_term	treatment_term	$	Cidofovir	DNA polymerase inhibitor considered for severe cases.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4681	5179	216	Monkeypox	Monkeypox.yaml	treatments	4	Brincidofovir	Lipid conjugate of cidofovir explored as oral antiviral candidate.	treatment_term	treatment_term	$	Brincidofovir	Lipid conjugate of cidofovir explored as oral antiviral candidate.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4682	5180	216	Monkeypox	Monkeypox.yaml	treatments	5	Isolation and Infection Control	Preventing the spread through quarantine of infected individuals and proper hygiene practices.	treatment_term	treatment_term	$	Isolation and Infection Control	Preventing the spread through quarantine of infected individuals and proper hygiene practices.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
4683	5183	217	Muenke Syndrome	Muenke_Syndrome.yaml	pathophysiology	0	FGFR3 Gain-of-Function in Cranial Sutures	"The P250R mutation in FGFR3 causes altered ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. In cranial sutures, this leads to premature osteogenic differentiation and suture fusion. The mechanism differs from achondroplasia-type mutations that affect growth plate chondrocytes.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
4684	5183	217	Muenke Syndrome	Muenke_Syndrome.yaml	pathophysiology	0	FGFR3 Gain-of-Function in Cranial Sutures	"The P250R mutation in FGFR3 causes altered ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. In cranial sutures, this leads to premature osteogenic differentiation and suture fusion. The mechanism differs from achondroplasia-type mutations that affect growth plate chondrocytes.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
4685	5183	217	Muenke Syndrome	Muenke_Syndrome.yaml	pathophysiology	0	FGFR3 Gain-of-Function in Cranial Sutures	"The P250R mutation in FGFR3 causes altered ligand binding specificity, allowing aberrant activation by non-cognate FGF ligands. In cranial sutures, this leads to premature osteogenic differentiation and suture fusion. The mechanism differs from achondroplasia-type mutations that affect growth plate chondrocytes.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
4686	5184	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	0	Coronal Craniosynostosis	"Uni- or bilateral coronal suture fusion is the most common feature. Bilateral involvement causes brachycephaly; unilateral causes plagiocephaly.
"	phenotype_term	phenotype_term	$	Coronal Craniosynostosis	"Uni- or bilateral coronal suture fusion is the most common feature. Bilateral involvement causes brachycephaly; unilateral causes plagiocephaly.
"	Coronal craniosynostosis	HP:0004440	Coronal craniosynostosis		"{""preferred_term"": ""Coronal craniosynostosis"", ""term"": {""id"": ""HP:0004440"", ""label"": ""Coronal craniosynostosis""}}"																											
4687	5185	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	1	Midface Retrusion	"Midface hypoplasia may be present but is typically milder than in Crouzon or Apert syndromes.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Midface hypoplasia may be present but is typically milder than in Crouzon or Apert syndromes.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
4688	5186	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	2	Sensorineural Hearing Loss	"Sensorineural hearing loss is common and may be progressive. It is an important feature distinguishing Muenke from other craniosynostosis syndromes.
"	phenotype_term	phenotype_term	$	Sensorineural Hearing Loss	"Sensorineural hearing loss is common and may be progressive. It is an important feature distinguishing Muenke from other craniosynostosis syndromes.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
4689	5187	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	3	Brachydactyly	"Short hands with brachydactyly may occur, though limb involvement is generally mild.
"	phenotype_term	phenotype_term	$	Brachydactyly	"Short hands with brachydactyly may occur, though limb involvement is generally mild.
"	Brachydactyly	HP:0001156	Brachydactyly		"{""preferred_term"": ""Brachydactyly"", ""term"": {""id"": ""HP:0001156"", ""label"": ""Brachydactyly""}}"																											
4690	5188	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	4	Carpal/Tarsal Fusion	"Fusion of carpal or tarsal bones may be seen on radiographs.
"	phenotype_term	phenotype_term	$	Carpal/Tarsal Fusion	"Fusion of carpal or tarsal bones may be seen on radiographs.
"	Carpal synostosis	HP:0009702	Carpal synostosis		"{""preferred_term"": ""Carpal synostosis"", ""term"": {""id"": ""HP:0009702"", ""label"": ""Carpal synostosis""}}"																											
4691	5189	217	Muenke Syndrome	Muenke_Syndrome.yaml	phenotypes	5	Intellectual Disability	"Developmental delay or intellectual disability occurs in a subset of patients, though many have normal intelligence.
"	phenotype_term	phenotype_term	$	Intellectual Disability	"Developmental delay or intellectual disability occurs in a subset of patients, though many have normal intelligence.
"	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
4692	5190	217	Muenke Syndrome	Muenke_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4693	5192	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	biochemical	0	Serum Calcitonin		biomarker_term	biomarker_term	$	Serum Calcitonin		Calcitonin	NCIT:C2281	Calcitonin		"{""preferred_term"": ""Calcitonin"", ""term"": {""id"": ""NCIT:C2281"", ""label"": ""Calcitonin""}}"																											
4694	5199	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	0	RET Oncogene Activation	Germline activating mutations in RET cause ligand-independent receptor dimerization and constitutive tyrosine kinase activation. Unlike tumor suppressor syndromes, only one mutant allele is required (no second hit). This represents a gain-of-function oncogene mechanism.	biological_processes[0]	biological_processes	biological_processes			transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""transmembrane receptor protein tyrosine kinase signaling pathway"", ""term"": {""id"": ""GO:0007169"", ""label"": ""transmembrane receptor protein tyrosine kinase signaling pathway""}}"			INCREASED																								
4695	5199	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	0	RET Oncogene Activation	Germline activating mutations in RET cause ligand-independent receptor dimerization and constitutive tyrosine kinase activation. Unlike tumor suppressor syndromes, only one mutant allele is required (no second hit). This represents a gain-of-function oncogene mechanism.	gene_products[0]	gene_products	gene_products			RET receptor	NCIT:C18539	Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret		"{""preferred_term"": ""RET receptor"", ""term"": {""id"": ""NCIT:C18539"", ""label"": ""Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret""}}"																											
4696	5200	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	1	Downstream Signaling Cascade Activation	Constitutively active RET phosphorylates intracellular substrates and activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways. These promote cell proliferation, survival, and transformation of neuroendocrine cell populations.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4697	5200	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	1	Downstream Signaling Cascade Activation	Constitutively active RET phosphorylates intracellular substrates and activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways. These promote cell proliferation, survival, and transformation of neuroendocrine cell populations.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
4698	5201	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	2	Neuroendocrine Cell Transformation	Constitutive RET signaling drives transformation of neuroendocrine cell populations. C-cell hyperplasia precedes MTC development and serves as a preneoplastic lesion. Similar processes affect adrenal chromaffin cells leading to pheochromocytoma.	cell_types[0]	cell_types	cell_types			parafollicular cell	CL:0000570	parafollicular cell		"{""preferred_term"": ""parafollicular cell"", ""term"": {""id"": ""CL:0000570"", ""label"": ""parafollicular cell""}}"																											
4699	5201	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	2	Neuroendocrine Cell Transformation	Constitutive RET signaling drives transformation of neuroendocrine cell populations. C-cell hyperplasia precedes MTC development and serves as a preneoplastic lesion. Similar processes affect adrenal chromaffin cells leading to pheochromocytoma.	cell_types[1]	cell_types	cell_types			chromaffin cell	CL:0000166	chromaffin cell		"{""preferred_term"": ""chromaffin cell"", ""term"": {""id"": ""CL:0000166"", ""label"": ""chromaffin cell""}}"																											
4700	5201	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	pathophysiology	2	Neuroendocrine Cell Transformation	Constitutive RET signaling drives transformation of neuroendocrine cell populations. C-cell hyperplasia precedes MTC development and serves as a preneoplastic lesion. Similar processes affect adrenal chromaffin cells leading to pheochromocytoma.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4701	5203	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	0	Medullary Thyroid Carcinoma	MTC occurs in virtually all MEN2 patients and is the primary cause of morbidity and mortality. Develops from thyroid C-cells that produce calcitonin. Age of onset depends on RET mutation: MEN2B patients may develop MTC in infancy while some FMTC mutations cause later onset. Prophylactic thyroidectomy timing is based on mutation risk category.	phenotype_term	phenotype_term	$	Medullary Thyroid Carcinoma	MTC occurs in virtually all MEN2 patients and is the primary cause of morbidity and mortality. Develops from thyroid C-cells that produce calcitonin. Age of onset depends on RET mutation: MEN2B patients may develop MTC in infancy while some FMTC mutations cause later onset. Prophylactic thyroidectomy timing is based on mutation risk category.	Medullary thyroid carcinoma	HP:0002865	Medullary thyroid carcinoma		"{""preferred_term"": ""Medullary thyroid carcinoma"", ""term"": {""id"": ""HP:0002865"", ""label"": ""Medullary thyroid carcinoma""}}"																											
4702	5204	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	1	Pheochromocytoma	Pheochromocytomas occur in approximately 50% of MEN2A and MEN2B patients. Often bilateral (50-80%) and may be diagnosed before, concurrent with, or after MTC. Screening with plasma metanephrines is essential before any surgery. Generally benign but can cause hypertensive crises if undiagnosed.	phenotype_term	phenotype_term	$	Pheochromocytoma	Pheochromocytomas occur in approximately 50% of MEN2A and MEN2B patients. Often bilateral (50-80%) and may be diagnosed before, concurrent with, or after MTC. Screening with plasma metanephrines is essential before any surgery. Generally benign but can cause hypertensive crises if undiagnosed.	Pheochromocytoma	HP:0002666	Pheochromocytoma		"{""preferred_term"": ""Pheochromocytoma"", ""term"": {""id"": ""HP:0002666"", ""label"": ""Pheochromocytoma""}}"																											
4703	5205	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	2	Primary Hyperparathyroidism	Primary hyperparathyroidism occurs in 20-30% of MEN2A patients but not in MEN2B. Usually multigland disease. May be asymptomatic or cause hypercalcemia symptoms. Often milder than MEN1-associated hyperparathyroidism.	phenotype_term	phenotype_term	$	Primary Hyperparathyroidism	Primary hyperparathyroidism occurs in 20-30% of MEN2A patients but not in MEN2B. Usually multigland disease. May be asymptomatic or cause hypercalcemia symptoms. Often milder than MEN1-associated hyperparathyroidism.	Hyperparathyroidism	HP:0000843	Hyperparathyroidism		"{""preferred_term"": ""Hyperparathyroidism"", ""term"": {""id"": ""HP:0000843"", ""label"": ""Hyperparathyroidism""}}"																											
4704	5206	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	3	Mucosal Neuromas	Mucosal neuromas of the lips, tongue, and eyelids are characteristic of MEN2B and may be present from early childhood. They produce a distinctive bumpy, nodular appearance of the lips and thickened appearance of the eyelids.	phenotype_term	phenotype_term	$	Mucosal Neuromas	Mucosal neuromas of the lips, tongue, and eyelids are characteristic of MEN2B and may be present from early childhood. They produce a distinctive bumpy, nodular appearance of the lips and thickened appearance of the eyelids.	Ganglioneuroma	HP:0003005	Ganglioneuroma		"{""preferred_term"": ""Ganglioneuroma"", ""term"": {""id"": ""HP:0003005"", ""label"": ""Ganglioneuroma""}}"																											
4705	5207	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	4	Intestinal Ganglioneuromatosis	Diffuse ganglioneuromatosis of the gastrointestinal tract occurs in MEN2B, causing constipation, megacolon, and feeding difficulties from infancy.	phenotype_term	phenotype_term	$	Intestinal Ganglioneuromatosis	Diffuse ganglioneuromatosis of the gastrointestinal tract occurs in MEN2B, causing constipation, megacolon, and feeding difficulties from infancy.	Ganglioneuroma	HP:0003005	Ganglioneuroma		"{""preferred_term"": ""Ganglioneuroma"", ""term"": {""id"": ""HP:0003005"", ""label"": ""Ganglioneuroma""}}"																											
4706	5208	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	phenotypes	5	Marfanoid Habitus	MEN2B patients often have a marfanoid body habitus with tall stature, long limbs, arachnodactyly, pectus excavatum, and high-arched palate. Unlike true Marfan syndrome, they do not have lens dislocation or aortic root dilation.	phenotype_term	phenotype_term	$	Marfanoid Habitus	MEN2B patients often have a marfanoid body habitus with tall stature, long limbs, arachnodactyly, pectus excavatum, and high-arched palate. Unlike true Marfan syndrome, they do not have lens dislocation or aortic root dilation.	Arachnodactyly	HP:0001166	Arachnodactyly		"{""preferred_term"": ""Arachnodactyly"", ""term"": {""id"": ""HP:0001166"", ""label"": ""Arachnodactyly""}}"																											
4707	5209	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	0	Prophylactic Thyroidectomy	Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included.	treatment_term	treatment_term	$	Prophylactic Thyroidectomy	Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4708	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term	treatment_term	$	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}]}"				selpercatinib	CHEBI:175074																						
4709	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			selpercatinib	CHEBI:175074	selpercatinib		"{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}"																											
4710	5211	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	2	Surveillance Protocol	Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy.	treatment_term	treatment_term	$	Surveillance Protocol	Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
4711	5212	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	3	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
4712	5217	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	environmental	0	Vitamin D Deficiency		exposure_term	exposure_term	$	Vitamin D Deficiency		Vitamin D exposure (deficiency)	ECTO:9000133	exposure to vitamin D		"{""preferred_term"": ""Vitamin D exposure (deficiency)"", ""term"": {""id"": ""ECTO:9000133"", ""label"": ""exposure to vitamin D""}}"																											
4713	5218	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	environmental	1	Epstein-Barr Virus Infection		exposure_term	exposure_term	$	Epstein-Barr Virus Infection		Epstein-Barr virus exposure	ECTO:3000001	exposure to virus		"{""preferred_term"": ""Epstein-Barr virus exposure"", ""term"": {""id"": ""ECTO:3000001"", ""label"": ""exposure to virus""}}"																											
4714	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[0]	cell_types	cell_types			Oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""Oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
4715	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4716	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[2]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4717	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[3]	cell_types	cell_types			Microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""Microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
4718	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[4]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
4719	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	cell_types[5]	cell_types	cell_types			CD4-positive, alpha-beta T cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
4720	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	biological_processes[0]	biological_processes	biological_processes			Antigen processing and presentation of peptide antigen via MHC class II	GO:0002495	antigen processing and presentation of peptide antigen via MHC class II		"{""preferred_term"": ""Antigen processing and presentation of peptide antigen via MHC class II"", ""term"": {""id"": ""GO:0002495"", ""label"": ""antigen processing and presentation of peptide antigen via MHC class II""}}"																											
4721	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	biological_processes[1]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
4722	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	biological_processes[2]	biological_processes	biological_processes			Cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway		"{""preferred_term"": ""Cytokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"																											
4723	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	biological_processes[3]	biological_processes	biological_processes			Complement activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
4724	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	biological_processes[4]	biological_processes	biological_processes			Myelination	GO:0042552	myelination		"{""preferred_term"": ""Myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
4725	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[0]	locations	locations			Central nervous system	UBERON:0001017	central nervous system		"{""preferred_term"": ""Central nervous system"", ""term"": {""id"": ""UBERON:0001017"", ""label"": ""central nervous system""}}"																											
4726	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[1]	locations	locations			Meninges	UBERON:0002303	meninges		"{""preferred_term"": ""Meninges"", ""term"": {""id"": ""UBERON:0002303"", ""label"": ""meninges""}}"																											
4727	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[2]	locations	locations			White matter	UBERON:0002316	white matter		"{""preferred_term"": ""White matter"", ""term"": {""id"": ""UBERON:0002316"", ""label"": ""white matter""}}"																											
4728	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[3]	locations	locations			Gray matter	UBERON:0002020	gray matter		"{""preferred_term"": ""Gray matter"", ""term"": {""id"": ""UBERON:0002020"", ""label"": ""gray matter""}}"																											
4729	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[4]	locations	locations			Brain	UBERON:0000955	brain		"{""preferred_term"": ""Brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
4730	5225	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	pathophysiology	0	Demyelination	The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.	locations[5]	locations	locations			Spinal cord	UBERON:0002240	spinal cord		"{""preferred_term"": ""Spinal cord"", ""term"": {""id"": ""UBERON:0002240"", ""label"": ""spinal cord""}}"																											
4731	5228	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	0	Muscle Weakness		phenotype_term	phenotype_term	$	Muscle Weakness		Muscle weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
4732	5230	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4733	5232	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	4	Spasticity		phenotype_term	phenotype_term	$	Spasticity		Spasticity	HP:0001257	Spasticity		"{""preferred_term"": ""Spasticity"", ""term"": {""id"": ""HP:0001257"", ""label"": ""Spasticity""}}"																											
4734	5233	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	5	Cognitive Impairment		phenotype_term	phenotype_term	$	Cognitive Impairment		Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
4735	5236	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	8	Ataxia		phenotype_term	phenotype_term	$	Ataxia		Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
4736	5237	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	9	Optic Neuritis		phenotype_term	phenotype_term	$	Optic Neuritis		Optic neuritis	HP:0100653	Optic neuritis		"{""preferred_term"": ""Optic neuritis"", ""term"": {""id"": ""HP:0100653"", ""label"": ""Optic neuritis""}}"																											
4737	5238	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	phenotypes	10	Dysesthesia		phenotype_term	phenotype_term	$	Dysesthesia		Dysesthesia	HP:0012534	Dysesthesia		"{""preferred_term"": ""Dysesthesia"", ""term"": {""id"": ""HP:0012534"", ""label"": ""Dysesthesia""}}"																											
4738	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	Disease-Modifying Therapies (DMTs)	Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.	treatment_term	treatment_term	$	Disease-Modifying Therapies (DMTs)	Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4739	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	Symptomatic Treatments	Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.	treatment_term	treatment_term	$	Symptomatic Treatments	Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4740	5246	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	2	Physical Therapy and Rehabilitation	Exercise programs and physical therapy to maintain mobility, strength, and function.	treatment_term	treatment_term	$	Physical Therapy and Rehabilitation	Exercise programs and physical therapy to maintain mobility, strength, and function.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4741	5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	Corticosteroids	Used to reduce inflammation and speed recovery during acute exacerbations.	treatment_term	treatment_term	$	Corticosteroids	Used to reduce inflammation and speed recovery during acute exacerbations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4742	5269	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	infectious_agent	0	Severe acute respiratory syndrome coronavirus 2		infectious_agent_term	infectious_agent_term	$	Severe acute respiratory syndrome coronavirus 2		Severe acute respiratory syndrome coronavirus 2	NCBITaxon:2697049	Severe acute respiratory syndrome coronavirus 2		"{""preferred_term"": ""Severe acute respiratory syndrome coronavirus 2"", ""term"": {""id"": ""NCBITaxon:2697049"", ""label"": ""Severe acute respiratory syndrome coronavirus 2""}}"																											
4743	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[0]	genes	genes			IL6	hgnc:6018	IL6		"{""preferred_term"": ""IL6"", ""term"": {""id"": ""hgnc:6018"", ""label"": ""IL6""}}"																											
4744	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[1]	genes	genes			IL10	hgnc:5962	IL10		"{""preferred_term"": ""IL10"", ""term"": {""id"": ""hgnc:5962"", ""label"": ""IL10""}}"																											
4745	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[2]	genes	genes			TNF	hgnc:11892	TNF		"{""preferred_term"": ""TNF"", ""term"": {""id"": ""hgnc:11892"", ""label"": ""TNF""}}"																											
4746	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[3]	genes	genes			IL18	hgnc:5973	IL18		"{""preferred_term"": ""IL18"", ""term"": {""id"": ""hgnc:5973"", ""label"": ""IL18""}}"																											
4747	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[4]	genes	genes			IL1B	hgnc:5992	IL1B		"{""preferred_term"": ""IL1B"", ""term"": {""id"": ""hgnc:5992"", ""label"": ""IL1B""}}"																											
4748	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[5]	genes	genes			IL17A	hgnc:5981	IL17A		"{""preferred_term"": ""IL17A"", ""term"": {""id"": ""hgnc:5981"", ""label"": ""IL17A""}}"																											
4749	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[6]	genes	genes			IFNG	hgnc:5438	IFNG		"{""preferred_term"": ""IFNG"", ""term"": {""id"": ""hgnc:5438"", ""label"": ""IFNG""}}"																											
4750	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[7]	genes	genes			CXCL9	hgnc:10563	CXCL9		"{""preferred_term"": ""CXCL9"", ""term"": {""id"": ""hgnc:10563"", ""label"": ""CXCL9""}}"																											
4751	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	genes[8]	genes	genes			CXCL10	hgnc:10637	CXCL10		"{""preferred_term"": ""CXCL10"", ""term"": {""id"": ""hgnc:10637"", ""label"": ""CXCL10""}}"																											
4752	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	cell_types[0]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
4753	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4754	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	cell_types[2]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell		"{""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4755	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	cell_types[3]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
4756	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4757	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	biological_processes[1]	biological_processes	biological_processes			cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway		"{""preferred_term"": ""cytokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"																											
4758	5271	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	1	Cytokine Storm	Excessive production of pro-inflammatory cytokines, leading to widespread inflammation.	locations[0]	locations	locations			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
4759	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	genes[0]	genes	genes			TRBV11-2	hgnc:12262	TRBV11-2		"{""preferred_term"": ""TRBV11-2"", ""term"": {""id"": ""hgnc:12262"", ""label"": ""TRBV11-2""}}"																											
4760	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	genes[1]	genes	genes			IL18	hgnc:5973	IL18		"{""preferred_term"": ""IL18"", ""term"": {""id"": ""hgnc:5973"", ""label"": ""IL18""}}"																											
4761	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	genes[2]	genes	genes			FAS	hgnc:11920	FAS		"{""preferred_term"": ""FAS"", ""term"": {""id"": ""hgnc:11920"", ""label"": ""FAS""}}"																											
4762	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4763	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	cell_types[1]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell		"{""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4764	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	cell_types[2]	cell_types	cell_types			monocyte	CL:0000576	monocyte		"{""preferred_term"": ""monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
4765	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	biological_processes[0]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
4766	5272	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	2	T-Cell Receptor V21.3 Skewing and IL-18-FAS Activation	Expansion of TRBV11-2 (V21.3+) T cells with skewed differentiation accompanied by elevated IL-18 and CD95/FAS signaling in NK cells and monocytes, creating an innate-adaptive immune activation axis.	biological_processes[1]	biological_processes	biological_processes			immune response-activating signal transduction	GO:0002757	immune response-activating signal transduction		"{""preferred_term"": ""immune response-activating signal transduction"", ""term"": {""id"": ""GO:0002757"", ""label"": ""immune response-activating signal transduction""}}"																											
4767	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	genes[0]	genes	genes			SNX8	hgnc:14972	SNX8		"{""preferred_term"": ""SNX8"", ""term"": {""id"": ""hgnc:14972"", ""label"": ""SNX8""}}"																											
4768	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	genes[1]	genes	genes			MAVS	hgnc:29233	MAVS		"{""preferred_term"": ""MAVS"", ""term"": {""id"": ""hgnc:29233"", ""label"": ""MAVS""}}"																											
4769	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4770	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	cell_types[1]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4771	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	biological_processes[0]	biological_processes	biological_processes			response to virus	GO:0009615	response to virus		"{""preferred_term"": ""response to virus"", ""term"": {""id"": ""GO:0009615"", ""label"": ""response to virus""}}"																											
4772	5273	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	3	Molecular Mimicry and SNX8 Autoimmunity	Cross-reactive immune responses targeting both SARS-CoV-2 nucleocapsid protein and host protein SNX8, with autoantibodies and T cells engaging both epitopes, linking viral infection to autoimmune pathology.	biological_processes[1]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4773	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	genes[0]	genes	genes			CFH	hgnc:4883	CFH		"{""preferred_term"": ""CFH"", ""term"": {""id"": ""hgnc:4883"", ""label"": ""CFH""}}"																											
4774	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	genes[1]	genes	genes			C5	hgnc:1331	C5		"{""preferred_term"": ""C5"", ""term"": {""id"": ""hgnc:1331"", ""label"": ""C5""}}"																											
4775	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	genes[2]	genes	genes			PLA2G2A	hgnc:9031	PLA2G2A		"{""preferred_term"": ""PLA2G2A"", ""term"": {""id"": ""hgnc:9031"", ""label"": ""PLA2G2A""}}"																											
4776	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4777	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
4778	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	biological_processes[1]	biological_processes	biological_processes			blood coagulation	GO:0007596	blood coagulation		"{""preferred_term"": ""blood coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
4779	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	locations[0]	locations	locations			blood vessel	UBERON:0001981	blood vessel		"{""preferred_term"": ""blood vessel"", ""term"": {""id"": ""UBERON:0001981"", ""label"": ""blood vessel""}}"																											
4780	5274	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	4	Endothelial Injury and Complement Activation	Vascular endothelial damage with activation of the complement cascade, elevated soluble C5b-9, and occasional autoantibodies to complement regulators (e.g., Factor H), contributing to thrombotic microangiopathy and vasculopathy.	locations[1]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
4781	5275	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	5	Intestinal Barrier Dysfunction and Antigen Persistence	Persistent SARS-CoV-2 viral antigens in intestinal tissue with increased gut permeability, elevated zonulin and lipopolysaccharide-binding protein (LBP), leading to antigen translocation and elevated mucosal IgA responses.	cell_types[0]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
4782	5275	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	5	Intestinal Barrier Dysfunction and Antigen Persistence	Persistent SARS-CoV-2 viral antigens in intestinal tissue with increased gut permeability, elevated zonulin and lipopolysaccharide-binding protein (LBP), leading to antigen translocation and elevated mucosal IgA responses.	cell_types[1]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
4783	5275	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	5	Intestinal Barrier Dysfunction and Antigen Persistence	Persistent SARS-CoV-2 viral antigens in intestinal tissue with increased gut permeability, elevated zonulin and lipopolysaccharide-binding protein (LBP), leading to antigen translocation and elevated mucosal IgA responses.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4784	5275	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	5	Intestinal Barrier Dysfunction and Antigen Persistence	Persistent SARS-CoV-2 viral antigens in intestinal tissue with increased gut permeability, elevated zonulin and lipopolysaccharide-binding protein (LBP), leading to antigen translocation and elevated mucosal IgA responses.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
4785	5276	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	6	Cardiac Involvement and Myocardial Dysfunction	Direct cardiac involvement with myocarditis, ventricular dysfunction, and occasional coronary artery changes, correlating with T-cell activation signatures and inflammatory markers.	cell_types[0]	cell_types	cell_types			cardiac muscle cell	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiac muscle cell"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
4786	5276	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	6	Cardiac Involvement and Myocardial Dysfunction	Direct cardiac involvement with myocarditis, ventricular dysfunction, and occasional coronary artery changes, correlating with T-cell activation signatures and inflammatory markers.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
4787	5276	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	6	Cardiac Involvement and Myocardial Dysfunction	Direct cardiac involvement with myocarditis, ventricular dysfunction, and occasional coronary artery changes, correlating with T-cell activation signatures and inflammatory markers.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
4788	5276	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	pathophysiology	6	Cardiac Involvement and Myocardial Dysfunction	Direct cardiac involvement with myocarditis, ventricular dysfunction, and occasional coronary artery changes, correlating with T-cell activation signatures and inflammatory markers.	locations[0]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
4789	5277	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	0	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
4790	5278	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	1	Hypotension		phenotype_term	phenotype_term	$	Hypotension		Hypotension	HP:0002615	Hypotension		"{""preferred_term"": ""Hypotension"", ""term"": {""id"": ""HP:0002615"", ""label"": ""Hypotension""}}"																											
4791	5279	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	2	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
4792	5280	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	3	Rash		phenotype_term	phenotype_term	$	Rash		Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
4793	5281	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	4	Coagulopathy		phenotype_term	phenotype_term	$	Coagulopathy		Coagulopathy	HP:0003256	Abnormality of the coagulation cascade		"{""preferred_term"": ""Coagulopathy"", ""term"": {""id"": ""HP:0003256"", ""label"": ""Abnormality of the coagulation cascade""}}"																											
4794	5282	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	5	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4795	5283	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	6	Cough		phenotype_term	phenotype_term	$	Cough		Cough	HP:0012735	Cough		"{""preferred_term"": ""Cough"", ""term"": {""id"": ""HP:0012735"", ""label"": ""Cough""}}"																											
4796	5284	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	7	Myocarditis		phenotype_term	phenotype_term	$	Myocarditis		Myocarditis	HP:0012819	Myocarditis		"{""preferred_term"": ""Myocarditis"", ""term"": {""id"": ""HP:0012819"", ""label"": ""Myocarditis""}}"																											
4797	5285	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	8	Reduced Left Ventricular Ejection Fraction		phenotype_term	phenotype_term	$	Reduced Left Ventricular Ejection Fraction		Reduced left ventricular ejection fraction	HP:0012664	Reduced left ventricular ejection fraction		"{""preferred_term"": ""Reduced left ventricular ejection fraction"", ""term"": {""id"": ""HP:0012664"", ""label"": ""Reduced left ventricular ejection fraction""}}"																											
4798	5286	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	9	Diarrhea		phenotype_term	phenotype_term	$	Diarrhea		Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
4799	5287	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	10	Lymphopenia		phenotype_term	phenotype_term	$	Lymphopenia		Lymphopenia	HP:0001888	Decreased total lymphocyte count		"{""preferred_term"": ""Lymphopenia"", ""term"": {""id"": ""HP:0001888"", ""label"": ""Decreased total lymphocyte count""}}"																											
4800	5288	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	phenotypes	11	Conjunctival Injection		phenotype_term	phenotype_term	$	Conjunctival Injection		Conjunctival hyperemia	HP:0030953	Conjunctival hyperemia		"{""preferred_term"": ""Conjunctival hyperemia"", ""term"": {""id"": ""HP:0030953"", ""label"": ""Conjunctival hyperemia""}}"																											
4801	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	Used to modulate the immune response and reduce inflammation.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	Used to modulate the immune response and reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4802	5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	Corticosteroids	Anti-inflammatory medicines to reduce immune system activity and inflammation.	treatment_term	treatment_term	$	Corticosteroids	Anti-inflammatory medicines to reduce immune system activity and inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4803	5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	Aspirin	Used in cases with high risk of blood clots to prevent thrombotic complications.	treatment_term	treatment_term	$	Aspirin	Used in cases with high risk of blood clots to prevent thrombotic complications.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
4804	5294	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	3	Supportive Care	Including fluids, blood pressure support, and respiratory support as needed.	treatment_term	treatment_term	$	Supportive Care	Including fluids, blood pressure support, and respiratory support as needed.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4805	5301	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	0	Innate Immune Hyperreactivity	Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.	cell_types[0]	cell_types	cell_types			Natural Killer Cell	CL:0000623	natural killer cell		"{""preferred_term"": ""Natural Killer Cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4806	5301	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	0	Innate Immune Hyperreactivity	Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.	cell_types[1]	cell_types	cell_types			Monocyte	CL:0000576	monocyte		"{""preferred_term"": ""Monocyte"", ""term"": {""id"": ""CL:0000576"", ""label"": ""monocyte""}}"																											
4807	5301	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	0	Innate Immune Hyperreactivity	Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.	biological_processes[0]	biological_processes	biological_processes			Innate Immune Response	GO:0045087	innate immune response		"{""preferred_term"": ""Innate Immune Response"", ""term"": {""id"": ""GO:0045087"", ""label"": ""innate immune response""}}"																											
4808	5301	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	0	Innate Immune Hyperreactivity	Exaggerated innate immune responses to microbial ligands, with exercise-triggered increases in proinflammatory signals, complement activation, and oxidative stress that contribute to post-exertional malaise.	biological_processes[1]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
4809	5302	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	1	Natural Killer Cell Dysfunction	Reproducible deficits in natural killer cell cytotoxicity and phenotype abnormalities, representing one of the most consistent biological findings in ME/CFS.	cell_types[0]	cell_types	cell_types			Natural Killer Cell	CL:0000623	natural killer cell		"{""preferred_term"": ""Natural Killer Cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4810	5303	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	2	T-Cell Immunometabolic Dysfunction	CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.	cell_types[0]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
4811	5303	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	2	T-Cell Immunometabolic Dysfunction	CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.	cell_types[1]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
4812	5303	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	2	T-Cell Immunometabolic Dysfunction	CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.	biological_processes[0]	biological_processes	biological_processes			T Cell Activation	GO:0042110	T cell activation		"{""preferred_term"": ""T Cell Activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
4813	5303	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	2	T-Cell Immunometabolic Dysfunction	CD8+ T cells exhibit reduced mitochondrial membrane potential and both CD4+ and CD8+ T cells show impaired glycolysis at rest and after activation, consistent with chronic immune stress and exhaustion.	biological_processes[1]	biological_processes	biological_processes			Glycolysis	GO:0006096	glycolytic process		"{""preferred_term"": ""Glycolysis"", ""term"": {""id"": ""GO:0006096"", ""label"": ""glycolytic process""}}"																											
4814	5304	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	3	Endothelial Dysfunction and Coagulopathy	Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
4815	5304	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	3	Endothelial Dysfunction and Coagulopathy	Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.	cell_types[1]	cell_types	cell_types			Platelet	CL:0000233	platelet		"{""preferred_term"": ""Platelet"", ""term"": {""id"": ""CL:0000233"", ""label"": ""platelet""}}"																											
4816	5304	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	3	Endothelial Dysfunction and Coagulopathy	Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.	biological_processes[0]	biological_processes	biological_processes			Blood Coagulation	GO:0007596	blood coagulation		"{""preferred_term"": ""Blood Coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
4817	5304	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	3	Endothelial Dysfunction and Coagulopathy	Dysregulated endothelial function with coagulation abnormalities, platelet hyperactivation, and microcirculatory impairment leading to tissue hypoperfusion.	biological_processes[1]	biological_processes	biological_processes			Platelet Activation	GO:0030168	platelet activation		"{""preferred_term"": ""Platelet Activation"", ""term"": {""id"": ""GO:0030168"", ""label"": ""platelet activation""}}"																											
4818	5305	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	4	TRPM3 Ion Channel Dysfunction	Impaired TRPM3 calcium channel function in natural killer cells leads to reduced calcium flux, affecting immune and autonomic signaling pathways.	cell_types[0]	cell_types	cell_types			Natural Killer Cell	CL:0000623	natural killer cell		"{""preferred_term"": ""Natural Killer Cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
4819	5305	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	4	TRPM3 Ion Channel Dysfunction	Impaired TRPM3 calcium channel function in natural killer cells leads to reduced calcium flux, affecting immune and autonomic signaling pathways.	biological_processes[0]	biological_processes	biological_processes			Calcium Ion Transmembrane Transport	GO:0070588	calcium ion transmembrane transport		"{""preferred_term"": ""Calcium Ion Transmembrane Transport"", ""term"": {""id"": ""GO:0070588"", ""label"": ""calcium ion transmembrane transport""}}"																											
4820	5306	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	5	Neuroinflammation and Cerebral Hypoperfusion	Brainstem involvement, reduced cerebral blood flow, and neuroinflammatory signaling contribute to cognitive dysfunction and dysautonomia.	locations[0]	locations	locations			Brain	UBERON:0000955	brain		"{""preferred_term"": ""Brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
4821	5306	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	5	Neuroinflammation and Cerebral Hypoperfusion	Brainstem involvement, reduced cerebral blood flow, and neuroinflammatory signaling contribute to cognitive dysfunction and dysautonomia.	locations[1]	locations	locations			Brainstem	UBERON:0002298	brainstem		"{""preferred_term"": ""Brainstem"", ""term"": {""id"": ""UBERON:0002298"", ""label"": ""brainstem""}}"																											
4822	5307	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	6	Mitochondrial Dysfunction	Impaired mitochondrial function and metabolic inflexibility that worsen with exertion, contributing to fatigue and post-exertional malaise.	cellular_components[0]	cellular_components	cellular_components			Mitochondrion	GO:0005739	mitochondrion		"{""preferred_term"": ""Mitochondrion"", ""term"": {""id"": ""GO:0005739"", ""label"": ""mitochondrion""}}"																											
4823	5307	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	6	Mitochondrial Dysfunction	Impaired mitochondrial function and metabolic inflexibility that worsen with exertion, contributing to fatigue and post-exertional malaise.	biological_processes[0]	biological_processes	biological_processes			Fatty Acid Beta-Oxidation	GO:0006635	fatty acid beta-oxidation		"{""preferred_term"": ""Fatty Acid Beta-Oxidation"", ""term"": {""id"": ""GO:0006635"", ""label"": ""fatty acid beta-oxidation""}}"																											
4824	5307	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	pathophysiology	6	Mitochondrial Dysfunction	Impaired mitochondrial function and metabolic inflexibility that worsen with exertion, contributing to fatigue and post-exertional malaise.	biological_processes[1]	biological_processes	biological_processes			Response to Oxidative Stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""Response to Oxidative Stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
4825	5308	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	0	Post-Exertional Malaise	Worsening of symptoms following physical or mental exertion, often delayed by 24-72 hours and lasting days to weeks.	phenotype_term	phenotype_term	$	Post-Exertional Malaise	Worsening of symptoms following physical or mental exertion, often delayed by 24-72 hours and lasting days to weeks.	Post-Exertional Malaise	HP:0030973	Postexertional symptom exacerbation		"{""preferred_term"": ""Post-Exertional Malaise"", ""term"": {""id"": ""HP:0030973"", ""label"": ""Postexertional symptom exacerbation""}}"																											
4826	5309	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	1	Fatigue	Profound, debilitating fatigue not substantially alleviated by rest and not explained by other medical conditions.	phenotype_term	phenotype_term	$	Fatigue	Profound, debilitating fatigue not substantially alleviated by rest and not explained by other medical conditions.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4827	5310	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	2	Cognitive Impairment	Difficulties with concentration, short-term memory, and information processing, commonly described as brain fog.	phenotype_term	phenotype_term	$	Cognitive Impairment	Difficulties with concentration, short-term memory, and information processing, commonly described as brain fog.	Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
4828	5311	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	3	Orthostatic Intolerance	Worsening of symptoms upon assuming and maintaining upright posture, including lightheadedness, dizziness, and presyncope.	phenotype_term	phenotype_term	$	Orthostatic Intolerance	Worsening of symptoms upon assuming and maintaining upright posture, including lightheadedness, dizziness, and presyncope.	Orthostatic Intolerance	HP:0001278	Orthostatic hypotension		"{""preferred_term"": ""Orthostatic Intolerance"", ""term"": {""id"": ""HP:0001278"", ""label"": ""Orthostatic hypotension""}}"																											
4829	5312	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	4	Sleep Disturbance	Unrefreshing sleep despite adequate duration, difficulty falling or staying asleep, and altered sleep architecture.	phenotype_term	phenotype_term	$	Sleep Disturbance	Unrefreshing sleep despite adequate duration, difficulty falling or staying asleep, and altered sleep architecture.	Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
4830	5313	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	5	Myalgia	Muscle pain that may be widespread or localized, often worsened after exertion.	phenotype_term	phenotype_term	$	Myalgia	Muscle pain that may be widespread or localized, often worsened after exertion.	Myalgia	HP:0003326	Myalgia		"{""preferred_term"": ""Myalgia"", ""term"": {""id"": ""HP:0003326"", ""label"": ""Myalgia""}}"																											
4831	5314	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	phenotypes	6	Headache	New or worsened headaches of various types, often triggered by exertion.	phenotype_term	phenotype_term	$	Headache	New or worsened headaches of various types, often triggered by exertion.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4832	5318	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	0	Pacing	Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.	treatment_term	treatment_term	$	Pacing	Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4833	5319	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	1	Symptomatic Treatment	Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.	treatment_term	treatment_term	$	Symptomatic Treatment	Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4834	5320	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	2	Low-Dose Naltrexone	Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.	treatment_term	treatment_term	$	Low-Dose Naltrexone	Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4835	5336	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	pathophysiology	0	Autoantibody-Mediated NMJ Dysfunction	"Autoantibodies (primarily anti-AChR) target the postsynaptic membrane at neuromuscular junctions. Antibodies cause receptor internalization, complement-mediated destruction, and functional blockade, reducing acetylcholine signaling efficiency.
"	cell_types[0]	cell_types	cell_types			Skeletal Muscle Cell	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Cell"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
4836	5336	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	pathophysiology	0	Autoantibody-Mediated NMJ Dysfunction	"Autoantibodies (primarily anti-AChR) target the postsynaptic membrane at neuromuscular junctions. Antibodies cause receptor internalization, complement-mediated destruction, and functional blockade, reducing acetylcholine signaling efficiency.
"	biological_processes[0]	biological_processes	biological_processes			Neuromuscular Transmission	GO:0007274	neuromuscular synaptic transmission		"{""preferred_term"": ""Neuromuscular Transmission"", ""term"": {""id"": ""GO:0007274"", ""label"": ""neuromuscular synaptic transmission""}}"																											
4837	5337	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	pathophysiology	1	Complement Activation	"Anti-AChR antibodies activate the classical complement pathway, leading to membrane attack complex formation and destruction of the postsynaptic membrane architecture.
"	biological_processes[0]	biological_processes	biological_processes			Complement Activation	GO:0006956	complement activation		"{""preferred_term"": ""Complement Activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
4838	5338	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	pathophysiology	2	Thymic Abnormalities	"Thymic hyperplasia (65-75% of patients) or thymoma (10-15%) is common. The thymus may serve as the site of autoimmunization, containing myoid cells expressing AChR that activate autoreactive T cells.
"	cell_types[0]	cell_types	cell_types			Thymic Epithelial Cell	CL:0002293	epithelial cell of thymus		"{""preferred_term"": ""Thymic Epithelial Cell"", ""term"": {""id"": ""CL:0002293"", ""label"": ""epithelial cell of thymus""}}"																											
4839	5339	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	0	Muscle Weakness		phenotype_term	phenotype_term	$	Muscle Weakness		Muscle Weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle Weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
4840	5340	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	1	Ptosis		phenotype_term	phenotype_term	$	Ptosis		Ptosis	HP:0000508	Ptosis		"{""preferred_term"": ""Ptosis"", ""term"": {""id"": ""HP:0000508"", ""label"": ""Ptosis""}}"																											
4841	5341	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	2	Diplopia		phenotype_term	phenotype_term	$	Diplopia		Diplopia	HP:0000651	Diplopia		"{""preferred_term"": ""Diplopia"", ""term"": {""id"": ""HP:0000651"", ""label"": ""Diplopia""}}"																											
4842	5342	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	3	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
4843	5343	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	4	Dysarthria		phenotype_term	phenotype_term	$	Dysarthria		Dysarthria	HP:0001260	Dysarthria		"{""preferred_term"": ""Dysarthria"", ""term"": {""id"": ""HP:0001260"", ""label"": ""Dysarthria""}}"																											
4844	5344	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	5	Respiratory Insufficiency		phenotype_term	phenotype_term	$	Respiratory Insufficiency		Respiratory Insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory Insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
4845	5345	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	phenotypes	6	Fatigability		phenotype_term	phenotype_term	$	Fatigability		Fatigability	HP:0003473	Fatigable weakness		"{""preferred_term"": ""Fatigability"", ""term"": {""id"": ""HP:0003473"", ""label"": ""Fatigable weakness""}}"																											
4846	5346	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	0	Acetylcholinesterase Inhibitors	First-line symptomatic treatment (pyridostigmine).	treatment_term	treatment_term	$	Acetylcholinesterase Inhibitors	First-line symptomatic treatment (pyridostigmine).	acetylcholinesterase inhibitor therapy	MAXO:0000645	acetylcholinesterase inhibitor therapy		"{""preferred_term"": ""acetylcholinesterase inhibitor therapy"", ""term"": {""id"": ""MAXO:0000645"", ""label"": ""acetylcholinesterase inhibitor therapy""}}"																											
4847	5347	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	1	Corticosteroids	Prednisone for immunosuppression, mainstay of therapy.	treatment_term	treatment_term	$	Corticosteroids	Prednisone for immunosuppression, mainstay of therapy.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
4848	5348	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	2	Thymectomy	Surgical removal of thymus, improves outcomes in appropriate patients.	treatment_term	treatment_term	$	Thymectomy	Surgical removal of thymus, improves outcomes in appropriate patients.	thymectomy	MAXO:0001079	thymectomy		"{""preferred_term"": ""thymectomy"", ""term"": {""id"": ""MAXO:0001079"", ""label"": ""thymectomy""}}"																											
4849	5349	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	3	Azathioprine	Steroid-sparing immunosuppressant.	treatment_term	treatment_term	$	Azathioprine	Steroid-sparing immunosuppressant.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4850	5350	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	4	Mycophenolate Mofetil	Alternative immunosuppressant.	treatment_term	treatment_term	$	Mycophenolate Mofetil	Alternative immunosuppressant.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4851	5351	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	5	Rituximab	Anti-CD20 antibody, effective in refractory cases.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 antibody, effective in refractory cases.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4852	5352	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	6	Eculizumab	Complement inhibitor (anti-C5), approved for refractory AChR+ MG.	treatment_term	treatment_term	$	Eculizumab	Complement inhibitor (anti-C5), approved for refractory AChR+ MG.	complement 5 inhibitor agent therapy	MAXO:0001483	complement 5 inhibitor agent therapy		"{""preferred_term"": ""complement 5 inhibitor agent therapy"", ""term"": {""id"": ""MAXO:0001483"", ""label"": ""complement 5 inhibitor agent therapy""}}"																											
4853	5356	223	Mycetoma	Mycetoma.yaml	phenotypes	0	Subcutaneous nodule		phenotype_term	phenotype_term	$	Subcutaneous nodule		Subcutaneous nodule	HP:0001482	Subcutaneous nodule		"{""preferred_term"": ""Subcutaneous nodule"", ""term"": {""id"": ""HP:0001482"", ""label"": ""Subcutaneous nodule""}}"																											
4854	5360	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	histopathology	0	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	finding_term	finding_term	$	Myeloblast Predominance	Acute myeloid leukemia features increased myeloblasts in blood or marrow.	Myeloblasts Present	NCIT:C155995	Myeloblasts Present		"{""preferred_term"": ""Myeloblasts Present"", ""term"": {""id"": ""NCIT:C155995"", ""label"": ""Myeloblasts Present""}}"																											
4855	5361	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	0	NPM1 Cytoplasmic Mislocalization	NPM1 is a nucleolar phosphoprotein that shuttles between the nucleolus, nucleoplasm, and cytoplasm. Wild-type NPM1 localizes predominantly to nucleoli due to a C-terminal nucleolar localization signal. Mutations in exon 12 disrupt this signal and create a nuclear export signal, causing aberrant cytoplasmic accumulation (NPMc+). This depletes nucleolar NPM1, disrupting its normal functions.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
4856	5362	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	1	ARF-p53 Pathway Disruption	Wild-type NPM1 stabilizes the ARF tumor suppressor in the nucleolus. Cytoplasmic NPM1 delocalizes ARF, reducing its ability to inhibit MDM2 and stabilize p53. This impairs the p53-mediated response to oncogenic stress and DNA damage.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
4857	5363	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	2	HOX Gene Dysregulation	NPM1-mutated AML consistently shows upregulation of HOXA and HOXB cluster genes, including HOXA9 and MEIS1. These transcription factors promote self-renewal of leukemic cells and block normal myeloid differentiation. This HOX signature is a defining feature of NPM1-mutated AML.	cell_types[0]	cell_types	cell_types			myeloblast	CL:0000835	myeloblast		"{""preferred_term"": ""myeloblast"", ""term"": {""id"": ""CL:0000835"", ""label"": ""myeloblast""}}"																											
4858	5363	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	2	HOX Gene Dysregulation	NPM1-mutated AML consistently shows upregulation of HOXA and HOXB cluster genes, including HOXA9 and MEIS1. These transcription factors promote self-renewal of leukemic cells and block normal myeloid differentiation. This HOX signature is a defining feature of NPM1-mutated AML.	biological_processes[0]	biological_processes	biological_processes			myeloid cell differentiation	GO:0030099	myeloid cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myeloid cell differentiation"", ""term"": {""id"": ""GO:0030099"", ""label"": ""myeloid cell differentiation""}}"			DECREASED																								
4859	5364	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	3	Impaired Tumor Suppression	The combined effects of ARF-p53 pathway disruption and loss of NPM1 nucleolar functions impair the cell's ability to respond to oncogenic signals with appropriate growth arrest or apoptosis.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
4860	5365	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	4	Differentiation Block	NPM1-mutated AML blasts show a characteristic partial differentiation with monocytic features. The HOX gene signature and NPM1 cytoplasmic localization maintain the cells in a progenitor state while allowing some differentiation along the myelomonocytic lineage.	cell_types[0]	cell_types	cell_types			myeloid cell	CL:0000763	myeloid cell		"{""preferred_term"": ""myeloid cell"", ""term"": {""id"": ""CL:0000763"", ""label"": ""myeloid cell""}}"																											
4861	5365	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	pathophysiology	4	Differentiation Block	NPM1-mutated AML blasts show a characteristic partial differentiation with monocytic features. The HOX gene signature and NPM1 cytoplasmic localization maintain the cells in a progenitor state while allowing some differentiation along the myelomonocytic lineage.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
4862	5366	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	phenotypes	0	Leukocytosis	Elevated white blood cell count, though less pronounced than in FLT3-ITD mutated AML.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count, though less pronounced than in FLT3-ITD mutated AML.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
4863	5367	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	phenotypes	1	Anemia	Normocytic normochromic anemia from bone marrow replacement and ineffective erythropoiesis.	phenotype_term	phenotype_term	$	Anemia	Normocytic normochromic anemia from bone marrow replacement and ineffective erythropoiesis.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
4864	5368	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	phenotypes	2	Thrombocytopenia	Low platelet count due to bone marrow infiltration by leukemic blasts.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count due to bone marrow infiltration by leukemic blasts.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
4865	5369	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	phenotypes	3	Fatigue	Fatigue related to anemia and systemic effects of leukemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue related to anemia and systemic effects of leukemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4866	5370	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	phenotypes	4	Recurrent Infections	Increased infection susceptibility from neutropenia and dysfunctional myeloid cells.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased infection susceptibility from neutropenia and dysfunctional myeloid cells.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
4867	5371	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	0	Intensive Chemotherapy (7+3)	Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4868	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term	treatment_term	$	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
4869	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
4870	5373	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
4871	5374	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	3	MRD-Guided Therapy	NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse.	treatment_term	treatment_term	$	MRD-Guided Therapy	NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse.	genetic testing	MAXO:0000127	genetic testing		"{""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}"																											
4872	5378	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	histopathology	0	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	finding_term	finding_term	$	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	Melanocytic Neoplasm	NCIT:C7058	Melanocytic Neoplasm		"{""preferred_term"": ""Melanocytic Neoplasm"", ""term"": {""id"": ""NCIT:C7058"", ""label"": ""Melanocytic Neoplasm""}}"																											
4873	5379	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	0	NRAS Q61 Oncogenic Mutation	NRAS mutations at codon 61 (Q61R, Q61K, Q61L) impair intrinsic GTPase activity and reduce sensitivity to GTPase-activating proteins (GAPs), resulting in constitutively GTP-bound active NRAS. This locks the protein in its active conformation, continuously stimulating downstream effector pathways.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
4874	5379	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	0	NRAS Q61 Oncogenic Mutation	NRAS mutations at codon 61 (Q61R, Q61K, Q61L) impair intrinsic GTPase activity and reduce sensitivity to GTPase-activating proteins (GAPs), resulting in constitutively GTP-bound active NRAS. This locks the protein in its active conformation, continuously stimulating downstream effector pathways.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
4875	5380	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	1	Dual MAPK and PI3K Pathway Activation	Unlike BRAF mutations that primarily activate MAPK signaling, oncogenic NRAS simultaneously activates both the RAF-MEK-ERK (MAPK) pathway and the PI3K-AKT pathway. This dual pathway activation contributes to the aggressive biology and relative treatment resistance of NRAS-mutant melanoma.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4876	5381	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK pathway activation downstream of mutant NRAS drives melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle entry and progression.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
4877	5381	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK pathway activation downstream of mutant NRAS drives melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle entry and progression.	locations[0]	locations	locations			skin of body	UBERON:0002097	skin of body		"{""preferred_term"": ""skin of body"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
4878	5381	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	2	Uncontrolled Melanocyte Proliferation	Constitutive MAPK pathway activation downstream of mutant NRAS drives melanocyte proliferation through ERK-mediated transcriptional programs promoting cell cycle entry and progression.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4879	5382	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	pathophysiology	3	Enhanced Cell Survival	PI3K-AKT pathway activation downstream of NRAS promotes melanoma cell survival through phosphorylation and inactivation of pro-apoptotic proteins, activation of mTOR signaling, and metabolic reprogramming. This contributes to therapy resistance and the need for combination treatment strategies.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
4880	5383	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	phenotypes	0	Cutaneous Melanoma	Melanoma arising from cutaneous melanocytes. NRAS-mutant melanomas are typically associated with chronic sun damage sites and may present with thicker primary tumors compared to BRAF-mutant disease.	phenotype_term	phenotype_term	$	Cutaneous Melanoma	Melanoma arising from cutaneous melanocytes. NRAS-mutant melanomas are typically associated with chronic sun damage sites and may present with thicker primary tumors compared to BRAF-mutant disease.	Cutaneous melanoma	HP:0012056	Cutaneous melanoma		"{""preferred_term"": ""Cutaneous melanoma"", ""term"": {""id"": ""HP:0012056"", ""label"": ""Cutaneous melanoma""}}"																											
4881	5384	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	phenotypes	1	Pigmented Skin Lesion	Primary tumor presenting as an asymmetric pigmented lesion, often arising on chronically sun-damaged skin in older patients.	phenotype_term	phenotype_term	$	Pigmented Skin Lesion	Primary tumor presenting as an asymmetric pigmented lesion, often arising on chronically sun-damaged skin in older patients.	Neoplasm of the skin	HP:0008069	Neoplasm of the skin		"{""preferred_term"": ""Neoplasm of the skin"", ""term"": {""id"": ""HP:0008069"", ""label"": ""Neoplasm of the skin""}}"																											
4882	5385	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	0	MEK Inhibitors	MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype.	treatment_term	treatment_term	$	MEK Inhibitors	MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4883	5386	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	1	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4884	5387	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	2	Combination Targeted Therapy	Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma.	treatment_term	treatment_term	$	Combination Targeted Therapy	Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4885	5395	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	histopathology	0	Histology-Agnostic Solid Tumors	NTRK gene fusions are found across cancer types.	finding_term	finding_term	$	Histology-Agnostic Solid Tumors	NTRK gene fusions are found across cancer types.	Malignant Solid Neoplasm	NCIT:C132146	Malignant Solid Neoplasm		"{""preferred_term"": ""Malignant Solid Neoplasm"", ""term"": {""id"": ""NCIT:C132146"", ""label"": ""Malignant Solid Neoplasm""}}"																											
4886	5396	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	0	NTRK Gene Fusion and Constitutive TRK Activation	Chromosomal rearrangements fuse the kinase domain of NTRK genes with various upstream partners that provide dimerization domains. This creates constitutively active chimeric TRK proteins that signal independently of neurotrophin ligands.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
4887	5397	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	Constitutive TRK activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting uncontrolled cell proliferation. This is a major effector pathway of TRK-mediated oncogenesis.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4888	5398	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	TRK activation recruits PI3K and stimulates AKT-mTOR signaling, promoting cell survival and resistance to apoptosis. Combined with MAPK activation, this drives aggressive tumor growth.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
4889	5399	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	phenotypes	0	Tumor Growth	Clinical presentation depends on tumor type and location. NTRK fusions can occur in virtually any solid tumor type.	phenotype_term	phenotype_term	$	Tumor Growth	Clinical presentation depends on tumor type and location. NTRK fusions can occur in virtually any solid tumor type.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
4890	5400	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	phenotypes	1	Fatigue	Constitutional symptoms are common in advanced disease regardless of tumor histology.	phenotype_term	phenotype_term	$	Fatigue	Constitutional symptoms are common in advanced disease regardless of tumor histology.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
4891	5401	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	0	Larotrectinib	Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.	treatment_term	treatment_term	$	Larotrectinib	Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4892	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term	treatment_term	$	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}]}"				entrectinib	CHEBI:195558																						
4893	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			entrectinib	CHEBI:195558	entrectinib		"{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}"																											
4894	5403	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	2	Repotrectinib	Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.	treatment_term	treatment_term	$	Repotrectinib	Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4895	5413	227	Narcolepsy	Narcolepsy.yaml	pathophysiology	0	Orexin/Hypocretin Deficiency	"Loss of orexin-producing neurons in the lateral hypothalamus leads to instability of sleep-wake states. Orexin normally promotes and stabilizes wakefulness. In Type 1 narcolepsy, >90% of orexin neurons are destroyed, likely through autoimmune mechanisms.
"	cell_types[0]	cell_types	cell_types			Orexin Neuron	CL:0011109	hypocretin-secreting neuron		"{""preferred_term"": ""Orexin Neuron"", ""term"": {""id"": ""CL:0011109"", ""label"": ""hypocretin-secreting neuron""}}"																											
4896	5413	227	Narcolepsy	Narcolepsy.yaml	pathophysiology	0	Orexin/Hypocretin Deficiency	"Loss of orexin-producing neurons in the lateral hypothalamus leads to instability of sleep-wake states. Orexin normally promotes and stabilizes wakefulness. In Type 1 narcolepsy, >90% of orexin neurons are destroyed, likely through autoimmune mechanisms.
"	biological_processes[0]	biological_processes	biological_processes			Sleep-Wake Regulation	GO:0042745	circadian sleep/wake cycle		"{""preferred_term"": ""Sleep-Wake Regulation"", ""term"": {""id"": ""GO:0042745"", ""label"": ""circadian sleep/wake cycle""}}"																											
4897	5414	227	Narcolepsy	Narcolepsy.yaml	pathophysiology	1	Autoimmune Destruction	"Strong HLA-DQB1*06:02 association suggests autoimmune etiology. T-cell mediated destruction of hypocretin neurons is the leading hypothesis. Environmental triggers (infections, H1N1 vaccination) may initiate the autoimmune response in genetically susceptible individuals.
"	biological_processes[0]	biological_processes	biological_processes			Autoimmune Response	GO:0002460	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains		"{""preferred_term"": ""Autoimmune Response"", ""term"": {""id"": ""GO:0002460"", ""label"": ""adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains""}}"																											
4898	5415	227	Narcolepsy	Narcolepsy.yaml	phenotypes	0	Excessive Daytime Sleepiness		phenotype_term	phenotype_term	$	Excessive Daytime Sleepiness		Excessive Daytime Sleepiness	HP:0002329	Drowsiness		"{""preferred_term"": ""Excessive Daytime Sleepiness"", ""term"": {""id"": ""HP:0002329"", ""label"": ""Drowsiness""}}"																											
4899	5416	227	Narcolepsy	Narcolepsy.yaml	phenotypes	1	Cataplexy		phenotype_term	phenotype_term	$	Cataplexy		Cataplexy	HP:0002524	Cataplexy		"{""preferred_term"": ""Cataplexy"", ""term"": {""id"": ""HP:0002524"", ""label"": ""Cataplexy""}}"																											
4900	5417	227	Narcolepsy	Narcolepsy.yaml	phenotypes	2	Sleep Paralysis		phenotype_term	phenotype_term	$	Sleep Paralysis		Sleep Paralysis	HP:0025233	Sleep paralysis		"{""preferred_term"": ""Sleep Paralysis"", ""term"": {""id"": ""HP:0025233"", ""label"": ""Sleep paralysis""}}"																											
4901	5418	227	Narcolepsy	Narcolepsy.yaml	phenotypes	3	Hypnagogic Hallucinations		phenotype_term	phenotype_term	$	Hypnagogic Hallucinations		Hypnagogic Hallucination	HP:0002519	Hypnagogic hallucination		"{""preferred_term"": ""Hypnagogic Hallucination"", ""term"": {""id"": ""HP:0002519"", ""label"": ""Hypnagogic hallucination""}}"																											
4902	5419	227	Narcolepsy	Narcolepsy.yaml	phenotypes	4	Disrupted Nighttime Sleep		phenotype_term	phenotype_term	$	Disrupted Nighttime Sleep		Sleep Disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep Disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
4903	5420	227	Narcolepsy	Narcolepsy.yaml	treatments	0	Sodium Oxybate	First-line for cataplexy and daytime sleepiness, improves nighttime sleep.	treatment_term	treatment_term	$	Sodium Oxybate	First-line for cataplexy and daytime sleepiness, improves nighttime sleep.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4904	5421	227	Narcolepsy	Narcolepsy.yaml	treatments	1	Modafinil	Wake-promoting agent for excessive daytime sleepiness.	treatment_term	treatment_term	$	Modafinil	Wake-promoting agent for excessive daytime sleepiness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4905	5422	227	Narcolepsy	Narcolepsy.yaml	treatments	2	Pitolisant	Histamine H3 receptor antagonist, promotes wakefulness.	treatment_term	treatment_term	$	Pitolisant	Histamine H3 receptor antagonist, promotes wakefulness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4906	5423	227	Narcolepsy	Narcolepsy.yaml	treatments	3	Solriamfetol	Dopamine/norepinephrine reuptake inhibitor for sleepiness.	treatment_term	treatment_term	$	Solriamfetol	Dopamine/norepinephrine reuptake inhibitor for sleepiness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4907	5424	227	Narcolepsy	Narcolepsy.yaml	treatments	4	Amphetamines	Traditional stimulants (amphetamine, methylphenidate).	treatment_term	treatment_term	$	Amphetamines	Traditional stimulants (amphetamine, methylphenidate).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4908	5425	227	Narcolepsy	Narcolepsy.yaml	treatments	5	Antidepressants	SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).	treatment_term	treatment_term	$	Antidepressants	SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4909	5426	227	Narcolepsy	Narcolepsy.yaml	treatments	6	Scheduled Naps	Short planned naps can improve alertness.	treatment_term	treatment_term	$	Scheduled Naps	Short planned naps can improve alertness.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
4910	5435	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	histopathology	0	Squamous Cell Carcinoma	Nasopharyngeal squamous cell carcinoma is an uncommon subtype of NPC.	finding_term	finding_term	$	Squamous Cell Carcinoma	Nasopharyngeal squamous cell carcinoma is an uncommon subtype of NPC.	Squamous Cell Carcinoma	NCIT:C2929	Squamous Cell Carcinoma		"{""preferred_term"": ""Squamous Cell Carcinoma"", ""term"": {""id"": ""NCIT:C2929"", ""label"": ""Squamous Cell Carcinoma""}}"																											
4911	5436	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	infectious_agent	0	Epstein-Barr Virus (EBV)	EBV is present in virtually all non-keratinizing NPC and is essential for carcinogenesis. The virus establishes latent infection with expression of specific viral proteins (LMP1, LMP2, EBNA1) and non-coding RNAs (EBERs, BARTs) that drive oncogenic transformation.	infectious_agent_term	infectious_agent_term	$	Epstein-Barr Virus (EBV)	EBV is present in virtually all non-keratinizing NPC and is essential for carcinogenesis. The virus establishes latent infection with expression of specific viral proteins (LMP1, LMP2, EBNA1) and non-coding RNAs (EBERs, BARTs) that drive oncogenic transformation.	Epstein-Barr virus	NCBITaxon:10376	human gammaherpesvirus 4		"{""preferred_term"": ""Epstein-Barr virus"", ""term"": {""id"": ""NCBITaxon:10376"", ""label"": ""human gammaherpesvirus 4""}}"																											
4912	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	cell_types[0]	cell_types	cell_types			squamous epithelial cell	CL:0000076	squamous epithelial cell		"{""preferred_term"": ""squamous epithelial cell"", ""term"": {""id"": ""CL:0000076"", ""label"": ""squamous epithelial cell""}}"																											
4913	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	biological_processes[0]	biological_processes	biological_processes			NF-kappaB signaling	GO:0038061	NIK/NF-kappaB signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""NF-kappaB signaling"", ""term"": {""id"": ""GO:0038061"", ""label"": ""NIK/NF-kappaB signaling""}}"			INCREASED																								
4914	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4915	5437	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	0	EBV Latent Membrane Protein 1 (LMP1) Signaling	LMP1 is the primary EBV oncoprotein in NPC, functioning as a constitutively active receptor that mimics CD40 signaling. LMP1 activates NF-kB, MAPK, and PI3K/AKT pathways, promoting cell survival, proliferation, and epithelial-mesenchymal transition.	locations[0]	locations	locations			nasopharynx	UBERON:0001728	nasopharynx		"{""preferred_term"": ""nasopharynx"", ""term"": {""id"": ""UBERON:0001728"", ""label"": ""nasopharynx""}}"																											
4916	5438	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	1	LMP2A-Mediated B Cell Receptor Mimicry	LMP2A is a viral protein that mimics an activated B cell receptor, providing survival signals that prevent viral lytic reactivation and maintain latency. In epithelial cells, LMP2A activates PI3K/AKT and promotes cell motility.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
4917	5439	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	2	EBNA1-Mediated Viral Maintenance	EBNA1 is essential for EBV genome replication and maintenance during latency. It tethers viral episomes to host chromosomes and contributes to genomic instability by inducing oxidative stress and interfering with DNA damage responses.	biological_processes[0]	biological_processes	biological_processes			viral genome replication	GO:0019079	viral genome replication		"{""preferred_term"": ""viral genome replication"", ""term"": {""id"": ""GO:0019079"", ""label"": ""viral genome replication""}}"																											
4918	5440	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	3	Host Genetic Susceptibility	Specific HLA haplotypes, particularly HLA-A2, are associated with increased NPC risk in endemic populations. Additional susceptibility loci have been identified in GWAS studies, including genes involved in immune function and DNA repair.	genes[0]	genes	genes			HLA-A				"{""preferred_term"": ""HLA-A""}"																											
4919	5441	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	pathophysiology	4	Immune Evasion	EBV-infected NPC cells evade immune surveillance through multiple mechanisms including PD-L1 upregulation, suppression of antigen presentation, and recruitment of regulatory T cells. This provides rationale for immune checkpoint inhibition.	biological_processes[0]	biological_processes	biological_processes			negative regulation of T cell mediated immunity	GO:0002710	negative regulation of T cell mediated immunity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""negative regulation of T cell mediated immunity"", ""term"": {""id"": ""GO:0002710"", ""label"": ""negative regulation of T cell mediated immunity""}}"			INCREASED																								
4920	5442	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	0	Cervical Lymphadenopathy	Painless neck mass from nodal metastases is the most common presenting symptom (60-90% of cases). Often the primary tumor is small and asymptomatic while nodal disease is prominent.	phenotype_term	phenotype_term	$	Cervical Lymphadenopathy	Painless neck mass from nodal metastases is the most common presenting symptom (60-90% of cases). Often the primary tumor is small and asymptomatic while nodal disease is prominent.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
4921	5443	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	1	Nasal Obstruction	Nasal stuffiness and obstruction occur when the tumor enlarges in the nasopharynx, blocking the posterior nares.	phenotype_term	phenotype_term	$	Nasal Obstruction	Nasal stuffiness and obstruction occur when the tumor enlarges in the nasopharynx, blocking the posterior nares.	Nasal congestion	HP:0001742	Nasal congestion		"{""preferred_term"": ""Nasal congestion"", ""term"": {""id"": ""HP:0001742"", ""label"": ""Nasal congestion""}}"																											
4922	5444	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	2	Hearing Loss	Conductive hearing loss and middle ear effusion occur due to eustachian tube obstruction by the nasopharyngeal tumor.	phenotype_term	phenotype_term	$	Hearing Loss	Conductive hearing loss and middle ear effusion occur due to eustachian tube obstruction by the nasopharyngeal tumor.	Conductive hearing impairment	HP:0000405	Conductive hearing impairment		"{""preferred_term"": ""Conductive hearing impairment"", ""term"": {""id"": ""HP:0000405"", ""label"": ""Conductive hearing impairment""}}"																											
4923	5445	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	3	Epistaxis	Nosebleeds may occur from tumor surface ulceration or erosion into blood vessels.	phenotype_term	phenotype_term	$	Epistaxis	Nosebleeds may occur from tumor surface ulceration or erosion into blood vessels.	Epistaxis	HP:0000421	Epistaxis		"{""preferred_term"": ""Epistaxis"", ""term"": {""id"": ""HP:0000421"", ""label"": ""Epistaxis""}}"																											
4924	5446	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	4	Cranial Nerve Involvement	Skull base invasion can cause cranial nerve palsies, particularly CN V (trigeminal) causing facial numbness, and CN VI (abducens) causing diplopia. Advanced tumors may involve CN IX-XII.	phenotype_term	phenotype_term	$	Cranial Nerve Involvement	Skull base invasion can cause cranial nerve palsies, particularly CN V (trigeminal) causing facial numbness, and CN VI (abducens) causing diplopia. Advanced tumors may involve CN IX-XII.	Cranial nerve paralysis	HP:0006824	Cranial nerve paralysis		"{""preferred_term"": ""Cranial nerve paralysis"", ""term"": {""id"": ""HP:0006824"", ""label"": ""Cranial nerve paralysis""}}"																											
4925	5447	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	phenotypes	5	Headache	Headache may indicate skull base invasion or intracranial extension.	phenotype_term	phenotype_term	$	Headache	Headache may indicate skull base invasion or intracranial extension.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
4926	5448	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	0	Intensity-Modulated Radiation Therapy	NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem.	treatment_term	treatment_term	$	Intensity-Modulated Radiation Therapy	NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4927	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term	treatment_term	$	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
4928	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	treatment_term	$	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}, {""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				gemcitabine; cisplatin	CHEBI:175901; CHEBI:27899																						
4930	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			gemcitabine	CHEBI:175901	gemcitabine		"{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}"																											
4931	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4932	5451	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	3	Immunotherapy	PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation.	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4933	5465	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	0	Ciliary Dysfunction	Mutations in NPHP genes disrupt the structure and function of primary cilia, which are essential for cell signaling and homeostasis.	genes[0]	genes	genes			NPHP1	hgnc:7905	NPHP1		"{""preferred_term"": ""NPHP1"", ""term"": {""id"": ""hgnc:7905"", ""label"": ""NPHP1""}}"																											
4934	5465	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	0	Ciliary Dysfunction	Mutations in NPHP genes disrupt the structure and function of primary cilia, which are essential for cell signaling and homeostasis.	cellular_components[0]	cellular_components	cellular_components			Primary Cilium	GO:0005929	cilium		"{""preferred_term"": ""Primary Cilium"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
4935	5465	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	0	Ciliary Dysfunction	Mutations in NPHP genes disrupt the structure and function of primary cilia, which are essential for cell signaling and homeostasis.	cell_types[0]	cell_types	cell_types			Renal Tubular Epithelial Cell	CL:1000494	nephron tubule epithelial cell		"{""preferred_term"": ""Renal Tubular Epithelial Cell"", ""term"": {""id"": ""CL:1000494"", ""label"": ""nephron tubule epithelial cell""}}"																											
4936	5466	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	1	Impaired Cell Signaling	Defective primary cilia lead to disrupted signaling pathways including Wnt, Hedgehog, EGFR, and Hippo/YAP pathways, affecting cell differentiation, proliferation, and polarity.	pathways[0]	pathways	pathways			Wnt Pathway	GO:0016055	Wnt signaling pathway		"{""preferred_term"": ""Wnt Pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"																											
4937	5466	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	1	Impaired Cell Signaling	Defective primary cilia lead to disrupted signaling pathways including Wnt, Hedgehog, EGFR, and Hippo/YAP pathways, affecting cell differentiation, proliferation, and polarity.	pathways[1]	pathways	pathways			Hedgehog Pathway	GO:0007224	smoothened signaling pathway		"{""preferred_term"": ""Hedgehog Pathway"", ""term"": {""id"": ""GO:0007224"", ""label"": ""smoothened signaling pathway""}}"																											
4938	5466	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	1	Impaired Cell Signaling	Defective primary cilia lead to disrupted signaling pathways including Wnt, Hedgehog, EGFR, and Hippo/YAP pathways, affecting cell differentiation, proliferation, and polarity.	pathways[2]	pathways	pathways			EGFR Signaling	GO:0038127	ERBB signaling pathway		"{""preferred_term"": ""EGFR Signaling"", ""term"": {""id"": ""GO:0038127"", ""label"": ""ERBB signaling pathway""}}"																											
4939	5466	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	1	Impaired Cell Signaling	Defective primary cilia lead to disrupted signaling pathways including Wnt, Hedgehog, EGFR, and Hippo/YAP pathways, affecting cell differentiation, proliferation, and polarity.	pathways[3]	pathways	pathways			Hippo Signaling	GO:0035329	hippo signaling		"{""preferred_term"": ""Hippo Signaling"", ""term"": {""id"": ""GO:0035329"", ""label"": ""hippo signaling""}}"																											
4940	5467	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	2	Renal Tubular Dysfunction	Ciliary dysfunction in renal tubular epithelial cells impairs fluid and electrolyte balance, leading to polyuria and polydipsia.	locations[0]	locations	locations			Renal Tubule	UBERON:0009773	renal tubule		"{""preferred_term"": ""Renal Tubule"", ""term"": {""id"": ""UBERON:0009773"", ""label"": ""renal tubule""}}"																											
4941	5468	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	3	Interstitial Fibrosis	Chronic tubular dysfunction and inflammation lead to the accumulation of extracellular matrix and progressive interstitial fibrosis.	locations[0]	locations	locations			Kidney Interstitium	UBERON:0005215	kidney interstitium		"{""preferred_term"": ""Kidney Interstitium"", ""term"": {""id"": ""UBERON:0005215"", ""label"": ""kidney interstitium""}}"																											
4942	5468	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	3	Interstitial Fibrosis	Chronic tubular dysfunction and inflammation lead to the accumulation of extracellular matrix and progressive interstitial fibrosis.	cell_types[0]	cell_types	cell_types			Renal Interstitial Fibroblast	CL:1000692	kidney interstitial fibroblast		"{""preferred_term"": ""Renal Interstitial Fibroblast"", ""term"": {""id"": ""CL:1000692"", ""label"": ""kidney interstitial fibroblast""}}"																											
4943	5469	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	4	Renal Cyst Formation	Abnormal cell proliferation and differentiation result in the formation of cysts in the kidney tubules, contributing to the loss of renal function.	locations[0]	locations	locations			Renal Tubule	UBERON:0009773	renal tubule		"{""preferred_term"": ""Renal Tubule"", ""term"": {""id"": ""UBERON:0009773"", ""label"": ""renal tubule""}}"																											
4944	5471	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	6	Extrarenal Manifestations	Some forms of nephronophthisis, such as Senior-Loken syndrome, may involve other organs due to the presence of primary cilia in various tissues.	locations[0]	locations	locations			Liver	UBERON:0002107	liver		"{""preferred_term"": ""Liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
4945	5471	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	6	Extrarenal Manifestations	Some forms of nephronophthisis, such as Senior-Loken syndrome, may involve other organs due to the presence of primary cilia in various tissues.	locations[1]	locations	locations			Retina	UBERON:0000966	retina		"{""preferred_term"": ""Retina"", ""term"": {""id"": ""UBERON:0000966"", ""label"": ""retina""}}"																											
4946	5471	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	6	Extrarenal Manifestations	Some forms of nephronophthisis, such as Senior-Loken syndrome, may involve other organs due to the presence of primary cilia in various tissues.	locations[2]	locations	locations			Brain	UBERON:0000955	brain		"{""preferred_term"": ""Brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
4947	5474	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	9	DNA Damage and Senescence	NPHP1 deficiency impairs DNA damage repair, leading to increased cellular senescence and contributing to interstitial fibrosis. Nephrocystin-1 translocates to the nucleus after DNA damage stress.	locations[0]	locations	locations			Nucleus	GO:0005634	nucleus		"{""preferred_term"": ""Nucleus"", ""term"": {""id"": ""GO:0005634"", ""label"": ""nucleus""}}"																											
4948	5474	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	9	DNA Damage and Senescence	NPHP1 deficiency impairs DNA damage repair, leading to increased cellular senescence and contributing to interstitial fibrosis. Nephrocystin-1 translocates to the nucleus after DNA damage stress.	locations[1]	locations	locations			Renal Tubule	UBERON:0009773	renal tubule		"{""preferred_term"": ""Renal Tubule"", ""term"": {""id"": ""UBERON:0009773"", ""label"": ""renal tubule""}}"																											
4949	5474	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	9	DNA Damage and Senescence	NPHP1 deficiency impairs DNA damage repair, leading to increased cellular senescence and contributing to interstitial fibrosis. Nephrocystin-1 translocates to the nucleus after DNA damage stress.	genes[0]	genes	genes			NPHP1	hgnc:7905	NPHP1		"{""preferred_term"": ""NPHP1"", ""term"": {""id"": ""hgnc:7905"", ""label"": ""NPHP1""}}"																											
4950	5475	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	10	Aberrant Actin Remodeling and Hippo Activation	Ciliary dysfunction leads to aberrant RhoA signaling from the centrosome, activating ROCK and engaging Hippo signaling. This contributes to cystogenesis, fibrosis, and inflammation. GEF-H1 knockdown can rescue phenotypes in NPHP1 models.	locations[0]	locations	locations			Ciliary Base	GO:0097546	ciliary base		"{""preferred_term"": ""Ciliary Base"", ""term"": {""id"": ""GO:0097546"", ""label"": ""ciliary base""}}"																											
4951	5475	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	10	Aberrant Actin Remodeling and Hippo Activation	Ciliary dysfunction leads to aberrant RhoA signaling from the centrosome, activating ROCK and engaging Hippo signaling. This contributes to cystogenesis, fibrosis, and inflammation. GEF-H1 knockdown can rescue phenotypes in NPHP1 models.	locations[1]	locations	locations			Centrosome	GO:0005813	centrosome		"{""preferred_term"": ""Centrosome"", ""term"": {""id"": ""GO:0005813"", ""label"": ""centrosome""}}"																											
4952	5475	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	10	Aberrant Actin Remodeling and Hippo Activation	Ciliary dysfunction leads to aberrant RhoA signaling from the centrosome, activating ROCK and engaging Hippo signaling. This contributes to cystogenesis, fibrosis, and inflammation. GEF-H1 knockdown can rescue phenotypes in NPHP1 models.	pathways[0]	pathways	pathways			Hippo Signaling	GO:0035329	hippo signaling		"{""preferred_term"": ""Hippo Signaling"", ""term"": {""id"": ""GO:0035329"", ""label"": ""hippo signaling""}}"																											
4953	5475	229	Nephronophthisis	Nephronophthisis.yaml	pathophysiology	10	Aberrant Actin Remodeling and Hippo Activation	Ciliary dysfunction leads to aberrant RhoA signaling from the centrosome, activating ROCK and engaging Hippo signaling. This contributes to cystogenesis, fibrosis, and inflammation. GEF-H1 knockdown can rescue phenotypes in NPHP1 models.	pathways[1]	pathways	pathways			Actin Cytoskeleton Organization	GO:0030036	actin cytoskeleton organization		"{""preferred_term"": ""Actin Cytoskeleton Organization"", ""term"": {""id"": ""GO:0030036"", ""label"": ""actin cytoskeleton organization""}}"																											
4954	5477	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	1	Hypertension		phenotype_term	phenotype_term	$	Hypertension		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
4955	5479	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	3	Retinitis Pigmentosa		phenotype_term	phenotype_term	$	Retinitis Pigmentosa		Retinitis Pigmentosa	HP:0000510	Rod-cone dystrophy		"{""preferred_term"": ""Retinitis Pigmentosa"", ""term"": {""id"": ""HP:0000510"", ""label"": ""Rod-cone dystrophy""}}"																											
4956	5480	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	4	Growth Retardation		phenotype_term	phenotype_term	$	Growth Retardation		Growth Retardation	HP:0001510	Growth delay		"{""preferred_term"": ""Growth Retardation"", ""term"": {""id"": ""HP:0001510"", ""label"": ""Growth delay""}}"																											
4957	5482	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	6	Secondary Hyperparathyroidism		phenotype_term	phenotype_term	$	Secondary Hyperparathyroidism		Secondary Hyperparathyroidism	HP:0000867	Secondary hyperparathyroidism		"{""preferred_term"": ""Secondary Hyperparathyroidism"", ""term"": {""id"": ""HP:0000867"", ""label"": ""Secondary hyperparathyroidism""}}"																											
4958	5483	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	7	Polyuria		phenotype_term	phenotype_term	$	Polyuria		Polyuria	HP:0000103	Polyuria		"{""preferred_term"": ""Polyuria"", ""term"": {""id"": ""HP:0000103"", ""label"": ""Polyuria""}}"																											
4959	5484	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	8	Polydipsia		phenotype_term	phenotype_term	$	Polydipsia		Polydipsia	HP:0001959	Polydipsia		"{""preferred_term"": ""Polydipsia"", ""term"": {""id"": ""HP:0001959"", ""label"": ""Polydipsia""}}"																											
4960	5485	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	9	Electrolyte Imbalance		phenotype_term	phenotype_term	$	Electrolyte Imbalance		Electrolyte Imbalance	HP:0003111	Abnormal blood ion concentration		"{""preferred_term"": ""Electrolyte Imbalance"", ""term"": {""id"": ""HP:0003111"", ""label"": ""Abnormal blood ion concentration""}}"																											
4961	5486	229	Nephronophthisis	Nephronophthisis.yaml	phenotypes	10	End-Stage Renal Disease		phenotype_term	phenotype_term	$	End-Stage Renal Disease		End-Stage Renal Disease	HP:0003774	Stage 5 chronic kidney disease		"{""preferred_term"": ""End-Stage Renal Disease"", ""term"": {""id"": ""HP:0003774"", ""label"": ""Stage 5 chronic kidney disease""}}"																											
4962	5488	229	Nephronophthisis	Nephronophthisis.yaml	treatments	0	Renal Replacement Therapy	Dialysis or kidney transplantation for end-stage renal disease.	treatment_term	treatment_term	$	Renal Replacement Therapy	Dialysis or kidney transplantation for end-stage renal disease.	renal dialysis	MAXO:0000601	renal dialysis		"{""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}"																											
4963	5489	229	Nephronophthisis	Nephronophthisis.yaml	treatments	1	Antihypertensive Therapy	Management of blood pressure with medications.	treatment_term	treatment_term	$	Antihypertensive Therapy	Management of blood pressure with medications.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4964	5490	229	Nephronophthisis	Nephronophthisis.yaml	treatments	2	Supportive Care	Symptomatic treatment and monitoring to manage associated complications.	treatment_term	treatment_term	$	Supportive Care	Symptomatic treatment and monitoring to manage associated complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4965	5493	230	Neuroblastoma	Neuroblastoma.yaml	datasets	0		Microarray expression profiling of primary neuroblastoma tumors for expression analysis and subgroup discovery.	organism	organism	$		Microarray expression profiling of primary neuroblastoma tumors for expression analysis and subgroup discovery.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
4966	5493	230	Neuroblastoma	Neuroblastoma.yaml	datasets	0		Microarray expression profiling of primary neuroblastoma tumors for expression analysis and subgroup discovery.	sample_types[0]	sample_types	sample_types			neuroblastoma tumor tissue				"{""preferred_term"": ""neuroblastoma tumor tissue"", ""tissue_term"": {""preferred_term"": ""adrenal gland"", ""term"": {""id"": ""UBERON:0002369"", ""label"": ""adrenal gland""}}}"																											
4967	5493	230	Neuroblastoma	Neuroblastoma.yaml	datasets	0		Microarray expression profiling of primary neuroblastoma tumors for expression analysis and subgroup discovery.	sample_types[0].tissue_term	sample_types	sample_types[0]			adrenal gland	UBERON:0002369	adrenal gland		"{""preferred_term"": ""adrenal gland"", ""term"": {""id"": ""UBERON:0002369"", ""label"": ""adrenal gland""}}"																											
4968	5500	230	Neuroblastoma	Neuroblastoma.yaml	histopathology	0	Neural Crest Tumor	Neuroblastoma is a malignant tumor of neural crest origin.	finding_term	finding_term	$	Neural Crest Tumor	Neuroblastoma is a malignant tumor of neural crest origin.	Neuroblastoma	NCIT:C3270	Neuroblastoma		"{""preferred_term"": ""Neuroblastoma"", ""term"": {""id"": ""NCIT:C3270"", ""label"": ""Neuroblastoma""}}"																											
4969	5501	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	0	Neural Crest Developmental Arrest	Neuroblastoma arises from neural crest-derived sympathoadrenal progenitor cells that fail to complete differentiation. The tumor cells retain characteristics of immature neuroblasts with variable capacity for sympathetic neuronal differentiation.	cell_types[0]	cell_types	cell_types			neural crest derived neuroblast	CL:0002676	neural crest derived neuroblast		"{""preferred_term"": ""neural crest derived neuroblast"", ""term"": {""id"": ""CL:0002676"", ""label"": ""neural crest derived neuroblast""}}"																											
4970	5501	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	0	Neural Crest Developmental Arrest	Neuroblastoma arises from neural crest-derived sympathoadrenal progenitor cells that fail to complete differentiation. The tumor cells retain characteristics of immature neuroblasts with variable capacity for sympathetic neuronal differentiation.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
4971	5501	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	0	Neural Crest Developmental Arrest	Neuroblastoma arises from neural crest-derived sympathoadrenal progenitor cells that fail to complete differentiation. The tumor cells retain characteristics of immature neuroblasts with variable capacity for sympathetic neuronal differentiation.	locations[0]	locations	locations			adrenal gland	UBERON:0002369	adrenal gland		"{""preferred_term"": ""adrenal gland"", ""term"": {""id"": ""UBERON:0002369"", ""label"": ""adrenal gland""}}"																											
4972	5502	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	1	MYCN-Driven Proliferation	MYCN amplification results in massive overexpression of the MYCN transcription factor, which drives cell cycle progression, inhibits differentiation, and promotes genomic instability. MYCN-amplified tumors have a distinct aggressive phenotype with rapid growth and early metastasis.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4973	5503	230	Neuroblastoma	Neuroblastoma.yaml	pathophysiology	2	ALK Signaling Activation	ALK (anaplastic lymphoma kinase) is activated by point mutations in approximately 8-10% of neuroblastomas, and by amplification in additional cases. ALK mutations are enriched in familial neuroblastoma and represent a therapeutic target for ALK inhibitors.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4974	5504	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	0	Abdominal Mass	An abdominal mass is the most common presentation, typically arising from the adrenal gland or paraspinal sympathetic ganglia. The mass may be incidentally discovered or cause abdominal distension.	phenotype_term	phenotype_term	$	Abdominal Mass	An abdominal mass is the most common presentation, typically arising from the adrenal gland or paraspinal sympathetic ganglia. The mass may be incidentally discovered or cause abdominal distension.	Abdominal mass	HP:0031500	Abdominal mass		"{""preferred_term"": ""Abdominal mass"", ""term"": {""id"": ""HP:0031500"", ""label"": ""Abdominal mass""}}"																											
4975	5505	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	1	Hypertension	Hypertension may occur due to catecholamine secretion by tumor cells or renal artery compression by the tumor mass.	phenotype_term	phenotype_term	$	Hypertension	Hypertension may occur due to catecholamine secretion by tumor cells or renal artery compression by the tumor mass.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
4976	5506	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	2	Fever	Fever may occur as a paraneoplastic symptom or with advanced disease.	phenotype_term	phenotype_term	$	Fever	Fever may occur as a paraneoplastic symptom or with advanced disease.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
4977	5507	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	3	Weight Loss	Weight loss and failure to thrive can occur, particularly with advanced or metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Weight loss and failure to thrive can occur, particularly with advanced or metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
4978	5508	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	4	Proptosis	Periorbital metastases causing proptosis and periorbital ecchymosis (raccoon eyes) are characteristic of metastatic neuroblastoma.	phenotype_term	phenotype_term	$	Proptosis	Periorbital metastases causing proptosis and periorbital ecchymosis (raccoon eyes) are characteristic of metastatic neuroblastoma.	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
4979	5509	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	5	Bone Pain	Bone pain from skeletal metastases is common in high-risk neuroblastoma. Metastatic bone disease may cause limping or irritability in young children.	phenotype_term	phenotype_term	$	Bone Pain	Bone pain from skeletal metastases is common in high-risk neuroblastoma. Metastatic bone disease may cause limping or irritability in young children.	Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
4980	5510	230	Neuroblastoma	Neuroblastoma.yaml	phenotypes	6	Diarrhea	Secretory diarrhea can occur as a paraneoplastic syndrome due to tumor secretion of vasoactive intestinal peptide (VIP).	phenotype_term	phenotype_term	$	Diarrhea	Secretory diarrhea can occur as a paraneoplastic syndrome due to tumor secretion of vasoactive intestinal peptide (VIP).	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	treatment_term	$	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				cisplatin; etoposide; cyclophosphamide	CHEBI:27899; CHEBI:4911; CHEBI:4026																						
4982	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4983	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
4984	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
4985	5512	230	Neuroblastoma	Neuroblastoma.yaml	treatments	1	Surgical Resection	Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity.	treatment_term	treatment_term	$	Surgical Resection	Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4986	5513	230	Neuroblastoma	Neuroblastoma.yaml	treatments	2	Autologous Stem Cell Transplant	High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit.	treatment_term	treatment_term	$	Autologous Stem Cell Transplant	High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
4987	5514	230	Neuroblastoma	Neuroblastoma.yaml	treatments	3	Radiation Therapy	Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant.	treatment_term	treatment_term	$	Radiation Therapy	Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4988	5515	230	Neuroblastoma	Neuroblastoma.yaml	treatments	4	Anti-GD2 Immunotherapy	Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells.	treatment_term	treatment_term	$	Anti-GD2 Immunotherapy	Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells.	immunotherapy procedure	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
4989	5516	230	Neuroblastoma	Neuroblastoma.yaml	treatments	5	Isotretinoin (Retinoic Acid)	13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk.	treatment_term	treatment_term	$	Isotretinoin (Retinoic Acid)	13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4990	5519	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	0	NF1 Tumor Suppressor Loss	Germline heterozygous NF1 mutations result in haploinsufficiency for neurofibromin function. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates neurofibromin completely, resulting in loss of RAS negative regulation and driving tumorigenesis. This follows Knudson's two-hit hypothesis.	biological_processes[0]	biological_processes	biological_processes			regulation of Ras protein signal transduction	GO:0046578	regulation of Ras protein signal transduction		"{""modifier"": ""DECREASED"", ""preferred_term"": ""regulation of Ras protein signal transduction"", ""term"": {""id"": ""GO:0046578"", ""label"": ""regulation of Ras protein signal transduction""}}"			DECREASED																								
4991	5520	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	1	RAS-MAPK Pathway Hyperactivation	Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival.	biological_processes[0]	biological_processes	biological_processes			Ras protein signal transduction	GO:0007265	Ras protein signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Ras protein signal transduction"", ""term"": {""id"": ""GO:0007265"", ""label"": ""Ras protein signal transduction""}}"			INCREASED																								
4992	5520	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	1	RAS-MAPK Pathway Hyperactivation	Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival.	biological_processes[1]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
4993	5521	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	2	Uncontrolled Neural Crest Cell Proliferation	Neural crest-derived cells (Schwann cells, melanocytes) show particular dependence on RAS-MAPK signaling. Loss of neurofibromin drives uncontrolled proliferation of these cell types, resulting in neurofibromas (Schwann cell tumors) and hyperpigmented skin lesions (cafe-au-lait macules from melanocyte hyperproliferation).	cell_types[0]	cell_types	cell_types			Schwann cell	CL:0002573	Schwann cell		"{""preferred_term"": ""Schwann cell"", ""term"": {""id"": ""CL:0002573"", ""label"": ""Schwann cell""}}"																											
4994	5521	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	pathophysiology	2	Uncontrolled Neural Crest Cell Proliferation	Neural crest-derived cells (Schwann cells, melanocytes) show particular dependence on RAS-MAPK signaling. Loss of neurofibromin drives uncontrolled proliferation of these cell types, resulting in neurofibromas (Schwann cell tumors) and hyperpigmented skin lesions (cafe-au-lait macules from melanocyte hyperproliferation).	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
4995	5523	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	0	Cafe-au-lait Macules	Flat, hyperpigmented skin lesions present in >99% of NF1 patients. Six or more cafe-au-lait macules >5mm (prepubertal) or >15mm (postpubertal) meet one of the NIH diagnostic criteria. Usually present at birth or develop in first years of life.	phenotype_term	phenotype_term	$	Cafe-au-lait Macules	Flat, hyperpigmented skin lesions present in >99% of NF1 patients. Six or more cafe-au-lait macules >5mm (prepubertal) or >15mm (postpubertal) meet one of the NIH diagnostic criteria. Usually present at birth or develop in first years of life.	Multiple cafe-au-lait spots	HP:0007565	Multiple cafe-au-lait spots		"{""preferred_term"": ""Multiple cafe-au-lait spots"", ""term"": {""id"": ""HP:0007565"", ""label"": ""Multiple cafe-au-lait spots""}}"																											
4996	5524	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	1	Cutaneous Neurofibromas	Benign peripheral nerve sheath tumors arising from Schwann cells. Typically appear around puberty and increase in number with age. May cause cosmetic concerns but rarely become malignant.	phenotype_term	phenotype_term	$	Cutaneous Neurofibromas	Benign peripheral nerve sheath tumors arising from Schwann cells. Typically appear around puberty and increase in number with age. May cause cosmetic concerns but rarely become malignant.	Neurofibroma	HP:0001067	Neurofibroma		"{""preferred_term"": ""Neurofibroma"", ""term"": {""id"": ""HP:0001067"", ""label"": ""Neurofibroma""}}"																											
4997	5525	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	2	Plexiform Neurofibromas	Diffuse neurofibromas involving multiple nerve fascicles, often present at birth. Can cause significant morbidity through mass effect, disfigurement, and pain. Approximately 8-13% lifetime risk of malignant transformation to MPNST.	phenotype_term	phenotype_term	$	Plexiform Neurofibromas	Diffuse neurofibromas involving multiple nerve fascicles, often present at birth. Can cause significant morbidity through mass effect, disfigurement, and pain. Approximately 8-13% lifetime risk of malignant transformation to MPNST.	Plexiform neurofibroma	HP:0009732	Plexiform neurofibroma		"{""preferred_term"": ""Plexiform neurofibroma"", ""term"": {""id"": ""HP:0009732"", ""label"": ""Plexiform neurofibroma""}}"																											
4998	5526	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	3	Lisch Nodules	Melanocytic hamartomas of the iris, appearing as tan-brown dome-shaped elevations. Present in >90% of adults with NF1. Best visualized by slit-lamp examination. Pathognomonic for NF1 and do not affect vision.	phenotype_term	phenotype_term	$	Lisch Nodules	Melanocytic hamartomas of the iris, appearing as tan-brown dome-shaped elevations. Present in >90% of adults with NF1. Best visualized by slit-lamp examination. Pathognomonic for NF1 and do not affect vision.	Lisch nodules	HP:0009737	Lisch nodules		"{""preferred_term"": ""Lisch nodules"", ""term"": {""id"": ""HP:0009737"", ""label"": ""Lisch nodules""}}"																											
4999	5527	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	4	Optic Pathway Glioma	Low-grade gliomas of the optic nerve, chiasm, or tract occur in 15-20% of NF1 patients. Usually pilocytic astrocytomas. Most are asymptomatic and nonprogressive, but can cause vision loss. Peak incidence in first 6 years of life.	phenotype_term	phenotype_term	$	Optic Pathway Glioma	Low-grade gliomas of the optic nerve, chiasm, or tract occur in 15-20% of NF1 patients. Usually pilocytic astrocytomas. Most are asymptomatic and nonprogressive, but can cause vision loss. Peak incidence in first 6 years of life.	Optic nerve glioma	HP:0009734	Optic nerve glioma		"{""preferred_term"": ""Optic nerve glioma"", ""term"": {""id"": ""HP:0009734"", ""label"": ""Optic nerve glioma""}}"																											
5000	5528	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	5	Malignant Peripheral Nerve Sheath Tumor	Aggressive sarcoma arising from peripheral nerves, often from transformation of plexiform neurofibromas. Lifetime risk 8-13% in NF1. Leading cause of NF1-related mortality. Presents with rapid growth, pain, or new neurologic deficits.	phenotype_term	phenotype_term	$	Malignant Peripheral Nerve Sheath Tumor	Aggressive sarcoma arising from peripheral nerves, often from transformation of plexiform neurofibromas. Lifetime risk 8-13% in NF1. Leading cause of NF1-related mortality. Presents with rapid growth, pain, or new neurologic deficits.	Neurofibrosarcoma	HP:0100697	Neurofibrosarcoma		"{""preferred_term"": ""Neurofibrosarcoma"", ""term"": {""id"": ""HP:0100697"", ""label"": ""Neurofibrosarcoma""}}"																											
5001	5529	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	6	Scoliosis	Spinal curvature occurs in 10-30% of NF1 patients. Can be idiopathic-type or dystrophic (sharply angulated, short segment) forms. Dystrophic scoliosis may progress rapidly and require surgical intervention.	phenotype_term	phenotype_term	$	Scoliosis	Spinal curvature occurs in 10-30% of NF1 patients. Can be idiopathic-type or dystrophic (sharply angulated, short segment) forms. Dystrophic scoliosis may progress rapidly and require surgical intervention.	Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
5002	5530	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	phenotypes	7	Learning Difficulties	Learning disabilities and attention deficits occur in 50-75% of children with NF1. Intelligence is usually normal but specific learning disabilities, ADHD, and executive function problems are common. Motor coordination difficulties may occur.	phenotype_term	phenotype_term	$	Learning Difficulties	Learning disabilities and attention deficits occur in 50-75% of children with NF1. Intelligence is usually normal but specific learning disabilities, ADHD, and executive function problems are common. Motor coordination difficulties may occur.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
5003	5531	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	0	MEK Inhibitors	Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.	treatment_term	treatment_term	$	MEK Inhibitors	Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5004	5532	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	1	Surgical Management	Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.	treatment_term	treatment_term	$	Surgical Management	Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5005	5533	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	2	Surveillance Protocol	Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.	treatment_term	treatment_term	$	Surveillance Protocol	Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
5006	5534	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	3	Genetic Counseling	Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5007	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[0]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Optic neuritis	HP:0100653	Optic neuritis		"{""preferred_term"": ""Optic neuritis"", ""term"": {""id"": ""HP:0100653"", ""label"": ""Optic neuritis""}}"																											
5008	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[1]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Acute myelitis	HP:0012486	Myelitis	Acute inflammatory myelitis.	"{""description"": ""Acute inflammatory myelitis."", ""preferred_term"": ""Acute myelitis"", ""term"": {""id"": ""HP:0012486"", ""label"": ""Myelitis""}}"																											
5009	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[2]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Area postrema syndrome	HP:0002017	Nausea and vomiting	Episode of otherwise unexplained hiccups or nausea and vomiting.	"{""description"": ""Episode of otherwise unexplained hiccups or nausea and vomiting."", ""preferred_term"": ""Area postrema syndrome"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
5010	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[3]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Acute brainstem syndrome				"{""preferred_term"": ""Acute brainstem syndrome""}"																											
5011	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[4]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Symptomatic narcolepsy or acute diencephalic syndrome			With NMOSD-typical diencephalic MRI lesions.	"{""description"": ""With NMOSD-typical diencephalic MRI lesions."", ""preferred_term"": ""Symptomatic narcolepsy or acute diencephalic syndrome""}"																											
5012	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].core_clinical_characteristics[5]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Symptomatic cerebral syndrome			With NMOSD-typical brain lesions.	"{""description"": ""With NMOSD-typical brain lesions."", ""preferred_term"": ""Symptomatic cerebral syndrome""}"																											
5013	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].laboratory_requirements[0]	criteria_sets	criteria_sets[0].laboratory_requirements			AQP4-IgG positive			Positive test using best available detection method (cell-based assay recommended).	"{""description"": ""Positive test using best available detection method (cell-based assay recommended)."", ""preferred_term"": ""AQP4-IgG positive""}"																											
5014	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[0].exclusion_criteria[0]	criteria_sets	criteria_sets[0].exclusion_criteria			Alternative diagnoses excluded				"{""preferred_term"": ""Alternative diagnoses excluded""}"																											
5015	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[0]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Optic neuritis	HP:0100653	Optic neuritis		"{""preferred_term"": ""Optic neuritis"", ""term"": {""id"": ""HP:0100653"", ""label"": ""Optic neuritis""}}"																											
5016	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[1]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Acute myelitis	HP:0012486	Myelitis	Acute inflammatory myelitis.	"{""description"": ""Acute inflammatory myelitis."", ""preferred_term"": ""Acute myelitis"", ""term"": {""id"": ""HP:0012486"", ""label"": ""Myelitis""}}"																											
5017	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[2]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Area postrema syndrome	HP:0002017	Nausea and vomiting	Episode of otherwise unexplained hiccups or nausea and vomiting.	"{""description"": ""Episode of otherwise unexplained hiccups or nausea and vomiting."", ""preferred_term"": ""Area postrema syndrome"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
5018	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[3]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Acute brainstem syndrome				"{""preferred_term"": ""Acute brainstem syndrome""}"																											
5019	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[4]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Symptomatic narcolepsy or acute diencephalic syndrome			With NMOSD-typical diencephalic MRI lesions.	"{""description"": ""With NMOSD-typical diencephalic MRI lesions."", ""preferred_term"": ""Symptomatic narcolepsy or acute diencephalic syndrome""}"																											
5020	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].core_clinical_characteristics[5]	criteria_sets	criteria_sets[1].core_clinical_characteristics			Symptomatic cerebral syndrome			With NMOSD-typical brain lesions.	"{""description"": ""With NMOSD-typical brain lesions."", ""preferred_term"": ""Symptomatic cerebral syndrome""}"																											
5021	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].additional_requirements[0]	criteria_sets	criteria_sets[1].additional_requirements			At least one key core characteristic			At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis (LETM), or area postrema syndrome.	"{""description"": ""At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis (LETM), or area postrema syndrome."", ""preferred_term"": ""At least one key core characteristic""}"																											
5022	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].additional_requirements[1]	criteria_sets	criteria_sets[1].additional_requirements			Dissemination in space			Two or more different core clinical characteristics.	"{""description"": ""Two or more different core clinical characteristics."", ""preferred_term"": ""Dissemination in space""}"																											
5023	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].imaging_requirements[0]	criteria_sets	criteria_sets[1].imaging_requirements			Acute optic neuritis MRI requirement			Brain MRI normal or only nonspecific white matter lesions, or optic nerve MRI with T2-hyperintense or T1-weighted gadolinium-enhancing lesion extending over >1/2 optic nerve length or involving optic chiasm.	"{""description"": ""Brain MRI normal or only nonspecific white matter lesions, or optic nerve MRI with T2-hyperintense or T1-weighted gadolinium-enhancing lesion extending over >1/2 optic nerve length or involving optic chiasm."", ""preferred_term"": ""Acute optic neuritis MRI requirement""}"																											
5024	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].imaging_requirements[1]	criteria_sets	criteria_sets[1].imaging_requirements			Acute myelitis MRI requirement			Intramedullary MRI lesion extending over >=3 contiguous segments (LETM), or >=3 contiguous segments of focal spinal cord atrophy with history compatible with acute myelitis.	"{""description"": ""Intramedullary MRI lesion extending over >=3 contiguous segments (LETM), or >=3 contiguous segments of focal spinal cord atrophy with history compatible with acute myelitis."", ""preferred_term"": ""Acute myelitis MRI requirement""}"																											
5025	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].imaging_requirements[2]	criteria_sets	criteria_sets[1].imaging_requirements			Area postrema syndrome MRI requirement			Associated dorsal medulla/area postrema lesions.	"{""description"": ""Associated dorsal medulla/area postrema lesions."", ""preferred_term"": ""Area postrema syndrome MRI requirement""}"																											
5026	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].imaging_requirements[3]	criteria_sets	criteria_sets[1].imaging_requirements			Acute brainstem syndrome MRI requirement			Associated periependymal brainstem lesions.	"{""description"": ""Associated periependymal brainstem lesions."", ""preferred_term"": ""Acute brainstem syndrome MRI requirement""}"																											
5027	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].laboratory_requirements[0]	criteria_sets	criteria_sets[1].laboratory_requirements			AQP4-IgG negative or testing unavailable			Negative test using best available detection method, or testing unavailable.	"{""description"": ""Negative test using best available detection method, or testing unavailable."", ""preferred_term"": ""AQP4-IgG negative or testing unavailable""}"																											
5028	5535	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	definitions	0	2015 IPND NMOSD Diagnostic Criteria (Adults)	International consensus diagnostic criteria for NMOSD, stratified by AQP4-IgG status.	criteria_sets[1].exclusion_criteria[0]	criteria_sets	criteria_sets[1].exclusion_criteria			Alternative diagnoses excluded				"{""preferred_term"": ""Alternative diagnoses excluded""}"																											
5029	5536	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	pathophysiology	0	AQP4-IgG-Mediated Astrocyte Injury	Autoantibodies against AQP4 bind astrocytic end-feet and trigger complement-dependent astrocyte damage, driving neuroinflammation.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5030	5536	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	pathophysiology	0	AQP4-IgG-Mediated Astrocyte Injury	Autoantibodies against AQP4 bind astrocytic end-feet and trigger complement-dependent astrocyte damage, driving neuroinflammation.	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"			INCREASED																								
5031	5537	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	pathophysiology	1	AQP4 Endocytosis and Complement-Independent Cytotoxicity	NMO-IgG can induce complement-independent astrocyte injury, with antibody- induced endocytosis of AQP4 implicated in this mechanism.	biological_processes[0]	biological_processes	biological_processes			endocytosis	GO:0006897	endocytosis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""endocytosis"", ""term"": {""id"": ""GO:0006897"", ""label"": ""endocytosis""}}"			INCREASED																								
5032	5538	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	phenotypes	0	Visual Loss		phenotype_term	phenotype_term	$	Visual Loss		Visual loss	HP:0000572	Visual loss		"{""preferred_term"": ""Visual loss"", ""term"": {""id"": ""HP:0000572"", ""label"": ""Visual loss""}}"																											
5033	5539	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	phenotypes	1	Muscle Weakness		phenotype_term	phenotype_term	$	Muscle Weakness		Muscle weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
5034	5540	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	phenotypes	2	Nausea and Vomiting		phenotype_term	phenotype_term	$	Nausea and Vomiting		Nausea and vomiting	HP:0002017	Nausea and vomiting		"{""preferred_term"": ""Nausea and vomiting"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
5035	5541	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	0	Eculizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Eculizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5036	5542	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	1	Inebilizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Inebilizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5037	5543	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	2	Satralizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Satralizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5038	5548	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	0	Aquaporin-4 Autoimmunity	"Anti-AQP4 (NMO-IgG) antibodies bind to aquaporin-4 water channels predominantly expressed on astrocyte end-feet at the blood-brain barrier. This initiates complement-dependent cytotoxicity leading to astrocyte death, secondary oligodendrocyte damage, demyelination, and neuronal injury.
"	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5039	5548	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	0	Aquaporin-4 Autoimmunity	"Anti-AQP4 (NMO-IgG) antibodies bind to aquaporin-4 water channels predominantly expressed on astrocyte end-feet at the blood-brain barrier. This initiates complement-dependent cytotoxicity leading to astrocyte death, secondary oligodendrocyte damage, demyelination, and neuronal injury.
"	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
5040	5549	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	1	Complement-Mediated Astrocyte Destruction	"AQP4-IgG binding activates the classical complement cascade, leading to membrane attack complex formation and astrocyte lysis. This distinguishes NMOSD from MS where complement activation is less prominent.
"	biological_processes[0]	biological_processes	biological_processes			complement activation, classical pathway	GO:0006958	complement activation, classical pathway		"{""preferred_term"": ""complement activation, classical pathway"", ""term"": {""id"": ""GO:0006958"", ""label"": ""complement activation, classical pathway""}}"																											
5041	5550	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	2	Blood-Brain Barrier Disruption	"Inflammatory infiltrates including neutrophils, eosinophils, and macrophages cross the disrupted blood-brain barrier. Granulocyte infiltration is a hallmark feature distinguishing NMOSD lesions from MS plaques.
"	locations[0]	locations	locations			blood brain barrier	UBERON:0000120	blood brain barrier		"{""preferred_term"": ""blood brain barrier"", ""term"": {""id"": ""UBERON:0000120"", ""label"": ""blood brain barrier""}}"																											
5042	5550	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	2	Blood-Brain Barrier Disruption	"Inflammatory infiltrates including neutrophils, eosinophils, and macrophages cross the disrupted blood-brain barrier. Granulocyte infiltration is a hallmark feature distinguishing NMOSD lesions from MS plaques.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
5043	5550	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	2	Blood-Brain Barrier Disruption	"Inflammatory infiltrates including neutrophils, eosinophils, and macrophages cross the disrupted blood-brain barrier. Granulocyte infiltration is a hallmark feature distinguishing NMOSD lesions from MS plaques.
"	cell_types[1]	cell_types	cell_types			eosinophil	CL:0000771	eosinophil		"{""preferred_term"": ""eosinophil"", ""term"": {""id"": ""CL:0000771"", ""label"": ""eosinophil""}}"																											
5044	5551	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	3	Secondary Demyelination	"Unlike MS where oligodendrocytes are primary targets, in NMOSD demyelination occurs secondary to astrocyte loss. Loss of astrocyte trophic support leads to oligodendrocyte death and myelin breakdown.
"	cell_types[0]	cell_types	cell_types			oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
5045	5551	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	3	Secondary Demyelination	"Unlike MS where oligodendrocytes are primary targets, in NMOSD demyelination occurs secondary to astrocyte loss. Loss of astrocyte trophic support leads to oligodendrocyte death and myelin breakdown.
"	biological_processes[0]	biological_processes	biological_processes			myelination	GO:0042552	myelination		"{""preferred_term"": ""myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
5046	5551	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	pathophysiology	3	Secondary Demyelination	"Unlike MS where oligodendrocytes are primary targets, in NMOSD demyelination occurs secondary to astrocyte loss. Loss of astrocyte trophic support leads to oligodendrocyte death and myelin breakdown.
"	cellular_components[0]	cellular_components	cellular_components			myelin sheath	GO:0043209	myelin sheath		"{""preferred_term"": ""myelin sheath"", ""term"": {""id"": ""GO:0043209"", ""label"": ""myelin sheath""}}"																											
5047	5552	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	phenotypes	0	Optic Neuritis	"Inflammation of the optic nerve causing acute vision loss, eye pain, and color vision impairment. Often bilateral and severe in NMOSD compared to MS-associated optic neuritis.
"	phenotype_term	phenotype_term	$	Optic Neuritis	"Inflammation of the optic nerve causing acute vision loss, eye pain, and color vision impairment. Often bilateral and severe in NMOSD compared to MS-associated optic neuritis.
"	optic neuritis	HP:0100653	Optic neuritis		"{""preferred_term"": ""optic neuritis"", ""term"": {""id"": ""HP:0100653"", ""label"": ""Optic neuritis""}}"																											
5048	5553	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	phenotypes	1	Longitudinally Extensive Transverse Myelitis	"Longitudinally extensive transverse myelitis (LETM) affecting three or more vertebral segments is characteristic of NMOSD, distinguishing it from the shorter lesions typical of multiple sclerosis. Causes paraplegia, sensory loss, and bladder/bowel dysfunction. LETM is a core diagnostic criterion for NMOSD.
"	phenotype_term	phenotype_term	$	Longitudinally Extensive Transverse Myelitis	"Longitudinally extensive transverse myelitis (LETM) affecting three or more vertebral segments is characteristic of NMOSD, distinguishing it from the shorter lesions typical of multiple sclerosis. Causes paraplegia, sensory loss, and bladder/bowel dysfunction. LETM is a core diagnostic criterion for NMOSD.
"	myelitis	HP:0012486	Myelitis		"{""preferred_term"": ""myelitis"", ""term"": {""id"": ""HP:0012486"", ""label"": ""Myelitis""}}"																											
5049	5554	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	phenotypes	2	Area Postrema Syndrome	"Intractable nausea, vomiting, and hiccups due to inflammation of the area postrema (UBERON:0002162) in the dorsal medulla. A characteristic early manifestation that may precede other symptoms. This is a syndrome involving a specific anatomical location rather than a simple phenotype.
"	phenotype_term	phenotype_term	$	Area Postrema Syndrome	"Intractable nausea, vomiting, and hiccups due to inflammation of the area postrema (UBERON:0002162) in the dorsal medulla. A characteristic early manifestation that may precede other symptoms. This is a syndrome involving a specific anatomical location rather than a simple phenotype.
"	intractable nausea and vomiting	HP:0002017	Nausea and vomiting		"{""preferred_term"": ""intractable nausea and vomiting"", ""term"": {""id"": ""HP:0002017"", ""label"": ""Nausea and vomiting""}}"																											
5050	5557	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	0	Acute Attack Treatment - Corticosteroids	"High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
"	treatment_term	treatment_term	$	Acute Attack Treatment - Corticosteroids	"High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5051	5559	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	2	Rituximab	"Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
"	treatment_term	treatment_term	$	Rituximab	"Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5052	5560	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	3	Eculizumab	"Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
"	treatment_term	treatment_term	$	Eculizumab	"Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5053	5561	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	4	Inebilizumab	"Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
"	treatment_term	treatment_term	$	Inebilizumab	"Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5054	5562	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	5	Satralizumab	"IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
"	treatment_term	treatment_term	$	Satralizumab	"IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5055	5564	234	Noma	Noma.yaml	phenotypes	0	Gangrene		phenotype_term	phenotype_term	$	Gangrene		Gangrene	HP:0100758	Gangrene		"{""preferred_term"": ""Gangrene"", ""term"": {""id"": ""HP:0100758"", ""label"": ""Gangrene""}}"																											
5056	5567	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	0		Large-scale single-cell RNA sequencing from 11 adjacent normal and 15 tumor tissue samples from NSCLC patients (stages I-IV). After quality filtering, 98,504 cells retained including 16,046 epithelial, 5,468 stromal, and 76,990 immune cells.	organism	organism	$		Large-scale single-cell RNA sequencing from 11 adjacent normal and 15 tumor tissue samples from NSCLC patients (stages I-IV). After quality filtering, 98,504 cells retained including 16,046 epithelial, 5,468 stromal, and 76,990 immune cells.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5057	5567	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	0		Large-scale single-cell RNA sequencing from 11 adjacent normal and 15 tumor tissue samples from NSCLC patients (stages I-IV). After quality filtering, 98,504 cells retained including 16,046 epithelial, 5,468 stromal, and 76,990 immune cells.	sample_types[0]	sample_types	sample_types			lung tumor tissue				"{""preferred_term"": ""lung tumor tissue"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
5058	5567	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	0		Large-scale single-cell RNA sequencing from 11 adjacent normal and 15 tumor tissue samples from NSCLC patients (stages I-IV). After quality filtering, 98,504 cells retained including 16,046 epithelial, 5,468 stromal, and 76,990 immune cells.	sample_types[0].tissue_term	sample_types	sample_types[0]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
5059	5568	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	1		Single-cell RNA sequencing profiling over 9,000 individual cells from tumor and adjacent normal tissues of 20 patients with stage I-IV NSCLC using modified STRT-seq technique.	organism	organism	$		Single-cell RNA sequencing profiling over 9,000 individual cells from tumor and adjacent normal tissues of 20 patients with stage I-IV NSCLC using modified STRT-seq technique.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5060	5568	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	1		Single-cell RNA sequencing profiling over 9,000 individual cells from tumor and adjacent normal tissues of 20 patients with stage I-IV NSCLC using modified STRT-seq technique.	sample_types[0]	sample_types	sample_types			lung tumor tissue				"{""preferred_term"": ""lung tumor tissue"", ""tissue_term"": {""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}}"																											
5061	5568	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	datasets	1		Single-cell RNA sequencing profiling over 9,000 individual cells from tumor and adjacent normal tissues of 20 patients with stage I-IV NSCLC using modified STRT-seq technique.	sample_types[0].tissue_term	sample_types	sample_types[0]			lung	UBERON:0002048	lung		"{""preferred_term"": ""lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
5062	5569	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	environmental	0	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
5063	5570	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	environmental	1	Radon Exposure		exposure_term	exposure_term	$	Radon Exposure		Radon exposure	ECTO:9000097	exposure to radon		"{""preferred_term"": ""Radon exposure"", ""term"": {""id"": ""ECTO:9000097"", ""label"": ""exposure to radon""}}"																											
5064	5582	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
5065	5583	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	0	Oncogenic Driver Mutations	Mutations in genes like EGFR, ALK, ROS1, and BRAF lead to uncontrolled cell growth and survival.	biological_processes[0]	biological_processes	biological_processes			transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	Dysregulated RTK signaling via EGFR, ALK, MET drives proliferation and survival	"{""description"": ""Dysregulated RTK signaling via EGFR, ALK, MET drives proliferation and survival"", ""preferred_term"": ""transmembrane receptor protein tyrosine kinase signaling pathway"", ""term"": {""id"": ""GO:0007169"", ""label"": ""transmembrane receptor protein tyrosine kinase signaling pathway""}}"																											
5066	5583	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	0	Oncogenic Driver Mutations	Mutations in genes like EGFR, ALK, ROS1, and BRAF lead to uncontrolled cell growth and survival.	biological_processes[1]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade	Constitutive MAPK activation via KRAS, EGFR, ALK mutations	"{""description"": ""Constitutive MAPK activation via KRAS, EGFR, ALK mutations"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
5067	5584	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	1	Immune Evasion	Cancer cells develop mechanisms to evade detection and destruction by the immune system.	biological_processes[0]	biological_processes	biological_processes			epithelial to mesenchymal transition	GO:0001837	epithelial to mesenchymal transition	EMT programs linked to immune suppression and therapy resistance; EGFR-mutant tumors may transform to SCLC	"{""description"": ""EMT programs linked to immune suppression and therapy resistance; EGFR-mutant tumors may transform to SCLC"", ""preferred_term"": ""epithelial to mesenchymal transition"", ""term"": {""id"": ""GO:0001837"", ""label"": ""epithelial to mesenchymal transition""}}"																											
5068	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage	Tumor-associated macrophages (TAMs) reprogrammed to cholesterol export and iron efflux states; dominant immunosuppressive population	"{""description"": ""Tumor-associated macrophages (TAMs) reprogrammed to cholesterol export and iron efflux states; dominant immunosuppressive population"", ""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
5069	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell	Reduced T cell infiltration and cytotoxicity in immunosuppressive niches; altered checkpoint co-expression patterns	"{""description"": ""Reduced T cell infiltration and cytotoxicity in immunosuppressive niches; altered checkpoint co-expression patterns"", ""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5070	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	cell_types[2]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell	Reduced NK cell cytotoxicity; inverse relationship with anti-inflammatory macrophages	"{""description"": ""Reduced NK cell cytotoxicity; inverse relationship with anti-inflammatory macrophages"", ""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
5071	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	cell_types[3]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast	Cancer-associated fibroblasts (CAFs) contribute to immunosuppressive niches and stromal remodeling	"{""description"": ""Cancer-associated fibroblasts (CAFs) contribute to immunosuppressive niches and stromal remodeling"", ""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
5072	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	biological_processes[0]	biological_processes	biological_processes			regulation of T cell activation	GO:0050863	regulation of T cell activation	Altered T cell activation in TME; checkpoint co-expression patterns; dual ICI modulates CD4+ responses	"{""description"": ""Altered T cell activation in TME; checkpoint co-expression patterns; dual ICI modulates CD4+ responses"", ""preferred_term"": ""regulation of T cell activation"", ""term"": {""id"": ""GO:0050863"", ""label"": ""regulation of T cell activation""}}"																											
5073	5586	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Tumor Microenvironment Remodeling	Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.	locations[0]	locations	locations			parenchyma of lung	UBERON:0008946	parenchyma of lung	Primary site of TME remodeling	"{""description"": ""Primary site of TME remodeling"", ""preferred_term"": ""parenchyma of lung"", ""term"": {""id"": ""UBERON:0008946"", ""label"": ""parenchyma of lung""}}"																											
5074	5587	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	4	Metabolic Rewiring	KRAS/LKB1 co-mutant tumors depend on oxidative pentose phosphate pathway (PPP) via G6PD for NADPH production, redox balance, and lipogenesis; G6PD ablation selectively suppresses tumor growth and activates p53.	biological_processes[0]	biological_processes	biological_processes			pentose-phosphate shunt	GO:0006098	pentose-phosphate shunt	KRAS/LKB1 tumors depend on oxidative PPP via G6PD for NADPH and lipogenesis	"{""description"": ""KRAS/LKB1 tumors depend on oxidative PPP via G6PD for NADPH and lipogenesis"", ""preferred_term"": ""pentose-phosphate shunt"", ""term"": {""id"": ""GO:0006098"", ""label"": ""pentose-phosphate shunt""}}"																											
5075	5587	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	pathophysiology	4	Metabolic Rewiring	KRAS/LKB1 co-mutant tumors depend on oxidative pentose phosphate pathway (PPP) via G6PD for NADPH production, redox balance, and lipogenesis; G6PD ablation selectively suppresses tumor growth and activates p53.	biological_processes[1]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress	G6PD impairment disrupts redox balance and activates p53	"{""description"": ""G6PD impairment disrupts redox balance and activates p53"", ""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
5076	5590	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	1	Hemoptysis		phenotype_term	phenotype_term	$	Hemoptysis		Hemoptysis	HP:0002105	Hemoptysis		"{""preferred_term"": ""Hemoptysis"", ""term"": {""id"": ""HP:0002105"", ""label"": ""Hemoptysis""}}"																											
5077	5591	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	2	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
5078	5592	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	3	Bone Pain		phenotype_term	phenotype_term	$	Bone Pain		Bone Pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone Pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
5079	5593	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	4	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5080	5594	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	5	Bone Pain		phenotype_term	phenotype_term	$	Bone Pain		Bone Pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone Pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
5081	5595	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	6	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
5082	5596	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	7	Recurrent Pneumonia		phenotype_term	phenotype_term	$	Recurrent Pneumonia		Recurrent Pneumonia	HP:0006532	Recurrent pneumonia		"{""preferred_term"": ""Recurrent Pneumonia"", ""term"": {""id"": ""HP:0006532"", ""label"": ""Recurrent pneumonia""}}"																											
5083	5597	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	phenotypes	8	Headache		phenotype_term	phenotype_term	$	Headache		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
5084	5599	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	0	Surgery	Lobectomy or pneumonectomy for localized disease	treatment_term	treatment_term	$	Surgery	Lobectomy or pneumonectomy for localized disease	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5085	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	Chemotherapy	Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5086	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	Targeted Therapy	Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)	treatment_term	treatment_term	$	Targeted Therapy	Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5087	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5088	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	Radiation Therapy	Used for localized disease, palliation of symptoms, or brain metastases	treatment_term	treatment_term	$	Radiation Therapy	Used for localized disease, palliation of symptoms, or brain metastases	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5089	5604	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	0	PTPN11		gene_term	gene_term	$	PTPN11		PTPN11	hgnc:9644	PTPN11		"{""preferred_term"": ""PTPN11"", ""term"": {""id"": ""hgnc:9644"", ""label"": ""PTPN11""}}"																											
5090	5605	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	1	SOS1		gene_term	gene_term	$	SOS1		SOS1	hgnc:11187	SOS1		"{""preferred_term"": ""SOS1"", ""term"": {""id"": ""hgnc:11187"", ""label"": ""SOS1""}}"																											
5091	5606	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	2	RAF1		gene_term	gene_term	$	RAF1		RAF1	hgnc:9829	RAF1		"{""preferred_term"": ""RAF1"", ""term"": {""id"": ""hgnc:9829"", ""label"": ""RAF1""}}"																											
5092	5607	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	3	RIT1		gene_term	gene_term	$	RIT1		RIT1	hgnc:10023	RIT1		"{""preferred_term"": ""RIT1"", ""term"": {""id"": ""hgnc:10023"", ""label"": ""RIT1""}}"																											
5093	5608	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	4	KRAS		gene_term	gene_term	$	KRAS		KRAS	hgnc:6407	KRAS		"{""preferred_term"": ""KRAS"", ""term"": {""id"": ""hgnc:6407"", ""label"": ""KRAS""}}"																											
5094	5609	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	5	LZTR1		gene_term	gene_term	$	LZTR1		LZTR1	hgnc:6742	LZTR1		"{""preferred_term"": ""LZTR1"", ""term"": {""id"": ""hgnc:6742"", ""label"": ""LZTR1""}}"																											
5095	5610	236	Noonan Syndrome	Noonan_Syndrome.yaml	has_subtypes	0	Noonan Syndrome 1 (PTPN11-related)	Most common form caused by PTPN11 mutations, accounting for approximately 50% of cases.	subtype_term	subtype_term	$	Noonan Syndrome 1 (PTPN11-related)	Most common form caused by PTPN11 mutations, accounting for approximately 50% of cases.	Noonan syndrome 1	MONDO:0008104	Noonan syndrome 1		"{""preferred_term"": ""Noonan syndrome 1"", ""term"": {""id"": ""MONDO:0008104"", ""label"": ""Noonan syndrome 1""}}"																											
5096	5611	236	Noonan Syndrome	Noonan_Syndrome.yaml	has_subtypes	1	Noonan Syndrome with Multiple Lentigines	Formerly known as LEOPARD syndrome, characterized by lentigines and hypertrophic cardiomyopathy.	subtype_term	subtype_term	$	Noonan Syndrome with Multiple Lentigines	Formerly known as LEOPARD syndrome, characterized by lentigines and hypertrophic cardiomyopathy.	Noonan syndrome with multiple lentigines	MONDO:0007893	Noonan syndrome with multiple lentigines		"{""preferred_term"": ""Noonan syndrome with multiple lentigines"", ""term"": {""id"": ""MONDO:0007893"", ""label"": ""Noonan syndrome with multiple lentigines""}}"																											
5097	5613	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	0	SHP2 Gain-of-Function Activation	PTPN11 mutations destabilize the autoinhibitory interaction between the N-SH2 and PTP domains, resulting in constitutively elevated phosphatase activity. SHP2 is a positive regulator of RAS-MAPK signaling and gain-of-function mutations lead to enhanced ERK activation.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine phosphatase activity	GO:0004725	protein tyrosine phosphatase activity		"{""preferred_term"": ""protein tyrosine phosphatase activity"", ""term"": {""id"": ""GO:0004725"", ""label"": ""protein tyrosine phosphatase activity""}}"																											
5098	5614	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	1	SOS1-Mediated RAS-GTP Loading	SOS1 gain-of-function mutations encode guanine nucleotide exchange factor variants with enhanced activity, increasing the rate of RAS-GDP to RAS-GTP conversion and amplifying downstream MAPK signaling.	biological_processes[0]	biological_processes	biological_processes			Ras guanyl-nucleotide exchange factor activity	GO:0005088	Ras guanyl-nucleotide exchange factor activity		"{""preferred_term"": ""Ras guanyl-nucleotide exchange factor activity"", ""term"": {""id"": ""GO:0005088"", ""label"": ""Ras guanyl-nucleotide exchange factor activity""}}"																											
5099	5615	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	2	RAF1 Kinase Hyperactivation	RAF1 mutations, particularly those altering Ser259 and flanking residues, disrupt 14-3-3 binding and autoinhibition, resulting in constitutively elevated serine-threonine kinase activity and enhanced MEK phosphorylation.	biological_processes[0]	biological_processes	biological_processes			protein serine/threonine kinase activity	GO:0004674	protein serine/threonine kinase activity		"{""preferred_term"": ""protein serine/threonine kinase activity"", ""term"": {""id"": ""GO:0004674"", ""label"": ""protein serine/threonine kinase activity""}}"																											
5100	5616	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	3	RIT1-Mediated RAF Recruitment	RIT1 gain-of-function mutations cause aberrant membrane localization and RAF recruitment, bypassing normal RAS regulation and driving excessive MAPK pathway activation.	biological_processes[0]	biological_processes	biological_processes			Ras protein signal transduction	GO:0007265	Ras protein signal transduction		"{""preferred_term"": ""Ras protein signal transduction"", ""term"": {""id"": ""GO:0007265"", ""label"": ""Ras protein signal transduction""}}"																											
5101	5617	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	4	LZTR1-Mediated RAS Proteostasis Defect	Loss of LZTR1-mediated RAS proteostasis through CRL3 E3 ligase increases RAS-family protein levels (including MRAS, RIT1, and KRAS) and MAPK signaling. Dominant LZTR1 mutations act in a dominant-negative manner to disrupt ubiquitination and degradation of RAS proteins.	biological_processes[0]	biological_processes	biological_processes			protein ubiquitination	GO:0016567	protein ubiquitination		"{""preferred_term"": ""protein ubiquitination"", ""term"": {""id"": ""GO:0016567"", ""label"": ""protein ubiquitination""}}"																											
5102	5617	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	4	LZTR1-Mediated RAS Proteostasis Defect	Loss of LZTR1-mediated RAS proteostasis through CRL3 E3 ligase increases RAS-family protein levels (including MRAS, RIT1, and KRAS) and MAPK signaling. Dominant LZTR1 mutations act in a dominant-negative manner to disrupt ubiquitination and degradation of RAS proteins.	biological_processes[1]	biological_processes	biological_processes			regulation of proteolysis	GO:0030162	regulation of proteolysis		"{""preferred_term"": ""regulation of proteolysis"", ""term"": {""id"": ""GO:0030162"", ""label"": ""regulation of proteolysis""}}"																											
5103	5618	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	5	ERK Cascade Hyperactivation	Convergent point where all upstream RAS-MAPK pathway defects lead to sustained ERK1/2 phosphorylation and hyperactivation. This affects cell proliferation, differentiation, and survival during embryonic development and postnatal life.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"																											
5104	5618	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	5	ERK Cascade Hyperactivation	Convergent point where all upstream RAS-MAPK pathway defects lead to sustained ERK1/2 phosphorylation and hyperactivation. This affects cell proliferation, differentiation, and survival during embryonic development and postnatal life.	biological_processes[1]	biological_processes	biological_processes			regulation of ERK1 and ERK2 cascade	GO:0070372	regulation of ERK1 and ERK2 cascade		"{""preferred_term"": ""regulation of ERK1 and ERK2 cascade"", ""term"": {""id"": ""GO:0070372"", ""label"": ""regulation of ERK1 and ERK2 cascade""}}"																											
5105	5619	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	6	Cardiac Valve Morphogenesis Defects	In endocardial and valvular tissues, perturbed ERK signaling alters endocardial-mesenchymal transition and valve morphogenesis, underlying pulmonary valve stenosis, the most common cardiac defect in Noonan syndrome.	biological_processes[0]	biological_processes	biological_processes			endocardial cushion to mesenchymal transition	GO:0001837	epithelial to mesenchymal transition involved in endocardial cushion formation		"{""preferred_term"": ""endocardial cushion to mesenchymal transition"", ""term"": {""id"": ""GO:0001837"", ""label"": ""epithelial to mesenchymal transition involved in endocardial cushion formation""}}"																											
5106	5619	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	6	Cardiac Valve Morphogenesis Defects	In endocardial and valvular tissues, perturbed ERK signaling alters endocardial-mesenchymal transition and valve morphogenesis, underlying pulmonary valve stenosis, the most common cardiac defect in Noonan syndrome.	biological_processes[1]	biological_processes	biological_processes			heart valve morphogenesis	GO:0003179	heart valve morphogenesis		"{""preferred_term"": ""heart valve morphogenesis"", ""term"": {""id"": ""GO:0003179"", ""label"": ""heart valve morphogenesis""}}"																											
5107	5619	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	6	Cardiac Valve Morphogenesis Defects	In endocardial and valvular tissues, perturbed ERK signaling alters endocardial-mesenchymal transition and valve morphogenesis, underlying pulmonary valve stenosis, the most common cardiac defect in Noonan syndrome.	cell_types[0]	cell_types	cell_types			endocardial cell	CL:0002350	endocardial cell		"{""preferred_term"": ""endocardial cell"", ""term"": {""id"": ""CL:0002350"", ""label"": ""endocardial cell""}}"																											
5108	5619	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	6	Cardiac Valve Morphogenesis Defects	In endocardial and valvular tissues, perturbed ERK signaling alters endocardial-mesenchymal transition and valve morphogenesis, underlying pulmonary valve stenosis, the most common cardiac defect in Noonan syndrome.	locations[0]	locations	locations			pulmonary valve	UBERON:0002146	pulmonary valve		"{""preferred_term"": ""pulmonary valve"", ""term"": {""id"": ""UBERON:0002146"", ""label"": ""pulmonary valve""}}"																											
5109	5619	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	6	Cardiac Valve Morphogenesis Defects	In endocardial and valvular tissues, perturbed ERK signaling alters endocardial-mesenchymal transition and valve morphogenesis, underlying pulmonary valve stenosis, the most common cardiac defect in Noonan syndrome.	locations[1]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
5110	5620	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	7	Cardiomyocyte Hypertrophy	In cardiomyocytes, sustained ERK signaling (and intersecting AKT/mTOR activity) promotes hypertrophic growth and fetal gene reprogramming, leading to hypertrophic cardiomyopathy, particularly in patients with RAF1 and RIT1 mutations.	biological_processes[0]	biological_processes	biological_processes			cardiac muscle hypertrophy	GO:0003300	cardiac muscle hypertrophy		"{""preferred_term"": ""cardiac muscle hypertrophy"", ""term"": {""id"": ""GO:0003300"", ""label"": ""cardiac muscle hypertrophy""}}"																											
5111	5620	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	7	Cardiomyocyte Hypertrophy	In cardiomyocytes, sustained ERK signaling (and intersecting AKT/mTOR activity) promotes hypertrophic growth and fetal gene reprogramming, leading to hypertrophic cardiomyopathy, particularly in patients with RAF1 and RIT1 mutations.	cell_types[0]	cell_types	cell_types			cardiomyocyte	CL:0000746	cardiac muscle cell		"{""preferred_term"": ""cardiomyocyte"", ""term"": {""id"": ""CL:0000746"", ""label"": ""cardiac muscle cell""}}"																											
5112	5620	236	Noonan Syndrome	Noonan_Syndrome.yaml	pathophysiology	7	Cardiomyocyte Hypertrophy	In cardiomyocytes, sustained ERK signaling (and intersecting AKT/mTOR activity) promotes hypertrophic growth and fetal gene reprogramming, leading to hypertrophic cardiomyopathy, particularly in patients with RAF1 and RIT1 mutations.	locations[0]	locations	locations			heart	UBERON:0000948	heart		"{""preferred_term"": ""heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
5113	5621	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	0	Hypertelorism	Widely spaced eyes are a characteristic facial feature of Noonan syndrome.	phenotype_term	phenotype_term	$	Hypertelorism	Widely spaced eyes are a characteristic facial feature of Noonan syndrome.	Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
5114	5622	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	1	Downslanted Palpebral Fissures	Downward slanting of the eye openings is a common facial feature.	phenotype_term	phenotype_term	$	Downslanted Palpebral Fissures	Downward slanting of the eye openings is a common facial feature.	Downslanted palpebral fissures	HP:0000494	Downslanted palpebral fissures		"{""preferred_term"": ""Downslanted palpebral fissures"", ""term"": {""id"": ""HP:0000494"", ""label"": ""Downslanted palpebral fissures""}}"																											
5115	5623	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	2	Ptosis	Drooping of the upper eyelids is frequently observed.	phenotype_term	phenotype_term	$	Ptosis	Drooping of the upper eyelids is frequently observed.	Ptosis	HP:0000508	Ptosis		"{""preferred_term"": ""Ptosis"", ""term"": {""id"": ""HP:0000508"", ""label"": ""Ptosis""}}"																											
5116	5624	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	3	Low-set Ears	Posteriorly rotated, low-set ears are characteristic.	phenotype_term	phenotype_term	$	Low-set Ears	Posteriorly rotated, low-set ears are characteristic.	Low-set ears	HP:0000369	Low-set ears		"{""preferred_term"": ""Low-set ears"", ""term"": {""id"": ""HP:0000369"", ""label"": ""Low-set ears""}}"																											
5117	5625	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	4	Webbed Neck	Excess skin on the lateral neck creating a webbed appearance.	phenotype_term	phenotype_term	$	Webbed Neck	Excess skin on the lateral neck creating a webbed appearance.	Webbed neck	HP:0000465	Webbed neck		"{""preferred_term"": ""Webbed neck"", ""term"": {""id"": ""HP:0000465"", ""label"": ""Webbed neck""}}"																											
5118	5626	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	5	Pulmonary Valve Stenosis	Dysplastic pulmonary valve stenosis is the most common cardiac defect, occurring in approximately 50-60% of patients. Associated with PTPN11 and SOS1 genotypes.	phenotype_term	phenotype_term	$	Pulmonary Valve Stenosis	Dysplastic pulmonary valve stenosis is the most common cardiac defect, occurring in approximately 50-60% of patients. Associated with PTPN11 and SOS1 genotypes.	Pulmonic stenosis	HP:0001642	Pulmonic stenosis		"{""preferred_term"": ""Pulmonic stenosis"", ""term"": {""id"": ""HP:0001642"", ""label"": ""Pulmonic stenosis""}}"																											
5119	5627	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	6	Hypertrophic Cardiomyopathy	Left ventricular hypertrophy occurring in approximately 20% of patients overall, but up to 70-95% in those with RAF1 or RIT1 mutations. Can be present at birth or develop during infancy.	phenotype_term	phenotype_term	$	Hypertrophic Cardiomyopathy	Left ventricular hypertrophy occurring in approximately 20% of patients overall, but up to 70-95% in those with RAF1 or RIT1 mutations. Can be present at birth or develop during infancy.	Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
5120	5628	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	7	Atrial Septal Defect	Atrial septal defects occur in 6-10% of individuals with Noonan syndrome.	phenotype_term	phenotype_term	$	Atrial Septal Defect	Atrial septal defects occur in 6-10% of individuals with Noonan syndrome.	Atrial septal defect	HP:0001631	Atrial septal defect		"{""preferred_term"": ""Atrial septal defect"", ""term"": {""id"": ""HP:0001631"", ""label"": ""Atrial septal defect""}}"																											
5121	5629	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	8	Short Stature	Postnatal growth retardation resulting in adult height typically at or below the third percentile for the general population. Linked to RAS/MAPK effects on GH signaling and chondrocyte differentiation.	phenotype_term	phenotype_term	$	Short Stature	Postnatal growth retardation resulting in adult height typically at or below the third percentile for the general population. Linked to RAS/MAPK effects on GH signaling and chondrocyte differentiation.	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5122	5630	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	9	Pectus Deformity	Chest wall deformities including pectus excavatum and pectus carinatum are common.	phenotype_term	phenotype_term	$	Pectus Deformity	Chest wall deformities including pectus excavatum and pectus carinatum are common.	Pectus excavatum	HP:0000767	Pectus excavatum		"{""preferred_term"": ""Pectus excavatum"", ""term"": {""id"": ""HP:0000767"", ""label"": ""Pectus excavatum""}}"																											
5123	5631	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	10	Cryptorchidism	Undescended testes in males is a common finding.	phenotype_term	phenotype_term	$	Cryptorchidism	Undescended testes in males is a common finding.	Cryptorchidism	HP:0000028	Cryptorchidism		"{""preferred_term"": ""Cryptorchidism"", ""term"": {""id"": ""HP:0000028"", ""label"": ""Cryptorchidism""}}"																											
5124	5632	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	11	Bruising Susceptibility	Coagulation defects including factor XI deficiency and platelet dysfunction, leading to easy bruising and prolonged bleeding after surgery or trauma.	phenotype_term	phenotype_term	$	Bruising Susceptibility	Coagulation defects including factor XI deficiency and platelet dysfunction, leading to easy bruising and prolonged bleeding after surgery or trauma.	Bruising susceptibility	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""Bruising susceptibility"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
5125	5633	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	12	Lymphedema	Peripheral lymphedema and central conducting lymphatic anomalies occur in a substantial minority. ERK/SOX18 signaling axis is implicated in lymphatic dysplasia.	phenotype_term	phenotype_term	$	Lymphedema	Peripheral lymphedema and central conducting lymphatic anomalies occur in a substantial minority. ERK/SOX18 signaling axis is implicated in lymphatic dysplasia.	Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
5126	5634	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	13	Global Developmental Delay	Mild cognitive impairment and motor delays are common, with learning disabilities in approximately 25% of individuals.	phenotype_term	phenotype_term	$	Global Developmental Delay	Mild cognitive impairment and motor delays are common, with learning disabilities in approximately 25% of individuals.	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5127	5635	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	14	Mild Intellectual Disability	Approximately 15-35% of individuals have mild intellectual disability.	phenotype_term	phenotype_term	$	Mild Intellectual Disability	Approximately 15-35% of individuals have mild intellectual disability.	Mild intellectual disability	HP:0001256	Mild intellectual disability		"{""preferred_term"": ""Mild intellectual disability"", ""term"": {""id"": ""HP:0001256"", ""label"": ""Mild intellectual disability""}}"																											
5128	5636	236	Noonan Syndrome	Noonan_Syndrome.yaml	phenotypes	15	Feeding Difficulties in Infancy	Many infants experience feeding difficulties and failure to thrive in early life.	phenotype_term	phenotype_term	$	Feeding Difficulties in Infancy	Many infants experience feeding difficulties and failure to thrive in early life.	Feeding difficulties in infancy	HP:0008872	Feeding difficulties in infancy		"{""preferred_term"": ""Feeding difficulties in infancy"", ""term"": {""id"": ""HP:0008872"", ""label"": ""Feeding difficulties in infancy""}}"																											
5129	5637	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	0	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	treatment_term	treatment_term	$	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	human growth hormone replacement therapy	MAXO:0000780	human growth hormone replacement therapy		"{""preferred_term"": ""human growth hormone replacement therapy"", ""term"": {""id"": ""MAXO:0000780"", ""label"": ""human growth hormone replacement therapy""}}"																											
5130	5637	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	0	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5131	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	treatment_term	treatment_term	$	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5132	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonic stenosis	HP:0001642	Pulmonic stenosis		"{""preferred_term"": ""Pulmonic stenosis"", ""term"": {""id"": ""HP:0001642"", ""label"": ""Pulmonic stenosis""}}"																											
5133	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
5134	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	treatment_term	treatment_term	$	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5135	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
5136	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
5137	5640	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	3	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	treatment_term	treatment_term	$	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	early intervention services	MAXO:0009101	early intervention services		"{""preferred_term"": ""early intervention services"", ""term"": {""id"": ""MAXO:0009101"", ""label"": ""early intervention services""}}"																											
5138	5640	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	3	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5139	5641	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	4	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	treatment_term	treatment_term	$	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
5140	5641	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	4	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5141	5642	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	5	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	treatment_term	treatment_term	$	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5142	5642	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	5	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5143	5647	237	Obesity	Obesity.yaml	datasets	0		Whole metagenome shotgun sequencing characterizing gut microbial community of obese patients following weight-loss intervention. Tracks microbiome changes with weight loss.	organism	organism	$		Whole metagenome shotgun sequencing characterizing gut microbial community of obese patients following weight-loss intervention. Tracks microbiome changes with weight loss.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5144	5647	237	Obesity	Obesity.yaml	datasets	0		Whole metagenome shotgun sequencing characterizing gut microbial community of obese patients following weight-loss intervention. Tracks microbiome changes with weight loss.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5145	5647	237	Obesity	Obesity.yaml	datasets	0		Whole metagenome shotgun sequencing characterizing gut microbial community of obese patients following weight-loss intervention. Tracks microbiome changes with weight loss.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5146	5648	237	Obesity	Obesity.yaml	datasets	1		Shotgun metagenomics examining taxonomic and functional differences between microbiomes of youth with obesity with and without non-alcoholic fatty liver disease (NAFLD).	organism	organism	$		Shotgun metagenomics examining taxonomic and functional differences between microbiomes of youth with obesity with and without non-alcoholic fatty liver disease (NAFLD).	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5147	5648	237	Obesity	Obesity.yaml	datasets	1		Shotgun metagenomics examining taxonomic and functional differences between microbiomes of youth with obesity with and without non-alcoholic fatty liver disease (NAFLD).	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5148	5648	237	Obesity	Obesity.yaml	datasets	1		Shotgun metagenomics examining taxonomic and functional differences between microbiomes of youth with obesity with and without non-alcoholic fatty liver disease (NAFLD).	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5149	5649	237	Obesity	Obesity.yaml	datasets	2		Metagenomic characterization of gut microbiome in metabolically healthy obese (MHO) patients and correlations with metabolic and inflammatory profiles. 120 obese individuals without metabolic comorbidities.	organism	organism	$		Metagenomic characterization of gut microbiome in metabolically healthy obese (MHO) patients and correlations with metabolic and inflammatory profiles. 120 obese individuals without metabolic comorbidities.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5150	5649	237	Obesity	Obesity.yaml	datasets	2		Metagenomic characterization of gut microbiome in metabolically healthy obese (MHO) patients and correlations with metabolic and inflammatory profiles. 120 obese individuals without metabolic comorbidities.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5151	5649	237	Obesity	Obesity.yaml	datasets	2		Metagenomic characterization of gut microbiome in metabolically healthy obese (MHO) patients and correlations with metabolic and inflammatory profiles. 120 obese individuals without metabolic comorbidities.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5152	5650	237	Obesity	Obesity.yaml	datasets	3		High-resolution analysis of intra-species diversity in gut microbiome focusing on Clostridia class associations with obesity. 16S rRNA, dnaK, and gyrB gene sequencing.	organism	organism	$		High-resolution analysis of intra-species diversity in gut microbiome focusing on Clostridia class associations with obesity. 16S rRNA, dnaK, and gyrB gene sequencing.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5153	5650	237	Obesity	Obesity.yaml	datasets	3		High-resolution analysis of intra-species diversity in gut microbiome focusing on Clostridia class associations with obesity. 16S rRNA, dnaK, and gyrB gene sequencing.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5154	5650	237	Obesity	Obesity.yaml	datasets	3		High-resolution analysis of intra-species diversity in gut microbiome focusing on Clostridia class associations with obesity. 16S rRNA, dnaK, and gyrB gene sequencing.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5155	5661	237	Obesity	Obesity.yaml	pathophysiology	0	Energy Imbalance	"Chronic positive energy balance from excess caloric intake relative to expenditure leads to fat accumulation. Multiple regulatory systems (leptin, ghrelin, insulin) fail to restore balance.
"	biological_processes[0]	biological_processes	biological_processes			Energy Homeostasis	GO:0097009	energy homeostasis		"{""preferred_term"": ""Energy Homeostasis"", ""term"": {""id"": ""GO:0097009"", ""label"": ""energy homeostasis""}}"																											
5156	5662	237	Obesity	Obesity.yaml	pathophysiology	1	Adipose Tissue Dysfunction	"Expanded adipose tissue becomes dysfunctional with increased inflammation, altered adipokine secretion, and impaired metabolic function. Adipocyte hypertrophy leads to hypoxia and macrophage infiltration.
"	cell_types[0]	cell_types	cell_types			Adipocyte	CL:0000136	adipocyte		"{""preferred_term"": ""Adipocyte"", ""term"": {""id"": ""CL:0000136"", ""label"": ""adipocyte""}}"																											
5157	5662	237	Obesity	Obesity.yaml	pathophysiology	1	Adipose Tissue Dysfunction	"Expanded adipose tissue becomes dysfunctional with increased inflammation, altered adipokine secretion, and impaired metabolic function. Adipocyte hypertrophy leads to hypoxia and macrophage infiltration.
"	cell_types[1]	cell_types	cell_types			Adipose Tissue Macrophage	CL:0000863	inflammatory macrophage		"{""preferred_term"": ""Adipose Tissue Macrophage"", ""term"": {""id"": ""CL:0000863"", ""label"": ""inflammatory macrophage""}}"																											
5158	5662	237	Obesity	Obesity.yaml	pathophysiology	1	Adipose Tissue Dysfunction	"Expanded adipose tissue becomes dysfunctional with increased inflammation, altered adipokine secretion, and impaired metabolic function. Adipocyte hypertrophy leads to hypoxia and macrophage infiltration.
"	biological_processes[0]	biological_processes	biological_processes			Adipokine Secretion	GO:0070163	regulation of adiponectin secretion		"{""preferred_term"": ""Adipokine Secretion"", ""term"": {""id"": ""GO:0070163"", ""label"": ""regulation of adiponectin secretion""}}"																											
5159	5663	237	Obesity	Obesity.yaml	pathophysiology	2	Chronic Low-Grade Inflammation	"Systemic inflammation from adipose tissue contributes to insulin resistance, cardiovascular disease, and other complications. Elevated CRP, IL-6, and TNF-alpha levels.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5160	5664	237	Obesity	Obesity.yaml	pathophysiology	3	Hypothalamic Dysregulation	"Central appetite regulation becomes impaired with leptin resistance and altered reward signaling, perpetuating overeating despite adequate energy stores. Hypothalamic neuroinflammation involves microglial and astrocyte activation that impairs melanocortin signaling.
"	cell_types[0]	cell_types	cell_types			Hypothalamus Cell	CL:2000030	hypothalamus cell		"{""preferred_term"": ""Hypothalamus Cell"", ""term"": {""id"": ""CL:2000030"", ""label"": ""hypothalamus cell""}}"																											
5161	5664	237	Obesity	Obesity.yaml	pathophysiology	3	Hypothalamic Dysregulation	"Central appetite regulation becomes impaired with leptin resistance and altered reward signaling, perpetuating overeating despite adequate energy stores. Hypothalamic neuroinflammation involves microglial and astrocyte activation that impairs melanocortin signaling.
"	cell_types[1]	cell_types	cell_types			Microglial Cell	CL:0000129	microglial cell		"{""preferred_term"": ""Microglial Cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
5162	5664	237	Obesity	Obesity.yaml	pathophysiology	3	Hypothalamic Dysregulation	"Central appetite regulation becomes impaired with leptin resistance and altered reward signaling, perpetuating overeating despite adequate energy stores. Hypothalamic neuroinflammation involves microglial and astrocyte activation that impairs melanocortin signaling.
"	biological_processes[0]	biological_processes	biological_processes			Feeding Behavior	GO:0007631	feeding behavior		"{""preferred_term"": ""Feeding Behavior"", ""term"": {""id"": ""GO:0007631"", ""label"": ""feeding behavior""}}"																											
5163	5665	237	Obesity	Obesity.yaml	pathophysiology	4	Adipocyte Mitochondrial Dysfunction	"Obesity causes mitochondrial fragmentation in white adipocytes through RalA-mediated activation of the fission protein DRP1 (DNM1L). This leads to reduced oxidative capacity and contributes to weight gain and insulin resistance. Mitochondrial dynamics shift toward excessive fission.
"	cell_types[0]	cell_types	cell_types			Adipocyte	CL:0000136	adipocyte		"{""preferred_term"": ""Adipocyte"", ""term"": {""id"": ""CL:0000136"", ""label"": ""adipocyte""}}"																											
5164	5665	237	Obesity	Obesity.yaml	pathophysiology	4	Adipocyte Mitochondrial Dysfunction	"Obesity causes mitochondrial fragmentation in white adipocytes through RalA-mediated activation of the fission protein DRP1 (DNM1L). This leads to reduced oxidative capacity and contributes to weight gain and insulin resistance. Mitochondrial dynamics shift toward excessive fission.
"	biological_processes[0]	biological_processes	biological_processes			Mitochondrial Fission	GO:0000266	mitochondrial fission		"{""preferred_term"": ""Mitochondrial Fission"", ""term"": {""id"": ""GO:0000266"", ""label"": ""mitochondrial fission""}}"																											
5165	5665	237	Obesity	Obesity.yaml	pathophysiology	4	Adipocyte Mitochondrial Dysfunction	"Obesity causes mitochondrial fragmentation in white adipocytes through RalA-mediated activation of the fission protein DRP1 (DNM1L). This leads to reduced oxidative capacity and contributes to weight gain and insulin resistance. Mitochondrial dynamics shift toward excessive fission.
"	biological_processes[1]	biological_processes	biological_processes			Fatty Acid Oxidation	GO:0019395	fatty acid oxidation		"{""preferred_term"": ""Fatty Acid Oxidation"", ""term"": {""id"": ""GO:0019395"", ""label"": ""fatty acid oxidation""}}"																											
5166	5666	237	Obesity	Obesity.yaml	phenotypes	0	Increased Body Mass Index		phenotype_term	phenotype_term	$	Increased Body Mass Index		Obesity	HP:0001513	Obesity		"{""preferred_term"": ""Obesity"", ""term"": {""id"": ""HP:0001513"", ""label"": ""Obesity""}}"																											
5167	5667	237	Obesity	Obesity.yaml	phenotypes	1	Insulin Resistance		phenotype_term	phenotype_term	$	Insulin Resistance		Insulin Resistance	HP:0000855	Insulin resistance		"{""preferred_term"": ""Insulin Resistance"", ""term"": {""id"": ""HP:0000855"", ""label"": ""Insulin resistance""}}"																											
5168	5668	237	Obesity	Obesity.yaml	phenotypes	2	Dyslipidemia		phenotype_term	phenotype_term	$	Dyslipidemia		Dyslipidemia	HP:0003077	Hyperlipidemia		"{""preferred_term"": ""Dyslipidemia"", ""term"": {""id"": ""HP:0003077"", ""label"": ""Hyperlipidemia""}}"																											
5169	5669	237	Obesity	Obesity.yaml	phenotypes	3	Hypertension		phenotype_term	phenotype_term	$	Hypertension		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
5170	5670	237	Obesity	Obesity.yaml	phenotypes	4	Obstructive Sleep Apnea		phenotype_term	phenotype_term	$	Obstructive Sleep Apnea		Sleep Apnea	HP:0010535	Sleep apnea		"{""preferred_term"": ""Sleep Apnea"", ""term"": {""id"": ""HP:0010535"", ""label"": ""Sleep apnea""}}"																											
5171	5671	237	Obesity	Obesity.yaml	phenotypes	5	Joint Pain		phenotype_term	phenotype_term	$	Joint Pain		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
5172	5672	237	Obesity	Obesity.yaml	phenotypes	6	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5173	5673	237	Obesity	Obesity.yaml	treatments	0	Lifestyle Modification	Dietary changes and increased physical activity as foundation of treatment.	treatment_term	treatment_term	$	Lifestyle Modification	Dietary changes and increased physical activity as foundation of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5174	5674	237	Obesity	Obesity.yaml	treatments	1	GLP-1 Receptor Agonists	Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.	treatment_term	treatment_term	$	GLP-1 Receptor Agonists	Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5175	5675	237	Obesity	Obesity.yaml	treatments	2	GLP-1/GIP Dual Agonists	Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.	treatment_term	treatment_term	$	GLP-1/GIP Dual Agonists	Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5176	5676	237	Obesity	Obesity.yaml	treatments	3	Bariatric Surgery	Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.	treatment_term	treatment_term	$	Bariatric Surgery	Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5177	5677	237	Obesity	Obesity.yaml	treatments	4	Behavioral Therapy	Cognitive behavioral therapy for eating behaviors.	treatment_term	treatment_term	$	Behavioral Therapy	Cognitive behavioral therapy for eating behaviors.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
5178	5678	237	Obesity	Obesity.yaml	treatments	5	Orlistat	Lipase inhibitor reducing fat absorption.	treatment_term	treatment_term	$	Orlistat	Lipase inhibitor reducing fat absorption.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5179	5689	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	pathophysiology	0	Upper Airway Collapse	"During sleep, reduced muscle tone allows pharyngeal soft tissues to collapse, obstructing airflow. Anatomical factors (retrognathia, large tonsils, obesity) predispose to collapse.
"	biological_processes[0]	biological_processes	biological_processes			Muscle Relaxation	GO:0006939	smooth muscle contraction		"{""preferred_term"": ""Muscle Relaxation"", ""term"": {""id"": ""GO:0006939"", ""label"": ""smooth muscle contraction""}}"																											
5180	5690	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	pathophysiology	1	Intermittent Hypoxia	"Repeated episodes of oxygen desaturation trigger oxidative stress, sympathetic activation, and systemic inflammation. Contributes to cardiovascular complications.
"	biological_processes[0]	biological_processes	biological_processes			Response to Hypoxia	GO:0001666	response to hypoxia		"{""preferred_term"": ""Response to Hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"																											
5181	5691	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	pathophysiology	2	Sleep Fragmentation	"Frequent arousals to restore airway patency disrupt sleep architecture, reducing restorative sleep and causing daytime sleepiness.
"	biological_processes[0]	biological_processes	biological_processes			Sleep Regulation	GO:0030431	sleep		"{""preferred_term"": ""Sleep Regulation"", ""term"": {""id"": ""GO:0030431"", ""label"": ""sleep""}}"																											
5182	5693	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	pathophysiology	4	Systemic Inflammation	"Intermittent hypoxia activates inflammatory pathways (NF-kB), elevating CRP, IL-6, and TNF-alpha. Contributes to metabolic dysfunction and atherosclerosis.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5183	5694	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	0	Snoring		phenotype_term	phenotype_term	$	Snoring		Snoring	HP:0025267	Snoring		"{""preferred_term"": ""Snoring"", ""term"": {""id"": ""HP:0025267"", ""label"": ""Snoring""}}"																											
5184	5695	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	1	Witnessed Apneas		phenotype_term	phenotype_term	$	Witnessed Apneas		Sleep Apnea	HP:0010535	Sleep apnea		"{""preferred_term"": ""Sleep Apnea"", ""term"": {""id"": ""HP:0010535"", ""label"": ""Sleep apnea""}}"																											
5185	5696	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	2	Excessive Daytime Sleepiness		phenotype_term	phenotype_term	$	Excessive Daytime Sleepiness		Excessive Daytime Somnolence	HP:0001262	Excessive daytime somnolence		"{""preferred_term"": ""Excessive Daytime Somnolence"", ""term"": {""id"": ""HP:0001262"", ""label"": ""Excessive daytime somnolence""}}"																											
5186	5697	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	3	Morning Headaches		phenotype_term	phenotype_term	$	Morning Headaches		Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
5187	5698	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	4	Nocturia		phenotype_term	phenotype_term	$	Nocturia		Nocturia	HP:0000017	Nocturia		"{""preferred_term"": ""Nocturia"", ""term"": {""id"": ""HP:0000017"", ""label"": ""Nocturia""}}"																											
5188	5699	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	5	Cognitive Impairment		phenotype_term	phenotype_term	$	Cognitive Impairment		Cognitive Impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive Impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
5189	5700	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	phenotypes	6	Hypertension		phenotype_term	phenotype_term	$	Hypertension		Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
5190	5708	239	Onchocerciasis	Onchocerciasis.yaml	infectious_agent	0	Onchocerca volvulus	Filarial nematode responsible for onchocerciasis.	infectious_agent_term	infectious_agent_term	$	Onchocerca volvulus	Filarial nematode responsible for onchocerciasis.	Onchocerca volvulus	NCBITaxon:6282	Onchocerca volvulus		"{""preferred_term"": ""Onchocerca volvulus"", ""term"": {""id"": ""NCBITaxon:6282"", ""label"": ""Onchocerca volvulus""}}"																											
5191	5709	239	Onchocerciasis	Onchocerciasis.yaml	phenotypes	0	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5192	5710	239	Onchocerciasis	Onchocerciasis.yaml	phenotypes	1	Dermatitis		phenotype_term	phenotype_term	$	Dermatitis		Eczematoid dermatitis	HP:0000964	Eczematoid dermatitis		"{""preferred_term"": ""Eczematoid dermatitis"", ""term"": {""id"": ""HP:0000964"", ""label"": ""Eczematoid dermatitis""}}"																											
5193	5711	239	Onchocerciasis	Onchocerciasis.yaml	phenotypes	2	Blindness		phenotype_term	phenotype_term	$	Blindness		Blindness	HP:0000618	Blindness		"{""preferred_term"": ""Blindness"", ""term"": {""id"": ""HP:0000618"", ""label"": ""Blindness""}}"																											
5194	5713	239	Onchocerciasis	Onchocerciasis.yaml	treatments	0	Ivermectin therapy	Ivermectin is the drug of choice for skin and ocular manifestations.	treatment_term	treatment_term	$	Ivermectin therapy	Ivermectin is the drug of choice for skin and ocular manifestations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5195	5725	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	0	Cartilage Degradation	"Progressive loss of articular cartilage due to imbalance between catabolic and anabolic processes. Matrix metalloproteinases and aggrecanases degrade cartilage components.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
5196	5725	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	0	Cartilage Degradation	"Progressive loss of articular cartilage due to imbalance between catabolic and anabolic processes. Matrix metalloproteinases and aggrecanases degrade cartilage components.
"	biological_processes[0]	biological_processes	biological_processes			Cartilage Catabolism	GO:0071346	cellular response to interferon-gamma		"{""preferred_term"": ""Cartilage Catabolism"", ""term"": {""id"": ""GO:0071346"", ""label"": ""cellular response to interferon-gamma""}}"																											
5197	5726	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	1	Subchondral Bone Changes	"Bone remodeling with subchondral sclerosis, cyst formation, and osteophyte development at joint margins. Bone changes may precede and contribute to cartilage damage.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5198	5726	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	1	Subchondral Bone Changes	"Bone remodeling with subchondral sclerosis, cyst formation, and osteophyte development at joint margins. Bone changes may precede and contribute to cartilage damage.
"	cell_types[1]	cell_types	cell_types			Osteoclast	CL:0000092	osteoclast		"{""preferred_term"": ""Osteoclast"", ""term"": {""id"": ""CL:0000092"", ""label"": ""osteoclast""}}"																											
5199	5727	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	2	Synovial Inflammation	"Low-grade synovitis with macrophage infiltration contributes to pain and cartilage destruction through inflammatory mediator release.
"	cell_types[0]	cell_types	cell_types			Synoviocyte	CL:0000214	synovial cell		"{""preferred_term"": ""Synoviocyte"", ""term"": {""id"": ""CL:0000214"", ""label"": ""synovial cell""}}"																											
5200	5727	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	2	Synovial Inflammation	"Low-grade synovitis with macrophage infiltration contributes to pain and cartilage destruction through inflammatory mediator release.
"	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
5201	5727	240	Osteoarthritis	Osteoarthritis.yaml	pathophysiology	2	Synovial Inflammation	"Low-grade synovitis with macrophage infiltration contributes to pain and cartilage destruction through inflammatory mediator release.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5202	5728	240	Osteoarthritis	Osteoarthritis.yaml	phenotypes	0	Joint Pain		phenotype_term	phenotype_term	$	Joint Pain		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
5203	5729	240	Osteoarthritis	Osteoarthritis.yaml	phenotypes	1	Joint Stiffness		phenotype_term	phenotype_term	$	Joint Stiffness		Joint Stiffness	HP:0001387	Joint stiffness		"{""preferred_term"": ""Joint Stiffness"", ""term"": {""id"": ""HP:0001387"", ""label"": ""Joint stiffness""}}"																											
5204	5730	240	Osteoarthritis	Osteoarthritis.yaml	phenotypes	2	Joint Swelling		phenotype_term	phenotype_term	$	Joint Swelling		Joint Swelling	HP:0001386	Joint swelling		"{""preferred_term"": ""Joint Swelling"", ""term"": {""id"": ""HP:0001386"", ""label"": ""Joint swelling""}}"																											
5205	5731	240	Osteoarthritis	Osteoarthritis.yaml	phenotypes	3	Reduced Range of Motion		phenotype_term	phenotype_term	$	Reduced Range of Motion		Limited Joint Mobility	HP:0001376	Limitation of joint mobility		"{""preferred_term"": ""Limited Joint Mobility"", ""term"": {""id"": ""HP:0001376"", ""label"": ""Limitation of joint mobility""}}"																											
5206	5732	240	Osteoarthritis	Osteoarthritis.yaml	phenotypes	4	Crepitus		phenotype_term	phenotype_term	$	Crepitus		Joint Crepitus	HP:0034431	Joint crepitus		"{""preferred_term"": ""Joint Crepitus"", ""term"": {""id"": ""HP:0034431"", ""label"": ""Joint crepitus""}}"																											
5207	5742	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	pathophysiology	0	Type I Collagen Haploinsufficiency	"Null mutations in COL1A1 (nonsense, frameshift, splice site mutations causing nonsense-mediated mRNA decay) result in ~50% reduction in type I collagen production. The collagen that is produced has normal structure, explaining the milder phenotype compared to dominant-negative structural mutations.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5208	5742	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	pathophysiology	0	Type I Collagen Haploinsufficiency	"Null mutations in COL1A1 (nonsense, frameshift, splice site mutations causing nonsense-mediated mRNA decay) result in ~50% reduction in type I collagen production. The collagen that is produced has normal structure, explaining the milder phenotype compared to dominant-negative structural mutations.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Fibril Organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""Collagen Fibril Organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
5209	5742	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	pathophysiology	0	Type I Collagen Haploinsufficiency	"Null mutations in COL1A1 (nonsense, frameshift, splice site mutations causing nonsense-mediated mRNA decay) result in ~50% reduction in type I collagen production. The collagen that is produced has normal structure, explaining the milder phenotype compared to dominant-negative structural mutations.
"	biological_processes[1]	biological_processes	biological_processes			Bone Development	GO:0060348	bone development		"{""preferred_term"": ""Bone Development"", ""term"": {""id"": ""GO:0060348"", ""label"": ""bone development""}}"																											
5210	5743	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	0	Blue Sclerae	"Blue or blue-gray scleral hue is characteristic and persists into adulthood, distinguishing type I from type IV OI where sclerae normalize with age.
"	phenotype_term	phenotype_term	$	Blue Sclerae	"Blue or blue-gray scleral hue is characteristic and persists into adulthood, distinguishing type I from type IV OI where sclerae normalize with age.
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5211	5744	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	1	Recurrent Fractures	"Increased bone fragility leads to fractures, often with minimal trauma. Fracture frequency is variable and typically decreases after puberty.
"	phenotype_term	phenotype_term	$	Recurrent Fractures	"Increased bone fragility leads to fractures, often with minimal trauma. Fracture frequency is variable and typically decreases after puberty.
"	Recurrent fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Recurrent fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5212	5745	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	2	Near-Normal Stature	"Height is typically in the low-normal range, distinguishing type I from the more severe forms with significant short stature.
"	phenotype_term	phenotype_term	$	Near-Normal Stature	"Height is typically in the low-normal range, distinguishing type I from the more severe forms with significant short stature.
"	Normal stature	HP:0000002	Abnormality of body height		"{""preferred_term"": ""Normal stature"", ""term"": {""id"": ""HP:0000002"", ""label"": ""Abnormality of body height""}}"																											
5213	5746	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	3	Hearing Impairment	"Progressive hearing loss develops in approximately 50% of adults with OI type I, typically beginning in the second or third decade.
"	phenotype_term	phenotype_term	$	Hearing Impairment	"Progressive hearing loss develops in approximately 50% of adults with OI type I, typically beginning in the second or third decade.
"	Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
5214	5747	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	4	Joint Hypermobility	"Generalized joint hypermobility due to connective tissue laxity.
"	phenotype_term	phenotype_term	$	Joint Hypermobility	"Generalized joint hypermobility due to connective tissue laxity.
"	Joint hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
5215	5748	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	phenotypes	5	Easy Bruising	"Increased tendency to bruise due to connective tissue fragility.
"	phenotype_term	phenotype_term	$	Easy Bruising	"Increased tendency to bruise due to connective tissue fragility.
"	Easy bruisability	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""Easy bruisability"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
5216	5749	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5217	5750	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	1	Physical Therapy	"Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.
"	treatment_term	treatment_term	$	Physical Therapy	"Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5218	5751	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	2	Fracture Management	"Standard orthopedic management of fractures with appropriate immobilization.
"	treatment_term	treatment_term	$	Fracture Management	"Standard orthopedic management of fractures with appropriate immobilization.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5219	5754	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	pathophysiology	0	Dominant-Negative Collagen Disruption	"Glycine substitutions in the Gly-X-Y repeat of the collagen triple helical domain disrupt normal helix formation. The abnormal alpha chains are incorporated into trimers, producing structurally defective collagen that cannot form proper fibrils (dominant-negative effect). This results in severe deficiency of functional bone matrix.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5220	5754	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	pathophysiology	0	Dominant-Negative Collagen Disruption	"Glycine substitutions in the Gly-X-Y repeat of the collagen triple helical domain disrupt normal helix formation. The abnormal alpha chains are incorporated into trimers, producing structurally defective collagen that cannot form proper fibrils (dominant-negative effect). This results in severe deficiency of functional bone matrix.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Fibril Organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""Collagen Fibril Organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
5221	5754	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	pathophysiology	0	Dominant-Negative Collagen Disruption	"Glycine substitutions in the Gly-X-Y repeat of the collagen triple helical domain disrupt normal helix formation. The abnormal alpha chains are incorporated into trimers, producing structurally defective collagen that cannot form proper fibrils (dominant-negative effect). This results in severe deficiency of functional bone matrix.
"	biological_processes[1]	biological_processes	biological_processes			Ossification	GO:0001503	ossification		"{""preferred_term"": ""Ossification"", ""term"": {""id"": ""GO:0001503"", ""label"": ""ossification""}}"																											
5222	5755	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	pathophysiology	1	ER Stress and Osteoblast Dysfunction	"Misfolded procollagen accumulates in the endoplasmic reticulum, triggering ER stress responses that impair osteoblast function and survival.
"	biological_processes[0]	biological_processes	biological_processes			ER Stress Response	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""ER Stress Response"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
5223	5756	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	0	Multiple Fractures	"Numerous fractures present at birth, including ribs, long bones, and skull. Fractures occur in utero from normal fetal movements.
"	phenotype_term	phenotype_term	$	Multiple Fractures	"Numerous fractures present at birth, including ribs, long bones, and skull. Fractures occur in utero from normal fetal movements.
"	Multiple fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Multiple fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5224	5757	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	1	Dark Sclerae	"Dark blue or gray sclerae due to extreme thinning, allowing visualization of underlying choroidal pigment.
"	phenotype_term	phenotype_term	$	Dark Sclerae	"Dark blue or gray sclerae due to extreme thinning, allowing visualization of underlying choroidal pigment.
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5225	5758	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	2	Severe Micromelia	"Extreme shortening of all limbs due to multiple fractures and impaired bone formation.
"	phenotype_term	phenotype_term	$	Severe Micromelia	"Extreme shortening of all limbs due to multiple fractures and impaired bone formation.
"	Micromelia	HP:0002983	Micromelia		"{""preferred_term"": ""Micromelia"", ""term"": {""id"": ""HP:0002983"", ""label"": ""Micromelia""}}"																											
5226	5759	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	3	Abnormal Rib Morphology	"Multiple rib fractures produce characteristic beaded appearance on imaging.
"	phenotype_term	phenotype_term	$	Abnormal Rib Morphology	"Multiple rib fractures produce characteristic beaded appearance on imaging.
"	Abnormal rib morphology	HP:0000772	Abnormal rib morphology		"{""preferred_term"": ""Abnormal rib morphology"", ""term"": {""id"": ""HP:0000772"", ""label"": ""Abnormal rib morphology""}}"																											
5227	5760	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	4	Pulmonary Hypoplasia	"Underdeveloped lungs secondary to small thoracic cage, contributing to perinatal lethality.
"	phenotype_term	phenotype_term	$	Pulmonary Hypoplasia	"Underdeveloped lungs secondary to small thoracic cage, contributing to perinatal lethality.
"	Pulmonary hypoplasia	HP:0002089	Pulmonary hypoplasia		"{""preferred_term"": ""Pulmonary hypoplasia"", ""term"": {""id"": ""HP:0002089"", ""label"": ""Pulmonary hypoplasia""}}"																											
5228	5761	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	phenotypes	5	Wormian Bones	"Multiple wormian (intrasutural) bones in the skull due to defective ossification.
"	phenotype_term	phenotype_term	$	Wormian Bones	"Multiple wormian (intrasutural) bones in the skull due to defective ossification.
"	Wormian bones	HP:0002645	Wormian bones		"{""preferred_term"": ""Wormian bones"", ""term"": {""id"": ""HP:0002645"", ""label"": ""Wormian bones""}}"																											
5229	5762	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	treatments	0	Supportive Care	"Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.
"	treatment_term	treatment_term	$	Supportive Care	"Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5230	5765	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	pathophysiology	0	Dominant-Negative Collagen Defect	"Structural mutations in COL1A1 or COL1A2, typically glycine substitutions in the triple helical domain, produce abnormal collagen that disrupts fibril assembly. The mutations are generally less severe than those causing type II, allowing survival but with progressive deformity.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5231	5765	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	pathophysiology	0	Dominant-Negative Collagen Defect	"Structural mutations in COL1A1 or COL1A2, typically glycine substitutions in the triple helical domain, produce abnormal collagen that disrupts fibril assembly. The mutations are generally less severe than those causing type II, allowing survival but with progressive deformity.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Fibril Organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""Collagen Fibril Organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
5232	5765	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	pathophysiology	0	Dominant-Negative Collagen Defect	"Structural mutations in COL1A1 or COL1A2, typically glycine substitutions in the triple helical domain, produce abnormal collagen that disrupts fibril assembly. The mutations are generally less severe than those causing type II, allowing survival but with progressive deformity.
"	biological_processes[1]	biological_processes	biological_processes			Bone Development	GO:0060348	bone development		"{""preferred_term"": ""Bone Development"", ""term"": {""id"": ""GO:0060348"", ""label"": ""bone development""}}"																											
5233	5766	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	0	Severe Short Stature	"Profound growth deficiency with adult height often under 100 cm due to progressive skeletal deformity and impaired bone growth.
"	phenotype_term	phenotype_term	$	Severe Short Stature	"Profound growth deficiency with adult height often under 100 cm due to progressive skeletal deformity and impaired bone growth.
"	Severe short stature	HP:0003510	Severe short stature		"{""preferred_term"": ""Severe short stature"", ""term"": {""id"": ""HP:0003510"", ""label"": ""Severe short stature""}}"																											
5234	5767	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	1	Progressive Skeletal Deformity	"Progressive bowing of long bones, kyphoscoliosis, and chest wall deformities that worsen with repeated fractures and weight bearing.
"	phenotype_term	phenotype_term	$	Progressive Skeletal Deformity	"Progressive bowing of long bones, kyphoscoliosis, and chest wall deformities that worsen with repeated fractures and weight bearing.
"	Abnormality of the skeletal system	HP:0000924	Abnormality of the skeletal system		"{""preferred_term"": ""Abnormality of the skeletal system"", ""term"": {""id"": ""HP:0000924"", ""label"": ""Abnormality of the skeletal system""}}"																											
5235	5768	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	2	Multiple Fractures	"Hundreds of fractures over a lifetime, occurring with minimal trauma.
"	phenotype_term	phenotype_term	$	Multiple Fractures	"Hundreds of fractures over a lifetime, occurring with minimal trauma.
"	Recurrent fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Recurrent fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5236	5769	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	3	Dentinogenesis Imperfecta	"Abnormal dentin formation producing opalescent, discolored teeth that are prone to breakage. Present in most type III patients.
"	phenotype_term	phenotype_term	$	Dentinogenesis Imperfecta	"Abnormal dentin formation producing opalescent, discolored teeth that are prone to breakage. Present in most type III patients.
"	Dentinogenesis imperfecta	HP:0000703	Dentinogenesis imperfecta		"{""preferred_term"": ""Dentinogenesis imperfecta"", ""term"": {""id"": ""HP:0000703"", ""label"": ""Dentinogenesis imperfecta""}}"																											
5237	5770	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	4	Triangular Facies	"Characteristic triangular face shape with prominent forehead and underdeveloped midface.
"	phenotype_term	phenotype_term	$	Triangular Facies	"Characteristic triangular face shape with prominent forehead and underdeveloped midface.
"	Triangular face	HP:0000325	Triangular face		"{""preferred_term"": ""Triangular face"", ""term"": {""id"": ""HP:0000325"", ""label"": ""Triangular face""}}"																											
5238	5771	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	5	Kyphoscoliosis	"Progressive spinal curvature contributing to respiratory compromise and mobility limitations.
"	phenotype_term	phenotype_term	$	Kyphoscoliosis	"Progressive spinal curvature contributing to respiratory compromise and mobility limitations.
"	Kyphoscoliosis	HP:0002751	Kyphoscoliosis		"{""preferred_term"": ""Kyphoscoliosis"", ""term"": {""id"": ""HP:0002751"", ""label"": ""Kyphoscoliosis""}}"																											
5239	5772	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	6	Hearing Impairment	"Progressive hearing loss, often beginning in childhood.
"	phenotype_term	phenotype_term	$	Hearing Impairment	"Progressive hearing loss, often beginning in childhood.
"	Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
5240	5773	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	phenotypes	7	Blue Sclerae	"Sclerae may be blue at birth but often normalize during childhood.
"	phenotype_term	phenotype_term	$	Blue Sclerae	"Sclerae may be blue at birth but often normalize during childhood.
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5241	5774	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	0	Bisphosphonate Therapy	"Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5242	5775	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	1	Rodding Surgery	"Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.
"	treatment_term	treatment_term	$	Rodding Surgery	"Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5243	5776	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	2	Spinal Fusion	"Surgical stabilization of severe scoliosis to prevent respiratory compromise.
"	treatment_term	treatment_term	$	Spinal Fusion	"Surgical stabilization of severe scoliosis to prevent respiratory compromise.
"	Spinal surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5244	5777	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	3	Physical Therapy	"Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.
"	treatment_term	treatment_term	$	Physical Therapy	"Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5245	5780	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	pathophysiology	0	Moderate Collagen Structural Defect	"Structural mutations in COL1A1 or COL1A2 that produce collagen with intermediate levels of dysfunction. The mutations allow more normal fibril formation than in types II/III but still compromise bone matrix integrity.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5246	5780	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	pathophysiology	0	Moderate Collagen Structural Defect	"Structural mutations in COL1A1 or COL1A2 that produce collagen with intermediate levels of dysfunction. The mutations allow more normal fibril formation than in types II/III but still compromise bone matrix integrity.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Fibril Organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""Collagen Fibril Organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
5247	5780	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	pathophysiology	0	Moderate Collagen Structural Defect	"Structural mutations in COL1A1 or COL1A2 that produce collagen with intermediate levels of dysfunction. The mutations allow more normal fibril formation than in types II/III but still compromise bone matrix integrity.
"	biological_processes[1]	biological_processes	biological_processes			Bone Development	GO:0060348	bone development		"{""preferred_term"": ""Bone Development"", ""term"": {""id"": ""GO:0060348"", ""label"": ""bone development""}}"																											
5248	5781	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	0	Moderate Short Stature	"Variable short stature, typically mild to moderate. Some individuals achieve near-normal height.
"	phenotype_term	phenotype_term	$	Moderate Short Stature	"Variable short stature, typically mild to moderate. Some individuals achieve near-normal height.
"	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5249	5782	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	1	Recurrent Fractures	"Increased fracture frequency, though typically less than type III. Fractures decrease after puberty.
"	phenotype_term	phenotype_term	$	Recurrent Fractures	"Increased fracture frequency, though typically less than type III. Fractures decrease after puberty.
"	Recurrent fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Recurrent fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5250	5783	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	2	Normal Scleral Hue	"Sclerae are typically white or light gray in adults, distinguishing type IV from type I (which has persistently blue sclerae).
"	phenotype_term	phenotype_term	$	Normal Scleral Hue	"Sclerae are typically white or light gray in adults, distinguishing type IV from type I (which has persistently blue sclerae).
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5251	5784	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	3	Dentinogenesis Imperfecta	"Variable presence of dentinogenesis imperfecta with opalescent teeth.
"	phenotype_term	phenotype_term	$	Dentinogenesis Imperfecta	"Variable presence of dentinogenesis imperfecta with opalescent teeth.
"	Dentinogenesis imperfecta	HP:0000703	Dentinogenesis imperfecta		"{""preferred_term"": ""Dentinogenesis imperfecta"", ""term"": {""id"": ""HP:0000703"", ""label"": ""Dentinogenesis imperfecta""}}"																											
5252	5785	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	4	Skeletal Deformity	"Mild to moderate bowing of long bones. Less progressive than type III.
"	phenotype_term	phenotype_term	$	Skeletal Deformity	"Mild to moderate bowing of long bones. Less progressive than type III.
"	Bowing of the long bones	HP:0006487	Bowing of the long bones		"{""preferred_term"": ""Bowing of the long bones"", ""term"": {""id"": ""HP:0006487"", ""label"": ""Bowing of the long bones""}}"																											
5253	5786	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	phenotypes	5	Hearing Impairment	"Progressive hearing loss may develop, typically in adulthood.
"	phenotype_term	phenotype_term	$	Hearing Impairment	"Progressive hearing loss may develop, typically in adulthood.
"	Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
5254	5787	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5255	5788	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	1	Orthopedic Management	"Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.
"	treatment_term	treatment_term	$	Orthopedic Management	"Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5256	5789	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	2	Physical Therapy	"Exercise programs to strengthen muscles and maintain bone health.
"	treatment_term	treatment_term	$	Physical Therapy	"Exercise programs to strengthen muscles and maintain bone health.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5257	5792	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	pathophysiology	0	IFITM5 Gain-of-Function	"The c.-14C>T mutation creates an upstream start codon, producing an IFITM5 protein with 5 additional N-terminal amino acids. This altered protein disrupts normal bone mineralization and matrix organization, leading to the characteristic histological and clinical features. IFITM5 (BRIL) is an osteoblast-specific protein involved in mineralization.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5258	5792	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	pathophysiology	0	IFITM5 Gain-of-Function	"The c.-14C>T mutation creates an upstream start codon, producing an IFITM5 protein with 5 additional N-terminal amino acids. This altered protein disrupts normal bone mineralization and matrix organization, leading to the characteristic histological and clinical features. IFITM5 (BRIL) is an osteoblast-specific protein involved in mineralization.
"	biological_processes[0]	biological_processes	biological_processes			Bone Mineralization	GO:0030282	bone mineralization		"{""preferred_term"": ""Bone Mineralization"", ""term"": {""id"": ""GO:0030282"", ""label"": ""bone mineralization""}}"																											
5259	5792	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	pathophysiology	0	IFITM5 Gain-of-Function	"The c.-14C>T mutation creates an upstream start codon, producing an IFITM5 protein with 5 additional N-terminal amino acids. This altered protein disrupts normal bone mineralization and matrix organization, leading to the characteristic histological and clinical features. IFITM5 (BRIL) is an osteoblast-specific protein involved in mineralization.
"	biological_processes[1]	biological_processes	biological_processes			Osteoblast Differentiation	GO:0001649	osteoblast differentiation		"{""preferred_term"": ""Osteoblast Differentiation"", ""term"": {""id"": ""GO:0001649"", ""label"": ""osteoblast differentiation""}}"																											
5260	5793	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	0	Hyperplastic Callus Formation	"Exuberant callus formation after fractures or surgery, sometimes mimicking osteosarcoma. This is a hallmark feature of type V OI.
"	phenotype_term	phenotype_term	$	Hyperplastic Callus Formation	"Exuberant callus formation after fractures or surgery, sometimes mimicking osteosarcoma. This is a hallmark feature of type V OI.
"	Hyperplastic callus formation	HP:0030268	Hyperplastic callus formation		"{""preferred_term"": ""Hyperplastic callus formation"", ""term"": {""id"": ""HP:0030268"", ""label"": ""Hyperplastic callus formation""}}"																											
5261	5794	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	1	Radioulnar Synostosis	"Progressive calcification of the interosseous membrane between radius and ulna, restricting forearm rotation (pronation/supination).
"	phenotype_term	phenotype_term	$	Radioulnar Synostosis	"Progressive calcification of the interosseous membrane between radius and ulna, restricting forearm rotation (pronation/supination).
"	Radioulnar synostosis	HP:0002974	Radioulnar synostosis		"{""preferred_term"": ""Radioulnar synostosis"", ""term"": {""id"": ""HP:0002974"", ""label"": ""Radioulnar synostosis""}}"																											
5262	5795	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	2	Radial Head Dislocation	"Congenital or acquired dislocation of the radial head, contributing to forearm limitation.
"	phenotype_term	phenotype_term	$	Radial Head Dislocation	"Congenital or acquired dislocation of the radial head, contributing to forearm limitation.
"	Radial head dislocation	HP:0003083	Dislocated radial head		"{""preferred_term"": ""Radial head dislocation"", ""term"": {""id"": ""HP:0003083"", ""label"": ""Dislocated radial head""}}"																											
5263	5796	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	3	Recurrent Fractures	"Bone fragility with recurrent fractures, typically of moderate severity.
"	phenotype_term	phenotype_term	$	Recurrent Fractures	"Bone fragility with recurrent fractures, typically of moderate severity.
"	Recurrent fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Recurrent fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5264	5797	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	4	Normal Sclerae	"Scleral hue is normal (white), distinguishing type V from type I.
"	phenotype_term	phenotype_term	$	Normal Sclerae	"Scleral hue is normal (white), distinguishing type V from type I.
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5265	5798	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	5	Absence of Dentinogenesis Imperfecta	"Teeth are normal, unlike many other OI types.
"	phenotype_term	phenotype_term	$	Absence of Dentinogenesis Imperfecta	"Teeth are normal, unlike many other OI types.
"	Dentinogenesis imperfecta	HP:0000703	Dentinogenesis imperfecta		"{""preferred_term"": ""Dentinogenesis imperfecta"", ""term"": {""id"": ""HP:0000703"", ""label"": ""Dentinogenesis imperfecta""}}"																											
5266	5799	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	phenotypes	6	Moderate Short Stature	"Variable short stature, typically mild to moderate.
"	phenotype_term	phenotype_term	$	Moderate Short Stature	"Variable short stature, typically mild to moderate.
"	Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5267	5800	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5268	5801	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	1	Surgical Management	"Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.
"	treatment_term	treatment_term	$	Surgical Management	"Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5269	5802	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	2	Interosseous Membrane Excision	"Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.
"	treatment_term	treatment_term	$	Interosseous Membrane Excision	"Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.
"	Surgical excision	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Surgical excision"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5270	5805	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	pathophysiology	0	Collagen 3-Hydroxylation Deficiency	"CRTAP is a component of the prolyl 3-hydroxylation complex that modifies Pro986 in the alpha1(I) chain of type I collagen. Loss of this modification delays collagen folding, causing overmodification of the helix and altered collagen structure and cross-linking.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5271	5805	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	pathophysiology	0	Collagen 3-Hydroxylation Deficiency	"CRTAP is a component of the prolyl 3-hydroxylation complex that modifies Pro986 in the alpha1(I) chain of type I collagen. Loss of this modification delays collagen folding, causing overmodification of the helix and altered collagen structure and cross-linking.
"	biological_processes[0]	biological_processes	biological_processes			Protein Hydroxylation	GO:0018126	protein hydroxylation		"{""preferred_term"": ""Protein Hydroxylation"", ""term"": {""id"": ""GO:0018126"", ""label"": ""protein hydroxylation""}}"																											
5272	5805	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	pathophysiology	0	Collagen 3-Hydroxylation Deficiency	"CRTAP is a component of the prolyl 3-hydroxylation complex that modifies Pro986 in the alpha1(I) chain of type I collagen. Loss of this modification delays collagen folding, causing overmodification of the helix and altered collagen structure and cross-linking.
"	biological_processes[1]	biological_processes	biological_processes			Collagen Fibril Organization	GO:0030199	collagen fibril organization		"{""preferred_term"": ""Collagen Fibril Organization"", ""term"": {""id"": ""GO:0030199"", ""label"": ""collagen fibril organization""}}"																											
5273	5806	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	pathophysiology	1	ER Stress from Abnormal Collagen Folding	"Delayed collagen folding leads to accumulation of procollagen in the ER, triggering ER stress and contributing to osteoblast dysfunction.
"	biological_processes[0]	biological_processes	biological_processes			ER Stress Response	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""ER Stress Response"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
5274	5807	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	0	Severe Bone Fragility	"Multiple fractures at birth or in early infancy, with ongoing fracture susceptibility throughout life.
"	phenotype_term	phenotype_term	$	Severe Bone Fragility	"Multiple fractures at birth or in early infancy, with ongoing fracture susceptibility throughout life.
"	Recurrent fractures	HP:0002757	Recurrent fractures		"{""preferred_term"": ""Recurrent fractures"", ""term"": {""id"": ""HP:0002757"", ""label"": ""Recurrent fractures""}}"																											
5275	5808	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	1	Rhizomelia	"Characteristic shortening of the proximal limb segments (humerus, femur), which helps distinguish recessive OI from dominant forms.
"	phenotype_term	phenotype_term	$	Rhizomelia	"Characteristic shortening of the proximal limb segments (humerus, femur), which helps distinguish recessive OI from dominant forms.
"	Rhizomelia	HP:0008905	Rhizomelia		"{""preferred_term"": ""Rhizomelia"", ""term"": {""id"": ""HP:0008905"", ""label"": ""Rhizomelia""}}"																											
5276	5809	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	2	Severe Short Stature	"Profound growth deficiency with adult height significantly below normal.
"	phenotype_term	phenotype_term	$	Severe Short Stature	"Profound growth deficiency with adult height significantly below normal.
"	Severe short stature	HP:0003510	Severe short stature		"{""preferred_term"": ""Severe short stature"", ""term"": {""id"": ""HP:0003510"", ""label"": ""Severe short stature""}}"																											
5277	5810	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	3	White Sclerae	"Sclerae are typically white or light gray, distinguishing type VII from collagen-mutation OI types with blue sclerae.
"	phenotype_term	phenotype_term	$	White Sclerae	"Sclerae are typically white or light gray, distinguishing type VII from collagen-mutation OI types with blue sclerae.
"	Blue sclerae	HP:0000592	Blue sclerae		"{""preferred_term"": ""Blue sclerae"", ""term"": {""id"": ""HP:0000592"", ""label"": ""Blue sclerae""}}"																											
5278	5811	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	4	Coxa Vara	"Abnormal angle of the femoral neck contributing to hip dysfunction.
"	phenotype_term	phenotype_term	$	Coxa Vara	"Abnormal angle of the femoral neck contributing to hip dysfunction.
"	Coxa vara	HP:0002812	Coxa vara		"{""preferred_term"": ""Coxa vara"", ""term"": {""id"": ""HP:0002812"", ""label"": ""Coxa vara""}}"																											
5279	5812	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	phenotypes	5	Osteopenia	"Severely reduced bone mineral density on imaging.
"	phenotype_term	phenotype_term	$	Osteopenia	"Severely reduced bone mineral density on imaging.
"	Osteopenia	HP:0000938	Osteopenia		"{""preferred_term"": ""Osteopenia"", ""term"": {""id"": ""HP:0000938"", ""label"": ""Osteopenia""}}"																											
5280	5813	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5281	5814	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	1	Orthopedic Management	"Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.
"	treatment_term	treatment_term	$	Orthopedic Management	"Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5282	5815	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	2	Physical Therapy	"Careful rehabilitation to maintain mobility while minimizing fracture risk.
"	treatment_term	treatment_term	$	Physical Therapy	"Careful rehabilitation to maintain mobility while minimizing fracture risk.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5283	5816	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	3	Genetic Counseling	"Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.
"	treatment_term	treatment_term	$	Genetic Counseling	"Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.
"	Genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""Genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5284	5831	247	Osteoporosis	Osteoporosis.yaml	pathophysiology	0	Bone Remodeling Imbalance	"Increased osteoclast-mediated bone resorption relative to osteoblast- mediated bone formation leads to net bone loss. This imbalance accelerates with aging and estrogen deficiency.
"	cell_types[0]	cell_types	cell_types			Osteoclast	CL:0000092	osteoclast		"{""preferred_term"": ""Osteoclast"", ""term"": {""id"": ""CL:0000092"", ""label"": ""osteoclast""}}"																											
5285	5831	247	Osteoporosis	Osteoporosis.yaml	pathophysiology	0	Bone Remodeling Imbalance	"Increased osteoclast-mediated bone resorption relative to osteoblast- mediated bone formation leads to net bone loss. This imbalance accelerates with aging and estrogen deficiency.
"	cell_types[1]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5286	5831	247	Osteoporosis	Osteoporosis.yaml	pathophysiology	0	Bone Remodeling Imbalance	"Increased osteoclast-mediated bone resorption relative to osteoblast- mediated bone formation leads to net bone loss. This imbalance accelerates with aging and estrogen deficiency.
"	biological_processes[0]	biological_processes	biological_processes			Bone Remodeling	GO:0046849	bone remodeling		"{""preferred_term"": ""Bone Remodeling"", ""term"": {""id"": ""GO:0046849"", ""label"": ""bone remodeling""}}"																											
5287	5832	247	Osteoporosis	Osteoporosis.yaml	pathophysiology	1	RANKL/OPG Dysregulation	"Increased RANKL and decreased osteoprotegerin (OPG) ratio promotes osteoclast differentiation and activation. Estrogen normally suppresses RANKL and increases OPG.
"	biological_processes[0]	biological_processes	biological_processes			Osteoclast Differentiation	GO:0030316	osteoclast differentiation		"{""preferred_term"": ""Osteoclast Differentiation"", ""term"": {""id"": ""GO:0030316"", ""label"": ""osteoclast differentiation""}}"																											
5288	5834	247	Osteoporosis	Osteoporosis.yaml	phenotypes	0	Decreased Bone Mineral Density		phenotype_term	phenotype_term	$	Decreased Bone Mineral Density		Decreased Bone Density	HP:0004349	Reduced bone mineral density		"{""preferred_term"": ""Decreased Bone Density"", ""term"": {""id"": ""HP:0004349"", ""label"": ""Reduced bone mineral density""}}"																											
5289	5835	247	Osteoporosis	Osteoporosis.yaml	phenotypes	1	Vertebral Fractures		phenotype_term	phenotype_term	$	Vertebral Fractures		Vertebral Compression Fractures	HP:0002953	Vertebral compression fracture		"{""preferred_term"": ""Vertebral Compression Fractures"", ""term"": {""id"": ""HP:0002953"", ""label"": ""Vertebral compression fracture""}}"																											
5290	5836	247	Osteoporosis	Osteoporosis.yaml	phenotypes	2	Femur Fractures		phenotype_term	phenotype_term	$	Femur Fractures		Femur Fractures	HP:0031846	Femur fracture		"{""preferred_term"": ""Femur Fractures"", ""term"": {""id"": ""HP:0031846"", ""label"": ""Femur fracture""}}"																											
5291	5837	247	Osteoporosis	Osteoporosis.yaml	phenotypes	3	Kyphosis		phenotype_term	phenotype_term	$	Kyphosis		Kyphosis	HP:0002808	Kyphosis		"{""preferred_term"": ""Kyphosis"", ""term"": {""id"": ""HP:0002808"", ""label"": ""Kyphosis""}}"																											
5292	5838	247	Osteoporosis	Osteoporosis.yaml	phenotypes	4	Height Loss		phenotype_term	phenotype_term	$	Height Loss		Short Stature	HP:0004322	Short stature		"{""preferred_term"": ""Short Stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5293	5839	247	Osteoporosis	Osteoporosis.yaml	treatments	0	Bisphosphonates	First-line antiresorptives (alendronate, risedronate, zoledronic acid).	treatment_term	treatment_term	$	Bisphosphonates	First-line antiresorptives (alendronate, risedronate, zoledronic acid).	bisphosphonate agent therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""bisphosphonate agent therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5294	5840	247	Osteoporosis	Osteoporosis.yaml	treatments	1	Denosumab	RANKL inhibitor, potent antiresorptive.	treatment_term	treatment_term	$	Denosumab	RANKL inhibitor, potent antiresorptive.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5295	5841	247	Osteoporosis	Osteoporosis.yaml	treatments	2	Teriparatide	PTH analog, anabolic agent for severe osteoporosis.	treatment_term	treatment_term	$	Teriparatide	PTH analog, anabolic agent for severe osteoporosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5296	5842	247	Osteoporosis	Osteoporosis.yaml	treatments	3	Romosozumab	Sclerostin inhibitor with dual anabolic/antiresorptive effect.	treatment_term	treatment_term	$	Romosozumab	Sclerostin inhibitor with dual anabolic/antiresorptive effect.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5297	5843	247	Osteoporosis	Osteoporosis.yaml	treatments	4	Calcium Supplementation	Ensure adequate intake (1000-1200 mg/day).	treatment_term	treatment_term	$	Calcium Supplementation	Ensure adequate intake (1000-1200 mg/day).	calcium supplementation	MAXO:0001139	calcium supplementation		"{""preferred_term"": ""calcium supplementation"", ""term"": {""id"": ""MAXO:0001139"", ""label"": ""calcium supplementation""}}"																											
5298	5844	247	Osteoporosis	Osteoporosis.yaml	treatments	5	Vitamin D Supplementation	Maintain 25(OH)D >30 ng/mL.	treatment_term	treatment_term	$	Vitamin D Supplementation	Maintain 25(OH)D >30 ng/mL.	vitamin D supplementation	MAXO:0000110	vitamin D supplementation		"{""preferred_term"": ""vitamin D supplementation"", ""term"": {""id"": ""MAXO:0000110"", ""label"": ""vitamin D supplementation""}}"																											
5299	5845	247	Osteoporosis	Osteoporosis.yaml	treatments	6	Weight-Bearing Exercise	Helps maintain bone density.	treatment_term	treatment_term	$	Weight-Bearing Exercise	Helps maintain bone density.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5300	5846	248	Osteosarcoma	Osteosarcoma.yaml	datasets	0		Microarray dataset of osteosarcoma and normal bone samples used for differential expression analyses.	organism	organism	$		Microarray dataset of osteosarcoma and normal bone samples used for differential expression analyses.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5301	5846	248	Osteosarcoma	Osteosarcoma.yaml	datasets	0		Microarray dataset of osteosarcoma and normal bone samples used for differential expression analyses.	sample_types[0]	sample_types	sample_types			bone tissue				"{""preferred_term"": ""bone tissue"", ""tissue_term"": {""preferred_term"": ""bone element"", ""term"": {""id"": ""UBERON:0001474"", ""label"": ""bone element""}}}"																											
5302	5846	248	Osteosarcoma	Osteosarcoma.yaml	datasets	0		Microarray dataset of osteosarcoma and normal bone samples used for differential expression analyses.	sample_types[0].tissue_term	sample_types	sample_types[0]			bone element	UBERON:0001474	bone element		"{""preferred_term"": ""bone element"", ""term"": {""id"": ""UBERON:0001474"", ""label"": ""bone element""}}"																											
5303	5848	248	Osteosarcoma	Osteosarcoma.yaml	pathophysiology	1	Tumor Immune Microenvironment Remodeling	Osteosarcoma progression involves interactions with immune cells in the tumor microenvironment, including tumor-infiltrating lymphocytes and tumor-associated macrophages, alongside immune checkpoint expression.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5304	5848	248	Osteosarcoma	Osteosarcoma.yaml	pathophysiology	1	Tumor Immune Microenvironment Remodeling	Osteosarcoma progression involves interactions with immune cells in the tumor microenvironment, including tumor-infiltrating lymphocytes and tumor-associated macrophages, alongside immune checkpoint expression.	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
5305	5848	248	Osteosarcoma	Osteosarcoma.yaml	pathophysiology	1	Tumor Immune Microenvironment Remodeling	Osteosarcoma progression involves interactions with immune cells in the tumor microenvironment, including tumor-infiltrating lymphocytes and tumor-associated macrophages, alongside immune checkpoint expression.	biological_processes[0]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"			ABNORMAL																								
5306	5850	248	Osteosarcoma	Osteosarcoma.yaml	phenotypes	0	Bone Pain		phenotype_term	phenotype_term	$	Bone Pain		Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
5307	5851	248	Osteosarcoma	Osteosarcoma.yaml	phenotypes	1	Gait Disturbance		phenotype_term	phenotype_term	$	Gait Disturbance		Gait disturbance	HP:0001288	Gait disturbance		"{""preferred_term"": ""Gait disturbance"", ""term"": {""id"": ""HP:0001288"", ""label"": ""Gait disturbance""}}"																											
5308	5852	248	Osteosarcoma	Osteosarcoma.yaml	treatments	0	Surgical Resection	Surgical removal of the primary tumor when feasible.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of the primary tumor when feasible.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5309	5853	248	Osteosarcoma	Osteosarcoma.yaml	treatments	1	Multi-Agent Chemotherapy	Combination chemotherapy used in neoadjuvant and adjuvant settings.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Combination chemotherapy used in neoadjuvant and adjuvant settings.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5310	5856	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	histopathology	0	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	finding_term	finding_term	$	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	Invasive Breast Carcinoma of No Special Type	NCIT:C4194	Invasive Breast Carcinoma of No Special Type		"{""preferred_term"": ""Invasive Breast Carcinoma of No Special Type"", ""term"": {""id"": ""NCIT:C4194"", ""label"": ""Invasive Breast Carcinoma of No Special Type""}}"																											
5311	5857	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	0	PIK3CA Oncogenic Mutations	Activating PIK3CA mutations occur as somatic events in breast cancer cells. Hotspot mutations cluster in the helical domain (E542K, E545K) and kinase domain (H1047R). These mutations cause constitutive PI3K activity independent of upstream receptor tyrosine kinase signaling.	cell_types[0]	cell_types	cell_types			luminal epithelial cell of mammary gland	CL:0002326	luminal epithelial cell of mammary gland		"{""preferred_term"": ""luminal epithelial cell of mammary gland"", ""term"": {""id"": ""CL:0002326"", ""label"": ""luminal epithelial cell of mammary gland""}}"																											
5312	5857	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	0	PIK3CA Oncogenic Mutations	Activating PIK3CA mutations occur as somatic events in breast cancer cells. Hotspot mutations cluster in the helical domain (E542K, E545K) and kinase domain (H1047R). These mutations cause constitutive PI3K activity independent of upstream receptor tyrosine kinase signaling.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
5313	5858	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	1	Constitutive PI3K-AKT Pathway Activation	Mutant PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting and activating AKT (protein kinase B). Activated AKT phosphorylates numerous substrates promoting cell survival, proliferation, metabolism, and resistance to apoptosis.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol-mediated signaling	GO:0048015	phosphatidylinositol-mediated signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol-mediated signaling"", ""term"": {""id"": ""GO:0048015"", ""label"": ""phosphatidylinositol-mediated signaling""}}"			INCREASED																								
5314	5858	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	1	Constitutive PI3K-AKT Pathway Activation	Mutant PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting and activating AKT (protein kinase B). Activated AKT phosphorylates numerous substrates promoting cell survival, proliferation, metabolism, and resistance to apoptosis.	biological_processes[1]	biological_processes	biological_processes			protein kinase B signaling	GO:0043491	protein kinase B signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein kinase B signaling"", ""term"": {""id"": ""GO:0043491"", ""label"": ""protein kinase B signaling""}}"			INCREASED																								
5315	5859	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	2	mTOR Pathway Activation	AKT activates mTORC1 by inhibiting the TSC1/TSC2 complex, relieving suppression of the small GTPase Rheb. Active mTORC1 promotes protein synthesis, cell growth, and metabolic reprogramming through S6K1 and 4E-BP1 phosphorylation.	biological_processes[0]	biological_processes	biological_processes			TOR signaling	GO:0031929	TOR signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""TOR signaling"", ""term"": {""id"": ""GO:0031929"", ""label"": ""TOR signaling""}}"			INCREASED																								
5316	5860	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	3	Cell Survival and Proliferation	PI3K-AKT signaling promotes cell survival through phosphorylation and inactivation of pro-apoptotic proteins (BAD, FOXO transcription factors) and cell proliferation through multiple mechanisms including cyclin D1 stabilization.	biological_processes[0]	biological_processes	biological_processes			negative regulation of apoptotic process	GO:0043066	negative regulation of apoptotic process		"{""modifier"": ""INCREASED"", ""preferred_term"": ""negative regulation of apoptotic process"", ""term"": {""id"": ""GO:0043066"", ""label"": ""negative regulation of apoptotic process""}}"			INCREASED																								
5317	5860	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	3	Cell Survival and Proliferation	PI3K-AKT signaling promotes cell survival through phosphorylation and inactivation of pro-apoptotic proteins (BAD, FOXO transcription factors) and cell proliferation through multiple mechanisms including cyclin D1 stabilization.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
5318	5861	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	pathophysiology	4	Endocrine Resistance	In ER+ breast cancer, PIK3CA mutations confer partial resistance to endocrine therapy through crosstalk between PI3K and ER signaling. PI3K pathway activation can maintain tumor growth despite estrogen deprivation.	biological_processes[0]	biological_processes	biological_processes			intracellular estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""intracellular estrogen receptor signaling pathway"", ""term"": {""id"": ""GO:0030520"", ""label"": ""intracellular estrogen receptor signaling pathway""}}"			ABNORMAL																								
5319	5862	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	phenotypes	0	Breast Carcinoma	PIK3CA mutations occur across breast cancer subtypes but are most frequent in ER+ disease. Tumors are typically invasive ductal carcinomas.	phenotype_term	phenotype_term	$	Breast Carcinoma	PIK3CA mutations occur across breast cancer subtypes but are most frequent in ER+ disease. Tumors are typically invasive ductal carcinomas.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
5320	5863	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	phenotypes	1	PIK3CA Mutation	Defining feature is presence of activating PIK3CA mutation. Three hotspots (E542K, E545K, H1047R) account for approximately 80% of mutations. Testing by NGS or PCR-based assays is required for treatment selection.	phenotype_term	phenotype_term	$	PIK3CA Mutation	Defining feature is presence of activating PIK3CA mutation. Three hotspots (E542K, E545K, H1047R) account for approximately 80% of mutations. Testing by NGS or PCR-based assays is required for treatment selection.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
5321	5864	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	0	Alpelisib	PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling.	treatment_term	treatment_term	$	Alpelisib	PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5322	5865	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	1	Endocrine Therapy Plus CDK4/6 Inhibitors	First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen.	treatment_term	treatment_term	$	Endocrine Therapy Plus CDK4/6 Inhibitors	First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5323	5866	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	2	Capivasertib	AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy.	treatment_term	treatment_term	$	Capivasertib	AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5324	5871	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	0		Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.	organism	organism	$		Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5325	5871	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	0		Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.	sample_types[0]	sample_types	sample_types			fecal sample	OBI:0002503	feces specimen		"{""preferred_term"": ""fecal sample"", ""term"": {""id"": ""OBI:0002503"", ""label"": ""feces specimen""}, ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5326	5871	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	0		Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5327	5872	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	1		Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.	organism	organism	$		Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5328	5872	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	1		Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.	sample_types[0]	sample_types	sample_types			fecal sample	OBI:0002503	feces specimen		"{""preferred_term"": ""fecal sample"", ""term"": {""id"": ""OBI:0002503"", ""label"": ""feces specimen""}, ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5329	5872	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	1		Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5330	5873	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	2		Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.	organism	organism	$		Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5331	5873	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	2		Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.	sample_types[0]	sample_types	sample_types			fecal sample	OBI:0002503	feces specimen		"{""preferred_term"": ""fecal sample"", ""term"": {""id"": ""OBI:0002503"", ""label"": ""feces specimen""}, ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5332	5873	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	2		Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5333	5874	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	3		Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.	organism	organism	$		Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
5334	5874	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	3		Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.	sample_types[0]	sample_types	sample_types			fecal sample	OBI:0002503	feces specimen		"{""preferred_term"": ""fecal sample"", ""term"": {""id"": ""OBI:0002503"", ""label"": ""feces specimen""}, ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
5335	5874	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	3		Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
5336	5875	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	4		LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and medicated cohorts, compared with well-matched controls to identify lipid pathway alterations.	organism	organism	$		LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and medicated cohorts, compared with well-matched controls to identify lipid pathway alterations.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5337	5876	250	Parkinson's Disease	Parkinsons_Disease.yaml	datasets	5		Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and GBA1-associated Parkinson's disease cohorts with controls.	organism	organism	$		Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and GBA1-associated Parkinson's disease cohorts with controls.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5338	5885	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	0	Dopaminergic Neuron Loss	"Progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta leads to dopamine deficiency in the striatum, causing motor symptoms. Symptoms appear after 60-80% neuron loss.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5339	5885	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	0	Dopaminergic Neuron Loss	"Progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta leads to dopamine deficiency in the striatum, causing motor symptoms. Symptoms appear after 60-80% neuron loss.
"	biological_processes[0]	biological_processes	biological_processes			Dopamine Biosynthesis	GO:0042416	dopamine biosynthetic process		"{""preferred_term"": ""Dopamine Biosynthesis"", ""term"": {""id"": ""GO:0042416"", ""label"": ""dopamine biosynthetic process""}}"																											
5340	5886	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	1	Alpha-Synuclein Aggregation	"Misfolded alpha-synuclein protein accumulates to form Lewy bodies and Lewy neurites. These aggregates spread through the nervous system in a prion-like manner, contributing to neurodegeneration.
"	biological_processes[0]	biological_processes	biological_processes			inclusion body assembly	GO:0070841	inclusion body assembly		"{""preferred_term"": ""inclusion body assembly"", ""term"": {""id"": ""GO:0070841"", ""label"": ""inclusion body assembly""}}"																											
5341	5887	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	2	Mitochondrial Dysfunction	"Impaired mitochondrial function, particularly complex I deficiency, leads to oxidative stress and neuronal death. Multiple PD genes (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.
"	biological_processes[0]	biological_processes	biological_processes			mitochondrion organization	GO:0007005	mitochondrion organization		"{""preferred_term"": ""mitochondrion organization"", ""term"": {""id"": ""GO:0007005"", ""label"": ""mitochondrion organization""}}"																											
5342	5888	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	3	Neuroinflammation	"Activated microglia and astrocytes contribute to neurodegeneration through release of pro-inflammatory cytokines and oxidative stress.
"	cell_types[0]	cell_types	cell_types			Microglia	CL:0000129	microglial cell		"{""preferred_term"": ""Microglia"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
5343	5888	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	3	Neuroinflammation	"Activated microglia and astrocytes contribute to neurodegeneration through release of pro-inflammatory cytokines and oxidative stress.
"	cell_types[1]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5344	5889	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	4	Autophagy-Lysosome Pathway Dysfunction	"Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35, ATP13A2) regulate lysosomal function, and their mutations impair protein degradation capacity leading to toxic protein accumulation.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5345	5889	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	4	Autophagy-Lysosome Pathway Dysfunction	"Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35, ATP13A2) regulate lysosomal function, and their mutations impair protein degradation capacity leading to toxic protein accumulation.
"	biological_processes[0]	biological_processes	biological_processes			Autophagy	GO:0006914	autophagy		"{""preferred_term"": ""Autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
5346	5889	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	4	Autophagy-Lysosome Pathway Dysfunction	"Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35, ATP13A2) regulate lysosomal function, and their mutations impair protein degradation capacity leading to toxic protein accumulation.
"	biological_processes[1]	biological_processes	biological_processes			Chaperone-mediated Autophagy	GO:0061684	chaperone-mediated autophagy		"{""preferred_term"": ""Chaperone-mediated Autophagy"", ""term"": {""id"": ""GO:0061684"", ""label"": ""chaperone-mediated autophagy""}}"																											
5347	5890	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	5	Gut-Brain Axis Dysfunction	"Alterations in gut microbiota composition trigger intestinal inflammation and may initiate alpha-synuclein misfolding in enteric neurons. Pathological alpha-synuclein spreads from gut to brain via the vagus nerve, supporting the gut-first hypothesis of PD pathogenesis.
"	cell_types[0]	cell_types	cell_types			Enteric Neuron	CL:0000107	autonomic neuron		"{""preferred_term"": ""Enteric Neuron"", ""term"": {""id"": ""CL:0000107"", ""label"": ""autonomic neuron""}}"																											
5348	5890	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	5	Gut-Brain Axis Dysfunction	"Alterations in gut microbiota composition trigger intestinal inflammation and may initiate alpha-synuclein misfolding in enteric neurons. Pathological alpha-synuclein spreads from gut to brain via the vagus nerve, supporting the gut-first hypothesis of PD pathogenesis.
"	cell_types[1]	cell_types	cell_types			Enteroendocrine Cell	CL:0000164	enteroendocrine cell		"{""preferred_term"": ""Enteroendocrine Cell"", ""term"": {""id"": ""CL:0000164"", ""label"": ""enteroendocrine cell""}}"																											
5349	5890	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	5	Gut-Brain Axis Dysfunction	"Alterations in gut microbiota composition trigger intestinal inflammation and may initiate alpha-synuclein misfolding in enteric neurons. Pathological alpha-synuclein spreads from gut to brain via the vagus nerve, supporting the gut-first hypothesis of PD pathogenesis.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5350	5891	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	6	Oxidative Stress	"Excessive reactive oxygen species from dopamine metabolism and mitochondrial dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage. Dopamine auto-oxidation generates toxic quinones that preferentially damage substantia nigra neurons.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5351	5891	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	6	Oxidative Stress	"Excessive reactive oxygen species from dopamine metabolism and mitochondrial dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage. Dopamine auto-oxidation generates toxic quinones that preferentially damage substantia nigra neurons.
"	biological_processes[0]	biological_processes	biological_processes			Response to Oxidative Stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""Response to Oxidative Stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
5352	5891	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	6	Oxidative Stress	"Excessive reactive oxygen species from dopamine metabolism and mitochondrial dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage. Dopamine auto-oxidation generates toxic quinones that preferentially damage substantia nigra neurons.
"	biological_processes[1]	biological_processes	biological_processes			ROS Metabolic Process	GO:0072593	reactive oxygen species metabolic process		"{""preferred_term"": ""ROS Metabolic Process"", ""term"": {""id"": ""GO:0072593"", ""label"": ""reactive oxygen species metabolic process""}}"																											
5353	5892	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	7	Calcium Dysregulation	"Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3) for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes contributes to oxidative stress and cell death.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5354	5892	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	7	Calcium Dysregulation	"Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3) for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes contributes to oxidative stress and cell death.
"	biological_processes[0]	biological_processes	biological_processes			Calcium Ion Homeostasis	GO:0055074	calcium ion homeostasis		"{""preferred_term"": ""Calcium Ion Homeostasis"", ""term"": {""id"": ""GO:0055074"", ""label"": ""calcium ion homeostasis""}}"																											
5355	5892	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	7	Calcium Dysregulation	"Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3) for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes contributes to oxidative stress and cell death.
"	biological_processes[1]	biological_processes	biological_processes			Calcium Ion Transport	GO:0070588	calcium ion transmembrane transport		"{""preferred_term"": ""Calcium Ion Transport"", ""term"": {""id"": ""GO:0070588"", ""label"": ""calcium ion transmembrane transport""}}"																											
5356	5893	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	8	Endoplasmic Reticulum Stress	"Accumulation of misfolded proteins in the ER activates the unfolded protein response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly impair ER function.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5357	5893	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	8	Endoplasmic Reticulum Stress	"Accumulation of misfolded proteins in the ER activates the unfolded protein response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly impair ER function.
"	biological_processes[0]	biological_processes	biological_processes			ER Stress Response	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""ER Stress Response"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
5358	5893	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	8	Endoplasmic Reticulum Stress	"Accumulation of misfolded proteins in the ER activates the unfolded protein response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly impair ER function.
"	biological_processes[1]	biological_processes	biological_processes			Unfolded Protein Response	GO:0030968	endoplasmic reticulum unfolded protein response		"{""preferred_term"": ""Unfolded Protein Response"", ""term"": {""id"": ""GO:0030968"", ""label"": ""endoplasmic reticulum unfolded protein response""}}"																											
5359	5894	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	9	Synaptic Dysfunction	"Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6, SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction leads to synaptic failure before overt neurodegeneration.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5360	5894	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	9	Synaptic Dysfunction	"Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6, SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction leads to synaptic failure before overt neurodegeneration.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Vesicle Cycle	GO:0099504	synaptic vesicle cycle		"{""preferred_term"": ""Synaptic Vesicle Cycle"", ""term"": {""id"": ""GO:0099504"", ""label"": ""synaptic vesicle cycle""}}"																											
5361	5894	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	9	Synaptic Dysfunction	"Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6, SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction leads to synaptic failure before overt neurodegeneration.
"	biological_processes[1]	biological_processes	biological_processes			Synaptic Vesicle Endocytosis	GO:0048488	synaptic vesicle endocytosis		"{""preferred_term"": ""Synaptic Vesicle Endocytosis"", ""term"": {""id"": ""GO:0048488"", ""label"": ""synaptic vesicle endocytosis""}}"																											
5362	5895	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	10	Iron Accumulation and Ferroptosis	"Abnormal iron deposition in the substantia nigra promotes ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. Iron catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated iron metabolism contributes to oxidative damage.
"	cell_types[0]	cell_types	cell_types			Dopaminergic Neuron	CL:0000700	dopaminergic neuron		"{""preferred_term"": ""Dopaminergic Neuron"", ""term"": {""id"": ""CL:0000700"", ""label"": ""dopaminergic neuron""}}"																											
5363	5895	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	10	Iron Accumulation and Ferroptosis	"Abnormal iron deposition in the substantia nigra promotes ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. Iron catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated iron metabolism contributes to oxidative damage.
"	biological_processes[0]	biological_processes	biological_processes			Iron Ion Homeostasis	GO:0055072	iron ion homeostasis		"{""preferred_term"": ""Iron Ion Homeostasis"", ""term"": {""id"": ""GO:0055072"", ""label"": ""iron ion homeostasis""}}"																											
5364	5895	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	10	Iron Accumulation and Ferroptosis	"Abnormal iron deposition in the substantia nigra promotes ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. Iron catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated iron metabolism contributes to oxidative damage.
"	biological_processes[1]	biological_processes	biological_processes			Ferroptosis	GO:0097707	ferroptotic cell death		"{""preferred_term"": ""Ferroptosis"", ""term"": {""id"": ""GO:0097707"", ""label"": ""ferroptotic cell death""}}"																											
5365	5896	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	11	Blood-Brain Barrier Dysfunction	"Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
"	cell_types[0]	cell_types	cell_types			Brain Endothelial Cell	CL:0002618	endothelial cell of umbilical vein		"{""preferred_term"": ""Brain Endothelial Cell"", ""term"": {""id"": ""CL:0002618"", ""label"": ""endothelial cell of umbilical vein""}}"																											
5366	5896	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	11	Blood-Brain Barrier Dysfunction	"Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
"	cell_types[1]	cell_types	cell_types			Pericyte	CL:0000669	pericyte		"{""preferred_term"": ""Pericyte"", ""term"": {""id"": ""CL:0000669"", ""label"": ""pericyte""}}"																											
5367	5896	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	11	Blood-Brain Barrier Dysfunction	"Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
"	cell_types[2]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5368	5896	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	11	Blood-Brain Barrier Dysfunction	"Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
"	biological_processes[0]	biological_processes	biological_processes			BBB Maintenance	GO:0035633	maintenance of blood-brain barrier		"{""preferred_term"": ""BBB Maintenance"", ""term"": {""id"": ""GO:0035633"", ""label"": ""maintenance of blood-brain barrier""}}"																											
5369	5896	250	Parkinson's Disease	Parkinsons_Disease.yaml	pathophysiology	11	Blood-Brain Barrier Dysfunction	"Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
"	biological_processes[1]	biological_processes	biological_processes			Vascular Permeability	GO:0043114	regulation of vascular permeability		"{""preferred_term"": ""Vascular Permeability"", ""term"": {""id"": ""GO:0043114"", ""label"": ""regulation of vascular permeability""}}"																											
5370	5897	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	0	Resting Tremor		phenotype_term	phenotype_term	$	Resting Tremor		Resting Tremor	HP:0002322	Resting tremor		"{""preferred_term"": ""Resting Tremor"", ""term"": {""id"": ""HP:0002322"", ""label"": ""Resting tremor""}}"																											
5371	5898	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	1	Bradykinesia		phenotype_term	phenotype_term	$	Bradykinesia		Bradykinesia	HP:0002067	Bradykinesia		"{""preferred_term"": ""Bradykinesia"", ""term"": {""id"": ""HP:0002067"", ""label"": ""Bradykinesia""}}"																											
5372	5899	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	2	Rigidity		phenotype_term	phenotype_term	$	Rigidity		Rigidity	HP:0002063	Rigidity		"{""preferred_term"": ""Rigidity"", ""term"": {""id"": ""HP:0002063"", ""label"": ""Rigidity""}}"																											
5373	5900	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	3	Postural Instability		phenotype_term	phenotype_term	$	Postural Instability		Postural Instability	HP:0002172	Postural instability		"{""preferred_term"": ""Postural Instability"", ""term"": {""id"": ""HP:0002172"", ""label"": ""Postural instability""}}"																											
5374	5901	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	4	Hyposmia		phenotype_term	phenotype_term	$	Hyposmia		Hyposmia	HP:0004409	Hyposmia		"{""preferred_term"": ""Hyposmia"", ""term"": {""id"": ""HP:0004409"", ""label"": ""Hyposmia""}}"																											
5375	5902	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	5	Constipation		phenotype_term	phenotype_term	$	Constipation		Constipation	HP:0002019	Constipation		"{""preferred_term"": ""Constipation"", ""term"": {""id"": ""HP:0002019"", ""label"": ""Constipation""}}"																											
5376	5903	250	Parkinson's Disease	Parkinsons_Disease.yaml	phenotypes	6	Depression		phenotype_term	phenotype_term	$	Depression		Depression	HP:0000716	Depression		"{""preferred_term"": ""Depression"", ""term"": {""id"": ""HP:0000716"", ""label"": ""Depression""}}"																											
5377	5904	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	0	Levodopa/Carbidopa	Gold standard treatment, replaces dopamine precursor.	treatment_term	treatment_term	$	Levodopa/Carbidopa	Gold standard treatment, replaces dopamine precursor.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5378	5905	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	1	Dopamine Agonists	Directly stimulate dopamine receptors.	treatment_term	treatment_term	$	Dopamine Agonists	Directly stimulate dopamine receptors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5379	5906	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	2	MAO-B Inhibitors	Prevent dopamine breakdown (selegiline, rasagiline).	treatment_term	treatment_term	$	MAO-B Inhibitors	Prevent dopamine breakdown (selegiline, rasagiline).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5380	5907	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	3	COMT Inhibitors	Extend levodopa duration (entacapone).	treatment_term	treatment_term	$	COMT Inhibitors	Extend levodopa duration (entacapone).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5381	5908	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	4	Deep Brain Stimulation	Surgical therapy for advanced motor fluctuations.	treatment_term	treatment_term	$	Deep Brain Stimulation	Surgical therapy for advanced motor fluctuations.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5382	5909	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	5	Physical Therapy	Maintains mobility and reduces fall risk.	treatment_term	treatment_term	$	Physical Therapy	Maintains mobility and reduces fall risk.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5383	5915	251	Pars Planitis	Pars_Planitis.yaml	differential_diagnoses	0	Birdshot Retinochoroiditis	Retinal vasculitis with HLA-A29 positivity can mimic intermediate uveitis but has a distinct angiographic signature.	disease_term	disease_term	$	Birdshot Retinochoroiditis	Retinal vasculitis with HLA-A29 positivity can mimic intermediate uveitis but has a distinct angiographic signature.	birdshot chorioretinopathy	MONDO:0011599	birdshot chorioretinopathy		"{""preferred_term"": ""birdshot chorioretinopathy"", ""term"": {""id"": ""MONDO:0011599"", ""label"": ""birdshot chorioretinopathy""}}"																											
5384	5916	251	Pars Planitis	Pars_Planitis.yaml	differential_diagnoses	1	Retinoblastoma (Masquerade Syndrome)	Retinoblastoma can present with vitreous seeding and mimic inflammatory vitreous snowballs seen in pars planitis.	disease_term	disease_term	$	Retinoblastoma (Masquerade Syndrome)	Retinoblastoma can present with vitreous seeding and mimic inflammatory vitreous snowballs seen in pars planitis.	retinoblastoma	MONDO:0008380	retinoblastoma		"{""preferred_term"": ""retinoblastoma"", ""term"": {""id"": ""MONDO:0008380"", ""label"": ""retinoblastoma""}}"																											
5385	5918	251	Pars Planitis	Pars_Planitis.yaml	differential_diagnoses	3	Intraocular Lymphoma (Masquerade Syndrome)	Primary intraocular lymphoma can imitate intermediate uveitis with vitreous cells and requires oncologic evaluation.	disease_term	disease_term	$	Intraocular Lymphoma (Masquerade Syndrome)	Primary intraocular lymphoma can imitate intermediate uveitis with vitreous cells and requires oncologic evaluation.	intraocular lymphoma	MONDO:0004351	intraocular lymphoma		"{""preferred_term"": ""intraocular lymphoma"", ""term"": {""id"": ""MONDO:0004351"", ""label"": ""intraocular lymphoma""}}"																											
5386	5919	251	Pars Planitis	Pars_Planitis.yaml	differential_diagnoses	4	Multiple Sclerosis-Associated Intermediate Uveitis	Intermediate uveitis secondary to multiple sclerosis can resemble pars planitis but carries neurologic signs and demyelinating lesions.	disease_term	disease_term	$	Multiple Sclerosis-Associated Intermediate Uveitis	Intermediate uveitis secondary to multiple sclerosis can resemble pars planitis but carries neurologic signs and demyelinating lesions.	multiple sclerosis	MONDO:0005301	multiple sclerosis		"{""preferred_term"": ""multiple sclerosis"", ""term"": {""id"": ""MONDO:0005301"", ""label"": ""multiple sclerosis""}}"																											
5387	5920	251	Pars Planitis	Pars_Planitis.yaml	differential_diagnoses	5	Sarcoidosis-Associated Intermediate Uveitis with Vasoproliferative Tumor	Sarcoidosis-related intermediate uveitis can produce peripheral vasoproliferative tumors and exudative detachment, mimicking complicated pars planitis.	disease_term	disease_term	$	Sarcoidosis-Associated Intermediate Uveitis with Vasoproliferative Tumor	Sarcoidosis-related intermediate uveitis can produce peripheral vasoproliferative tumors and exudative detachment, mimicking complicated pars planitis.	sarcoidosis	MONDO:0019338	sarcoidosis		"{""preferred_term"": ""sarcoidosis"", ""term"": {""id"": ""MONDO:0019338"", ""label"": ""sarcoidosis""}}"																											
5388	5927	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	0	Autoimmune T-Cell Predominant Inflammation	Pars planitis shows a T cell-driven autoimmune response within the vitreous and pars plana.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5389	5927	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	0	Autoimmune T-Cell Predominant Inflammation	Pars planitis shows a T cell-driven autoimmune response within the vitreous and pars plana.	biological_processes[0]	biological_processes	biological_processes			Adaptive immune response	GO:0002250	adaptive immune response		"{""preferred_term"": ""Adaptive immune response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
5390	5927	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	0	Autoimmune T-Cell Predominant Inflammation	Pars planitis shows a T cell-driven autoimmune response within the vitreous and pars plana.	locations[0]	locations	locations			Vitreous humor	UBERON:0001286	vitreous humor		"{""preferred_term"": ""Vitreous humor"", ""term"": {""id"": ""UBERON:0001286"", ""label"": ""vitreous humor""}}"																											
5391	5927	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	0	Autoimmune T-Cell Predominant Inflammation	Pars planitis shows a T cell-driven autoimmune response within the vitreous and pars plana.	locations[1]	locations	locations			Pars plana	UBERON:0004548	pars plana of ciliary body		"{""preferred_term"": ""Pars plana"", ""term"": {""id"": ""UBERON:0004548"", ""label"": ""pars plana of ciliary body""}}"																											
5392	5928	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	1	Vitreous Cell Infiltration	Dense inflammatory cell infiltration and haze within the vitreous cavity.	cell_types[0]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5393	5928	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	1	Vitreous Cell Infiltration	Dense inflammatory cell infiltration and haze within the vitreous cavity.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5394	5928	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	1	Vitreous Cell Infiltration	Dense inflammatory cell infiltration and haze within the vitreous cavity.	locations[0]	locations	locations			Vitreous humor	UBERON:0001286	vitreous humor		"{""preferred_term"": ""Vitreous humor"", ""term"": {""id"": ""UBERON:0001286"", ""label"": ""vitreous humor""}}"																											
5395	5929	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	2	Snowbank Formation at Pars Plana	Exudative and fibrocellular snowbank deposition along the pars plana and vitreous base.	cell_types[0]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5396	5929	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	2	Snowbank Formation at Pars Plana	Exudative and fibrocellular snowbank deposition along the pars plana and vitreous base.	biological_processes[0]	biological_processes	biological_processes			Extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""Extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
5397	5929	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	2	Snowbank Formation at Pars Plana	Exudative and fibrocellular snowbank deposition along the pars plana and vitreous base.	locations[0]	locations	locations			Pars plana	UBERON:0004548	pars plana of ciliary body		"{""preferred_term"": ""Pars plana"", ""term"": {""id"": ""UBERON:0004548"", ""label"": ""pars plana of ciliary body""}}"																											
5398	5929	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	2	Snowbank Formation at Pars Plana	Exudative and fibrocellular snowbank deposition along the pars plana and vitreous base.	locations[1]	locations	locations			Peripheral retina	UBERON:0001789	retina		"{""preferred_term"": ""Peripheral retina"", ""term"": {""id"": ""UBERON:0001789"", ""label"": ""retina""}}"																											
5399	5930	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	3	Peripheral Retinal Vasculitis and Sheathing	Inflammation of peripheral retinal vessels leading to vascular sheathing and leakage.	cell_types[0]	cell_types	cell_types			Endothelial cell of vascular tree	CL:0002139	endothelial cell of vascular tree		"{""preferred_term"": ""Endothelial cell of vascular tree"", ""term"": {""id"": ""CL:0002139"", ""label"": ""endothelial cell of vascular tree""}}"																											
5400	5930	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	3	Peripheral Retinal Vasculitis and Sheathing	Inflammation of peripheral retinal vessels leading to vascular sheathing and leakage.	biological_processes[0]	biological_processes	biological_processes			Inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5401	5930	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	3	Peripheral Retinal Vasculitis and Sheathing	Inflammation of peripheral retinal vessels leading to vascular sheathing and leakage.	locations[0]	locations	locations			Peripheral retina	UBERON:0001789	retina		"{""preferred_term"": ""Peripheral retina"", ""term"": {""id"": ""UBERON:0001789"", ""label"": ""retina""}}"																											
5402	5931	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	4	Macular Thickening from Blood-Retinal Barrier Breakdown	Inflammatory vascular leakage causes subclinical or clinical macular thickening that can progress to cystoid macular edema.	cell_types[0]	cell_types	cell_types			Endothelial cell of vascular tree	CL:0002139	endothelial cell of vascular tree		"{""preferred_term"": ""Endothelial cell of vascular tree"", ""term"": {""id"": ""CL:0002139"", ""label"": ""endothelial cell of vascular tree""}}"																											
5403	5931	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	4	Macular Thickening from Blood-Retinal Barrier Breakdown	Inflammatory vascular leakage causes subclinical or clinical macular thickening that can progress to cystoid macular edema.	biological_processes[0]	biological_processes	biological_processes			Regulation of vascular permeability	GO:0043112	regulation of vascular permeability		"{""preferred_term"": ""Regulation of vascular permeability"", ""term"": {""id"": ""GO:0043112"", ""label"": ""regulation of vascular permeability""}}"																											
5404	5931	251	Pars Planitis	Pars_Planitis.yaml	pathophysiology	4	Macular Thickening from Blood-Retinal Barrier Breakdown	Inflammatory vascular leakage causes subclinical or clinical macular thickening that can progress to cystoid macular edema.	locations[0]	locations	locations			Macula of retina	UBERON:0008901	macula lutea		"{""preferred_term"": ""Macula of retina"", ""term"": {""id"": ""UBERON:0008901"", ""label"": ""macula lutea""}}"																											
5405	5932	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	0	Blurred Vision		phenotype_term	phenotype_term	$	Blurred Vision		Blurred vision	HP:0000622	Blurred vision		"{""preferred_term"": ""Blurred vision"", ""term"": {""id"": ""HP:0000622"", ""label"": ""Blurred vision""}}"																											
5406	5933	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	1	Floaters		phenotype_term	phenotype_term	$	Floaters		Vitreous floaters	HP:0100832	Vitreous floaters		"{""preferred_term"": ""Vitreous floaters"", ""term"": {""id"": ""HP:0100832"", ""label"": ""Vitreous floaters""}}"																											
5407	5934	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	2	Visual Impairment		phenotype_term	phenotype_term	$	Visual Impairment		Visual impairment	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual impairment"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
5408	5935	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	3	Vitreous Opacities		phenotype_term	phenotype_term	$	Vitreous Opacities		Abnormal vitreous humor morphology	HP:0004327	Abnormal vitreous humor morphology		"{""preferred_term"": ""Abnormal vitreous humor morphology"", ""term"": {""id"": ""HP:0004327"", ""label"": ""Abnormal vitreous humor morphology""}}"																											
5409	5936	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	4	Macular Edema		phenotype_term	phenotype_term	$	Macular Edema		Macular edema	HP:0040049	Macular edema		"{""preferred_term"": ""Macular edema"", ""term"": {""id"": ""HP:0040049"", ""label"": ""Macular edema""}}"																											
5410	5937	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	5	Optic Disc Swelling		phenotype_term	phenotype_term	$	Optic Disc Swelling		Optic disc edema	HP:0001085	Papilledema		"{""preferred_term"": ""Optic disc edema"", ""term"": {""id"": ""HP:0001085"", ""label"": ""Papilledema""}}"																											
5411	5938	251	Pars Planitis	Pars_Planitis.yaml	phenotypes	6	Retinal Pigmentation Abnormality (Bone Spicules)		phenotype_term	phenotype_term	$	Retinal Pigmentation Abnormality (Bone Spicules)		Abnormality of retinal pigmentation	HP:0007703	Abnormality of retinal pigmentation		"{""preferred_term"": ""Abnormality of retinal pigmentation"", ""term"": {""id"": ""HP:0007703"", ""label"": ""Abnormality of retinal pigmentation""}}"																											
5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	treatment_term	$	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Triamcinolone; Prednisone	NCIT:C901; NCIT:C770	NCIT:C2259			
5413	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5414	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			triamcinolone	NCIT:C901	Triamcinolone		"{""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}"																											
5415	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5416	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			prednisone	NCIT:C770	Prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}"																											
5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	treatment_term	$	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Methotrexate; Mycophenolate Mofetil; Azathioprine; Cyclosporine	NCIT:C642; NCIT:C1468; NCIT:C290; NCIT:C406	NCIT:C2259			
5418	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5419	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			methotrexate	NCIT:C642	Methotrexate		"{""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}"																											
5420	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5421	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			mycophenolate mofetil	NCIT:C1468	Mycophenolate Mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}"																											
5422	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5423	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			azathioprine	NCIT:C290	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}"																											
5424	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[3].predicate	treatment_term	treatment_term.qualifiers[3]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5425	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[3].value	treatment_term	treatment_term.qualifiers[3]			cyclosporine	NCIT:C406	Cyclosporine		"{""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}"																											
5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	treatment_term	$	Biological Therapy	TNF-alpha inhibitors for refractory cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Adalimumab; Infliximab	NCIT:C65216; NCIT:C1789	NCIT:C2259			
5427	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5428	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			adalimumab	NCIT:C65216	Adalimumab		"{""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}"																											
5429	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5430	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			infliximab	NCIT:C1789	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}"																											
5431	5942	251	Pars Planitis	Pars_Planitis.yaml	treatments	3	Pars Plana Vitrectomy	Surgical intervention for severe vitreous opacities or complications.	treatment_term	treatment_term	$	Pars Plana Vitrectomy	Surgical intervention for severe vitreous opacities or complications.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5432	5949	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	infectious_agent	0	Parvovirus B19	A single-stranded DNA virus known to cause several clinical conditions, particularly in children.	infectious_agent_term	infectious_agent_term	$	Parvovirus B19	A single-stranded DNA virus known to cause several clinical conditions, particularly in children.	Human parvovirus B19	NCBITaxon:10798	Human parvovirus B19		"{""preferred_term"": ""Human parvovirus B19"", ""term"": {""id"": ""NCBITaxon:10798"", ""label"": ""Human parvovirus B19""}}"																											
5433	5950	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	0	Viral Replication	The virus primarily targets erythroid progenitor cells in the bone marrow, leading to disrupted red blood cell production.	cell_types[0]	cell_types	cell_types			Erythroid Progenitor Cells	CL:0000038	erythroid progenitor cell		"{""preferred_term"": ""Erythroid Progenitor Cells"", ""term"": {""id"": ""CL:0000038"", ""label"": ""erythroid progenitor cell""}}"																											
5434	5950	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	0	Viral Replication	The virus primarily targets erythroid progenitor cells in the bone marrow, leading to disrupted red blood cell production.	biological_processes[0]	biological_processes	biological_processes			viral genome replication	GO:0019079	viral genome replication		"{""preferred_term"": ""viral genome replication"", ""term"": {""id"": ""GO:0019079"", ""label"": ""viral genome replication""}}"																											
5435	5950	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	0	Viral Replication	The virus primarily targets erythroid progenitor cells in the bone marrow, leading to disrupted red blood cell production.	biological_processes[1]	biological_processes	biological_processes			DNA replication	GO:0006260	DNA replication		"{""preferred_term"": ""DNA replication"", ""term"": {""id"": ""GO:0006260"", ""label"": ""DNA replication""}}"																											
5436	5950	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	0	Viral Replication	The virus primarily targets erythroid progenitor cells in the bone marrow, leading to disrupted red blood cell production.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
5437	5952	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	2	Receptor-Mediated Entry	Initial viral entry involves binding to globoside (P antigen) on cell surfaces, followed by VP1u-mediated internalization into erythroid progenitor cells. Acidic pH in endosomes facilitates globoside-dependent infectious trafficking and VP1u conformational changes for endosomal escape.	biological_processes[0]	biological_processes	biological_processes			viral entry into host cell	GO:0046718	viral entry into host cell		"{""preferred_term"": ""viral entry into host cell"", ""term"": {""id"": ""GO:0046718"", ""label"": ""viral entry into host cell""}}"																											
5438	5952	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	2	Receptor-Mediated Entry	Initial viral entry involves binding to globoside (P antigen) on cell surfaces, followed by VP1u-mediated internalization into erythroid progenitor cells. Acidic pH in endosomes facilitates globoside-dependent infectious trafficking and VP1u conformational changes for endosomal escape.	biological_processes[1]	biological_processes	biological_processes			endocytosis	GO:0006897	endocytosis		"{""preferred_term"": ""endocytosis"", ""term"": {""id"": ""GO:0006897"", ""label"": ""endocytosis""}}"																											
5439	5952	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	2	Receptor-Mediated Entry	Initial viral entry involves binding to globoside (P antigen) on cell surfaces, followed by VP1u-mediated internalization into erythroid progenitor cells. Acidic pH in endosomes facilitates globoside-dependent infectious trafficking and VP1u conformational changes for endosomal escape.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
5440	5952	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	2	Receptor-Mediated Entry	Initial viral entry involves binding to globoside (P antigen) on cell surfaces, followed by VP1u-mediated internalization into erythroid progenitor cells. Acidic pH in endosomes facilitates globoside-dependent infectious trafficking and VP1u conformational changes for endosomal escape.	locations[1]	locations	locations			fetal liver	UBERON:0002107	fetal liver		"{""preferred_term"": ""fetal liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""fetal liver""}}"																											
5441	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	genes[0]	genes	genes			ATR	hgnc:882	ATR		"{""preferred_term"": ""ATR"", ""term"": {""id"": ""hgnc:882"", ""label"": ""ATR""}}"																											
5442	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	genes[1]	genes	genes			PRKDC	hgnc:9413	PRKDC		"{""preferred_term"": ""PRKDC"", ""term"": {""id"": ""hgnc:9413"", ""label"": ""PRKDC""}}"																											
5443	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	biological_processes[0]	biological_processes	biological_processes			DNA damage response	GO:0006974	cellular response to DNA damage stimulus		"{""preferred_term"": ""DNA damage response"", ""term"": {""id"": ""GO:0006974"", ""label"": ""cellular response to DNA damage stimulus""}}"																											
5444	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	biological_processes[1]	biological_processes	biological_processes			cell cycle arrest	GO:0007050	regulation of cell cycle		"{""preferred_term"": ""cell cycle arrest"", ""term"": {""id"": ""GO:0007050"", ""label"": ""regulation of cell cycle""}}"																											
5445	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	biological_processes[2]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
5446	5953	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	3	Cell Cycle Arrest and Apoptosis	Viral NS1 protein and replication intermediates activate the DNA damage response (DDR) pathway, particularly ATR and DNA-PKcs, leading to late S/G2 phase arrest and apoptotic death of infected erythroid progenitor cells.	cell_types[0]	cell_types	cell_types			Erythroid Progenitor Cells	CL:0000038	erythroid progenitor cell		"{""preferred_term"": ""Erythroid Progenitor Cells"", ""term"": {""id"": ""CL:0000038"", ""label"": ""erythroid progenitor cell""}}"																											
5447	5954	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	4	EPO-STAT5 Signaling Pathway	Erythropoietin (EPO) signaling through STAT5A and STAT5B creates a permissive transcriptional environment for B19V replication in erythroid progenitor cells. Hypoxic conditions enhance STAT5A activity and viral replication.	genes[0]	genes	genes			EPOR	hgnc:3416	EPOR		"{""preferred_term"": ""EPOR"", ""term"": {""id"": ""hgnc:3416"", ""label"": ""EPOR""}}"																											
5448	5954	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	4	EPO-STAT5 Signaling Pathway	Erythropoietin (EPO) signaling through STAT5A and STAT5B creates a permissive transcriptional environment for B19V replication in erythroid progenitor cells. Hypoxic conditions enhance STAT5A activity and viral replication.	genes[1]	genes	genes			STAT5A	hgnc:11367	STAT5A		"{""preferred_term"": ""STAT5A"", ""term"": {""id"": ""hgnc:11367"", ""label"": ""STAT5A""}}"																											
5449	5954	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	4	EPO-STAT5 Signaling Pathway	Erythropoietin (EPO) signaling through STAT5A and STAT5B creates a permissive transcriptional environment for B19V replication in erythroid progenitor cells. Hypoxic conditions enhance STAT5A activity and viral replication.	genes[2]	genes	genes			STAT5B	hgnc:11368	STAT5B		"{""preferred_term"": ""STAT5B"", ""term"": {""id"": ""hgnc:11368"", ""label"": ""STAT5B""}}"																											
5450	5954	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	4	EPO-STAT5 Signaling Pathway	Erythropoietin (EPO) signaling through STAT5A and STAT5B creates a permissive transcriptional environment for B19V replication in erythroid progenitor cells. Hypoxic conditions enhance STAT5A activity and viral replication.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT cascade	GO:0007259	receptor signaling pathway via JAK-STAT		"{""preferred_term"": ""JAK-STAT cascade"", ""term"": {""id"": ""GO:0007259"", ""label"": ""receptor signaling pathway via JAK-STAT""}}"																											
5451	5954	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	pathophysiology	4	EPO-STAT5 Signaling Pathway	Erythropoietin (EPO) signaling through STAT5A and STAT5B creates a permissive transcriptional environment for B19V replication in erythroid progenitor cells. Hypoxic conditions enhance STAT5A activity and viral replication.	cell_types[0]	cell_types	cell_types			Erythroid Progenitor Cells	CL:0000038	erythroid progenitor cell		"{""preferred_term"": ""Erythroid Progenitor Cells"", ""term"": {""id"": ""CL:0000038"", ""label"": ""erythroid progenitor cell""}}"																											
5452	5957	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	phenotypes	2	Arthropathy	Symmetric polyarthritis affecting small joints of hands, wrists, and knees, more common in adult women.	phenotype_term	phenotype_term	$	Arthropathy	Symmetric polyarthritis affecting small joints of hands, wrists, and knees, more common in adult women.	Arthropathy	HP:0003040	Arthropathy		"{""preferred_term"": ""Arthropathy"", ""term"": {""id"": ""HP:0003040"", ""label"": ""Arthropathy""}}"																											
5453	5958	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	phenotypes	3	Hydrops Fetalis	Severe fetal condition with fluid accumulation in body cavities due to profound anemia from viral destruction of fetal erythroid precursors.	phenotype_term	phenotype_term	$	Hydrops Fetalis	Severe fetal condition with fluid accumulation in body cavities due to profound anemia from viral destruction of fetal erythroid precursors.	Hydrops Fetalis	HP:0001789	Hydrops fetalis		"{""preferred_term"": ""Hydrops Fetalis"", ""term"": {""id"": ""HP:0001789"", ""label"": ""Hydrops fetalis""}}"																											
5454	5959	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	phenotypes	4	Slapped Cheek Rash	Bright red malar erythema giving the face a slapped appearance, pathognomonic for erythema infectiosum.	phenotype_term	phenotype_term	$	Slapped Cheek Rash	Bright red malar erythema giving the face a slapped appearance, pathognomonic for erythema infectiosum.	Slapped Cheek Rash	HP:0025300	Malar rash		"{""preferred_term"": ""Slapped Cheek Rash"", ""term"": {""id"": ""HP:0025300"", ""label"": ""Malar rash""}}"																											
5455	5960	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	phenotypes	5	Myocarditis	Inflammation of heart muscle associated with endothelial cell infection and viral persistence in cardiac tissues.	phenotype_term	phenotype_term	$	Myocarditis	Inflammation of heart muscle associated with endothelial cell infection and viral persistence in cardiac tissues.	Myocarditis	HP:0012819	Myocarditis		"{""preferred_term"": ""Myocarditis"", ""term"": {""id"": ""HP:0012819"", ""label"": ""Myocarditis""}}"																											
5456	5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	Supportive Care	Includes rest, fluids, and analgesics for managing symptoms.	treatment_term	treatment_term	$	Supportive Care	Includes rest, fluids, and analgesics for managing symptoms.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5457	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	Intravenous Immunoglobulin (IVIG)	Used in severe cases, particularly for individuals with immunodeficiency or severe anemia.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	Used in severe cases, particularly for individuals with immunodeficiency or severe anemia.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5458	5971	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	0	Anti-Desmoglein Autoantibodies	IgG autoantibodies against desmoglein 3 (mucosal-dominant) and desmoglein 1 (mucocutaneous) directly cause loss of keratinocyte adhesion. Antibody binding triggers intracellular signaling leading to desmosome disassembly.	cell_types[0]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
5459	5971	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	0	Anti-Desmoglein Autoantibodies	IgG autoantibodies against desmoglein 3 (mucosal-dominant) and desmoglein 1 (mucocutaneous) directly cause loss of keratinocyte adhesion. Antibody binding triggers intracellular signaling leading to desmosome disassembly.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
5460	5972	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	1	Acantholysis and Blister Formation	Loss of desmosomal adhesion causes keratinocytes to detach from each other (acantholysis). Suprabasal clefting occurs as basal keratinocytes remain attached to the basement membrane while upper layers separate.	biological_processes[0]	biological_processes	biological_processes			Cell Adhesion	GO:0007155	cell adhesion		"{""preferred_term"": ""Cell Adhesion"", ""term"": {""id"": ""GO:0007155"", ""label"": ""cell adhesion""}}"																											
5461	5973	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	2	Signaling-Mediated Cytoskeletal Changes	Anti-desmoglein antibodies activate p38 MAPK and other signaling pathways, causing keratin filament retraction and further weakening of cell-cell adhesion independent of direct steric hindrance.	biological_processes[0]	biological_processes	biological_processes			Signal Transduction	GO:0007165	signal transduction		"{""preferred_term"": ""Signal Transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"																											
5462	5974	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	3	Immune Dysregulation and Th2/Th17 Skewing	Pemphigus vulgaris is characterized by a shift toward Th2 and Th17 cytokine profiles with elevated IL-4, IL-6, and IL-17A, along with a marked reduction in regulatory T cells (Tregs). This imbalance promotes autoreactive B cell activation and pathogenic autoantibody production.	biological_processes[0]	biological_processes	biological_processes			T Cell Differentiation	GO:0030217	T cell differentiation		"{""preferred_term"": ""T Cell Differentiation"", ""term"": {""id"": ""GO:0030217"", ""label"": ""T cell differentiation""}}"																											
5463	5974	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	pathophysiology	3	Immune Dysregulation and Th2/Th17 Skewing	Pemphigus vulgaris is characterized by a shift toward Th2 and Th17 cytokine profiles with elevated IL-4, IL-6, and IL-17A, along with a marked reduction in regulatory T cells (Tregs). This imbalance promotes autoreactive B cell activation and pathogenic autoantibody production.	biological_processes[1]	biological_processes	biological_processes			Cytokine Production	GO:0001816	cytokine production		"{""preferred_term"": ""Cytokine Production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"																											
5464	5975	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	phenotypes	0	Oral Ulcers		phenotype_term	phenotype_term	$	Oral Ulcers		Oral Ulcer	HP:0000155	Oral ulcer		"{""preferred_term"": ""Oral Ulcer"", ""term"": {""id"": ""HP:0000155"", ""label"": ""Oral ulcer""}}"																											
5465	5976	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	phenotypes	1	Skin Blisters		phenotype_term	phenotype_term	$	Skin Blisters		Skin Vesicle	HP:0200037	Skin vesicle		"{""preferred_term"": ""Skin Vesicle"", ""term"": {""id"": ""HP:0200037"", ""label"": ""Skin vesicle""}}"																											
5466	5977	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	phenotypes	2	Skin Erosions		phenotype_term	phenotype_term	$	Skin Erosions		Abnormality of the Skin	HP:0000951	Abnormality of the skin		"{""preferred_term"": ""Abnormality of the Skin"", ""term"": {""id"": ""HP:0000951"", ""label"": ""Abnormality of the skin""}}"																											
5467	5978	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	phenotypes	3	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
5468	5995	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	0	Atherosclerosis	"Progressive buildup of lipid-rich plaques in peripheral arteries, predominantly affecting lower extremities. Same pathophysiology as coronary artery disease.
"	cell_types[0]	cell_types	cell_types			Foam Cell	CL:0000891	foam cell		"{""preferred_term"": ""Foam Cell"", ""term"": {""id"": ""CL:0000891"", ""label"": ""foam cell""}}"																											
5469	5995	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	0	Atherosclerosis	"Progressive buildup of lipid-rich plaques in peripheral arteries, predominantly affecting lower extremities. Same pathophysiology as coronary artery disease.
"	biological_processes[0]	biological_processes	biological_processes			Lipid Accumulation	GO:0034383	low-density lipoprotein particle clearance		"{""preferred_term"": ""Lipid Accumulation"", ""term"": {""id"": ""GO:0034383"", ""label"": ""low-density lipoprotein particle clearance""}}"																											
5470	5996	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	1	Endothelial Dysfunction	"Impaired endothelium-dependent vasodilation reduces blood flow reserve. Decreased nitric oxide production and increased endothelin contribute.
"	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
5471	5996	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	1	Endothelial Dysfunction	"Impaired endothelium-dependent vasodilation reduces blood flow reserve. Decreased nitric oxide production and increased endothelin contribute.
"	biological_processes[0]	biological_processes	biological_processes			Vasodilation	GO:0042311	vasodilation		"{""preferred_term"": ""Vasodilation"", ""term"": {""id"": ""GO:0042311"", ""label"": ""vasodilation""}}"																											
5472	5997	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	2	Thrombosis	"Plaque rupture or erosion triggers thrombosis, potentially causing acute limb ischemia. Platelet activation on disrupted plaque.
"	biological_processes[0]	biological_processes	biological_processes			Thrombosis	GO:0007596	blood coagulation		"{""preferred_term"": ""Thrombosis"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"																											
5473	5998	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	pathophysiology	3	Inflammation	"Chronic inflammation drives plaque progression and instability. Elevated CRP and inflammatory markers predict cardiovascular events.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5474	5999	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	phenotypes	0	Intermittent Claudication		phenotype_term	phenotype_term	$	Intermittent Claudication		Limb Pain	HP:0009763	Limb pain		"{""preferred_term"": ""Limb Pain"", ""term"": {""id"": ""HP:0009763"", ""label"": ""Limb pain""}}"																											
5475	6000	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	phenotypes	1	Rest Pain		phenotype_term	phenotype_term	$	Rest Pain		Limb Pain at Rest	HP:0012532	Chronic pain		"{""preferred_term"": ""Limb Pain at Rest"", ""term"": {""id"": ""HP:0012532"", ""label"": ""Chronic pain""}}"																											
5476	6001	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	phenotypes	2	Non-Healing Wounds		phenotype_term	phenotype_term	$	Non-Healing Wounds		Impaired Wound Healing	HP:0001058	Poor wound healing		"{""preferred_term"": ""Impaired Wound Healing"", ""term"": {""id"": ""HP:0001058"", ""label"": ""Poor wound healing""}}"																											
5477	6002	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	phenotypes	3	Skin Changes		phenotype_term	phenotype_term	$	Skin Changes		Skin Changes	HP:0000951	Abnormality of the skin		"{""preferred_term"": ""Skin Changes"", ""term"": {""id"": ""HP:0000951"", ""label"": ""Abnormality of the skin""}}"																											
5478	6025	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	0	Peroxisome Biogenesis Defect	Mutations in PEX genes disrupt the assembly and function of peroxisomes, leading to impaired metabolic processes.	cellular_components[0]	cellular_components	cellular_components			Peroxisome	GO:0005777	peroxisome		"{""preferred_term"": ""Peroxisome"", ""term"": {""id"": ""GO:0005777"", ""label"": ""peroxisome""}}"																											
5479	6026	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	1	Accumulation of Toxic Metabolites	The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.	biological_processes[0]	biological_processes	biological_processes			fatty acid beta-oxidation	GO:0006635	fatty acid beta-oxidation		"{""preferred_term"": ""fatty acid beta-oxidation"", ""term"": {""id"": ""GO:0006635"", ""label"": ""fatty acid beta-oxidation""}}"																											
5480	6026	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	1	Accumulation of Toxic Metabolites	The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.	biological_processes[1]	biological_processes	biological_processes			very long-chain fatty acid metabolic process	GO:0000038	very long-chain fatty acid metabolic process		"{""preferred_term"": ""very long-chain fatty acid metabolic process"", ""term"": {""id"": ""GO:0000038"", ""label"": ""very long-chain fatty acid metabolic process""}}"																											
5481	6026	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	1	Accumulation of Toxic Metabolites	The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.	chemical_entities[0]	chemical_entities	chemical_entities			VLCFAs				"{""preferred_term"": ""VLCFAs""}"																											
5482	6026	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	1	Accumulation of Toxic Metabolites	The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.	chemical_entities[1]	chemical_entities	chemical_entities			Bile Acid Intermediates				"{""preferred_term"": ""Bile Acid Intermediates""}"																											
5483	6026	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	1	Accumulation of Toxic Metabolites	The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.	chemical_entities[2]	chemical_entities	chemical_entities			Phytanic Acid	CHEBI:16285	phytanic acid		"{""preferred_term"": ""Phytanic Acid"", ""term"": {""id"": ""CHEBI:16285"", ""label"": ""phytanic acid""}}"																											
5484	6027	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	2	Deficiency of Essential Compounds	Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.	biological_processes[0]	biological_processes	biological_processes			ether lipid biosynthetic process	GO:0008611	ether lipid biosynthetic process		"{""preferred_term"": ""ether lipid biosynthetic process"", ""term"": {""id"": ""GO:0008611"", ""label"": ""ether lipid biosynthetic process""}}"																											
5485	6027	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	2	Deficiency of Essential Compounds	Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.	biological_processes[1]	biological_processes	biological_processes			bile acid biosynthetic process	GO:0006699	bile acid biosynthetic process		"{""preferred_term"": ""bile acid biosynthetic process"", ""term"": {""id"": ""GO:0006699"", ""label"": ""bile acid biosynthetic process""}}"																											
5486	6027	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	2	Deficiency of Essential Compounds	Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.	chemical_entities[0]	chemical_entities	chemical_entities			Plasmalogen				"{""preferred_term"": ""Plasmalogen""}"																											
5487	6027	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	2	Deficiency of Essential Compounds	Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.	chemical_entities[1]	chemical_entities	chemical_entities			Docosahexaenoic acid	CHEBI:28125	docosahexaenoic acid		"{""preferred_term"": ""Docosahexaenoic acid"", ""term"": {""id"": ""CHEBI:28125"", ""label"": ""docosahexaenoic acid""}}"																											
5488	6028	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	3	Neurological Dysfunction	Accumulation of toxic metabolites and deficiency of essential compounds lead to demyelination, neuronal migration defects, and neurodegeneration.	locations[0]	locations	locations			central nervous system	UBERON:0001017	central nervous system		"{""preferred_term"": ""central nervous system"", ""term"": {""id"": ""UBERON:0001017"", ""label"": ""central nervous system""}}"																											
5489	6028	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	3	Neurological Dysfunction	Accumulation of toxic metabolites and deficiency of essential compounds lead to demyelination, neuronal migration defects, and neurodegeneration.	cell_types[0]	cell_types	cell_types			oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
5490	6029	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	4	Hepatic Dysfunction	Accumulation of bile acid intermediates and VLCFAs, along with oxidative stress, cause hepatomegaly, fibrosis, and liver failure.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
5491	6029	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	4	Hepatic Dysfunction	Accumulation of bile acid intermediates and VLCFAs, along with oxidative stress, cause hepatomegaly, fibrosis, and liver failure.	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
5492	6030	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	5	Skeletal Abnormalities	Plasmalogen deficiency disrupts normal bone formation, leading to rhizomelic shortening of limbs and chondrodysplasia punctata.	locations[0]	locations	locations			bones	UBERON:0001474	bone element		"{""preferred_term"": ""bones"", ""term"": {""id"": ""UBERON:0001474"", ""label"": ""bone element""}}"																											
5493	6030	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	5	Skeletal Abnormalities	Plasmalogen deficiency disrupts normal bone formation, leading to rhizomelic shortening of limbs and chondrodysplasia punctata.	locations[1]	locations	locations			cartilage	UBERON:0002418	cartilage tissue		"{""preferred_term"": ""cartilage"", ""term"": {""id"": ""UBERON:0002418"", ""label"": ""cartilage tissue""}}"																											
5494	6032	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	7	Microglial Dysfunction and Neuroinflammation	Peroxisomal defects in microglial cells induce a disease-associated microglial (DAM) signature with altered lipid metabolism, lipid droplet accumulation, and impaired autophagy, contributing to neurodegeneration.	locations[0]	locations	locations			central nervous system	UBERON:0001017	central nervous system		"{""preferred_term"": ""central nervous system"", ""term"": {""id"": ""UBERON:0001017"", ""label"": ""central nervous system""}}"																											
5495	6032	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	7	Microglial Dysfunction and Neuroinflammation	Peroxisomal defects in microglial cells induce a disease-associated microglial (DAM) signature with altered lipid metabolism, lipid droplet accumulation, and impaired autophagy, contributing to neurodegeneration.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
5496	6033	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	8	Peroxisome-Organelle Crosstalk Disruption	Disruption of peroxisome-ER-mitochondria interactions impairs lipid trafficking and metabolic coordination, particularly affecting VLCFA and ether-lipid flux between organelles.	cellular_components[0]	cellular_components	cellular_components			peroxisome	GO:0005777	peroxisome		"{""preferred_term"": ""peroxisome"", ""term"": {""id"": ""GO:0005777"", ""label"": ""peroxisome""}}"																											
5497	6033	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	8	Peroxisome-Organelle Crosstalk Disruption	Disruption of peroxisome-ER-mitochondria interactions impairs lipid trafficking and metabolic coordination, particularly affecting VLCFA and ether-lipid flux between organelles.	cellular_components[1]	cellular_components	cellular_components			endoplasmic reticulum	GO:0005783	endoplasmic reticulum		"{""preferred_term"": ""endoplasmic reticulum"", ""term"": {""id"": ""GO:0005783"", ""label"": ""endoplasmic reticulum""}}"																											
5498	6033	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	8	Peroxisome-Organelle Crosstalk Disruption	Disruption of peroxisome-ER-mitochondria interactions impairs lipid trafficking and metabolic coordination, particularly affecting VLCFA and ether-lipid flux between organelles.	cellular_components[2]	cellular_components	cellular_components			mitochondrion	GO:0005739	mitochondrion		"{""preferred_term"": ""mitochondrion"", ""term"": {""id"": ""GO:0005739"", ""label"": ""mitochondrion""}}"																											
5499	6034	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	9	Retinal Pigment Epithelium Dysfunction	In peroxisome biogenesis disorders, retinal pigment epithelium shows progressive lipid remodeling with decreased plasmalogens and increased very-long-chain lysophosphatidylcholines, leading to structural degeneration and vision loss.	locations[0]	locations	locations			retina	UBERON:0000966	retina		"{""preferred_term"": ""retina"", ""term"": {""id"": ""UBERON:0000966"", ""label"": ""retina""}}"																											
5500	6034	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	9	Retinal Pigment Epithelium Dysfunction	In peroxisome biogenesis disorders, retinal pigment epithelium shows progressive lipid remodeling with decreased plasmalogens and increased very-long-chain lysophosphatidylcholines, leading to structural degeneration and vision loss.	cell_types[0]	cell_types	cell_types			retinal pigment epithelial cell	CL:0002586	retinal pigment epithelial cell		"{""preferred_term"": ""retinal pigment epithelial cell"", ""term"": {""id"": ""CL:0002586"", ""label"": ""retinal pigment epithelial cell""}}"																											
5501	6034	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	9	Retinal Pigment Epithelium Dysfunction	In peroxisome biogenesis disorders, retinal pigment epithelium shows progressive lipid remodeling with decreased plasmalogens and increased very-long-chain lysophosphatidylcholines, leading to structural degeneration and vision loss.	cell_types[1]	cell_types	cell_types			photoreceptor cell	CL:0000210	photoreceptor cell		"{""preferred_term"": ""photoreceptor cell"", ""term"": {""id"": ""CL:0000210"", ""label"": ""photoreceptor cell""}}"																											
5502	6035	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	10	Impaired Peroxisome Biogenesis and Import	Mutations in PEX genes disrupt the peroxisomal protein import machinery, including PEX5/PEX7 receptors, the PEX13/PEX14 docking complex, and the PEX1-PEX6 AAA+ ATPase export complex, preventing proper assembly and function of peroxisomes.	cellular_components[0]	cellular_components	cellular_components			peroxisome	GO:0005777	peroxisome		"{""preferred_term"": ""peroxisome"", ""term"": {""id"": ""GO:0005777"", ""label"": ""peroxisome""}}"																											
5503	6035	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	10	Impaired Peroxisome Biogenesis and Import	Mutations in PEX genes disrupt the peroxisomal protein import machinery, including PEX5/PEX7 receptors, the PEX13/PEX14 docking complex, and the PEX1-PEX6 AAA+ ATPase export complex, preventing proper assembly and function of peroxisomes.	biological_processes[0]	biological_processes	biological_processes			protein import into peroxisome matrix	GO:0016558	protein import into peroxisome matrix		"{""preferred_term"": ""protein import into peroxisome matrix"", ""term"": {""id"": ""GO:0016558"", ""label"": ""protein import into peroxisome matrix""}}"																											
5504	6035	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	pathophysiology	10	Impaired Peroxisome Biogenesis and Import	Mutations in PEX genes disrupt the peroxisomal protein import machinery, including PEX5/PEX7 receptors, the PEX13/PEX14 docking complex, and the PEX1-PEX6 AAA+ ATPase export complex, preventing proper assembly and function of peroxisomes.	biological_processes[1]	biological_processes	biological_processes			peroxisome organization	GO:0007031	peroxisome organization		"{""preferred_term"": ""peroxisome organization"", ""term"": {""id"": ""GO:0007031"", ""label"": ""peroxisome organization""}}"																											
5505	6036	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	0	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
5506	6037	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	1	Developmental Delay		phenotype_term	phenotype_term	$	Developmental Delay		Developmental Delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Developmental Delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5507	6038	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	2	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
5508	6039	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	3	Leukodystrophy		phenotype_term	phenotype_term	$	Leukodystrophy		Leukodystrophy	HP:0002415	Leukodystrophy		"{""preferred_term"": ""Leukodystrophy"", ""term"": {""id"": ""HP:0002415"", ""label"": ""Leukodystrophy""}}"																											
5509	6040	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	4	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
5510	6041	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	5	Cholestasis		phenotype_term	phenotype_term	$	Cholestasis		Cholestasis	HP:0001396	Cholestasis		"{""preferred_term"": ""Cholestasis"", ""term"": {""id"": ""HP:0001396"", ""label"": ""Cholestasis""}}"																											
5511	6042	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	6	Renal Dysfunction		phenotype_term	phenotype_term	$	Renal Dysfunction		Abnormal renal physiology	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Abnormal renal physiology"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
5512	6043	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	7	Retinopathy		phenotype_term	phenotype_term	$	Retinopathy		Retinopathy	HP:0000488	Retinopathy		"{""preferred_term"": ""Retinopathy"", ""term"": {""id"": ""HP:0000488"", ""label"": ""Retinopathy""}}"																											
5513	6044	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	8	Hearing Loss		phenotype_term	phenotype_term	$	Hearing Loss		Hearing Loss	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing Loss"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
5514	6046	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	10	Adrenal Insufficiency		phenotype_term	phenotype_term	$	Adrenal Insufficiency		Adrenal Insufficiency	HP:0000846	Adrenal insufficiency		"{""preferred_term"": ""Adrenal Insufficiency"", ""term"": {""id"": ""HP:0000846"", ""label"": ""Adrenal insufficiency""}}"																											
5515	6048	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	12	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
5516	6049	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	13	Cardiomyopathy		phenotype_term	phenotype_term	$	Cardiomyopathy		Cardiomyopathy	HP:0001638	Cardiomyopathy		"{""preferred_term"": ""Cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""Cardiomyopathy""}}"																											
5517	6050	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	phenotypes	14	Heart Failure		phenotype_term	phenotype_term	$	Heart Failure		Heart Failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Heart Failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
5518	6052	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	0	Symptomatic Management	Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.	treatment_term	treatment_term	$	Symptomatic Management	Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5519	6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	Nutritional Support	Specialized diet and supplements to manage biochemical abnormalities.	treatment_term	treatment_term	$	Nutritional Support	Specialized diet and supplements to manage biochemical abnormalities.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5520	6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	Liver Transplant	Considered in severe cases with significant liver dysfunction.	treatment_term	treatment_term	$	Liver Transplant	Considered in severe cases with significant liver dysfunction.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
5521	6055	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	3	Genetic Counseling	Providing information and support to families regarding inheritance and implications.	treatment_term	treatment_term	$	Genetic Counseling	Providing information and support to families regarding inheritance and implications.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5522	6056	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	biochemical	0	Butyric acid		biomarker_term	biomarker_term	$	Butyric acid		butyric acid	NCIT:C68327	Butyric Acid		"{""preferred_term"": ""butyric acid"", ""term"": {""id"": ""NCIT:C68327"", ""label"": ""Butyric Acid""}}"																											
5523	6057	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	differential_diagnoses	0	Juvenile polyposis syndrome	"Juvenile polyps are also hamartomatous but present earlier in childhood, usually multiple but fewer than Peutz-Jeghers polyps. Lack the characteristic oral pigmentation. Juvenile polyposis is caused by BMPR1A or SMAD4 mutations, not STK11.
"	disease_term	disease_term	$	Juvenile polyposis syndrome	"Juvenile polyps are also hamartomatous but present earlier in childhood, usually multiple but fewer than Peutz-Jeghers polyps. Lack the characteristic oral pigmentation. Juvenile polyposis is caused by BMPR1A or SMAD4 mutations, not STK11.
"	juvenile polyposis syndrome	MONDO:0017380	juvenile polyposis syndrome		"{""preferred_term"": ""juvenile polyposis syndrome"", ""term"": {""id"": ""MONDO:0017380"", ""label"": ""juvenile polyposis syndrome""}}"																											
5524	6058	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	differential_diagnoses	1	Cowden syndrome	"Hamartomatous polyposis syndrome caused by PTEN mutations with mucocutaneous lesions and increased breast, thyroid, and endometrial cancer risks.
"	disease_term	disease_term	$	Cowden syndrome	"Hamartomatous polyposis syndrome caused by PTEN mutations with mucocutaneous lesions and increased breast, thyroid, and endometrial cancer risks.
"	Cowden syndrome	MONDO:0008021	Cowden syndrome 1		"{""preferred_term"": ""Cowden syndrome"", ""term"": {""id"": ""MONDO:0008021"", ""label"": ""Cowden syndrome 1""}}"																											
5525	6059	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	differential_diagnoses	2	Familial adenomatous polyposis (FAP)	"FAP presents with hundreds to thousands of adenomatous polyps. Polyps are adenomas (dysplastic), not benign hamartomas like Peutz-Jeghers. FAP is caused by APC mutations and does not include characteristic oral pigmentation.
"	disease_term	disease_term	$	Familial adenomatous polyposis (FAP)	"FAP presents with hundreds to thousands of adenomatous polyps. Polyps are adenomas (dysplastic), not benign hamartomas like Peutz-Jeghers. FAP is caused by APC mutations and does not include characteristic oral pigmentation.
"	classic familial adenomatous polyposis	MONDO:0021055	classic familial adenomatous polyposis		"{""preferred_term"": ""classic familial adenomatous polyposis"", ""term"": {""id"": ""MONDO:0021055"", ""label"": ""classic familial adenomatous polyposis""}}"																											
5526	6060	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	differential_diagnoses	3	Lynch syndrome	"Lynch syndrome involves microsatellite instability and increased cancer risk but does not feature polyp burden or oral pigmentation. Caused by mismatch repair gene mutations, not STK11.
"	disease_term	disease_term	$	Lynch syndrome	"Lynch syndrome involves microsatellite instability and increased cancer risk but does not feature polyp burden or oral pigmentation. Caused by mismatch repair gene mutations, not STK11.
"	Lynch syndrome	MONDO:0005835	Lynch syndrome		"{""preferred_term"": ""Lynch syndrome"", ""term"": {""id"": ""MONDO:0005835"", ""label"": ""Lynch syndrome""}}"																											
5527	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	cell_types[0]	cell_types	cell_types			intestinal smooth muscle cell	CL:0002504	enteric smooth muscle cell		"{""preferred_term"": ""intestinal smooth muscle cell"", ""term"": {""id"": ""CL:0002504"", ""label"": ""enteric smooth muscle cell""}}"																											
5528	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	cell_types[1]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
5529	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"																											
5530	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	biological_processes[1]	biological_processes	biological_processes			cell proliferation	GO:0008283	cell proliferation		"{""preferred_term"": ""cell proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell proliferation""}}"																											
5531	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	locations[0]	locations	locations			small intestine	UBERON:0002116	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002116"", ""label"": ""small intestine""}}"																											
5532	6064	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	0	STK11 loss-of-function signaling disruption	"Germline loss-of-function variants in STK11 (LKB1) disrupt tumor suppressor signaling and drive hamartomatous polyp formation throughout the GI tract.
"	locations[1]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
5533	6065	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	1	mTORC1 pathway hyperactivation	"LKB1-deficient tissues and hamartomas show increased mTORC1 signaling that promotes polyp growth and proliferation.
"	biological_processes[0]	biological_processes	biological_processes			mTORC1 signaling	GO:0031929	TOR signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""mTORC1 signaling"", ""term"": {""id"": ""GO:0031929"", ""label"": ""TOR signaling""}}"			INCREASED																								
5534	6065	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	1	mTORC1 pathway hyperactivation	"LKB1-deficient tissues and hamartomas show increased mTORC1 signaling that promotes polyp growth and proliferation.
"	biological_processes[1]	biological_processes	biological_processes			cell proliferation	GO:0008283	cell proliferation		"{""preferred_term"": ""cell proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell proliferation""}}"																											
5535	6065	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	1	mTORC1 pathway hyperactivation	"LKB1-deficient tissues and hamartomas show increased mTORC1 signaling that promotes polyp growth and proliferation.
"	locations[0]	locations	locations			small intestine	UBERON:0002116	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002116"", ""label"": ""small intestine""}}"																											
5536	6066	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	2	Arborizing smooth muscle core formation	"Hamartomatous polyps contain branching bundles of smooth muscle fibers covered by hyperplastic mucosa, producing the characteristic arborizing architecture.
"	cell_types[0]	cell_types	cell_types			smooth muscle cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""smooth muscle cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
5537	6066	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	2	Arborizing smooth muscle core formation	"Hamartomatous polyps contain branching bundles of smooth muscle fibers covered by hyperplastic mucosa, producing the characteristic arborizing architecture.
"	biological_processes[0]	biological_processes	biological_processes			smooth muscle cell differentiation	GO:0051145	smooth muscle cell differentiation		"{""preferred_term"": ""smooth muscle cell differentiation"", ""term"": {""id"": ""GO:0051145"", ""label"": ""smooth muscle cell differentiation""}}"																											
5538	6066	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	2	Arborizing smooth muscle core formation	"Hamartomatous polyps contain branching bundles of smooth muscle fibers covered by hyperplastic mucosa, producing the characteristic arborizing architecture.
"	biological_processes[1]	biological_processes	biological_processes			tissue morphogenesis	GO:0048569	tissue morphogenesis		"{""preferred_term"": ""tissue morphogenesis"", ""term"": {""id"": ""GO:0048569"", ""label"": ""tissue morphogenesis""}}"																											
5539	6066	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	pathophysiology	2	Arborizing smooth muscle core formation	"Hamartomatous polyps contain branching bundles of smooth muscle fibers covered by hyperplastic mucosa, producing the characteristic arborizing architecture.
"	locations[0]	locations	locations			small intestine	UBERON:0002116	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002116"", ""label"": ""small intestine""}}"																											
5540	6067	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	0	Small intestinal polyposis	"Multiple hamartomatous polyps predominantly in the small intestine. These polyps are benign but can grow large and cause complications.
"	phenotype_term	phenotype_term	$	Small intestinal polyposis	"Multiple hamartomatous polyps predominantly in the small intestine. These polyps are benign but can grow large and cause complications.
"	Small intestinal polyposis	HP:0030256	Small intestinal polyposis		"{""preferred_term"": ""Small intestinal polyposis"", ""term"": {""id"": ""HP:0030256"", ""label"": ""Small intestinal polyposis""}}"																											
5541	6068	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	1	Gastrointestinal hemorrhage	"Bleeding from polyps can occur, presenting as hematemesis, melena, or positive fecal occult blood. Chronic blood loss may lead to iron deficiency anemia.
"	phenotype_term	phenotype_term	$	Gastrointestinal hemorrhage	"Bleeding from polyps can occur, presenting as hematemesis, melena, or positive fecal occult blood. Chronic blood loss may lead to iron deficiency anemia.
"	Gastrointestinal hemorrhage	HP:0002239	Gastrointestinal hemorrhage		"{""preferred_term"": ""Gastrointestinal hemorrhage"", ""term"": {""id"": ""HP:0002239"", ""label"": ""Gastrointestinal hemorrhage""}}"																											
5542	6069	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	2	Abdominal pain	"Abdominal pain due to polyp-related obstruction, intussusception, or inflammation.
"	phenotype_term	phenotype_term	$	Abdominal pain	"Abdominal pain due to polyp-related obstruction, intussusception, or inflammation.
"	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
5543	6070	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	3	Abnormal pigmentation of oral mucosa	"Characteristic dark brown macules on the lips and intraoral mucosa, often present before gastrointestinal manifestations appear.
"	phenotype_term	phenotype_term	$	Abnormal pigmentation of oral mucosa	"Characteristic dark brown macules on the lips and intraoral mucosa, often present before gastrointestinal manifestations appear.
"	Abnormal pigmentation of oral mucosa	HP:0100669	Abnormal pigmentation of the oral mucosa		"{""preferred_term"": ""Abnormal pigmentation of oral mucosa"", ""term"": {""id"": ""HP:0100669"", ""label"": ""Abnormal pigmentation of the oral mucosa""}}"																											
5544	6071	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	4	Abnormal lip pigmentation	"Pigmented macules on the lips that often precede gastrointestinal symptoms.
"	phenotype_term	phenotype_term	$	Abnormal lip pigmentation	"Pigmented macules on the lips that often precede gastrointestinal symptoms.
"	Abnormal lip pigmentation	HP:0032453	Abnormal lip pigmentation		"{""preferred_term"": ""Abnormal lip pigmentation"", ""term"": {""id"": ""HP:0032453"", ""label"": ""Abnormal lip pigmentation""}}"																											
5545	6072	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	phenotypes	5	Increased cancer risk	"Significantly elevated lifetime risk of gastrointestinal cancers (stomach, duodenal, colorectal, pancreatic) and non-GI cancers (breast, lung, ovarian).
"	phenotype_term	phenotype_term	$	Increased cancer risk	"Significantly elevated lifetime risk of gastrointestinal cancers (stomach, duodenal, colorectal, pancreatic) and non-GI cancers (breast, lung, ovarian).
"	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
5546	6073	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	0	Endoscopic polypectomy	"Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.
"	treatment_term	treatment_term	$	Endoscopic polypectomy	"Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.
"	endoscopic procedure	MAXO:0000130	endoscopic procedure		"{""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""MAXO:0000130"", ""label"": ""endoscopic procedure""}}"																											
5547	6074	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	1	Surgical resection	"Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.
"	treatment_term	treatment_term	$	Surgical resection	"Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.
"	surgical resection	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical resection"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5548	6075	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	2	Genetic counseling	"Family members should receive counseling and cascade genetic testing for STK11 mutations.
"	treatment_term	treatment_term	$	Genetic counseling	"Family members should receive counseling and cascade genetic testing for STK11 mutations.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5549	6078	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	pathophysiology	0	FGFR Gain-of-Function Signaling	"Mutations in FGFR1 (P252R) or FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal limb development. FGFR2 mutations causing Types 2 and 3 often affect the tyrosine kinase domain or cause more severe receptor dysregulation than Type 1 mutations.
"	cell_types[0]	cell_types	cell_types			Osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""Osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
5550	6078	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	pathophysiology	0	FGFR Gain-of-Function Signaling	"Mutations in FGFR1 (P252R) or FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal limb development. FGFR2 mutations causing Types 2 and 3 often affect the tyrosine kinase domain or cause more severe receptor dysregulation than Type 1 mutations.
"	biological_processes[0]	biological_processes	biological_processes			FGFR Signaling	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR Signaling"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
5551	6078	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	pathophysiology	0	FGFR Gain-of-Function Signaling	"Mutations in FGFR1 (P252R) or FGFR2 cause constitutive receptor activation, leading to premature cranial suture fusion and abnormal limb development. FGFR2 mutations causing Types 2 and 3 often affect the tyrosine kinase domain or cause more severe receptor dysregulation than Type 1 mutations.
"	biological_processes[1]	biological_processes	biological_processes			Cranial Suture Morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial Suture Morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
5552	6079	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	0	Craniosynostosis	"Premature fusion of cranial sutures, with severity correlating with clinical subtype. Cloverleaf skull (Kleeblattschdel) in Type 2.
"	phenotype_term	phenotype_term	$	Craniosynostosis	"Premature fusion of cranial sutures, with severity correlating with clinical subtype. Cloverleaf skull (Kleeblattschdel) in Type 2.
"	Craniosynostosis	HP:0001363	Craniosynostosis		"{""preferred_term"": ""Craniosynostosis"", ""term"": {""id"": ""HP:0001363"", ""label"": ""Craniosynostosis""}}"																											
5553	6080	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	1	Broad Thumbs	"Broad, medially deviated thumbs are a hallmark feature distinguishing Pfeiffer from other craniosynostosis syndromes.
"	phenotype_term	phenotype_term	$	Broad Thumbs	"Broad, medially deviated thumbs are a hallmark feature distinguishing Pfeiffer from other craniosynostosis syndromes.
"	Broad thumb	HP:0011304	Broad thumb		"{""preferred_term"": ""Broad thumb"", ""term"": {""id"": ""HP:0011304"", ""label"": ""Broad thumb""}}"																											
5554	6081	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	2	Broad Great Toes	"Broad, medially deviated great toes complement the thumb abnormalities.
"	phenotype_term	phenotype_term	$	Broad Great Toes	"Broad, medially deviated great toes complement the thumb abnormalities.
"	Broad hallux	HP:0010055	Broad hallux		"{""preferred_term"": ""Broad hallux"", ""term"": {""id"": ""HP:0010055"", ""label"": ""Broad hallux""}}"																											
5555	6082	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	3	Midface Retrusion	"Midface hypoplasia contributing to characteristic facial appearance and potential airway compromise.
"	phenotype_term	phenotype_term	$	Midface Retrusion	"Midface hypoplasia contributing to characteristic facial appearance and potential airway compromise.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
5556	6083	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	4	Proptosis	"Ocular proptosis due to shallow orbits, more severe in Types 2 and 3.
"	phenotype_term	phenotype_term	$	Proptosis	"Ocular proptosis due to shallow orbits, more severe in Types 2 and 3.
"	Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
5557	6084	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	5	Partial Syndactyly	"Variable soft tissue syndactyly of hands and feet, less severe than in Apert syndrome.
"	phenotype_term	phenotype_term	$	Partial Syndactyly	"Variable soft tissue syndactyly of hands and feet, less severe than in Apert syndrome.
"	Finger syndactyly	HP:0006101	Finger syndactyly		"{""preferred_term"": ""Finger syndactyly"", ""term"": {""id"": ""HP:0006101"", ""label"": ""Finger syndactyly""}}"																											
5558	6085	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	phenotypes	6	Elbow Ankylosis	"Limited elbow mobility or ankylosis may occur.
"	phenotype_term	phenotype_term	$	Elbow Ankylosis	"Limited elbow mobility or ankylosis may occur.
"	Elbow ankylosis	HP:0003070	Elbow ankylosis		"{""preferred_term"": ""Elbow ankylosis"", ""term"": {""id"": ""HP:0003070"", ""label"": ""Elbow ankylosis""}}"																											
5559	6086	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5560	6087	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	1	Airway Management	"Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.
"	treatment_term	treatment_term	$	Airway Management	"Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.
"	Airway management	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Airway management"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5561	6092	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	histopathology	0	Lymphoblastic Neoplasm	Acute lymphoblastic leukemia is a malignancy of B- or T-lymphoblasts.	finding_term	finding_term	$	Lymphoblastic Neoplasm	Acute lymphoblastic leukemia is a malignancy of B- or T-lymphoblasts.	Acute Lymphoblastic Leukemia	NCIT:C3167	Acute Lymphoblastic Leukemia		"{""preferred_term"": ""Acute Lymphoblastic Leukemia"", ""term"": {""id"": ""NCIT:C3167"", ""label"": ""Acute Lymphoblastic Leukemia""}}"																											
5562	6093	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene in Lymphoid Progenitors	The t(9;22)(q34;q11) translocation fuses BCR on chromosome 22 with ABL1 on chromosome 9, creating the Philadelphia chromosome. In ALL, the fusion typically produces the p190 BCR-ABL1 protein (compared to p210 in CML), which has enhanced transforming activity in lymphoid cells. The fusion kinase is constitutively active, driving proliferation and survival signaling.	cell_types[0]	cell_types	cell_types			B-lymphoblast	CL:0017006	B-lymphoblast		"{""preferred_term"": ""B-lymphoblast"", ""term"": {""id"": ""CL:0017006"", ""label"": ""B-lymphoblast""}}"																											
5563	6093	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	0	BCR-ABL1 Fusion Oncogene in Lymphoid Progenitors	The t(9;22)(q34;q11) translocation fuses BCR on chromosome 22 with ABL1 on chromosome 9, creating the Philadelphia chromosome. In ALL, the fusion typically produces the p190 BCR-ABL1 protein (compared to p210 in CML), which has enhanced transforming activity in lymphoid cells. The fusion kinase is constitutively active, driving proliferation and survival signaling.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
5564	6094	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	1	Constitutive Signaling Pathway Activation	BCR-ABL1 activates RAS-MAPK, PI3K-AKT, and JAK-STAT signaling pathways independently of normal growth factor regulation. This drives uncontrolled proliferation and confers resistance to apoptosis, enabling leukemic transformation of B-lymphoid progenitors.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
5565	6095	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	2	B-lymphoid Differentiation Block	BCR-ABL1 signaling interferes with normal B-cell development, arresting cells at an immature lymphoblast stage. The resulting cells express B-lineage markers (CD19, CD22) but lack complete B-cell maturation. IKZF1 (Ikaros) deletions, common in Ph+ ALL, further impair B-cell development.	cell_types[0]	cell_types	cell_types			B-lymphoblast	CL:0017006	B-lymphoblast		"{""preferred_term"": ""B-lymphoblast"", ""term"": {""id"": ""CL:0017006"", ""label"": ""B-lymphoblast""}}"																											
5566	6095	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	2	B-lymphoid Differentiation Block	BCR-ABL1 signaling interferes with normal B-cell development, arresting cells at an immature lymphoblast stage. The resulting cells express B-lineage markers (CD19, CD22) but lack complete B-cell maturation. IKZF1 (Ikaros) deletions, common in Ph+ ALL, further impair B-cell development.	biological_processes[0]	biological_processes	biological_processes			B cell differentiation	GO:0030183	B cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""B cell differentiation"", ""term"": {""id"": ""GO:0030183"", ""label"": ""B cell differentiation""}}"			DECREASED																								
5567	6096	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	3	Apoptosis Resistance	BCR-ABL1 activates PI3K-AKT signaling, phosphorylating and inactivating pro-apoptotic proteins including BAD. This confers resistance to normal apoptotic signals and contributes to the aggressive clinical behavior of Ph+ ALL.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
5568	6097	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	4	Lymphoblast Accumulation	The combination of enhanced proliferation, blocked differentiation, and apoptosis resistance leads to accumulation of immature B-lymphoblasts in the bone marrow, blood, and extramedullary sites.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
5569	6097	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	pathophysiology	4	Lymphoblast Accumulation	The combination of enhanced proliferation, blocked differentiation, and apoptosis resistance leads to accumulation of immature B-lymphoblasts in the bone marrow, blood, and extramedullary sites.	cell_types[0]	cell_types	cell_types			B-lymphoblast	CL:0017006	B-lymphoblast		"{""preferred_term"": ""B-lymphoblast"", ""term"": {""id"": ""CL:0017006"", ""label"": ""B-lymphoblast""}}"																											
5570	6098	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	0	Pancytopenia	Reduction in all blood cell lines from bone marrow replacement by leukemic lymphoblasts.	phenotype_term	phenotype_term	$	Pancytopenia	Reduction in all blood cell lines from bone marrow replacement by leukemic lymphoblasts.	Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
5571	6099	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	1	Leukocytosis	Elevated white blood cell count with circulating lymphoblasts. Ph+ ALL often presents with higher WBC counts than Ph-negative ALL.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count with circulating lymphoblasts. Ph+ ALL often presents with higher WBC counts than Ph-negative ALL.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
5572	6100	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	2	Fatigue	Fatigue from anemia and systemic effects of leukemia.	phenotype_term	phenotype_term	$	Fatigue	Fatigue from anemia and systemic effects of leukemia.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5573	6101	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	3	Lymphadenopathy	Enlarged lymph nodes from leukemic infiltration.	phenotype_term	phenotype_term	$	Lymphadenopathy	Enlarged lymph nodes from leukemic infiltration.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
5574	6102	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	4	Splenomegaly	Spleen enlargement from leukemic infiltration and extramedullary hematopoiesis.	phenotype_term	phenotype_term	$	Splenomegaly	Spleen enlargement from leukemic infiltration and extramedullary hematopoiesis.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
5575	6103	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	phenotypes	5	Recurrent Infections	Increased susceptibility to infections due to neutropenia and immunodeficiency.	phenotype_term	phenotype_term	$	Recurrent Infections	Increased susceptibility to infections due to neutropenia and immunodeficiency.	Recurrent infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	treatment_term	$	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}, {""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				dasatinib; imatinib	CHEBI:49375; CHEBI:45783																						
5577	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"																											
5578	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
5579	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term	treatment_term	$	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}"				ponatinib	CHEBI:78543																						
5580	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"																											
5581	6106	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	2	Blinatumomab	CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens.	treatment_term	treatment_term	$	Blinatumomab	CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5582	6107	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
5583	6108	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
5584	6113	259	Phenylketonuria	Phenylketonuria.yaml	computational_models	0	Multi-compartment PKU FBA Model	Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids	perturbations[0]	perturbations	perturbations			PAH	hgnc:8582	PAH		"{""modifier"": ""ABSENT"", ""preferred_term"": ""PAH"", ""term"": {""id"": ""hgnc:8582"", ""label"": ""PAH""}}"			ABSENT																								
5585	6114	259	Phenylketonuria	Phenylketonuria.yaml	computational_models	1	Recon3D with PAH knockout	Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency	perturbations[0]	perturbations	perturbations			PAH	hgnc:8582	PAH		"{""modifier"": ""ABSENT"", ""preferred_term"": ""PAH"", ""term"": {""id"": ""hgnc:8582"", ""label"": ""PAH""}}"			ABSENT																								
5586	6115	259	Phenylketonuria	Phenylketonuria.yaml	computational_models	2	Harvey Whole-Body PKU Model	Sex-specific whole-body model (28 organs) for IEM biomarker prediction	perturbations[0]	perturbations	perturbations			PAH				"{""preferred_term"": ""PAH""}"																											
5587	6122	259	Phenylketonuria	Phenylketonuria.yaml	pathophysiology	0	Phenylalanine Hydroxylase Deficiency	"Mutations in PAH gene cause deficient phenylalanine hydroxylase enzyme activity. Phenylalanine cannot be converted to tyrosine, leading to phenylalanine accumulation in blood and tissues.
"	biological_processes[0]	biological_processes	biological_processes			Phenylalanine Metabolism	GO:0006558	L-phenylalanine metabolic process		"{""preferred_term"": ""Phenylalanine Metabolism"", ""term"": {""id"": ""GO:0006558"", ""label"": ""L-phenylalanine metabolic process""}}"																											
5588	6123	259	Phenylketonuria	Phenylketonuria.yaml	pathophysiology	1	Neurotoxicity	"Elevated phenylalanine in the brain interferes with neurotransmitter synthesis, myelin formation, and protein synthesis. Phenylalanine competes with other large neutral amino acids for transport across the blood-brain barrier.
"	biological_processes[0]	biological_processes	biological_processes			Neurodevelopment	GO:0007399	nervous system development		"{""preferred_term"": ""Neurodevelopment"", ""term"": {""id"": ""GO:0007399"", ""label"": ""nervous system development""}}"																											
5589	6124	259	Phenylketonuria	Phenylketonuria.yaml	pathophysiology	2	Melanin Deficiency	"Reduced tyrosine availability impairs melanin synthesis, causing fair skin, light hair, and blue eyes characteristic of untreated PKU.
"	biological_processes[0]	biological_processes	biological_processes			Melanin Biosynthesis	GO:0042438	melanin biosynthetic process		"{""preferred_term"": ""Melanin Biosynthesis"", ""term"": {""id"": ""GO:0042438"", ""label"": ""melanin biosynthetic process""}}"																											
5590	6125	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	0	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
5591	6126	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	1	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
5592	6127	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	2	Microcephaly		phenotype_term	phenotype_term	$	Microcephaly		Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
5593	6128	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	3	Hypertonia		phenotype_term	phenotype_term	$	Hypertonia		Hypertonia	HP:0001276	Hypertonia		"{""preferred_term"": ""Hypertonia"", ""term"": {""id"": ""HP:0001276"", ""label"": ""Hypertonia""}}"																											
5594	6129	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	4	Hypopigmentation		phenotype_term	phenotype_term	$	Hypopigmentation		Hypopigmentation	HP:0001010	Hypopigmentation of the skin		"{""preferred_term"": ""Hypopigmentation"", ""term"": {""id"": ""HP:0001010"", ""label"": ""Hypopigmentation of the skin""}}"																											
5595	6130	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	5	Eczema		phenotype_term	phenotype_term	$	Eczema		Eczema	HP:0000964	Eczematoid dermatitis		"{""preferred_term"": ""Eczema"", ""term"": {""id"": ""HP:0000964"", ""label"": ""Eczematoid dermatitis""}}"																											
5596	6131	259	Phenylketonuria	Phenylketonuria.yaml	phenotypes	6	Musty Odor		phenotype_term	phenotype_term	$	Musty Odor		Musty Odor	HP:0410021	Musty odor		"{""preferred_term"": ""Musty Odor"", ""term"": {""id"": ""HP:0410021"", ""label"": ""Musty odor""}}"																											
5597	6132	259	Phenylketonuria	Phenylketonuria.yaml	treatments	0	Phenylalanine-Restricted Diet	Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.	treatment_term	treatment_term	$	Phenylalanine-Restricted Diet	Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5598	6133	259	Phenylketonuria	Phenylketonuria.yaml	treatments	1	Medical Formula	Phenylalanine-free amino acid supplements to provide protein needs.	treatment_term	treatment_term	$	Medical Formula	Phenylalanine-free amino acid supplements to provide protein needs.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5599	6134	259	Phenylketonuria	Phenylketonuria.yaml	treatments	2	Sapropterin (Kuvan)	BH4 cofactor replacement for responsive patients, allows dietary liberalization.	treatment_term	treatment_term	$	Sapropterin (Kuvan)	BH4 cofactor replacement for responsive patients, allows dietary liberalization.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5600	6135	259	Phenylketonuria	Phenylketonuria.yaml	treatments	3	Pegvaliase (Palynziq)	Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.	treatment_term	treatment_term	$	Pegvaliase (Palynziq)	Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5601	6136	259	Phenylketonuria	Phenylketonuria.yaml	treatments	4	Large Neutral Amino Acids	Compete with phenylalanine for brain transport, adjunctive therapy.	treatment_term	treatment_term	$	Large Neutral Amino Acids	Compete with phenylalanine for brain transport, adjunctive therapy.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5602	6147	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	histopathology	0	Neuroendocrine Tumor	Pheochromocytomas and paragangliomas are rare neuroendocrine tumors.	finding_term	finding_term	$	Neuroendocrine Tumor	Pheochromocytomas and paragangliomas are rare neuroendocrine tumors.	Neuroendocrine Tumor	NCIT:C188218	Neuroendocrine Tumor		"{""preferred_term"": ""Neuroendocrine Tumor"", ""term"": {""id"": ""NCIT:C188218"", ""label"": ""Neuroendocrine Tumor""}}"																											
5603	6148	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	0	Succinate Dehydrogenase Complex Dysfunction	Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) impair mitochondrial complex II function, leading to succinate accumulation. Succinate acts as an oncometabolite, inhibiting alpha-ketoglutarate-dependent dioxygenases and causing pseudohypoxia and epigenetic dysregulation.	cell_types[0]	cell_types	cell_types			chromaffin cell	CL:0000166	chromaffin cell		"{""preferred_term"": ""chromaffin cell"", ""term"": {""id"": ""CL:0000166"", ""label"": ""chromaffin cell""}}"																											
5604	6148	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	0	Succinate Dehydrogenase Complex Dysfunction	Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) impair mitochondrial complex II function, leading to succinate accumulation. Succinate acts as an oncometabolite, inhibiting alpha-ketoglutarate-dependent dioxygenases and causing pseudohypoxia and epigenetic dysregulation.	biological_processes[0]	biological_processes	biological_processes			succinate dehydrogenase activity	GO:0000104	succinate dehydrogenase activity		"{""modifier"": ""DECREASED"", ""preferred_term"": ""succinate dehydrogenase activity"", ""term"": {""id"": ""GO:0000104"", ""label"": ""succinate dehydrogenase activity""}}"			DECREASED																								
5605	6148	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	0	Succinate Dehydrogenase Complex Dysfunction	Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) impair mitochondrial complex II function, leading to succinate accumulation. Succinate acts as an oncometabolite, inhibiting alpha-ketoglutarate-dependent dioxygenases and causing pseudohypoxia and epigenetic dysregulation.	locations[0]	locations	locations			adrenal gland	UBERON:0002369	adrenal gland		"{""preferred_term"": ""adrenal gland"", ""term"": {""id"": ""UBERON:0002369"", ""label"": ""adrenal gland""}}"																											
5606	6149	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	1	Pseudohypoxia and HIF Activation	SDHx and VHL mutations cause constitutive stabilization of hypoxia-inducible factors (HIF1/2) under normoxic conditions. This pseudohypoxic state activates genes promoting angiogenesis, glycolysis, and cell survival, driving tumorigenesis.	biological_processes[0]	biological_processes	biological_processes			response to hypoxia	GO:0001666	response to hypoxia		"{""modifier"": ""INCREASED"", ""preferred_term"": ""response to hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"			INCREASED																								
5607	6150	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	2	RET Proto-Oncogene Activation	Germline RET mutations in MEN2 syndrome cause pheochromocytoma through constitutive receptor tyrosine kinase activation. RET-driven pheochromocytomas have distinct catecholamine profiles (epinephrine-predominant) compared to SDHx-related tumors.	biological_processes[0]	biological_processes	biological_processes			receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""receptor signaling protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004716"", ""label"": ""receptor signaling protein tyrosine kinase activity""}}"			INCREASED																								
5608	6151	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	pathophysiology	3	Catecholamine Hypersecretion	Secreting PPGLs produce excess catecholamines (norepinephrine, epinephrine, dopamine), causing characteristic symptoms. The catecholamine profile provides clues to underlying genetics: norepinephrine-predominant suggests SDHx/VHL, epinephrine-predominant suggests RET/NF1.	biological_processes[0]	biological_processes	biological_processes			catecholamine biosynthetic process	GO:0042423	catecholamine biosynthetic process		"{""modifier"": ""INCREASED"", ""preferred_term"": ""catecholamine biosynthetic process"", ""term"": {""id"": ""GO:0042423"", ""label"": ""catecholamine biosynthetic process""}}"			INCREASED																								
5609	6152	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	phenotypes	0	Hypertension	Paroxysmal or sustained hypertension due to catecholamine excess. Episodes may be precipitated by physical activity, anesthesia, or certain medications.	phenotype_term	phenotype_term	$	Hypertension	Paroxysmal or sustained hypertension due to catecholamine excess. Episodes may be precipitated by physical activity, anesthesia, or certain medications.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
5610	6153	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	phenotypes	1	Headache	Severe headaches during hypertensive episodes are a classic symptom of catecholamine excess.	phenotype_term	phenotype_term	$	Headache	Severe headaches during hypertensive episodes are a classic symptom of catecholamine excess.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
5611	6154	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	phenotypes	2	Palpitations	Tachycardia and palpitations during catecholamine surges. May be associated with arrhythmias.	phenotype_term	phenotype_term	$	Palpitations	Tachycardia and palpitations during catecholamine surges. May be associated with arrhythmias.	Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
5612	6155	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	phenotypes	3	Diaphoresis	Excessive sweating during hypertensive paroxysms is a classic feature of pheochromocytoma.	phenotype_term	phenotype_term	$	Diaphoresis	Excessive sweating during hypertensive paroxysms is a classic feature of pheochromocytoma.	Hyperhidrosis	HP:0000975	Hyperhidrosis		"{""preferred_term"": ""Hyperhidrosis"", ""term"": {""id"": ""HP:0000975"", ""label"": ""Hyperhidrosis""}}"																											
5613	6156	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	0	Surgical Resection	Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5614	6157	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	1	Alpha-Adrenergic Blockade	Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery.	treatment_term	treatment_term	$	Alpha-Adrenergic Blockade	Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5615	6158	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	2	MIBG Therapy	131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved.	treatment_term	treatment_term	$	MIBG Therapy	131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5616	6159	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	3	Temozolomide	Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation.	treatment_term	treatment_term	$	Temozolomide	Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5617	6160	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	4	Sunitinib	Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data.	treatment_term	treatment_term	$	Sunitinib	Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5618	6162	261	Pick Disease	Pick_Disease.yaml	biochemical	0	Tau Protein Accumulation		cell_types[0]	cell_types	cell_types			Glial Cell	CL:0000125	glial cell		"{""preferred_term"": ""Glial Cell"", ""term"": {""id"": ""CL:0000125"", ""label"": ""glial cell""}}"																											
5619	6162	261	Pick Disease	Pick_Disease.yaml	biochemical	0	Tau Protein Accumulation		cell_types[1]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
5620	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
5621	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5622	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	cell_types[2]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
5623	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	biological_processes[0]	biological_processes	biological_processes			microtubule-based movement	GO:0007018	microtubule-based movement		"{""preferred_term"": ""microtubule-based movement"", ""term"": {""id"": ""GO:0007018"", ""label"": ""microtubule-based movement""}}"																											
5624	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	biological_processes[1]	biological_processes	biological_processes			cytoskeleton organization	GO:0007010	cytoskeleton organization		"{""preferred_term"": ""cytoskeleton organization"", ""term"": {""id"": ""GO:0007010"", ""label"": ""cytoskeleton organization""}}"																											
5625	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	locations[0]	locations	locations			frontal cortex	UBERON:0001870	frontal cortex		"{""preferred_term"": ""frontal cortex"", ""term"": {""id"": ""UBERON:0001870"", ""label"": ""frontal cortex""}}"																											
5626	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	locations[1]	locations	locations			temporal lobe	UBERON:0001871	temporal lobe		"{""preferred_term"": ""temporal lobe"", ""term"": {""id"": ""UBERON:0001871"", ""label"": ""temporal lobe""}}"																											
5627	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	locations[2]	locations	locations			hippocampus	UBERON:0001954	hippocampus		"{""preferred_term"": ""hippocampus"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""hippocampus""}}"																											
5628	6169	261	Pick Disease	Pick_Disease.yaml	pathophysiology	0	Tauopathy	Accumulation of 3R tau proteins forming Pick bodies in the brain, leading to neuron damage and loss of brain function. Pick disease is defined by disease-specific 3R tau filament folds that propagate in a prion-like manner.	locations[3]	locations	locations			dentate gyrus of hippocampal formation	UBERON:0001883	dentate gyrus of hippocampal formation		"{""preferred_term"": ""dentate gyrus of hippocampal formation"", ""term"": {""id"": ""UBERON:0001883"", ""label"": ""dentate gyrus of hippocampal formation""}}"																											
5629	6170	261	Pick Disease	Pick_Disease.yaml	pathophysiology	1	Neuroinflammation	Astrocyte reactivity and adaptive immune involvement with chemokine-driven recruitment of T lymphocytes. Microglial activation is relatively modest compared to Alzheimer's disease.	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
5630	6170	261	Pick Disease	Pick_Disease.yaml	pathophysiology	1	Neuroinflammation	Astrocyte reactivity and adaptive immune involvement with chemokine-driven recruitment of T lymphocytes. Microglial activation is relatively modest compared to Alzheimer's disease.	cell_types[1]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
5631	6170	261	Pick Disease	Pick_Disease.yaml	pathophysiology	1	Neuroinflammation	Astrocyte reactivity and adaptive immune involvement with chemokine-driven recruitment of T lymphocytes. Microglial activation is relatively modest compared to Alzheimer's disease.	cell_types[2]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5632	6171	261	Pick Disease	Pick_Disease.yaml	pathophysiology	2	Neuronal Loss	Degeneration and loss of nerve cells in the frontal and temporal lobes of the brain.	locations[0]	locations	locations			Frontal Lobe	UBERON:0016525	frontal lobe		"{""preferred_term"": ""Frontal Lobe"", ""term"": {""id"": ""UBERON:0016525"", ""label"": ""frontal lobe""}}"																											
5633	6171	261	Pick Disease	Pick_Disease.yaml	pathophysiology	2	Neuronal Loss	Degeneration and loss of nerve cells in the frontal and temporal lobes of the brain.	locations[1]	locations	locations			Temporal Lobe	UBERON:0001871	temporal lobe		"{""preferred_term"": ""Temporal Lobe"", ""term"": {""id"": ""UBERON:0001871"", ""label"": ""temporal lobe""}}"																											
5634	6174	261	Pick Disease	Pick_Disease.yaml	phenotypes	2	Compulsive Behaviors		phenotype_term	phenotype_term	$	Compulsive Behaviors		Compulsive Behaviors	HP:0000722	Compulsive behaviors		"{""preferred_term"": ""Compulsive Behaviors"", ""term"": {""id"": ""HP:0000722"", ""label"": ""Compulsive behaviors""}}"																											
5635	6175	261	Pick Disease	Pick_Disease.yaml	phenotypes	3	Aphasia		phenotype_term	phenotype_term	$	Aphasia		Aphasia	HP:0002381	Aphasia		"{""preferred_term"": ""Aphasia"", ""term"": {""id"": ""HP:0002381"", ""label"": ""Aphasia""}}"																											
5636	6176	261	Pick Disease	Pick_Disease.yaml	phenotypes	4	Parkinsonism		phenotype_term	phenotype_term	$	Parkinsonism		Parkinsonism	HP:0001300	Parkinsonism		"{""preferred_term"": ""Parkinsonism"", ""term"": {""id"": ""HP:0001300"", ""label"": ""Parkinsonism""}}"																											
5637	6179	261	Pick Disease	Pick_Disease.yaml	phenotypes	7	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
5638	6180	261	Pick Disease	Pick_Disease.yaml	phenotypes	8	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
5639	6181	261	Pick Disease	Pick_Disease.yaml	phenotypes	9	Memory Impairment		phenotype_term	phenotype_term	$	Memory Impairment		Memory impairment	HP:0002354	Memory impairment		"{""preferred_term"": ""Memory impairment"", ""term"": {""id"": ""HP:0002354"", ""label"": ""Memory impairment""}}"																											
5640	6182	261	Pick Disease	Pick_Disease.yaml	phenotypes	10	Inappropriate Behavior		phenotype_term	phenotype_term	$	Inappropriate Behavior		Inappropriate behavior	HP:0000719	Inappropriate behavior		"{""preferred_term"": ""Inappropriate behavior"", ""term"": {""id"": ""HP:0000719"", ""label"": ""Inappropriate behavior""}}"																											
5641	6183	261	Pick Disease	Pick_Disease.yaml	phenotypes	11	Loss of Social Awareness		phenotype_term	phenotype_term	$	Loss of Social Awareness		Loss of Social Awareness				"{""preferred_term"": ""Loss of Social Awareness""}"																											
5642	6186	261	Pick Disease	Pick_Disease.yaml	treatments	0	Symptomatic Management	Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.	treatment_term	treatment_term	$	Symptomatic Management	Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5643	6187	261	Pick Disease	Pick_Disease.yaml	treatments	1	Physical Therapy	Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages.	treatment_term	treatment_term	$	Physical Therapy	Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5644	6188	261	Pick Disease	Pick_Disease.yaml	treatments	2	Occupational Therapy	Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress.	treatment_term	treatment_term	$	Occupational Therapy	Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
5645	6189	261	Pick Disease	Pick_Disease.yaml	treatments	3	Speech Therapy	Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities.	treatment_term	treatment_term	$	Speech Therapy	Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
5646	6190	261	Pick Disease	Pick_Disease.yaml	treatments	4	Caregiver Support	Education and resources for caregivers to manage progressive symptoms and provide quality care.	treatment_term	treatment_term	$	Caregiver Support	Education and resources for caregivers to manage progressive symptoms and provide quality care.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
5647	6192	262	Pinta	Pinta.yaml	phenotypes	0	Abnormality of skin pigmentation		phenotype_term	phenotype_term	$	Abnormality of skin pigmentation		Abnormality of skin pigmentation	HP:0001000	Abnormality of skin pigmentation		"{""preferred_term"": ""Abnormality of skin pigmentation"", ""term"": {""id"": ""HP:0001000"", ""label"": ""Abnormality of skin pigmentation""}}"																											
5648	6193	262	Pinta	Pinta.yaml	treatments	0	Penicillin injection	Single-dose intramuscular penicillin treats all stages of pinta.	treatment_term	treatment_term	$	Penicillin injection	Single-dose intramuscular penicillin treats all stages of pinta.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5649	6194	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	differential_diagnoses	0	Cystic echinococcosis	Unilocular hydatid disease caused by E. granulosus that presents with solitary liver cysts rather than multilocular lesions.	disease_term	disease_term	$	Cystic echinococcosis	Unilocular hydatid disease caused by E. granulosus that presents with solitary liver cysts rather than multilocular lesions.	cystic echinococcosis	MONDO:0018408	cystic echinococcosis		"{""preferred_term"": ""cystic echinococcosis"", ""term"": {""id"": ""MONDO:0018408"", ""label"": ""cystic echinococcosis""}}"																											
5650	6195	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	differential_diagnoses	1	Alveolar echinococcosis	Invasive hepatic lesions from E. multilocularis that mimic tumors and require distinction from polycystic hydatid disease.	disease_term	disease_term	$	Alveolar echinococcosis	Invasive hepatic lesions from E. multilocularis that mimic tumors and require distinction from polycystic hydatid disease.	alveolar echinococcosis	MONDO:0017282	alveolar echinococcosis		"{""preferred_term"": ""alveolar echinococcosis"", ""term"": {""id"": ""MONDO:0017282"", ""label"": ""alveolar echinococcosis""}}"																											
5651	6196	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	differential_diagnoses	2	Hepatocellular carcinoma	Primary liver malignancy that can coexist with or mimic hydatid lesions, requiring imaging and pathology to distinguish.	disease_term	disease_term	$	Hepatocellular carcinoma	Primary liver malignancy that can coexist with or mimic hydatid lesions, requiring imaging and pathology to distinguish.	hepatocellular carcinoma	MONDO:0007256	hepatocellular carcinoma		"{""preferred_term"": ""hepatocellular carcinoma"", ""term"": {""id"": ""MONDO:0007256"", ""label"": ""hepatocellular carcinoma""}}"																											
5652	6197	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	environmental	0	Bush dogpaca sylvatic cycle and domestic dog bridging	Transmission amplified when bush dogs or domestic dogs ingest paca viscera, sustaining E. vogeli eggs that contaminate food or water for humans.	environment_context	environment_context	$	Bush dogpaca sylvatic cycle and domestic dog bridging	Transmission amplified when bush dogs or domestic dogs ingest paca viscera, sustaining E. vogeli eggs that contaminate food or water for humans.	rural settlement	ENVO:01000763	rural settlement		"{""preferred_term"": ""rural settlement"", ""term"": {""id"": ""ENVO:01000763"", ""label"": ""rural settlement""}}"																											
5653	6199	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	infectious_agent	0	Echinococcus vogeli	The cestode species responsible for polycystic echinococcosis in humans.	infectious_agent_term	infectious_agent_term	$	Echinococcus vogeli	The cestode species responsible for polycystic echinococcosis in humans.	Echinococcus vogeli	NCBITaxon:6213	Echinococcus vogeli		"{""preferred_term"": ""Echinococcus vogeli"", ""term"": {""id"": ""NCBITaxon:6213"", ""label"": ""Echinococcus vogeli""}}"																											
5654	6200	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	pathophysiology	0	Hepatic metacestode implantation	Oncospheres establish multilocular metacestode vesicles within the liver parenchyma, anchoring infection to hepatic tissue.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
5655	6201	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	pathophysiology	1	Daughter cyst proliferation and matrix remodeling	Metacestodes bud daughter cysts that coalesce into a multilocular mass, expanding through hepatic parenchyma while remodeling surrounding extracellular matrix.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
5656	6201	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	pathophysiology	1	Daughter cyst proliferation and matrix remodeling	Metacestodes bud daughter cysts that coalesce into a multilocular mass, expanding through hepatic parenchyma while remodeling surrounding extracellular matrix.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
5657	6202	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	pathophysiology	2	Mass effect and local invasion	The enlarging multilocular cyst complex compresses adjacent hepatic tissue and can invade neighboring structures, generating space-occupying effects.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
5658	6203	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	phenotypes	0	Polycystic hepatic lesion	Large multilocular hydatid cysts occupying the liver.	phenotype_term	phenotype_term	$	Polycystic hepatic lesion	Large multilocular hydatid cysts occupying the liver.	Hepatic cysts	HP:0001407	Hepatic cysts		"{""preferred_term"": ""Hepatic cysts"", ""term"": {""id"": ""HP:0001407"", ""label"": ""Hepatic cysts""}}"																											
5659	6204	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	phenotypes	1	Hepatic abscess complication	Secondary infection of hepatic hydatid lesions leading to abscess formation.	phenotype_term	phenotype_term	$	Hepatic abscess complication	Secondary infection of hepatic hydatid lesions leading to abscess formation.	Liver abscess	HP:0100523	Liver abscess		"{""preferred_term"": ""Liver abscess"", ""term"": {""id"": ""HP:0100523"", ""label"": ""Liver abscess""}}"																											
5660	6205	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	phenotypes	2	Thoracic abscess from hepatic fistula	Extension of the hepatic abscess through the diaphragm into the thoracic cavity, resulting in a secondary thoracic abscess.	phenotype_term	phenotype_term	$	Thoracic abscess from hepatic fistula	Extension of the hepatic abscess through the diaphragm into the thoracic cavity, resulting in a secondary thoracic abscess.	Lung abscess	HP:0025044	Lung abscess		"{""preferred_term"": ""Lung abscess"", ""term"": {""id"": ""HP:0025044"", ""label"": ""Lung abscess""}}"																											
5661	6208	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	0	Albendazole therapy	Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery.	treatment_term	treatment_term	$	Albendazole therapy	Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5662	6209	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	1	Radical hepatic resection	Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected.	treatment_term	treatment_term	$	Radical hepatic resection	Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5663	6212	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	0		Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.	organism	organism	$		Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5664	6212	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	0		Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.	sample_types[0]	sample_types	sample_types			kidney epithelium				"{""preferred_term"": ""kidney epithelium"", ""tissue_term"": {""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}}"																											
5665	6212	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	0		Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.	sample_types[0].tissue_term	sample_types	sample_types[0]			kidney	UBERON:0002113	kidney		"{""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
5666	6213	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	1		Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.	organism	organism	$		Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
5667	6213	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	1		Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.	sample_types[0]	sample_types	sample_types			kidney cortex				"{""preferred_term"": ""kidney cortex"", ""tissue_term"": {""preferred_term"": ""kidney cortex"", ""term"": {""id"": ""UBERON:0001225"", ""label"": ""kidney cortex""}}}"																											
5668	6213	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	datasets	1		Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.	sample_types[0].tissue_term	sample_types	sample_types[0]			kidney cortex	UBERON:0001225	kidney cortex		"{""preferred_term"": ""kidney cortex"", ""term"": {""id"": ""UBERON:0001225"", ""label"": ""kidney cortex""}}"																											
5669	6214	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	differential_diagnoses	0	Simple Renal Cysts (Age-Related)	"Solitary or few benign cysts that enlarge slowly with age and lack family history or extrarenal cysts. ADPKD shows bilateral numerous cysts with progressive total kidney volume growth.
"	disease_term	disease_term	$	Simple Renal Cysts (Age-Related)	"Solitary or few benign cysts that enlarge slowly with age and lack family history or extrarenal cysts. ADPKD shows bilateral numerous cysts with progressive total kidney volume growth.
"	simple renal cyst	MONDO:0004840	non-congenital cyst of kidney		"{""preferred_term"": ""simple renal cyst"", ""term"": {""id"": ""MONDO:0004840"", ""label"": ""non-congenital cyst of kidney""}}"																											
5670	6215	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	differential_diagnoses	1	Acquired Cystic Kidney Disease (ACKD)	"Cystic change that develops in chronically dialyzed kidneys, usually in the setting of long-standing kidney failure. Kidneys are often small or normal size rather than massively enlarged as in ADPKD.
"	disease_term	disease_term	$	Acquired Cystic Kidney Disease (ACKD)	"Cystic change that develops in chronically dialyzed kidneys, usually in the setting of long-standing kidney failure. Kidneys are often small or normal size rather than massively enlarged as in ADPKD.
"	acquired cystic kidney disease	MONDO:0002473	cystic kidney disease		"{""preferred_term"": ""acquired cystic kidney disease"", ""term"": {""id"": ""MONDO:0002473"", ""label"": ""cystic kidney disease""}}"																											
5671	6216	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	differential_diagnoses	2	Tuberous Sclerosis Complex (TSC)	"Genetic disorder with renal cysts and angiomyolipomas that can mimic ADPKD but accompanied by dermatologic and neurologic manifestations.
"	disease_term	disease_term	$	Tuberous Sclerosis Complex (TSC)	"Genetic disorder with renal cysts and angiomyolipomas that can mimic ADPKD but accompanied by dermatologic and neurologic manifestations.
"	tuberous sclerosis	MONDO:0001734	tuberous sclerosis		"{""preferred_term"": ""tuberous sclerosis"", ""term"": {""id"": ""MONDO:0001734"", ""label"": ""tuberous sclerosis""}}"																											
5672	6223	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	0	Vasopressin/cAMP-Driven Cyst Expansion	"Elevated vasopressin signaling via V2 receptors increases cAMP in tubular epithelial cells, driving chloride and fluid secretion into cysts and promoting cyst wall growth. Blocking V2 signaling slows total kidney volume expansion.
"	cell_types[0]	cell_types	cell_types			nephron tubule epithelial cell	CL:1000494	nephron tubule epithelial cell		"{""preferred_term"": ""nephron tubule epithelial cell"", ""term"": {""id"": ""CL:1000494"", ""label"": ""nephron tubule epithelial cell""}}"																											
5673	6223	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	0	Vasopressin/cAMP-Driven Cyst Expansion	"Elevated vasopressin signaling via V2 receptors increases cAMP in tubular epithelial cells, driving chloride and fluid secretion into cysts and promoting cyst wall growth. Blocking V2 signaling slows total kidney volume expansion.
"	biological_processes[0]	biological_processes	biological_processes			cAMP/PKA signal transduction	GO:0141156	cAMP/PKA signal transduction		"{""preferred_term"": ""cAMP/PKA signal transduction"", ""term"": {""id"": ""GO:0141156"", ""label"": ""cAMP/PKA signal transduction""}}"																											
5674	6224	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	1	Epithelial Proliferation and Kidney Enlargement	"Reduced polycystin-mediated restraint on epithelial proliferation leads to progressive cyst wall growth and parenchymal compression, increasing total kidney volume and reducing renal function.
"	cell_types[0]	cell_types	cell_types			nephron tubule epithelial cell	CL:1000494	nephron tubule epithelial cell		"{""preferred_term"": ""nephron tubule epithelial cell"", ""term"": {""id"": ""CL:1000494"", ""label"": ""nephron tubule epithelial cell""}}"																											
5675	6224	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	1	Epithelial Proliferation and Kidney Enlargement	"Reduced polycystin-mediated restraint on epithelial proliferation leads to progressive cyst wall growth and parenchymal compression, increasing total kidney volume and reducing renal function.
"	biological_processes[0]	biological_processes	biological_processes			regulation of cell proliferation	GO:0042127	regulation of cell proliferation		"{""preferred_term"": ""regulation of cell proliferation"", ""term"": {""id"": ""GO:0042127"", ""label"": ""regulation of cell proliferation""}}"																											
5676	6225	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	2	Ciliary Dysfunction	"Primary cilia act as mechanosensors in renal tubular epithelial cells. Polycystin dysfunction impairs ciliary signaling, disrupting normal tubular architecture and promoting cyst formation through increased cAMP signaling.
"	cell_types[0]	cell_types	cell_types			nephron tubule epithelial cell	CL:1000494	nephron tubule epithelial cell		"{""preferred_term"": ""nephron tubule epithelial cell"", ""term"": {""id"": ""CL:1000494"", ""label"": ""nephron tubule epithelial cell""}}"																											
5677	6225	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	2	Ciliary Dysfunction	"Primary cilia act as mechanosensors in renal tubular epithelial cells. Polycystin dysfunction impairs ciliary signaling, disrupting normal tubular architecture and promoting cyst formation through increased cAMP signaling.
"	biological_processes[0]	biological_processes	biological_processes			cilium organization	GO:0044782	cilium organization		"{""preferred_term"": ""cilium organization"", ""term"": {""id"": ""GO:0044782"", ""label"": ""cilium organization""}}"																											
5678	6225	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	2	Ciliary Dysfunction	"Primary cilia act as mechanosensors in renal tubular epithelial cells. Polycystin dysfunction impairs ciliary signaling, disrupting normal tubular architecture and promoting cyst formation through increased cAMP signaling.
"	biological_processes[1]	biological_processes	biological_processes			cAMP/PKA signal transduction	GO:0141156	cAMP/PKA signal transduction		"{""preferred_term"": ""cAMP/PKA signal transduction"", ""term"": {""id"": ""GO:0141156"", ""label"": ""cAMP/PKA signal transduction""}}"																											
5679	6226	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	3	Fibrosis and Inflammation	"Progressive cyst growth triggers interstitial inflammation and fibrosis. Activated myofibroblasts deposit extracellular matrix, contributing to nephron loss and declining kidney function.
"	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
5680	6226	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	pathophysiology	3	Fibrosis and Inflammation	"Progressive cyst growth triggers interstitial inflammation and fibrosis. Activated myofibroblasts deposit extracellular matrix, contributing to nephron loss and declining kidney function.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5681	6227	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	0	Multiple Renal Cysts	Multiple fluid-filled cysts in both kidneys, progressively enlarging over time.	phenotype_term	phenotype_term	$	Multiple Renal Cysts	Multiple fluid-filled cysts in both kidneys, progressively enlarging over time.	Multiple renal cysts	HP:0005562	Multiple renal cysts		"{""preferred_term"": ""Multiple renal cysts"", ""term"": {""id"": ""HP:0005562"", ""label"": ""Multiple renal cysts""}}"																											
5682	6228	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	1	Hypertension	High blood pressure, often preceding decline in renal function.	phenotype_term	phenotype_term	$	Hypertension	High blood pressure, often preceding decline in renal function.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
5683	6229	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	2	Chronic Kidney Disease	Progressive decline in kidney function, with approximately 50% reaching end-stage renal disease by age 60.	phenotype_term	phenotype_term	$	Chronic Kidney Disease	Progressive decline in kidney function, with approximately 50% reaching end-stage renal disease by age 60.	Chronic kidney disease	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Chronic kidney disease"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
5684	6230	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	3	Hepatic Cysts	Liver cysts are common extrarenal manifestation, more prevalent in women.	phenotype_term	phenotype_term	$	Hepatic Cysts	Liver cysts are common extrarenal manifestation, more prevalent in women.	Hepatic cysts	HP:0001407	Hepatic cysts		"{""preferred_term"": ""Hepatic cysts"", ""term"": {""id"": ""HP:0001407"", ""label"": ""Hepatic cysts""}}"																											
5685	6231	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	4	Intracranial Aneurysm	Cerebral berry aneurysms occur in 5-10% of ADPKD patients, with risk of rupture.	phenotype_term	phenotype_term	$	Intracranial Aneurysm	Cerebral berry aneurysms occur in 5-10% of ADPKD patients, with risk of rupture.	Cerebral berry aneurysm	HP:0007029	Cerebral berry aneurysm		"{""preferred_term"": ""Cerebral berry aneurysm"", ""term"": {""id"": ""HP:0007029"", ""label"": ""Cerebral berry aneurysm""}}"																											
5686	6232	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	phenotypes	5	Flank Pain	Chronic or acute pain due to cyst hemorrhage, infection, or mass effect.	phenotype_term	phenotype_term	$	Flank Pain	Chronic or acute pain due to cyst hemorrhage, infection, or mass effect.	Flank pain	HP:0030157	Flank pain		"{""preferred_term"": ""Flank pain"", ""term"": {""id"": ""HP:0030157"", ""label"": ""Flank pain""}}"																											
5687	6233	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	0	Tolvaptan	"Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.
"	treatment_term	treatment_term	$	Tolvaptan	"Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5688	6234	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	1	Blood Pressure Control	"Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.
"	treatment_term	treatment_term	$	Blood Pressure Control	"Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5689	6235	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	2	Renal Dialysis	"Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.
"	treatment_term	treatment_term	$	Renal Dialysis	"Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.
"	renal dialysis	MAXO:0000601	renal dialysis		"{""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}"																											
5690	6236	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	3	Kidney Transplantation	"Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.
"	treatment_term	treatment_term	$	Kidney Transplantation	"Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.
"	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
5691	6249	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	pathophysiology	0	Hyperandrogenism	"Excess androgen production from ovarian theca cells and adrenal glands leads to hirsutism, acne, and alopecia. Elevated LH stimulates theca cell androgen production.
"	biological_processes[0]	biological_processes	biological_processes			Androgen Biosynthesis	GO:0006702	androgen biosynthetic process		"{""preferred_term"": ""Androgen Biosynthesis"", ""term"": {""id"": ""GO:0006702"", ""label"": ""androgen biosynthetic process""}}"																											
5692	6250	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	pathophysiology	1	Insulin Resistance	"Peripheral insulin resistance leads to compensatory hyperinsulinemia, which stimulates ovarian androgen production and inhibits hepatic SHBG synthesis, increasing free androgens.
"	biological_processes[0]	biological_processes	biological_processes			Insulin Signaling	GO:0008286	insulin receptor signaling pathway		"{""preferred_term"": ""Insulin Signaling"", ""term"": {""id"": ""GO:0008286"", ""label"": ""insulin receptor signaling pathway""}}"																											
5693	6251	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	pathophysiology	2	Ovulatory Dysfunction	"Disrupted folliculogenesis with arrest at small antral stage leads to anovulation. Multiple small follicles accumulate (polycystic morphology) without dominant follicle selection.
"	biological_processes[0]	biological_processes	biological_processes			Ovulation	GO:0030728	ovulation		"{""preferred_term"": ""Ovulation"", ""term"": {""id"": ""GO:0030728"", ""label"": ""ovulation""}}"																											
5694	6252	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	pathophysiology	3	Chronic Low-Grade Inflammation	"Elevated inflammatory markers (CRP, IL-6) contribute to insulin resistance and cardiovascular risk in PCOS.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5695	6253	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	0	Irregular Menstruation		phenotype_term	phenotype_term	$	Irregular Menstruation		Irregular Menstruation	HP:0000858	Irregular menstruation		"{""preferred_term"": ""Irregular Menstruation"", ""term"": {""id"": ""HP:0000858"", ""label"": ""Irregular menstruation""}}"																											
5696	6254	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	1	Hirsutism		phenotype_term	phenotype_term	$	Hirsutism		Hirsutism	HP:0001007	Hirsutism		"{""preferred_term"": ""Hirsutism"", ""term"": {""id"": ""HP:0001007"", ""label"": ""Hirsutism""}}"																											
5697	6255	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	2	Acne		phenotype_term	phenotype_term	$	Acne		Acne	HP:0001061	Acne		"{""preferred_term"": ""Acne"", ""term"": {""id"": ""HP:0001061"", ""label"": ""Acne""}}"																											
5698	6256	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	3	Obesity		phenotype_term	phenotype_term	$	Obesity		Obesity	HP:0001513	Obesity		"{""preferred_term"": ""Obesity"", ""term"": {""id"": ""HP:0001513"", ""label"": ""Obesity""}}"																											
5699	6257	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	4	Infertility		phenotype_term	phenotype_term	$	Infertility		Infertility	HP:0000789	Infertility		"{""preferred_term"": ""Infertility"", ""term"": {""id"": ""HP:0000789"", ""label"": ""Infertility""}}"																											
5700	6258	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	phenotypes	5	Alopecia		phenotype_term	phenotype_term	$	Alopecia		Alopecia	HP:0001596	Alopecia		"{""preferred_term"": ""Alopecia"", ""term"": {""id"": ""HP:0001596"", ""label"": ""Alopecia""}}"																											
5701	6268	266	Polycythemia Vera	Polycythemia_Vera.yaml	histopathology	0	Erythrocytosis	Polycythemia vera is typically characterized by erythrocytosis.	finding_term	finding_term	$	Erythrocytosis	Polycythemia vera is typically characterized by erythrocytosis.	Erythrocytosis	NCIT:C113711	Erythrocytosis		"{""preferred_term"": ""Erythrocytosis"", ""term"": {""id"": ""NCIT:C113711"", ""label"": ""Erythrocytosis""}}"																											
5702	6269	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	0	JAK2 V617F Constitutive Activation	The JAK2 V617F mutation in the pseudokinase domain eliminates auto-inhibition, causing constitutive JAK2 tyrosine kinase activity. This renders erythroid progenitors hypersensitive to or independent of erythropoietin, driving uncontrolled red blood cell production.	cell_types[0]	cell_types	cell_types			erythroid progenitor cell	CL:0000038	erythroid progenitor cell		"{""preferred_term"": ""erythroid progenitor cell"", ""term"": {""id"": ""CL:0000038"", ""label"": ""erythroid progenitor cell""}}"																											
5703	6269	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	0	JAK2 V617F Constitutive Activation	The JAK2 V617F mutation in the pseudokinase domain eliminates auto-inhibition, causing constitutive JAK2 tyrosine kinase activity. This renders erythroid progenitors hypersensitive to or independent of erythropoietin, driving uncontrolled red blood cell production.	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
5704	6269	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	0	JAK2 V617F Constitutive Activation	The JAK2 V617F mutation in the pseudokinase domain eliminates auto-inhibition, causing constitutive JAK2 tyrosine kinase activity. This renders erythroid progenitors hypersensitive to or independent of erythropoietin, driving uncontrolled red blood cell production.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
5705	6270	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	1	STAT5 Hyperactivation	Constitutive JAK2 activation leads to sustained STAT5 phosphorylation and transcriptional activation of genes promoting erythroid proliferation and survival, including BCL-XL and cyclin D1.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""JAK-STAT signaling pathway"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"			INCREASED																								
5706	6271	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	2	Erythropoietin-Independent Erythropoiesis	JAK2 V617F-mutant erythroid progenitors can proliferate and differentiate in the absence of erythropoietin, forming endogenous erythroid colonies (EEC) in culture. This erythropoietin independence is a diagnostic hallmark of PV.	biological_processes[0]	biological_processes	biological_processes			erythrocyte differentiation	GO:0030218	erythrocyte differentiation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""erythrocyte differentiation"", ""term"": {""id"": ""GO:0030218"", ""label"": ""erythrocyte differentiation""}}"			INCREASED																								
5707	6272	266	Polycythemia Vera	Polycythemia_Vera.yaml	pathophysiology	3	Hyperviscosity and Thrombosis Risk	Elevated red blood cell mass increases blood viscosity and promotes thrombosis. The prothrombotic state is multifactorial, including abnormal red cell interactions, platelet activation, and endothelial dysfunction.	biological_processes[0]	biological_processes	biological_processes			blood coagulation	GO:0007596	blood coagulation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""blood coagulation"", ""term"": {""id"": ""GO:0007596"", ""label"": ""blood coagulation""}}"			ABNORMAL																								
5708	6273	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	0	Polycythemia	Elevated hemoglobin and hematocrit reflecting increased red blood cell mass. WHO diagnostic criterion is hemoglobin >16.5 g/dL in men or >16 g/dL in women.	phenotype_term	phenotype_term	$	Polycythemia	Elevated hemoglobin and hematocrit reflecting increased red blood cell mass. WHO diagnostic criterion is hemoglobin >16.5 g/dL in men or >16 g/dL in women.	Polycythemia	HP:0001901	Polycythemia		"{""preferred_term"": ""Polycythemia"", ""term"": {""id"": ""HP:0001901"", ""label"": ""Polycythemia""}}"																											
5709	6274	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	1	Thrombocytosis	Elevated platelet count occurs in approximately 50% of patients, contributing to thrombotic and sometimes bleeding complications.	phenotype_term	phenotype_term	$	Thrombocytosis	Elevated platelet count occurs in approximately 50% of patients, contributing to thrombotic and sometimes bleeding complications.	Thrombocytosis	HP:0001894	Thrombocytosis		"{""preferred_term"": ""Thrombocytosis"", ""term"": {""id"": ""HP:0001894"", ""label"": ""Thrombocytosis""}}"																											
5710	6275	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	2	Leukocytosis	Elevated white blood cell count reflects pan-myeloid proliferation driven by JAK2 activation.	phenotype_term	phenotype_term	$	Leukocytosis	Elevated white blood cell count reflects pan-myeloid proliferation driven by JAK2 activation.	Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
5711	6276	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	3	Aquagenic Pruritus	Intense itching triggered by contact with water is highly characteristic of PV. Mechanism involves basophil and mast cell activation.	phenotype_term	phenotype_term	$	Aquagenic Pruritus	Intense itching triggered by contact with water is highly characteristic of PV. Mechanism involves basophil and mast cell activation.	Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5712	6277	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	4	Headache	Headaches are common due to hyperviscosity and may improve with phlebotomy. Severe headache may herald thrombotic complication.	phenotype_term	phenotype_term	$	Headache	Headaches are common due to hyperviscosity and may improve with phlebotomy. Severe headache may herald thrombotic complication.	Headache	HP:0002315	Headache		"{""preferred_term"": ""Headache"", ""term"": {""id"": ""HP:0002315"", ""label"": ""Headache""}}"																											
5713	6278	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	5	Splenomegaly	Spleen enlargement from extramedullary hematopoiesis and sequestration. Massive splenomegaly suggests disease progression toward myelofibrosis.	phenotype_term	phenotype_term	$	Splenomegaly	Spleen enlargement from extramedullary hematopoiesis and sequestration. Massive splenomegaly suggests disease progression toward myelofibrosis.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
5714	6279	266	Polycythemia Vera	Polycythemia_Vera.yaml	phenotypes	6	Fatigue	Fatigue is one of the most common and impactful symptoms, significantly affecting quality of life even in well-controlled disease.	phenotype_term	phenotype_term	$	Fatigue	Fatigue is one of the most common and impactful symptoms, significantly affecting quality of life even in well-controlled disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5715	6280	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	0	Therapeutic Phlebotomy	Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity.	treatment_term	treatment_term	$	Therapeutic Phlebotomy	Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity.	therapeutic procedure	MAXO:0000002	therapeutic procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""MAXO:0000002"", ""label"": ""therapeutic procedure""}}"																											
5716	6281	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	1	Low-Dose Aspirin	Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis.	treatment_term	treatment_term	$	Low-Dose Aspirin	Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5717	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term	treatment_term	$	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
5718	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
5719	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term	treatment_term	$	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}"				ruxolitinib	CHEBI:66919																						
5720	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"																											
5721	6284	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	4	Interferon-alpha	Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden.	treatment_term	treatment_term	$	Interferon-alpha	Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5722	6290	267	Polymyositis	Polymyositis.yaml	pathophysiology	0	CD8+ T Cell-Mediated Cytotoxicity	Clonally expanded CD8+ cytotoxic T cells infiltrate muscle fibers and directly attack myocytes expressing MHC class I. Perforin and granzyme release leads to muscle fiber necrosis.	cell_types[0]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
5723	6290	267	Polymyositis	Polymyositis.yaml	pathophysiology	0	CD8+ T Cell-Mediated Cytotoxicity	Clonally expanded CD8+ cytotoxic T cells infiltrate muscle fibers and directly attack myocytes expressing MHC class I. Perforin and granzyme release leads to muscle fiber necrosis.	cell_types[1]	cell_types	cell_types			Skeletal Muscle Cell	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Cell"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
5724	6290	267	Polymyositis	Polymyositis.yaml	pathophysiology	0	CD8+ T Cell-Mediated Cytotoxicity	Clonally expanded CD8+ cytotoxic T cells infiltrate muscle fibers and directly attack myocytes expressing MHC class I. Perforin and granzyme release leads to muscle fiber necrosis.	biological_processes[0]	biological_processes	biological_processes			T Cell Cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T Cell Cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
5725	6291	267	Polymyositis	Polymyositis.yaml	pathophysiology	1	Aberrant MHC Class I Expression	Muscle fibers, which normally do not express MHC class I, show aberrant upregulation making them targets for CD8+ T cell recognition and attack.	biological_processes[0]	biological_processes	biological_processes			MHC Class I Antigen Presentation	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I		"{""preferred_term"": ""MHC Class I Antigen Presentation"", ""term"": {""id"": ""GO:0002474"", ""label"": ""antigen processing and presentation of peptide antigen via MHC class I""}}"																											
5726	6292	267	Polymyositis	Polymyositis.yaml	pathophysiology	2	Myositis-Specific Autoantibodies	Anti-synthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12) define antisynthetase syndrome with myositis, ILD, and arthritis. Anti-SRP antibodies associate with necrotizing myopathy.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
5727	6293	267	Polymyositis	Polymyositis.yaml	pathophysiology	3	Pro-inflammatory Cytokine Production	IL-1, TNF-alpha, and IFN-gamma produced by infiltrating immune cells perpetuate muscle inflammation and contribute to muscle weakness independent of direct fiber destruction.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5728	6294	267	Polymyositis	Polymyositis.yaml	pathophysiology	4	ER Stress and Unfolded Protein Response	Overexpression of MHC class I in muscle fibers triggers endoplasmic reticulum stress and activation of the unfolded protein response (UPR). This includes upregulation of GRP78/BiP and NF-kappaB pathway activation, contributing to muscle fiber dysfunction independent of immune-mediated damage.	biological_processes[0]	biological_processes	biological_processes			Endoplasmic Reticulum Stress Response	GO:0034976	response to endoplasmic reticulum stress		"{""preferred_term"": ""Endoplasmic Reticulum Stress Response"", ""term"": {""id"": ""GO:0034976"", ""label"": ""response to endoplasmic reticulum stress""}}"																											
5729	6295	267	Polymyositis	Polymyositis.yaml	pathophysiology	5	Necroptosis and DAMP Release	Muscle fibers undergo necroptosis, a form of regulated cell death, releasing damage-associated molecular patterns (DAMPs) including HMGB1. This amplifies inflammation and contributes to persistent muscle weakness even after initial immune attack.	biological_processes[0]	biological_processes	biological_processes			Necroptotic Process	GO:0070266	necroptotic process		"{""preferred_term"": ""Necroptotic Process"", ""term"": {""id"": ""GO:0070266"", ""label"": ""necroptotic process""}}"																											
5730	6296	267	Polymyositis	Polymyositis.yaml	pathophysiology	6	Apoptosis of Muscle Fibers	Apoptotic cell death occurs in muscle fibers surrounding those undergoing partial invasion by CD8+ T cells. Fibers with apoptotic nuclei are surrounded by CD8+ T cells, granzyme B-positive cells, and macrophages, suggesting cytotoxic T cell-mediated apoptosis occurs in parallel to direct invasion.	biological_processes[0]	biological_processes	biological_processes			Apoptotic Process	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptotic Process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
5731	6297	267	Polymyositis	Polymyositis.yaml	phenotypes	0	Proximal Muscle Weakness		phenotype_term	phenotype_term	$	Proximal Muscle Weakness		Limb Muscle Weakness	HP:0003690	Limb muscle weakness		"{""preferred_term"": ""Limb Muscle Weakness"", ""term"": {""id"": ""HP:0003690"", ""label"": ""Limb muscle weakness""}}"																											
5732	6298	267	Polymyositis	Polymyositis.yaml	phenotypes	1	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
5733	6299	267	Polymyositis	Polymyositis.yaml	phenotypes	2	Pulmonary Fibrosis		phenotype_term	phenotype_term	$	Pulmonary Fibrosis		Pulmonary Fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary Fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
5734	6300	267	Polymyositis	Polymyositis.yaml	phenotypes	3	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
5735	6308	268	Pouchitis	Pouchitis.yaml	pathophysiology	0	Bacterial Dysbiosis	"Altered gut microbiome composition in the ileal pouch, with decreased microbial diversity and shifts toward pathogenic bacterial species. The pouch environment lacks normal colonic bacteria and experiences reduced butyrate-producing bacteria, leading to an imbalanced microbial ecosystem that triggers inflammation.
"	locations[0]	locations	locations			ileum	UBERON:0002116	ileum		"{""preferred_term"": ""ileum"", ""term"": {""id"": ""UBERON:0002116"", ""label"": ""ileum""}}"																											
5736	6309	268	Pouchitis	Pouchitis.yaml	pathophysiology	1	Mucosal Immune Dysregulation	"Chronic inflammation of the ileal pouch mucosa characterized by increased pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-8), enhanced neutrophil infiltration, and impaired epithelial barrier function. The adaptive immune response shows increased Th1 and Th17 cell activity.
"	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
5737	6309	268	Pouchitis	Pouchitis.yaml	pathophysiology	1	Mucosal Immune Dysregulation	"Chronic inflammation of the ileal pouch mucosa characterized by increased pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-8), enhanced neutrophil infiltration, and impaired epithelial barrier function. The adaptive immune response shows increased Th1 and Th17 cell activity.
"	cell_types[1]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
5738	6309	268	Pouchitis	Pouchitis.yaml	pathophysiology	1	Mucosal Immune Dysregulation	"Chronic inflammation of the ileal pouch mucosa characterized by increased pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-8), enhanced neutrophil infiltration, and impaired epithelial barrier function. The adaptive immune response shows increased Th1 and Th17 cell activity.
"	cell_types[2]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5739	6309	268	Pouchitis	Pouchitis.yaml	pathophysiology	1	Mucosal Immune Dysregulation	"Chronic inflammation of the ileal pouch mucosa characterized by increased pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-8), enhanced neutrophil infiltration, and impaired epithelial barrier function. The adaptive immune response shows increased Th1 and Th17 cell activity.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5740	6309	268	Pouchitis	Pouchitis.yaml	pathophysiology	1	Mucosal Immune Dysregulation	"Chronic inflammation of the ileal pouch mucosa characterized by increased pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-8), enhanced neutrophil infiltration, and impaired epithelial barrier function. The adaptive immune response shows increased Th1 and Th17 cell activity.
"	biological_processes[1]	biological_processes	biological_processes			cytokine production	GO:0001816	cytokine production		"{""preferred_term"": ""cytokine production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"																											
5741	6310	268	Pouchitis	Pouchitis.yaml	pathophysiology	2	Epithelial Barrier Dysfunction	"Disruption of tight junction proteins and increased intestinal permeability in the pouch mucosa, allowing bacterial translocation and antigenic stimulation of the underlying immune system, perpetuating the inflammatory cycle.
"	cell_types[0]	cell_types	cell_types			intestinal epithelial cell	CL:0002563	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002563"", ""label"": ""intestinal epithelial cell""}}"																											
5742	6310	268	Pouchitis	Pouchitis.yaml	pathophysiology	2	Epithelial Barrier Dysfunction	"Disruption of tight junction proteins and increased intestinal permeability in the pouch mucosa, allowing bacterial translocation and antigenic stimulation of the underlying immune system, perpetuating the inflammatory cycle.
"	biological_processes[0]	biological_processes	biological_processes			bicellular tight junction assembly	GO:0070830	bicellular tight junction assembly		"{""preferred_term"": ""bicellular tight junction assembly"", ""term"": {""id"": ""GO:0070830"", ""label"": ""bicellular tight junction assembly""}}"																											
5743	6311	268	Pouchitis	Pouchitis.yaml	pathophysiology	3	NOD2 Genetic Susceptibility	"Genetic polymorphisms in NOD2 (nucleotide-binding oligomerization domain-containing protein 2), particularly the NOD2insC variant (rs2066847), are strongly associated with increased risk of chronic pouchitis and Crohn's disease-like pouch phenotypes. NOD2 normally functions as an intracellular bacterial sensor that regulates autophagy and antimicrobial responses; loss-of-function variants impair bacterial clearance and increase susceptibility to inflammation.
"	genes[0]	genes	genes			NOD2	hgnc:5331	NOD2		"{""preferred_term"": ""NOD2"", ""term"": {""id"": ""hgnc:5331"", ""label"": ""NOD2""}}"																											
5744	6312	268	Pouchitis	Pouchitis.yaml	phenotypes	0	Increased Stool Frequency	"Patients experience increased bowel movements, often exceeding 8-10 times per day, due to inflammation and reduced absorptive capacity of the pouch.
"	phenotype_term	phenotype_term	$	Increased Stool Frequency	"Patients experience increased bowel movements, often exceeding 8-10 times per day, due to inflammation and reduced absorptive capacity of the pouch.
"	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
5745	6313	268	Pouchitis	Pouchitis.yaml	phenotypes	1	Abdominal Pain	"Lower abdominal cramping and discomfort, particularly in the pelvic region where the ileal pouch is located.
"	phenotype_term	phenotype_term	$	Abdominal Pain	"Lower abdominal cramping and discomfort, particularly in the pelvic region where the ileal pouch is located.
"	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
5746	6314	268	Pouchitis	Pouchitis.yaml	phenotypes	2	Rectal Bleeding	"Blood in stool due to mucosal inflammation and ulceration within the pouch.
"	phenotype_term	phenotype_term	$	Rectal Bleeding	"Blood in stool due to mucosal inflammation and ulceration within the pouch.
"	Hematochezia	HP:0002573	Hematochezia		"{""preferred_term"": ""Hematochezia"", ""term"": {""id"": ""HP:0002573"", ""label"": ""Hematochezia""}}"																											
5747	6315	268	Pouchitis	Pouchitis.yaml	phenotypes	3	Urgency	"Sudden compelling need to defecate, reflecting inflammatory irritation of the pouch mucosa.
"	phenotype_term	phenotype_term	$	Urgency	"Sudden compelling need to defecate, reflecting inflammatory irritation of the pouch mucosa.
"	Bowel urgency	HP:0012701	Bowel urgency		"{""preferred_term"": ""Bowel urgency"", ""term"": {""id"": ""HP:0012701"", ""label"": ""Bowel urgency""}}"																											
5748	6316	268	Pouchitis	Pouchitis.yaml	phenotypes	4	Fever	"Systemic inflammatory response with elevated body temperature in acute or severe pouchitis episodes.
"	phenotype_term	phenotype_term	$	Fever	"Systemic inflammatory response with elevated body temperature in acute or severe pouchitis episodes.
"	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
5749	6317	268	Pouchitis	Pouchitis.yaml	treatments	0	Antibiotic Therapy	"First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.
"	treatment_term	treatment_term	$	Antibiotic Therapy	"First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																											
5750	6318	268	Pouchitis	Pouchitis.yaml	treatments	1	Probiotic Therapy	"VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.
"	treatment_term	treatment_term	$	Probiotic Therapy	"VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5751	6319	268	Pouchitis	Pouchitis.yaml	treatments	2	Anti-inflammatory Medications	"Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.
"	treatment_term	treatment_term	$	Anti-inflammatory Medications	"Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.
"	anti-inflammatory agent therapy	MAXO:0000169	anti-inflammatory agent therapy		"{""preferred_term"": ""anti-inflammatory agent therapy"", ""term"": {""id"": ""MAXO:0000169"", ""label"": ""anti-inflammatory agent therapy""}}"																											
5752	6320	268	Pouchitis	Pouchitis.yaml	treatments	3	Immunosuppressive Therapy	"For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.
"	treatment_term	treatment_term	$	Immunosuppressive Therapy	"For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5753	6328	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	pathophysiology	0	Anti-Mitochondrial Antibody Response	Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) are highly specific for PBC. These antibodies may directly contribute to biliary epithelial cell damage through immune complex formation and complement activation.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
5754	6329	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	pathophysiology	1	Biliary Epithelial Cell Targeting	CD4+ and CD8+ T cells infiltrate portal tracts and specifically target small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic cholangiocytes may initiate the autoimmune response.	cell_types[0]	cell_types	cell_types			Cholangiocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Cholangiocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
5755	6329	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	pathophysiology	1	Biliary Epithelial Cell Targeting	CD4+ and CD8+ T cells infiltrate portal tracts and specifically target small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic cholangiocytes may initiate the autoimmune response.	cell_types[1]	cell_types	cell_types			CD8+ T Cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
5756	6329	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	pathophysiology	1	Biliary Epithelial Cell Targeting	CD4+ and CD8+ T cells infiltrate portal tracts and specifically target small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic cholangiocytes may initiate the autoimmune response.	biological_processes[0]	biological_processes	biological_processes			T Cell Cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T Cell Cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
5757	6330	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	pathophysiology	2	Progressive Ductopenia and Cholestasis	Destruction of bile ducts leads to ductopenia, impaired bile flow, and accumulation of toxic bile acids. Retained bile acids cause further hepatocyte damage and promote fibrosis.	biological_processes[0]	biological_processes	biological_processes			Bile Acid Metabolic Process	GO:0008206	bile acid metabolic process		"{""preferred_term"": ""Bile Acid Metabolic Process"", ""term"": {""id"": ""GO:0008206"", ""label"": ""bile acid metabolic process""}}"																											
5758	6331	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	phenotypes	0	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5759	6332	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	phenotypes	1	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5760	6333	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	phenotypes	2	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
5761	6334	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	phenotypes	3	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
5762	6343	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	environmental	0	Air Pollution		exposure_term	exposure_term	$	Air Pollution		Air pollution exposure	ECTO:8000036	exposure to air pollution		"{""preferred_term"": ""Air pollution exposure"", ""term"": {""id"": ""ECTO:8000036"", ""label"": ""exposure to air pollution""}}"																											
5763	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	genes[0]	genes	genes			DNAI1	hgnc:2954	DNAI1		"{""preferred_term"": ""DNAI1"", ""term"": {""id"": ""hgnc:2954"", ""label"": ""DNAI1""}}"																											
5764	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	genes[1]	genes	genes			DNAH5	hgnc:2950	DNAH5		"{""preferred_term"": ""DNAH5"", ""term"": {""id"": ""hgnc:2950"", ""label"": ""DNAH5""}}"																											
5765	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	cell_types[0]	cell_types	cell_types			respiratory ciliated cell	CL:0002368	respiratory tract epithelial cell		"{""preferred_term"": ""respiratory ciliated cell"", ""term"": {""id"": ""CL:0002368"", ""label"": ""respiratory tract epithelial cell""}}"																											
5766	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	cell_types[1]	cell_types	cell_types			ependymal cell	CL:0000065	ependymal cell		"{""preferred_term"": ""ependymal cell"", ""term"": {""id"": ""CL:0000065"", ""label"": ""ependymal cell""}}"																											
5767	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	biological_processes[0]	biological_processes	biological_processes			cilium movement	GO:0003341	cilium movement		"{""preferred_term"": ""cilium movement"", ""term"": {""id"": ""GO:0003341"", ""label"": ""cilium movement""}}"																											
5768	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	biological_processes[1]	biological_processes	biological_processes			cilium assembly	GO:0060271	cilium assembly		"{""preferred_term"": ""cilium assembly"", ""term"": {""id"": ""GO:0060271"", ""label"": ""cilium assembly""}}"																											
5769	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	biological_processes[2]	biological_processes	biological_processes			axoneme assembly	GO:0035082	axoneme assembly		"{""preferred_term"": ""axoneme assembly"", ""term"": {""id"": ""GO:0035082"", ""label"": ""axoneme assembly""}}"																											
5770	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	locations[0]	locations	locations			respiratory tract epithelium	UBERON:0004808	respiratory tract epithelium		"{""preferred_term"": ""respiratory tract epithelium"", ""term"": {""id"": ""UBERON:0004808"", ""label"": ""respiratory tract epithelium""}}"																											
5771	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	locations[1]	locations	locations			nasal cavity epithelium	UBERON:0000398	nasal cavity epithelium		"{""preferred_term"": ""nasal cavity epithelium"", ""term"": {""id"": ""UBERON:0000398"", ""label"": ""nasal cavity epithelium""}}"																											
5772	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	locations[2]	locations	locations			trachea	UBERON:0003126	trachea		"{""preferred_term"": ""trachea"", ""term"": {""id"": ""UBERON:0003126"", ""label"": ""trachea""}}"																											
5773	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	locations[3]	locations	locations			bronchus	UBERON:0002185	bronchus		"{""preferred_term"": ""bronchus"", ""term"": {""id"": ""UBERON:0002185"", ""label"": ""bronchus""}}"																											
5774	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	cellular_components[0]	cellular_components	cellular_components			Cilia	GO:0005929	cilium		"{""preferred_term"": ""Cilia"", ""term"": {""id"": ""GO:0005929"", ""label"": ""cilium""}}"																											
5775	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	cellular_components[1]	cellular_components	cellular_components			axoneme	GO:0005930	axoneme		"{""preferred_term"": ""axoneme"", ""term"": {""id"": ""GO:0005930"", ""label"": ""axoneme""}}"																											
5776	6356	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	0	Ciliary Dysfunction	Defects in the structure and function of motile cilia impair mucociliary clearance.	cellular_components[2]	cellular_components	cellular_components			outer dynein arm	GO:0036157	outer dynein arm		"{""preferred_term"": ""outer dynein arm"", ""term"": {""id"": ""GO:0036157"", ""label"": ""outer dynein arm""}}"																											
5777	6357	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	1	Impaired Mucociliary Clearance	Failure to effectively remove mucus and pathogens from respiratory passages.	biological_processes[0]	biological_processes	biological_processes			mucociliary clearance	GO:0120197	mucociliary clearance		"{""preferred_term"": ""mucociliary clearance"", ""term"": {""id"": ""GO:0120197"", ""label"": ""mucociliary clearance""}}"																											
5778	6357	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	1	Impaired Mucociliary Clearance	Failure to effectively remove mucus and pathogens from respiratory passages.	locations[0]	locations	locations			respiratory system	UBERON:0001004	respiratory system		"{""preferred_term"": ""respiratory system"", ""term"": {""id"": ""UBERON:0001004"", ""label"": ""respiratory system""}}"																											
5779	6357	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	1	Impaired Mucociliary Clearance	Failure to effectively remove mucus and pathogens from respiratory passages.	locations[1]	locations	locations			paranasal sinus	UBERON:0001825	paranasal sinus		"{""preferred_term"": ""paranasal sinus"", ""term"": {""id"": ""UBERON:0001825"", ""label"": ""paranasal sinus""}}"																											
5780	6358	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	2	Situs Inversus	Abnormal placement of internal organs due to ciliary dysfunction during embryonic development.	biological_processes[0]	biological_processes	biological_processes			determination of left/right symmetry	GO:0007368	determination of left/right symmetry		"{""preferred_term"": ""determination of left/right symmetry"", ""term"": {""id"": ""GO:0007368"", ""label"": ""determination of left/right symmetry""}}"																											
5781	6358	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	2	Situs Inversus	Abnormal placement of internal organs due to ciliary dysfunction during embryonic development.	biological_processes[1]	biological_processes	biological_processes			nodal cilium assembly	GO:1904955	motile cilium assembly		"{""preferred_term"": ""nodal cilium assembly"", ""term"": {""id"": ""GO:1904955"", ""label"": ""motile cilium assembly""}}"																											
5782	6358	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	pathophysiology	2	Situs Inversus	Abnormal placement of internal organs due to ciliary dysfunction during embryonic development.	locations[0]	locations	locations			embryo	UBERON:0000922	embryo		"{""preferred_term"": ""embryo"", ""term"": {""id"": ""UBERON:0000922"", ""label"": ""embryo""}}"																											
5783	6359	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	0	Chronic Cough		phenotype_term	phenotype_term	$	Chronic Cough		Chronic Cough	HP:0034315	Chronic cough		"{""preferred_term"": ""Chronic Cough"", ""term"": {""id"": ""HP:0034315"", ""label"": ""Chronic cough""}}"																											
5784	6360	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	1	Recurrent Respiratory Infections		phenotype_term	phenotype_term	$	Recurrent Respiratory Infections		Recurrent Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
5785	6361	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	2	Bronchiectasis		phenotype_term	phenotype_term	$	Bronchiectasis		Bronchiectasis	HP:0002110	Bronchiectasis		"{""preferred_term"": ""Bronchiectasis"", ""term"": {""id"": ""HP:0002110"", ""label"": ""Bronchiectasis""}}"																											
5786	6362	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	3	Chronic Otitis Media		phenotype_term	phenotype_term	$	Chronic Otitis Media		Chronic Otitis Media	HP:0000389	Chronic otitis media		"{""preferred_term"": ""Chronic Otitis Media"", ""term"": {""id"": ""HP:0000389"", ""label"": ""Chronic otitis media""}}"																											
5787	6363	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	4	Hearing Loss		phenotype_term	phenotype_term	$	Hearing Loss		Hearing Loss	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing Loss"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
5788	6365	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	6	Situs Inversus Totalis		phenotype_term	phenotype_term	$	Situs Inversus Totalis		Situs Inversus Totalis	HP:0001696	Situs inversus totalis		"{""preferred_term"": ""Situs Inversus Totalis"", ""term"": {""id"": ""HP:0001696"", ""label"": ""Situs inversus totalis""}}"																											
5789	6366	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	7	Chronic Respiratory Infections		phenotype_term	phenotype_term	$	Chronic Respiratory Infections		Chronic Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Chronic Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
5790	6367	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	8	Sinusitis		phenotype_term	phenotype_term	$	Sinusitis		Sinusitis	HP:0000246	Sinusitis		"{""preferred_term"": ""Sinusitis"", ""term"": {""id"": ""HP:0000246"", ""label"": ""Sinusitis""}}"																											
5791	6368	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	9	Otitis Media		phenotype_term	phenotype_term	$	Otitis Media		Otitis Media	HP:0000388	Otitis media		"{""preferred_term"": ""Otitis Media"", ""term"": {""id"": ""HP:0000388"", ""label"": ""Otitis media""}}"																											
5792	6369	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	10	Neonatal Respiratory Distress		phenotype_term	phenotype_term	$	Neonatal Respiratory Distress		Neonatal respiratory distress	HP:0002643	Neonatal respiratory distress		"{""preferred_term"": ""Neonatal respiratory distress"", ""term"": {""id"": ""HP:0002643"", ""label"": ""Neonatal respiratory distress""}}"																											
5793	6370	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	11	Male Infertility		phenotype_term	phenotype_term	$	Male Infertility		Male infertility	HP:0003251	Male infertility		"{""preferred_term"": ""Male infertility"", ""term"": {""id"": ""HP:0003251"", ""label"": ""Male infertility""}}"																											
5794	6371	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	phenotypes	12	Chronic Rhinosinusitis		phenotype_term	phenotype_term	$	Chronic Rhinosinusitis		Chronic rhinosinusitis	HP:0011109	Chronic sinusitis		"{""preferred_term"": ""Chronic rhinosinusitis"", ""term"": {""id"": ""HP:0011109"", ""label"": ""Chronic sinusitis""}}"																											
5795	6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	Airway Clearance Techniques	Methods to help clear mucus from the lungs, such as chest physical therapy.	treatment_term	treatment_term	$	Airway Clearance Techniques	Methods to help clear mucus from the lungs, such as chest physical therapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5796	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Recurrent Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
5797	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	treatment_term	treatment_term	$	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5798	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	Bronchodilators	Medications to help open airways and ease breathing.	treatment_term	treatment_term	$	Bronchodilators	Medications to help open airways and ease breathing.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5799	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	Nasal Steroids	Used to treat nasal polyps and chronic sinusitis.	treatment_term	treatment_term	$	Nasal Steroids	Used to treat nasal polyps and chronic sinusitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5800	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	Hearing Aids	Assistive devices for hearing loss management.	treatment_term	treatment_term	$	Hearing Aids	Assistive devices for hearing loss management.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5801	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	Genetic Counseling	Provides information and support for affected individuals and families.	treatment_term	treatment_term	$	Genetic Counseling	Provides information and support for affected individuals and families.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5802	6381	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	phenotypes	0	Spasticity		phenotype_term	phenotype_term	$	Spasticity		Spasticity	HP:0001257	Spasticity		"{""preferred_term"": ""Spasticity"", ""term"": {""id"": ""HP:0001257"", ""label"": ""Spasticity""}}"																											
5803	6382	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	phenotypes	1	Dysarthria		phenotype_term	phenotype_term	$	Dysarthria		Dysarthria	HP:0001260	Dysarthria		"{""preferred_term"": ""Dysarthria"", ""term"": {""id"": ""HP:0001260"", ""label"": ""Dysarthria""}}"																											
5804	6383	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	phenotypes	2	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
5805	6384	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	treatments	0	Supportive Care	Symptomatic management and supportive interventions.	treatment_term	treatment_term	$	Supportive Care	Symptomatic management and supportive interventions.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5806	6391	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	histopathology	0	Bone Marrow Fibrosis	Primary myelofibrosis is characterized by bone marrow fibrosis.	finding_term	finding_term	$	Bone Marrow Fibrosis	Primary myelofibrosis is characterized by bone marrow fibrosis.	Bone Marrow Fibrosis	NCIT:C36212	Bone Marrow Fibrosis		"{""preferred_term"": ""Bone Marrow Fibrosis"", ""term"": {""id"": ""NCIT:C36212"", ""label"": ""Bone Marrow Fibrosis""}}"																											
5807	6392	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL all converge on constitutive activation of JAK-STAT signaling. JAK2 V617F directly activates the kinase; CALR and MPL mutations lead to activation of MPL receptor signaling.	cell_types[0]	cell_types	cell_types			megakaryocyte	CL:0000556	megakaryocyte		"{""preferred_term"": ""megakaryocyte"", ""term"": {""id"": ""CL:0000556"", ""label"": ""megakaryocyte""}}"																											
5808	6392	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL all converge on constitutive activation of JAK-STAT signaling. JAK2 V617F directly activates the kinase; CALR and MPL mutations lead to activation of MPL receptor signaling.	cell_types[1]	cell_types	cell_types			hematopoietic stem cell	CL:0000037	hematopoietic stem cell		"{""preferred_term"": ""hematopoietic stem cell"", ""term"": {""id"": ""CL:0000037"", ""label"": ""hematopoietic stem cell""}}"																											
5809	6392	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL all converge on constitutive activation of JAK-STAT signaling. JAK2 V617F directly activates the kinase; CALR and MPL mutations lead to activation of MPL receptor signaling.	biological_processes[0]	biological_processes	biological_processes			JAK-STAT signaling pathway	GO:0007259	JAK-STAT cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""JAK-STAT signaling pathway"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"			INCREASED																								
5810	6392	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	0	JAK-STAT Pathway Hyperactivation	Driver mutations in JAK2, CALR, or MPL all converge on constitutive activation of JAK-STAT signaling. JAK2 V617F directly activates the kinase; CALR and MPL mutations lead to activation of MPL receptor signaling.	locations[0]	locations	locations			bone marrow	UBERON:0002371	bone marrow		"{""preferred_term"": ""bone marrow"", ""term"": {""id"": ""UBERON:0002371"", ""label"": ""bone marrow""}}"																											
5811	6393	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	1	Abnormal Megakaryopoiesis	Driver mutations cause aberrant megakaryocyte proliferation and maturation. Megakaryocytes show characteristic atypia with clustering, abnormal lobation, and defective platelet production.	biological_processes[0]	biological_processes	biological_processes			megakaryocyte differentiation	GO:0030219	megakaryocyte differentiation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""megakaryocyte differentiation"", ""term"": {""id"": ""GO:0030219"", ""label"": ""megakaryocyte differentiation""}}"			ABNORMAL																								
5812	6394	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	2	Cytokine-Mediated Marrow Fibrosis	Atypical megakaryocytes release profibrotic cytokines including TGF-beta, PDGF, and bFGF, stimulating marrow stromal cells to deposit reticulin and collagen fibers. Progressive fibrosis replaces normal hematopoietic tissue.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""modifier"": ""INCREASED"", ""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"			INCREASED																								
5813	6395	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	3	Extramedullary Hematopoiesis	As bone marrow function declines due to fibrosis, hematopoiesis shifts to spleen, liver, and other sites. This causes massive splenomegaly and hepatomegaly with associated symptoms.	locations[0]	locations	locations			spleen	UBERON:0002106	spleen		"{""preferred_term"": ""spleen"", ""term"": {""id"": ""UBERON:0002106"", ""label"": ""spleen""}}"																											
5814	6395	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	pathophysiology	3	Extramedullary Hematopoiesis	As bone marrow function declines due to fibrosis, hematopoiesis shifts to spleen, liver, and other sites. This causes massive splenomegaly and hepatomegaly with associated symptoms.	biological_processes[0]	biological_processes	biological_processes			hematopoiesis	GO:0030097	hemopoiesis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""hematopoiesis"", ""term"": {""id"": ""GO:0030097"", ""label"": ""hemopoiesis""}}"			ABNORMAL																								
5815	6396	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	0	Splenomegaly	Massive splenomegaly from extramedullary hematopoiesis is a hallmark of PMF. May extend to pelvis causing abdominal discomfort, early satiety, and portal hypertension.	phenotype_term	phenotype_term	$	Splenomegaly	Massive splenomegaly from extramedullary hematopoiesis is a hallmark of PMF. May extend to pelvis causing abdominal discomfort, early satiety, and portal hypertension.	Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
5816	6397	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	1	Anemia	Progressive anemia from bone marrow failure is common. May be multifactorial including ineffective erythropoiesis, splenic sequestration, and iron deficiency.	phenotype_term	phenotype_term	$	Anemia	Progressive anemia from bone marrow failure is common. May be multifactorial including ineffective erythropoiesis, splenic sequestration, and iron deficiency.	Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
5817	6398	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	2	Fatigue	Profound fatigue is one of the most debilitating symptoms, significantly impacting quality of life.	phenotype_term	phenotype_term	$	Fatigue	Profound fatigue is one of the most debilitating symptoms, significantly impacting quality of life.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5818	6399	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	3	Cachexia	Weight loss and cachexia from hypermetabolic state driven by inflammatory cytokine production.	phenotype_term	phenotype_term	$	Cachexia	Weight loss and cachexia from hypermetabolic state driven by inflammatory cytokine production.	Decreased body weight	HP:0004325	Decreased body weight		"{""preferred_term"": ""Decreased body weight"", ""term"": {""id"": ""HP:0004325"", ""label"": ""Decreased body weight""}}"																											
5819	6400	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	4	Thrombocytopenia	Low platelet count develops as disease progresses, reflecting bone marrow failure and splenic sequestration. Increases bleeding risk.	phenotype_term	phenotype_term	$	Thrombocytopenia	Low platelet count develops as disease progresses, reflecting bone marrow failure and splenic sequestration. Increases bleeding risk.	Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
5820	6401	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	phenotypes	5	Hepatomegaly	Liver enlargement from extramedullary hematopoiesis and portal hypertension.	phenotype_term	phenotype_term	$	Hepatomegaly	Liver enlargement from extramedullary hematopoiesis and portal hypertension.	Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
5821	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term	treatment_term	$	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}"				ruxolitinib	CHEBI:66919																						
5822	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"																											
5823	6405	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	1	Fedratinib	JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile.	treatment_term	treatment_term	$	Fedratinib	JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5824	6406	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
5825	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term	treatment_term	$	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
5826	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
5827	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term	treatment_term	$	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}"				anagrelide	CHEBI:142290																						
5828	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"																											
5829	6415	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	phenotypes	0	Aphasia		phenotype_term	phenotype_term	$	Aphasia		Aphasia	HP:0002381	Aphasia		"{""preferred_term"": ""Aphasia"", ""term"": {""id"": ""HP:0002381"", ""label"": ""Aphasia""}}"																											
5830	6416	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	phenotypes	1	Atypical Behavior		phenotype_term	phenotype_term	$	Atypical Behavior		Atypical behavior	HP:0000708	Atypical behavior		"{""preferred_term"": ""Atypical behavior"", ""term"": {""id"": ""HP:0000708"", ""label"": ""Atypical behavior""}}"																											
5831	6425	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	pathophysiology	0	Bile Duct Inflammation and Fibrosis	Periductal inflammation with concentric fibrosis (onion-skinning) leads to progressive stricture formation. Both innate and adaptive immune cells infiltrate the bile duct epithelium.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
5832	6425	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	pathophysiology	0	Bile Duct Inflammation and Fibrosis	Periductal inflammation with concentric fibrosis (onion-skinning) leads to progressive stricture formation. Both innate and adaptive immune cells infiltrate the bile duct epithelium.	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5833	6426	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	pathophysiology	1	Gut-Liver Axis Dysregulation	Aberrant homing of gut-primed lymphocytes to the liver through shared adhesion molecules (MAdCAM-1, CCL25). Bacterial translocation and altered bile acid metabolism contribute to hepatic inflammation.	cell_types[0]	cell_types	cell_types			T Cell	CL:0000084	T cell		"{""preferred_term"": ""T Cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
5834	6426	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	pathophysiology	1	Gut-Liver Axis Dysregulation	Aberrant homing of gut-primed lymphocytes to the liver through shared adhesion molecules (MAdCAM-1, CCL25). Bacterial translocation and altered bile acid metabolism contribute to hepatic inflammation.	biological_processes[0]	biological_processes	biological_processes			Cell Migration	GO:0016477	cell migration		"{""preferred_term"": ""Cell Migration"", ""term"": {""id"": ""GO:0016477"", ""label"": ""cell migration""}}"																											
5835	6427	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	pathophysiology	2	Cholangiocyte Senescence	Biliary epithelial cells undergo premature senescence with SASP (senescence- associated secretory phenotype), promoting inflammation and fibrosis through release of pro-inflammatory mediators.	biological_processes[0]	biological_processes	biological_processes			Cellular Senescence	GO:0090398	cellular senescence		"{""preferred_term"": ""Cellular Senescence"", ""term"": {""id"": ""GO:0090398"", ""label"": ""cellular senescence""}}"																											
5836	6428	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	phenotypes	0	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5837	6429	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	phenotypes	1	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5838	6430	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	phenotypes	2	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
5839	6431	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	phenotypes	3	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
5840	6440	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	histopathology	0	Diffuse Large B-Cell Lymphoma	DLBC was the most frequent histology in primary tonsillar lymphoma.	finding_term	finding_term	$	Diffuse Large B-Cell Lymphoma	DLBC was the most frequent histology in primary tonsillar lymphoma.	Diffuse Large B-Cell Lymphoma	NCIT:C8851	Diffuse Large B-Cell Lymphoma		"{""preferred_term"": ""Diffuse Large B-Cell Lymphoma"", ""term"": {""id"": ""NCIT:C8851"", ""label"": ""Diffuse Large B-Cell Lymphoma""}}"																											
5841	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	cell_types[0]	cell_types	cell_types			germinal center B cell	CL:0000844	germinal center B cell		"{""preferred_term"": ""germinal center B cell"", ""term"": {""id"": ""CL:0000844"", ""label"": ""germinal center B cell""}}"																											
5842	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	genes[0]	genes	genes			BCL2			Anti-apoptotic protein, frequently mutated or translocated in GCB-type tonsillar lymphoma	"{""description"": ""Anti-apoptotic protein, frequently mutated or translocated in GCB-type tonsillar lymphoma"", ""preferred_term"": ""BCL2""}"																											
5843	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	genes[1]	genes	genes			EZH2			Histone methyltransferase component of PRC2 complex, gain-of-function mutations drive epigenetic dysregulation	"{""description"": ""Histone methyltransferase component of PRC2 complex, gain-of-function mutations drive epigenetic dysregulation"", ""preferred_term"": ""EZH2""}"																											
5844	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	genes[2]	genes	genes			BCL6			Transcriptional repressor essential for germinal center formation	"{""description"": ""Transcriptional repressor essential for germinal center formation"", ""preferred_term"": ""BCL6""}"																											
5845	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	biological_processes[0]	biological_processes	biological_processes			regulation of apoptotic process				"{""preferred_term"": ""regulation of apoptotic process""}"																											
5846	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	biological_processes[1]	biological_processes	biological_processes			histone H3-K27 methylation				"{""preferred_term"": ""histone H3-K27 methylation""}"																											
5847	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	biological_processes[2]	biological_processes	biological_processes			germinal center formation				"{""preferred_term"": ""germinal center formation""}"																											
5848	6441	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	0	Malignant B-cell Proliferation (Germinal Center Type)	Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.	locations[0]	locations	locations			palatine tonsil	UBERON:0002373	palatine tonsil		"{""preferred_term"": ""palatine tonsil"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""palatine tonsil""}}"																											
5849	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
5850	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	genes[0]	genes	genes			CD79B			B-cell receptor component, mutations lead to chronic active BCR signaling	"{""description"": ""B-cell receptor component, mutations lead to chronic active BCR signaling"", ""preferred_term"": ""CD79B""}"																											
5851	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	genes[1]	genes	genes			MYD88			Adaptor protein in Toll-like receptor signaling, mutations activate NF-B pathway	"{""description"": ""Adaptor protein in Toll-like receptor signaling, mutations activate NF-B pathway"", ""preferred_term"": ""MYD88""}"																											
5852	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	biological_processes[0]	biological_processes	biological_processes			B cell receptor signaling pathway				"{""preferred_term"": ""B cell receptor signaling pathway""}"																											
5853	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	biological_processes[1]	biological_processes	biological_processes			NF-kappaB signaling				"{""preferred_term"": ""NF-kappaB signaling""}"																											
5854	6442	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	1	Malignant B-cell Proliferation (Activated B-cell Type)	Chronic active B-cell receptor signaling with downstream NF-B activation due to CD79B and MYD88 mutations.	locations[0]	locations	locations			palatine tonsil	UBERON:0002373	palatine tonsil		"{""preferred_term"": ""palatine tonsil"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""palatine tonsil""}}"																											
5855	6443	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	2	IRF4-rearranged Large B-cell Lymphoma	IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer's ring.	cell_types[0]	cell_types	cell_types			germinal center B cell	CL:0000844	germinal center B cell		"{""preferred_term"": ""germinal center B cell"", ""term"": {""id"": ""CL:0000844"", ""label"": ""germinal center B cell""}}"																											
5856	6443	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	2	IRF4-rearranged Large B-cell Lymphoma	IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer's ring.	cell_types[1]	cell_types	cell_types			plasmablast	CL:0000980	plasmablast		"{""preferred_term"": ""plasmablast"", ""term"": {""id"": ""CL:0000980"", ""label"": ""plasmablast""}}"																											
5857	6443	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	2	IRF4-rearranged Large B-cell Lymphoma	IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer's ring.	genes[0]	genes	genes			IRF4			Interferon regulatory factor 4, rearrangement drives MUM1 expression and plasmacytic differentiation	"{""description"": ""Interferon regulatory factor 4, rearrangement drives MUM1 expression and plasmacytic differentiation"", ""preferred_term"": ""IRF4""}"																											
5858	6443	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	2	IRF4-rearranged Large B-cell Lymphoma	IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer's ring.	biological_processes[0]	biological_processes	biological_processes			plasma cell differentiation				"{""preferred_term"": ""plasma cell differentiation""}"																											
5859	6443	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	2	IRF4-rearranged Large B-cell Lymphoma	IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer's ring.	locations[0]	locations	locations			palatine tonsil	UBERON:0002373	palatine tonsil		"{""preferred_term"": ""palatine tonsil"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""palatine tonsil""}}"																											
5860	6444	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	3	EBV-positive Diffuse Large B-cell Lymphoma	Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
5861	6444	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	3	EBV-positive Diffuse Large B-cell Lymphoma	Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.	biological_processes[0]	biological_processes	biological_processes			response to virus				"{""preferred_term"": ""response to virus""}"																											
5862	6444	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	3	EBV-positive Diffuse Large B-cell Lymphoma	Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.	biological_processes[1]	biological_processes	biological_processes			immune evasion				"{""preferred_term"": ""immune evasion""}"																											
5863	6444	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	3	EBV-positive Diffuse Large B-cell Lymphoma	Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.	locations[0]	locations	locations			palatine tonsil	UBERON:0002373	palatine tonsil		"{""preferred_term"": ""palatine tonsil"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""palatine tonsil""}}"																											
5864	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
5865	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	genes[0]	genes	genes			MYC			Transcription factor, rearrangement drives cellular proliferation	"{""description"": ""Transcription factor, rearrangement drives cellular proliferation"", ""preferred_term"": ""MYC""}"																											
5866	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	genes[1]	genes	genes			BCL2			Anti-apoptotic protein, co-rearrangement with MYC confers high-grade biology	"{""description"": ""Anti-apoptotic protein, co-rearrangement with MYC confers high-grade biology"", ""preferred_term"": ""BCL2""}"																											
5867	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	genes[2]	genes	genes			BCL6			Germinal center transcriptional repressor, co-rearrangement with MYC confers high-grade biology	"{""description"": ""Germinal center transcriptional repressor, co-rearrangement with MYC confers high-grade biology"", ""preferred_term"": ""BCL6""}"																											
5868	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	biological_processes[0]	biological_processes	biological_processes			regulation of transcription by RNA polymerase II				"{""preferred_term"": ""regulation of transcription by RNA polymerase II""}"																											
5869	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	biological_processes[1]	biological_processes	biological_processes			negative regulation of apoptotic process				"{""preferred_term"": ""negative regulation of apoptotic process""}"																											
5870	6445	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	pathophysiology	4	Double/Triple-hit High-grade B-cell Lymphoma	MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.	locations[0]	locations	locations			palatine tonsil	UBERON:0002373	palatine tonsil		"{""preferred_term"": ""palatine tonsil"", ""term"": {""id"": ""UBERON:0002373"", ""label"": ""palatine tonsil""}}"																											
5871	6446	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	0	Enlarged Tonsil		phenotype_term	phenotype_term	$	Enlarged Tonsil		Enlarged Tonsil	HP:0030812	Enlarged tonsils		"{""preferred_term"": ""Enlarged Tonsil"", ""term"": {""id"": ""HP:0030812"", ""label"": ""Enlarged tonsils""}}"																											
5872	6447	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	1	Fever		phenotype_term	phenotype_term	$	Fever		Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
5873	6448	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	2	Night Sweats		phenotype_term	phenotype_term	$	Night Sweats		Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
5874	6449	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	3	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
5875	6450	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	4	Lymphadenopathy		phenotype_term	phenotype_term	$	Lymphadenopathy		Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
5876	6452	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	phenotypes	6	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
5877	6457	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	0	Stage I	Cancer is found in a single region of lymph nodes or a single extralymphatic organ.	pathophysiology[0].cell_types[0]	pathophysiology	pathophysiology[0].cell_types			B-cell Lymphocyte				"{""preferred_term"": ""B-cell Lymphocyte""}"																											
5878	6457	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	0	Stage I	Cancer is found in a single region of lymph nodes or a single extralymphatic organ.	pathophysiology[0].cell_types[1]	pathophysiology	pathophysiology[0].cell_types			T-cell Lymphocyte				"{""preferred_term"": ""T-cell Lymphocyte""}"																											
5879	6458	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	1	Stage II	Cancer is found in two or more lymph regions on the same side of the diaphragm, or the cancer has spread from one lymph node region to a nearby organ.	pathophysiology[0].cell_types[0]	pathophysiology	pathophysiology[0].cell_types			B-cell Lymphocyte				"{""preferred_term"": ""B-cell Lymphocyte""}"																											
5880	6458	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	1	Stage II	Cancer is found in two or more lymph regions on the same side of the diaphragm, or the cancer has spread from one lymph node region to a nearby organ.	pathophysiology[0].cell_types[1]	pathophysiology	pathophysiology[0].cell_types			T-cell Lymphocyte				"{""preferred_term"": ""T-cell Lymphocyte""}"																											
5881	6459	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	2	Stage III	Cancer is found in lymph node regions or organs on both sides of the diaphragm.	pathophysiology[0].cell_types[0]	pathophysiology	pathophysiology[0].cell_types			B-cell Lymphocyte				"{""preferred_term"": ""B-cell Lymphocyte""}"																											
5882	6459	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	2	Stage III	Cancer is found in lymph node regions or organs on both sides of the diaphragm.	pathophysiology[0].cell_types[1]	pathophysiology	pathophysiology[0].cell_types			T-cell Lymphocyte				"{""preferred_term"": ""T-cell Lymphocyte""}"																											
5883	6460	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	3	Stage IV	Cancer has spread throughout one or more organs outside the lymph system or to the liver, bone marrow, or lungs.	pathophysiology[0].cell_types[0]	pathophysiology	pathophysiology[0].cell_types			B-cell Lymphocyte				"{""preferred_term"": ""B-cell Lymphocyte""}"																											
5884	6460	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	stages	3	Stage IV	Cancer has spread throughout one or more organs outside the lymph system or to the liver, bone marrow, or lungs.	pathophysiology[0].cell_types[1]	pathophysiology	pathophysiology[0].cell_types			T-cell Lymphocyte				"{""preferred_term"": ""T-cell Lymphocyte""}"																											
5885	6461	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	0	Chemotherapy	Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).	treatment_term	treatment_term	$	Chemotherapy	Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5886	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	Radiation Therapy	Targeted radiation to the tonsil and surrounding structures to control local disease.	treatment_term	treatment_term	$	Radiation Therapy	Targeted radiation to the tonsil and surrounding structures to control local disease.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5887	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	Targeted Therapy	Use of drugs like rituximab for B-cell lymphomas.	treatment_term	treatment_term	$	Targeted Therapy	Use of drugs like rituximab for B-cell lymphomas.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5888	6464	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	3	Stem Cell Transplant	Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.	treatment_term	treatment_term	$	Stem Cell Transplant	Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5889	6472	276	Proteus syndrome	Proteus_syndrome.yaml	differential_diagnoses	1	Madelung's disease (multiple symmetric lipomatosis)	"Symmetric lipomatous overgrowth can resemble Proteus syndrome and should be differentiated based on distribution and accompanying malformations.
"	disease_term	disease_term	$	Madelung's disease (multiple symmetric lipomatosis)	"Symmetric lipomatous overgrowth can resemble Proteus syndrome and should be differentiated based on distribution and accompanying malformations.
"	multiple symmetric lipomatosis	MONDO:0007908	multiple symmetric lipomatosis		"{""preferred_term"": ""multiple symmetric lipomatosis"", ""term"": {""id"": ""MONDO:0007908"", ""label"": ""multiple symmetric lipomatosis""}}"																											
5890	6473	276	Proteus syndrome	Proteus_syndrome.yaml	differential_diagnoses	2	Neurofibromatosis type I	"Neurocutaneous overgrowth and benign tumors can overlap with Proteus syndrome, but NF1 has distinct diagnostic features.
"	disease_term	disease_term	$	Neurofibromatosis type I	"Neurocutaneous overgrowth and benign tumors can overlap with Proteus syndrome, but NF1 has distinct diagnostic features.
"	neurofibromatosis type 1	MONDO:0018975	neurofibromatosis type 1		"{""preferred_term"": ""neurofibromatosis type 1"", ""term"": {""id"": ""MONDO:0018975"", ""label"": ""neurofibromatosis type 1""}}"																											
5891	6474	276	Proteus syndrome	Proteus_syndrome.yaml	differential_diagnoses	3	CLOVES syndrome	"Segmental overgrowth with complex vascular and soft tissue malformations can overlap with Proteus syndrome presentations.
"	disease_term	disease_term	$	CLOVES syndrome	"Segmental overgrowth with complex vascular and soft tissue malformations can overlap with Proteus syndrome presentations.
"	CLOVES syndrome	MONDO:0013038	CLOVES syndrome		"{""preferred_term"": ""CLOVES syndrome"", ""term"": {""id"": ""MONDO:0013038"", ""label"": ""CLOVES syndrome""}}"																											
5892	6475	276	Proteus syndrome	Proteus_syndrome.yaml	differential_diagnoses	4	PTEN hamartoma tumor syndrome	"PTEN-related overgrowth and hamartomatous features can mimic Proteus syndrome, requiring molecular differentiation.
"	disease_term	disease_term	$	PTEN hamartoma tumor syndrome	"PTEN-related overgrowth and hamartomatous features can mimic Proteus syndrome, requiring molecular differentiation.
"	PTEN hamartoma tumor syndrome	MONDO:0017623	PTEN hamartoma tumor syndrome		"{""preferred_term"": ""PTEN hamartoma tumor syndrome"", ""term"": {""id"": ""MONDO:0017623"", ""label"": ""PTEN hamartoma tumor syndrome""}}"																											
5893	6476	276	Proteus syndrome	Proteus_syndrome.yaml	differential_diagnoses	5	Bannayan-Riley-Ruvalcaba syndrome	"PTEN-related overgrowth syndrome that can overlap with Proteus-like features and should be distinguished by germline PTEN findings and classic mucocutaneous/hamartomatous manifestations.
"	disease_term	disease_term	$	Bannayan-Riley-Ruvalcaba syndrome	"PTEN-related overgrowth syndrome that can overlap with Proteus-like features and should be distinguished by germline PTEN findings and classic mucocutaneous/hamartomatous manifestations.
"	Bannayan-Riley-Ruvalcaba syndrome	MONDO:0007924	Bannayan-Riley-Ruvalcaba syndrome		"{""preferred_term"": ""Bannayan-Riley-Ruvalcaba syndrome"", ""term"": {""id"": ""MONDO:0007924"", ""label"": ""Bannayan-Riley-Ruvalcaba syndrome""}}"																											
5894	6483	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	1	Elevated PI3K/AKT signaling in AKT1-mutant cells	"AKT1 p.E17K drives increased PI3K/AKT pathway activity in mutation-positive cells, promoting downstream overgrowth signals.
"	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase/protein kinase B signal transduction	GO:0043491	phosphatidylinositol 3-kinase/protein kinase B signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase/protein kinase B signal transduction"", ""term"": {""id"": ""GO:0043491"", ""label"": ""phosphatidylinositol 3-kinase/protein kinase B signal transduction""}}"			INCREASED																								
5895	6484	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	2	Increased pAKT signaling in AKT1-mutant lesion cells	"Lesion cells harboring AKT1 p.E17K show increased pAKT signaling within hyperplastic regions.
"	biological_processes[0]	biological_processes	biological_processes			protein phosphorylation	GO:0006468	protein phosphorylation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein phosphorylation"", ""term"": {""id"": ""GO:0006468"", ""label"": ""protein phosphorylation""}}"			INCREASED																								
5896	6485	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	3	Non-cell-autonomous pAKT activation in adjacent cells	"AKT1-mutant clones can induce increased pAKT signaling in nearby mutation-negative cells, consistent with non-cell-autonomous lesion propagation.
"	biological_processes[0]	biological_processes	biological_processes			cell-cell signaling	GO:0007267	cell-cell signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell-cell signaling"", ""term"": {""id"": ""GO:0007267"", ""label"": ""cell-cell signaling""}}"			INCREASED																								
5897	6486	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	4	AKT overactivation induces excessive vasculogenesis	"AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
"	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
5898	6486	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	4	AKT overactivation induces excessive vasculogenesis	"AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
"	biological_processes[0]	biological_processes	biological_processes			vasculogenesis	GO:0001570	vasculogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""vasculogenesis"", ""term"": {""id"": ""GO:0001570"", ""label"": ""vasculogenesis""}}"			INCREASED																								
5899	6486	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	4	AKT overactivation induces excessive vasculogenesis	"AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
"	biological_processes[1]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
5900	6487	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	5	Mural cell dysfunction destabilizes vascular connections	"AKT-driven vascular malformations include dysfunctional PDGFR+ mural cells with impaired matrix secretion, contributing to unstable vessel connections.
"	cell_types[0]	cell_types	cell_types			pericyte	CL:0000669	pericyte		"{""preferred_term"": ""pericyte"", ""term"": {""id"": ""CL:0000669"", ""label"": ""pericyte""}}"																											
5901	6487	276	Proteus syndrome	Proteus_syndrome.yaml	pathophysiology	5	Mural cell dysfunction destabilizes vascular connections	"AKT-driven vascular malformations include dysfunctional PDGFR+ mural cells with impaired matrix secretion, contributing to unstable vessel connections.
"	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""modifier"": ""DECREASED"", ""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"			DECREASED																								
5902	6488	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	0	Overgrowth		phenotype_term	phenotype_term	$	Overgrowth		Overgrowth	HP:0001548	Overgrowth		"{""preferred_term"": ""Overgrowth"", ""term"": {""id"": ""HP:0001548"", ""label"": ""Overgrowth""}}"																											
5903	6489	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	1	Asymmetric growth		phenotype_term	phenotype_term	$	Asymmetric growth		Asymmetric growth	HP:0100555	Asymmetric growth		"{""preferred_term"": ""Asymmetric growth"", ""term"": {""id"": ""HP:0100555"", ""label"": ""Asymmetric growth""}}"																											
5904	6490	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	2	Venous malformation		phenotype_term	phenotype_term	$	Venous malformation		Venous malformation	HP:0012721	Venous malformation		"{""preferred_term"": ""Venous malformation"", ""term"": {""id"": ""HP:0012721"", ""label"": ""Venous malformation""}}"																											
5905	6491	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	3	Cerebriform connective tissue nevus		phenotype_term	phenotype_term	$	Cerebriform connective tissue nevus		Cerebriform connective tissue nevus	HP:6000009	Cerebriform connective tissue nevus		"{""preferred_term"": ""Cerebriform connective tissue nevus"", ""term"": {""id"": ""HP:6000009"", ""label"": ""Cerebriform connective tissue nevus""}}"																											
5906	6492	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	4	Epidermal nevus		phenotype_term	phenotype_term	$	Epidermal nevus		Epidermal nevus	HP:0010816	Epidermal nevus		"{""preferred_term"": ""Epidermal nevus"", ""term"": {""id"": ""HP:0010816"", ""label"": ""Epidermal nevus""}}"																											
5907	6493	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	5	Capillary malformation		phenotype_term	phenotype_term	$	Capillary malformation		Capillary malformation	HP:0025104	Capillary malformation		"{""preferred_term"": ""Capillary malformation"", ""term"": {""id"": ""HP:0025104"", ""label"": ""Capillary malformation""}}"																											
5908	6494	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	6	Varicose veins		phenotype_term	phenotype_term	$	Varicose veins		Varicose veins	HP:0002619	Varicose veins		"{""preferred_term"": ""Varicose veins"", ""term"": {""id"": ""HP:0002619"", ""label"": ""Varicose veins""}}"																											
5909	6495	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	7	Pain		phenotype_term	phenotype_term	$	Pain		Pain	HP:0012531	Pain		"{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
5910	6496	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	8	Scoliosis		phenotype_term	phenotype_term	$	Scoliosis		Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
5911	6497	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	9	Emphysema		phenotype_term	phenotype_term	$	Emphysema		Emphysema	HP:0002097	Emphysema		"{""preferred_term"": ""Emphysema"", ""term"": {""id"": ""HP:0002097"", ""label"": ""Emphysema""}}"																											
5912	6498	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	10	Multiple pulmonary cysts		phenotype_term	phenotype_term	$	Multiple pulmonary cysts		Multiple pulmonary cysts	HP:0005948	Multiple pulmonary cysts		"{""preferred_term"": ""Multiple pulmonary cysts"", ""term"": {""id"": ""HP:0005948"", ""label"": ""Multiple pulmonary cysts""}}"																											
5913	6499	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	11	Deep vein thrombosis		phenotype_term	phenotype_term	$	Deep vein thrombosis		Deep venous thrombosis	HP:0002625	Deep venous thrombosis		"{""preferred_term"": ""Deep venous thrombosis"", ""term"": {""id"": ""HP:0002625"", ""label"": ""Deep venous thrombosis""}}"																											
5914	6500	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	12	Pulmonary embolism		phenotype_term	phenotype_term	$	Pulmonary embolism		Pulmonary embolism	HP:0002204	Pulmonary embolism		"{""preferred_term"": ""Pulmonary embolism"", ""term"": {""id"": ""HP:0002204"", ""label"": ""Pulmonary embolism""}}"																											
5915	6501	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	13	Lipoma		phenotype_term	phenotype_term	$	Lipoma		Lipoma	HP:0012032	Lipoma		"{""preferred_term"": ""Lipoma"", ""term"": {""id"": ""HP:0012032"", ""label"": ""Lipoma""}}"																											
5916	6502	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	14	Limbal dermoid		phenotype_term	phenotype_term	$	Limbal dermoid		Limbal dermoid	HP:0001140	Limbal dermoid		"{""preferred_term"": ""Limbal dermoid"", ""term"": {""id"": ""HP:0001140"", ""label"": ""Limbal dermoid""}}"																											
5917	6503	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	15	Cataract		phenotype_term	phenotype_term	$	Cataract		Cataract	HP:0000518	Cataract		"{""preferred_term"": ""Cataract"", ""term"": {""id"": ""HP:0000518"", ""label"": ""Cataract""}}"																											
5918	6504	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	16	Nystagmus		phenotype_term	phenotype_term	$	Nystagmus		Nystagmus	HP:0000639	Nystagmus		"{""preferred_term"": ""Nystagmus"", ""term"": {""id"": ""HP:0000639"", ""label"": ""Nystagmus""}}"																											
5919	6505	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	17	Myopia		phenotype_term	phenotype_term	$	Myopia		Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
5920	6506	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	18	Optic disc drusen		phenotype_term	phenotype_term	$	Optic disc drusen		Optic disc drusen	HP:0012426	Optic disc drusen		"{""preferred_term"": ""Optic disc drusen"", ""term"": {""id"": ""HP:0012426"", ""label"": ""Optic disc drusen""}}"																											
5921	6507	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	19	Proptosis		phenotype_term	phenotype_term	$	Proptosis		Proptosis	HP:0000520	Proptosis		"{""preferred_term"": ""Proptosis"", ""term"": {""id"": ""HP:0000520"", ""label"": ""Proptosis""}}"																											
5922	6508	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	20	Visual impairment		phenotype_term	phenotype_term	$	Visual impairment		Visual impairment	HP:0000505	Visual impairment		"{""preferred_term"": ""Visual impairment"", ""term"": {""id"": ""HP:0000505"", ""label"": ""Visual impairment""}}"																											
5923	6509	276	Proteus syndrome	Proteus_syndrome.yaml	phenotypes	21	Neoplasm		phenotype_term	phenotype_term	$	Neoplasm		Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
5924	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term	treatment_term	$	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Miransertib	NCIT:C99172	NCIT:C2259			
5925	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5926	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			miransertib	NCIT:C99172	Miransertib		"{""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}"																											
5927	6513	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	1	Surgical intervention	Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.	treatment_term	treatment_term	$	Surgical intervention	Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5928	6515	277	Prurigo Nodularis	Prurigo_Nodularis.yaml	phenotypes	0	Pruritus	Intense itch associated with nodular skin lesions.	phenotype_term	phenotype_term	$	Pruritus	Intense itch associated with nodular skin lesions.	Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5929	6516	277	Prurigo Nodularis	Prurigo_Nodularis.yaml	phenotypes	1	Skin nodule	Nodular skin lesions characteristic of prurigo nodularis.	phenotype_term	phenotype_term	$	Skin nodule	Nodular skin lesions characteristic of prurigo nodularis.	Skin nodule	HP:0200036	Skin nodule		"{""preferred_term"": ""Skin nodule"", ""term"": {""id"": ""HP:0200036"", ""label"": ""Skin nodule""}}"																											
5930	6534	278	Psoriasis	Psoriasis.yaml	pathophysiology	0	T Cell-Mediated Inflammation	"Activated T cells (Th1, Th17, Th22) infiltrate skin and release cytokines including IL-17, IL-22, TNF-alpha, and IFN-gamma that drive keratinocyte hyperproliferation and inflammation.
"	cell_types[0]	cell_types	cell_types			T Helper 17 Cell	CL:0000899	T-helper 17 cell		"{""preferred_term"": ""T Helper 17 Cell"", ""term"": {""id"": ""CL:0000899"", ""label"": ""T-helper 17 cell""}}"																											
5931	6534	278	Psoriasis	Psoriasis.yaml	pathophysiology	0	T Cell-Mediated Inflammation	"Activated T cells (Th1, Th17, Th22) infiltrate skin and release cytokines including IL-17, IL-22, TNF-alpha, and IFN-gamma that drive keratinocyte hyperproliferation and inflammation.
"	cell_types[1]	cell_types	cell_types			T Helper 1 Cell	CL:0000545	T-helper 1 cell		"{""preferred_term"": ""T Helper 1 Cell"", ""term"": {""id"": ""CL:0000545"", ""label"": ""T-helper 1 cell""}}"																											
5932	6534	278	Psoriasis	Psoriasis.yaml	pathophysiology	0	T Cell-Mediated Inflammation	"Activated T cells (Th1, Th17, Th22) infiltrate skin and release cytokines including IL-17, IL-22, TNF-alpha, and IFN-gamma that drive keratinocyte hyperproliferation and inflammation.
"	biological_processes[0]	biological_processes	biological_processes			T Cell Activation	GO:0042110	T cell activation		"{""preferred_term"": ""T Cell Activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
5933	6535	278	Psoriasis	Psoriasis.yaml	pathophysiology	1	Keratinocyte Hyperproliferation	"Inflammatory cytokines stimulate rapid keratinocyte proliferation, reducing epidermal turnover from 28 days to 3-4 days. This produces characteristic thick, scaly plaques.
"	cell_types[0]	cell_types	cell_types			Keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""Keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
5934	6535	278	Psoriasis	Psoriasis.yaml	pathophysiology	1	Keratinocyte Hyperproliferation	"Inflammatory cytokines stimulate rapid keratinocyte proliferation, reducing epidermal turnover from 28 days to 3-4 days. This produces characteristic thick, scaly plaques.
"	biological_processes[0]	biological_processes	biological_processes			Cell Proliferation	GO:0008283	cell population proliferation		"{""preferred_term"": ""Cell Proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"																											
5935	6536	278	Psoriasis	Psoriasis.yaml	pathophysiology	2	Dendritic Cell Activation	"Plasmacytoid and myeloid dendritic cells produce inflammatory cytokines and present antigens to activate T cells, initiating and perpetuating the inflammatory cascade.
"	cell_types[0]	cell_types	cell_types			Dendritic Cell	CL:0000451	dendritic cell		"{""preferred_term"": ""Dendritic Cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
5936	6537	278	Psoriasis	Psoriasis.yaml	pathophysiology	3	IL-23/IL-17 Axis	"IL-23 produced by dendritic cells drives Th17 cell differentiation and IL-17 production. This axis is the major therapeutic target in modern psoriasis treatment.
"	biological_processes[0]	biological_processes	biological_processes			Cytokine Signaling	GO:0019221	cytokine-mediated signaling pathway		"{""preferred_term"": ""Cytokine Signaling"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"																											
5937	6538	278	Psoriasis	Psoriasis.yaml	phenotypes	0	Erythematous Plaques		phenotype_term	phenotype_term	$	Erythematous Plaques		Skin Plaque	HP:0200034	Papule		"{""preferred_term"": ""Skin Plaque"", ""term"": {""id"": ""HP:0200034"", ""label"": ""Papule""}}"																											
5938	6539	278	Psoriasis	Psoriasis.yaml	phenotypes	1	Silvery Scales		phenotype_term	phenotype_term	$	Silvery Scales		Scaling Skin	HP:0040189	Scaling skin		"{""preferred_term"": ""Scaling Skin"", ""term"": {""id"": ""HP:0040189"", ""label"": ""Scaling skin""}}"																											
5939	6540	278	Psoriasis	Psoriasis.yaml	phenotypes	2	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
5940	6541	278	Psoriasis	Psoriasis.yaml	phenotypes	3	Nail Changes		phenotype_term	phenotype_term	$	Nail Changes		Nail Dystrophy	HP:0008404	Nail dystrophy		"{""preferred_term"": ""Nail Dystrophy"", ""term"": {""id"": ""HP:0008404"", ""label"": ""Nail dystrophy""}}"																											
5941	6542	278	Psoriasis	Psoriasis.yaml	phenotypes	4	Joint Pain		phenotype_term	phenotype_term	$	Joint Pain		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
5942	6553	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	pathophysiology	1	Cytokine Pathway Activation	Dysregulated cytokine signaling, particularly IL-23/IL-17 and TNF pathways, sustains inflammatory responses in affected tissues.	biological_processes[0]	biological_processes	biological_processes			cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cytokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"			INCREASED																								
5943	6555	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	phenotypes	0	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
5944	6556	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	phenotypes	1	Enthesitis		phenotype_term	phenotype_term	$	Enthesitis		Enthesitis	HP:0100686	Enthesitis		"{""preferred_term"": ""Enthesitis"", ""term"": {""id"": ""HP:0100686"", ""label"": ""Enthesitis""}}"																											
5945	6557	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	phenotypes	2	Spondylitis		phenotype_term	phenotype_term	$	Spondylitis		Spondylitis	HP:0033631	Spondylitis		"{""preferred_term"": ""Spondylitis"", ""term"": {""id"": ""HP:0033631"", ""label"": ""Spondylitis""}}"																											
5946	6558	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	phenotypes	3	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
5947	6559	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	treatments	0	Targeted Cytokine Biologic Therapy	Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity.	treatment_term	treatment_term	$	Targeted Cytokine Biologic Therapy	Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5948	6560	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	biochemical	0	N-terminal pro b-type Natriuretic Peptide (NT-proBNP)		biomarker_term	biomarker_term	$	N-terminal pro b-type Natriuretic Peptide (NT-proBNP)		NT-proBNP	NCIT:C88524	N-Terminal Fragment Brain Natriuretic Protein		"{""preferred_term"": ""NT-proBNP"", ""term"": {""id"": ""NCIT:C88524"", ""label"": ""N-Terminal Fragment Brain Natriuretic Protein""}}"																											
5949	6561	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	diagnosis	0	Echocardiogram		diagnosis_term	diagnosis_term	$	Echocardiogram		echocardiography	MAXO:0010203	echocardiography		"{""preferred_term"": ""echocardiography"", ""term"": {""id"": ""MAXO:0010203"", ""label"": ""echocardiography""}}"																											
5950	6562	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	diagnosis	1	Right Heart Catheterization		diagnosis_term	diagnosis_term	$	Right Heart Catheterization		right heart catheterization	MAXO:0035118	cardiac catheterization		"{""located_in"": {""preferred_term"": ""right cardiac chamber"", ""term"": {""id"": ""UBERON:0035554"", ""label"": ""right cardiac chamber""}}, ""preferred_term"": ""right heart catheterization"", ""term"": {""id"": ""MAXO:0035118"", ""label"": ""cardiac catheterization""}}"	right cardiac chamber	UBERON:0035554																									
5951	6562	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	diagnosis	1	Right Heart Catheterization		diagnosis_term.located_in	diagnosis_term	diagnosis_term			right cardiac chamber	UBERON:0035554	right cardiac chamber		"{""preferred_term"": ""right cardiac chamber"", ""term"": {""id"": ""UBERON:0035554"", ""label"": ""right cardiac chamber""}}"																											
5952	6563	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	environmental	0	High-Altitude Exposure		environment_context	environment_context	$	High-Altitude Exposure		Mountain environment	ENVO:00000081	mountain		"{""preferred_term"": ""Mountain environment"", ""term"": {""id"": ""ENVO:00000081"", ""label"": ""mountain""}}"																											
5953	6573	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	has_subtypes	0	Pulmonary Arterial Hypertension (PAH)	A type of pulmonary hypertension characterized by high blood pressure in the arteries that supply the lungs, often idiopathic or associated with other conditions.	subtype_term	subtype_term	$	Pulmonary Arterial Hypertension (PAH)	A type of pulmonary hypertension characterized by high blood pressure in the arteries that supply the lungs, often idiopathic or associated with other conditions.	pulmonary arterial hypertension	MONDO:0015924	pulmonary arterial hypertension		"{""preferred_term"": ""pulmonary arterial hypertension"", ""term"": {""id"": ""MONDO:0015924"", ""label"": ""pulmonary arterial hypertension""}}"																											
5954	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	cell_types[0]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
5955	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	cell_types[1]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
5956	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	cell_types[2]	cell_types	cell_types			fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
5957	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	cell_types[3]	cell_types	cell_types			pericyte	CL:0000669	pericyte		"{""preferred_term"": ""pericyte"", ""term"": {""id"": ""CL:0000669"", ""label"": ""pericyte""}}"																											
5958	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	locations[0]	locations	locations			pulmonary artery	UBERON:0002012	pulmonary artery		"{""preferred_term"": ""pulmonary artery"", ""term"": {""id"": ""UBERON:0002012"", ""label"": ""pulmonary artery""}}"																											
5959	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	biological_processes[0]	biological_processes	biological_processes			extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
5960	6575	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	0	Vascular Remodeling	Structural changes in the pulmonary vasculature including smooth muscle hypertrophy, intimal proliferation, and fibrosis.	biological_processes[1]	biological_processes	biological_processes			smooth muscle cell proliferation	GO:0048661	positive regulation of smooth muscle cell proliferation		"{""preferred_term"": ""smooth muscle cell proliferation"", ""term"": {""id"": ""GO:0048661"", ""label"": ""positive regulation of smooth muscle cell proliferation""}}"																											
5961	6576	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	1	Endothelial Dysfunction	Endothelial injury and apoptosis with loss of BMPR2/BMP protective signaling; endothelial-to-mesenchymal transition contributing to vascular remodeling.	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
5962	6576	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	1	Endothelial Dysfunction	Endothelial injury and apoptosis with loss of BMPR2/BMP protective signaling; endothelial-to-mesenchymal transition contributing to vascular remodeling.	locations[0]	locations	locations			pulmonary artery	UBERON:0002012	pulmonary artery		"{""preferred_term"": ""pulmonary artery"", ""term"": {""id"": ""UBERON:0002012"", ""label"": ""pulmonary artery""}}"																											
5963	6576	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	1	Endothelial Dysfunction	Endothelial injury and apoptosis with loss of BMPR2/BMP protective signaling; endothelial-to-mesenchymal transition contributing to vascular remodeling.	biological_processes[0]	biological_processes	biological_processes			endothelial to mesenchymal transition	GO:0001837	epithelial to mesenchymal transition		"{""preferred_term"": ""endothelial to mesenchymal transition"", ""term"": {""id"": ""GO:0001837"", ""label"": ""epithelial to mesenchymal transition""}}"																											
5964	6576	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	1	Endothelial Dysfunction	Endothelial injury and apoptosis with loss of BMPR2/BMP protective signaling; endothelial-to-mesenchymal transition contributing to vascular remodeling.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
5965	6576	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	1	Endothelial Dysfunction	Endothelial injury and apoptosis with loss of BMPR2/BMP protective signaling; endothelial-to-mesenchymal transition contributing to vascular remodeling.	biological_processes[2]	biological_processes	biological_processes			BMP signaling pathway	GO:0030509	BMP signaling pathway		"{""preferred_term"": ""BMP signaling pathway"", ""term"": {""id"": ""GO:0030509"", ""label"": ""BMP signaling pathway""}}"																											
5966	6577	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	2	Inflammation and Immune Activation	Perivascular immune cell infiltration and cytokine release fueling proliferative and fibrotic processes.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
5967	6577	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	2	Inflammation and Immune Activation	Perivascular immune cell infiltration and cytokine release fueling proliferative and fibrotic processes.	locations[0]	locations	locations			pulmonary artery	UBERON:0002012	pulmonary artery		"{""preferred_term"": ""pulmonary artery"", ""term"": {""id"": ""UBERON:0002012"", ""label"": ""pulmonary artery""}}"																											
5968	6577	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	2	Inflammation and Immune Activation	Perivascular immune cell infiltration and cytokine release fueling proliferative and fibrotic processes.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
5969	6577	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	2	Inflammation and Immune Activation	Perivascular immune cell infiltration and cytokine release fueling proliferative and fibrotic processes.	biological_processes[1]	biological_processes	biological_processes			NF-kappaB signaling	GO:0038061	NIK/NF-kappaB signaling		"{""preferred_term"": ""NF-kappaB signaling"", ""term"": {""id"": ""GO:0038061"", ""label"": ""NIK/NF-kappaB signaling""}}"																											
5970	6578	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	3	Metabolic Reprogramming	Shift from oxidative phosphorylation to glycolysis in vascular cells, supporting proliferation and apoptosis resistance.	cell_types[0]	cell_types	cell_types			Smooth Muscle Cell	CL:0000192	smooth muscle cell		"{""preferred_term"": ""Smooth Muscle Cell"", ""term"": {""id"": ""CL:0000192"", ""label"": ""smooth muscle cell""}}"																											
5971	6578	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	3	Metabolic Reprogramming	Shift from oxidative phosphorylation to glycolysis in vascular cells, supporting proliferation and apoptosis resistance.	cell_types[1]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
5972	6578	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	3	Metabolic Reprogramming	Shift from oxidative phosphorylation to glycolysis in vascular cells, supporting proliferation and apoptosis resistance.	biological_processes[0]	biological_processes	biological_processes			glycolytic process	GO:0006096	glycolytic process		"{""preferred_term"": ""glycolytic process"", ""term"": {""id"": ""GO:0006096"", ""label"": ""glycolytic process""}}"																											
5973	6578	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	3	Metabolic Reprogramming	Shift from oxidative phosphorylation to glycolysis in vascular cells, supporting proliferation and apoptosis resistance.	biological_processes[1]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
5974	6579	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	4	Hypoxia Signaling	Hypoxia-inducible factor (HIF) pathway activation contributing to vasoconstriction and vascular remodeling.	biological_processes[0]	biological_processes	biological_processes			response to hypoxia	GO:0001666	response to hypoxia		"{""preferred_term"": ""response to hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"																											
5975	6579	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	4	Hypoxia Signaling	Hypoxia-inducible factor (HIF) pathway activation contributing to vasoconstriction and vascular remodeling.	biological_processes[1]	biological_processes	biological_processes			HIF-1-alpha signaling pathway	GO:0097411	hypoxia-inducible factor-1alpha signaling pathway		"{""preferred_term"": ""HIF-1-alpha signaling pathway"", ""term"": {""id"": ""GO:0097411"", ""label"": ""hypoxia-inducible factor-1alpha signaling pathway""}}"																											
5976	6580	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	5	Increased Pulmonary Vascular Resistance	Result of vascular remodeling and vasoconstriction leading to elevated pressure in the pulmonary artery.	locations[0]	locations	locations			pulmonary artery	UBERON:0002012	pulmonary artery		"{""preferred_term"": ""pulmonary artery"", ""term"": {""id"": ""UBERON:0002012"", ""label"": ""pulmonary artery""}}"																											
5977	6581	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	pathophysiology	6	Right Ventricular Hypertrophy	The right ventricle thickens in response to increased workload from elevated pulmonary arterial pressure.	locations[0]	locations	locations			right cardiac ventricle	UBERON:0002080	right cardiac ventricle		"{""preferred_term"": ""right cardiac ventricle"", ""term"": {""id"": ""UBERON:0002080"", ""label"": ""right cardiac ventricle""}}"																											
5978	6582	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	0	Dyspnea		phenotype_term	phenotype_term	$	Dyspnea		Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
5979	6583	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	1	Chest Pain		phenotype_term	phenotype_term	$	Chest Pain		Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
5980	6584	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	2	Syncope		phenotype_term	phenotype_term	$	Syncope		Syncope	HP:0001279	Syncope		"{""preferred_term"": ""Syncope"", ""term"": {""id"": ""HP:0001279"", ""label"": ""Syncope""}}"																											
5981	6585	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	3	Palpitations		phenotype_term	phenotype_term	$	Palpitations		Palpitations	HP:0001962	Palpitations		"{""preferred_term"": ""Palpitations"", ""term"": {""id"": ""HP:0001962"", ""label"": ""Palpitations""}}"																											
5982	6586	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	4	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
5983	6587	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	5	Edema		phenotype_term	phenotype_term	$	Edema		Edema	HP:0000969	Edema		"{""preferred_term"": ""Edema"", ""term"": {""id"": ""HP:0000969"", ""label"": ""Edema""}}"																											
5984	6588	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	6	Reduced Exercise Tolerance		phenotype_term	phenotype_term	$	Reduced Exercise Tolerance		Reduced Exercise Tolerance	HP:0003546	Exercise intolerance		"{""preferred_term"": ""Reduced Exercise Tolerance"", ""term"": {""id"": ""HP:0003546"", ""label"": ""Exercise intolerance""}}"																											
5985	6589	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	phenotypes	7	Cyanosis		phenotype_term	phenotype_term	$	Cyanosis		Cyanosis	HP:0000961	Cyanosis		"{""preferred_term"": ""Cyanosis"", ""term"": {""id"": ""HP:0000961"", ""label"": ""Cyanosis""}}"																											
5986	6592	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	0	Phosphodiesterase-5 Inhibitors	Medications like sildenafil and tadalafil that relax blood vessels in the lungs	treatment_term	treatment_term	$	Phosphodiesterase-5 Inhibitors	Medications like sildenafil and tadalafil that relax blood vessels in the lungs	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5987	6593	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	1	Endothelin Receptor Antagonists	Medications that block the effects of endothelin and help decrease blood pressure in the lungs	treatment_term	treatment_term	$	Endothelin Receptor Antagonists	Medications that block the effects of endothelin and help decrease blood pressure in the lungs	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5988	6594	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	2	Prostacyclin Analogues	Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds	treatment_term	treatment_term	$	Prostacyclin Analogues	Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5989	6595	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	3	Oxygen Therapy	Used to reduce symptoms in patients with hypoxemia	treatment_term	treatment_term	$	Oxygen Therapy	Used to reduce symptoms in patients with hypoxemia	artificial respiration	MAXO:0000503	artificial respiration		"{""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}"																											
5990	6596	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	4	Anticoagulation	Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications	treatment_term	treatment_term	$	Anticoagulation	Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
5991	6603	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	histopathology	0	Papillary Thyroid Carcinoma	Papillary thyroid carcinomas are the most common thyroid cancers.	finding_term	finding_term	$	Papillary Thyroid Carcinoma	Papillary thyroid carcinomas are the most common thyroid cancers.	Thyroid Gland Papillary Carcinoma	NCIT:C4035	Thyroid Gland Papillary Carcinoma		"{""preferred_term"": ""Thyroid Gland Papillary Carcinoma"", ""term"": {""id"": ""NCIT:C4035"", ""label"": ""Thyroid Gland Papillary Carcinoma""}}"																											
5992	6604	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	0	RET Fusion and Constitutive Kinase Activation	Chromosomal rearrangements fuse the RET tyrosine kinase domain with upstream partners that provide dimerization domains. This creates constitutively active chimeric proteins that signal independently of RET ligands (GDNF family members).	cell_types[0]	cell_types	cell_types			thyroid follicular cell	CL:0002258	thyroid follicular cell		"{""preferred_term"": ""thyroid follicular cell"", ""term"": {""id"": ""CL:0002258"", ""label"": ""thyroid follicular cell""}}"																											
5993	6604	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	0	RET Fusion and Constitutive Kinase Activation	Chromosomal rearrangements fuse the RET tyrosine kinase domain with upstream partners that provide dimerization domains. This creates constitutively active chimeric proteins that signal independently of RET ligands (GDNF family members).	biological_processes[0]	biological_processes	biological_processes			receptor signaling protein tyrosine kinase activity	GO:0004716	receptor signaling protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""receptor signaling protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004716"", ""label"": ""receptor signaling protein tyrosine kinase activity""}}"			INCREASED																								
5994	6604	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	0	RET Fusion and Constitutive Kinase Activation	Chromosomal rearrangements fuse the RET tyrosine kinase domain with upstream partners that provide dimerization domains. This creates constitutively active chimeric proteins that signal independently of RET ligands (GDNF family members).	locations[0]	locations	locations			thyroid gland	UBERON:0002046	thyroid gland		"{""preferred_term"": ""thyroid gland"", ""term"": {""id"": ""UBERON:0002046"", ""label"": ""thyroid gland""}}"																											
5995	6605	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	1	RAS-MAPK Pathway Activation	Constitutive RET kinase activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting uncontrolled thyroid follicular cell proliferation. This is a major effector of RET-mediated thyroid tumorigenesis.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
5996	6606	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	pathophysiology	2	PI3K-AKT Pathway Activation	RET activation recruits PI3K and stimulates AKT-mTOR signaling, promoting cell survival and resistance to apoptosis. Combined with MAPK activation, this drives thyroid cancer progression.	biological_processes[0]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
5997	6607	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	phenotypes	0	Thyroid Nodule	Patients typically present with a thyroid nodule. RET fusion-positive PTCs may present at younger ages, particularly in radiation-associated cases.	phenotype_term	phenotype_term	$	Thyroid Nodule	Patients typically present with a thyroid nodule. RET fusion-positive PTCs may present at younger ages, particularly in radiation-associated cases.	Thyroid carcinoma	HP:0002890	Thyroid carcinoma		"{""preferred_term"": ""Thyroid carcinoma"", ""term"": {""id"": ""HP:0002890"", ""label"": ""Thyroid carcinoma""}}"																											
5998	6608	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	phenotypes	1	Cervical Lymphadenopathy	Cervical lymph node metastases are common at presentation. RET fusion- positive PTCs tend to have favorable overall prognosis despite lymph node involvement.	phenotype_term	phenotype_term	$	Cervical Lymphadenopathy	Cervical lymph node metastases are common at presentation. RET fusion- positive PTCs tend to have favorable overall prognosis despite lymph node involvement.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
5999	6609	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	phenotypes	2	Fatigue	Constitutional symptoms are uncommon at diagnosis but may occur with advanced metastatic disease.	phenotype_term	phenotype_term	$	Fatigue	Constitutional symptoms are uncommon at diagnosis but may occur with advanced metastatic disease.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6000	6610	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6001	6611	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors.	treatment_term	treatment_term	$	Radioiodine Therapy	Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6002	6612	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	2	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control.	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6003	6613	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	3	Pralsetinib	Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib.	treatment_term	treatment_term	$	Pralsetinib	Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6004	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term	treatment_term	$	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
6005	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
6006	6621	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
6007	6622	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	0	RET Gene Rearrangement	RET rearrangements result from chromosomal inversions or translocations that fuse the RET kinase domain (10q11.21) to an N-terminal partner gene. The partner gene provides a dimerization domain, causing constitutive RET kinase activation independent of ligand. RET normally signals through GDNF family ligands and GFR-alpha co-receptors.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
6008	6622	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	0	RET Gene Rearrangement	RET rearrangements result from chromosomal inversions or translocations that fuse the RET kinase domain (10q11.21) to an N-terminal partner gene. The partner gene provides a dimerization domain, causing constitutive RET kinase activation independent of ligand. RET normally signals through GDNF family ligands and GFR-alpha co-receptors.	biological_processes[0]	biological_processes	biological_processes			protein kinase activity	GO:0004672	protein kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein kinase activity"", ""term"": {""id"": ""GO:0004672"", ""label"": ""protein kinase activity""}}"			INCREASED																								
6009	6623	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive RET Signaling	RET fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and PLCgamma pathways. RET also activates SRC family kinases and JAK-STAT signaling.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
6010	6623	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive RET Signaling	RET fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and PLCgamma pathways. RET also activates SRC family kinases and JAK-STAT signaling.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
6011	6624	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	RET-rearranged tumors exhibit oncogene addiction, becoming dependent on continued RET signaling for survival. Selective RET inhibition leads to rapid and durable tumor responses.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
6012	6625	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	pathophysiology	3	RET Inhibitor Resistance	Resistance to selective RET inhibitors can develop through secondary RET kinase mutations (G810R/S/C solvent front mutations, V804L/M gatekeeper), RET amplification, or bypass pathway activation (MET, KRAS, BRAF). Solvent front mutations are the most common resistance mechanism.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
6013	6626	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	RET-rearranged NSCLC is almost exclusively adenocarcinoma histology. Typically presents in younger patients.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	RET-rearranged NSCLC is almost exclusively adenocarcinoma histology. Typically presents in younger patients.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
6014	6627	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	phenotypes	1	Young Age at Diagnosis	RET-positive patients are typically younger than average NSCLC patients, similar to ALK/ROS1 demographics (median age ~60).	phenotype_term	phenotype_term	$	Young Age at Diagnosis	RET-positive patients are typically younger than average NSCLC patients, similar to ALK/ROS1 demographics (median age ~60).	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6015	6628	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	phenotypes	2	Never/Light Smoker	Like other fusion-driven NSCLC, RET-positive tumors occur predominantly in never-smokers or light smokers.	phenotype_term	phenotype_term	$	Never/Light Smoker	Like other fusion-driven NSCLC, RET-positive tumors occur predominantly in never-smokers or light smokers.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6016	6629	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	phenotypes	3	Brain Metastases	Brain metastases occur in approximately 25-45% of RET-positive NSCLC patients. Selpercatinib has excellent CNS penetration and demonstrated intracranial activity.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in approximately 25-45% of RET-positive NSCLC patients. Selpercatinib has excellent CNS penetration and demonstrated intracranial activity.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
6017	6630	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	0	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation).	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6018	6631	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	1	Pralsetinib	Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis.	treatment_term	treatment_term	$	Pralsetinib	Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6019	6632	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	2	Cabozantinib	Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition.	treatment_term	treatment_term	$	Cabozantinib	Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6020	6633	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6021	6634	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6022	6641	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	histopathology	0	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	finding_term	finding_term	$	Adenocarcinoma Predominance	Adenocarcinoma is the most common histologic subtype in NSCLC.	Lung Adenocarcinoma	NCIT:C3512	Lung Adenocarcinoma		"{""preferred_term"": ""Lung Adenocarcinoma"", ""term"": {""id"": ""NCIT:C3512"", ""label"": ""Lung Adenocarcinoma""}}"																											
6023	6642	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	0	ROS1 Gene Rearrangement	ROS1 rearrangements result from chromosomal translocations that fuse the ROS1 kinase domain (6q22) to an N-terminal partner gene. The partner provides a dimerization domain, causing constitutive ROS1 kinase activation independent of ligand. ROS1 shares ~49% amino acid identity with ALK in the kinase domain, explaining cross-sensitivity to ALK inhibitors.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
6024	6642	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	0	ROS1 Gene Rearrangement	ROS1 rearrangements result from chromosomal translocations that fuse the ROS1 kinase domain (6q22) to an N-terminal partner gene. The partner provides a dimerization domain, causing constitutive ROS1 kinase activation independent of ligand. ROS1 shares ~49% amino acid identity with ALK in the kinase domain, explaining cross-sensitivity to ALK inhibitors.	biological_processes[0]	biological_processes	biological_processes			protein kinase activity	GO:0004672	protein kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein kinase activity"", ""term"": {""id"": ""GO:0004672"", ""label"": ""protein kinase activity""}}"			INCREASED																								
6025	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
6026	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
6027	6643	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	1	Constitutive ROS1 Signaling	ROS1 fusion proteins are constitutively dimerized and auto-phosphorylated, activating downstream signaling including RAS-MAPK, PI3K-AKT, and JAK-STAT3 pathways. These pathways promote cell proliferation, survival, and migration. ROS1 shares significant kinase domain homology with ALK.	biological_processes[2]	biological_processes	biological_processes			JAK-STAT cascade	GO:0007259	JAK-STAT cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""JAK-STAT cascade"", ""term"": {""id"": ""GO:0007259"", ""label"": ""JAK-STAT cascade""}}"			INCREASED																								
6028	6644	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	2	Oncogene Addiction	ROS1-rearranged tumors exhibit oncogene addiction, becoming dependent on continued ROS1 signaling for survival. ROS1 inhibition leads to dramatic tumor responses, often within days to weeks of starting therapy.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
6029	6645	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	pathophysiology	3	ROS1 Inhibitor Resistance	Resistance to ROS1 inhibitors develops through ROS1-dependent mechanisms (secondary mutations like G2032R, D2033N, L2026M) or ROS1-independent bypass pathways (MET amplification, KRAS mutations, EGFR activation). The G2032R solvent front mutation is the most common and confers resistance to crizotinib.	biological_processes[0]	biological_processes	biological_processes			response to drug	GO:0042493	response to drug		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""response to drug"", ""term"": {""id"": ""GO:0042493"", ""label"": ""response to drug""}}"			ABNORMAL																								
6030	6646	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	phenotypes	0	Lung Adenocarcinoma	ROS1-rearranged NSCLC is almost exclusively adenocarcinoma histology. Typically presents in younger patients as peripheral lung nodules.	phenotype_term	phenotype_term	$	Lung Adenocarcinoma	ROS1-rearranged NSCLC is almost exclusively adenocarcinoma histology. Typically presents in younger patients as peripheral lung nodules.	Lung adenocarcinoma	HP:0030078	Lung adenocarcinoma		"{""preferred_term"": ""Lung adenocarcinoma"", ""term"": {""id"": ""HP:0030078"", ""label"": ""Lung adenocarcinoma""}}"																											
6031	6647	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	phenotypes	1	Young Age at Diagnosis	ROS1-positive patients are typically younger than other NSCLC patients (median age ~50s). Similar demographics to ALK-rearranged disease.	phenotype_term	phenotype_term	$	Young Age at Diagnosis	ROS1-positive patients are typically younger than other NSCLC patients (median age ~50s). Similar demographics to ALK-rearranged disease.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6032	6648	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	phenotypes	2	Never/Light Smoker	Like EGFR-mutant and ALK-rearranged NSCLC, ROS1-positive tumors occur predominantly in never-smokers or light smokers.	phenotype_term	phenotype_term	$	Never/Light Smoker	Like EGFR-mutant and ALK-rearranged NSCLC, ROS1-positive tumors occur predominantly in never-smokers or light smokers.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6033	6649	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	phenotypes	3	Brain Metastases	Brain metastases occur in approximately 35-40% of ROS1-positive NSCLC patients. CNS-penetrant inhibitors (entrectinib, lorlatinib) provide improved intracranial disease control compared to crizotinib.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases occur in approximately 35-40% of ROS1-positive NSCLC patients. CNS-penetrant inhibitors (entrectinib, lorlatinib) provide improved intracranial disease control compared to crizotinib.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
6034	6650	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	0	Crizotinib	First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation.	treatment_term	treatment_term	$	Crizotinib	First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6035	6651	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	1	Entrectinib	ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions.	treatment_term	treatment_term	$	Entrectinib	ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6036	6652	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	2	Lorlatinib	Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors.	treatment_term	treatment_term	$	Lorlatinib	Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6037	6653	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	3	Repotrectinib	Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations.	treatment_term	treatment_term	$	Repotrectinib	Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6038	6654	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6039	6655	284	Rabies	Rabies.yaml	infectious_agent	0	Rabies virus	Neurotropic lyssavirus causing rabies.	infectious_agent_term	infectious_agent_term	$	Rabies virus	Neurotropic lyssavirus causing rabies.	Lyssavirus rabies	NCBITaxon:11292	Lyssavirus rabies		"{""preferred_term"": ""Lyssavirus rabies"", ""term"": {""id"": ""NCBITaxon:11292"", ""label"": ""Lyssavirus rabies""}}"																											
6040	6658	284	Rabies	Rabies.yaml	phenotypes	0	Infectious encephalitis		phenotype_term	phenotype_term	$	Infectious encephalitis		Infectious encephalitis	HP:0002383	Infectious encephalitis		"{""preferred_term"": ""Infectious encephalitis"", ""term"": {""id"": ""HP:0002383"", ""label"": ""Infectious encephalitis""}}"																											
6041	6660	284	Rabies	Rabies.yaml	treatments	0	Rabies post-exposure vaccination	Post-exposure prophylaxis includes rabies vaccination.	treatment_term	treatment_term	$	Rabies post-exposure vaccination	Post-exposure prophylaxis includes rabies vaccination.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
6042	6661	284	Rabies	Rabies.yaml	treatments	1	Rabies immunoglobulin administration	Rabies immune globulin is used in post-exposure prophylaxis.	treatment_term	treatment_term	$	Rabies immunoglobulin administration	Rabies immune globulin is used in post-exposure prophylaxis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6043	6662	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	0	Phosphate		biomarker_term	biomarker_term	$	Phosphate		phosphate measurement	NCIT:C64857	Phosphate Measurement		"{""preferred_term"": ""phosphate measurement"", ""term"": {""id"": ""NCIT:C64857"", ""label"": ""Phosphate Measurement""}}"																											
6044	6663	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	1	Potassium		biomarker_term	biomarker_term	$	Potassium		potassium measurement	NCIT:C64853	Potassium Measurement		"{""preferred_term"": ""potassium measurement"", ""term"": {""id"": ""NCIT:C64853"", ""label"": ""Potassium Measurement""}}"																											
6045	6664	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	2	Magnesium		biomarker_term	biomarker_term	$	Magnesium		magnesium measurement	NCIT:C64840	Magnesium Measurement		"{""preferred_term"": ""magnesium measurement"", ""term"": {""id"": ""NCIT:C64840"", ""label"": ""Magnesium Measurement""}}"																											
6046	6668	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	differential_diagnoses	0	Alcoholic ketoacidosis	Acute metabolic derangement that can present with hypophosphatemia in high-risk settings and may overlap biochemically with refeeding syndrome.	disease_term	disease_term	$	Alcoholic ketoacidosis	Acute metabolic derangement that can present with hypophosphatemia in high-risk settings and may overlap biochemically with refeeding syndrome.	alcoholic ketoacidosis	MONDO:0100160	alcoholic ketoacidosis		"{""preferred_term"": ""alcoholic ketoacidosis"", ""term"": {""id"": ""MONDO:0100160"", ""label"": ""alcoholic ketoacidosis""}}"																											
6047	6669	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	differential_diagnoses	1	Hyperventilation-induced hypophosphatemia	Respiratory alkalosis from hyperventilation can cause intracellular phosphate shifting and severe hypophosphatemia, mimicking refeeding-related electrolyte disturbances.	disease_term	disease_term	$	Hyperventilation-induced hypophosphatemia	Respiratory alkalosis from hyperventilation can cause intracellular phosphate shifting and severe hypophosphatemia, mimicking refeeding-related electrolyte disturbances.	hypophosphatemia	MONDO:0000313	hypophosphatemia		"{""preferred_term"": ""hypophosphatemia"", ""term"": {""id"": ""MONDO:0000313"", ""label"": ""hypophosphatemia""}}"																											
6048	6670	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	differential_diagnoses	2	Thyrotoxic periodic paralysis	Thyrotoxic periodic paralysis can cause acute weakness with significant hypokalemia and may be confused with refeeding-related electrolyte shifts.	disease_term	disease_term	$	Thyrotoxic periodic paralysis	Thyrotoxic periodic paralysis can cause acute weakness with significant hypokalemia and may be confused with refeeding-related electrolyte shifts.	thyrotoxic periodic paralysis	MONDO:0019201	thyrotoxic periodic paralysis		"{""preferred_term"": ""thyrotoxic periodic paralysis"", ""term"": {""id"": ""MONDO:0019201"", ""label"": ""thyrotoxic periodic paralysis""}}"																											
6049	6687	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	0	Edema	Sodium and fluid retention leading to edema during refeeding.	phenotype_term	phenotype_term	$	Edema	Sodium and fluid retention leading to edema during refeeding.	Edema	HP:0000969	Edema		"{""preferred_term"": ""Edema"", ""term"": {""id"": ""HP:0000969"", ""label"": ""Edema""}}"																											
6050	6688	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	1	Arrhythmia	Cardiac rhythm disturbances related to electrolyte abnormalities.	phenotype_term	phenotype_term	$	Arrhythmia	Cardiac rhythm disturbances related to electrolyte abnormalities.	Arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
6051	6689	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	2	Congestive Heart Failure	Systolic heart failure due to electrolyte shifts and fluid overload.	phenotype_term	phenotype_term	$	Congestive Heart Failure	Systolic heart failure due to electrolyte shifts and fluid overload.	Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
6052	6691	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	4	Respiratory Insufficiency	Respiratory failure linked to severe electrolyte derangements.	phenotype_term	phenotype_term	$	Respiratory Insufficiency	Respiratory failure linked to severe electrolyte derangements.	Respiratory insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
6053	6692	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	5	Pancytopenia	Decrease in all blood cell lines during refeeding in severe malnutrition.	phenotype_term	phenotype_term	$	Pancytopenia	Decrease in all blood cell lines during refeeding in severe malnutrition.	Pancytopenia	HP:0001876	Pancytopenia		"{""preferred_term"": ""Pancytopenia"", ""term"": {""id"": ""HP:0001876"", ""label"": ""Pancytopenia""}}"																											
6054	6693	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	6	Seizures	Seizures as a systemic complication during refeeding syndrome.	phenotype_term	phenotype_term	$	Seizures	Seizures as a systemic complication during refeeding syndrome.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6055	6694	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	phenotypes	7	Delirium	Delirium occurring after refeeding in a severely malnourished patient.	phenotype_term	phenotype_term	$	Delirium	Delirium occurring after refeeding in a severely malnourished patient.	Delirium	HP:0031258	Delirium		"{""preferred_term"": ""Delirium"", ""term"": {""id"": ""HP:0031258"", ""label"": ""Delirium""}}"																											
6056	6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	Controlled refeeding and caloric advancement	Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts.	treatment_term	treatment_term	$	Controlled refeeding and caloric advancement	Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts.	nutrition intervention	MAXO:0000009	nutrition intervention		"{""preferred_term"": ""nutrition intervention"", ""term"": {""id"": ""MAXO:0000009"", ""label"": ""nutrition intervention""}}"																											
6057	6700	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	1	Electrolyte supplementation and monitoring	Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding.	treatment_term	treatment_term	$	Electrolyte supplementation and monitoring	Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
6058	6701	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	2	Thiamine (vitamin B1) supplementation	Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications.	treatment_term	treatment_term	$	Thiamine (vitamin B1) supplementation	Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications.	vitamin B1 supplementation	MAXO:0010019	vitamin B1 supplementation		"{""preferred_term"": ""vitamin B1 supplementation"", ""term"": {""id"": ""MAXO:0010019"", ""label"": ""vitamin B1 supplementation""}}"																											
6059	6702	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	3	Micronutrient supplementation during refeeding	Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome.	treatment_term	treatment_term	$	Micronutrient supplementation during refeeding	Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome.	micronutrient supplementation	MAXO:0001262	micronutrient supplementation		"{""preferred_term"": ""micronutrient supplementation"", ""term"": {""id"": ""MAXO:0001262"", ""label"": ""micronutrient supplementation""}}"																											
6060	6703	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	datasets	0		Microarray dataset of clear cell renal cell carcinoma and matched adjacent normal kidney tissue.	organism	organism	$		Microarray dataset of clear cell renal cell carcinoma and matched adjacent normal kidney tissue.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6061	6703	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	datasets	0		Microarray dataset of clear cell renal cell carcinoma and matched adjacent normal kidney tissue.	sample_types[0]	sample_types	sample_types			kidney tissue				"{""preferred_term"": ""kidney tissue"", ""tissue_term"": {""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}}"																											
6062	6703	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	datasets	0		Microarray dataset of clear cell renal cell carcinoma and matched adjacent normal kidney tissue.	sample_types[0].tissue_term	sample_types	sample_types[0]			kidney	UBERON:0002113	kidney		"{""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
6063	6706	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	phenotypes	0	Hematuria		phenotype_term	phenotype_term	$	Hematuria		Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
6064	6707	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	phenotypes	1	Flank Pain		phenotype_term	phenotype_term	$	Flank Pain		Flank pain	HP:0030157	Flank pain		"{""preferred_term"": ""Flank pain"", ""term"": {""id"": ""HP:0030157"", ""label"": ""Flank pain""}}"																											
6065	6708	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	0	Radical Nephrectomy	Surgical removal of the kidney for localized renal cell carcinoma.	treatment_term	treatment_term	$	Radical Nephrectomy	Surgical removal of the kidney for localized renal cell carcinoma.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6066	6709	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	1	Targeted Systemic Therapy	Molecularly targeted agents used to treat advanced renal cell carcinoma.	treatment_term	treatment_term	$	Targeted Systemic Therapy	Molecularly targeted agents used to treat advanced renal cell carcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6067	6710	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	HIF-2 inhibitor approved for treating renal cell carcinoma.	treatment_term	treatment_term	$	Belzutifan	HIF-2 inhibitor approved for treating renal cell carcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6068	6715	287	Retinoblastoma	Retinoblastoma.yaml	histopathology	0	Intraocular Malignancy	Retinoblastoma is the most common intraocular malignancy.	finding_term	finding_term	$	Intraocular Malignancy	Retinoblastoma is the most common intraocular malignancy.	Retinoblastoma	NCIT:C7541	Retinoblastoma		"{""preferred_term"": ""Retinoblastoma"", ""term"": {""id"": ""NCIT:C7541"", ""label"": ""Retinoblastoma""}}"																											
6069	6716	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	0	RB1 Tumor Suppressor Inactivation	The RB1 gene encodes the retinoblastoma protein (pRB), a critical regulator of the cell cycle. Biallelic RB1 loss removes the constraint on E2F transcription factors, allowing uncontrolled progression through the G1/S checkpoint. Retinoblastoma exemplifies Knudson's two-hit hypothesis: in hereditary cases, one mutation is inherited and the second is somatic; in sporadic cases, both mutations occur somatically in the same cell.	cell_types[0]	cell_types	cell_types			retinal progenitor cell	CL:0002672	retinal progenitor cell		"{""preferred_term"": ""retinal progenitor cell"", ""term"": {""id"": ""CL:0002672"", ""label"": ""retinal progenitor cell""}}"																											
6070	6716	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	0	RB1 Tumor Suppressor Inactivation	The RB1 gene encodes the retinoblastoma protein (pRB), a critical regulator of the cell cycle. Biallelic RB1 loss removes the constraint on E2F transcription factors, allowing uncontrolled progression through the G1/S checkpoint. Retinoblastoma exemplifies Knudson's two-hit hypothesis: in hereditary cases, one mutation is inherited and the second is somatic; in sporadic cases, both mutations occur somatically in the same cell.	biological_processes[0]	biological_processes	biological_processes			G1/S transition of mitotic cell cycle	GO:0000082	G1/S transition of mitotic cell cycle		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0000082"", ""label"": ""G1/S transition of mitotic cell cycle""}}"			ABNORMAL																								
6071	6716	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	0	RB1 Tumor Suppressor Inactivation	The RB1 gene encodes the retinoblastoma protein (pRB), a critical regulator of the cell cycle. Biallelic RB1 loss removes the constraint on E2F transcription factors, allowing uncontrolled progression through the G1/S checkpoint. Retinoblastoma exemplifies Knudson's two-hit hypothesis: in hereditary cases, one mutation is inherited and the second is somatic; in sporadic cases, both mutations occur somatically in the same cell.	locations[0]	locations	locations			retina	UBERON:0000966	retina		"{""preferred_term"": ""retina"", ""term"": {""id"": ""UBERON:0000966"", ""label"": ""retina""}}"																											
6072	6717	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	1	Loss of Cell Cycle Checkpoint Control	pRB normally binds and inhibits E2F transcription factors during G1 phase. When pRB is phosphorylated by cyclin-dependent kinases or functionally lost, E2F is released to activate genes required for S-phase entry, including cyclins, DNA replication factors, and proliferative genes.	biological_processes[0]	biological_processes	biological_processes			cell cycle checkpoint signaling	GO:0000075	cell cycle checkpoint signaling		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell cycle checkpoint signaling"", ""term"": {""id"": ""GO:0000075"", ""label"": ""cell cycle checkpoint signaling""}}"			DECREASED																								
6073	6717	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	1	Loss of Cell Cycle Checkpoint Control	pRB normally binds and inhibits E2F transcription factors during G1 phase. When pRB is phosphorylated by cyclin-dependent kinases or functionally lost, E2F is released to activate genes required for S-phase entry, including cyclins, DNA replication factors, and proliferative genes.	biological_processes[1]	biological_processes	biological_processes			positive regulation of transcription by RNA polymerase II	GO:0045944	positive regulation of transcription by RNA polymerase II		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of transcription by RNA polymerase II"", ""term"": {""id"": ""GO:0045944"", ""label"": ""positive regulation of transcription by RNA polymerase II""}}"			INCREASED																								
6074	6718	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	2	Uncontrolled Retinal Cell Proliferation	Loss of pRB-mediated cell cycle control results in constitutive E2F activity, driving retinal progenitor cells through repeated rounds of DNA replication and cell division. This uncontrolled proliferation leads to tumor formation.	cell_types[0]	cell_types	cell_types			retinal progenitor cell	CL:0002672	retinal progenitor cell		"{""preferred_term"": ""retinal progenitor cell"", ""term"": {""id"": ""CL:0002672"", ""label"": ""retinal progenitor cell""}}"																											
6075	6718	287	Retinoblastoma	Retinoblastoma.yaml	pathophysiology	2	Uncontrolled Retinal Cell Proliferation	Loss of pRB-mediated cell cycle control results in constitutive E2F activity, driving retinal progenitor cells through repeated rounds of DNA replication and cell division. This uncontrolled proliferation leads to tumor formation.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
6076	6719	287	Retinoblastoma	Retinoblastoma.yaml	phenotypes	0	Leukocoria	White pupillary reflex (cat's eye reflex) is the most common presenting sign, resulting from light reflecting off the tumor surface. Often noticed in photographs or by parents.	phenotype_term	phenotype_term	$	Leukocoria	White pupillary reflex (cat's eye reflex) is the most common presenting sign, resulting from light reflecting off the tumor surface. Often noticed in photographs or by parents.	Leukocoria	HP:0000555	Leukocoria		"{""preferred_term"": ""Leukocoria"", ""term"": {""id"": ""HP:0000555"", ""label"": ""Leukocoria""}}"																											
6077	6720	287	Retinoblastoma	Retinoblastoma.yaml	phenotypes	1	Strabismus	Misalignment of the eyes is the second most common presenting sign, occurring when the tumor affects macular vision and disrupts binocular fusion.	phenotype_term	phenotype_term	$	Strabismus	Misalignment of the eyes is the second most common presenting sign, occurring when the tumor affects macular vision and disrupts binocular fusion.	Strabismus	HP:0000486	Strabismus		"{""preferred_term"": ""Strabismus"", ""term"": {""id"": ""HP:0000486"", ""label"": ""Strabismus""}}"																											
6078	6721	287	Retinoblastoma	Retinoblastoma.yaml	phenotypes	2	Decreased Visual Acuity	Vision loss occurs when the tumor involves the macula or becomes large enough to obstruct the visual axis.	phenotype_term	phenotype_term	$	Decreased Visual Acuity	Vision loss occurs when the tumor involves the macula or becomes large enough to obstruct the visual axis.	Decreased visual acuity	HP:0007663	Reduced visual acuity		"{""preferred_term"": ""Decreased visual acuity"", ""term"": {""id"": ""HP:0007663"", ""label"": ""Reduced visual acuity""}}"																											
6079	6722	287	Retinoblastoma	Retinoblastoma.yaml	phenotypes	3	Ocular Pain	Eye pain may occur with advanced disease causing secondary glaucoma or inflammation.	phenotype_term	phenotype_term	$	Ocular Pain	Eye pain may occur with advanced disease causing secondary glaucoma or inflammation.	Eye pain	HP:0200026	Ocular pain		"{""preferred_term"": ""Eye pain"", ""term"": {""id"": ""HP:0200026"", ""label"": ""Ocular pain""}}"																											
6080	6723	287	Retinoblastoma	Retinoblastoma.yaml	phenotypes	4	Secondary Malignancies	Patients with hereditary retinoblastoma have significantly increased risk of secondary cancers, particularly osteosarcoma, soft tissue sarcomas, and melanoma. Risk is increased further by external beam radiation therapy.	phenotype_term	phenotype_term	$	Secondary Malignancies	Patients with hereditary retinoblastoma have significantly increased risk of secondary cancers, particularly osteosarcoma, soft tissue sarcomas, and melanoma. Risk is increased further by external beam radiation therapy.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
6081	6724	287	Retinoblastoma	Retinoblastoma.yaml	treatments	0	Focal Therapy (Laser/Cryotherapy)	Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity.	treatment_term	treatment_term	$	Focal Therapy (Laser/Cryotherapy)	Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity.	laser ablation therapy	MAXO:0000453	laser ablation therapy		"{""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}"																											
6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}]}"				carboplatin; vincristine; etoposide; melphalan	CHEBI:31355; CHEBI:27375; CHEBI:4911; CHEBI:28876																						
6083	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			carboplatin	CHEBI:31355	carboplatin		"{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}"																											
6084	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"																											
6085	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
6086	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			melphalan	CHEBI:28876	melphalan		"{""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}"																											
6087	6726	287	Retinoblastoma	Retinoblastoma.yaml	treatments	2	Enucleation	Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread.	treatment_term	treatment_term	$	Enucleation	Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6088	6727	287	Retinoblastoma	Retinoblastoma.yaml	treatments	3	External Beam Radiation	Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field.	treatment_term	treatment_term	$	External Beam Radiation	Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6089	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	cell_types[0]	cell_types	cell_types			muscle cell	CL:0000187	muscle cell		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""muscle cell"", ""term"": {""id"": ""CL:0000187"", ""label"": ""muscle cell""}}"			ABNORMAL																								
6090	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	cell_types[1]	cell_types	cell_types			sensory neuron	CL:0000101	sensory neuron		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""sensory neuron"", ""term"": {""id"": ""CL:0000101"", ""label"": ""sensory neuron""}}"			ABNORMAL																								
6091	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	biological_processes[0]	biological_processes	biological_processes			regulation of muscle contraction	GO:0006937	regulation of muscle contraction		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of muscle contraction"", ""term"": {""id"": ""GO:0006937"", ""label"": ""regulation of muscle contraction""}}"			ABNORMAL																								
6092	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	biological_processes[1]	biological_processes	biological_processes			skeletal muscle contraction	GO:0003009	skeletal muscle contraction		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""skeletal muscle contraction"", ""term"": {""id"": ""GO:0003009"", ""label"": ""skeletal muscle contraction""}}"			ABNORMAL																								
6093	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	locations[0]	locations	locations			upper esophageal sphincter	UBERON:0007268	upper esophageal sphincter		"{""preferred_term"": ""upper esophageal sphincter"", ""term"": {""id"": ""UBERON:0007268"", ""label"": ""upper esophageal sphincter""}}"																											
6094	6730	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	0	Failure of Upper Esophageal Sphincter Relaxation	The cricopharyngeus muscle, which constitutes the upper esophageal sphincter, fails to relax in response to retrograde esophageal gaseous distension that normally triggers belching. This is a reflex-specific deficit, as deglutitive (swallowing-related) UES relaxation remains intact.	locations[1]	locations	locations			cricopharyngeus muscle	UBERON:0010928	cricopharyngeus muscle		"{""preferred_term"": ""cricopharyngeus muscle"", ""term"": {""id"": ""UBERON:0010928"", ""label"": ""cricopharyngeus muscle""}}"																											
6095	6731	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	1	Elevated Upper Esophageal Sphincter Basal Pressure	Patients with R-CPD have significantly higher resting UES pressure compared to healthy controls, contributing to the inability to release trapped gas.	cell_types[0]	cell_types	cell_types			muscle cell	CL:0000187	muscle cell		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""muscle cell"", ""term"": {""id"": ""CL:0000187"", ""label"": ""muscle cell""}}"			ABNORMAL																								
6096	6731	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	1	Elevated Upper Esophageal Sphincter Basal Pressure	Patients with R-CPD have significantly higher resting UES pressure compared to healthy controls, contributing to the inability to release trapped gas.	biological_processes[0]	biological_processes	biological_processes			muscle contraction	GO:0006936	muscle contraction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""muscle contraction"", ""term"": {""id"": ""GO:0006936"", ""label"": ""muscle contraction""}}"			INCREASED																								
6097	6731	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	pathophysiology	1	Elevated Upper Esophageal Sphincter Basal Pressure	Patients with R-CPD have significantly higher resting UES pressure compared to healthy controls, contributing to the inability to release trapped gas.	locations[0]	locations	locations			upper esophageal sphincter	UBERON:0007268	upper esophageal sphincter		"{""preferred_term"": ""upper esophageal sphincter"", ""term"": {""id"": ""UBERON:0007268"", ""label"": ""upper esophageal sphincter""}}"																											
6098	6732	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	phenotypes	0	Inability to Belch	Complete or near-complete inability to belch (eructate), which is the cardinal feature of R-CPD. Patients cannot voluntarily or reflexively release gas from the esophagus through the pharynx.	phenotype_term	phenotype_term	$	Inability to Belch	Complete or near-complete inability to belch (eructate), which is the cardinal feature of R-CPD. Patients cannot voluntarily or reflexively release gas from the esophagus through the pharynx.	Abnormality of the digestive system	HP:0025031	Abnormality of the digestive system		"{""preferred_term"": ""Abnormality of the digestive system"", ""term"": {""id"": ""HP:0025031"", ""label"": ""Abnormality of the digestive system""}}"																											
6099	6733	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	phenotypes	1	Abdominal Distention	Abdominal bloating and distension due to trapped air that cannot be expelled through belching.	phenotype_term	phenotype_term	$	Abdominal Distention	Abdominal bloating and distension due to trapped air that cannot be expelled through belching.	Abdominal distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
6100	6734	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	phenotypes	2	Chest Pain	Chest discomfort or pain, particularly after eating, related to air entrapment in the esophagus.	phenotype_term	phenotype_term	$	Chest Pain	Chest discomfort or pain, particularly after eating, related to air entrapment in the esophagus.	Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
6101	6735	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	phenotypes	3	Nausea	Nausea, often occurring after meals due to air entrapment and inability to release gastric gas.	phenotype_term	phenotype_term	$	Nausea	Nausea, often occurring after meals due to air entrapment and inability to release gastric gas.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
6102	6736	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	phenotypes	4	Gurgling Sounds	Socially awkward gurgling noises from the chest and lower neck as the esophagus churns attempting to expel trapped air.	phenotype_term	phenotype_term	$	Gurgling Sounds	Socially awkward gurgling noises from the chest and lower neck as the esophagus churns attempting to expel trapped air.	Abnormality of the digestive system	HP:0025031	Abnormality of the digestive system		"{""preferred_term"": ""Abnormality of the digestive system"", ""term"": {""id"": ""HP:0025031"", ""label"": ""Abnormality of the digestive system""}}"																											
6103	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	Botulinum Toxin Injection	Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch.	treatment_term	treatment_term	$	Botulinum Toxin Injection	Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch.	botulinum toxin type A therapy	MAXO:0009016	botulinum toxin type A therapy		"{""preferred_term"": ""botulinum toxin type A therapy"", ""term"": {""id"": ""MAXO:0009016"", ""label"": ""botulinum toxin type A therapy""}}"																											
6104	6742	289	Rett Syndrome	Rett_Syndrome.yaml	pathophysiology	0	MECP2 Dysfunction	"Mutations in MECP2 gene cause loss of methyl-CpG-binding protein 2 function. MECP2 is a transcriptional regulator that binds methylated DNA and modulates gene expression critical for neuronal maturation and synaptic function.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6105	6742	289	Rett Syndrome	Rett_Syndrome.yaml	pathophysiology	0	MECP2 Dysfunction	"Mutations in MECP2 gene cause loss of methyl-CpG-binding protein 2 function. MECP2 is a transcriptional regulator that binds methylated DNA and modulates gene expression critical for neuronal maturation and synaptic function.
"	biological_processes[0]	biological_processes	biological_processes			Gene Expression Regulation	GO:0010468	regulation of gene expression		"{""preferred_term"": ""Gene Expression Regulation"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"																											
6106	6743	289	Rett Syndrome	Rett_Syndrome.yaml	pathophysiology	1	Abnormal Neuronal Development	"Loss of MECP2 leads to reduced dendritic arborization, decreased synapse formation, and impaired synaptic plasticity. Neurons have smaller cell bodies and reduced connectivity, particularly affecting inhibitory circuits.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6107	6743	289	Rett Syndrome	Rett_Syndrome.yaml	pathophysiology	1	Abnormal Neuronal Development	"Loss of MECP2 leads to reduced dendritic arborization, decreased synapse formation, and impaired synaptic plasticity. Neurons have smaller cell bodies and reduced connectivity, particularly affecting inhibitory circuits.
"	biological_processes[0]	biological_processes	biological_processes			Synaptic Transmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""Synaptic Transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
6108	6744	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	0	Developmental Regression		phenotype_term	phenotype_term	$	Developmental Regression		Developmental Regression	HP:0002376	Developmental regression		"{""preferred_term"": ""Developmental Regression"", ""term"": {""id"": ""HP:0002376"", ""label"": ""Developmental regression""}}"																											
6109	6745	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	1	Stereotypical Hand Movements		phenotype_term	phenotype_term	$	Stereotypical Hand Movements		Stereotypical Hand Wringing	HP:0012171	Stereotypical hand wringing		"{""preferred_term"": ""Stereotypical Hand Wringing"", ""term"": {""id"": ""HP:0012171"", ""label"": ""Stereotypical hand wringing""}}"																											
6110	6746	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	2	Gait Abnormalities		phenotype_term	phenotype_term	$	Gait Abnormalities		Gait Ataxia	HP:0002066	Gait ataxia		"{""preferred_term"": ""Gait Ataxia"", ""term"": {""id"": ""HP:0002066"", ""label"": ""Gait ataxia""}}"																											
6111	6747	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	3	Secondary Microcephaly		phenotype_term	phenotype_term	$	Secondary Microcephaly		Secondary Microcephaly	HP:0005484	Secondary microcephaly		"{""preferred_term"": ""Secondary Microcephaly"", ""term"": {""id"": ""HP:0005484"", ""label"": ""Secondary microcephaly""}}"																											
6112	6748	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	4	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6113	6749	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	5	Breathing Abnormalities		phenotype_term	phenotype_term	$	Breathing Abnormalities		Abnormal Breathing Pattern	HP:0005957	Breathing dysregulation		"{""preferred_term"": ""Abnormal Breathing Pattern"", ""term"": {""id"": ""HP:0005957"", ""label"": ""Breathing dysregulation""}}"																											
6114	6750	289	Rett Syndrome	Rett_Syndrome.yaml	phenotypes	6	Scoliosis		phenotype_term	phenotype_term	$	Scoliosis		Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
6115	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[0].inclusion_criteria[0]	criteria_sets	criteria_sets[0].inclusion_criteria			Rheumatoid arthritis concept set (condition + observation)			OHDSI RA concept set of 15 concepts used in condition and observation domains.	"{""description"": ""OHDSI RA concept set of 15 concepts used in condition and observation domains."", ""preferred_term"": ""Rheumatoid arthritis concept set (condition + observation)""}"																											
6116	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[0].inclusion_criteria[1]	criteria_sets	criteria_sets[0].inclusion_criteria			First occurrence in history			Index date is the first RA event in the patient's history.	"{""description"": ""Index date is the first RA event in the patient's history."", ""preferred_term"": ""First occurrence in history""}"																											
6117	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[0].inclusion_criteria[2]	criteria_sets	criteria_sets[0].inclusion_criteria			Cohort exit at end of observation			Cohort end is the end of continuous observation.	"{""description"": ""Cohort end is the end of continuous observation."", ""preferred_term"": ""Cohort exit at end of observation""}"																											
6118	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[1].inclusion_criteria[0]	criteria_sets	criteria_sets[1].inclusion_criteria			Rheumatoid arthritis concept set (condition + observation)			OHDSI RA concept set of 15 concepts used in condition and observation domains.	"{""description"": ""OHDSI RA concept set of 15 concepts used in condition and observation domains."", ""preferred_term"": ""Rheumatoid arthritis concept set (condition + observation)""}"																											
6119	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[1].inclusion_criteria[1]	criteria_sets	criteria_sets[1].inclusion_criteria			Confirming RA event			Second RA diagnosis or observation code 31 to 365 days after index.	"{""description"": ""Second RA diagnosis or observation code 31 to 365 days after index."", ""preferred_term"": ""Confirming RA event""}"																											
6120	6760	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	definitions	0	OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis	OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.	criteria_sets[1].inclusion_criteria[2]	criteria_sets	criteria_sets[1].inclusion_criteria			Cohort exit at end of observation			Cohort end is the end of continuous observation.	"{""description"": ""Cohort end is the end of continuous observation."", ""preferred_term"": ""Cohort exit at end of observation""}"																											
6121	6761	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	environmental	0	Smoking		exposure_term	exposure_term	$	Smoking		Tobacco smoking exposure	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""Tobacco smoking exposure"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
6122	6762	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	environmental	1	Infections		exposure_term	exposure_term	$	Infections		Infectious agent exposure	ECTO:3000000	exposure to organism		"{""preferred_term"": ""Infectious agent exposure"", ""term"": {""id"": ""ECTO:3000000"", ""label"": ""exposure to organism""}}"																											
6123	6775	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	0	Autoimmune Response	The immune system mistakenly attacks the body's own tissues, particularly the synovial membrane lining the joints.	cell_types[0]	cell_types	cell_types			Th17 Cell	CL:0000899	T-helper 17 cell		"{""preferred_term"": ""Th17 Cell"", ""term"": {""id"": ""CL:0000899"", ""label"": ""T-helper 17 cell""}}"																											
6124	6776	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	1	Inflammatory Cytokine Production	Overproduction of inflammatory cytokines like TNF-, IL-1, and IL-6 leads to joint inflammation and damage.	biological_processes[0]	biological_processes	biological_processes			cytokine production	GO:0001816	cytokine production		"{""preferred_term"": ""cytokine production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"																											
6125	6776	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	1	Inflammatory Cytokine Production	Overproduction of inflammatory cytokines like TNF-, IL-1, and IL-6 leads to joint inflammation and damage.	locations[0]	locations	locations			synovial membrane	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
6126	6777	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	2	Synovial Hyperplasia	The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.	cell_types[0]	cell_types	cell_types			Synoviocyte	CL:0000214	synovial cell		"{""preferred_term"": ""Synoviocyte"", ""term"": {""id"": ""CL:0000214"", ""label"": ""synovial cell""}}"																											
6127	6777	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	2	Synovial Hyperplasia	The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6128	6777	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	2	Synovial Hyperplasia	The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.	locations[0]	locations	locations			synovial membrane	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
6129	6778	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	3	Cartilage and Bone Destruction	Chronic inflammation and pannus formation lead to the erosion of articular cartilage and underlying bone.	locations[0]	locations	locations			synovial joint	UBERON:0002217	synovial joint		"{""preferred_term"": ""synovial joint"", ""term"": {""id"": ""UBERON:0002217"", ""label"": ""synovial joint""}}"																											
6130	6778	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	3	Cartilage and Bone Destruction	Chronic inflammation and pannus formation lead to the erosion of articular cartilage and underlying bone.	locations[1]	locations	locations			articular cartilage	UBERON:0003676	articular cartilage tissue		"{""preferred_term"": ""articular cartilage"", ""term"": {""id"": ""UBERON:0003676"", ""label"": ""articular cartilage tissue""}}"																											
6131	6779	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	4	JAK/STAT Signaling	The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.	biological_processes[0]	biological_processes	biological_processes			cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway		"{""preferred_term"": ""cytokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"																											
6132	6779	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	4	JAK/STAT Signaling	The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
6133	6779	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	4	JAK/STAT Signaling	The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6134	6779	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	4	JAK/STAT Signaling	The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.	locations[0]	locations	locations			synovial membrane	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
6135	6780	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	5	NF-B Activation	NF-B transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.	biological_processes[0]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
6136	6780	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	5	NF-B Activation	NF-B transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.	biological_processes[1]	biological_processes	biological_processes			cytokine production	GO:0001816	cytokine production		"{""preferred_term"": ""cytokine production"", ""term"": {""id"": ""GO:0001816"", ""label"": ""cytokine production""}}"																											
6137	6780	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	5	NF-B Activation	NF-B transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
6138	6780	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	5	NF-B Activation	NF-B transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6139	6781	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	6	Neutrophil Extracellular Trap Formation	Neutrophils release extracellular traps containing citrullinated histones and autoantigens via PAD4-mediated citrullination, amplifying autoimmunity.	cell_types[0]	cell_types	cell_types			Neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""Neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6140	6781	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	6	Neutrophil Extracellular Trap Formation	Neutrophils release extracellular traps containing citrullinated histones and autoantigens via PAD4-mediated citrullination, amplifying autoimmunity.	biological_processes[0]	biological_processes	biological_processes			immune response	GO:0006955	immune response		"{""preferred_term"": ""immune response"", ""term"": {""id"": ""GO:0006955"", ""label"": ""immune response""}}"																											
6141	6782	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	7	B Cell and Plasma Cell Responses	B cells and plasma cells generate autoantibodies (ACPA, RF) locally within synovium and at mucosal sites, forming ectopic lymphoid structures.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6142	6782	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	7	B Cell and Plasma Cell Responses	B cells and plasma cells generate autoantibodies (ACPA, RF) locally within synovium and at mucosal sites, forming ectopic lymphoid structures.	cell_types[1]	cell_types	cell_types			Plasma cell	CL:0000786	plasma cell		"{""preferred_term"": ""Plasma cell"", ""term"": {""id"": ""CL:0000786"", ""label"": ""plasma cell""}}"																											
6143	6782	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	7	B Cell and Plasma Cell Responses	B cells and plasma cells generate autoantibodies (ACPA, RF) locally within synovium and at mucosal sites, forming ectopic lymphoid structures.	locations[0]	locations	locations			synovial membrane	UBERON:0002018	synovial membrane of synovial joint		"{""preferred_term"": ""synovial membrane"", ""term"": {""id"": ""UBERON:0002018"", ""label"": ""synovial membrane of synovial joint""}}"																											
6144	6783	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	8	Mucosal Origins and Dysbiosis	Aberrant immune activation in lung, oral, and gut mucosa precedes systemic autoimmunity, driven by dysbiosis, epithelial barrier dysfunction, and local citrullination.	locations[0]	locations	locations			respiratory system mucosa	UBERON:0004785	respiratory system mucosa		"{""preferred_term"": ""respiratory system mucosa"", ""term"": {""id"": ""UBERON:0004785"", ""label"": ""respiratory system mucosa""}}"																											
6145	6783	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	8	Mucosal Origins and Dysbiosis	Aberrant immune activation in lung, oral, and gut mucosa precedes systemic autoimmunity, driven by dysbiosis, epithelial barrier dysfunction, and local citrullination.	locations[1]	locations	locations			oral mucosa	UBERON:0003343	oral mucosa		"{""preferred_term"": ""oral mucosa"", ""term"": {""id"": ""UBERON:0003343"", ""label"": ""oral mucosa""}}"																											
6146	6783	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	pathophysiology	8	Mucosal Origins and Dysbiosis	Aberrant immune activation in lung, oral, and gut mucosa precedes systemic autoimmunity, driven by dysbiosis, epithelial barrier dysfunction, and local citrullination.	locations[2]	locations	locations			intestinal mucosa	UBERON:0001277	intestinal mucosa		"{""preferred_term"": ""intestinal mucosa"", ""term"": {""id"": ""UBERON:0001277"", ""label"": ""intestinal mucosa""}}"																											
6147	6784	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	0	Symmetric Polyarthritis		phenotype_term	phenotype_term	$	Symmetric Polyarthritis		Symmetric Polyarthritis	HP:0040311	Symmetric polyarthritis		"{""preferred_term"": ""Symmetric Polyarthritis"", ""term"": {""id"": ""HP:0040311"", ""label"": ""Symmetric polyarthritis""}}"																											
6148	6785	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	1	Morning Stiffness		phenotype_term	phenotype_term	$	Morning Stiffness		Morning Stiffness	HP:0005197	Generalized morning stiffness		"{""preferred_term"": ""Morning Stiffness"", ""term"": {""id"": ""HP:0005197"", ""label"": ""Generalized morning stiffness""}}"																											
6149	6786	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	2	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6150	6792	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	8	Scleritis		phenotype_term	phenotype_term	$	Scleritis		Scleritis	HP:0100532	Scleritis		"{""preferred_term"": ""Scleritis"", ""term"": {""id"": ""HP:0100532"", ""label"": ""Scleritis""}}"																											
6151	6793	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	9	Pericarditis		phenotype_term	phenotype_term	$	Pericarditis		Pericarditis	HP:0001701	Pericarditis		"{""preferred_term"": ""Pericarditis"", ""term"": {""id"": ""HP:0001701"", ""label"": ""Pericarditis""}}"																											
6152	6795	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	11	Joint Deformity		phenotype_term	phenotype_term	$	Joint Deformity		Joint Deformity	HP:0001367	Abnormal joint morphology		"{""preferred_term"": ""Joint Deformity"", ""term"": {""id"": ""HP:0001367"", ""label"": ""Abnormal joint morphology""}}"																											
6153	6796	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	12	Reduced Mobility		phenotype_term	phenotype_term	$	Reduced Mobility		Reduced Mobility	HP:0001288	Gait disturbance		"{""preferred_term"": ""Reduced Mobility"", ""term"": {""id"": ""HP:0001288"", ""label"": ""Gait disturbance""}}"																											
6154	6797	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	13	Joint Swelling		phenotype_term	phenotype_term	$	Joint Swelling		Joint swelling	HP:0001386	Joint swelling		"{""preferred_term"": ""Joint swelling"", ""term"": {""id"": ""HP:0001386"", ""label"": ""Joint swelling""}}"																											
6155	6798	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	phenotypes	14	Erosive Arthritis		phenotype_term	phenotype_term	$	Erosive Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
6156	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduce pain and inflammation.	treatment_term	treatment_term	$	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduce pain and inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6157	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	Disease-Modifying Antirheumatic Drugs (DMARDs)	Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).	treatment_term	treatment_term	$	Disease-Modifying Antirheumatic Drugs (DMARDs)	Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6158	6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	Biologics	Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors).	treatment_term	treatment_term	$	Biologics	Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6159	6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	Glucocorticoids	Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.	treatment_term	treatment_term	$	Glucocorticoids	Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6160	6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	Physical Therapy	Maintains joint mobility and strengthens surrounding muscles.	treatment_term	treatment_term	$	Physical Therapy	Maintains joint mobility and strengthens surrounding muscles.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
6161	6812	291	Roifman-syndrome	Roifman-syndrome.yaml	pathophysiology	1	Decreased NK Cell Function		cell_types[0]	cell_types	cell_types			NK Cell	CL:0000623	natural killer cell		"{""preferred_term"": ""NK Cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
6162	6813	291	Roifman-syndrome	Roifman-syndrome.yaml	pathophysiology	2	Decreased total and memory B cells		cell_types[0]	cell_types	cell_types			Memory B cell	CL:0000787	memory B cell		"{""preferred_term"": ""Memory B cell"", ""term"": {""id"": ""CL:0000787"", ""label"": ""memory B cell""}}"																											
6163	6815	291	Roifman-syndrome	Roifman-syndrome.yaml	phenotypes	0	Recurrent Infections		phenotype_term	phenotype_term	$	Recurrent Infections		Recurrent Infections	HP:0002719	Recurrent infections		"{""preferred_term"": ""Recurrent Infections"", ""term"": {""id"": ""HP:0002719"", ""label"": ""Recurrent infections""}}"																											
6164	6816	291	Roifman-syndrome	Roifman-syndrome.yaml	phenotypes	1	Growth Retardation		phenotype_term	phenotype_term	$	Growth Retardation		Growth Retardation	HP:0001510	Growth delay		"{""preferred_term"": ""Growth Retardation"", ""term"": {""id"": ""HP:0001510"", ""label"": ""Growth delay""}}"																											
6165	6817	291	Roifman-syndrome	Roifman-syndrome.yaml	phenotypes	2	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual Disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual Disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
6166	6819	291	Roifman-syndrome	Roifman-syndrome.yaml	phenotypes	4	Strabismus		phenotype_term	phenotype_term	$	Strabismus		Strabismus	HP:0000486	Strabismus		"{""preferred_term"": ""Strabismus"", ""term"": {""id"": ""HP:0000486"", ""label"": ""Strabismus""}}"																											
6167	6822	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	0	Immunoglobulin Replacement Therapy	Regular infusions to prevent infections.	treatment_term	treatment_term	$	Immunoglobulin Replacement Therapy	Regular infusions to prevent infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6168	6823	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	1	Antibiotic Prophylaxis	Preventative antibiotic treatment to reduce infection risk.	treatment_term	treatment_term	$	Antibiotic Prophylaxis	Preventative antibiotic treatment to reduce infection risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6169	6824	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	2	Growth Hormone Therapy	May be used to address growth retardation.	treatment_term	treatment_term	$	Growth Hormone Therapy	May be used to address growth retardation.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
6170	6825	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	3	Supportive Educational Programs	Tailored to address intellectual disability and developmental delays.	treatment_term	treatment_term	$	Supportive Educational Programs	Tailored to address intellectual disability and developmental delays.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6171	6826	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	4	Surgical Interventions	For severe skeletal or craniofacial abnormalities.	treatment_term	treatment_term	$	Surgical Interventions	For severe skeletal or craniofacial abnormalities.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6172	6827	292	SADDAN	SADDAN.yaml	genetic	0	FGFR3 K650M mutation		gene_term	gene_term	$	FGFR3 K650M mutation		FGFR3	hgnc:3690	FGFR3		"{""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"																											
6173	6829	292	SADDAN	SADDAN.yaml	pathophysiology	0	FGFR3 p.Lys650Met mutation	"A single missense mutation at codon 650 (p.Lys650Met) in FGFR3 causes SADDAN.
"	gene	gene	$	FGFR3 p.Lys650Met mutation	"A single missense mutation at codon 650 (p.Lys650Met) in FGFR3 causes SADDAN.
"	FGFR3	hgnc:3690	FGFR3		"{""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"																											
6174	6830	292	SADDAN	SADDAN.yaml	pathophysiology	1	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	gene	gene	$	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	FGFR3	hgnc:3690	FGFR3		"{""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"																											
6175	6830	292	SADDAN	SADDAN.yaml	pathophysiology	1	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	biological_processes[0]	biological_processes	biological_processes			protein tyrosine kinase activity	GO:0004713	protein tyrosine kinase activity		"{""modifier"": ""INCREASED"", ""preferred_term"": ""protein tyrosine kinase activity"", ""term"": {""id"": ""GO:0004713"", ""label"": ""protein tyrosine kinase activity""}}"			INCREASED																								
6176	6830	292	SADDAN	SADDAN.yaml	pathophysiology	1	Constitutive FGFR3 kinase activity	"The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
"	biological_processes[1]	biological_processes	biological_processes			fibroblast growth factor receptor signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""fibroblast growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"			INCREASED																								
6177	6831	292	SADDAN	SADDAN.yaml	pathophysiology	2	Severe disturbances in endochondral bone growth	"The Lys650Met mutation results in severe disturbances in endochondral bone growth.
"	cell_types[0]	cell_types	cell_types			Growth plate chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth plate chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
6178	6832	292	SADDAN	SADDAN.yaml	phenotypes	0	Severe short stature	"Severe disproportionate short stature, more severe than achondroplasia but with potential for survival beyond the neonatal period.
"	phenotype_term	phenotype_term	$	Severe short stature	"Severe disproportionate short stature, more severe than achondroplasia but with potential for survival beyond the neonatal period.
"	Severe short stature	HP:0003510	Severe short stature		"{""preferred_term"": ""Severe short stature"", ""term"": {""id"": ""HP:0003510"", ""label"": ""Severe short stature""}}"																											
6179	6833	292	SADDAN	SADDAN.yaml	phenotypes	1	Developmental delay	"Delayed developmental milestones and intellectual disability are characteristic features that distinguish SADDAN from achondroplasia and thanatophoric dysplasia.
"	phenotype_term	phenotype_term	$	Developmental delay	"Delayed developmental milestones and intellectual disability are characteristic features that distinguish SADDAN from achondroplasia and thanatophoric dysplasia.
"	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
6180	6834	292	SADDAN	SADDAN.yaml	phenotypes	2	Acanthosis nigricans	"Hyperpigmented, velvety, thickened skin typically in flexural areas (neck, axillae, groin). This distinctive skin finding is not seen in achondroplasia or thanatophoric dysplasia and is part of the defining features of SADDAN.
"	phenotype_term	phenotype_term	$	Acanthosis nigricans	"Hyperpigmented, velvety, thickened skin typically in flexural areas (neck, axillae, groin). This distinctive skin finding is not seen in achondroplasia or thanatophoric dysplasia and is part of the defining features of SADDAN.
"	Acanthosis nigricans	HP:0000956	Acanthosis nigricans		"{""preferred_term"": ""Acanthosis nigricans"", ""term"": {""id"": ""HP:0000956"", ""label"": ""Acanthosis nigricans""}}"																											
6181	6835	292	SADDAN	SADDAN.yaml	phenotypes	3	Seizures	Seizures reported in surviving SADDAN patients.	phenotype_term	phenotype_term	$	Seizures	Seizures reported in surviving SADDAN patients.	Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6182	6836	292	SADDAN	SADDAN.yaml	phenotypes	4	Hearing loss	Hearing loss reported in SADDAN.	phenotype_term	phenotype_term	$	Hearing loss	Hearing loss reported in SADDAN.	Hearing loss	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing loss"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
6183	6837	292	SADDAN	SADDAN.yaml	phenotypes	5	Hydranencephaly	Absence of a cerebral hemisphere reported in a SADDAN case.	phenotype_term	phenotype_term	$	Hydranencephaly	Absence of a cerebral hemisphere reported in a SADDAN case.	Hydranencephaly	HP:0002324	Hydranencephaly		"{""preferred_term"": ""Hydranencephaly"", ""term"": {""id"": ""HP:0002324"", ""label"": ""Hydranencephaly""}}"																											
6184	6838	292	SADDAN	SADDAN.yaml	phenotypes	6	Ventriculomegaly	Ventricular dilatation reported in a SADDAN case.	phenotype_term	phenotype_term	$	Ventriculomegaly	Ventricular dilatation reported in a SADDAN case.	Ventriculomegaly	HP:0002119	Ventriculomegaly		"{""preferred_term"": ""Ventriculomegaly"", ""term"": {""id"": ""HP:0002119"", ""label"": ""Ventriculomegaly""}}"																											
6185	6839	292	SADDAN	SADDAN.yaml	phenotypes	7	Femoral bowing	Femoral bowing is reported in some patients with SADDAN.	phenotype_term	phenotype_term	$	Femoral bowing	Femoral bowing is reported in some patients with SADDAN.	Femoral bowing	HP:0002980	Femoral bowing		"{""preferred_term"": ""Femoral bowing"", ""term"": {""id"": ""HP:0002980"", ""label"": ""Femoral bowing""}}"																											
6186	6840	292	SADDAN	SADDAN.yaml	phenotypes	8	Tibial bowing	Tibial bowing is reported in some patients with SADDAN.	phenotype_term	phenotype_term	$	Tibial bowing	Tibial bowing is reported in some patients with SADDAN.	Tibial bowing	HP:0002982	Tibial bowing		"{""preferred_term"": ""Tibial bowing"", ""term"": {""id"": ""HP:0002982"", ""label"": ""Tibial bowing""}}"																											
6187	6841	292	SADDAN	SADDAN.yaml	phenotypes	9	Fibular bowing	Fibular bowing is reported in some patients with SADDAN.	phenotype_term	phenotype_term	$	Fibular bowing	Fibular bowing is reported in some patients with SADDAN.	Fibular bowing	HP:0010502	Fibular bowing		"{""preferred_term"": ""Fibular bowing"", ""term"": {""id"": ""HP:0010502"", ""label"": ""Fibular bowing""}}"																											
6188	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term	treatment_term	$	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}]}"				growth hormone	CHEBI:37845																						
6189	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			growth hormone	CHEBI:37845	growth hormone		"{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}"																											
6190	6843	293	Salla Disease	Salla_Disease.yaml	biochemical	0	Free Sialic Acid		biomarker_term	biomarker_term	$	Free Sialic Acid		N-acetylneuraminic acid	CHEBI:17012	N-acetylneuraminic acid		"{""preferred_term"": ""N-acetylneuraminic acid"", ""term"": {""id"": ""CHEBI:17012"", ""label"": ""N-acetylneuraminic acid""}}"																											
6191	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	organism	organism	$		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6192	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	sample_types[0]	sample_types	sample_types			Neuron				"{""cell_type_term"": {""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}, ""preferred_term"": ""Neuron""}"																											
6193	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	sample_types[0].cell_type_term	sample_types	sample_types[0]			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6194	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	sample_types[1]	sample_types	sample_types			Astrocyte				"{""cell_type_term"": {""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}, ""preferred_term"": ""Astrocyte""}"																											
6195	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	sample_types[1].cell_type_term	sample_types	sample_types[1]			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
6196	6845	293	Salla Disease	Salla_Disease.yaml	datasets	0		"Transcriptomic analysis of iPSC-derived neural cell types (radial glial cells, astrocytes, neurons) from FSASD patients and healthy controls. Identifies dysregulated glycosphingolipid metabolism genes, elevated lysosomal glycohydrolase activities, and differential expression patterns in mature astrocytes.
"	genes[0]	genes	genes			SLC17A5	hgnc:10933	SLC17A5		"{""preferred_term"": ""SLC17A5"", ""term"": {""id"": ""hgnc:10933"", ""label"": ""SLC17A5""}}"																											
6197	6846	293	Salla Disease	Salla_Disease.yaml	differential_diagnoses	0	Infantile Free Sialic Acid Storage Disorder	Most severe form of FSASD with earlier onset (typically first weeks to months of life), rapid neurodegeneration, and shortened lifespan. Presents with severe hypotonia and profound developmental impairment, often fatal by early childhood.	disease_term	disease_term	$	Infantile Free Sialic Acid Storage Disorder	Most severe form of FSASD with earlier onset (typically first weeks to months of life), rapid neurodegeneration, and shortened lifespan. Presents with severe hypotonia and profound developmental impairment, often fatal by early childhood.	Infantile free sialic acid storage disease	MONDO:0010027	free sialic acid storage disease, infantile form		"{""preferred_term"": ""Infantile free sialic acid storage disease"", ""term"": {""id"": ""MONDO:0010027"", ""label"": ""free sialic acid storage disease, infantile form""}}"																											
6198	6847	293	Salla Disease	Salla_Disease.yaml	differential_diagnoses	1	Niemann-Pick Disease Type C	Lysosomal storage disorder with overlapping neurological manifestations including developmental delay, hypotonia, ataxia, and white matter abnormalities on MRI.	disease_term	disease_term	$	Niemann-Pick Disease Type C	Lysosomal storage disorder with overlapping neurological manifestations including developmental delay, hypotonia, ataxia, and white matter abnormalities on MRI.	Niemann-Pick disease type C	MONDO:0009757	Niemann-Pick disease, type C1		"{""preferred_term"": ""Niemann-Pick disease type C"", ""term"": {""id"": ""MONDO:0009757"", ""label"": ""Niemann-Pick disease, type C1""}}"																											
6199	6848	293	Salla Disease	Salla_Disease.yaml	genetic	0	SLC17A5		gene_term	gene_term	$	SLC17A5		SLC17A5	hgnc:10933	SLC17A5		"{""preferred_term"": ""SLC17A5"", ""term"": {""id"": ""hgnc:10933"", ""label"": ""SLC17A5""}}"																											
6200	6851	293	Salla Disease	Salla_Disease.yaml	pathophysiology	0	SLC17A5 Gene Mutation	Biallelic pathogenic variants in SLC17A5 disrupt the coding or regulatory regions necessary for sialin protein function. The c.115C>T (p.Arg39Cys) Finnish founder mutation is the most common variant in Salla disease.	gene	gene	$	SLC17A5 Gene Mutation	Biallelic pathogenic variants in SLC17A5 disrupt the coding or regulatory regions necessary for sialin protein function. The c.115C>T (p.Arg39Cys) Finnish founder mutation is the most common variant in Salla disease.	SLC17A5	hgnc:10933	SLC17A5		"{""preferred_term"": ""SLC17A5"", ""term"": {""id"": ""hgnc:10933"", ""label"": ""SLC17A5""}}"																											
6201	6852	293	Salla Disease	Salla_Disease.yaml	pathophysiology	1	Loss of Sialin Protein Function	SLC17A5 mutations result in loss or substantial reduction of sialin protein expression or function. Sialin is a 12-transmembrane transporter required for proton-coupled export of free sialic acid (Neu5Ac) from lysosomes to cytosol. Mutations can occur as de novo, inherited biallelic variants, or in mosaic patterns affecting specific tissues.	biological_processes[0]	biological_processes	biological_processes			Sialic acid transport	GO:0015739	sialic acid transport		"{""modifier"": ""DECREASED"", ""preferred_term"": ""Sialic acid transport"", ""term"": {""id"": ""GO:0015739"", ""label"": ""sialic acid transport""}}"			DECREASED																								
6202	6854	293	Salla Disease	Salla_Disease.yaml	pathophysiology	3	Glycosphingolipid Metabolic Dysregulation	Impaired sialic acid export triggers secondary alterations in glycosphingolipid (GSL) metabolism in neural cells. Elevated lysosomal glycohydrolase activities and altered GSL composition observed in patient-derived iPSC neural models and in CSF and plasma of patients. Mature astrocytes show the most pronounced alterations.	cell_types[0]	cell_types	cell_types			Oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""Oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
6203	6854	293	Salla Disease	Salla_Disease.yaml	pathophysiology	3	Glycosphingolipid Metabolic Dysregulation	Impaired sialic acid export triggers secondary alterations in glycosphingolipid (GSL) metabolism in neural cells. Elevated lysosomal glycohydrolase activities and altered GSL composition observed in patient-derived iPSC neural models and in CSF and plasma of patients. Mature astrocytes show the most pronounced alterations.	cell_types[1]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6204	6854	293	Salla Disease	Salla_Disease.yaml	pathophysiology	3	Glycosphingolipid Metabolic Dysregulation	Impaired sialic acid export triggers secondary alterations in glycosphingolipid (GSL) metabolism in neural cells. Elevated lysosomal glycohydrolase activities and altered GSL composition observed in patient-derived iPSC neural models and in CSF and plasma of patients. Mature astrocytes show the most pronounced alterations.	cell_types[2]	cell_types	cell_types			Astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""Astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
6205	6854	293	Salla Disease	Salla_Disease.yaml	pathophysiology	3	Glycosphingolipid Metabolic Dysregulation	Impaired sialic acid export triggers secondary alterations in glycosphingolipid (GSL) metabolism in neural cells. Elevated lysosomal glycohydrolase activities and altered GSL composition observed in patient-derived iPSC neural models and in CSF and plasma of patients. Mature astrocytes show the most pronounced alterations.	biological_processes[0]	biological_processes	biological_processes			Glycosphingolipid metabolic process	GO:0006687	glycosphingolipid metabolic process		"{""preferred_term"": ""Glycosphingolipid metabolic process"", ""term"": {""id"": ""GO:0006687"", ""label"": ""glycosphingolipid metabolic process""}}"																											
6206	6854	293	Salla Disease	Salla_Disease.yaml	pathophysiology	3	Glycosphingolipid Metabolic Dysregulation	Impaired sialic acid export triggers secondary alterations in glycosphingolipid (GSL) metabolism in neural cells. Elevated lysosomal glycohydrolase activities and altered GSL composition observed in patient-derived iPSC neural models and in CSF and plasma of patients. Mature astrocytes show the most pronounced alterations.	biological_processes[1]	biological_processes	biological_processes			Myelination	GO:0042552	myelination		"{""preferred_term"": ""Myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
6207	6855	293	Salla Disease	Salla_Disease.yaml	pathophysiology	4	Oligodendroglial Dysfunction and Hypomyelination	Oligodendrocytes vulnerable to sialic acid accumulation and GSL dysregulation. This leads to impaired myelin formation and white matter hypomyelination, reflected in corpus callosum hypoplasia and white matter abnormalities on MRI.	cell_types[0]	cell_types	cell_types			Oligodendrocyte	CL:0000128	oligodendrocyte		"{""preferred_term"": ""Oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
6208	6855	293	Salla Disease	Salla_Disease.yaml	pathophysiology	4	Oligodendroglial Dysfunction and Hypomyelination	Oligodendrocytes vulnerable to sialic acid accumulation and GSL dysregulation. This leads to impaired myelin formation and white matter hypomyelination, reflected in corpus callosum hypoplasia and white matter abnormalities on MRI.	biological_processes[0]	biological_processes	biological_processes			Myelination	GO:0042552	myelination		"{""preferred_term"": ""Myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
6209	6855	293	Salla Disease	Salla_Disease.yaml	pathophysiology	4	Oligodendroglial Dysfunction and Hypomyelination	Oligodendrocytes vulnerable to sialic acid accumulation and GSL dysregulation. This leads to impaired myelin formation and white matter hypomyelination, reflected in corpus callosum hypoplasia and white matter abnormalities on MRI.	biological_processes[1]	biological_processes	biological_processes			CNS myelination	GO:0022010	central nervous system myelination		"{""preferred_term"": ""CNS myelination"", ""term"": {""id"": ""GO:0022010"", ""label"": ""central nervous system myelination""}}"																											
6210	6856	293	Salla Disease	Salla_Disease.yaml	pathophysiology	5	Neuronal Dysfunction and Neurodegeneration	Neurons accumulate free sialic acid and display altered GSL composition. Biochemical changes contribute to progressive neurodegeneration, manifesting as developmental delay, cognitive impairment, and progressive neurological regression.	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6211	6856	293	Salla Disease	Salla_Disease.yaml	pathophysiology	5	Neuronal Dysfunction and Neurodegeneration	Neurons accumulate free sialic acid and display altered GSL composition. Biochemical changes contribute to progressive neurodegeneration, manifesting as developmental delay, cognitive impairment, and progressive neurological regression.	biological_processes[0]	biological_processes	biological_processes			Glycosphingolipid metabolic process	GO:0006687	glycosphingolipid metabolic process		"{""preferred_term"": ""Glycosphingolipid metabolic process"", ""term"": {""id"": ""GO:0006687"", ""label"": ""glycosphingolipid metabolic process""}}"																											
6212	6857	293	Salla Disease	Salla_Disease.yaml	phenotypes	0	Intellectual Disability	Progressive cognitive impairment ranging from mild to severe, with variable onset and progression depending on disease severity.	phenotype_term	phenotype_term	$	Intellectual Disability	Progressive cognitive impairment ranging from mild to severe, with variable onset and progression depending on disease severity.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
6213	6858	293	Salla Disease	Salla_Disease.yaml	phenotypes	1	Developmental Delay	Delayed motor and cognitive milestones in infancy and early childhood, typically becoming apparent within the first year of life.	phenotype_term	phenotype_term	$	Developmental Delay	Delayed motor and cognitive milestones in infancy and early childhood, typically becoming apparent within the first year of life.	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
6214	6859	293	Salla Disease	Salla_Disease.yaml	phenotypes	2	Prenatal Hydrops Fetalis	Excessive accumulation of serous fluid in the fetus (nonimmune hydrops fetalis), which can be a presenting feature of infantile-onset FSASD. Detectable on prenatal ultrasound at 24 weeks gestation or earlier.	phenotype_term	phenotype_term	$	Prenatal Hydrops Fetalis	Excessive accumulation of serous fluid in the fetus (nonimmune hydrops fetalis), which can be a presenting feature of infantile-onset FSASD. Detectable on prenatal ultrasound at 24 weeks gestation or earlier.	Nonimmune hydrops fetalis	HP:0001790	Nonimmune hydrops fetalis		"{""preferred_term"": ""Nonimmune hydrops fetalis"", ""term"": {""id"": ""HP:0001790"", ""label"": ""Nonimmune hydrops fetalis""}}"																											
6215	6860	293	Salla Disease	Salla_Disease.yaml	phenotypes	3	Hypotonia	Reduced muscle tone (hypotonia) typically beginning during the first year of life, followed by slowly progressive neurological problems. Early hypotonia is often the first neurological manifestation of Salla disease.	phenotype_term	phenotype_term	$	Hypotonia	Reduced muscle tone (hypotonia) typically beginning during the first year of life, followed by slowly progressive neurological problems. Early hypotonia is often the first neurological manifestation of Salla disease.	Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
6216	6861	293	Salla Disease	Salla_Disease.yaml	phenotypes	4	Ataxia	Lack of muscle coordination affecting voluntary movements, contributing to motor dysfunction.	phenotype_term	phenotype_term	$	Ataxia	Lack of muscle coordination affecting voluntary movements, contributing to motor dysfunction.	Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
6217	6862	293	Salla Disease	Salla_Disease.yaml	phenotypes	5	Nystagmus	Involuntary eye movements.	phenotype_term	phenotype_term	$	Nystagmus	Involuntary eye movements.	Nystagmus	HP:0000639	Nystagmus		"{""preferred_term"": ""Nystagmus"", ""term"": {""id"": ""HP:0000639"", ""label"": ""Nystagmus""}}"																											
6218	6863	293	Salla Disease	Salla_Disease.yaml	phenotypes	6	Spasticity	Increased muscle tone and stiffness in limbs.	phenotype_term	phenotype_term	$	Spasticity	Increased muscle tone and stiffness in limbs.	Spasticity	HP:0001257	Spasticity		"{""preferred_term"": ""Spasticity"", ""term"": {""id"": ""HP:0001257"", ""label"": ""Spasticity""}}"																											
6219	6864	293	Salla Disease	Salla_Disease.yaml	phenotypes	7	Corpus Callosum Hypoplasia	Marked thinning of the corpus callosum visible on brain MRI, indicating impaired myelination and white matter development.	phenotype_term	phenotype_term	$	Corpus Callosum Hypoplasia	Marked thinning of the corpus callosum visible on brain MRI, indicating impaired myelination and white matter development.	Hypoplasia of the corpus callosum	HP:0002079	Hypoplasia of the corpus callosum		"{""preferred_term"": ""Hypoplasia of the corpus callosum"", ""term"": {""id"": ""HP:0002079"", ""label"": ""Hypoplasia of the corpus callosum""}}"																											
6220	6865	293	Salla Disease	Salla_Disease.yaml	phenotypes	8	White Matter Hypomyelination	Decreased myelin formation in cerebral white matter, reflecting oligodendroglial dysfunction and impaired CNS myelination.	phenotype_term	phenotype_term	$	White Matter Hypomyelination	Decreased myelin formation in cerebral white matter, reflecting oligodendroglial dysfunction and impaired CNS myelination.	Cerebral hypomyelination	HP:0006808	Cerebral hypomyelination		"{""preferred_term"": ""Cerebral hypomyelination"", ""term"": {""id"": ""HP:0006808"", ""label"": ""Cerebral hypomyelination""}}"																											
6221	6866	293	Salla Disease	Salla_Disease.yaml	phenotypes	9	Cerebellar Atrophy	Progressive atrophy of the cerebellum visible on MRI, contributing to ataxia and motor coordination deficits.	phenotype_term	phenotype_term	$	Cerebellar Atrophy	Progressive atrophy of the cerebellum visible on MRI, contributing to ataxia and motor coordination deficits.	Cerebellar atrophy	HP:0001272	Cerebellar atrophy		"{""preferred_term"": ""Cerebellar atrophy"", ""term"": {""id"": ""HP:0001272"", ""label"": ""Cerebellar atrophy""}}"																											
6222	6867	293	Salla Disease	Salla_Disease.yaml	phenotypes	10	Psychotic Disorder	Psychotic symptoms including hallucinations and delusions, reported in adolescent and adult Salla disease patients. A previously underrecognized neuropsychiatric manifestation of the disease.	phenotype_term	phenotype_term	$	Psychotic Disorder	Psychotic symptoms including hallucinations and delusions, reported in adolescent and adult Salla disease patients. A previously underrecognized neuropsychiatric manifestation of the disease.	Psychosis	HP:0000709	Psychosis		"{""preferred_term"": ""Psychosis"", ""term"": {""id"": ""HP:0000709"", ""label"": ""Psychosis""}}"																											
6223	6868	293	Salla Disease	Salla_Disease.yaml	phenotypes	11	Sleep Disturbance	Sleep disorders including insomnia and other sleep abnormalities, frequently encountered in Salla disease patients.	phenotype_term	phenotype_term	$	Sleep Disturbance	Sleep disorders including insomnia and other sleep abnormalities, frequently encountered in Salla disease patients.	Sleep disturbance	HP:0002360	Sleep disturbance		"{""preferred_term"": ""Sleep disturbance"", ""term"": {""id"": ""HP:0002360"", ""label"": ""Sleep disturbance""}}"																											
6224	6869	293	Salla Disease	Salla_Disease.yaml	phenotypes	12	Aggressive Behavior	Behavioral disturbances including aggression, restlessness, and related behavioral disorders occurring in Salla disease patients.	phenotype_term	phenotype_term	$	Aggressive Behavior	Behavioral disturbances including aggression, restlessness, and related behavioral disorders occurring in Salla disease patients.	Aggressive behavior	HP:0000718	Aggressive behavior		"{""preferred_term"": ""Aggressive behavior"", ""term"": {""id"": ""HP:0000718"", ""label"": ""Aggressive behavior""}}"																											
6225	6885	294	Sarcoidosis	Sarcoidosis.yaml	pathophysiology	0	Granuloma Formation	"Non-caseating granulomas consist of organized collections of activated macrophages (epithelioid cells), multinucleated giant cells, and CD4+ T cells. Th1/Th17 immune responses drive granuloma development in response to unidentified antigens.
"	cell_types[0]	cell_types	cell_types			epithelioid macrophage	CL:0002150	epithelioid macrophage		"{""preferred_term"": ""epithelioid macrophage"", ""term"": {""id"": ""CL:0002150"", ""label"": ""epithelioid macrophage""}}"																											
6226	6885	294	Sarcoidosis	Sarcoidosis.yaml	pathophysiology	0	Granuloma Formation	"Non-caseating granulomas consist of organized collections of activated macrophages (epithelioid cells), multinucleated giant cells, and CD4+ T cells. Th1/Th17 immune responses drive granuloma development in response to unidentified antigens.
"	cell_types[1]	cell_types	cell_types			CD4-positive helper T cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""CD4-positive helper T cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
6227	6885	294	Sarcoidosis	Sarcoidosis.yaml	pathophysiology	0	Granuloma Formation	"Non-caseating granulomas consist of organized collections of activated macrophages (epithelioid cells), multinucleated giant cells, and CD4+ T cells. Th1/Th17 immune responses drive granuloma development in response to unidentified antigens.
"	biological_processes[0]	biological_processes	biological_processes			granuloma formation	GO:0002432	granuloma formation		"{""preferred_term"": ""granuloma formation"", ""term"": {""id"": ""GO:0002432"", ""label"": ""granuloma formation""}}"																											
6228	6886	294	Sarcoidosis	Sarcoidosis.yaml	pathophysiology	1	Dysregulated Immune Response	"Exaggerated CD4+ T helper cell response with Th1 polarization leads to interferon-gamma and TNF-alpha production. Regulatory T cell dysfunction contributes to persistent inflammation. Paradoxical peripheral anergy coexists with organ-specific hyperactivity.
"	cell_types[0]	cell_types	cell_types			CD4-positive helper T cell	CL:0000492	CD4-positive helper T cell		"{""preferred_term"": ""CD4-positive helper T cell"", ""term"": {""id"": ""CL:0000492"", ""label"": ""CD4-positive helper T cell""}}"																											
6229	6886	294	Sarcoidosis	Sarcoidosis.yaml	pathophysiology	1	Dysregulated Immune Response	"Exaggerated CD4+ T helper cell response with Th1 polarization leads to interferon-gamma and TNF-alpha production. Regulatory T cell dysfunction contributes to persistent inflammation. Paradoxical peripheral anergy coexists with organ-specific hyperactivity.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
6230	6888	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	0	Mediastinal Lymphadenopathy	Symmetric enlargement of hilar and mediastinal lymph nodes, often the presenting finding on chest radiograph.	phenotype_term	phenotype_term	$	Mediastinal Lymphadenopathy	Symmetric enlargement of hilar and mediastinal lymph nodes, often the presenting finding on chest radiograph.	Mediastinal lymphadenopathy	HP:0100721	Mediastinal lymphadenopathy		"{""preferred_term"": ""Mediastinal lymphadenopathy"", ""term"": {""id"": ""HP:0100721"", ""label"": ""Mediastinal lymphadenopathy""}}"																											
6231	6889	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	1	Dyspnea	Shortness of breath due to pulmonary involvement and reduced lung function.	phenotype_term	phenotype_term	$	Dyspnea	Shortness of breath due to pulmonary involvement and reduced lung function.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
6232	6890	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	2	Nonproductive Cough	Dry, non-productive cough from airway and parenchymal inflammation.	phenotype_term	phenotype_term	$	Nonproductive Cough	Dry, non-productive cough from airway and parenchymal inflammation.	Nonproductive cough	HP:0031246	Nonproductive cough		"{""preferred_term"": ""Nonproductive cough"", ""term"": {""id"": ""HP:0031246"", ""label"": ""Nonproductive cough""}}"																											
6233	6891	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	3	Fatigue	Chronic fatigue is one of the most debilitating symptoms, often persisting after disease resolution.	phenotype_term	phenotype_term	$	Fatigue	Chronic fatigue is one of the most debilitating symptoms, often persisting after disease resolution.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6234	6892	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	4	Erythema Nodosum	Painful red nodules on the shins, often associated with acute sarcoidosis (Lofgren syndrome).	phenotype_term	phenotype_term	$	Erythema Nodosum	Painful red nodules on the shins, often associated with acute sarcoidosis (Lofgren syndrome).	Erythema nodosum	HP:0012219	Erythema nodosum		"{""preferred_term"": ""Erythema nodosum"", ""term"": {""id"": ""HP:0012219"", ""label"": ""Erythema nodosum""}}"																											
6235	6893	294	Sarcoidosis	Sarcoidosis.yaml	phenotypes	5	Uveitis	Eye inflammation that can lead to vision impairment if untreated. May be anterior, posterior, or panuveitis.	phenotype_term	phenotype_term	$	Uveitis	Eye inflammation that can lead to vision impairment if untreated. May be anterior, posterior, or panuveitis.	Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
6236	6894	294	Sarcoidosis	Sarcoidosis.yaml	treatments	0	Corticosteroid Therapy	"First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.
"	treatment_term	treatment_term	$	Corticosteroid Therapy	"First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.
"	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
6237	6895	294	Sarcoidosis	Sarcoidosis.yaml	treatments	1	Methotrexate	"Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.
"	treatment_term	treatment_term	$	Methotrexate	"Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6238	6896	294	Sarcoidosis	Sarcoidosis.yaml	treatments	2	Anti-TNF Therapy	"Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.
"	treatment_term	treatment_term	$	Anti-TNF Therapy	"Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6239	6897	295	Scabies	Scabies.yaml	infectious_agent	0	Sarcoptes scabiei	Parasitic mite that infests human skin.	infectious_agent_term	infectious_agent_term	$	Sarcoptes scabiei	Parasitic mite that infests human skin.	Sarcoptes scabiei	NCBITaxon:52283	Sarcoptes scabiei		"{""preferred_term"": ""Sarcoptes scabiei"", ""term"": {""id"": ""NCBITaxon:52283"", ""label"": ""Sarcoptes scabiei""}}"																											
6240	6899	295	Scabies	Scabies.yaml	phenotypes	0	Pruritus		phenotype_term	phenotype_term	$	Pruritus		Pruritus	HP:0000989	Pruritus		"{""preferred_term"": ""Pruritus"", ""term"": {""id"": ""HP:0000989"", ""label"": ""Pruritus""}}"																											
6241	6900	295	Scabies	Scabies.yaml	phenotypes	1	Skin rash		phenotype_term	phenotype_term	$	Skin rash		Skin rash	HP:0000988	Skin rash		"{""preferred_term"": ""Skin rash"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
6242	6902	295	Scabies	Scabies.yaml	treatments	0	Permethrin cream or ivermectin	Mass treatment can use permethrin cream or ivermectin.	treatment_term	treatment_term	$	Permethrin cream or ivermectin	Mass treatment can use permethrin cream or ivermectin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6243	6903	296	Schistosomiasis	Schistosomiasis.yaml	infectious_agent	0	Schistosoma spp.	Blood flukes responsible for human schistosomiasis.	infectious_agent_term	infectious_agent_term	$	Schistosoma spp.	Blood flukes responsible for human schistosomiasis.	Schistosoma	NCBITaxon:6181	Schistosoma		"{""preferred_term"": ""Schistosoma"", ""term"": {""id"": ""NCBITaxon:6181"", ""label"": ""Schistosoma""}}"																											
6244	6905	296	Schistosomiasis	Schistosomiasis.yaml	pathophysiology	1	Egg trapping triggers granulomatous inflammation	Eggs lodged in tissues such as the liver or bladder provoke granulomatous inflammatory responses.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
6245	6905	296	Schistosomiasis	Schistosomiasis.yaml	pathophysiology	1	Egg trapping triggers granulomatous inflammation	Eggs lodged in tissues such as the liver or bladder provoke granulomatous inflammatory responses.	locations[1]	locations	locations			urinary bladder	UBERON:0001255	urinary bladder		"{""preferred_term"": ""urinary bladder"", ""term"": {""id"": ""UBERON:0001255"", ""label"": ""urinary bladder""}}"																											
6246	6906	296	Schistosomiasis	Schistosomiasis.yaml	pathophysiology	2	Periportal fibrosis with portal hypertension	Chronic egg-driven inflammation promotes periportal fibrosis and portal hypertension.	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
6247	6908	296	Schistosomiasis	Schistosomiasis.yaml	phenotypes	0	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
6248	6909	296	Schistosomiasis	Schistosomiasis.yaml	phenotypes	1	Hepatosplenomegaly		phenotype_term	phenotype_term	$	Hepatosplenomegaly		Hepatosplenomegaly	HP:0001433	Hepatosplenomegaly		"{""preferred_term"": ""Hepatosplenomegaly"", ""term"": {""id"": ""HP:0001433"", ""label"": ""Hepatosplenomegaly""}}"																											
6249	6911	296	Schistosomiasis	Schistosomiasis.yaml	treatments	0	Praziquantel mass drug administration	Periodic praziquantel treatment to suppress morbidity in endemic regions.	treatment_term	treatment_term	$	Praziquantel mass drug administration	Periodic praziquantel treatment to suppress morbidity in endemic regions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6250	6914	297	Schizophrenia	Schizophrenia.yaml	environmental	0	Prenatal Stress	Exposure to stress during fetal development may increase risk.	exposure_term	exposure_term	$	Prenatal Stress	Exposure to stress during fetal development may increase risk.	Prenatal stress exposure				"{""preferred_term"": ""Prenatal stress exposure""}"																											
6251	6915	297	Schizophrenia	Schizophrenia.yaml	environmental	1	Cannabis Use	Associated with increased risk and earlier onset in genetically predisposed individuals.	exposure_term	exposure_term	$	Cannabis Use	Associated with increased risk and earlier onset in genetically predisposed individuals.	Cannabis exposure	ECTO:0100005	exposure to cannabis		"{""preferred_term"": ""Cannabis exposure"", ""term"": {""id"": ""ECTO:0100005"", ""label"": ""exposure to cannabis""}}"																											
6252	6927	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	0	Dysregulation of Dopamine Neurotransmission	Imbalance in dopamine transmission in the brain, particularly in the mesolimbic and mesocortical pathways.	biological_processes[0]	biological_processes	biological_processes			dopamine secretion	GO:0014046	dopamine secretion		"{""preferred_term"": ""dopamine secretion"", ""term"": {""id"": ""GO:0014046"", ""label"": ""dopamine secretion""}}"																											
6253	6927	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	0	Dysregulation of Dopamine Neurotransmission	Imbalance in dopamine transmission in the brain, particularly in the mesolimbic and mesocortical pathways.	locations[0]	locations	locations			striatum				"{""preferred_term"": ""striatum""}"																											
6254	6928	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	1	Abnormality of Glutamergic Signaling	Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.	cell_types[0]	cell_types	cell_types			parvalbumin-positive interneuron	CL:0000099	interneuron	NMDA hypofunction on parvalbumin interneurons leads to cortical disinhibition.	"{""description"": ""NMDA hypofunction on parvalbumin interneurons leads to cortical disinhibition."", ""preferred_term"": ""parvalbumin-positive interneuron"", ""term"": {""id"": ""CL:0000099"", ""label"": ""interneuron""}}"																											
6255	6928	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	1	Abnormality of Glutamergic Signaling	Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.	biological_processes[0]	biological_processes	biological_processes			synaptic transmission, glutamatergic	GO:0035249	synaptic transmission, glutamatergic		"{""preferred_term"": ""synaptic transmission, glutamatergic"", ""term"": {""id"": ""GO:0035249"", ""label"": ""synaptic transmission, glutamatergic""}}"																											
6256	6928	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	1	Abnormality of Glutamergic Signaling	Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.	locations[0]	locations	locations			prefrontal cortex	UBERON:0000451	prefrontal cortex		"{""preferred_term"": ""prefrontal cortex"", ""term"": {""id"": ""UBERON:0000451"", ""label"": ""prefrontal cortex""}}"																											
6257	6928	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	1	Abnormality of Glutamergic Signaling	Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.	locations[1]	locations	locations			hippocampus	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""hippocampus"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
6258	6929	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	2	Abnormality of GABAergic Signaling	Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.	cell_types[0]	cell_types	cell_types			parvalbumin-positive interneuron	CL:0000099	interneuron	Parvalbumin-positive GABAergic interneurons show reduced function, leading to cortical disinhibition.	"{""description"": ""Parvalbumin-positive GABAergic interneurons show reduced function, leading to cortical disinhibition."", ""preferred_term"": ""parvalbumin-positive interneuron"", ""term"": {""id"": ""CL:0000099"", ""label"": ""interneuron""}}"																											
6259	6929	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	2	Abnormality of GABAergic Signaling	Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.	biological_processes[0]	biological_processes	biological_processes			synaptic transmission, GABAergic	GO:0051932	synaptic transmission, GABAergic		"{""preferred_term"": ""synaptic transmission, GABAergic"", ""term"": {""id"": ""GO:0051932"", ""label"": ""synaptic transmission, GABAergic""}}"																											
6260	6929	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	2	Abnormality of GABAergic Signaling	Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.	locations[0]	locations	locations			prefrontal cortex	UBERON:0000451	prefrontal cortex		"{""preferred_term"": ""prefrontal cortex"", ""term"": {""id"": ""UBERON:0000451"", ""label"": ""prefrontal cortex""}}"																											
6261	6930	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	3	Complement-Mediated Excessive Synaptic Pruning	Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.	cell_types[0]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell	Microglia eliminate synapses tagged by complement components during critical developmental periods.	"{""description"": ""Microglia eliminate synapses tagged by complement components during critical developmental periods."", ""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
6262	6930	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	3	Complement-Mediated Excessive Synaptic Pruning	Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
6263	6930	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	3	Complement-Mediated Excessive Synaptic Pruning	Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.	biological_processes[1]	biological_processes	biological_processes			synapse pruning	GO:0098883	synapse pruning		"{""preferred_term"": ""synapse pruning"", ""term"": {""id"": ""GO:0098883"", ""label"": ""synapse pruning""}}"																											
6264	6930	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	3	Complement-Mediated Excessive Synaptic Pruning	Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.	locations[0]	locations	locations			prefrontal cortex	UBERON:0000451	prefrontal cortex		"{""preferred_term"": ""prefrontal cortex"", ""term"": {""id"": ""UBERON:0000451"", ""label"": ""prefrontal cortex""}}"																											
6265	6930	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	3	Complement-Mediated Excessive Synaptic Pruning	Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.	locations[1]	locations	locations			hippocampus	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""hippocampus"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
6266	6931	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	4	Oligodendrocyte and Myelin Dysfunction	Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.	cell_types[0]	cell_types	cell_types			oligodendrocyte	CL:0000128	oligodendrocyte	Oligodendrocyte dysfunction contributes to impaired myelination and dysconnectivity.	"{""description"": ""Oligodendrocyte dysfunction contributes to impaired myelination and dysconnectivity."", ""preferred_term"": ""oligodendrocyte"", ""term"": {""id"": ""CL:0000128"", ""label"": ""oligodendrocyte""}}"																											
6267	6931	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	4	Oligodendrocyte and Myelin Dysfunction	Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.	biological_processes[0]	biological_processes	biological_processes			myelination	GO:0042552	myelination		"{""preferred_term"": ""myelination"", ""term"": {""id"": ""GO:0042552"", ""label"": ""myelination""}}"																											
6268	6931	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	4	Oligodendrocyte and Myelin Dysfunction	Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.	locations[0]	locations	locations			prefrontal cortex	UBERON:0000451	prefrontal cortex		"{""preferred_term"": ""prefrontal cortex"", ""term"": {""id"": ""UBERON:0000451"", ""label"": ""prefrontal cortex""}}"																											
6269	6931	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	4	Oligodendrocyte and Myelin Dysfunction	Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.	locations[1]	locations	locations			hippocampus	UBERON:0001954	Ammon's horn		"{""preferred_term"": ""hippocampus"", ""term"": {""id"": ""UBERON:0001954"", ""label"": ""Ammon's horn""}}"																											
6270	6932	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	5	Mitochondrial Dysfunction and Oxidative Stress	Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.	biological_processes[0]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"																											
6271	6932	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	5	Mitochondrial Dysfunction and Oxidative Stress	Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.	biological_processes[1]	biological_processes	biological_processes			cellular response to oxidative stress	GO:0034599	cellular response to oxidative stress		"{""preferred_term"": ""cellular response to oxidative stress"", ""term"": {""id"": ""GO:0034599"", ""label"": ""cellular response to oxidative stress""}}"																											
6272	6932	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	5	Mitochondrial Dysfunction and Oxidative Stress	Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.	locations[0]	locations	locations			prefrontal cortex	UBERON:0000451	prefrontal cortex		"{""preferred_term"": ""prefrontal cortex"", ""term"": {""id"": ""UBERON:0000451"", ""label"": ""prefrontal cortex""}}"																											
6273	6933	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	6	Blood-Brain Barrier Dysfunction	Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.	cell_types[0]	cell_types	cell_types			endothelial cell	CL:0000115	endothelial cell		"{""preferred_term"": ""endothelial cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
6274	6933	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	6	Blood-Brain Barrier Dysfunction	Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.	cell_types[1]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
6275	6933	297	Schizophrenia	Schizophrenia.yaml	pathophysiology	6	Blood-Brain Barrier Dysfunction	Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.	locations[0]	locations	locations			blood-brain barrier				"{""preferred_term"": ""blood-brain barrier""}"																											
6276	6934	297	Schizophrenia	Schizophrenia.yaml	phenotypes	0	Hallucinations		phenotype_term	phenotype_term	$	Hallucinations		Hallucinations	HP:0000738	Hallucinations		"{""preferred_term"": ""Hallucinations"", ""term"": {""id"": ""HP:0000738"", ""label"": ""Hallucinations""}}"																											
6277	6935	297	Schizophrenia	Schizophrenia.yaml	phenotypes	1	Delusions		phenotype_term	phenotype_term	$	Delusions		Delusions	HP:0000746	Delusion		"{""preferred_term"": ""Delusions"", ""term"": {""id"": ""HP:0000746"", ""label"": ""Delusion""}}"																											
6278	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	Antipsychotic Medications	Medications such as risperidone, olanzapine, and clozapine to manage symptoms.	treatment_term	treatment_term	$	Antipsychotic Medications	Medications such as risperidone, olanzapine, and clozapine to manage symptoms.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6279	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	Cognitive Behavioral Therapy (CBT)	Therapy aimed at changing maladaptive thought patterns and behaviors.	treatment_term	treatment_term	$	Cognitive Behavioral Therapy (CBT)	Therapy aimed at changing maladaptive thought patterns and behaviors.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6280	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	Social Skills Training	Programs to enhance social interactions and functioning.	treatment_term	treatment_term	$	Social Skills Training	Programs to enhance social interactions and functioning.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6281	6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	Supportive Therapy	Ongoing support to help manage daily life and stress.	treatment_term	treatment_term	$	Supportive Therapy	Ongoing support to help manage daily life and stress.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6282	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	Vocational Rehabilitation	Help with gaining and maintaining employment.	treatment_term	treatment_term	$	Vocational Rehabilitation	Help with gaining and maintaining employment.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
6283	6950	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	0	NCT00891527	Pilot study using bevacizumab (Avastin) and imatinib (Gleevec) to treat progression of multivessel intraluminal pulmonary vein stenosis in children. Pulmonary vein stenosis is a major postoperative complication of scimitar syndrome repair.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6284	6951	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	1	NCT01548950	Combined preoperative and postoperative sildenafil and bosentan treatment for congenital heart disease associated with pulmonary arterial hypertension. Tests whether PAH drug therapy reduces perioperative mortality and residual PAH in children undergoing cardiac repair for left-to-right shunts.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6285	6952	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	clinical_trials	2	NCT03431649	Randomized comparison of beraprost sodium versus sildenafil for treatment of pulmonary hypertension in children with left-to-right shunt congenital heart defects. Directly relevant to pharmacological management of PAH in scimitar syndrome.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6286	6953	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	datasets	0		Microarray analysis of circular RNA expression in plasma from 8 children with pulmonary arterial hypertension secondary to congenital heart disease compared to 5 controls without PAH. Identifies differentially expressed circRNAs that may serve as biomarkers for PAH-CHD.	organism	organism	$		Microarray analysis of circular RNA expression in plasma from 8 children with pulmonary arterial hypertension secondary to congenital heart disease compared to 5 controls without PAH. Identifies differentially expressed circRNAs that may serve as biomarkers for PAH-CHD.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6287	6954	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	diagnosis	0	Chest radiograph (scimitar sign)	"The characteristic curvilinear shadow along the right heart border on posteroanterior chest radiograph, representing the anomalous pulmonary vein draining toward the IVC. This finding gives the syndrome its name and is visible in approximately 82% of overall cases, though less frequently in infants.
"	diagnosis_term	diagnosis_term	$	Chest radiograph (scimitar sign)	"The characteristic curvilinear shadow along the right heart border on posteroanterior chest radiograph, representing the anomalous pulmonary vein draining toward the IVC. This finding gives the syndrome its name and is visible in approximately 82% of overall cases, though less frequently in infants.
"	radiograph imaging procedure	MAXO:0000595	radiograph imaging procedure		"{""preferred_term"": ""radiograph imaging procedure"", ""term"": {""id"": ""MAXO:0000595"", ""label"": ""radiograph imaging procedure""}}"																											
6288	6955	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	diagnosis	1	CT angiography or cardiac MRI	"Cross-sectional imaging precisely delineates the anomalous venous drainage, anomalous arterial supply, pulmonary anatomy, and associated cardiac defects. CT angiography with 3D and MIP reconstructions or cardiac MRI have largely replaced invasive catheterization for diagnostic purposes, providing superior anatomic detail for surgical planning.
"	diagnosis_term	diagnosis_term	$	CT angiography or cardiac MRI	"Cross-sectional imaging precisely delineates the anomalous venous drainage, anomalous arterial supply, pulmonary anatomy, and associated cardiac defects. CT angiography with 3D and MIP reconstructions or cardiac MRI have largely replaced invasive catheterization for diagnostic purposes, providing superior anatomic detail for surgical planning.
"	angiography	MAXO:0001259	angiography		"{""preferred_term"": ""angiography"", ""term"": {""id"": ""MAXO:0001259"", ""label"": ""angiography""}}"																											
6289	6956	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	diagnosis	2	Cardiac catheterization	"Invasive hemodynamic assessment quantifies shunt magnitude (Qp:Qs ratio), pulmonary artery pressures, and pulmonary vascular resistance to guide intervention decisions. Selective angiography confirms anomalous venous drainage and identifies aortopulmonary collaterals.
"	diagnosis_term	diagnosis_term	$	Cardiac catheterization	"Invasive hemodynamic assessment quantifies shunt magnitude (Qp:Qs ratio), pulmonary artery pressures, and pulmonary vascular resistance to guide intervention decisions. Selective angiography confirms anomalous venous drainage and identifies aortopulmonary collaterals.
"	cardiac catheterization	MAXO:0035118	cardiac catheterization		"{""preferred_term"": ""cardiac catheterization"", ""term"": {""id"": ""MAXO:0035118"", ""label"": ""cardiac catheterization""}}"																											
6290	6957	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	differential_diagnoses	0	Isolated partial anomalous pulmonary venous return	"Non-scimitar forms of partial anomalous pulmonary venous return (PAPVR), where pulmonary veins drain to the right atrium, superior vena cava, or innominate vein rather than the IVC. These lack the characteristic scimitar vein course along the right heart border and are not typically associated with right lung hypoplasia or systemic arterial supply anomalies.
"	disease_term	disease_term	$	Isolated partial anomalous pulmonary venous return	"Non-scimitar forms of partial anomalous pulmonary venous return (PAPVR), where pulmonary veins drain to the right atrium, superior vena cava, or innominate vein rather than the IVC. These lack the characteristic scimitar vein course along the right heart border and are not typically associated with right lung hypoplasia or systemic arterial supply anomalies.
"	congenital pulmonary venous return anomaly	MONDO:0017705	congenital pulmonary venous return anomaly		"{""preferred_term"": ""congenital pulmonary venous return anomaly"", ""term"": {""id"": ""MONDO:0017705"", ""label"": ""congenital pulmonary venous return anomaly""}}"																											
6291	6958	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	differential_diagnoses	1	Bronchopulmonary sequestration	"A mass of non-functioning lung tissue with anomalous systemic arterial supply and no normal connection with the tracheobronchial tree. Intralobar sequestration shares features with scimitar syndrome including systemic arterial supply, but lacks the anomalous pulmonary venous drainage to the IVC that defines scimitar syndrome. The two conditions may coexist.
"	disease_term	disease_term	$	Bronchopulmonary sequestration	"A mass of non-functioning lung tissue with anomalous systemic arterial supply and no normal connection with the tracheobronchial tree. Intralobar sequestration shares features with scimitar syndrome including systemic arterial supply, but lacks the anomalous pulmonary venous drainage to the IVC that defines scimitar syndrome. The two conditions may coexist.
"	congenital pulmonary sequestration	MONDO:0017843	congenital pulmonary sequestration		"{""preferred_term"": ""congenital pulmonary sequestration"", ""term"": {""id"": ""MONDO:0017843"", ""label"": ""congenital pulmonary sequestration""}}"																											
6292	6959	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	differential_diagnoses	2	Atrial septal defect	"Isolated ASD produces a left-to-right shunt at the atrial level with right heart volume overload similar to scimitar syndrome. Distinguished by normal pulmonary venous drainage, normal lung anatomy, and absence of the scimitar sign. ASD commonly coexists with scimitar syndrome and may mask the diagnosis.
"	disease_term	disease_term	$	Atrial septal defect	"Isolated ASD produces a left-to-right shunt at the atrial level with right heart volume overload similar to scimitar syndrome. Distinguished by normal pulmonary venous drainage, normal lung anatomy, and absence of the scimitar sign. ASD commonly coexists with scimitar syndrome and may mask the diagnosis.
"	atrial septal defect	MONDO:0006664	atrial septal defect		"{""preferred_term"": ""atrial septal defect"", ""term"": {""id"": ""MONDO:0006664"", ""label"": ""atrial septal defect""}}"																											
6293	6960	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	differential_diagnoses	3	Congenital diaphragmatic hernia	"Congenital diaphragmatic hernia can produce lung hypoplasia and mediastinal shift mimicking the radiographic appearance of scimitar syndrome. Distinguished by the presence of abdominal viscera in the thorax and absence of anomalous pulmonary venous drainage.
"	disease_term	disease_term	$	Congenital diaphragmatic hernia	"Congenital diaphragmatic hernia can produce lung hypoplasia and mediastinal shift mimicking the radiographic appearance of scimitar syndrome. Distinguished by the presence of abdominal viscera in the thorax and absence of anomalous pulmonary venous drainage.
"	congenital diaphragmatic hernia	MONDO:0005711	congenital diaphragmatic hernia		"{""preferred_term"": ""congenital diaphragmatic hernia"", ""term"": {""id"": ""MONDO:0005711"", ""label"": ""congenital diaphragmatic hernia""}}"																											
6294	6962	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	0	Embryologic developmental disruption	"The anomalies in scimitar syndrome arise from disrupted cardiopulmonary embryogenesis during the fourth to fifth week of gestation. Faulty incorporation of the common pulmonary vein into the left atrium results in the anomalous venous drainage, while abnormal branching morphogenesis of the right lung bud produces ipsilateral pulmonary hypoplasia. Aberrant systemic arterial connections and bronchopulmonary sequestration reflect concurrent errors in vascular patterning. The exact triggers are unknown, and no consistent environmental teratogenic exposure has been identified. The condition is typically sporadic.
"	biological_processes[0]	biological_processes	biological_processes			Lung development	GO:0030324	lung development		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Lung development"", ""term"": {""id"": ""GO:0030324"", ""label"": ""lung development""}}"			ABNORMAL																								
6295	6962	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	0	Embryologic developmental disruption	"The anomalies in scimitar syndrome arise from disrupted cardiopulmonary embryogenesis during the fourth to fifth week of gestation. Faulty incorporation of the common pulmonary vein into the left atrium results in the anomalous venous drainage, while abnormal branching morphogenesis of the right lung bud produces ipsilateral pulmonary hypoplasia. Aberrant systemic arterial connections and bronchopulmonary sequestration reflect concurrent errors in vascular patterning. The exact triggers are unknown, and no consistent environmental teratogenic exposure has been identified. The condition is typically sporadic.
"	biological_processes[1]	biological_processes	biological_processes			Pulmonary vein morphogenesis	GO:0060577	pulmonary vein morphogenesis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Pulmonary vein morphogenesis"", ""term"": {""id"": ""GO:0060577"", ""label"": ""pulmonary vein morphogenesis""}}"			ABNORMAL																								
6296	6963	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	1	Anomalous pulmonary venous drainage	"The hallmark of scimitar syndrome is partial or complete anomalous drainage of the right pulmonary veins into the inferior vena cava (IVC) rather than the left atrium. This creates a left-to-right shunt as oxygenated blood from the right lung is returned to the systemic venous circulation instead of the left heart. The anomalous vein typically drains into the IVC at or below the diaphragm, though supradiaphragmatic and hepatic vein drainage variants exist. The hemodynamic significance depends on the proportion of pulmonary venous drainage that is anomalous and the degree of associated right lung hypoplasia.
"	locations[0]	locations	locations			Pulmonary vein	UBERON:0002016	pulmonary vein		"{""preferred_term"": ""Pulmonary vein"", ""term"": {""id"": ""UBERON:0002016"", ""label"": ""pulmonary vein""}}"																											
6297	6963	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	1	Anomalous pulmonary venous drainage	"The hallmark of scimitar syndrome is partial or complete anomalous drainage of the right pulmonary veins into the inferior vena cava (IVC) rather than the left atrium. This creates a left-to-right shunt as oxygenated blood from the right lung is returned to the systemic venous circulation instead of the left heart. The anomalous vein typically drains into the IVC at or below the diaphragm, though supradiaphragmatic and hepatic vein drainage variants exist. The hemodynamic significance depends on the proportion of pulmonary venous drainage that is anomalous and the degree of associated right lung hypoplasia.
"	locations[1]	locations	locations			Inferior vena cava	UBERON:0001072	inferior vena cava		"{""preferred_term"": ""Inferior vena cava"", ""term"": {""id"": ""UBERON:0001072"", ""label"": ""inferior vena cava""}}"																											
6298	6963	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	1	Anomalous pulmonary venous drainage	"The hallmark of scimitar syndrome is partial or complete anomalous drainage of the right pulmonary veins into the inferior vena cava (IVC) rather than the left atrium. This creates a left-to-right shunt as oxygenated blood from the right lung is returned to the systemic venous circulation instead of the left heart. The anomalous vein typically drains into the IVC at or below the diaphragm, though supradiaphragmatic and hepatic vein drainage variants exist. The hemodynamic significance depends on the proportion of pulmonary venous drainage that is anomalous and the degree of associated right lung hypoplasia.
"	biological_processes[0]	biological_processes	biological_processes			Pulmonary vein morphogenesis	GO:0060577	pulmonary vein morphogenesis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Pulmonary vein morphogenesis"", ""term"": {""id"": ""GO:0060577"", ""label"": ""pulmonary vein morphogenesis""}}"			ABNORMAL																								
6299	6963	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	1	Anomalous pulmonary venous drainage	"The hallmark of scimitar syndrome is partial or complete anomalous drainage of the right pulmonary veins into the inferior vena cava (IVC) rather than the left atrium. This creates a left-to-right shunt as oxygenated blood from the right lung is returned to the systemic venous circulation instead of the left heart. The anomalous vein typically drains into the IVC at or below the diaphragm, though supradiaphragmatic and hepatic vein drainage variants exist. The hemodynamic significance depends on the proportion of pulmonary venous drainage that is anomalous and the degree of associated right lung hypoplasia.
"	cell_types[0]	cell_types	cell_types			Blood vessel endothelial cell	CL:0000071	blood vessel endothelial cell		"{""preferred_term"": ""Blood vessel endothelial cell"", ""term"": {""id"": ""CL:0000071"", ""label"": ""blood vessel endothelial cell""}}"																											
6300	6964	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	2	Right lung hypoplasia	"The right lung is hypoplastic in most cases, ranging from mild volume reduction to severe underdevelopment with only one or two lobes. Right lung hypoplasia reduces the volume of blood flow through the anomalous circuit, which may paradoxically limit the hemodynamic impact of the left-to-right shunt. The hypoplasia results in dextroposition of the heart (shifting of the mediastinum to the right) rather than true dextrocardia. Right pulmonary artery hypoplasia frequently accompanies lung hypoplasia, further reducing the pulmonary vascular bed.
"	locations[0]	locations	locations			Right lung	UBERON:0002167	right lung		"{""preferred_term"": ""Right lung"", ""term"": {""id"": ""UBERON:0002167"", ""label"": ""right lung""}}"																											
6301	6964	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	2	Right lung hypoplasia	"The right lung is hypoplastic in most cases, ranging from mild volume reduction to severe underdevelopment with only one or two lobes. Right lung hypoplasia reduces the volume of blood flow through the anomalous circuit, which may paradoxically limit the hemodynamic impact of the left-to-right shunt. The hypoplasia results in dextroposition of the heart (shifting of the mediastinum to the right) rather than true dextrocardia. Right pulmonary artery hypoplasia frequently accompanies lung hypoplasia, further reducing the pulmonary vascular bed.
"	biological_processes[0]	biological_processes	biological_processes			Right lung morphogenesis	GO:0060461	right lung morphogenesis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Right lung morphogenesis"", ""term"": {""id"": ""GO:0060461"", ""label"": ""right lung morphogenesis""}}"			ABNORMAL																								
6302	6965	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	3	Anomalous systemic arterial supply	"An anomalous systemic artery arising from the thoracic or abdominal aorta supplies part of the right lower lobe in many cases. This arterial supply creates an additional left-to-right shunt by delivering systemic-pressure blood to the pulmonary vascular bed, contributing to pulmonary overcirculation and pulmonary hypertension. Bronchopulmonary sequestration frequently coexists, and aortopulmonary collateral arteries may also be present.
"	biological_processes[0]	biological_processes	biological_processes			Blood vessel development	GO:0001568	blood vessel development		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""Blood vessel development"", ""term"": {""id"": ""GO:0001568"", ""label"": ""blood vessel development""}}"			ABNORMAL																								
6303	6966	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	4	Pulmonary hypertension pathogenesis	"Pulmonary hypertension in scimitar syndrome arises from multiple converging factors. The left-to-right shunt from anomalous venous drainage produces pulmonary overcirculation; right lung hypoplasia reduces the pulmonary vascular bed; anomalous systemic arterial supply adds high-pressure systemic inflow; and stenosis or obstruction of the scimitar vein elevates post-capillary pressure. These factors drive vascular remodeling including endothelial dysfunction and smooth muscle cell hypertrophy in small pulmonary arteries. Pulmonary hypertension is the major determinant of prognosis, especially in infants.
"	cell_types[0]	cell_types	cell_types			Blood vessel endothelial cell	CL:0000071	blood vessel endothelial cell		"{""preferred_term"": ""Blood vessel endothelial cell"", ""term"": {""id"": ""CL:0000071"", ""label"": ""blood vessel endothelial cell""}}"																											
6304	6966	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	4	Pulmonary hypertension pathogenesis	"Pulmonary hypertension in scimitar syndrome arises from multiple converging factors. The left-to-right shunt from anomalous venous drainage produces pulmonary overcirculation; right lung hypoplasia reduces the pulmonary vascular bed; anomalous systemic arterial supply adds high-pressure systemic inflow; and stenosis or obstruction of the scimitar vein elevates post-capillary pressure. These factors drive vascular remodeling including endothelial dysfunction and smooth muscle cell hypertrophy in small pulmonary arteries. Pulmonary hypertension is the major determinant of prognosis, especially in infants.
"	cell_types[1]	cell_types	cell_types			Blood vessel smooth muscle cell	CL:0019018	blood vessel smooth muscle cell		"{""preferred_term"": ""Blood vessel smooth muscle cell"", ""term"": {""id"": ""CL:0019018"", ""label"": ""blood vessel smooth muscle cell""}}"																											
6305	6967	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	5	Associated atrial septal defect	"Atrial septal defect (ASD) is one of the most common cardiac malformations associated with scimitar syndrome, reported in approximately 18-43% of cases. ASD compounds the left-to-right shunt already present from the anomalous pulmonary venous drainage, increasing right heart volume overload. ASD may mask the diagnosis of scimitar syndrome by providing an apparent explanation for the shunt on echocardiography.
"	locations[0]	locations	locations			Interatrial septum	UBERON:0002085	interatrial septum		"{""preferred_term"": ""Interatrial septum"", ""term"": {""id"": ""UBERON:0002085"", ""label"": ""interatrial septum""}}"																											
6306	6968	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	6	Associated ventricular septal defect	"Ventricular septal defect (VSD) is reported in approximately 27% of scimitar syndrome cases, creating an additional left-to-right shunt at the ventricular level. Combined with the anomalous pulmonary venous drainage, VSD further increases pulmonary blood flow and the risk of pulmonary hypertension.
"	locations[0]	locations	locations			Interventricular septum	UBERON:0002094	interventricular septum		"{""preferred_term"": ""Interventricular septum"", ""term"": {""id"": ""UBERON:0002094"", ""label"": ""interventricular septum""}}"																											
6307	6969	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	7	Patent ductus arteriosus and aortic arch anomalies	"Patent ductus arteriosus (PDA) and coarctation of the aorta are reported in a subset of scimitar syndrome cases. PDA provides an additional left-to-right shunt at the great vessel level, while coarctation may increase afterload and complicate surgical management. These great vessel anomalies are more common in the infantile form.
"	locations[0]	locations	locations			Ductus arteriosus	UBERON:0005440	ductus arteriosus		"{""preferred_term"": ""Ductus arteriosus"", ""term"": {""id"": ""UBERON:0005440"", ""label"": ""ductus arteriosus""}}"																											
6308	6969	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	7	Patent ductus arteriosus and aortic arch anomalies	"Patent ductus arteriosus (PDA) and coarctation of the aorta are reported in a subset of scimitar syndrome cases. PDA provides an additional left-to-right shunt at the great vessel level, while coarctation may increase afterload and complicate surgical management. These great vessel anomalies are more common in the infantile form.
"	locations[1]	locations	locations			Arch of aorta	UBERON:0001508	arch of aorta		"{""preferred_term"": ""Arch of aorta"", ""term"": {""id"": ""UBERON:0001508"", ""label"": ""arch of aorta""}}"																											
6309	6970	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	pathophysiology	8	Complex congenital heart disease	"A subset of scimitar syndrome patients, particularly those presenting in infancy, have complex congenital heart disease including tetralogy of Fallot, single ventricle physiology, double outlet right ventricle, or heterotaxy. Single ventricle physiology carries particularly poor prognosis. Complex CHD is significantly more common in the infantile form and is an independent predictor of mortality.
"	locations[0]	locations	locations			Heart	UBERON:0000948	heart		"{""preferred_term"": ""Heart"", ""term"": {""id"": ""UBERON:0000948"", ""label"": ""heart""}}"																											
6310	6971	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	0	Partial anomalous pulmonary venous return	"Anomalous pulmonary venous return from the right lung to the inferior vena cava, creating a left-to-right shunt. This is the defining anatomic feature of scimitar syndrome and is present in all cases.
"	phenotype_term	phenotype_term	$	Partial anomalous pulmonary venous return	"Anomalous pulmonary venous return from the right lung to the inferior vena cava, creating a left-to-right shunt. This is the defining anatomic feature of scimitar syndrome and is present in all cases.
"	Partial anomalous pulmonary venous return	HP:0010773	Partial anomalous pulmonary venous return		"{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}"																											
6311	6972	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	1	Right lung hypoplasia	"Underdevelopment of the right lung, ranging from mild volume reduction to severe hypoplasia with abnormal lobation. Present in approximately 55-75% of cases, with the higher end in infantile presentations.
"	phenotype_term	phenotype_term	$	Right lung hypoplasia	"Underdevelopment of the right lung, ranging from mild volume reduction to severe hypoplasia with abnormal lobation. Present in approximately 55-75% of cases, with the higher end in infantile presentations.
"	Pulmonary hypoplasia	HP:0002089	Pulmonary hypoplasia		"{""preferred_term"": ""Pulmonary hypoplasia"", ""term"": {""id"": ""HP:0002089"", ""label"": ""Pulmonary hypoplasia""}}"																											
6312	6973	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	2	Pulmonary arterial hypertension	"Elevated pulmonary artery pressure resulting from the left-to-right shunt, anomalous systemic arterial supply, reduced pulmonary vascular bed, or pulmonary venous stenosis. More common and severe in the infantile form and a major determinant of prognosis.
"	phenotype_term	phenotype_term	$	Pulmonary arterial hypertension	"Elevated pulmonary artery pressure resulting from the left-to-right shunt, anomalous systemic arterial supply, reduced pulmonary vascular bed, or pulmonary venous stenosis. More common and severe in the infantile form and a major determinant of prognosis.
"	Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6313	6974	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	3	Recurrent respiratory infections	"Recurrent pneumonia or bronchitis affecting the right lower lobe, related to anomalous arterial supply, bronchial abnormalities, or sequestration-like physiology. Reported in approximately one-sixth of patients on long-term follow-up even after surgical intervention.
"	phenotype_term	phenotype_term	$	Recurrent respiratory infections	"Recurrent pneumonia or bronchitis affecting the right lower lobe, related to anomalous arterial supply, bronchial abnormalities, or sequestration-like physiology. Reported in approximately one-sixth of patients on long-term follow-up even after surgical intervention.
"	Recurrent pneumonia	HP:0006532	Recurrent pneumonia		"{""preferred_term"": ""Recurrent pneumonia"", ""term"": {""id"": ""HP:0006532"", ""label"": ""Recurrent pneumonia""}}"																											
6314	6975	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	4	Dextroposition of the heart	"Rightward displacement of the heart within the thorax secondary to reduced right lung volume, rather than true dextrocardia (mirror-image reversal of cardiac structures). Reported in approximately 55% of cases.
"	phenotype_term	phenotype_term	$	Dextroposition of the heart	"Rightward displacement of the heart within the thorax secondary to reduced right lung volume, rather than true dextrocardia (mirror-image reversal of cardiac structures). Reported in approximately 55% of cases.
"	Dextrocardia	HP:0001651	Dextrocardia		"{""preferred_term"": ""Dextrocardia"", ""term"": {""id"": ""HP:0001651"", ""label"": ""Dextrocardia""}}"																											
6315	6976	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	phenotypes	5	Congestive heart failure	"Right-sided heart failure from volume overload due to the left-to-right shunt. More common in the infantile form and may present with failure to thrive, tachypnea, and hepatomegaly.
"	phenotype_term	phenotype_term	$	Congestive heart failure	"Right-sided heart failure from volume overload due to the left-to-right shunt. More common in the infantile form and may present with failure to thrive, tachypnea, and hepatomegaly.
"	Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
6316	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	treatment_term	treatment_term	$	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6317	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Partial anomalous pulmonary venous return	HP:0010773	Partial anomalous pulmonary venous return		"{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}"																											
6318	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
6319	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	treatment_term	treatment_term	$	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	catheterization	MAXO:0001389	catheterization		"{""preferred_term"": ""catheterization"", ""term"": {""id"": ""MAXO:0001389"", ""label"": ""catheterization""}}"																											
6320	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6321	6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	treatment_term	treatment_term	$	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6322	6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Partial anomalous pulmonary venous return	HP:0010773	Partial anomalous pulmonary venous return		"{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}"																											
6323	6986	299	Scurvy	Scurvy.yaml	phenotypes	0	Perifollicular Hemorrhages	Small hemorrhages around hair follicles due to fragile blood vessels from defective collagen.	phenotype_term	phenotype_term	$	Perifollicular Hemorrhages	Small hemorrhages around hair follicles due to fragile blood vessels from defective collagen.	perifollicular hemorrhage	HP:0000967	Petechiae		"{""preferred_term"": ""perifollicular hemorrhage"", ""term"": {""id"": ""HP:0000967"", ""label"": ""Petechiae""}}"																											
6324	6987	299	Scurvy	Scurvy.yaml	phenotypes	1	Ecchymoses	Larger areas of subcutaneous bleeding appearing as bruises, resulting from capillary fragility and impaired collagen formation.	phenotype_term	phenotype_term	$	Ecchymoses	Larger areas of subcutaneous bleeding appearing as bruises, resulting from capillary fragility and impaired collagen formation.	ecchymoses	HP:0000978	Bruising susceptibility		"{""preferred_term"": ""ecchymoses"", ""term"": {""id"": ""HP:0000978"", ""label"": ""Bruising susceptibility""}}"																											
6325	6989	299	Scurvy	Scurvy.yaml	phenotypes	3	Gingival Bleeding	Spontaneous bleeding and swelling of the gums due to fragile mucosa and impaired collagen.	phenotype_term	phenotype_term	$	Gingival Bleeding	Spontaneous bleeding and swelling of the gums due to fragile mucosa and impaired collagen.	gingival bleeding	HP:0000225	Gingival bleeding		"{""preferred_term"": ""gingival bleeding"", ""term"": {""id"": ""HP:0000225"", ""label"": ""Gingival bleeding""}}"																											
6326	6990	299	Scurvy	Scurvy.yaml	phenotypes	4	Arthralgias	Joint pain resulting from hemarthrosis and periarticular hemorrhages due to capillary fragility.	phenotype_term	phenotype_term	$	Arthralgias	Joint pain resulting from hemarthrosis and periarticular hemorrhages due to capillary fragility.	arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
6327	6991	299	Scurvy	Scurvy.yaml	phenotypes	5	Fatigue	General weakness and malaise, potentially related to impaired carnitine biosynthesis and reduced catecholamine synthesis.	phenotype_term	phenotype_term	$	Fatigue	General weakness and malaise, potentially related to impaired carnitine biosynthesis and reduced catecholamine synthesis.	fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6328	6992	299	Scurvy	Scurvy.yaml	phenotypes	6	Impaired Wound Healing	Delayed or abnormal wound healing due to defective collagen synthesis and impaired tissue repair.	phenotype_term	phenotype_term	$	Impaired Wound Healing	Delayed or abnormal wound healing due to defective collagen synthesis and impaired tissue repair.	impaired wound healing	HP:0001058	Poor wound healing		"{""preferred_term"": ""impaired wound healing"", ""term"": {""id"": ""HP:0001058"", ""label"": ""Poor wound healing""}}"																											
6329	6993	299	Scurvy	Scurvy.yaml	treatments	0	Vitamin C Supplementation	"Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.
"	treatment_term	treatment_term	$	Vitamin C Supplementation	"Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.
"	vitamin C supplementation	MAXO:0000109	vitamin C supplementation		"{""preferred_term"": ""vitamin C supplementation"", ""term"": {""id"": ""MAXO:0000109"", ""label"": ""vitamin C supplementation""}}"																											
6330	6995	300	Secondary Hypertension	Secondary_Hypertension.yaml	phenotypes	0	Hypertension	Elevated blood pressure attributable to an identifiable cause.	phenotype_term	phenotype_term	$	Hypertension	Elevated blood pressure attributable to an identifiable cause.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
6331	6998	301	Semantic Dementia	Semantic_Dementia.yaml	phenotypes	0	Anomic Aphasia		phenotype_term	phenotype_term	$	Anomic Aphasia		Anomic aphasia	HP:0030784	Anomic aphasia		"{""preferred_term"": ""Anomic aphasia"", ""term"": {""id"": ""HP:0030784"", ""label"": ""Anomic aphasia""}}"																											
6332	6999	301	Semantic Dementia	Semantic_Dementia.yaml	phenotypes	1	Dyslexia		phenotype_term	phenotype_term	$	Dyslexia		Dyslexia	HP:0010522	Dyslexia		"{""preferred_term"": ""Dyslexia"", ""term"": {""id"": ""HP:0010522"", ""label"": ""Dyslexia""}}"																											
6333	7000	301	Semantic Dementia	Semantic_Dementia.yaml	phenotypes	2	Prosopagnosia		phenotype_term	phenotype_term	$	Prosopagnosia		Prosopagnosia	HP:0010528	Prosopagnosia		"{""preferred_term"": ""Prosopagnosia"", ""term"": {""id"": ""HP:0010528"", ""label"": ""Prosopagnosia""}}"																											
6334	7001	301	Semantic Dementia	Semantic_Dementia.yaml	phenotypes	3	Atypical Behavior		phenotype_term	phenotype_term	$	Atypical Behavior		Atypical behavior	HP:0000708	Atypical behavior		"{""preferred_term"": ""Atypical behavior"", ""term"": {""id"": ""HP:0000708"", ""label"": ""Atypical behavior""}}"																											
6335	7002	301	Semantic Dementia	Semantic_Dementia.yaml	treatments	0	Speech and Language Therapy	Communication support provided by specialist speech and language therapists.	treatment_term	treatment_term	$	Speech and Language Therapy	Communication support provided by specialist speech and language therapists.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6336	7006	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	0	Bony Dehiscence of Semicircular Canal	An abnormal opening or thinning in the bone overlying the superior semicircular canal creates a pathological third mobile window in the inner ear, in addition to the oval and round windows. This dehiscence may result from congenitally thin otic capsule bone predisposition with subsequent trauma trigger.	locations[0]	locations	locations			superior semicircular canal	UBERON:0001841	anterior semicircular canal		"{""preferred_term"": ""superior semicircular canal"", ""term"": {""id"": ""UBERON:0001841"", ""label"": ""anterior semicircular canal""}}"																											
6337	7006	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	0	Bony Dehiscence of Semicircular Canal	An abnormal opening or thinning in the bone overlying the superior semicircular canal creates a pathological third mobile window in the inner ear, in addition to the oval and round windows. This dehiscence may result from congenitally thin otic capsule bone predisposition with subsequent trauma trigger.	locations[1]	locations	locations			otic capsule	UBERON:0005411	bony otic capsule		"{""preferred_term"": ""otic capsule"", ""term"": {""id"": ""UBERON:0005411"", ""label"": ""bony otic capsule""}}"																											
6338	7007	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	1	Third Window Effect	The dehiscence acts as a third mobile window that shunts acoustic energy away from the cochlea and toward the vestibular system. A third window introduces a low mechanical impedance, shunting part of the inner ear fluid pressure and fluid volume flow at the site of the window.	biological_processes[0]	biological_processes	biological_processes			mechanotransduction	GO:0050957	sensory perception of sound		"{""preferred_term"": ""mechanotransduction"", ""term"": {""id"": ""GO:0050957"", ""label"": ""sensory perception of sound""}}"																											
6339	7007	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	1	Third Window Effect	The dehiscence acts as a third mobile window that shunts acoustic energy away from the cochlea and toward the vestibular system. A third window introduces a low mechanical impedance, shunting part of the inner ear fluid pressure and fluid volume flow at the site of the window.	biological_processes[1]	biological_processes	biological_processes			vestibular receptor stimulus detection	GO:0050911	vestibular receptor cell stimulus detection		"{""preferred_term"": ""vestibular receptor stimulus detection"", ""term"": {""id"": ""GO:0050911"", ""label"": ""vestibular receptor cell stimulus detection""}}"																											
6340	7008	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	2	Abnormal Sound and Pressure Transmission	Sounds and pressure changes that normally would not affect the vestibular system can now stimulate the superior semicircular canal, leading to vestibular symptoms triggered by loud sounds (Tullio phenomenon) or pressure changes (Hennebert sign). Sound energy diverted toward the dehiscence generates pressure differences across the membranous vestibular labyrinth that excite traveling waves.	cell_types[0]	cell_types	cell_types			vestibular hair cell	CL:0000609	vestibular hair cell		"{""preferred_term"": ""vestibular hair cell"", ""term"": {""id"": ""CL:0000609"", ""label"": ""vestibular hair cell""}}"																											
6341	7009	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	3	Otic Capsule Bone Biology	The otic capsule exhibits unique bone physiology with greatly suppressed remodeling. Histopathological examination shows absence of active bone resorption in SCDS cases, supporting developmental thin-bone predisposition rather than active resorption.	cell_types[0]	cell_types	cell_types			osteoclast	CL:0000092	osteoclast		"{""preferred_term"": ""osteoclast"", ""term"": {""id"": ""CL:0000092"", ""label"": ""osteoclast""}}"																											
6342	7009	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	3	Otic Capsule Bone Biology	The otic capsule exhibits unique bone physiology with greatly suppressed remodeling. Histopathological examination shows absence of active bone resorption in SCDS cases, supporting developmental thin-bone predisposition rather than active resorption.	cell_types[1]	cell_types	cell_types			osteoblast	CL:0000062	osteoblast		"{""preferred_term"": ""osteoblast"", ""term"": {""id"": ""CL:0000062"", ""label"": ""osteoblast""}}"																											
6343	7009	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	pathophysiology	3	Otic Capsule Bone Biology	The otic capsule exhibits unique bone physiology with greatly suppressed remodeling. Histopathological examination shows absence of active bone resorption in SCDS cases, supporting developmental thin-bone predisposition rather than active resorption.	biological_processes[0]	biological_processes	biological_processes			bone remodeling	GO:0046849	bone remodeling		"{""preferred_term"": ""bone remodeling"", ""term"": {""id"": ""GO:0046849"", ""label"": ""bone remodeling""}}"																											
6344	7010	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	0	Vertigo	Episodic vertigo triggered by loud sounds or pressure changes such as coughing, sneezing, or straining.	phenotype_term	phenotype_term	$	Vertigo	Episodic vertigo triggered by loud sounds or pressure changes such as coughing, sneezing, or straining.	Vertigo	HP:0002321	Vertigo		"{""preferred_term"": ""Vertigo"", ""term"": {""id"": ""HP:0002321"", ""label"": ""Vertigo""}}"																											
6345	7011	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	1	Sound-Induced Nystagmus	Vestibular symptoms including eye movements (nystagmus) induced by loud sounds, also known as Tullio phenomenon.	phenotype_term	phenotype_term	$	Sound-Induced Nystagmus	Vestibular symptoms including eye movements (nystagmus) induced by loud sounds, also known as Tullio phenomenon.	Nystagmus	HP:0000639	Nystagmus		"{""preferred_term"": ""Nystagmus"", ""term"": {""id"": ""HP:0000639"", ""label"": ""Nystagmus""}}"																											
6346	7012	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	2	Oscillopsia	Visual disturbance in which objects appear to oscillate, particularly during movement or exposure to triggering stimuli.	phenotype_term	phenotype_term	$	Oscillopsia	Visual disturbance in which objects appear to oscillate, particularly during movement or exposure to triggering stimuli.	Oscillopsia	HP:0034773	Oscillopsia		"{""preferred_term"": ""Oscillopsia"", ""term"": {""id"": ""HP:0034773"", ""label"": ""Oscillopsia""}}"																											
6347	7013	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	3	Autophony	Abnormally loud perception of one's own voice, breathing, heartbeat, or eye movements due to enhanced bone conduction.	phenotype_term	phenotype_term	$	Autophony	Abnormally loud perception of one's own voice, breathing, heartbeat, or eye movements due to enhanced bone conduction.	Autophony	HP:6000032	Autophony		"{""preferred_term"": ""Autophony"", ""term"": {""id"": ""HP:6000032"", ""label"": ""Autophony""}}"																											
6348	7014	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	4	Pulsatile Tinnitus	Perception of rhythmic sounds synchronous with the heartbeat.	phenotype_term	phenotype_term	$	Pulsatile Tinnitus	Perception of rhythmic sounds synchronous with the heartbeat.	Pulsatile tinnitus	HP:0008629	Pulsatile tinnitus		"{""preferred_term"": ""Pulsatile tinnitus"", ""term"": {""id"": ""HP:0008629"", ""label"": ""Pulsatile tinnitus""}}"																											
6349	7015	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	5	Conductive Hearing Loss	Low-frequency conductive hearing loss due to shunting of acoustic energy through the dehiscence rather than to the cochlea. Characterized by air-bone gap with sometimes supranormal bone conduction thresholds.	phenotype_term	phenotype_term	$	Conductive Hearing Loss	Low-frequency conductive hearing loss due to shunting of acoustic energy through the dehiscence rather than to the cochlea. Characterized by air-bone gap with sometimes supranormal bone conduction thresholds.	Conductive hearing impairment	HP:0000405	Conductive hearing impairment		"{""preferred_term"": ""Conductive hearing impairment"", ""term"": {""id"": ""HP:0000405"", ""label"": ""Conductive hearing impairment""}}"																											
6350	7016	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	6	Chronic Disequilibrium	Persistent sensation of imbalance or unsteadiness.	phenotype_term	phenotype_term	$	Chronic Disequilibrium	Persistent sensation of imbalance or unsteadiness.	Gait imbalance	HP:0002141	Gait imbalance		"{""preferred_term"": ""Gait imbalance"", ""term"": {""id"": ""HP:0002141"", ""label"": ""Gait imbalance""}}"																											
6351	7017	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	phenotypes	7	Hyperacusis	Increased sensitivity to bone-conducted sounds.	phenotype_term	phenotype_term	$	Hyperacusis	Increased sensitivity to bone-conducted sounds.	Hyperacusis	HP:0010780	Hyperacusis		"{""preferred_term"": ""Hyperacusis"", ""term"": {""id"": ""HP:0010780"", ""label"": ""Hyperacusis""}}"																											
6352	7019	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	1	Surgical Canal Plugging	Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing.	treatment_term	treatment_term	$	Surgical Canal Plugging	Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6353	7020	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	2	Surgical Resurfacing	Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen.	treatment_term	treatment_term	$	Surgical Resurfacing	Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6354	7021	303	Sengers syndrome	Sengers_syndrome.yaml	biochemical	0	Lactate		biomarker_term	biomarker_term	$	Lactate		lactate	CHEBI:24996	lactate		"{""preferred_term"": ""lactate"", ""term"": {""id"": ""CHEBI:24996"", ""label"": ""lactate""}}"																											
6355	7023	303	Sengers syndrome	Sengers_syndrome.yaml	biochemical	2	3-hydroxybutyrate		biomarker_term	biomarker_term	$	3-hydroxybutyrate		3-hydroxybutyrate	CHEBI:37054	3-hydroxybutyrate		"{""preferred_term"": ""3-hydroxybutyrate"", ""term"": {""id"": ""CHEBI:37054"", ""label"": ""3-hydroxybutyrate""}}"																											
6356	7024	303	Sengers syndrome	Sengers_syndrome.yaml	differential_diagnoses	0	Barth syndrome	"X-linked mitochondrial disorder with cardiomyopathy and metabolic features that can overlap with Sengers syndrome.
"	disease_term	disease_term	$	Barth syndrome	"X-linked mitochondrial disorder with cardiomyopathy and metabolic features that can overlap with Sengers syndrome.
"	Barth syndrome	MONDO:0010543	Barth syndrome		"{""preferred_term"": ""Barth syndrome"", ""term"": {""id"": ""MONDO:0010543"", ""label"": ""Barth syndrome""}}"																											
6357	7025	303	Sengers syndrome	Sengers_syndrome.yaml	differential_diagnoses	1	3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome	"SERAC1-related mitochondrial disorder (MEGDEL syndrome) with multisystem involvement and overlapping metabolic features.
"	disease_term	disease_term	$	3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome	"SERAC1-related mitochondrial disorder (MEGDEL syndrome) with multisystem involvement and overlapping metabolic features.
"	3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome	MONDO:0013875	3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome		"{""preferred_term"": ""3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome"", ""term"": {""id"": ""MONDO:0013875"", ""label"": ""3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome""}}"																											
6358	7030	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	0	AGK loss of function disrupts lipid signaling	"Loss of functional AGK impairs lipid signaling activity attributed to mitochondrial acylglycerol kinase.
"	biological_processes[0]	biological_processes	biological_processes			phosphatidic acid metabolic process	GO:0046473	phosphatidic acid metabolic process		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""phosphatidic acid metabolic process"", ""term"": {""id"": ""GO:0046473"", ""label"": ""phosphatidic acid metabolic process""}}"			DYSREGULATED																								
6359	7031	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	1	TIM22 complex assembly defect	"Disrupted TIM22 complex assembly at the mitochondrial inner membrane impairs the carrier protein import machinery.
"	cellular_components[0]	cellular_components	cellular_components			mitochondrial inner membrane	GO:0005743	mitochondrial inner membrane		"{""preferred_term"": ""mitochondrial inner membrane"", ""term"": {""id"": ""GO:0005743"", ""label"": ""mitochondrial inner membrane""}}"																											
6360	7032	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	2	Reduced TIM22-mediated import of inner-membrane carrier proteins	"Disruption of the TIM22 complex reduces import of multi-pass carrier proteins and sideroflexins into the inner mitochondrial membrane.
"	biological_processes[0]	biological_processes	biological_processes			protein insertion into mitochondrial inner membrane	GO:0045039	protein insertion into mitochondrial inner membrane		"{""modifier"": ""DECREASED"", ""preferred_term"": ""protein insertion into mitochondrial inner membrane"", ""term"": {""id"": ""GO:0045039"", ""label"": ""protein insertion into mitochondrial inner membrane""}}"			DECREASED																								
6361	7033	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	3	Impaired mitochondrial one-carbon metabolism	"Reduced abundance of sideroflexins and one-carbon enzymes disrupts mitochondrial one-carbon metabolism.
"	biological_processes[0]	biological_processes	biological_processes			one-carbon metabolic process	GO:0006730	one-carbon metabolic process		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""one-carbon metabolic process"", ""term"": {""id"": ""GO:0006730"", ""label"": ""one-carbon metabolic process""}}"			DYSREGULATED																								
6362	7034	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	4	Disrupted mitochondrial phospholipid metabolism	"AGK loss alters phospholipid metabolism in mitochondrial membranes, contributing to disease pathogenesis.
"	biological_processes[0]	biological_processes	biological_processes			phospholipid metabolic process	GO:0006644	phospholipid metabolic process		"{""modifier"": ""DYSREGULATED"", ""preferred_term"": ""phospholipid metabolic process"", ""term"": {""id"": ""GO:0006644"", ""label"": ""phospholipid metabolic process""}}"			DYSREGULATED																								
6363	7035	303	Sengers syndrome	Sengers_syndrome.yaml	pathophysiology	5	Oxidative phosphorylation deficiency	"Impaired respiratory chain function with reduced complex I and V activity and decreased oxygen consumption in patient cells.
"	biological_processes[0]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"			DECREASED																								
6364	7036	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	0	Hypertrophic cardiomyopathy		phenotype_term	phenotype_term	$	Hypertrophic cardiomyopathy		Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
6365	7037	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	1	Developmental cataract		phenotype_term	phenotype_term	$	Developmental cataract		Developmental cataract	HP:0000519	Developmental cataract		"{""preferred_term"": ""Developmental cataract"", ""term"": {""id"": ""HP:0000519"", ""label"": ""Developmental cataract""}}"																											
6366	7038	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	2	Myopathy		phenotype_term	phenotype_term	$	Myopathy		Myopathy	HP:0003198	Myopathy		"{""preferred_term"": ""Myopathy"", ""term"": {""id"": ""HP:0003198"", ""label"": ""Myopathy""}}"																											
6367	7039	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	3	Lactic acidosis		phenotype_term	phenotype_term	$	Lactic acidosis		Lactic acidosis	HP:0003128	Lactic acidosis		"{""preferred_term"": ""Lactic acidosis"", ""term"": {""id"": ""HP:0003128"", ""label"": ""Lactic acidosis""}}"																											
6368	7040	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	4	Congestive heart failure		phenotype_term	phenotype_term	$	Congestive heart failure		Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
6369	7041	303	Sengers syndrome	Sengers_syndrome.yaml	phenotypes	5	Aplasia of the ovary		phenotype_term	phenotype_term	$	Aplasia of the ovary		Aplasia of the ovary	HP:0010463	Aplasia of the ovary		"{""preferred_term"": ""Aplasia of the ovary"", ""term"": {""id"": ""HP:0010463"", ""label"": ""Aplasia of the ovary""}}"																											
6370	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term	treatment_term	$	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	coenzyme Q10 supplementation	MAXO:0010012	coenzyme Q10 supplementation		"{""preferred_term"": ""coenzyme Q10 supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}}], ""term"": {""id"": ""MAXO:0010012"", ""label"": ""coenzyme Q10 supplementation""}}"																						Coenzyme Q10	NCIT:C916	NCIT:C2259			
6371	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6372	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			coenzyme Q10	NCIT:C916	Coenzyme Q10		"{""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}"																											
6373	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term	treatment_term	$	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	carnitine supplementation	MAXO:0010006	carnitine supplementation		"{""preferred_term"": ""carnitine supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}}], ""term"": {""id"": ""MAXO:0010006"", ""label"": ""carnitine supplementation""}}"																						Levocarnitine	NCIT:C26657	NCIT:C2259			
6374	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6375	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			levocarnitine	NCIT:C26657	Levocarnitine		"{""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}"																											
6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	treatment_term	$	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	B vitamin supplementation	MAXO:0000761	B vitamin supplementation		"{""preferred_term"": ""B vitamin supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}}], ""term"": {""id"": ""MAXO:0000761"", ""label"": ""B vitamin supplementation""}}"																						Thiamine; Riboflavin	NCIT:C874; NCIT:C808	NCIT:C2259			
6377	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6378	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			thiamine	NCIT:C874	Thiamine		"{""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}"																											
6379	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6380	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			riboflavin	NCIT:C808	Riboflavin		"{""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}"																											
6381	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term	treatment_term	$	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy		"{""preferred_term"": ""ACE inhibitor therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}}], ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}"																						Captopril	NCIT:C340	NCIT:C2259			
6382	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6383	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			captopril	NCIT:C340	Captopril		"{""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}"																											
6384	7047	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	4	Cardiac transplantation	Heart transplantation for severe cardiomyopathy in Sengers syndrome.	treatment_term	treatment_term	$	Cardiac transplantation	Heart transplantation for severe cardiomyopathy in Sengers syndrome.	cardiac transplantation	MAXO:0010032	cardiac transplantation		"{""preferred_term"": ""cardiac transplantation"", ""term"": {""id"": ""MAXO:0010032"", ""label"": ""cardiac transplantation""}}"																											
6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	treatment_term	$	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	diuretic agent therapy	MAXO:0000165	diuretic agent therapy		"{""preferred_term"": ""diuretic agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000165"", ""label"": ""diuretic agent therapy""}}"																						Furosemide; Spironolactone	NCIT:C515; NCIT:C840	NCIT:C2259			
6386	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6387	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			furosemide	NCIT:C515	Furosemide		"{""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}"																											
6388	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6389	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			spironolactone	NCIT:C840	Spironolactone		"{""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}"																											
6390	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term	treatment_term	$	Levosimendan infusion	Levosimendan infusions used for heart failure support.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Levosimendan	NCIT:C174653	NCIT:C2259			
6391	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6392	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			levosimendan	NCIT:C174653	Levosimendan		"{""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}"																											
6393	7053	304	Shigellosis	Shigellosis.yaml	datasets	0		Gene expression profiling of macrophage-mediated immune response to Shigella infection. Characterizes the role of macrophage-derived IL-12 and IFN- in controlling bacterial survival in intestinal epithelial cells during early shigellosis infection.	organism	organism	$		Gene expression profiling of macrophage-mediated immune response to Shigella infection. Characterizes the role of macrophage-derived IL-12 and IFN- in controlling bacterial survival in intestinal epithelial cells during early shigellosis infection.	Homo sapiens	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""Homo sapiens"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6394	7053	304	Shigellosis	Shigellosis.yaml	datasets	0		Gene expression profiling of macrophage-mediated immune response to Shigella infection. Characterizes the role of macrophage-derived IL-12 and IFN- in controlling bacterial survival in intestinal epithelial cells during early shigellosis infection.	sample_types[0]	sample_types	sample_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6395	7053	304	Shigellosis	Shigellosis.yaml	datasets	0		Gene expression profiling of macrophage-mediated immune response to Shigella infection. Characterizes the role of macrophage-derived IL-12 and IFN- in controlling bacterial survival in intestinal epithelial cells during early shigellosis infection.	sample_types[1]	sample_types	sample_types			intestinal epithelial cell	CL:0002669	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002669"", ""label"": ""intestinal epithelial cell""}}"																											
6396	7054	304	Shigellosis	Shigellosis.yaml	datasets	1		Transcriptomics study using intestinal organoid model to characterize Shigella colonization mechanisms and host epithelial cell responses at the molecular level. Provides genome-wide insights into pathogen-host interactions during infection.	organism	organism	$		Transcriptomics study using intestinal organoid model to characterize Shigella colonization mechanisms and host epithelial cell responses at the molecular level. Provides genome-wide insights into pathogen-host interactions during infection.	Homo sapiens	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""Homo sapiens"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6397	7054	304	Shigellosis	Shigellosis.yaml	datasets	1		Transcriptomics study using intestinal organoid model to characterize Shigella colonization mechanisms and host epithelial cell responses at the molecular level. Provides genome-wide insights into pathogen-host interactions during infection.	sample_types[0]	sample_types	sample_types			intestinal epithelial cell	CL:0002669	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002669"", ""label"": ""intestinal epithelial cell""}}"																											
6398	7055	304	Shigellosis	Shigellosis.yaml	datasets	2		Gene expression analysis of Shigella flexneri during infection of human intestinal epithelial cells (Henle-407). Tracks bacterial and host transcriptional changes during acute infection providing molecular insights into pathogenic mechanisms.	organism	organism	$		Gene expression analysis of Shigella flexneri during infection of human intestinal epithelial cells (Henle-407). Tracks bacterial and host transcriptional changes during acute infection providing molecular insights into pathogenic mechanisms.	Homo sapiens	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""Homo sapiens"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6399	7055	304	Shigellosis	Shigellosis.yaml	datasets	2		Gene expression analysis of Shigella flexneri during infection of human intestinal epithelial cells (Henle-407). Tracks bacterial and host transcriptional changes during acute infection providing molecular insights into pathogenic mechanisms.	sample_types[0]	sample_types	sample_types			intestinal epithelial cell	CL:0002669	intestinal epithelial cell		"{""preferred_term"": ""intestinal epithelial cell"", ""term"": {""id"": ""CL:0002669"", ""label"": ""intestinal epithelial cell""}}"																											
6400	7056	304	Shigellosis	Shigellosis.yaml	differential_diagnoses	0	Enteroinvasive E. coli (EIEC) infection	"Enteroinvasive E. coli causes a dysentery-like illness similar to Shigella with invasive colitis and bloody diarrhea. However, EIEC is less transmissible than Shigella (higher inoculum required) and tends to affect older children and adults more frequently.
"	disease_term	disease_term	$	Enteroinvasive E. coli (EIEC) infection	"Enteroinvasive E. coli causes a dysentery-like illness similar to Shigella with invasive colitis and bloody diarrhea. However, EIEC is less transmissible than Shigella (higher inoculum required) and tends to affect older children and adults more frequently.
"	Escherichia coli infection				"{""preferred_term"": ""Escherichia coli infection""}"																											
6401	7057	304	Shigellosis	Shigellosis.yaml	differential_diagnoses	1	Campylobacteriosis	"Campylobacter jejuni causes bacterial enteritis with bloody diarrhea and fever, clinically indistinguishable from shigellosis. However, Campylobacter is typically from poultry sources and has a longer incubation period (2-5 days vs 1-4 days for Shigella).
"	disease_term	disease_term	$	Campylobacteriosis	"Campylobacter jejuni causes bacterial enteritis with bloody diarrhea and fever, clinically indistinguishable from shigellosis. However, Campylobacter is typically from poultry sources and has a longer incubation period (2-5 days vs 1-4 days for Shigella).
"	campylobacteriosis	MONDO:0005688	campylobacteriosis		"{""preferred_term"": ""campylobacteriosis"", ""term"": {""id"": ""MONDO:0005688"", ""label"": ""campylobacteriosis""}}"																											
6402	7058	304	Shigellosis	Shigellosis.yaml	differential_diagnoses	2	Inflammatory bowel disease (Crohn's disease or ulcerative colitis)	"Idiopathic inflammatory bowel disease can present with bloody diarrhea, abdominal pain, and fever. Chronic course, extra-intestinal manifestations, and disease in genetically susceptible individuals help distinguish from acute infectious shigellosis.
"	disease_term	disease_term	$	Inflammatory bowel disease (Crohn's disease or ulcerative colitis)	"Idiopathic inflammatory bowel disease can present with bloody diarrhea, abdominal pain, and fever. Chronic course, extra-intestinal manifestations, and disease in genetically susceptible individuals help distinguish from acute infectious shigellosis.
"	inflammatory bowel disease	MONDO:0005265	inflammatory bowel disease		"{""preferred_term"": ""inflammatory bowel disease"", ""term"": {""id"": ""MONDO:0005265"", ""label"": ""inflammatory bowel disease""}}"																											
6403	7059	304	Shigellosis	Shigellosis.yaml	environmental	0	Contaminated water or food		environment_context	environment_context	$	Contaminated water or food		contaminated water	ENVO:00002186	contaminated water		"{""preferred_term"": ""contaminated water"", ""term"": {""id"": ""ENVO:00002186"", ""label"": ""contaminated water""}}"																											
6404	7068	304	Shigellosis	Shigellosis.yaml	infectious_agent	0	Shigella	"Shigella is a Gram-negative, facultative intracellular bacterium of the Enterobacteriaceae family. Four serogroups are recognized: S. dysenteriae, S. sonnei, S. flexneri, and S. boydii. The bacteria produce toxins and virulence factors that enable invasion and destruction of intestinal epithelium.
"	infectious_agent_term	infectious_agent_term	$	Shigella	"Shigella is a Gram-negative, facultative intracellular bacterium of the Enterobacteriaceae family. Four serogroups are recognized: S. dysenteriae, S. sonnei, S. flexneri, and S. boydii. The bacteria produce toxins and virulence factors that enable invasion and destruction of intestinal epithelium.
"	Shigella	NCBITaxon:620	Shigella		"{""preferred_term"": ""Shigella"", ""term"": {""id"": ""NCBITaxon:620"", ""label"": ""Shigella""}}"																											
6405	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	cell_types[0]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
6406	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	cell_types[1]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6407	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	biological_processes[0]	biological_processes	biological_processes			type III protein secretion system	GO:0030257	type III protein secretion system		"{""preferred_term"": ""type III protein secretion system"", ""term"": {""id"": ""GO:0030257"", ""label"": ""type III protein secretion system""}}"																											
6408	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	biological_processes[1]	biological_processes	biological_processes			pyroptosis	GO:0070269	pyroptosis		"{""preferred_term"": ""pyroptosis"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptosis""}}"																											
6409	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	biological_processes[2]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
6410	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
6411	7069	304	Shigellosis	Shigellosis.yaml	pathophysiology	0	Type III secretion system-mediated invasion and vacuolar escape	"Shigella uses a plasmid-encoded Type III secretion system (T3SS/mxi-spa) to deliver bacterial effector proteins directly into host cells. The translocon proteins IpaB and IpaC assemble a funnel-shaped pore in target membranes through which the injectisome docks and delivers effectors. IpaC activates small GTPases and actin nucleation to promote bacterial uptake. IpaB mediates phagosomal membrane disruption and directly activates caspase-1 in macrophages, triggering pyroptotic cell death. This allows bacterial escape from the phagolysosome into the cytosol, where Shigella replicates and spreads.
"	locations[1]	locations	locations			small intestine	UBERON:0002116	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002116"", ""label"": ""small intestine""}}"																											
6412	7070	304	Shigellosis	Shigellosis.yaml	pathophysiology	1	Actin-based motility and cell-to-cell spread	"Within the host cell cytosol, Shigella recruits the host actin polymerization machinery via the polar adhesin IcsA/VirG. The N-WASP (WASL) and Arp2/3 complex are recruited to the bacterial pole, forming actin comet tails that propel the pathogen toward and through the cell membrane into adjacent cells. IcsP regulates IcsA surface distribution; IcsB aids in autophagy evasion. This cell-to-cell spread mechanism drives epithelial fenestration, mucosal ulceration, and the characteristic invasive colitis phenotype without exposure to the lumen.
"	cell_types[0]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
6413	7070	304	Shigellosis	Shigellosis.yaml	pathophysiology	1	Actin-based motility and cell-to-cell spread	"Within the host cell cytosol, Shigella recruits the host actin polymerization machinery via the polar adhesin IcsA/VirG. The N-WASP (WASL) and Arp2/3 complex are recruited to the bacterial pole, forming actin comet tails that propel the pathogen toward and through the cell membrane into adjacent cells. IcsP regulates IcsA surface distribution; IcsB aids in autophagy evasion. This cell-to-cell spread mechanism drives epithelial fenestration, mucosal ulceration, and the characteristic invasive colitis phenotype without exposure to the lumen.
"	cell_types[1]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6414	7070	304	Shigellosis	Shigellosis.yaml	pathophysiology	1	Actin-based motility and cell-to-cell spread	"Within the host cell cytosol, Shigella recruits the host actin polymerization machinery via the polar adhesin IcsA/VirG. The N-WASP (WASL) and Arp2/3 complex are recruited to the bacterial pole, forming actin comet tails that propel the pathogen toward and through the cell membrane into adjacent cells. IcsP regulates IcsA surface distribution; IcsB aids in autophagy evasion. This cell-to-cell spread mechanism drives epithelial fenestration, mucosal ulceration, and the characteristic invasive colitis phenotype without exposure to the lumen.
"	biological_processes[0]	biological_processes	biological_processes			actin filament polymerization	GO:0030041	actin filament polymerization		"{""preferred_term"": ""actin filament polymerization"", ""term"": {""id"": ""GO:0030041"", ""label"": ""actin filament polymerization""}}"																											
6415	7070	304	Shigellosis	Shigellosis.yaml	pathophysiology	1	Actin-based motility and cell-to-cell spread	"Within the host cell cytosol, Shigella recruits the host actin polymerization machinery via the polar adhesin IcsA/VirG. The N-WASP (WASL) and Arp2/3 complex are recruited to the bacterial pole, forming actin comet tails that propel the pathogen toward and through the cell membrane into adjacent cells. IcsP regulates IcsA surface distribution; IcsB aids in autophagy evasion. This cell-to-cell spread mechanism drives epithelial fenestration, mucosal ulceration, and the characteristic invasive colitis phenotype without exposure to the lumen.
"	biological_processes[1]	biological_processes	biological_processes			regulation of cell shape	GO:0008360	regulation of cell shape		"{""preferred_term"": ""regulation of cell shape"", ""term"": {""id"": ""GO:0008360"", ""label"": ""regulation of cell shape""}}"																											
6416	7070	304	Shigellosis	Shigellosis.yaml	pathophysiology	1	Actin-based motility and cell-to-cell spread	"Within the host cell cytosol, Shigella recruits the host actin polymerization machinery via the polar adhesin IcsA/VirG. The N-WASP (WASL) and Arp2/3 complex are recruited to the bacterial pole, forming actin comet tails that propel the pathogen toward and through the cell membrane into adjacent cells. IcsP regulates IcsA surface distribution; IcsB aids in autophagy evasion. This cell-to-cell spread mechanism drives epithelial fenestration, mucosal ulceration, and the characteristic invasive colitis phenotype without exposure to the lumen.
"	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
6417	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6418	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	cell_types[1]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
6419	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	biological_processes[0]	biological_processes	biological_processes			inflammasome complex	GO:0061702	inflammasome complex		"{""preferred_term"": ""inflammasome complex"", ""term"": {""id"": ""GO:0061702"", ""label"": ""inflammasome complex""}}"																											
6420	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	biological_processes[1]	biological_processes	biological_processes			pyroptosis	GO:0070269	pyroptosis		"{""preferred_term"": ""pyroptosis"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptosis""}}"																											
6421	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	biological_processes[2]	biological_processes	biological_processes			inflammatory response to bacterium	GO:0009626	inflammatory response to bacterium		"{""preferred_term"": ""inflammatory response to bacterium"", ""term"": {""id"": ""GO:0009626"", ""label"": ""inflammatory response to bacterium""}}"																											
6422	7071	304	Shigellosis	Shigellosis.yaml	pathophysiology	2	Inflammasome sensing and pyroptotic inflammation	"Cytosolic detection of Shigella T3SS components (MxiH, MxiI) and other danger signals activates the NAIP/NLRC4 inflammasome complex. Non-canonical inflammasome sensing via caspase-4/5 detects cytosolic lipopolysaccharide (LPS). Both pathways converge on caspase-1 and caspase-4/5 activation, which cleave gasdermin D (GSDMD) to form membrane pores, leading to pyroptotic cell death, cytokine release (IL-1, IL-18, IL-8), and recruitment of neutrophils. Shigella modulates this response via IpaH family E3 ligases (e.g., IpaH7.8) to favor bacterial survival and dissemination.
"	locations[0]	locations	locations			colon	UBERON:0001155	colon		"{""preferred_term"": ""colon"", ""term"": {""id"": ""UBERON:0001155"", ""label"": ""colon""}}"																											
6423	7072	304	Shigellosis	Shigellosis.yaml	pathophysiology	3	Bacterial toxin production and endothelial damage	"Shigella species, particularly S. dysenteriae, produce Shiga toxins (Stx) which inhibit protein synthesis in host cells via ribosome inactivation. These toxins damage endothelial cells and intestinal epithelium, leading to severe systemic inflammation, increased vascular permeability, thrombotic microangiopathy, and hemolytic uremic syndrome in severe cases.
"	biological_processes[0]	biological_processes	biological_processes			translation	GO:0006412	translation		"{""preferred_term"": ""translation"", ""term"": {""id"": ""GO:0006412"", ""label"": ""translation""}}"																											
6424	7072	304	Shigellosis	Shigellosis.yaml	pathophysiology	3	Bacterial toxin production and endothelial damage	"Shigella species, particularly S. dysenteriae, produce Shiga toxins (Stx) which inhibit protein synthesis in host cells via ribosome inactivation. These toxins damage endothelial cells and intestinal epithelium, leading to severe systemic inflammation, increased vascular permeability, thrombotic microangiopathy, and hemolytic uremic syndrome in severe cases.
"	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
6425	7072	304	Shigellosis	Shigellosis.yaml	pathophysiology	3	Bacterial toxin production and endothelial damage	"Shigella species, particularly S. dysenteriae, produce Shiga toxins (Stx) which inhibit protein synthesis in host cells via ribosome inactivation. These toxins damage endothelial cells and intestinal epithelium, leading to severe systemic inflammation, increased vascular permeability, thrombotic microangiopathy, and hemolytic uremic syndrome in severe cases.
"	cell_types[0]	cell_types	cell_types			blood vessel endothelial cell	CL:0000071	blood vessel endothelial cell		"{""preferred_term"": ""blood vessel endothelial cell"", ""term"": {""id"": ""CL:0000071"", ""label"": ""blood vessel endothelial cell""}}"																											
6426	7073	304	Shigellosis	Shigellosis.yaml	pathophysiology	4	Intestinal barrier dysfunction and increased permeability	"Invasion and destruction of intestinal epithelium compromises the intestinal barrier function. Loss of epithelial cell integrity increases paracellular transport and bacterial translocation. This leads to increased fluid secretion, electrolyte loss, and systemic bacterial dissemination.
"	biological_processes[0]	biological_processes	biological_processes			tight junction assembly	GO:0070830	bicellular tight junction assembly		"{""preferred_term"": ""tight junction assembly"", ""term"": {""id"": ""GO:0070830"", ""label"": ""bicellular tight junction assembly""}}"																											
6427	7073	304	Shigellosis	Shigellosis.yaml	pathophysiology	4	Intestinal barrier dysfunction and increased permeability	"Invasion and destruction of intestinal epithelium compromises the intestinal barrier function. Loss of epithelial cell integrity increases paracellular transport and bacterial translocation. This leads to increased fluid secretion, electrolyte loss, and systemic bacterial dissemination.
"	biological_processes[1]	biological_processes	biological_processes			ion transport	GO:0006811	ion transport		"{""preferred_term"": ""ion transport"", ""term"": {""id"": ""GO:0006811"", ""label"": ""ion transport""}}"																											
6428	7074	304	Shigellosis	Shigellosis.yaml	phenotypes	0	Diarrhea	"Watery diarrhea due to intestinal inflammation and increased fluid secretion. Often progresses to bloody diarrhea (dysentery) as mucosal invasion and ulceration occur.
"	phenotype_term	phenotype_term	$	Diarrhea	"Watery diarrhea due to intestinal inflammation and increased fluid secretion. Often progresses to bloody diarrhea (dysentery) as mucosal invasion and ulceration occur.
"	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
6429	7075	304	Shigellosis	Shigellosis.yaml	phenotypes	1	Bloody diarrhea	"Blood in stool due to intestinal mucosal ulceration and inflammatory bleeding. This is the hallmark symptom of shigellosis and bacterial dysentery.
"	phenotype_term	phenotype_term	$	Bloody diarrhea	"Blood in stool due to intestinal mucosal ulceration and inflammatory bleeding. This is the hallmark symptom of shigellosis and bacterial dysentery.
"	Bloody diarrhea	HP:0025085	Bloody diarrhea		"{""preferred_term"": ""Bloody diarrhea"", ""term"": {""id"": ""HP:0025085"", ""label"": ""Bloody diarrhea""}}"																											
6430	7076	304	Shigellosis	Shigellosis.yaml	phenotypes	2	Abdominal pain	"Severe cramping abdominal pain due to intestinal inflammation and mucosal ulceration.
"	phenotype_term	phenotype_term	$	Abdominal pain	"Severe cramping abdominal pain due to intestinal inflammation and mucosal ulceration.
"	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
6431	7077	304	Shigellosis	Shigellosis.yaml	phenotypes	3	Fever	"Systemic inflammatory response to bacterial infection.
"	phenotype_term	phenotype_term	$	Fever	"Systemic inflammatory response to bacterial infection.
"	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
6432	7078	304	Shigellosis	Shigellosis.yaml	phenotypes	4	Dehydration	"Fluid loss due to diarrhea and vomiting, leading to dehydration and electrolyte imbalance.
"	phenotype_term	phenotype_term	$	Dehydration	"Fluid loss due to diarrhea and vomiting, leading to dehydration and electrolyte imbalance.
"	Dehydration	HP:0001944	Dehydration		"{""preferred_term"": ""Dehydration"", ""term"": {""id"": ""HP:0001944"", ""label"": ""Dehydration""}}"																											
6433	7079	304	Shigellosis	Shigellosis.yaml	treatments	0	Antibiotic therapy	"Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.
"	treatment_term	treatment_term	$	Antibiotic therapy	"Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6434	7080	304	Shigellosis	Shigellosis.yaml	treatments	1	Oral rehydration therapy	"Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.
"	treatment_term	treatment_term	$	Oral rehydration therapy	"Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6435	7081	304	Shigellosis	Shigellosis.yaml	treatments	2	Fluid and electrolyte replacement	"Intravenous fluid replacement in severe cases with significant dehydration.
"	treatment_term	treatment_term	$	Fluid and electrolyte replacement	"Intravenous fluid replacement in severe cases with significant dehydration.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6436	7095	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	0	Hemoglobin Polymerization	"Deoxygenated HbS polymerizes into rigid fibers, deforming red blood cells into sickle shape. HbS has glutamic acid to valine substitution at position 6 of beta-globin.
"	biological_processes[0]	biological_processes	biological_processes			Protein Polymerization	GO:0051258	protein polymerization		"{""preferred_term"": ""Protein Polymerization"", ""term"": {""id"": ""GO:0051258"", ""label"": ""protein polymerization""}}"																											
6437	7096	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	1	Red Blood Cell Sickling	"Sickled RBCs are rigid and fragile, leading to hemolytic anemia and shortened RBC lifespan (10-20 days vs normal 120 days).
"	cell_types[0]	cell_types	cell_types			Red Blood Cell	CL:0000232	erythrocyte		"{""preferred_term"": ""Red Blood Cell"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}"																											
6438	7096	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	1	Red Blood Cell Sickling	"Sickled RBCs are rigid and fragile, leading to hemolytic anemia and shortened RBC lifespan (10-20 days vs normal 120 days).
"	biological_processes[0]	biological_processes	biological_processes			Hemolysis	GO:0030218	erythrocyte differentiation		"{""preferred_term"": ""Hemolysis"", ""term"": {""id"": ""GO:0030218"", ""label"": ""erythrocyte differentiation""}}"																											
6439	7097	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	2	Vaso-Occlusion	"Sickled cells adhere to vascular endothelium and obstruct microcirculation, causing tissue ischemia and pain crises. Inflammation amplifies adhesion.
"	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
6440	7097	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	2	Vaso-Occlusion	"Sickled cells adhere to vascular endothelium and obstruct microcirculation, causing tissue ischemia and pain crises. Inflammation amplifies adhesion.
"	biological_processes[0]	biological_processes	biological_processes			Cell Adhesion	GO:0007155	cell adhesion		"{""preferred_term"": ""Cell Adhesion"", ""term"": {""id"": ""GO:0007155"", ""label"": ""cell adhesion""}}"																											
6441	7099	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	pathophysiology	4	Chronic Organ Damage	"Repeated vaso-occlusion and ischemia-reperfusion injury cause progressive damage to spleen, kidneys, lungs, and brain.
"	biological_processes[0]	biological_processes	biological_processes			Tissue Damage	GO:0006954	inflammatory response		"{""preferred_term"": ""Tissue Damage"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
6442	7100	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	0	Pain Crises		phenotype_term	phenotype_term	$	Pain Crises		Pain Crisis	HP:0012531	Pain		"{""preferred_term"": ""Pain Crisis"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
6443	7101	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	1	Chronic Anemia		phenotype_term	phenotype_term	$	Chronic Anemia		Hemolytic Anemia	HP:0001878	Hemolytic anemia		"{""preferred_term"": ""Hemolytic Anemia"", ""term"": {""id"": ""HP:0001878"", ""label"": ""Hemolytic anemia""}}"																											
6444	7102	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	2	Jaundice		phenotype_term	phenotype_term	$	Jaundice		Jaundice	HP:0000952	Jaundice		"{""preferred_term"": ""Jaundice"", ""term"": {""id"": ""HP:0000952"", ""label"": ""Jaundice""}}"																											
6445	7103	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	3	Splenic Sequestration		phenotype_term	phenotype_term	$	Splenic Sequestration		Splenomegaly	HP:0001744	Splenomegaly		"{""preferred_term"": ""Splenomegaly"", ""term"": {""id"": ""HP:0001744"", ""label"": ""Splenomegaly""}}"																											
6446	7104	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	4	Acute Chest Syndrome		phenotype_term	phenotype_term	$	Acute Chest Syndrome		Respiratory Distress	HP:0002098	Respiratory distress		"{""preferred_term"": ""Respiratory Distress"", ""term"": {""id"": ""HP:0002098"", ""label"": ""Respiratory distress""}}"																											
6447	7105	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	5	Stroke		phenotype_term	phenotype_term	$	Stroke		Stroke	HP:0001297	Stroke		"{""preferred_term"": ""Stroke"", ""term"": {""id"": ""HP:0001297"", ""label"": ""Stroke""}}"																											
6448	7106	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	6	Priapism		phenotype_term	phenotype_term	$	Priapism		Priapism	HP:0200023	Priapism		"{""preferred_term"": ""Priapism"", ""term"": {""id"": ""HP:0200023"", ""label"": ""Priapism""}}"																											
6449	7107	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	phenotypes	7	Leg Ulcers		phenotype_term	phenotype_term	$	Leg Ulcers		Skin Ulcer	HP:0200042	Skin ulcer		"{""preferred_term"": ""Skin Ulcer"", ""term"": {""id"": ""HP:0200042"", ""label"": ""Skin ulcer""}}"																											
6450	7117	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	diagnosis	0	CT Scan of Paranasal Sinuses	Shows opacified and contracted maxillary sinus with inward bowing of sinus walls, particularly the orbital floor. Characteristic imaging features include maxillary sinus outlet obstruction, sinus opacification, and sinus volume loss.	diagnosis_term	diagnosis_term	$	CT Scan of Paranasal Sinuses	Shows opacified and contracted maxillary sinus with inward bowing of sinus walls, particularly the orbital floor. Characteristic imaging features include maxillary sinus outlet obstruction, sinus opacification, and sinus volume loss.	computed tomography procedure	MAXO:0000571	computed tomography procedure		"{""preferred_term"": ""computed tomography procedure"", ""term"": {""id"": ""MAXO:0000571"", ""label"": ""computed tomography procedure""}}"																											
6451	7120	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	pathophysiology	1	Maxillary Sinus Atelectasis	Progressive collapse and inward retraction of the maxillary sinus walls due to chronic negative pressure within the sinus cavity. The gas resorption causes negative pressure, which leads to osteopenia, bone remodeling, and sinus wall retraction.	locations[0]	locations	locations			maxillary sinus	UBERON:0001764	maxillary sinus		"{""preferred_term"": ""maxillary sinus"", ""term"": {""id"": ""UBERON:0001764"", ""label"": ""maxillary sinus""}}"																											
6452	7122	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	phenotypes	0	Enophthalmos	Posterior displacement of the globe within the orbit due to increased orbital volume from orbital floor descent. This is the hallmark presenting feature of silent sinus syndrome.	phenotype_term	phenotype_term	$	Enophthalmos	Posterior displacement of the globe within the orbit due to increased orbital volume from orbital floor descent. This is the hallmark presenting feature of silent sinus syndrome.	Deeply set eye	HP:0000490	Deeply set eye		"{""preferred_term"": ""Deeply set eye"", ""term"": {""id"": ""HP:0000490"", ""label"": ""Deeply set eye""}}"																											
6453	7124	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	phenotypes	2	Facial Asymmetry	Visible asymmetry of the midface due to cheek flattening from maxillary sinus collapse and malar depression.	phenotype_term	phenotype_term	$	Facial Asymmetry	Visible asymmetry of the midface due to cheek flattening from maxillary sinus collapse and malar depression.	Facial asymmetry	HP:0000324	Facial asymmetry		"{""preferred_term"": ""Facial asymmetry"", ""term"": {""id"": ""HP:0000324"", ""label"": ""Facial asymmetry""}}"																											
6454	7125	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	phenotypes	3	Diplopia	Double vision that may occur due to altered globe position affecting binocular alignment.	phenotype_term	phenotype_term	$	Diplopia	Double vision that may occur due to altered globe position affecting binocular alignment.	Diplopia	HP:0000651	Diplopia		"{""preferred_term"": ""Diplopia"", ""term"": {""id"": ""HP:0000651"", ""label"": ""Diplopia""}}"																											
6455	7127	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	0	Functional Endoscopic Sinus Surgery	Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction.	treatment_term	treatment_term	$	Functional Endoscopic Sinus Surgery	Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction.	nasal endoscopy	MAXO:0035089	nasal endoscopy		"{""preferred_term"": ""nasal endoscopy"", ""term"": {""id"": ""MAXO:0035089"", ""label"": ""nasal endoscopy""}}"																											
6456	7128	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	1	Orbital Floor Reconstruction	Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS.	treatment_term	treatment_term	$	Orbital Floor Reconstruction	Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS.	surgical plastic reconstruction of face	MAXO:0001292	surgical plastic reconstruction of face		"{""preferred_term"": ""surgical plastic reconstruction of face"", ""term"": {""id"": ""MAXO:0001292"", ""label"": ""surgical plastic reconstruction of face""}}"																											
6457	7138	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	0	Exocrine Gland Lymphocytic Infiltration	CD4+ T cells and B cells infiltrate salivary and lacrimal glands, forming ectopic germinal center-like structures. This lymphocytic infiltration leads to progressive glandular destruction and dysfunction.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
6458	7138	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	0	Exocrine Gland Lymphocytic Infiltration	CD4+ T cells and B cells infiltrate salivary and lacrimal glands, forming ectopic germinal center-like structures. This lymphocytic infiltration leads to progressive glandular destruction and dysfunction.	cell_types[1]	cell_types	cell_types			B Cell	CL:0000236	B cell		"{""preferred_term"": ""B Cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6459	7138	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	0	Exocrine Gland Lymphocytic Infiltration	CD4+ T cells and B cells infiltrate salivary and lacrimal glands, forming ectopic germinal center-like structures. This lymphocytic infiltration leads to progressive glandular destruction and dysfunction.	biological_processes[0]	biological_processes	biological_processes			Adaptive Immune Response	GO:0002250	adaptive immune response		"{""preferred_term"": ""Adaptive Immune Response"", ""term"": {""id"": ""GO:0002250"", ""label"": ""adaptive immune response""}}"																											
6460	7139	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	1	Autoantibody Production	Characteristic autoantibodies include anti-Ro/SSA and anti-La/SSB, which target ribonucleoprotein complexes. These antibodies serve as diagnostic markers and may contribute to tissue damage through immune complex formation.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
6461	7140	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	2	Type I Interferon Signature	Elevated type I interferon activity drives disease pathogenesis through activation of plasmacytoid dendritic cells and upregulation of interferon-stimulated genes in affected tissues.	biological_processes[0]	biological_processes	biological_processes			Type I Interferon Response	GO:0034340	response to type I interferon		"{""preferred_term"": ""Type I Interferon Response"", ""term"": {""id"": ""GO:0034340"", ""label"": ""response to type I interferon""}}"																											
6462	7141	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	3	Epithelial Cell Dysfunction	Salivary and lacrimal gland epithelial cells exhibit intrinsic abnormalities including aberrant apoptosis, antigen presentation via MHC class II, and production of pro-inflammatory cytokines including BAFF.	cell_types[0]	cell_types	cell_types			Epithelial Cell	CL:0000066	epithelial cell		"{""preferred_term"": ""Epithelial Cell"", ""term"": {""id"": ""CL:0000066"", ""label"": ""epithelial cell""}}"																											
6463	7141	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	pathophysiology	3	Epithelial Cell Dysfunction	Salivary and lacrimal gland epithelial cells exhibit intrinsic abnormalities including aberrant apoptosis, antigen presentation via MHC class II, and production of pro-inflammatory cytokines including BAFF.	biological_processes[0]	biological_processes	biological_processes			Apoptotic Process	GO:0006915	apoptotic process		"{""preferred_term"": ""Apoptotic Process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
6464	7142	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	phenotypes	0	Xerostomia		phenotype_term	phenotype_term	$	Xerostomia		Xerostomia	HP:0000217	Xerostomia		"{""preferred_term"": ""Xerostomia"", ""term"": {""id"": ""HP:0000217"", ""label"": ""Xerostomia""}}"																											
6465	7143	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	phenotypes	1	Keratoconjunctivitis Sicca		phenotype_term	phenotype_term	$	Keratoconjunctivitis Sicca		Keratoconjunctivitis Sicca	HP:0001097	Keratoconjunctivitis sicca		"{""preferred_term"": ""Keratoconjunctivitis Sicca"", ""term"": {""id"": ""HP:0001097"", ""label"": ""Keratoconjunctivitis sicca""}}"																											
6466	7144	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	phenotypes	2	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
6467	7145	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	phenotypes	3	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6468	7151	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	environmental	0	Tobacco Smoking	Cigarette smoking is the dominant risk factor for SCLC, with a much stronger association than for lung adenocarcinoma. Tobacco carcinogens drive widespread genomic damage and contribute to TP53 and RB1 inactivation.	exposure_term	exposure_term	$	Tobacco Smoking	Cigarette smoking is the dominant risk factor for SCLC, with a much stronger association than for lung adenocarcinoma. Tobacco carcinogens drive widespread genomic damage and contribute to TP53 and RB1 inactivation.	exposure to tobacco smoking	ECTO:6000029	exposure to tobacco smoking		"{""preferred_term"": ""exposure to tobacco smoking"", ""term"": {""id"": ""ECTO:6000029"", ""label"": ""exposure to tobacco smoking""}}"																											
6469	7162	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	histopathology	0	Neuroendocrine Carcinoma	Small-cell lung cancer is a very aggressive neuroendocrine carcinoma.	finding_term	finding_term	$	Neuroendocrine Carcinoma	Small-cell lung cancer is a very aggressive neuroendocrine carcinoma.	Neuroendocrine Carcinoma	NCIT:C3773	Neuroendocrine Carcinoma		"{""preferred_term"": ""Neuroendocrine Carcinoma"", ""term"": {""id"": ""NCIT:C3773"", ""label"": ""Neuroendocrine Carcinoma""}}"																											
6470	7163	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	0	TP53 Inactivation	TP53 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of p53 function eliminates the G1/S checkpoint and apoptotic response to DNA damage, enabling survival despite genomic instability.	cell_types[0]	cell_types	cell_types			type II pneumocyte	CL:0002063	pulmonary alveolar type 2 cell		"{""preferred_term"": ""type II pneumocyte"", ""term"": {""id"": ""CL:0002063"", ""label"": ""pulmonary alveolar type 2 cell""}}"																											
6471	7163	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	0	TP53 Inactivation	TP53 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of p53 function eliminates the G1/S checkpoint and apoptotic response to DNA damage, enabling survival despite genomic instability.	biological_processes[0]	biological_processes	biological_processes			DNA damage response, signal transduction by p53 class mediator	GO:0030330	DNA damage response, signal transduction by p53 class mediator		"{""modifier"": ""ABSENT"", ""preferred_term"": ""DNA damage response, signal transduction by p53 class mediator"", ""term"": {""id"": ""GO:0030330"", ""label"": ""DNA damage response, signal transduction by p53 class mediator""}}"			ABSENT																								
6472	7164	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	1	RB1 Inactivation	RB1 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of Rb function eliminates the G1/S checkpoint by releasing E2F transcription factors, enabling uncontrolled S-phase entry.	biological_processes[0]	biological_processes	biological_processes			negative regulation of G1/S transition of mitotic cell cycle	GO:0045736	negative regulation of G1/S transition of mitotic cell cycle		"{""modifier"": ""ABSENT"", ""preferred_term"": ""negative regulation of G1/S transition of mitotic cell cycle"", ""term"": {""id"": ""GO:0045736"", ""label"": ""negative regulation of G1/S transition of mitotic cell cycle""}}"			ABSENT																								
6473	7165	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	2	Loss of Cell Cycle Checkpoints	Combined TP53 and RB1 loss eliminates major cell cycle checkpoints. Cells proliferate rapidly without the normal restraints on replication. This explains the rapid doubling time and initial chemosensitivity (dividing cells are vulnerable to chemotherapy).	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
6474	7166	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	3	Genomic Instability	Loss of TP53 and RB1 leads to widespread genomic instability with frequent chromosomal gains and losses. Amplification of MYC family genes (MYC, MYCL, MYCN) occurs in ~20% of SCLC and is associated with worse prognosis.	biological_processes[0]	biological_processes	biological_processes			DNA repair	GO:0006281	DNA repair		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""DNA repair"", ""term"": {""id"": ""GO:0006281"", ""label"": ""DNA repair""}}"			ABNORMAL																								
6475	7167	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	4	Neuroendocrine Differentiation	SCLC cells exhibit neuroendocrine differentiation, expressing markers such as synaptophysin, chromogranin A, and CD56 (NCAM). Neuroendocrine phenotype is regulated by lineage transcription factors (ASCL1, NEUROD1). Some SCLC produces paraneoplastic hormones (ACTH, ADH).	biological_processes[0]	biological_processes	biological_processes			neuron differentiation	GO:0030182	neuron differentiation		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""neuron differentiation"", ""term"": {""id"": ""GO:0030182"", ""label"": ""neuron differentiation""}}"			ABNORMAL																								
6476	7168	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	5	Functional Neuron-SCLC Synapses	SCLC cells can form functional synapses with neurons and receive synaptic transmission.	biological_processes[0]	biological_processes	biological_processes			synapse assembly	GO:0007416	synapse assembly		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""synapse assembly"", ""term"": {""id"": ""GO:0007416"", ""label"": ""synapse assembly""}}"			ABNORMAL																								
6477	7168	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	5	Functional Neuron-SCLC Synapses	SCLC cells can form functional synapses with neurons and receive synaptic transmission.	biological_processes[1]	biological_processes	biological_processes			chemical synaptic transmission	GO:0007268	chemical synaptic transmission		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""chemical synaptic transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"			ABNORMAL																								
6478	7169	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	6	Neuron-Driven Proliferation	SCLC cells gain a proliferation advantage when co-cultured with neurons.	biological_processes[0]	biological_processes	biological_processes			positive regulation of cell population proliferation	GO:0008284	positive regulation of cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""positive regulation of cell population proliferation"", ""term"": {""id"": ""GO:0008284"", ""label"": ""positive regulation of cell population proliferation""}}"			INCREASED																								
6479	7170	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	7	Glutamate Signaling Dependency	Inhibition of glutamate signaling has therapeutic efficacy in SCLC models, implicating glutamatergic signaling in tumor growth.	biological_processes[0]	biological_processes	biological_processes			glutamate receptor signaling pathway	GO:0007215	glutamate receptor signaling pathway		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""glutamate receptor signaling pathway"", ""term"": {""id"": ""GO:0007215"", ""label"": ""glutamate receptor signaling pathway""}}"			ABNORMAL																								
6480	7170	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	pathophysiology	7	Glutamate Signaling Dependency	Inhibition of glutamate signaling has therapeutic efficacy in SCLC models, implicating glutamatergic signaling in tumor growth.	biological_processes[1]	biological_processes	biological_processes			synaptic transmission, glutamatergic	GO:0035249	synaptic transmission, glutamatergic		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""synaptic transmission, glutamatergic"", ""term"": {""id"": ""GO:0035249"", ""label"": ""synaptic transmission, glutamatergic""}}"			ABNORMAL																								
6481	7171	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	phenotypes	0	Lung Neoplasm	SCLC typically presents as a central/hilar mass with extensive mediastinal lymphadenopathy. Peripheral nodules are rare.	phenotype_term	phenotype_term	$	Lung Neoplasm	SCLC typically presents as a central/hilar mass with extensive mediastinal lymphadenopathy. Peripheral nodules are rare.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6482	7172	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	phenotypes	1	Smoking Association	SCLC is strongly associated with tobacco smoking, with >95% of patients having smoking history. SCLC rarely occurs in never-smokers.	phenotype_term	phenotype_term	$	Smoking Association	SCLC is strongly associated with tobacco smoking, with >95% of patients having smoking history. SCLC rarely occurs in never-smokers.	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6483	7173	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	phenotypes	2	Brain Metastases	Brain metastases are extremely common in SCLC, occurring in up to 50-80% of patients during disease course. Prophylactic cranial irradiation (PCI) may reduce this risk in responders.	phenotype_term	phenotype_term	$	Brain Metastases	Brain metastases are extremely common in SCLC, occurring in up to 50-80% of patients during disease course. Prophylactic cranial irradiation (PCI) may reduce this risk in responders.	Neoplasm of the nervous system	HP:0004375	Neoplasm of the nervous system		"{""preferred_term"": ""Neoplasm of the nervous system"", ""term"": {""id"": ""HP:0004375"", ""label"": ""Neoplasm of the nervous system""}}"																											
6484	7174	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	phenotypes	3	Paraneoplastic Syndromes	SCLC commonly produces paraneoplastic syndromes including SIADH (hyponatremia), Cushing syndrome (ectopic ACTH), Lambert-Eaton myasthenic syndrome (anti-VGCC antibodies), and limbic encephalitis (anti-Hu antibodies).	phenotype_term	phenotype_term	$	Paraneoplastic Syndromes	SCLC commonly produces paraneoplastic syndromes including SIADH (hyponatremia), Cushing syndrome (ectopic ACTH), Lambert-Eaton myasthenic syndrome (anti-VGCC antibodies), and limbic encephalitis (anti-Hu antibodies).	Neoplasm of the lung	HP:0100526	Neoplasm of the lung		"{""preferred_term"": ""Neoplasm of the lung"", ""term"": {""id"": ""HP:0100526"", ""label"": ""Neoplasm of the lung""}}"																											
6485	7175	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	0	Platinum-Etoposide Chemotherapy	Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.	treatment_term	treatment_term	$	Platinum-Etoposide Chemotherapy	Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6486	7176	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	1	Atezolizumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.	treatment_term	treatment_term	$	Atezolizumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6487	7177	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	2	Durvalumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.	treatment_term	treatment_term	$	Durvalumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6488	7178	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	3	Thoracic Radiation	Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.	treatment_term	treatment_term	$	Thoracic Radiation	Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6489	7179	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	4	Prophylactic Cranial Irradiation	Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.	treatment_term	treatment_term	$	Prophylactic Cranial Irradiation	Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6490	7180	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	5	Lurbinectedin	Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.	treatment_term	treatment_term	$	Lurbinectedin	Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6491	7181	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	6	Topotecan	Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.	treatment_term	treatment_term	$	Topotecan	Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6492	7182	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	pathophysiology	0	Bacterial overgrowth in small intestine	"Excessive bacterial colonization of the small intestine leads to malabsorption, nutrient deficiencies, and gastrointestinal symptoms. Disruption of gastric acid, motility (including migrating motor complex), and the ileocecal barrier promotes overgrowth. Bacterial fermentation produces hydrogen, methane, and short-chain fatty acids while bile acid deconjugation impairs fat absorption.
"	biological_processes[0]	biological_processes	biological_processes			response to bile acid	GO:0033993	response to bile acid		"{""preferred_term"": ""response to bile acid"", ""term"": {""id"": ""GO:0033993"", ""label"": ""response to bile acid""}}"																											
6493	7182	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	pathophysiology	0	Bacterial overgrowth in small intestine	"Excessive bacterial colonization of the small intestine leads to malabsorption, nutrient deficiencies, and gastrointestinal symptoms. Disruption of gastric acid, motility (including migrating motor complex), and the ileocecal barrier promotes overgrowth. Bacterial fermentation produces hydrogen, methane, and short-chain fatty acids while bile acid deconjugation impairs fat absorption.
"	biological_processes[1]	biological_processes	biological_processes			tight junction assembly	GO:0070830	tight junction assembly		"{""preferred_term"": ""tight junction assembly"", ""term"": {""id"": ""GO:0070830"", ""label"": ""tight junction assembly""}}"																											
6494	7182	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	pathophysiology	0	Bacterial overgrowth in small intestine	"Excessive bacterial colonization of the small intestine leads to malabsorption, nutrient deficiencies, and gastrointestinal symptoms. Disruption of gastric acid, motility (including migrating motor complex), and the ileocecal barrier promotes overgrowth. Bacterial fermentation produces hydrogen, methane, and short-chain fatty acids while bile acid deconjugation impairs fat absorption.
"	cell_types[0]	cell_types	cell_types			enterocyte	CL:0000584	enterocyte		"{""preferred_term"": ""enterocyte"", ""term"": {""id"": ""CL:0000584"", ""label"": ""enterocyte""}}"																											
6495	7182	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	pathophysiology	0	Bacterial overgrowth in small intestine	"Excessive bacterial colonization of the small intestine leads to malabsorption, nutrient deficiencies, and gastrointestinal symptoms. Disruption of gastric acid, motility (including migrating motor complex), and the ileocecal barrier promotes overgrowth. Bacterial fermentation produces hydrogen, methane, and short-chain fatty acids while bile acid deconjugation impairs fat absorption.
"	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
6496	7183	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	phenotypes	0	Abdominal bloating	Distension and discomfort from bacterial fermentation of carbohydrates.	phenotype_term	phenotype_term	$	Abdominal bloating	Distension and discomfort from bacterial fermentation of carbohydrates.	Abdominal distention	HP:0003270	Abdominal distention		"{""preferred_term"": ""Abdominal distention"", ""term"": {""id"": ""HP:0003270"", ""label"": ""Abdominal distention""}}"																											
6497	7184	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	phenotypes	1	Diarrhea	Loose stools due to malabsorption and bacterial metabolites.	phenotype_term	phenotype_term	$	Diarrhea	Loose stools due to malabsorption and bacterial metabolites.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
6498	7185	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	phenotypes	2	Malabsorption	Impaired nutrient absorption leading to deficiencies, especially vitamin B12.	phenotype_term	phenotype_term	$	Malabsorption	Impaired nutrient absorption leading to deficiencies, especially vitamin B12.	Intestinal malabsorption	HP:0002024	Malabsorption		"{""preferred_term"": ""Intestinal malabsorption"", ""term"": {""id"": ""HP:0002024"", ""label"": ""Malabsorption""}}"																											
6499	7186	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	phenotypes	3	Abdominal pain		phenotype_term	phenotype_term	$	Abdominal pain		Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
6500	7187	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	phenotypes	4	Vitamin B12 deficiency		phenotype_term	phenotype_term	$	Vitamin B12 deficiency		Vitamin B12 deficiency	HP:0100502	Decreased circulating vitamin B12 concentration		"{""preferred_term"": ""Vitamin B12 deficiency"", ""term"": {""id"": ""HP:0100502"", ""label"": ""Decreased circulating vitamin B12 concentration""}}"																											
6501	7188	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	0	Antibiotic therapy	Rifaximin or other antibiotics to reduce bacterial overgrowth.	treatment_term	treatment_term	$	Antibiotic therapy	Rifaximin or other antibiotics to reduce bacterial overgrowth.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6502	7189	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	1	Dietary modification	Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.	treatment_term	treatment_term	$	Dietary modification	Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
6503	7190	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	2	Prokinetic agents	Medications to improve intestinal motility and reduce stasis.	treatment_term	treatment_term	$	Prokinetic agents	Medications to improve intestinal motility and reduce stasis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6504	7193	310	Snakebite envenoming	Snakebite_Envenoming.yaml	phenotypes	0	Edema		phenotype_term	phenotype_term	$	Edema		Edema	HP:0000969	Edema		"{""preferred_term"": ""Edema"", ""term"": {""id"": ""HP:0000969"", ""label"": ""Edema""}}"																											
6505	7194	310	Snakebite envenoming	Snakebite_Envenoming.yaml	phenotypes	1	Abnormal bleeding		phenotype_term	phenotype_term	$	Abnormal bleeding		Abnormal bleeding	HP:0001892	Abnormal bleeding		"{""preferred_term"": ""Abnormal bleeding"", ""term"": {""id"": ""HP:0001892"", ""label"": ""Abnormal bleeding""}}"																											
6506	7195	310	Snakebite envenoming	Snakebite_Envenoming.yaml	phenotypes	2	Paralysis		phenotype_term	phenotype_term	$	Paralysis		Paralysis	HP:0003470	Paralysis		"{""preferred_term"": ""Paralysis"", ""term"": {""id"": ""HP:0003470"", ""label"": ""Paralysis""}}"																											
6507	7196	310	Snakebite envenoming	Snakebite_Envenoming.yaml	phenotypes	3	Acute kidney injury		phenotype_term	phenotype_term	$	Acute kidney injury		Acute kidney injury	HP:0001919	Acute kidney injury		"{""preferred_term"": ""Acute kidney injury"", ""term"": {""id"": ""HP:0001919"", ""label"": ""Acute kidney injury""}}"																											
6508	7197	310	Snakebite envenoming	Snakebite_Envenoming.yaml	treatments	0	Antivenom administration	Intravenous antivenom is the only specific therapy to counteract envenoming.	treatment_term	treatment_term	$	Antivenom administration	Intravenous antivenom is the only specific therapy to counteract envenoming.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6509	7198	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	infectious_agent	0	Ascaris lumbricoides	Intestinal roundworm causing ascariasis.	infectious_agent_term	infectious_agent_term	$	Ascaris lumbricoides	Intestinal roundworm causing ascariasis.	Ascaris lumbricoides	NCBITaxon:6252	Ascaris lumbricoides		"{""preferred_term"": ""Ascaris lumbricoides"", ""term"": {""id"": ""NCBITaxon:6252"", ""label"": ""Ascaris lumbricoides""}}"																											
6510	7199	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	infectious_agent	1	Trichuris trichiura	Whipworm causing trichuriasis.	infectious_agent_term	infectious_agent_term	$	Trichuris trichiura	Whipworm causing trichuriasis.	Trichuris trichiura	NCBITaxon:36087	Trichuris trichiura		"{""preferred_term"": ""Trichuris trichiura"", ""term"": {""id"": ""NCBITaxon:36087"", ""label"": ""Trichuris trichiura""}}"																											
6511	7200	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	infectious_agent	2	Ancylostoma duodenale	Hookworm species infecting humans.	infectious_agent_term	infectious_agent_term	$	Ancylostoma duodenale	Hookworm species infecting humans.	Ancylostoma duodenale	NCBITaxon:51022	Ancylostoma duodenale		"{""preferred_term"": ""Ancylostoma duodenale"", ""term"": {""id"": ""NCBITaxon:51022"", ""label"": ""Ancylostoma duodenale""}}"																											
6512	7201	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	infectious_agent	3	Necator americanus	Predominant hookworm species infecting humans.	infectious_agent_term	infectious_agent_term	$	Necator americanus	Predominant hookworm species infecting humans.	Necator americanus	NCBITaxon:51031	Necator americanus		"{""preferred_term"": ""Necator americanus"", ""term"": {""id"": ""NCBITaxon:51031"", ""label"": ""Necator americanus""}}"																											
6513	7202	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	infectious_agent	4	Strongyloides stercoralis	Threadworm included among soil-transmitted helminths.	infectious_agent_term	infectious_agent_term	$	Strongyloides stercoralis	Threadworm included among soil-transmitted helminths.	Strongyloides stercoralis	NCBITaxon:6248	Strongyloides stercoralis		"{""preferred_term"": ""Strongyloides stercoralis"", ""term"": {""id"": ""NCBITaxon:6248"", ""label"": ""Strongyloides stercoralis""}}"																											
6514	7204	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	phenotypes	0	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
6515	7206	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	treatments	0	Albendazole or mebendazole therapy	Benzimidazole anthelmintics used for treatment and preventive deworming.	treatment_term	treatment_term	$	Albendazole or mebendazole therapy	Benzimidazole anthelmintics used for treatment and preventive deworming.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6516	7208	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	datasets	0		RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.	organism	organism	$		RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.	mouse	NCBITaxon:10090	Mus musculus		"{""preferred_term"": ""mouse"", ""term"": {""id"": ""NCBITaxon:10090"", ""label"": ""Mus musculus""}}"																											
6517	7208	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	datasets	0		RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.	sample_types[0]	sample_types	sample_types			motor neuron				"{""cell_type_term"": {""preferred_term"": ""motor neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}, ""preferred_term"": ""motor neuron""}"																											
6518	7208	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	datasets	0		RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.	sample_types[0].cell_type_term	sample_types	sample_types[0]			motor neuron	CL:0000100	motor neuron		"{""preferred_term"": ""motor neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
6519	7215	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	pathophysiology	0	SMN Protein Deficiency	"Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor neuron protein. SMN2 gene produces some functional protein but mostly truncated due to exon 7 skipping. SMN protein is essential for motor neuron survival and function.
"	cell_types[0]	cell_types	cell_types			Motor Neuron	CL:0000100	motor neuron		"{""preferred_term"": ""Motor Neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
6520	7215	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	pathophysiology	0	SMN Protein Deficiency	"Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor neuron protein. SMN2 gene produces some functional protein but mostly truncated due to exon 7 skipping. SMN protein is essential for motor neuron survival and function.
"	biological_processes[0]	biological_processes	biological_processes			Motor Neuron Development	GO:0048666	neuron development		"{""preferred_term"": ""Motor Neuron Development"", ""term"": {""id"": ""GO:0048666"", ""label"": ""neuron development""}}"																											
6521	7216	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	pathophysiology	1	Motor Neuron Degeneration	"Loss of alpha motor neurons in the anterior horn of the spinal cord leads to progressive denervation of skeletal muscles. Proximal muscles are more severely affected than distal muscles.
"	cell_types[0]	cell_types	cell_types			Motor Neuron	CL:0000100	motor neuron		"{""preferred_term"": ""Motor Neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
6522	7216	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	pathophysiology	1	Motor Neuron Degeneration	"Loss of alpha motor neurons in the anterior horn of the spinal cord leads to progressive denervation of skeletal muscles. Proximal muscles are more severely affected than distal muscles.
"	biological_processes[0]	biological_processes	biological_processes			Neurodegeneration	GO:0070997	neuron death		"{""preferred_term"": ""Neurodegeneration"", ""term"": {""id"": ""GO:0070997"", ""label"": ""neuron death""}}"																											
6523	7217	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	0	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
6524	7218	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	1	Progressive Muscle Weakness		phenotype_term	phenotype_term	$	Progressive Muscle Weakness		Progressive Muscle Weakness	HP:0003323	Progressive muscle weakness		"{""preferred_term"": ""Progressive Muscle Weakness"", ""term"": {""id"": ""HP:0003323"", ""label"": ""Progressive muscle weakness""}}"																											
6525	7219	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	2	Areflexia		phenotype_term	phenotype_term	$	Areflexia		Areflexia	HP:0001284	Areflexia		"{""preferred_term"": ""Areflexia"", ""term"": {""id"": ""HP:0001284"", ""label"": ""Areflexia""}}"																											
6526	7220	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	3	Fasciculations		phenotype_term	phenotype_term	$	Fasciculations		Fasciculations	HP:0002380	Fasciculations		"{""preferred_term"": ""Fasciculations"", ""term"": {""id"": ""HP:0002380"", ""label"": ""Fasciculations""}}"																											
6527	7221	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	4	Respiratory Failure		phenotype_term	phenotype_term	$	Respiratory Failure		Respiratory Failure	HP:0002878	Respiratory failure		"{""preferred_term"": ""Respiratory Failure"", ""term"": {""id"": ""HP:0002878"", ""label"": ""Respiratory failure""}}"																											
6528	7222	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	phenotypes	5	Scoliosis		phenotype_term	phenotype_term	$	Scoliosis		Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
6529	7229	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEMD Strudwick produce abnormal type II collagen that disrupts cartilage matrix integrity. The characteristic metaphyseal changes reflect abnormal endochondral ossification at the growth plate. The specific mutations may cause distinctive structural abnormalities in the collagen triple helix.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6530	7229	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEMD Strudwick produce abnormal type II collagen that disrupts cartilage matrix integrity. The characteristic metaphyseal changes reflect abnormal endochondral ossification at the growth plate. The specific mutations may cause distinctive structural abnormalities in the collagen triple helix.
"	cell_types[1]	cell_types	cell_types			Growth Plate Chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth Plate Chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
6531	7229	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEMD Strudwick produce abnormal type II collagen that disrupts cartilage matrix integrity. The characteristic metaphyseal changes reflect abnormal endochondral ossification at the growth plate. The specific mutations may cause distinctive structural abnormalities in the collagen triple helix.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
6532	7229	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEMD Strudwick produce abnormal type II collagen that disrupts cartilage matrix integrity. The characteristic metaphyseal changes reflect abnormal endochondral ossification at the growth plate. The specific mutations may cause distinctive structural abnormalities in the collagen triple helix.
"	biological_processes[1]	biological_processes	biological_processes			Endochondral Ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral Ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
6533	7230	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	0	Disproportionate Short-Trunk Short Stature	"Short stature with disproportionately short trunk evident from infancy.
"	phenotype_term	phenotype_term	$	Disproportionate Short-Trunk Short Stature	"Short stature with disproportionately short trunk evident from infancy.
"	Disproportionate short-trunk short stature	HP:0003521	Disproportionate short-trunk short stature		"{""preferred_term"": ""Disproportionate short-trunk short stature"", ""term"": {""id"": ""HP:0003521"", ""label"": ""Disproportionate short-trunk short stature""}}"																											
6534	7231	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	1	Scoliosis	"Progressive scoliosis is a major feature requiring monitoring and often surgical intervention.
"	phenotype_term	phenotype_term	$	Scoliosis	"Progressive scoliosis is a major feature requiring monitoring and often surgical intervention.
"	Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
6535	7232	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	2	Pectus Carinatum	"Protuberant chest deformity is characteristic.
"	phenotype_term	phenotype_term	$	Pectus Carinatum	"Protuberant chest deformity is characteristic.
"	Pectus carinatum	HP:0000768	Pectus carinatum		"{""preferred_term"": ""Pectus carinatum"", ""term"": {""id"": ""HP:0000768"", ""label"": ""Pectus carinatum""}}"																											
6536	7233	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	3	Platyspondyly	"Flattened vertebral bodies visible on spine radiographs.
"	phenotype_term	phenotype_term	$	Platyspondyly	"Flattened vertebral bodies visible on spine radiographs.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
6537	7234	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	4	Metaphyseal Irregularity	"Characteristic dappled or striated metaphyseal changes on radiographs, distinctive of the Strudwick type.
"	phenotype_term	phenotype_term	$	Metaphyseal Irregularity	"Characteristic dappled or striated metaphyseal changes on radiographs, distinctive of the Strudwick type.
"	Abnormal metaphysis morphology	HP:0000944	Abnormal metaphysis morphology		"{""preferred_term"": ""Abnormal metaphysis morphology"", ""term"": {""id"": ""HP:0000944"", ""label"": ""Abnormal metaphysis morphology""}}"																											
6538	7235	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	5	Cleft Palate	"Cleft palate occurs in some affected individuals.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Cleft palate occurs in some affected individuals.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
6539	7236	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	6	Genu Valgum	"Knock-knees may develop with growth.
"	phenotype_term	phenotype_term	$	Genu Valgum	"Knock-knees may develop with growth.
"	Genu valgum	HP:0002857	Genu valgum		"{""preferred_term"": ""Genu valgum"", ""term"": {""id"": ""HP:0002857"", ""label"": ""Genu valgum""}}"																											
6540	7237	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	7	Myopia	"Myopia may occur as in other type 2 collagenopathies.
"	phenotype_term	phenotype_term	$	Myopia	"Myopia may occur as in other type 2 collagenopathies.
"	Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
6541	7238	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	8	Hearing Loss	"Sensorineural hearing loss may occur.
"	phenotype_term	phenotype_term	$	Hearing Loss	"Sensorineural hearing loss may occur.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
6542	7239	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	phenotypes	9	Early-Onset Osteoarthritis	"Premature degenerative osteoarthrosis is a significant complication affecting the course of the disease.
"	phenotype_term	phenotype_term	$	Early-Onset Osteoarthritis	"Premature degenerative osteoarthrosis is a significant complication affecting the course of the disease.
"	Osteoarthritis	HP:0002758	Osteoarthritis		"{""preferred_term"": ""Osteoarthritis"", ""term"": {""id"": ""HP:0002758"", ""label"": ""Osteoarthritis""}}"																											
6543	7240	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	0	Orthopedic Management	"Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6544	7243	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	3	Cleft Palate Repair	"Surgical repair if cleft palate present.
"	treatment_term	treatment_term	$	Cleft Palate Repair	"Surgical repair if cleft palate present.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6545	7246	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEDC produce partially functional type II collagen that is incorporated into cartilage matrix but with compromised structural integrity. This results in abnormal endochondral ossification affecting the spine and epiphyses, as well as ocular and auricular cartilage abnormalities.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6546	7246	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEDC produce partially functional type II collagen that is incorporated into cartilage matrix but with compromised structural integrity. This results in abnormal endochondral ossification affecting the spine and epiphyses, as well as ocular and auricular cartilage abnormalities.
"	cell_types[1]	cell_types	cell_types			Growth Plate Chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth Plate Chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
6547	7246	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEDC produce partially functional type II collagen that is incorporated into cartilage matrix but with compromised structural integrity. This results in abnormal endochondral ossification affecting the spine and epiphyses, as well as ocular and auricular cartilage abnormalities.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
6548	7246	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEDC produce partially functional type II collagen that is incorporated into cartilage matrix but with compromised structural integrity. This results in abnormal endochondral ossification affecting the spine and epiphyses, as well as ocular and auricular cartilage abnormalities.
"	biological_processes[1]	biological_processes	biological_processes			Cartilage Development	GO:0051216	cartilage development		"{""preferred_term"": ""Cartilage Development"", ""term"": {""id"": ""GO:0051216"", ""label"": ""cartilage development""}}"																											
6549	7246	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	0	Type II Collagen Dysfunction	"COL2A1 mutations in SEDC produce partially functional type II collagen that is incorporated into cartilage matrix but with compromised structural integrity. This results in abnormal endochondral ossification affecting the spine and epiphyses, as well as ocular and auricular cartilage abnormalities.
"	biological_processes[2]	biological_processes	biological_processes			Endochondral Ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral Ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
6550	7247	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	pathophysiology	1	Vitreous Collagen Abnormality	"Type II collagen is a major component of the vitreous humor. Abnormal collagen leads to vitreous liquefaction, posterior vitreous detachment, and increased risk of retinal detachment.
"	biological_processes[0]	biological_processes	biological_processes			Eye Development	GO:0001654	eye development		"{""preferred_term"": ""Eye Development"", ""term"": {""id"": ""GO:0001654"", ""label"": ""eye development""}}"																											
6551	7248	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	0	Disproportionate Short-Trunk Short Stature	"Short stature with disproportionately short trunk. Adult height typically ranges from 84-128 cm.
"	phenotype_term	phenotype_term	$	Disproportionate Short-Trunk Short Stature	"Short stature with disproportionately short trunk. Adult height typically ranges from 84-128 cm.
"	Disproportionate short-trunk short stature	HP:0003521	Disproportionate short-trunk short stature		"{""preferred_term"": ""Disproportionate short-trunk short stature"", ""term"": {""id"": ""HP:0003521"", ""label"": ""Disproportionate short-trunk short stature""}}"																											
6552	7249	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	1	Platyspondyly	"Flattened vertebral bodies visible on spine radiographs, contributing to short trunk.
"	phenotype_term	phenotype_term	$	Platyspondyly	"Flattened vertebral bodies visible on spine radiographs, contributing to short trunk.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
6553	7250	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	2	Flat Face	"Midface hypoplasia with flat facial profile is characteristic.
"	phenotype_term	phenotype_term	$	Flat Face	"Midface hypoplasia with flat facial profile is characteristic.
"	Flat face	HP:0012368	Flat face		"{""preferred_term"": ""Flat face"", ""term"": {""id"": ""HP:0012368"", ""label"": ""Flat face""}}"																											
6554	7251	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	3	Myopia	"High myopia is common due to abnormal eye development and increased axial length.
"	phenotype_term	phenotype_term	$	Myopia	"High myopia is common due to abnormal eye development and increased axial length.
"	Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
6555	7252	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	4	Retinal Detachment	"Increased risk of retinal detachment due to vitreous abnormalities.
"	phenotype_term	phenotype_term	$	Retinal Detachment	"Increased risk of retinal detachment due to vitreous abnormalities.
"	Retinal detachment	HP:0000541	Retinal detachment		"{""preferred_term"": ""Retinal detachment"", ""term"": {""id"": ""HP:0000541"", ""label"": ""Retinal detachment""}}"																											
6556	7253	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	5	Sensorineural Hearing Loss	"Progressive sensorineural hearing impairment occurs in many affected individuals.
"	phenotype_term	phenotype_term	$	Sensorineural Hearing Loss	"Progressive sensorineural hearing impairment occurs in many affected individuals.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
6557	7254	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	6	Odontoid Hypoplasia	"Underdevelopment of the odontoid process creates risk of atlantoaxial instability and cervical myelopathy.
"	phenotype_term	phenotype_term	$	Odontoid Hypoplasia	"Underdevelopment of the odontoid process creates risk of atlantoaxial instability and cervical myelopathy.
"	Odontoid hypoplasia	HP:0003311	Hypoplasia of the odontoid process		"{""preferred_term"": ""Odontoid hypoplasia"", ""term"": {""id"": ""HP:0003311"", ""label"": ""Hypoplasia of the odontoid process""}}"																											
6558	7255	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	7	Pectus Carinatum	"Protuberant chest deformity commonly observed.
"	phenotype_term	phenotype_term	$	Pectus Carinatum	"Protuberant chest deformity commonly observed.
"	Pectus carinatum	HP:0000768	Pectus carinatum		"{""preferred_term"": ""Pectus carinatum"", ""term"": {""id"": ""HP:0000768"", ""label"": ""Pectus carinatum""}}"																											
6559	7256	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	8	Coxa Vara	"Hip deformity with reduced femoral neck angle, contributing to waddling gait and early-onset hip osteoarthritis.
"	phenotype_term	phenotype_term	$	Coxa Vara	"Hip deformity with reduced femoral neck angle, contributing to waddling gait and early-onset hip osteoarthritis.
"	Coxa vara	HP:0002812	Coxa vara		"{""preferred_term"": ""Coxa vara"", ""term"": {""id"": ""HP:0002812"", ""label"": ""Coxa vara""}}"																											
6560	7257	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	9	Clubfoot	"Congenital clubfoot occurs in some affected individuals.
"	phenotype_term	phenotype_term	$	Clubfoot	"Congenital clubfoot occurs in some affected individuals.
"	Talipes equinovarus	HP:0001762	Talipes equinovarus		"{""preferred_term"": ""Talipes equinovarus"", ""term"": {""id"": ""HP:0001762"", ""label"": ""Talipes equinovarus""}}"																											
6561	7258	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	phenotypes	10	Cleft Palate	"Cleft palate, including submucous cleft palate, is a common feature in SEDC and may be associated with Pierre Robin sequence.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Cleft palate, including submucous cleft palate, is a common feature in SEDC and may be associated with Pierre Robin sequence.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
6562	7259	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	treatments	0	Orthopedic Management	"Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6563	7264	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	pathophysiology	0	Type II Collagen Haploinsufficiency	"Most STL1 mutations cause premature termination codons leading to nonsense- mediated decay and haploinsufficiency of type II collagen. This results in quantitative rather than qualitative collagen deficiency, producing a milder phenotype than dominant-negative mutations. Tissues with high type II collagen content (vitreous, cartilage, inner ear) are primarily affected.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6564	7264	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	pathophysiology	0	Type II Collagen Haploinsufficiency	"Most STL1 mutations cause premature termination codons leading to nonsense- mediated decay and haploinsufficiency of type II collagen. This results in quantitative rather than qualitative collagen deficiency, producing a milder phenotype than dominant-negative mutations. Tissues with high type II collagen content (vitreous, cartilage, inner ear) are primarily affected.
"	biological_processes[0]	biological_processes	biological_processes			Collagen Biosynthesis	GO:0032964	collagen biosynthetic process		"{""preferred_term"": ""Collagen Biosynthesis"", ""term"": {""id"": ""GO:0032964"", ""label"": ""collagen biosynthetic process""}}"																											
6565	7264	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	pathophysiology	0	Type II Collagen Haploinsufficiency	"Most STL1 mutations cause premature termination codons leading to nonsense- mediated decay and haploinsufficiency of type II collagen. This results in quantitative rather than qualitative collagen deficiency, producing a milder phenotype than dominant-negative mutations. Tissues with high type II collagen content (vitreous, cartilage, inner ear) are primarily affected.
"	biological_processes[1]	biological_processes	biological_processes			Eye Development	GO:0001654	eye development		"{""preferred_term"": ""Eye Development"", ""term"": {""id"": ""GO:0001654"", ""label"": ""eye development""}}"																											
6566	7265	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	pathophysiology	1	Vitreous Collagen Abnormality	"Type II collagen is essential for vitreous structure. Reduced collagen leads to vitreous liquefaction with characteristic membranous remnants visible on slit-lamp examination, posterior vitreous detachment, and increased retinal detachment risk.
"	biological_processes[0]	biological_processes	biological_processes			Eye Development	GO:0001654	eye development		"{""preferred_term"": ""Eye Development"", ""term"": {""id"": ""GO:0001654"", ""label"": ""eye development""}}"																											
6567	7266	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	0	Membranous Vitreous	"Characteristic membranous vitreous appearance on slit-lamp examination, pathognomonic for STL1.
"	phenotype_term	phenotype_term	$	Membranous Vitreous	"Characteristic membranous vitreous appearance on slit-lamp examination, pathognomonic for STL1.
"	Membranous vitreous appearance	HP:0031153	Membranous vitreous appearance		"{""preferred_term"": ""Membranous vitreous appearance"", ""term"": {""id"": ""HP:0031153"", ""label"": ""Membranous vitreous appearance""}}"																											
6568	7267	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	1	High Myopia	"Congenital high myopia, often severe, is a cardinal feature.
"	phenotype_term	phenotype_term	$	High Myopia	"Congenital high myopia, often severe, is a cardinal feature.
"	Myopia	HP:0000545	Myopia		"{""preferred_term"": ""Myopia"", ""term"": {""id"": ""HP:0000545"", ""label"": ""Myopia""}}"																											
6569	7268	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	2	Retinal Detachment	"Significantly increased lifetime risk of retinal detachment, often giant retinal tears. May be bilateral and recurrent.
"	phenotype_term	phenotype_term	$	Retinal Detachment	"Significantly increased lifetime risk of retinal detachment, often giant retinal tears. May be bilateral and recurrent.
"	Retinal detachment	HP:0000541	Retinal detachment		"{""preferred_term"": ""Retinal detachment"", ""term"": {""id"": ""HP:0000541"", ""label"": ""Retinal detachment""}}"																											
6570	7269	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	3	Sensorineural Hearing Loss	"Progressive sensorineural hearing loss, typically high-frequency, affects many individuals.
"	phenotype_term	phenotype_term	$	Sensorineural Hearing Loss	"Progressive sensorineural hearing loss, typically high-frequency, affects many individuals.
"	Sensorineural hearing impairment	HP:0000407	Sensorineural hearing impairment		"{""preferred_term"": ""Sensorineural hearing impairment"", ""term"": {""id"": ""HP:0000407"", ""label"": ""Sensorineural hearing impairment""}}"																											
6571	7270	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	4	Midface Hypoplasia	"Flat midface with depressed nasal bridge is common.
"	phenotype_term	phenotype_term	$	Midface Hypoplasia	"Flat midface with depressed nasal bridge is common.
"	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
6572	7271	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	5	Cleft Palate	"Cleft palate, often Pierre Robin sequence with micrognathia and glossoptosis, occurs in some affected individuals.
"	phenotype_term	phenotype_term	$	Cleft Palate	"Cleft palate, often Pierre Robin sequence with micrognathia and glossoptosis, occurs in some affected individuals.
"	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
6573	7272	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	6	Joint Hypermobility	"Generalized joint hypermobility is common in childhood, often evolving into joint pain and early-onset osteoarthritis.
"	phenotype_term	phenotype_term	$	Joint Hypermobility	"Generalized joint hypermobility is common in childhood, often evolving into joint pain and early-onset osteoarthritis.
"	Joint hypermobility	HP:0001382	Joint hypermobility		"{""preferred_term"": ""Joint hypermobility"", ""term"": {""id"": ""HP:0001382"", ""label"": ""Joint hypermobility""}}"																											
6574	7273	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	phenotypes	7	Premature Osteoarthritis	"Premature degenerative joint disease, particularly affecting weight-bearing joints.
"	phenotype_term	phenotype_term	$	Premature Osteoarthritis	"Premature degenerative joint disease, particularly affecting weight-bearing joints.
"	Premature osteoarthritis	HP:0003088	Premature osteoarthritis		"{""preferred_term"": ""Premature osteoarthritis"", ""term"": {""id"": ""HP:0003088"", ""label"": ""Premature osteoarthritis""}}"																											
6575	7274	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	0	Prophylactic Retinal Treatment	"Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.
"	treatment_term	treatment_term	$	Prophylactic Retinal Treatment	"Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.
"	Ophthalmologic procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Ophthalmologic procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6576	7276	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	2	Joint Protection	"Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.
"	treatment_term	treatment_term	$	Joint Protection	"Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
6577	7277	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	3	Cleft Repair	"Surgical repair for cleft palate; management of Pierre Robin sequence if present.
"	treatment_term	treatment_term	$	Cleft Repair	"Surgical repair for cleft palate; management of Pierre Robin sequence if present.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6578	7286	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	0	GABAergic Inhibition Impairment	Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that synthesizes GABA from glutamate. This leads to reduced GABA production and impaired inhibitory neurotransmission, resulting in neuronal hyperexcitability. GAD65 is predominantly localized to synaptic vesicles and provides additional GABA synthesis when there is increased demand for rapid neurotransmitter release during high-frequency neural firing.	cell_types[0]	cell_types	cell_types			GABAergic Interneuron	CL:0011005	GABAergic interneuron		"{""preferred_term"": ""GABAergic Interneuron"", ""term"": {""id"": ""CL:0011005"", ""label"": ""GABAergic interneuron""}}"																											
6579	7286	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	0	GABAergic Inhibition Impairment	Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that synthesizes GABA from glutamate. This leads to reduced GABA production and impaired inhibitory neurotransmission, resulting in neuronal hyperexcitability. GAD65 is predominantly localized to synaptic vesicles and provides additional GABA synthesis when there is increased demand for rapid neurotransmitter release during high-frequency neural firing.	cell_types[1]	cell_types	cell_types			Purkinje cell	CL:0000121	Purkinje cell		"{""preferred_term"": ""Purkinje cell"", ""term"": {""id"": ""CL:0000121"", ""label"": ""Purkinje cell""}}"																											
6580	7286	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	0	GABAergic Inhibition Impairment	Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that synthesizes GABA from glutamate. This leads to reduced GABA production and impaired inhibitory neurotransmission, resulting in neuronal hyperexcitability. GAD65 is predominantly localized to synaptic vesicles and provides additional GABA synthesis when there is increased demand for rapid neurotransmitter release during high-frequency neural firing.	biological_processes[0]	biological_processes	biological_processes			GABAergic synaptic transmission	GO:0051932	synaptic transmission, GABAergic		"{""preferred_term"": ""GABAergic synaptic transmission"", ""term"": {""id"": ""GO:0051932"", ""label"": ""synaptic transmission, GABAergic""}}"																											
6581	7286	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	0	GABAergic Inhibition Impairment	Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that synthesizes GABA from glutamate. This leads to reduced GABA production and impaired inhibitory neurotransmission, resulting in neuronal hyperexcitability. GAD65 is predominantly localized to synaptic vesicles and provides additional GABA synthesis when there is increased demand for rapid neurotransmitter release during high-frequency neural firing.	biological_processes[1]	biological_processes	biological_processes			Inhibitory chemical synaptic transmission	GO:0098977	inhibitory chemical synaptic transmission		"{""preferred_term"": ""Inhibitory chemical synaptic transmission"", ""term"": {""id"": ""GO:0098977"", ""label"": ""inhibitory chemical synaptic transmission""}}"																											
6582	7287	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	1	Loss of Reciprocal Inhibition	Failure of GABAergic interneurons to inhibit antagonist motor neurons during voluntary movement, resulting in co-contraction of opposing muscle groups and the characteristic rigid posture.	cell_types[0]	cell_types	cell_types			Motor Neuron	CL:0000100	motor neuron		"{""preferred_term"": ""Motor Neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
6583	7288	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	pathophysiology	2	Intrathecal B-cell Autoimmunity	B-cell-mediated autoimmune inflammation with clonal B-cell activation specifically within the central nervous system. Approximately 67% of patients demonstrate oligoclonal IgG bands in the CSF, and 85% exhibit increased GAD65-specific IgG index values, indicating intrathecal antibody synthesis.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6584	7289	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	0	Muscle Rigidity		phenotype_term	phenotype_term	$	Muscle Rigidity		Rigidity	HP:0002063	Rigidity		"{""preferred_term"": ""Rigidity"", ""term"": {""id"": ""HP:0002063"", ""label"": ""Rigidity""}}"																											
6585	7290	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	1	Painful Muscle Spasms		phenotype_term	phenotype_term	$	Painful Muscle Spasms		Intermittent painful muscle spasms	HP:0011964	Intermittent painful muscle spasms		"{""preferred_term"": ""Intermittent painful muscle spasms"", ""term"": {""id"": ""HP:0011964"", ""label"": ""Intermittent painful muscle spasms""}}"																											
6586	7291	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	2	Exaggerated Startle Response		phenotype_term	phenotype_term	$	Exaggerated Startle Response		Exaggerated startle response	HP:0002267	Exaggerated startle response		"{""preferred_term"": ""Exaggerated startle response"", ""term"": {""id"": ""HP:0002267"", ""label"": ""Exaggerated startle response""}}"																											
6587	7292	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	3	Gait Disturbance		phenotype_term	phenotype_term	$	Gait Disturbance		Gait disturbance	HP:0001288	Gait disturbance		"{""preferred_term"": ""Gait disturbance"", ""term"": {""id"": ""HP:0001288"", ""label"": ""Gait disturbance""}}"																											
6588	7293	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	4	Lumbar Hyperlordosis		phenotype_term	phenotype_term	$	Lumbar Hyperlordosis		Hyperlordosis	HP:0003307	Hyperlordosis		"{""preferred_term"": ""Hyperlordosis"", ""term"": {""id"": ""HP:0003307"", ""label"": ""Hyperlordosis""}}"																											
6589	7294	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	5	Frequent Falls		phenotype_term	phenotype_term	$	Frequent Falls		Frequent falls	HP:0002359	Frequent falls		"{""preferred_term"": ""Frequent falls"", ""term"": {""id"": ""HP:0002359"", ""label"": ""Frequent falls""}}"																											
6590	7295	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	phenotypes	6	Anxiety		phenotype_term	phenotype_term	$	Anxiety		Anxiety	HP:0000739	Anxiety		"{""preferred_term"": ""Anxiety"", ""term"": {""id"": ""HP:0000739"", ""label"": ""Anxiety""}}"																											
6591	7296	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	0	Benzodiazepines	First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.	treatment_term	treatment_term	$	Benzodiazepines	First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6592	7297	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	1	Baclofen	GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.	treatment_term	treatment_term	$	Baclofen	GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6593	7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	Intravenous Immunoglobulin	Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.	treatment_term	treatment_term	$	Intravenous Immunoglobulin	Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6594	7299	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	3	Rituximab	Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6595	7306	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	histopathology	0	Synovial Sarcoma	Synovial sarcoma is a rare soft tissue tumor.	finding_term	finding_term	$	Synovial Sarcoma	Synovial sarcoma is a rare soft tissue tumor.	Synovial Sarcoma	NCIT:C3400	Synovial Sarcoma		"{""preferred_term"": ""Synovial Sarcoma"", ""term"": {""id"": ""NCIT:C3400"", ""label"": ""Synovial Sarcoma""}}"																											
6596	7307	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	0	SS18-SSX Fusion Oncogene	The t(X;18)(p11;q11) translocation fuses the SS18 gene on chromosome 18 to one of three SSX genes (SSX1, SSX2, or rarely SSX4) on the X chromosome. The SS18-SSX fusion protein disrupts the BAF (SWI/SNF) chromatin remodeling complex, leading to aberrant transcriptional regulation and epigenetic reprogramming.	biological_processes[0]	biological_processes	biological_processes			chromatin remodeling	GO:0006338	chromatin remodeling		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""chromatin remodeling"", ""term"": {""id"": ""GO:0006338"", ""label"": ""chromatin remodeling""}}"			ABNORMAL																								
6597	7308	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	1	BAF Complex Disruption	The SS18-SSX fusion protein incorporates into the BAF chromatin remodeling complex, displacing wild-type SS18. This alters BAF complex targeting and function, particularly affecting polycomb-mediated gene repression. The fusion protein causes eviction of BAF47 (SMARCB1) from the complex at certain genomic loci.	biological_processes[0]	biological_processes	biological_processes			regulation of gene expression	GO:0010468	regulation of gene expression		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""regulation of gene expression"", ""term"": {""id"": ""GO:0010468"", ""label"": ""regulation of gene expression""}}"			ABNORMAL																								
6598	7309	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	pathophysiology	2	Epigenetic Reprogramming	SS18-SSX-containing BAF complexes fail to properly oppose polycomb repressive complexes, leading to abnormal silencing of tumor suppressors and activation of oncogenic programs. Key target genes include BCL2 (antiapoptotic) and multiple receptor tyrosine kinases.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"			DECREASED																								
6599	7310	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	phenotypes	0	Soft Tissue Mass	A slowly growing soft tissue mass, often present for months to years before diagnosis. Most commonly located in the lower extremities near joints but not within the joint itself. The mass is typically deep-seated and firm.	phenotype_term	phenotype_term	$	Soft Tissue Mass	A slowly growing soft tissue mass, often present for months to years before diagnosis. Most commonly located in the lower extremities near joints but not within the joint itself. The mass is typically deep-seated and firm.	Soft tissue neoplasm	HP:0031459	Soft tissue neoplasm		"{""preferred_term"": ""Soft tissue neoplasm"", ""term"": {""id"": ""HP:0031459"", ""label"": ""Soft tissue neoplasm""}}"																											
6600	7311	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	phenotypes	1	Localized Pain	Pain and tenderness at the tumor site, which may be attributed to other causes given the young patient age. Pain may worsen with tumor growth.	phenotype_term	phenotype_term	$	Localized Pain	Pain and tenderness at the tumor site, which may be attributed to other causes given the young patient age. Pain may worsen with tumor growth.	Bone pain	HP:0002653	Bone pain		"{""preferred_term"": ""Bone pain"", ""term"": {""id"": ""HP:0002653"", ""label"": ""Bone pain""}}"																											
6601	7312	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	phenotypes	2	Weight Loss	Weight loss is uncommon at presentation but may occur with advanced or metastatic disease.	phenotype_term	phenotype_term	$	Weight Loss	Weight loss is uncommon at presentation but may occur with advanced or metastatic disease.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
6602	7313	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	phenotypes	3	Metastatic Disease	Lung metastases occur in approximately 50% of patients over the disease course. Metastatic disease at presentation is relatively uncommon.	phenotype_term	phenotype_term	$	Metastatic Disease	Lung metastases occur in approximately 50% of patients over the disease course. Metastatic disease at presentation is relatively uncommon.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
6603	7314	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	0	Surgical Resection	Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible.	treatment_term	treatment_term	$	Surgical Resection	Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6604	7315	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	1	Radiation Therapy	Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	treatment_term	$	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				ifosfamide; doxorubicin	CHEBI:5864; CHEBI:28748																						
6606	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
6607	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
6608	7317	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	animal_models	0		genetically prone to develop lupus-like symptoms and APS	genes[0]	genes	genes			FAS	hgnc:11920	FAS		"{""preferred_term"": ""FAS"", ""term"": {""id"": ""hgnc:11920"", ""label"": ""FAS""}}"																											
6609	7323	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	environmental	0	UV Exposure		exposure_term	exposure_term	$	UV Exposure		UV light exposure	ECTO:0000006	exposure to ultraviolet radiation		"{""preferred_term"": ""UV light exposure"", ""term"": {""id"": ""ECTO:0000006"", ""label"": ""exposure to ultraviolet radiation""}}"																											
6610	7324	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	environmental	1	Infection		exposure_term	exposure_term	$	Infection		Infectious agent exposure	ECTO:3000000	exposure to organism		"{""preferred_term"": ""Infectious agent exposure"", ""term"": {""id"": ""ECTO:3000000"", ""label"": ""exposure to organism""}}"																											
6611	7325	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	environmental	2	Stress		exposure_term	exposure_term	$	Stress		Psychological stress exposure				"{""preferred_term"": ""Psychological stress exposure""}"																											
6612	7340	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	0	Formation of Immune Complexes		cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6613	7340	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	0	Formation of Immune Complexes		cell_types[1]	cell_types	cell_types			plasma cell	CL:0000786	plasma cell		"{""preferred_term"": ""plasma cell"", ""term"": {""id"": ""CL:0000786"", ""label"": ""plasma cell""}}"																											
6614	7340	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	0	Formation of Immune Complexes		cell_types[2]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6615	7341	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	1	Glomerular Immune Complex Deposition	"Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies lodge in kidney glomeruli, activating complement and recruiting inflammatory cells.
"	locations[0]	locations	locations			Kidney	UBERON:0002113	kidney		"{""preferred_term"": ""Kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
6616	7341	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	1	Glomerular Immune Complex Deposition	"Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies lodge in kidney glomeruli, activating complement and recruiting inflammatory cells.
"	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
6617	7342	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	2	Cutaneous Immune Complex Deposition	"Immune complexes deposit at the dermal-epidermal junction and in vessel walls of the skin, leading to cutaneous manifestations of lupus.
"	locations[0]	locations	locations			Skin	UBERON:0002097	skin of body		"{""preferred_term"": ""Skin"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
6618	7342	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	2	Cutaneous Immune Complex Deposition	"Immune complexes deposit at the dermal-epidermal junction and in vessel walls of the skin, leading to cutaneous manifestations of lupus.
"	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
6619	7343	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	3	Synovial Immune Complex Deposition	"Immune complexes accumulate in synovial fluid and tissue of joints, activating complement and triggering inflammatory arthritis.
"	locations[0]	locations	locations			Skeletal Joint	UBERON:0000982	skeletal joint		"{""preferred_term"": ""Skeletal Joint"", ""term"": {""id"": ""UBERON:0000982"", ""label"": ""skeletal joint""}}"																											
6620	7343	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	3	Synovial Immune Complex Deposition	"Immune complexes accumulate in synovial fluid and tissue of joints, activating complement and triggering inflammatory arthritis.
"	biological_processes[0]	biological_processes	biological_processes			complement activation	GO:0006956	complement activation		"{""preferred_term"": ""complement activation"", ""term"": {""id"": ""GO:0006956"", ""label"": ""complement activation""}}"																											
6621	7347	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	7	Type I Interferon Pathway Activation	Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.	cell_types[0]	cell_types	cell_types			plasmacytoid dendritic cell	CL:0000784	plasmacytoid dendritic cell		"{""preferred_term"": ""plasmacytoid dendritic cell"", ""term"": {""id"": ""CL:0000784"", ""label"": ""plasmacytoid dendritic cell""}}"																											
6622	7347	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	7	Type I Interferon Pathway Activation	Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.	cell_types[1]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6623	7347	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	7	Type I Interferon Pathway Activation	Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.	cell_types[2]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
6624	7347	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	7	Type I Interferon Pathway Activation	Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.	biological_processes[0]	biological_processes	biological_processes			type I interferon signaling pathway	GO:0060337	type I interferon signaling pathway		"{""preferred_term"": ""type I interferon signaling pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon signaling pathway""}}"																											
6625	7348	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	8	TLR7/TLR9-Mediated Nucleic Acid Sensing	B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6626	7348	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	8	TLR7/TLR9-Mediated Nucleic Acid Sensing	B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.	cell_types[1]	cell_types	cell_types			plasmacytoid dendritic cell	CL:0000784	plasmacytoid dendritic cell		"{""preferred_term"": ""plasmacytoid dendritic cell"", ""term"": {""id"": ""CL:0000784"", ""label"": ""plasmacytoid dendritic cell""}}"																											
6627	7348	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	8	TLR7/TLR9-Mediated Nucleic Acid Sensing	B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.	biological_processes[0]	biological_processes	biological_processes			toll-like receptor signaling pathway	GO:0002224	toll-like receptor signaling pathway		"{""preferred_term"": ""toll-like receptor signaling pathway"", ""term"": {""id"": ""GO:0002224"", ""label"": ""toll-like receptor signaling pathway""}}"																											
6628	7348	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	8	TLR7/TLR9-Mediated Nucleic Acid Sensing	B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.	biological_processes[1]	biological_processes	biological_processes			toll-like receptor 7 signaling pathway	GO:0034154	toll-like receptor 7 signaling pathway		"{""preferred_term"": ""toll-like receptor 7 signaling pathway"", ""term"": {""id"": ""GO:0034154"", ""label"": ""toll-like receptor 7 signaling pathway""}}"																											
6629	7348	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	8	TLR7/TLR9-Mediated Nucleic Acid Sensing	B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.	biological_processes[2]	biological_processes	biological_processes			toll-like receptor 9 signaling pathway	GO:0034162	toll-like receptor 9 signaling pathway		"{""preferred_term"": ""toll-like receptor 9 signaling pathway"", ""term"": {""id"": ""GO:0034162"", ""label"": ""toll-like receptor 9 signaling pathway""}}"																											
6630	7349	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	9	NETosis and Neutrophil Extracellular Trap Formation	Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6631	7349	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	9	NETosis and Neutrophil Extracellular Trap Formation	Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.	biological_processes[0]	biological_processes	biological_processes			neutrophil degranulation	GO:0043312	neutrophil degranulation		"{""preferred_term"": ""neutrophil degranulation"", ""term"": {""id"": ""GO:0043312"", ""label"": ""neutrophil degranulation""}}"																											
6632	7349	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	9	NETosis and Neutrophil Extracellular Trap Formation	Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.	biological_processes[1]	biological_processes	biological_processes			neutrophil extracellular trap formation	GO:0036230	neutrophil extracellular trap formation		"{""preferred_term"": ""neutrophil extracellular trap formation"", ""term"": {""id"": ""GO:0036230"", ""label"": ""neutrophil extracellular trap formation""}}"																											
6633	7350	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	10	Age-Associated B Cell Expansion	Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.	cell_types[0]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6634	7350	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	10	Age-Associated B Cell Expansion	Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.	biological_processes[0]	biological_processes	biological_processes			B cell activation	GO:0042113	B cell activation		"{""preferred_term"": ""B cell activation"", ""term"": {""id"": ""GO:0042113"", ""label"": ""B cell activation""}}"																											
6635	7350	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	10	Age-Associated B Cell Expansion	Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.	biological_processes[1]	biological_processes	biological_processes			B cell differentiation	GO:0030183	B cell differentiation		"{""preferred_term"": ""B cell differentiation"", ""term"": {""id"": ""GO:0030183"", ""label"": ""B cell differentiation""}}"																											
6636	7351	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	11	T Follicular Helper Cell Dysregulation	T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.	cell_types[0]	cell_types	cell_types			T follicular helper cell	CL:0002038	T follicular helper cell		"{""preferred_term"": ""T follicular helper cell"", ""term"": {""id"": ""CL:0002038"", ""label"": ""T follicular helper cell""}}"																											
6637	7351	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	11	T Follicular Helper Cell Dysregulation	T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.	cell_types[1]	cell_types	cell_types			T cell	CL:0000084	T cell		"{""preferred_term"": ""T cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
6638	7351	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	11	T Follicular Helper Cell Dysregulation	T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.	biological_processes[0]	biological_processes	biological_processes			T cell activation	GO:0042110	T cell activation		"{""preferred_term"": ""T cell activation"", ""term"": {""id"": ""GO:0042110"", ""label"": ""T cell activation""}}"																											
6639	7351	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	11	T Follicular Helper Cell Dysregulation	T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.	biological_processes[1]	biological_processes	biological_processes			germinal center formation	GO:0002467	germinal center formation		"{""preferred_term"": ""germinal center formation"", ""term"": {""id"": ""GO:0002467"", ""label"": ""germinal center formation""}}"																											
6640	7352	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	12	Impaired Apoptotic Cell Clearance	Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.	biological_processes[0]	biological_processes	biological_processes			apoptotic cell clearance	GO:0043277	apoptotic cell clearance		"{""preferred_term"": ""apoptotic cell clearance"", ""term"": {""id"": ""GO:0043277"", ""label"": ""apoptotic cell clearance""}}"																											
6641	7352	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	12	Impaired Apoptotic Cell Clearance	Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.	biological_processes[1]	biological_processes	biological_processes			efferocytosis	GO:0043277	apoptotic cell clearance		"{""preferred_term"": ""efferocytosis"", ""term"": {""id"": ""GO:0043277"", ""label"": ""apoptotic cell clearance""}}"																											
6642	7353	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	13	Complement Pathway Dysregulation	Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.	biological_processes[0]	biological_processes	biological_processes			complement activation, classical pathway	GO:0006958	complement activation, classical pathway		"{""preferred_term"": ""complement activation, classical pathway"", ""term"": {""id"": ""GO:0006958"", ""label"": ""complement activation, classical pathway""}}"																											
6643	7353	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	13	Complement Pathway Dysregulation	Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.	locations[0]	locations	locations			Kidney	UBERON:0002113	kidney		"{""preferred_term"": ""Kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
6644	7353	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	pathophysiology	13	Complement Pathway Dysregulation	Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.	locations[1]	locations	locations			Glomerulus	UBERON:0000074	renal glomerulus		"{""preferred_term"": ""Glomerulus"", ""term"": {""id"": ""UBERON:0000074"", ""label"": ""renal glomerulus""}}"																											
6645	7354	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	0	Malar Rash		phenotype_term	phenotype_term	$	Malar Rash		Malar Rash	HP:0025300	Malar rash		"{""preferred_term"": ""Malar Rash"", ""term"": {""id"": ""HP:0025300"", ""label"": ""Malar rash""}}"																											
6646	7355	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	1	Photosensitivity		phenotype_term	phenotype_term	$	Photosensitivity		Photosensitivity	HP:0000992	Cutaneous photosensitivity		"{""preferred_term"": ""Photosensitivity"", ""term"": {""id"": ""HP:0000992"", ""label"": ""Cutaneous photosensitivity""}}"																											
6647	7356	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	2	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
6648	7359	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	5	Lupus Nephritis		phenotype_term	phenotype_term	$	Lupus Nephritis		Lupus Nephritis	HP:0033726	Lupus nephritis		"{""preferred_term"": ""Lupus Nephritis"", ""term"": {""id"": ""HP:0033726"", ""label"": ""Lupus nephritis""}}"																											
6649	7360	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	6	Leukopenia		phenotype_term	phenotype_term	$	Leukopenia		Leukopenia	HP:0001882	Decreased total leukocyte count		"{""preferred_term"": ""Leukopenia"", ""term"": {""id"": ""HP:0001882"", ""label"": ""Decreased total leukocyte count""}}"																											
6650	7361	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	7	Thrombocytopenia		phenotype_term	phenotype_term	$	Thrombocytopenia		Thrombocytopenia	HP:0001873	Thrombocytopenia		"{""preferred_term"": ""Thrombocytopenia"", ""term"": {""id"": ""HP:0001873"", ""label"": ""Thrombocytopenia""}}"																											
6651	7362	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	8	Hemolytic Anemia		phenotype_term	phenotype_term	$	Hemolytic Anemia		Hemolytic Anemia	HP:0001878	Hemolytic anemia		"{""preferred_term"": ""Hemolytic Anemia"", ""term"": {""id"": ""HP:0001878"", ""label"": ""Hemolytic anemia""}}"																											
6652	7363	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	9	Pericarditis		phenotype_term	phenotype_term	$	Pericarditis		Pericarditis	HP:0001701	Pericarditis		"{""preferred_term"": ""Pericarditis"", ""term"": {""id"": ""HP:0001701"", ""label"": ""Pericarditis""}}"																											
6653	7364	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	10	Pleuritis		phenotype_term	phenotype_term	$	Pleuritis		Pleuritis	HP:0002102	Pleuritis		"{""preferred_term"": ""Pleuritis"", ""term"": {""id"": ""HP:0002102"", ""label"": ""Pleuritis""}}"																											
6654	7365	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	11	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6655	7366	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	phenotypes	12	Psychosis		phenotype_term	phenotype_term	$	Psychosis		Psychosis	HP:0000709	Psychosis		"{""preferred_term"": ""Psychosis"", ""term"": {""id"": ""HP:0000709"", ""label"": ""Psychosis""}}"																											
6656	7367	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	0	Type I Interferon Receptor Antagonist	Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.	treatment_term	treatment_term	$	Type I Interferon Receptor Antagonist	Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6657	7368	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	1	B Cell Depletion Therapy	Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.	treatment_term	treatment_term	$	B Cell Depletion Therapy	Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6658	7369	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	2	BAFF Pathway Inhibition	Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.	treatment_term	treatment_term	$	BAFF Pathway Inhibition	Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6659	7370	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	3	Immunosuppressive Therapy	Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.	treatment_term	treatment_term	$	Immunosuppressive Therapy	Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6660	7371	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	4	Supportive Care	Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.	treatment_term	treatment_term	$	Supportive Care	Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6661	7378	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	0	Vascular Injury and Endothelial Dysfunction	Early endothelial cell injury leads to vascular damage, intimal proliferation, and obliterative vasculopathy. Raynaud's phenomenon reflects vasospasm and structural vascular changes.	cell_types[0]	cell_types	cell_types			Endothelial Cell	CL:0000115	endothelial cell		"{""preferred_term"": ""Endothelial Cell"", ""term"": {""id"": ""CL:0000115"", ""label"": ""endothelial cell""}}"																											
6662	7378	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	0	Vascular Injury and Endothelial Dysfunction	Early endothelial cell injury leads to vascular damage, intimal proliferation, and obliterative vasculopathy. Raynaud's phenomenon reflects vasospasm and structural vascular changes.	biological_processes[0]	biological_processes	biological_processes			Blood Vessel Development	GO:0001568	blood vessel development		"{""preferred_term"": ""Blood Vessel Development"", ""term"": {""id"": ""GO:0001568"", ""label"": ""blood vessel development""}}"																											
6663	7379	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	1	Immune Activation and Autoantibody Production	Characteristic autoantibodies include anti-centromere (limited disease), anti-Scl-70/topoisomerase I (diffuse disease), and anti-RNA polymerase III. T cells and macrophages infiltrate affected tissues and produce pro-fibrotic cytokines.	cell_types[0]	cell_types	cell_types			CD4+ T Cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4+ T Cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
6664	7379	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	1	Immune Activation and Autoantibody Production	Characteristic autoantibodies include anti-centromere (limited disease), anti-Scl-70/topoisomerase I (diffuse disease), and anti-RNA polymerase III. T cells and macrophages infiltrate affected tissues and produce pro-fibrotic cytokines.	cell_types[1]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6665	7379	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	1	Immune Activation and Autoantibody Production	Characteristic autoantibodies include anti-centromere (limited disease), anti-Scl-70/topoisomerase I (diffuse disease), and anti-RNA polymerase III. T cells and macrophages infiltrate affected tissues and produce pro-fibrotic cytokines.	biological_processes[0]	biological_processes	biological_processes			Immunoglobulin Production	GO:0002377	immunoglobulin production		"{""preferred_term"": ""Immunoglobulin Production"", ""term"": {""id"": ""GO:0002377"", ""label"": ""immunoglobulin production""}}"																											
6666	7380	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	2	Fibroblast Activation and Fibrosis	TGF-beta signaling drives fibroblast activation and differentiation into myofibroblasts. Excessive collagen and extracellular matrix deposition leads to progressive fibrosis of skin and internal organs.	cell_types[0]	cell_types	cell_types			Fibroblast	CL:0000057	fibroblast		"{""preferred_term"": ""Fibroblast"", ""term"": {""id"": ""CL:0000057"", ""label"": ""fibroblast""}}"																											
6667	7380	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	2	Fibroblast Activation and Fibrosis	TGF-beta signaling drives fibroblast activation and differentiation into myofibroblasts. Excessive collagen and extracellular matrix deposition leads to progressive fibrosis of skin and internal organs.	cell_types[1]	cell_types	cell_types			Myofibroblast	CL:0000186	myofibroblast cell		"{""preferred_term"": ""Myofibroblast"", ""term"": {""id"": ""CL:0000186"", ""label"": ""myofibroblast cell""}}"																											
6668	7380	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	2	Fibroblast Activation and Fibrosis	TGF-beta signaling drives fibroblast activation and differentiation into myofibroblasts. Excessive collagen and extracellular matrix deposition leads to progressive fibrosis of skin and internal organs.	biological_processes[0]	biological_processes	biological_processes			Extracellular Matrix Organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""Extracellular Matrix Organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
6669	7380	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	pathophysiology	2	Fibroblast Activation and Fibrosis	TGF-beta signaling drives fibroblast activation and differentiation into myofibroblasts. Excessive collagen and extracellular matrix deposition leads to progressive fibrosis of skin and internal organs.	biological_processes[1]	biological_processes	biological_processes			TGF-beta Signaling	GO:0007179	transforming growth factor beta receptor signaling pathway		"{""preferred_term"": ""TGF-beta Signaling"", ""term"": {""id"": ""GO:0007179"", ""label"": ""transforming growth factor beta receptor signaling pathway""}}"																											
6670	7381	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	phenotypes	0	Raynaud Phenomenon		phenotype_term	phenotype_term	$	Raynaud Phenomenon		Raynaud Phenomenon	HP:0030880	Raynaud phenomenon		"{""preferred_term"": ""Raynaud Phenomenon"", ""term"": {""id"": ""HP:0030880"", ""label"": ""Raynaud phenomenon""}}"																											
6671	7382	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	phenotypes	1	Skin Thickening		phenotype_term	phenotype_term	$	Skin Thickening		Thick Skin	HP:0001072	Thickened skin		"{""preferred_term"": ""Thick Skin"", ""term"": {""id"": ""HP:0001072"", ""label"": ""Thickened skin""}}"																											
6672	7383	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	phenotypes	2	Pulmonary Fibrosis		phenotype_term	phenotype_term	$	Pulmonary Fibrosis		Pulmonary Fibrosis	HP:0002206	Pulmonary fibrosis		"{""preferred_term"": ""Pulmonary Fibrosis"", ""term"": {""id"": ""HP:0002206"", ""label"": ""Pulmonary fibrosis""}}"																											
6673	7384	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	phenotypes	3	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
6674	7395	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	0	RBM10-mediated alternative splicing dysregulation	Loss-of-function mutations in RBM10 (RNA Binding Motif Protein 10) impair its role as a U2-associated splicing repressor, leading to widespread dysregulation of alternative splicing across the transcriptome. RBM10 normally promotes cassette exon skipping through interaction with U2 snRNP at intron branch sites on chromatin. Loss of RBM10 function shifts hundreds to thousands of splicing events toward exon inclusion. Key downstream effects include NOTCH pathway de-repression via NUMB missplicing and dysregulation of extracellular matrix and cytoskeletal signaling through isoform changes in VCL, CD44, and TNC. These splicing defects disrupt developmental pathways controlling craniofacial morphogenesis, limb patterning, and cardiac development, leading to the characteristic TARP phenotype.	biological_processes[0]	biological_processes	biological_processes			Regulation of alternative mRNA splicing via spliceosome	GO:0000381	regulation of alternative mRNA splicing, via spliceosome		"{""preferred_term"": ""Regulation of alternative mRNA splicing via spliceosome"", ""term"": {""id"": ""GO:0000381"", ""label"": ""regulation of alternative mRNA splicing, via spliceosome""}}"																											
6675	7395	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	0	RBM10-mediated alternative splicing dysregulation	Loss-of-function mutations in RBM10 (RNA Binding Motif Protein 10) impair its role as a U2-associated splicing repressor, leading to widespread dysregulation of alternative splicing across the transcriptome. RBM10 normally promotes cassette exon skipping through interaction with U2 snRNP at intron branch sites on chromatin. Loss of RBM10 function shifts hundreds to thousands of splicing events toward exon inclusion. Key downstream effects include NOTCH pathway de-repression via NUMB missplicing and dysregulation of extracellular matrix and cytoskeletal signaling through isoform changes in VCL, CD44, and TNC. These splicing defects disrupt developmental pathways controlling craniofacial morphogenesis, limb patterning, and cardiac development, leading to the characteristic TARP phenotype.	biological_processes[1]	biological_processes	biological_processes			Notch signaling pathway	GO:0007219	Notch signaling pathway		"{""preferred_term"": ""Notch signaling pathway"", ""term"": {""id"": ""GO:0007219"", ""label"": ""Notch signaling pathway""}}"																											
6676	7395	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	0	RBM10-mediated alternative splicing dysregulation	Loss-of-function mutations in RBM10 (RNA Binding Motif Protein 10) impair its role as a U2-associated splicing repressor, leading to widespread dysregulation of alternative splicing across the transcriptome. RBM10 normally promotes cassette exon skipping through interaction with U2 snRNP at intron branch sites on chromatin. Loss of RBM10 function shifts hundreds to thousands of splicing events toward exon inclusion. Key downstream effects include NOTCH pathway de-repression via NUMB missplicing and dysregulation of extracellular matrix and cytoskeletal signaling through isoform changes in VCL, CD44, and TNC. These splicing defects disrupt developmental pathways controlling craniofacial morphogenesis, limb patterning, and cardiac development, leading to the characteristic TARP phenotype.	biological_processes[2]	biological_processes	biological_processes			Extracellular matrix organization	GO:0030198	extracellular matrix organization		"{""preferred_term"": ""Extracellular matrix organization"", ""term"": {""id"": ""GO:0030198"", ""label"": ""extracellular matrix organization""}}"																											
6677	7395	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	0	RBM10-mediated alternative splicing dysregulation	Loss-of-function mutations in RBM10 (RNA Binding Motif Protein 10) impair its role as a U2-associated splicing repressor, leading to widespread dysregulation of alternative splicing across the transcriptome. RBM10 normally promotes cassette exon skipping through interaction with U2 snRNP at intron branch sites on chromatin. Loss of RBM10 function shifts hundreds to thousands of splicing events toward exon inclusion. Key downstream effects include NOTCH pathway de-repression via NUMB missplicing and dysregulation of extracellular matrix and cytoskeletal signaling through isoform changes in VCL, CD44, and TNC. These splicing defects disrupt developmental pathways controlling craniofacial morphogenesis, limb patterning, and cardiac development, leading to the characteristic TARP phenotype.	biological_processes[3]	biological_processes	biological_processes			Cytoskeleton organization	GO:0007010	cytoskeleton organization		"{""preferred_term"": ""Cytoskeleton organization"", ""term"": {""id"": ""GO:0007010"", ""label"": ""cytoskeleton organization""}}"																											
6678	7396	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	1	RBM10 splicing-independent replication fork dysfunction	RBM10 also functions in a splicing-independent manner at DNA replication forks, where it recruits HDAC1 to promote H4K16 deacetylation and maintains fork stability. Loss of RBM10 induces replication stress and creates synthetic-lethal interactions with WEE1 inhibition. This dual role provides additional pathological mechanisms affecting developmental processes through both transcriptional and chromosomal instability pathways.	biological_processes[0]	biological_processes	biological_processes			DNA replication	GO:0006268	DNA replication		"{""preferred_term"": ""DNA replication"", ""term"": {""id"": ""GO:0006268"", ""label"": ""DNA replication""}}"																											
6679	7396	320	TARP syndrome	TARP_syndrome.yaml	pathophysiology	1	RBM10 splicing-independent replication fork dysfunction	RBM10 also functions in a splicing-independent manner at DNA replication forks, where it recruits HDAC1 to promote H4K16 deacetylation and maintains fork stability. Loss of RBM10 induces replication stress and creates synthetic-lethal interactions with WEE1 inhibition. This dual role provides additional pathological mechanisms affecting developmental processes through both transcriptional and chromosomal instability pathways.	biological_processes[1]	biological_processes	biological_processes			H4-K16 deacetylation	GO:0043111	H4-K16 deacetylation		"{""preferred_term"": ""H4-K16 deacetylation"", ""term"": {""id"": ""GO:0043111"", ""label"": ""H4-K16 deacetylation""}}"																											
6680	7397	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	0	Atrial septal defect	Defect in the atrial septum allowing right-to-left shunting of blood, a cardinal feature of TARP syndrome.	phenotype_term	phenotype_term	$	Atrial septal defect	Defect in the atrial septum allowing right-to-left shunting of blood, a cardinal feature of TARP syndrome.	Atrial septal defect	HP:0001631	Atrial septal defect		"{""preferred_term"": ""Atrial septal defect"", ""term"": {""id"": ""HP:0001631"", ""label"": ""Atrial septal defect""}}"																											
6681	7398	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	1	Micrognathia	Underdevelopment of the mandible, a key feature of Robin sequence observed in TARP syndrome.	phenotype_term	phenotype_term	$	Micrognathia	Underdevelopment of the mandible, a key feature of Robin sequence observed in TARP syndrome.	Micrognathia	HP:0000347	Micrognathia		"{""preferred_term"": ""Micrognathia"", ""term"": {""id"": ""HP:0000347"", ""label"": ""Micrognathia""}}"																											
6682	7399	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	2	Cleft palate	Cleft of the palate, part of the Robin sequence triad in TARP syndrome.	phenotype_term	phenotype_term	$	Cleft palate	Cleft of the palate, part of the Robin sequence triad in TARP syndrome.	Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
6683	7400	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	3	Talipes equinovarus	Congenital clubfoot deformity, a key feature of TARP syndrome.	phenotype_term	phenotype_term	$	Talipes equinovarus	Congenital clubfoot deformity, a key feature of TARP syndrome.	Talipes equinovarus	HP:0001762	Talipes equinovarus		"{""preferred_term"": ""Talipes equinovarus"", ""term"": {""id"": ""HP:0001762"", ""label"": ""Talipes equinovarus""}}"																											
6684	7401	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	4	Glossoptosis	Posterior displacement of the tongue, part of Robin sequence.	phenotype_term	phenotype_term	$	Glossoptosis	Posterior displacement of the tongue, part of Robin sequence.	Glossoptosis	HP:0000162	Glossoptosis		"{""preferred_term"": ""Glossoptosis"", ""term"": {""id"": ""HP:0000162"", ""label"": ""Glossoptosis""}}"																											
6685	7402	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	5	Vitelline vascular remnant	Remnant of the vitelline duct vasculature that can cause intestinal obstruction; rare gastrointestinal complication in TARP syndrome.	phenotype_term	phenotype_term	$	Vitelline vascular remnant	Remnant of the vitelline duct vasculature that can cause intestinal obstruction; rare gastrointestinal complication in TARP syndrome.	Abnormality of the gastrointestinal tract	HP:0011024	Abnormality of the gastrointestinal tract		"{""preferred_term"": ""Abnormality of the gastrointestinal tract"", ""term"": {""id"": ""HP:0011024"", ""label"": ""Abnormality of the gastrointestinal tract""}}"																											
6686	7403	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	6	Horseshoe kidney	Fusion of the bilateral kidneys at the lower poles, forming a horseshoe-shaped structure; rare renal malformation reported in TARP syndrome.	phenotype_term	phenotype_term	$	Horseshoe kidney	Fusion of the bilateral kidneys at the lower poles, forming a horseshoe-shaped structure; rare renal malformation reported in TARP syndrome.	Horseshoe kidney	HP:0000085	Horseshoe kidney		"{""preferred_term"": ""Horseshoe kidney"", ""term"": {""id"": ""HP:0000085"", ""label"": ""Horseshoe kidney""}}"																											
6687	7404	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	7	Optic nerve atrophy	Degeneration and loss of optic nerve tissue leading to reduced visual function; rare ophthalmic manifestation in TARP syndrome.	phenotype_term	phenotype_term	$	Optic nerve atrophy	Degeneration and loss of optic nerve tissue leading to reduced visual function; rare ophthalmic manifestation in TARP syndrome.	Optic atrophy	HP:0000648	Optic atrophy		"{""preferred_term"": ""Optic atrophy"", ""term"": {""id"": ""HP:0000648"", ""label"": ""Optic atrophy""}}"																											
6688	7405	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	8	Intellectual disability	Severe to profound intellectual disability, a consistent feature across TARP syndrome cases affecting cognitive development and learning.	phenotype_term	phenotype_term	$	Intellectual disability	Severe to profound intellectual disability, a consistent feature across TARP syndrome cases affecting cognitive development and learning.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
6689	7406	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	9	Esotropia	Inward deviation of the eye(s), an ophthalmic manifestation documented in adult TARP syndrome.	phenotype_term	phenotype_term	$	Esotropia	Inward deviation of the eye(s), an ophthalmic manifestation documented in adult TARP syndrome.	Esotropia	HP:0000565	Esotropia		"{""preferred_term"": ""Esotropia"", ""term"": {""id"": ""HP:0000565"", ""label"": ""Esotropia""}}"																											
6690	7407	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	10	Scoliosis	Abnormal lateral curvature of the spine; rare skeletal manifestation requiring surgical intervention in some TARP patients.	phenotype_term	phenotype_term	$	Scoliosis	Abnormal lateral curvature of the spine; rare skeletal manifestation requiring surgical intervention in some TARP patients.	Scoliosis	HP:0002650	Scoliosis		"{""preferred_term"": ""Scoliosis"", ""term"": {""id"": ""HP:0002650"", ""label"": ""Scoliosis""}}"																											
6691	7408	320	TARP syndrome	TARP_syndrome.yaml	phenotypes	11	Prominent nose	Abnormally prominent nasal structure, part of the expanding craniofacial phenotype in TARP syndrome.	phenotype_term	phenotype_term	$	Prominent nose	Abnormally prominent nasal structure, part of the expanding craniofacial phenotype in TARP syndrome.	Prominent nose	HP:0000448	Prominent nose		"{""preferred_term"": ""Prominent nose"", ""term"": {""id"": ""HP:0000448"", ""label"": ""Prominent nose""}}"																											
6692	7409	320	TARP syndrome	TARP_syndrome.yaml	treatments	0	Cardiac surgery	Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications	treatment_term	treatment_term	$	Cardiac surgery	Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6693	7410	320	TARP syndrome	TARP_syndrome.yaml	treatments	1	Palatal cleft repair	Surgical correction of cleft palate to restore normal feeding and speech development	treatment_term	treatment_term	$	Palatal cleft repair	Surgical correction of cleft palate to restore normal feeding and speech development	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6694	7411	320	TARP syndrome	TARP_syndrome.yaml	treatments	2	Orthopedic surgery	Surgical management of talipes and other skeletal deformities	treatment_term	treatment_term	$	Orthopedic surgery	Surgical management of talipes and other skeletal deformities	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6695	7413	320	TARP syndrome	TARP_syndrome.yaml	treatments	4	Multidisciplinary supportive care	Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management	treatment_term	treatment_term	$	Multidisciplinary supportive care	Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6696	7414	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	infectious_agent	0	Taenia solium	Pork tapeworm responsible for taeniasis and cysticercosis.	infectious_agent_term	infectious_agent_term	$	Taenia solium	Pork tapeworm responsible for taeniasis and cysticercosis.	Taenia solium	NCBITaxon:6204	Taenia solium		"{""preferred_term"": ""Taenia solium"", ""term"": {""id"": ""NCBITaxon:6204"", ""label"": ""Taenia solium""}}"																											
6697	7416	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	phenotypes	0	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6698	7417	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	0	Antiparasitic therapy	Antiparasitic drugs are used to kill brain parasites in neurocysticercosis.	treatment_term	treatment_term	$	Antiparasitic therapy	Antiparasitic drugs are used to kill brain parasites in neurocysticercosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6699	7418	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	1	Surgical management	Surgical interventions may be used in selected cases.	treatment_term	treatment_term	$	Surgical management	Surgical interventions may be used in selected cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6700	7421	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	genetic	0	HEXA		gene_term	gene_term	$	HEXA		HEXA	hgnc:4878	HEXA		"{""preferred_term"": ""HEXA"", ""term"": {""id"": ""hgnc:4878"", ""label"": ""HEXA""}}"																											
6701	7425	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	0	HEXA mutations	"Pathogenic variants in HEXA disrupt hexosaminidase A activity.
"	genes[0]	genes	genes			HEXA	hgnc:4878	HEXA		"{""preferred_term"": ""HEXA"", ""term"": {""id"": ""hgnc:4878"", ""label"": ""HEXA""}}"																											
6702	7426	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	1	Hexosaminidase A deficiency	"Lysosomal beta-hexosaminidase A enzyme activity is deficient in Tay-Sachs disease.
"	biological_processes[0]	biological_processes	biological_processes			ganglioside catabolic process	GO:0006689	ganglioside catabolic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""ganglioside catabolic process"", ""term"": {""id"": ""GO:0006689"", ""label"": ""ganglioside catabolic process""}}"			DECREASED																								
6703	7427	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	2	GM2 ganglioside accumulation in neurons	"GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6704	7428	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	3	Neuron death	"Progressive neuronal loss occurs in the nervous system.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6705	7428	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	pathophysiology	3	Neuron death	"Progressive neuronal loss occurs in the nervous system.
"	biological_processes[0]	biological_processes	biological_processes			neuron death	GO:0070997	neuron death		"{""preferred_term"": ""neuron death"", ""term"": {""id"": ""GO:0070997"", ""label"": ""neuron death""}}"																											
6706	7429	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	0	Developmental Regression		phenotype_term	phenotype_term	$	Developmental Regression		Developmental Regression	HP:0002376	Developmental regression		"{""preferred_term"": ""Developmental Regression"", ""term"": {""id"": ""HP:0002376"", ""label"": ""Developmental regression""}}"																											
6707	7430	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	1	Cherry-Red Spot		phenotype_term	phenotype_term	$	Cherry-Red Spot		Cherry-Red Spot	HP:0010729	Cherry red spot of the macula		"{""preferred_term"": ""Cherry-Red Spot"", ""term"": {""id"": ""HP:0010729"", ""label"": ""Cherry red spot of the macula""}}"																											
6708	7431	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	2	Exaggerated Startle Response		phenotype_term	phenotype_term	$	Exaggerated Startle Response		Exaggerated Startle Response	HP:0002267	Exaggerated startle response		"{""preferred_term"": ""Exaggerated Startle Response"", ""term"": {""id"": ""HP:0002267"", ""label"": ""Exaggerated startle response""}}"																											
6709	7432	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	3	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
6710	7433	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	4	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizures	HP:0001250	Seizure		"{""preferred_term"": ""Seizures"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
6711	7434	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	5	Macrocephaly		phenotype_term	phenotype_term	$	Macrocephaly		Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
6712	7435	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	phenotypes	6	Blindness		phenotype_term	phenotype_term	$	Blindness		Blindness	HP:0000618	Blindness		"{""preferred_term"": ""Blindness"", ""term"": {""id"": ""HP:0000618"", ""label"": ""Blindness""}}"																											
6713	7436	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	0	Supportive Care	Symptomatic management including seizure control, nutrition support, respiratory care.	treatment_term	treatment_term	$	Supportive Care	Symptomatic management including seizure control, nutrition support, respiratory care.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6714	7437	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	1	Genetic Counseling	Carrier screening especially in high-risk populations.	treatment_term	treatment_term	$	Genetic Counseling	Carrier screening especially in high-risk populations.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
6715	7438	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	2	Substrate Reduction Therapy	Investigational approaches to reduce GM2 synthesis.	treatment_term	treatment_term	$	Substrate Reduction Therapy	Investigational approaches to reduce GM2 synthesis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6716	7439	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	3	Gene Therapy	Experimental AAV-based gene therapy in clinical trials.	treatment_term	treatment_term	$	Gene Therapy	Experimental AAV-based gene therapy in clinical trials.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
6717	7440	323	Tetanus	Tetanus.yaml	datasets	0		PBMC RNA-seq comparing transcriptional responses in infants receiving DTP (whole-cell pertussis with diphtheria and tetanus toxoids) versus DTaP primary vaccination.	organism	organism	$		PBMC RNA-seq comparing transcriptional responses in infants receiving DTP (whole-cell pertussis with diphtheria and tetanus toxoids) versus DTaP primary vaccination.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6718	7440	323	Tetanus	Tetanus.yaml	datasets	0		PBMC RNA-seq comparing transcriptional responses in infants receiving DTP (whole-cell pertussis with diphtheria and tetanus toxoids) versus DTaP primary vaccination.	sample_types[0]	sample_types	sample_types			peripheral blood mononuclear cell				"{""preferred_term"": ""peripheral blood mononuclear cell"", ""tissue_term"": {""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}}"																											
6719	7440	323	Tetanus	Tetanus.yaml	datasets	0		PBMC RNA-seq comparing transcriptional responses in infants receiving DTP (whole-cell pertussis with diphtheria and tetanus toxoids) versus DTaP primary vaccination.	sample_types[0].tissue_term	sample_types	sample_types[0]			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
6720	7441	323	Tetanus	Tetanus.yaml	datasets	1		Bulk RNA-seq from healthy adult whole blood samples used as baseline controls for vaccine response comparisons.	organism	organism	$		Bulk RNA-seq from healthy adult whole blood samples used as baseline controls for vaccine response comparisons.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
6721	7441	323	Tetanus	Tetanus.yaml	datasets	1		Bulk RNA-seq from healthy adult whole blood samples used as baseline controls for vaccine response comparisons.	sample_types[0]	sample_types	sample_types			whole blood				"{""preferred_term"": ""whole blood"", ""tissue_term"": {""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}}"																											
6722	7441	323	Tetanus	Tetanus.yaml	datasets	1		Bulk RNA-seq from healthy adult whole blood samples used as baseline controls for vaccine response comparisons.	sample_types[0].tissue_term	sample_types	sample_types[0]			blood	UBERON:0000178	blood		"{""preferred_term"": ""blood"", ""term"": {""id"": ""UBERON:0000178"", ""label"": ""blood""}}"																											
6723	7442	323	Tetanus	Tetanus.yaml	differential_diagnoses	0	Botulism	"Flaccid descending paralysis from botulinum toxin can mimic early bulbar involvement but lacks the painful spasms and rigidity seen in tetanus.
"	disease_term	disease_term	$	Botulism	"Flaccid descending paralysis from botulinum toxin can mimic early bulbar involvement but lacks the painful spasms and rigidity seen in tetanus.
"	botulism	MONDO:0005498	botulism		"{""preferred_term"": ""botulism"", ""term"": {""id"": ""MONDO:0005498"", ""label"": ""botulism""}}"																											
6724	7443	323	Tetanus	Tetanus.yaml	differential_diagnoses	1	Infectious Meningitis	"Meningitis presents with fever, headache, and neck stiffness, which can be confused with early tetanus, but lacks generalized spasms and risus sardonicus.
"	disease_term	disease_term	$	Infectious Meningitis	"Meningitis presents with fever, headache, and neck stiffness, which can be confused with early tetanus, but lacks generalized spasms and risus sardonicus.
"	infectious meningitis	MONDO:0021108	meningitis		"{""preferred_term"": ""infectious meningitis"", ""term"": {""id"": ""MONDO:0021108"", ""label"": ""meningitis""}}"																											
6725	7445	323	Tetanus	Tetanus.yaml	pathophysiology	0	Tetanus Toxin (Tetanospasmin) Action	"Clostridium tetani produces tetanospasmin, a potent neurotoxin that is transported retrogradely along motor neurons to the spinal cord. The toxin blocks the release of inhibitory neurotransmitters (GABA and glycine) from presynaptic terminals in the spinal cord, leading to unopposed muscle contraction and characteristic spasms.
"	cell_types[0]	cell_types	cell_types			motor neuron	CL:0000100	motor neuron		"{""preferred_term"": ""motor neuron"", ""term"": {""id"": ""CL:0000100"", ""label"": ""motor neuron""}}"																											
6726	7445	323	Tetanus	Tetanus.yaml	pathophysiology	0	Tetanus Toxin (Tetanospasmin) Action	"Clostridium tetani produces tetanospasmin, a potent neurotoxin that is transported retrogradely along motor neurons to the spinal cord. The toxin blocks the release of inhibitory neurotransmitters (GABA and glycine) from presynaptic terminals in the spinal cord, leading to unopposed muscle contraction and characteristic spasms.
"	biological_processes[0]	biological_processes	biological_processes			synaptic transmission, GABAergic	GO:0051932	synaptic transmission, GABAergic		"{""preferred_term"": ""synaptic transmission, GABAergic"", ""term"": {""id"": ""GO:0051932"", ""label"": ""synaptic transmission, GABAergic""}}"																											
6727	7445	323	Tetanus	Tetanus.yaml	pathophysiology	0	Tetanus Toxin (Tetanospasmin) Action	"Clostridium tetani produces tetanospasmin, a potent neurotoxin that is transported retrogradely along motor neurons to the spinal cord. The toxin blocks the release of inhibitory neurotransmitters (GABA and glycine) from presynaptic terminals in the spinal cord, leading to unopposed muscle contraction and characteristic spasms.
"	biological_processes[1]	biological_processes	biological_processes			synaptic transmission, glycinergic	GO:0060012	synaptic transmission, glycinergic		"{""preferred_term"": ""synaptic transmission, glycinergic"", ""term"": {""id"": ""GO:0060012"", ""label"": ""synaptic transmission, glycinergic""}}"																											
6728	7445	323	Tetanus	Tetanus.yaml	pathophysiology	0	Tetanus Toxin (Tetanospasmin) Action	"Clostridium tetani produces tetanospasmin, a potent neurotoxin that is transported retrogradely along motor neurons to the spinal cord. The toxin blocks the release of inhibitory neurotransmitters (GABA and glycine) from presynaptic terminals in the spinal cord, leading to unopposed muscle contraction and characteristic spasms.
"	biological_processes[2]	biological_processes	biological_processes			negative regulation of neurotransmitter secretion	GO:0046929	negative regulation of neurotransmitter secretion		"{""preferred_term"": ""negative regulation of neurotransmitter secretion"", ""term"": {""id"": ""GO:0046929"", ""label"": ""negative regulation of neurotransmitter secretion""}}"																											
6729	7446	323	Tetanus	Tetanus.yaml	pathophysiology	1	Autonomic Nervous System Dysfunction	"Tetanus toxin affects the autonomic nervous system, causing sympathetic overactivity that manifests as tachycardia, hypertension, arrhythmias, and hyperthermia. This autonomic instability is a major cause of morbidity and mortality in severe tetanus.
"	cell_types[0]	cell_types	cell_types			noradrenergic neuron	CL:0008025	noradrenergic neuron		"{""preferred_term"": ""noradrenergic neuron"", ""term"": {""id"": ""CL:0008025"", ""label"": ""noradrenergic neuron""}}"																											
6730	7446	323	Tetanus	Tetanus.yaml	pathophysiology	1	Autonomic Nervous System Dysfunction	"Tetanus toxin affects the autonomic nervous system, causing sympathetic overactivity that manifests as tachycardia, hypertension, arrhythmias, and hyperthermia. This autonomic instability is a major cause of morbidity and mortality in severe tetanus.
"	biological_processes[0]	biological_processes	biological_processes			synaptic transmission, noradrenergic	GO:0099155	synaptic transmission, noradrenergic		"{""preferred_term"": ""synaptic transmission, noradrenergic"", ""term"": {""id"": ""GO:0099155"", ""label"": ""synaptic transmission, noradrenergic""}}"																											
6731	7448	323	Tetanus	Tetanus.yaml	phenotypes	0	Trismus (Lockjaw)	"Sustained contraction of the masseter muscles causing inability to open the mouth, often the first presenting symptom of tetanus.
"	phenotype_term	phenotype_term	$	Trismus (Lockjaw)	"Sustained contraction of the masseter muscles causing inability to open the mouth, often the first presenting symptom of tetanus.
"	trismus	HP:0000211	Trismus		"{""preferred_term"": ""trismus"", ""term"": {""id"": ""HP:0000211"", ""label"": ""Trismus""}}"																											
6732	7449	323	Tetanus	Tetanus.yaml	phenotypes	1	Generalized Muscle Rigidity	"Sustained muscle contraction affecting the entire body, including the characteristic ""risus sardonicus"" (sardonic smile) from facial muscle involvement.
"	phenotype_term	phenotype_term	$	Generalized Muscle Rigidity	"Sustained muscle contraction affecting the entire body, including the characteristic ""risus sardonicus"" (sardonic smile) from facial muscle involvement.
"	muscle rigidity	HP:0002063	Rigidity		"{""preferred_term"": ""muscle rigidity"", ""term"": {""id"": ""HP:0002063"", ""label"": ""Rigidity""}}"																											
6733	7450	323	Tetanus	Tetanus.yaml	phenotypes	2	Opisthotonus	"Severe hyperextension of the spine with arching of the back due to sustained contraction of extensor muscles, a classic sign of generalized tetanus.
"	phenotype_term	phenotype_term	$	Opisthotonus	"Severe hyperextension of the spine with arching of the back due to sustained contraction of extensor muscles, a classic sign of generalized tetanus.
"	opisthotonus	HP:0002179	Opisthotonus		"{""preferred_term"": ""opisthotonus"", ""term"": {""id"": ""HP:0002179"", ""label"": ""Opisthotonus""}}"																											
6734	7451	323	Tetanus	Tetanus.yaml	phenotypes	3	Reflex Spasms	"Painful, generalized muscle spasms triggered by minor stimuli such as noise, light, or touch. These spasms can be severe enough to cause fractures.
"	phenotype_term	phenotype_term	$	Reflex Spasms	"Painful, generalized muscle spasms triggered by minor stimuli such as noise, light, or touch. These spasms can be severe enough to cause fractures.
"	muscle spasms	HP:0003394	Muscle spasm		"{""preferred_term"": ""muscle spasms"", ""term"": {""id"": ""HP:0003394"", ""label"": ""Muscle spasm""}}"																											
6735	7452	323	Tetanus	Tetanus.yaml	phenotypes	4	Dysphagia	"Difficulty swallowing due to pharyngeal muscle spasm, which increases risk of aspiration pneumonia.
"	phenotype_term	phenotype_term	$	Dysphagia	"Difficulty swallowing due to pharyngeal muscle spasm, which increases risk of aspiration pneumonia.
"	dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
6736	7453	323	Tetanus	Tetanus.yaml	phenotypes	5	Respiratory Failure	"Spasm of respiratory muscles and laryngospasm can cause life-threatening respiratory compromise, the leading cause of death in tetanus.
"	phenotype_term	phenotype_term	$	Respiratory Failure	"Spasm of respiratory muscles and laryngospasm can cause life-threatening respiratory compromise, the leading cause of death in tetanus.
"	respiratory failure	HP:0002878	Respiratory failure		"{""preferred_term"": ""respiratory failure"", ""term"": {""id"": ""HP:0002878"", ""label"": ""Respiratory failure""}}"																											
6737	7454	323	Tetanus	Tetanus.yaml	treatments	0	Tetanus Immunoglobulin (TIG)	"Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.
"	treatment_term	treatment_term	$	Tetanus Immunoglobulin (TIG)	"Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6738	7455	323	Tetanus	Tetanus.yaml	treatments	1	Wound Debridement	"Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.
"	treatment_term	treatment_term	$	Wound Debridement	"Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6739	7456	323	Tetanus	Tetanus.yaml	treatments	2	Antibiotic Therapy	"Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.
"	treatment_term	treatment_term	$	Antibiotic Therapy	"Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6740	7457	323	Tetanus	Tetanus.yaml	treatments	3	Muscle Relaxants and Sedation	"Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.
"	treatment_term	treatment_term	$	Muscle Relaxants and Sedation	"Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6741	7458	323	Tetanus	Tetanus.yaml	treatments	4	Supportive Care	"ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.
"	treatment_term	treatment_term	$	Supportive Care	"ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6742	7459	323	Tetanus	Tetanus.yaml	treatments	5	Active Immunization	"Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.
"	treatment_term	treatment_term	$	Active Immunization	"Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.
"	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
6743	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	gene	gene	$	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	FGFR3	hgnc:3690	FGFR3	Fibroblast growth factor receptor 3 with severe gain-of-function mutations.	"{""description"": ""Fibroblast growth factor receptor 3 with severe gain-of-function mutations."", ""modifier"": ""INCREASED"", ""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"			INCREASED																								
6744	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	cell_types[0]	cell_types	cell_types			Growth plate chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth plate chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
6745	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	cell_types[1]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6746	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	biological_processes[0]	biological_processes	biological_processes			FGFR signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
6747	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	biological_processes[1]	biological_processes	biological_processes			Negative regulation of chondrocyte differentiation	GO:0032331	negative regulation of chondrocyte differentiation		"{""preferred_term"": ""Negative regulation of chondrocyte differentiation"", ""term"": {""id"": ""GO:0032331"", ""label"": ""negative regulation of chondrocyte differentiation""}}"																											
6748	7462	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	0	Severe FGFR3 gain-of-function	"TD1 mutations cause severe constitutive activation of FGFR3, leading to profound inhibition of chondrocyte proliferation and differentiation in the growth plate. The R248C mutation in the extracellular domain causes ligand-independent receptor dimerization and activation. This results in severely shortened and disorganized growth plates with minimal longitudinal bone growth.
"	biological_processes[2]	biological_processes	biological_processes			Endochondral ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
6749	7463	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	1	Pulmonary hypoplasia	"The severely narrow thorax restricts lung development in utero, resulting in pulmonary hypoplasia that is the primary cause of perinatal death due to respiratory insufficiency.
"	cell_types[0]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6750	7463	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	pathophysiology	1	Pulmonary hypoplasia	"The severely narrow thorax restricts lung development in utero, resulting in pulmonary hypoplasia that is the primary cause of perinatal death due to respiratory insufficiency.
"	biological_processes[0]	biological_processes	biological_processes			Lung development	GO:0030324	lung development		"{""preferred_term"": ""Lung development"", ""term"": {""id"": ""GO:0030324"", ""label"": ""lung development""}}"																											
6751	7464	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	0	Lethal short-limbed short stature	"Extreme micromelia (severely shortened limbs) with rhizomelic predominance. The limbs are so short that they appear flipper-like.
"	phenotype_term	phenotype_term	$	Lethal short-limbed short stature	"Extreme micromelia (severely shortened limbs) with rhizomelic predominance. The limbs are so short that they appear flipper-like.
"	Lethal short-limbed short stature	HP:0008909	Lethal short-limbed short stature		"{""preferred_term"": ""Lethal short-limbed short stature"", ""term"": {""id"": ""HP:0008909"", ""label"": ""Lethal short-limbed short stature""}}"																											
6752	7465	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	1	Curved femurs	"The femurs are characteristically bowed (curved) in TD1, described as having a ""telephone receiver"" appearance. This distinguishes TD1 from TD2.
"	phenotype_term	phenotype_term	$	Curved femurs	"The femurs are characteristically bowed (curved) in TD1, described as having a ""telephone receiver"" appearance. This distinguishes TD1 from TD2.
"	Bowed long bones	HP:0006487	Bowing of the long bones		"{""preferred_term"": ""Bowed long bones"", ""term"": {""id"": ""HP:0006487"", ""label"": ""Bowing of the long bones""}}"																											
6753	7466	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	2	Narrow thorax	"Severely narrow, bell-shaped thorax with short ribs leading to pulmonary hypoplasia and respiratory failure.
"	phenotype_term	phenotype_term	$	Narrow thorax	"Severely narrow, bell-shaped thorax with short ribs leading to pulmonary hypoplasia and respiratory failure.
"	Narrow chest	HP:0000774	Narrow chest		"{""preferred_term"": ""Narrow chest"", ""term"": {""id"": ""HP:0000774"", ""label"": ""Narrow chest""}}"																											
6754	7467	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	3	Platyspondyly	"Severe flattening of the vertebral bodies is characteristic, with H-shaped or U-shaped vertebrae on radiographs.
"	phenotype_term	phenotype_term	$	Platyspondyly	"Severe flattening of the vertebral bodies is characteristic, with H-shaped or U-shaped vertebrae on radiographs.
"	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
6755	7468	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	4	Macrocephaly	Large head circumference with frontal bossing.	phenotype_term	phenotype_term	$	Macrocephaly	Large head circumference with frontal bossing.	Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
6756	7469	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	5	Frontal bossing	Prominent forehead is characteristic of the facial features.	phenotype_term	phenotype_term	$	Frontal bossing	Prominent forehead is characteristic of the facial features.	Frontal bossing	HP:0002007	Frontal bossing		"{""preferred_term"": ""Frontal bossing"", ""term"": {""id"": ""HP:0002007"", ""label"": ""Frontal bossing""}}"																											
6757	7470	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	6	Midface retrusion	Depressed nasal bridge and midface hypoplasia.	phenotype_term	phenotype_term	$	Midface retrusion	Depressed nasal bridge and midface hypoplasia.	Midface retrusion	HP:0011800	Midface retrusion		"{""preferred_term"": ""Midface retrusion"", ""term"": {""id"": ""HP:0011800"", ""label"": ""Midface retrusion""}}"																											
6758	7471	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	phenotypes	7	Respiratory insufficiency	"Severe respiratory failure due to pulmonary hypoplasia is the cause of perinatal death in most cases.
"	phenotype_term	phenotype_term	$	Respiratory insufficiency	"Severe respiratory failure due to pulmonary hypoplasia is the cause of perinatal death in most cases.
"	Respiratory insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
6759	7472	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.
"	treatment_term	treatment_term	$	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6760	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	gene	gene	$	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	FGFR3	hgnc:3690	FGFR3	Fibroblast growth factor receptor 3 with severe gain-of-function mutation in the kinase domain.	"{""description"": ""Fibroblast growth factor receptor 3 with severe gain-of-function mutation in the kinase domain."", ""modifier"": ""INCREASED"", ""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}"			INCREASED																								
6761	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	cell_types[0]	cell_types	cell_types			Growth plate chondrocyte	CL:1000217	growth plate cartilage chondrocyte		"{""preferred_term"": ""Growth plate chondrocyte"", ""term"": {""id"": ""CL:1000217"", ""label"": ""growth plate cartilage chondrocyte""}}"																											
6762	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	cell_types[1]	cell_types	cell_types			Chondrocyte	CL:0000138	chondrocyte		"{""preferred_term"": ""Chondrocyte"", ""term"": {""id"": ""CL:0000138"", ""label"": ""chondrocyte""}}"																											
6763	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	biological_processes[0]	biological_processes	biological_processes			FGFR signaling pathway	GO:0008543	fibroblast growth factor receptor signaling pathway		"{""preferred_term"": ""FGFR signaling pathway"", ""term"": {""id"": ""GO:0008543"", ""label"": ""fibroblast growth factor receptor signaling pathway""}}"																											
6764	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	biological_processes[1]	biological_processes	biological_processes			Negative regulation of chondrocyte differentiation	GO:0032331	negative regulation of chondrocyte differentiation		"{""preferred_term"": ""Negative regulation of chondrocyte differentiation"", ""term"": {""id"": ""GO:0032331"", ""label"": ""negative regulation of chondrocyte differentiation""}}"																											
6765	7475	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	0	Severe FGFR3 gain-of-function (K650E)	"The K650E mutation in the tyrosine kinase domain causes severe constitutive activation of FGFR3 through autophosphorylation, independent of ligand binding. This profoundly inhibits chondrocyte proliferation and differentiation, resulting in minimal endochondral bone growth. The K650E mutation causes more severe receptor activation than the K650M mutation (associated with SADDAN syndrome).
"	biological_processes[2]	biological_processes	biological_processes			Endochondral ossification	GO:0001958	endochondral ossification		"{""preferred_term"": ""Endochondral ossification"", ""term"": {""id"": ""GO:0001958"", ""label"": ""endochondral ossification""}}"																											
6766	7476	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	pathophysiology	1	Premature craniosynostosis	"The FGFR3 K650E mutation affects cranial suture development, leading to the cloverleaf skull deformity (kleeblattschadel) seen in many TD2 cases. This involves premature fusion of multiple cranial sutures with compensatory bulging at patent sutures.
"	biological_processes[0]	biological_processes	biological_processes			Cranial suture morphogenesis	GO:0060363	cranial suture morphogenesis		"{""preferred_term"": ""Cranial suture morphogenesis"", ""term"": {""id"": ""GO:0060363"", ""label"": ""cranial suture morphogenesis""}}"																											
6767	7477	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	0	Lethal short-limbed short stature	"Extreme micromelia with severely shortened limbs appearing flipper-like.
"	phenotype_term	phenotype_term	$	Lethal short-limbed short stature	"Extreme micromelia with severely shortened limbs appearing flipper-like.
"	Lethal short-limbed short stature	HP:0008909	Lethal short-limbed short stature		"{""preferred_term"": ""Lethal short-limbed short stature"", ""term"": {""id"": ""HP:0008909"", ""label"": ""Lethal short-limbed short stature""}}"																											
6768	7478	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	1	Straight femurs	"Unlike TD1, the femurs in TD2 are straight rather than bowed. This is a key distinguishing feature between the two types.
"	phenotype_term	phenotype_term	$	Straight femurs	"Unlike TD1, the femurs in TD2 are straight rather than bowed. This is a key distinguishing feature between the two types.
"	Short femur	HP:0003097	Short femur		"{""preferred_term"": ""Short femur"", ""term"": {""id"": ""HP:0003097"", ""label"": ""Short femur""}}"																											
6769	7479	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	2	Cloverleaf skull	"Kleeblattschadel (cloverleaf skull) deformity with trilobed skull shape due to premature craniosynostosis is highly characteristic of TD2 and helps distinguish it from TD1.
"	phenotype_term	phenotype_term	$	Cloverleaf skull	"Kleeblattschadel (cloverleaf skull) deformity with trilobed skull shape due to premature craniosynostosis is highly characteristic of TD2 and helps distinguish it from TD1.
"	Cloverleaf skull	HP:0002676	Cloverleaf skull		"{""preferred_term"": ""Cloverleaf skull"", ""term"": {""id"": ""HP:0002676"", ""label"": ""Cloverleaf skull""}}"																											
6770	7480	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	3	Narrow thorax	"Severely narrow, bell-shaped thorax with short ribs leading to pulmonary hypoplasia.
"	phenotype_term	phenotype_term	$	Narrow thorax	"Severely narrow, bell-shaped thorax with short ribs leading to pulmonary hypoplasia.
"	Narrow chest	HP:0000774	Narrow chest		"{""preferred_term"": ""Narrow chest"", ""term"": {""id"": ""HP:0000774"", ""label"": ""Narrow chest""}}"																											
6771	7481	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	4	Platyspondyly	Severe flattening of the vertebral bodies.	phenotype_term	phenotype_term	$	Platyspondyly	Severe flattening of the vertebral bodies.	Platyspondyly	HP:0000926	Platyspondyly		"{""preferred_term"": ""Platyspondyly"", ""term"": {""id"": ""HP:0000926"", ""label"": ""Platyspondyly""}}"																											
6772	7482	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	5	Macrocephaly	Large head circumference, often with cloverleaf deformity.	phenotype_term	phenotype_term	$	Macrocephaly	Large head circumference, often with cloverleaf deformity.	Macrocephaly	HP:0000256	Macrocephaly		"{""preferred_term"": ""Macrocephaly"", ""term"": {""id"": ""HP:0000256"", ""label"": ""Macrocephaly""}}"																											
6773	7483	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	6	Frontal bossing	Prominent forehead.	phenotype_term	phenotype_term	$	Frontal bossing	Prominent forehead.	Frontal bossing	HP:0002007	Frontal bossing		"{""preferred_term"": ""Frontal bossing"", ""term"": {""id"": ""HP:0002007"", ""label"": ""Frontal bossing""}}"																											
6774	7484	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	phenotypes	7	Respiratory insufficiency	"Severe respiratory failure due to pulmonary hypoplasia causes perinatal death.
"	phenotype_term	phenotype_term	$	Respiratory insufficiency	"Severe respiratory failure due to pulmonary hypoplasia causes perinatal death.
"	Respiratory insufficiency	HP:0002093	Respiratory insufficiency		"{""preferred_term"": ""Respiratory insufficiency"", ""term"": {""id"": ""HP:0002093"", ""label"": ""Respiratory insufficiency""}}"																											
6775	7485	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.
"	treatment_term	treatment_term	$	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6776	7486	326	Trachoma	Trachoma.yaml	infectious_agent	0	Chlamydia trachomatis	Conjunctival strains of C. trachomatis cause trachoma.	infectious_agent_term	infectious_agent_term	$	Chlamydia trachomatis	Conjunctival strains of C. trachomatis cause trachoma.	Chlamydia trachomatis	NCBITaxon:813	Chlamydia trachomatis		"{""preferred_term"": ""Chlamydia trachomatis"", ""term"": {""id"": ""NCBITaxon:813"", ""label"": ""Chlamydia trachomatis""}}"																											
6777	7488	326	Trachoma	Trachoma.yaml	phenotypes	0	Blindness		phenotype_term	phenotype_term	$	Blindness		Blindness	HP:0000618	Blindness		"{""preferred_term"": ""Blindness"", ""term"": {""id"": ""HP:0000618"", ""label"": ""Blindness""}}"																											
6778	7489	326	Trachoma	Trachoma.yaml	treatments	0	Antibiotic mass drug administration (SAFE strategy)	Antibiotic mass drug administration reduces infection prevalence and transmission.	treatment_term	treatment_term	$	Antibiotic mass drug administration (SAFE strategy)	Antibiotic mass drug administration reduces infection prevalence and transmission.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6779	7494	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	0	Melanocyte Activation	An unknown trigger, possibly related to the transition from intrauterine to extrauterine life, leads to the activation of melanocytes in the skin.	cell_types[0]	cell_types	cell_types			Melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""Melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
6780	7494	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	0	Melanocyte Activation	An unknown trigger, possibly related to the transition from intrauterine to extrauterine life, leads to the activation of melanocytes in the skin.	biological_processes[0]	biological_processes	biological_processes			pigmentation	GO:0043473	pigmentation		"{""preferred_term"": ""pigmentation"", ""term"": {""id"": ""GO:0043473"", ""label"": ""pigmentation""}}"																											
6781	7495	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	1	Melanin Accumulation	Activated melanocytes produce and release excessive amounts of melanin, which accumulates in the superficial layers of the skin.	locations[0]	locations	locations			Epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""Epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
6782	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	locations[0]	locations	locations			Epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""Epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
6783	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6784	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	cell_types[1]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
6785	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	biological_processes[0]	biological_processes	biological_processes			neutrophil chemotaxis	GO:0030593	neutrophil chemotaxis		"{""preferred_term"": ""neutrophil chemotaxis"", ""term"": {""id"": ""GO:0030593"", ""label"": ""neutrophil chemotaxis""}}"																											
6786	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	biological_processes[1]	biological_processes	biological_processes			epidermis development	GO:0008544	epidermis development		"{""preferred_term"": ""epidermis development"", ""term"": {""id"": ""GO:0008544"", ""label"": ""epidermis development""}}"																											
6787	7496	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	2	Pustule Formation	The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life. Pustules contain predominantly neutrophils in an intra- or subcorneal location.	biological_processes[2]	biological_processes	biological_processes			keratinization	GO:0031424	keratinization		"{""preferred_term"": ""keratinization"", ""term"": {""id"": ""GO:0031424"", ""label"": ""keratinization""}}"																											
6788	7497	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	3	Hyper pigmentation	As the pustules resolve, they may leave behind areas of hyper pigmentation or dark spots on the skin, representing the sites of melanin accumulation. Commonly affected sites include face, neck, and back.	locations[0]	locations	locations			Skin	UBERON:0002097	skin of body		"{""preferred_term"": ""Skin"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
6789	7497	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	3	Hyper pigmentation	As the pustules resolve, they may leave behind areas of hyper pigmentation or dark spots on the skin, representing the sites of melanin accumulation. Commonly affected sites include face, neck, and back.	locations[1]	locations	locations			skin of face	UBERON:0001456	skin of face		"{""preferred_term"": ""skin of face"", ""term"": {""id"": ""UBERON:0001456"", ""label"": ""skin of face""}}"																											
6790	7497	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	3	Hyper pigmentation	As the pustules resolve, they may leave behind areas of hyper pigmentation or dark spots on the skin, representing the sites of melanin accumulation. Commonly affected sites include face, neck, and back.	locations[2]	locations	locations			neck	UBERON:0000974	neck		"{""preferred_term"": ""neck"", ""term"": {""id"": ""UBERON:0000974"", ""label"": ""neck""}}"																											
6791	7497	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	3	Hyper pigmentation	As the pustules resolve, they may leave behind areas of hyper pigmentation or dark spots on the skin, representing the sites of melanin accumulation. Commonly affected sites include face, neck, and back.	locations[3]	locations	locations			back	UBERON:0002410	back		"{""preferred_term"": ""back"", ""term"": {""id"": ""UBERON:0002410"", ""label"": ""back""}}"																											
6792	7498	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	pathophysiology	4	Desquamation	In some cases, the resolution of pustules may be followed by a period of superficial skin peeling or desquamation.	locations[0]	locations	locations			Skin	UBERON:0002097	skin of body		"{""preferred_term"": ""Skin"", ""term"": {""id"": ""UBERON:0002097"", ""label"": ""skin of body""}}"																											
6793	7501	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	phenotypes	0	Pustules		phenotype_term	phenotype_term	$	Pustules		Pustules	HP:0200039	Pustule		"{""preferred_term"": ""Pustules"", ""term"": {""id"": ""HP:0200039"", ""label"": ""Pustule""}}"																											
6794	7502	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	phenotypes	1	Hyperpigmented Macules		phenotype_term	phenotype_term	$	Hyperpigmented Macules		Hyperpigmentation of the skin	HP:0000953	Hyperpigmentation of the skin		"{""preferred_term"": ""Hyperpigmentation of the skin"", ""term"": {""id"": ""HP:0000953"", ""label"": ""Hyperpigmentation of the skin""}}"																											
6795	7503	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	phenotypes	2	Scaling Skin		phenotype_term	phenotype_term	$	Scaling Skin		Scaling skin	HP:0000988	Skin rash		"{""preferred_term"": ""Scaling skin"", ""term"": {""id"": ""HP:0000988"", ""label"": ""Skin rash""}}"																											
6796	7509	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	treatments	0	None Required	Condition is self-limiting and resolves without treatment.	treatment_term	treatment_term	$	None Required	Condition is self-limiting and resolves without treatment.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6797	7513	328	Transverse Myelitis	Transverse_Myelitis.yaml	definitions	0	Clinical presentation summary (StatPearls)	Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction.	criteria_sets[0].core_clinical_characteristics[0]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Rapid onset weakness	HP:0001324	Muscle weakness	Rapid onset muscle weakness.	"{""description"": ""Rapid onset muscle weakness."", ""preferred_term"": ""Rapid onset weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
6798	7513	328	Transverse Myelitis	Transverse_Myelitis.yaml	definitions	0	Clinical presentation summary (StatPearls)	Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction.	criteria_sets[0].core_clinical_characteristics[1]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Sensory deficits	HP:0003474	Somatic sensory dysfunction		"{""preferred_term"": ""Sensory deficits"", ""term"": {""id"": ""HP:0003474"", ""label"": ""Somatic sensory dysfunction""}}"																											
6799	7513	328	Transverse Myelitis	Transverse_Myelitis.yaml	definitions	0	Clinical presentation summary (StatPearls)	Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction.	criteria_sets[0].core_clinical_characteristics[2]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Neurogenic bladder	HP:0000011	Neurogenic bladder		"{""preferred_term"": ""Neurogenic bladder"", ""term"": {""id"": ""HP:0000011"", ""label"": ""Neurogenic bladder""}}"																											
6800	7513	328	Transverse Myelitis	Transverse_Myelitis.yaml	definitions	0	Clinical presentation summary (StatPearls)	Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction.	criteria_sets[0].core_clinical_characteristics[3]	criteria_sets	criteria_sets[0].core_clinical_characteristics			Bowel incontinence	HP:0002607	Bowel incontinence		"{""preferred_term"": ""Bowel incontinence"", ""term"": {""id"": ""HP:0002607"", ""label"": ""Bowel incontinence""}}"																											
6801	7514	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	0	Spinal Cord Inflammation	Focal inflammatory injury within the spinal cord disrupts motor and sensory pathways, leading to neurologic deficits.	locations[0]	locations	locations			spinal cord	UBERON:0002240	spinal cord		"{""preferred_term"": ""spinal cord"", ""term"": {""id"": ""UBERON:0002240"", ""label"": ""spinal cord""}}"																											
6802	7514	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	0	Spinal Cord Inflammation	Focal inflammatory injury within the spinal cord disrupts motor and sensory pathways, leading to neurologic deficits.	biological_processes[0]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""modifier"": ""INCREASED"", ""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"			INCREASED																								
6803	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	locations[0]	locations	locations			spinal cord	UBERON:0002240	spinal cord		"{""preferred_term"": ""spinal cord"", ""term"": {""id"": ""UBERON:0002240"", ""label"": ""spinal cord""}}"																											
6804	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	locations[1]	locations	locations			blood brain barrier	UBERON:0000120	blood brain barrier		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""blood brain barrier"", ""term"": {""id"": ""UBERON:0000120"", ""label"": ""blood brain barrier""}}"			ABNORMAL																								
6805	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	cell_types[0]	cell_types	cell_types			neuron	CL:0000540	neuron		"{""preferred_term"": ""neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
6806	7515	328	Transverse Myelitis	Transverse_Myelitis.yaml	pathophysiology	1	Immune-Mediated Neural Injury	In idiopathic acute transverse myelitis, cellular influx into the spinal cord disrupts the blood-brain barrier and causes demyelination and neuronal injury.	cellular_components[0]	cellular_components	cellular_components			myelin sheath	GO:0043209	myelin sheath		"{""modifier"": ""DECREASED"", ""preferred_term"": ""myelin sheath"", ""term"": {""id"": ""GO:0043209"", ""label"": ""myelin sheath""}}"			DECREASED																								
6807	7517	328	Transverse Myelitis	Transverse_Myelitis.yaml	phenotypes	0	Muscle Weakness		phenotype_term	phenotype_term	$	Muscle Weakness		Muscle weakness	HP:0001324	Muscle weakness		"{""preferred_term"": ""Muscle weakness"", ""term"": {""id"": ""HP:0001324"", ""label"": ""Muscle weakness""}}"																											
6808	7518	328	Transverse Myelitis	Transverse_Myelitis.yaml	phenotypes	1	Sensory Disturbance		phenotype_term	phenotype_term	$	Sensory Disturbance		Sensory disturbance	HP:0003474	Somatic sensory dysfunction		"{""preferred_term"": ""Sensory disturbance"", ""term"": {""id"": ""HP:0003474"", ""label"": ""Somatic sensory dysfunction""}}"																											
6809	7519	328	Transverse Myelitis	Transverse_Myelitis.yaml	phenotypes	2	Neurogenic Bladder		phenotype_term	phenotype_term	$	Neurogenic Bladder		Neurogenic bladder	HP:0000011	Neurogenic bladder		"{""preferred_term"": ""Neurogenic bladder"", ""term"": {""id"": ""HP:0000011"", ""label"": ""Neurogenic bladder""}}"																											
6810	7520	328	Transverse Myelitis	Transverse_Myelitis.yaml	phenotypes	3	Bowel Incontinence		phenotype_term	phenotype_term	$	Bowel Incontinence		Bowel incontinence	HP:0002607	Bowel incontinence		"{""preferred_term"": ""Bowel incontinence"", ""term"": {""id"": ""HP:0002607"", ""label"": ""Bowel incontinence""}}"																											
6811	7521	328	Transverse Myelitis	Transverse_Myelitis.yaml	phenotypes	4	Paraplegia		phenotype_term	phenotype_term	$	Paraplegia		Paraplegia	HP:0010550	Paraplegia		"{""preferred_term"": ""Paraplegia"", ""term"": {""id"": ""HP:0010550"", ""label"": ""Paraplegia""}}"																											
6812	7522	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	0	Corticosteroid Therapy	High-dose steroids as standard acute therapy.	treatment_term	treatment_term	$	Corticosteroid Therapy	High-dose steroids as standard acute therapy.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
6813	7523	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	1	Plasma Exchange	Plasma exchange for more severe transverse myelitis.	treatment_term	treatment_term	$	Plasma Exchange	Plasma exchange for more severe transverse myelitis.	plasma exchange				"{""preferred_term"": ""plasma exchange""}"																											
6814	7524	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	differential_diagnoses	0	Campylobacter enteritis	Common bacterial cause of travelers diarrhea presenting with febrile inflammatory diarrhea.	disease_term	disease_term	$	Campylobacter enteritis	Common bacterial cause of travelers diarrhea presenting with febrile inflammatory diarrhea.	campylobacteriosis	MONDO:0005688	campylobacteriosis		"{""preferred_term"": ""campylobacteriosis"", ""term"": {""id"": ""MONDO:0005688"", ""label"": ""campylobacteriosis""}}"																											
6815	7525	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	differential_diagnoses	1	Giardiasis	Parasitic infection causing prolonged watery diarrhea and malabsorption that can be acquired during travel.	disease_term	disease_term	$	Giardiasis	Parasitic infection causing prolonged watery diarrhea and malabsorption that can be acquired during travel.	giardiasis	MONDO:0001103	giardiasis		"{""preferred_term"": ""giardiasis"", ""term"": {""id"": ""MONDO:0001103"", ""label"": ""giardiasis""}}"																											
6816	7527	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	infectious_agent	0	Enterotoxigenic Escherichia coli		infectious_agent_term	infectious_agent_term	$	Enterotoxigenic Escherichia coli		Enterotoxigenic Escherichia coli	NCBITaxon:562	Escherichia coli		"{""preferred_term"": ""Enterotoxigenic Escherichia coli"", ""term"": {""id"": ""NCBITaxon:562"", ""label"": ""Escherichia coli""}}"																											
6817	7528	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	pathophysiology	0	Ingestion of contaminated food or water during travel	Travelers ingest enteric pathogens through unsafe food and water, initiating diarrheal illness.	locations[0]	locations	locations			gastrointestinal tract	UBERON:0005409	gastrointestinal tract		"{""preferred_term"": ""gastrointestinal tract"", ""term"": {""id"": ""UBERON:0005409"", ""label"": ""gastrointestinal tract""}}"																											
6818	7529	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	pathophysiology	1	ETEC adherence via colonization factors	Enterotoxigenic E. coli use colonization factors to adhere to intestinal epithelium and establish infection.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
6819	7530	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	pathophysiology	2	Enterotoxin-driven secretory diarrhea	ETEC heat-labile and heat-stable enterotoxins bind epithelial receptors, driving chloride and water secretion and watery diarrhea.	locations[0]	locations	locations			small intestine	UBERON:0002108	small intestine		"{""preferred_term"": ""small intestine"", ""term"": {""id"": ""UBERON:0002108"", ""label"": ""small intestine""}}"																											
6820	7531	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	phenotypes	0	Acute watery diarrhea	Sudden onset of loose, watery stools during or shortly after travel.	phenotype_term	phenotype_term	$	Acute watery diarrhea	Sudden onset of loose, watery stools during or shortly after travel.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
6821	7532	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	phenotypes	1	Abdominal cramps	Cramping pain accompanying diarrhea.	phenotype_term	phenotype_term	$	Abdominal cramps	Cramping pain accompanying diarrhea.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
6822	7533	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	phenotypes	2	Nausea	Feeling of sickness often preceding or accompanying diarrhea.	phenotype_term	phenotype_term	$	Nausea	Feeling of sickness often preceding or accompanying diarrhea.	Nausea	HP:0002018	Nausea		"{""preferred_term"": ""Nausea"", ""term"": {""id"": ""HP:0002018"", ""label"": ""Nausea""}}"																											
6823	7534	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	0	Oral rehydration therapy	Fluid and electrolyte replacement is the cornerstone of treatment.	treatment_term	treatment_term	$	Oral rehydration therapy	Fluid and electrolyte replacement is the cornerstone of treatment.	fluid replacement therapy	MAXO:0000618	fluid replacement therapy		"{""preferred_term"": ""fluid replacement therapy"", ""term"": {""id"": ""MAXO:0000618"", ""label"": ""fluid replacement therapy""}}"																											
6824	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term	treatment_term	$	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Loperamide Hydrochloride	NCIT:C62046	NCIT:C2259			
6825	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6826	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			loperamide hydrochloride	NCIT:C62046	Loperamide Hydrochloride		"{""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}"																											
6827	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term	treatment_term	$	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Ciprofloxacin	NCIT:C376	NCIT:C2259			
6828	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6829	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			ciprofloxacin	NCIT:C376	Ciprofloxacin		"{""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}"																											
6830	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term	treatment_term	$	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						rifaximin	NCIT:C95262	NCIT:C2259			
6831	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6832	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			rifaximin	NCIT:C95262	rifaximin		"{""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}"																											
6833	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term	treatment_term	$	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Bismuth Subsalicylate	NCIT:C333	NCIT:C2259			
6834	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6835	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			bismuth subsalicylate	NCIT:C333	Bismuth Subsalicylate		"{""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}"																											
6836	7539	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	5	Probiotic prophylaxis	Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.	treatment_term	treatment_term	$	Probiotic prophylaxis	Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6837	7540	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	6	Education on safe food and water practices	Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.	treatment_term	treatment_term	$	Education on safe food and water practices	Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6838	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term	treatment_term	$	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						rifaximin	NCIT:C95262	NCIT:C2259			
6839	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6840	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			rifaximin	NCIT:C95262	rifaximin		"{""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}"																											
6841	7551	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	histopathology	0	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	finding_term	finding_term	$	Invasive Ductal Carcinoma	Invasive ductal carcinoma is the most common type of breast cancer.	Invasive Breast Carcinoma of No Special Type	NCIT:C4194	Invasive Breast Carcinoma of No Special Type		"{""preferred_term"": ""Invasive Breast Carcinoma of No Special Type"", ""term"": {""id"": ""NCIT:C4194"", ""label"": ""Invasive Breast Carcinoma of No Special Type""}}"																											
6842	7552	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	0	Loss of Hormone Receptor Signaling	TNBC lacks expression of estrogen receptor alpha (ESR1) and progesterone receptor (PGR), eliminating the growth-promoting effects of estrogen signaling that drive most breast cancers. This absence removes a key therapeutic target but also indicates fundamentally different tumor biology.	biological_processes[0]	biological_processes	biological_processes			estrogen receptor signaling pathway	GO:0030520	intracellular estrogen receptor signaling pathway		"{""modifier"": ""ABSENT"", ""preferred_term"": ""estrogen receptor signaling pathway"", ""term"": {""id"": ""GO:0030520"", ""label"": ""intracellular estrogen receptor signaling pathway""}}"			ABSENT																								
6843	7553	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	1	Alternative Oncogenic Pathways	In the absence of hormone receptor signaling, TNBC is driven by alternative oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this tumor suppressor checkpoint.	biological_processes[0]	biological_processes	biological_processes			epidermal growth factor receptor signaling pathway	GO:0007173	epidermal growth factor receptor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""epidermal growth factor receptor signaling pathway"", ""term"": {""id"": ""GO:0007173"", ""label"": ""epidermal growth factor receptor signaling pathway""}}"			INCREASED																								
6844	7553	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	1	Alternative Oncogenic Pathways	In the absence of hormone receptor signaling, TNBC is driven by alternative oncogenic pathways including EGFR signaling, PI3K-AKT-mTOR activation, and Wnt/beta-catenin signaling. Many TNBCs have TP53 mutations eliminating this tumor suppressor checkpoint.	biological_processes[1]	biological_processes	biological_processes			phosphatidylinositol 3-kinase signaling	GO:0014065	phosphatidylinositol 3-kinase signaling		"{""modifier"": ""INCREASED"", ""preferred_term"": ""phosphatidylinositol 3-kinase signaling"", ""term"": {""id"": ""GO:0014065"", ""label"": ""phosphatidylinositol 3-kinase signaling""}}"			INCREASED																								
6845	7554	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	2	DNA Repair Deficiency	A significant subset of TNBC (~20%) harbors germline or somatic BRCA1/2 mutations resulting in homologous recombination deficiency. This creates sensitivity to platinum chemotherapy and PARP inhibitors through synthetic lethality.	biological_processes[0]	biological_processes	biological_processes			homologous recombination	GO:0035825	homologous recombination		"{""modifier"": ""DECREASED"", ""preferred_term"": ""homologous recombination"", ""term"": {""id"": ""GO:0035825"", ""label"": ""homologous recombination""}}"			DECREASED																								
6846	7555	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	pathophysiology	3	Aggressive Tumor Behavior	TNBC is characterized by high proliferation rates, early metastasis (especially to viscera and brain), and shorter time to recurrence compared to other breast cancer subtypes. The aggressive biology reflects activation of multiple oncogenic pathways and loss of tumor suppressors.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
6847	7556	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	phenotypes	0	Breast Carcinoma	Triple-negative breast cancers are typically high-grade invasive ductal carcinomas with high mitotic rates. Medullary and metaplastic histologies are enriched in the TNBC population.	phenotype_term	phenotype_term	$	Breast Carcinoma	Triple-negative breast cancers are typically high-grade invasive ductal carcinomas with high mitotic rates. Medullary and metaplastic histologies are enriched in the TNBC population.	Breast carcinoma	HP:0003002	Breast carcinoma		"{""preferred_term"": ""Breast carcinoma"", ""term"": {""id"": ""HP:0003002"", ""label"": ""Breast carcinoma""}}"																											
6848	7557	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	phenotypes	1	Early Visceral Metastases	TNBC has a predilection for visceral metastases (lung, liver) and brain metastases, occurring earlier and more frequently than in ER+ breast cancer.	phenotype_term	phenotype_term	$	Early Visceral Metastases	TNBC has a predilection for visceral metastases (lung, liver) and brain metastases, occurring earlier and more frequently than in ER+ breast cancer.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
6849	7558	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	phenotypes	2	Triple-Negative Phenotype	Defining feature is absence of ER (<1%), PR (<1%), and HER2 (IHC 0-1+ or FISH non-amplified). This is a diagnosis of exclusion from other breast cancer subtypes.	phenotype_term	phenotype_term	$	Triple-Negative Phenotype	Defining feature is absence of ER (<1%), PR (<1%), and HER2 (IHC 0-1+ or FISH non-amplified). This is a diagnosis of exclusion from other breast cancer subtypes.	Neoplasm	HP:0002664	Neoplasm		"{""preferred_term"": ""Neoplasm"", ""term"": {""id"": ""HP:0002664"", ""label"": ""Neoplasm""}}"																											
6850	7559	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	0	Neoadjuvant Chemotherapy	Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.	treatment_term	treatment_term	$	Neoadjuvant Chemotherapy	Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6851	7560	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	1	Pembrolizumab Plus Chemotherapy	PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.	treatment_term	treatment_term	$	Pembrolizumab Plus Chemotherapy	PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6852	7561	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	2	PARP Inhibitors	Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.	treatment_term	treatment_term	$	PARP Inhibitors	Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6853	7562	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	3	Sacituzumab Govitecan	Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.	treatment_term	treatment_term	$	Sacituzumab Govitecan	Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6854	7563	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	4	Platinum Chemotherapy	Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.	treatment_term	treatment_term	$	Platinum Chemotherapy	Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6855	7577	331	Tuberculosis	Tuberculosis.yaml	infectious_agent	0	Mycobacterium tuberculosis	A bacterium that primarily affects the lungs but can affect other organs.	infectious_agent_term	infectious_agent_term	$	Mycobacterium tuberculosis	A bacterium that primarily affects the lungs but can affect other organs.	Mycobacterium tuberculosis	NCBITaxon:1773	Mycobacterium tuberculosis		"{""preferred_term"": ""Mycobacterium tuberculosis"", ""term"": {""id"": ""NCBITaxon:1773"", ""label"": ""Mycobacterium tuberculosis""}}"																											
6856	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6857	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	cell_types[1]	cell_types	cell_types			T Cell	CL:0000084	T cell		"{""preferred_term"": ""T Cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
6858	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	cell_types[2]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6859	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	cell_types[3]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
6860	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	biological_processes[0]	biological_processes	biological_processes			type I interferon signaling pathway	GO:0034138	type I interferon signaling pathway		"{""preferred_term"": ""type I interferon signaling pathway"", ""term"": {""id"": ""GO:0034138"", ""label"": ""type I interferon signaling pathway""}}"																											
6861	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	biological_processes[1]	biological_processes	biological_processes			autophagy	GO:0006914	autophagy		"{""preferred_term"": ""autophagy"", ""term"": {""id"": ""GO:0006914"", ""label"": ""autophagy""}}"																											
6862	7578	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	0	Phagocytosis	Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.	biological_processes[2]	biological_processes	biological_processes			phagosome maturation	GO:0090382	phagosome maturation		"{""preferred_term"": ""phagosome maturation"", ""term"": {""id"": ""GO:0090382"", ""label"": ""phagosome maturation""}}"																											
6863	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	cell_types[0]	cell_types	cell_types			Macrophage	CL:0000235	macrophage		"{""preferred_term"": ""Macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6864	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	cell_types[1]	cell_types	cell_types			T Cell	CL:0000084	T cell		"{""preferred_term"": ""T Cell"", ""term"": {""id"": ""CL:0000084"", ""label"": ""T cell""}}"																											
6865	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	biological_processes[0]	biological_processes	biological_processes			lipid metabolic process	GO:0006629	lipid metabolic process		"{""preferred_term"": ""lipid metabolic process"", ""term"": {""id"": ""GO:0006629"", ""label"": ""lipid metabolic process""}}"																											
6866	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	biological_processes[1]	biological_processes	biological_processes			cholesterol transport	GO:0030301	cholesterol transport		"{""preferred_term"": ""cholesterol transport"", ""term"": {""id"": ""GO:0030301"", ""label"": ""cholesterol transport""}}"																											
6867	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	biological_processes[2]	biological_processes	biological_processes			inflammatory response	GO:0006954	inflammatory response		"{""preferred_term"": ""inflammatory response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
6868	7579	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	1	Granuloma Formation	Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.	locations[0]	locations	locations			Lung	UBERON:0002048	lung		"{""preferred_term"": ""Lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
6869	7580	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	2	Neutrophil Activation and NETosis	Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.	cell_types[0]	cell_types	cell_types			neutrophil	CL:0000775	neutrophil		"{""preferred_term"": ""neutrophil"", ""term"": {""id"": ""CL:0000775"", ""label"": ""neutrophil""}}"																											
6870	7580	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	2	Neutrophil Activation and NETosis	Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.	biological_processes[0]	biological_processes	biological_processes			neutrophil degranulation	GO:0043312	neutrophil degranulation		"{""preferred_term"": ""neutrophil degranulation"", ""term"": {""id"": ""GO:0043312"", ""label"": ""neutrophil degranulation""}}"																											
6871	7580	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	2	Neutrophil Activation and NETosis	Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.	biological_processes[1]	biological_processes	biological_processes			neutrophil extracellular trap formation	GO:0062025	neutrophil extracellular trap formation		"{""preferred_term"": ""neutrophil extracellular trap formation"", ""term"": {""id"": ""GO:0062025"", ""label"": ""neutrophil extracellular trap formation""}}"																											
6872	7580	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	2	Neutrophil Activation and NETosis	Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.	locations[0]	locations	locations			Lung	UBERON:0002048	lung		"{""preferred_term"": ""Lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
6873	7581	331	Tuberculosis	Tuberculosis.yaml	pathophysiology	3	Tissue Damage	Active TB can cause cavitation and destruction of lung tissue.	locations[0]	locations	locations			Lung	UBERON:0002048	lung		"{""preferred_term"": ""Lung"", ""term"": {""id"": ""UBERON:0002048"", ""label"": ""lung""}}"																											
6874	7582	331	Tuberculosis	Tuberculosis.yaml	phenotypes	0	Chronic Cough	Persistent cough lasting more than 3 weeks, often productive with sputum, the cardinal respiratory symptom of pulmonary TB.	phenotype_term	phenotype_term	$	Chronic Cough	Persistent cough lasting more than 3 weeks, often productive with sputum, the cardinal respiratory symptom of pulmonary TB.	Chronic Cough	HP:0034315	Chronic cough		"{""preferred_term"": ""Chronic Cough"", ""term"": {""id"": ""HP:0034315"", ""label"": ""Chronic cough""}}"																											
6875	7583	331	Tuberculosis	Tuberculosis.yaml	phenotypes	1	Fever	Low-grade fever typically occurring in the afternoon and evening, often accompanied by chills.	phenotype_term	phenotype_term	$	Fever	Low-grade fever typically occurring in the afternoon and evening, often accompanied by chills.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
6876	7584	331	Tuberculosis	Tuberculosis.yaml	phenotypes	2	Night Sweats	Profuse sweating during sleep requiring change of bedclothes, a classic constitutional symptom of active TB.	phenotype_term	phenotype_term	$	Night Sweats	Profuse sweating during sleep requiring change of bedclothes, a classic constitutional symptom of active TB.	Night sweats	HP:0030166	Night sweats		"{""preferred_term"": ""Night sweats"", ""term"": {""id"": ""HP:0030166"", ""label"": ""Night sweats""}}"																											
6877	7585	331	Tuberculosis	Tuberculosis.yaml	phenotypes	3	Weight Loss	"Unintentional weight loss and wasting, giving rise to the historical term ""consumption"" for TB."	phenotype_term	phenotype_term	$	Weight Loss	"Unintentional weight loss and wasting, giving rise to the historical term ""consumption"" for TB."	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
6878	7586	331	Tuberculosis	Tuberculosis.yaml	phenotypes	4	Hemoptysis	Coughing up blood or blood-streaked sputum, indicating cavitary disease or erosion into blood vessels.	phenotype_term	phenotype_term	$	Hemoptysis	Coughing up blood or blood-streaked sputum, indicating cavitary disease or erosion into blood vessels.	Hemoptysis	HP:0002105	Hemoptysis		"{""preferred_term"": ""Hemoptysis"", ""term"": {""id"": ""HP:0002105"", ""label"": ""Hemoptysis""}}"																											
6879	7587	331	Tuberculosis	Tuberculosis.yaml	phenotypes	5	Chest Pain	Pleuritic chest pain worsening with breathing or coughing, often indicating pleural involvement.	phenotype_term	phenotype_term	$	Chest Pain	Pleuritic chest pain worsening with breathing or coughing, often indicating pleural involvement.	Chest pain	HP:0100749	Chest pain		"{""preferred_term"": ""Chest pain"", ""term"": {""id"": ""HP:0100749"", ""label"": ""Chest pain""}}"																											
6880	7588	331	Tuberculosis	Tuberculosis.yaml	phenotypes	6	Dyspnea	Shortness of breath due to extensive pulmonary involvement, pleural effusion, or fibrosis.	phenotype_term	phenotype_term	$	Dyspnea	Shortness of breath due to extensive pulmonary involvement, pleural effusion, or fibrosis.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
6881	7589	331	Tuberculosis	Tuberculosis.yaml	phenotypes	7	Fatigue	Persistent tiredness and weakness associated with chronic infection and inflammatory response.	phenotype_term	phenotype_term	$	Fatigue	Persistent tiredness and weakness associated with chronic infection and inflammatory response.	Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6882	7590	331	Tuberculosis	Tuberculosis.yaml	phenotypes	8	Back Pain	Localized spinal pain that may indicate vertebral TB (Pott's disease) with potential neurological complications.	phenotype_term	phenotype_term	$	Back Pain	Localized spinal pain that may indicate vertebral TB (Pott's disease) with potential neurological complications.	Back Pain	HP:0003418	Back pain		"{""preferred_term"": ""Back Pain"", ""term"": {""id"": ""HP:0003418"", ""label"": ""Back pain""}}"																											
6883	7591	331	Tuberculosis	Tuberculosis.yaml	phenotypes	9	Lymphadenopathy	Enlarged lymph nodes, particularly cervical, often cold and matted, indicating extrapulmonary TB.	phenotype_term	phenotype_term	$	Lymphadenopathy	Enlarged lymph nodes, particularly cervical, often cold and matted, indicating extrapulmonary TB.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
6884	7596	331	Tuberculosis	Tuberculosis.yaml	treatments	0	Isoniazid	First-line antibiotic for TB treatment.	treatment_term	treatment_term	$	Isoniazid	First-line antibiotic for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6885	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	Rifampicin	Bactericidal antibiotic used for TB treatment.	treatment_term	treatment_term	$	Rifampicin	Bactericidal antibiotic used for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6886	7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	Ethambutol	Bacteriostatic antibiotic used for TB treatment.	treatment_term	treatment_term	$	Ethambutol	Bacteriostatic antibiotic used for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6887	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	Directly Observed Therapy (DOT)	Health worker observes and records patients taking their medication to ensure adherence.	treatment_term	treatment_term	$	Directly Observed Therapy (DOT)	Health worker observes and records patients taking their medication to ensure adherence.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6888	7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	Latent TB Treatment	Isoniazid or rifapentine used to prevent latent TB from becoming active.	treatment_term	treatment_term	$	Latent TB Treatment	Isoniazid or rifapentine used to prevent latent TB from becoming active.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6889	7601	331	Tuberculosis	Tuberculosis.yaml	treatments	5	Host-Directed Therapy	Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.	treatment_term	treatment_term	$	Host-Directed Therapy	Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6890	7607	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	0		Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled, double-blind type 2 diabetes study. Samples at baseline and after 4 months of metformin treatment to assess drug-microbiome interactions.	organism	organism	$		Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled, double-blind type 2 diabetes study. Samples at baseline and after 4 months of metformin treatment to assess drug-microbiome interactions.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
6891	7607	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	0		Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled, double-blind type 2 diabetes study. Samples at baseline and after 4 months of metformin treatment to assess drug-microbiome interactions.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
6892	7607	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	0		Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled, double-blind type 2 diabetes study. Samples at baseline and after 4 months of metformin treatment to assess drug-microbiome interactions.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
6893	7608	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	1		16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes patients and controls in urban African populations, examining geographic and dietary influences on diabetes-associated microbiome signatures.	organism	organism	$		16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes patients and controls in urban African populations, examining geographic and dietary influences on diabetes-associated microbiome signatures.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
6894	7608	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	1		16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes patients and controls in urban African populations, examining geographic and dietary influences on diabetes-associated microbiome signatures.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
6895	7608	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	1		16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes patients and controls in urban African populations, examining geographic and dietary influences on diabetes-associated microbiome signatures.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
6896	7609	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	2		16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing obese individuals with type 2 diabetes to healthy controls. V3-V4 hypervariable regions sequenced.	organism	organism	$		16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing obese individuals with type 2 diabetes to healthy controls. V3-V4 hypervariable regions sequenced.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
6897	7609	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	2		16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing obese individuals with type 2 diabetes to healthy controls. V3-V4 hypervariable regions sequenced.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
6898	7609	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	2		16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing obese individuals with type 2 diabetes to healthy controls. V3-V4 hypervariable regions sequenced.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
6899	7610	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	3		Landmark metagenome-wide association study (MGWAS) comparing gut microbial DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers and established metagenomic linkage groups.	organism	organism	$		Landmark metagenome-wide association study (MGWAS) comparing gut microbial DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers and established metagenomic linkage groups.	human gut metagenome	NCBITaxon:408170	human gut metagenome		"{""preferred_term"": ""human gut metagenome"", ""term"": {""id"": ""NCBITaxon:408170"", ""label"": ""human gut metagenome""}}"																											
6900	7610	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	3		Landmark metagenome-wide association study (MGWAS) comparing gut microbial DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers and established metagenomic linkage groups.	sample_types[0]	sample_types	sample_types			fecal sample				"{""preferred_term"": ""fecal sample"", ""tissue_term"": {""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}}"																											
6901	7610	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	datasets	3		Landmark metagenome-wide association study (MGWAS) comparing gut microbial DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers and established metagenomic linkage groups.	sample_types[0].tissue_term	sample_types	sample_types[0]			feces	UBERON:0001988	feces		"{""preferred_term"": ""feces"", ""term"": {""id"": ""UBERON:0001988"", ""label"": ""feces""}}"																											
6902	7618	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin Resistance	"Peripheral tissues (muscle, liver, adipose) become resistant to insulin action, requiring higher insulin levels to maintain glucose homeostasis. This leads to compensatory hyperinsulinemia and eventually beta cell exhaustion.
"	cell_types[0]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
6903	7618	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin Resistance	"Peripheral tissues (muscle, liver, adipose) become resistant to insulin action, requiring higher insulin levels to maintain glucose homeostasis. This leads to compensatory hyperinsulinemia and eventually beta cell exhaustion.
"	cell_types[1]	cell_types	cell_types			Skeletal Muscle Cell	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Cell"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
6904	7618	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin Resistance	"Peripheral tissues (muscle, liver, adipose) become resistant to insulin action, requiring higher insulin levels to maintain glucose homeostasis. This leads to compensatory hyperinsulinemia and eventually beta cell exhaustion.
"	cell_types[2]	cell_types	cell_types			Adipocyte	CL:0000136	adipocyte		"{""preferred_term"": ""Adipocyte"", ""term"": {""id"": ""CL:0000136"", ""label"": ""adipocyte""}}"																											
6905	7618	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	0	Insulin Resistance	"Peripheral tissues (muscle, liver, adipose) become resistant to insulin action, requiring higher insulin levels to maintain glucose homeostasis. This leads to compensatory hyperinsulinemia and eventually beta cell exhaustion.
"	biological_processes[0]	biological_processes	biological_processes			Insulin Signaling	GO:0008286	insulin receptor signaling pathway		"{""preferred_term"": ""Insulin Signaling"", ""term"": {""id"": ""GO:0008286"", ""label"": ""insulin receptor signaling pathway""}}"																											
6906	7619	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	1	Beta Cell Dysfunction	"Progressive loss of pancreatic beta cell function and mass leads to inadequate insulin secretion relative to insulin demand. Beta cell failure is the key determinant of disease progression.
"	cell_types[0]	cell_types	cell_types			Pancreatic Beta Cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""Pancreatic Beta Cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6907	7619	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	1	Beta Cell Dysfunction	"Progressive loss of pancreatic beta cell function and mass leads to inadequate insulin secretion relative to insulin demand. Beta cell failure is the key determinant of disease progression.
"	biological_processes[0]	biological_processes	biological_processes			Insulin Secretion	GO:0030073	insulin secretion		"{""preferred_term"": ""Insulin Secretion"", ""term"": {""id"": ""GO:0030073"", ""label"": ""insulin secretion""}}"																											
6908	7620	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	2	Hepatic Glucose Overproduction	"Impaired suppression of hepatic gluconeogenesis leads to elevated fasting glucose levels. The liver fails to respond appropriately to insulin signals.
"	cell_types[0]	cell_types	cell_types			Hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""Hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
6909	7620	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	2	Hepatic Glucose Overproduction	"Impaired suppression of hepatic gluconeogenesis leads to elevated fasting glucose levels. The liver fails to respond appropriately to insulin signals.
"	biological_processes[0]	biological_processes	biological_processes			Gluconeogenesis	GO:0006094	gluconeogenesis		"{""preferred_term"": ""Gluconeogenesis"", ""term"": {""id"": ""GO:0006094"", ""label"": ""gluconeogenesis""}}"																											
6910	7621	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	3	Mitochondrial Dysfunction and Oxidative Stress	"Early-onset mitochondrial dysfunction and pathological reactive oxygen species (ROS) generation occur across multiple metabolic tissues including pancreatic beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and mitochondrial dynamics contribute to disease progression. Extracellular vesicle-mediated inter-organ miscommunication propagates oxidative damage.
"	cell_types[0]	cell_types	cell_types			Pancreatic Beta Cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""Pancreatic Beta Cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6911	7621	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	3	Mitochondrial Dysfunction and Oxidative Stress	"Early-onset mitochondrial dysfunction and pathological reactive oxygen species (ROS) generation occur across multiple metabolic tissues including pancreatic beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and mitochondrial dynamics contribute to disease progression. Extracellular vesicle-mediated inter-organ miscommunication propagates oxidative damage.
"	cell_types[1]	cell_types	cell_types			Skeletal Muscle Cell	CL:0000188	cell of skeletal muscle		"{""preferred_term"": ""Skeletal Muscle Cell"", ""term"": {""id"": ""CL:0000188"", ""label"": ""cell of skeletal muscle""}}"																											
6912	7621	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	3	Mitochondrial Dysfunction and Oxidative Stress	"Early-onset mitochondrial dysfunction and pathological reactive oxygen species (ROS) generation occur across multiple metabolic tissues including pancreatic beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and mitochondrial dynamics contribute to disease progression. Extracellular vesicle-mediated inter-organ miscommunication propagates oxidative damage.
"	biological_processes[0]	biological_processes	biological_processes			Oxidative Stress Response	GO:0006979	response to oxidative stress		"{""preferred_term"": ""Oxidative Stress Response"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
6913	7621	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	3	Mitochondrial Dysfunction and Oxidative Stress	"Early-onset mitochondrial dysfunction and pathological reactive oxygen species (ROS) generation occur across multiple metabolic tissues including pancreatic beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and mitochondrial dynamics contribute to disease progression. Extracellular vesicle-mediated inter-organ miscommunication propagates oxidative damage.
"	biological_processes[1]	biological_processes	biological_processes			Mitophagy	GO:0000422	autophagy of mitochondrion		"{""preferred_term"": ""Mitophagy"", ""term"": {""id"": ""GO:0000422"", ""label"": ""autophagy of mitochondrion""}}"																											
6914	7622	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	4	Incretin Axis Dysfunction	"Impaired incretin hormone signaling, particularly blunted glucose-dependent insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively preserved. The incretin effect amplifies insulin secretion in response to oral glucose via cAMP-PKA signaling pathways.
"	cell_types[0]	cell_types	cell_types			Pancreatic Beta Cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""Pancreatic Beta Cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6915	7622	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	4	Incretin Axis Dysfunction	"Impaired incretin hormone signaling, particularly blunted glucose-dependent insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively preserved. The incretin effect amplifies insulin secretion in response to oral glucose via cAMP-PKA signaling pathways.
"	cell_types[1]	cell_types	cell_types			Enteroendocrine Cell	CL:0000164	enteroendocrine cell		"{""preferred_term"": ""Enteroendocrine Cell"", ""term"": {""id"": ""CL:0000164"", ""label"": ""enteroendocrine cell""}}"																											
6916	7622	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	4	Incretin Axis Dysfunction	"Impaired incretin hormone signaling, particularly blunted glucose-dependent insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively preserved. The incretin effect amplifies insulin secretion in response to oral glucose via cAMP-PKA signaling pathways.
"	biological_processes[0]	biological_processes	biological_processes			cAMP Signaling	GO:0019933	cAMP-mediated signaling		"{""preferred_term"": ""cAMP Signaling"", ""term"": {""id"": ""GO:0019933"", ""label"": ""cAMP-mediated signaling""}}"																											
6917	7622	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	pathophysiology	4	Incretin Axis Dysfunction	"Impaired incretin hormone signaling, particularly blunted glucose-dependent insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively preserved. The incretin effect amplifies insulin secretion in response to oral glucose via cAMP-PKA signaling pathways.
"	biological_processes[1]	biological_processes	biological_processes			Insulin Secretion Regulation	GO:0050796	regulation of insulin secretion		"{""preferred_term"": ""Insulin Secretion Regulation"", ""term"": {""id"": ""GO:0050796"", ""label"": ""regulation of insulin secretion""}}"																											
6918	7623	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	0	Hyperglycemia		phenotype_term	phenotype_term	$	Hyperglycemia		Hyperglycemia	HP:0003074	Hyperglycemia		"{""preferred_term"": ""Hyperglycemia"", ""term"": {""id"": ""HP:0003074"", ""label"": ""Hyperglycemia""}}"																											
6919	7624	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	1	Polydipsia		phenotype_term	phenotype_term	$	Polydipsia		Polydipsia	HP:0001959	Polydipsia		"{""preferred_term"": ""Polydipsia"", ""term"": {""id"": ""HP:0001959"", ""label"": ""Polydipsia""}}"																											
6920	7625	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	2	Polyuria		phenotype_term	phenotype_term	$	Polyuria		Polyuria	HP:0000103	Polyuria		"{""preferred_term"": ""Polyuria"", ""term"": {""id"": ""HP:0000103"", ""label"": ""Polyuria""}}"																											
6921	7626	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	3	Obesity		phenotype_term	phenotype_term	$	Obesity		Obesity	HP:0001513	Obesity		"{""preferred_term"": ""Obesity"", ""term"": {""id"": ""HP:0001513"", ""label"": ""Obesity""}}"																											
6922	7627	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	4	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6923	7628	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	5	Insulin Resistance		phenotype_term	phenotype_term	$	Insulin Resistance		Insulin Resistance	HP:0000855	Insulin resistance		"{""preferred_term"": ""Insulin Resistance"", ""term"": {""id"": ""HP:0000855"", ""label"": ""Insulin resistance""}}"																											
6924	7629	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	6	Impaired Glucose Tolerance		phenotype_term	phenotype_term	$	Impaired Glucose Tolerance		Impaired Glucose Tolerance	HP:0001952	Glucose intolerance		"{""preferred_term"": ""Impaired Glucose Tolerance"", ""term"": {""id"": ""HP:0001952"", ""label"": ""Glucose intolerance""}}"																											
6925	7630	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	7	Hyperinsulinemia		phenotype_term	phenotype_term	$	Hyperinsulinemia		Hyperinsulinemia	HP:0000842	Hyperinsulinemia		"{""preferred_term"": ""Hyperinsulinemia"", ""term"": {""id"": ""HP:0000842"", ""label"": ""Hyperinsulinemia""}}"																											
6926	7631	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	8	Diabetic Retinopathy		phenotype_term	phenotype_term	$	Diabetic Retinopathy		Retinopathy	HP:0000488	Retinopathy		"{""preferred_term"": ""Retinopathy"", ""term"": {""id"": ""HP:0000488"", ""label"": ""Retinopathy""}}"																											
6927	7632	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	phenotypes	9	Peripheral Neuropathy		phenotype_term	phenotype_term	$	Peripheral Neuropathy		Peripheral Neuropathy	HP:0009830	Peripheral neuropathy		"{""preferred_term"": ""Peripheral Neuropathy"", ""term"": {""id"": ""HP:0009830"", ""label"": ""Peripheral neuropathy""}}"																											
6928	7633	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	0	Metformin	First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.	treatment_term	treatment_term	$	Metformin	First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6929	7634	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	1	Lifestyle Modification	Diet and exercise interventions to reduce weight and improve metabolic health.	treatment_term	treatment_term	$	Lifestyle Modification	Diet and exercise interventions to reduce weight and improve metabolic health.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
6930	7635	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	2	GLP-1 Receptor Agonists	Injectable medications that enhance insulin secretion and promote weight loss.	treatment_term	treatment_term	$	GLP-1 Receptor Agonists	Injectable medications that enhance insulin secretion and promote weight loss.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6931	7636	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	3	SGLT2 Inhibitors	Oral medications that increase urinary glucose excretion.	treatment_term	treatment_term	$	SGLT2 Inhibitors	Oral medications that increase urinary glucose excretion.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6932	7637	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	4	Insulin Therapy	Required when beta cell function declines significantly.	treatment_term	treatment_term	$	Insulin Therapy	Required when beta cell function declines significantly.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6933	7638	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	5	GLP-1/GIP Dual Agonists	Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.	treatment_term	treatment_term	$	GLP-1/GIP Dual Agonists	Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6934	7641	333	Type I Diabetes	Type_I_Diabetes.yaml	environmental	0	Viral Infections		exposure_term	exposure_term	$	Viral Infections		Viral infection exposure	ECTO:3000001	exposure to virus		"{""preferred_term"": ""Viral infection exposure"", ""term"": {""id"": ""ECTO:3000001"", ""label"": ""exposure to virus""}}"																											
6935	7642	333	Type I Diabetes	Type_I_Diabetes.yaml	environmental	1	Early Dietary Factors		exposure_term	exposure_term	$	Early Dietary Factors		Early dietary exposure				"{""preferred_term"": ""Early dietary exposure""}"																											
6936	7652	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	0	Genetic Susceptibility	Certain HLA gene variants (HLA-DQ2, HLA-DQ8) and other susceptibility genes (INS) increase the risk of developing Type I Diabetes.	genes[0]	genes	genes			HLA-DQ2				"{""preferred_term"": ""HLA-DQ2""}"																											
6937	7652	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	0	Genetic Susceptibility	Certain HLA gene variants (HLA-DQ2, HLA-DQ8) and other susceptibility genes (INS) increase the risk of developing Type I Diabetes.	genes[1]	genes	genes			HLA-DQ8				"{""preferred_term"": ""HLA-DQ8""}"																											
6938	7652	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	0	Genetic Susceptibility	Certain HLA gene variants (HLA-DQ2, HLA-DQ8) and other susceptibility genes (INS) increase the risk of developing Type I Diabetes.	genes[2]	genes	genes			INS	hgnc:6081	INS		"{""preferred_term"": ""INS"", ""term"": {""id"": ""hgnc:6081"", ""label"": ""INS""}}"																											
6939	7653	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	1	Environmental Triggers	Viral infections or early dietary factors (cow's milk, gluten) may trigger the autoimmune response in genetically susceptible individuals.	triggers[0]	triggers	triggers			Viral Infections				"{""preferred_term"": ""Viral Infections""}"																											
6940	7653	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	1	Environmental Triggers	Viral infections or early dietary factors (cow's milk, gluten) may trigger the autoimmune response in genetically susceptible individuals.	triggers[1]	triggers	triggers			Early Dietary Factors				"{""preferred_term"": ""Early Dietary Factors""}"																											
6941	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	cell_types[0]	cell_types	cell_types			type B pancreatic cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""type B pancreatic cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6942	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	biological_processes[0]	biological_processes	biological_processes			type I interferon signaling pathway	GO:0060337	type I interferon signaling pathway		"{""preferred_term"": ""type I interferon signaling pathway"", ""term"": {""id"": ""GO:0060337"", ""label"": ""type I interferon signaling pathway""}}"																											
6943	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	biological_processes[1]	biological_processes	biological_processes			antigen processing and presentation of peptide antigen via MHC class I	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I		"{""preferred_term"": ""antigen processing and presentation of peptide antigen via MHC class I"", ""term"": {""id"": ""GO:0002474"", ""label"": ""antigen processing and presentation of peptide antigen via MHC class I""}}"																											
6944	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	biological_processes[2]	biological_processes	biological_processes			chemokine production	GO:0032602	chemokine production		"{""preferred_term"": ""chemokine production"", ""term"": {""id"": ""GO:0032602"", ""label"": ""chemokine production""}}"																											
6945	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	biological_processes[3]	biological_processes	biological_processes			oxidative phosphorylation	GO:0006119	oxidative phosphorylation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""oxidative phosphorylation"", ""term"": {""id"": ""GO:0006119"", ""label"": ""oxidative phosphorylation""}}"			DECREASED																								
6946	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	chemical_entities[0]	chemical_entities	chemical_entities			interferon-alpha			Type I interferon that drives antiviral and antigen-presentation programs	"{""description"": ""Type I interferon that drives antiviral and antigen-presentation programs"", ""preferred_term"": ""interferon-alpha""}"																											
6947	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	chemical_entities[1]	chemical_entities	chemical_entities			interferon-gamma			Type II interferon that induces HLA class I upregulation and chemokine production	"{""description"": ""Type II interferon that induces HLA class I upregulation and chemokine production"", ""preferred_term"": ""interferon-gamma""}"																											
6948	7654	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	2	Interferon-Driven Beta Cell Response	Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.	chemical_entities[2]	chemical_entities	chemical_entities			C-X-C motif chemokine 10			Chemokine (CXCL10) that recruits autoreactive T cells to islets	"{""description"": ""Chemokine (CXCL10) that recruits autoreactive T cells to islets"", ""preferred_term"": ""C-X-C motif chemokine 10""}"																											
6949	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[0]	cell_types	cell_types			type B pancreatic cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""type B pancreatic cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6950	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[1]	cell_types	cell_types			CD8-positive, alpha-beta cytotoxic T cell	CL:0000794	CD8-positive, alpha-beta cytotoxic T cell		"{""preferred_term"": ""CD8-positive, alpha-beta cytotoxic T cell"", ""term"": {""id"": ""CL:0000794"", ""label"": ""CD8-positive, alpha-beta cytotoxic T cell""}}"																											
6951	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[2]	cell_types	cell_types			CD4-positive, alpha-beta T cell	CL:0000624	CD4-positive, alpha-beta T cell		"{""preferred_term"": ""CD4-positive, alpha-beta T cell"", ""term"": {""id"": ""CL:0000624"", ""label"": ""CD4-positive, alpha-beta T cell""}}"																											
6952	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[3]	cell_types	cell_types			regulatory T cell	CL:0000815	regulatory T cell		"{""preferred_term"": ""regulatory T cell"", ""term"": {""id"": ""CL:0000815"", ""label"": ""regulatory T cell""}}"																											
6953	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[4]	cell_types	cell_types			B cell	CL:0000236	B cell		"{""preferred_term"": ""B cell"", ""term"": {""id"": ""CL:0000236"", ""label"": ""B cell""}}"																											
6954	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[5]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
6955	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	cell_types[6]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
6956	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	biological_processes[0]	biological_processes	biological_processes			T cell mediated cytotoxicity	GO:0001913	T cell mediated cytotoxicity		"{""preferred_term"": ""T cell mediated cytotoxicity"", ""term"": {""id"": ""GO:0001913"", ""label"": ""T cell mediated cytotoxicity""}}"																											
6957	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	biological_processes[1]	biological_processes	biological_processes			autoantibody production				"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""autoantibody production""}"			ABNORMAL																								
6958	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	biological_processes[2]	biological_processes	biological_processes			cytokine-mediated signaling pathway	GO:0019221	cytokine-mediated signaling pathway		"{""preferred_term"": ""cytokine-mediated signaling pathway"", ""term"": {""id"": ""GO:0019221"", ""label"": ""cytokine-mediated signaling pathway""}}"																											
6959	7655	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	3	Autoimmune Destruction of Beta Cells	The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.	locations[0]	locations	locations			pancreatic islet	UBERON:0000006	islet of Langerhans		"{""preferred_term"": ""pancreatic islet"", ""term"": {""id"": ""UBERON:0000006"", ""label"": ""islet of Langerhans""}}"																											
6960	7657	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	5	Hyperglycemia	Lack of insulin results in high blood glucose levels, as glucose cannot be efficiently taken up by cells.	assays[0]	assays	assays			Elevated Blood Glucose				"{""preferred_term"": ""Elevated Blood Glucose""}"																											
6961	7657	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	5	Hyperglycemia	Lack of insulin results in high blood glucose levels, as glucose cannot be efficiently taken up by cells.	assays[1]	assays	assays			Elevated Hemoglobin A1c (HbA1c)				"{""preferred_term"": ""Elevated Hemoglobin A1c (HbA1c)""}"																											
6962	7659	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	7	ER Stress and Unfolded Protein Response	Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.	cell_types[0]	cell_types	cell_types			type B pancreatic cell	CL:0000169	type B pancreatic cell		"{""preferred_term"": ""type B pancreatic cell"", ""term"": {""id"": ""CL:0000169"", ""label"": ""type B pancreatic cell""}}"																											
6963	7659	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	7	ER Stress and Unfolded Protein Response	Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.	biological_processes[0]	biological_processes	biological_processes			endoplasmic reticulum unfolded protein response	GO:0030968	endoplasmic reticulum unfolded protein response		"{""preferred_term"": ""endoplasmic reticulum unfolded protein response"", ""term"": {""id"": ""GO:0030968"", ""label"": ""endoplasmic reticulum unfolded protein response""}}"																											
6964	7659	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	7	ER Stress and Unfolded Protein Response	Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.	biological_processes[1]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
6965	7659	333	Type I Diabetes	Type_I_Diabetes.yaml	pathophysiology	7	ER Stress and Unfolded Protein Response	Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.	chemical_entities[0]	chemical_entities	chemical_entities			interleukin-1beta			Proinflammatory cytokine that contributes to beta-cell stress and ER dysfunction	"{""description"": ""Proinflammatory cytokine that contributes to beta-cell stress and ER dysfunction"", ""preferred_term"": ""interleukin-1beta""}"																											
6966	7663	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	0	Hyperglycemia		phenotype_term	phenotype_term	$	Hyperglycemia		Hyperglycemia	HP:0003074	Hyperglycemia		"{""preferred_term"": ""Hyperglycemia"", ""term"": {""id"": ""HP:0003074"", ""label"": ""Hyperglycemia""}}"																											
6967	7664	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	1	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
6968	7665	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	2	Polyuria		phenotype_term	phenotype_term	$	Polyuria		Polyuria	HP:0000103	Polyuria		"{""preferred_term"": ""Polyuria"", ""term"": {""id"": ""HP:0000103"", ""label"": ""Polyuria""}}"																											
6969	7666	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	3	Polydipsia		phenotype_term	phenotype_term	$	Polydipsia		Polydipsia	HP:0001959	Polydipsia		"{""preferred_term"": ""Polydipsia"", ""term"": {""id"": ""HP:0001959"", ""label"": ""Polydipsia""}}"																											
6970	7667	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	4	Diabetic Ketoacidosis		phenotype_term	phenotype_term	$	Diabetic Ketoacidosis		Diabetic Ketoacidosis	HP:0001953	Diabetic ketoacidosis		"{""preferred_term"": ""Diabetic Ketoacidosis"", ""term"": {""id"": ""HP:0001953"", ""label"": ""Diabetic ketoacidosis""}}"																											
6971	7671	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	8	Glucosuria		phenotype_term	phenotype_term	$	Glucosuria		Glucosuria	HP:0003076	Glycosuria		"{""preferred_term"": ""Glucosuria"", ""term"": {""id"": ""HP:0003076"", ""label"": ""Glycosuria""}}"																											
6972	7672	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	9	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6973	7673	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	10	Retinopathy		phenotype_term	phenotype_term	$	Retinopathy		Retinopathy	HP:0000488	Retinopathy		"{""preferred_term"": ""Retinopathy"", ""term"": {""id"": ""HP:0000488"", ""label"": ""Retinopathy""}}"																											
6974	7674	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	11	Neuropathy		phenotype_term	phenotype_term	$	Neuropathy		Neuropathy	HP:0009830	Peripheral neuropathy		"{""preferred_term"": ""Neuropathy"", ""term"": {""id"": ""HP:0009830"", ""label"": ""Peripheral neuropathy""}}"																											
6975	7675	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	12	Nephropathy		phenotype_term	phenotype_term	$	Nephropathy		Nephropathy	HP:0000112	Nephropathy		"{""preferred_term"": ""Nephropathy"", ""term"": {""id"": ""HP:0000112"", ""label"": ""Nephropathy""}}"																											
6976	7676	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	13	Cardiovascular Disease		phenotype_term	phenotype_term	$	Cardiovascular Disease		Cardiovascular Disease	HP:0001626	Abnormality of the cardiovascular system		"{""preferred_term"": ""Cardiovascular Disease"", ""term"": {""id"": ""HP:0001626"", ""label"": ""Abnormality of the cardiovascular system""}}"																											
6977	7677	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	14	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
6978	7678	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	15	Vomiting		phenotype_term	phenotype_term	$	Vomiting		Vomiting	HP:0002013	Vomiting		"{""preferred_term"": ""Vomiting"", ""term"": {""id"": ""HP:0002013"", ""label"": ""Vomiting""}}"																											
6979	7679	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	16	Rapid Breathing		phenotype_term	phenotype_term	$	Rapid Breathing		Rapid Breathing	HP:0002789	Tachypnea		"{""preferred_term"": ""Rapid Breathing"", ""term"": {""id"": ""HP:0002789"", ""label"": ""Tachypnea""}}"																											
6980	7680	333	Type I Diabetes	Type_I_Diabetes.yaml	phenotypes	17	Confusion		phenotype_term	phenotype_term	$	Confusion		Confusion	HP:0001289	Confusion		"{""preferred_term"": ""Confusion"", ""term"": {""id"": ""HP:0001289"", ""label"": ""Confusion""}}"																											
6981	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	Insulin Therapy	Essential treatment to replace the missing insulin and regulate blood glucose levels.	treatment_term	treatment_term	$	Insulin Therapy	Essential treatment to replace the missing insulin and regulate blood glucose levels.	insulin treatment	MAXO:0000259	insulin treatment		"{""preferred_term"": ""insulin treatment"", ""term"": {""id"": ""MAXO:0000259"", ""label"": ""insulin treatment""}}"																											
6982	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	Lifestyle Modifications	Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.	treatment_term	treatment_term	$	Lifestyle Modifications	Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
6983	7703	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	0	Mucosal Inflammation	"Continuous inflammation limited to the colonic mucosa, starting at the rectum and extending proximally. Crypt abscesses, goblet cell depletion, and mucosal ulceration are characteristic.
"	cell_types[0]	cell_types	cell_types			Colonic Epithelial Cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""Colonic Epithelial Cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
6984	7703	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	0	Mucosal Inflammation	"Continuous inflammation limited to the colonic mucosa, starting at the rectum and extending proximally. Crypt abscesses, goblet cell depletion, and mucosal ulceration are characteristic.
"	biological_processes[0]	biological_processes	biological_processes			Inflammatory Response	GO:0006954	inflammatory response		"{""preferred_term"": ""Inflammatory Response"", ""term"": {""id"": ""GO:0006954"", ""label"": ""inflammatory response""}}"																											
6985	7704	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	1	Dysregulated Immune Response	"Aberrant immune response to commensal gut bacteria in genetically susceptible individuals. Th2-skewed response with IL-13 driving epithelial dysfunction.
"	cell_types[0]	cell_types	cell_types			T Helper 2 Cell	CL:0000546	T-helper 2 cell		"{""preferred_term"": ""T Helper 2 Cell"", ""term"": {""id"": ""CL:0000546"", ""label"": ""T-helper 2 cell""}}"																											
6986	7705	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	2	Epithelial Barrier Dysfunction	"Disrupted tight junctions and mucus layer allow bacterial translocation, perpetuating inflammation. Goblet cell depletion reduces protective mucus.
"	biological_processes[0]	biological_processes	biological_processes			Epithelial Barrier Function	GO:0090557	establishment of endothelial intestinal barrier		"{""preferred_term"": ""Epithelial Barrier Function"", ""term"": {""id"": ""GO:0090557"", ""label"": ""establishment of endothelial intestinal barrier""}}"																											
6987	7706	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	3	Loss of Microbial Diversity	"Reduced alpha diversity (species richness and evenness) in the colonic microbiome. Shannon and Chao1 indices are decreased compared to healthy controls, representing ecological collapse of the microbial community.
"	biological_processes[0]	biological_processes	biological_processes			Microbiome Community Dynamics	GO:0044003	modification by symbiont of host morphology or physiology		"{""preferred_term"": ""Microbiome Community Dynamics"", ""term"": {""id"": ""GO:0044003"", ""label"": ""modification by symbiont of host morphology or physiology""}}"																											
6988	7709	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	6	Decreased Butyrate Production	"Reduced fecal short-chain fatty acid (SCFA) concentrations, particularly butyrate. Butyrate is the primary energy source for colonocytes (providing ~70% of energy needs) and exerts anti-inflammatory effects via HDAC inhibition and GPR109A signaling.
"	biological_processes[0]	biological_processes	biological_processes			Short-chain Fatty Acid Metabolism	GO:0046459	short-chain fatty acid metabolic process		"{""preferred_term"": ""Short-chain Fatty Acid Metabolism"", ""term"": {""id"": ""GO:0046459"", ""label"": ""short-chain fatty acid metabolic process""}}"																											
6989	7710	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	7	Impaired Colonocyte Energy Metabolism	"Colonocytes deprived of butyrate shift from beta-oxidation to glycolysis, causing energy deficit. This impairs tight junction maintenance, mucus production by goblet cells, and epithelial renewal from crypt stem cells.
"	cell_types[0]	cell_types	cell_types			Colonic Epithelial Cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""Colonic Epithelial Cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
6990	7712	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	9	NLRP3 Inflammasome-Mediated Pyroptosis	"Epithelial cell pyroptosis driven by NLRP3 inflammasome activation contributes to barrier disruption and inflammation. SLC6A14 promotes pyroptosis by upregulating NLRP3.
"	cell_types[0]	cell_types	cell_types			Colonic Epithelial Cell	CL:0011108	colon epithelial cell		"{""preferred_term"": ""Colonic Epithelial Cell"", ""term"": {""id"": ""CL:0011108"", ""label"": ""colon epithelial cell""}}"																											
6991	7712	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	pathophysiology	9	NLRP3 Inflammasome-Mediated Pyroptosis	"Epithelial cell pyroptosis driven by NLRP3 inflammasome activation contributes to barrier disruption and inflammation. SLC6A14 promotes pyroptosis by upregulating NLRP3.
"	biological_processes[0]	biological_processes	biological_processes			Pyroptosis	GO:0070269	pyroptosis		"{""preferred_term"": ""Pyroptosis"", ""term"": {""id"": ""GO:0070269"", ""label"": ""pyroptosis""}}"																											
6992	7713	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	0	Bloody Diarrhea		phenotype_term	phenotype_term	$	Bloody Diarrhea		Bloody Diarrhea	HP:0025085	Bloody diarrhea		"{""preferred_term"": ""Bloody Diarrhea"", ""term"": {""id"": ""HP:0025085"", ""label"": ""Bloody diarrhea""}}"																											
6993	7714	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	1	Abdominal Pain		phenotype_term	phenotype_term	$	Abdominal Pain		Abdominal Pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal Pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
6994	7715	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	2	Urgency		phenotype_term	phenotype_term	$	Urgency		Fecal Incontinence	HP:0002607	Bowel incontinence		"{""preferred_term"": ""Fecal Incontinence"", ""term"": {""id"": ""HP:0002607"", ""label"": ""Bowel incontinence""}}"																											
6995	7716	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	3	Tenesmus		phenotype_term	phenotype_term	$	Tenesmus		Tenesmus	HP:0025085	Bloody diarrhea		"{""preferred_term"": ""Tenesmus"", ""term"": {""id"": ""HP:0025085"", ""label"": ""Bloody diarrhea""}}"																											
6996	7717	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	4	Weight Loss		phenotype_term	phenotype_term	$	Weight Loss		Weight Loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight Loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
6997	7718	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	5	Fatigue		phenotype_term	phenotype_term	$	Fatigue		Fatigue	HP:0012378	Fatigue		"{""preferred_term"": ""Fatigue"", ""term"": {""id"": ""HP:0012378"", ""label"": ""Fatigue""}}"																											
6998	7719	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	phenotypes	6	Anemia		phenotype_term	phenotype_term	$	Anemia		Anemia	HP:0001903	Anemia		"{""preferred_term"": ""Anemia"", ""term"": {""id"": ""HP:0001903"", ""label"": ""Anemia""}}"																											
6999	7728	335	Urticaria	Urticaria.yaml	pathophysiology	0	Mast cell-driven inflammation	Mast cells are central to chronic spontaneous urticaria, with multiple mediators contributing to disease.	cell_types[0]	cell_types	cell_types			mast cell	CL:0000097	mast cell		"{""preferred_term"": ""mast cell"", ""term"": {""id"": ""CL:0000097"", ""label"": ""mast cell""}}"																											
7000	7728	335	Urticaria	Urticaria.yaml	pathophysiology	0	Mast cell-driven inflammation	Mast cells are central to chronic spontaneous urticaria, with multiple mediators contributing to disease.	biological_processes[0]	biological_processes	biological_processes			mast cell degranulation	GO:0043303	mast cell degranulation		"{""preferred_term"": ""mast cell degranulation"", ""term"": {""id"": ""GO:0043303"", ""label"": ""mast cell degranulation""}}"																											
7001	7729	335	Urticaria	Urticaria.yaml	phenotypes	0	Urticaria	Recurrent wheals consistent with urticaria.	phenotype_term	phenotype_term	$	Urticaria	Recurrent wheals consistent with urticaria.	Urticaria	HP:0001025	Urticaria		"{""preferred_term"": ""Urticaria"", ""term"": {""id"": ""HP:0001025"", ""label"": ""Urticaria""}}"																											
7002	7738	336	Uveal Melanoma	Uveal_Melanoma.yaml	histopathology	0	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	finding_term	finding_term	$	Melanocytic Neoplasm	Malignant melanoma represents a neoplasm stemming from melanocytes.	Melanocytic Neoplasm	NCIT:C7058	Melanocytic Neoplasm		"{""preferred_term"": ""Melanocytic Neoplasm"", ""term"": {""id"": ""NCIT:C7058"", ""label"": ""Melanocytic Neoplasm""}}"																											
7003	7739	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	0	GNAQ/GNA11 Oncogenic Mutations	GNAQ and GNA11 encode alpha subunits of heterotrimeric Gq/11 G-proteins. Mutations at Q209 (most common) or R183 lock the protein in a constitutively active GTP-bound state, resulting in persistent downstream signaling through phospholipase C beta, protein kinase C, and ultimately the MAPK pathway. These mutations are mutually exclusive and early, initiating events.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
7004	7739	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	0	GNAQ/GNA11 Oncogenic Mutations	GNAQ and GNA11 encode alpha subunits of heterotrimeric Gq/11 G-proteins. Mutations at Q209 (most common) or R183 lock the protein in a constitutively active GTP-bound state, resulting in persistent downstream signaling through phospholipase C beta, protein kinase C, and ultimately the MAPK pathway. These mutations are mutually exclusive and early, initiating events.	biological_processes[0]	biological_processes	biological_processes			signal transduction	GO:0007165	signal transduction		"{""modifier"": ""INCREASED"", ""preferred_term"": ""signal transduction"", ""term"": {""id"": ""GO:0007165"", ""label"": ""signal transduction""}}"			INCREASED																								
7005	7739	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	0	GNAQ/GNA11 Oncogenic Mutations	GNAQ and GNA11 encode alpha subunits of heterotrimeric Gq/11 G-proteins. Mutations at Q209 (most common) or R183 lock the protein in a constitutively active GTP-bound state, resulting in persistent downstream signaling through phospholipase C beta, protein kinase C, and ultimately the MAPK pathway. These mutations are mutually exclusive and early, initiating events.	locations[0]	locations	locations			uvea	UBERON:0001768	uvea		"{""preferred_term"": ""uvea"", ""term"": {""id"": ""UBERON:0001768"", ""label"": ""uvea""}}"																											
7006	7740	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	1	PKC-MAPK Pathway Activation	Constitutively active GNAQ/GNA11 signaling activates phospholipase C-beta, generating diacylglycerol (DAG) that activates protein kinase C (PKC). PKC in turn activates the RAF-MEK-ERK cascade, driving melanocyte proliferation. This pathway represents a therapeutic target with MEK and PKC inhibitors.	biological_processes[0]	biological_processes	biological_processes			MAPK cascade	GO:0000165	MAPK cascade		"{""modifier"": ""INCREASED"", ""preferred_term"": ""MAPK cascade"", ""term"": {""id"": ""GO:0000165"", ""label"": ""MAPK cascade""}}"			INCREASED																								
7007	7741	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	2	Uncontrolled Uveal Melanocyte Proliferation	Persistent MAPK signaling drives proliferation of uveal melanocytes, leading to tumor formation. Unlike cutaneous melanoma, uveal melanoma rarely harbors BRAF or NRAS mutations.	cell_types[0]	cell_types	cell_types			melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
7008	7741	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	2	Uncontrolled Uveal Melanocyte Proliferation	Persistent MAPK signaling drives proliferation of uveal melanocytes, leading to tumor formation. Unlike cutaneous melanoma, uveal melanoma rarely harbors BRAF or NRAS mutations.	locations[0]	locations	locations			uvea	UBERON:0001768	uvea		"{""preferred_term"": ""uvea"", ""term"": {""id"": ""UBERON:0001768"", ""label"": ""uvea""}}"																											
7009	7741	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	2	Uncontrolled Uveal Melanocyte Proliferation	Persistent MAPK signaling drives proliferation of uveal melanocytes, leading to tumor formation. Unlike cutaneous melanoma, uveal melanoma rarely harbors BRAF or NRAS mutations.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
7010	7742	336	Uveal Melanoma	Uveal_Melanoma.yaml	pathophysiology	3	BAP1 Loss and Metastatic Progression	BAP1 (BRCA1-associated protein 1) is a tumor suppressor encoding a deubiquitinase involved in chromatin remodeling and DNA damage response. BAP1 loss occurs in approximately 40% of uveal melanomas and is strongly associated with metastatic disease and poor prognosis. BAP1-deficient tumors exhibit altered gene expression patterns consistent with a more aggressive, less differentiated phenotype.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
7011	7743	336	Uveal Melanoma	Uveal_Melanoma.yaml	phenotypes	0	Uveal Melanoma	Intraocular melanoma arising from uveal melanocytes. Most commonly presents in the choroid (85%), with ciliary body and iris involvement less common.	phenotype_term	phenotype_term	$	Uveal Melanoma	Intraocular melanoma arising from uveal melanocytes. Most commonly presents in the choroid (85%), with ciliary body and iris involvement less common.	Uveal melanoma	HP:0007716	Uveal melanoma		"{""preferred_term"": ""Uveal melanoma"", ""term"": {""id"": ""HP:0007716"", ""label"": ""Uveal melanoma""}}"																											
7012	7744	336	Uveal Melanoma	Uveal_Melanoma.yaml	phenotypes	1	Decreased Visual Acuity	Vision loss occurs when the tumor involves the macula, causes retinal detachment, or obstructs the visual axis. Many tumors are discovered incidentally before causing visual symptoms.	phenotype_term	phenotype_term	$	Decreased Visual Acuity	Vision loss occurs when the tumor involves the macula, causes retinal detachment, or obstructs the visual axis. Many tumors are discovered incidentally before causing visual symptoms.	Reduced visual acuity	HP:0007663	Reduced visual acuity		"{""preferred_term"": ""Reduced visual acuity"", ""term"": {""id"": ""HP:0007663"", ""label"": ""Reduced visual acuity""}}"																											
7013	7745	336	Uveal Melanoma	Uveal_Melanoma.yaml	phenotypes	2	Visual Field Defect	Visual field defects corresponding to the location of retinal detachment or tumor position may be the presenting symptom.	phenotype_term	phenotype_term	$	Visual Field Defect	Visual field defects corresponding to the location of retinal detachment or tumor position may be the presenting symptom.	Visual field defect	HP:0001123	Visual field defect		"{""preferred_term"": ""Visual field defect"", ""term"": {""id"": ""HP:0001123"", ""label"": ""Visual field defect""}}"																											
7014	7746	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	0	Tebentafusp	Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients).	treatment_term	treatment_term	$	Tebentafusp	Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7015	7747	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	1	Plaque Brachytherapy	Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases.	treatment_term	treatment_term	$	Plaque Brachytherapy	Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7016	7748	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	2	Enucleation	Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease.	treatment_term	treatment_term	$	Enucleation	Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7017	7749	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7018	7752	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	pathophysiology	0	Visual Cortex Hyperexcitability	"Visual snow syndrome is thought to involve cortical hyperexcitability, particularly in the lingual gyrus and other visual processing areas. Electrophysiological studies have revealed cortical hyperresponsivity in visual brain areas, and imaging studies demonstrated microstructural and functional connectivity alterations in multiple cortical and thalamic regions.
"	cell_types[0]	cell_types	cell_types			cortical interneuron	CL:0008031	cortical interneuron		"{""preferred_term"": ""cortical interneuron"", ""term"": {""id"": ""CL:0008031"", ""label"": ""cortical interneuron""}}"																											
7019	7752	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	pathophysiology	0	Visual Cortex Hyperexcitability	"Visual snow syndrome is thought to involve cortical hyperexcitability, particularly in the lingual gyrus and other visual processing areas. Electrophysiological studies have revealed cortical hyperresponsivity in visual brain areas, and imaging studies demonstrated microstructural and functional connectivity alterations in multiple cortical and thalamic regions.
"	biological_processes[0]	biological_processes	biological_processes			visual perception	GO:0007601	visual perception		"{""preferred_term"": ""visual perception"", ""term"": {""id"": ""GO:0007601"", ""label"": ""visual perception""}}"																											
7020	7753	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	pathophysiology	1	Thalamocortical Network Dysfunction	"Visual snow syndrome appears to be a network disorder involving dysfunction in the thalamocortical pathway. The thalamus normally filters sensory information, and its dysfunction may lead to failure to suppress unnecessary visual noise.
"	biological_processes[0]	biological_processes	biological_processes			synaptic transmission	GO:0007268	chemical synaptic transmission		"{""preferred_term"": ""synaptic transmission"", ""term"": {""id"": ""GO:0007268"", ""label"": ""chemical synaptic transmission""}}"																											
7021	7756	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	phenotypes	2	Photophobia		phenotype_term	phenotype_term	$	Photophobia		Photophobia	HP:0000613	Photophobia		"{""preferred_term"": ""Photophobia"", ""term"": {""id"": ""HP:0000613"", ""label"": ""Photophobia""}}"																											
7022	7757	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	phenotypes	3	Nyctalopia		phenotype_term	phenotype_term	$	Nyctalopia		Nyctalopia	HP:0000662	Nyctalopia		"{""preferred_term"": ""Nyctalopia"", ""term"": {""id"": ""HP:0000662"", ""label"": ""Nyctalopia""}}"																											
7023	7759	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	phenotypes	5	Photopsia		phenotype_term	phenotype_term	$	Photopsia		Photopsia	HP:0030786	Photopsia		"{""preferred_term"": ""Photopsia"", ""term"": {""id"": ""HP:0030786"", ""label"": ""Photopsia""}}"																											
7024	7760	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	phenotypes	6	Tinnitus		phenotype_term	phenotype_term	$	Tinnitus		Tinnitus	HP:0000360	Tinnitus		"{""preferred_term"": ""Tinnitus"", ""term"": {""id"": ""HP:0000360"", ""label"": ""Tinnitus""}}"																											
7025	7761	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	phenotypes	7	Vitreous Floaters		phenotype_term	phenotype_term	$	Vitreous Floaters		Vitreous floaters	HP:0100832	Vitreous floaters		"{""preferred_term"": ""Vitreous floaters"", ""term"": {""id"": ""HP:0100832"", ""label"": ""Vitreous floaters""}}"																											
7026	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	Lamotrigine	Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients.	treatment_term	treatment_term	$	Lamotrigine	Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7027	7765	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	3	Benzodiazepines	May provide symptom relief in some patients, though long-term use carries risks.	treatment_term	treatment_term	$	Benzodiazepines	May provide symptom relief in some patients, though long-term use carries risks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7028	7766	338	Vitiligo	Vitiligo.yaml	animal_models	0			genes[0]	genes	genes			zmiz1a				"{""preferred_term"": ""zmiz1a""}"																											
7029	7766	338	Vitiligo	Vitiligo.yaml	animal_models	0			genes[1]	genes	genes			zmiz1b				"{""preferred_term"": ""zmiz1b""}"																											
7030	7769	338	Vitiligo	Vitiligo.yaml	environmental	0	UV Exposure	Promotes the repigmentation process in some cases, but can exacerbate the contrast in others.	exposure_term	exposure_term	$	UV Exposure	Promotes the repigmentation process in some cases, but can exacerbate the contrast in others.	UV light exposure	ECTO:0000006	exposure to ultraviolet radiation		"{""preferred_term"": ""UV light exposure"", ""term"": {""id"": ""ECTO:0000006"", ""label"": ""exposure to ultraviolet radiation""}}"																											
7031	7770	338	Vitiligo	Vitiligo.yaml	environmental	1	Stress	Psychological stress is implicated in the exacerbation or onset of the disease.	exposure_term	exposure_term	$	Stress	Psychological stress is implicated in the exacerbation or onset of the disease.	Psychological stress exposure				"{""preferred_term"": ""Psychological stress exposure""}"																											
7032	7771	338	Vitiligo	Vitiligo.yaml	environmental	2	Chemical Exposure	Certain phenolic compounds and other chemicals can induce or exacerbate vitiligo.	exposure_term	exposure_term	$	Chemical Exposure	Certain phenolic compounds and other chemicals can induce or exacerbate vitiligo.	Chemical exposure	ECTO:0000231	exposure to chemical		"{""preferred_term"": ""Chemical exposure"", ""term"": {""id"": ""ECTO:0000231"", ""label"": ""exposure to chemical""}}"																											
7033	7785	338	Vitiligo	Vitiligo.yaml	pathophysiology	0	Melanocyte Destruction	Autoimmune-mediated destruction where the immune system targets melanocytes, leading to loss of skin pigment.	cell_types[0]	cell_types	cell_types			Melanocyte	CL:0000148	melanocyte		"{""preferred_term"": ""Melanocyte"", ""term"": {""id"": ""CL:0000148"", ""label"": ""melanocyte""}}"																											
7034	7785	338	Vitiligo	Vitiligo.yaml	pathophysiology	0	Melanocyte Destruction	Autoimmune-mediated destruction where the immune system targets melanocytes, leading to loss of skin pigment.	cell_types[1]	cell_types	cell_types			CD8+ T Lymphocyte	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T Lymphocyte"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
7035	7789	338	Vitiligo	Vitiligo.yaml	pathophysiology	4	IFN-gamma-CXCL9/CXCL10 Chemokine Axis	IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.	cell_types[0]	cell_types	cell_types			keratinocyte	CL:0000312	keratinocyte		"{""preferred_term"": ""keratinocyte"", ""term"": {""id"": ""CL:0000312"", ""label"": ""keratinocyte""}}"																											
7036	7789	338	Vitiligo	Vitiligo.yaml	pathophysiology	4	IFN-gamma-CXCL9/CXCL10 Chemokine Axis	IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.	cell_types[1]	cell_types	cell_types			CD8+ T cell	CL:0000625	CD8-positive, alpha-beta T cell		"{""preferred_term"": ""CD8+ T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
7037	7789	338	Vitiligo	Vitiligo.yaml	pathophysiology	4	IFN-gamma-CXCL9/CXCL10 Chemokine Axis	IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.	biological_processes[0]	biological_processes	biological_processes			response to type II interferon	GO:0034341	response to type II interferon		"{""preferred_term"": ""response to type II interferon"", ""term"": {""id"": ""GO:0034341"", ""label"": ""response to type II interferon""}}"																											
7038	7789	338	Vitiligo	Vitiligo.yaml	pathophysiology	4	IFN-gamma-CXCL9/CXCL10 Chemokine Axis	IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.	biological_processes[1]	biological_processes	biological_processes			leukocyte chemotaxis	GO:0030595	leukocyte chemotaxis		"{""preferred_term"": ""leukocyte chemotaxis"", ""term"": {""id"": ""GO:0030595"", ""label"": ""leukocyte chemotaxis""}}"																											
7039	7789	338	Vitiligo	Vitiligo.yaml	pathophysiology	4	IFN-gamma-CXCL9/CXCL10 Chemokine Axis	IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 chemokines, which recruit CXCR3-positive CD8+ T cells to skin. These cytotoxic T cells mediate melanocyte destruction via perforin/granzyme and Fas-FasL pathways. Elevated serum CXCL9/CXCL10 correlate with disease activity.	locations[0]	locations	locations			skin epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""skin epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
7040	7790	338	Vitiligo	Vitiligo.yaml	pathophysiology	5	IL-15 and Tissue-Resident Memory T Cells	IL-15 promotes survival and cytotoxic function of CD8+ tissue-resident memory T cells (TRM) in skin, maintaining local immune surveillance and contributing to disease persistence and relapse. Serum IL-15 is elevated and correlates with disease extent.	cell_types[0]	cell_types	cell_types			CD8+ tissue-resident memory T cell	CL:0000625	CD8-positive, alpha-beta T cell	Specifically tissue-resident memory (TRM) phenotype with CD69+CD103+ markers	"{""description"": ""Specifically tissue-resident memory (TRM) phenotype with CD69+CD103+ markers"", ""preferred_term"": ""CD8+ tissue-resident memory T cell"", ""term"": {""id"": ""CL:0000625"", ""label"": ""CD8-positive, alpha-beta T cell""}}"																											
7041	7790	338	Vitiligo	Vitiligo.yaml	pathophysiology	5	IL-15 and Tissue-Resident Memory T Cells	IL-15 promotes survival and cytotoxic function of CD8+ tissue-resident memory T cells (TRM) in skin, maintaining local immune surveillance and contributing to disease persistence and relapse. Serum IL-15 is elevated and correlates with disease extent.	locations[0]	locations	locations			skin epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""skin epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
7042	7791	338	Vitiligo	Vitiligo.yaml	pathophysiology	6	Innate Immune Activation	DAMP-driven activation of plasmacytoid dendritic cells and conventional dendritic cells promotes type I interferon signaling, antigen presentation, and licensing of Th1/cytotoxic immunity. NK cells and innate lymphoid cells participate in bridging innate to adaptive immune responses.	cell_types[0]	cell_types	cell_types			dendritic cell	CL:0000451	dendritic cell		"{""preferred_term"": ""dendritic cell"", ""term"": {""id"": ""CL:0000451"", ""label"": ""dendritic cell""}}"																											
7043	7791	338	Vitiligo	Vitiligo.yaml	pathophysiology	6	Innate Immune Activation	DAMP-driven activation of plasmacytoid dendritic cells and conventional dendritic cells promotes type I interferon signaling, antigen presentation, and licensing of Th1/cytotoxic immunity. NK cells and innate lymphoid cells participate in bridging innate to adaptive immune responses.	cell_types[1]	cell_types	cell_types			natural killer cell	CL:0000623	natural killer cell		"{""preferred_term"": ""natural killer cell"", ""term"": {""id"": ""CL:0000623"", ""label"": ""natural killer cell""}}"																											
7044	7791	338	Vitiligo	Vitiligo.yaml	pathophysiology	6	Innate Immune Activation	DAMP-driven activation of plasmacytoid dendritic cells and conventional dendritic cells promotes type I interferon signaling, antigen presentation, and licensing of Th1/cytotoxic immunity. NK cells and innate lymphoid cells participate in bridging innate to adaptive immune responses.	locations[0]	locations	locations			skin epidermis	UBERON:0001003	skin epidermis		"{""preferred_term"": ""skin epidermis"", ""term"": {""id"": ""UBERON:0001003"", ""label"": ""skin epidermis""}}"																											
7045	7795	338	Vitiligo	Vitiligo.yaml	phenotypes	3	Uveitis		phenotype_term	phenotype_term	$	Uveitis		Uveitis	HP:0000554	Uveitis		"{""preferred_term"": ""Uveitis"", ""term"": {""id"": ""HP:0000554"", ""label"": ""Uveitis""}}"																											
7046	7797	338	Vitiligo	Vitiligo.yaml	phenotypes	5	Increased Sensitivity To Sunlight		phenotype_term	phenotype_term	$	Increased Sensitivity To Sunlight		Increased Sensitivity To Sunlight	HP:0000992	Cutaneous photosensitivity		"{""preferred_term"": ""Increased Sensitivity To Sunlight"", ""term"": {""id"": ""HP:0000992"", ""label"": ""Cutaneous photosensitivity""}}"																											
7047	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	Topical Corticosteroid	Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.	treatment_term	treatment_term	$	Topical Corticosteroid	Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7048	7799	338	Vitiligo	Vitiligo.yaml	treatments	1	JAK Inhibitor Therapy	Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.	treatment_term	treatment_term	$	JAK Inhibitor Therapy	Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7049	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	Phototherapy	UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.	treatment_term	treatment_term	$	Phototherapy	UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7050	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	Skin Graft	can be used for stable vitiligo.	treatment_term	treatment_term	$	Skin Graft	can be used for stable vitiligo.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7051	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	Melanocyte Transplantation	can be used for stable vitiligo.	treatment_term	treatment_term	$	Melanocyte Transplantation	can be used for stable vitiligo.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
7052	7803	338	Vitiligo	Vitiligo.yaml	treatments	5	Monobenzone Cream	Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.	treatment_term	treatment_term	$	Monobenzone Cream	Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7053	7811	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	0	VHL Tumor Suppressor Loss	Germline heterozygous VHL mutations result in one functional allele. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates VHL function, initiating tumorigenesis. This follows Knudson's two-hit hypothesis for tumor suppressor gene inactivation.	biological_processes[0]	biological_processes	biological_processes			cellular response to hypoxia	GO:0071456	cellular response to hypoxia		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""cellular response to hypoxia"", ""term"": {""id"": ""GO:0071456"", ""label"": ""cellular response to hypoxia""}}"			ABNORMAL																								
7054	7812	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	1	Loss of HIF Degradation	VHL protein (pVHL) functions as the substrate recognition component of an E3 ubiquitin ligase complex that targets hydroxylated HIF-alpha subunits for proteasomal degradation under normoxic conditions. Loss of VHL function prevents HIF-alpha degradation, allowing HIF accumulation even in the presence of oxygen.	biological_processes[0]	biological_processes	biological_processes			proteasome-mediated ubiquitin-dependent protein catabolic process	GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process		"{""modifier"": ""DECREASED"", ""preferred_term"": ""proteasome-mediated ubiquitin-dependent protein catabolic process"", ""term"": {""id"": ""GO:0043161"", ""label"": ""proteasome-mediated ubiquitin-dependent protein catabolic process""}}"			DECREASED																								
7055	7813	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	2	Constitutive HIF Activation	Stabilized HIF-alpha (primarily HIF-2alpha in RCC) dimerizes with HIF-1beta (ARNT) and translocates to the nucleus where it activates transcription of hypoxia-responsive genes. This occurs constitutively regardless of oxygen levels, creating a pseudo-hypoxic state.	biological_processes[0]	biological_processes	biological_processes			response to hypoxia	GO:0001666	response to hypoxia		"{""modifier"": ""INCREASED"", ""preferred_term"": ""response to hypoxia"", ""term"": {""id"": ""GO:0001666"", ""label"": ""response to hypoxia""}}"			INCREASED																								
7056	7814	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	3	VEGF Overexpression and Angiogenesis	VEGF (vascular endothelial growth factor) is a direct HIF target gene. Constitutive HIF activation leads to chronic VEGF overexpression, driving extensive tumor angiogenesis. This explains the highly vascular nature of VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.	biological_processes[0]	biological_processes	biological_processes			vascular endothelial growth factor signaling pathway	GO:0038084	vascular endothelial growth factor signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""vascular endothelial growth factor signaling pathway"", ""term"": {""id"": ""GO:0038084"", ""label"": ""vascular endothelial growth factor signaling pathway""}}"			INCREASED																								
7057	7814	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	3	VEGF Overexpression and Angiogenesis	VEGF (vascular endothelial growth factor) is a direct HIF target gene. Constitutive HIF activation leads to chronic VEGF overexpression, driving extensive tumor angiogenesis. This explains the highly vascular nature of VHL-associated tumors, particularly hemangioblastomas and clear cell RCC.	biological_processes[1]	biological_processes	biological_processes			angiogenesis	GO:0001525	angiogenesis		"{""modifier"": ""INCREASED"", ""preferred_term"": ""angiogenesis"", ""term"": {""id"": ""GO:0001525"", ""label"": ""angiogenesis""}}"			INCREASED																								
7058	7815	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	4	Growth Factor and Metabolic Reprogramming	HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1, and glycolytic enzymes. This promotes cell proliferation, survival, and a shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.	biological_processes[0]	biological_processes	biological_processes			cellular glucose homeostasis	GO:0001678	cellular glucose homeostasis		"{""modifier"": ""ABNORMAL"", ""preferred_term"": ""cellular glucose homeostasis"", ""term"": {""id"": ""GO:0001678"", ""label"": ""cellular glucose homeostasis""}}"			ABNORMAL																								
7059	7815	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	pathophysiology	4	Growth Factor and Metabolic Reprogramming	HIF activates transcription of genes including PDGF, TGF-alpha, EGFR, GLUT1, and glycolytic enzymes. This promotes cell proliferation, survival, and a shift toward glycolytic metabolism (Warburg effect) that supports tumor growth.	biological_processes[1]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
7060	7817	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	0	Clear Cell Renal Cell Carcinoma	Clear cell RCC occurs in approximately 70% of VHL patients. Tumors are often bilateral and multifocal. Mean age of diagnosis is 39 years, compared to 62 years for sporadic RCC. Leading cause of mortality in VHL patients.	phenotype_term	phenotype_term	$	Clear Cell Renal Cell Carcinoma	Clear cell RCC occurs in approximately 70% of VHL patients. Tumors are often bilateral and multifocal. Mean age of diagnosis is 39 years, compared to 62 years for sporadic RCC. Leading cause of mortality in VHL patients.	Clear cell renal cell carcinoma	HP:0006770	Clear cell renal cell carcinoma		"{""preferred_term"": ""Clear cell renal cell carcinoma"", ""term"": {""id"": ""HP:0006770"", ""label"": ""Clear cell renal cell carcinoma""}}"																											
7061	7818	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	1	Cerebellar Hemangioblastoma	Hemangioblastomas of the cerebellum are the most common CNS manifestation, occurring in 60-80% of VHL patients. These highly vascular tumors may cause symptoms through mass effect or associated cyst formation.	phenotype_term	phenotype_term	$	Cerebellar Hemangioblastoma	Hemangioblastomas of the cerebellum are the most common CNS manifestation, occurring in 60-80% of VHL patients. These highly vascular tumors may cause symptoms through mass effect or associated cyst formation.	Hemangioblastoma	HP:0010797	Hemangioblastoma		"{""preferred_term"": ""Hemangioblastoma"", ""term"": {""id"": ""HP:0010797"", ""label"": ""Hemangioblastoma""}}"																											
7062	7819	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	2	Retinal Hemangioblastoma	Retinal hemangioblastomas (also called retinal capillary hemangiomas) occur in 25-60% of VHL patients and may be the presenting manifestation. They can cause vision loss through exudation, hemorrhage, or retinal detachment.	phenotype_term	phenotype_term	$	Retinal Hemangioblastoma	Retinal hemangioblastomas (also called retinal capillary hemangiomas) occur in 25-60% of VHL patients and may be the presenting manifestation. They can cause vision loss through exudation, hemorrhage, or retinal detachment.	Retinal capillary hemangioma	HP:0009711	Retinal capillary hemangioma		"{""preferred_term"": ""Retinal capillary hemangioma"", ""term"": {""id"": ""HP:0009711"", ""label"": ""Retinal capillary hemangioma""}}"																											
7063	7820	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	3	Pheochromocytoma	Pheochromocytomas occur in 10-20% of VHL patients overall but are more common in Type 2 families (up to 60%). Often bilateral and may occur at young ages. Screening by plasma or urine metanephrines is recommended.	phenotype_term	phenotype_term	$	Pheochromocytoma	Pheochromocytomas occur in 10-20% of VHL patients overall but are more common in Type 2 families (up to 60%). Often bilateral and may occur at young ages. Screening by plasma or urine metanephrines is recommended.	Pheochromocytoma	HP:0002666	Pheochromocytoma		"{""preferred_term"": ""Pheochromocytoma"", ""term"": {""id"": ""HP:0002666"", ""label"": ""Pheochromocytoma""}}"																											
7064	7821	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	4	Pancreatic Neuroendocrine Tumor	Pancreatic neuroendocrine tumors occur in 5-17% of VHL patients. Most are nonfunctional. The main concern is metastatic potential, though most are indolent. Size-based surveillance guides management.	phenotype_term	phenotype_term	$	Pancreatic Neuroendocrine Tumor	Pancreatic neuroendocrine tumors occur in 5-17% of VHL patients. Most are nonfunctional. The main concern is metastatic potential, though most are indolent. Size-based surveillance guides management.	Neuroendocrine neoplasm	HP:0100634	Neuroendocrine neoplasm		"{""preferred_term"": ""Neuroendocrine neoplasm"", ""term"": {""id"": ""HP:0100634"", ""label"": ""Neuroendocrine neoplasm""}}"																											
7065	7822	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	5	Renal Cysts	Multiple renal cysts are common in VHL patients and may precede RCC development. Some cysts contain foci of clear cell RCC. Surveillance imaging monitors for solid enhancing components.	phenotype_term	phenotype_term	$	Renal Cysts	Multiple renal cysts are common in VHL patients and may precede RCC development. Some cysts contain foci of clear cell RCC. Surveillance imaging monitors for solid enhancing components.	Renal cyst	HP:0000107	Renal cyst		"{""preferred_term"": ""Renal cyst"", ""term"": {""id"": ""HP:0000107"", ""label"": ""Renal cyst""}}"																											
7066	7823	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	phenotypes	6	Pancreatic Cysts	Pancreatic cysts (serous cystadenomas) are common in VHL patients but are almost always benign. They are distinct from pancreatic neuroendocrine tumors.	phenotype_term	phenotype_term	$	Pancreatic Cysts	Pancreatic cysts (serous cystadenomas) are common in VHL patients but are almost always benign. They are distinct from pancreatic neuroendocrine tumors.	Pancreatic cysts	HP:0001737	Pancreatic cysts		"{""preferred_term"": ""Pancreatic cysts"", ""term"": {""id"": ""HP:0001737"", ""label"": ""Pancreatic cysts""}}"																											
7067	7824	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	0	Surveillance Protocol	Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.	treatment_term	treatment_term	$	Surveillance Protocol	Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
7068	7825	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	1	Nephron-Sparing Surgery	Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.	treatment_term	treatment_term	$	Nephron-Sparing Surgery	Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7069	7826	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	2	Belzutifan	HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.	treatment_term	treatment_term	$	Belzutifan	HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7070	7827	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	3	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
7071	7828	340	Whipple Disease	Whipple_Disease.yaml	differential_diagnoses	0	Crohn disease		disease_term	disease_term	$	Crohn disease		Crohn disease	MONDO:0005011	Crohn disease		"{""preferred_term"": ""Crohn disease"", ""term"": {""id"": ""MONDO:0005011"", ""label"": ""Crohn disease""}}"																											
7072	7829	340	Whipple Disease	Whipple_Disease.yaml	differential_diagnoses	1	Intestinal tuberculosis		disease_term	disease_term	$	Intestinal tuberculosis		intestinal tuberculosis	MONDO:0001678	intestinal tuberculosis		"{""preferred_term"": ""intestinal tuberculosis"", ""term"": {""id"": ""MONDO:0001678"", ""label"": ""intestinal tuberculosis""}}"																											
7073	7830	340	Whipple Disease	Whipple_Disease.yaml	differential_diagnoses	2	Sarcoidosis		disease_term	disease_term	$	Sarcoidosis		sarcoidosis	MONDO:0019338	sarcoidosis		"{""preferred_term"": ""sarcoidosis"", ""term"": {""id"": ""MONDO:0019338"", ""label"": ""sarcoidosis""}}"																											
7074	7831	340	Whipple Disease	Whipple_Disease.yaml	differential_diagnoses	3	HIV enteropathy		disease_term	disease_term	$	HIV enteropathy		HIV infectious disease	MONDO:0005109	HIV infectious disease		"{""preferred_term"": ""HIV infectious disease"", ""term"": {""id"": ""MONDO:0005109"", ""label"": ""HIV infectious disease""}}"																											
7075	7832	340	Whipple Disease	Whipple_Disease.yaml	environmental	0	Sewage exposure	Higher carriage rates reported in sewage workers, suggesting wastewater as a reservoir.	environment_context	environment_context	$	Sewage exposure	Higher carriage rates reported in sewage workers, suggesting wastewater as a reservoir.	sewage	ENVO:00002018	sewage		"{""preferred_term"": ""sewage"", ""term"": {""id"": ""ENVO:00002018"", ""label"": ""sewage""}}"																											
7076	7833	340	Whipple Disease	Whipple_Disease.yaml	environmental	1	Soil exposure	Soil reported as an environmental reservoir for Tropheryma whipplei.	environment_context	environment_context	$	Soil exposure	Soil reported as an environmental reservoir for Tropheryma whipplei.	soil	ENVO:00001998	soil		"{""preferred_term"": ""soil"", ""term"": {""id"": ""ENVO:00001998"", ""label"": ""soil""}}"																											
7077	7834	340	Whipple Disease	Whipple_Disease.yaml	infectious_agent	0	Tropheryma whipplei	Gram-positive actinomycete responsible for Whipple disease.	infectious_agent_term	infectious_agent_term	$	Tropheryma whipplei	Gram-positive actinomycete responsible for Whipple disease.	Tropheryma whipplei	NCBITaxon:2039	Tropheryma whipplei		"{""preferred_term"": ""Tropheryma whipplei"", ""term"": {""id"": ""NCBITaxon:2039"", ""label"": ""Tropheryma whipplei""}}"																											
7078	7835	340	Whipple Disease	Whipple_Disease.yaml	pathophysiology	0	Macrophage dysfunction and malabsorption	Chronic small bowel infection by Tropheryma whipplei leads to lymphostasis and impaired nutrient absorption driven by macrophage dysfunction.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
7079	7835	340	Whipple Disease	Whipple_Disease.yaml	pathophysiology	0	Macrophage dysfunction and malabsorption	Chronic small bowel infection by Tropheryma whipplei leads to lymphostasis and impaired nutrient absorption driven by macrophage dysfunction.	biological_processes[0]	biological_processes	biological_processes			macrophage activation	GO:0042116	macrophage activation		"{""preferred_term"": ""macrophage activation"", ""term"": {""id"": ""GO:0042116"", ""label"": ""macrophage activation""}}"																											
7080	7836	340	Whipple Disease	Whipple_Disease.yaml	pathophysiology	1	Host susceptibility and immune dysregulation	Only a small fraction of exposed individuals develop Whipple disease, implicating rare inborn or acquired immune defects and risk from anti-TNF therapy.	biological_processes[0]	biological_processes	biological_processes			immune system process	GO:0002376	immune system process		"{""preferred_term"": ""immune system process"", ""term"": {""id"": ""GO:0002376"", ""label"": ""immune system process""}}"																											
7081	7837	340	Whipple Disease	Whipple_Disease.yaml	pathophysiology	2	TNF-inhibitordriven macrophage apoptosis	Anti-TNF biologics can reprogram macrophages infected with Tropheryma whipplei, increasing bacterial replication and macrophage apoptosis, exacerbating latent disease.	cell_types[0]	cell_types	cell_types			macrophage	CL:0000235	macrophage		"{""preferred_term"": ""macrophage"", ""term"": {""id"": ""CL:0000235"", ""label"": ""macrophage""}}"																											
7082	7837	340	Whipple Disease	Whipple_Disease.yaml	pathophysiology	2	TNF-inhibitordriven macrophage apoptosis	Anti-TNF biologics can reprogram macrophages infected with Tropheryma whipplei, increasing bacterial replication and macrophage apoptosis, exacerbating latent disease.	biological_processes[0]	biological_processes	biological_processes			apoptotic process	GO:0006915	apoptotic process		"{""preferred_term"": ""apoptotic process"", ""term"": {""id"": ""GO:0006915"", ""label"": ""apoptotic process""}}"																											
7083	7838	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	0	Chronic diarrhea	Persistent watery or steatorrheal stools reflecting malabsorption.	phenotype_term	phenotype_term	$	Chronic diarrhea	Persistent watery or steatorrheal stools reflecting malabsorption.	Diarrhea	HP:0002014	Diarrhea		"{""preferred_term"": ""Diarrhea"", ""term"": {""id"": ""HP:0002014"", ""label"": ""Diarrhea""}}"																											
7084	7839	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	1	Steatorrhea	Fatty, malabsorptive stools accompanying chronic infection.	phenotype_term	phenotype_term	$	Steatorrhea	Fatty, malabsorptive stools accompanying chronic infection.	Steatorrhea	HP:0002570	Steatorrhea		"{""preferred_term"": ""Steatorrhea"", ""term"": {""id"": ""HP:0002570"", ""label"": ""Steatorrhea""}}"																											
7085	7840	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	2	Weight loss	Progressive weight loss due to malabsorption.	phenotype_term	phenotype_term	$	Weight loss	Progressive weight loss due to malabsorption.	Weight loss	HP:0001824	Weight loss		"{""preferred_term"": ""Weight loss"", ""term"": {""id"": ""HP:0001824"", ""label"": ""Weight loss""}}"																											
7086	7841	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	3	Migratory polyarthralgia	Migratory peripheral joint pain often preceding gastrointestinal symptoms.	phenotype_term	phenotype_term	$	Migratory polyarthralgia	Migratory peripheral joint pain often preceding gastrointestinal symptoms.	Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
7087	7842	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	4	Cognitive dysfunction	Cognitive impairment and other CNS manifestations that can occur with systemic or isolated CNS disease.	phenotype_term	phenotype_term	$	Cognitive dysfunction	Cognitive impairment and other CNS manifestations that can occur with systemic or isolated CNS disease.	Cognitive impairment	HP:0100543	Cognitive impairment		"{""preferred_term"": ""Cognitive impairment"", ""term"": {""id"": ""HP:0100543"", ""label"": ""Cognitive impairment""}}"																											
7088	7843	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	5	Fever	Low-grade to episodic fever during prodromal phase.	phenotype_term	phenotype_term	$	Fever	Low-grade to episodic fever during prodromal phase.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
7089	7844	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	6	Abdominal pain	Colicky abdominal pain accompanying diarrhea and malabsorption.	phenotype_term	phenotype_term	$	Abdominal pain	Colicky abdominal pain accompanying diarrhea and malabsorption.	Abdominal pain	HP:0002027	Abdominal pain		"{""preferred_term"": ""Abdominal pain"", ""term"": {""id"": ""HP:0002027"", ""label"": ""Abdominal pain""}}"																											
7090	7845	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	7	Lymphadenopathy	Enlarged lymph nodes reflecting systemic infection.	phenotype_term	phenotype_term	$	Lymphadenopathy	Enlarged lymph nodes reflecting systemic infection.	Lymphadenopathy	HP:0002716	Lymphadenopathy		"{""preferred_term"": ""Lymphadenopathy"", ""term"": {""id"": ""HP:0002716"", ""label"": ""Lymphadenopathy""}}"																											
7091	7846	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	8	Respiratory involvement	Pulmonary symptoms such as cough, chest pain, and dyspnea with plaques or nodules on imaging.	phenotype_term	phenotype_term	$	Respiratory involvement	Pulmonary symptoms such as cough, chest pain, and dyspnea with plaques or nodules on imaging.	Dyspnea	HP:0002094	Dyspnea		"{""preferred_term"": ""Dyspnea"", ""term"": {""id"": ""HP:0002094"", ""label"": ""Dyspnea""}}"																											
7092	7847	340	Whipple Disease	Whipple_Disease.yaml	phenotypes	9	Spinal cord involvement	Isolated spinal cord inflammation leading to neurologic damage.	phenotype_term	phenotype_term	$	Spinal cord involvement	Isolated spinal cord inflammation leading to neurologic damage.	Abnormality of the nervous system	HP:0000707	Abnormality of the nervous system		"{""preferred_term"": ""Abnormality of the nervous system"", ""term"": {""id"": ""HP:0000707"", ""label"": ""Abnormality of the nervous system""}}"																											
7093	7848	340	Whipple Disease	Whipple_Disease.yaml	treatments	0	Ceftriaxone induction followed by trimethoprim/sulfamethoxazole	Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse.	treatment_term	treatment_term	$	Ceftriaxone induction followed by trimethoprim/sulfamethoxazole	Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7094	7849	340	Whipple Disease	Whipple_Disease.yaml	treatments	1	Doxycycline plus hydroxychloroquine regimen	Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention.	treatment_term	treatment_term	$	Doxycycline plus hydroxychloroquine regimen	Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7095	7858	341	Wilms Tumor	Wilms_Tumor.yaml	histopathology	0	Pediatric Renal Malignancy	Wilms tumour is the most common paediatric renal malignancy.	finding_term	finding_term	$	Pediatric Renal Malignancy	Wilms tumour is the most common paediatric renal malignancy.	Wilms Tumor	NCIT:C3267	Wilms Tumor		"{""preferred_term"": ""Wilms Tumor"", ""term"": {""id"": ""NCIT:C3267"", ""label"": ""Wilms Tumor""}}"																											
7096	7859	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	0	WT1 Inactivation	WT1 is a transcription factor essential for normal kidney and gonad development. Biallelic WT1 inactivation occurs in 10-20% of Wilms tumors. Germline WT1 mutations cause WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, intellectual disability) and Denys-Drash syndrome.	biological_processes[0]	biological_processes	biological_processes			cell differentiation	GO:0030154	cell differentiation		"{""modifier"": ""DECREASED"", ""preferred_term"": ""cell differentiation"", ""term"": {""id"": ""GO:0030154"", ""label"": ""cell differentiation""}}"			DECREASED																								
7097	7859	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	0	WT1 Inactivation	WT1 is a transcription factor essential for normal kidney and gonad development. Biallelic WT1 inactivation occurs in 10-20% of Wilms tumors. Germline WT1 mutations cause WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, intellectual disability) and Denys-Drash syndrome.	locations[0]	locations	locations			kidney	UBERON:0002113	kidney		"{""preferred_term"": ""kidney"", ""term"": {""id"": ""UBERON:0002113"", ""label"": ""kidney""}}"																											
7098	7860	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	1	WTX/CTNNB1 Wnt Pathway Activation	WTX (AMER1) is a negative regulator of Wnt signaling mutated in approximately 15-20% of Wilms tumors. CTNNB1 (beta-catenin) activating mutations occur in approximately 15% of cases. Both result in constitutive Wnt pathway activation, promoting proliferation and blocking differentiation.	biological_processes[0]	biological_processes	biological_processes			Wnt signaling pathway	GO:0016055	Wnt signaling pathway		"{""modifier"": ""INCREASED"", ""preferred_term"": ""Wnt signaling pathway"", ""term"": {""id"": ""GO:0016055"", ""label"": ""Wnt signaling pathway""}}"			INCREASED																								
7099	7861	341	Wilms Tumor	Wilms_Tumor.yaml	pathophysiology	2	Blocked Nephron Differentiation	Wilms tumor arises from nephrogenic rests - foci of embryonic blastemal cells that persist beyond the normal period of nephrogenesis. These cells retain proliferative capacity but fail to undergo terminal differentiation into mature nephrons.	biological_processes[0]	biological_processes	biological_processes			cell population proliferation	GO:0008283	cell population proliferation		"{""modifier"": ""INCREASED"", ""preferred_term"": ""cell population proliferation"", ""term"": {""id"": ""GO:0008283"", ""label"": ""cell population proliferation""}}"			INCREASED																								
7100	7862	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	0	Abdominal Mass	A palpable abdominal mass is the most common presenting finding, often noticed incidentally by parents during bathing. The mass is typically smooth, firm, and does not cross the midline.	phenotype_term	phenotype_term	$	Abdominal Mass	A palpable abdominal mass is the most common presenting finding, often noticed incidentally by parents during bathing. The mass is typically smooth, firm, and does not cross the midline.	Abdominal mass	HP:0031500	Abdominal mass		"{""preferred_term"": ""Abdominal mass"", ""term"": {""id"": ""HP:0031500"", ""label"": ""Abdominal mass""}}"																											
7101	7863	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	1	Hematuria	Gross or microscopic hematuria occurs in approximately 20-25% of patients and may be the presenting symptom.	phenotype_term	phenotype_term	$	Hematuria	Gross or microscopic hematuria occurs in approximately 20-25% of patients and may be the presenting symptom.	Hematuria	HP:0000790	Hematuria		"{""preferred_term"": ""Hematuria"", ""term"": {""id"": ""HP:0000790"", ""label"": ""Hematuria""}}"																											
7102	7864	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	2	Hypertension	Hypertension occurs in approximately 25% of patients due to renin secretion by the tumor or renal artery compression.	phenotype_term	phenotype_term	$	Hypertension	Hypertension occurs in approximately 25% of patients due to renin secretion by the tumor or renal artery compression.	Hypertension	HP:0000822	Hypertension		"{""preferred_term"": ""Hypertension"", ""term"": {""id"": ""HP:0000822"", ""label"": ""Hypertension""}}"																											
7103	7865	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	3	Fever	Low-grade fever may occur as a constitutional symptom.	phenotype_term	phenotype_term	$	Fever	Low-grade fever may occur as a constitutional symptom.	Fever	HP:0001945	Fever		"{""preferred_term"": ""Fever"", ""term"": {""id"": ""HP:0001945"", ""label"": ""Fever""}}"																											
7104	7866	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	4	Aniridia	Aniridia (absence of the iris) occurs in WAGR syndrome, caused by contiguous deletion of WT1 and PAX6 on chromosome 11p13. Children with sporadic aniridia require screening for Wilms tumor.	phenotype_term	phenotype_term	$	Aniridia	Aniridia (absence of the iris) occurs in WAGR syndrome, caused by contiguous deletion of WT1 and PAX6 on chromosome 11p13. Children with sporadic aniridia require screening for Wilms tumor.	Aniridia	HP:0000526	Aniridia		"{""preferred_term"": ""Aniridia"", ""term"": {""id"": ""HP:0000526"", ""label"": ""Aniridia""}}"																											
7105	7867	341	Wilms Tumor	Wilms_Tumor.yaml	phenotypes	5	Hemihypertrophy	Hemihypertrophy (asymmetric overgrowth) is associated with Beckwith-Wiedemann syndrome and increased Wilms tumor risk. Children with hemihypertrophy require tumor surveillance.	phenotype_term	phenotype_term	$	Hemihypertrophy	Hemihypertrophy (asymmetric overgrowth) is associated with Beckwith-Wiedemann syndrome and increased Wilms tumor risk. Children with hemihypertrophy require tumor surveillance.	Hemihypertrophy	HP:0001528	Hemihypertrophy		"{""preferred_term"": ""Hemihypertrophy"", ""term"": {""id"": ""HP:0001528"", ""label"": ""Hemihypertrophy""}}"																											
7106	7868	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	0	Surgical Resection	Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first.	treatment_term	treatment_term	$	Surgical Resection	Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	treatment_term	$	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				actinomycin D; vincristine; doxorubicin	CHEBI:27666; CHEBI:28445; CHEBI:28748																						
7108	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
7109	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
7110	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
7111	7870	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	2	Radiation Therapy	Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination.	treatment_term	treatment_term	$	Radiation Therapy	Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7112	7876	342	Wilson Disease	Wilsons_Disease.yaml	datasets	0		Microarray expression profiling of liver tissue from Wilson disease patients and controls.	organism	organism	$		Microarray expression profiling of liver tissue from Wilson disease patients and controls.	human	NCBITaxon:9606	Homo sapiens		"{""preferred_term"": ""human"", ""term"": {""id"": ""NCBITaxon:9606"", ""label"": ""Homo sapiens""}}"																											
7113	7876	342	Wilson Disease	Wilsons_Disease.yaml	datasets	0		Microarray expression profiling of liver tissue from Wilson disease patients and controls.	sample_types[0]	sample_types	sample_types			liver tissue				"{""preferred_term"": ""liver tissue"", ""tissue_term"": {""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}}"																											
7114	7876	342	Wilson Disease	Wilsons_Disease.yaml	datasets	0		Microarray expression profiling of liver tissue from Wilson disease patients and controls.	sample_types[0].tissue_term	sample_types	sample_types[0]			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
7115	7879	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	0	Copper Accumulation	"ATP7B mutations impair copper excretion into bile and incorporation into ceruloplasmin. Copper accumulates in many organs, especially liver and brain. Free copper is toxic and promotes oxidative damage and cellular toxicity. ATP7B normally resides in the trans-Golgi network where it loads copper into apoceruloplasmin and traffics to the bile canalicular membrane for biliary copper excretion when intracellular copper is elevated.
"	biological_processes[0]	biological_processes	biological_processes			copper ion transport	GO:0006825	copper ion transport		"{""preferred_term"": ""copper ion transport"", ""term"": {""id"": ""GO:0006825"", ""label"": ""copper ion transport""}}"																											
7116	7879	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	0	Copper Accumulation	"ATP7B mutations impair copper excretion into bile and incorporation into ceruloplasmin. Copper accumulates in many organs, especially liver and brain. Free copper is toxic and promotes oxidative damage and cellular toxicity. ATP7B normally resides in the trans-Golgi network where it loads copper into apoceruloplasmin and traffics to the bile canalicular membrane for biliary copper excretion when intracellular copper is elevated.
"	biological_processes[1]	biological_processes	biological_processes			copper ion homeostasis	GO:0055070	copper ion homeostasis		"{""preferred_term"": ""copper ion homeostasis"", ""term"": {""id"": ""GO:0055070"", ""label"": ""copper ion homeostasis""}}"																											
7117	7879	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	0	Copper Accumulation	"ATP7B mutations impair copper excretion into bile and incorporation into ceruloplasmin. Copper accumulates in many organs, especially liver and brain. Free copper is toxic and promotes oxidative damage and cellular toxicity. ATP7B normally resides in the trans-Golgi network where it loads copper into apoceruloplasmin and traffics to the bile canalicular membrane for biliary copper excretion when intracellular copper is elevated.
"	cellular_components[0]	cellular_components	cellular_components			Golgi apparatus	GO:0005794	Golgi apparatus		"{""preferred_term"": ""Golgi apparatus"", ""term"": {""id"": ""GO:0005794"", ""label"": ""Golgi apparatus""}}"																											
7118	7880	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	1	Hepatocyte Injury	"Copper accumulation in hepatocytes causes oxidative stress, mitochondrial dysfunction, and cell death. Progressive liver damage leads to fibrosis and cirrhosis. Copper overload activates autophagy and mitophagy-based mitochondrial quality control responses.
"	cell_types[0]	cell_types	cell_types			hepatocyte	CL:0000182	hepatocyte		"{""preferred_term"": ""hepatocyte"", ""term"": {""id"": ""CL:0000182"", ""label"": ""hepatocyte""}}"																											
7119	7880	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	1	Hepatocyte Injury	"Copper accumulation in hepatocytes causes oxidative stress, mitochondrial dysfunction, and cell death. Progressive liver damage leads to fibrosis and cirrhosis. Copper overload activates autophagy and mitophagy-based mitochondrial quality control responses.
"	locations[0]	locations	locations			liver	UBERON:0002107	liver		"{""preferred_term"": ""liver"", ""term"": {""id"": ""UBERON:0002107"", ""label"": ""liver""}}"																											
7120	7880	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	1	Hepatocyte Injury	"Copper accumulation in hepatocytes causes oxidative stress, mitochondrial dysfunction, and cell death. Progressive liver damage leads to fibrosis and cirrhosis. Copper overload activates autophagy and mitophagy-based mitochondrial quality control responses.
"	biological_processes[0]	biological_processes	biological_processes			response to oxidative stress	GO:0006979	response to oxidative stress		"{""preferred_term"": ""response to oxidative stress"", ""term"": {""id"": ""GO:0006979"", ""label"": ""response to oxidative stress""}}"																											
7121	7880	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	1	Hepatocyte Injury	"Copper accumulation in hepatocytes causes oxidative stress, mitochondrial dysfunction, and cell death. Progressive liver damage leads to fibrosis and cirrhosis. Copper overload activates autophagy and mitophagy-based mitochondrial quality control responses.
"	biological_processes[1]	biological_processes	biological_processes			mitophagy	GO:0000423	mitophagy		"{""preferred_term"": ""mitophagy"", ""term"": {""id"": ""GO:0000423"", ""label"": ""mitophagy""}}"																											
7122	7881	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	2	Neurodegeneration	"Copper deposition is thought to drive brain cellular damage with characteristic striatal/basal ganglia lesions. Reactive astrogliosis and microglial activation with increased CNS inflammatory cytokines indicate neuroinflammation contributing to movement and psychiatric symptoms.
"	cell_types[0]	cell_types	cell_types			astrocyte	CL:0000127	astrocyte		"{""preferred_term"": ""astrocyte"", ""term"": {""id"": ""CL:0000127"", ""label"": ""astrocyte""}}"																											
7123	7881	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	2	Neurodegeneration	"Copper deposition is thought to drive brain cellular damage with characteristic striatal/basal ganglia lesions. Reactive astrogliosis and microglial activation with increased CNS inflammatory cytokines indicate neuroinflammation contributing to movement and psychiatric symptoms.
"	cell_types[1]	cell_types	cell_types			microglial cell	CL:0000129	microglial cell		"{""preferred_term"": ""microglial cell"", ""term"": {""id"": ""CL:0000129"", ""label"": ""microglial cell""}}"																											
7124	7881	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	2	Neurodegeneration	"Copper deposition is thought to drive brain cellular damage with characteristic striatal/basal ganglia lesions. Reactive astrogliosis and microglial activation with increased CNS inflammatory cytokines indicate neuroinflammation contributing to movement and psychiatric symptoms.
"	locations[0]	locations	locations			collection of basal ganglia	UBERON:0010011	collection of basal ganglia		"{""preferred_term"": ""collection of basal ganglia"", ""term"": {""id"": ""UBERON:0010011"", ""label"": ""collection of basal ganglia""}}"																											
7125	7881	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	2	Neurodegeneration	"Copper deposition is thought to drive brain cellular damage with characteristic striatal/basal ganglia lesions. Reactive astrogliosis and microglial activation with increased CNS inflammatory cytokines indicate neuroinflammation contributing to movement and psychiatric symptoms.
"	locations[1]	locations	locations			putamen	UBERON:0001874	putamen		"{""preferred_term"": ""putamen"", ""term"": {""id"": ""UBERON:0001874"", ""label"": ""putamen""}}"																											
7126	7881	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	2	Neurodegeneration	"Copper deposition is thought to drive brain cellular damage with characteristic striatal/basal ganglia lesions. Reactive astrogliosis and microglial activation with increased CNS inflammatory cytokines indicate neuroinflammation contributing to movement and psychiatric symptoms.
"	biological_processes[0]	biological_processes	biological_processes			neuron death	GO:0070997	neuron death		"{""preferred_term"": ""neuron death"", ""term"": {""id"": ""GO:0070997"", ""label"": ""neuron death""}}"																											
7127	7882	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	3	Cuproptosis	"Copper-dependent cell death involving binding of copper to lipoylated enzymes in the tricarboxylic acid (TCA) cycle, leading to proteotoxic stress and mitochondrial dysfunction.
"	biological_processes[0]	biological_processes	biological_processes			cuproptosis	GO:0160119	cuproptosis		"{""preferred_term"": ""cuproptosis"", ""term"": {""id"": ""GO:0160119"", ""label"": ""cuproptosis""}}"																											
7128	7883	342	Wilson Disease	Wilsons_Disease.yaml	pathophysiology	4	Ferroptosis	"Iron-related cell death pathway involving phospholipid peroxidation. Increased iron deposits in Wilson disease liver may contribute to ferroptosis alongside copper-mediated injury.
"	biological_processes[0]	biological_processes	biological_processes			ferroptosis	GO:0097707	ferroptosis		"{""preferred_term"": ""ferroptosis"", ""term"": {""id"": ""GO:0097707"", ""label"": ""ferroptosis""}}"																											
7129	7884	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	0	Hepatomegaly		phenotype_term	phenotype_term	$	Hepatomegaly		Hepatomegaly	HP:0002240	Hepatomegaly		"{""preferred_term"": ""Hepatomegaly"", ""term"": {""id"": ""HP:0002240"", ""label"": ""Hepatomegaly""}}"																											
7130	7885	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	1	Cirrhosis		phenotype_term	phenotype_term	$	Cirrhosis		Cirrhosis	HP:0001394	Cirrhosis		"{""preferred_term"": ""Cirrhosis"", ""term"": {""id"": ""HP:0001394"", ""label"": ""Cirrhosis""}}"																											
7131	7886	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	2	Kayser-Fleischer Rings		phenotype_term	phenotype_term	$	Kayser-Fleischer Rings		Kayser-Fleischer Ring	HP:0200032	Kayser-Fleischer ring		"{""preferred_term"": ""Kayser-Fleischer Ring"", ""term"": {""id"": ""HP:0200032"", ""label"": ""Kayser-Fleischer ring""}}"																											
7132	7887	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	3	Tremor		phenotype_term	phenotype_term	$	Tremor		Tremor	HP:0001337	Tremor		"{""preferred_term"": ""Tremor"", ""term"": {""id"": ""HP:0001337"", ""label"": ""Tremor""}}"																											
7133	7888	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	4	Dysarthria		phenotype_term	phenotype_term	$	Dysarthria		Dysarthria	HP:0001260	Dysarthria		"{""preferred_term"": ""Dysarthria"", ""term"": {""id"": ""HP:0001260"", ""label"": ""Dysarthria""}}"																											
7134	7889	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	5	Dystonia		phenotype_term	phenotype_term	$	Dystonia		Dystonia	HP:0001332	Dystonia		"{""preferred_term"": ""Dystonia"", ""term"": {""id"": ""HP:0001332"", ""label"": ""Dystonia""}}"																											
7135	7890	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	6	Psychiatric Symptoms		phenotype_term	phenotype_term	$	Psychiatric Symptoms		Psychiatric Abnormality	HP:0000708	Atypical behavior		"{""preferred_term"": ""Psychiatric Abnormality"", ""term"": {""id"": ""HP:0000708"", ""label"": ""Atypical behavior""}}"																											
7136	7891	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	7	Ataxia		phenotype_term	phenotype_term	$	Ataxia		Ataxia	HP:0001251	Ataxia		"{""preferred_term"": ""Ataxia"", ""term"": {""id"": ""HP:0001251"", ""label"": ""Ataxia""}}"																											
7137	7892	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	8	Parkinsonism		phenotype_term	phenotype_term	$	Parkinsonism		Parkinsonism	HP:0001300	Parkinsonism		"{""preferred_term"": ""Parkinsonism"", ""term"": {""id"": ""HP:0001300"", ""label"": ""Parkinsonism""}}"																											
7138	7893	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	9	Dysphagia		phenotype_term	phenotype_term	$	Dysphagia		Dysphagia	HP:0002015	Dysphagia		"{""preferred_term"": ""Dysphagia"", ""term"": {""id"": ""HP:0002015"", ""label"": ""Dysphagia""}}"																											
7139	7894	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	10	Cardiomyopathy		phenotype_term	phenotype_term	$	Cardiomyopathy		Cardiomyopathy	HP:0001638	Cardiomyopathy		"{""preferred_term"": ""Cardiomyopathy"", ""term"": {""id"": ""HP:0001638"", ""label"": ""Cardiomyopathy""}}"																											
7140	7895	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	11	Renal Tubular Dysfunction		phenotype_term	phenotype_term	$	Renal Tubular Dysfunction		Renal Tubular Dysfunction	HP:0000124	Renal tubular dysfunction		"{""preferred_term"": ""Renal Tubular Dysfunction"", ""term"": {""id"": ""HP:0000124"", ""label"": ""Renal tubular dysfunction""}}"																											
7141	7896	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	12	Hemolytic Anemia		phenotype_term	phenotype_term	$	Hemolytic Anemia		Hemolytic Anemia	HP:0001878	Hemolytic anemia		"{""preferred_term"": ""Hemolytic Anemia"", ""term"": {""id"": ""HP:0001878"", ""label"": ""Hemolytic anemia""}}"																											
7142	7897	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	13	Osteoporosis		phenotype_term	phenotype_term	$	Osteoporosis		Osteoporosis	HP:0000939	Osteoporosis		"{""preferred_term"": ""Osteoporosis"", ""term"": {""id"": ""HP:0000939"", ""label"": ""Osteoporosis""}}"																											
7143	7898	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	14	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
7144	7899	342	Wilson Disease	Wilsons_Disease.yaml	phenotypes	15	Hepatitis		phenotype_term	phenotype_term	$	Hepatitis		Hepatitis	HP:0012115	Hepatitis		"{""preferred_term"": ""Hepatitis"", ""term"": {""id"": ""HP:0012115"", ""label"": ""Hepatitis""}}"																											
7145	7900	342	Wilson Disease	Wilsons_Disease.yaml	treatments	0	D-Penicillamine	Copper chelator, first-line therapy, promotes urinary copper excretion.	treatment_term	treatment_term	$	D-Penicillamine	Copper chelator, first-line therapy, promotes urinary copper excretion.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}"																											
7146	7901	342	Wilson Disease	Wilsons_Disease.yaml	treatments	1	Trientine	Alternative copper chelator, better tolerated than penicillamine.	treatment_term	treatment_term	$	Trientine	Alternative copper chelator, better tolerated than penicillamine.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}"																											
7147	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term	treatment_term	$	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}]}"				zinc acetate	CHEBI:62984																						
7148	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			zinc acetate	CHEBI:62984	zinc acetate		"{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}"																											
7149	7903	342	Wilson Disease	Wilsons_Disease.yaml	treatments	3	Low Copper Diet	Avoid liver, shellfish, chocolate, nuts, mushrooms.	treatment_term	treatment_term	$	Low Copper Diet	Avoid liver, shellfish, chocolate, nuts, mushrooms.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
7150	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term	treatment_term	$	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}]}"				tetrathiomolybdate(2-)	CHEBI:30703																						
7151	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			tetrathiomolybdate	CHEBI:30703	tetrathiomolybdate(2-)		"{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}"																											
7152	7905	342	Wilson Disease	Wilsons_Disease.yaml	treatments	5	Liver Transplantation	Curative for hepatic Wilson disease, reverses copper metabolism defect.	treatment_term	treatment_term	$	Liver Transplantation	Curative for hepatic Wilson disease, reverses copper metabolism defect.	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
7153	7908	343	Wissler syndrome	Wissler_syndrome.yaml	differential_diagnoses	0	Sepsis	Early Wissler-Fanconi presentations can be difficult to distinguish from septicemia.	disease_term	disease_term	$	Sepsis	Early Wissler-Fanconi presentations can be difficult to distinguish from septicemia.	infectious disease with sepsis	MONDO:1040015	infectious disease with sepsis		"{""preferred_term"": ""infectious disease with sepsis"", ""term"": {""id"": ""MONDO:1040015"", ""label"": ""infectious disease with sepsis""}}"																											
7154	7909	343	Wissler syndrome	Wissler_syndrome.yaml	differential_diagnoses	1	Acute rheumatic fever	Considered in the differential diagnosis because of overlapping febrile inflammatory presentations.	disease_term	disease_term	$	Acute rheumatic fever	Considered in the differential diagnosis because of overlapping febrile inflammatory presentations.	rheumatic fever	MONDO:0017767	rheumatic fever		"{""preferred_term"": ""rheumatic fever"", ""term"": {""id"": ""MONDO:0017767"", ""label"": ""rheumatic fever""}}"																											
7155	7910	343	Wissler syndrome	Wissler_syndrome.yaml	differential_diagnoses	2	Rheumatoid arthritis	Inflammatory arthritis with systemic features can overlap with Wissler-Fanconi syndrome.	disease_term	disease_term	$	Rheumatoid arthritis	Inflammatory arthritis with systemic features can overlap with Wissler-Fanconi syndrome.	rheumatoid arthritis	MONDO:0008383	rheumatoid arthritis		"{""preferred_term"": ""rheumatoid arthritis"", ""term"": {""id"": ""MONDO:0008383"", ""label"": ""rheumatoid arthritis""}}"																											
7156	7911	343	Wissler syndrome	Wissler_syndrome.yaml	differential_diagnoses	3	Adult-onset Still's disease	Shares fever, rash, leukocytosis, and arthralgia; some authors consider Wissler-Fanconi syndrome related.	disease_term	disease_term	$	Adult-onset Still's disease	Shares fever, rash, leukocytosis, and arthralgia; some authors consider Wissler-Fanconi syndrome related.	adult-onset Still disease	MONDO:0019355	adult-onset Still disease		"{""preferred_term"": ""adult-onset Still disease"", ""term"": {""id"": ""MONDO:0019355"", ""label"": ""adult-onset Still disease""}}"																											
7157	7912	343	Wissler syndrome	Wissler_syndrome.yaml	differential_diagnoses	4	Autoimmune polyendocrine syndrome type 1	Reported in a case with subsepsis allergica; included as a differential context.	disease_term	disease_term	$	Autoimmune polyendocrine syndrome type 1	Reported in a case with subsepsis allergica; included as a differential context.	autoimmune polyendocrine syndrome type 1	MONDO:0009411	autoimmune polyendocrine syndrome type 1		"{""preferred_term"": ""autoimmune polyendocrine syndrome type 1"", ""term"": {""id"": ""MONDO:0009411"", ""label"": ""autoimmune polyendocrine syndrome type 1""}}"																											
7158	7913	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	0	Recurrent high fever		phenotype_term	phenotype_term	$	Recurrent high fever		Recurrent fever	HP:0001954	Recurrent fever		"{""preferred_term"": ""Recurrent fever"", ""term"": {""id"": ""HP:0001954"", ""label"": ""Recurrent fever""}}"																											
7159	7914	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	1	Exanthem		phenotype_term	phenotype_term	$	Exanthem		Exanthem	HP:4000054	Exanthem		"{""preferred_term"": ""Exanthem"", ""term"": {""id"": ""HP:4000054"", ""label"": ""Exanthem""}}"																											
7160	7915	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	2	Arthralgia		phenotype_term	phenotype_term	$	Arthralgia		Arthralgia	HP:0002829	Arthralgia		"{""preferred_term"": ""Arthralgia"", ""term"": {""id"": ""HP:0002829"", ""label"": ""Arthralgia""}}"																											
7161	7916	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	3	Leukocytosis		phenotype_term	phenotype_term	$	Leukocytosis		Leukocytosis	HP:0001974	Increased total leukocyte count		"{""preferred_term"": ""Leukocytosis"", ""term"": {""id"": ""HP:0001974"", ""label"": ""Increased total leukocyte count""}}"																											
7162	7917	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	4	Microscopic hematuria		phenotype_term	phenotype_term	$	Microscopic hematuria		Microscopic hematuria	HP:0002907	Microscopic hematuria		"{""preferred_term"": ""Microscopic hematuria"", ""term"": {""id"": ""HP:0002907"", ""label"": ""Microscopic hematuria""}}"																											
7163	7918	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	5	Arthritis		phenotype_term	phenotype_term	$	Arthritis		Arthritis	HP:0001369	Arthritis		"{""preferred_term"": ""Arthritis"", ""term"": {""id"": ""HP:0001369"", ""label"": ""Arthritis""}}"																											
7164	7919	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	6	Pericarditis		phenotype_term	phenotype_term	$	Pericarditis		Pericarditis	HP:0001701	Pericarditis		"{""preferred_term"": ""Pericarditis"", ""term"": {""id"": ""HP:0001701"", ""label"": ""Pericarditis""}}"																											
7165	7920	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	7	Myocarditis		phenotype_term	phenotype_term	$	Myocarditis		Myocarditis	HP:0012819	Myocarditis		"{""preferred_term"": ""Myocarditis"", ""term"": {""id"": ""HP:0012819"", ""label"": ""Myocarditis""}}"																											
7166	7921	343	Wissler syndrome	Wissler_syndrome.yaml	phenotypes	8	Congestive heart failure		phenotype_term	phenotype_term	$	Congestive heart failure		Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
7167	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term	treatment_term	$	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	NSAID therapy	MAXO:0000221	NSAID therapy		"{""preferred_term"": ""NSAID therapy"", ""term"": {""id"": ""MAXO:0000221"", ""label"": ""NSAID therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}]}"				Naproxen	NCIT:C680																						
7168	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			naproxen	NCIT:C680	Naproxen		"{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}"																											
7169	7925	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	1	Corticosteroids	Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation.	treatment_term	treatment_term	$	Corticosteroids	Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
7170	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term	treatment_term	$	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Dapsone	NCIT:C415	NCIT:C2259			
7171	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
7172	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			dapsone	NCIT:C415	Dapsone		"{""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}"																											
7173	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term	treatment_term	$	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Azathioprine	NCIT:C290	NCIT:C2259			
7174	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
7175	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			azathioprine	NCIT:C290	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}"																											
7176	7930	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	0	Characteristic Facial Features		phenotype_term	phenotype_term	$	Characteristic Facial Features		Abnormal facial shape	HP:0001999	Abnormal facial shape		"{""preferred_term"": ""Abnormal facial shape"", ""term"": {""id"": ""HP:0001999"", ""label"": ""Abnormal facial shape""}}"																											
7177	7931	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	1	Microcephaly		phenotype_term	phenotype_term	$	Microcephaly		Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
7178	7932	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	2	Hypertelorism		phenotype_term	phenotype_term	$	Hypertelorism		Hypertelorism	HP:0000316	Hypertelorism		"{""preferred_term"": ""Hypertelorism"", ""term"": {""id"": ""HP:0000316"", ""label"": ""Hypertelorism""}}"																											
7179	7933	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	3	Intrauterine Growth Retardation		phenotype_term	phenotype_term	$	Intrauterine Growth Retardation		Intrauterine growth retardation	HP:0001511	Intrauterine growth retardation		"{""preferred_term"": ""Intrauterine growth retardation"", ""term"": {""id"": ""HP:0001511"", ""label"": ""Intrauterine growth retardation""}}"																											
7180	7934	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	4	Postnatal Growth Retardation		phenotype_term	phenotype_term	$	Postnatal Growth Retardation		Postnatal growth retardation	HP:0008897	Postnatal growth retardation		"{""preferred_term"": ""Postnatal growth retardation"", ""term"": {""id"": ""HP:0008897"", ""label"": ""Postnatal growth retardation""}}"																											
7181	7935	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	5	Intellectual Disability		phenotype_term	phenotype_term	$	Intellectual Disability		Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
7182	7936	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	6	Severe Delayed Psychomotor Development		phenotype_term	phenotype_term	$	Severe Delayed Psychomotor Development		Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
7183	7937	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	7	Seizures		phenotype_term	phenotype_term	$	Seizures		Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
7184	7938	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	8	Hypotonia		phenotype_term	phenotype_term	$	Hypotonia		Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
7185	7939	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	9	Corpus Callosum Abnormalities		phenotype_term	phenotype_term	$	Corpus Callosum Abnormalities		Abnormal corpus callosum morphology	HP:0001273	Abnormal corpus callosum morphology		"{""preferred_term"": ""Abnormal corpus callosum morphology"", ""term"": {""id"": ""HP:0001273"", ""label"": ""Abnormal corpus callosum morphology""}}"																											
7186	7940	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	10	Congenital Heart Defects		phenotype_term	phenotype_term	$	Congenital Heart Defects		Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
7187	7941	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	11	Skeletal Anomalies		phenotype_term	phenotype_term	$	Skeletal Anomalies		Abnormality of the skeletal system	HP:0000924	Abnormality of the skeletal system		"{""preferred_term"": ""Abnormality of the skeletal system"", ""term"": {""id"": ""HP:0000924"", ""label"": ""Abnormality of the skeletal system""}}"																											
7188	7942	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	12	Renal Anomalies		phenotype_term	phenotype_term	$	Renal Anomalies		Abnormality of the kidney	HP:0000077	Abnormality of the kidney		"{""preferred_term"": ""Abnormality of the kidney"", ""term"": {""id"": ""HP:0000077"", ""label"": ""Abnormality of the kidney""}}"																											
7189	7943	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	13	Immunodeficiency		phenotype_term	phenotype_term	$	Immunodeficiency		Immunodeficiency	HP:0002721	Immunodeficiency		"{""preferred_term"": ""Immunodeficiency"", ""term"": {""id"": ""HP:0002721"", ""label"": ""Immunodeficiency""}}"																											
7190	7944	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	phenotypes	14	Cleft Lip or Palate		phenotype_term	phenotype_term	$	Cleft Lip or Palate		Cleft palate	HP:0000175	Cleft palate		"{""preferred_term"": ""Cleft palate"", ""term"": {""id"": ""HP:0000175"", ""label"": ""Cleft palate""}}"																											
7191	7947	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	0	Seizure Management with Levetiracetam	Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.	treatment_term	treatment_term	$	Seizure Management with Levetiracetam	Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7192	7948	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	1	Seizure Management with Valproic Acid	Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.	treatment_term	treatment_term	$	Seizure Management with Valproic Acid	Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7193	7949	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	2	Growth Hormone Therapy	Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.	treatment_term	treatment_term	$	Growth Hormone Therapy	Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7194	7950	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	3	Early Aggressive Seizure Management	Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.	treatment_term	treatment_term	$	Early Aggressive Seizure Management	Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7195	7951	345	Yaws	Yaws.yaml	infectious_agent	0	Treponema pallidum subsp. pertenue	Spirochete that causes yaws.	infectious_agent_term	infectious_agent_term	$	Treponema pallidum subsp. pertenue	Spirochete that causes yaws.	Treponema pallidum subsp. pertenue	NCBITaxon:168	Treponema pallidum subsp. pertenue		"{""preferred_term"": ""Treponema pallidum subsp. pertenue"", ""term"": {""id"": ""NCBITaxon:168"", ""label"": ""Treponema pallidum subsp. pertenue""}}"																											
7196	7952	345	Yaws	Yaws.yaml	phenotypes	0	Skin ulcer		phenotype_term	phenotype_term	$	Skin ulcer		Skin ulcer	HP:0200042	Skin ulcer		"{""preferred_term"": ""Skin ulcer"", ""term"": {""id"": ""HP:0200042"", ""label"": ""Skin ulcer""}}"																											
7197	7954	345	Yaws	Yaws.yaml	treatments	0	Azithromycin therapy	Oral azithromycin is preferred for treatment.	treatment_term	treatment_term	$	Azithromycin therapy	Oral azithromycin is preferred for treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7198	7956	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	pathophysiology	0	TTT complex dysfunction	"Mutations in TELO2 destabilize the TTT co-chaperone complex (TELO2-TTI1-TTI2), which is essential for co-translational maturation and stability of PIKKs including ATM, ATR, DNA-PKcs, mTOR, SMG1, and TRRAP. Loss of TELO2 leads to reduced PIKK protein levels, compromising DNA damage checkpoints, growth signaling via mTOR, and nonsense-mediated mRNA decay via SMG1.
"	cell_types[0]	cell_types	cell_types			Neuron	CL:0000540	neuron		"{""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}"																											
7199	7956	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	pathophysiology	0	TTT complex dysfunction	"Mutations in TELO2 destabilize the TTT co-chaperone complex (TELO2-TTI1-TTI2), which is essential for co-translational maturation and stability of PIKKs including ATM, ATR, DNA-PKcs, mTOR, SMG1, and TRRAP. Loss of TELO2 leads to reduced PIKK protein levels, compromising DNA damage checkpoints, growth signaling via mTOR, and nonsense-mediated mRNA decay via SMG1.
"	biological_processes[0]	biological_processes	biological_processes			Nonsense-mediated decay	GO:0000184	nuclear-transcribed mRNA catabolic process, nonsense-mediated decay		"{""preferred_term"": ""Nonsense-mediated decay"", ""term"": {""id"": ""GO:0000184"", ""label"": ""nuclear-transcribed mRNA catabolic process, nonsense-mediated decay""}}"																											
7200	7956	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	pathophysiology	0	TTT complex dysfunction	"Mutations in TELO2 destabilize the TTT co-chaperone complex (TELO2-TTI1-TTI2), which is essential for co-translational maturation and stability of PIKKs including ATM, ATR, DNA-PKcs, mTOR, SMG1, and TRRAP. Loss of TELO2 leads to reduced PIKK protein levels, compromising DNA damage checkpoints, growth signaling via mTOR, and nonsense-mediated mRNA decay via SMG1.
"	locations[0]	locations	locations			Brain	UBERON:0000955	brain		"{""preferred_term"": ""Brain"", ""term"": {""id"": ""UBERON:0000955"", ""label"": ""brain""}}"																											
7201	7957	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	0	Global developmental delay	Severely delayed motor and cognitive milestones from infancy.	phenotype_term	phenotype_term	$	Global developmental delay	Severely delayed motor and cognitive milestones from infancy.	Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
7202	7958	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	1	Intellectual disability	Impaired intellectual development, often severe.	phenotype_term	phenotype_term	$	Intellectual disability	Impaired intellectual development, often severe.	Intellectual disability	HP:0001249	Intellectual disability		"{""preferred_term"": ""Intellectual disability"", ""term"": {""id"": ""HP:0001249"", ""label"": ""Intellectual disability""}}"																											
7203	7959	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	2	Microcephaly	Small head circumference.	phenotype_term	phenotype_term	$	Microcephaly	Small head circumference.	Microcephaly	HP:0000252	Microcephaly		"{""preferred_term"": ""Microcephaly"", ""term"": {""id"": ""HP:0000252"", ""label"": ""Microcephaly""}}"																											
7204	7960	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	3	Congenital cataract	Lens opacity present at or soon after birth.	phenotype_term	phenotype_term	$	Congenital cataract	Lens opacity present at or soon after birth.	Cataract	HP:0000518	Cataract		"{""preferred_term"": ""Cataract"", ""term"": {""id"": ""HP:0000518"", ""label"": ""Cataract""}}"																											
7205	7961	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	4	Hypotonia	Reduced muscle tone in infancy.	phenotype_term	phenotype_term	$	Hypotonia	Reduced muscle tone in infancy.	Hypotonia	HP:0001252	Hypotonia		"{""preferred_term"": ""Hypotonia"", ""term"": {""id"": ""HP:0001252"", ""label"": ""Hypotonia""}}"																											
7206	7962	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	5	Hearing impairment	Variable hearing impairment.	phenotype_term	phenotype_term	$	Hearing impairment	Variable hearing impairment.	Hearing impairment	HP:0000365	Hearing impairment		"{""preferred_term"": ""Hearing impairment"", ""term"": {""id"": ""HP:0000365"", ""label"": ""Hearing impairment""}}"																											
7207	7963	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	6	Seizures	Seizures reported in some TELO2-deficient individuals.	phenotype_term	phenotype_term	$	Seizures	Seizures reported in some TELO2-deficient individuals.	Seizure	HP:0001250	Seizure		"{""preferred_term"": ""Seizure"", ""term"": {""id"": ""HP:0001250"", ""label"": ""Seizure""}}"																											
7208	7964	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	phenotypes	7	Congenital heart defect	Congenital cardiac malformations including atrial septal defect.	phenotype_term	phenotype_term	$	Congenital heart defect	Congenital cardiac malformations including atrial septal defect.	Congenital heart defect	HP:0001627	Abnormal heart morphology		"{""preferred_term"": ""Congenital heart defect"", ""term"": {""id"": ""HP:0001627"", ""label"": ""Abnormal heart morphology""}}"																											
7209	7965	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	0	Supportive care	"Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.
"	treatment_term	treatment_term	$	Supportive care	"Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
7210	7966	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	1	Cataract surgery	"Surgical removal of congenital cataracts can improve visual responses and social interactions.
"	treatment_term	treatment_term	$	Cataract surgery	"Surgical removal of congenital cataracts can improve visual responses and social interactions.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
